{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with widely metastatic cutaneous melanoma. PD-L1 was 5% on IHC and NGS reported TMB-high; BRAF testing was not performed prior to treatment. Given multiple symptomatic brain metastases he received combination immunotherapy with nivolumab plus ipilimumab and stereotactic radiosurgery to dominant intracranial lesions. Imaging after two cycles demonstrated some shrinking of index lesions but appearance of a new small lesion \u2014 overall assessment called a mixed response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 5%; TMB-high", "treatment": "nivolumab and ipilimumab; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Report: 42-year-old female with locally advanced left breast invasive ductal carcinoma, clinically T3N2. Core biopsy: ER positive, PR positive, HER2 amplification by ISH. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP). Imaging after three cycles demonstrated decrease in tumor size but residual disease on exam.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with de novo metastatic (stage IV) breast cancer. Tumor profiling demonstrates HER2 amplification with ER-positive and PR-positive receptor status. She received first-line combination therapy with trastuzumab, pertuzumab and docetaxel and achieved a partial response on first restaging; multiple hepatic lesions persist.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with localized prostate adenocarcinoma (Gleason 3+4). Clinical stage II. Pretreatment PSA was 12 ng/mL. He underwent radical prostatectomy followed by adjuvant radiation. No genomic sequencing was performed and there is no evidence of distant metastasis; post-operative PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (pre-treatment); undetectable post-operative PSA", "treatment": "radical prostatectomy and adjuvant radiation", "response": "no evidence of disease (NED)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with high-grade serous ovarian carcinoma, FIGO IIIC at diagnosis with extensive peritoneal carcinomatosis. Germline BRCA1 pathogenic variant identified. Underwent debulking surgery followed by adjuvant carboplatin and paclitaxel with good radiologic response; she is now on maintenance olaparib. Recent CA-125 has declined and CT shows decreased peritoneal implants consistent with partial response.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": null, "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma. Molecular testing identified EGFR L858R mutation and PD-L1 15% by IHC. Staging CT and brain MRI consistent with stage IV disease with brain and bone metastases. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and interval CT at 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic colorectal adenocarcinoma presenting with RUQ pain. CT demonstrates multiple hypodense hepatic lesions consistent with metastases. Tumor genotyping: KRAS G12D; MSI-stable. He was started on FOLFOX with bevacizumab. Interval imaging after 3 months shows decrease in size of liver lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX with bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with right invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER negative, PR negative; HER2 amplification by FISH. She received neoadjuvant docetaxel and carboplatin with trastuzumab, proceeded to mastectomy \u2014 pathology showed near-complete response (residual cellularity minimal, RCB I). Will continue adjuvant trastuzumab to complete one year.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab; surgery (mastectomy)", "response": "near complete response (pathologic RCB I)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colon adenocarcinoma (stage IV) presenting with multiple liver lesions. Tumor genotyping identified KRAS G12D; microsatellite testing reported MSS (microsatellite stable). He was started on FOLFOX plus bevacizumab and imaging after 3 months showed stable disease. CEA decreased compared with baseline.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX; bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 45F with left invasive ductal breast cancer, tumor 2.5 cm, sentinel nodes negative \u2014 pathologic stage IIA. ER positive, PR positive; HER2 amplified by FISH. NGS identified a PIK3CA E545K mutation. She underwent lumpectomy followed by adjuvant paclitaxel with concurrent trastuzumab and adjuvant radiotherapy. Surveillance imaging and clinical exam after completion of therapy show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel; trastuzumab; radiotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 65-year-old male with metastatic colorectal adenocarcinoma. Presenting CT shows multiple hepatic lesions consistent with metastases. NGS panel returned KRAS G12D. Started on FOLFOX plus bevacizumab. Restaging CT after 4 cycles demonstrates no new lesions and minimal change in size of liver mets \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with castration-resistant prostate adenocarcinoma. After radical prostatectomy in 2012 he developed biochemical recurrence and most recent staging CT demonstrates multiple pulmonary nodules consistent with metastatic spread. Tumor profiling identified a pathogenic BRCA2 variant. He received docetaxel with continued androgen deprivation therapy, then was transitioned to olaparib with interval decrease in size of lung nodules and falling PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": "BRCA2", "biomarker": null, "treatment": "docetaxel, androgen deprivation therapy, then olaparib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive, stage IV with bilateral pulmonary nodules. Initially received pembrolizumab but developed progression after six cycles; therapy was switched to dabrafenib plus trametinib. Follow-up PET/CT demonstrates a partial response in the lungs.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (initial), then dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male status post subtotal resection of a right temporal glioblastoma. Molecular testing: EGFRvIII positive, IDH1 R132H negative; MGMT promoter methylated. Given concurrent radiotherapy with temozolomide followed by adjuvant temozolomide. Six-week postoperative MRI shows expected postoperative enhancement without new lesions; clinical and radiographic appearance consistent with stable disease.", "output": {"cancer_type": "glioblastoma (GBM)", "stage": null, "gene_mutation": "EGFRvIII", "biomarker": "MGMT promoter methylated; IDH1 R132H negative", "treatment": "surgery followed by radiotherapy with concurrent and adjuvant temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma harboring EGFR L858R. Staging CT and MRI consistent with metastatic (stage IV) disease with multiple pulmonary nodules and lesions in the brain and spine. PD-L1 by IHC reported as 5%. She was started on osimertinib 80 mg daily and follow-up CT after 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with liver-dominant disease. Stage IV at diagnosis. Molecular profile: BRAF V600E positive, MSI-High and TMB-high; KRAS and NRAS wild-type. First-line therapy was FOLFOX with bevacizumab; after progression patient was started on pembrolizumab given MSI-H status. Best overall response to chemotherapy + bevacizumab was stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high; KRAS/NRAS wild-type", "treatment": "FOLFOX + bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed June 2024. Molecular testing identified EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging at diagnosis was IV with multiple brain and bone metastases. She was started on osimertinib 80 mg daily in July; follow-up CT chest and brain MRI demonstrate shrinkage of target lesions and decrease in size of intracranial metastases. Current assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with left breast invasive ductal carcinoma, ER+/PR+ and HER2 amplified by FISH. Clinical stage IIIA on initial staging. NGS identified PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and paclitaxel for 4 cycles and then underwent lumpectomy. Preoperative imaging was unchanged compared with baseline and was reported as stable disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and paclitaxel (neoadjuvant); lumpectomy", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old man with rapidly enlarging pigmented lesion on the back; biopsy confirmed cutaneous melanoma. Staging demonstrated pulmonary nodules and he was staged as stage IV. Molecular testing detected BRAF V600E mutation on PCR. He was started on dabrafenib and trametinib with symptomatic improvement and interval PET/CT at 10 weeks showing decreased metabolic activity and shrinkage of pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER positive, PR negative. Clinical stage IIIC with large fixed axillary nodes. She received neoadjuvant docetaxel, carboplatin and trastuzumab followed by modified radical mastectomy. Pathology returned with no residual invasive carcinoma in the breast or nodes (pathologic complete response). No distant metastatic disease identified on staging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC with visible omental and peritoneal implants at debulking. Germline testing positive for a pathogenic BRCA1 variant; tumor noted HRD-positive. Patient received optimal cytoreductive surgery followed by carboplatin and paclitaxel; started maintenance olaparib. Follow-up CT demonstrates decreased peritoneal disease burden consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum and omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 43-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Initially started on dabrafenib plus trametinib with a good partial response of extracranial disease, but subsequently developed new symptomatic intracranial metastases and was switched to ipilimumab/nivolumab. Most recent notes document progression in the brain despite systemic therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then ipilimumab/nivolumab", "response": "progression (intracranial)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed on CT-guided core biopsy. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 5%. Staging PET/CT demonstrated multiple pulmonary nodules and a 1.5 cm cerebellar lesion consistent with brain metastasis, overall stage IV. Patient started first-line osimertinib 80 mg daily with symptomatic improvement; follow-up CT at 8 weeks shows reduction in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with stage IV lung adenocarcinoma. Initial genotyping showed an EGFR L858R activating mutation; baseline PD-L1 TPS 20% and TMB reported at 12 mut/Mb. He received osimertinib in the first-line setting with extracranial control but developed progressive brain metastases. At progression he was switched to combination carboplatin + pemetrexed plus pembrolizumab. Interval MRI after two cycles demonstrated a partial response with decreased size of intracranial and pulmonary lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20% TPS; TMB-high (12 mut/Mb)", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 48-year-old woman with metastatic breast cancer (invasive ductal carcinoma) found to have hepatic lesions on CT. ER/PR positive, HER2 amplification by IHC 3+ and FISH confirmation. NGS identified PIK3CA H1047R. She received first-line trastuzumab and pertuzumab with docetaxel. After 4 cycles the CT shows reduction in size of hepatic metastases \u2014 partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+), ER+/PR+", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 54-year-old with a rapidly enlarging pigmented lesion on the scalp; excision proved malignant melanoma, BRAF V600E positive. Patient declined sentinel node biopsy; was started on pembrolizumab in the adjuvant setting. Early restaging scans show mixed response with shrinkage of the primary site but new subcentimeter pulmonary nodules of uncertain significance. No formal stage documented in the chart.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma treated with debulking surgery followed by adjuvant carboplatin and paclitaxel with bevacizumab. Germline testing identified a deleterious BRCA1 mutation; patient was enrolled on maintenance olaparib plus bevacizumab. CA-125 declined and clinical exam shows improvement.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": null, "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 (declining)", "treatment": "carboplatin + paclitaxel + bevacizumab; maintenance olaparib + bevacizumab", "response": "clinical improvement (CA-125 decline)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing detected EGFR L858R and no ALK/ROS1 rearrangement. PD-L1 tumor proportion score 30%. Started first-line osimertinib 80 mg daily with good tolerance; recent CT and MRI show reduction in pulmonary lesions and decreased size of brain metastases. Overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with newly diagnosed metastatic prostate adenocarcinoma, Gleason 9 (5+4), bone scan positive for multiple blastic bone lesions. He was started on androgen deprivation with leuprolide and received palliative external beam radiation to the pelvis. PSA has stabilized and follow-up imaging shows persistent blastic lesions without interval enlargement.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) and external beam radiation", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with a 1.1 mm superficial spreading melanoma on the right forearm, no ulceration, sentinel lymph node negative. Pathologic staging recorded as IB. Wide local excision was performed with clear margins; no adjuvant immunotherapy was given. BRAF testing was not performed per chart. Patient remains on routine dermatologic surveillance with no clinical evidence of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IB", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with metastatic colorectal adenocarcinoma with multiple liver metastases and peritoneal implants. Tumor profiling returned MSI-H and TMB-high (22 muts/Mb); BRAF V600E mutation was identified and KRAS was wild-type. She received first-line FOLFOX with bevacizumab with minimal tumor shrinkage and was then started on pembrolizumab monotherapy given MSI-H status, achieving a durable partial response on follow-up CT scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high; KRAS wild-type", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman underwent lumpectomy for a 1.8 cm invasive ductal carcinoma. Pathology: ER positive, PR positive, HER2 amplified by FISH; final pathologic stage pT1cN0 (stage I). She completed adjuvant paclitaxel and trastuzumab and is on routine surveillance with no evidence of disease. No pathogenic variants were reported on the tumor panel.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old male with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. PD-L1 by IHC reported at 5%. Staging confirmed stage IV disease with multiple pulmonary nodules. He was started on pembrolizumab but after clinical progression was switched to the BRAF/MEK inhibitor combination dabrafenib plus trametinib with a partial response on the first restaging CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab, then dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old premenopausal female with locally advanced left breast invasive ductal carcinoma, ER-positive, PR-positive, HER2 amplified by FISH. Clinical stage IIIB with fixed axillary nodes. She completed six cycles of neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) and then underwent modified radical mastectomy. Surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response). PIK3CA testing was not performed.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma. Molecular testing demonstrates BRAF V600E mutation. PD-L1 expression reported as >50%. He was started on pembrolizumab; initial scans showed a partial response but after 6 months developed new intracranial and osseous lesions and was transitioned to dabrafenib plus trametinib due to progression on checkpoint blockade.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab; later dabrafenib and trametinib", "response": "progression (after initial partial response)", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic sigmoid colon adenocarcinoma presenting with multiple liver lesions. Tumor was KRAS G12D positive and microsatellite stable (MSS) with low TMB. Started on FOLFOX plus bevacizumab; interval CT after 3 months showed no new lesions and modest shrinkage of dominant hepatic metastasis consistent with stable disease by RECIST.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS, low TMB", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with an ulcerated cutaneous melanoma of the left forearm, sentinel node positive, consistent with stage IIIA disease. Molecular testing demonstrated a BRAF V600E mutation. She underwent wide local excision and completion lymphadenectomy and was started on adjuvant dabrafenib and trametinib. Six\u2011month surveillance PET/CT shows no distant lesions and postoperative changes only; PD-L1 testing was negative.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 negative", "treatment": "wide local excision; completion lymphadenectomy; adjuvant dabrafenib and trametinib", "response": "stable disease (no distant spread)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with recurrent invasive ductal breast cancer, HER2-amplified on FISH. Prior lumpectomy and adjuvant chemo 3 years ago; now presents with multiple hepatic lesions on ultrasound consistent with metastases. PIK3CA E545K mutation identified on NGS. Patient initiated on trastuzumab, pertuzumab and docetaxel; first restaging CT after 3 cycles shows stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with newly diagnosed lung adenocarcinoma presented with headache and weakness. Imaging shows multiple enhancing lesions consistent with brain metastases and focal lytic lesions in the spine. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 tumor proportion score reported at 60%. Patient started on osimertinib 80 mg daily; after 8 weeks MRI demonstrates decrease in size of intracranial lesions and symptom improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 >50%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old man with a newly diagnosed superficial spreading melanoma on the left forearm. Lesion measured 1.2 mm Breslow depth without ulceration; wide local excision was performed and sentinel lymph node biopsy was negative. NGS ordered but results are pending and no PD-L1 or other biomarker testing has been done. Patient remains on active surveillance.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy", "response": "complete response / no residual disease after excision", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging CT and MRI consistent with stage IV disease with multiple liver lesions, a left femoral bone metastasis and a 1.2 cm cerebellar metastasis. Tumor NGS: EGFR L858R; PD-L1 TPS 10%. He was started on osimertinib and underwent stereotactic radiosurgery to the cerebellar lesion. First restaging CT at 8 weeks shows decrease in size of primary and mediastinal nodes and partial regression of bone lesions, consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "liver; bone; brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old presented with weight loss and cough. Colonoscopy revealed an ulcerating sigmoid mass; pathology consistent with colorectal adenocarcinoma. CT chest showed multiple pulmonary nodules suspicious for metastases. Tumor genotyping identified KRAS G12C. He received FOLFOX in combination with bevacizumab but interval CT demonstrates new pulmonary nodules and increasing size of existing lesions, consistent with progression of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy note: 48-year-old woman with T2N0M0 (clinical stage IIA) invasive ductal breast cancer. ER and PR negative on IHC; HER2 amplified by FISH (HER2/CEP17 ratio 6.2). She received weekly paclitaxel x12 with concurrent trastuzumab and subsequently underwent mastectomy. Final surgical pathology reported no residual invasive carcinoma (pathologic complete response). No tumor genomic sequencing was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 63-year-old male with metastatic colon adenocarcinoma to the liver. Molecular profile: KRAS G12D mutation, MSI-H and TMB-high 32 mut/Mb. He was started on FOLFOX plus bevacizumab for tumor reduction, then switched to pembrolizumab monotherapy given high microsatellite instability. After three months of pembrolizumab the scans show no new lesions and minimal shrinkage of hepatic metastases compared with baseline.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high (32 mut/Mb)", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "stable disease / minimal response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genotyping: KRAS G12D positive; microsatellite testing MSS (microsatellite stable). First-line systemic therapy with FOLFOX plus bevacizumab was administered. Follow-up CT after 4 cycles demonstrated shrinkage of hepatic lesions with subsequent scans showing disease control \u2014 stable disease at 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female diagnosed with metastatic lung adenocarcinoma harboring EGFR L858R. Staging PET/CT consistent with stage IV disease with known brain and bone metastases. PD-L1 tumor proportion score reported as 10%. Patient was started on osimertinib 80 mg daily and noted symptomatic improvement; interval imaging at 8 weeks demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Young woman with a 3.5 cm ER+/PR+, HER2-negative invasive ductal carcinoma of the left breast. Core biopsy next-gen sequencing identified PIK3CA H1047R. She received neoadjuvant doxorubicin/cyclophosphamide x4 then paclitaxel x12, proceeded to lumpectomy with sentinel node biopsy. Final pathology showed no residual invasive carcinoma (pathologic complete response). Adjuvant endocrine therapy with letrozole planned.", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+; HER2 negative", "treatment": "neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel; lumpectomy; adjuvant letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with BRAF V600E mutation; patient presented with symptomatic intracranial disease and multiple extracranial lesions. Initiated combination targeted therapy with dabrafenib and trametinib. Five-month imaging shows complete radiographic resolution of both brain and extracranial metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 68-year-old man with progressive cough and weight loss. CT chest showed a right upper lobe mass; biopsy confirmed lung adenocarcinoma. Staging workup demonstrated multiple cerebral metastases and a single lytic lesion in the femur \u2014 overall Stage IV. Molecular profiling positive for EGFR L858R; PD-L1 tumor proportion score ~1%. Patient was started on osimertinib 80 mg PO daily with stereotactic radiosurgery to the brain lesions. Restaging CT at 8 weeks documents marked shrinkage of the primary and decreased size of brain mets consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with castration-resistant prostate cancer presenting with diffuse osteoblastic lesions on bone scan. He remains on leuprolide and was recently started on abiraterone with prednisone. Prior targeted panel did not identify actionable genomic alterations. PSA levels have stabilized and the treating team documents stable osseous metastatic disease on current therapy.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Imaging shows stage IV disease with multiple brain and osseous metastases. Comprehensive NGS identified an EGFR exon 21 L858R mutation; ALK and ROS1 were negative. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy, with clinical improvement and interval CT/MRI at 8 weeks demonstrating a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old man diagnosed with metastatic colorectal adenocarcinoma in January. CT shows multiple hepatic lesions and peritoneal nodularity. Tumor genotyping: KRAS G12D, no NRAS mutations. MSI testing: microsatellite stable. He was started on FOLFOX with bevacizumab; after 3 months CT scans show stable size of liver lesions and CA19-9/CEA modestly decreased.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR exon 19 deletion; PD-L1 TPS reported as 10%. She was started on osimertinib 80 mg daily in January 2020. Follow-up brain MRI demonstrates decrease in size of multiple cerebral lesions. Current assessment: partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female referred with newly diagnosed metastatic lung adenocarcinoma. Biopsy confirmed adenocarcinoma with an EGFR exon 19 deletion. PD-L1 TPS reported 1\u201310%. Staging showed multiple cerebral and vertebral lesions \u2014 brain and bone metastases. Patient was started on osimertinib 80 mg PO daily in April; first restaging CT at 8 weeks demonstrated a partial response with shrinkage of the dominant right lower lobe mass and decreased size of several bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 1\u201310%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Diagnosis: pancreatic ductal adenocarcinoma. Germline testing positive for BRCA2 mutation. He received six cycles of gemcitabine and nab-paclitaxel with radiographic partial response and was transitioned to olaparib maintenance. CA19-9 was markedly elevated at diagnosis but has fallen with therapy. Current oncology note documents clinical benefit; staging and sites of spread are not listed in this note.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel followed by olaparib maintenance", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. Tumor sequencing identified BRAF V600E. Patient received frontline immune checkpoint blockade but developed progression in the chest and was started on targeted therapy with dabrafenib plus trametinib. Recent PET/CT demonstrates increasing pulmonary nodules and new pleural disease \u2014 interval progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, stage IV. Tumor testing shows KRAS G12D mutation and microsatellite stable (MSS). Disease is notable for peritoneal carcinomatosis with omental caking. He has been receiving FOLFOX plus bevacizumab with stable disease on most recent CT; CEA trending down.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed metastatic lung adenocarcinoma, clinical stage IV. Tissue NGS identified EGFR L858R; PD-L1 IHC reported 10%. Baseline MRI showed multiple brain metastases and bone lesions. He was started on osimertinib 80 mg daily as first-line targeted therapy. At first restaging (3 months) there was an interval decrease in measurable pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma positive for BRAF V600E on NGS. PD-L1 by IHC was 5%. He was started on dabrafenib/trametinib combination and had an early partial response, but developed systemic progression at 6 months and was switched to single-agent nivolumab. Brain MRI now shows new intracranial lesions. Stage was not formally documented in the notes.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later nivolumab", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with newly diagnosed prostate adenocarcinoma, clinical stage I (T1cN0M0), Gleason 3+4, PSA 6.8 ng/mL. Somatic testing identified a BRCA2 frameshift mutation. He elected for robotic radical prostatectomy; postoperative PSA is undetectable. No adjuvant radiation or systemic therapy planned at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": "BRCA2 frameshift", "biomarker": "PSA 6.8 ng/mL", "treatment": "robotic radical prostatectomy", "response": "undetectable PSA / no evidence of disease post-op", "metastasis_site": "no distant metastasis"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced breast cancer (cT3N2) on core biopsy: ER positive, PR negative, HER2 IHC 3+ with confirmed HER2 amplification by FISH and PIK3CA E545K on NGS. She received neoadjuvant trastuzumab and pertuzumab with docetaxel and then underwent mastectomy. Surgical pathology reported a pathologic complete response. Axillary nodes were previously involved.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel; mastectomy", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old with metastatic cutaneous melanoma. Molecular testing showed NRAS Q61R mutation. PD-L1 immunostain reported approximately 40% tumor cell positivity. Patient received single-agent nivolumab but developed new CNS lesions and extracranial progression after 6 months of therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 40%", "treatment": "nivolumab", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic colorectal adenocarcinoma presenting with multiple hepatic metastases. Tumor NGS showed KRAS G12D mutation; MSI testing was microsatellite stable (MSS). Baseline CEA elevated. Staged as IV disease. Treated with FOLFOX plus bevacizumab \u2014 CT after 4 cycles demonstrates decrease in size of liver lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma found to carry a germline BRCA2 truncating mutation. Extensive sclerotic bone metastases on bone scan. He progressed on abiraterone and was started on olaparib; most recent imaging demonstrates radiographic stable disease and declining PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "HRD positive (BRCA2-associated)", "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma. Imaging shows multiple bilateral pulmonary nodules and contrast MRI demonstrates two enhancing lesions in the cerebellum. Biopsy confirmed adenocarcinoma; molecular testing returned EGFR L858R. PD-L1 tumor proportion score reported at 10%. Patient was started on osimertinib 80 mg daily with stereotactic radiosurgery to the dominant brain lesion. At 3-month follow-up there is a RECIST partial response of the lung lesions and decreased size of brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma, Stage IV with multifocal bone metastases. Germline/somatic testing identified a deleterious BRCA2 mutation; tumor profiling also reported TMB-high. Initially treated with androgen deprivation therapy plus docetaxel; after progression he was switched to olaparib. Current scan assessment described a mixed response with progression in several bony lesions.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "TMB-high", "treatment": "androgen deprivation therapy, docetaxel, olaparib", "response": "mixed response with progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology clinic note: Thin superficial spreading melanoma on the left forearm, Breslow 0.6 mm, no ulceration. Clinically staged as IA following excision margins. No molecular testing was performed. Patient underwent wide local excision with clear margins and will continue routine dermatologic surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast, clinically stage IIIA. Tumor testing demonstrated HER2 amplification and was ER/PR negative. No genomic sequencing was performed. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) followed by mastectomy; surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old man with metastatic cutaneous melanoma. Initial molecular profiling identified BRAF V600E mutation. He received first-line dabrafenib plus trametinib with an initial RECIST partial response; after 9 months surveillance scans revealed new pulmonary and cerebellar lesions. Therapy was changed to nivolumab monotherapy, but scans show interval progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib \u2192 nivolumab", "response": "progression", "metastasis_site": "lung; brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "73-year-old man with metastatic castration-resistant prostate adenocarcinoma (Gleason 9 at diagnosis) presenting with diffuse sclerotic bone metastases. Somatic and germline testing identified a pathogenic truncating BRCA2 mutation. He received androgen deprivation therapy and six cycles of docetaxel; thereafter olaparib was started given BRCA2 positivity. PSA has been stable and imaging demonstrates no progression \u2014 overall radiographic stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (truncating mutation)", "biomarker": null, "treatment": "androgen deprivation therapy; docetaxel; olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal breast carcinoma, clinical stage IIIB. Biopsy: ER positive, PR negative, HER2 amplified by FISH. Tumor NGS identified PIK3CA E545K. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by mastectomy. Surgical pathology showed a pathologic complete response. No distant metastases were identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "paclitaxel + trastuzumab and pertuzumab (neoadjuvant), followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative clinic note: 54-year-old woman with high-grade invasive ductal carcinoma of the left breast, clinically T2N1, biopsy shows ER positive, PR negative, HER2 amplification by FISH and a PIK3CA H1047R mutation. Staged as IIIA on imaging. She received neoadjuvant trastuzumab and pertuzumab with docetaxel x 6 cycles prior to surgery. Pathology after modified radical mastectomy demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor profiling returned MSI-H and TMB-high. No actionable RAS mutation was found (KRAS/NRAS wild-type). He was started on pembrolizumab monotherapy and first interval scans showed shrinkage of hepatic lesions reported as a partial response with symptomatic improvement.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic invasive ductal carcinoma of the breast. Tumor is ER-positive, PR-negative; HER2 3+ by IHC with HER2 amplification confirmed by FISH. NGS detected PIK3CA H1047R. Staged IV with multiple bone and liver metastases. She was started on trastuzumab, pertuzumab and docetaxel combination therapy; after 4 cycles CT shows a partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+ (IHC); HER2 amplification (FISH); ER-positive; PR-negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "bone; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 55-year-old male with metastatic cutaneous melanoma. Initial molecular panel positive for BRAF V600E. He was treated with dabrafenib and trametinib for 5 months with mixed shrinkage of some pulmonary nodules but progression of a dominant upper lobe lesion; subsequently started pembrolizumab. Stage not clearly documented in the referral letter.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER/PR negative, HER2-amplified by FISH. Next-generation sequencing detected PIK3CA H1047R. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles and went to surgery. Surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced right breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER+, PR+, HER2 3+ by IHC and PIK3CA H1047R on NGS. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for six cycles with significant clinical tumor regression and underwent mastectomy. Surgical specimen showed no residual invasive carcinoma (pathologic complete response). No distant disease identified.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER+; PR+", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP) followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R. PD-L1 by IHC is 15%. Baseline staging showed brain metastases on MRI and multiple lytic bone lesions on PET/CT. Started osimertinib 80 mg daily in March 2024; restaging CT after 8 weeks demonstrated decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old man with advanced cutaneous melanoma, BRAF V600E positive. Patient had bulky nodal and pulmonary disease (stage IV) and was started on combo targeted therapy with dabrafenib and trametinib. After two months of therapy there was a radiographic partial response with >50% reduction in measurable nodal disease. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with high-grade serous ovarian carcinoma, stage IV with peritoneal carcinomatosis and hepatic implants. Germline testing positive for BRCA1 mutation. CA-125 markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by systemic therapy with carboplatin and paclitaxel plus bevacizumab; CT after three cycles demonstrated a partial response with decreased peritoneal disease and shrinkage of liver lesions.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1", "biomarker": "CA-125 elevated", "treatment": "debulking surgery followed by carboplatin and paclitaxel and bevacizumab", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old M with metastatic colorectal adenocarcinoma. Genomic profiling identified a KRAS G12D mutation. MSI testing revealed MSI-stable and TMB was reported low. He received FOLFOX with bevacizumab in the frontline setting but restaging CT shows progressive hepatic lesions and new porta hepatis adenopathy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman found to have stage IA high-grade serous ovarian carcinoma at time of staging laparotomy. Germline testing identified a pathogenic BRCA1 variant. Preoperative CA-125 was elevated. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and omentectomy followed by 6 cycles of carboplatin and paclitaxel. Post-treatment CA-125 normalized and CT scans indicate complete response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "I", "gene_mutation": "germline BRCA1 pathogenic variant", "biomarker": "elevated CA-125 (normalized post-treatment)", "treatment": "surgery (TAH-BSO, omentectomy) and carboplatin/paclitaxel", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with ER+/PR+ HER2-amplified invasive ductal carcinoma of the left breast, clinical stage IIA. She received neoadjuvant paclitaxel with trastuzumab, then lumpectomy and sentinel lymph node biopsy. Final pathology showed pathologic complete response. BRCA testing was negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Clinically staged as IIIA (T3N1). She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for six cycles followed by lumpectomy and sentinel node evaluation. Pathology returned with no residual invasive carcinoma \u2014 pathologic complete response. No distant disease on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant); surgery", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with invasive ductal carcinoma of the left breast, clinical stage IIIA. Tumor is ER-positive, PR-positive and shows HER2 amplification by FISH. Somatic sequencing reported a PIK3CA H1047R alteration. She underwent modified radical mastectomy followed by adjuvant doxorubicin/cyclophosphamide then weekly paclitaxel (AC-T) with trastuzumab for one year and is currently on adjuvant letrozole. Recent surveillance imaging shows no evidence of disease.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+; PR+; HER2 amplification", "treatment": "modified radical mastectomy; doxorubicin/cyclophosphamide; paclitaxel; trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with primary cutaneous melanoma, clinically staged IIIC for bulky nodal involvement. BRAF V600E mutation identified by PCR. Tumor mutational burden reported as TMB-high. He was treated with targeted therapy\u2014dabrafenib plus trametinib\u2014for 6 months with complete disappearance of nodal disease on CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with metastatic lung adenocarcinoma (stage IV) harboring EGFR L858R mutation. Baseline brain MRI demonstrated two enhancing lesions consistent with metastases. She was started on osimertinib 80 mg daily. Follow-up CT chest/abdomen shows interval decrease in size and number of pulmonary nodules and resolution of one brain lesion. Overall assessment: partial response. PD-L1 by IHC reported at 5%.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 45-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast, clinically T4N1 (stage IIIB). Tumor is ER positive, PR positive and HER2 amplified by FISH. Tumor panel identified PIK3CA E545K. She received weekly paclitaxel with trastuzumab followed by lumpectomy \u2014 surgical pathology demonstrates pathologic complete response (pCR). No distant metastases on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel and trastuzumab (neoadjuvant), lumpectomy", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Chest CT and brain MRI at presentation demonstrate multiple bilateral pulmonary nodules and a 1.8 cm enhancing lesion in the right frontal lobe consistent with metastatic disease. Staging: stage IV. Molecular testing on the core biopsy identified EGFR L858R mutation. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg PO daily. First follow-up imaging at 8 weeks shows decrease in size of the brain lesion and shrinkage of lung nodules \u2014 partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with high-grade serous ovarian carcinoma, optimal debulking performed; pathologic stage IIIC with extensive peritoneal carcinomatosis. Germline testing positive for deleterious BRCA1 mutation; somatic panel also shows TP53 mutation. CA-125 at presentation was 380 U/mL. She completed six cycles of carboplatin and paclitaxel with clinical partial response, and was placed on maintenance olaparib. Follow-up CT shows decreased peritoneal disease but persistent small-volume implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation; TP53 mutation", "biomarker": "CA-125 elevated (380 U/mL)", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology consult: 39-year-old male with nodular melanoma of the upper back, sentinel node positive. Pathology: NRAS Q61K mutation identified on next-generation sequencing. PD-L1 by IHC 5%. Underwent wide local excision with lymph node dissection and was started on adjuvant pembrolizumab. At 6-month interval imaging there is no new visceral disease but persistent nodal enlargement; response categorized as stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "NRAS Q61K", "biomarker": "PD-L1 5%", "treatment": "adjuvant pembrolizumab", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colon adenocarcinoma with multiple hepatic lesions. Molecular profiling identified KRAS G12D and MSS (microsatellite stable). Started on FOLFOX plus bevacizumab; restaging CT after 4 cycles demonstrates no new lesions with slight decrease in target liver metastases consistent with stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Medical oncology assessment: High\u2011grade prostate adenocarcinoma with castration\u2011resistant progression and extensive osseous metastases. Germline testing positive for a pathogenic BRCA2 variant. Prior therapy included androgen deprivation and docetaxel; patient was started on olaparib for BRCA2-associated disease. PSA has been stable on olaparib and most recent scans show no new lesions \u2014 disease currently assessed as stable on therapy. Stage at diagnosis recorded as IV.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "PSA rising previously; currently stable", "treatment": "olaparib (after androgen deprivation and docetaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male underwent wide local excision of a 1.1 mm non-ulcerated cutaneous melanoma on the upper back. Sentinel lymph node biopsy was negative. Final pathologic staging pT2a (AJCC stage IIA). No BRAF or NRAS testing was performed. No adjuvant therapy was recommended and patient will be followed with skin/lymph node surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIA", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy (no adjuvant therapy planned)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with metastatic invasive ductal carcinoma of the right breast, ER-/PR- and HER2 amplified by FISH. Bone scan revealed multiple lytic lesions in the pelvis and thoracic spine at presentation; classified as stage IV. She received first-line trastuzumab and pertuzumab with docetaxel q3 weeks. After four cycles the CT chest/abdomen/pelvis shows no new lesions and stable size of hepatic and osseous disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 56-year-old female with metastatic lung adenocarcinoma presenting with new headaches and left hip pain. Initial diagnosis 2019; molecular testing on biopsy returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging at diagnosis was IV with brain and osseous metastases. Patient started osimertinib 80 mg PO daily in June 2020 with rapid symptomatic improvement. Interval brain MRI and CT chest/abdomen in August show shrinkage of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 amplified by FISH; NGS reported a PIK3CA H1047R mutation. Clinical stage IIIB with fixation to chest wall. She received neoadjuvant paclitaxel plus trastuzumab, then underwent modified radical mastectomy; surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab, surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old with metastatic colorectal adenocarcinoma to the liver. Tumor testing showed high microsatellite instability (MSI-H) and TMB-high on panel sequencing; no actionable KRAS/NRAS/BRAF mutations were identified. He was started on pembrolizumab as first-line for MSI-H disease and has had shrinkage of hepatic lesions with ongoing partial response at 12 weeks.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female presents with abdominal distension and ascites; imaging and biopsy confirm high-grade serous ovarian carcinoma, stage IV with peritoneal carcinomatosis and liver implants. Germline testing returned BRCA1 185delAG pathogenic variant. CA-125 was 1,200 U/mL at diagnosis. She received 6 cycles of carboplatin and paclitaxel with interval cytoreductive surgery; imaging demonstrated partial response and CA-125 declined to 120 U/mL. She was started on maintenance olaparib thereafter.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 1200 U/mL (diagnosis); CA-125 decline to 120 U/mL after chemo", "treatment": "carboplatin and paclitaxel; interval cytoreductive surgery; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R mutation and PD-L1 10%. Staging CT showed multiple hepatic and bony lesions; MRI brain negative. Patient was started on osimertinib 80 mg daily with radiographic assessment at 12 weeks showing shrinkage of target lesions. Oncology note documents partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with high-grade serous ovarian carcinoma, stage IIIC, with diffuse peritoneal carcinomatosis. Germline testing returned a pathogenic BRCA1 variant and the tumor was HRD-positive. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel, achieved a complete clinical response and was started on olaparib maintenance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic castration-resistant prostate cancer, prior radical prostatectomy, now with rising PSA and multiple sclerotic bone metastases on bone scan. Germline and somatic testing revealed a pathogenic BRCA2 alteration. He received first-line docetaxel, progressed biochemically and was transitioned to olaparib with clinical and PSA improvement consistent with a partial response.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant prostate cancer)", "stage": "IV", "gene_mutation": "BRCA2 pathogenic mutation", "biomarker": null, "treatment": "docetaxel followed by olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma diagnosed at laparotomy with bulky peritoneal disease and ascites. Surgical staging was consistent with stage IIIC. Germline testing returned a deleterious BRCA1 variant. Patient underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel and was placed on olaparib maintenance. CA-125 was markedly elevated pre-treatment and normalized after chemotherapy. Radiology follow-up notes are pending and no formal response assessment is yet documented.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated pre-treatment", "treatment": "cytoreductive surgery; carboplatin + paclitaxel; olaparib maintenance", "response": null, "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with right-sided colon adenocarcinoma presenting with liver and bilateral pulmonary metastases. Tumor testing: mismatch repair deficient (MSI-H) and high tumor mutational burden; NGS detected BRAF V600E. Given metastatic disease he was started on pembrolizumab monotherapy. After 6 months of therapy PET/CT shows resolution of hypermetabolic activity in all known lesions consistent with complete response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63 yo F with newly diagnosed metastatic breast cancer. Core biopsy demonstrates high-grade invasive ductal carcinoma, ER-/PR-, HER2 amplified by FISH. Staging PET/CT shows multiple hypodense lesions in the liver consistent with metastases (stage IV). She was initiated on weekly paclitaxel with trastuzumab and pertuzumab; interim imaging after 3 cycles shows shrinkage of hepatic lesions. No molecular sequencing identified actionable point mutations in the report.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with widely metastatic cutaneous melanoma harboring BRAF V600E on tumor sequencing. Baseline brain MRI identified a solitary cerebellar metastasis that was treated with stereotactic radiosurgery. He was started on combination targeted therapy with dabrafenib and trametinib. Follow-up PET/CT and brain MRI demonstrate complete metabolic and radiographic response with no residual enhancing intracranial lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib; trametinib; stereotactic radiosurgery", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man presenting with progressive cough and weight loss found to have stage IV lung adenocarcinoma. Molecular testing identified an EGFR exon 19 deletion. PD-L1 tumor proportion score was 5%. Brain MRI showed two parenchymal metastases. He was started on osimertinib 80 mg daily with symptomatic improvement and interval CT chest demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic cutaneous melanoma. Next-generation sequencing positive for BRAF V600E. He presented with multiple pulmonary nodules and a solitary cerebellar metastasis. Systemic therapy with dabrafenib and trametinib produced a prompt reduction in chest nodules, but the cerebellar lesion progressed and was treated with stereotactic radiosurgery. Overall assessment documented as a mixed response with new activity in the brain despite improvement in extracranial disease.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with lung adenocarcinoma, clinical stage IV. Tissue NGS returned EGFR L858R mutation; PD-L1 TPS 10%. Patient started osimertinib 80 mg PO daily. First restaging CT and brain MRI after 8 weeks show decreased size of primary lung lesion and shrinkage of intracranial metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with locally advanced pancreatic ductal adenocarcinoma with encasement of the superior mesenteric artery and suspicious hepatic lesions on MRI consistent with metastatic disease (clinical stage IV). Tumor sequencing identified KRAS G12D. He was started on FOLFIRINOX and after 3 months has stable disease by RECIST. No molecular biomarkers (e.g., MSI or PD-L1) were reported in the chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRINOX", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer (clinical T4bN1M0, stage IIIB). Core biopsy: invasive ductal carcinoma, ER positive, PR negative. HER2 amplified by FISH (HER2/CEP17 ratio >2.2). She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles followed by mastectomy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 58-year-old female with high-grade serous ovarian carcinoma. At debulking laparotomy disease was noted throughout the pelvis and omentum consistent with peritoneal carcinomatosis (FIGO stage IIIC). Germline testing revealed a pathogenic BRCA1 variant. She completed adjuvant carboplatin and paclitaxel and was started on maintenance olaparib. CA-125 has stabilized and imaging shows no interval progression \u2014 disease remains controlled on maintenance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated then stabilized", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "stable disease / disease controlled on maintenance", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 45-year-old male with ulcerated primary melanoma of the left forearm with a positive sentinel node. Final stage IIIB. BRAF V600E mutation identified on PCR-based assay. PD-L1 expression 5% (tumor). Patient began targeted therapy with dabrafenib plus trametinib in the adjuvant setting due to nodal involvement; partial clinical and radiographic response noted with shrinkage of nodal disease.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma. Biopsy confirmed adenocarcinoma of the right upper lobe. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Staging scans show multiple cerebellar and thoracic spine lesions consistent with brain and bone metastases. Patient was started on osimertinib 80 mg daily after a single cycle of carboplatin/pemetrexed. Interim CT after 8 weeks demonstrates decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib (after carboplatin/pemetrexed)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy note: 48-year-old female with locally advanced, ER+/PR+ HER2-amplified invasive ductal carcinoma of the left breast, clinical stage IIIC. Core biopsy also identified a PIK3CA H1047R mutation. She completed 6 cycles of docetaxel with trastuzumab and pertuzumab prior to surgery. Final pathology after mastectomy demonstrated no residual invasive carcinoma (pathologic complete response). No distant disease on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "docetaxel + trastuzumab + pertuzumab (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up oncology note: Known metastatic colon adenocarcinoma with multiple hepatic lesions. Patient completed 6 cycles of FOLFOX with bevacizumab. Most recent CT abdomen shows stable size of dominant liver lesion compared with prior. No new extrahepatic disease identified. Genetic testing not available in chart; colon tumor markers were elevated at diagnosis but no microsatellite testing result documented here.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old man with clinically localized prostate adenocarcinoma (Gleason 3+4) staged at T2N0M0 (stage II). He underwent radical prostatectomy; pathology confirmed organ-confined disease. He received short-course adjuvant androgen deprivation with leuprolide and salvage pelvic radiation for a postoperative rise in PSA. No molecular testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy, androgen deprivation (leuprolide), pelvic radiation", "response": "undetectable/low PSA after treatment", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma. Initial staging at diagnosis was IV with multiple brain and bony lesions. Molecular testing returned EGFR L858R and low-level MET amplification; PD-L1 tumor proportion score 10%. Patient received first-line osimertinib for 11 months with partial response in pulmonary disease but progression in the brain. Following intracranial radiation he was switched to carboplatin + pemetrexed combined with pembrolizumab on a clinical protocol and achieved a second partial response systemically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "MET amplification; PD-L1 10%", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with right-sided colon adenocarcinoma presenting with obstructive symptoms. Imaging demonstrated multiple hypodense lesions in the liver and omental nodularity concerning for peritoneal spread. Staged as IV. Patient started palliative FOLFOX with bevacizumab. No actionable mutation detected on available testing. After three cycles there is radiographic progression in the liver.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male status post right hemicolectomy for colon adenocarcinoma found to have multiple hepatic lesions on staging CT consistent with metastases. Molecular panel returned KRAS G12D. CEA is elevated. He was started on FOLFOX plus bevacizumab and first restaging scans show stable disease. MSI testing was not available in the chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic colon adenocarcinoma presenting with multiple liver lesions. Tumor is mismatch repair deficient (MSI-H) and reported as TMB-high on NGS. He received FOLFOX plus bevacizumab with initial disease control (stable disease) and was later transitioned to pembrolizumab monotherapy. Comprehensive panel did not detect RAS or BRAF driver mutations.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab, then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with history of prostate adenocarcinoma status post radical prostatectomy now with rising PSA and new sclerotic lesions on bone scan consistent with metastatic spread. Given metastatic hormone-sensitive disease he was started on androgen deprivation with leuprolide and received docetaxel chemotherapy. PSA declined from 180 to 72 ng/mL at three months with symptomatic improvement in bone pain.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "partial biochemical response (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with Stage IV metastatic melanoma harboring BRAF V600E. Initially treated with pembrolizumab but progressed after 4 months with new pulmonary nodules and brain metastases. Switched to targeted therapy with dabrafenib and trametinib, which produced a partial response on interval scans. Tumor mutational burden reported as TMB-high.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab; dabrafenib + trametinib", "response": "progression on pembrolizumab; partial response on dabrafenib+trametinib", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with stage IIIC cutaneous melanoma of the right scalp. No molecular testing was performed at the time of diagnosis and PD-L1 was not reported. He completed adjuvant pembrolizumab every 3 weeks for one year. Surveillance PET/CT and clinical exam are negative and the patient is currently without evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "adjuvant pembrolizumab", "response": "no evidence of disease (complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed stage IV lung adenocarcinoma. NGS returned EGFR L858R mutation. PD-L1 tumor proportion score was 10%. Staging CT shows hepatic and bony metastases. Patient started osimertinib 80 mg daily as first-line targeted therapy. Interval imaging at 8 weeks demonstrates decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female referred for progressive cough and weight loss. Imaging and biopsy confirm metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 15%. Patient started osimertinib as systemic therapy. Interval CT at 8 weeks demonstrates decreased size of pulmonary nodules and resolution of several small brain metastases with overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 66-year-old male with metastatic pancreatic ductal adenocarcinoma. Germline BRCA2 mutation identified on genetic testing. He received first-line FOLFIRINOX with partial biochemical response and then was transitioned to maintenance olaparib due to BRCA2 positivity. After 8 months on maintenance therapy he developed symptomatic peritoneal carcinomatosis with radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; olaparib (maintenance)", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female underwent colonoscopy for rectal bleeding; biopsy confirmed sigmoid colon adenocarcinoma. Imaging staged as T3N0 (stage II). Tumor is MSI-H by PCR. KRAS testing reported as wild-type (no actionable mutation identified). She had low anterior resection with clear margins and declined adjuvant chemotherapy. At one-year surveillance there is no radiographic evidence of recurrence.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (low anterior resection)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Incidentally discovered 3.2 cm right renal mass on ultrasound. Partial nephrectomy performed; pathology consistent with clear cell renal cell carcinoma, stage I (pT1b). No adjuvant therapy was given and patient remains on routine surveillance with no evidence of recurrence.", "output": {"cancer_type": "renal cell carcinoma (clear cell)", "stage": "I (pT1b)", "gene_mutation": null, "biomarker": null, "treatment": "partial nephrectomy; surveillance", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 38-year-old male with metastatic cutaneous melanoma. Molecular panel positive for BRAF V600E. PD-L1 by IHC reported at 20%. Started targeted therapy with dabrafenib plus trametinib; initial shrinkage of measurable disease was noted, however after approximately 9 months on therapy there was radiographic progression with new pulmonary nodules and two intracranial metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old man with metastatic cutaneous melanoma; primary excised previously, now presents with multiple pulmonary nodules. Molecular testing positive for BRAF V600E and high tumor mutational burden (TMB-high). He was started on combination targeted therapy with dabrafenib + trametinib. Follow-up chest CT at 8 weeks shows near-complete resolution of nodules; treating team documents a complete response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with cutaneous melanoma presenting with metastatic disease. Molecular testing identified a BRAF V600E mutation. He was started on combination targeted therapy with dabrafenib and trametinib and initially achieved tumor shrinkage, but after six months developed clinical progression with new pulmonary and hepatic nodules and treatment was discontinued.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for left-sided invasive ductal breast carcinoma, clinically T3N1. ER positive, PR negative; HER2 amplified by FISH. Patient received weekly paclitaxel in combination with trastuzumab and pertuzumab prior to surgery. Imaging shows marked reduction in primary tumor size and no evidence of distant metastasis on PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man presenting with worsening lower back pain found to have metastatic prostate adenocarcinoma. PSA at presentation was 120 ng/mL. Bone scan shows multiple sclerotic metastases in the lumbar spine and pelvis. He was started on leuprolide depot for androgen deprivation and given six cycles of docetaxel; PSA decreased and pain improved. Germline and somatic mutation panels are pending and no actionable mutation has been reported to date.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL", "treatment": "leuprolide and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male referred for treatment of metastatic lung adenocarcinoma. PET/CT and brain MRI demonstrate multiple pulmonary nodules with biopsy-proven adenocarcinoma and enhancing cerebellar lesion. Molecular testing returned EGFR L858R positive. PD-L1 by IHC was 10%. Patient started osimertinib 80 mg PO daily. Follow-up CT at 8 weeks shows reduction in size of primary and brain lesions; clinician documents partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung (pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer. Core biopsy shows invasive ductal carcinoma, HER2 amplified by FISH, ER positive (80%), PR negative. Staging CT shows multiple liver lesions consistent with metastases; no brain disease. She was started on first-line trastuzumab and pertuzumab with docetaxel, transitioned to maintenance trastuzumab after six cycles. Disease has been radiographically stable over 4 months with good tolerability.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER 80% (PR negative)", "treatment": "trastuzumab + pertuzumab + docetaxel, then maintenance trastuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with moderately differentiated adenocarcinoma of the sigmoid colon. Pathology after surgery = pT3N1M0 (stage III). Tumor sequencing detected KRAS G12D; MSI testing reported MSI-stable. She underwent low anterior resection followed by adjuvant FOLFOX for six cycles. CEA normalized and surveillance CT at 12 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colorectal adenocarcinoma (sigmoid colon)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "low anterior resection, adjuvant FOLFOX (6 cycles)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and oncology summary: 45-year-old man with ulcerated pigmented lesion on the back \u2014 wide excision revealed melanoma, sentinel node positive; final stage IIIC. Molecular testing identified BRAF V600E. PD-L1 by IHC 5%. Patient was treated with adjuvant dabrafenib plus trametinib for one year; most recent PET/CT shows no hypermetabolic disease consistent with complete metabolic response of nodal disease.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib (adjuvant)", "response": "complete response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male presented with obstructing left-sided colon cancer. At laparotomy there was diffuse peritoneal carcinomatosis. Tumor testing returned MSI-H by PCR; extended RAS testing reported KRAS and NRAS wild-type (no actionable RAS mutation). Given MSI-H, the patient was started on pembrolizumab with the 12-week CT showing no significant change in peritoneal implants (stable disease).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma, pathologic stage pT3N1 (stage III) after low anterior resection. Molecular testing returned KRAS G12D mutant, BRAF wild-type; microsatellite status reported as microsatellite stable (MSS). He completed 12 cycles of adjuvant FOLFOX. Surveillance CT and CEA at 12 months show no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "surgery (low anterior resection) and adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "41-year-old woman with newly diagnosed high-grade serous ovarian carcinoma. At exploratory laparotomy she was found to have bulky peritoneal carcinomatosis and underwent optimal cytoreductive surgery. Germline testing returned positive for a BRCA1 pathogenic variant (c.68_69delAG). Baseline CA-125 was markedly elevated. She completed six cycles of carboplatin and paclitaxel and was transitioned to maintenance olaparib. Follow-up CT shows resolution of peritoneal implants, consistent with a complete clinical response. Stage IIIC at diagnosis.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation (germline)", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple liver lesions. Molecular testing returned BRAF V600E and concurrent MSI-H; TMB reported as high (22 muts/Mb). He was started on FOLFOX plus bevacizumab with modest radiographic control and subsequently transitioned to pembrolizumab. Latest CT shows no new lesions but overall tumor measurements consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (22 muts/Mb)", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma, clinical stage IV at presentation. Molecular testing positive for BRAF V600E. He was started on pembrolizumab and had an initial mixed response with shrinkage of several nodal sites but new hepatic lesions; PD-L1 reported at 60% TPS. After progression in the liver and lungs he was switched to dabrafenib plus trametinib with partial response in pulmonary metastases but persistent hepatic progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "initial mixed response then progression; partial response in lung with hepatic progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with metastatic invasive ductal carcinoma of the breast, ER positive, PR positive and HER2 amplification on IHC/FISH. PIK3CA E545K identified on next-generation sequencing of the primary. After identification of bone metastases she was started on trastuzumab, pertuzumab and docetaxel; imaging over 6 months has shown stable osseous disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging CT and MRI show stage IV disease with a solitary enhancing lesion in the left frontal lobe consistent with metastasis. NGS of the tumor demonstrated EGFR L858R; no T790M detected. PD-L1 TPS 5%. Patient was started on osimertinib 80 mg daily and first follow-up imaging at 8 weeks demonstrates a marked decrease in size of the primary and intracranial lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed metastatic prostate adenocarcinoma. PSA at diagnosis was 112 ng/mL. Bone scan revealed multiple sclerotic lesions in the spine and pelvis. He was started on androgen deprivation therapy with leuprolide and received docetaxel x6 cycles. Follow-up PSA has fallen and disease is currently described as stable. Genomic testing not performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 112 ng/mL", "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 62-year-old male with metastatic lung adenocarcinoma presented with headaches and new left-sided weakness. Diagnosis: stage IV lung adenocarcinoma with known EGFR L858R and acquired T790M reported on plasma NGS. PD-L1 TPS 15% and tumor mutational burden reported as low. MRI brain positive for multiple metastases; bone scan shows osseous disease. Patient was started on osimertinib in combination with bevacizumab as first-line targeted therapy due to rapid CNS progression. CT at 8 weeks shows decreased size of intracranial lesions and improvement in thoracic nodules \u2014 partial response documented.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, T790M", "biomarker": "PD-L1 15%, TMB-low", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with metastatic lung adenocarcinoma presented to clinic for follow-up. Initial diagnostic biopsy confirmed lung adenocarcinoma with EGFR L858R mutation. PD-L1 by IHC reported 10%. Staging CT and brain MRI showed multiple supratentorial metastases and osseous lesions. Patient was started on osimertinib as first-line targeted therapy and experienced a radiographic partial response at 8 weeks with shrinkage of both brain and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female presented with newly diagnosed metastatic lung adenocarcinoma. Molecular testing from biopsy detected EGFR L858R mutation. PD-L1 TPS reported at 10%. Baseline brain MRI demonstrated two enhancing lesions consistent with metastases. She was started on osimertinib 80 mg daily. Interval CT chest/abdomen at 8 weeks showed decrease in the size of the primary and nodal disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 44-year-old male underwent excision of a 0.6 mm pigmented lesion on the right forearm. Histology: superficial spreading melanoma, Breslow 0.6 mm, no ulceration, sentinel node negative. Pathologic stage I (T1a). Wide local excision performed; no adjuvant therapy recommended. Patient follow-up planned with dermatology every 6 months.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-sensitive prostate adenocarcinoma progressed to metastatic disease with new bone lesions on bone scan. Germline and somatic testing revealed a deleterious BRCA2 truncating mutation and genomic report states HRD-positive. He was started on androgen deprivation therapy with monthly leuprolide and, after discussion of targeted options, was initiated on olaparib as combination systemic therapy. PSA has stabilized and scans show no new lesions (stable disease).", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "HRD-positive", "treatment": "androgen deprivation therapy (leuprolide) + olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinically staged IIIB with fixed axillary nodes. Tumor was ER-negative, PR-negative; HER2 amplified by FISH. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide (AC) \u2192 paclitaxel with concurrent trastuzumab and pertuzumab. Patient underwent modified radical mastectomy with axillary dissection; pathology showed no residual invasive carcinoma (pathologic complete response). No somatic gene mutation testing was reported in the chart.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant AC, paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with advanced pancreatic ductal adenocarcinoma presenting with weight loss and obstructive jaundice. Imaging and biopsy consistent with stage IV disease with multiple hepatic metastases. Extended molecular panel returned no actionable mutations. Labs show CA19-9 markedly elevated; PD-L1 expression <1% on tumor cells. He received combination systemically with weekly nab\u2011paclitaxel plus gemcitabine and palliative hypofractionated radiation to a painful right hepatic lesion. Despite therapy, interval scans demonstrate progression in the liver.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated; PD-L1 <1%", "treatment": "nab-paclitaxel and gemcitabine; palliative radiation", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female presented with progressive cough and headaches. Imaging revealed a right upper lobe mass with multiple brain and bone lesions. Core biopsy: lung adenocarcinoma. Staging workup consistent with stage IV disease. Molecular testing identified EGFR exon 19 deletion (E746_A750del). PD-L1 tumor proportion score reported as 5%. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant brain metastasis. Three-month restaging CT/MRI demonstrates a radiologic partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion (E746_A750del)", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma presented with multiple liver and lung lesions. Molecular testing identified a BRAF V600E mutation. He was started on dabrafenib plus trametinib and had an initial partial response, but at 5 months developed radiographic progression with new brain metastases. PD-L1 testing was not performed prior to therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "liver; lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with biopsy-proven pancreatic ductal adenocarcinoma presenting with multiple liver lesions and omental nodularity on CT. She was started on first-line FOLFIRINOX and had stable disease after 3 cycles. At 6 months there was radiographic progression and she was switched to gemcitabine plus nab-paclitaxel. Germline testing was negative and somatic NGS did not reveal actionable alterations. Tumor marker CA 19-9 declined from 1200 U/mL at baseline to 400 U/mL on second-line therapy, but CT shows enlarging hepatic lesions consistent with progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 elevated (decreasing from 1200 to 400 U/mL)", "treatment": "FOLFIRINOX (first-line); gemcitabine + nab-paclitaxel (second-line)", "response": "progressive disease", "metastasis_site": "liver, peritoneum (omentum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma presented with progressive cough and headaches. Staging CT chest and brain MRI demonstrate multiple bilateral pulmonary nodules and a 1.5 cm enhancing cerebellar lesion. Biopsy confirmed lung adenocarcinoma, clinical stage IV. Molecular testing reported an EGFR exon 19 deletion. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily as first-line targeted therapy and had symptomatic improvement with a partial response on repeat imaging at 8 weeks; brain lesion decreased in size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed metastatic colorectal adenocarcinoma, stage IV, presenting with right upper quadrant pain. CT shows multiple liver lesions. Tumor genomics: BRAF V600E mutation; tumor was MSI-H with high tumor mutational burden (TMB-high). He initially received FOLFOXIRI plus bevacizumab but had radiographic progression after 4 months. He was switched to encorafenib plus cetuximab with interval partial response in hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOXIRI plus bevacizumab followed by encorafenib plus cetuximab", "response": "progression on FOLFOXIRI/bevacizumab, partial response to encorafenib plus cetuximab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 48-year-old female with locally advanced right breast invasive ductal carcinoma, clinical stage IIIC. Core biopsy: HER2 amplification by FISH, ER positive, PR positive. NGS panel detected PIK3CA H1047R. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) x6 cycles followed by right mastectomy. Surgical pathology shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 71-year-old man underwent right hemicolectomy for adenocarcinoma of the ascending colon. Final path staging pT3 N1 (Stage III). Tumor testing: KRAS G12D positive; mismatch repair proteins intact (microsatellite stable). Recommended adjuvant FOLFOX x 12. Clinic note documents uncomplicated recovery; adjuvant therapy initiated. No imaging evidence of distant disease pre-op.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MMR intact)", "treatment": "FOLFOX (adjuvant)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 55-year-old F with metastatic lung adenocarcinoma diagnosed 2019. Tumor profiling returned EGFR L858R positive; T790M negative. Baseline PD-L1 was 10% (22C3). She was started on osimertinib 80 mg daily in Jan 2024. Interval CT and brain MRI at 3 months demonstrate decreased size of the primary right lower lobe mass and reduced intracranial metastases. Continues on osimertinib with clinical improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma found to have KRAS G12D on molecular testing and MSI-stable status. CT abdomen shows multiple segment IV liver metastases. He was started on FOLFOX plus bevacizumab. After three cycles CEA rose and interval imaging demonstrated increase in size and number of hepatic lesions consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: 48-year-old woman with locally advanced invasive ductal breast carcinoma, HER2-positive, ER and PR positive on core biopsy. PIK3CA H1047R mutation was reported on the tumor panel. Clinical stage: T3N1 (stage IIIA). She received neoadjuvant therapy with trastuzumab, pertuzumab and docetaxel for six cycles prior to surgery. Imaging documented partial clinical response and reduction in tumor size; sentinel node was still suspicious on ultrasound.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "III A", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma, biopsy positive for BRAF V600E. He complains of progressive back pain; PET/CT reveals multiple osseous metastases in the thoracic spine and pelvis. He was initiated on dabrafenib and trametinib combination therapy and repeat scans after 8 weeks show decreased FDG uptake in bone lesions consistent with a partial response. PD-L1 IHC was negative (<1%). Stage IV.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 negative", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 52-year-old woman with hormone receptor\u2013positive, HER2-amplified metastatic breast cancer (Stage IV) with multiple liver metastases. Tumor NGS demonstrated PIK3CA E545K and TP53 R248Q. IHC: ER 80%, PR 0%, HER2 IHC 3+ with FISH-confirmed amplification. She was initiated on trastuzumab plus pertuzumab with docetaxel; after partial response the regimen was modified and alpelisib was later added for PIK3CA-directed therapy.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K; TP53 R248Q", "biomarker": "HER2 amplification; ER positive (80%); PR negative (0%)", "treatment": "trastuzumab + pertuzumab + docetaxel; later alpelisib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative biopsy: invasive ductal carcinoma, grade 3. ER positive, PR positive, HER2 amplified by FISH. PIK3CA H1047R mutation detected on panel. Patient received neoadjuvant paclitaxel and carboplatin with trastuzumab and pertuzumab for 4 cycles followed by lumpectomy and sentinel node biopsy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and carboplatin with trastuzumab and pertuzumab, surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic lung adenocarcinoma diagnosed 2019. Biopsy confirmed EGFR L858R mutation; subsequent NGS also showed MET amplification. PD-L1 by IHC 30%. He was started on osimertinib with an initial partial response, but progressed at 10 months with new liver and bone lesions. On progression he was enrolled on a combination protocol and currently receiving osimertinib plus savolitinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "MET amplification; PD-L1 30%", "treatment": "osimertinib; osimertinib + savolitinib", "response": "initial partial response, then progression", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-treatment note: 48-year-old woman with a large left breast mass. Core needle biopsy: invasive ductal carcinoma, ER-negative, PR-negative. HER2 amplification confirmed by ISH; diagnostic NGS detected PIK3CA H1047R. Clinical stage recorded as IIIB (T4bN2). She completed 6 cycles of neoadjuvant docetaxel, carboplatin and trastuzumab, proceeded to mastectomy. Surgical pathology reported a pathologic complete response. No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (HER2-amplified)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old woman with metastatic invasive ductal carcinoma of the breast. Core biopsy: HER2 IHC 3+, ER positive, PR negative. Next-generation sequencing identified PIK3CA H1047R. PET/CT showed multiple hepatic lesions consistent with progression \u2014 stage IV. She received first-line trastuzumab and pertuzumab with docetaxel; after six cycles therapy was continued on dual HER2 blockade alone. Follow-up CT shows stable size of liver lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER positive, PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (then trastuzumab + pertuzumab maintenance)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER-negative, PR-negative, HER2 IHC 3+ with HER2 amplification by FISH. Clinical stage cT2N0M0 (Stage IIA). She underwent lumpectomy with sentinel lymph node biopsy; margins negative. Planned adjuvant paclitaxel for 12 weeks followed by one year of trastuzumab. No genomic NGS was performed on the specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "lumpectomy with sentinel lymph node biopsy; planned adjuvant paclitaxel and trastuzumab", "response": "surgical margins negative / no residual disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient had right hemicolectomy for colon adenocarcinoma, path pT3N1 (stage III). Molecular testing: KRAS G12D positive and MSI-H on immunohistochemistry. Completed 6 months of adjuvant FOLFOX with good tolerance and is now on surveillance with CT scans that show no recurrent disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "surgery; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with high-risk prostate adenocarcinoma (clinical T3bN0M0, stage III). No molecular testing was performed. He was treated with external beam radiation therapy combined with androgen deprivation (leuprolide). PSA declined from 24 to 2.6 ng/mL but remained detectable; patient is on continued surveillance.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "partial biochemical response (PSA decline with persistent detectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly resected stage III colon adenocarcinoma. Tumor profiling identified KRAS G12D mutation and MSI-H by PCR. He completed adjuvant FOLFOX and is currently without radiographic evidence of disease on surveillance CT. No liver or lung metastases were seen at diagnosis.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with cutaneous melanoma of the left forearm, stage III with positive sentinel lymph node (stage IIIA). Molecular testing returned BRAF V600E. Started adjuvant dabrafenib and trametinib but therapy was discontinued for transaminitis; subsequently started nivolumab. Restaging PET/CT after 4 months shows persistent FDG-avid nodes but no distant spread \u2014 disease assessed as stable.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (stopped); nivolumab", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old F with newly diagnosed metastatic lung adenocarcinoma. Molecular testing demonstrated EGFR L858R sensitive mutation. Staging workup consistent with stage IV disease with intracranial and osseous involvement (MRI brain: multiple enhancing lesions; PET/CT: uptake in T7 and pelvis). Patient started osimertinib 80 mg PO daily. Interval imaging at 8 weeks shows decrease in size of brain lesions and reduction in metabolic activity in bone lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman found to have a 2.2 cm left breast invasive ductal carcinoma. Tumor was ER+/PR+, HER2 negative by IHC/FISH. Sentinel lymph node negative; pathologic staging pT2N0 (Stage IIA). She underwent breast-conserving surgery followed by adjuvant doxorubicin and cyclophosphamide then paclitaxel (AC-T) and has been started on tamoxifen. Surveillance mammogram and clinical exam at 18 months show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; adjuvant doxorubicin and cyclophosphamide followed by paclitaxel; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "37-year-old female with metastatic cutaneous melanoma, BRAF V600E positive. Initial management was pembrolizumab monotherapy, but after three cycles she developed new symptomatic brain metastases. Therapy was changed to dabrafenib plus trametinib; extracranial lesions regressed while a solitary cerebellar metastasis progressed and was treated with stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (initial), then dabrafenib and trametinib; stereotactic radiosurgery to cerebellar lesion", "response": "mixed response (extracranial regression, intracranial progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "40-year-old man with metastatic cutaneous melanoma found to harbor a BRAF V600E mutation. He presented with a symptomatic brain metastasis. Treated with dabrafenib plus trametinib; there was initial shrinkage of lesions but restaging at four months demonstrated progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progression after initial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for a colon mass. Final pathology staged as stage III colon adenocarcinoma with 4 of 18 nodes positive. Tumor testing returned MSI-H and a concurrent BRAF V600E mutation on tumor NGS. He completed 6 months of adjuvant FOLFOX without major complications. Surveillance CT and CEA at 12 months show no evidence of metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX (6 months)", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with a 3.2 mm ulcerated cutaneous melanoma, clinical stage II (T3b). Wide local excision and sentinel lymph node biopsy were performed; nodes negative. Molecular testing was deferred and not available in the chart. Patient is being followed with routine skin checks and currently has no clinical or radiographic evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision and sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with high-grade serous ovarian carcinoma status post primary debulking. She completed 6 cycles of adjuvant carboplatin and paclitaxel with good tolerance. BRCA testing was not performed and no molecular markers were reported in the chart. CA-125 normalized after chemotherapy and clinical exam is without evidence of disease; she is being observed off therapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel", "response": "clinical complete response (on surveillance)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with obstructive symptoms and was found to have sigmoid colon mass. CT chest showed multiple bilateral pulmonary nodules consistent with metastatic disease; pathologic stage IV. Molecular testing on the primary tumor detected KRAS G12D. The tumor was also reported as MSI-high on PCR testing. He was started on FOLFOX with bevacizumab, but interval imaging after three months documented growth of several lung nodules consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-high", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative core biopsy of a left breast mass: invasive ductal carcinoma, ER positive, PR positive. HER2 amplified by FISH. Clinical stage documented as IIIB. NGS panel showed a PIK3CA H1047R hotspot mutation. She received neoadjuvant docetaxel with trastuzumab and pertuzumab (TCHP) for six cycles with excellent tumor shrinkage and underwent mastectomy. Final pathology demonstrated no residual invasive carcinoma consistent with a pathologic complete response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with right upper quadrant pain; CT shows multiple hepatic lesions. Primary tumor genotyping identified KRAS G12D; microsatellite testing MSI-stable. He was started on FOLFIRI with bevacizumab. Interval imaging after three cycles demonstrated no new lesions and slight decrease in size of dominant liver metastasis consistent with stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Imaging showed multiple pulmonary nodules and several enhancing brain lesions. Biopsy confirmed adenocarcinoma; molecular testing detected EGFR L858R and acquired T790M. PD-L1 was 10%. He was started on osimertinib and had a partial response on first follow-up CT with shrinkage of brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R and T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old man with a 0.9 mm non-ulcerated cutaneous melanoma of the upper back, sentinel node negative \u2192 consistent with stage I (IA). Tumor testing reported BRAF V600E. Underwent wide local excision with clear margins; no adjuvant therapy recommended and patient remains under surveillance with no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC. CA-125 was markedly elevated at presentation. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with normalization of CA-125 and no radiographic evidence of disease. Maintenance niraparib was initiated. BRCA testing is pending.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated at diagnosis (normalized after treatment)", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance niraparib", "response": "complete clinical response / no evidence of disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Tumor board: 62M with sigmoid colon adenocarcinoma and multiple hepatic metastases. Molecular profiling shows KRAS G12D mutation. MSI testing returned MSI-H. Patient treated with FOLFOX plus bevacizumab as first-line therapy; surveillance CT after 6 months demonstrates new hepatic lesions and enlarging primary \u2014 assessment: progression of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma harboring BRAF V600E. Presents with multiple pulmonary nodules and a new adrenal metastasis on staging CT consistent with stage IV disease. He was started on dabrafenib plus trametinib; interval imaging at 4 months demonstrates enlarging pulmonary nodules and new adrenal lesion consistent with progression. PD-L1 evaluation was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "lung, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man with recurrent cutaneous melanoma originally resected from the right forearm. Surveillance scans now show multiple pulmonary nodules and a solitary 1.5 cm cerebellar metastasis. Comprehensive NGS identifies an NRAS Q61R driver. He received combination immunotherapy with ipilimumab and nivolumab; chest CT demonstrates shrinkage of several lung nodules but MRI shows a new brain lesion\u2014overall assessment described as mixed response. PD-L1 testing was not performed / not reported.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic pancreatic ductal adenocarcinoma, stage IV with peritoneal carcinomatosis. Tumor profiling did not identify any actionable mutations and PD-L1 was not reported. She received 4 cycles of FOLFIRINOX with interval CT showing stable disease by RECIST; plan is to continue chemotherapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent wide local excision for a pigmented lesion on the left forearm. Final pathology: cutaneous melanoma, stage I (T1b), sentinel lymph node negative. Reflex panel detected BRAF V600E mutation. No adjuvant systemic therapy was recommended and patient remains under dermatologic surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with prostate adenocarcinoma diagnosed on screening biopsy, Gleason 3+3=6, clinical stage T1c (stage I). PSA 6.2 ng/mL. No symptoms and no evidence of metastatic disease on workup. Multidisciplinary team and patient opted for active surveillance; PSA has remained stable over 18 months.", "output": {"cancer_type": "prostate cancer (prostate adenocarcinoma)", "stage": "I (T1c)", "gene_mutation": null, "biomarker": null, "treatment": "active surveillance", "response": "stable disease / PSA stable", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with metastatic cutaneous melanoma. Tumor sequencing positive for BRAF V600E. Patient was initiated on dabrafenib plus trametinib. Within three months he developed radiographic progression with new hepatic lesions and leptomeningeal involvement. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver, leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 68-year-old male with clear cell renal cell carcinoma, status post nephrectomy, now with new right adrenal mass consistent with metastatic recurrence. PD-L1 was 1% on archival tissue. He was started on nivolumab in combination with cabozantinib; follow-up CT at 10 weeks demonstrates no significant change in size of the adrenal lesion (stable disease). VHL mutation testing pending but not reported in this note.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 1%", "treatment": "nivolumab with cabozantinib", "response": "stable disease", "metastasis_site": "adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old male underwent right hemicolectomy for colon adenocarcinoma. Pathology: T3N1, stage III. Molecular testing shows KRAS G12C mutation. He completed adjuvant FOLFOX for six cycles. Surveillance CT and CEA at 12 months show no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "right hemicolectomy; adjuvant FOLFOX x6", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor testing demonstrated microsatellite instability-high (MSI-H). Extended RAS and BRAF testing were negative. After progression on first-line FOLFOX, the patient was started on pembrolizumab with interval radiologic reduction of hepatic tumors.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab (after FOLFOX)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced, HER2-positive invasive ductal carcinoma of the breast. ER positive, PR negative on IHC. FoundationOne testing identified a PIK3CA H1047R mutation in addition to HER2 amplification by FISH. Staging imaging demonstrated hepatic metastases. She received combination therapy with trastuzumab, pertuzumab and docetaxel (T + P + D) as first-line systemic therapy with partial radiologic response prior to hepatic resection.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dear Colleague \u2014 The patient is a 45-year-old man with metastatic cutaneous melanoma. BRAF V600E mutation was detected on prior testing. He received combination targeted therapy with dabrafenib and trametinib for 6 months; initially had tumor shrinkage but recent PET/CT shows new lytic lesions in the left iliac bone and progressive uptake elsewhere, indicating progression on targeted therapy. PD-L1 reported as 1%.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman found to have a 3.2 cm invasive ductal carcinoma of the right breast, clinical stage IIB. ER and PR were strongly positive, HER2 amplified by FISH. Tumor NGS identified a PIK3CA H1047R mutation. She was treated with neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by lumpectomy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant); lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with stage IV invasive ductal carcinoma of the breast with liver metastases. Tumor is HER2-positive by IHC and FISH (HER2 amplification), ER/PR negative. Next-generation sequencing identified a PIK3CA H1047R mutation. She was started on first-line docetaxel with trastuzumab and pertuzumab. Interim CT after 3 cycles shows a 40% reduction in hepatic lesions consistent with a partial response; tolerating therapy well.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with cutaneous melanoma of the right thigh. Sentinel lymph node biopsy was positive and clinical stage was IIIB. Tumor NGS showed a BRAF V600E alteration. He underwent wide local excision and completion lymphadenectomy followed by adjuvant dabrafenib plus trametinib. Follow-up imaging shows no radiographic evidence of distant disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III B", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, lymphadenectomy, adjuvant dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated multiple cerebral lesions and lytic lesions in the spine consistent with metastatic disease. Molecular testing from the primary tumor identified EGFR L858R. PD-L1 by IHC was 1%. Assigned stage IV. Patient was started on osimertinib 80 mg daily; follow-up CT after 8 weeks shows decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 67-year-old male underwent right hemicolectomy for colon adenocarcinoma. Final path indicates stage IIIC (pT3N2). Molecular panel: BRAF V600E positive; MSI testing returned MSI-H. Initially treated with adjuvant FOLFOX (5-FU, leucovorin, oxaliplatin) but developed new pelvic nodal enlargement at 9 months and was transitioned to pembrolizumab. Short-interval scans show stable disease on immunotherapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX; pembrolizumab", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with liver-dominant disease. Tumor profiling identified BRAF V600E mutation and MSI-H; TMB reported as high. He received first-line FOLFOX plus bevacizumab and was later transitioned to pembrolizumab. Most recent scans demonstrate stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male underwent subtotal resection of a right temporal mass; pathology confirmed glioblastoma (WHO grade IV). He completed concurrent radiation with temozolomide followed by adjuvant temozolomide. MGMT promoter methylation was reported as methylated; comprehensive NGS was not performed. Follow-up MRI at 3 months showed stable postsurgical change without clear recurrence.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "surgery, radiation with concurrent temozolomide, adjuvant temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma after CT-guided biopsy. NGS returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Brain MRI demonstrated two small parenchymal metastases and PET/CT showed osseous involvement. She was started on osimertinib 80 mg daily as first-line targeted therapy with symptomatic improvement and interval decrease in size of CNS and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary for a 58-year-old woman with high-grade serous ovarian carcinoma who underwent optimal primary debulking. Surgical findings included extensive peritoneal carcinomatosis. CA-125 was markedly elevated pre-operatively and has been falling post-op. She completed adjuvant carboplatin and paclitaxel with radiologic reduction of peritoneal disease and decreasing tumor marker levels.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "primary debulking surgery followed by carboplatin and paclitaxel", "response": "partial response with falling CA-125", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed lung adenocarcinoma, stage IV with brain and bone metastases. Comprehensive NGS returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on first-line osimertinib 80 mg daily with symptomatic improvement. Interim imaging after 8 weeks demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Treatment summary: 69-year-old male diagnosed with high-risk localized prostate adenocarcinoma, clinical stage III (T3aN0M0) based on MRI showing extracapsular extension. He completed a course of definitive external beam radiation therapy with concurrent androgen deprivation therapy (leuprolide). PSA declined from 12.4 ng/mL at diagnosis to 0.8 ng/mL at 6 months. No molecular sequencing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "PSA decline / stable response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a 2.8 cm invasive ductal carcinoma, triple-negative on core biopsy (ER/PR negative, HER2 IHC 0). Germline testing identified a pathogenic BRCA1 variant. Clinical staging prior to therapy was T2N1 (clinical stage IIB). She received neoadjuvant dose-dense doxorubicin/cyclophosphamide x4 followed by weekly paclitaxel x12, then breast-conserving surgery. Final surgical pathology revealed no residual invasive carcinoma (ypT0), consistent with pathologic complete response.", "output": {"cancer_type": "triple-negative breast cancer", "stage": "IIB", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "ER negative; PR negative; HER2 negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel; breast-conserving surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: Stage IIIB superficial spreading melanoma of the right calf, sentinel node positive. NGS demonstrated BRAF V600E. Patient completed wide local excision and was started on adjuvant dabrafenib plus trametinib for one year. On surveillance, a chest CT found a 1.5 cm pulmonary nodule and therapy was changed to systemic nivolumab; current disease remains radiographically stable.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib; trametinib; nivolumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult: Patient with cutaneous melanoma, sentinel node positive, initial stage IIIC. Molecular testing identified BRAF V600E. After nodal recurrence and development of several pulmonary nodules he was started on dabrafenib + trametinib. Despite initial control the patient developed enlarging lung metastases and clinical progression after approximately 9 months on therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung; lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: High-grade serous ovarian carcinoma, FIGO stage IIIC, diagnosed 2021. Germline testing positive for BRCA2 mutation. Patient underwent optimal cytoreductive surgery followed by 6 cycles of carboplatin and paclitaxel with normalization of CA-125. Started maintenance olaparib; remains progression-free at 12-month surveillance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA-125 (elevated at diagnosis, normalized post-treatment)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "progression-free at 12 months", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Older male with newly progressive prostate adenocarcinoma, Gleason score 4+5=9, extensive sclerotic bone lesions on isotope bone scan. Patient was started on androgen deprivation therapy with leuprolide depot and concurrent abiraterone plus low-dose prednisone. PSA has declined from baseline but bone disease remains on imaging without interval new lesions. Somatic NGS reported no actionable mutations identified.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide depot; abiraterone + prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma with multiple lesions in the liver. Molecular profile: KRAS G12D, BRAF wild-type, MSI-stable. Treated with FOLFOX plus bevacizumab as first-line systemic therapy; latest restaging scans show stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old presenting with right upper quadrant pain. Biopsy confirmed colorectal adenocarcinoma with multiple hypodense liver lesions consistent with metastases. Molecular panel: KRAS G12D mutation detected; tumor is MSI-H. Clinical stage IV. Started on FOLFOX plus bevacizumab; interval CT after 8 weeks shows stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old man presented with a pigmented lesion on the right forearm; wide local excision and sentinel lymph node biopsy confirmed cutaneous melanoma with positive sentinel node. Tumor sequencing identified a BRAF V600E mutation. PD-L1 testing was not performed. Patient received adjuvant pembrolizumab but developed pulmonary nodules within six months consistent with metastatic spread. Started on dabrafenib plus trametinib with short-lived stable disease and subsequent progression of lung metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "adjuvant pembrolizumab; then dabrafenib + trametinib", "response": "disease progression after brief stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with resected sigmoid colon adenocarcinoma, pathologic stage III (pT3N1). Molecular testing on the primary tumor detected KRAS G12D. Mismatch repair IHC was intact (MSS). Patient completed 12 cycles of adjuvant FOLFOX without complications and remains on surveillance with CT chest/abdomen/pelvis showing no recurrent disease.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (mismatch repair proficient)", "treatment": "surgical resection; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old male with a pigmented lesion on the left calf; wide local excision and sentinel node biopsy revealed melanoma with one positive node, pathologic stage IIIA. Tumor sequencing identified BRAF V600E. Patient underwent completion lymphadenectomy and was started on adjuvant dabrafenib and trametinib for 12 months. Follow-up at 18 months shows no clinical or radiographic recurrence.", "output": {"cancer_type": "melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; lymphadenectomy; dabrafenib + trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, stage IV, found to harbor BRAF V600E mutation on tumor sequencing. Treated with dabrafenib and trametinib combination therapy; had an initial clinical and radiographic improvement but developed progression with new pulmonary nodules at 8 months and was switched to second-line immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progression after initial response", "metastasis_site": "lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old F with a 2.1 cm invasive ductal carcinoma of the right breast. Pathology: ER positive, PR positive, HER2 amplified by FISH. PIK3CA H1047R mutation reported on NGS. Clinical stage IIA (T2N0M0). Patient underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and 1 year of trastuzumab. Last follow-up imaging and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel; trastuzumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, stage IV, BRAF V600E positive on PCR. PD-L1 approximately 5% and tumor mutational burden reported as high. Initial targeted combination with dabrafenib + trametinib produced partial reduction of extracranial disease but CNS lesions progressed; subsequently started on combination immunotherapy with nivolumab plus ipilimumab. Overall response described as mixed response with extracranial shrinkage but new small brain metastases.", "output": {"cancer_type": "melanoma (cutaneous, metastatic)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 ~5%; TMB-high", "treatment": "dabrafenib + trametinib followed by nivolumab + ipilimumab", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man presented with a symptomatic right frontal glioblastoma multiforme. He underwent craniotomy with subtotal debulking. MGMT promoter methylation was positive. Treated with concurrent radiotherapy and temozolomide per Stupp protocol, but MRI at three months shows tumor progression. No TNM stage assigned; molecular panel did not reveal actionable point mutations.", "output": {"cancer_type": "glioblastoma multiforme", "stage": null, "gene_mutation": null, "biomarker": "MGMT promoter methylation positive", "treatment": "radiotherapy and temozolomide (concurrent)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 43-year-old with locally advanced left breast cancer. Tumor is ER negative, PR negative; HER2 IHC 3+ and FISH confirms HER2 amplification. Clinical stage IIIB with skin tethering. Neoadjuvant therapy initiated with weekly paclitaxel followed by trastuzumab. After 12 weeks patient has excellent clinical response with no palpable residual mass. No targeted genomic panel reported in chart.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 48-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Tumor profiling: HER2 amplification, PIK3CA H1047R; ER/PR negative. She received neoadjuvant docetaxel with trastuzumab and pertuzumab followed by mastectomy. Surgical pathology showed pathologic complete response (pCR). No distant metastases on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel; trastuzumab; pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with high-grade serous ovarian carcinoma underwent primary debulking; residual peritoneal implants were left at surgery. Pre-op CA-125 was markedly elevated. Germline BRCA testing was not performed prior to adjuvant treatment and tumor NGS report is pending. She completed adjuvant carboplatin and paclitaxel. Follow-up CT shows persistent peritoneal disease without new distant organ lesions; response categorized as stable disease.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; primary debulking surgery", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with sigmoid colon adenocarcinoma underwent colectomy. Pathology T3N2M0 (stage III) with 5/18 positive nodes. Tumor sequencing identified BRAF V600E mutation and high microsatellite instability (MSI-H). He completed adjuvant FOLFOX and surveillance CTs show no evidence of distant metastasis; currently disease-free after 12 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "colectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Staged clinically as IIA (T2 N0 M0). NGS panel detected PIK3CA H1047R. She underwent lumpectomy with sentinel lymph node biopsy followed by adjuvant paclitaxel for 12 weeks and trastuzumab; completed radiation therapy. Surveillance imaging and exam show no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "lumpectomy, paclitaxel, trastuzumab, radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 71-year-old man with metastatic castration-resistant prostate cancer (Gleason 9) with bone-predominant disease. Germline testing detected a pathogenic BRCA2 alteration. Prior therapy included ADT and abiraterone; he was transitioned to olaparib for maintenance. Recent scans show stable osseous lesions and PSA decline from 180 to 55 ng/mL \u2014 ongoing radiographic stable disease.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "olaparib (after ADT and abiraterone)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma of the left forearm, 1.0 mm Breslow, ulceration absent. Wide local excision performed with negative margins; sentinel node biopsy negative. Molecular panel detected BRAF V600E. Patient was observed without adjuvant systemic therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy (observation afterwards)", "response": "complete response / no residual disease after excision", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (concise): Metastatic cutaneous melanoma, BRAF V600E positive. Initial therapy with pembrolizumab led to clinical progression in the lungs and brain after 4 cycles; PD-L1 testing showed 5% TPS. Patient was switched to targeted therapy \u2014 dabrafenib plus trametinib \u2014 and most recent MRI and CT demonstrate stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab then dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old female with metastatic lung adenocarcinoma presenting with headaches and progressive back pain. Biopsy of the right upper lobe confirmed adenocarcinoma; molecular testing detected EGFR L858R mutation. PD-L1 by IHC was 10%. MRI brain demonstrated multiple small enhancing lesions and bone scan showed metastatic uptake in the thoracic spine. She was started on osimertinib 80 mg daily and received palliative radiation to T8 for pain control. Restaging CT at 8 weeks showed shrinkage of the primary lung lesion and partial resolution of brain metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; palliative radiation to T8", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female with newly diagnosed lung adenocarcinoma. Molecular testing returned EGFR L858R and PD-L1 10%. MRI brain showed three enhancing lesions consistent with metastases. Clinical stage IV disease. Osimertinib 80 mg daily was started and repeat imaging at 8 weeks demonstrates decrease in size of intracranial lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with locally advanced invasive ductal carcinoma of the left breast. Tumor is ER-/PR-; HER2 3+ by IHC and FISH confirms HER2 amplification. Clinical exam and imaging consistent with stage IIIB disease with fixed axillary nodes. She received neoadjuvant carboplatin and docetaxel with trastuzumab and proceeded to mastectomy; surgical pathology shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-/PR-", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Molecular testing returned EGFR L858R sensitizing mutation; PD-L1 tumor proportion score 5%. Staging workup consistent with stage IV disease with multiple brain mets and focal lytic lesions in the femur. Patient started osimertinib 80 mg daily as first-line targeted therapy. Interval MRI after 8 weeks shows decrease in size of brain lesions and reduction in pulmonary nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast invasive ductal carcinoma, HER2-amplified on FISH (ratio 5.2), ER/PR negative. Clinically T4bN2 \u2014 locally advanced disease with fixed axillary adenopathy; clinical stage IIIC. No distant disease on staging CT. Neoadjuvant plan: weekly paclitaxel with concurrent trastuzumab followed by surgical resection.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": null, "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral letter: 55-year-old man with metastatic melanoma. PET demonstrated osseous disease in the pelvis and right femur. Molecular testing positive for BRAF V600E; PD-L1 not reported. He was started on dabrafenib and trametinib; after 2 months there is radiographic progression with new bone lesions and rising LDH.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 65-year-old male with newly diagnosed lung adenocarcinoma. Plasma NGS identified EGFR L858R. PD-L1 tumor proportion score 15%. Staging PET/CT demonstrates widespread disease with multiple brain metastases and lytic bone lesions consistent with stage IV disease. Patient started osimertinib 80 mg daily. Follow-up CT and brain MRI after 8 weeks show decrease in target lesions consistent with a partial response and symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed last year. Molecular testing returned EGFR L858R mutation and PD-L1 20%. Staging at diagnosis was IV with brain and bone lesions on MRI and PET. He was started on osimertinib and experienced symptomatic improvement; first restaging CT showed decrease in size of pulmonary and intracranial lesions. Current assessment: partial response on targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old female with locally advanced, HER2-positive invasive ductal carcinoma of the breast (cT3N2) treated neoadjuvantly. Core biopsy showed HER2 amplification by FISH and ER+/PR+ by IHC; PIK3CA E545K noted on hotspot sequencing. She received neoadjuvant trastuzumab and pertuzumab combined with docetaxel for 6 cycles followed by mastectomy. Surgical pathology revealed a pathologic complete response (pCR). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab and pertuzumab with docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male status post emergent right hemicolectomy for obstructing ascending colon tumor. Pathology: moderately differentiated adenocarcinoma, pT3N1 (stage III). Molecular testing: KRAS G12D; MSI-stable. He completed adjuvant FOLFOX x6 cycles. Surveillance CT scans and CEA monitoring show no radiographic evidence of disease. Nodes were involved at presentation (regional lymph nodes positive on pathology).", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma (stage IV) now with multiple hepatic lesions. Tumor profiling: BRAF V600E mutation, MSI-H and TMB-high. First-line therapy was FOLFOX plus bevacizumab with radiographic progression at 5 months; patient was started on pembrolizumab given MSI-H/TMB-high status and has achieved durable stable disease for 9 months to date.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with multiple pulmonary and hepatic lesions. Biopsy confirmed metastatic melanoma; molecular testing showed BRAF V600E. Patient received pembrolizumab as first line but imaging after 12 weeks documented interval progression. He was switched to targeted therapy with dabrafenib plus trametinib with subsequent shrinkage of liver and lung nodules on follow-up scans. PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab then dabrafenib + trametinib", "response": "progression on pembrolizumab; partial response on dabrafenib + trametinib", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC. Somatic testing identified a BRCA2 mutation and HRD-positive status. She received six cycles of carboplatin and paclitaxel with partial radiographic response and then was placed on olaparib maintenance. Most recent follow-up shows stable CA-125 and unchanged peritoneal implants on CT consistent with stable disease.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA2", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic sigmoid colon adenocarcinoma presented with right upper quadrant pain. CT shows multiple liver metastases; biopsy confirmed colorectal primary. Tumor is MSI-H by PCR and TMB-high on sequencing. NGS identified BRAF V600E mutation; KRAS and NRAS were wild-type. Patient started pembrolizumab monotherapy due to MSI-H status and poor tolerance of oxaliplatin; first restaging CT at 12 weeks showed a 35% decrease in sum of target lesions \u2014 partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with invasive ductal carcinoma, pathologic stage IIA (T2N0). ER and PR positive, HER2 amplified by FISH. PIK3CA H1047R mutation detected on next-generation sequencing. She underwent lumpectomy followed by adjuvant paclitaxel and one year of trastuzumab with whole-breast irradiation. Surveillance imaging and exam show no evidence of disease.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel; trastuzumab; radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. NGS identified BRAF V600E. PD-L1 tumor proportion score 30% and tumor mutational burden reported as TMB-high. He was started on pembrolizumab initially with mixed response (stable nodal disease but new/progressive pulmonary nodules). On progression he was switched to dabrafenib plus trametinib with a partial radiographic response of the lung metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 30%; TMB-high", "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old female incidentally found to have a 1.2 cm thyroid nodule. Lobectomy pathology consistent with papillary thyroid carcinoma, pT1aN0 (stage I). Completed completion thyroidectomy and received a single dose of radioactive iodine ablation. BRAF testing was not performed; there is no clinical or radiographic evidence of metastatic disease. Patient doing well on levothyroxine replacement.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "total thyroidectomy (completion) and radioactive iodine", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic sigmoid adenocarcinoma. Liver metastases identified on MRI and PET with CEA 120 ng/mL. Molecular testing returned KRAS G12D and microsatellite stable (MSS). He was started on FOLFIRI plus bevacizumab; after three months of therapy scans demonstrate stable disease.", "output": {"cancer_type": "sigmoid (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 120 ng/mL; MSS", "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced HER2-positive invasive ductal carcinoma (cT4N2M0). Core biopsy: HER2 amplification by FISH, ER positive, PR negative; PIK3CA H1047R detected on targeted panel. She received neoadjuvant trastuzumab, pertuzumab and docetaxel for six cycles, underwent mastectomy with clear margins and completed adjuvant radiation. Post-operative imaging shows no radiographic disease.", "output": {"cancer_type": "invasive ductal breast carcinoma (HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel; mastectomy; radiation", "response": "complete response / no radiographic disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: 71-year-old male underwent right hemicolectomy for sigmoid mass. Final dx: moderately differentiated adenocarcinoma of the colon, pT3N1 \u2014 pathologic stage III. Molecular testing: KRAS G12D positive; microsatellite stable (MSS). Patient was referred for adjuvant FOLFOX. No distant mets identified on pre-op CT; involved regional lymph nodes noted.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "surgery (right hemicolectomy); adjuvant FOLFOX", "response": "no evidence of distant metastasis / planned adjuvant therapy", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "31-year-old female with a superficial spreading melanoma on the left forearm, Breslow depth 0.8 mm, sentinel node negative consistent with stage I disease. Molecular testing detected BRAF V600E. She underwent wide local excision with negative margins and was observed without adjuvant therapy. Surveillance exam at 12 months shows no recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no recurrence / complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Staging PET/CT demonstrated a primary left upper lobe mass and multiple osseous lesions; brain MRI confirmed two small metastases. Molecular testing on biopsy was positive for EGFR L858R; PD-L1 expression was 10%. He was started on osimertinib 80 mg daily with excellent symptomatic improvement. Follow-up CT at 3 months showed a decrease in size of the pulmonary lesion and bone lesions (partial response), but at 14 months there was radiographic progression in the liver.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 38-year-old with metastatic melanoma harboring BRAF V600E. Initial presentation included a rapidly enlarging primary on the right forearm and PET/CT showed pulmonary nodules. The patient received targeted therapy with dabrafenib and trametinib for 6 months with significant tumor shrinkage; currently being transitioned to immunotherapy for consolidation. PD-L1 testing was not performed. Recent imaging: marked decrease in size of lung nodules.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (planned transition to immunotherapy)", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. CT demonstrates multiple hepatic lesions consistent with metastases. Tumor sequencing shows KRAS G12D; microsatellite testing is stable and tumor mutational burden is low. He was started on FOLFOX combined with bevacizumab; interval scans at 12 weeks show stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; TMB-low", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IV with bulky peritoneal disease and a 3 cm liver metastasis. Tumor sequencing identified a pathogenic BRCA1 germline mutation. CA-125 was markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with initial partial radiographic response, then started on olaparib maintenance; most recent scans show progression on maintenance therapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "debulking surgery, carboplatin and paclitaxel, olaparib maintenance", "response": "progression", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with locally advanced pancreatic ductal adenocarcinoma (stage III) involving the pancreatic head with encasement of the superior mesenteric artery; no distant metastases on staging CT. CA19-9 was markedly elevated at 1,200 U/mL. Comprehensive NGS did not reveal actionable mutations. He was started on modified FOLFIRINOX and after 3 months has stable disease on restaging imaging; chemoradiation is being planned.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated (1200 U/mL)", "treatment": "modified FOLFIRINOX; planned chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma treated at outside center. Tumor NGS showed BRAF V600E and high tumor mutational burden; PD-L1 reported at 20%. He was started on combination dabrafenib plus trametinib with brisk symptomatic improvement and reduction in cutaneous and nodal disease; after six months nivolumab was added as part of a trial combining targeted therapy with checkpoint blockade. Recent MRI revealed a decreasing intracranial lesion.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 20%", "treatment": "dabrafenib + trametinib; nivolumab (added)", "response": "decrease in intracranial lesion; clinical improvement", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain and multiple liver lesions. Tumor profiling: MSI-H and BRAF V600E mutation identified. Initial therapy was FOLFOX with bevacizumab; CT after 4 months showed interval progression. Given MSI-H status he was transitioned to pembrolizumab \u2014 achieved stable disease for approximately 6 months before new hepatic progression was documented.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "progression on FOLFOX/bevacizumab; stable disease on pembrolizumab followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with glioblastoma (WHO grade IV) who underwent gross total resection. Tumor sequencing showed IDH1 R132H; MGMT promoter was unmethylated. He completed concurrent radiotherapy with daily temozolomide. Surveillance MRI at six months shows new multifocal enhancing lesions consistent with progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter unmethylated", "treatment": "radiation with concurrent temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal breast carcinoma, ER positive, PR positive and HER2 amplification by FISH. NGS identified a PIK3CA H1047R alteration. Clinical staging was IIIA. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab for six cycles. Mastectomy specimen showed no residual invasive tumor (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal breast carcinoma, clinical stage IIIB (cT3N1). Tumor workup: HER2 amplification by FISH, ER 80% positive, PR 30% positive. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab, pertuzumab and docetaxel x6 cycles and went to surgery; pathology reports complete pathologic response. No distant metastases identified on staging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "MRI brain report: multiple new enhancing lesions in the left cerebellum and right frontal lobe consistent with metastatic melanoma. The patient has known BRAF V600E\u2013mutant cutaneous melanoma and had been on dabrafenib plus trametinib for nine months with an initial partial response. Current findings represent progressive intracranial disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male diagnosed with metastatic lung adenocarcinoma in June 2023. Staging PET/CT demonstrated a 2.5 cm left lower lobe primary with multiple pulmonary nodules and known brain and osseous metastases. Molecular testing returned EGFR L858R. PD-L1 by IHC was 10% TPS. He was started on osimertinib 80 mg daily in July and underwent SRS to a dominant cerebellar lesion. First follow-up CT and MRI showed reduction in size of the lung primary and decrease in brain lesion size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma, liver-dominant disease. Tumor profiling: KRAS G12D mutation; MSI-H and TMB-high. He progressed after first-line FOLFOX plus bevacizumab and was started on pembrolizumab. Interval CT after 12 weeks shows significant shrinkage of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal cancer", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old with a 0.8 cm superficial spreading melanoma of the forearm, Breslow 0.6 mm, sentinel lymph node negative \u2014 clinical stage I. Targeted panel did not detect BRAF or NRAS mutations. Managed with wide local excision and close dermatologic surveillance.", "output": {"cancer_type": "melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma presented with progressive cough. Staging consistent with stage IV disease with known brain and bone metastases. Molecular testing demonstrated an EGFR L858R mutation; PD-L1 tumor proportion score was 10%. After progression on first-line erlotinib he was transitioned to osimertinib in combination with bevacizumab. Interval CT and MRI show a partial response to the osimertinib + bevacizumab regimen.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib and bevacizumab (after prior erlotinib)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with biopsy-proven BRAF V600E mutation. PD-L1 reported as >50% on tumor cells. Multiple bilateral pulmonary nodules identified on staging CT. Patient started on dabrafenib plus trametinib with shrinkage of several cutaneous lesions but a heterogeneous response in the lungs; therapy was later switched to pembrolizumab with interval decrease in some nodules. Overall the treating team documented a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER 95%, PR 40%, HER2 negative by IHC/FISH. She underwent lumpectomy and sentinel node biopsy; final pathologic stage pT2N0 (Stage IIA). FoundationOne shows PIK3CA H1047R mutation. Completed adjuvant radiation and was started on letrozole. On routine follow-up she remains disease-free.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER 95%; PR 40%; HER2 negative", "treatment": "lumpectomy; radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with unresectable cutaneous melanoma found to have multiple hepatic and pulmonary metastases on staging CT. Molecular testing showed BRAF V600E mutation; PD-L1 by IHC 20% and high TMB reported on NGS. She was started on combination targeted therapy with dabrafenib plus trametinib. After 12 weeks there was marked shrinkage of target lesions consistent with a partial response and treatment is ongoing.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%; TMB-high", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man followed in thoracic oncology for lung adenocarcinoma. Initial staging showed stage IV disease with brain and bony metastases on MRI and PET-CT. Molecular testing detected EGFR L858R mutation; PD-L1 IHC reported 10%. He was started on osimertinib 80 mg PO daily. Three-month restaging CT demonstrates decrease in size of pulmonary and osseous lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radical prostatectomy performed for clinically localized prostate adenocarcinoma (Gleason 3+4). Pathology reported pT2 disease. He is on intermittent androgen deprivation with leuprolide for rising PSA after surgery; current PSA trend shows biochemical recurrence despite castrate-level testosterone. No radiographic evidence of metastatic disease on bone scan and CT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; intermittent androgen deprivation (leuprolide)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old male with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric vessels (borderline resectable, staged as III). Germline testing identified a deleterious BRCA2 mutation. He received 6 cycles of modified FOLFIRINOX with radiographic downsizing and started maintenance olaparib. CA 19-9 declined and scans show stable disease on current therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III (locally advanced)", "gene_mutation": "BRCA2 deleterious (germline)", "biomarker": null, "treatment": "modified FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old F with newly diagnosed lung adenocarcinoma. Staging CT/PET consistent with widespread disease, multiple cerebral lesions and lytic lesions in the thoracic spine. Molecular testing returned EGFR L858R mutation. PD-L1 by IHC 10%. Patient started osimertinib 80 mg daily as first-line targeted therapy with symptomatic improvement and interval shrinkage of lesions on first restaging scan \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old male with a primary cutaneous melanoma of the right forearm. Wide local excision pathology: ulcerated melanoma, stage III (positive sentinel node). Tumor sequencing identified NRAS Q61R mutation. Patient received adjuvant immune checkpoint therapy on protocol with nivolumab plus ipilimumab. Despite therapy he developed progression in the regional nodal basin requiring completion lymphadenectomy.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "nivolumab plus ipilimumab", "response": "progression (regional nodal)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary high-grade serous ovarian carcinoma diagnosed after abdominal distension and ascites. At laparotomy there was bulky peritoneal disease and omental caking; optimal cytoreductive surgery performed. Standard adjuvant chemotherapy with carboplatin and paclitaxel was given. No molecular testing results documented in the chart. Post-chemo CT shows marked reduction in peritoneal implants and resolution of ascites.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "clinical/radiographic response (marked reduction)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with metastatic invasive ductal carcinoma of the breast. Biopsy showed HER2 amplification by FISH, ER positive, PR negative. CT scan demonstrates a solitary 3.5 cm liver lesion consistent with metastasis; overall AJCC stage IV. No actionable somatic mutations were reported on the targeted panel. She has been treated with trastuzumab in combination with docetaxel and has had stable disease for 6 months on imaging.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "trastuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old woman underwent excision of a 0.4 mm superficial spreading melanoma from the right forearm. Pathology: non-ulcerated, mitotic rate low, sentinel lymph node negative. Final stage IA. No adjuvant therapy recommended; surveillance only. BRAF testing was not performed and PD-L1 was not assessed. She remains clinically disease-free at follow-up.", "output": {"cancer_type": "melanoma", "stage": "IA", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery); surveillance", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed 03/2024. Staging at presentation: IV with multiple cerebral and skeletal lesions. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Started osimertinib 80 mg daily in April with marked symptomatic improvement. Follow-up MRI at 8 weeks showed decreased size of brain metastases and interval improvement of bone pain. Plan: continue osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma, staged IV. Comprehensive genomic profiling identified EGFR L858R mutation. PD-L1 tumor proportion score reported at 15%. MRI brain demonstrates multiple small enhancing lesions consistent with metastases. Patient started on osimertinib 80 mg daily as first-line targeted therapy; interval CT after 8 weeks shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma presented with weight loss and rising CA19-9. Staging confirmed liver metastases. Germline testing positive for pathogenic BRCA2. She received first-line FOLFIRINOX with initial tumor shrinkage, but progressed after 5 months and was switched to gemcitabine/nab-paclitaxel with continued radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline pathogenic)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by gemcitabine/nab-paclitaxel", "response": "progression on second-line therapy", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma. Molecular profiling showed BRAF V600E mutation and MSI-H; tumor mutational burden was reported as high. He was started on FOLFOX plus bevacizumab with partial radiographic response of dominant liver lesions but persistent pulmonary nodules. Given BRAF V600E he subsequently received encorafenib in combination with cetuximab on a compassionate-use protocol with shrinkage of liver mets; later received pembrolizumab for MSI-H disease with mixed response (continued control in liver, progression in lung).", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab; pembrolizumab", "response": "mixed response (partial response in liver, progression in lung)", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with recurrent cutaneous melanoma now metastatic with multiple pulmonary nodules. Prior primary excision; molecular testing was inconclusive for targetable driver mutations. Genomic report notes high tumor mutational burden (TMB-high, 25 mut/Mb) and PD-L1 ~70% TPS. Started on pembrolizumab monotherapy; 12-week restaging shows stable disease by RECIST.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "TMB-high (25 mut/Mb); PD-L1 70%", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old woman with ER+/PR+/HER2-amplified invasive ductal carcinoma. Initial staging revealed metastatic osseous disease; bone scan positive for multiple lytic lesions. Core biopsy also showed PIK3CA H1047R mutation. She received neoadjuvant docetaxel with trastuzumab and pertuzumab, followed by definitive mastectomy. Post-op imaging demonstrates partial radiographic response of bone lesions and continued endocrine therapy planned.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, trastuzumab, pertuzumab; endocrine therapy", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 62-year-old woman underwent primary cytoreductive surgery for high-grade serous ovarian carcinoma; extensive omental disease and diaphragmatic implants were noted. Final pathologic stage was IIIC. Germline testing identified a pathogenic BRCA1 frameshift mutation. She was started on adjuvant carboplatin and paclitaxel every 3 weeks; interval CT after three cycles showed decrease in omental disease but not complete resolution. PD-L1 testing was not performed.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (pathogenic frameshift)", "biomarker": null, "treatment": "carboplatin and paclitaxel; cytoreductive surgery", "response": "partial response (decrease in disease)", "metastasis_site": "omentum; diaphragm (peritoneal implants)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with an incidentally discovered 1.8 cm left upper lobe pulmonary nodule. Wedge resection and subsequent VATS lobectomy confirmed lung adenocarcinoma, pathologic Stage IA, no nodal involvement. Molecular testing returned EGFR L858R. She was started on adjuvant osimertinib after surgery. 12-month surveillance CT shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IA", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "VATS lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old female with stage I invasive ductal carcinoma of the left breast (ER+, PR+, HER2 amplified). Tumor panel detected PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy and completed adjuvant weekly paclitaxel followed by trastuzumab for 1 year and exemestane. Surveillance imaging and exam show no evidence of disease.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+; PR+; HER2 amplification", "treatment": "lumpectomy; paclitaxel; trastuzumab; exemestane", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 48-year-old woman with locally advanced invasive ductal carcinoma, ER-negative/PR-negative, HER2 amplified by FISH. Clinical stage IIIB with skin involvement. Core biopsy also identified a PIK3CA H1047R mutation. She received neoadjuvant docetaxel and carboplatin with trastuzumab for four cycles. Mastectomy specimen shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male underwent right hemicolectomy for adenocarcinoma. Pathology: pT3 N2 (4/18 nodes) consistent with stage IIIC colon adenocarcinoma. Molecular testing returned KRAS G12D. Mismatch repair proteins intact (MMR proficient). No distant disease on CT chest/abdomen/pelvis. Adjuvant FOLFOX recommended and started.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology notes: 63-year-old female with metastatic colorectal adenocarcinoma, stage IV at diagnosis with pulmonary nodules and peritoneal implants. Tumor testing returned MSI-H and high tumor mutational burden; BRAF V600E was detected. She received FOLFOX plus bevacizumab up front with minor radiographic shrinkage, then switched to single-agent pembrolizumab for MSI-H disease. Imaging after 3 months demonstrates a partial response of the peritoneal disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "lung, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with invasive ductal carcinoma, clinical stage II (T2N0). Tumor is ER positive, PR positive and HER2 negative. A somatic PIK3CA hotspot mutation was identified on next-generation sequencing. She underwent breast-conserving surgery with negative sentinel nodes followed by adjuvant docetaxel and cyclophosphamide x4 cycles and was transitioned to tamoxifen for endocrine therapy. Follow-up imaging and physical exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA", "biomarker": "ER+, PR+, HER2-negative", "treatment": "lumpectomy, docetaxel and cyclophosphamide, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with pancreatic ductal adenocarcinoma complicated by metastatic nodules in the right lung. Germline testing revealed a deleterious BRCA2 mutation; patient received palliative FOLFIRINOX with initial mixed response but ultimately was switched to olaparib maintenance and now has progressive pulmonary nodules on most recent imaging.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the breast. Core biopsy: ER positive, PR positive, HER2 IHC 3+ with FISH amplification. Tumor NGS identified PIK3CA H1047R. Clinical stage recorded as IIIB. She received neoadjuvant docetaxel, carboplatin and trastuzumab; final surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old with newly diagnosed high-grade serous ovarian carcinoma, optimal cytoreductive surgery performed in March. Pathologic stage IIIC with peritoneal implants. Germline testing returned a deleterious BRCA2 mutation. She completed 6 cycles of adjuvant carboplatin/paclitaxel and was started on maintenance olaparib. CA-125 normalized and CT scan after 3 months shows no measurable disease \u2014 currently recorded as no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA-125 (elevated at diagnosis then normalized)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete radiographic response / no evidence of disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma, stage IV at presentation. NGS reported EGFR L858R mutation. PD-L1 tumor proportion score 10%. He was started on osimertinib and repeat CT at 8 weeks demonstrated a marked decrease in size of the primary and nodal disease consistent with a partial response. Brain MRI showed a single enhancing cerebellar metastasis that was treated with stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 48-year-old woman with locally advanced, HER2-positive breast cancer presenting with chest wall involvement. Core biopsy confirmed invasive ductal carcinoma, HER2 amplification by FISH, ER/PR negative. PIK3CA H1047R detected on panel. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab and pertuzumab for 12 weeks, proceeded to mastectomy and axillary dissection, and completed adjuvant trastuzumab. Pathology report shows no residual invasive tumor (pCR). No distant mets identified on staging imaging.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "neoadjuvant trastuzumab and pertuzumab with paclitaxel; surgery and adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 39-year-old man diagnosed with stage III cutaneous melanoma of the left forearm with involved sentinel nodes. Tumor sequencing returned BRAF V600E. Patient completed wide local excision and lymphadenectomy and was started on adjuvant dabrafenib with trametinib. At 6-month clinic visit there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant); surgery (wide local excision, lymphadenectomy)", "response": "no evidence of disease / complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 62-year-old male diagnosed with colorectal adenocarcinoma with synchronous liver metastases. Molecular testing returned KRAS G12D. He was staged as IV at diagnosis. Treated with FOLFOX plus bevacizumab for 4 months; surveillance CT shows stable hepatic lesions with no new sites. MSI testing not performed.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology and pathology summary: 70-year-old male with newly progressive abdominal pain. CT shows multiple hypodense hepatic lesions. Colonoscopy revealed an obstructing sigmoid mass; biopsy: moderately differentiated colorectal adenocarcinoma. Molecular profile: KRAS G12D mutation detected; MSI testing: MSI-H. He was started on FOLFOX with bevacizumab. Restaging after 8 weeks demonstrates increase in size and number of liver metastases \u2014 interval progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. PET/CT and MRI show widespread osseous disease and a small cerebellar metastasis. Biopsy confirmed adenocarcinoma with EGFR L858R mutation; PD-L1 reported at 10%. Staged as IV. Patient was started on osimertinib with an initial radiographic partial response, but surveillance imaging at 9 months demonstrated intracranial progression and new bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response followed by progression", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, presented with liver-dominant disease on CT. Tumor testing demonstrated high microsatellite instability (MSI-H) with loss of MLH1/PMS2. KRAS and NRAS sequencing showed no actionable mutations. After progression on adjuvant FOLFOX the patient was started on pembrolizumab and achieved durable stable disease for approximately 9 months with decreased size of some hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H (loss of MLH1/PMS2)", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 58-year-old man with high-risk cutaneous melanoma on the left forearm. Wide local excision and sentinel node biopsy positive for nodal involvement; final stage IIIB. Tumor sequencing detected BRAF V600E and TMB-high on panel testing. He was started on dabrafenib plus trametinib for unresectable nodal disease with good symptomatic improvement; interval PET/CT shows partial response of involved nodes.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man with metastatic castration-resistant prostate adenocarcinoma with extensive sclerotic bone metastases. Germline/somatic testing identified a deleterious BRCA2 mutation. Baseline PSA was 120 ng/mL. He initiated olaparib therapy after failing second-line hormonal agents; after 6 months his PSA has stabilized and bone scans are unchanged consistent with stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA 120 ng/mL", "treatment": "olaparib (after prior hormonal therapy)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with metastatic castration-sensitive prostate cancer. Bone scan shows multiple osseous lesions consistent with metastatic disease; clinical staging consistent with stage IV. He was started on androgen deprivation with leuprolide and received docetaxel x6 cycles. PSA has declined and symptoms are controlled with stable disease. No genomic testing or biomarker results available.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide), docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old man with newly diagnosed lung adenocarcinoma, clinical stage IV. Molecular testing identified an EGFR L858R mutation. Baseline PD-L1 tumor proportion score was 10%. He was started on osimertinib 80 mg daily in May. Interval MRI brain and CT chest/abdomen show shrinkage of the primary lung mass and decrease in several brain metastases and sclerotic osseous lesions consistent with a partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 62-year-old man with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E; PD-L1 tumor proportion score >50% and reported TMB-high. He was initiated on targeted therapy with dabrafenib and trametinib, and because of persistent bulky CNS disease, pembrolizumab was added as part of a combined approach. Interval MRI shows decreased size of several brain metastases and ongoing partial response systemically.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "dabrafenib + trametinib + pembrolizumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with right invasive ductal carcinoma, pathologic stage I (T1N0). ER-positive, PR-positive, HER2 negative by IHC/FISH. She underwent lumpectomy with clear margins and sentinel node biopsy; adjuvant endocrine therapy with tamoxifen was initiated. Genetic testing was not contributory.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER+/PR+, HER2-negative", "treatment": "lumpectomy; tamoxifen (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man with metastatic castration-resistant prostate cancer, bone-predominant disease on whole-body scan. Germline and somatic testing identified a truncating BRCA2 mutation. PSA at presentation was 135 ng/mL. He received androgen deprivation with leuprolide and a trial of enzalutamide; after biochemical and radiographic progression he was started on olaparib with subsequent decline in PSA and improvement in bone pain with partial radiographic response of several bone lesions.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 truncating mutation", "biomarker": "PSA 135 ng/mL", "treatment": "leuprolide; enzalutamide; olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old female found to have a 1.2 cm papillary thyroid carcinoma confined to the thyroid. She underwent total thyroidectomy followed by radioactive iodine ablation. Final pathology pT1bN0 (stage I). Limited molecular panel reported no actionable mutations. Post-ablation thyroglobulin is undetectable; she is on suppressive levothyroxine and doing well.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": "thyroglobulin undetectable", "treatment": "total thyroidectomy, radioactive iodine", "response": "remission / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with ER-positive, PR-negative, HER2-amplified breast cancer. At presentation she had bulky axillary nodes and multiple hypodense liver lesions. Biopsy confirmed metastatic ductal carcinoma. She was started on combination trastuzumab and pertuzumab with docetaxel. After six cycles there is radiologic stable disease and symptomatic improvement of right upper quadrant pain.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology consult: patient with recurrent cutaneous melanoma, biopsy-positive and BRAF V600E mutation identified. PET/CT shows multiple pulmonary nodules and new adrenal lesion \u2014 consistent with metastatic (stage IV) disease. Started on combination targeted therapy with dabrafenib plus trametinib. After 3 months the CT shows radiographic progression with enlarging lung nodules and the adrenal lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with right-sided colon adenocarcinoma, presented with obstruction. Pathology: T3N1, stage III. Tumor was MSI-H by PCR testing. Underwent right hemicolectomy followed by adjuvant FOLFOX for six cycles. Surveillance CTs at 12 and 24 months show no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 67-year-old male with metastatic lung adenocarcinoma diagnosed on core biopsy. Staging CT showed multiple bilateral pulmonary nodules and solitary cerebellar lesion. Molecular testing returned EGFR L858R and PD-L1 10%. He was started on osimertinib 80 mg PO daily in January and received stereotactic radiosurgery to the brain lesion. On first reassessment CT at 8 weeks there is decrease in size of lung nodules and resolution of several target lesions. Impression: partial response to osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female presented with abdominal distension and CA-125 of 1200 U/mL. Imaging demonstrated bulky peritoneal disease and omental cake. Biopsy confirmed high-grade serous ovarian carcinoma. Germline testing positive for a deleterious BRCA1 mutation. She received neoadjuvant carboplatin and paclitaxel followed by interval debulking surgery; CT after three cycles showed decrease in peritoneal implants consistent with a partial response. Maintenance PARP inhibitor planned pending recovery.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "III", "gene_mutation": "BRCA1 mutation", "biomarker": "elevated CA-125", "treatment": "carboplatin and paclitaxel; interval debulking; planned PARP inhibitor", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a 1.2 mm superficial spreading cutaneous melanoma of the left forearm, sentinel node negative \u2014 final pathologic stage I. Tumor sequencing detected a BRAF V600E alteration. Managed with wide local excision and close dermatologic/oncology follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease / surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the breast. Core biopsy: ER 60%, PR 10%, HER2 IHC 3+ with FISH-confirmed HER2 amplification. Clinical stage IIIB with fixed axillary nodes. Neoadjuvant plan is docetaxel, carboplatin plus trastuzumab and pertuzumab for six cycles. After four cycles the imaging shows disease stability and surgery is being scheduled. No NGS-level gene mutation was reported in the chart.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER 60%; PR 10%", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab", "response": "stable disease", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions and peritoneal implants. Tumor profiling returned BRAF V600E and high microsatellite instability (MSI-H). After progression on first-line FOLFOX the patient was started on encorafenib plus cetuximab. CT at 8 weeks documents no new lesions and overall disease control without shrinkage of all targets.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "encorafenib + cetuximab (after FOLFOX)", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma diagnosed January 2023. Molecular testing identified EGFR L858R. Staging at diagnosis was IV with multiple brain and osseous lesions. PD-L1 was 10%. He was started on osimertinib 80 mg daily in February 2023. Interval MRI and CT at 3 months showed decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "31-year-old man with a 1.0 mm ulcerated superficial spreading cutaneous melanoma on the upper back, staged as IA (T1b) by AJCC. He underwent wide local excision with negative sentinel lymph node biopsy. Tumor molecular testing identified BRAF V600E. PD-L1 by IHC was <1%. No adjuvant systemic therapy was recommended. At 6-month follow-up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "wide local excision", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology / follow-up: 59-year-old man with localized prostate adenocarcinoma (clinical T2c, stage II) and preoperative PSA 12 ng/mL. Underwent radical prostatectomy with pelvic lymph node sampling. Final pathology: organ-confined disease, negative margins, nodes negative. Post-op PSA undetectable. No evidence of metastatic disease on imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (pre-op)", "treatment": "radical prostatectomy (surgery)", "response": "no evidence of disease (undetectable PSA post-op)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology clinic: 45-year-old with a 0.9 cm superficial spreading melanoma on the left forearm, Breslow 0.8 mm, no ulceration, sentinel node negative. Final path stage IA. Wide local excision performed with negative margins; no adjuvant systemic therapy recommended. Tumor testing identified BRAF V600E mutation. Surveillance dermatologic exam and imaging remain clear.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy (negative)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, bulky peritoneal disease at presentation. Germline BRCA1 pathogenic variant identified and HRD positive; CA-125 elevated at diagnosis. She underwent optimal cytoreductive debulking followed by six cycles of carboplatin and paclitaxel. Given BRCA1 mutation and response, maintenance therapy with olaparib in combination with bevacizumab was started. Patient achieved a complete clinical response but recurred at 14 months with peritoneal implants.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD positive; CA-125 elevated", "treatment": "cytoreductive surgery then carboplatin and paclitaxel; maintenance olaparib plus bevacizumab", "response": "complete response (recurrence at 14 months)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with left breast invasive ductal carcinoma, clinical stage IIB (T2N1M0). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with trastuzumab for four cycles with significant clinical tumor shrinkage and is scheduled for lumpectomy. No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "partial response (clinical tumor shrinkage)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 1.5 cm invasive ductal carcinoma of the left breast. Pathology: ER positive, PR positive, HER2 negative. Stage I disease (T1cN0). She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant radiation and was started on tamoxifen. Germline testing returned a pathogenic BRCA2 variant. No evidence of disease on most recent visit.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "ER+/PR+, HER2-negative", "treatment": "lumpectomy (breast-conserving surgery) followed by radiation and tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man presented with rapidly progressive cutaneous melanoma with pulmonary and intracranial metastases. BRAF testing returned V600E. PD-L1 was 5%. He underwent whole-brain radiation for symptomatic lesions and was started on combination targeted therapy with dabrafenib and trametinib, followed by nivolumab upon mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "whole-brain radiation; dabrafenib + trametinib; nivolumab", "response": "mixed response", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old with metastatic cutaneous melanoma, BRAF V600E positive. Initially treated with pembrolizumab for 3 cycles but progressed with worsening pulmonary nodules and new brain lesions; switched to targeted therapy with dabrafenib plus trametinib. After 6 months on BRAF/MEK inhibition there was radiographic progression with enlarging cerebral metastases and new adrenal lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib plus trametinib", "response": "progression", "metastasis_site": "brain, lung, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic lung adenocarcinoma diagnosed November 2023. Tumor NGS detected EGFR L858R mutation; PD-L1 by IHC 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Follow-up MRI brain at 8 weeks demonstrated decrease in size of multiple enhancing lesions consistent with a partial response. Brain metastases were present at diagnosis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: Patient with high\u2011grade prostatic adenocarcinoma, Gleason 9, presents with symptomatic bone metastases. Started on leuprolide depot for androgen deprivation therapy and received 6 cycles of docetaxel. PSA initially fell but now rising over 3 consecutive measurements; plan to consider second-line systemic therapy. No tumor sequencing performed to date.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "progression (rising PSA)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced (stage III) pancreatic ductal adenocarcinoma encasing the superior mesenteric artery not amenable to upfront resection. Germline testing returned positive for BRCA2 mutation. CA19-9 was elevated at 250 U/mL. Patient received FOLFIRINOX with radiographic and biochemical stabilization, then transitioned to maintenance olaparib. Most recent scans show stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 250 U/mL", "treatment": "FOLFIRINOX then maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with recurrent cutaneous melanoma now with stage IV disease. Molecular profile positive for BRAF V600E; tumor mutational burden reported as TMB-high and PD-L1 5%. Staging shows multiple hepatic lesions and several brain metastases. He was started on dabrafenib plus trametinib with an initial clinical benefit, but at six months scans demonstrated progression with new brain metastases and enlarging liver lesions; therapy was switched to ipilimumab and nivolumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 5%", "treatment": "dabrafenib + trametinib; later ipilimumab + nivolumab", "response": "progression (after initial response)", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 47-year-old female with ER+/PR+ invasive ductal carcinoma of the left breast, HER2 FISH shows HER2 amplification. Clinical stage: T4bN1 (IIIB). PIK3CA H1047R mutation identified on NGS panel. Neoadjuvant therapy with docetaxel and trastuzumab was administered for 6 cycles. Post-treatment MRI demonstrates marked reduction in tumor volume but residual enhancing mass remains.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology record: 55-year-old with metastatic cutaneous melanoma. Primary was ulcerated; molecular testing positive for BRAF V600E. PET/CT identified several bilateral pulmonary nodules suspicious for mets. Therapy with dabrafenib plus trametinib was initiated. Interval imaging after 6 weeks shows reduction in size and number of nodules; clinical notes state a partial response and improved dyspnea.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER/PR-negative, HER2-positive invasive ductal carcinoma of the left breast, clinical stage IIB based on imaging. Core biopsy FISH was positive for HER2 amplification. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for six cycles followed by lumpectomy. Surgical pathology showed no residual invasive tumor (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP); lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with intermediate-risk prostate adenocarcinoma, clinical stage II (T2b N0 M0). Baseline PSA 12 ng/mL. Germline testing positive for a pathogenic BRCA2 variant. He proceeded to radical prostatectomy; post-operative PSA is undetectable at 3-month follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA 12 ng/mL (baseline)", "treatment": "radical prostatectomy", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with newly diagnosed lung adenocarcinoma presented with cough and headache. Staging CT and brain MRI consistent with Stage IV disease with multiple brain and bone metastases. Molecular testing: EGFR L858R positive; PD-L1 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to a solitary cerebellar lesion. Imaging at 8 weeks shows a decrease in pulmonary nodules and shrinkage of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic colorectal adenocarcinoma diagnosed after liver biopsy of a hepatic lesion. Initial staging consistent with stage IV disease with multiple liver mets. Tumor profiling: BRAF V600E mutation and MSI-H on PCR. He received first-line FOLFOX with bevacizumab with modest tumor shrinkage, then at progression was started on the targeted combination encorafenib plus cetuximab with radiologic stable disease on first restaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; then encorafenib + cetuximab", "response": "stable disease (on encorafenib + cetuximab)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with progressive abdominal distension and early satiety. Diagnostic laparoscopy revealed high-grade serous carcinoma of the ovary with diffuse peritoneal carcinomatosis. CA-125 markedly elevated preoperatively. Optimal cytoreductive surgery was performed followed by adjuvant carboplatin and paclitaxel. BRCA testing was not informative in the record. Latest CT shows reduction in peritoneal implants consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neuro-oncology note: 72-year-old female with newly diagnosed glioblastoma (WHO grade IV). Subtotal resection performed; IDH immunostain negative (IDH\u2011wildtype). MGMT promoter methylation detected. She proceeded with standard concomitant radiation and temozolomide. Early post-treatment MRI was stable but subsequent scan at 4 months shows progression at the resection cavity. No reportable targetable mutation was identified on the panel.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "surgical resection followed by radiation + temozolomide", "response": "initially stable disease then progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with pancreatic ductal adenocarcinoma, initially stage IV at presentation with multiple liver lesions on CT. Tumor genomics show KRAS G12D and TP53 R175H. CA 19-9 markedly elevated. He received FOLFIRINOX first-line, progressed after 4 months and was switched to gemcitabine plus nab-paclitaxel; repeat scans show enlarging hepatic lesions and clinical progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 R175H", "biomarker": "elevated CA 19-9", "treatment": "FOLFIRINOX; gemcitabine + nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female presenting with jaundice and weight loss. CT showed a pancreatic head mass with multiple liver lesions and peritoneal nodularity. Biopsy: pancreatic ductal adenocarcinoma. Germline and somatic testing positive for pathogenic BRCA2 mutation. CA19-9 elevated at 2,100 U/mL. She received modified FOLFIRINOX with initial decrease in tumor markers and size (partial response) followed by maintenance olaparib after 6 months. On most recent restaging there is stable disease in the liver and persistent peritoneal disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated", "treatment": "modified FOLFIRINOX; maintenance olaparib", "response": "initial partial response then stable disease on maintenance", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presenting with right upper quadrant pain found to have colon adenocarcinoma with multiple liver lesions on CT. Tumor profiling identified BRAF V600E mutation and MSI testing returned MSI-H. He was started on FOLFOX plus bevacizumab; after four months of therapy restaging CT shows interval progression in the liver.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental disease. Germline testing positive for a deleterious BRCA1 mutation (c.5266dupC) and tumor HRD assay returned positive. Patient underwent primary debulking followed by 6 cycles of carboplatin and paclitaxel and is now on maintenance olaparib. Most recent CT shows stable omental/peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation (c.5266dupC)", "biomarker": "HRD-positive", "treatment": "surgery; carboplatin and paclitaxel; olaparib (maintenance)", "response": "stable disease", "metastasis_site": "omentum/peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 52-year-old with metastatic cutaneous melanoma diagnosed last year (stage IV) with pulmonary and intracranial lesions. Baseline testing demonstrated BRAF V600E mutation and PD-L1 >50%. Treated initially with dabrafenib/trametinib with rapid symptomatic improvement and partial response on CT; later progressed intracranially and was started on pembrolizumab, with mixed response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib and trametinib; later pembrolizumab", "response": "initial partial response then progression / mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R; PD-L1 TPS 10%. Started osimertinib 80 mg PO daily with clinical improvement. Interval MRI shows decrease in size of several intracranial lesions. Stage IV disease with known brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old with metastatic colorectal adenocarcinoma. Colonoscopy biopsy confirmed adenocarcinoma; CT shows multiple liver metastases consistent with stage IV. Tumor profiling: KRAS G12D mutation identified; microsatellite testing returned MSI-H and tumor mutational burden reported as TMB-high. He was switched to pembrolizumab monotherapy after progression on FOLFOX. Repeat CT at 12 weeks demonstrates a significant decrease in size of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (after FOLFOX)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a left breast mass. Core biopsy: invasive ductal carcinoma, grade 3, ER negative, PR negative, HER2 FISH non-amplified. Germline testing returned a pathogenic BRCA1 variant. Clinical staging was T2N1M0 (stage IIB). She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel and underwent lumpectomy with sentinel node biopsy; final pathology showed no residual invasive carcinoma (pCR).", "output": {"cancer_type": "breast cancer (triple-negative, invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "ER negative; PR negative; HER2 non-amplified", "treatment": "neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left breast cancer, clinical T4N1 (stage IIIB). Biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER and PR negative. She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) x6 cycles and then underwent mastectomy. Pathology reported no residual invasive tumor (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R positive; PD-L1 tumor proportion score 10%. Baseline staging CT and MRI showed multiple brain and osseous metastases. He was started on osimertinib 80 mg PO daily in June. First restaging CT at 8 weeks demonstrates a decrease in size of the target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "37-year-old woman with recurrent metastatic breast cancer. Biopsy confirmed invasive ductal carcinoma, ER/PR negative, HER2 amplified. At relapse she has multiple hepatic lesions consistent with stage IV disease. NGS reported PIK3CA H1047R. Treatment initiated with docetaxel plus trastuzumab and pertuzumab. Restaging after 3 cycles shows decrease in size of liver metastases consistent with a partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old with newly diagnosed high-grade serous ovarian carcinoma with diffuse peritoneal carcinomatosis and omental caking. Clinical stage IIIC. Underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with bevacizumab maintenance. CA-125 declined post-treatment; interval CT shows persistent small-volume peritoneal implants without clear progression.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel; bevacizumab maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old woman with left breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+ with FISH confirming HER2 amplification. Clinical staging cT2N1M0 (stage IIB). She received neoadjuvant paclitaxel and carboplatin with trastuzumab and pertuzumab x6 cycles. She underwent lumpectomy and sentinel node biopsy; surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and carboplatin; trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with muscle-invasive urothelial carcinoma of the bladder, clinical stage IV with pelvic nodal and bilateral lung metastases. Tumor PD-L1 tumor proportion score >50%. He received cisplatin and gemcitabine in the frontline setting and, after progression, was started on atezolizumab as second-line therapy\u2014PET/CT at 6 months shows complete metabolic response.", "output": {"cancer_type": "urothelial carcinoma of the bladder", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 >50% TPS", "treatment": "cisplatin and gemcitabine; atezolizumab", "response": "complete response", "metastasis_site": "pelvic lymph nodes, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal breast carcinoma, clinical stage IIIB. ER positive, PR negative; HER2 amplification confirmed by FISH. NGS demonstrated a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab with docetaxel followed by lumpectomy. Final pathology showed a complete pathologic response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab; pertuzumab; docetaxel; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Imaging and staging consistent with stage IV disease with multiple enhancing brain metastases and a solitary lytic lesion in the thoracic spine. Comprehensive molecular profiling identified EGFR L858R (exon 21). PD-L1 tumor proportion score 5%. Patient started osimertinib 80 mg daily; 8-week MRI shows reduction in size of intracranial lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: 54-year-old woman with ER+/PR+/HER2-amplified metastatic breast cancer, biopsy-proven liver metastases. Genomic profiling identified PIK3CA E545K. Initial therapy included combination trastuzumab and pertuzumab with docetaxel (every 3 weeks). After six cycles she was transitioned to maintenance trastuzumab and pertuzumab; disease remained stable. On progression of a single hepatic lesion she received stereotactic radiation and was later started on alpelisib in combination with fulvestrant for PIK3CA-mutant, endocrine-resistant disease.", "output": {"cancer_type": "breast cancer (ER+/PR+/HER2-amplified)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and pertuzumab with docetaxel; maintenance trastuzumab and pertuzumab; alpelisib with fulvestrant", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 62-year-old female with newly diagnosed lung adenocarcinoma presenting with headache and shortness of breath. Imaging showed multiple enhancing lesions in the cerebrum consistent with metastatic disease. Biopsy of the lung primary confirmed adenocarcinoma; molecular testing returned EGFR L858R. PD-L1 TPS reported at 10%. Staged as IV at diagnosis. Patient was started on osimertinib 80 mg daily with rapid symptomatic improvement and interval CT at 8 weeks demonstrated decrease in size of both pulmonary and intracranial lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic cutaneous melanoma, stage IV with pulmonary nodules. Tumor NGS positive for BRAF V600E. PD-L1 low at ~5%. Started on dabrafenib plus trametinib. Follow-up CT chest at 12 weeks shows resolution of several lung nodules and marked decrease in remaining lesions \u2014 documented complete response on imaging while on targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with dyspnea. CT chest shows multiple pulmonary nodules consistent with metastatic disease. Primary colon tumor tested positive for KRAS G12D. He was started on FOLFOX plus bevacizumab in the community hospital; after 4 cycles there is radiographic progression in the lungs and new pleural effusion, plans to change systemic therapy are under discussion.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with newly diagnosed metastatic lung adenocarcinoma. PET/CT shows multiple pulmonary nodules with biopsy-proven adenocarcinoma and scattered osseous lesions. Brain MRI demonstrates two enhancing lesions consistent with metastases. Next-generation sequencing returned EGFR L858R (exon 21) mutation; PD-L1 TPS 10%. Patient was started on osimertinib 80 mg daily with good tolerance and first restaging CT at 8 weeks showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT consistent with metastatic disease to the brain and multiple osseous sites. Biopsy from right lower lobe confirmed adenocarcinoma. Molecular testing returned EGFR L858R. PD-L1 by IHC 10%. Patient started on osimertinib 80 mg daily as first-line targeted therapy; stereotactic radiosurgery performed to a dominant cerebellar lesion. Interval MRI at 8 weeks shows reduction in size of intracranial lesions and shrinkage of primary \u2014 clinically a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with new onset jaundice found to have sigmoid mass and multiple liver lesions. Colonoscopy biopsy: colorectal adenocarcinoma, stage IV with hepatic metastases. Tumor sequencing shows KRAS G12D mutation; tumor testing reported MSI-high and high tumor mutational burden. Given the MSI-H/TMB-high status he was started on pembrolizumab monotherapy. Restaging after 4 cycles shows no further growth of liver lesions.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-high; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with stage IV lung adenocarcinoma presented with progressive headaches and was found to have a cerebellar metastasis. Molecular testing from the primary tumor identified EGFR L858R. PD-L1 IHC returned 10%. She was started on osimertinib 80 mg daily for systemic and CNS disease. Follow-up brain MRI at 8 weeks demonstrated shrinkage of the cerebellar lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma with hepatic lesions. Tumor testing positive for BRAF V600E and PD-L1 expression >50%. He was initiated on pembrolizumab 200 mg q3 weeks. After three cycles restaging CT/MRI demonstrates stable disease and the plan is to continue single-agent immunotherapy.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic prostate adenocarcinoma, bone-predominant disease with multiple sclerotic lesions on bone scan. Germline and somatic testing detected a deleterious BRCA2 mutation. PSA at diagnosis was 75 ng/mL. He was started on androgen deprivation therapy with leuprolide and concurrently began olaparib given BRCA2 positivity. Follow-up imaging and PSA trend show decreased uptake in several bony lesions and falling PSA consistent with a partial biochemical and radiographic response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 75 ng/mL", "treatment": "leuprolide and olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "27-year-old male with metastatic cutaneous melanoma, ulcerated primary on the back. PET/CT consistent with Stage IV disease with both intracranial and osseous involvement. Tumor sequencing positive for BRAF V600E. Initial therapy with pembrolizumab produced mixed radiographic results and symptomatic progression, so he was transitioned to BRAF/MEK inhibition (dabrafenib plus trametinib) with subsequent partial radiologic response noted in extracranial sites. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib plus trametinib", "response": "partial response (after switch); mixed response initially", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 40%. Staging documented as IV with multiple intracranial and osseous lesions on MRI/PET. Started osimertinib 80 mg daily in January 2024. Follow-up CT and brain MRI after 8 weeks show interval shrinkage of the primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 40%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with intermediate-risk prostate adenocarcinoma (Gleason 3+4) treated with definitive external beam radiation therapy combined with long\u2011term androgen deprivation (leuprolide). PSA fell from 12 ng/mL pre-treatment to 0.2 ng/mL on follow-up. No germline or somatic sequencing was performed and there is no radiographic evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA elevated pre-treatment (12 ng/mL), nadir 0.2 ng/mL", "treatment": "external beam radiation therapy + leuprolide (androgen deprivation therapy)", "response": "treatment response (PSA decline to 0.2 ng/mL)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with high-grade serous ovarian carcinoma, surgically staged IIIC. Germline testing positive for BRCA1 mutation. CA-125 markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Follow-up imaging demonstrates peritoneal carcinomatosis; patient has had a partial response to platinum-based chemotherapy.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with high-grade serous ovarian carcinoma underwent optimal debulking for bulky pelvic disease, final stage IIIC. Germline testing positive for BRCA1 deleterious mutation and tumor was HRD-positive; baseline CA-125 markedly elevated. She completed six cycles of carboplatin and paclitaxel and was started on combination maintenance with olaparib plus bevacizumab. Follow-up CT chest/abdomen/pelvis at 12 weeks showed complete radiographic response and normalization of CA-125.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "HRD-positive, CA-125 elevated (normalized on treatment)", "treatment": "carboplatin and paclitaxel; maintenance olaparib + bevacizumab", "response": "complete radiographic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with hepatic metastases from colorectal primary. Liver biopsy confirmed colorectal adenocarcinoma. Molecular testing: KRAS G12D positive and high microsatellite instability (MSI-H). At diagnosis he was staged as IV with multiple liver and bilateral pulmonary lesions. Given MSI-H status he was initiated on pembrolizumab monotherapy. CT scans at 6 months show complete radiographic resolution of previously identified hepatic lesions and no measurable disease in the chest.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology/path report: Excisional biopsy of an axillary node positive for metastatic melanoma. Molecular testing detected BRAF V600E. PET/CT demonstrates multiple pulmonary nodules and several intracranial lesions consistent with stage IV disease. Patient began dabrafenib + trametinib; 8-week restaging showed shrinkage of lung nodules but enlargement of a cerebellar lesion (mixed response). He was transitioned to nivolumab thereafter, with subsequent MRI showing further intracranial progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib, then nivolumab", "response": "mixed response followed by progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed stage IV lung adenocarcinoma harboring an EGFR L858R mutation. He was started on osimertinib 80 mg daily after biopsy confirmation. PD-L1 IHC returned 5%. Brain MRI demonstrated multiple enhancing lesions consistent with metastases; he underwent stereotactic radiosurgery to two dominant lesions. Systemic disease has shown a partial response on follow-up CT chest.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast, clinical stage IIA (T2N0M0). Core biopsy: HER2 amplification by FISH, ER 80% positive, PR 20% positive. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab; imaging after three cycles demonstrates a partial response. No distant metastases identified.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with de novo metastatic breast cancer. Core biopsy of the left breast showed high-grade invasive ductal carcinoma, ER/PR negative, HER2 FISH positive (HER2 amplification). CT abdomen revealed multiple hypodense lesions concerning for hepatic metastases. She was started on first-line trastuzumab, pertuzumab and docetaxel with symptomatic improvement and radiographic stable disease after 4 cycles. No next-generation sequencing was performed on the specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with colorectal adenocarcinoma metastatic to the liver. Molecular profiling revealed KRAS G12D mutation; tumor testing was microsatellite stable (MSS). He was initiated on FOLFOX with bevacizumab and at the 3-month CT the disease was reported as stable by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Emergency oncology note: 67-year-old male with metastatic pancreatic ductal adenocarcinoma diagnosed on ERCP biopsy. Imaging shows widespread hepatic and peritoneal implants consistent with Stage IV disease. CA19-9 at presentation 540 U/mL. Treated with first-line FOLFIRINOX, then progressed and switched to gemcitabine/nab\u2011paclitaxel. No next-generation sequencing was available. Current assessment: progressive disease with worsening ascites.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 540 U/mL; TMB-low", "treatment": "FOLFIRINOX followed by gemcitabine/nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with omental and peritoneal implants. Germline testing identified a deleterious BRCA1 185delAG mutation; tumor reported HRD-positive. She underwent optimal cytoreductive surgery followed by 6 cycles of carboplatin and paclitaxel. Maintenance olaparib was initiated. CA-125 normalized post-therapy and 3-month CT shows no residual measurable disease \u2014 complete radiographic response documented in clinic note.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (germline)", "biomarker": "HRD-positive (CA-125 normalized)", "treatment": "cytoreductive surgery, carboplatin + paclitaxel, olaparib maintenance", "response": "complete radiographic response", "metastasis_site": "omentum/peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case review: 62-year-old female with high-grade serous ovarian carcinoma presenting with diffuse peritoneal carcinomatosis and markedly elevated CA-125. She underwent neoadjuvant carboplatin/paclitaxel followed by interval debulking surgery achieving no gross residual disease; maintenance niraparib was begun. Germline and somatic BRCA testing not detected in available reports.", "output": {"cancer_type": "ovarian serous carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; interval debulking surgery; maintenance niraparib", "response": "complete cytoreduction with biochemical response (CA-125 normalization)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 54-year-old with bulky nodal melanoma of the left axilla. Molecular testing positive for BRAF V600E. He received neoadjuvant dabrafenib and trametinib for 8 weeks with marked clinical reduction of nodes; subsequent radical node dissection showed only treatment effect and no viable tumor \u2014 pathologic complete response. Adjuvant plan discussed.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (neoadjuvant), surgical node dissection", "response": "pathologic complete response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman presented with a 2.5 cm palpable right breast mass. Core biopsy showed invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. She underwent lumpectomy with sentinel node biopsy (final path pT2N0) and was staged as IIA. Molecular testing identified a PIK3CA H1047R mutation. She completed adjuvant weekly paclitaxel followed by a planned 1-year course of trastuzumab and was started on tamoxifen. At 12-month follow-up exam and CT chest the patient is NED.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "lumpectomy; sentinel node biopsy; paclitaxel; trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with newly diagnosed high-grade serous ovarian carcinoma, FIGO stage IIIC with extensive peritoneal carcinomatosis. Germline testing identified a pathogenic BRCA1 variant. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel, and is currently receiving maintenance olaparib. CA-125 has normalized and recent CT shows complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma presenting with abdominal distension and omental caking/ascites. At laparotomy there were extensive peritoneal implants and optimal cytoreductive surgery including omentectomy was performed. Patient completed six cycles of carboplatin and paclitaxel with resolution of ascites and no radiographic evidence of residual disease on post-treatment CT. BRCA and other molecular testing not documented in chart.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel x6", "response": "clinical/radiographic remission (no radiographic evidence of residual disease)", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma harboring BRAF V600E. Staging PET/CT revealed multiple bilateral pulmonary nodules consistent with metastatic disease. PD-L1 by IHC 60%; tumor noted to be TMB-high. Started on dabrafenib plus trametinib \u2014 PET after 4 months shows complete metabolic response in the chest.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female referred for progressive dyspnea. Imaging and biopsy confirm lung adenocarcinoma with multiple lesions in the brain and spine. Molecular testing returned EGFR L858R. She was started on osimertinib and had a radiographic partial response for approximately 8 months before developing systemic progression. Received palliative whole-brain radiation for symptomatic brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib; whole-brain radiation", "response": "partial response followed by progression", "metastasis_site": "brain, bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma presented with progressive dyspnea. Biopsy confirmed adenocarcinoma, molecular testing positive for EGFR exon 19 deletion. PD-L1 tumor proportion score was 20%. She previously received erlotinib and was switched to osimertinib 80 mg daily. Baseline staging showed multiple brain metastases and vertebral osseous disease. After 3 months on osimertinib there was a marked decrease in size of pulmonary nodules and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 20%", "treatment": "osimertinib (after erlotinib)", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic follow-up: 71-year-old male with clear cell renal cell carcinoma status-post radical nephrectomy 6 months ago. Pathology: pT3a. CT chest/abdomen today shows a 2.5 cm pulmonary nodule suspicious for metastatic disease. No PD-L1 testing reported in chart. Targeted sequencing detected a VHL frameshift mutation. Given metastatic recurrence, patient was started on nivolumab plus ipilimumab. First response assessment at 12 weeks demonstrates a partial response of the lung lesion.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "III", "gene_mutation": "VHL frameshift mutation", "biomarker": null, "treatment": "nivolumab plus ipilimumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old woman with locally advanced invasive ductal carcinoma of the breast. Biopsy: HER2 amplification, ER positive, PR positive; PIK3CA E545K identified on NGS. Clinical stage IIIA. She received neoadjuvant docetaxel, carboplatin with dual HER2 blockade (trastuzumab and pertuzumab) and had an excellent clinical response; surgical pathology reported a pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic clear cell renal cell carcinoma, stage IV with pulmonary and osseous metastases. Baseline comprehensive panel reported no actionable driver mutations. PD-L1 expression by IHC was 30%. He was started on combination immunotherapy with nivolumab and ipilimumab; after three cycles restaging scans demonstrate interval progression.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 30%", "treatment": "nivolumab and ipilimumab", "response": "progression", "metastasis_site": "lung, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed 2023. PET/CT and brain MRI consistent with stage IV disease with multiple brain and bone lesions. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 5%. He was started on osimertinib 80 mg daily in June. First follow-up CT at 8 weeks demonstrated a confirmed partial response with shrinkage of pulmonary and osseous lesions; brain lesions are stable on stereotactic RT follow-up.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old with a 0.9 mm superficial spreading cutaneous melanoma on the left forearm, staged as I (T1b). She underwent wide local excision and sentinel lymph node biopsy which was negative. Tumor sequencing detected BRAF V600E. No adjuvant systemic therapy was given; patient remains clinically well with no evidence of disease at 12-month follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision and sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma (EGFR mutation positive) presented with headaches. MRI brain demonstrated two supratentorial metastases. Molecular testing: EGFR L858R; PD-L1 tumor proportion score 5%. Staged as IV at diagnosis. Started on osimertinib 80 mg daily with excellent systemic control; intracranial lesion progressed after 6 months and she underwent stereotactic radiosurgery. Current plan: continue osimertinib for systemic disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "systemic partial response / intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presenting with cough found to have lung adenocarcinoma with widespread disease. Staging: IV (T2N3M1c). Molecular testing: EGFR exon 19 deletion. PD-L1 tumor proportion score 10%. MRI brain shows two enhancing lesions; bone scan demonstrates metastatic foci in the thoracic spine. Patient started on osimertinib; follow-up CT at 8 weeks demonstrates a marked decrease in tumor burden consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic prostate adenocarcinoma presenting with bone pain and PSA 94 ng/mL. Imaging shows widespread osseous metastases. Germline and somatic testing detect BRCA2 truncating mutation. He was started on androgen deprivation therapy (leuprolide) plus enzalutamide; initial PSA decline was seen but after 6 months there was biochemical and radiographic progression. He subsequently received olaparib on a compassionate-use basis with stabilization of disease for several months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 truncating mutation", "biomarker": "PSA 94 ng/mL", "treatment": "androgen deprivation therapy (leuprolide), enzalutamide, olaparib", "response": "initial partial response (PSA decline) then progression; subsequent stabilization on olaparib", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed on biopsy with prostate adenocarcinoma (Gleason 3+4). Clinical stage II. He underwent radical prostatectomy followed by short-course androgen deprivation therapy with leuprolide. Post-operative PSA is undetectable and clinic assessment documents no evidence of disease. No molecular testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy and leuprolide (androgen deprivation therapy)", "response": "no evidence of disease (PSA undetectable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male referred for localized prostate adenocarcinoma, PSA 6.2 ng/mL, Gleason 3+4. Clinical stage I disease. He elected robot-assisted radical prostatectomy and pelvic lymph node sampling; nodes negative. No genomic alterations were identified on targeted sequencing. Post-op course uncomplicated and PSA undetectable on follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma harboring BRAF V600E. Staging showed a single sternal bone metastasis on bone scan and CT; classified as stage IV. Baseline PD-L1 by IHC was 20%. He was started on combination targeted therapy with dabrafenib and trametinib. Follow-up PET-CT at 12 weeks demonstrated complete metabolic response in the known sternal lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male presented with seizures; MRI revealed a right temporal mass and subtotal resection was performed. Pathology: glioblastoma, WHO grade IV. Molecular workup: IDH1 R132H mutation positive; MGMT promoter methylated. He was treated with concurrent radiotherapy and temozolomide per Stupp protocol. Surveillance MRI at 3 months shows increasing enhancement at the resection cavity concerning for tumor progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylated", "treatment": "surgical resection followed by radiation and temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old man with a 1.2 cm superficial spreading melanoma on the forearm, Breslow 0.9 mm, no ulceration. Clinical stage I. He underwent wide local excision and sentinel lymph node biopsy which was negative. No actionable mutation was reported on the limited panel performed. Patient remains with no evidence of disease on follow-up.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision and sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed metastatic lung adenocarcinoma. Staging scans consistent with stage IV disease with multiple cerebral and osseous lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score ~10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. At first follow-up imaging (8 weeks) there is shrinkage of the primary mass and several brain lesions \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old woman with papillary thyroid carcinoma confined to the thyroid gland. Final pathology was pT1aN0M0 (stage I). No molecular testing was performed on the tumor. She underwent total thyroidectomy followed by radioactive iodine ablation. Follow-up neck ultrasound and thyroglobulin are undetectable.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "total thyroidectomy, radioactive iodine ablation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old with a 1.2 mm superficial spreading cutaneous melanoma of the right forearm, AJCC stage I (T2aN0). Wide local excision with 1 cm margins performed; sentinel lymph node negative. Tumor sequencing detected BRAF V600E. No adjuvant systemic therapy was recommended and the patient remains under dermatologic surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with lung adenocarcinoma, staged IV on initial PET/CT. Molecular testing identified EGFR L858R mutation. Baseline imaging demonstrated multiple brain and bone metastases. PD-L1 reported as <1%. Patient was started on osimertinib 80 mg daily and achieved a radiographic partial response at first restaging (8 weeks).", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric artery. CA 19-9 at diagnosis 2,000 U/mL. Multimodality therapy included concurrent chemoradiation with weekly gemcitabine after diagnostic laparoscopy; no actionable genomic alterations were identified on NGS. On restaging CT there is a modest decrease in primary tumor size and CA 19-9 has fallen to 900 U/mL \u2014 disease considered stable following chemoradiation.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA 19-9 2,000 U/mL (declined to 900 U/mL)", "treatment": "concurrent chemoradiation with gemcitabine", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with right-sided colon adenocarcinoma, biopsy-proven stage IV with multiple hepatic lesions on CT. Tumor NGS: KRAS G12D mutation. MSI testing: MSI-stable. He was treated with FOLFOX plus bevacizumab as first-line systemic therapy but interval scans show enlarging liver lesions consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 42-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast, cT2N1 (IIB). ER positive, PR negative; HER2 amplified by FISH. No germline mutation identified on panel. Received neoadjuvant paclitaxel with dual HER2 blockade (trastuzumab + pertuzumab). Underwent lumpectomy and sentinel node biopsy \u2014 pathology shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive, PR negative", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic castration-resistant prostate adenocarcinoma in a 68-year-old man with extensive sclerotic bone metastases. Germline testing identified a pathogenic BRCA2 mutation. PSA at presentation was 85 ng/mL. He was started on androgen deprivation therapy and olaparib; interval scans show no new lesions and stable size of bone metastases.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 85 ng/mL", "treatment": "olaparib and androgen deprivation therapy", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old female with newly diagnosed left breast invasive ductal carcinoma. Core biopsy: ER positive, PR negative, HER2 3+ by IHC with confirmed HER2 amplification on FISH. Germline testing returned a pathogenic BRCA1 variant. Staged clinically as IIB (T2 N1). She underwent lumpectomy with sentinel node biopsy followed by adjuvant doxorubicin/cyclophosphamide then paclitaxel and trastuzumab; currently completing trastuzumab. No radiographic evidence of disease on postoperative CT chest/abdomen.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIB", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "ER positive; HER2 amplification (IHC 3+ / FISH positive)", "treatment": "lumpectomy; adjuvant doxorubicin and cyclophosphamide then paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with intermediate-risk prostate adenocarcinoma (Gleason 3+4, cT2b) \u2014 clinical stage II. No genomic testing was performed. He received definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide). PSA fell initially but has begun to rise over three consecutive measurements consistent with biochemical recurrence.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation and androgen deprivation therapy (leuprolide)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative clinic note: 46-year-old woman with locally advanced right breast mass. Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER positive (80%), PR negative. Clinical stage IIIB with fixed axillary nodes. Neoadjuvant plan: weekly paclitaxel with trastuzumab for 12 weeks followed by definitive surgery. Post-neoadjuvant imaging shows marked reduction in size; patient proceeded to mastectomy and surgical pathology demonstrated a complete pathologic response (no residual invasive carcinoma).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant); mastectomy", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 43-year-old female with locally advanced invasive ductal carcinoma of the right breast, ER negative, PR negative, HER2 IHC 3+ consistent with HER2 amplification. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant chemotherapy with docetaxel and carboplatin in combination with trastuzumab for 6 cycles. Surgery followed by pathologic review showed no residual invasive carcinoma (pCR). No distant disease identified on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 55-year-old man with metastatic cutaneous melanoma, BRAF V600E positive on tumor PCR. Presented with progressive dyspnea; CT shows multiple pulmonary nodules consistent with metastases. Started targeted therapy with dabrafenib and trametinib but follow-up at 8 weeks documents new lesions and overall radiographic progression. No PD-L1 or TMB reported in this chart.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT showed multiple bilateral pulmonary nodules and a 2.5 cm cerebellar lesion consistent with metastasis. Molecular testing returned EGFR L858R; PD-L1 reported at 10%. Patient was started on osimertinib 80 mg daily with plan for stereotactic radiosurgery to the brain lesion. Interval imaging after 8 weeks demonstrates a decrease in size of measurable disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER+/PR+ HER2-amplified metastatic breast cancer (stage IV) presenting with multiple sclerotic lesions in the spine and pelvis. She received first-line docetaxel with trastuzumab and pertuzumab. Interval imaging demonstrates stable disease in the bones.", "output": {"cancer_type": "metastatic breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 58-year-old male diagnosed with lung adenocarcinoma in Jan 2024. Staging workup confirmed stage IV disease with multiple enhancing lesions on brain MRI consistent with metastases. Molecular testing identified EGFR L858R mutation. PD-L1 reported 10%. Patient was started on osimertinib 80 mg PO daily in February; 8-week scan demonstrates decrease in size of intracranial lesions and shrinking primary, consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent wide local excision for stage III cutaneous melanoma. Molecular testing on the primary showed BRAF V600E. Given high risk for recurrence she was started on adjuvant pembrolizumab. Surveillance at 6 months identified a new lung nodule which biopsy confirmed as metastatic melanoma; therapy was changed to dabrafenib plus trametinib. The course showed an initial partial response but later progression with new brain lesions at month 14.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib plus trametinib", "response": "initial partial response followed by progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female presenting with cough and headaches. Imaging and biopsy confirm stage IV lung adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 by IHC 10%. MRI shows multiple small brain metastases and focal lytic lesions in the thoracic spine. Patient was started on osimertinib 80 mg daily; 8-week scan demonstrates reduction in size of both intracranial and pulmonary lesions. Assessment: partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma. Tumor sequencing demonstrated BRAF V600E and the tumor is MSI-H by PCR. CT abdomen shows multiple hepatic lesions consistent with liver metastases. Given MSI-H status the patient was started on pembrolizumab as first-line immunotherapy; restaging after 12 weeks demonstrated stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with invasive ductal breast cancer, clinical stage IIB. Tumor was ER positive, PR positive and HER2 amplified by FISH. NGS identified a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy, then received adjuvant doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab and pertuzumab. Completed adjuvant therapy and is currently NED on surveillance.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "surgery (lumpectomy); doxorubicin/cyclophosphamide; paclitaxel; trastuzumab; pertuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with a 0.8 mm superficial spreading melanoma on the right forearm (Breslow 0.8 mm, Clark II), staged as IA. He underwent wide local excision with 1 cm margins; no sentinel lymph node biopsy was performed. No molecular testing or systemic therapy was done. At six-month follow-up there is no clinical evidence of disease.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging showed metastatic disease to brain and bones with additional focal lesions in the liver. Molecular testing revealed EGFR L858R and PD-L1 10%. He was started on osimertinib with an initial partial response on first CT, but interval scans after 6 months demonstrated progression in the liver.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "initial partial response, later progression", "metastasis_site": "brain; bone; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with localized prostate adenocarcinoma, clinical stage II (cT2b N0 M0), Gleason score 3+4=7. He underwent radical prostatectomy with negative margins and pelvic lymph node sampling; postoperative PSA is undetectable. No molecular testing or biomarker data available; no adjuvant systemic therapy was given.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy (pelvic lymph node sampling)", "response": "undetectable PSA / disease-free post-op", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old gentleman with castrate-resistant prostate adenocarcinoma. He has progressive PSA rise despite ongoing androgen deprivation therapy and was started on docetaxel last month. Imaging demonstrates new sclerotic bone lesions consistent with osseous metastases and worsening bone pain. No molecular testing or PD-L1 results are available in the record.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left invasive ductal carcinoma of the breast. Clinical stage IIIB. Core biopsy showed HER2 IHC 3+ with HER2 amplification by FISH, ER and PR were negative. She received neoadjuvant paclitaxel with trastuzumab for six cycles and subsequently underwent a modified radical mastectomy. Final pathology demonstrated a complete pathologic response. No distant metastases were identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Imaging and oncology follow-up: 68-year-old man with symptomatic ascending colon mass. Biopsy confirmed adenocarcinoma with KRAS G12D mutation. Baseline CEA 150 ng/mL. CT shows multiple hypovascular hepatic lesions consistent with metastases. He was started on FOLFOX with bevacizumab. Three-month restaging CT shows no new lesions and minimal change in size of liver mets \u2014 radiographic assessment: stable disease. Final impression: Stage IV colon adenocarcinoma with liver metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 150 ng/mL", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly progressive colorectal adenocarcinoma. Tissue NGS showed KRAS G12D. CT abdomen/pelvis demonstrates multiple targetable-appearing lesions in both hepatic lobes consistent with liver metastases. He completed 3 cycles of FOLFOX with bevacizumab but interval imaging documents increase in size and number of hepatic lesions \u2014 evidence of progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male presenting with cough and headache. Imaging revealed primary lung adenocarcinoma with multiple pulmonary nodules and brain metastases. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score ~10%. He was started on osimertinib as first-line therapy. At 8-week restaging MRI there is decreased size of brain lesions and thoracic CT shows reduction in pulmonary nodules consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer (T4b N2) referred to neoadjuvant therapy. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with confirmed HER2 amplification by FISH, ER 80%+, PR 30%. PIK3CA hotspot mutation H1047R reported on targeted panel. She was treated with neoadjuvant trastuzumab, pertuzumab and docetaxel for six cycles. Letrozole was planned post-op. Clinical exam and imaging after chemo show marked reduction in tumor size (partial response). No distant metastases identified on PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and pertuzumab with docetaxel; letrozole planned", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "De novo stage IV invasive ductal carcinoma of the breast, ER positive, PR negative, HER2 3+ by IHC with HER2 amplification on FISH. Tumor NGS identified PIK3CA H1047R. Patient received first-line trastuzumab + pertuzumab with docetaxel (TCHP) and alpelisib was added for PIK3CA-driven disease. PET/CT at 12 weeks showed marked regression of hepatic lesions and significant symptomatic improvement.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel; later alpelisib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male presents with obstructing sigmoid mass. Pathology: colon adenocarcinoma, clinically metastatic at presentation. Molecular profiling: BRAF V600E positive; tumor is MSI-H and TMB-high. Staging consistent with stage IV disease with multiple hepatic lesions. Given pembrolizumab monotherapy due to MSI-H status with interval scans demonstrating complete radiographic response at 6 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man presented with progressive dyspnea. Imaging and biopsy confirmed lung adenocarcinoma with multiple bilateral pulmonary nodules and brain metastases. Staging was consistent with stage IV disease. Molecular testing identified EGFR L858R. PD-L1 tumor proportion score was 10%. He was started on osimertinib as first-line targeted therapy. Interval scans after 8 weeks showed a partial response in the thorax but a new focal lesion in the T8 vertebral body concerning for osseous spread.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma presenting with headaches and bone pain. Imaging demonstrated multiple cerebral and osseous lesions. Molecular testing returned an EGFR exon 19 deletion; PD-L1 was 10% and tumor mutational burden reported as low. He was started on osimertinib and subsequently underwent stereotactic radiosurgery to the dominant brain metastases. On first follow-up imaging there was a decrease in size of systemic disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%; TMB-low", "treatment": "osimertinib; stereotactic radiosurgery to brain lesions", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Imaging addendum (CT chest/abdomen): Patient with metastatic cutaneous melanoma. Numerous pulmonary nodules noted; no new intracranial lesions on recent MRI. Known BRAF V600E positive tumor treated with combination targeted therapy (dabrafenib + trametinib) for 4 months. Interval imaging demonstrates small decrease in several nodules with overall disease stability. PD-L1 and TMB results not available in chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 62-year-old with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. Colonoscopy primary in ascending colon, KRAS G12D identified on NGS. Tumor characterized as microsatellite-stable (MSI-stable). CT abdomen shows multiple liver lesions consistent with metastases. Treated with FOLFOX and bevacizumab for 6 cycles; restaging demonstrates increase in size of hepatic lesions and rising CEA\u2014treatment considered progressive disease and plan is to switch to irinotecan-based regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with T3N1M0 (stage IIIA) invasive ductal carcinoma of the left breast. ER 80%, PR 60%, HER2 FISH positive consistent with HER2 amplification. NGS identified PIK3CA H1047R. She received neoadjuvant docetaxel/carboplatin with trastuzumab and pertuzumab for 6 cycles with excellent clinical shrinkage; mastectomy specimen showed no residual invasive carcinoma (pathologic complete response). No distant metastases on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old woman with HER2-positive metastatic breast cancer (invasive ductal carcinoma). Core biopsy showed HER2 amplification by FISH, ER positive, PR positive; PIK3CA H1047R mutation identified on NGS. Clinical stage at presentation was IV with hepatic metastases. She received combination therapy with trastuzumab, pertuzumab and docetaxel followed by maintenance trastuzumab; most recent CT shows a good partial response in the liver.", "output": {"cancer_type": "metastatic breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+, PR+", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic lung adenocarcinoma presented with progressive cough. Molecular testing returned EGFR L858R. PD-L1 reported as 10%. MRI brain shows two enhancing lesions and bone scan positive for osseous involvement. Started osimertinib 80 mg daily in May; interval CT chest/abdomen shows shrinkage of target lesions and decreased enhancement of the brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Diagnostic workup confirmed stage IV disease. Next-generation sequencing detected KRAS G12D and the tumor was microsatellite stable (MSS). He was treated with FOLFOX plus bevacizumab. CT at 12 weeks demonstrated stable disease of the liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental disease at presentation. Germline BRCA1 pathogenic variant identified on hereditary testing. CA-125 markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel and has been started on maintenance olaparib. Most recent CT shows stable residual peritoneal/omental disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum / omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 43-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical T4bN1 \u2014 stage IIIB. Core biopsy showed HER2 amplification by FISH and ER+/PR+ by IHC. Germline testing identified a deleterious BRCA1 mutation. She completed neoadjuvant regimen with docetaxel, carboplatin and trastuzumab, proceeded to modified radical mastectomy; surgical pathology revealed no residual invasive carcinoma (pathologic complete response). No distant disease noted on imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing on the primary tumor identified EGFR L858R and EGFR T790M. PD-L1 TPS reported at 10% and tumor mutational burden described as TMB-high (12 mut/Mb). She initially received osimertinib with a partial response, but on systemic progression was started on pembrolizumab in combination with carboplatin and pemetrexed, currently demonstrating ongoing partial response. Imaging shows brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%; TMB-high", "treatment": "osimertinib; pembrolizumab + carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with a 1.2 cm invasive ductal carcinoma of the right breast. Core biopsy: ER 80%, PR 60%, HER2 IHC 3+ consistent with HER2 amplification on FISH. She underwent lumpectomy with sentinel node biopsy (0/3 nodes) followed by adjuvant paclitaxel and trastuzumab for 12 months. At last follow-up (24 months) she is without evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman underwent lumpectomy for a 1.2 cm invasive ductal carcinoma. Pathology: ER 90%, PR 40%, HER2 IHC 3+ with confirmation of HER2 amplification by FISH. Sentinel lymph node biopsy negative. Pathologic staging pT1bN0 (Stage I). No somatic sequencing mutations were reported on the clinical report. Adjuvant plan: weekly paclitaxel x12 with trastuzumab to complete one year. On 3-month surgical follow-up there is no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old F with right-sided colorectal adenocarcinoma presenting with multiple liver lesions. Clinical stage IV disease. Tumor sequencing: BRAF V600E mutation; MSI-High on PCR. Given MSI-H status she was started on pembrolizumab monotherapy. Interval CT at 12 weeks shows marked reduction in size of hepatic metastases consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-High", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with advanced cutaneous melanoma (stage IV) found to harbor BRAF V600E on tumor sequencing. PD-L1 expression was low (about 5%). After resection of the primary lesion he was started on dabrafenib plus trametinib; despite initial symptom control he developed new symptomatic brain metastases and interval imaging documented progression. He was treated with stereotactic radiosurgery to the brain lesions and systemic therapy was changed to nivolumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; later nivolumab (after SRS)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology clinic note: 70-year-old male with metastatic prostate adenocarcinoma, bone-predominant disease. Initial PSA was 118 ng/mL. Germline testing positive for BRCA2 pathogenic variant. Patient started on androgen deprivation therapy plus docetaxel; PSA initially fell but later rose and imaging confirmed progression in multiple sclerotic bone lesions. Plan for switch to second-line AR-targeted therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation (germline)", "biomarker": "PSA 118 ng/mL", "treatment": "androgen deprivation therapy and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with widely metastatic cutaneous melanoma presented with headaches. MRI brain shows multiple enhancing metastases; chest CT demonstrates numerous pulmonary nodules. Tumor sequencing positive for BRAF V600E. He was started on dabrafenib plus trametinib with symptomatic improvement and a partial response on first reassessment scan. PD-L1 and TMB were not reported.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with sigmoid colon adenocarcinoma status post colectomy initially staged as T3N1. Recurrence on surveillance CT with multiple pulmonary nodules consistent with metastatic spread. Tumor sequencing identified KRAS G12D. MSI testing was stable. He was started on FOLFOX with bevacizumab and has had no radiographic progression after three cycles.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV (recurrent metastatic)", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 65-year-old M with obstructing sigmoid mass and synchronous liver lesions. Colonoscopy biopsy = adenocarcinoma. CT shows multiple hepatic metastases consistent with stage IV disease. Tumor genotyping: KRAS G12D; MMR intact (MSI-stable). Started FOLFOX with bevacizumab. Interval restaging CT after 3 cycles: hepatic lesions stable in size \u2014 provider documents stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MMR proficient)", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with metastatic pancreatic ductal adenocarcinoma diagnosed after presentation with jaundice. CT shows a pancreatic head mass with multiple hepatic lesions. Germline testing revealed a deleterious BRCA2 mutation. CA19-9 markedly elevated at diagnosis. He received 8 cycles of FOLFIRINOX with good tumor shrinkage followed by olaparib maintenance; after 10 months there was new growth in the liver lesions consistent with progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "initial partial response followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male referred for metastatic colorectal adenocarcinoma after presentation with abdominal pain and weight loss. CT abdomen/pelvis shows multiple hepatic metastases and peritoneal nodularity. Molecular profile returned BRAF V600E mutation and high microsatellite instability (MSI-H); tumor mutational burden reported as TMB-high. First-line FOLFOXIRI plus bevacizumab led to clinical progression; patient was switched to encorafenib and cetuximab with a subsequent radiographic partial response on restaging scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOXIRI plus bevacizumab; encorafenib and cetuximab", "response": "partial response (after encorafenib/cetuximab)", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER positive (80%), PR negative. She received neoadjuvant trastuzumab and pertuzumab in combination with docetaxel for six cycles followed by mastectomy. Final pathology reported a pathologic complete response (pCR). No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma. Biopsy of a pulmonary nodule confirmed BRAF V600E mutation; PD-L1 by IHC was 10%. He was started on dabrafenib plus trametinib and initially had shrinkage of lung lesions, but after four months developed new hepatic lesions consistent with progression and required palliative hepatic embolization.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib; hepatic embolization (palliative)", "response": "progression", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 63-year-old with borderline resectable pancreatic head mass underwent pancreaticoduodenectomy. Final pathology: pancreatic ductal adenocarcinoma, tumor 3.2 cm, perineural invasion present, 1/15 nodes positive. Clinical stage was III prior to surgery. Patient started adjuvant gemcitabine and capecitabine; surveillance CT at 6 months shows no evidence of disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "pancreaticoduodenectomy (Whipple) followed by adjuvant gemcitabine and capecitabine", "response": "no evidence of disease on 6-month surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV metastatic cutaneous melanoma harboring BRAF V600E mutation. PET/CT showed an FDG-avid lesion in the left femur consistent with osseous metastasis. Baseline tumor profiling reported high tumor mutational burden. He was initiated on combination BRAF/MEK inhibition (dabrafenib plus trametinib) and has had a partial radiologic response with decreased size and sclerosis of the femoral lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op oncology note: 43-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical stage IIIA. Tumor is ER positive, PR negative and HER2 amplified by FISH. She received 6 cycles of neoadjuvant docetaxel with trastuzumab and pertuzumab. Post-treatment imaging and surgical pathology show no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Biopsy confirmed adenocarcinoma and molecular testing returned EGFR L858R positive. PD-L1 tumor proportion score was 10%. She received carboplatin and pemetrexed x4 with initial symptomatic improvement and was transitioned to osimertinib 80 mg daily for systemic therapy with CNS penetration given known brain metastases. Most recent CT and MRI show decrease in size of pulmonary nodules and shrinkage of intracranial lesions \u2014 overall partial response. Stage IV disease with brain and bone involvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "carboplatin and pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for a T3 mass. Final pathology: moderately differentiated adenocarcinoma of the colon, pathologic stage II (T3N0). MSI testing returned MSI-H. Tumor sequencing detected KRAS G12D. Multidisciplinary team elected surveillance without adjuvant 5-FU\u2013based chemotherapy given MSI-H status. Surveillance CT at 12 months shows no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "right hemicolectomy (surgical resection); surveillance (no adjuvant chemotherapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with stage II left breast invasive ductal carcinoma, ER positive, PR positive, HER2 negative on IHC/FISH. Core biopsy sequencing detected a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy (0/3 nodes) and completed adjuvant dose-dense doxorubicin + cyclophosphamide x4 followed by paclitaxel x12. She is currently receiving adjuvant letrozole and annual imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "surgery (lumpectomy), adjuvant doxorubicin + cyclophosphamide then paclitaxel, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 62-year-old female with metastatic pancreatic ductal adenocarcinoma presenting with multiple hepatic lesions (stage IV). Germline testing returned a deleterious BRCA2 mutation. Baseline CA19-9 was 500 U/mL. She received FOLFIRINOX with initial tumor shrinkage, was switched to maintenance olaparib, and now has radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "CA19-9 500 U/mL", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with metastatic colorectal adenocarcinoma, stage IV at diagnosis. NGS panel detected KRAS G12D. Tumor testing returned MSI-H and high tumor mutational burden (TMB-high). He was started on FOLFOX plus bevacizumab with mixed radiographic response in the liver, then transitioned to pembrolizumab given MSI-H status; most recent scans show stable disease in hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high\u2011grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a deleterious BRCA1 mutation (c.68_69delAG, 185delAG). Underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel; maintenance olaparib was initiated thereafter. CA-125 has normalized and CT chest/abdomen/pelvis shows no evidence of disease at 6 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.68_69delAG (185delAG)", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Presented with multiple symptomatic brain and bone lesions and staged IV. Molecular testing detected EGFR L858R and an acquired EGFR T790M. PD-L1 was 5% by IHC and tumor mutational burden reported as 8 mut/Mb. He previously received carboplatin and pemetrexed with pembrolizumab for 4 cycles with radiographic progression and was transitioned to osimertinib 80 mg daily. Follow-up CT/MRI at 8 weeks shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 5%; TMB 8 mut/Mb", "treatment": "carboplatin + pemetrexed + pembrolizumab; osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old female presented with progressive cough and was found to have metastatic lung adenocarcinoma, stage IV. Molecular testing showed EGFR L858R mutation. MRI head demonstrated two small parenchymal brain metastases and PET/CT revealed focal uptake in the T8 vertebral body. She was started on osimertinib 80 mg daily with rapid symptomatic improvement and interval imaging at 8 weeks showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (T8)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma presented with progressive cough. Baseline staging CT and brain MRI confirmed stage IV disease with a solitary cerebellar metastasis. Molecular testing returned EGFR L858R; PD-L1 was 30% by 22C3. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the cerebellar lesion. Interval imaging at 8 weeks shows shrinkage of the primary and decreased size of the brain lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30% (22C3)", "treatment": "osimertinib 80 mg daily; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with metastatic cutaneous melanoma. Molecular profiling positive for BRAF V600E. Baseline imaging showed multiple pulmonary nodules and a solitary cerebellar metastasis. He initiated dabrafenib plus trametinib. After two months the pulmonary lesions have decreased but a new small cerebellar lesion was identified on MRI \u2014 overall a mixed response; patient subsequently received stereotactic radiosurgery to the brain and continued targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery to brain", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and pathology: Right hemicolectomy for adenocarcinoma of the proximal colon. Final path: pT3 N1 (stage III). MSI testing reported MSI-H. Patient completed surgery and adjuvant FOLFOX x6; KRAS/NRAS sequencing not available on initial report. On surveillance CT at 12 months there is no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man diagnosed with localized prostate adenocarcinoma, Gleason 3+4=7, clinical stage IIA. He completed definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide). No genomic or biomarker testing was performed at the time of diagnosis. Post-treatment PSA has declined compared with baseline and there is no radiographic evidence of metastatic disease on recent scans.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation; androgen deprivation therapy (leuprolide)", "response": "PSA decline / no radiographic evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman presented with a left breast mass. Core needle biopsy: invasive ductal carcinoma, ER positive (80%), PR negative, HER2 3+ by IHC; FISH confirmed HER2 amplification. Clinical staging was cT4bN1M0 (stage IIIB). Neoadjuvant therapy consisted of weekly paclitaxel with dual HER2 blockade (trastuzumab and pertuzumab) for 12 weeks. She underwent lumpectomy and axillary dissection; surgical pathology reported no residual invasive carcinoma and negative nodes (pathologic complete response). Adjuvant radiation was delivered to the breast and regional nodes. No distant metastases identified on staging CT/PET.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel + trastuzumab + pertuzumab; surgery; adjuvant radiation", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma (stage IV) with multiple liver lesions. Molecular testing revealed KRAS G12D and microsatellite stable (MSS) status. He was started on FOLFOX with bevacizumab; restaging after 3 cycles showed stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male status post right hemicolectomy for adenocarcinoma of the colon. Pathology stage III (T3N1). Molecular testing identified KRAS G12D; MSI testing was MSS. He completed six months of adjuvant FOLFOX and surveillance CTs show no measurable disease at this time.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note/pathology: 52-year-old with left breast invasive ductal carcinoma, lumpectomy performed. Pathology: 2.1 cm tumor, 0/3 sentinel nodes involved. ER 90%+, PR 40%+, HER2 IHC 0. Patient underwent adjuvant whole-breast radiation and was started on tamoxifen. No genomic panel was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. Staging consistent with stage IV disease. Molecular profiling returned EGFR L858R and an acquired T790M mutation. PD-L1 expression by TPS was 60%. She was started on osimertinib with good intracranial response; after systemic progression she received pembrolizumab in combination with carboplatin and pemetrexed. Imaging shows reduction in lung primary but persistent small brain lesions and osseous metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 \u226550%", "treatment": "osimertinib; pembrolizumab + carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 IHC 3+ with FISH confirmation of HER2 amplification. Clinical stage II (T2N0). PIK3CA H1047R identified on NGS panel. She received neoadjuvant docetaxel, carboplatin and trastuzumab for 4 cycles followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man diagnosed with prostate adenocarcinoma, clinical stage II (T2bN0M0). PSA at presentation was 12 ng/mL. Management plan: definitive external beam radiation therapy with concurrent androgen deprivation therapy (leuprolide). Bone scan and CT showed no evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "external beam radiation therapy and leuprolide (androgen deprivation)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and follow-up: 67-year-old male underwent radical prostatectomy for localized prostate adenocarcinoma, Gleason 3+4=7. Path report pT2, margins negative, no LVI. PSA fell to undetectable post-op. No adjuvant systemic therapy administered; patient on routine PSA surveillance with no radiographic evidence of disease at last visit.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 38-year-old with a 0.8 cm cutaneous melanoma on the left forearm, Breslow 0.9 mm, staged as I after wide local excision and negative sentinel node biopsy. Molecular testing returned positive for BRAF V600E. No adjuvant systemic therapy was recommended given low-risk features.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with high-risk prostate adenocarcinoma underwent radical prostatectomy; pathology revealed extraprostatic extension and seminal vesicle invasion with one positive lymph node (pT3b N1). Post-op PSA began to rise and he received salvage external beam radiotherapy with concurrent androgen-deprivation therapy (leuprolide). His PSA subsequently fell to undetectable levels and he is currently in biochemical remission. No somatic genomic testing or PD-L1/other biomarkers were reported in the record.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "pT3b N1", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; salvage external beam radiation; leuprolide (androgen-deprivation therapy)", "response": "biochemical remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma presented with progressive dyspnea. Staging confirmed stage IV disease with multiple bilateral pulmonary nodules and brain metastases. NGS of the primary tumor identified an EGFR exon 19 deletion. PD-L1 by IHC was 10%. He was started on first-line osimertinib and received stereotactic radiosurgery to a 1.2 cm cerebellar lesion. Interval CT and MRI at 8 weeks demonstrate a marked decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male with newly diagnosed metastatic lung adenocarcinoma. CT-guided biopsy (March 2024) confirmed lung adenocarcinoma. Molecular testing: EGFR L858R mutation identified; PD-L1 TPS 10%. Staging shows multiple brain and bone lesions consistent with metastatic disease (stage IV). Patient started osimertinib 80 mg PO daily in April. Repeat imaging at 12 weeks demonstrated a partial response with reduction in size of both pulmonary and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 48-year-old female with a 3.5 cm left breast mass, biopsy-proven invasive ductal carcinoma, clinically T2N1. ER and PR positive, HER2 IHC 3+ with confirmatory FISH showing HER2 amplification. No germline mutation testing performed. Clinical stage assigned as IIIA. She received neoadjuvant chemotherapy with docetaxel plus trastuzumab and pertuzumab for six cycles. Patient went to definitive lumpectomy and sentinel node biopsy; pathology showed no residual invasive carcinoma (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel with trastuzumab and pertuzumab; surgery (lumpectomy)", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "24-year-old male diagnosed with metastatic cutaneous melanoma. Biopsy of a supraclavicular node confirmed melanoma harboring BRAF V600E. He initially received dabrafenib and trametinib with marked regression of pulmonary nodules but interval MRI showed new hepatic lesions. Subsequent therapy was switched to nivolumab monotherapy. Current radiology describes mixed response \u2014 ongoing partial response in lungs with progression in the liver.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then nivolumab", "response": "mixed response (partial response in lung, progression in liver)", "metastasis_site": "lung; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old woman with high-grade serous ovarian carcinoma presenting with ascites and multiple liver lesions consistent with metastatic disease, clinical stage IV. Germline testing returned BRCA1 pathogenic variant. CA-125 at diagnosis was 1,250 U/mL. She received frontline carboplatin and paclitaxel with bevacizumab; after three cycles there was radiographic progression in the liver and rising CA-125. She was transitioned to palliative therapy and later started maintenance olaparib for BRCA1.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IV", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 1250 U/mL", "treatment": "carboplatin and paclitaxel with bevacizumab; later olaparib maintenance", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with metastatic melanoma presenting with multiple liver lesions. Biopsy confirmed melanoma, BRAF V600E positive. High tumor mutational burden reported. He received first-line pembrolizumab with initial radiologic stable disease; after 4 months progressive hepatic enlargement and rising LFTs prompted switch to dabrafenib + trametinib but the scan after 6 weeks showed further progression in the liver.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab followed by dabrafenib + trametinib", "response": "initial stable disease then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma to the liver. Pathology shows MSI-H and high tumor mutational burden. Genomic profiling identified a BRAF V600E mutation. Given MSI-H status he was started on pembrolizumab as first-line therapy and interval CT at 12 weeks demonstrated a partial response with reduction of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 42-year-old woman with locally advanced invasive ductal carcinoma, clinically T3N2 (stage IIIB). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. Tumor sequencing detected a PIK3CA H1047R mutation. She received 6 cycles of neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab. Surgery report later documented no residual invasive carcinoma (pathologic complete response) in the breast and nodes.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic right-sided colorectal adenocarcinoma. Molecular testing: MSI-high on immunohistochemistry and NGS reported TMB-high; tumor also harbors a BRAF V600E mutation. At diagnosis there were multiple hepatic lesions and peritoneal nodules. He was started on pembrolizumab and achieved a partial response, but progressed after 6 months with enlarging liver lesions. He was then switched to encorafenib plus cetuximab with subsequent disease stabilization on imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (initial) then encorafenib + cetuximab", "response": "initial partial response then progression on pembrolizumab; subsequent stable disease on encorafenib + cetuximab", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with ascites and multiple liver lesions. Tumor profiling returned BRAF V600E mutation and high microsatellite instability (MSI-H) with TMB-high. He received single-agent pembrolizumab as first-line immunotherapy with initial disease control, then was transitioned to FOLFIRI plus bevacizumab after mixed radiologic changes. Current impression: radiology describes shrinkage of some hepatic lesions but new peritoneal implants.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab then FOLFIRI plus bevacizumab", "response": "mixed response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with invasive ductal carcinoma of the breast, pathologic stage IIA (T2N0M0). Tumor was ER positive, PR positive and HER2 amplified by FISH. NGS panel detected a PIK3CA E545K mutation. She underwent lumpectomy and sentinel node biopsy followed by adjuvant paclitaxel and planned trastuzumab. Six-month follow-up mammogram and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female diagnosed with lung adenocarcinoma after workup for cough. Staging confirmed stage IV disease with brain and bone metastases. Tumor NGS demonstrated EGFR L858R mutation; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy. CT/MRI at 12 weeks showed decrease in size of pulmonary and CNS lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman with locally advanced breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 amplification by FISH. She received neoadjuvant TCH (docetaxel, carboplatin, trastuzumab) x6 with marked tumor shrinkage and then underwent mastectomy. Final pathology demonstrated no residual invasive carcinoma (pathologic complete response). No evidence of distant metastases on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic pancreatic ductal adenocarcinoma presenting with progressive jaundice. Staging CT shows multiple liver metastases. Next-generation sequencing demonstrated KRAS G12V. No actionable biomarkers (no MSI testing or PD-L1 reported) were documented. He was started on FOLFIRINOX; restaging after three cycles indicates interval progression of hepatic disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V", "biomarker": null, "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "40-year-old male with a 2.1 cm ulcerated melanoma on the back, final pathologic stage IIB after wide local excision. Tumor testing identified a BRAF V600E mutation. Given high-risk features the patient was started on adjuvant pembrolizumab; surveillance imaging and exam are consistent with no evidence of disease.", "output": {"cancer_type": "melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; adjuvant pembrolizumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chemotherapy note: 52-year-old woman with ER-positive, PR-negative, HER2-amplified metastatic breast cancer (initially stage II, now stage IV) with progressive liver and bone metastases. Tumor genotyping identified a PIK3CA H1047R mutation. She started first-line therapy with trastuzumab, pertuzumab and docetaxel. After three cycles imaging shows disease stable compared with baseline.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with pancreatic ductal adenocarcinoma, germline BRCA2 mutation identified. CT shows multifocal liver lesions and peritoneal nodularity consistent with stage IV disease. Treated with FOLFIRINOX with initial tumor shrinkage and falling CA 19-9, then transitioned to olaparib maintenance; recent scans and rising CA 19-9 indicate radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "progressive disease after initial partial response", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology clinic: 62-year-old man with newly diagnosed prostate adenocarcinoma, PSA 6.2 ng/mL, biopsy Gleason 3+3=6 in two cores. Clinical stage I (T1c). Given low-risk features he opted for active surveillance with serial PSA and MRI; no evidence of extraprostatic extension on imaging and no metastatic symptoms.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "active surveillance", "response": "stable disease / no progression on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma presenting with abdominal distension and ascites. At laparoscopy there is widespread peritoneal carcinomatosis; optimal debulking followed by adjuvant carboplatin and paclitaxel was completed. CA-125 normalized after treatment and follow-up CT shows no residual disease signal.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "surgery (optimal debulking) and carboplatin plus paclitaxel", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 47-year-old woman with core biopsy showing invasive ductal carcinoma, ER 90%+, PR negative, HER2 IHC 3+ with FISH-confirmed HER2 amplification. Clinical stage was T2N1 (stage II). She received neoadjuvant chemotherapy \u2014 dose-dense AC x4 then paclitaxel with concurrent trastuzumab \u2014 and underwent mastectomy. Final pathology: no residual invasive carcinoma in breast or nodes (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "dose-dense doxorubicin/cyclophosphamide then paclitaxel with trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma. Molecular panel from the biopsy returned EGFR L858R (exon 21). PD-L1 TPS reported as 10%. Staging at presentation was IV with known intracranial and osseous involvement. Patient was started on osimertinib 80 mg daily in March and tolerated therapy well. Interval CT chest and brain MRI after 8 weeks showed shrinkage of pulmonary nodules and decreasing size of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R (exon 21)", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging workup shows stage IV disease with multiple hepatic lesions and two enhancing lesions in the cerebellum consistent with brain metastases. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 10%. She was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the cerebellar lesions. Interval CT at 8 weeks demonstrates decrease in size of hepatic metastases and improvement of the dominant right lower lobe mass \u2014 overall assessment: partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "liver, brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old male had an irregular pigmented lesion on the left forearm excised. Final pathology: superficial spreading melanoma, Breslow 0.6 mm, no ulceration, sentinel lymph node biopsy negative. Final stage IA. Tumor sequencing detected BRAF V600E. No adjuvant systemic therapy recommended; surveillance with skin exams and periodic imaging was planned.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "IA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy (no adjuvant therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Tumor sequencing also reported high tumor mutational burden (TMB-high). He presented with liver and pulmonary metastases. He initially received pembrolizumab but progressed at 3 months and was transitioned to dabrafenib plus trametinib; after a short-lived partial response he again developed systemic progression.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female referred to medical oncology for metastatic lung disease. Biopsy confirmed lung adenocarcinoma, clinical stage IV with both brain and bone lesions on MRI and PET. Tumor NGS identified EGFR L858R mutation; PD-L1 testing returned 10% TPS. She was started on osimertinib 80 mg daily in January; interval imaging after 8 weeks shows shrinkage of pulmonary nodules and decreased enhancement of brain metastases. Impression: partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Gynecologic oncology summary: Patient diagnosed with high-grade serous ovarian carcinoma, extensive peritoneal carcinomatosis consistent with stage IIIC disease. Germline and somatic testing positive for BRCA1 5382insC. Tumor shown to be HRD-positive. She completed six cycles of carboplatin and paclitaxel with good clinical response and was transitioned to maintenance olaparib. CA-125 normalized and CT shows resolution of bulky disease \u2014 complete clinical response to therapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 5382insC", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op consultation: 43-year-old woman with left breast mass. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with confirmatory FISH showing HER2 amplification; ER positive, PR negative. PIK3CA H1047R mutation detected on NGS panel. Clinical stage IIIB due to matted axillary nodes. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles. Follow-up surgical pathology after mastectomy demonstrated no residual invasive carcinoma (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presented with progressive hepatic disease. MSI testing returned MSI-H and tumor mutational burden was reported as high. Prior therapy included FOLFOX + bevacizumab x8 cycles with initial minor shrinkage followed by progression in the liver. Patient was transitioned to pembrolizumab. Recent hepatic MRI documents enlarging right hepatic lobe lesions compared with prior study.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (after FOLFOX + bevacizumab)", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Wide local excision was performed for a 2.1 cm pigmented lesion on the forearm. Pathology returned nodular cutaneous melanoma, Breslow 3.2 mm, no ulceration, sentinel node negative \u2014 staged as IIB. Tumor sequencing detected BRAF V600E. Patient is on active surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision and sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 62-year-old male underwent right hemicolectomy for colon adenocarcinoma. Final staging pT3 N1, consistent with stage III disease. Tumor genotyping returned KRAS G12D mutation. Adjuvant chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU) initiated 4 weeks post-op. MSI testing was not performed at our center and no MSI-H reported. At 6-month surveillance CT there is no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "surgical resection (right hemicolectomy); adjuvant FOLFOX", "response": "no radiographic evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Molecular Tumor Board summary: Patient with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIA. ER/PR negative, HER2 IHC 3+ confirmed by FISH with HER2 amplification. Received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by mastectomy. Surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 IHC 3+ (HER2 amplification); ER/PR negative", "treatment": "paclitaxel and trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed colorectal adenocarcinoma with multiple liver metastases. Molecular testing: MSI-H by PCR and BRAF V600E mutation on NGS. Given the MSI-high status he was started on pembrolizumab monotherapy. Restaging CT at 12 weeks shows stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Presentation: 49-year-old female with progressive abdominal distension. Imaging shows bilateral adnexal masses and omental caking. CA-125 was 620 U/mL. Laparotomy confirmed high-grade serous ovarian carcinoma, stage IIIC with peritoneal carcinomatosis and omental disease; small liver surface implants noted. Germline testing positive for a deleterious BRCA1 mutation. She received neoadjuvant carboplatin and paclitaxel followed by interval debulking; CA-125 fell to 120 U/mL but restaging CT after six cycles showed new hepatic lesions and increasing nodularity consistent with disease progression. Plan to change systemic therapy to bevacizumab plus liposomal doxorubicin.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 620 U/mL (initial)", "treatment": "neoadjuvant carboplatin and paclitaxel; interval debulking; planned bevacizumab and liposomal doxorubicin", "response": "progression", "metastasis_site": "peritoneum; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old man with metastatic cutaneous melanoma. Initial therapy with nivolumab led to early progression in the brain and lungs; subsequent molecular testing revealed BRAF V600E and he was started on dabrafenib/trametinib with reduction in intracranial lesions. PD-L1 testing was not performed at the outside center.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab (prior); dabrafenib + trametinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with right breast mass. Biopsy: invasive ductal carcinoma, ER-negative, PR-negative. Clinical stage IIIB. FISH demonstrates HER2 amplification; targeted NGS reported PIK3CA H1047R mutation. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by mastectomy. Pathology reveals no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP); surgery", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast invasive ductal carcinoma, clinically T4bN2 \u2014 stage IIIB. Core biopsy: ER negative, PR negative, HER2 amplified by FISH (HER2/CEP17 ratio 4.2). She received neoadjuvant weekly paclitaxel with concurrent trastuzumab for 12 weeks prior to mastectomy. Final pathology after surgery demonstrated no residual invasive carcinoma in the breast or axillary nodes (pathologic complete response). No somatic gene panel mutations were reported in the chart.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with high-grade serous ovarian carcinoma who presented with abdominal distension. At laparotomy there was bulky omental caking and diffuse peritoneal implants; optimal debulking performed. CA-125 was markedly elevated pre-op. BRCA testing sample sent; result pending. She completed adjuvant carboplatin and paclitaxel and was started on olaparib maintenance because of strong family history. At 6-month surveillance CA-125 has risen and PET/CT suggests progressive peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "optimal debulking; carboplatin and paclitaxel; olaparib maintenance", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a 2.7 cm invasive ductal carcinoma, ER-positive, PR-positive. FISH demonstrated HER2 amplification. Pathology after lumpectomy and sentinel lymph node biopsy was T1c N1 M0 (stage IIA). She completed adjuvant paclitaxel and is receiving trastuzumab; mammogram and clinical exam at 6 months show no evidence of disease.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 62-year-old with metastatic cutaneous melanoma, stage IV. Tumor sequencing positive for BRAF V600E and high tumor mutational burden (TMB-high). He received dabrafenib plus trametinib initially but developed new pulmonary nodules and leptomeningeal enhancement on MRI at 4 months. Oncology documents systemic progression and recommends change of systemic therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "lung, brain (leptomeningeal)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male underwent colonoscopy for anemia; biopsy showed sigmoid colon adenocarcinoma. CT staging consistent with T3N0M0 (stage II). Tumor testing returned MSI-H by PCR; KRAS and BRAF were not detected. He had a low anterior resection with negative margins and node-negative disease. Given his MSI-H status and node-negative pathology, no adjuvant chemotherapy was administered. Surveillance imaging at 6 months shows no recurrent disease.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "low anterior resection (surgery); no adjuvant chemotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old female with newly diagnosed invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and HER2 negative. Pathology reports pT2N0 (stage IIA). She underwent lumpectomy with sentinel node biopsy followed by whole-breast radiation and was started on adjuvant tamoxifen. Post-op imaging shows no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel node biopsy; radiation; tamoxifen", "response": "no evidence of disease / no residual disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Biopsy-confirmed stage IV disease with brain and bone lesions. Molecular testing returned EGFR L858R and acquired EGFR T790M. PD-L1 tumor proportion score 10%. He was started on osimertinib and bevacizumab combination; first restaging CT/MRI shows a partial response with decreased size of intracranial and vertebral lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 34-year-old patient with a 1.1 cm pigmented lesion on the forearm removed by wide local excision. Final pathology: cutaneous melanoma, Breslow 0.8 mm, non-ulcerated, sentinel node negative \u2014 Stage I. Tumor sent for molecular testing and returned positive for BRAF V600E. No adjuvant therapy recommended; surveillance planned.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "complete response / no residual disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed on bronchoscopy biopsy. Molecular testing returned EGFR L858R and PD-L1 TPS 10%. Patient started osimertinib 80 mg daily in January 2024. Baseline brain MRI showed a 1.2 cm cerebellar metastasis; after 3 months of therapy repeat CT chest and brain MRI demonstrate decrease in size of pulmonary nodules and partial resolution of the cerebellar lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic metastases on CT. Started on FOLFOX with bevacizumab in the outpatient infusion center. CEA has decreased from 320 to 180 after 3 months, interval CT shows stable size of liver lesions compared with prior scan. KRAS/NRAS testing was not performed due to insurance delay.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 61-year-old female with high-grade serous ovarian carcinoma, optimally debulked at primary cytoreductive surgery; stage IIIC with extensive peritoneal involvement. Germline and somatic testing detected a BRCA2 frameshift mutation and genomic scar consistent with homologous recombination deficiency. CA-125 pre-op was markedly elevated. She completed adjuvant carboplatin and paclitaxel and was started on maintenance olaparib; interval CT shows no evidence of disease \u2014 complete response clinically and biochemically.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 frameshift mutation", "biomarker": "HRD-positive; CA-125 elevated pre-treatment", "treatment": "cytoreductive surgery; adjuvant carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 62-year-old man presented with an ulcerated cutaneous melanoma and multiple pulmonary nodules on staging CT. Extended molecular panel did not identify BRAF or NRAS mutations. PD-L1 tumor proportion score reported as >50%. He was treated with single-agent pembrolizumab but exhibited radiographic progression after four months.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative note: 59-year-old male with stage III (pT3N1) moderately differentiated colon adenocarcinoma. Tumor sequencing identified KRAS G12D; microsatellite testing shows MSS. Adjuvant FOLFOX was initiated. Follow-up CT after 4 cycles shows no new distant lesions and nodal beds stable compared with postoperative baseline.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX (adjuvant)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with right upper quadrant pain. Liver lesions on CT consistent with metastases. Tumor profiling: KRAS G12D, MSI-H, TMB-high; PD-L1 5%. Initially treated with FOLFOX plus bevacizumab with stable disease, later transitioned to pembrolizumab because of MSI-H and high TMB.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high; PD-L1 5%", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with locally advanced inflammatory breast cancer (skin involvement) presented to oncology. Tumor is ER positive, PR positive and HER2 amplified by FISH. Hotspot panel detected a PIK3CA H1047R mutation. She received neoadjuvant docetaxel and carboplatin with concurrent trastuzumab; interval imaging after three cycles showed marked reduction in primary tumor size. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (inflammatory)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old male who underwent right hemicolectomy for colon adenocarcinoma, pathology pT3N1 consistent with stage III disease. Molecular testing showed KRAS G12D mutation and microsatellite stable (MSS) status. He completed adjuvant FOLFOX for 6 months without complications and is on surveillance with no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment note: 45\u2011year\u2011old female with locally advanced invasive ductal carcinoma of the left breast, ER positive, PR positive and HER2 amplified by FISH. Clinical stage IIIB with fixed axillary nodes. She completed 12 weeks of weekly paclitaxel combined with trastuzumab prior to breast\u2011conserving surgery. Final pathology after lumpectomy and sentinel node biopsy showed no residual invasive carcinoma consistent with a pathologic complete response. No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and paclitaxel (neoadjuvant) followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left breast invasive ductal carcinoma, clinical stage II (T2N0M0). Tumor is ER positive, PR positive and HER2 negative by IHC/FISH. Targeted panel identified PIK3CA H1047R. She underwent lumpectomy followed by adjuvant doxorubicin and cyclophosphamide then paclitaxel (AC\u2192T) and has been started on letrozole.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; adjuvant doxorubicin and cyclophosphamide followed by paclitaxel; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 48-year-old woman diagnosed with invasive ductal carcinoma of the right breast. Clinical stage IIIA. ER/PR negative, HER2 amplification by FISH confirmed. Tumor NGS identified a PIK3CA H1047R mutation. She received neoadjuvant therapy with trastuzumab plus docetaxel and carboplatin for 6 cycles. Surgical specimen reported no residual invasive carcinoma \u2014 pathologic complete response (pCR). No evidence of distant metastasis.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "trastuzumab, docetaxel and carboplatin (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate adenocarcinoma (mCRPC). Baseline staging IV with extensive sclerotic bone metastases. Germline testing revealed a deleterious BRCA2 mutation. After progression on abiraterone and ADT he was started on olaparib; PSA initially fell but rose again and repeat imaging demonstrated radiographic progression. No molecular biomarker panel available in the chart.", "output": {"cancer_type": "prostate adenocarcinoma (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "olaparib (after abiraterone and ADT)", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated metastatic disease with a solitary enhancing lesion in the right frontal lobe consistent with brain metastasis. Molecular testing detected EGFR L858R mutation; PD-L1 IHC was 5%. She was started on osimertinib 80 mg daily and follow-up MRI at 8 weeks showed a partial response of both the pulmonary primary and the intracranial lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology: 2.1 cm adenocarcinoma of the right upper lobe, staged pT1bN0 (Stage IA). Tumor NGS detected EGFR L858R. PD-L1 TPS reported as 1%. Patient underwent right upper lobectomy with mediastinal lymph node sampling; no adjuvant chemotherapy was given. Follow-up CT chest/abdomen shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IA", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 1%", "treatment": "right upper lobectomy with mediastinal lymph node sampling", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old with metastatic colorectal adenocarcinoma. Liver and bilateral pulmonary metastases were noted on CT. Molecular profile: KRAS G12D, microsatellite stable. He was started on FOLFOX plus bevacizumab; after 6 cycles there was radiographic progression with enlarging liver lesions and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma found to harbor a BRAF V600E mutation. He received ipilimumab plus nivolumab previously but developed symptomatic brain metastases requiring stereotactic radiosurgery. Tumor sequencing reported TMB-high and PD-L1 expression around 5%. He was started on targeted combination therapy with dabrafenib and trametinib, with subsequent partial response of extracranial disease and shrinkage of some nodal metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%, TMB-high", "treatment": "ipilimumab + nivolumab (prior); stereotactic radiosurgery; dabrafenib + trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 62-year-old woman diagnosed with stage IV lung adenocarcinoma in 03/2024. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 1%. Baseline MRI showed multiple enhancing lesions consistent with brain metastases. She was started on osimertinib 80 mg qd and received stereotactic radiosurgery to two dominant lesions. CT chest/abdomen at 8 weeks demonstrated a marked decrease in size of pulmonary nodules and shrinkage of intracranial lesions \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation note (brief): Patient with metastatic melanoma with a biopsy-proven BRAF V600E mutation. Was started on single-agent pembrolizumab as front-line immunotherapy but had interval growth of pulmonary nodules. Patient subsequently initiated targeted therapy with dabrafenib plus trametinib last month and is clinically unchanged with no new symptoms. No formal staging recorded in referral; PD-L1 testing not documented.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (prior), dabrafenib and trametinib (current)", "response": "stable disease", "metastasis_site": "lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R; PD-L1 tumor proportion score ~10%. Patient was started on osimertinib 80 mg daily in January 2020 with radiographic partial response. Prior therapy included carboplatin and pemetrexed. In 2022 she developed progressive disease with new bone and brain metastases and received palliative cranial radiation.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed; cranial radiation", "response": "partial response", "metastasis_site": "bone and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma presenting with multiple pulmonary nodules and a solitary cerebellar metastasis. Molecular testing returned BRAF V600E. He was started on dabrafenib plus trametinib; initial CT at 8 weeks showed partial response in the chest but subsequent brain MRI at 16 weeks demonstrated growth of the cerebellar lesion with new enhancing foci \u2014 overall called progressive disease and plan to refer for stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "progressive disease", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic castration-resistant prostate adenocarcinoma. Germline testing identified a deleterious BRCA2 alteration. Extensive sclerotic bone metastases on bone scan. He previously progressed on docetaxel and androgen receptor pathway inhibitors (enzalutamide) and was started on the PARP inhibitor olaparib; however PSA and imaging show radiographic progression after 8 weeks.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (metastatic castration-resistant)", "gene_mutation": "BRCA2 deleterious", "biomarker": null, "treatment": "olaparib (after docetaxel and enzalutamide)", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 71-year-old male with newly diagnosed metastatic prostate adenocarcinoma, Gleason 4+5=9. PSA very elevated. Bone scan shows multiple sclerotic lesions consistent with osseous metastases. Patient started leuprolide depot and docetaxel q3 weeks for castration-sensitive metastatic disease. PSA has declined but radiographic disease remains stable. Germline and somatic testing not yet performed; PD-L1 not reported.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) + docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed 2023. Molecular testing identified EGFR L858R and TP53 mutation. PD-L1 tumor proportion score approximately 10%. He presented with headaches and back pain; MRI showed multiple brain mets and PET confirmed osseous lesions. Started first-line osimertinib 80 mg daily in June with marked clinical improvement. Most recent CT shows decrease in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old with metastatic cutaneous melanoma, BRAF V600E positive. PD-L1 reported at 60%. CT chest shows multiple pulmonary nodules consistent with metastatic disease. Patient was initiated on dabrafenib plus trametinib with dramatic decrease in size of lung metastases on first restaging \u2014 overall partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma (stage IV) presenting with headaches and back pain. MRI shows multiple brain and vertebral metastases. Molecular testing on the biopsy returned EGFR L858R mutation; PD-L1 TPS 10%. He was started on first-line osimertinib 80 mg daily. Interval CT/MRI at 12 weeks demonstrates a partial response with shrinkage of intracranial lesions and decreased size of spinal metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 4 cm right breast mass. Core biopsy: invasive ductal carcinoma, ER+, PR+, HER2 IHC 3+ with FISH-confirmed HER2 amplification; clinical stage IIIB due to chest wall involvement. Tumor NGS detected PIK3CA E545K. She received neoadjuvant docetaxel, carboplatin and trastuzumab for 6 cycles, underwent mastectomy and axillary dissection \u2014 pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: Patient with metastatic invasive ductal carcinoma, ER/PR negative, HER2 amplification by FISH. New painful lytic lesions in the pelvis and thoracic spine consistent with osseous metastases. She completed six cycles of docetaxel with trastuzumab and pertuzumab with imaging showing no significant change from prior \u2014 disease is considered stable. No somatic sequencing report available.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR negative", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma, stage IV. Molecular testing positive for BRAF V600E; PD-L1 reported at 20%. He initially received pembrolizumab but developed growth of several pulmonary nodules and was switched to targeted therapy with dabrafenib plus trametinib. Extra-cranial lesions responded with shrinkage, but a new small brain lesion was identified on MRI \u2014 overall mixed response on restaging.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "pembrolizumab, then dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with recurrent metastatic invasive ductal carcinoma of the breast. Liver biopsy confirmed metastatic breast cancer; staging consistent with stage IV disease. Tumor testing: HER2 amplification by FISH positive, ER/PR negative; PIK3CA H1047R mutation identified on panel. She received first-line trastuzumab, pertuzumab and docetaxel with interval CT demonstrating decrease in size of hepatic lesions and overall partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old female with metastatic invasive ductal carcinoma of the breast. Biopsy of hepatic lesion confirms metastasis. Tumor is HER2 amplified, ER negative, PR negative; next-gen panel shows PIK3CA H1047R. She was started on first-line trastuzumab and pertuzumab with docetaxel. After 4 cycles the liver lesions have decreased in size (PR); therapy to continue with HER2-directed maintenance afterwards.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 39-year-old man with metastatic melanoma presented with multiple brain metastases. PD-L1 staining was low (approximately 1%). No actionable driver mutation was identified on panel testing. He was treated with combination ipilimumab and nivolumab followed by stereotactic radiosurgery to the largest cerebellar lesion. Imaging after 3 cycles demonstrated stable disease in the brain and extracranial sites.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 ~1%", "treatment": "ipilimumab + nivolumab; stereotactic radiosurgery", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma with extensive bone metastases. Germline NGS detected a deleterious BRCA2 mutation. Prior therapies included androgen-deprivation therapy, abiraterone and docetaxel. He was started on the PARP inhibitor olaparib with symptomatic and radiographic improvement.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (deleterious)", "biomarker": null, "treatment": "androgen-deprivation therapy; abiraterone; docetaxel; olaparib", "response": "radiographic and symptomatic improvement (partial response)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colorectal adenocarcinoma, liver-dominant disease. Molecular profile: KRAS G12D mutation. Tumor testing also reported MSI-H and TMB-high. He received first-line FOLFOX with bevacizumab with stable disease radiographically. After 6 months and rising CEA, therapy was transitioned to pembrolizumab monotherapy given MSI-H status, with ongoing disease control of hepatic lesions and small-volume peritoneal disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed last year. Molecular testing identified EGFR L858R mutation; PD-L1 by IHC reported at 10%. She has known brain metastases treated with SRS and lytic bone lesions in the thoracic spine. Started osimertinib 80 mg daily three months ago. Interval CT and MRI show decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with metastatic cutaneous melanoma diagnosed with multiple pulmonary nodules and liver lesions. Molecular profiling positive for BRAF V600E and reported high tumor mutational burden (TMB-high). He was started on dabrafenib plus trametinib with an initial partial response, but at 9 months developed progressive disease with enlarging hepatic lesions and rising LDH; therapy was switched to nivolumab but scans continue to show progression.", "output": {"cancer_type": "melanoma (cutaneous melanoma)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib; later nivolumab", "response": "initial partial response then progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed 03/2024. NGS returned EGFR L858R; PD-L1 TPS 10%. Patient was started on osimertinib 80 mg daily. Interval MRI and CT at 3 months show shrinkage of the primary and known brain lesions with decreased metabolic activity. Assessment: partial response. Brain metastases remain radiographically evident.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old woman with ER+/PR+/HER2+ invasive ductal carcinoma of the right breast, clinical stage II (T2N1). Core biopsy demonstrated HER2 amplification by FISH and a PIK3CA H1047R mutation. She underwent breast-conserving surgery followed by adjuvant paclitaxel for 12 weeks with trastuzumab planned for 1 year. Current status: no palpable disease and surgical margins negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: localized prostate adenocarcinoma diagnosed on TRUS biopsy, Gleason 3+4=7. Clinical stage T2b, no evidence of nodal involvement on pelvic MRI. Patient underwent robotic radical prostatectomy followed by adjuvant external beam radiation for adverse features. No molecular testing was performed; postoperative PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy and adjuvant external beam radiation", "response": "no evidence of disease (PSA undetectable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male with locally advanced colon adenocarcinoma, staged as III (T3N1). Tumor testing showed BRAF V600E and microsatellite instability-high (MSI-H). He received neoadjuvant FOLFOX, with interval CT demonstrating a partial response of the primary and nodal disease. No distant organ metastases identified \u2014 disease confined to regional lymph nodes.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX (neoadjuvant)", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor testing returned MSI-H by PCR. He was enrolled on a protocol and received FOLFOX with bevacizumab and pembrolizumab as first-line therapy. Follow-up scans at 12 weeks show stable disease. No somatic mutation was reported in the available notes.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab + pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma patient, 62-year-old, originally stage IIIC cutaneous lesion on the back; now presents with new nodal and cutaneous metastases as well as a small cerebellar lesion. BRAF testing positive for V600E. He received single-agent pembrolizumab for three cycles with mixed results\u2014regression of skin and nodal disease but MRI shows enlarging cerebellar metastasis; subsequently switched to dabrafenib plus trametinib.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib plus trametinib", "response": "mixed response (extracranial regression, intracranial progression)", "metastasis_site": "skin, lymph nodes, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma, clinical stage IV with extensive sclerotic bone metastases. Germline and somatic testing identified a deleterious BRCA2 mutation. PSA on presentation was 120 ng/mL. He received androgen deprivation therapy initially, then progressed and was started on olaparib with transient disease stabilization followed by progression in the spine.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 120 ng/mL", "treatment": "androgen deprivation therapy; olaparib", "response": "initial stable disease then progression", "metastasis_site": "bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with high-grade serous ovarian carcinoma, presenting with abdominal distension and omental caking. Surgical staging confirmed stage IIIC disease with widespread peritoneal implants. Germline testing revealed a pathogenic BRCA1 variant; somatic testing also showed TP53 mutation. CA-125 markedly elevated at diagnosis. She underwent optimal debulking followed by carboplatin and paclitaxel chemotherapy and achieved radiographic complete response; she was started on maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant; TP53 mutation", "biomarker": "CA-125 elevated", "treatment": "debulking surgery then carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment planned for a 48-year-old woman with left breast invasive ductal carcinoma, clinical T2N0 (stage II). IHC HER2 3+ with FISH-confirmed HER2 amplification; ER 80%, PR 20%. Comprehensive profiling detected a PIK3CA E545K mutation. She received weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks, underwent lumpectomy, and completed adjuvant radiotherapy. Surgical pathology showed no residual invasive disease (pathologic complete response).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER 80%; PR 20%", "treatment": "paclitaxel, trastuzumab and pertuzumab; lumpectomy; radiotherapy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma, BRAF V600E positive and high tumor mutational burden. He was started on dabrafenib plus trametinib and obtained an initial partial response; progression occurred at 9 months, at which time therapy was switched to combination nivolumab and ipilimumab. Current imaging demonstrates disease control with stable pulmonary nodules.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib plus trametinib; nivolumab plus ipilimumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. Tumor testing returned MSI-H by PCR and KRAS G12D on NGS; BRAF was wild type. He was treated with FOLFOX plus bevacizumab with mixed radiographic changes, then switched to pembrolizumab given MSI-H status. Most recent scans demonstrate stable disease of hepatic and peritoneal implants.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old male with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E. He was started on dabrafenib and trametinib combination therapy; initially there was a good clinical and radiographic response of skin and subcutaneous disease. On interval PET/CT a new painful lytic lesion of the left femur was identified and biopsy confirmed melanoma \u2014 overall assessment: progression after initial response. No PD-L1 testing was available in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression after initial partial response", "metastasis_site": "femur (bone)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing returned a pathogenic BRCA1 mutation. She underwent primary debulking surgery followed by adjuvant carboplatin and paclitaxel with bevacizumab maintenance. CA-125 normalized after three cycles and she had a complete clinical response; on surveillance at 18 months a recurrent pelvic mass consistent with disease progression was noted.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 (elevated at baseline, normalized with treatment)", "treatment": "debulking surgery; carboplatin and paclitaxel; bevacizumab maintenance", "response": "complete response followed by recurrence/progression", "metastasis_site": "pelvis"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed metastatic colon adenocarcinoma (stage IV). Tumor sequencing demonstrated BRAF V600E and testing returned MSI-H. CT abdomen/pelvis shows multiple hypodense hepatic lesions and chest CT with bilateral pulmonary nodules. He was started on FOLFOX with bevacizumab in January 2024. After three cycles CEA rose and interval imaging revealed enlargement of liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab", "response": "progressive disease", "metastasis_site": "liver, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female referred for metastatic colorectal adenocarcinoma with dominant liver disease. NGS shows KRAS G12D mutation; MSI testing is microsatellite stable (MSS). Baseline CEA was 12.4 ng/mL. She was started on FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab. Restaging CT after 4 cycles demonstrates small decrease in size of the hepatic lesions consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; CEA 12.4 ng/mL", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with nodal-stage melanoma of the right axilla. Wide local excision and sentinel node biopsy performed; final staging IIIB due to multiple involved nodes. Tumor NGS identified BRAF V600E mutation. PD-L1 testing showed 10% expression. He was treated with adjuvant dabrafenib and trametinib for 12 months and surveillance PET/CT now shows no evidence of disease.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib (adjuvant)", "response": "complete response / no evidence of disease", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 57-year-old with metastatic cutaneous melanoma presenting with pulmonary nodules. BRAF testing not performed at outside hospital and no actionable mutation is documented. Immunotherapy with pembrolizumab was started three months ago. Recent CT shows interval growth of several lung lesions and new mediastinal nodes consistent with radiographic progression; plan to change systemic therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer, clinical T4bN2M0 (stage IIIB). Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER/PR negative; PIK3CA H1047R mutation detected on NGS. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab for 6 cycles followed by mastectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma diagnosed after liver lesions found on CT. Stage IV at presentation. Molecular profile: KRAS G12D, no NRAS mutation. Tumor testing reports MSI-High and high tumor mutational burden. He received first-line FOLFOX with bevacizumab; given MSI-H the team transitioned to pembrolizumab monotherapy after 6 cycles. Most recent scans show stable disease in the liver and new small pulmonary nodules under observation.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab \u2192 pembrolizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with metastatic cutaneous melanoma. BRAF V600E mutation detected. Initial therapy with dabrafenib plus trametinib produced a partial response for 9 months but patient later developed progression with new hepatic metastases and pulmonary nodules (stage IV). Switched to pembrolizumab; had a mixed radiographic response with shrinkage of some lung lesions but growth of liver mets over 4 months.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib followed by pembrolizumab", "response": "partial response to BRAF/MEK then progression; mixed response to pembrolizumab", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC at primary debulking with extensive omental caking and peritoneal implants. Germline testing returned a pathogenic BRCA1 variant. CA-125 remains elevated pre-treatment. She completed six cycles of carboplatin and paclitaxel with interval CT showing no new disease but persistent peritoneal nodularity; started on olaparib maintenance thereafter with overall stable disease on surveillance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with recurrent cutaneous melanoma of the left scalp. Excisional biopsy confirmed malignant melanoma and staging PET/CT revealed a solitary cerebellar metastasis. NGS identified BRAF V600E and he was started on dabrafenib plus trametinib with stereotactic radiosurgery to the brain lesion. Imaging at two months showed stable disease without new lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with metastatic breast cancer. Core biopsy revealed invasive ductal carcinoma, ER+/PR+, HER2 amplification by FISH. PIK3CA H1047R was detected on NGS. Patient initiated first-line therapy with trastuzumab, pertuzumab and docetaxel. After 4 cycles CT shows decrease in size of hepatic and osseous lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female presenting with progressive cough. Imaging and biopsy confirm lung adenocarcinoma with multiple intracranial lesions. Staging consistent with metastatic disease (stage IV). Molecular testing returned EGFR L858R. PD-L1 TPS reported as 10%. Patient was started on osimertinib 80 mg daily. Follow-up CT at 8 weeks demonstrates a decrease in size of the target lesions consistent with a partial response; brain metastases are radiographically stable.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old woman with high-grade serous ovarian carcinoma, optimal debulking performed; intraoperative disease included implants on the omentum and peritoneum consistent with stage IIIC. Germline testing positive for BRCA1 deleterious mutation. She completed 6 cycles of carboplatin and paclitaxel with excellent radiographic response and was transitioned to maintenance olaparib.", "output": {"cancer_type": "ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": null, "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "radiographic response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with progressive cough and weight loss. Bronchoscopic biopsy demonstrated lung adenocarcinoma. Molecular testing returned EGFR L858R mutation. Staging CT/PET showed multiple bilateral lung nodules and a solitary enhancing lesion in the cerebellum consistent with metastasis. Clinical stage IV. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the cerebellar lesion. Follow-up imaging at 8 weeks shows decrease in size of the primary and brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 60-year-old female with stage IV lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation. PD-L1 was reported at 10%. Patient started osimertinib 80 mg daily in March 2020 with marked symptomatic improvement. Interval CT chest/abdomen demonstrates decrease in size of multiple pulmonary and hepatic lesions consistent with a partial response. MRI brain shows two small enhancing lesions that were treated with stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/clinic note: 47-year-old female with a left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 3+ by IHC with FISH amplification. Clinically T4bN1 \u2014 staged as IIIB preoperatively. She received neoadjuvant carboplatin and paclitaxel with concurrent trastuzumab; post\u2011treatment imaging showed tumor reduction but residual disease on surgical specimen consistent with a partial pathologic response. No distant metastases identified.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+ (FISH amplified); ER positive; PR positive", "treatment": "neoadjuvant carboplatin and paclitaxel with trastuzumab", "response": "partial pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ and confirmed HER2 amplification by FISH; ER and PR both positive. Staging workup consistent with clinical stage IIIB (T4bN2). Tumor sequencing shows PIK3CA H1047R. She was started on neoadjuvant combination chemotherapy: docetaxel + carboplatin with dual HER2-targeted therapy trastuzumab and pertuzumab. She underwent modified radical mastectomy after 6 cycles and pathology reported no residual invasive carcinoma (pCR). Adjuvant T-DM1 was discussed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "Neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab; adjuvant T-DM1 planned", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male presenting with right upper quadrant pain; CT abdomen showed multiple hepatic lesions and peritoneal nodularity. Colonoscopy confirmed sigmoid adenocarcinoma. Staging laparotomy confirmed metastatic disease. Mutational analysis reported KRAS G12D and TP53 R273H. He was started on FOLFOX with bevacizumab but scan after three cycles demonstrated interval progression in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 R273H", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical oncology operative summary: high-grade serous ovarian carcinoma debulked to no gross residual disease. BRCA1 pathogenic germline mutation identified; HRD-positive assay. She received adjuvant carboplatin and paclitaxel and was started on maintenance olaparib in combination with bevacizumab per protocol. CA-125 normalized and current PET/CT shows no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin + paclitaxel; olaparib + bevacizumab (maintenance)", "response": "no evidence of disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT abdomen shows dominant hepatic lesions; colonoscopy confirmed primary sigmoid tumor. Next-generation sequencing reported KRAS G12D and TP53 mutation; tumor was microsatellite stable (MSS). He was started on FOLFOX with bevacizumab. After 4 cycles the patient has radiographic disease control without shrinkage \u2014 impression: stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX, bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with borderline resectable pancreatic ductal adenocarcinoma, clinical stage III. Comprehensive genomic profiling did not identify actionable mutations; testing did not reveal KRAS or BRCA1/2 alterations. PD-L1 testing was not performed. He completed neoadjuvant modified FOLFIRINOX followed by chemoradiation and surveillance imaging shows stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "modified FOLFIRINOX; chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic castration-resistant prostate cancer presenting with diffuse painful skeletal metastases. He underwent surgical castration and was treated with leuprolide, followed by docetaxel for symptomatic disease. On progression he received enzalutamide and palliative radium-223. No tumor genomic testing was performed and no molecular biomarkers are available in the chart.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; docetaxel; enzalutamide; radium-223", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Note: 39-year-old with cutaneous melanoma of the right forearm. Sentinel node positive; subsequent surveillance CT found a solitary pulmonary nodule confirmed to represent metastatic melanoma. Molecular panel identified BRAF V600E. Patient was started on dabrafenib plus trametinib with rapid radiographic clearance of lung lesion. Stage not documented in this note \u2014 plan for continued targeted therapy given excellent clinical response.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colon adenocarcinoma, KRAS G12D positive on tumor panel. Tumor found to be microsatellite-stable. He received 8 cycles of FOLFOX with bevacizumab; restaging CT shows multiple new lesions in the liver consistent with progressive disease after an initial period of stable disease. Patient transitioned to second-line irinotecan-based therapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX with bevacizumab; then irinotecan-based second-line", "response": "initially stable disease then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Unresectable stage IV cutaneous melanoma with BRAF V600E mutation. Patient had high tumor mutational burden (TMB-high) on genomic profiling and PD-L1 ~1% by IHC. He started dabrafenib and trametinib with a marked reduction in pulmonary nodules (partial response), but after 9 months developed new intracranial lesions. Therapy was switched to pembrolizumab; subsequent imaging showed a mixed response with shrinkage of some extracranial lesions and enlargement of two brain metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 1%", "treatment": "dabrafenib + trametinib; pembrolizumab", "response": "mixed response (initial partial response then intracranial progression)", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Primary rectosigmoid tumor on colonoscopy. Next-generation sequencing identified BRAF V600E mutation and microsatellite instability-high (MSI-H). He received FOLFOX followed by FOLFIRI with progression, and was started on pembrolizumab for MSI-H disease. CT at 12 weeks shows stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab; prior FOLFOX and FOLFIRI", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman diagnosed with invasive ductal carcinoma of the right breast. Tumor measured 2.4 cm, nodes negative on sentinel node biopsy; final path stage IIA. ER and PR reported positive, HER2 amplified by ISH. She underwent lumpectomy followed by adjuvant AC-T and one year of trastuzumab; started endocrine therapy with letrozole. Germline and somatic mutation panel not performed. Most recent follow-up: no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant doxorubicin + cyclophosphamide then paclitaxel (AC-T); trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, liver-dominant disease. Tumor profiling: BRAF V600E positive; MSI-H and TMB-high. After progression on first-line FOLFOX and bevacizumab he was started on encorafenib plus cetuximab. Restaging MRI at 8 weeks demonstrates stable size of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "encorafenib + cetuximab (after FOLFOX + bevacizumab)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old premenopausal woman with Stage IIB invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR negative, HER2 amplified by FISH; NGS demonstrated a PIK3CA E545K mutation. She received neoadjuvant paclitaxel with concurrent trastuzumab followed by lumpectomy and sentinel node biopsy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). She was discharged on adjuvant letrozole for endocrine suppression.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy; letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with newly diagnosed metastatic lung adenocarcinoma (EGFR L858R) presented in March. PET/CT and brain MRI demonstrated multifocal bone lesions and several cerebellar metastases consistent with stage IV disease. PD-L1 by IHC reported 10%. He was started on osimertinib 80 mg daily; interval imaging after 8 weeks shows decrease in size of target lesions and improvement of neurologic symptoms.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Molecular testing returned KRAS G12D mutation. Tumor also characterized as MSI-H with high tumor mutational burden. Stage documented as IV. He was treated with FOLFOX plus bevacizumab first-line; because of MSI-H he was transitioned to pembrolizumab on progression. Recent scans show stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology telephone note: 56-year-old man with metastatic cutaneous melanoma presented with new headaches. Brain MRI confirmed multiple brain metastases; staging CT also demonstrated pulmonary nodules. Molecular testing returned BRAF V600E. PD-L1 was low at 2%. He received first-line ipilimumab plus nivolumab but interval imaging after 3 months showed radiographic progression. Switched to targeted therapy with dabrafenib and trametinib, with subsequent shrinkage of both intracranial and pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%", "treatment": "ipilimumab plus nivolumab; then dabrafenib and trametinib", "response": "initial progression on immunotherapy; partial response to BRAF/MEK therapy", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed metastatic lung adenocarcinoma. NGS returned EGFR L858R; PD-L1 tumor proportion score 10%. Imaging and clinical staging consistent with stage IV disease with a solitary enhancing cerebellar metastasis. Patient was started on osimertinib 80 mg PO daily. Interval imaging after 8 weeks demonstrates reduction in size of the primary and intracranial lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: 45-year-old man with a primary cutaneous melanoma on the left forearm. Initial wide excision revealed nodal metastasis; staging upstaged to IV after PET/CT detected multiple pulmonary nodules. Molecular testing positive for BRAF V600E. PD-L1 by IHC was 5%. He was started on dabrafenib and trametinib with an initial partial response of the lung lesions, but subsequent oligoprogression led to switch to pembrolizumab. Current note documents ongoing partial response in pulmonary metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; then pembrolizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing identified KRAS G12D and the tumor was MSI-H by PCR. He initially received FOLFIRI with bevacizumab with disease control for 6 months followed by progression in the liver. Switched to pembrolizumab in January 2025; current CT scans show stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFIRI and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old man with metastatic melanoma. Initial sequencing identified BRAF V600E. He progressed on frontline ipilimumab/nivolumab combination and was switched to targeted therapy with dabrafenib plus trametinib. Follow-up PET/CT at 12 weeks shows decreased metabolic activity in several lesions with new small cerebellar lesion; clinical read: mixed response with overall improvement of extracranial disease but intracranial progression requiring stereotactic radiosurgery.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "ipilimumab, nivolumab (prior); dabrafenib and trametinib (current)", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (melanoma clinic): 47-year-old man with recurrent cutaneous melanoma of the left forearm, prior wide local excision and sentinel node biopsy (initial stage II). Now with new pulmonary nodules and two small cerebellar metastases consistent with stage IV disease. NGS demonstrates NRAS Q61R. PD-L1 was 5% by IHC. Patient started single-agent nivolumab; interval imaging after 3 months shows stable disease by RECIST. Brain lesions were managed with stereotactic radiosurgery.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 5%", "treatment": "nivolumab; stereotactic radiosurgery", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic right-sided colon adenocarcinoma. Liver biopsy confirmed adenocarcinoma; next-generation sequencing detected BRAF V600E. MSI testing returned MSI-high and tumor mutational burden reported as TMB-high. Given MSI-H status he was started on pembrolizumab monotherapy. After 4 cycles CT shows stable disease in the hepatic lesions without new sites of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic cutaneous melanoma, stage IV with brain and pulmonary lesions. Molecular testing identified BRAF V600E. PD-L1 was 10% and tumor mutational burden was high. He started dabrafenib plus trametinib and initially had a partial response systemically, but developed intracranial progression. Therapy was changed to ipilimumab and nivolumab; subsequent imaging demonstrated a partial intracranial response with mixed overall response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib + trametinib; then ipilimumab + nivolumab", "response": "mixed response (initial PR on BRAF/MEK, intracranial progression, partial response to ipi+nivo)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old F with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing showed EGFR L858R. PD-L1 was 10%. Started first-line erlotinib with initial response but progressed after 11 months; switched to osimertinib in 2021 with radiographic partial response. Recent MRI demonstrates new small brain metastases and focal lumbar vertebral involvement on PET-CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "erlotinib; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology oncology note: 55-year-old female with a 2.3 cm ulcerated cutaneous melanoma on the left forearm. Wide local excision with 1 cm margins performed; sentinel node biopsy negative. Tumor genotyping detected BRAF V600E. Given negative nodes and stage II classification, patient observed without systemic therapy and remains clinically disease-free.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic lung adenocarcinoma presented to clinic. Initial biopsy demonstrated EGFR L858R mutation; repeat testing at progression showed EGFR T790M. PD-L1 TPS was 60% and TMB was reported as high. She received first-line carboplatin and pemetrexed with pembrolizumab (chemo-immunotherapy) with an initial partial response. On restaging three months later she developed new symptomatic brain metastases and progressive bone lesions; liquid biopsy confirmed T790M and she was switched to osimertinib. Prior therapies: palliative radiation to T6 vertebra.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "carboplatin and pemetrexed + pembrolizumab; osimertinib; palliative radiation", "response": "initial partial response, then progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referred for a 2.5 cm pancreatic head mass. CT and biopsy consistent with pancreatic ductal adenocarcinoma, clinical stage I (T1N0). CA19-9 was 480 U/mL pre-op and normalized after Whipple. Germline testing pending and no somatic driver reported in the chart. Patient received adjuvant gemcitabine.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "CA19-9 480 U/mL (pre-op); normalized post-op", "treatment": "surgical resection (Whipple); adjuvant gemcitabine", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy of the right lower lobe. Staging workup demonstrated stage IV disease with MRI brain showing a single cerebellar metastasis. Molecular testing returned EGFR L858R positive. PD-L1 TPS 10%. Patient was started on osimertinib 80 mg daily with repeat CT at 8 weeks showing decrease in size of the primary and intracranial lesion consistent with a partial response. Plans for stereotactic radiosurgery to the brain lesion after multidisciplinary review.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old woman diagnosed with cutaneous melanoma of the right forearm, clinically stage III with regional nodal involvement. Molecular testing positive for BRAF V600E; PD-L1 approximately 5%. She underwent wide local excision and sentinel lymph node dissection and was started on adjuvant dabrafenib plus trametinib. Restaging PET/CT at 6 months shows no residual disease \u2014 described as complete response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; surgery (wide excision and sentinel node dissection)", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma. Baseline tumor sequencing showed BRAF V600E. PD-L1 by IHC was 5%. He was started on dabrafenib plus trametinib and had an initial morphologic partial response with ~60% reduction in target lesions on first CT. After 9 months he developed new hepatic and pulmonary lesions consistent with progression and was switched to pembrolizumab.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; later pembrolizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with stage II invasive ductal carcinoma of the breast, ER+/PR+ and HER2 amplified by FISH. NGS showed a PIK3CA E545K mutation. She received neoadjuvant paclitaxel with concurrent trastuzumab with approximately 60% reduction in tumor size followed by breast-conserving surgery.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab; surgery", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R; PD-L1 TPS 10%. He was started on osimertinib 80 mg daily with an initial partial response on CT at 8 weeks. After 14 months developed new headaches and MRI showed multiple enhancing lesions consistent with brain metastases and focal progression in a thoracic vertebral lesion. Systemic therapy continued until radiographic progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "initial partial response followed by progression", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman status post lumpectomy for a 1.8 cm invasive ductal carcinoma. Final pathology: ER positive, PR positive, HER2 negative (IHC 0). Stage recorded as IIA (pT1cN1a). Tumor genotyping identified a PIK3CA H1047R mutation. Patient completed adjuvant whole-breast radiation and was started on tamoxifen. No evidence of disease at 6-month follow-up.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2-", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 45 y/o F with left breast invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+ (HER2 amplification confirmed by FISH). Pathologic stage after lumpectomy and sentinel node sampling was IIIA (T2 N2 M0). Tumor NGS identified PIK3CA H1047R. She completed adjuvant weekly paclitaxel followed by one year of trastuzumab with no evidence of disease on last surveillance CT \u2014 clinically NED/complete response.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+)", "treatment": "lumpectomy, paclitaxel, trastuzumab", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic lung adenocarcinoma diagnosed on bronchoscopy. Molecular testing returned EGFR L858R mutation. PD-L1 by IHC 10%. She was started on osimertinib 80 mg daily with marked shrinkage of the primary tumor on first CT (partial response). After 9 months she developed new headaches and MRI showed progressive brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response then progression (brain)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old male who underwent gross total resection of a right temporal lobe mass. Final pathology: glioblastoma (WHO grade IV). Tumor sequencing detected IDH1 R132H mutation and methylation analysis reported MGMT promoter methylated. He completed concurrent external beam radiation with daily temozolomide followed by adjuvant temozolomide cycles. Surveillance MRI at 6 months demonstrated radiographic progression at the resection cavity with new enhancing nodularity consistent with recurrence. No extracranial disease identified.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylated", "treatment": "surgical resection; concurrent radiotherapy with temozolomide; adjuvant temozolomide", "response": "radiographic progression (recurrence) at 6 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with recurrent colon adenocarcinoma. Previously resected sigmoid primary (01/2023); now presents with multiple hepatic lesions. Staged as IV. Molecular profiling shows KRAS G12D mutation, BRAF wild-type, and microsatellite stable. Patient was started on FOLFOX with bevacizumab; after 4 cycles scans are consistent with stable disease. CEA has decreased but remains above normal.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right thigh primary melanoma initially excised; patient now presents with recurrent metastatic disease to brain and soft tissue consistent with stage IV melanoma. Tumor genotyping identified a BRAF V600E mutation. PD-L1 was not performed. The patient started combination targeted therapy with dabrafenib and trametinib and has had symptomatic improvement with radiographic partial response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "partial response", "metastasis_site": "brain, soft tissue"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma status post sigmoid resection. Tumor genotyping identified KRAS G12D and MSI-stable. Over the past year he developed multiple bilateral pulmonary nodules consistent with metastatic disease. Treated with FOLFOX plus bevacizumab; initial restaging showed stable disease but most recent CT demonstrates new and enlarging lung nodules consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic letter: 55-year-old man with metastatic cutaneous melanoma. Initial diagnosis was Stage IV with multiple cerebral metastases; neurosurgical resection of a symptomatic lesion performed last month. Tumor sequencing identified BRAF V600E. He was started on targeted therapy with dabrafenib plus trametinib. After two months there was radiographic progression in the brain and extracranial disease; patient then enrolled on combination immunotherapy (ipilimumab + nivolumab).", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib \u2192 ipilimumab + nivolumab", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. CT abdomen/pelvis shows multiple liver lesions and peritoneal nodularity \u2014 stage IV. Tumor profiling identified BRAF V600E and high microsatellite instability (MSI-H). He was started on FOLFOX with bevacizumab; after three months there was shrinkage of several liver metastases but new peritoneal implants. Therapy was changed to pembrolizumab given MSI-H status. Clinical note summarizes initial partial response to chemotherapy followed by progression of peritoneal disease.", "output": {"cancer_type": "colorectal (colorectal adenocarcinoma)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; later pembrolizumab", "response": "initial partial response then progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man diagnosed with pancreatic ductal adenocarcinoma. Germline testing returned positive for BRCA2 pathogenic variant. He completed 8 cycles of modified FOLFIRINOX with disease control and CA19-9 trending down from 1200 to 180 U/mL; now being transitioned to maintenance olaparib. No formal AJCC stage recorded in the note.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated (downtrending)", "treatment": "modified FOLFIRINOX followed by maintenance olaparib", "response": "stable disease / biochemical response (CA19-9 decrease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old male with metastatic colorectal adenocarcinoma. Molecular profiling identified KRAS G12D mutation. He received FOLFOX plus bevacizumab in the palliative setting. Unfortunately CT now shows increasing peritoneal nodularity and malignant ascites consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment summary: 47-year-old woman with locally advanced invasive ductal breast carcinoma, clinical stage IIIB. Tumor was ER-/PR-, HER2 3+ by IHC with HER2 amplification on FISH; NGS reported PIK3CA E545K. She received TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles followed by modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma (pCR). No distant mets identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with unresectable cutaneous melanoma found to harbor BRAF V600E on mutation testing. Presents with a symptomatic solitary cerebellar metastasis on MRI. Tumor sequencing shows high tumor mutational burden (TMB-high). Patient was started on combined BRAF/MEK inhibition (dabrafenib plus trametinib) with interval MRI demonstrating reduction in the cerebellar lesion and improvement in symptoms consistent with a partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old F with newly diagnosed lung adenocarcinoma. Staging workup reveals multiple pulmonary nodules and intracranial lesions consistent with metastatic disease. Molecular testing returned EGFR L858R; PD-L1 by IHC 5%. Patient was started on osimertinib as first-line therapy with imaging at 8 weeks showing reduction in size of both brain and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. NGS showed EGFR L858R mutation; PD-L1 tumor proportion score 5%. Staging CT and brain MRI confirm stage IV disease with multiple enhancing lesions consistent with brain metastases. Patient was started on osimertinib 80 mg daily in August. First imaging at 8 weeks demonstrates decrease in size of intracranial and pulmonary lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma (stage IV) presented with progressive headaches and back pain. Comprehensive NGS returned EGFR L858R mutation; PD-L1 TPS 20%. He was started on osimertinib 80 mg daily in March. Interval MRI and CT after 8 weeks demonstrated a decrease in size of the brain lesions and pulmonary nodules. Bone scan confirmed multiple lytic lesions. Patient has clinical improvement on therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up: 62-year-old female s/p right upper lobectomy for a 2.1 cm peripheral lung mass (T1bN0). Final pathology: lung adenocarcinoma, stage I. Molecular testing returned EGFR L858R. PD-L1 by IHC 2%. Given EGFR mutation and per patient preference started adjuvant osimertinib 80 mg daily after recovery from surgery. Most recent CT chest shows no new lesions and CXR stable.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "I", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 2%", "treatment": "right upper lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47 F with right breast invasive ductal carcinoma, clinical stage IIB (T2N1M0). ER positive, PR positive, HER2 IHC 3+ with confirmatory FISH showing HER2 amplification. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for 6 cycles. Surgical pathology after lumpectomy/axillary dissection showed no residual invasive carcinoma (pathologic complete response). No distant mets on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 66-year-old male with metastatic colon adenocarcinoma, stage IV at diagnosis. Molecular testing returned KRAS G12D. MSI status reported as MSS. He received FOLFOX with bevacizumab as first-line therapy with initial disease control, but recent CT shows new hepatic lesions and rising CEA consistent with progression in the liver.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with a newly diagnosed invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and HER2 negative by IHC/FISH. NGS identified PIK3CA H1047R. Clinical staging reported as stage I (T1cN0M0). She underwent lumpectomy with sentinel node biopsy followed by adjuvant radiotherapy and was started on tamoxifen. 12-month follow-up: no radiographic evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I (T1cN0M0)", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, sentinel node biopsy, adjuvant radiotherapy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with lung adenocarcinoma after biopsy of a right upper lobe mass. Staging workup consistent with stage IV (T2N2M1c). Tissue NGS identified EGFR L858R. PD-L1 tumor proportion score reported at 12%. Patient started osimertinib 80 mg daily. Interim CT chest at 8 weeks shows ~40% reduction in target lesions consistent with a partial response. Brain MRI confirms a single enhancing lesion consistent with metastatic disease to the brain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 12%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note: 52-year-old woman with invasive ductal carcinoma of the left breast, pathologic stage pT2N0 (AJCC Stage IIA). Tumor was ER positive (90%), PR positive (40%), HER2 by IHC 0 and FISH non-amplified. She underwent lumpectomy with sentinel lymph node biopsy (0/3 nodes) and completed adjuvant whole-breast radiation. Started adjuvant endocrine therapy with tamoxifen. No genomic profiling performed. Currently on surveillance with no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "lumpectomy, radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma metastatic to the liver. Tumor sequencing showed KRAS G12D and high tumor mutational burden; MSI testing returned MSI-H. After progression on adjuvant FOLFOX, he was started on pembrolizumab and follow-up scans show a significant decrease in size of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old man with metastatic lung adenocarcinoma diagnosed on transbronchial biopsy. Molecular profile: EGFR L858R; PD-L1 TPS 10%. Staged as IV at presentation due to multiple pulmonary nodules and a symptomatic brain lesion. Started oral osimertinib 80 mg daily; interval chest CT and MRI show shrinkage of pulmonary lesions and stereotactic radiosurgery was performed to the brain metastasis. Clinical course consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib, stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic encounter: 38-year-old man with unresectable metastatic cutaneous melanoma. BRAF V600E mutation identified on PCR. Patient has multiple parenchymal and cerebellar brain metastases; underwent stereotactic radiosurgery to two cerebellar lesions. Systemic therapy initiated with dabrafenib 150 mg BID and trametinib 2 mg daily. At 3-month follow-up there is marked shrinkage of extracranial disease and radiographic stability of treated brain lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery to brain", "response": "partial response (extracranial); stable disease (brain)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic colorectal adenocarcinoma with liver-dominant disease and multiple pulmonary nodules. Clinical stage IV. Tumor testing shows MSI-H and TMB-high; PD-L1 <1% by IHC. Patient received FOLFOX plus bevacizumab first-line and achieved stable disease. Chemotherapy was discontinued for toxicity and she was transitioned to pembrolizumab. Extended molecular testing results (KRAS/NRAS/BRAF) are pending.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high, PD-L1 <1%", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed metastatic lung adenocarcinoma on bronchoscopic biopsy. Comprehensive NGS found EGFR L858R; PD-L1 TPS reported at 10%. MRI brain demonstrated multiple enhancing lesions. He was started on osimertinib 80 mg daily. At first follow-up CT and MRI (8 weeks) there is interval shrinkage of both pulmonary and intracranial disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Note: 68-year-old male with metastatic colon adenocarcinoma. Tumor genotyping: KRAS G12D positive. CT chest shows two new pulmonary nodules consistent with metastases. Treated with FOLFOX plus bevacizumab in the palliative setting; disease has been radiographically stable for 6 months on therapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old with metastatic cutaneous melanoma. Biopsy of a pulmonary nodule confirmed melanoma and molecular testing detected BRAF V600E. The patient was started on targeted therapy with dabrafenib plus trametinib. Interval CT at 12 weeks shows decrease in size of pulmonary lesions and symptom improvement consistent with a partial response. PD-L1 was not reported on the pathology lab report.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with HER2-amplified metastatic breast cancer. She presented with right upper quadrant pain and was found to have multiple hepatic lesions on ultrasound. Biopsy confirmed invasive ductal carcinoma, ER/PR negative, HER2 FISH positive. No genomic driver mutation reported on panel. First-line therapy with trastuzumab, pertuzumab and weekly paclitaxel was initiated with good clinical tolerance; follow-up CT shows shrinkage of liver mets.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR negative", "treatment": "trastuzumab, pertuzumab, paclitaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with urothelial carcinoma of the bladder presenting with pelvic adenopathy and lytic lesions in the femur. Targeted sequencing identified an FGFR3 S249C activating substitution. PD-L1 testing could not be completed due to insufficient tissue. He was started on erdafitinib on protocol and interval imaging demonstrates stable disease.", "output": {"cancer_type": "urothelial carcinoma (bladder)", "stage": "IV", "gene_mutation": "FGFR3 S249C", "biomarker": null, "treatment": "erdafitinib", "response": "stable disease", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient in their mid-50s with primary cutaneous melanoma underwent wide local excision; sentinel lymph node was positive and the disease was staged as III. PD-L1 IHC reported 5%. Comprehensive NGS panel did not detect any actionable driver mutations. The patient was started on adjuvant pembrolizumab and serial imaging shows stable disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "III", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (adjuvant)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female presented with abdominal pain and was found to have pancreatic ductal adenocarcinoma with extensive peritoneal carcinomatosis and ascites at diagnosis. BRCA testing had not been completed prior to initiation of therapy. She received six cycles of FOLFIRINOX but developed progressive disease with worsening ascites and declining performance status; care was transitioned to best supportive measures.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX", "response": "progressive disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman found to have a left breast tumor on screening mammogram. Core biopsy: high-grade invasive carcinoma, ER negative, PR negative, HER2 negative (triple-negative). Clinical exam consistent with stage IIIB disease with fixed axillary nodes. Germline testing positive for a pathogenic BRCA1 variant. She received neoadjuvant carboplatin and paclitaxel in combination with pembrolizumab on protocol. Subsequent mastectomy pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "triple-negative breast cancer", "stage": "IIIB", "gene_mutation": "BRCA1 (germline pathogenic variant)", "biomarker": "ER-/PR-/HER2-", "treatment": "carboplatin, paclitaxel, pembrolizumab (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a locally advanced breast tumor underwent core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplification by FISH. Clinical stage was IIIB with peau d'orange and fixed axillary nodes. She received neoadjuvant combination therapy with docetaxel and carboplatin plus dual anti-HER2 antibodies trastuzumab and pertuzumab. After three cycles there was a marked decrease in tumor size (partial response) and she is scheduled for surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old premenopausal woman with locally advanced invasive ductal carcinoma of the breast. Immunohistochemistry: ER 90% positive, PR 40% positive, HER2 negative by IHC/FISH. Clinical stage IIIB with chest wall involvement. She received neoadjuvant dose-dense AC (doxorubicin/cyclophosphamide) followed by paclitaxel, then underwent modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). Genetic testing results pending.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right hemicolectomy performed for colon adenocarcinoma, final pathology pT3N1 (stage III). Tumor genomic profiling detected KRAS G12D. MSI testing was not completed prior to discharge. Patient was started on adjuvant FOLFOX. Surveillance CT at 8 months after surgery shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "adjuvant FOLFOX (oxaliplatin, leucovorin, 5-FU)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT abdomen shows multiple hepatic lesions consistent with metastases. Biopsy confirms adenocarcinoma of colon (stage IV). Molecular panel reports KRAS G12D mutation. Patient initiated on FOLFOX with bevacizumab; after 4 cycles scans show no new lesions and modest shrinkage of liver mets \u2014 stable disease clinically. MSI testing was not completed at the time of note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with right-sided colorectal adenocarcinoma with multiple liver metastases. Tumor profiling revealed KRAS G12D and TP53 mutations; tumor was MSI-High. She received first-line FOLFOX with bevacizumab but progressed on imaging at 4 months. Given MSI-H status she was switched to pembrolizumab and achieved a durable partial response of hepatic disease on subsequent CTs.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 mutation", "biomarker": "MSI-H", "treatment": "FOLFOX; bevacizumab; pembrolizumab", "response": "progression on FOLFOX/bevacizumab then partial response on pembrolizumab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man presented with seizures and a left frontal mass; craniotomy performed and pathology consistent with glioblastoma (WHO grade IV). MGMT promoter was methylated; IDH1 testing not reported. He underwent concurrent radiotherapy with temozolomide followed by adjuvant temozolomide. Surveillance MRI at 6 months demonstrated interval increase in contrast-enhancing tumor consistent with progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylated", "treatment": "surgery; concurrent radiotherapy with temozolomide; adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer, ER+/PR+ and HER2 amplified, presents with multiple hepatic metastases. Tumor NGS detected PIK3CA H1047R in addition to HER2 amplification. She was started on trastuzumab with docetaxel. After 3 cycles there was a documented shrinkage of liver lesions on CT.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 62-year-old man with metastatic colon adenocarcinoma presenting with abdominal distension. CT showed omental caking and fluid; laparoscopy confirmed peritoneal carcinomatosis. Tumor genotyping returned KRAS G12D. MSI testing reported MSI-stable. Patient started systemic therapy with FOLFOX plus bevacizumab. Interval CT after 4 cycles demonstrates no new lesions and minimal change in omental disease\u2014overall assessment: stable disease. Stage at diagnosis IV.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic melanoma presented with symptomatic lung nodules and an enhancing brain lesion. Tumor testing positive for BRAF V600E and PD-L1 approximately 10%. Initially started on pembrolizumab but developed intracranial progression; treated with stereotactic radiosurgery to the brain lesion and switched to dabrafenib plus trametinib. Imaging after two months of targeted therapy shows shrinkage of lung nodules and decreased size of the treated brain lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab; stereotactic radiosurgery; dabrafenib + trametinib", "response": "partial response (shrinkage of lung nodules and reduction of brain lesion)", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic cutaneous melanoma. Molecular testing identified a BRAF V600E mutation; PD-L1 staining 10%. He presented with multiple pulmonary nodules and several brain metastases. Initially started on dabrafenib and trametinib with good intracranial response but extracranial progression after 4 months; subsequently switched to nivolumab with an overall mixed response on restaging scans.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib followed by nivolumab", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric artery (clinical Stage III). Initial targeted panel did not report any actionable mutations. CA19-9 was elevated at diagnosis. He completed induction FOLFIRINOX and then received consolidative chemoradiation. Imaging after four months shows stable disease by RECIST.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presented with colorectal adenocarcinoma and synchronous liver metastases. Molecular profiling revealed a KRAS G12D mutation; tumor testing was MSI-H with a TMB-high (20 mut/Mb). Initial therapy was FOLFOX with bevacizumab for six cycles with mixed radiographic changes, then transitioned to pembrolizumab because of MSI-H status. Disease remained stable for approximately 9 months on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (20 mut/Mb)", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 45-year-old woman with locally advanced invasive ductal carcinoma of the right breast, ER+/PR+, HER2 amplified on FISH. Clinical stage IIIB (T4bN1). Preoperative regimen: TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) x6 cycles. Tumor genomics: PIK3CA E545K identified on NGS. Underwent mastectomy; pathology shows no residual invasive carcinoma (ypT0N0) \u2014 pathologic complete response. No distant metastases noted.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Presented with symptomatic cerebellar metastasis; staged as IV. Treatment plan included targeted therapy with dabrafenib and trametinib and stereotactic radiosurgery to the brain lesion. Interim PET/CT at 12 weeks showed decreased metabolic activity of nodal and extracranial disease consistent with a partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 42-year-old male with biopsy-proven cutaneous melanoma of the left forearm, sentinel node positive, designated stage III disease. Tumor genotyping showed BRAF V600E. He underwent wide local excision with completion lymphadenectomy and was placed on adjuvant nivolumab. Surveillance imaging remains negative and patient is currently NED.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgery (wide local excision, lymphadenectomy) and adjuvant nivolumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with newly diagnosed lung adenocarcinoma. Staging CT and MRI showed multiple bilateral pulmonary nodules and a solitary cerebellar lesion consistent with metastasis \u2014 overall clinical stage IV. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score ~10%. He was started on osimertinib 80 mg daily. Interval imaging at 8 weeks demonstrated decrease in size of lung lesions and the brain lesion, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 ~10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing identified EGFR L858R mutation; PD-L1 10% TPS. Clinical stage IV with known brain and bone metastases. Patient started osimertinib 80 mg daily in January and interval MRI/CT after 8 weeks shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman presented with abdominal distension and was found to have a pelvic mass. Surgical exploration revealed high-grade serous ovarian carcinoma with extensive omental disease; final stage IIIC after optimal primary debulking. She completed six cycles of adjuvant carboplatin and paclitaxel and was started on bevacizumab maintenance. CA-125 normalized post-treatment and follow-up CT shows no radiographic evidence of disease. Somatic and germline BRCA testing are pending; initial somatic panel did not identify actionable mutations.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 normalized", "treatment": "primary debulking surgery, carboplatin and paclitaxel, bevacizumab maintenance", "response": "complete clinical response", "metastasis_site": "omentum, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man with metastatic lung adenocarcinoma first seen in 2019. Tumor sequencing identified EGFR L858R. PD-L1 TPS reported at 10%. At diagnosis he was stage IV with multiple brain and bone metastases. He was started on first-line osimertinib 80 mg daily. Interval imaging at 3 months showed shrinkage of pulmonary nodules and decreased size of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer (mCRPC) with bone-predominant disease. He underwent surgical castration previously and received first-line docetaxel with symptomatic improvement. Germline and somatic testing were inconclusive and no actionable mutation was reported. After biochemical progression (rising PSA) and radiographic stability for three months, he was enrolled on a PARP inhibitor trial (olaparib) for clinical benefit. Most recent assessment: stable disease by RECIST and PSA decline plateaued.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant prostate cancer)", "stage": "IV (metastatic)", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel; olaparib (PARP inhibitor trial)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male presented with right upper quadrant pain and was found to have metastatic colorectal adenocarcinoma. Molecular panel: KRAS G12D; microsatellite status: MSS. Baseline CEA 120 ng/mL. CT abdomen shows multiple hepatic lesions consistent with liver metastases. He was started on FOLFOX plus bevacizumab; restaging after 4 cycles demonstrates stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; elevated CEA", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with muscle-invasive urothelial carcinoma of the bladder underwent radical cystectomy. Pathology consistent with stage III disease. He completed adjuvant cisplatin and gemcitabine x4 cycles. Surveillance CTs at 6 and 12 months show no evidence of recurrent disease. No tumor genomic testing was performed.", "output": {"cancer_type": "urothelial carcinoma of the bladder", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical cystectomy; adjuvant cisplatin and gemcitabine", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hematology/Oncology summary: 68-year-old male with newly diagnosed diffuse large B-cell lymphoma presenting with bulky cervical and mediastinal nodes. Staging PET consistent with stage II disease. Treated with six cycles of R-CHOP with subsequent PET/CT showing complete metabolic response. No molecular mutation panel available in chart.", "output": {"cancer_type": "diffuse large B-cell lymphoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "R-CHOP", "response": "complete metabolic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with high-risk prostate adenocarcinoma, pathologic stage III (pT3aN0M0) after radical prostatectomy. He received adjuvant external beam radiation and androgen deprivation therapy with leuprolide. No molecular sequencing was performed and no biomarkers reported. Recent PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant radiation; androgen deprivation therapy (leuprolide)", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with metastatic lung adenocarcinoma diagnosed in January 2024. Molecular testing identified EGFR L858R; PD-L1 expression ~10%. Brain MRI in March showed two enhancing lesions consistent with metastases. Osimertinib 80 mg daily was initiated and first restaging CT after 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male presented with metastatic colorectal adenocarcinoma with multiple hepatic lesions and pulmonary nodules at diagnosis (stage IV). Tumor NGS showed a KRAS G12D mutation. MSI testing returned microsatellite stable (MSS) and TMB was reported as low. He was started on FOLFOX combined with bevacizumab but after 4 months imaging demonstrated progression in the liver. Anti-EGFR therapy was not considered because of the KRAS mutation.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS, TMB-low", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic colon adenocarcinoma presenting with multiple hepatic metastases. Molecular profiling identified KRAS G12D and the tumor is microsatellite stable (MSS). Clinical stage IV at diagnosis. He was treated with FOLFOX plus bevacizumab; after six cycles CT shows interval growth of liver lesions consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer presenting with diffuse sclerotic bone lesions on bone scan. Germline testing revealed a pathogenic BRCA2 variant; PSA at presentation was 120 ng/mL. He was managed with continued androgen deprivation therapy and started on olaparib for BRCA2-associated disease. Follow-up imaging shows reduction in size of several osseous lesions consistent with a partial response.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "elevated PSA", "treatment": "androgen deprivation therapy and olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging confirmed stage IV disease with brain and bone metastases. Molecular testing returned EGFR exon 19 deletion and acquired EGFR T790M; MET amplification was also reported on NGS. PD-L1 tumor proportion score 10%. Patient was started on osimertinib, and after partial radiologic response a MET inhibitor (savolitinib) was added as combination therapy given progression in nodal disease. Currently on osimertinib + savolitinib with ongoing PR.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion, EGFR T790M", "biomarker": "MET amplification; PD-L1 10%", "treatment": "osimertinib + savolitinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female referred for management of metastatic lung adenocarcinoma. Tumor NGS identified EGFR L858R. Staging CT and brain MRI confirmed stage IV disease with two enhancing brain metastases. PD-L1 by IHC was 10% TPS. She was started on osimertinib 80 mg daily in June; interval imaging after 8 weeks showed shrinkage of target lesions and reduced size of the brain metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology letter: Patient is a 45-year-old man with stage IV cutaneous melanoma with pulmonary nodules. Molecular testing revealed BRAF V600E; tumor mutational burden reported as TMB-high. He was started on combination targeted therapy with dabrafenib and trametinib and after 3 months CT chest shows resolution of lung nodules \u2014 complete radiographic response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with biopsy-proven invasive ductal carcinoma of the breast. Tumor is HER2 IHC 3+ with FISH ratio 4.2; ER and PR negative. Staging scans reveal multiple lytic lesions in the thoracic and lumbar spine and pelvic bones. She was started on first-line trastuzumab, pertuzumab and docetaxel. CA 15-3 has been stable on therapy. No tumor NGS was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+ / FISH ratio 4.2); ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced breast cancer (invasive ductal carcinoma), clinical stage cT3N1M0, stage IIIA. Core biopsy: ER positive, PR negative; HER2 amplification by FISH. Patient received neoadjuvant paclitaxel with trastuzumab for six cycles followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma consistent with a pathologic complete response.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation: 56-year-old woman with high\u2011grade serous ovarian carcinoma presenting with bulky pelvic disease and omental caking. Imaging and operative staging consistent with FIGO stage IIIC. Germline testing returned positive for a deleterious BRCA1 c.5266dupC mutation. CA-125 was elevated at 320 U/mL. She received 6 cycles of carboplatin and paclitaxel with interval CT showing reduction in disease burden. She transitioned to maintenance olaparib. Response per RECIST was documented as partial response.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 c.5266dupC", "biomarker": "elevated CA-125 (320 U/mL)", "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma with diffuse bone metastases. Germline testing identified a deleterious BRCA2 mutation. He received docetaxel with progression and was started on olaparib with subsequent PSA decline and partial radiographic response in the bone lesions.", "output": {"cancer_type": "prostate adenocarcinoma (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "PSA (decline after olaparib)", "treatment": "olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old with metastatic cutaneous melanoma diagnosed after excision of a forearm lesion. Staging demonstrated multiple hepatic and cerebellar metastases \u2014 Stage IV. Molecular profiling identified BRAF V600E. He initially received combined immunotherapy with ipilimumab/nivolumab with a brief partial response, then on progression was switched to dabrafenib plus trametinib. Recent scans show disease progression in the liver with rising LDH.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "ipilimumab + nivolumab followed by dabrafenib + trametinib", "response": "progression", "metastasis_site": "liver, brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic cutaneous melanoma with confirmed BRAF V600E mutation. Started on dabrafenib and trametinib combination therapy after wide local excision and nodal recurrence. Interval PET/CT shows marked decrease in subcutaneous and nodal disease burden but follow-up brain MRI revealed a new solitary enhancing lesion. Overall assessment: partial response extracranially; new brain metastasis being considered for stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib", "response": "partial response (extracranial); new brain metastasis", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female presented with progressive abdominal distension. Imaging and operative findings revealed extensive peritoneal carcinomatosis; optimal cytoreductive surgery was performed. Preop CA-125 was markedly elevated. Germline testing returned positive for a deleterious BRCA1 mutation. She completed adjuvant carboplatin and paclitaxel; CA-125 has declined but CT shows residual peritoneal nodules consistent with a partial response. Stage at diagnosis was not explicitly recorded in the operative note.", "output": {"cancer_type": "ovarian carcinoma", "stage": null, "gene_mutation": "BRCA1 mutation", "biomarker": "elevated CA-125", "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with newly diagnosed lung adenocarcinoma (EGFR L858R) presented to clinic. Staging CT demonstrated multiple pulmonary nodules and lytic lesions in the spine consistent with metastatic disease; brain MRI showed two subcentimeter metastases. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily. First restaging at 8 weeks shows marked decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 52-year-old male with metastatic cutaneous melanoma. Initial genotyping showed BRAF V600E. He received front-line dabrafenib plus trametinib with initial tumor shrinkage but developed progression in the liver after 7 months and was switched to pembrolizumab. On pembrolizumab he has had stable disease on two consecutive CT scans. Metastatic deposits noted in liver and bilateral lungs.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib then pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. NGS detected EGFR L858R alteration; PD-L1 TPS was 10%. MRI brain at presentation showed multiple enhancing lesions consistent with brain metastases. Patient started osimertinib 80 mg daily in March 2020 with marked radiographic shrinkage of pulmonary and intracranial disease \u2014 documented partial response at the 8-week scan. No other actionable drivers reported.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with stage IV colorectal adenocarcinoma. Molecular testing identified KRAS G12D; tumor is microsatellite-stable (MSS). Multiple new pulmonary nodules were noted on surveillance CT consistent with metastatic disease. He progressed after three cycles of FOLFOX plus bevacizumab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite-stable)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E; PD-L1 reported 5% and noted to have high tumor mutational burden. Started on combination BRAF/MEK inhibitor therapy (dabrafenib plus trametinib) with a partial response lasting 8 months, then developed new pulmonary nodules consistent with progression. He was transitioned to pembrolizumab and has had a mixed radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib; pembrolizumab", "response": "initial partial response then progression; mixed response on pembrolizumab", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic colorectal adenocarcinoma presented with multiple hepatic metastases. Tumor genotyping showed KRAS G12D mutation and microsatellite stable (MSS) status. She was started on FOLFOX plus bevacizumab; after 4 cycles the CEA rose and CT shows enlargement of liver lesions consistent with progression. Notes: anti-EGFR therapy not appropriate given KRAS mutation.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presented with obstructing sigmoid mass, underwent sigmoidectomy. Pathology: stage III (T3N1) colon adenocarcinoma. Tumor profiling showed KRAS G12D and MSI-H. He completed adjuvant FOLFOX for six months. Surveillance CT at 18 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "surgery followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with a pigmented, ulcerated lesion on the back underwent excision; pathology demonstrated cutaneous melanoma with one positive sentinel node consistent with stage III disease. BRAF V600E was detected by PCR. He was started on adjuvant dabrafenib plus trametinib. Baseline staging CT showed no distant metastases and at 6-month follow-up there is no measurable disease on imaging.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female diagnosed with metastatic lung adenocarcinoma in Jan 2024. Biopsy confirmed EGFR L858R mutation; PD-L1 tumor proportion score 10%. Staging at diagnosis: IV with multiple enhancing lesions in the brain and lytic lesions on PET in the spine. Patient started osimertinib 80 mg PO daily in February. Interval MRI shows shrinkage of intracranial lesions and decreased FDG uptake in osseous sites consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case summary: 67-year-old male with castration-resistant prostate adenocarcinoma with extensive sclerotic bone metastases. Germline and tumor testing revealed pathogenic BRCA2 mutation; no PD-L1 testing was performed. Given prior docetaxel and progression on androgen deprivation, he was started on olaparib with disease control and pain improved but scans show minimal interval change (clinically stable disease).", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "olaparib (after prior docetaxel and androgen deprivation)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient, 52, presented with metastatic cutaneous melanoma with multiple pulmonary nodules and brain lesions. Tumor was BRAF V600E positive. He was started on combination targeted therapy with dabrafenib plus trametinib and attained good extracranial response, but developed CNS progression at 8 months and underwent stereotactic radiosurgery to brain metastases; immunotherapy with nivolumab was started thereafter. Three-month restaging showed a mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; nivolumab", "response": "good extracranial response; CNS progression; mixed response on nivolumab", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. NGS shows EGFR exon 19 deletion. Current clinical stage IV with known brain and bone metastases. PD-L1 by IHC 60% and reported TMB-high. Patient was started on osimertinib initially; after radiographic progression she was switched to combined carboplatin + pemetrexed with pembrolizumab. CT after 3 cycles demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 60%, TMB-high", "treatment": "osimertinib; then carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a 2.1 cm invasive ductal carcinoma of the left breast. ER positive, PR positive, HER2 negative (IHC 0). Pathologic staging after lumpectomy and sentinel node biopsy was pT2N0 (stage IIA). No genomic testing was performed. She completed adjuvant whole-breast radiation and was started on tamoxifen. Surgical margins were negative and she is currently without evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; whole-breast radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with high-risk prostate adenocarcinoma (Gleason 4+4) \u2014 underwent radical prostatectomy with pT3 disease. Given adverse features he completed adjuvant external beam radiation and is on androgen deprivation therapy with leuprolide. Pathologic stage was III; PSA reached nadir post-treatment and has remained stable without evidence of distant metastasis.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "stable disease (PSA nadir)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with newly diagnosed high-grade serous ovarian carcinoma, stage IIIC with peritoneal carcinomatosis. Germline testing positive for deleterious BRCA1 frameshift; tumor NGS also showed TP53 mutation. CA-125 markedly elevated at diagnosis. She underwent interval debulking followed by six cycles of carboplatin and paclitaxel, then started maintenance olaparib. CT after completion of chemo and two months of maintenance demonstrates no residual measurable disease \u2014 complete radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious frameshift); TP53 mutation", "biomarker": "elevated CA-125", "treatment": "carboplatin and paclitaxel, surgery (interval debulking), olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology phone note: Patient with recurrent metastatic cutaneous melanoma. Molecular testing reports BRAF V600E mutation and a high tumor mutational burden. Started on combination dabrafenib and trametinib after progression on ipilimumab/nivolumab. Recent MRI demonstrates a new cerebellar metastasis with clinical decline; systemic disease showed mixed radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "mixed response (with new brain metastasis/progression)", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor testing: MSI-H by PCR and high tumor mutational burden on NGS; KRAS G12D mutation identified. He received first-line FOLFOX with radiographic stable disease for 4 months, then was transitioned to pembrolizumab because of MSI-H status and has maintained disease stabilization on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma of the ascending colon. CT shows bulky peritoneal carcinomatosis and small omental implants. Tumor genotyping: KRAS G12D. Patient received 6 cycles of FOLFOX with bevacizumab but interval imaging demonstrates new peritoneal nodularity and clinical decline consistent with progression. MSI testing not available in chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic colorectal adenocarcinoma. Liver mets identified on CT; biopsy from the colon showed MSI-H by PCR and next\u2011gen sequencing identified KRAS G12D. Given MSI-high status he was started on pembrolizumab; after 4 cycles the scan showed stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal disease at presentation. Germline testing positive for BRCA1 pathogenic variant (185delAG); tumor tested HRD-positive. CA-125 at diagnosis 1,200 U/mL. Patient underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Given BRCA1 mutation and residual risk, maintenance olaparib in combination with bevacizumab was started. CT and CA-125 after 6 months show no radiographic disease and CA-125 normalized.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "HRD-positive; CA-125 1,200 U/mL (at diagnosis)", "treatment": "cytoreductive surgery, carboplatin + paclitaxel, maintenance olaparib + bevacizumab", "response": "no radiographic disease / CA-125 normalization", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note: 70-year-old male status post right hemicolectomy for adenocarcinoma of the ascending colon, pathologic stage III (T3N1). Tumor showed high microsatellite instability (MSI-H). Patient completed 12 cycles of adjuvant FOLFOX (oxaliplatin, leucovorin, 5-FU) without complications. Surveillance CT and CEA are negative; no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX (oxaliplatin + 5-FU/leucovorin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient status post sigmoid colectomy for adenocarcinoma, pathologic stage II (T3N0). Tumor testing returned MSI-H by PCR. No actionable point mutations were identified on the limited hotspot panel. She completed adjuvant 5-FU-based chemotherapy and surveillance CTs have been negative to date.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgical resection; adjuvant 5-FU", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old man with metastatic lung adenocarcinoma originally diagnosed in 2018. Molecular testing of the primary tumor identified EGFR L858R; subsequent progression on first-line erlotinib revealed EGFR T790M on repeat plasma genotyping. PD-L1 by IHC is 1%. He was switched to osimertinib 80 mg daily with marked clinical improvement. Recent brain MRI shows a decrease in size of enhancing lesions and bone scan shows multifocal uptake consistent with osseous metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 1%", "treatment": "erlotinib then osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic pancreatic ductal adenocarcinoma presenting with multiple hepatic lesions and rising CA19-9. Germline testing positive for BRCA2 pathogenic variant. He received first-line modified FOLFIRINOX with partial radiologic response in the liver, then started maintenance olaparib given BRCA2 mutation; CA19-9 declined but remains above normal.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "CA19-9 elevated", "treatment": "mFOLFIRINOX; maintenance olaparib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old male with rapidly enlarging pigmented lesion on the back. Excisional biopsy confirmed malignant melanoma. Staging PET/CT demonstrated multiple pulmonary nodules consistent with metastases. Molecular testing detected BRAF V600E; PD-L1 was reported at 5%. The patient was started on dabrafenib plus trametinib with prompt symptomatic improvement and interval CT at 6 weeks reported a partial response.", "output": {"cancer_type": "malignant melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly symptomatic metastatic prostate adenocarcinoma. Bone scan and CT show multifocal osseous metastases involving the lumbar spine and pelvis. Staged as IV disease. He was started on androgen deprivation with leuprolide depot and concurrent abiraterone acetate with prednisone. PSA has fallen from 180 to 12 ng/mL and follow-up CT demonstrates no new lesions; overall disease is radiographically stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and abiraterone with prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with metastatic lung adenocarcinoma in July 2024. He was started empirically on carboplatin and pemetrexed with pembrolizumab for three cycles while awaiting molecular results. NGS later returned EGFR L858R and PD-L1 15%, so therapy was switched to osimertinib and the patient underwent stereotactic radiosurgery to a solitary cerebellar metastasis. Restaging CT shows decrease in primary lung mass and no new systemic lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "carboplatin and pemetrexed with pembrolizumab; switched to osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with metastatic cutaneous melanoma diagnosed in 2022. Molecular testing positive for BRAF V600E; PD-L1 reported 5%. He started first-line targeted therapy with dabrafenib and trametinib and achieved a marked tumor shrinkage by week 8 (partial response). After 9 months he developed progressive pulmonary nodules and was switched to pembrolizumab for disease progression in the lungs.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib, then pembrolizumab", "response": "progression after initial partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 45-year-old premenopausal woman with left invasive ductal carcinoma, clinical stage IIIB. ER positive, PR negative, HER2 amplified by FISH; NGS revealed a PIK3CA H1047R mutation. She received neoadjuvant therapy with docetaxel and carboplatin plus dual anti-HER2 agents trastuzumab and pertuzumab. Mastectomy pathology showed a pathologic complete response with no residual invasive tumor in the breast or nodes.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel and carboplatin; trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 55-year-old man with recurrent cutaneous melanoma of the upper back. Molecular profiling positive for BRAF V600E and high tumor mutational burden (TMB-high). Surveillance CT showed multiple pulmonary nodules suspicious for metastatic disease; staged as IV. He started pembrolizumab but had mixed radiographic findings and was transitioned to dabrafenib plus trametinib. Follow-up PET/CT shows no new lesions and stable metabolic activity of known nodules \u2014 overall stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (initial) then dabrafenib plus trametinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, biopsy-proven, presenting with pulmonary nodules. Molecular profile: KRAS G12D mutation identified; tumor also tested MSI-H by PCR. He was started on FOLFOX with bevacizumab as first-line systemic therapy. Repeat CT after 4 cycles demonstrated no new lesions and minimal shrinkage of target nodules \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma status post resection for a T3N1 tumor (stage III). Molecular profiling identified KRAS G12D; mismatch repair testing showed MSS. He completed adjuvant FOLFOX and on first surveillance CT demonstrates no new lesions; CEA stable. Clinically described as stable disease on follow-up notes.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "adjuvant FOLFOX", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed sigmoid colon adenocarcinoma and multiple hepatic lesions consistent with metastases. Molecular testing on the primary tumor reported KRAS G12D mutation, NRAS wild-type, and BRAF V600E negative. Tumor was microsatellite stable. He was started on FOLFOX with bevacizumab; first restaging CT at 12 weeks showed no progression compared with baseline.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 68-year-old with intermediate-risk prostate adenocarcinoma (Gleason 3+4) treated with definitive external beam radiation and concurrent androgen deprivation therapy (leuprolide). Pre-treatment PSA was 18 ng/mL. On surveillance his PSA has declined to 0.4 ng/mL three months after completion of RT. No molecular testing for somatic mutations documented; no radiographic evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 18 ng/mL (pre-treatment); PSA 0.4 ng/mL at 3 months", "treatment": "external beam radiation therapy and leuprolide (androgen deprivation therapy)", "response": "PSA decline", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed on core biopsy 2023. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score ~10%. Staging at presentation: IV with multiple enhancing cerebellar lesions and lytic lesions in the thoracic spine. Started osimertinib 80 mg daily in August; interval MRI shows decrease in size of brain metastases and improved pain from bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma (stage IV) presenting with diffuse bony pain. Imaging shows extensive vertebral and pelvic bone metastases and pelvic nodal involvement. He was started on androgen deprivation therapy with leuprolide and received six cycles of docetaxel; later treated with enzalutamide. Most recent scans demonstrate radiographic progression in the spine with increasing PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation (leuprolide), docetaxel, enzalutamide", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 65-year-old male with metastatic colon adenocarcinoma diagnosed with multiple hepatic lesions. Tumor genotyping returned KRAS G12D. He was started on FOLFOX plus bevacizumab with disease stabilization for six months but recent imaging shows interval progression of liver metastases. MSI testing was attempted but was non-diagnostic.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic lung adenocarcinoma diagnosed 2019. Next-generation sequencing identified EGFR L858R mutation. PD-L1 tumor proportion score ~10%. Patient started osimertinib 80 mg daily in Jan 2020 with interval CT showing a partial response. In Sept 2021 MRI revealed a new cerebellar metastasis and progressive lytic lesions of the thoracic spine; received stereotactic radiosurgery to the brain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response then progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with locally advanced, hormone receptor\u2013positive, HER2-amplified breast cancer (clinical T4N1). Core biopsy: ER 60%+, PR 0%, HER2 FISH positive. Tumor NGS identified a PIK3CA H1047R mutation. She received neoadjuvant chemotherapy with docetaxel plus trastuzumab and pertuzumab for six cycles followed by mastectomy; surgical pathology reported no residual invasive carcinoma (pCR). No distant metastases on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with high-grade serous ovarian carcinoma who underwent optimal cytoreductive surgery. FIGO stage IIIC with bulky omental and peritoneal disease at presentation. Germline testing identified BRCA1 185delAG pathogenic variant; tumor genomic assay reported HRD-positive. She completed adjuvant carboplatin and paclitaxel and was started on maintenance olaparib. Six-month CT shows decreased peritoneal implants and omental disease, consistent with partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (germline)", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER positive, PR positive, HER2 3+ by IHC and HER2 amplification confirmed by FISH. NGS panel detected a PIK3CA E545K hotspot mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles prior to mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). CT chest/abdomen was negative for distant disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrated multiple bilateral pulmonary nodules, a 2.5 cm cerebellar metastasis and a focal lytic lesion at T8. Molecular testing identified EGFR L858R. PD-L1 tumor proportion score reported at 10%. He was started on osimertinib 80 mg PO daily as first-line therapy. Interval MRI and chest CT after 8 weeks show shrinkage of the brain lesion and decreased size of pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with invasive ductal carcinoma of the breast, ER+/PR+, HER2-amplified, clinical stage IIA (T2N0). She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant chemotherapy (docetaxel and carboplatin), trastuzumab for HER2 amplification, and adjuvant endocrine therapy with letrozole. No residual disease on postoperative imaging and currently NED at 12-month follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel and carboplatin, trastuzumab, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male diagnosed with colorectal adenocarcinoma with multiple liver lesions on CT \u2014 clinical stage IV. Tumor next-gen panel showed KRAS G12D. MSI testing reported MSS. He was started on FOLFOX with bevacizumab; restaging after 4 cycles demonstrated no new lesions and minor decrease in size of hepatic metastases consistent with stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX; bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 59-year-old male with bulky node-positive squamous cell carcinoma of the oropharynx. Clinical stage is IVA with large ipsilateral cervical nodes. PD-L1 CPS reported at 20%. Plan is concurrent high-dose radiotherapy with weekly cisplatin. No targeted genomic sequencing was performed. Patient has not yet started definitive therapy and no response assessment is available.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx", "stage": "IVA", "gene_mutation": null, "biomarker": "PD-L1 20% (CPS)", "treatment": "cisplatin and radiotherapy", "response": null, "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old with metastatic colorectal adenocarcinoma. Imaging shows multiple liver metastases and peritoneal implants. Molecular testing: MSI-H and TMB 22 muts/Mb; KRAS G12D detected, BRAF wild-type. After progression on FOLFIRI plus bevacizumab the patient was started on nivolumab plus ipilimumab with documented RECIST partial response on first follow-up.", "output": {"cancer_type": "colorectal adenocarcinoma (metastatic colorectal cancer)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "nivolumab plus ipilimumab (after FOLFIRI + bevacizumab)", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. KRAS G12D identified on PCR; tumor was MSI-stable on PCR testing and reported as TMB-low. CT abdomen demonstrates multiple hepatic lesions consistent with metastases. He was treated with FOLFOX plus bevacizumab as first-line systemic therapy and interval imaging at 12 weeks shows stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; TMB-low", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Staging at diagnosis: stage IV with brain and osseous involvement on MRI. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 5%. She was started on osimertinib 80 mg daily in combination with bevacizumab q3wks. Follow-up CT and brain MRI after 8 weeks show reduction in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 49-year-old woman with metastatic invasive ductal carcinoma of the breast. ER/PR positive and HER2 amplification on FISH. Liver metastases at presentation (stage IV). Tumor sequencing detected PIK3CA H1047R. She received first-line chemotherapy with docetaxel plus trastuzumab and pertuzumab and achieved a sustained partial response; now maintained on single-agent trastuzumab every 3 weeks.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "docetaxel + trastuzumab + pertuzumab; maintenance trastuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man diagnosed with metastatic lung adenocarcinoma. Staging at presentation was IV with multiple intracranial lesions and lytic lesions in the thoracic spine. Molecular testing returned EGFR L858R positive; PD-L1 tumor proportion score ~10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. After 3 months of therapy imaging showed decrease in size of brain lesions and reduction of spinal disease burden consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old man with stage IV lung adenocarcinoma. NGS showed EGFR L858R mutation. PD-L1 tumor proportion score 15%. Baseline brain MRI demonstrated multiple small enhancing metastases. He was started on osimertinib and had a documented partial response at the first restaging CT, but developed CNS progression after 6 months and was transitioned to platinum-doublet chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib; later platinum-doublet chemotherapy", "response": "initial partial response then progression (CNS progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with metastatic invasive ductal breast carcinoma confirmed on biopsy of a hepatic lesion. Tumor is ER positive, PR negative and HER2 amplified by FISH. Somatic testing revealed PIK3CA H1047R. She received first-line trastuzumab and pertuzumab with docetaxel; interval CT after three cycles shows no significant change in size of liver lesions \u2014 overall stable disease. CA 15-3 mildly elevated.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR-, HER2 amplification", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old male with metastatic lung adenocarcinoma diagnosed 03/2024. Molecular testing positive for EGFR L858R; PD-L1 tumor proportion score ~20%. Started osimertinib 80 mg daily in April with marked improvement of pulmonary lesions and decreased dyspnea. Brain MRI in June showed a small cerebellar metastasis. Current assessment: partial response to osimertinib with residual intracranial disease under stereotactic radiosurgery consideration.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case note: Patient with metastatic melanoma, initial staging IV with multiple pulmonary nodules. Molecular testing positive for BRAF V600E; tumor mutational burden reported as TMB\u2011high. Began targeted therapy with dabrafenib and trametinib, had an initial partial radiographic response but subsequently developed clinical progression with new liver metastases and enlarging lung lesions. Switched to pembrolizumab but continued to progress on immunotherapy.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma (presenting with cough and weight loss). Initial testing documented an EGFR exon 19 deletion and concurrent TP53 R248Q. He was started on osimertinib 80 mg daily with initial benefit but developed radiographic progression after 11 months. Repeat staging showed new hepatic and osseous lesions consistent with metastatic disease (stage IV). Given progression, he was switched to carboplatin and pemetrexed combined with pembrolizumab. Baseline biomarkers included PD-L1 ~15% and TMB-high at 18 muts/Mb. On first restaging after three cycles the patient had a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; TP53 R248Q", "biomarker": "PD-L1 15%; TMB-high (18 muts/Mb)", "treatment": "osimertinib; then carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "liver; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma (mCRPC) presented with worsening bone pain. Staging consistent with stage IV disease with extensive osseous metastases. PSA on presentation was 120 ng/mL. He was continued on androgen deprivation therapy and started on combination systemic therapy with docetaxel plus abiraterone. No tumor genomic testing was performed at this time.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL", "treatment": "androgen deprivation therapy + docetaxel + abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman with metastatic lung adenocarcinoma presents for follow-up. Molecular testing identified EGFR L858R mutation; PD-L1 reported at 30%. Baseline MRI showed multiple cerebral metastases. She was started on osimertinib 80 mg PO daily as first-line targeted therapy and after 8 weeks has a confirmed partial response by RECIST.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with locally advanced pancreatic ductal adenocarcinoma, clinical stage III. Comprehensive NGS panel showed no actionable alterations. Patient received systemic chemotherapy with gemcitabine plus nab-paclitaxel concurrent with radiation. Interval CT at 3 months showed new hepatic lesions consistent with progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine + nab-paclitaxel with concurrent radiation", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple liver lesions. PCR-based assay detected KRAS G12D. Tumor testing reported MSI-H and high tumor mutational burden (TMB-high). After progression on FOLFOX, patient was started on pembrolizumab; most recent scans show stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left breast invasive ductal carcinoma, clinically staged IIIB. Core biopsy: ER-negative, PR-negative, HER2 IHC 3+; FISH confirmed HER2 amplification. She received neoadjuvant carboplatin and paclitaxel with trastuzumab for six cycles followed by modified radical mastectomy. Pathology reported no residual invasive carcinoma (pathologic complete response). No tumor genomic sequencing was performed at this time.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+)", "treatment": "carboplatin and paclitaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic lung adenocarcinoma diagnosed by bronchoscopic biopsy. Molecular testing identified EGFR L858R mutation and PD-L1 tumor proportion score ~10%. MRI brain demonstrated two enhancing lesions and bone scan showed a lytic lesion at T8 consistent with osseous metastasis. He was started on osimertinib 80 mg daily in March; follow-up CT chest shows decrease in size of pulmonary nodules and interval response. Current assessment: partial response on osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with history of prostate adenocarcinoma treated with definitive external beam radiation two years ago now has a rising PSA. No new cross-sectional imaging or staging reported in clinic note. He was started on leuprolide depot for androgen deprivation with an initial decline in PSA values. No tumor genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation therapy)", "response": "PSA decline", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female diagnosed with stage IV lung adenocarcinoma 11 months ago. Molecular testing from the primary tumor identified EGFR L858R. PD-L1 tumor proportion score reported at 10%. She was started on first-line osimertinib with symptomatic improvement and a partial response on CT chest. Recent MRI brain demonstrates new enhancing lesions consistent with intracranial progression; plan discussed to proceed with stereotactic radiosurgery and change systemic therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; planned stereotactic radiosurgery", "response": "partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old female with a 1.2 cm papillary thyroid carcinoma identified incidentally and managed with right thyroid lobectomy. Final stage recorded as I (T1aN0M0). No molecular testing was performed on the specimen. No radioactive iodine was given; surveillance neck ultrasound at 12 months shows no evidence of residual disease.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "thyroid lobectomy (no radioactive iodine)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and oncology follow-up: 59-year-old female with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery for bulky pelvic disease and peritoneal carcinomatosis. Final FIGO stage IIIC. Germline testing returned positive for a deleterious BRCA1 mutation; tumor HRD assay also reported HRD-positive. She completed 6 cycles of carboplatin and paclitaxel with good tolerance and was placed on maintenance olaparib. CT scans after chemotherapy showed no radiographic evidence of disease \u2014 complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin + paclitaxel; maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for adenocarcinoma of the cecum. Final pathology pT3N1 (stage IIIB). Tumor testing returned MSI-H / dMMR. No actionable somatic mutations were identified on routine panel. Patient completed adjuvant FOLFOX x12 with good tolerance and is on surveillance with no evidence of recurrence at 12-month CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "MSI-H / dMMR", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male underwent right hemicolectomy for a colonic mass. Pathology: moderately differentiated adenocarcinoma, stage III (T3N1). Tumor genotyping returned KRAS G12D and MSI testing showed MSI-high. He completed adjuvant FOLFOX for 6 months. Surveillance CT at 12 months demonstrates no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-high", "treatment": "surgery (right hemicolectomy) followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old woman with high-grade serous ovarian carcinoma, stage IIIC at diagnosis with extensive peritoneal carcinomatosis. Germline testing identified a BRCA1 pathogenic variant. CA-125 was markedly elevated pre-treatment. She underwent optimal debulking followed by carboplatin and paclitaxel and has been started on olaparib maintenance with a partial radiographic response of residual peritoneal disease.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "CA-125 elevated", "treatment": "debulking surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman with stage II invasive ductal carcinoma of the right breast. Tumor was ER+/PR+, HER2 amplified by FISH. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab; endocrine therapy with tamoxifen was initiated. Post-operative imaging and clinical exam show no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy; paclitaxel and trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with metastatic colorectal adenocarcinoma presenting with liver-dominant disease. Molecular testing returned KRAS G12D and TP53 mutation; microsatellite stable (MSS). Patient started on FOLFOX with bevacizumab. Interval CT after 12 weeks shows minor decrease in hepatic lesions with no new sites \u2014 disease categorized as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with unresectable metastatic melanoma (stage IV). PCR confirmed BRAF V600E mutation. He started on dabrafenib and trametinib with rapid clinical and radiographic regression; after 9 months developed new nodal disease and was transitioned to nivolumab immunotherapy. Recent PET/CT reports a mixed response with regression of lung metastases but progression of several subcutaneous nodules and regional lymph nodes.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; nivolumab", "response": "mixed response", "metastasis_site": "lung; subcutaneous nodules; regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Unresectable cutaneous melanoma, stage IV, molecular testing positive for BRAF V600E. Baseline PD-L1 was 5%. Patient started combination targeted therapy with dabrafenib and trametinib and had a complete radiologic response at 12 weeks; previously documented pulmonary metastases resolved on follow-up CT.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib; trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with newly diagnosed invasive ductal carcinoma of the right breast. Tumor is ER+/PR+, HER2 negative by IHC (0). Pathology shows a 1.8 cm lesion, sentinel nodes negative \u2014 pathologic stage I (T1cN0). She underwent lumpectomy with sentinel lymph node biopsy; margins clear. Oncotype DX score 14. Started adjuvant endocrine therapy with tamoxifen. No radiographic evidence of metastatic disease on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative (IHC 0); Oncotype DX 14", "treatment": "lumpectomy with sentinel lymph node biopsy; tamoxifen", "response": "no radiographic evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC, with carcinomatosis and peritoneal implants. Germline testing returned a pathogenic BRCA1 mutation. Tumor HRD assay positive. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel and was transitioned to maintenance olaparib. CA-125 is falling and scans show a partial response of peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD positive", "treatment": "carboplatin and paclitaxel; olaparib (maintenance)", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman diagnosed with metastatic lung adenocarcinoma (stage IV) presenting with headaches and hip pain. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily. Interval imaging and brain MRI after 8 weeks demonstrate shrinkage of the primary and intracranial lesions consistent with a partial response. Documented metastatic sites include brain and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma (stage IV) presenting with multiple liver lesions. Molecular testing: KRAS G12D and TP53 R273H; tumor is microsatellite-stable. Baseline CEA was 120 ng/mL. He received FOLFOX plus bevacizumab as first-line therapy; first restaging CT shows progressive enlargement of hepatic metastases consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 R273H", "biomarker": "MSI-stable; CEA 120 ng/mL", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple liver lesions and peritoneal carcinomatosis. Molecular testing returned MSI-H and TMB-high (20 muts/Mb) and identified a BRAF V600E mutation with KRAS wild-type. He was treated with the BRAF-targeted combination encorafenib plus cetuximab; due to MSI-H status pembrolizumab was considered and later given. Best response to encorafenib/cetuximab was partial response on CT.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (20 muts/Mb); KRAS wild-type", "treatment": "encorafenib + cetuximab; pembrolizumab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 mutation and the tumor showed HRD-positive status. She underwent primary debulking followed by adjuvant carboplatin and paclitaxel and was started on maintenance olaparib. CA-125 normalized and CT scan after completion of chemotherapy shows no measurable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "surgery (debulking), carboplatin, paclitaxel, olaparib (maintenance)", "response": "complete response (no measurable disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient diagnosed with high-grade serous ovarian carcinoma after cytology and omental biopsy; imaging revealed bilateral adnexal masses and diffuse omental caking consistent with peritoneal spread. Germline testing positive for a deleterious BRCA1 pathogenic variant. CA-125 markedly elevated at presentation. At laparotomy optimal debulking was achieved. She completed 6 cycles of carboplatin and paclitaxel with marked radiographic reduction in disease and normalization of CA-125; documented as a complete clinical response. Plan is to start PARP inhibitor maintenance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "elevated CA-125", "treatment": "debulking surgery, carboplatin and paclitaxel, planned PARP inhibitor maintenance", "response": "complete clinical response", "metastasis_site": "omentum, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging PET/CT showed multiple pulmonary nodules and enhancing lesions in the cerebellum and T8 vertebra. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Started first-line osimertinib 80 mg daily. After 8 weeks there is decrease in size of measurable nodules and reduction of brain lesions on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left-sided invasive ductal carcinoma. Tumor is ER-negative, PR-negative with HER2 amplification on FISH. Patient presented with progressive hepatic lesions on surveillance imaging and was restaged. She received first-line trastuzumab and pertuzumab in combination with docetaxel after surgery; follow-up CT shows reduction in size of liver metastases.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for a 48-year-old woman with locally advanced, HER2-amplified invasive ductal carcinoma of the breast (clinical T3N2, Stage IIIC). Pre-treatment NGS identified a PIK3CA H1047R mutation. She received 6 cycles of docetaxel with trastuzumab and pertuzumab prior to surgery. Surgical pathology after mastectomy showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing from the initial biopsy confirmed EGFR L858R. She was started on osimertinib 80 mg daily with an initial partial response on imaging. Recent surveillance MRI shows two new cerebellar metastases and progressive lytic disease in the pelvis. No PD-L1 result is documented in the chart.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man presents with newly diagnosed lung adenocarcinoma. Imaging and biopsy consistent with stage IV disease with multiple pulmonary nodules and a 1.5 cm cerebellar metastasis. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily with good tolerance and shows a partial response on first restaging CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic prostate adenocarcinoma presenting with progressive bone pain. Imaging reveals multiple osteoblastic and lytic lesions throughout the pelvis and thoracic spine. Germline testing returned a deleterious BRCA2 mutation. He was treated with androgen deprivation therapy plus abiraterone but developed biochemical and radiographic progression after four months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "androgen deprivation therapy and abiraterone", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with high-grade serous ovarian carcinoma, stage IIIC. Tumor testing positive for BRCA1 mutation and pathogenic TP53 mutation; HRD-positive on genomic scarring assay. She underwent debulking followed by combination carboplatin, paclitaxel and bevacizumab and is now on maintenance olaparib. Recent imaging and CA-125 are consistent with a complete response; disease was noted diffusely across the peritoneum and omentum at diagnosis.", "output": {"cancer_type": "ovarian cancer (high-grade serous carcinoma)", "stage": "IIIC", "gene_mutation": "BRCA1 mutation; TP53 mutation", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel with bevacizumab, then olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with recurrent cutaneous melanoma now with metastatic disease. Molecular testing positive for BRAF V600E. Staging scans show lesions in the brain and both lungs, and later a new hepatic focus. He initially received dabrafenib and trametinib with a brisk clinical and radiographic response, but developed new progressive liver disease after 9 months and was transitioned to combination ipilimumab/nivolumab with mixed radiographic findings.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib + trametinib; later ipilimumab + nivolumab", "response": "progression", "metastasis_site": "brain, lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Clinical stage T3N1 (Stage IIB). She received neoadjuvant weekly paclitaxel with dual HER2 blockade (trastuzumab and pertuzumab) for 12 weeks. Imaging after therapy demonstrated significant tumor shrinkage but residual disease on exam; clinical response reported as partial response. Patient is scheduled for modified radical mastectomy.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel, trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage III (cT3N1M0). Tumor was ER positive, PR positive and HER2 amplified by FISH; NGS also detected a PIK3CA E545K mutation. She received neoadjuvant docetaxel, carboplatin and trastuzumab with marked clinical shrinkage. Surgical specimen after mastectomy showed residual invasive carcinoma but significant treatment effect (partial response). Adjuvant radiotherapy planned.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant); surgery; planned adjuvant radiotherapy", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 59-year-old male with metastatic colorectal adenocarcinoma diagnosed after right hemicolectomy. Liver lesions were confirmed on CT and biopsy. Genomic profiling identified KRAS G12D mutation; MSI testing returned MSI-H. He received FOLFOX plus bevacizumab first-line with progression at 6 months and was switched to pembrolizumab given MSI-H status. On pembrolizumab he has had stable disease on two consecutive scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX plus bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: Patient with metastatic cutaneous melanoma. BRAF testing positive for V600E. Baseline brain MRI showed two small metastases; chest CT with multiple pulmonary nodules. Started targeted therapy with dabrafenib plus trametinib. After two months there has been a marked decrease in extracranial disease burden; intracranial lesions have partially regressed. PET/CT impression: overall partial response. PD-L1 testing done earlier was 5%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with unresectable cutaneous melanoma, stage IV with several small brain metastases on MRI. Tumor sequencing positive for BRAF V600E; PD-L1 expression <1%. He was started on combination dabrafenib and trametinib (BRAF/MEK inhibitors). After extracranial progression ipilimumab was added to the regimen. Initial response to BRAF/MEK was a marked partial response with reduction in size of both systemic and intracranial lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib + trametinib; ipilimumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging workup confirmed stage IV disease with multiple brain and bony metastases. Molecular testing returned EGFR L858R with a coexisting TP53 R273H; PD-L1 tumor proportion score 10%. He was started on osimertinib in combination with bevacizumab given bulky extracranial disease. Interim CT and MRI after 8 weeks demonstrate a partial response with shrinkage of dominant lung mass and decreased enhancement of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 R273H", "biomarker": "PD-L1 10%", "treatment": "osimertinib and bevacizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67M with symptomatic weight loss and right upper quadrant pain. CT abdomen/pelvis: multiple hepatic lesions and several pulmonary nodules concerning for metastatic colorectal primary. Colonoscopy confirmed sigmoid adenocarcinoma. Molecular testing: KRAS G12D mutation detected. Patient started on FOLFIRI with bevacizumab; imaging after 3 cycles shows minor decrease in size of some liver lesions but overall disease burden stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma consult note: 52-year-old with ulcerated primary on the back, now with pulmonary nodules on chest CT. Excisional biopsy confirmed cutaneous melanoma BRAF V600E positive. Patient received combination targeted therapy with dabrafenib and trametinib. Follow-up imaging demonstrates complete disappearance of measurable lung metastases and resolution of symptoms. No PD-L1 or other biomarker testing reported in chart.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with metastatic colorectal adenocarcinoma after CT showed multiple hypodense liver lesions. Clinical stage IV disease. Tumor sequencing revealed KRAS G12D. Baseline CEA was 120 ng/mL. Patient started on FOLFOX with bevacizumab; restaging after three cycles demonstrated stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 120 ng/mL", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with cutaneous melanoma of the left arm. PET/CT showed multiple pulmonary nodules suspicious for metastatic disease. Molecular testing detected BRAF V600E. He was started on dabrafenib with trametinib and at first restaging had marked reduction in chest nodules. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with castration-resistant prostate adenocarcinoma, extensive symptomatic bone metastases on technetium bone scan. NGS did not reveal targetable somatic mutations; circulating AR-V7 was detected. He was treated with abiraterone acetate and prednisone and external beam RT to a solitary painful vertebral lesion. Recent follow-up indicates stable disease by PSA and imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "AR-V7 positive", "treatment": "abiraterone acetate and prednisone; external beam radiation", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male underwent sigmoid colectomy for moderately differentiated colorectal adenocarcinoma, pathologic stage III (pT3N1) in 2022. Tumor was MSI-H by PCR. He completed adjuvant CAPOX (capecitabine and oxaliplatin) for 6 cycles. Post-treatment surveillance CTs show no evidence of recurrent disease in the chest, abdomen or pelvis; KRAS/BRAF testing was not reported in this chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "colectomy followed by CAPOX (capecitabine and oxaliplatin)", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 65-year-old female with high-grade serous ovarian carcinoma (FIGO IIIC). Germline BRCA1 pathogenic variant detected on panel testing. Preoperative CA-125 was 680 U/mL. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Post-treatment CA-125 decreased to 120 U/mL and CT shows decreased peritoneal nodularity consistent with a partial response. Peritoneal carcinomatosis was confirmed at surgery.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated (pre-op 680 U/mL)", "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent right hemicolectomy for T3N1 colon adenocarcinoma (stage III). Tumor sequencing showed KRAS G12D; MSI was reported as MSI-stable. He received adjuvant FOLFOX. Six months after completing chemotherapy surveillance CT demonstrated multiple hypodense lesions in the liver consistent with metastatic disease. Systemic therapy was changed to FOLFIRI with bevacizumab and follow-up CT scans have shown stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX (adjuvant); then FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma presenting with multiple pulmonary and brain lesions. NGS panel was negative for BRAF and NRAS (no actionable mutation identified); PD-L1 testing was not performed. He was started on combination ipilimumab and nivolumab but developed early progression in the brain on follow-up MRI.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 66-year-old man with newly diagnosed lung adenocarcinoma. Staging PET/CT and brain MRI show multiple cerebral lesions and lytic lesions in the thoracic spine consistent with metastatic disease; overall clinical stage IV. Molecular testing from core biopsy returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. First restaging CT at 8 weeks demonstrates a decrease in size of pulmonary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with newly diagnosed invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and HER2 negative on IHC/FISH. Clinical stage documented as IIA (T2N0M0). She underwent lumpectomy with sentinel lymph node biopsy (nodes negative), completed adjuvant whole-breast radiation and was started on tamoxifen for endocrine therapy. Follow-up mammogram and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel lymph node biopsy; adjuvant radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced pancreatic ductal adenocarcinoma with KRAS G12D identified on tumor sequencing. CA19-9 at diagnosis was 1,200 U/mL. Clinical stage III disease. Treated with modified FOLFIRINOX for six cycles followed by consolidative chemoradiation. Most recent CT shows no new lesions and overall stable disease compared with prior scan.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "CA19-9 >1200 U/mL", "treatment": "FOLFIRINOX and chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor profiling demonstrated KRAS G12D mutation. He was started on FOLFOX with bevacizumab; restaging CT after 4 cycles shows overall stable disease and persistent hepatic involvement.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with pancreatic ductal adenocarcinoma after presenting with jaundice and weight loss. Imaging demonstrated metastatic disease with multiple liver lesions and peritoneal nodules (stage IV). Tumor sequencing identified KRAS G12D; baseline CA 19-9 was markedly elevated at 12,000 U/mL. He received 3 cycles of FOLFIRINOX but restaging CT showed progression with increasing hepatic tumor burden and rising CA 19-9; he was transitioned to gemcitabine plus nab-paclitaxel for palliative therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male status post right hemicolectomy for colon adenocarcinoma, pathologic stage III (pT3N1). Tumor NGS returned KRAS G12D. Patient was started on adjuvant mFOLFOX6. Interim CT after 4 cycles shows reduction in size of the mesenteric nodes compared to pre-treatment imaging. No distant hepatic or pulmonary metastases were seen.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "mFOLFOX6 (adjuvant FOLFOX)", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man diagnosed with localized prostate adenocarcinoma after rising PSA. Clinical stage T2, biopsy Gleason 3+4 in multiple cores. He underwent radical prostatectomy followed by adjuvant external beam radiation for close margins. Post-treatment PSA is undetectable and he is considered NED at last follow-up. No molecular testing or biomarkers were reported in the chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation", "response": "no evidence of disease (NED)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old man with localized prostate cancer found on PSA screening (PSA 12 ng/mL). Biopsies revealed adenocarcinoma, Gleason 3+4, clinical stage II. He elected definitive surgical management and underwent radical prostatectomy with pelvic lymph node sampling. Final pathology confined to the prostate, no nodes involved; postoperative PSA undetectable.", "output": {"cancer_type": "prostate cancer (adenocarcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (pre-op); postoperative PSA undetectable", "treatment": "radical prostatectomy with pelvic lymph node sampling", "response": "no evidence of disease (postoperative undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma treated with wide local excision and sentinel node biopsy positive for tumor cells; final stage reported as IIIB. Tumor sequencing detected BRAF V600E. Patient was started on adjuvant dabrafenib and trametinib. No radiographic recurrence at 12-month follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male presents with metastatic lung adenocarcinoma diagnosed on core biopsy. Imaging shows multiple cerebral metastases. Molecular testing demonstrated EGFR L858R mutation; PD-L1 TPS 10%. He was started on osimertinib after initial steroid taper. Interim MRI shows reduction in lesion size. Plan to continue targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old man with a primary cutaneous melanoma resected from the forearm. Pathology showed BRAF V600E mutation and extranodal extension to regional lymph nodes; clinical stage III. He underwent wide local excision and sentinel node dissection and was started on adjuvant pembrolizumab. Restaging PET/CT demonstrates reduction in nodal uptake and overall partial response of regional disease. No distant metastatic disease identified.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, sentinel node dissection, adjuvant pembrolizumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with squamous cell carcinoma of the oropharynx, bulky cervical nodes and extranodal extension \u2014 AJCC stage IV. No molecular testing was performed and PD-L1 was not assessed in the initial workup. He underwent definitive concurrent cisplatin-based chemoradiation. Restaging PET/CT at 3 months shows complete metabolic response in the primary site and cervical nodes.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx (head and neck)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin-based chemoradiation", "response": "complete metabolic response", "metastasis_site": "cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old male who underwent right hemicolectomy for ascending colon adenocarcinoma, pathologic stage III (T3N1). Adjuvant chemotherapy with FOLFOX was recommended and completed. MSI testing returned MSI-H, but extended somatic panel was not performed prior to adjuvant therapy. Surveillance CTs to date show no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with a 1.1 mm superficial spreading melanoma on the upper back. Sentinel node biopsy was negative and the lesion was staged as IA (stage I). Molecular testing returned BRAF V600E positive. Treated with wide local excision; no adjuvant therapy recommended. Patient remains on routine dermatology follow-up with no signs of recurrence.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old man seen in clinic for newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrated multiple pulmonary nodules and intracranial lesions; overall stage IV. Molecular testing returned EGFR exon 21 L858R. PD-L1 tumor proportion score approximately 10%. Patient was started on osimertinib 80 mg daily with stereotactic radiosurgery to a solitary 1.2 cm cerebellar metastasis. At 8-week follow-up there is shrinkage of the primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 47-year-old woman with metastatic invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and HER2 amplification confirmed by FISH. NGS detected a PIK3CA H1047R mutation. Clinical imaging shows multiple hepatic lesions. She received first-line trastuzumab and pertuzumab in combination with docetaxel. After six cycles there is a partial radiographic response in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old former smoker with newly diagnosed lung adenocarcinoma. Staging PET/CT consistent with metastatic disease to the brain and contralateral lung; overall clinical stage recorded as IV. Molecular testing identified EGFR L858R mutation. PD-L1 TPS reported at 5%. Patient was started on osimertinib 80 mg daily with stereotactic radiosurgery to the dominant 2.5 cm cerebellar lesion. Early restaging at 8 weeks demonstrated a partial response in the chest and decrease in size of the brain metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with weight loss and right upper quadrant pain. Colonoscopy with biopsy confirmed colon adenocarcinoma with multiple hepatic lesions on CT consistent with stage IV disease. Comprehensive sequencing identified KRAS G12D; tumor is microsatellite stable (MSS). He was started on FOLFOX plus bevacizumab and interval scans after 3 months showed stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology consult / pathology: 54-year-old man with a pigmented lesion on the left forearm. Excisional biopsy: superficial spreading melanoma, Breslow 0.6 mm, no ulceration, margins negative, sentinel node negative \u2014 AJCC stage I. Tumor molecular testing reported BRAF V600E mutation. No adjuvant therapy recommended; patient to follow with dermatology and periodic imaging. PD-L1 / other immunologic markers were not assessed in this specimen.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (excisional biopsy); observation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman presented with abdominal distension and was found to have a large pelvic mass. Operative report: high-grade serous ovarian carcinoma; primary debulking performed followed by systemic chemotherapy with paclitaxel and carboplatin. BRCA testing samples submitted; results pending. No documentation of metastatic sites in the operative note.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "surgery (primary debulking), paclitaxel and carboplatin", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with castration-resistant prostate cancer, originally stage IV at diagnosis with extensive bone metastases. Germline BRCA2 mutation identified on hereditary panel. Prior therapies included LHRH analogue, docetaxel and abiraterone. Started olaparib after progression; PSA stabilized and imaging shows no new lesions to date (stable disease).", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 germline mutation", "biomarker": null, "treatment": "olaparib (after LHRH analogue, docetaxel, abiraterone)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with stage I invasive ductal breast cancer: ER positive, PR positive, HER2 negative. Surgical specimen sequencing revealed a PIK3CA E545K mutation. She underwent lumpectomy with sentinel node biopsy (0/3 nodes) and was started on adjuvant tamoxifen. Surveillance mammography and clinic exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA E545K", "biomarker": "ER+, PR+, HER2-negative", "treatment": "lumpectomy and tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male diagnosed with metastatic colorectal adenocarcinoma. Molecular testing demonstrated KRAS G12D. Tumor was MSI-H and reported as TMB-high. Baseline CT showed multiple liver lesions consistent with metastatic disease (stage IV). He received FOLFOX with bevacizumab as first-line therapy but progressed after 6 months. Given MSI-H status he was transitioned to pembrolizumab, however the most recent scans indicate disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal cancer diagnosed after liver lesions found on CT. Colonoscopy showed an obstructing sigmoid mass; pathology: adenocarcinoma. Staging consistent with stage IV disease with multiple hepatic metastases. Tumor genotyping returned KRAS G12D. Patient was started on FOLFOX plus bevacizumab; interval imaging after 3 cycles showed no new lesions and minor decrease in size of dominant hepatic lesion\u2014overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Tumor sequencing identified an EGFR L858R mutation. PD-L1 expression 10% by IHC. Staged IV with multiple intracranial lesions on brain MRI. She was started on osimertinib 80 mg daily; interval MRI and CT chest/abdomen show decrease in size of brain and lung lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma. PET/CT showed an FDG-avid right adrenal mass in addition to the primary skin lesion. BRAF V600E mutation identified on tumor panel. He was started on dabrafenib plus trametinib; interval imaging after 8 weeks demonstrates decreased size of the adrenal lesion and symptomatic improvement. No PD-L1 or TMB result available in chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma. MRI brain performed for new headaches showed a 2.2 cm cerebellar metastasis. Molecular testing of the lung biopsy identified EGFR L858R. The patient was started on osimertinib 80 mg daily and tolerated therapy well. Restaging CT at 8 weeks demonstrated shrinkage of the pulmonary primary and nodal disease consistent with partial response. PD-L1 testing was not performed. Documented stage at diagnosis: IV.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with a pigmented lesion on the left calf. Excisional biopsy: superficial spreading melanoma, Breslow 0.6 mm, no ulceration \u2014 stage I. BRAF testing positive for V600E. Decision made for wide local excision only; no adjuvant immunotherapy. Follow-up at 6 months: healed wound, no clinical or radiologic evidence of disease.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced right breast cancer, clinically T3N2 (stage IIIB). Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with FISH-confirmed HER2 amplification; ER and PR negative. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab, then underwent modified radical mastectomy. Surgical pathology showed no residual invasive tumor (pathologic complete response). She completed adjuvant chest wall radiotherapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab; surgery; adjuvant radiotherapy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions (stage IV). Tumor sequencing: KRAS G12D and TP53 mutation; MSI-stable. He was started on FOLFOX with bevacizumab. After three cycles the CT showed modest shrinkage of some hepatic lesions but overall disease did not meet RECIST criteria for PR \u2014 best response recorded as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic cutaneous melanoma, BRAF V600E positive and TMB-high on NGS. Had prior pembrolizumab with progression; started combination targeted therapy with dabrafenib and trametinib. Initial CT at 8 weeks showed a partial response in measurable disease but at 6 months there is clear progression in the lungs with new nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib (prior pembrolizumab)", "response": "initial partial response followed by progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma. Molecular testing demonstrated MSI-H and a high tumor mutational burden (~20 mut/Mb); BRAF V600E mutation was also reported. He received FOLFOX plus bevacizumab with initial disease control, then was transitioned to pembrolizumab because of MSI-H. Current scans show stable hepatic and peritoneal disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma, multiple hepatic lesions on CT. Tumor genotyping identified KRAS G12D. MSI testing returned MSI-H. Started palliative FOLFOX with bevacizumab; interval CT after 4 cycles demonstrates stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 54-year-old with high-grade serous ovarian carcinoma presenting with bulky pelvic disease and omental caking. CA-125 initially 1,200 U/mL. Germline testing returned BRCA1 pathogenic variant. Patient received 3 cycles neoadjuvant carboplatin and paclitaxel with good radiographic reduction of disease and drop in CA-125, then underwent interval debulking with optimal cytoreduction.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "elevated CA-125", "treatment": "neoadjuvant carboplatin and paclitaxel followed by interval debulking surgery", "response": "partial response with CA-125 decline and radiographic reduction", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male underwent right hemicolectomy for colon adenocarcinoma. Pathology: T3 N1 M0 consistent with stage III disease. Tumor was microsatellite stable (MSS) on PCR; routine NGS panel did not identify actionable somatic mutations. He completed 6 cycles of adjuvant FOLFOX. At 12-month surveillance CEA is within normal limits and CT abdomen/pelvis shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSS", "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. Staging CT shows diffuse peritoneal carcinomatosis and bilobar liver metastases (stage IV). Tumor testing reported MSI-H by PCR; no actionable KRAS/NRAS/BRAF mutations were detected on the panel. He was started on pembrolizumab as first-line systemic therapy. After 12 weeks the CT demonstrates no significant change in size of dominant lesions \u2014 overall impression: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old female with a new diagnosis of invasive ductal carcinoma of the right breast. Pathology: pT2N0 (stage IIA) invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Tumor NGS demonstrated PIK3CA E545K. She underwent breast-conserving surgery with sentinel lymph node biopsy followed by adjuvant paclitaxel and one year of trastuzumab. Surveillance imaging and physical exam are unremarkable and she is currently without evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy (breast-conserving surgery), paclitaxel, trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple liver lesions and pulmonary nodules. Biopsy confirmed stage IV disease. Tumor genotyping: KRAS G12D; microsatellite stable (MSS); TMB low. Started on FOLFOX plus bevacizumab. After four cycles imaging demonstrated interval growth of hepatic lesions and new pleural nodules consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable); TMB-low", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR positive, HER2 IHC 3+ confirming HER2 amplification. Next-gen sequencing identified a PIK3CA H1047R mutation. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab, underwent mastectomy and axillary dissection; pathology showed no residual invasive carcinoma (pCR). No evidence of distant spread on imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma (stage IV) diagnosed 02/2024. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. She presented with new headaches and MRI brain demonstrated multiple enhancing lesions consistent with brain metastases. Osimertinib 80 mg PO daily was initiated in March 2024 with a steroid taper. Interval CT chest/abdomen 6 weeks after starting therapy shows decrease in size of pulmonary nodules and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Thin 39-year-old male with metastatic cutaneous melanoma. Biopsy shows BRAF V600E mutation and PD-L1 expression approximately 80%; tumor mutational burden reported as TMB-high on comprehensive profiling. He initially received pembrolizumab monotherapy but developed symptomatic progression in the chest; subsequently switched to dabrafenib and trametinib with partial regression of several pulmonary and intracranial lesions. Overall clinical picture described as a mixed response to sequential therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 80%; TMB-high", "treatment": "pembrolizumab (initial) then dabrafenib plus trametinib", "response": "mixed response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology clinic note: 34-year-old man with a 1.2 cm pigmented lesion on the left forearm. Excisional biopsy shows superficial spreading melanoma, Breslow 0.9 mm, no ulceration, sentinel node negative \u2014 clinical stage IA. BRAF V600E mutation detected on molecular panel. Wide local excision with 1 cm margins performed; no adjuvant therapy indicated.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease / sentinel node negative", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma, initially stage III (pT3N1) after low anterior resection. Tumor genotyping: KRAS G12D; PCR shows MSI-H. Completed adjuvant FOLFOX but developed new solitary liver lesion on surveillance CT 10 months after finishing chemotherapy. Received pembrolizumab for recurrent disease with decrease in size of the hepatic lesion on interval imaging.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX (adjuvant); pembrolizumab (for recurrence)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: 68-year-old male underwent right hemicolectomy for colon adenocarcinoma. Final pathologic stage pT3 N1 (stage IIIB). Mismatch repair testing returned MSI-H. Somatic testing detected KRAS G12D. Patient completed six months of adjuvant FOLFOX chemotherapy. Surveillance CT scans and CEA are currently without evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIB", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with newly diagnosed lung adenocarcinoma, clinical stage IV at presentation. Molecular testing returned EGFR L858R mutation; PD-L1 expression 10% by IHC. Patient was started on osimertinib 80 mg daily. Interval CT and brain MRI after 8 weeks show decrease in size of target lesions consistent with partial response. Staging scans demonstrate known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced pancreatic ductal adenocarcinoma, borderline resectable (clinical stage III). Germline testing positive for pathogenic BRCA2 variant; tumor reported HRD-positive on genomic assay. Patient received 8 cycles of FOLFIRINOX with partial radiographic downsizing, followed by consolidative chemoradiation. He was placed on maintenance olaparib after platinum-based induction. CA19-9 declined from 1300 U/mL at diagnosis to 180 U/mL on therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "HRD-positive", "treatment": "FOLFIRINOX; chemoradiation; maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left invasive ductal carcinoma, ER+/PR+, HER2-amplified on FISH. Clinical stage IIIA at presentation. Core needle biopsy also identified a PIK3CA E545K mutation. She received neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab. Surgical pathology after mastectomy demonstrated complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Advanced cutaneous melanoma with symptomatic pulmonary and brain metastases. BRAF V600E mutation detected; high TMB and PD-L1 >50%. Patient received dabrafenib + trametinib with rapid clinical benefit but progressed intracranially after 6 months, then switched to combination immunotherapy with nivolumab and ipilimumab with mixed radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 >50%", "treatment": "dabrafenib + trametinib; nivolumab + ipilimumab", "response": "initial partial response then progression / mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV with liver and lung metastases. Molecular testing: KRAS G12D mutation, MSI-H and TMB-high. He was started on FOLFOX plus bevacizumab; best response on first-line chemo was stable disease. After progression was transitioned to pembrolizumab given MSI-H status and achieved a durable partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease on FOLFOX/bevacizumab; partial response on pembrolizumab", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman presented with a 1.8 cm left breast invasive ductal carcinoma. Core biopsy: ER positive, PR negative, HER2 3+ by IHC. No germline testing performed. She underwent lumpectomy with clear margins and sentinel node biopsy (0/3 nodes). Adjuvant plan: paclitaxel for 12 weeks with trastuzumab planned for one year followed by endocrine therapy with tamoxifen. Latest visit: no clinical or radiographic evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "I", "gene_mutation": null, "biomarker": "HER2 3+, ER positive, PR negative", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: patient underwent wide local excision of a cutaneous melanoma on the right forearm. Sentinel node positive; path staged as pT2aN1b (Stage IIIA). No molecular testing was performed on the specimen. Adjuvant nivolumab was initiated. PD-L1 reported at 20% on the tumor sample. No distant metastases identified on PET/CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "PD-L1 20%", "treatment": "nivolumab (adjuvant)", "response": "no evidence of distant disease / NED", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with glioblastoma (WHO grade IV). Molecular testing: IDH1 R132H positive; MGMT promoter methylated. He underwent gross total resection followed by concurrent radiotherapy with temozolomide. Six\u2011month MRI shows interval increase in enhancing mass consistent with progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation", "treatment": "surgical resection, radiotherapy, temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with a new diagnosis of invasive ductal carcinoma of the right breast. Tumor was ER positive, PR positive and HER2 amplified by FISH. Pathologic staging after lumpectomy and sentinel node biopsy was pT2N0, stage IIA. Targeted NGS identified a PIK3CA E545K alteration. She completed adjuvant doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab and was started on adjuvant letrozole. Most recent mammogram and PET-CT show no radiographic evidence of disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy, sentinel node biopsy, doxorubicin/cyclophosphamide, paclitaxel, trastuzumab, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with metastatic breast cancer. Core biopsy showed HER2 amplification; ER-negative, PR-negative. Bone scan and PET demonstrate multiple lytic lesions in the spine and pelvis. Documented as stage IV disease. Started on weekly paclitaxel with trastuzumab and pertuzumab. Repeat imaging after three months shows stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions and peritoneal nodularity. Stage IV at diagnosis. Tumor testing: BRAF V600E mutation and high microsatellite instability (MSI-H) with elevated TMB. Given MSI-H status, he was started on pembrolizumab monotherapy. After 3 months imaging showed stable size of most liver lesions with slight decrease in peritoneal implants\u2014overall assessment: stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma. Biopsy confirmed adenocarcinoma of the lung; molecular testing returned EGFR L858R mutation. Staging studies show multiple intracranial lesions and a right lower lobe primary consistent with stage IV disease. Patient was started on osimertinib 80 mg daily in clinic two weeks ago with interval imaging showing a decrease in size of the dominant lung and brain lesions \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma, presented with multiple liver metastases. Tumor testing: BRAF V600E mutation and MSI-H on PCR. Given MSI-H status he was started on pembrolizumab monotherapy as first-line treatment; imaging at 12 weeks demonstrated stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presenting with multiple pulmonary nodules and a symptomatic cerebellar lesion. Molecular testing positive for BRAF V600E; tumor sequencing reported TMB-high. She began combination targeted therapy with dabrafenib and trametinib. Interval PET/CT after 3 months showed a partial response in the chest and decreased metabolic activity in the brain lesion.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma. Tumor sequencing revealed a BRAF V600E mutation. He presented with multiple pulmonary nodules and several brain metastases. Treated with dabrafenib and trametinib with initial shrinkage of chest lesions (partial response) but developed a new cerebellar metastasis after 7 months consistent with disease progression. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression (new brain lesion)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a 2.1 cm invasive ductal carcinoma of the right breast. Tumor is ER-positive, PR-positive and HER2-negative. Sentinel lymph node biopsy was negative. Pathologic stage IIA (pT2N0). NGS panel detected PIK3CA H1047R. She underwent lumpectomy with clear margins and was started on adjuvant tamoxifen. Six-month follow-up exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; adjuvant tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with high-grade serous ovarian carcinoma who underwent optimal cytoreductive surgery. Peritoneal carcinomatosis noted intraoperatively, consistent with FIGO IIIC disease. Post-op CA-125 was elevated. She completed 6 cycles of adjuvant carboplatin plus paclitaxel with symptomatic improvement and was started on maintenance bevacizumab. Germline and somatic testing pending at the time of the note.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance bevacizumab", "response": "clinical improvement (symptomatic improvement)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma, stage IV with pulmonary and small brain metastases. Tumor sequencing positive for BRAF V600E; PD-L1 IHC reported 60%. He received first-line pembrolizumab but after extracranial progression was transitioned to dabrafenib plus trametinib, with radiographic partial response on follow-up scans.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman presented with a 1.8 cm palpable mass in the left breast. Core biopsy revealed invasive ductal carcinoma, ER+/PR+, HER2 negative. Tumor genomics identified a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy (0/3 nodes) followed by adjuvant radiation and endocrine therapy with letrozole. On last follow-up there is no radiographic evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+, HER2 negative", "treatment": "lumpectomy, adjuvant radiation, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right thigh cutaneous melanoma, BRAF V600E positive on molecular testing. Patient underwent wide local excision followed by adjuvant nivolumab. Eight months later developed multiple pulmonary nodules and an enhancing cerebellar lesion consistent with metastatic disease \u2014 clinical stage IV. Immunotherapy was stopped and targeted therapy with dabrafenib plus trametinib was initiated; follow-up imaging showed reduction in size of lung mets and improvement of the brain lesion = partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab; then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male diagnosed with metastatic colorectal adenocarcinoma, stage IV with bulky liver metastases. Tumor profiling showed MSI-H and BRAF V600E mutation; PD-L1 expression 5%. KRAS and NRAS were wild-type. He received first-line FOLFOX with bevacizumab with short disease control, then was switched to pembrolizumab based on MSI-H status and has achieved prolonged stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; PD-L1 5%", "treatment": "FOLFOX + bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with diffuse peritoneal carcinomatosis. Tumor testing showed a deleterious BRCA1 mutation and homologous recombination deficiency (HRD-positive); TP53 mutation also reported. She underwent frontline debulking followed by combination chemotherapy with carboplatin and paclitaxel in combination with bevacizumab, then was placed on maintenance olaparib plus bevacizumab per HRD-positive protocol. CA-125 normalized and CT shows complete clinical response.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation; TP53 mutation", "biomarker": "HRD-positive; BRCA1 mutation", "treatment": "carboplatin + paclitaxel + bevacizumab followed by maintenance olaparib + bevacizumab", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with metastatic castration-resistant prostate adenocarcinoma with diffuse sclerotic bone metastases. Prior therapy included leuprolide, docetaxel and abiraterone with clinical progression. Germline/somatic testing identified a BRCA2 truncating mutation. PSA is 58 ng/mL and he is considered HRR-deficient. He was started on the PARP inhibitor olaparib; first PSA check and imaging after 3 months show stable bone disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 truncating mutation", "biomarker": "PSA 58 ng/mL; HRR-deficient", "treatment": "olaparib (after prior leuprolide, docetaxel, abiraterone)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-resistant prostate cancer with symptomatic bone metastases. Germline/somatic testing did not reveal actionable point mutations on panel. Tumor expresses AR signaling; PSA rising on ADT. He received docetaxel chemotherapy followed by addition of olaparib as maintenance in the setting of prior response to platinum; continued androgen deprivation with enzalutamide. Imaging after 4 months shows decreasing intensity of bone lesions and PSA decline.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "AR signaling positive, PSA rising (prior), BRCA status negative on panel", "treatment": "docetaxel; olaparib (maintenance); enzalutamide (ADT)", "response": "partial response (PSA decline, decreased bone lesion activity)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology addendum: Patient with metastatic cutaneous melanoma noted to have multiple pulmonary nodules and a dominant right lower lobe mass. Prior genotyping reported NRAS Q61K. He was initiated on combined nivolumab and ipilimumab; interval chest CT at 8 weeks demonstrates decrease in size of several nodules but appearance of a new 1.5 cm lesion in the left lower lobe \u2014 impression: mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "nivolumab and ipilimumab", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Notes: 59-year-old man with locally advanced pancreatic adenocarcinoma encasing the celiac axis (unresectable). No molecular profiling available in chart. Started on gemcitabine/nab-paclitaxel and concurrent radiotherapy as palliative approach. Imaging after two months demonstrates interval enlargement of the primary mass and worsening pain.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel with radiation", "response": "progressive disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative summary: 71-year-old male with a 3.8 cm pancreatic head mass consistent with pancreatic ductal adenocarcinoma. Underwent pancreaticoduodenectomy (Whipple). Post-op CA19-9 was elevated at 320 U/mL. No actionable mutations were detected on the submitted panel. He was started on adjuvant gemcitabine. Current status: clinically well with no radiographic metastatic disease after completion of adjuvant therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "CA19-9 elevated (320 U/mL)", "treatment": "pancreaticoduodenectomy (Whipple) and adjuvant gemcitabine", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 48-year-old female with left breast invasive ductal carcinoma, ER positive, PR negative, HER2 amplification by FISH. Clinical stage IIIB with fixity to chest wall. She received 6 cycles of paclitaxel and trastuzumab followed by axillary sentinel node biopsy. Surgical pathology returned with no residual invasive carcinoma (pathologic complete response). No distant mets identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive, PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma, presenting with diffuse osteoblastic bone metastases and pelvic lymphadenopathy. Germline testing identified a pathogenic BRCA2 deletion. He received leuprolide followed by 6 cycles of docetaxel with radiographic progression; subsequently started olaparib with biochemical and radiographic partial response noted on follow-up scans.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic, castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "androgen deprivation (leuprolide); docetaxel; olaparib", "response": "partial response", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Tumor board summary: 59-year-old man with locally advanced pancreatic ductal adenocarcinoma involving the superior mesenteric artery \u2014 considered borderline resectable (clinical stage III). CA 19-9 is elevated at 480 U/mL. No comprehensive genomic testing available due to limited tissue. He received neoadjuvant FOLFIRINOX followed by consolidative chemoradiation with capecitabine. Interval CT shows disease stability without new distant lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "neoadjuvant FOLFIRINOX; chemoradiation with capecitabine", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old male with metastatic colorectal adenocarcinoma. Genomic profiling identified KRAS G12D mutation. He was started on FOLFOX with bevacizumab as first-line therapy. CEA was elevated at diagnosis but decreased slightly on therapy. Repeat imaging after 3 months shows stable size of hepatic lesions without new sites of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated (decreasing on therapy)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, FIGO Stage IV at presentation with peritoneal carcinomatosis and hepatic implants. Germline testing identified a deleterious BRCA1 5382insC mutation. CA-125 was 1,200 U/mL at diagnosis. She underwent primary debulking followed by adjuvant carboplatin and paclitaxel with interval CT showing decrease in size of peritoneal disease; started on maintenance olaparib. Overall assessment: partial response with falling CA-125.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 5382insC", "biomarker": "CA-125 1200 U/mL", "treatment": "primary debulking; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with stage IV lung adenocarcinoma with bulky bilateral pulmonary nodules and leptomeningeal enhancement. Molecular testing returned EGFR L858R and MET amplification; PD-L1 10% and TMB 8 mut/Mb. She received two cycles of carboplatin and pemetrexed with pembrolizumab, progressed, and was started on osimertinib plus bevacizumab with a subsequent partial response and reduction in brain and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 10%; TMB 8 mut/Mb", "treatment": "carboplatin and pemetrexed with pembrolizumab; then osimertinib plus bevacizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Diagnostic core biopsy: ER positive, PR positive, HER2 amplified by FISH. Next-generation sequencing revealed a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab + pertuzumab with docetaxel for six cycles, underwent mastectomy, and pathology showed a pathologic complete response (pCR). No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent right hemicolectomy for a T3N0 colon adenocarcinoma (stage II). Tumor testing returned MSI-high (MSI-H). No KRAS or BRAF testing was performed pre-op. Oncology note documents consideration of adjuvant 5-FU based chemotherapy given high-risk features; current surveillance CT abdomen/pelvis shows no distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant 5-FU considered", "response": "no evidence of disease after surgery", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic cutaneous melanoma with BRAF V600E mutation. Patient initiated on dabrafenib plus trametinib. Initially had measurable tumor shrinkage in the chest, but after 4 months developed neurological symptoms; MRI and CT confirm new intracranial and pulmonary lesions consistent with progressive disease. PD-L1 status was not reported in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer with progressive bone pain. Germline and somatic sequencing identified a deleterious BRCA2 truncating mutation. He was treated with androgen-deprivation therapy followed by abiraterone; after progression on hormonal therapy he was started on olaparib. Recent bone scan shows stable sclerotic disease without new lesions.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 truncation", "biomarker": null, "treatment": "androgen-deprivation therapy; abiraterone; olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. CT-guided biopsy confirmed colorectal primary; molecular testing positive for KRAS G12D. No MSI testing or PD-L1 reported in this note. Stage IV disease. He is receiving FOLFOX plus bevacizumab and most recent scans show stable disease in the hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presented with obstructive jaundice and was found to have pancreatic ductal adenocarcinoma with multiple hepatic metastases. Germline testing revealed a pathogenic BRCA2 mutation. He received first-line FOLFIRINOX with initial tumor shrinkage but developed progression in the liver after 8 months and was transitioned to maintenance olaparib given BRCA2. PD-L1 and TMB not reported.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; maintenance olaparib", "response": "progression after initial partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "77-year-old male with castration-resistant prostate adenocarcinoma metastatic to the axial skeleton and pelvic lymph nodes. Germline testing identified a BRCA2 mutation. PSA is 250 ng/mL. He was started on abiraterone with prednisone but reports worsening bone pain and recent bone scan shows progression in the spine.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (castration-resistant)", "gene_mutation": "BRCA2 (germline)", "biomarker": "PSA 250 ng/mL", "treatment": "abiraterone + prednisone", "response": "radiographic progression", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent total thyroidectomy for papillary thyroid carcinoma. Final pathology: classic papillary carcinoma; BRAF V600E mutation detected on next-generation sequencing. The patient received radioactive iodine ablation postoperatively. Follow-up neck ultrasound and thyroglobulin are undetectable; no adjuvant systemic therapy planned.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "radioactive iodine ablation", "response": "no residual disease / undetectable thyroglobulin", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man presented with a pigmented lesion and a positive sentinel node consistent with cutaneous melanoma, stage III. BRAF V600E mutation was identified on tumor genotyping. He received adjuvant therapy with dabrafenib plus trametinib for one year and surveillance PET/CT thereafter showed no evidence of disease. No distant metastases were identified at last follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "adjuvant dabrafenib and trametinib", "response": "complete response (no evidence of disease on surveillance)", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: Right breast invasive ductal carcinoma, clinical stage IIIB. ER and PR positive on IHC; HER2 IHC 3+ with confirmatory FISH demonstrating HER2 amplification. Neoadjuvant regimen: weekly paclitaxel with trastuzumab and pertuzumab; patient had significant tumor shrinkage but residual disease on imaging (partial clinical response). Surgical resection planned following completion of targeted therapy.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "paclitaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing identified EGFR L858R on initial biopsy and an acquired T790M on repeat biopsy. PD-L1 by IHC was 30%. He was started on osimertinib 80 mg daily with marked clinical improvement; CT and MRI at 12 weeks show decrease in size of pulmonary nodules and intracranial lesions consistent with a partial response. Known sites of disease include multiple brain metastases and lytic lesions in the thoracic spine.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with nodular melanoma of the left thigh, Breslow 4.2 mm, sentinel node positive. Underwent wide local excision and completion lymphadenectomy. Pathologic staging consistent with stage IIIA. Tumor sequencing identified BRAF V600E. She was enrolled on adjuvant targeted therapy and received dabrafenib plus trametinib for one year. Current surveillance CT shows no residual disease.", "output": {"cancer_type": "melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; lymphadenectomy; adjuvant dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 15%. He was started on osimertinib in July 2024 with rapid symptomatic improvement. Follow-up CT and MRI show decrease in size of pulmonary and hepatic lesions consistent with partial response. Has known brain and bone metastases; received palliative radiation to a skull base lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib; palliative radiation", "response": "partial response", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast, ER+ PR+ and HER2 amplified by FISH. Core biopsy also reported PIK3CA E545K mutation. She received neoadjuvant docetaxel and trastuzumab for 6 cycles followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel and trastuzumab (neoadjuvant), surgery", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma. Staging confirmed Stage IV disease with multiple enhancing brain metastases and lytic lesions in the spine. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line systemic therapy and had clinical improvement with a radiographic partial response on 8-week CT/MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic prostate adenocarcinoma, bone-predominant disease on bone scan. Germline and somatic testing detected a deleterious BRCA2 frameshift mutation. He was started on androgen deprivation therapy with leuprolide and later transitioned to olaparib after castrate progression. PSA fell from 120 to 35 ng/mL and radiographic disease has been stable over 4 months on olaparib.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (frameshift)", "biomarker": "PSA (decreased from 120 to 35 ng/mL)", "treatment": "androgen deprivation therapy (leuprolide) followed by olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced left breast invasive ductal carcinoma, ER+, PR+, HER2 amplification by FISH. Clinical stage IIIB. She completed neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and proceeded to modified radical mastectomy with axillary dissection. Surgical pathology shows no residual invasive carcinoma (pathologic complete response). Adjuvant radiation planned. No evidence of distant metastasis on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "doxorubicin and cyclophosphamide (AC) \u2192 paclitaxel with trastuzumab; surgery; planned radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast carcinoma, clinical stage IIIA. Core biopsy: invasive ductal carcinoma, ER/PR negative; HER2 IHC 3+ consistent with HER2 amplification. She received neoadjuvant trastuzumab and pertuzumab with paclitaxel, then underwent modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant mets on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+); ER/PR negative", "treatment": "neoadjuvant trastuzumab and pertuzumab with paclitaxel; surgery (modified radical mastectomy)", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female underwent optimal cytoreductive surgery for high-grade serous ovarian carcinoma, FIGO stage IIIC with diffuse peritoneal implants. Germline testing identified a deleterious BRCA1 mutation. She completed 6 cycles of carboplatin and paclitaxel with good CA-125 response and was placed on maintenance olaparib. Recent CT shows near-complete resolution of peritoneal disease; documented as complete response clinically and radiographically.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": null, "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with metastatic prostate adenocarcinoma presenting with worsening bone pain. PSA is 120 ng/mL. He started androgen deprivation therapy with leuprolide and received docetaxel chemotherapy; no pathogenic germline or somatic mutations were identified on panel testing. Bone scan demonstrates multifocal osseous metastases.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL", "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with progressive dyspnea found to have stage IV lung adenocarcinoma. NGS of the biopsy identified EGFR L858R and an acquired T790M. PD-L1 expression 10% (SP263). MRI brain demonstrates multiple enhancing lesions and bone scan shows metastatic disease in the thoracic spine. Patient was started on osimertinib 80 mg daily as first-line targeted therapy; interval CT at 8 weeks shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with left breast mass. Core biopsy: invasive ductal carcinoma, ER-negative, PR-negative, HER2 amplified by FISH. Nodal involvement on MRI consistent with clinical stage IIIA. Tumor NGS returned PIK3CA H1047R. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles. She then underwent lumpectomy with axillary dissection; surgical pathology showed no residual invasive carcinoma (pCR).", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with de novo metastatic invasive ductal breast carcinoma. ER positive, PR positive, HER2 amplification on IHC/FISH. Staging at diagnosis was IV with multiple liver and bony metastases. Molecular testing identified a PIK3CA H1047R mutation. She was started on first-line combination therapy with docetaxel plus trastuzumab and pertuzumab. Imaging after 3 cycles showed a partial response and CA 15-3 is falling.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology\u2013oncology note: 45-year-old man with recurrent cutaneous melanoma of the left forearm. Wide local excision with sentinel node biopsy returned positive sentinel node; pathologic stage III. Molecular testing identified BRAF V600E mutation. Patient was started on dabrafenib plus trametinib; after three months PET/CT shows new FDG-avid pulmonary nodules and increase in size of known lesions, consistent with progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 71-year-old male with metastatic colorectal adenocarcinoma presenting with hepatic lesions. Initial molecular profile: KRAS G12D mutation; tumor was MSI-H and TMB-high. Given pembrolizumab monotherapy due to MSI-H status. Restaging after 4 cycles shows decreased size of dominant hepatic lesion consistent with partial response and overall clinical improvement.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 45-year-old man with thin cutaneous melanoma on the left forearm. Final staging was Stage I (T1b). Sentinel node negative. BRAF testing returned V600E positive. Patient underwent wide local excision; no adjuvant systemic therapy given. Follow-up exam indicates no recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 67-year-old female with newly diagnosed lung adenocarcinoma. Staging CT/PET consistent with stage IV disease with multiple pulmonary nodules and small cerebellar metastases. Molecular testing returned EGFR L858R; ALK and ROS1 negative. PD-L1 TPS 30%. Patient was started on osimertinib 80 mg daily. Interim brain MRI at 8 weeks shows decrease in size of cerebellar lesions and shrinkage of lung nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma, stage IV, presenting with progressive headaches. Molecular testing identified EGFR L858R mutation and PD-L1 tumor proportion score 5%. Patient started osimertinib 80 mg daily. Stereotactic radiosurgery was delivered to a 1.2 cm cerebellar metastasis. Interval CT chest and brain MRI at 8 weeks demonstrate decrease in size of target lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old man with metastatic cutaneous melanoma harboring BRAF V600E mutation. He started combination targeted therapy with dabrafenib plus trametinib and had an initial partial response, but subsequently developed intracranial progression. PD-L1 was 1% and tumor profiling reported TMB-high. Brain metastases were documented on MRI. Stage IV at diagnosis.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%; TMB-high", "treatment": "dabrafenib + trametinib", "response": "partial response followed by progression (intracranial)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 1.2 cm invasive ductal carcinoma of the right breast underwent lumpectomy last month. Pathology: ER positive, PR positive, HER2 non-amplified by FISH. PIK3CA H1047R was identified on targeted panel. Stage was pT1bN0 (stage I). She was started on adjuvant radiation followed by endocrine therapy with letrozole. No evidence of residual disease on post-op imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 non-amplified", "treatment": "lumpectomy; adjuvant radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with invasive ductal carcinoma of the breast, clinical stage IIIA. Tumor is HER2-amplified and ER positive, PR negative on IHC/FISH. She received neoadjuvant doxorubicin/cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and pertuzumab, then underwent modified radical mastectomy. Surgical pathology demonstrated no residual invasive cancer (pathologic complete response). No radiographic evidence of distant metastasis.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant AC then paclitaxel with trastuzumab and pertuzumab; surgery", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58-year-old F with newly diagnosed metastatic lung adenocarcinoma. Biopsy confirmed adenocarcinoma, molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 10%. Started osimertinib 80 mg daily two weeks ago. Baseline brain MRI showed two small enhancing lesions consistent with metastases. CT chest/abdomen at 3 months shows a 40% decrease in target lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with left invasive ductal carcinoma, ER positive, PR negative. Core biopsy showed HER2 IHC 3+ and FISH-confirmed HER2 amplification. Clinically staged as IIIB with fixed axillary nodes. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab for 12 weeks followed by modified radical mastectomy. Final pathology reported a pathologic complete response (pCR). Germline BRCA testing was negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab; modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 43-year-old female with right invasive ductal carcinoma, ER positive, PR positive; HER2 amplification by FISH. Tumor genotyping identified PIK3CA H1047R. Clinical stage IIIA (T2N2). She completed 6 cycles of paclitaxel with dual HER2 blockade (trastuzumab + pertuzumab) prior to surgery. Imaging after therapy shows marked decrease in primary size but residual disease \u2014 partial response. No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "III A", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology note: Recurrent cutaneous melanoma on left thigh. BRAF V600E mutation identified on sequencing. Tumor mutational burden high (TMB-high, 20 mut/Mb). Prior wide local excision and sentinel node positive \u2014 current disease confined to regional nodes (stage III). Patient was started on dabrafenib plus trametinib; PET/CT at 12 weeks shows stable uptake in the nodal basins consistent with stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (20 mut/Mb)", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced right breast carcinoma. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+; FISH confirmed HER2 amplification. PIK3CA H1047R mutation detected on NGS panel. Clinical stage recorded as IIIB with fixed axillary nodal involvement. Neoadjuvant therapy with TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) \u00d76 cycles was administered. Post-treatment MRI shows marked decrease in primary mass but persistent residual disease in axilla.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP)", "response": "partial response / residual disease", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with invasive ductal carcinoma of the left breast, clinical stage II (T2N0). Core biopsy: ER 80%, PR 50%, HER2 FISH amplified. She underwent lumpectomy with clear margins followed by adjuvant paclitaxel and trastuzumab. Surgical pathology confirmed node negative disease and she is currently without evidence of disease on follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy, paclitaxel and trastuzumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly progressive metastatic lung adenocarcinoma. Initial biopsy in 2019 showed EGFR L858R mutation; PD-L1 by IHC 1%. Staging at progression consistent with stage IV with multiple intracranial lesions on MRI consistent with brain metastases. Patient was started on osimertinib 80 mg daily in January 2020 with significant clinical improvement and interval CT/MRI showing a partial response of both lung and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and follow-up: 59-year-old female underwent optimal cytoreductive surgery for high-grade serous ovarian carcinoma. Intraop: bulky omental caking and peritoneal implants; stage IIIC. Germline testing positive for BRCA1 pathogenic variant. CA-125 pre-op elevated at 860 U/mL. She completed six cycles of carboplatin and paclitaxel with normalization of CA-125 and then was started on maintenance olaparib. She remained in remission for 14 months but presented with recurrent abdominal distension; imaging shows recurrent peritoneal carcinomatosis.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "elevated CA-125", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "initial complete response then recurrence/progression at 14 months", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with biopsy-proven lung adenocarcinoma presenting with cough and headache. NGS identified EGFR L858R; PD-L1 TPS 5%. Staging workup consistent with stage IV disease with brain and multiple bone metastases. Patient progressed on first-line erlotinib and was switched to osimertinib 80 mg daily. Interval CT and MRI after 8 weeks show decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with high-grade serous ovarian carcinoma, optimal cytoreduction performed. Pathology staged as IIIC. Germline testing positive for deleterious BRCA1 185delAG mutation and tumor HRD-positive. CA-125 was markedly elevated pre-op. Adjuvant therapy: six cycles of carboplatin and paclitaxel followed by maintenance with olaparib plus bevacizumab. Patient achieved normalization of CA-125 and a clinical complete response on CT at 3 months post-treatment.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (deleterious germline)", "biomarker": "HRD-positive; elevated CA-125 (normalized post-treatment)", "treatment": "cytoreductive surgery; carboplatin + paclitaxel; maintenance olaparib + bevacizumab", "response": "clinical complete response; CA-125 normalization", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic cutaneous melanoma. Biopsy of a liver lesion confirmed melanoma with BRAF V600E mutation. She received first-line pembrolizumab but developed progression in the liver and was switched to targeted therapy with dabrafenib/trametinib. Tumor mutational burden reported as TMB-high. Imaging after two months demonstrated mixed response with shrinkage of lung nodules but enlargement of dominant hepatic lesion.", "output": {"cancer_type": "melanoma (cutaneous melanoma)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab followed by dabrafenib + trametinib", "response": "mixed response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female presented with new-onset seizures. MRI showed a heterogeneously enhancing left temporal mass; patient underwent near-total resection. Pathology consistent with glioblastoma, WHO grade IV. MGMT promoter was reported methylated; IDH1 R132H immunostain negative. She completed concurrent radiotherapy with daily temozolomide per Stupp protocol followed by adjuvant temozolomide. Surveillance MRI at 7 months demonstrated new nodular enhancement in the ipsilateral frontal lobe consistent with progression; consideration given to bevacizumab for symptomatic control.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylated", "treatment": "surgical resection; radiotherapy with concurrent temozolomide (Stupp protocol) followed by adjuvant temozolomide", "response": "progression", "metastasis_site": "brain (ipsilateral frontal lobe)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed metastatic lung adenocarcinoma (Stage IV) found to harbor an EGFR L858R mutation. PD-L1 tumor proportion score is 10%. He was started on osimertinib 80 mg daily in January; after three months interval CT and MRI brain show interval decrease in size of pulmonary lesions and reduction of several brain metastases. Current assessment: partial response on targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma with multiple liver lesions. Tumor NGS shows BRAF V600E mutation; mismatch repair testing is MSI-high and TMB-high. He was started first-line pembrolizumab given MSI-H status and achieved disease stabilization for approximately 5 months before progression in the liver. He was then switched to targeted therapy with encorafenib plus cetuximab. Current CT shows stable disease in the liver lesions. Stage IV at diagnosis.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab; encorafenib + cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with advanced high-grade serous ovarian carcinoma, FIGO stage IIIC with omental and diffuse peritoneal disease. Germline testing detected a pathogenic BRCA1 variant and tumor was HRD-positive. She underwent optimal debulking followed by carboplatin and paclitaxel and was transitioned to maintenance olaparib. At six-month follow-up CT there is no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin + paclitaxel; maintenance olaparib", "response": "no evidence of disease / complete response", "metastasis_site": "omentum; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with unresectable metastatic melanoma presenting with bulky hepatic and pulmonary disease (stage IV). Tumor testing identified BRAF V600E. He was started on dabrafenib plus trametinib. PET after 3 months showed complete metabolic response in the liver, but CT at 9 months revealed new nodal disease and growth of a lung nodule consistent with a mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "mixed response (initial complete metabolic response, later nodal progression)", "metastasis_site": "liver, lung, lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic colon adenocarcinoma to the liver. Tumor profiling identified BRAF V600E and high microsatellite instability (MSI-H) with TMB-high. Given poor response to FOLFOX, patient was switched to pembrolizumab monotherapy and achieved complete radiographic remission of hepatic lesions at 4 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (after FOLFOX)", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female diagnosed with lung adenocarcinoma in 2019. Current status: Stage IV disease with multiple enhancing brain metastases noted on MRI. Molecular testing returned EGFR L858R (exon 21). PD-L1 tumor proportion score reported at 10%. She was started on osimertinib 80 mg daily after prior platinum doublet; follow-up imaging demonstrates decrease in pulmonary nodules and improved control of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with recurrent glioblastoma multiforme status post subtotal resection. Concurrent chemoradiation with temozolomide completed last month. No actionable mutations were identified on the institutional 50-gene panel; MGMT methylation status not reported. Follow-up MRI at 3 months shows no interval enlargement of the operative cavity and no new enhancing lesions \u2014 disease radiographically stable.", "output": {"cancer_type": "glioblastoma multiforme", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "surgery, radiation, temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female diagnosed with stage I invasive ductal carcinoma of the right breast. ER positive (90%), PR positive (60%), HER2 negative by IHC. Tumor sequencing identified PIK3CA E545K. She underwent lumpectomy with sentinel node biopsy followed by adjuvant whole-breast radiotherapy and was started on tamoxifen. At 12-month follow-up there is no radiographic or clinical evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "I", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, whole-breast radiotherapy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging shows multiple brain metastases and lytic lesions in the spine. Molecular testing returned EGFR L858R; PD-L1 expression 10%. Clinical stage IV disease. Patient was started on osimertinib 80 mg daily with very good symptomatic improvement and radiographic partial response at first restaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male presented with metastatic colorectal adenocarcinoma with liver and pulmonary lesions. Tumor testing reported MSI-H and TMB-high (>20 mut/Mb). Chart review did not document KRAS/NRAS mutation testing. He completed 6 cycles of FOLFOX with bevacizumab achieving disease stabilization, then was transitioned to pembrolizumab monotherapy and subsequently had a complete metabolic response on PET.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "complete response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic pancreatic ductal adenocarcinoma, BRCA2 pathogenic germline variant identified. Baseline CA19-9 was markedly elevated. He began modified FOLFIRINOX with good symptomatic benefit and radiographic tumor control, then was transitioned to maintenance olaparib after six cycles. Disease remained controlled (stable disease) for six months before interval enlargement of liver metastases was noted.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "elevated CA19-9", "treatment": "modified FOLFIRINOX then maintenance olaparib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old woman with metastatic invasive ductal carcinoma of the breast. Biopsy of a hepatic lesion confirmed metastasis; disease classified as Stage IV. Tumor profiling showed PIK3CA H1047R. ER/PR positive, HER2 amplification by FISH. First-line therapy was trastuzumab and pertuzumab with docetaxel. After 4 cycles the scan shows stable disease in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with obstructing sigmoid mass; pathology consistent with moderately differentiated adenocarcinoma of the colon. CT abdomen revealed multiple hypodense lesions in the liver. Tumor testing reported MSI-H on PCR. Patient received FOLFOX and bevacizumab but developed rising CEA and interval growth of hepatic lesions \u2014 radiographic progression noted.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with a newly diagnosed right upper lobe lung adenocarcinoma, clinical stage IB (T2aN0M0). Molecular testing returned EGFR exon 21 L858R positive. PD-L1 tumor proportion score reported at 1%. She underwent VATS right upper lobectomy with mediastinal lymph node sampling and was started on adjuvant osimertinib 80 mg daily. At 12-month follow-up there is no radiographic evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IB", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "VATS right upper lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma. NGS identified BRAF V600E mutation. PD-L1 testing was high (PD-L1 >50%) and tumor sequencing reported TMB-high. He was treated with frontline dabrafenib plus trametinib with an initial partial response; after 6 months developed new pulmonary and CNS lesions consistent with progression and was transitioned to pembrolizumab, with mixed radiographic response noted on follow-up.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "dabrafenib + trametinib (then pembrolizumab)", "response": "progression after initial partial response", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Note: 46 y/o premenopausal woman with invasive ductal carcinoma of the right breast, clinically T2N0, biopsy HER2 IHC 3+ and ER/PR positive. She received neoadjuvant chemotherapy (docetaxel and carboplatin) with trastuzumab and had a good radiographic reduction in tumor size prior to lumpectomy. Sentinel nodes were negative on final pathology.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+); ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; lumpectomy", "response": "partial response (clinical/radiographic); node-negative on pathology", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/Oncology note: 43-year-old man with ulcerated primary melanoma of the left calf, sentinel node positive with 2/2 nodes involved\u2014AJCC stage III. Tumor testing revealed BRAF V600E mutation. He was enrolled on neoadjuvant dabrafenib plus trametinib and has had a significant clinical reduction in nodal burden on imaging (clinically described as partial response). He is scheduled for completion lymphadenectomy in 4 weeks.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "neoadjuvant dabrafenib and trametinib; planned lymphadenectomy", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male diagnosed with locally advanced pancreatic ductal adenocarcinoma, unresectable at presentation (stage III). Germline testing identified a pathogenic BRCA2 mutation. Baseline CA19-9 was 1250 U/mL. He received eight cycles of FOLFIRINOX followed by intensity-modulated radiotherapy with capecitabine, and is currently on maintenance olaparib. Most recent CT shows no interval enlargement of the primary mass or new distant lesions \u2014 disease categorized as stable.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2", "biomarker": "elevated CA19-9", "treatment": "FOLFIRINOX; chemoradiation (IMRT with capecitabine); maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic melanoma presented with new seizures; MRI demonstrated multiple intracranial lesions. He was treated with combination immunotherapy (ipilimumab plus nivolumab). PD-L1 was reported at 5% on tumor sample; BRAF testing was not available at the time of treatment decision. After two doses he experienced shrinkage of brain metastases and reduction in extracranial disease burden consistent with a partial response, complicated by immune-related colitis that required steroids.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "ipilimumab + nivolumab (combination immunotherapy); steroids for irAE", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with localized prostate adenocarcinoma, clinical stage II, presenting with rising PSA of 12 ng/mL. Underwent radical prostatectomy followed by adjuvant external beam radiation due to positive margins. No somatic gene panel was reported and there is no evidence of metastatic disease on bone scan. Postoperative PSA is undetectable so far.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (preoperative); postoperative undetectable", "treatment": "radical prostatectomy; adjuvant external beam radiation", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric artery, deemed borderline resectable (clinical stage III). No actionable mutations were reported at outside institution and no biomarkers recorded in the oncology note. She received 6 cycles of gemcitabine with nab-paclitaxel followed by consolidative SBRT for local control. Imaging after treatment showed stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III (locally advanced / borderline resectable)", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine + nab-paclitaxel, followed by SBRT", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation; PD-L1 TPS ~10%. At presentation he had brain and bone metastases. Started osimertinib 80 mg PO daily in Jan 2020. Interval MRI and CT after 3 months show decrease in size of intracranial lesions and lytic bone lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology report: core needle biopsy of the left breast demonstrates invasive ductal carcinoma, ER 80% positive, PR 40% positive, HER2 IHC 3+ with FISH confirming HER2 amplification. Staging workup shows no distant metastasis; clinical stage IIB. Tumor genomic profiling identified PIK3CA H1047R. The patient received neoadjuvant paclitaxel with trastuzumab followed by breast-conserving surgery. Final surgical pathology shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER 80%; PR 40%", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma after presenting with cough and headaches. Staging workup showed multiple intracranial lesions and lytic lesions in the spine consistent with stage IV disease. Molecular testing returned EGFR L858R mutation and PD-L1 10%. She was started on osimertinib 80 mg daily; follow-up CT/MRI at 8 weeks demonstrates decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic invasive ductal breast carcinoma (ER+, PR+, HER2 amplified) presenting with multiple painful lytic lesions. Biopsy confirms grade 3 disease, stage IV. NGS detected a PIK3CA E545K alteration. She was started on docetaxel with trastuzumab and pertuzumab; interval imaging after 4 cycles shows reduction in size of bony lesions consistent with partial response.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with metastatic lung adenocarcinoma presented to clinic. Initial testing showed EGFR L858R and a high tumor mutational burden (TMB-high). PD-L1 TPS was 30%. He was started on osimertinib with an initial partial response, but after 10 months developed progression in the brain and a new bone lesion. He was transitioned to carboplatin and pemetrexed in combination with pembrolizumab; subsequent imaging demonstrates stable disease on this regimen.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%, TMB-high", "treatment": "osimertinib; then carboplatin and pemetrexed with pembrolizumab", "response": "stable disease", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH (HER2/CEP17 ratio 6.2). Targeted NGS identified a PIK3CA H1047R mutation. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant docetaxel and carboplatin plus trastuzumab for 6 cycles, then left mastectomy; pathology reported no residual invasive carcinoma (pathologic complete response). No distant metastases identified on PET-CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing detected EGFR L858R on PCR; PD-L1 TPS reported at 10%. He was started on osimertinib and achieved an initial partial response but subsequently developed symptomatic brain and bone metastases with radiographic progression on therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "initial partial response then progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with cutaneous melanoma initially treated with wide local excision. Subsequent progression with pulmonary nodules and a solitary cerebellar metastasis\u2014radiation to the brain was delivered. Tumor testing demonstrates BRAF V600E mutation; PD-L1 5%. Patient received single-agent nivolumab but progressed systemically and was then started on dabrafenib plus trametinib with an initial partial response; most recent scans show new intracranial progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "nivolumab; then dabrafenib + trametinib", "response": "progression after initial partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old man with newly diagnosed glioblastoma after craniotomy. Molecular pathology: IDH1 R132H negative (IDH1 wild-type). MGMT promoter is methylated. He underwent maximal safe resection followed by concurrent temozolomide and focal radiotherapy (Stupp protocol). Three-month MRI shows a new small enhancing nodule at the resection cavity with surrounding edema; radiology states this could represent treatment effect versus early progression.", "output": {"cancer_type": "glioblastoma", "stage": null, "gene_mutation": "IDH1 wild-type", "biomarker": "MGMT promoter methylation", "treatment": "surgery; concurrent temozolomide and radiotherapy (Stupp protocol)", "response": "mixed response / possible progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma presented with worsening headaches and new left-sided weakness. Initial staging: stage IV disease with known brain and bone metastases. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. He was started on first-line osimertinib with good symptom control for 8 months, then developed radiographic progression in the brain. Systemic therapy was changed to combination carboplatin and pemetrexed with pembrolizumab. On most recent scans there is a partial response in the chest and stable size of the brain lesions after stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 55-year-old man with metastatic cutaneous melanoma diagnosed last year. Molecular panel positive for BRAF V600E. PD-L1 by IHC 5%. He was started on combination targeted therapy with dabrafenib + trametinib and also underwent stereotactic ablative radiotherapy to a dominant liver metastasis. Interval PET/CT shows decreased metabolic activity in multiple lesions and size reduction of pulmonary nodules \u2014 overall best response recorded as partial response.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-intermediate", "treatment": "Dabrafenib + trametinib (BRAF/MEK combination) and stereotactic liver radiotherapy", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 65-year-old female with locally advanced pancreatic ductal adenocarcinoma encasing the SMA; deemed unresectable (clinical stage III). Comprehensive NGS showed no actionable alterations. Patient completed 8 cycles of modified FOLFIRINOX followed by consolidative chemoradiation. CA19-9 has fallen compared with baseline and CT shows a stable primary mass without distant metastatic disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "modified FOLFIRINOX followed by consolidative chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with Stage IV disease with multiple brain and bony lesions. Molecular testing returned EGFR L858R mutation and PD-L1 10%. She was started on osimertinib 80 mg daily in July and tolerated therapy well; first restaging CT and brain MRI at 8 weeks demonstrated a decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "The patient is a 62-year-old male with newly diagnosed lung adenocarcinoma. Staging workup showed extensive bilateral pulmonary nodules and multiple enhancing lesions in the cerebellum consistent with metastases \u2014 overall TNM consistent with stage IV disease. Molecular testing returned EGFR L858R mutation; PD-L1 TPS was 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain metastasis. Interval CT at 8 weeks demonstrates a decrease in size of most lung lesions and resolution of the treated brain target \u2014 assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; lung (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic castration-resistant prostate adenocarcinoma (mCRPC) with predominant bone metastases. Germline testing identified a deleterious BRCA2 mutation. AR-V7 assay was negative. He previously received androgen-deprivation therapy and docetaxel; more recently was started on the PARP inhibitor olaparib with a decline in PSA and partial radiographic response of several sclerotic bone lesions.", "output": {"cancer_type": "prostate adenocarcinoma (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "AR-V7 negative", "treatment": "androgen-deprivation therapy; docetaxel; olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology/path report summary: 72-year-old male with biopsy-proven sigmoid adenocarcinoma, stage IV at diagnosis with multiple hepatic metastases. Molecular panel: KRAS G12D positive; microsatellite stable (MSS). Patient initiated on FOLFOX with bevacizumab. Restaging after 4 cycles showed interval increase in size of dominant liver lesion consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man with metastatic cutaneous melanoma presenting with symptomatic pulmonary nodules and a single cerebellar metastasis. Tissue sequencing showed BRAF V600E mutation; tumor profiling reported PD-L1 approximately 60% and tumor mutational burden high (~20 mutations/Mb). He was started on dabrafenib and trametinib; follow-up imaging at 6 weeks demonstrated a partial response in the chest and reduction in the size of the brain lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%; TMB-high (~20 mut/Mb)", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with newly diagnosed metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor profiling showed BRAF V600E mutation and high microsatellite instability (MSI-H). Given MSI-H status, patient was started on pembrolizumab monotherapy as first-line systemic treatment and after 6 cycles imaging demonstrated complete radiographic response in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Rash and enlarging right-sided pulmonary nodules in a 48-year-old male with metastatic melanoma. Tumor sequencing identified BRAF V600E. He was started on dabrafenib with trametinib; after two months there has been a marked reduction in size of the dominant lung mass but several subcentimeter nodules persist.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with localized prostate adenocarcinoma, Gleason 3+4=7, clinical stage T2b (Stage II). PSA at diagnosis 7.8 ng/mL. He underwent robotic radical prostatectomy with negative margins. No molecular testing was performed; adjuvant radiation deferred. Early post-operative PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "robotic radical prostatectomy", "response": "undetectable PSA / no evidence of biochemical disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for a deleterious BRCA1 mutation and tumor NGS identified a somatic TP53 mutation. Tumor was HRD-positive and CA-125 was markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel, and is currently on maintenance olaparib with partial radiographic response and decreased peritoneal disease burden.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 (germline); TP53 (somatic)", "biomarker": "HRD-positive; elevated CA-125", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 48-year-old man with metastatic cutaneous melanoma presented with headaches. MRI showed multiple enhancing lesions in the cerebrum consistent with brain metastases and new pulmonary nodules. BRAF V600E mutation was identified on tumor sequencing. PD-L1 expression low (2%). He was started on targeted therapy with dabrafenib and trametinib. Interim scans after 6 weeks show a marked reduction in the size of both brain and lung lesions \u2014 assessed as partial response by RECIST criteria. Patient tolerated therapy well with mild pyrexia.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%", "treatment": "dabrafenib; trametinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. Liver biopsy confirmed metastatic colon cancer. Molecular profile shows KRAS G12D and high microsatellite instability (MSI\u2011H). Started on pembrolizumab monotherapy for MSI\u2011H disease. Restaging CT after 3 cycles shows minimal change in lesion size \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal (colorectal adenocarcinoma)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Baseline testing demonstrated EGFR L858R mutation and PD-L1 10% (TPS). She was started on osimertinib 80 mg PO daily and received stereotactic radiosurgery to a 1.5 cm cerebellar metastasis. Interval MRI at 3 months shows a 45% reduction in measurable pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma. Initial CT showed bulky hepatic metastases; colonoscopy-proven primary ascending colon tumor. Tumor testing returned MSI-H and TMB-high; BRAF V600E mutation was identified on PCR. He received first-line FOLFOX with bevacizumab with disease stabilization, then on progression was started on targeted therapy with encorafenib plus cetuximab per molecular tumor board recommendations. Current status: stable disease on therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, biopsy-proven stage IV disease. Tumor testing revealed BRAF V600E mutation. He presented with progressive ascites and imaging consistent with peritoneal carcinomatosis; small hepatic lesions were also noted. After progression on first-line FOLFOX plus bevacizumab he was started on encorafenib with cetuximab and interval CT shows a partial radiographic response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "CEA elevated", "treatment": "FOLFOX and bevacizumab; then encorafenib plus cetuximab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with unresectable metastatic melanoma. Molecular testing positive for BRAF V600E. He was treated with dabrafenib plus trametinib and achieved a complete response in extracranial disease initially, but after 10 months developed new symptomatic brain lesions and systemic progression. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial complete response followed by progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with metastatic colorectal adenocarcinoma (stage IV). NGS identified KRAS G12D and the tumor was MSI-H with TMB-high. He received FOLFOX with bevacizumab as induction therapy, progressed after six cycles and was switched to pembrolizumab monotherapy with stable disease on the 12-week scan. Sites of disease include peritoneal carcinomatosis and multiple liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old with metastatic cutaneous melanoma, presenting with brain metastases. Genotyping positive for BRAF V600E. PD-L1 by IHC was 1%; tumor mutational burden reported as high. Patient received targeted combination therapy with dabrafenib + trametinib and achieved an initial partial response; intracranial progression later prompted change to combination ipilimumab + nivolumab immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%; TMB-high", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab", "response": "partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old with high-grade serous ovarian carcinoma, Stage IV at diagnosis with peritoneal carcinomatosis and hepatic implants. BRCA testing negative. She received debulking surgery followed by carboplatin and paclitaxel, then bevacizumab maintenance. Recent scans show increase in peritoneal disease and new liver lesions consistent with progression.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "BRCA1/2 negative", "treatment": "debulking surgery; carboplatin and paclitaxel; bevacizumab maintenance", "response": "progression", "metastasis_site": "peritoneum and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed lung adenocarcinoma, stage IV. Molecular testing identified EGFR L858R (exon 21). PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily. Follow-up CT and MRI after eight weeks demonstrate decrease in size of the primary and intracranial lesions consistent with partial response. Metastatic disease noted in brain and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: patient underwent wide local excision for a high-grade pleomorphic soft tissue sarcoma of the thigh. Margins were focally positive and multidisciplinary tumor board recommended adjuvant radiotherapy. No molecular testing was performed on the specimen and no distant disease was identified on preoperative CT.", "output": {"cancer_type": "soft tissue sarcoma (pleomorphic)", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "surgery; adjuvant radiotherapy", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman found to have a sigmoid mass and multiple hepatic lesions. Biopsy of a liver lesion confirmed metastatic colorectal adenocarcinoma. Molecular panel: KRAS G12D mutation detected, BRAF wild-type, microsatellite stable (MSS). She was started on FOLFOX with bevacizumab. Interval CT at 12 weeks demonstrated stable size of the hepatic metastases and no new sites of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 62-year-old man with metastatic lung adenocarcinoma diagnosed 03/2024. Molecular testing on the biopsy showed EGFR L858R mutation. PD-L1 TPS 10%. Baseline MRI demonstrates two small enhancing lesions in the cerebellum and lytic lesions in the T8 vertebral body. Patient was started on osimertinib 80 mg daily in April with good clinical improvement. First CT re-staging at 8 weeks shows reduction in target lesions \u2014 overall partial response per RECIST; brain lesions decreased in size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast core biopsy: invasive ductal carcinoma, ER positive, PR positive. HER2 FISH positive with HER2 amplification noted. Clinical staging cT2N1 (stage IIIA). Neoadjuvant therapy consisted of dose-dense doxorubicin and cyclophosphamide x4 followed by weekly paclitaxel with concurrent trastuzumab. Mastectomy specimen shows no residual invasive carcinoma or nodal metastasis \u2014 pathologic complete response achieved. Germline BRCA testing negative.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Unresectable cutaneous melanoma in a 67-year-old man presented with multiple hepatic and pulmonary lesions. Biopsy confirmed metastatic melanoma, BRAF V600E positive. Baseline PD-L1 was 5% and tumor sequencing reported TMB-high (20 muts/Mb). He received pembrolizumab for 3 months but developed radiographic progression; therapy was switched to dabrafenib plus trametinib with a subsequent partial response and marked reduction in liver metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progression on pembrolizumab; partial response to dabrafenib/trametinib", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left-sided invasive ductal carcinoma, ER+/PR+, HER2-amplified, pathologic stage IIA (pT2N0). Genomic testing detected a PIK3CA H1047R mutation. She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab; endocrine therapy with tamoxifen was planned. Patient remains on surveillance with no evidence of recurrence.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+, HER2 amplification", "treatment": "lumpectomy with sentinel node biopsy; adjuvant paclitaxel and trastuzumab; planned tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old male noted a new pigmented lesion on the left forearm. Excisional biopsy: superficial spreading melanoma, Breslow 1.2 mm, non-ulcerated, sentinel node negative \u2014 stage I. Molecular testing returned positive for BRAF V600E. Wide local excision performed; no adjuvant systemic therapy recommended. Patient remains clinically disease-free on follow-up exams.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old male with metastatic pancreatic ductal adenocarcinoma, BRCA2 pathogenic germline mutation identified on hereditary panel. Presents with multiple hepatic metastases on baseline CT. Received FOLFIRINOX with good CA19-9 decline, transitioned to maintenance olaparib. Latest CT shows reduction in liver lesions \u2014 partial response.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "HRD-positive; CA19-9 elevated", "treatment": "FOLFIRINOX, then maintenance olaparib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with widely metastatic cutaneous melanoma presenting with multiple pulmonary nodules and subcutaneous implants. He received combination immunotherapy with nivolumab plus ipilimumab and stereotactic radiosurgery to dominant lung lesions. Comprehensive genomic panel was pending at the time of treatment and PD-L1 testing was not performed. PET/CT after induction shows complete metabolic response of all previously avid lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab + ipilimumab; stereotactic radiosurgery", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Core biopsy of right upper lobe confirmed adenocarcinoma. Molecular testing: EGFR L858R detected; PD-L1 tumor proportion score 10%. Patient was started on first-line osimertinib 80 mg daily with significant improvement in cough and reduction of the primary mass on CT at 8 weeks. After 11 months on therapy she developed headaches; brain MRI demonstrated two new enhancing lesions consistent with metastases and enlargement of a known T6 vertebral lesion. Osimertinib was continued while stereotactic radiosurgery (SRS) was planned for intracranial disease. Overall course: initial partial response in thorax followed by intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery (planned)", "response": "partial response then intracranial progression", "metastasis_site": "brain; bone (T6 vertebra)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with locally advanced pancreatic ductal adenocarcinoma, clinical stage III at presentation. She underwent induction chemoradiation with weekly gemcitabine and concurrent external beam radiation, followed by systemic induction with modified FOLFIRINOX. Limited panel testing showed no actionable mutations on the report. CA19-9 is elevated at 420 U/mL. There is no radiographic evidence of distant metastasis at this time; disease is considered stable on recent restaging.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "gemcitabine + radiation followed by modified FOLFIRINOX", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with multiple liver lesions and peritoneal implants. Molecular testing: KRAS G12D mutation. Tumor was MSI-high and reported as TMB-high on NGS. First-line therapy consisted of FOLFOX plus bevacizumab; given the MSI-H status pembrolizumab was added subsequently. Cross-sectional imaging after 8 weeks demonstrated overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with left invasive ductal carcinoma, ER positive/PR positive, HER2 amplification on FISH. Clinical stage was II (T2N1M0). Tumor next-generation sequencing detected a PIK3CA E545K mutation. She received neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab, then underwent lumpectomy and sentinel node biopsy. Surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin and cyclophosphamide, paclitaxel, trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man referred for systemic therapy. Diagnosis: lung adenocarcinoma, stage IV with brain and bone metastases. Molecular testing returned EGFR L858R positive; PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg PO daily in June; follow-up MRI/CT demonstrates decrease in size of primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up for metastatic colon adenocarcinoma. Patient with synchronous liver metastases at diagnosis. Tumor genotyping showed KRAS G12D mutation; MSI testing: microsatellite stable (MSS). He was started on FOLFOX with bevacizumab and has completed 8 cycles with interval CT demonstrating no new lesions and overall stable disease by RECIST.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presents with metastatic lung adenocarcinoma. Molecular testing revealed EGFR L858R. Staging consistent with Stage IV disease with multiple brain metastases and osseous lesions. PD-L1 TPS 5%. He was started on osimertinib 80 mg daily with symptomatic improvement; 8-week CT showed partial response of the thoracic disease while brain MRI reported a mixed response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response in chest; mixed response in brain", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC, with extensive peritoneal carcinomatosis at diagnosis. Germline testing identified a deleterious BRCA1 mutation. She underwent primary optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with complete clinical and radiographic response. She remains on maintenance olaparib with no evidence of disease on most recent CT abdomen/pelvis.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": null, "treatment": "debulking surgery, carboplatin and paclitaxel followed by maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male presented with an obstructing sigmoid mass. Pathology: moderately differentiated colorectal adenocarcinoma, pathologic stage III (T3N1). Molecular testing reported KRAS G12D. He underwent low anterior resection followed by adjuvant FOLFOX for 6 months. Surveillance CT at 12 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "low anterior resection; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with high-volume metastatic prostate adenocarcinoma, castration-sensitive at diagnosis, with multiple osteoblastic metastases in the thoracic spine and pelvis. Baseline PSA 180 ng/mL. No genomic testing performed. He was started on androgen deprivation with leuprolide plus docetaxel; after three months PSA fell to 25 ng/mL indicating a partial biochemical response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 180 ng/mL (baseline)", "treatment": "leuprolide and docetaxel", "response": "partial biochemical response (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 58-year-old female with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT shows multiple hypodense liver lesions consistent with hepatic metastases. Tumor sequencing: KRAS G12D, microsatellite stable (MSI-stable). Started systemic therapy with FOLFOX plus bevacizumab. After 3 months of therapy the CEA is down modestly and CT shows no significant change in size of hepatic lesions \u2014 assessed as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old man with widespread metastatic melanoma to lung and brain. Tumor sequencing detected BRAF V600E. He initially received pembrolizumab but had radiographic progression after three doses; therapy was changed to dabrafenib plus trametinib with interval decrease in size of pulmonary nodules and intracranial metastatic burden consistent with a partial response.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib plus trametinib", "response": "progression on pembrolizumab then partial response to dabrafenib+trametinib", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: Patient with cutaneous melanoma of the right thigh underwent wide local excision and sentinel lymph node biopsy; pathology positive for nodal involvement\u2014AJCC stage III. BRAF and NRAS sequencing returned negative. Adjuvant therapy with nivolumab was administered, but surveillance imaging documented nodal progression within 8 months and the patient was referred for repeat surgical resection.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab", "response": "progression", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma presenting with cough and headache. Staging workup demonstrated Stage IV disease with multiple pulmonary nodules and both brain and bone metastases. Comprehensive molecular testing identified EGFR L858R; ALK and ROS1 negative. PD-L1 was <1%. She was started on osimertinib 80 mg daily in June 2024 with interval CT and MRI showing decrease in target lesions and improvement in CNS symptoms.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with stage IV lung adenocarcinoma harboring an EGFR L858R mutation. He was started on osimertinib 80 mg daily in January 2024 and achieved a partial response on first restaging CT. Brain MRI demonstrated two enhancing lesions consistent with metastases and he received stereotactic radiosurgery to those lesions. PD-L1 testing was not performed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration\u2011resistant prostate adenocarcinoma with diffuse osteoblastic bone metastases. Initially managed with androgen deprivation therapy; after progression started on abiraterone acetate with prednisone. Best radiographic/clinical status on abiraterone was stable disease for approximately six months. No tumor genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy; abiraterone and prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with nodular cutaneous melanoma of the back, sentinel node positive and several in-transit metastases \u2014 overall stage III disease. Tumor genotyping identified a BRAF V600E mutation. Patient was started on adjuvant targeted therapy with dabrafenib plus trametinib. On surveillance imaging new pulmonary nodules have appeared consistent with metastatic progression.", "output": {"cancer_type": "cutaneous melanoma (nodular melanoma)", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with a 2.5 cm left breast mass. Core biopsy showed invasive ductal carcinoma, ER positive, PR positive, HER2 negative. Staging workup consistent with stage IIA (T2N0). Tumor sequencing identified a PIK3CA E545K mutation. She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant radiation and was started on letrozole. Post-treatment imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "breast-conserving surgery; radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV metastatic melanoma harboring BRAF V600E mutation. Multiple pulmonary nodules were seen on chest CT consistent with lung metastases. Tumor profiling indicated a high tumor mutational burden. She initially progressed on single-agent pembrolizumab and was transitioned to dabrafenib plus trametinib, with interval scans showing a partial response in the chest lesions.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female with metastatic lung adenocarcinoma diagnosed 08/2023. Molecular testing showed EGFR L858R and concurrent TP53 R273H. PD-L1 tumor proportion score 20% and high TMB reported on NGS. MRI brain positive for two small cerebellar metastases and PET/CT with osseous lesions. She was started on osimertinib and enrolled on a protocol adding bevacizumab; stereotactic radiosurgery was performed to the dominant cerebellar lesion. On most recent CT (3 months) there is measurable decrease in size of pulmonary nodules and no new lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 R273H", "biomarker": "PD-L1 20%; TMB-high", "treatment": "osimertinib + bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, initial CT showing multiple hepatic metastases and peritoneal nodularity. Molecular testing returned BRAF V600E and MSI-H; tumor mutational burden was reported as TMB-high. He was started on modified FOLFOX6 with bevacizumab for tumor control, with plans to switch to pembrolizumab given the MSI-H status. After two months on FOLFOX/bevacizumab imaging indicated stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX (modified FOLFOX6) + bevacizumab; planned pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man newly diagnosed with metastatic prostate adenocarcinoma, Gleason 9, presenting with diffuse sclerotic bone metastases consistent with Stage IV disease. He was started on androgen deprivation therapy (leuprolide) and received palliative radiotherapy to the right hip for pain control. No genomic panel was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide); palliative radiotherapy to right hip", "response": "symptomatic improvement (pain control); radiographic response pending", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic pancreatic ductal adenocarcinoma (stage IV) found to have a deleterious germline BRCA2 mutation. CA19-9 was elevated at diagnosis. He received FOLFIRINOX for six cycles with good radiographic response then transitioned to maintenance olaparib. Most recent restaging shows reduction in primary and hepatic deposits, consistent with a partial response.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; maintenance olaparib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 3.5 cm left invasive ductal carcinoma of the breast, clinically staged IIIA. Tumor is ER+/PR+ and HER2 amplified by FISH; molecular testing identified a PIK3CA H1047R mutation. She received neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab, then lumpectomy with sentinel node biopsy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant carboplatin, docetaxel, trastuzumab, pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "27-year-old male with metastatic cutaneous melanoma, numerous pulmonary nodules on CT. Initial genotyping identified BRAF V600E. He received frontline pembrolizumab but developed progressive lung disease after 3 months and was switched to targeted therapy with dabrafenib and trametinib. On the combination regimen his chest CT at 6 weeks shows decrease in size and number of nodules consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 (not reported quantitatively)", "treatment": "pembrolizumab then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma (EGFR L858R). Staging CT demonstrated multiple pulmonary nodules, a 1.5 cm enhancing cerebellar lesion and lytic lesions in the femur consistent with metastases. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily; early follow-up CT at 8 weeks showed a radiographic partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with metastatic cutaneous melanoma presenting with pulmonary and intracranial lesions. BRAF V600E mutation identified; NRAS wild-type. PD-L1 expression <1% but high TMB noted on sequencing. Patient received combination targeted therapy with dabrafenib and trametinib; after an initial partial response the intracranial disease progressed and treatment was switched to nivolumab. Clinical course: initial PR on BRAF/MEK inhibitors, subsequent progression on follow-up MRI.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%; TMB-high", "treatment": "dabrafenib + trametinib, then nivolumab", "response": "initial partial response then progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with lung adenocarcinoma, stage IV with multiple brain and bone metastases. NGS revealed an EGFR exon 19 deletion. PD-L1 tumor proportion score reported at 10%. Patient started first-line osimertinib 80 mg daily; follow-up CT and MRI at 8 weeks demonstrate marked tumor shrinkage consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 35-year-old with metastatic cutaneous melanoma presented with widespread disease to liver and multiple brain metastases. BRAF V600E mutation was identified; NRAS was wild-type. PD-L1 testing returned >50% and TMB-high. He received combination targeted therapy with dabrafenib plus trametinib achieving a rapid partial response systemically, but after 7 months developed CNS progression and was transitioned to combination immunotherapy with nivolumab and ipilimumab; subsequent imaging showed mixed response with new hepatic lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%, TMB-high, NRAS wild-type", "treatment": "dabrafenib + trametinib; nivolumab + ipilimumab", "response": "partial response (initial), mixed response/progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with localized prostate adenocarcinoma, clinical stage II, Gleason 3+4. Underwent radical prostatectomy; final pathology showed positive margin so adjuvant external beam radiation was given. PSA is undetectable at 12-month follow-up. No molecular sequencing was performed and there is no radiologic evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy and adjuvant external beam radiation", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic cutaneous melanoma with multiple pulmonary and hepatic nodules on staging CT (Stage IV). Tumor was positive for BRAF V600E on molecular testing. She was started on dabrafenib plus trametinib. After three months PET/CT demonstrated complete metabolic response. PD-L1 and TMB were not reported in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with newly diagnosed invasive ductal carcinoma of the left breast. Pathology: ER+/PR+, HER2 negative; PIK3CA H1047R identified on NGS. Tumor measured 2.3 cm, sentinel nodes negative \u2014 clinical stage IIA. She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant AC \u00d74 then radiation; adjuvant endocrine therapy with tamoxifen planned. Currently NED on 6-month follow-up exam.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+, HER2 negative", "treatment": "lumpectomy (breast-conserving surgery), adjuvant doxorubicin/cyclophosphamide (AC) \u00d74, radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colon adenocarcinoma. Liver biopsy confirmed adenocarcinoma consistent with colorectal primary. Molecular testing detected KRAS G12D. He completed 12 cycles of FOLFOX with bevacizumab; scans every 8 weeks demonstrated lack of progression without objective shrinkage, categorized as stable disease. No EGFR-targeted agents were given due to KRAS mutation.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "metastatic (stage IV)", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration\u2011resistant prostate adenocarcinoma presenting with worsening bone pain and rising PSA. Germline testing identified a pathogenic BRCA2 variant. Prior therapies included androgen deprivation therapy and docetaxel; he is currently taking olaparib with partial symptomatic improvement and a decline in PSA. Bone scan demonstrates multifocal osseous metastases.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (metastatic castration-resistant)", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "rising PSA (then PSA decrease on treatment)", "treatment": "androgen deprivation therapy; docetaxel; olaparib", "response": "partial response (symptomatic improvement, PSA decrease)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 63-year-old male with metastatic colon adenocarcinoma diagnosed last year. Primary tumor testing showed KRAS G12D mutation. He received FOLFOX with bevacizumab initially with partial benefit but recently developed increasing ascites and CT shows diffuse peritoneal nodularity and new bilateral pulmonary nodules. He was switched to irinotecan-based second line but has clinical decline and radiographic progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX with bevacizumab; later irinotecan-based therapy", "response": "progression", "metastasis_site": "peritoneum; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and follow-up note: 65-year-old male underwent radical prostatectomy for acinar adenocarcinoma of the prostate (Gleason 3+4=7). Pathologic stage pT2, negative margins. He subsequently received adjuvant external beam radiation and androgen deprivation with leuprolide. PSA is undetectable at 12-month follow up and there is no evidence of metastatic disease on imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy, external beam radiation, leuprolide (androgen deprivation therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with biopsy-proven cutaneous melanoma now with multiple pulmonary nodules on staging CT consistent with metastatic disease. BRAF testing was not yet resulted at the time of treatment decision. He was started on single-agent nivolumab; after 3 months there is interval growth of several lung nodules and new respiratory symptoms.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma presented with headaches and back pain. Biopsy confirmed EGFR L858R mutation and next-gen sequencing showed concurrent low-level MET amplification. PD-L1 was 10%. Staging was IV with brain and bone metastases on MRI. She was started on osimertinib plus bevacizumab after prior carboplatin/pemetrexed. On first restaging there was a significant shrinkage of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 10%", "treatment": "osimertinib plus bevacizumab (after carboplatin/pemetrexed)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old woman with de novo metastatic breast cancer. Core biopsy showed invasive ductal carcinoma, ER positive, PR positive and HER2 amplified by FISH. Next-generation sequencing reported a PIK3CA H1047R mutation. Staging PET/CT revealed multiple liver lesions. She started first-line therapy with trastuzumab, pertuzumab and paclitaxel; imaging at 12 weeks showed stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old female referred for management of metastatic lung adenocarcinoma. MRI brain showed multiple enhancing lesions; CT chest/abdomen confirmed a right lower lobe primary with mediastinal nodes. Molecular testing demonstrated an EGFR exon 19 deletion (EGFR del19). PD-L1 tumor proportion score reported at 10%. She was started on osimertinib 80 mg daily as first-line therapy in June. Interval imaging and clinical exam document shrinkage of brain lesions and resolution of headaches \u2014 consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Initial staging showed lung and liver metastases (stage IV). Treated with pembrolizumab as first-line therapy with a partial response at 12 weeks; progression at 8 months prompted switch to dabrafenib plus trametinib with mixed radiologic findings.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "progression after initial partial response", "metastasis_site": "lung and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma. EGFR testing returned positive for L858R mutation. PD-L1 tumor proportion score 5%. MRI brain showed two small parenchymal metastases and bone scan revealed osseous involvement. Patient was started on osimertinib 80 mg daily in July; interval CT demonstrates decrease in size of pulmonary and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive, presented with multiple pulmonary nodules and two small enhancing brain lesions. PD-L1 reported at 5%. He was started on combination targeted therapy with dabrafenib and trametinib. Interim imaging after 10 weeks shows disease that is stable in size without new lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with unresectable pancreatic head adenocarcinoma presenting with liver metastases (stage IV). CA19-9 was markedly elevated at 1200 U/mL. A targeted NGS panel did not reveal actionable mutations. He received gemcitabine with nab-paclitaxel; interval CT after two cycles showed enlarging hepatic lesions consistent with progression.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 1200 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male status post right hemicolectomy for colorectal adenocarcinoma. Pathology showed moderately differentiated tumor; staging workup documented pulmonary nodules consistent with metastases. Molecular profile demonstrates KRAS G12D and tumor is MSI-H. He was started on FOLFOX with bevacizumab but interval CT demonstrates new and enlarging lung nodules consistent with progression. Recorded stage: IV.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: recurrent metastatic cutaneous melanoma (stage IV). NGS: BRAF V600E positive. Patient received combination immunotherapy with nivolumab plus ipilimumab initially with clinical benefit, then transitioned to targeted therapy with dabrafenib and trametinib for BRAF-mutant disease. Recent MRI/CT shows a mixed response with decrease in pulmonary nodules but progression of intracranial lesions; plan for stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab + ipilimumab; dabrafenib + trametinib", "response": "mixed response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with metastatic colorectal adenocarcinoma, presented with multiple liver lesions consistent with metastases (stage IV). Molecular testing: KRAS G12D identified; MSI-H by PCR; PD-L1 2%. He was started on FOLFOX plus bevacizumab. Restaging after 4 cycles demonstrates increase in size and number of hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; PD-L1 2%", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman underwent diagnostic laparotomy for pelvic mass. Final pathology: high-grade serous ovarian carcinoma with bulky omental disease and peritoneal implants. FIGO stage IIIC. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. Post-chemotherapy CT shows decreased size of peritoneal implants consistent with a partial radiographic response. Germline and somatic BRCA testing were not performed and no molecular biomarkers are reported in the chart.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old male with newly diagnosed prostate adenocarcinoma presenting with bone pain. Bone scan and CT showed multiple sclerotic metastases in the pelvis and lumbar spine. Clinical stage IV (metastatic castration-sensitive). Baseline PSA 250 ng/mL. He was started on leuprolide depot and abiraterone acetate with prednisone. After 12 weeks PSA fell to 30 ng/mL and repeat CT showed no progression; disease considered radiographically stable with a biochemical response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 250 ng/mL -> 30 ng/mL", "treatment": "leuprolide and abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with pancreatic ductal adenocarcinoma diagnosed on EUS-guided biopsy. Germline and somatic testing identified a pathogenic BRCA2 alteration and HRD-positive profile. Imaging demonstrated a dominant liver lesion consistent with metastasis. She received six cycles of FOLFIRINOX followed by olaparib maintenance per BRCA-targeted strategy. CA19-9 declined but follow-up imaging assessment is pending.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 pathogenic mutation", "biomarker": "BRCA2; HRD-positive", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": null, "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of cutaneous melanoma, now with new bilateral pulmonary nodules on chest CT suspicious for metastatic disease. BRAF V600E mutation identified on tumor sequencing. PD-L1 reported at 5%. Treated with dabrafenib and trametinib combination; after two months there is interval growth of several nodules and development of new lesions \u2014 progressive disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with de novo metastatic invasive ductal carcinoma of the breast presenting with jaundice from liver lesions. Tumor profile: HER2 amplification by FISH, ER positive, PR negative, PIK3CA H1047R mutation identified on NGS. Staging consistent with stage IV disease. She was treated with first-line trastuzumab + pertuzumab in combination with docetaxel for six cycles, then transitioned to maintenance trastuzumab with letrozole. Interval imaging shows marked reduction in hepatic disease burden.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel; maintenance trastuzumab and letrozole", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: high\u2011grade urothelial carcinoma of the bladder treated with transurethral resection followed by radical cystectomy. Final pathologic stage pT2. Patient completed adjuvant cisplatin and gemcitabine. No molecular testing or PD-L1 report available in the chart. Current follow-up shows no evidence of disease on imaging.", "output": {"cancer_type": "urothelial carcinoma of the bladder", "stage": "pT2", "gene_mutation": null, "biomarker": null, "treatment": "radical cystectomy; cisplatin and gemcitabine", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old female with a left breast mass. Core biopsy: invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH. Genomic profiling showed PIK3CA H1047R. She received neoadjuvant doxorubicin and cyclophosphamide x4 \u2192 paclitaxel x12 with trastuzumab; subsequent lumpectomy with sentinel node biopsy demonstrated a pathologic complete response. No metastatic disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 amplification", "treatment": "neoadjuvant doxorubicin and cyclophosphamide, paclitaxel, trastuzumab; lumpectomy and sentinel node biopsy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma presented with multiple cerebral metastases and extracranial nodal disease. BRAF V600E mutation was detected on tumor genotyping. Initially treated with dabrafenib plus trametinib with rapid regression of several cutaneous lesions, but after 4 months developed enlarging brain lesions while extracranial nodes were stable. Subsequently switched to nivolumab. Overall described as mixed response to sequential targeted therapy and immunotherapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 not reported", "treatment": "dabrafenib + trametinib followed by nivolumab", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive NGS reported EGFR L858R with acquired T790M. PD-L1 TPS was 5%. He received 4 cycles of cisplatin and pemetrexed with initial disease control, then was started on osimertinib for T790M and had a partial response. Recent MRI showed decrease in brain metastases and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 TPS 5%", "treatment": "cisplatin and pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman with a 1.6 cm invasive ductal carcinoma of the right breast. ER 90%, PR 40%, HER2 negative by IHC/FISH. Sentinel lymph node biopsy was negative and the tumor was staged as pT1cN0 (stage IA). She underwent breast-conserving surgery with whole-breast radiation and is on adjuvant tamoxifen. No somatic mutation panel was performed on the tumor. Currently no evidence of disease on follow-up.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IA", "gene_mutation": null, "biomarker": "ER positive 90%; PR positive 40%; HER2 negative", "treatment": "lumpectomy; radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma, clinical stage IIIA. Core biopsy: HER2 amplified by FISH, ER positive, PR negative. NGS panel detected a PIK3CA H1047R mutation. She received neoadjuvant carboplatin and paclitaxel with trastuzumab and pertuzumab followed by lumpectomy. Imaging after neoadjuvant therapy showed marked tumor shrinkage but residual viable tumor was present at surgery.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "carboplatin and paclitaxel; trastuzumab and pertuzumab; lumpectomy", "response": "partial response (residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Presenting with lytic lesions in the femur and hip causing pain. PD-L1 reported at 5%. Started targeted therapy with dabrafenib and trametinib; serial CT and PET scans show stable disease over 4 months.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Invasive ductal carcinoma of the right breast, ER/PR negative, HER2 amplified by FISH. Clinical presentation with hepatic lesions and bone pain; workup consistent with metastatic (stage IV) disease. Patient received first-line trastuzumab with paclitaxel. Disease was stable for approximately six months before evidence of slow progression on therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab and paclitaxel", "response": "stable disease followed by progression", "metastasis_site": "liver and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma, KRAS G12D identified on next-generation sequencing. Initial presentation included painless jaundice and CT abdomen showed multiple hepatic metastases. He completed 6 cycles of FOLFOX with bevacizumab but recent imaging demonstrates progression in the liver with enlarging lesions and rising CEA. MSI testing was MSS. Plan is to switch to second-line irinotecan-based regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX; bevacizumab (prior); planned irinotecan-based regimen", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with cutaneous melanoma of the left forearm initially underwent wide local excision with sentinel node biopsy; pathology revealed Stage III disease with positive regional lymph nodes. Next-generation sequencing identified a BRAF V600E mutation. He was started on frontline pembrolizumab but progressed after four cycles with enlarging nodal disease and new in-transit lesions; therapy was switched to dabrafenib plus trametinib with subsequent partial response of nodal and cutaneous lesions.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib plus trametinib", "response": "progression on pembrolizumab followed by partial response on dabrafenib/trametinib", "metastasis_site": "regional lymph nodes, in-transit cutaneous lesions"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man found to have localized prostate adenocarcinoma on biopsy (Gleason 3+4). Clinical staging consistent with stage I disease. PSA at diagnosis was 6.2 ng/mL. He underwent robotic radical prostatectomy without complications; post-operative PSA undetectable and he is currently without evidence of disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 6.2 ng/mL", "treatment": "robotic radical prostatectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing positive for an ALK rearrangement by FISH. Staged IV at presentation with brain and bone metastases. PD-L1 tumor proportion score 5%. He initially had a partial response to crizotinib but developed CNS progression and was switched to alectinib. On further progression he was given combination chemoimmunotherapy (carboplatin and pemetrexed plus pembrolizumab). Recent CT shows new liver lesions consistent with disease progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "ALK rearrangement", "biomarker": "PD-L1 5%", "treatment": "crizotinib; alectinib; carboplatin and pemetrexed plus pembrolizumab", "response": "partial response then progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Imaging shows multiple pulmonary nodules and enhancing lesions in the cerebellum and T8 vertebra. Biopsy confirmed adenocarcinoma, molecular testing positive for EGFR L858R. PD-L1 TPS reported as 10%. Staged as IV at diagnosis. Patient started first-line osimertinib 80 mg daily with significant clinical improvement and interval shrinkage of brain and bone lesions on first scan \u2014 documented as partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma, extensive sclerotic bone metastases on bone scan. Staged as IV at time of metastatic presentation. Somatic testing revealed a BRCA2 frameshift mutation. Prior androgen-deprivation therapy and enzalutamide failed; patient was started on olaparib 300 mg twice daily. After three months PSA dropped from 150 to 45 ng/mL and bone scans show decreased radiotracer uptake consistent with a partial clinical response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 frameshift mutation", "biomarker": "BRCA2 (somatic); PSA decline", "treatment": "olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with clear cell renal cell carcinoma initially treated with radical nephrectomy. Months later developed pulmonary nodules and lytic lesions in the femur. Treated first-line with sunitinib but switched to nivolumab due to intolerance. Imaging on nivolumab has shown stable disease. No targeted mutation report available in chart and PD-L1 testing was not performed.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "sunitinib; nivolumab", "response": "stable disease", "metastasis_site": "lung, bone (femur)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: patient with metastatic cutaneous melanoma, stage IV with multiple pulmonary nodules. Treated with combination immunotherapy (nivolumab with ipilimumab) and received stereotactic radiosurgery to a solitary cerebellar lesion. Molecular testing was not completed at the time and no BRAF result is available in the chart. PET/CT at 6 months shows complete metabolic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab and ipilimumab; stereotactic radiosurgery", "response": "complete response", "metastasis_site": "lung; brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital progress note: 54-year-old female with metastatic cutaneous melanoma. Initial molecular testing positive for BRAF V600E; PD-L1 reported >1% and tumor mutational burden high. Patient started on dabrafenib plus trametinib with excellent symptomatic improvement; after 4 months nivolumab was added due to mixed radiographic response. Current course described as mixed response \u2014 initial partial response of hepatic lesions with progression of several small brain metastases noted on surveillance MRI.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >1%, TMB-high", "treatment": "dabrafenib + trametinib with addition of nivolumab", "response": "mixed response (initial partial response then progression)", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colon adenocarcinoma diagnosed after weight loss and right upper quadrant pain. CT abdomen showed multiple hepatic lesions. Colonoscopy with biopsy confirmed adenocarcinoma of the ascending colon. Molecular profiling: KRAS G12D mutation; tumor MSI-stable. Patient started on FOLFOX with bevacizumab. Restaging after 3 months demonstrates stable size of liver lesions and no new sites of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma presenting with weight loss and elevated CA 19-9 (1200 U/mL). CT demonstrates multiple hepatic metastases. No actionable somatic mutations were identified on limited panel testing. She received gemcitabine plus nab-paclitaxel but progressed clinically after two cycles with rising CA 19-9 and enlarging liver lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 68-year-old man with metastatic cutaneous melanoma. Molecular assay detected BRAF V600E mutation. PD-L1 immunohistochemistry reported 5% expression. Staging CT shows multiple hepatic and bilateral pulmonary metastases. He was started on dabrafenib plus trametinib. Interval imaging after 8 weeks reveals shrinkage of several lung nodules with a small new hepatic lesion; overall assessment: ongoing partial response by treating physician.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic invasive ductal carcinoma of the breast. Core biopsy confirms ER positive, PR positive and HER2-amplified disease. PET/CT shows multifocal osseous uptake compatible with bone metastases. She was started on weekly paclitaxel with trastuzumab; on follow-up scans after 4 cycles there is no new disease and modest decrease in index lesions, clinically documented as stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology-oncology note: 55-year-old man with unresectable stage III cutaneous melanoma of the left shoulder with bulky nodal disease. Tumor genotyping identified BRAF V600E. He was started on combination targeted therapy with dabrafenib and trametinib. After four months of therapy there is reduction in nodal size and symptomatic improvement consistent with a partial response. No distant metastases detected on PET/CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genomic profiling revealed KRAS G12D. CEA at diagnosis was 150 ng/mL and microsatellite testing returned MSS. He was started on FOLFOX with bevacizumab; restaging CT after three cycles shows essentially unchanged hepatic disease consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 150 ng/mL; MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a 2.8 cm invasive ductal carcinoma of the right breast, ER positive, PR positive and HER2 amplified. Sentinel node showed 1/12 positive nodes; pathologic stage IIA. On genomic profiling the tumor harbored PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy and completed adjuvant docetaxel/cyclophosphamide x4 followed by trastuzumab planned for one year and endocrine therapy with tamoxifen. Surveillance imaging and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; docetaxel and cyclophosphamide; trastuzumab; tamoxifen", "response": "no evidence of disease (complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma, stage IV with extensive sclerotic bone metastases. He remains on androgen suppression (leuprolide) and was given combination systemic therapy with docetaxel plus abiraterone. Despite therapy his PSA is rising and scans show radiographic progression in the skeleton. Tumor sequencing did not identify actionable mutations and PD-L1 testing was not performed.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; docetaxel + abiraterone", "response": "progression (radiographic and PSA rise)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with metastatic cutaneous melanoma found to harbor BRAF V600E on tumor sequencing. She was started on combination therapy with dabrafenib and trametinib. Initial scans showed slight tumor shrinkage, but at 4 months there was interval appearance of multiple hepatic lesions and enlarging brain metastases consistent with progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic lung adenocarcinoma diagnosed 2019. Tumor molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging PET/CT demonstrates new cerebellar and thoracic vertebral lesions consistent with metastases. Patient was started on osimertinib 80 mg daily in January 2024 with symptomatic improvement; interval MRI shows decrease in size of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 70-year-old male with metastatic colon adenocarcinoma to the liver. Biopsy of hepatic lesion confirmed colorectal primary. Genotyping showed KRAS G12D; tumor is MSI-H. Patient was started on pembrolizumab 200 mg q3w given MSI-H disease after progression on FOLFOX. Best radiographic response to immunotherapy so far is stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging shows stage IV disease with brain and bone metastases. He was started on osimertinib 80 mg daily as first-line systemic therapy; CT and MRI at 12 weeks demonstrate a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old with primary cutaneous melanoma on the left forearm, Breslow depth 2.1 mm, Clark level IV. Underwent wide local excision and sentinel lymph node biopsy; sentinel node negative. No mutational testing was performed and no adjuvant therapy was given. Patient is being followed in clinic and currently has no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision, sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with metastatic pancreatic ductal adenocarcinoma found to have a germline BRCA2 pathogenic variant. CA19-9 was markedly elevated at diagnosis. Patient received six cycles of FOLFIRINOX with good radiographic control of hepatic lesions and peritoneal nodularity, then transitioned to maintenance olaparib. Latest CT demonstrates stable disease compared with prior scan.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX then maintenance olaparib", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for locally advanced right breast invasive ductal carcinoma, ER-negative, clinically staged IIIB. Core biopsy demonstrated HER2 amplification by FISH and PIK3CA H1047R mutation on targeted panel. Patient received 6 cycles of trastuzumab and pertuzumab with docetaxel with significant clinical downsizing, proceeded to modified radical mastectomy and adjuvant radiotherapy. Surgical pathology showed no residual invasive carcinoma (pCR). No distant metastases identified on staging PET-CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "trastuzumab and pertuzumab with docetaxel; surgery and adjuvant radiotherapy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with newly diagnosed localized prostate adenocarcinoma discovered on PSA screening (PSA 7.2). Biopsy Gleason 3+4=7. Clinical stage cT1cN0M0 (stage I). He underwent robotic radical prostatectomy; final pathology showed organ-confined disease with negative margins and post-operative PSA undetectable. No adjuvant therapy recommended.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman presented with high-grade serous ovarian carcinoma, FIGO stage IIIC with diffuse peritoneal disease. Germline testing identified a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel, then was placed on maintenance olaparib. CA-125 normalized and follow-up CTs showed resolution of measurable disease consistent with complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 normalized", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with incidentally elevated PSA. Prostate biopsy demonstrated Gleason 3+3 adenocarcinoma in two cores; clinical stage T1cN0M0 (stage I). No germline or somatic sequencing was performed. Patient elected active surveillance with PSA monitoring and periodic MRI.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "active surveillance", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma, diagnosed in 2019. NGS revealed EGFR L858R mutation. PD-L1 tumor proportion score 10%. Started osimertinib 80 mg PO daily in July 2020 with good CNS penetration. Interval CT and brain MRI demonstrate decrease in size of primary lung lesion and intracranial metastases \u2014 overall partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with colorectal adenocarcinoma with synchronous liver metastases. Tumor sequencing identified a KRAS G12D mutation; microsatellite testing returned MSS. He received palliative FOLFOX with bevacizumab. Restaging CT at 4 months demonstrates stable disease and a falling but still elevated CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History and assessment: 64-year-old male with newly diagnosed lung adenocarcinoma. Staging workup demonstrates Stage IV disease with multiple supraclavicular nodes and enhancing lesions in the brain and lytic lesions in the femur. Molecular testing from core biopsy returned EGFR L858R. PD-L1 by IHC is 10%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain lesion. First restaging CT at 8 weeks shows reduction in pulmonary nodules and decreased size of bone lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old man with BRAF V600E mutant metastatic cutaneous melanoma. Presents with progressive left arm pain; bone scan and MRI demonstrate metastatic involvement of the left humerus. He received targeted therapy with dabrafenib plus trametinib after diagnosis. Despite therapy he developed new lytic lesions and rising LDH over 6 weeks\u2014assessment: progressive disease. PD-L1 testing not contributory; tumor described as TMB-high on NGS.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the left breast, 1.2 cm, ER+, PR+, HER2 3+ by IHC. Clinical stage: I (T1bN0M0). Surgical lumpectomy with sentinel node biopsy was performed; margins negative. Tumor genotyping identified a PIK3CA E545K mutation. Patient completed adjuvant weekly paclitaxel followed by 1 year of trastuzumab. Surveillance mammogram and exam at 12 months show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 3+ by IHC; ER positive; PR positive", "treatment": "lumpectomy followed by adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease (complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic prostate adenocarcinoma presenting with extensive bone pain. Clinical stage IV with multiple lytic and blastic bone metastases on bone scan. He was started on combined androgen deprivation with leuprolide, abiraterone acetate, and docetaxel chemotherapy. Despite therapy PSA rose and imaging shows progression of osseous disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide + abiraterone + docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and oncology follow-up: 67-year-old male with sigmoid colon adenocarcinoma treated with hemicolectomy in 2022. Pathology and scans now show new osseous lesions on PET-CT (lumbar spine and right ilium) consistent with metastatic disease. Tumor sequencing reveals KRAS G12D and TP53 mutation; microsatellite stable. Patient was started on FOLFOX chemotherapy but after 3 months there is radiographic progression in bone and rising alkaline phosphatase.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Diagnosed in 2019 with prostate adenocarcinoma, Gleason 3+4=7, clinical stage II. Underwent radical prostatectomy with negative margins. No adjuvant radiation or systemic therapy was given. On surveillance his PSA remains undetectable and there is no clinical evidence of recurrence. No tumor genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with newly diagnosed pancreatic ductal adenocarcinoma found to have multiple liver lesions on staging CT consistent with metastatic disease (stage IV). Tumor profiling shows KRAS G12V mutation. CA19-9 markedly elevated at diagnosis. He was started on first-line FOLFIRINOX; restaging after 3 cycles demonstrates increasing size and number of hepatic metastases and rising CA19-9.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with invasive ductal carcinoma of the right breast, ER positive, PR negative, HER2 amplification confirmed by FISH. Clinical stage II (T2N0). She underwent breast-conserving surgery with clear margins and sentinel lymph node biopsy (negative). Completed adjuvant paclitaxel plus trastuzumab and continues on tamoxifen. Most recent follow-up exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "lumpectomy; paclitaxel and trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma metastatic at diagnosis. Comprehensive genomic profiling identified BRAF V600E and a high tumor mutational burden. Baseline brain MRI showed two small parenchymal metastases and CT chest noted multiple pulmonary nodules consistent with stage IV disease. Started on dabrafenib plus trametinib; extracranial disease had a complete radiographic response but intracranial lesions progressed \u2014 overall described as a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced left breast cancer, ER+/PR+, HER2 amplified on FISH. Core biopsy also revealed a PIK3CA H1047R mutation. Clinical stage was IIIB with fixity to chest wall. She received neoadjuvant weekly paclitaxel for 12 weeks with trastuzumab and pertuzumab followed by mastectomy. Surgical pathology returned without residual invasive carcinoma \u2014 pathologic complete response reported.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab, followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with symptomatic colorectal adenocarcinoma. CT chest shows multiple new pulmonary nodules suspicious for metastatic disease. Molecular profiling returned KRAS G12D; tumor reported as microsatellite stable (MSS). He was treated with FOLFOX plus bevacizumab in the metastatic setting, but interval chest CT after 3 cycles demonstrates enlarging lung lesions consistent with progression.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High\u2011grade serous ovarian carcinoma diagnosed after exploratory laparotomy; optimal cytoreductive surgery achieved. Pathologic stage IIIC with diffuse peritoneal implants. Germline BRCA1/2 testing was negative and a 50\u2011gene somatic panel did not reveal actionable mutations. Pre\u2011treatment CA\u2011125 was 820 U/mL. Patient completed 6 cycles of carboplatin and paclitaxel with CA\u2011125 decline to 120 U/mL and radiographic reduction of peritoneal disease.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": null, "biomarker": "elevated CA-125 (pre 820 U/mL \u2192 120 U/mL)", "treatment": "debulking surgery; carboplatin + paclitaxel", "response": "partial response (CA-125 decline and radiographic reduction)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma. Molecular profile positive for BRAF V600E. Initially treated with pembrolizumab monotherapy but developed progression with expanding pulmonary nodules; transitioned to targeted therapy with dabrafenib and trametinib. Interval chest CT after 8 weeks on targeted therapy shows decrease in size and number of nodules consistent with partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old with a 0.8 mm superficial spreading melanoma on the right forearm, no ulceration, sentinel lymph node negative \u2014 AJCC stage I. Wide local excision with 1 cm margins performed; no adjuvant therapy was recommended. BRAF testing was not performed. Patient is on routine dermatologic surveillance without signs of recurrence.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma, stage IV with liver-predominant disease. Tumor sequencing detected KRAS G12D and TP53 R273H; CA19-9 was markedly elevated at diagnosis. She received first-line FOLFIRINOX but restaging CT after two cycles demonstrated interval progression with new hepatic lesions, and care was transitioned to best supportive measures.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 R273H", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old male with sigmoid colon adenocarcinoma, pathologic stage III (T3N1M0) after low anterior resection. Tumor testing: KRAS G12D mutation; MSI-stable. He received adjuvant FOLFOX for 6 months without complications. Surveillance CT and CEA at 18 months off therapy show no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgical resection followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old female with metastatic melanoma, symptomatic for headaches and found to have brain metastases. Staging: IV. Comprehensive NGS identified BRAF V600E. PD-L1 testing returned >50% and TMB was reported as high. She was started on combined dabrafenib and trametinib (BRAF/MEK inhibitor combination). At 6-week restaging there is a marked reduction in both intracranial and extracranial disease consistent with a partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with omental and peritoneal implants. Germline testing positive for a deleterious BRCA1 mutation; tumor reported HRD-positive. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with concurrent bevacizumab, achieved no gross residual disease, and has been started on maintenance olaparib. CA-125 was markedly elevated at diagnosis and has normalized after treatment.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD-positive; CA-125 elevated (normalized after treatment)", "treatment": "cytoreductive surgery; carboplatin + paclitaxel with bevacizumab; olaparib maintenance", "response": "no gross residual disease / currently in clinical remission", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma presenting with headaches. Staging workup showed stage IV disease with a solitary brain metastasis. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg PO daily as first-line therapy with clinical and radiographic partial response at first follow-up.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and leg pain. Staging CT/PET demonstrated widespread disease consistent with Stage IV with brain and bone lesions. Molecular testing returned EGFR L858R. PD-L1 was 10%. He was started on osimertinib with symptomatic improvement and interval scans show a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with castration-resistant prostate cancer presenting with worsening bone pain. Imaging shows multiple sclerotic bone metastases. PSA is rising despite ongoing androgen deprivation therapy. No genomic testing performed; started abiraterone with prednisone.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "rising PSA", "treatment": "abiraterone and prednisone (after ADT)", "response": "treatment ongoing / PSA not yet controlled", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with right-sided colon adenocarcinoma presenting with multiple hepatic metastases. Tumor profiling: MSI-H and BRAF V600E mutation; RAS wild-type. Given MSI-H status, pembrolizumab was initiated as first-line therapy. Restaging scans at 12 weeks showed a partial response in the liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic pancreatic ductal adenocarcinoma, unresectable at presentation. Imaging documents multiple hypodense lesions in the liver consistent with metastases. Tumor genotyping: KRAS G12D and BRCA2 6174delT identified. Baseline CA19-9 was 2,350 U/mL. She received 6 cycles of FOLFIRINOX with initial tumor shrinkage, then started maintenance olaparib for BRCA2 mutation; most recent imaging shows new enlarging hepatic lesions and rising CA19-9.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; BRCA2 6174delT", "biomarker": "CA19-9 2350 U/mL", "treatment": "FOLFIRINOX; maintenance olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple liver lesions on CT. Tumor profiling: MSI-H (high microsatellite instability) and BRAF V600E mutation; KRAS reported wild-type. Classified as stage IV. Given MSI-H status, pembrolizumab monotherapy was initiated. After 4 cycles the CT scan showed no new lesions and minimal shrinkage of dominant hepatic mets, consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman diagnosed with stage II invasive ductal breast carcinoma (T2N0M0). Tumor was ER positive (95%), PR positive (40%), and HER2 amplified by FISH. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for 12 weeks followed by lumpectomy and sentinel node biopsy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). Adjuvant whole-breast radiation is planned.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "neoadjuvant paclitaxel + trastuzumab + pertuzumab; lumpectomy; planned adjuvant radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology summary: 67-year-old male diagnosed with sigmoid colon adenocarcinoma. NGS shows KRAS G12D mutation; tumor is MSI-stable. CT abdomen demonstrates multiple hepatic lesions consistent with metastases \u2014 clinical stage IV. Patient was started on FOLFOX plus bevacizumab. Interval imaging after 4 cycles demonstrates no new lesions and overall minor changes but essentially stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female diagnosed with high-grade serous ovarian carcinoma presenting with abdominal distension. CT abdomen/pelvis showed omental caking and peritoneal carcinomatosis. CA-125 elevated at 680 U/mL. Germline testing returned BRCA1 deleterious mutation. She received neoadjuvant carboplatin and paclitaxel with partial radiographic response, then underwent interval debulking; residual microscopic disease was reported. Patient will continue adjuvant chemotherapy and consider maintenance PARP inhibitor depending on recovery.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "neoadjuvant carboplatin and paclitaxel; interval debulking surgery; planned maintenance PARP inhibitor", "response": "partial response", "metastasis_site": "peritoneum (peritoneal carcinomatosis), omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease with multiple brain and osseous lesions. Molecular testing returned EGFR L858R; PD-L1 reported at 10%. He was started on osimertinib 80 mg daily and at first follow-up CT/MRI demonstrates reduction in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology follow-up: 63-year-old male diagnosed with localized prostate adenocarcinoma, clinical stage T2b N0 M0 (stage II). PSA was 6.8 ng/mL at diagnosis. He underwent radical prostatectomy with pelvic lymph node sampling; pathology Gleason 3+4, negative margins. No somatic gene panel abnormalities were reported in the available notes. Post-op PSA is undetectable. Adjuvant radiation deferred; patient under surveillance.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy (pelvic lymph node sampling); surveillance", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing: KRAS G12D, BRAF wild-type; tumor shown to be MSI-H with high tumor mutational burden (TMB-high). He received frontline FOLFOX with bevacizumab and, after limited benefit, was transitioned to pembrolizumab given MSI-H status. Current restaging demonstrates stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man underwent a right hemicolectomy for sigmoid/ascending colon adenocarcinoma. Final path: pT3N1, stage III. Tumor sequencing revealed KRAS G12D; MSI testing returned microsatellite stable (MSS). He completed adjuvant FOLFOX x6 in Nov 2024. Surveillance CT and CEA are stable with no evidence of disease on last follow-up.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old with metastatic cutaneous melanoma. BRAF V600E positive on molecular testing. Baseline staging demonstrated pulmonary nodules and two small brain metastases. PD-L1 reported 5% (1\u201349%). Initially started on dabrafenib plus trametinib with excellent extracranial control but intracranial progression after 6 months; switched to combination ipilimumab and nivolumab with mixed response on first follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1-49% (5%)", "treatment": "dabrafenib + trametinib; then ipilimumab + nivolumab", "response": "mixed response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive NGS on the tumor identified EGFR L858R. PD-L1 immunohistochemistry showed TPS 10%. She was started on first-line osimertinib 80 mg daily. Interval brain MRI and whole-body PET/CT after 8 weeks demonstrated decreased size of the known brain lesions and diminished uptake in several sclerotic bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic invasive ductal carcinoma of the breast. Liver biopsy confirmed metastatic carcinoma that was ER positive, PR negative and HER2 amplified by FISH. NGS of the primary showed PIK3CA H1047R. She was started on first-line trastuzumab and pertuzumab with weekly paclitaxel. After 3 cycles imaging shows stable disease in the liver lesions. Staging at presentation: IV.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with locally advanced invasive ductal breast cancer, clinical stage III (T2N2). Core biopsy ER positive, PR positive and HER2-amplified by FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab, pertuzumab and docetaxel for 6 cycles. Surgical pathology after chemotherapy showed no residual invasive disease (pathologic complete response). Adjuvant endocrine therapy with tamoxifen was started.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab + pertuzumab + docetaxel; tamoxifen", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, initially stage IV at diagnosis with multiple hepatic metastases. Molecular testing shows KRAS G12D mutation; microsatellite testing reported MSS (MSI-stable) and tumor mutational burden low. He was started on FOLFOX plus bevacizumab as palliative systemic therapy. Most recent CT shows no new lesions and minor decrease in largest liver lesion \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS); TMB-low", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with advanced cutaneous melanoma, stage IV with bulky nodal disease. Molecular testing identified BRAF V600E. He was started on combination BRAF/MEK therapy (dabrafenib and trametinib) with an initial partial response; progression occurred at 9 months and therapy was switched to nivolumab monotherapy. PD-L1 testing was not reported.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; then nivolumab", "response": "initial partial response then progression", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man presented with new-onset seizures and was found to have a right frontal mass. Craniotomy confirmed glioblastoma; patient underwent concurrent radiation with daily temozolomide followed by adjuvant temozolomide. Molecular testing results are not documented in the operative note. Surveillance MRI three months post-treatment shows new enhancing lesion at the resection cavity consistent with progressive disease.", "output": {"cancer_type": "glioblastoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "radiation with temozolomide (concurrent and adjuvant)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with locally advanced colon adenocarcinoma, pT3N1 (stage IIIB). Tumor genotyping shows KRAS G12D mutation and microsatellite stable (MSS). He underwent right hemicolectomy followed by adjuvant FOLFOX for 6 months. Surveillance CT at 12 months shows no radiographic evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIB", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old female with a newly diagnosed left breast invasive ductal carcinoma, 2.5 cm. Sentinel node biopsy negative. Pathology: ER positive, PR positive, HER2 IHC 3+. NGS panel identified PIK3CA H1047R. Clinical stage assigned as IIA. Patient underwent lumpectomy with sentinel node biopsy and has completed adjuvant paclitaxel and trastuzumab; started adjuvant letrozole. Last follow-up: no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER+; PR+", "treatment": "lumpectomy; sentinel node biopsy; paclitaxel; trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with obstructing sigmoid mass underwent emergency sigmoid colectomy. Pathology: adenocarcinoma, pT3N1 (stage III). Molecular testing showed KRAS G12D mutation and microsatellite stable (MSS). He completed 6 cycles of adjuvant FOLFOX. Surveillance CT at 12 months demonstrates no radiographic evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colorectal cancer (sigmoid adenocarcinoma)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "sigmoid colectomy; adjuvant FOLFOX (6 cycles)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO stage IIIC, with bulky peritoneal disease at presentation. Germline BRCA2 pathogenic variant identified. CA-125 was elevated at diagnosis. Patient underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with excellent radiographic response and normalization of CA-125; started maintenance olaparib with no evidence of disease on recent scan.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA-125 elevated at diagnosis", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "no evidence of disease after treatment (complete response)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, optimal cytoreductive surgery performed. Pathology staged as IIIC. Germline testing revealed a deleterious BRCA1 mutation and HRD-positive status. She completed six cycles of carboplatin and paclitaxel with complete radiologic response and was started on olaparib maintenance therapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "germline BRCA1 mutation", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative consult: 47-year-old with locally advanced left breast cancer (cT3N2) \u2014 clinical stage IIIB. Biopsy IHC: HER2 3+, ER negative, PR negative. Tumor NGS detected PIK3CA E545K. She received neoadjuvant carboplatin and docetaxel with trastuzumab for 6 cycles and then underwent mastectomy; pathology showed no residual invasive carcinoma (pathologic complete response, pCR).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification (IHC 3+); ER negative; PR negative", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly progressive headaches. MRI brain shows multiple enhancing lesions. Chest CT demonstrates a 3.2 cm RUL mass. Biopsy of lung lesion: lung adenocarcinoma. Molecular testing: EGFR L858R positive. PD-L1 tumor proportion score ~15%. Staged as IV at diagnosis due to brain mets. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to dominant lesion. Interval imaging at 8 weeks: decreased size of CNS lesions and primary lung lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing: KRAS G12D mutation; tumor is MSI-high by PCR and shows high tumor mutational burden (TMB-high). He received first-line FOLFOX with bevacizumab with mixed radiographic change, then was transitioned to pembrolizumab for MSI-H disease and has had stable disease on serial scans over 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic sigmoid colon adenocarcinoma, stage IV with multiple liver metastases. Tumor profiling returned BRAF V600E and MSI-H. She received FOLFOX plus bevacizumab as first-line therapy but had radiographic progression after 4 months. Therapy was changed to pembrolizumab with interval scans showing disease stabilization.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab, then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, optimal cytoreduction achieved at laparotomy; surgical staging consistent with FIGO stage IIIC with diffuse peritoneal carcinomatosis. Germline testing identified BRCA1 185delAG pathogenic variant and HRD-positive status. She received six cycles of carboplatin and paclitaxel with good initial clinical response, then was placed on maintenance olaparib. After 18 months from diagnosis and 6 months on olaparib she developed progressive peritoneal disease on CT and clinical worsening consistent with progression on PARP inhibitor.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (germline)", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "progression", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man with metastatic cutaneous melanoma carrying BRAF V600E mutation. At presentation there were several pulmonary nodules. He began dabrafenib plus trametinib and had an initial partial response for about 9 months, then developed progression of lung disease and was switched to pembrolizumab. On most recent scans he has had stable disease while on anti\u2011PD\u20111 therapy. PD\u2011L1 reported at 5% tumor proportion score.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib followed by pembrolizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Core biopsy confirmed adenocarcinoma of the lung; molecular testing positive for EGFR exon 19 deletion. PD-L1 TPS 15%. Staging CT chest/abdomen and brain MRI demonstrated multiple small brain metastases and lytic lesions in the thoracic spine consistent with metastatic disease \u2014 overall stage IV. Patient was started on osimertinib 80 mg daily and received focal stereotactic radiosurgery to the dominant brain lesion. Interval imaging at 8 weeks shows decrease in size of the primary lung mass and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 TPS 15%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male status post right hemicolectomy for colon adenocarcinoma, pathologic stage pT3N1 (stage III). Molecular testing identified KRAS G12D and the tumor was reported as MSI-H. He completed adjuvant FOLFOX for six months and is on surveillance with no radiographic evidence of disease at 12 months post-op.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "surgery; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical oncology: 60-year-old male underwent right hemicolectomy for stage III colon adenocarcinoma. Tumor testing reported MSI-H; no actionable somatic mutations were identified on panel testing. Patient completed adjuvant FOLFOX (oxaliplatin, leucovorin, 5-FU) over 6 months and is currently NED on surveillance CT and CEA.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery followed by adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic lung adenocarcinoma. Biopsy confirmed adenocarcinoma of the lung, stage IV with both liver and bone lesions on CT. Comprehensive NGS identified KRAS G12C and a co-occurring STK11 mutation. PD-L1 tumor proportion score 60%; tumor mutational burden reported as TMB-high. He was started on combination platinum doublet with immunotherapy (pembrolizumab + carboplatin + pemetrexed) and achieved a partial response on first restaging scans. After 8 months of response he progressed in the liver and was transitioned to sotorasib on compassionate use.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C; STK11 mutation", "biomarker": "PD-L1 60%; TMB-high", "treatment": "pembrolizumab + carboplatin + pemetrexed; sotorasib", "response": "partial response", "metastasis_site": "liver; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with invasive ductal carcinoma of the left breast, clinical stage II (T2N1). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by lumpectomy and axillary node dissection; surgical pathology demonstrated a pathologic complete response. No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel, trastuzumab, pertuzumab (neoadjuvant); lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with FIGO stage IIIC high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery. Germline testing returned a deleterious BRCA1 mutation (185delAG) and tumor HRD-positive status; CA-125 was markedly elevated at diagnosis. She completed adjuvant carboplatin and paclitaxel and was started on maintenance therapy with olaparib in combination with bevacizumab. Follow-up imaging and normalization of CA-125 indicate a complete clinical response to the surgery plus chemo and maintenance combination.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (germline)", "biomarker": "HRD-positive, CA-125 elevated at diagnosis", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib plus bevacizumab", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with ER+/PR+/HER2-amplified invasive ductal carcinoma of the right breast. Presenting stage IV with multiple hepatic lesions on CT. Tumor NGS identified a PIK3CA E545K mutation. She received trastuzumab, pertuzumab and docetaxel; imaging after six cycles demonstrated a partial response in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with newly diagnosed stage IV lung adenocarcinoma. Tissue genotyping reported EGFR L858R (exon 21). PD-L1 tumor proportion score 10%. Staging MRI brain and PET/CT show multiple small cerebellar metastases and lytic lesions in the thoracic spine. Patient started osimertinib 80 mg daily in April; interval CT after 8 weeks demonstrates decrease in size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma (stage IV) presenting with multiple liver lesions. Next-generation sequencing identified KRAS G12D. Tumor was microsatellite stable on PCR. Patient was started on FOLFOX plus bevacizumab; after six cycles there is interval enlargement of hepatic metastases consistent with progressive disease. Not a candidate for anti-EGFR therapy due to KRAS mutation.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with recurrent nodal melanoma. Next-generation sequencing detected an NRAS Q61R mutation. He completed four cycles of combination immunotherapy with nivolumab and ipilimumab. Follow-up PET/CT demonstrated metabolic resolution of axillary and cervical nodes. PD-L1 testing was not reported in the oncology note and no formal AJCC stage was documented here.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "nivolumab and ipilimumab", "response": "complete metabolic response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic cutaneous melanoma presented with new seizures. MRI showed multiple enhancing brain metastases. Primary tumor harbored BRAF V600E by PCR. PD-L1 was reported at 5%. He received pembrolizumab as first-line IO but progressed systemically; therapy was changed to dabrafenib plus trametinib for combined BRAF/MEK blockade. On targeted therapy his extracranial disease was stable with minor shrinkage of several lesions, but CNS lesions required stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (first-line); dabrafenib + trametinib (subsequent)", "response": "stable disease (extracranial) after dabrafenib + trametinib", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Telephone triage / oncology summary: Patient with recurrent stage IIIC cutaneous melanoma, BRAF V600E positive. Previously had wide local excision and nodal dissection. Treated with dabrafenib plus trametinib for bulky nodal disease with good radiographic shrinkage but later developed intracranial progression with a solitary brain metastasis. Therapy was switched to nivolumab; most recent scans demonstrate stable disease. PD-L1 testing reported at 5%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; switched to nivolumab", "response": "stable disease (after switch)", "metastasis_site": "brain, regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 45-year-old male with stage IV cutaneous melanoma. BRAF V600E mutation identified; PD-L1 was not reported. He received combination targeted therapy with dabrafenib and trametinib but developed new hepatic and brain metastases on interval imaging after 3 months.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with progressive cough found to have lung adenocarcinoma. Staging scans demonstrated multiple bilateral pulmonary nodules, lytic lesions in the spine, and several enhancing brain metastases consistent with stage IV disease. Tumor testing returned EGFR L858R mutation and PD-L1 TPS 10%. He was started on osimertinib and received whole-brain radiotherapy for symptomatic lesions. Interval CT/MRI at 3 months shows decrease in size of primary and extracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiotherapy", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old male with new neurologic deficits found to have a right temporal mass. Craniotomy and resection revealed glioblastoma (WHO grade IV). Molecular studies: IDH1 R132H mutation detected and MGMT promoter methylation positive. He underwent concurrent radiation with temozolomide per Stupp protocol. Interval MRI after 3 months demonstrates enlarging enhancing lesion at the resection margin consistent with progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation positive", "treatment": "surgery; radiation + temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with newly progressive metastatic lung adenocarcinoma. Staging CT and PET consistent with stage IV disease with multiple pulmonary nodules and a solitary enhancing lesion in the cerebellum. Tumor sequencing from biopsy reported EGFR L858R. PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily in March; first restaging at 8 weeks demonstrated reduction in size of intracranial and lung lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with newly diagnosed metastatic colorectal adenocarcinoma with dominant liver metastases. Tumor testing shows MSI-H and a KRAS G12D mutation. Patient was intolerant of FOLFOX and was started on pembrolizumab monotherapy given MSI-H status. Restaging CT at 12 weeks indicates no shrinkage but no new lesions \u2014 disease remains stable by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with abdominal pain; imaging revealed multiple hypoattenuating liver lesions and a colonic mass. Biopsy confirmed colon adenocarcinoma with liver metastases. Tumor genotyping identified a KRAS G12D mutation. The patient was started on FOLFOX with bevacizumab. CEA fell modestly; CT at 12 weeks shows no interval growth of hepatic lesions \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage III colon adenocarcinoma underwent right hemicolectomy. Tumor genotyping shows KRAS G12D and microsatellite-stable (MSS) phenotype. Received adjuvant FOLFOX for six months. Surveillance scans at 12 months show no residual or recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "right hemicolectomy followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with high-grade serous ovarian carcinoma found to have a pathogenic BRCA1 mutation on germline testing. Underwent cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. She was placed on maintenance olaparib given BRCA1 status. CT scans after completion of chemo and during maintenance show no evidence of residual disease \u2014 clinical complete response.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": null, "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: 52-year-old woman underwent right modified radical mastectomy for invasive ductal carcinoma. Final pathology pT3N1 (stage IIIA). IHC: HER2 3+ by IHC, ER negative, PR negative. Staging CT shows no distant metastases. Oncology plan is adjuvant chemotherapy with weekly paclitaxel followed by trastuzumab for HER2-directed therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 52-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Immunohistochemistry: ER positive, PR positive; FISH shows HER2 amplification. She completed 6 cycles of docetaxel and carboplatin combined with trastuzumab and pertuzumab prior to planned surgery. Post-treatment imaging demonstrated near-complete clinical response with marked reduction in tumor size.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "near complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed November 2023. Core biopsy PCR panel positive for EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. Staging imaging consistent with stage IV disease with intracranial lesions and lytic lesions in the femur. Started osimertinib 80 mg qday in August 2024 with symptomatic improvement; interval CT and brain MRI demonstrate a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced inflammatory breast cancer. Core biopsy: ER negative, PR negative, HER2 amplified by FISH. Clinical stage IIIB with extensive dermal involvement. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab, then underwent mastectomy; surgical pathology showed a pathologic complete response.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma, diagnosed in 2019. Molecular testing returned EGFR L858R mutation and PD-L1 10%. Patient started osimertinib 80 mg daily June 2020. Interval imaging shows decrease in size of pulmonary and hepatic lesions but new small enhancing lesions in the brain and lytic lesions in the femur. Oncology assessment documents a partial response on systemic therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 52-year-old male with unresectable metastatic melanoma of the upper back. Tumor testing positive for BRAF V600E. Baseline PD-L1 by IHC was low (5%). He was treated with combination targeted therapy \u2014 dabrafenib and trametinib \u2014 after rapid progression on anti-PD-1 monotherapy. Imaging at 6 weeks showed marked shrinkage of measurable lesions but a small new cerebellar lesion; overall assessment was mixed to partial response with planned stereotactic treatment to the brain focus.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; prior anti-PD-1 therapy; stereotactic radiosurgery planned", "response": "partial response (mixed with new brain lesion)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma, multiple pulmonary nodules and small brain metastases on MRI (AJCC stage IV). Tumor sequencing positive for BRAF V600E. PD-L1 immunostain reported ~20% TPS. Patient was started on targeted therapy with dabrafenib and trametinib; recent scans show stable disease in the chest and no interval enlargement of the intracranial lesions.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with invasive ductal carcinoma of the left breast. Initial core biopsy: ER positive, PR negative. HER2 IHC 3+ with confirmatory FISH showing HER2 amplification. PIK3CA H1047R point mutation identified on next-generation sequencing. Staging PET/CT revealed hepatic lesions consistent with metastatic disease (overall stage IV). She received docetaxel with carboplatin plus trastuzumab and pertuzumab; imaging after 4 cycles demonstrated partial response of hepatic metastases. Hepatic resection was subsequently performed and trastuzumab was continued in the adjuvant setting.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab; hepatic resection", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up imaging report: 68-year-old male with known metastatic colorectal adenocarcinoma. CT chest/abdomen/pelvis compared to prior shows stable size of multiple hepatic lesions. Molecular testing on primary tumor: KRAS G12D positive; MSI testing: microsatellite stable. Patient remains on FOLFOX plus bevacizumab with no interval radiographic progression.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with metastatic lung adenocarcinoma in 2023. Core biopsy showed EGFR L858R mutation and concurrent MET amplification on NGS. PD-L1 tumor proportion score 60% and TMB-high (14 muts/Mb). He presented with symptomatic brain and bone metastases and was started on frontline osimertinib plus bevacizumab; stereotactic radiosurgery was performed for a cerebellar lesion. Interval CT after 8 weeks demonstrated shrinkage of pulmonary nodules and the brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 60%; TMB-high (14 muts/Mb)", "treatment": "osimertinib + bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "31-year-old female diagnosed with a superficial spreading melanoma on the left forearm. Lesion thickness 0.8 mm (Breslow), no ulceration, sentinel node negative \u2014 pathologic stage I (pT1a). BRAF testing returned positive for BRAF V600E. Managed with wide local excision with 1 cm margins and observation; no adjuvant therapy recommended given low-risk features. Patient remains clinically well without local recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (1 cm margins); observation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old female with high-grade serous ovarian carcinoma, stage IIIC, found to carry a germline BRCA1 pathogenic variant (185delAG). She underwent primary cytoreductive surgery with residual minimal disease and completed six cycles of carboplatin plus paclitaxel with clinical and radiographic complete response. Maintenance olaparib was initiated. Disease involved extensive peritoneal implants at presentation.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": null, "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with locally advanced pancreatic ductal adenocarcinoma invading the superior mesenteric artery (TNM consistent with stage III). CA19-9 was markedly elevated to 2,500 U/mL at diagnosis. She underwent biliary stent placement then received concurrent chemoradiation with gemcitabine and capecitabine. First restaging CT showed no new metastatic disease and tumor measurements were unchanged compared with baseline. No next-generation sequencing performed to date.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 2,500 U/mL", "treatment": "gemcitabine and capecitabine with radiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma. Post-op CT chest/abdomen shows new 2.5 cm nodule in the right lower lobe consistent with pulmonary metastasis. Tumor sequencing: KRAS G12D; microsatellite status MSI-stable. He was started on FOLFOX with bevacizumab. After three months on therapy the CT demonstrates no new sites and minimal shrinkage of the lung nodule \u2014 best overall response assessed as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma presented with right upper quadrant pain. CT abdomen: multiple hepatic lesions consistent with liver metastases. Colonoscopy confirmed adenocarcinoma of the sigmoid colon. Molecular testing: KRAS G12D mutation detected. Patient received FOLFOX with bevacizumab for six cycles; most recent CT shows overall stable disease by RECIST with modest decrease in some lesions but new small lesion near segment IV being monitored.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with newly diagnosed metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 10% (TPS). Staging CT chest/abdomen/pelvis consistent with T2N2M1 (brain metastases on MRI). Patient started osimertinib 80 mg daily in March. Interval CT shows decrease in primary and intracranial lesions \u2014 assessment: partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: 1.2 cm invasive ductal carcinoma of the right breast, grade 2. Surgical margins negative; sentinel nodes negative (0/3). ER 90%+, PR 70%+, HER2 IHC 3+ with confirmatory FISH showing HER2 amplification. Patient underwent lumpectomy and sentinel node biopsy. Plan was for adjuvant paclitaxel x 12 weeks with concurrent trastuzumab for one year. She is currently without clinical or radiographic evidence of disease at 9-month follow up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 59-year-old male with metastatic colorectal adenocarcinoma diagnosed 2 years ago. CT today shows enlarging hepatic lesions consistent with liver-dominant disease. Prior molecular testing: KRAS G12D positive. Patient has been maintained on FOLFOX and bevacizumab for 5 months with overall stable disease by RECIST on most recent scans, but this visit demonstrates modest growth in the dominant segment VII lesion. No MSI testing reported in chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided colon adenocarcinoma with synchronous liver metastases. Pathology confirmed stage IV disease. Tumor profiling: BRAF V600E positive and MSI-H with high tumor mutational burden. Initially received FOLFOX with bevacizumab with mixed response; subsequently started encorafenib plus cetuximab for BRAF V600E\u2013mutant disease. Pembrolizumab was added later given MSI-H status. Disease has been radiographically stable on the current regimen.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab \u2192 encorafenib + cetuximab; later pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma, pT3N1 after resection (clinical stage III). Tumor harbors KRAS G12D on targeted panel and is microsatellite-stable (MSS). Received adjuvant FOLFOX for 6 months. Surveillance CT at 12 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "adjuvant FOLFOX (6 months)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed high-grade serous ovarian carcinoma, FIGO stage IV with peritoneal carcinomatosis and liver implants. Germline testing revealed a deleterious BRCA2 mutation and tumor was HRD-positive. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with bevacizumab, achieving a partial response on CT; transitioned to olaparib maintenance.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel with bevacizumab; olaparib maintenance", "response": "partial response", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with organ-confined prostate adenocarcinoma (Gleason 3+4=7), clinical stage II. He underwent radical prostatectomy; surgical margins were negative and there is no radiographic evidence of metastatic disease. No systemic therapy was given and patient will be followed with surveillance.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with unresectable cutaneous melanoma, staged IIIC at presentation. Tumor testing positive for BRAF V600E; PD-L1 expression <1%. Started on targeted therapy with dabrafenib and trametinib with rapid symptomatic improvement and marked tumor shrinkage (best radiographic response: partial response). After nine months new pulmonary nodules were noted and therapy was changed to nivolumab with a mixed radiologic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib; later nivolumab", "response": "partial response followed by mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman underwent optimal debulking for high-grade serous ovarian carcinoma. Final pathology staged as FIGO IIIC. Germline testing revealed a deleterious BRCA1 mutation and preoperative CA-125 was markedly elevated. She completed six cycles of carboplatin and paclitaxel and was transitioned to maintenance olaparib. Recent CT scans show no evidence of residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated pre-op", "treatment": "carboplatin + paclitaxel; maintenance olaparib", "response": "no evidence of residual disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic pancreatic ductal adenocarcinoma, stage IV at diagnosis with multiple hypodense lesions in the liver. NGS shows KRAS G12D and a germline BRCA2 frameshift mutation. CA19-9 markedly elevated at baseline. He received first-line FOLFIRINOX with a partial response and then transitioned to olaparib maintenance for the BRCA2 alteration; disease is currently stable on maintenance.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; BRCA2 frameshift", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease (after initial partial response)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology summary: 48-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER negative, PR negative; HER2 amplification by FISH (HER2/CEP17 ratio 5.2). She received neoadjuvant paclitaxel plus trastuzumab for 12 weeks and proceeded to right mastectomy. Final surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "paclitaxel and trastuzumab; mastectomy", "response": "complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 67-year-old man diagnosed with lung adenocarcinoma, stage IV (T2N2M1c) with symptomatic brain lesions on MRI. Molecular testing positive for EGFR L858R and PD-L1 TPS 10%. Started first-line osimertinib 80 mg daily three weeks ago with improvement in cough and decreased size of pulmonary and brain lesions on interval imaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old female with locally advanced left breast cancer (cT4N1). Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Targeted panel detected a PIK3CA H1047R mutation. Neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab was administered for six cycles. At the time of definitive mastectomy the pathology showed a pathologic complete response (no residual invasive carcinoma).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB (cT4N1)", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma. NGS revealed KRAS G12D and PCR-based testing demonstrated MSI-H status. He received first-line FOLFOX with bevacizumab with initial stable disease; because of MSI-H he was transitioned to pembrolizumab on progression and currently has ongoing stable disease on immunotherapy. Staging at diagnosis was IV with multiple hepatic and bilateral pulmonary lesions on CT.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative note: 63-year-old male with sigmoid colon adenocarcinoma pT3N1 (stage III) who underwent a low anterior resection. Tumor genomics: KRAS G12D mutation identified; MSI testing returned microsatellite stable. Started adjuvant FOLFOX chemotherapy six weeks after surgery. Surveillance CTs to date show no distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgery (low anterior resection); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed sigmoid adenocarcinoma. Staging CT shows multiple hypodense lesions in the liver consistent with metastases. Tumor sequencing reports KRAS G12D and MSI-stable (MSS). He was started on FOLFOX plus bevacizumab; interval CT after three cycles demonstrates stable disease of both the primary and hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma (sigmoid)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV cutaneous melanoma diagnosed last year. Molecular testing identified BRAF V600E. He was treated first-line with dabrafenib and trametinib and achieved a partial response, but developed progression in the brain after 8 months. He was switched to pembrolizumab; subsequent scans showed a mixed response with reduction of extracranial disease and stabilization of intracranial lesions. PD-L1 by IHC was reported at 5%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib followed by pembrolizumab", "response": "mixed response then stable disease on pembrolizumab", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma presented with progressive headaches. Imaging showed multiple enhancing lesions in the cerebrum and lytic lesions in the lumbar spine. Biopsy of the right lower lobe confirmed adenocarcinoma. Molecular testing: EGFR L858R positive; ALK and ROS1 negative. PD-L1 tumor proportion score ~10%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to a dominant brain metastasis. Interim CT at 8 weeks demonstrates decrease in size of pulmonary and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female with newly diagnosed lung adenocarcinoma. Molecular testing returned EGFR L858R mutation. Staging PET/CT demonstrated multiple bilateral pulmonary nodules and a 1.8 cm cerebellar lesion consistent with metastasis. PD-L1 tumor proportion score 10%. Patient staged as IV and started on osimertinib 80 mg daily. Interval imaging after 8 weeks shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma presented with headaches. CT head positive for two cerebellar metastases. Molecular testing returned EGFR L858R; PD-L1 was <1%. She was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the brain lesions. Imaging at 8 weeks showed decrease in both intracranial and pulmonary nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed prostate adenocarcinoma. PSA at presentation 18 ng/mL. Biopsy shows Gleason score 4+3=7 in multiple cores. Clinical exam and imaging support organ-confined disease, staged as II. Risks and options discussed; patient elected for external beam radiation therapy combined with androgen deprivation therapy (leuprolide). No tumor genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 18 ng/mL", "treatment": "external beam radiation therapy and leuprolide", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer. Biopsy of liver lesion confirmed invasive ductal carcinoma, HER2 amplification by FISH; ER and PR positive. Systemic panel did not reveal actionable somatic mutations. Staged as IV due to hepatic metastases. She was started on trastuzumab with weekly paclitaxel and after four cycles CT chest/abdomen shows no new lesions and shrinkage of majority of liver nodules.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. She presented with progressive headaches and was found to have multiple enhancing lesions on MRI consistent with brain metastases. Molecular testing returned EGFR L858R mutation. PD-L1 by IHC = 10%. Patient was started on osimertinib 80 mg daily in June and has tolerated therapy well. Follow-up imaging at 12 weeks shows shrinkage of pulmonary nodules and decreased size of the brain lesions \u2014 overall assessment: partial response. Bone scan demonstrated a single new focus in the right femur.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing: EGFR L858R positive. PD-L1 tumor proportion score 5%. Brain MRI showed a solitary cerebellar metastasis (resected March 2024). Currently on osimertinib 80 mg daily since resection with interval CT chest/abdomen showing decreased size of primary and no new extracranial disease \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed metastatic prostate adenocarcinoma presenting with bone pain and PSA of 680 ng/mL. Staging scans revealed widespread osseous metastases. He was started on combined androgen deprivation therapy with leuprolide plus docetaxel (six cycles) and has been maintained on androgen suppression. Repeat bone scan after three months shows no new lesions and PSA decline consistent with stable disease clinically.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) + docetaxel", "response": "stable disease (PSA decline, no new lesions)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (stage IV) found to harbor an EGFR L858R mutation. PD-L1 by IHC was reported as 60%. MRI brain demonstrated multiple enhancing lesions consistent with metastases. She was started on osimertinib and after three months had a partial response with decreased intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral note: 72-year-old male with rising PSA after transurethral resection; prostate biopsy scheduled next week. No prior systemic therapy. Patient reports urinary hesitancy and nocturia. Plan discussed for definitive treatment options including radiation versus prostatectomy pending biopsy results and staging.", "output": {"cancer_type": "prostate cancer", "stage": null, "gene_mutation": null, "biomarker": "PSA rising", "treatment": "definitive therapy planned (radiation or prostatectomy) - biopsy pending", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with stage IV lung adenocarcinoma diagnosed 2019. Molecular testing on the primary tumor returned EGFR L858R. He was started on osimertinib 80 mg PO daily in January 2020 with rapid symptomatic improvement. Brain MRI at 8 weeks showed decreased size of multiple metastases. PD-L1 testing was not performed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with cutaneous melanoma who developed metastatic disease. Molecular profiling detected BRAF V600E and high tumor mutational burden (TMB-high). He received dabrafenib plus trametinib with a partial response for nine months, then developed new brain and lung metastases. After progression on BRAF/MEK therapy he was started on nivolumab; imaging since then shows a mixed response with shrinking pulmonary nodules but enlarging intracranial disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; nivolumab", "response": "initial partial response then progression; mixed response to immunotherapy", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic pancreatic ductal adenocarcinoma. Tumor genotyping identified KRAS G12D. Baseline CA 19-9 was markedly elevated at 15,000 U/mL. Cross-sectional imaging demonstrates multiple liver metastases. He received FOLFIRINOX with an initial partial response but subsequently progressed and was switched to gemcitabine plus nab-paclitaxel.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX; then gemcitabine and nab-paclitaxel", "response": "partial response followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colon adenocarcinoma presenting with diffuse peritoneal nodularity and ascites. Tumor testing reported MSI-H / mismatch repair deficient by PCR/IHC. No actionable gene mutations were identified on the 50-gene panel. Given MSI-H status he was started on pembrolizumab monotherapy; after 3 cycles scans showed stable disease. Peritoneal disease remains the dominant site.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H (MMR deficient)", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with lung adenocarcinoma, presented with cough and weight loss. Staging PET/CT demonstrated stage IV disease with bilateral pulmonary nodules and liver lesions and a small enhancing brain metastasis. Molecular testing revealed EGFR L858R with acquired T790M. PD-L1 TPS was 10%. She was started on osimertinib with initial response but progressed after 11 months. Switched to carboplatin and pemetrexed combined with pembrolizumab; imaging after three cycles showed a marked decrease in size of liver and lung lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed plus pembrolizumab", "response": "progression on osimertinib; partial response to carboplatin/pemetrexed + pembrolizumab", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R mutation. PD-L1 was 10% TPS. Staging at diagnosis was IV. Brain MRI showed multiple enhancing lesions and PET/CT revealed osseous disease. He was started on first\u2011line osimertinib with a good partial response for ~14 months, then developed systemic progression and was transitioned to carboplatin and pemetrexed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib; carboplatin and pemetrexed", "response": "partial response (to osimertinib) then progression", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation: 55-year-old with metastatic cutaneous melanoma. PET/CT confirms pulmonary nodules and two cerebellar metastases. Tumor is BRAF V600E positive. Initially started on pembrolizumab but developed progression at 10 weeks; subsequently commenced dabrafenib with trametinib. Interval imaging shows regression of lung disease but new small brain metastases \u2014 overall mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed after biopsy of a RUL mass. Molecular testing positive for EGFR L858R. Baseline PD-L1 by IHC 10%. Started first-line osimertinib with an initial partial response; restaging CT and MRI now show progression with new brain metastases and progressive bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progressive disease", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with newly diagnosed stage IV lung adenocarcinoma. Molecular testing demonstrated EGFR L858R mutation; PD-L1 tumor proportion score 30%. She was started on osimertinib 80 mg daily. Follow-up CT and brain MRI at 8 weeks show decrease in size of pulmonary and intracranial lesions consistent with a partial response. Known bone metastases on baseline bone scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging PET/CT demonstrated widespread metastatic disease with multiple brain lesions and lytic lesions in the spine consistent with stage IV disease. Molecular testing returned EGFR L858R; PD-L1 10%. She was started on osimertinib as first-line targeted therapy with significant symptomatic improvement and interval shrinkage of intracranial and osseous lesions on first restaging \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male status post right hemicolectomy for colon adenocarcinoma staged pT3N2 (stage III). Tumor testing: MSI-H by PCR with loss of MLH1/PMS2 on IHC. No actionable hotspot mutations reported on the NGS panel. He completed adjuvant FOLFOX x 6 months. Surveillance CT chest/abdomen/pelvis shows no distant metastatic disease; only regional lymph node involvement was documented at surgery.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of distant disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "27-year-old with a pigmented lesion on the left forearm excised and diagnosed as superficial spreading melanoma, Breslow 0.8 mm, no ulceration. Clinical stage I (IA). Sentinel node negative. BRAF testing returned V600E positive. Patient underwent wide local excision and was placed on routine surveillance.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive. Initially treated with dabrafenib and trametinib with an early partial response; after 6 months developed intracranial progression with a new cerebellar metastasis. Therapy was changed to nivolumab monotherapy; on latest assessment extracranial disease is stable.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; later nivolumab", "response": "initial partial response, then intracranial progression; extracranial stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER-positive, PR-negative, HER2-overexpressing invasive ductal carcinoma of the breast. Core biopsy: HER2 amplification by FISH; somatic PIK3CA H1047R identified on panel. She developed diffuse osseous metastases on staging bone scan. Systemic therapy: docetaxel with trastuzumab and pertuzumab x6 cycles. Most recent scans show stable disease. Documented stage IV at metastatic diagnosis.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (oncology): Patient with metastatic cutaneous melanoma, multiple pulmonary nodules on CT. Molecular testing identified BRAF V600E. PD-L1 testing was not performed. Started combination targeted therapy with dabrafenib and trametinib three months ago; significant decrease in size of lung lesions and clinical improvement. Assessment: ongoing partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung (pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor testing demonstrated MSI-H and a BRAF V600E mutation. He was started on FOLFOX with bevacizumab but had radiographic progression after 4 cycles. He was subsequently transitioned to encorafenib plus cetuximab; follow-up imaging after 6 weeks shows shrinkage of hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; then encorafenib + cetuximab", "response": "partial response (after encorafenib + cetuximab)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging CT shows multiple bilateral pulmonary nodules and a 2.5 cm cerebellar lesion consistent with metastasis; clinical stage IV. Molecular testing returned EGFR exon 19 deletion. PD-L1 TPS 5%. Patient was started on osimertinib 80 mg daily in July and had interval shrinkage of measurable lesions on first follow-up imaging consistent with partial response. Planning stereotactic radiosurgery to the brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery. Pathology staged as IIIc with diffuse peritoneal carcinomatosis. Germline testing positive for BRCA1 deleterious mutation. Patient received adjuvant carboplatin and paclitaxel with initial CA-125 decline, started olaparib maintenance; however, follow-up CT shows increasing peritoneal nodularity consistent with progression.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIc", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated (decline then rise noted)", "treatment": "carboplatin and paclitaxel; olaparib (maintenance)", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with progressive cough and weight loss. Imaging revealed a right upper lobe mass with multiple enhancing lesions in the brain and lytic lesions in the spine. Biopsy confirmed lung adenocarcinoma. Molecular testing positive for EGFR exon 19 deletion; PD-L1 tumor proportion score approximately 10%. Patient started osimertinib 80 mg daily in April and has improvement in cough. Most recent MRI shows reduction in the size of brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer (clinical stage IIIB). Core biopsy: invasive ductal carcinoma, HER2 amplified (IHC 3+ / FISH positive), ER positive, PR positive. No actionable mutation reported on NGS panel. She received neoadjuvant docetaxel plus trastuzumab for 6 cycles, then underwent modified radical mastectomy followed by adjuvant radiation. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and trastuzumab, modified radical mastectomy, adjuvant radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 55-year-old man with bulky nodal melanoma of the left axilla. Final staging pT3bN2c \u2014 stage IIIC. Tumor was BRAF V600E positive. Underwent wide local excision and complete lymph node dissection followed by adjuvant dabrafenib with trametinib. PET/CT at 6 months shows no metabolically active disease.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgery (wide local excision and lymphadenectomy); adjuvant dabrafenib + trametinib", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging workup demonstrates metastatic disease to bone and brain; overall stage IV. Molecular testing identified an EGFR L858R point mutation. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily with improvement in symptoms and first CT/PET shows a partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic cutaneous melanoma, Stage IV, with known BRAF V600E. Baseline imaging showed pulmonary nodules and several enhancing brain metastases. Began combination targeted therapy with dabrafenib and trametinib. Follow-up scans demonstrated marked extracranial tumor regression but development of new enhancing intracranial lesions \u2014 overall described as a mixed response. PD-L1 was reported at 20% on archival tissue.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib + trametinib", "response": "mixed response", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic colorectal adenocarcinoma to the liver. Tumor characterized as MSI-H on PCR and showed high tumor mutational burden (TMB-high). BRAF V600E mutation was reported; KRAS and NRAS were wild-type. She was started on pembrolizumab and had stable disease on the first two surveillance CTs.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 62-year-old male with metastatic colorectal adenocarcinoma with liver-dominant disease. Tumor testing returned BRAF V600E and high microsatellite instability (MSI-H). He initially received FOLFOX with bevacizumab but progressed after 6 cycles; switched to encorafenib plus cetuximab on clinical trial with imaging showing stable disease for four months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; encorafenib plus cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colon adenocarcinoma presenting with multiple liver metastases. NGS shows KRAS G12C mutation; tumor is MSI-stable. He received FOLFIRI plus bevacizumab as first-line therapy but interval CT after 6 cycles demonstrated progression in the liver. Patient is being evaluated for a KRAS G12C inhibitor trial.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSI-stable", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with cutaneous melanoma of the upper back, positive sentinel node, staged as III (stage IIIB). Tumor testing showed BRAF V600E. Underwent wide local excision and completion lymphadenectomy and was placed on adjuvant dabrafenib plus trametinib. Surveillance scans at one year show no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgery (wide local excision and lymphadenectomy); adjuvant dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology consult: 45-year-old female with a pigmented lesion excised from left forearm. Final diagnosis: cutaneous melanoma, Breslow 0.8 mm, no ulceration, sentinel node negative \u2014 clinical stage I. Molecular testing performed on biopsy identified BRAF V600E. Wide local excision completed; no adjuvant therapy recommended. Patient remains free of recurrence at first-year follow-up.", "output": {"cancer_type": "melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with unresectable metastatic cutaneous melanoma. PET/CT revealed multiple osseous lesions in the spine and pelvis confirming bone metastases. Tumor testing positive for BRAF V600E. He was started on dabrafenib and trametinib and received palliative radiotherapy to a painful lumbar lesion. Subsequent imaging and pain scores indicate reduction in lesion size and improved symptoms; overall documented as partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; palliative radiotherapy", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with invasive ductal breast cancer, ER-negative/PR-negative, HER2 amplification on FISH. Tumor harbored a PIK3CA H1047R mutation on NGS. At diagnosis she had metastatic disease with multiple hypodense lesions in the liver. She received trastuzumab and pertuzumab in combination with docetaxel; interval CT shows marked reduction in hepatic lesions and clinical improvement, consistent with a partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, clinical stage IIIC at presentation. Germline testing identified a pathogenic BRCA1 frameshift mutation (BRCA1 185delAG) and tumor profiling showed HRD positive with pathogenic TP53 mutation. She underwent primary debulking surgery followed by adjuvant carboplatin and paclitaxel. After partial response to platinum-based therapy, maintenance olaparib was started. Disease progressed after 14 months on maintenance.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG; TP53 mutation", "biomarker": "HRD positive", "treatment": "primary debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response followed by progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 2.5 cm left breast invasive ductal carcinoma, ER positive, PR positive, HER2 amplification by FISH. Breast-conserving surgery with sentinel node biopsy (0/3 nodes) was performed. Oncotype testing showed PIK3CA H1047R mutation. She completed adjuvant AC-T (doxorubicin/cyclophosphamide followed by paclitaxel) and has been started on adjuvant tamoxifen. Last clinic note documents no evidence of disease on recent mammogram and exam.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 amplification", "treatment": "surgery (lumpectomy) with AC-T chemotherapy and tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative summary and plan: 71-year-old male underwent right hemicolectomy for colon adenocarcinoma. Pathology: stage III (pT3N1). Tumor sample harbored KRAS G12D mutation and was microsatellite stable (MSS). Adjuvant chemotherapy with FOLFOX was recommended; post-op CT shows no residual disease at 3 months (NED).", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "surgery (right hemicolectomy) and adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and lumbosacral pain. Staging PET/CT showed multiple pulmonary nodules and enhancing lesions in the cerebellum and lumbar spine consistent with metastatic disease. Tissue NGS identified EGFR L858R and PD-L1 TPS 5%. Patient was started on osimertinib 80 mg daily with dexamethasone for brain edema. At first follow-up imaging (8 weeks) there is a 45% decrease in size of the dominant lung mass and improvement of the CNS lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with borderline resectable pancreatic head adenocarcinoma (clinical stage III). CA19-9 elevated at diagnosis. No actionable alterations were identified on limited panel testing (no targetable mutation reported). He completed neoadjuvant combination chemotherapy with modified FOLFIRINOX and concurrent radiotherapy prior to planned Whipple; interval imaging showed disease stable in size.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "modified FOLFIRINOX + radiotherapy", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical stage cT3N2M0 (stage IIIB). She completed neoadjuvant weekly paclitaxel with concurrent trastuzumab prior to planned surgery. Post-treatment exam showed reduction in tumor size but residual palpable disease; patient proceeded to modified radical mastectomy.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "neoadjuvant weekly paclitaxel and trastuzumab followed by modified radical mastectomy", "response": "residual disease (not pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recurrent melanoma with BRAF V600E identified on molecular testing. Patient had prior wide local excision and adjuvant interferon years ago. Now presents with new cutaneous and brain lesions. Started on dabrafenib plus trametinib but developed progression within two months. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain and skin"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the right breast, ER positive, PR positive, HER2 amplification by FISH. Core biopsy also reports PIK3CA H1047R on NGS. Clinical stage cT2N0M0 (stage IIA). Patient received neoadjuvant trastuzumab and pertuzumab with docetaxel; following three cycles there was a marked clinical response and she proceeded to breast-conserving surgery. No distant mets identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+, PR+", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "marked clinical response / pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma diagnosed in 2020. Comprehensive NGS showed EGFR L858R mutation. PD-L1 tumor proportion score ~10%. Patient started osimertinib 80 mg daily in June 2020. Brain MRI in July demonstrated two enhancing lesions consistent with metastases. Restaging CT after 8 weeks demonstrated shrinkage of pulmonary lesions consistent with a partial response. Stage at diagnosis: IV.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma in 2023. Staging was T2N2M1 (stage IV) with known brain and bone metastases. Molecular testing identified EGFR L858R. PD-L1 TPS was 10%. Patient started first-line osimertinib 80 mg daily in June; CT and MRI after 8 weeks show decrease in size of pulmonary nodules and reduction of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma. Tumor genotyping returned KRAS G12D mutation and microsatellite testing reported MSS (microsatellite stable). Staging CT demonstrates multiple hypodense lesions in the right lobe of the liver consistent with metastatic disease. He was treated with FOLFOX plus bevacizumab for six cycles but interval imaging showed increase in size and number of hepatic metastases consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old F with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 5%. Patient presented with headaches; MRI demonstrated multiple brain metastases and staging PET/CT showed osseous lesions. Started first-line osimertinib with initial response in pulmonary disease but interval progression in the brain after 11 months; underwent whole brain radiotherapy. Systemic therapy continued but recent scans report overall progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; whole brain radiotherapy", "response": "progression", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male diagnosed with prostate adenocarcinoma, Gleason 3+4 on biopsy, clinical stage II. Patient elected definitive external beam radiation therapy with 6 months of short-course androgen deprivation therapy. PSA has fallen from 12 to 0.8 ng/mL and he remains on scheduled surveillance.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy and androgen deprivation therapy", "response": "stable/biochemical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient status post right hemicolectomy for colorectal adenocarcinoma now with liver-dominant metastatic disease on CT. Tumor sequencing returned KRAS G12D. He was started on palliative FOLFOX with bevacizumab and has had stable disease on interval imaging for 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 48-year-old woman with metastatic invasive ductal carcinoma confirmed on bone biopsy. ER/PR positive, HER2 amplified by FISH. Patient received first-line trastuzumab with weekly paclitaxel; zoledronic acid was added for bone pain. No genomic mutation reported in chart. Imaging shows stable lytic lesions in the spine after 3 cycles.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and paclitaxel; zoledronic acid", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old woman underwent primary debulking for suspected ovarian carcinoma. Surgical pathology: high-grade serous carcinoma, FIGO stage IIIC with bulky pelvic and omental disease. Tumor HRD assay returned positive. Germline BRCA testing is pending. She completed adjuvant carboplatin and paclitaxel and was transitioned to olaparib maintenance. CA-125 normalized post-treatment and current assessment indicates no radiographic evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HRD-positive; CA-125 normalization", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical response / no radiographic evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 58-year-old male with metastatic colorectal adenocarcinoma presenting with increasing abdominal distension. CT abdomen/pelvis reveals diffuse peritoneal nodularity consistent with peritoneal carcinomatosis. Tumor genotyping shows KRAS G12D mutation; microsatellite status reported as MSS. He received 8 cycles of FOLFOX with bevacizumab but now has clinical and radiographic progression.", "output": {"cancer_type": "colon (colorectal) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer (mCRPC) with diffuse painful sclerotic bone metastases. Comprehensive genomic profiling revealed a deleterious BRCA2 mutation. PSA at presentation was 120 ng/mL. After progression on enzalutamide, patient was started on olaparib with biochemical stabilization and radiographic disease control for approximately 9 months (stable disease).", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "PSA 120 ng/mL", "treatment": "enzalutamide; olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal breast carcinoma, clinical stage IIIB. Tumor was HER2 3+ by IHC, ER/PR negative. She received neoadjuvant trastuzumab with docetaxel for 6 cycles and subsequently underwent mastectomy; pathology reported no residual invasive disease (pathologic complete response). No radiographic evidence of distant metastasis.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+); ER/PR negative", "treatment": "trastuzumab and docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with metastatic lung adenocarcinoma diagnosed June 2023. Molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 20%. Brain MRI demonstrated two small parenchymal metastases. She was started on first-line osimertinib 80 mg daily; after 8 weeks CT chest/brain shows decrease in size of pulmonary nodules and shrinkage of the intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Male, 68, diagnosed with localized prostate adenocarcinoma, Gleason 3+4. Clinical stage T2b (stage II). Patient elected definitive radiation therapy with concurrent androgen deprivation (leuprolide). No genomic testing performed. PSA declined to undetectable at 12 months post-RT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radiation therapy with leuprolide (androgen deprivation)", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old with a superficial spreading melanoma of the upper back, Breslow depth 0.9 mm, staged as clinical stage I. Wide local excision with 1 cm margins was performed; sentinel lymph node biopsy was negative. No molecular testing was done and no adjuvant therapy recommended. Patient is being followed in melanoma clinic for surveillance.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision, sentinel lymph node biopsy", "response": "complete excision / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic cutaneous melanoma. Excisional biopsy from a nodular lesion showed BRAF V600E mutation. Staging CT found multiple pulmonary nodules consistent with metastatic disease. He was started on combination targeted therapy with dabrafenib and trametinib with rapid partial radiologic response of the lung nodules and improvement in performance status.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 58-year-old man with locally advanced squamous cell carcinoma of the oropharynx (p16 negative). Tumor staged as IVA with bulky ipsilateral cervical nodal disease but no distant spread on PET. Underwent definitive concurrent radiotherapy with high-dose cisplatin (100 mg/m2 q3 weeks). Mid-treatment exam shows minimal shrinkage of the primary and persistent bulky cervical nodes consistent with stable disease on clinical assessment.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx", "stage": "IVA", "gene_mutation": null, "biomarker": null, "treatment": "concurrent radiotherapy with high-dose cisplatin", "response": "stable disease", "metastasis_site": "cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old woman with high-grade serous ovarian carcinoma presented with bulky pelvic disease and peritoneal nodularity. She underwent optimal cytoreductive surgery; final stage IIIC. Germline testing identified a deleterious BRCA2 mutation and the tumor was HRD-positive. She completed six cycles of carboplatin and paclitaxel with complete clinical and radiographic response and was started on maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 (deleterious germline)", "biomarker": "HRD-positive", "treatment": "optimal cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced pancreatic ductal adenocarcinoma with borderline unresectable mass encasing the SMA. CA 19-9 elevated at diagnosis. Patient treated with FOLFIRINOX for six cycles followed by consolidative chemoradiation and consideration of maintenance therapy. No actionable somatic mutations reported on current panel.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX; chemoradiation (consolidative)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with advanced cutaneous melanoma. At presentation there were multiple hepatic and pulmonary lesions consistent with metastatic disease (stage IV). BRAF V600E mutation was identified; tumor has high tumor mutational burden. He was started on dabrafenib plus trametinib but progressed after 4 months and was switched to pembrolizumab with a mixed radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib, then pembrolizumab", "response": "progression on BRAF/MEK therapy; mixed response on pembrolizumab", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 49-year-old woman with metastatic cutaneous melanoma of the left forearm. BRAF V600E mutation identified on PCR. PD-L1 was not performed. Therapy initiated with dabrafenib and trametinib; first restaging PET/CT demonstrates small decreases in pulmonary nodules but no new lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of a right breast mass: invasive ductal carcinoma, ER positive, PR positive. HER2 amplified by FISH (ratio 3.6). NGS detected PIK3CA H1047R. Clinical stage cT2N1 (stage IIB). Patient received neoadjuvant docetaxel + carboplatin with trastuzumab and pertuzumab for 6 cycles; subsequent lumpectomy showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging and biopsy confirm stage IV disease with multiple brain and bone lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 1%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to a solitary cerebellar metastasis. Interval CT and MRI at 8 weeks show reduction in size of pulmonary primary and osseous lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with newly diagnosed high-grade serous ovarian carcinoma. At laparotomy there was bulky peritoneal carcinomatosis and optimal debulking was achieved. Germline testing returned positive for BRCA1 c.5266dupC (pathogenic). CA-125 at diagnosis was 450 U/mL. She completed adjuvant carboplatin and paclitaxel and was started on maintenance olaparib. Recent CT shows no measurable residual disease consistent with complete response. Stage documented as IIIC.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.5266dupC", "biomarker": "CA-125 450 U/mL", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage III cutaneous melanoma of the trunk. Surgical excision and nodal dissection were performed; tumor harbored BRAF V600E. Started adjuvant targeted therapy with dabrafenib plus trametinib in July 2023. Initial imaging showed a partial radiographic response but interval CT in March 2024 demonstrates disease progression with new pulmonary nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed 2018. NGS of the primary tumor identified EGFR L858R. PD-L1 tumor proportion score reported at ~10%. Patient started osimertinib 80 mg daily in 2019. Recent CT chest shows reduction of the primary mass and pulmonary nodules, but MRI brain demonstrates multiple new enhancing lesions consistent with intracranial metastases. Impression: mixed response with intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "mixed response (intracranial progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with biopsy-proven pancreatic ductal adenocarcinoma presented with multiple liver lesions on CT consistent with metastatic disease. Germline testing identified a pathogenic BRCA2 variant. He was started on FOLFIRINOX and had an initial minor radiographic response, but after four months progressed in the liver and was switched to gemcitabine plus nab-paclitaxel. PD-L1 was not assessed in this case.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": null, "treatment": "FOLFIRINOX then gemcitabine + nab-paclitaxel", "response": "progression after initial minor response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with localized prostate adenocarcinoma, Gleason 3+4, clinical T2a (stage II). He received definitive external beam radiation therapy with six months of androgen deprivation (leuprolide). PSA fell to undetectable levels and bone scan was negative. No molecular testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation, leuprolide (androgen deprivation)", "response": "biochemical complete response (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER+/PR+ invasive ductal carcinoma of the left breast, HER2 amplified by FISH. Initially presented with liver lesions on staging PET/CT and bulky left axillary lymphadenopathy \u2014 overall metastatic at diagnosis (stage IV). She received weekly paclitaxel combined with trastuzumab and pertuzumab. Most recent imaging after 4 cycles shows shrinkage of hepatic lesions with no new sites; disease is currently stable on therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "liver, left axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with metastatic lung adenocarcinoma, stage IV, with symptomatic bone pain and a solitary cerebellar metastasis treated with SRS. Molecular testing returned EGFR L858R and PD-L1 1%. He was started on osimertinib as first-line therapy. CT chest/abdomen at 8 weeks demonstrated decrease in primary lung mass and improvement of osseous lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib; stereotactic radiosurgery to cerebellar metastasis", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 49-year-old woman with ER-positive, PR-negative, HER2-amplified invasive ductal carcinoma of the right breast. Initial imaging revealed multiple hepatic lesions and scattered sclerotic bone lesions; patient was staged as IV. NGS reported a PIK3CA H1047R mutation. She was started on first-line pertuzumab + trastuzumab with weekly paclitaxel. After three cycles the disease is radiographically stable and clinically controlled; plan to continue targeted HER2 therapy plus chemotherapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "pertuzumab, trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage III (T3N2M0). Core biopsy: HER2 amplification by FISH, ER 80% positive, PR negative. Next-generation sequencing detected a PIK3CA E545K mutation. She received neoadjuvant combination therapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP). Post-neoadjuvant MRI demonstrated marked tumor shrinkage but residual enhancing disease; plan is mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op oncology summary: 48-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast, clinically T2N0 (stage IIA). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant therapy with docetaxel and carboplatin plus trastuzumab for 6 cycles. Patient subsequently underwent left lumpectomy and sentinel node biopsy; pathology reported no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male underwent colonoscopy for rectal bleeding; biopsy revealed moderately differentiated adenocarcinoma of the sigmoid colon. CT chest/abdomen/pelvis showed no distant disease. Tumor is mismatch repair deficient (MSI-H) on IHC and PCR. Patient proceeded to low anterior resection; pathology pT3N0 (stage II). No adjuvant chemotherapy was given due to MSI-H status and patient preference. Surveillance at 12 months shows no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgical resection (low anterior resection); no adjuvant chemotherapy", "response": "no evidence of disease / disease-free on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left breast invasive ductal carcinoma, clinical stage II (T2N0). Tumor is ER positive, PR positive, and HER2 amplification by FISH. She received neoadjuvant paclitaxel with concurrent trastuzumab and proceeded to lumpectomy with sentinel node biopsy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "paclitaxel and trastuzumab (neoadjuvant), lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with unresectable metastatic melanoma, stage IV, with pulmonary nodules. Molecular testing positive for BRAF V600E. PD-L1 by IHC was 60%. Treated with dabrafenib plus trametinib with a brisk partial response; later received pembrolizumab on trial after progression of one lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib; trametinib; pembrolizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinically T3N2M0 (stage IIIB). Core biopsy showed HER2 amplification by FISH; ER and PR negative. She received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with concurrent trastuzumab, then underwent mastectomy. Final pathology revealed no residual invasive carcinoma (ypT0N0) \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a left breast mass. Core needle biopsy: invasive ductal carcinoma, HER2 IHC 3+ and FISH positive for HER2 amplification; ER positive, PR negative. Clinical staging consistent with IIIB (skin involvement and fixed mass). No actionable mutations reported on the 50-gene panel. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles and had a complete clinical response prior to mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab; pertuzumab; docetaxel (neoadjuvant)", "response": "clinical complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old male with metastatic colorectal adenocarcinoma. CT abdomen showed multiple hepatic metastases and peritoneal nodularity. Tumor is stage IV. Molecular profiling identified BRAF V600E mutation. MSI testing returned MSI-H and the tumor mutational burden reported as TMB-high. He received first-line FOLFOX plus bevacizumab with disease control, and because of MSI-H/TMB-high status was transitioned to pembrolizumab monotherapy on protocol. Most recent restaging: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with stage IV lung adenocarcinoma metastatic to brain and bone. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 5%. He was started on osimertinib 80 mg daily as first-line systemic therapy. After 3 months of treatment CT and MRI scans showed decrease in size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: core biopsy of left breast shows invasive ductal carcinoma, grade 2. IHC: HER2 3+ (by IHC), ER negative, PR negative. Staging workup consistent with clinical stage IIA (T2N0M0). PIK3CA H1047R identified on NGS panel. Patient completed neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by lumpectomy and axillary node sampling. Final pathology revealed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+ (IHC), ER negative, PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery (lumpectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma, BRAF V600E\u2013positive, relapsed with pulmonary nodules. Initially received first-line pembrolizumab but had clinical progression after 4 months; subsequently started on dabrafenib with trametinib and achieved a good partial response on interval imaging. Tumor mutational burden reported as high on NGS panel. Staged as IV at recurrence.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (first-line), then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma. Liver metastases on CT and biopsy confirmed colorectal primary. Tumor testing: MSI-H by PCR and BRAF V600E mutation on NGS. Given MSI-H status, started pembrolizumab monotherapy. Restaging CT at 12 weeks demonstrates a 40% reduction in sum of target lesions in the liver consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old male with metastatic cutaneous melanoma. Tumor sequencing identified BRAF V600E. Presents with painful lytic lesion at T12 confirmed as metastatic melanoma. Initiated on dabrafenib plus trametinib and received palliative radiation to the spine. PET/CT at 12 weeks shows marked decrease in FDG uptake at the T12 lesion and reduced size of other foci.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; palliative radiation", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old female with locally advanced breast cancer (clinical stage IIIB) presenting with a 4.5 cm left breast mass and fixed axillary nodes. Biopsy: invasive ductal carcinoma, ER+, PR+, HER2 amplified by FISH. Next-generation sequencing identified PIK3CA H1047R and TP53 mutation. She received neoadjuvant combination therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles. Interval imaging and exam show a significant clinical and radiologic partial response; planning for modified radical mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R; TP53 mutation", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male underwent right hemicolectomy for ascending colon adenocarcinoma. Final path: pT3N1, stage III. Tumor was MSI-H by PCR; extended RAS/BRAF testing did not reveal actionable mutations. Received adjuvant FOLFOX for six cycles. Surveillance CT at 18 months shows no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "disease-free (no evidence of recurrence)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman diagnosed with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIA. Tumor is ER-negative, PR-negative and shows HER2 amplification by FISH. She received neoadjuvant docetaxel and carboplatin with dual HER2 blockade (trastuzumab and pertuzumab). Surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response). No somatic mutation panel was reported in the chart.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic right-sided colon adenocarcinoma presenting with multiple liver metastases. Tumor profiling returned MSI-H and TMB-high. No actionable KRAS/NRAS/BRAF alterations were identified in the report. Patient was started on pembrolizumab monotherapy; follow-up imaging at 9 months demonstrates complete metabolic response of hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old man with metastatic colorectal adenocarcinoma, liver-dominant disease discovered on diagnostic CT. Tumor genotyping reported KRAS G12D; MSI stable and tumor mutational burden low. He was treated with FOLFOX plus bevacizumab as first-line systemic therapy. Interval imaging after three cycles shows enlarging hepatic lesions consistent with progression of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma. Biopsy of skin lesion confirmed melanoma and molecular testing identified BRAF V600E. Staging PET/CT showed pulmonary nodules and a single cerebellar metastasis; overall stage IV disease. He was started on combination targeted therapy with dabrafenib and trametinib and underwent stereotactic radiosurgery to the cerebellar lesion. On follow-up imaging the chest lesions have decreased in size (partial response) but MRI brain shows enlargement of the treated cerebellar lesion and a new small lesion \u2014 clinical assessment: mixed response with intracranial progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "mixed response (extracranial partial response, intracranial progression)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/oncology correspondence: 58-year-old with cutaneous melanoma of the right thigh, sentinel node positive. Staged as IIIC. BRAF V600E mutation identified on molecular panel. Patient initiated adjuvant dabrafenib plus trametinib but surveillance imaging at 6 months showed new palpable inguinal nodes and PET-avid lymphadenopathy \u2014 interval progression; plan to change therapy discussed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "regional lymph nodes (inguinal)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 58-year-old male with metastatic colorectal adenocarcinoma. NGS returned KRAS G12D mutation. Imaging demonstrates multiple hepatic lesions consistent with metastases. He was started on FOLFOX first-line; repeat CT at 3 months shows new liver lesions and rising tumor markers consistent with progression, and he was switched to FOLFIRI plus bevacizumab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (first-line); switched to FOLFIRI + bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing identified BRAF V600E and the tumor was MSI-H with high tumor mutational burden on sequencing. Patient progressed on first-line FOLFOX and bevacizumab and was started on pembrolizumab monotherapy per tumor board given MSI-H status. Restaging scans after 3 months showed stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (after FOLFOX + bevacizumab)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "40-year-old man with metastatic cutaneous melanoma. Primary excision previously; now presents with new symptomatic cerebellar metastasis and scattered pulmonary nodules. Tumor sequencing shows BRAF V600E. PD-L1 by IHC was 5%. He was started on combination targeted therapy with dabrafenib and trametinib and underwent stereotactic radiosurgery to the cerebellar lesion. Interval PET/CT and brain MRI demonstrate notable decrease in extracranial tumor burden with residual treated intracranial lesion \u2014 overall assessment: partial response to systemic therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with a 2.5 cm right upper lobe lung mass. Biopsy consistent with lung adenocarcinoma, EGFR exon 21 L858R detected on NGS. PD-L1 tumor proportion score 5%. She underwent right upper lobectomy with mediastinal lymph node sampling; final path pT1bN0 (stage I). Started adjuvant osimertinib 80 mg daily. Post-op CT at 6 months shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "I", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "right upper lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with cutaneous melanoma. BRAF V600E detected by PCR. Baseline CT shows a solitary 2.5 cm adrenal metastasis; no other visceral disease identified. He was started on dabrafenib plus trametinib. Early restaging CT demonstrates shrinkage of the adrenal lesion but two new subcentimeter pulmonary nodules; overall described as a mixed response. PD-L1 in tumor cells was 10%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 TPS 10%", "treatment": "dabrafenib, trametinib", "response": "mixed response", "metastasis_site": "adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced, HER2-positive invasive ductal carcinoma of the breast (clinical stage IIIB). Core biopsy: HER2 3+ by IHC with FISH-confirmed amplification; ER and PR negative. Tumor sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles with excellent clinical response and underwent modified radical mastectomy. Surgical pathology reported a pathologic complete response. No evidence of distant disease on staging CT.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab; surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a history of sigmoid colon adenocarcinoma presented with increasing abdominal girth. CT abdomen/pelvis demonstrates diffuse peritoneal carcinomatosis. Tumor sequencing shows KRAS G12D; microsatellite testing reported MSS. The patient was previously treated with FOLFOX plus bevacizumab; most recent scans show enlarging peritoneal implants and clinical progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man underwent radical prostatectomy for Gleason 4+4 prostate adenocarcinoma, pathologic stage pT2N0 (stage II). Postoperative PSA became undetectable. Due to adverse features he received adjuvant external beam radiation and short-term androgen deprivation with leuprolide. No metastatic disease identified on imaging; somatic and germline sequencing were not performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant radiation; short-term androgen deprivation (leuprolide)", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic pancreatic ductal adenocarcinoma, stage IV with multiple liver metastases. Germline BRCA2 mutation identified on testing. He received 6 cycles of FOLFIRINOX with partial radiographic response and was transitioned to maintenance olaparib with ongoing stable disease at 4-month follow-up.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with invasive ductal carcinoma of the left breast, clinical stage II (T2N1M0). Biopsy shows ER+, PR+, HER2 amplification by FISH and a PIK3CA H1047R mutation on NGS. She received neoadjuvant chemotherapy with docetaxel, carboplatin and trastuzumab with good nodal downstaging and a radiologic partial response prior to surgery; axillary lymph nodes were initially involved. Planning for lumpectomy and completion of adjuvant HER2-directed therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with metastatic cutaneous melanoma. Initial tumor testing showed BRAF V600E mutation. He was started on dabrafenib and trametinib with a good partial response, but developed new symptomatic brain metastases after 10 months and was transitioned to nivolumab. Recent imaging and clinical exam indicate progressive disease in the CNS.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib followed by nivolumab", "response": "progression after initial partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male diagnosed with stage IV colon adenocarcinoma with multiple hepatic lesions on CT. Tumor panel shows KRAS G12D mutation. He was treated with FOLFOX plus bevacizumab; CT after six cycles shows a reduction in size of the liver mets consistent with a partial response. MSI status not reported in the chart.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and follow-up summary: 62-year-old male underwent right hemicolectomy for colon adenocarcinoma. Final pathology pT3N1 (3/18 nodes positive) \u2014 stage III. Molecular testing showed KRAS G12D mutation. Patient completed 12 cycles of adjuvant FOLFOX without complication. Surveillance CT at 12 months demonstrates no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic lung adenocarcinoma (diagnosed 2019). Molecular testing returned EGFR L858R and T790M positive. PD-L1 TPS 10%. He received first-line erlotinib with initial benefit but developed intracranial and osseous progression and was switched to osimertinib 80 mg PO daily. CT and MRI at 3 months show decrease in size of pulmonary nodules and shrinkage of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old male with metastatic cutaneous melanoma diagnosed last year. NGS positive for BRAF V600E. PD-L1 was low at ~5% by IHC. Patient developed multiple pulmonary nodules on surveillance CT consistent with lung metastases. He was started on targeted therapy with dabrafenib plus trametinib and has achieved a radiographic partial response with decreased size and number of pulmonary lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive, presented with pulmonary nodules on staging CT. Initial treatment was pembrolizumab monotherapy but after 3 cycles there was clinical and radiographic progression; switched to dabrafenib plus trametinib with prompt clinical improvement and reduction of lung nodules noted on CT (partial response). PD-L1 status was not reported in the chart.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (after pembrolizumab)", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male underwent right hemicolectomy for colon adenocarcinoma: pathology pT3N1 (stage III). Molecular testing identified KRAS G12D by PCR. MSI testing returned MSI-stable. Patient started adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin) and is on surveillance with no evidence of disease on most recent CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX (oxaliplatin + 5-FU)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female referred to thoracic oncology for progressive dyspnea. Biopsy confirmed lung adenocarcinoma. NGS revealed EGFR L858R mutation; PD-L1 TPS 5%. Staging scans consistent with stage IV disease with brain and bony metastases; new liver lesion noted on follow-up. She was started on osimertinib 80 mg daily with an initial partial response of pulmonary and osseous disease but developed hepatic progression after 11 months. Stereotactic radiosurgery was performed to the dominant brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "initial partial response, subsequent progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colon adenocarcinoma referred for systemic therapy. CT abdomen shows multiple hepatic metastases. Tumor profiling demonstrates BRAF V600E mutation and MSI-H. He was started on FOLFOX plus bevacizumab with tumor shrinkage and subsequently switched to pembrolizumab for durable disease control. Most recent scans show decreased size of several liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer with new bilateral pulmonary nodules on chest CT consistent with metastatic spread to the lungs. He previously progressed on docetaxel and abiraterone. Germline testing identified a pathogenic BRCA2 mutation; patient was started on olaparib. PSA has been stable since initiation. (Stage not restated in current note.)", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": null, "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "olaparib (after docetaxel and abiraterone)", "response": "stable disease (PSA stable)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology and oncology follow-up: 34-year-old with cutaneous melanoma of the right forearm, pT3bN2a (stage III). Molecular testing positive for BRAF V600E. Patient underwent wide local excision and sentinel node dissection and was started on adjuvant dabrafenib and trametinib. Surveillance CT at 12 months shows no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision and sentinel node dissection; adjuvant dabrafenib and trametinib", "response": "no evidence of disease (complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old female presented with a 2.3 cm left breast mass. Core biopsy showed invasive ductal carcinoma, ER+/PR+, HER2 IHC 0. CT chest/abdomen negative for metastatic disease. Underwent lumpectomy with sentinel node biopsy; pathology pT2N0 (stage IIA). Oncotype recurrence score low. Adjuvant endocrine therapy with tamoxifen was recommended. Patient is currently NED at 6-month follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 IHC 0", "treatment": "lumpectomy with sentinel node biopsy; adjuvant tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Tumor sequencing returned BRAF V600E and the tumor was MSI-H. He was started on FOLFOX plus bevacizumab and received two cycles; interval imaging shows enlarging liver metastases and new satellite lesions consistent with progression of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed metastatic lung adenocarcinoma. Molecular testing returned EGFR exon 21 L858R mutation. PD-L1 tumor proportion score approximately 5%. Patient started osimertinib 80 mg daily; first CT at 8 weeks showed decrease in size of pulmonary and osseous lesions consistent with a partial response. MRI brain demonstrates small enhancing lesions that have also regressed on therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma. Molecular testing returned BRAF V600E positive. Staging at progression was stage IV with multiple pulmonary nodules on chest CT. He was started on dabrafenib plus trametinib and achieved an initial partial response for approximately 6 months before radiographic progression in the lungs was documented. PD-L1 testing not reported.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 59-year-old male with metastatic pancreatic ductal adenocarcinoma diagnosed after presenting with jaundice. Imaging shows multiple liver metastases consistent with stage IV disease. Germline testing positive for a pathogenic BRCA2 variant. Baseline CA19-9 markedly elevated. He received 8 cycles of FOLFIRINOX with initial radiographic stability, then progression of hepatic lesions; switched to gemcitabine and nab-paclitaxel briefly, then started on olaparib maintenance given BRCA2 and prior platinum response. Most recent imaging demonstrates stable disease on olaparib.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (pathogenic germline)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel; olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with resected colon adenocarcinoma, pathology pT3N1 (stage III). Molecular testing: KRAS G12D identified; tumor is microsatellite stable (MSS). Completed 12 cycles of adjuvant FOLFOX with good tolerance. Surveillance CT at 12 months post-chemo shows no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma presenting with diffuse bone pain. PSA at presentation was 34 ng/mL. Targeted somatic panel did not identify actionable mutations. He was treated with enzalutamide and received palliative radiotherapy to the pelvis. At 4-month follow-up PSA has stabilized and bone scans show no interval progression (stable disease).", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 34 ng/mL", "treatment": "enzalutamide, palliative radiation", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Current stage IV CRC. NGS reported KRAS G12C mutation; MSI testing was microsatellite stable. He was started on FOLFOX plus bevacizumab as first-line systemic therapy. Interval CT after three cycles demonstrated no new lesions and overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with ER+/PR+ invasive ductal carcinoma of the left breast, clinical stage IIA (cT2N0M0) on imaging. Core biopsy showed HER2 amplification by FISH and a PIK3CA H1047R mutation on targeted panel. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab, then underwent lumpectomy and sentinel node biopsy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+/PR+", "treatment": "paclitaxel, trastuzumab, lumpectomy (surgery)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man with pancreatic ductal adenocarcinoma and peritoneal implants consistent with metastatic disease. He received FOLFIRINOX followed by consolidation chemoradiation. No molecular testing was performed and no biomarker results are available. Interval CT after treatment shows stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX and chemoradiation", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man presented with right-sided abdominal pain; CT shows multiple hepatic lesions. Colonoscopy confirmed adenocarcinoma of the sigmoid colon. Tumor testing: MSI-H and KRAS G12D mutation. Given metastatic disease to the liver (stage IV), he was started on pembrolizumab monotherapy. After 4 cycles there is marked reduction in size of liver metastases on repeat CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with lung adenocarcinoma, clinical stage IV with known brain and bone metastases. Broad-panel NGS detected EGFR L858R. PD-L1 TPS reported at 10%. She was started on combination first-line therapy with carboplatin and pemetrexed plus pembrolizumab. Interim CT at 8 weeks documented a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "carboplatin and pemetrexed with pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy note: 45-year-old female with locally advanced breast cancer, clinical stage IIIC. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 3+ by IHC (confirmed HER2 amplification on FISH). Foundation testing identified a PIK3CA E545K mutation. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles followed by mastectomy and post-op radiation. Surgical specimen demonstrated a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIC", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 3+ (IHC), HER2 amplification, ER negative, PR negative", "treatment": "trastuzumab and pertuzumab with docetaxel; surgery and radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with widely metastatic cutaneous melanoma. Initial staging demonstrated multiple liver lesions and several brain metastases consistent with stage IV disease. Tumor testing positive for BRAF V600E mutation; PD-L1 expression ~5%. He was started on pembrolizumab with an initial mixed response but subsequently developed intracranial progression and was transitioned to dabrafenib plus trametinib. Most recent MRI shows progressive intracranial disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with high-grade serous ovarian carcinoma, stage IIIC with peritoneal carcinomatosis. Germline BRCA1 deleterious mutation identified and HRD-positive status reported. CA-125 was elevated at diagnosis. She underwent optimal cytoreductive debulking followed by combination carboplatin and paclitaxel with good clinical response and then was transitioned to maintenance therapy with olaparib plus bevacizumab. Best overall response documented as partial response on RECIST.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive; CA-125 elevated", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib + bevacizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy: invasive ductal carcinoma of the breast, ER positive, PR negative. HER2 amplification confirmed by FISH. NGS reported PIK3CA H1047R. Clinical staging was IIIB. The patient received neoadjuvant dose-dense doxorubicin and cyclophosphamide (AC) followed by docetaxel with dual anti-HER2 therapy (trastuzumab and pertuzumab). She underwent mastectomy with pathologic complete response and will start adjuvant letrozole.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "neoadjuvant AC (doxorubicin + cyclophosphamide) then docetaxel + trastuzumab and pertuzumab; adjuvant letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female underwent right upper lobectomy for a Stage IB lung adenocarcinoma. Molecular testing identified an EGFR exon 19 deletion. She was started on adjuvant osimertinib 80 mg daily. Three-month CT chest showed no evidence of disease. PD-L1 testing was not performed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IB", "gene_mutation": "EGFR exon 19 deletion", "biomarker": null, "treatment": "right upper lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old woman with high-grade serous ovarian carcinoma, stage IIIC. Germline testing identified a deleterious BRCA1 frameshift mutation (BRCA1 5382insC) and tumor showed homologous recombination deficiency. She underwent optimal debulking followed by adjuvant carboplatin and paclitaxel and was started on maintenance olaparib. CA-125 normalized and CT at 9 months shows no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 5382insC (germline)", "biomarker": "HRD positive", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "no evidence of disease (complete response at 9 months)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with metastatic cutaneous melanoma presented with multiple hepatic and intracranial lesions. Tumor sequencing demonstrated BRAF V600E and a high tumor mutational burden. He started combination targeted therapy with dabrafenib plus trametinib. After three months of treatment the PET/CT shows resolution of most FDG-avid lesions and clinical exam is clear \u2014 documented complete response on imaging.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib; trametinib", "response": "complete response", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with biopsy-proven lung adenocarcinoma. Staging PET/CT and brain MRI demonstrate stage IV disease with multiple osseous lesions and a 1.5 cm cerebellar metastasis. NGS returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and tolerated therapy well. First restaging CT at 8 weeks shows a marked decrease in pulmonary nodules and improvement of bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male presented with weight loss and abdominal pain. Imaging showed a pancreatic head mass with multiple liver lesions; diagnosed with pancreatic ductal adenocarcinoma, stage IV. Germline testing identified a pathogenic BRCA2 variant. Baseline CA19-9 was 1,200 U/mL. He received modified FOLFIRINOX with initial disease control and was transitioned to maintenance olaparib, but recent CT demonstrates progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "CA19-9 1200 U/mL", "treatment": "modified FOLFIRINOX then maintenance olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left invasive ductal carcinoma, clinical stage IIIB with fixed axillary nodes. Tumor is ER/PR negative and HER2-amplified by FISH. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with excellent clinical downsizing and then underwent left modified radical mastectomy. Final pathology showed no residual invasive carcinoma in breast or nodes \u2014 pathologic complete response (pCR). No targeted genomic sequencing was performed.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with metastatic lung adenocarcinoma. Core biopsy of the right upper lobe was positive for EGFR L858R. PD-L1 tumor proportion score reported as 10%. MRI brain demonstrated multiple enhancing lesions consistent with metastases. Staged as IV. She was started on osimertinib and underwent stereotactic radiosurgery to the dominant cerebellar lesion. First restaging CT shows reduction in size of pulmonary nodules and decreased enhancement of the brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib and stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma, stage IV. Molecular testing identified an EGFR L858R activating mutation. Baseline PD-L1 tumor proportion score was 10%. He was started on osimertinib 80 mg daily and had dramatic radiographic shrinkage of the chest lesion and liver nodules at first restaging (partial response). At 4 months MRI showed progression in the brain with two new metastases for which stereotactic radiosurgery was delivered.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "initial partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old male with sigmoid colon adenocarcinoma, underwent right hemicolectomy \u2014 pathology pT3N1, consistent with stage III disease. Molecular testing returned KRAS G12D; MSI testing was microsatellite stable. Adjuvant FOLFOX was completed for 6 months and surveillance CTs have shown no evidence of disease at 18 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "adjuvant FOLFOX (oxaliplatin + 5-FU/leucovorin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old male with a 1.2 mm superficial spreading cutaneous melanoma of the left forearm. Sentinel lymph node biopsy was negative. AJCC stage I. Underwent wide local excision with clear margins; no adjuvant systemic therapy recommended. Patient remains without recurrence on dermatology follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old F with high-grade invasive ductal carcinoma of the right breast, clinically T2N2, stage IIIA. Biopsy: ER+, PR+, HER2 amplified by FISH. Next-generation sequencing identified PIK3CA H1047R. She received neoadjuvant docetaxel/carboplatin with trastuzumab and pertuzumab (TCHP) for six cycles followed by breast-conserving surgery. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response). No distant disease on staging; plan for adjuvant HER2-directed therapy.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with lung adenocarcinoma presenting with cough and headache. Biopsy confirmed adenocarcinoma; molecular testing identified EGFR L858R. At progression a MET amplification was detected on repeat NGS. PD-L1 TPS 1%. Imaging demonstrates brain and bone metastases. He began combined targeted therapy with osimertinib plus the MET inhibitor savolitinib on a clinical protocol; prior whole-brain radiotherapy was completed for symptomatic brain metastases. Current scans show disease control without significant shrinkage.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R and MET amplification", "biomarker": "PD-L1 1%", "treatment": "Osimertinib + savolitinib (combined EGFR and MET targeted therapy); prior whole-brain radiotherapy", "response": "stable disease", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer (clinical T4bN1). ER negative, PR negative; HER2 amplified by IHC 3+ and confirmed by FISH. Clinical stage IIIB. She received neoadjuvant chemotherapy with docetaxel and carboplatin in combination with trastuzumab and proceeded to mastectomy. Surgical pathology reports a pathologic complete response (no residual invasive carcinoma). No mutational panel was performed pre-treatment.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel and carboplatin plus trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with cutaneous melanoma metastatic to the lung. Tumor testing positive for BRAF V600E. PD-L1 by IHC was 5%. He received pembrolizumab initially and achieved stable disease; on progression he was transitioned to dabrafenib plus trametinib with subsequent reduction in pulmonary nodules consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab; dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic colorectal adenocarcinoma diagnosed 2019 with bulky hepatic metastases. Tumor profiling demonstrated KRAS G12D and MSI-H. After progression on prior FOLFOX, the patient was started on pembrolizumab given MSI-high status. Interval liver MRI at 12 weeks showed no new lesions and minimal change in size of dominant lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab; prior FOLFOX", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma. Biopsy positive for BRAF V600E mutation. Staging PET/CT demonstrates multiple bilateral pulmonary nodules consistent with lung metastases; no CNS involvement. He was started on combination targeted therapy with dabrafenib and trametinib. Interval CT at 12 weeks shows marked reduction in size and number of pulmonary nodules consistent with a deep partial response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Core biopsy demonstrated an EGFR exon 19 deletion; PD-L1 by IHC was 5%. Staged IV with brain and osseous metastases on baseline MRI and bone scan. Patient was started on osimertinib 80 mg daily as first-line targeted therapy with good intracranial activity; most recent CT chest/brain shows decrease in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with headaches. MRI demonstrated multiple enhancing lesions consistent with brain metastases. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. Staging workup consistent with stage IV disease. Patient started first-line osimertinib 80 mg daily with clinical improvement and RECIST assessment showing partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with newly diagnosed glioblastoma, WHO grade IV, underwent maximal safe resection. Tumor shows MGMT promoter methylation on PCR. He received concurrent radiotherapy with temozolomide followed by adjuvant temozolomide. Surveillance MRI at 9 months showed interval enlargement of the resection cavity suspicious for progression and patient was referred to neuro-oncology for second-line options.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "radiotherapy with concurrent temozolomide followed by adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man status post right hemicolectomy for adenocarcinoma of the colon. Path report: pT3 N1a (Stage III) with lymphovascular invasion. RAS testing shows KRAS G12D; BRAF wild-type. MSI testing reveals MSI-stable. Oncology recommended adjuvant FOLFOX for 6 months; bevacizumab was discussed but not initiated. At first post-op CT there is no radiologic evidence of distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "stable disease (no radiologic evidence of distant disease post-op)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left breast invasive ductal carcinoma, cT2N1 (clinical stage II). Core biopsy: ER positive, PR positive, HER2 amplification by FISH. Next-generation sequencing detected PIK3CA E545K. She received neoadjuvant carboplatin and paclitaxel with trastuzumab for four cycles and then underwent lumpectomy with sentinel node sampling. Final pathology showed no residual invasive tumor in the breast or nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin and paclitaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic gastric adenocarcinoma (stage IV). Tumor was HER2 amplified by IHC/FISH. He received first-line capecitabine and oxaliplatin in combination with trastuzumab. After 4 cycles the patient developed worsening pain and CT shows interval progression with new hepatic metastases.", "output": {"cancer_type": "gastric adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "capecitabine and oxaliplatin with trastuzumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male presented with a right frontal glioblastoma, underwent gross total resection in March. Pathology confirmed glioblastoma (WHO grade IV). Molecular workup: IDH1 R132H mutation detected; MGMT promoter methylation was positive. He received standard concurrent radiotherapy with temozolomide followed by adjuvant temozolomide. At 7 months MRI demonstrated a new enhancing lesion with leptomeningeal spread and clinical decline; therapy was changed to bevacizumab for symptomatic control.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylated", "treatment": "surgery; radiotherapy with concurrent temozolomide; bevacizumab", "response": "progression", "metastasis_site": "leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with high-grade serous ovarian carcinoma, optimal cytoreductive surgery performed; pathologic stage IIIC with bulky peritoneal disease. Germline testing revealed a deleterious BRCA1 mutation; tumor reported HRD-positive. She completed six cycles of carboplatin and paclitaxel with complete clinical response and then was started on maintenance olaparib combined with bevacizumab. She remained in remission for 18 months but then developed radiographic recurrence with peritoneal carcinomatosis.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HRD-positive", "treatment": "debulking surgery then carboplatin + paclitaxel x6; maintenance olaparib + bevacizumab", "response": "initial complete response, recurrence/progression at 18 months", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT abdomen showed multiple hepatic lesions consistent with metastases (stage IV). Tumor genotyping: KRAS G12D. MSI testing returned MSI-H and tumor mutational burden reported as high (25 muts/Mb). He was initiated on FOLFOX with bevacizumab; however restaging after four cycles demonstrated interval growth of liver lesions consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (25 muts/Mb)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing of the biopsy identified EGFR L858R. PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg PO daily in July 2024. First restaging CT and brain MRI show decreased pulmonary nodules and reduction of a cerebellar lesion consistent with a partial response; new focal uptake in the L3 vertebral body was suspicious for osseous involvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 68-year-old man with metastatic colorectal adenocarcinoma, KRAS G12D positive on NGS. Tumor is microsatellite stable (MSS). Baseline CT: multiple liver metastases consistent with stage IV disease. He was treated with 6 cycles of FOLFOX plus bevacizumab; interval imaging demonstrates progression in the liver with enlarging dominant lesion.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Ovarian cancer summary: 55-year-old woman with high-grade serous ovarian carcinoma, FIGO IIIC at presentation with bulky peritoneal disease. Germline testing returned positive for a pathogenic BRCA1 mutation. She underwent optimal cytoreductive surgery followed by 6 cycles of carboplatin and paclitaxel with radiographic partial response of peritoneal implants. Patient was placed on olaparib maintenance therapy. CA-125 has fallen but not normalized.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": null, "treatment": "surgery, carboplatin and paclitaxel, olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male underwent a left hemicolectomy for a sigmoid mass. Pathology: moderately differentiated adenocarcinoma, pT3N1 (2/15 nodes) consistent with stage IIIB colon cancer. Post-op CEA was 12 ng/mL. The tumor was MSS on IHC; extended RAS testing was not performed prior to starting adjuvant therapy. He completed 6 months of adjuvant FOLFOX with expected toxicity and is currently under surveillance with CT chest/abdomen and serial CEA measurements showing normalization.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "CEA 12 ng/mL (post-op); MSS", "treatment": "left hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with a nodular melanoma of the right forearm. Wide local excision and sentinel lymph node biopsy were performed; sentinel node positive. Molecular testing identified BRAF V600E. Completion lymphadenectomy performed; patient started adjuvant therapy with dabrafenib plus trametinib. Restaging CT and PET at 12 months show no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma (nodular)", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "no evidence of disease (complete response)", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man underwent right upper lobectomy for a 2.5 cm lung adenocarcinoma. Pathology staged it as IB (T2aN0M0). NGS returned EGFR L858R positive. PD-L1 was not reported. He was started on adjuvant osimertinib 80 mg daily. Three-month CT shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IB", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "right upper lobectomy followed by adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old woman presented with a 3 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical staging consistent with IIB (T2N1). Tumor sequencing revealed a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab; currently doing well with no evidence of disease at 18-month follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic cutaneous melanoma of the back. Baseline staging showed multiple pulmonary nodules consistent with stage IV disease. Tumor sequencing identified BRAF V600E. He was initially treated with pembrolizumab every 3 weeks but had radiographic progression after 4 cycles with enlarging lung lesions. Therapy was switched to dabrafenib plus trametinib with symptomatic improvement and a RECIST partial response on CT at 8 weeks. PD-L1 IHC was 1%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "pembrolizumab; then dabrafenib + trametinib", "response": "progression on pembrolizumab; partial response to dabrafenib+trametinib", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with newly diagnosed invasive ductal carcinoma of the right breast. Pathology: ER positive, PR positive, HER2 negative; PIK3CA E545K on NGS. Clinical stage T2N1 (stage IIA). She underwent lumpectomy with sentinel node biopsy (1/3 nodes positive) followed by adjuvant dose-dense AC x4 then paclitaxel x12, whole-breast radiation, and was started on letrozole. Currently NED on first surveillance scan at 6 months.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, sentinel node biopsy, adjuvant doxorubicin + cyclophosphamide then paclitaxel, whole-breast radiation, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 48-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 variant. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel and was discharged on maintenance olaparib. Preoperative CT showed peritoneal implants and bulky pelvic lymphadenopathy. CT at 3-month follow-up shows no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline pathogenic variant)", "biomarker": "BRCA1 pathogenic variant", "treatment": "carboplatin and paclitaxel; olaparib (maintenance)", "response": "complete response", "metastasis_site": "peritoneum, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 49-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB (T4bN1). Core biopsy: HER2 amplification by FISH, ER/PR negative; tumor genotyping detected PIK3CA H1047R. She completed 6 cycles of neoadjuvant paclitaxel with trastuzumab and pertuzumab and underwent mastectomy. Pathology showed no residual invasive carcinoma \u2014 complete pathological response. No distant mets identified on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with locally advanced pancreatic ductal adenocarcinoma not amenable to resection (stage III). Multidisciplinary tumor board recommended definitive chemoradiation. He completed concurrent gemcitabine with radiation then transitioned to systemic gemcitabine/nab-paclitaxel for disease control. Serial CT scans showed no interval progression with best overall assessment of stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "concurrent gemcitabine and radiation; gemcitabine and nab-paclitaxel", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic melanoma, BRAF V600E positive. Treated with dabrafenib plus trametinib with an initial partial response; however restaging at 8 months demonstrated progression in the liver and new pulmonary nodules. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression after initial partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient had excision of a pigmented lesion on the left forearm. Pathology: superficial spreading melanoma, 0.8 mm Breslow depth, stage I (T1b). Sentinel node biopsy negative. BRAF testing was not performed per dermatologist. Underwent wide local excision with clear margins and is on dermatologic surveillance. Exam today: no suspicious nodes, no evidence of disease.", "output": {"cancer_type": "melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old man with metastatic pancreatic ductal adenocarcinoma. Staging at diagnosis was IV with multiple hepatic lesions. Germline and somatic testing identified a pathogenic BRCA2 mutation. He received FOLFIRINOX for six cycles with initial symptomatic improvement, but follow-up imaging documented growth of several liver metastases consistent with progressive disease. Consideration for PARP inhibitor maintenance pending.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with unresectable stage IV cutaneous melanoma found to be BRAF V600E positive on NGS. Baseline workup showed small asymptomatic brain metastases. He was started on combination targeted therapy with dabrafenib and trametinib. Follow-up MRI and PET/CT at 6 months show complete metabolic and radiographic resolution of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female diagnosed with metastatic lung adenocarcinoma (stage IV) in January 2024. Molecular testing revealed EGFR L858R mutation and PD-L1 tumor proportion score of 10%. She was started on osimertinib 80 mg PO daily. Follow-up CT chest and brain MRI demonstrate a partial response in the cerebral metastases and shrinkage of pulmonary nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma, BRAF V600E positive on PCR. Baseline PD-L1 was 5%. He received first-line dabrafenib plus trametinib with objective shrinkage of the index scalp lesion and decrease in size of multiple cerebellar metastases; current assessment is ongoing partial response. Plans discussed to consider immunotherapy (nivolumab/ipilimumab) at progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain (cerebellar metastases)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with newly diagnosed lung adenocarcinoma. Biopsy confirmed EGFR exon 19 deletion; PD-L1 tumor proportion score <1%. Staging PET/CT shows multiple cerebral lesions and lytic lesions in the thoracic spine consistent with metastatic disease \u2014 overall stage IV. Patient started osimertinib 80 mg daily; after 3 months repeat imaging demonstrates decrease in size of brain mets and regression of spinal lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with locally advanced pancreatic ductal adenocarcinoma with encasement of the SMA (clinical stage III). Molecular profiling identified KRAS G12D and a concurrent TP53 mutation. CA19-9 at diagnosis was 1200 U/mL. He received six cycles of FOLFIRINOX with an initial decline in CA19-9 but interval CT showed growth of the primary mass, so therapy was changed to gemcitabine plus nab-paclitaxel. Most recent scans show stable disease on the second-line regimen.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D; TP53 mutation", "biomarker": "CA19-9 1200 U/mL", "treatment": "FOLFIRINOX followed by gemcitabine and nab-paclitaxel", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed after biopsy of a right upper lobe mass. Molecular testing returned EGFR L858R. PD-L1 TPS reported at 10%. Staged as IV with brain metastases on MRI. Started first-line osimertinib 80 mg daily; 8-week restaging CT/MRI demonstrates decrease in size of pulmonary lesions and shrinkage of brain mets consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging scans show multiple bilateral pulmonary nodules and enhancing lesions in the cerebellum and lumbar spine consistent with metastatic disease; overall TNM consistent with stage IV. Molecular testing returned EGFR exon 19 deletion. PD-L1 tumor proportion score 30%. Patient was started on osimertinib 80 mg daily with stereotactic radiosurgery to the brain mets. On first restaging CT at 8 weeks there is a marked decrease in size of pulmonary nodules and reduction in cerebellar lesion \u2014 assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 30%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone (lumbar spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: High\u2011grade prostate adenocarcinoma, Gleason 5+4=9. Patient presented with bone pain and imaging confirmed osseous metastases. Considered castrate-resistant after surgical orchiectomy; no actionable genomic alterations identified on targeted NGS panel. Management includes androgen deprivation with leuprolide and systemic abiraterone plus prednisone; palliative external beam radiation to left femur. PSA has declined and disease is currently stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and abiraterone (plus prednisone); palliative radiation", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62 y/o F with newly diagnosed metastatic lung adenocarcinoma. Biopsy revealed EGFR exon 21 L858R mutation and PD-L1 TPS 5%. Staging CT/PET shows multiple cerebral and vertebral lesions consistent with metastases (brain, bone). Patient was started on osimertinib 80 mg PO daily in July; first restaging CT at 8 weeks demonstrates a partial response with decrease in target lesion burden.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man with clinically localized prostate cancer (PSA 8.6, Gleason 3+4) cT2. He underwent radical prostatectomy followed by adjuvant external beam radiation for adverse pathology. No tumor genomic testing was performed. On surveillance his PSA is undetectable.", "output": {"cancer_type": "prostate cancer", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with metastatic invasive ductal breast carcinoma, ER positive, PR positive and HER2 amplification on FISH. Liver biopsy confirmed metastatic disease; NGS returned PIK3CA H1047R. Clinical stage recorded as stage IV. She received first-line therapy with trastuzumab, pertuzumab and paclitaxel with radiologic reduction of hepatic lesions; currently maintained on trastuzumab and pertuzumab with ongoing partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab, paclitaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with right-sided colon adenocarcinoma presenting with multiple hepatic metastases. Tumor profiling shows BRAF V600E and high microsatellite instability (MSI-H). He was started on FOLFOX with bevacizumab but developed radiographic progression after three cycles and clinical deterioration.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman with metastatic lung adenocarcinoma diagnosed on core biopsy. Initial molecular testing showed EGFR exon 19 deletion; on progression a repeat plasma assay detected EGFR T790M. PD-L1 TPS 10%. She presented with headaches and back pain; MRI demonstrates multiple brain metastases and lytic lesions in the thoracic spine. Started osimertinib after whole-brain radiation with symptomatic improvement and decreased CNS lesions on first follow-up CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiation", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: patient with metastatic cutaneous melanoma, biopsy-positive for BRAF V600E. Started targeted therapy with dabrafenib and trametinib. Follow-up chest CT shows reduction in bilateral pulmonary nodules. Stage not documented in referral letter.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with metastatic lung adenocarcinoma diagnosed March 2023. Tumor genotyping identified EGFR L858R. PD-L1 by IHC was 10%. She was started on osimertinib 80 mg daily in April and tolerated therapy well. Interval imaging after 8 weeks demonstrated reduction in size of the primary lesion and intracranial lesions with decreased pain \u2014 overall assessment: partial response. Known sites of disease include brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic colorectal carcinoma presenting with multiple liver lesions. Molecular profiling reported MSI-H and a high tumor mutational burden (TMB-high). No actionable RAS/RAF alterations were identified. He was started on pembrolizumab monotherapy; CT at 12 weeks shows stable disease.", "output": {"cancer_type": "colorectal carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: Invasive ductal carcinoma of the right breast, ER positive, PR negative, HER2 amplified by FISH. Clinical stage at presentation: IIIC (fixed axillary disease with skin tethering). Preoperative regimen consisted of docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles. PIK3CA E545K identified on NGS. Patient underwent mastectomy with axillary dissection; surgical specimen showed no residual invasive carcinoma \u2014 pathologic complete response. Adjuvant radiation delivered to chest wall.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab; surgery; radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Tissue NGS identified EGFR L858R mutation; PD-L1 tumor proportion score 20%. Patient started osimertinib 80 mg daily as first-line targeted therapy. After 14 months she developed symptomatic intracranial lesions and received stereotactic radiosurgery to two brain metastases; systemic osimertinib was continued. Most recent CT/MRI shows decrease in size of pulmonary lesions and intracranial deposits consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma with multiple liver lesions on CT. Tumor profiling demonstrated a KRAS G12D mutation. He completed 8 cycles of FOLFOX plus bevacizumab and follow-up imaging showed stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old male with metastatic cutaneous melanoma, presenting with symptomatic brain and pulmonary metastases. Molecular testing positive for BRAF V600E; PD-L1 by IHC reported at 10%. Started on targeted combination therapy with dabrafenib plus trametinib. Follow-up MRI and CT show a partial response intracranially and reduction in lung nodules.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R with an acquired T790M resistance mutation. PD-L1 by IHC 20%. He was started on erlotinib, progressed after 10 months and was switched to osimertinib with good intracranial response. On further progression he received pembrolizumab in combination with carboplatin and pemetrexed. CT after 3 cycles demonstrated a partial response in the lungs and decreased size of brain lesions. Stage IV disease with known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, EGFR T790M", "biomarker": "PD-L1 20%", "treatment": "erlotinib; osimertinib; pembrolizumab + carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left-sided invasive ductal breast carcinoma, ER+/PR+, HER2 3+ by IHC and confirmed HER2 amplification by FISH. Clinical stage IIIB. NGS panel detected PIK3CA H1047R. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles. Imaging after four cycles showed marked tumor reduction; surgical pathology at mastectomy demonstrated residual invasive tumor (not a pCR).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "partial response (residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic right-sided colon adenocarcinoma; CT shows multiple liver lesions consistent with metastases. Tumor testing demonstrated MSI-H and elevated tumor mutational burden. BRAF V600E mutation was reported on PCR panel. He initially received FOLFOX with bevacizumab but was switched to pembrolizumab given MSI-H status. On pembrolizumab the disease has been radiographically stable for 6 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 63-year-old female with newly diagnosed lung adenocarcinoma. PET/CT demonstrates multiple pulmonary nodules and enhancing cerebellar lesion. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 TPS 10%. Stage IV at diagnosis. Started first-line osimertinib 80 mg daily; interim MRI brain shows decrease in cerebellar lesion size. Clinical note documents partial response after 8 weeks of therapy and ongoing treatment. Prior smoking history 20 pack-years.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung nodules"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly progressive cough and weight loss. CT chest/brain showed a left upper lobe mass with multiple enhancing brain lesions. Biopsy confirmed lung adenocarcinoma. Molecular testing identified EGFR L858R; PD-L1 tumor proportion score ~10%. Staged as IV at diagnosis. She was started on osimertinib 80 mg daily with symptomatic improvement and interval shrinkage of both the lung primary and intracranial lesions on first restaging \u2014 assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old man with papillary thyroid carcinoma, underwent left thyroid lobectomy. Pathology reported a 2.2 cm tumor, staged as I (per AJCC age-based staging). No high-risk molecular testing was performed and no targeted markers reported. Patient is on surveillance without radioactive iodine.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "left thyroid lobectomy; active surveillance (no RAI)", "response": "no evidence of disease / surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic melanoma (stage IV) presented with symptomatic cerebellar metastasis. Molecular testing was positive for BRAF V600E. He was started on dabrafenib plus trametinib with marked tumor shrinkage on interval CT. PD-L1 testing was not performed.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Letter: Patient is a 55-year-old female with a primary cutaneous melanoma of the back. Wide local excision performed; sentinel node positive \u2014 assigned stage III (IIIB). Molecular testing identified BRAF V600E. She received adjuvant pembrolizumab but later developed pulmonary nodules consistent with metastatic melanoma and was started on dabrafenib plus trametinib with a subsequent partial radiographic response. No PD-L1 testing was documented.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III (IIIB)", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "partial response (to dabrafenib + trametinib)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. Liver biopsy confirms adenocarcinoma consistent with colonic primary. Molecular panel: KRAS G12D mutation; microsatellite stable (MSS). Staged IV with dominant hepatic metastases. Treated with FOLFOX plus bevacizumab; CT after 4 cycles shows no new lesions and minimal shrinkage of target lesions \u2014 response characterized as stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old F with metastatic lung adenocarcinoma diagnosed in 2019. Staging at presentation: Stage IV with multiple brain and axial skeleton lesions. Molecular testing revealed an EGFR exon 19 deletion. PD-L1 TPS reported as 20%. She was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and brain MRI at 8 weeks show shrinkage of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma on the upper back, subsequently developed pulmonary nodules. BRAF testing identified V600E substitution; tumor mutational burden reported as TMB-high (exome panel). Patient started targeted therapy with dabrafenib and trametinib and after two months had marked decrease in size of lung nodules with ongoing partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with locally advanced left breast invasive ductal carcinoma. Core biopsy: ER+, PR+, HER2 amplification by FISH; NGS detected a PIK3CA H1047R mutation. Clinically staged as IIIB with bulky axillary nodes and chest wall involvement but no distant metastases. She is receiving neoadjuvant weekly paclitaxel with trastuzumab and has achieved a partial radiographic response to therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "paclitaxel and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 48-year-old woman with locally advanced left breast carcinoma, ER+/PR+, HER2 amplified on FISH. Core biopsy also reported a PIK3CA H1047R hotspot mutation. She received neoadjuvant paclitaxel with trastuzumab (weekly paclitaxel x12 + trastuzumab) and underwent mastectomy. Surgical specimen showed no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant paclitaxel and trastuzumab, surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with right-sided colon cancer found to have multiple hepatic lesions on staging CT. Liver biopsy consistent with metastatic colorectal adenocarcinoma. Tumor genomics: KRAS G12D. Immunohistochemistry and PCR show MSI-H. Given MSI-H status, he was started on pembrolizumab; follow-up imaging at 12 weeks documents a partial response of the liver metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 48-year-old male with metastatic melanoma. Molecular testing identified BRAF V600E. Patient initiated dabrafenib and trametinib; experienced a brisk partial response in chest wall and pulmonary nodules at first imaging. After 6 months developed new contrast-enhancing lesions on brain MRI consistent with intracranial progression; switched to ipilimumab and nivolumab combination. PD-L1 was 5% on prior testing. Current assessment: systemic disease progressed with new brain metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later switched to ipilimumab + nivolumab", "response": "initial partial response then progression (intracranial progression)", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presented with obstructive symptoms and was found to have colon adenocarcinoma. CT scan revealed multiple hepatic metastases and peritoneal nodularity consistent with stage IV disease. Tumor sequencing identified a BRAF V600E mutation and high microsatellite instability (MSI-H). He was started on FOLFOX plus bevacizumab but after 4 months had radiographic progression in the liver. He was switched to encorafenib with cetuximab as second-line therapy and achieved a partial radiographic response on subsequent imaging.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab", "response": "progression on first-line; partial response on second-line", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male treated for primary cutaneous melanoma of the upper back. Wide local excision with negative margins was performed; final pathologic stage II (T3aN0M0). BRAF testing returned V600E positive. No adjuvant systemic therapy was given; patient on surveillance. Last dermatology note documents healing scars and no evidence of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man presented with gross hematuria. Cystoscopy found a solitary 2 cm papillary lesion; TURBT pathology: high-grade urothelial carcinoma invading lamina propria (Stage I). No molecular testing was performed. He received induction intravesical BCG after re-resection. Three-month surveillance cystoscopy shows no visible tumor.", "output": {"cancer_type": "bladder urothelial carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "TURBT; intravesical BCG", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary for a 62-year-old woman: high-grade serous ovarian carcinoma with extensive peritoneal carcinomatosis. FIGO staging consistent with IIIC. Germline testing returned positive for a pathogenic BRCA1 mutation. She completed 6 cycles of carboplatin and paclitaxel with a partial radiographic response and CA-125 normalized; currently receiving maintenance olaparib with interval reduction in peritoneal disease burden.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "CA-125 normalized", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with a 0.8 mm cutaneous melanoma (Breslow 0.8 mm) removed by wide local excision; sentinel node negative. Clinical stage I (T1b). BRAF V600E mutation detected by PCR. No adjuvant therapy recommended; patient remains NED on routine follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with newly diagnosed metastatic lung adenocarcinoma confirmed by bronchoscopic biopsy. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. MRI brain showed multiple enhancing lesions and PET demonstrated osseous involvement. Patient was started on osimertinib 80 mg daily with rapid symptomatic improvement and interval CT at 8 weeks showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 61-year-old male with metastatic colorectal adenocarcinoma presenting with progressive right upper quadrant pain. CT abdomen demonstrates multiple liver lesions consistent with metastases; stage IV. Tumor was found to be MSI-H on immunohistochemistry and confirmed by PCR. Given MSI-H status he was started on pembrolizumab monotherapy. Interval imaging after 12 weeks shows stable size of hepatic lesions, clinically stable performance status.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent diagnostic mammogram and core biopsy showing invasive ductal carcinoma. Pathology: ER positive, PR positive, HER2 amplification by ISH. Tumor measured 2.1 cm with 1 of 12 nodes positive (breast-conserving surgery performed). She completed adjuvant AC then paclitaxel with concurrent trastuzumab and is scheduled for 1 year total trastuzumab followed by tamoxifen. No evidence of disease on recent surveillance.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIA", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy, adjuvant doxorubicin/cyclophosphamide then paclitaxel, trastuzumab, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast carcinoma (cT2N2M0). Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER 90% ER-positive, PR 20% PR-positive. Tumor NGS detected PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for 6 cycles followed by surgery. Surgical pathology reported pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and pertuzumab with docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with castration-resistant prostate cancer, bone-predominant metastases. Germline and somatic testing identified a deleterious BRCA2 mutation and genomic scarring consistent with homologous recombination deficiency (HRD positive). After progression on abiraterone, he was started on olaparib with radiographic partial response and falling PSA.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "HRD positive", "treatment": "abiraterone then olaparib", "response": "radiographic partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old female with left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Tumor profiling detected PIK3CA H1047R on targeted NGS. Clinical stage IIB. She received neoadjuvant weekly paclitaxel with trastuzumab; imaging and clinical exam showed tumor shrinkage but residual disease at surgery (partial response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal breast carcinoma. ER positive, PR negative and HER2 amplified by IHC/CISH. Clinical stage IIIB. NGS identified a PIK3CA E545K mutation. Neoadjuvant regimen: trastuzumab and pertuzumab given concurrently with weekly paclitaxel. Imaging after 3 cycles demonstrates good tumor shrinkage and CA 15-3 is declining; plan is to proceed to surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "trastuzumab and pertuzumab with paclitaxel", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with unresectable nodal/in-transit cutaneous melanoma, clinical stage III. Tumor is BRAF V600E positive. Treated with oral dabrafenib combined with trametinib; on follow-up the patient has had a complete clinical response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly progressive colorectal adenocarcinoma, stage IV with liver and peritoneal implants. Molecular testing returned BRAF V600E mutation and tumor was MSI-H. He was enrolled on a combination regimen of encorafenib plus cetuximab with FOLFIRI as per tumor board recommendation. After two months on therapy the disease is assessed radiographically as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "encorafenib + cetuximab + FOLFIRI", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced squamous cell carcinoma of the oropharynx (HPV-positive) presenting with a large primary and ipsilateral pulmonary nodule consistent with metastatic spread, staged as IV. PD-L1 CPS 20 on tumor testing. No targeted molecular testing was performed and no actionable gene mutation reported. Patient underwent concurrent high-dose cisplatin and radiotherapy; plan is to escalate systemic therapy with combination immunotherapy (nivolumab plus ipilimumab) if disease progresses. Treatment is ongoing with no formal response assessment yet.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx (head and neck)", "stage": "IV", "gene_mutation": null, "biomarker": "HPV-positive; PD-L1 CPS 20", "treatment": "concurrent cisplatin + radiation; possible nivolumab + ipilimumab planned", "response": null, "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and oncology summary: 52-year-old female with metastatic invasive ductal carcinoma of the breast. ER/PR positive, HER2 amplification by FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. Patient received first-line trastuzumab with weekly paclitaxel; subsequent imaging shows stable osseous lesions and no new visceral disease \u2014 documented as stable disease. Metastatic deposits identified in the spine and segmental liver lesions on MRI/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology consult: 63-year-old male with biopsy-proven esophageal squamous cell carcinoma, T3N1 on PET/CT. He underwent definitive concurrent chemoradiation with weekly cisplatin and continuous infusion 5-FU. Post-treatment endoscopy shows marked tumor regression and no residual obstructing lesion; molecular testing was not performed.", "output": {"cancer_type": "esophageal squamous cell carcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "concurrent chemoradiation with cisplatin and 5-FU", "response": "clinical complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with sigmoid colon adenocarcinoma underwent low anterior resection. Pathology: stage III (T3N1M0). Molecular testing demonstrates KRAS G12D mutation; microsatellite stable (MSS). Completed adjuvant FOLFOX and is on surveillance with no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "low anterior resection; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR negative, HER2 amplified by FISH. PIK3CA H1047R identified on NGS. Clinical stage cT3N1 (stage IIIA). Patient received neoadjuvant dose-dense AC followed by paclitaxel with concurrent trastuzumab and had a good but incomplete clinical response; plan for lumpectomy and axillary dissection and adjuvant endocrine therapy thereafter.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "III (IIIA)", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant dose-dense doxorubicin/cyclophosphamide then paclitaxel with trastuzumab; surgery planned; endocrine therapy planned", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma. Molecular testing identified a BRAF V600E mutation and tumor mutational burden reported as high; PD-L1 by IHC was ~5%. Baseline scans showed pulmonary nodules and several cerebral metastases. He was started on combination targeted therapy with dabrafenib plus trametinib and had a documented partial response on restaging scans. Intracranial disease progressed later and the multidisciplinary team discussed adding ipilimumab/nivolumab after radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 5%", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presenting with metastatic colorectal adenocarcinoma with multiple hepatic lesions. Tumor profiling demonstrated BRAF V600E and high microsatellite instability (MSI-H). Clinical stage IV. Given MSI-H status he was started on pembrolizumab monotherapy. Follow-up CT at 12 weeks shows marked shrinkage of liver metastases consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with right invasive ductal carcinoma, clinical stage IIB. Tumor is ER positive, PR negative, HER2 amplified by FISH. NGS detected a PIK3CA H1047R somatic mutation; germline BRCA1 testing negative. She received neoadjuvant docetaxel and carboplatin in combination with trastuzumab and pertuzumab, followed by lumpectomy with sentinel node biopsy showing no residual invasive tumor (pathologic complete response).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel and carboplatin, trastuzumab and pertuzumab (neoadjuvant); surgery", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with invasive ductal carcinoma of the left breast. Tumor is ER-positive, PR-positive and HER2 negative by IHC. Tumor measured 2.2 cm; sentinel node biopsy negative and final path staged as IIA (pT2N0M0). NGS panel detected a PIK3CA mutation. Patient underwent breast-conserving surgery followed by adjuvant radiation and was started on tamoxifen. No evidence of distant metastasis on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA mutation", "biomarker": "ER-positive; PR-positive; HER2-negative", "treatment": "breast-conserving surgery; adjuvant radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with high-grade serous ovarian carcinoma presenting with pleural effusion and malignant pleural cytology. She underwent debulking surgery followed by adjuvant carboplatin and paclitaxel. Pre-treatment CA-125 was 1,200 U/mL and has normalized after therapy. BRCA testing was not performed. At 9-month visit there is no radiographic evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IVB", "gene_mutation": null, "biomarker": "CA-125 1200 U/mL (pre-treatment, normalized post-treatment)", "treatment": "debulking surgery and carboplatin + paclitaxel", "response": "complete response / no evidence of disease", "metastasis_site": "pleura"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female diagnosed with stage IV lung adenocarcinoma harboring EGFR L858R. She was started on osimertinib 80 mg daily in October and achieved an initial partial response on CT chest/abdomen. PD-L1 tumor proportion score 10%. Recent brain MRI demonstrates two new enhancing lesions consistent with brain metastases while systemic disease remains controlled.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response systemically; progression in brain", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with weight loss and abdominal pain. CT shows multiple hepatic and pulmonary lesions; biopsy of colon mass consistent with metastatic colorectal adenocarcinoma, stage IV. Molecular profiling identified BRAF V600E and high microsatellite instability (MSI-H) with TMB-high. He was started on pembrolizumab monotherapy and first restaging CT demonstrated a partial response with shrinkage of the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History and treatment summary: 68-year-old male with metastatic castration-resistant prostate cancer (stage IV) harboring a deleterious BRCA2 deletion on germline and somatic testing. He progressed on abiraterone/prednisone and subsequently started olaparib 300 mg twice daily. Baseline bone scan showed multiple osseous metastases. After 4 months of olaparib the PSA has fallen and CT/bone imaging show decrease in size and activity of bony lesions \u2014 partial radiographic response.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 deletion", "biomarker": null, "treatment": "olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 48-year-old woman with locally advanced left breast cancer, biopsy shows HER2-amplified, ER positive, PR positive invasive ductal carcinoma. Nodal disease with inflammatory features; clinical stage IIIB. Next-generation sequencing identified a PIK3CA H1047R mutation. She was started on neoadjuvant TCH (docetaxel, carboplatin, trastuzumab) with plan for surgery after four cycles. Interim exam: tumor decreased in size, partial clinical response to therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab (neoadjuvant TCH)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma. CT and biopsy confirm stage IV disease with multiple bilateral lung nodules and osteolytic lesions. Molecular testing: EGFR L858R and T790M mutations detected; PD-L1 tumor proportion score 10%. Patient progressed on first-line erlotinib and was started on osimertinib 80 mg daily two months ago. Recent MRI shows decreased size of brain metastases and improvement of pulmonary lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib (prior), osimertinib", "response": "partial response (improvement of brain and pulmonary lesions)", "metastasis_site": "brain; bone (osteolytic lesions)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 48-year-old female with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Tumor was ER positive, PR positive and HER2 amplified by FISH. On targeted NGS a PIK3CA E545K mutation was identified. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab for 6 cycles and proceeded to mastectomy and axillary dissection. Surgical pathology demonstrates no residual invasive carcinoma \u2014 pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with squamous cell carcinoma of the oropharynx (T3N2b). Treated definitively with concurrent high-dose cisplatin and radiation at the local hospital. No molecular profiling or NGS was performed. Post-treatment PET/CT demonstrates no FDG-avid disease in the primary and complete metabolic response in the cervical nodes.", "output": {"cancer_type": "oropharyngeal squamous cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin and radiation", "response": "complete response", "metastasis_site": "cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the left breast. ER and PR positive; HER2 amplified by FISH. Clinical stage documented as IIIB. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab. Patient underwent lumpectomy with clear margins and sentinel node biopsy was negative. Final pathology shows no residual invasive carcinoma (pathologic complete response). No distant metastases on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed lung adenocarcinoma presented with weight loss and progressive dyspnea. Staging PET/CT demonstrated multiple pulmonary nodules and brain and bony lesions consistent with stage IV disease. Molecular testing returned EGFR L858R; PD-L1 TPS 15%. He was started on osimertinib 80 mg daily as first-line targeted therapy with symptomatic improvement and repeat imaging at 8 weeks showed a partial response in the chest and decreased size of intracranial metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with metastatic lung adenocarcinoma in 2019. Molecular testing showed EGFR L858R; PD-L1 tumor proportion score 10%. Staging at presentation: IV with multiple intracranial lesions. She was started on osimertinib and had a partial intracranial response; extracranial disease later demonstrated progression and she underwent stereotactic radiosurgery to two brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial intracranial response, later extracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with intermediate-risk prostate adenocarcinoma (clinical T2b N0 M0, stage II). Underwent robotic-assisted radical prostatectomy last month. Surgical margins negative and post-op PSA is undetectable. No genomic testing or biomarker studies were performed prior to surgery.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic pancreatic ductal adenocarcinoma, presenting with weight loss and obstructive jaundice. Imaging shows multiple hypodense liver metastases. Staging consistent with stage IV disease. Comprehensive NGS reported no actionable alterations. CA19-9 markedly elevated at diagnosis. He received FOLFIRINOX, followed by palliative external-beam radiation to a painful hepatic lesion. Restaging scans show enlarging liver metastases and rising CA19-9 consistent with progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; palliative external-beam radiation", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma, stage IIIC at diagnosis with bulky peritoneal carcinomatosis. Germline testing positive for BRCA1 pathogenic variant. Initial debulking followed by carboplatin/paclitaxel with good CA-125 decline; started on olaparib maintenance. Last CT shows near-complete resolution of peritoneal implants.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "elevated CA-125 (prior); BRCA1", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response / near-complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIA. Tumor was ER-negative, PR-negative, HER2 amplified by FISH and harbored a PIK3CA E545K mutation on NGS. She received neoadjuvant docetaxel with dual HER2 blockade (trastuzumab and pertuzumab) and achieved a pathologic complete response at surgery. No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Brief: 67-year-old male with intermediate-risk prostate adenocarcinoma (Gleason 3+4). Pre-op PSA 24 ng/mL. He underwent radical prostatectomy with extended pelvic lymph node dissection followed by adjuvant external beam radiation for adverse pathology. No targeted molecular testing was reported in the chart. Recent follow-up shows PSA undetectable and no clinical evidence of recurrence.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 24 ng/mL (pre-op); undetectable post-op", "treatment": "radical prostatectomy followed by adjuvant radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology-oncology correspondence: 46-year-old with widely metastatic cutaneous melanoma. BRAF V600E mutation identified on next-generation sequencing. Baseline PET/CT demonstrated uptake in multiple vertebral bodies and a lytic lesion of the femur. Started targeted therapy with dabrafenib and trametinib; after 6 weeks symptoms improved and repeat imaging shows reduction in bone lesion size.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone (vertebrae, femur)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 52-year-old with metastatic cutaneous melanoma. BRAF testing returned V600E positive; PD-L1 by IHC was low at ~5%. He was started on combination targeted therapy with dabrafenib and trametinib and achieved a brisk partial response systemically. CNS surveillance later identified progressive brain metastases; he was transitioned to combination immunotherapy with ipilimumab plus nivolumab but had clinical progression in the brain and new pulmonary nodules.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab", "response": "initial partial response then progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with sigmoid colon adenocarcinoma, pathologic stage III (pT3N1). Tumor sequencing identified KRAS G12D; microsatellite testing shows MSS. Patient underwent low anterior resection and completed 12 cycles of adjuvant FOLFOX. Surveillance CT and CEA remain negative at 18 months.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "surgical resection (low anterior resection), adjuvant FOLFOX", "response": "no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old M status post right hemicolectomy for colon adenocarcinoma. Final pathology pT3N1, consistent with stage III disease. Molecular testing detected KRAS G12D mutation and MSI testing reported MSI-H. Patient completed adjuvant FOLFOX and is now on surveillance with CT scans every 6 months; current imaging shows no radiographic evidence of residual or recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with high-grade invasive ductal carcinoma of the left breast, clinical stage IIIA (T2N2M0). Tumor ER/PR negative, HER2 amplification by FISH. Germline testing returned positive for a deleterious BRCA1 mutation. She completed neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) and subsequent surgery showed no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 66-year-old female with stage IV lung adenocarcinoma harboring EGFR L858R mutation. Started osimertinib 80 mg daily 8 weeks ago. PD-L1 TPS 10% reported on initial biopsy. Follow-up CT shows decrease in size of primary lesion and partial response. Known brain metastases stable on treatment.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO stage IIIC at diagnosis. Germline testing positive for a deleterious BRCA1 mutation. CA-125 elevated to 780 U/mL pre-op. Patient underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel and is currently on maintenance olaparib. Surveillance imaging at 12 months shows no radiologic evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "no evidence of disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma with liver-dominant disease. Molecular testing: KRAS G12D and MSI-H on tumor sequencing. He completed 6 cycles of FOLFOX plus bevacizumab with stable disease by RECIST, then was switched to pembrolizumab for MSI-H disease and demonstrated a partial response on interval imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with biopsy-proven lung adenocarcinoma. Molecular testing detected EGFR L858R. PD-L1 tumor proportion score reported at 10%. Staging PET/CT consistent with stage IV disease with intracranial and osseous involvement. Patient received stereotactic radiosurgery to the right frontal lesion and was started on osimertinib 80 mg daily. Interval CT at 8 weeks demonstrates decreased size of pulmonary nodules and partial resolution of brain disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with high-risk localized prostate adenocarcinoma (Gleason 4+4) treated with definitive external beam radiation and long-term androgen deprivation therapy with leuprolide. Clinical stage III at diagnosis. Germline testing revealed a BRCA2 pathogenic variant. On PSA surveillance he has had stable disease for 18 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (pathogenic germline variant)", "biomarker": null, "treatment": "external beam radiation therapy and leuprolide (androgen deprivation therapy)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man presenting with weight loss and abdominal pain found to have pancreatic ductal adenocarcinoma with multiple liver metastases. Germline testing positive for BRCA2 deleterious mutation. He received FOLFIRINOX with initial radiographic stability followed by partial response at 4 months; switched to maintenance olaparib. Most recent scan documents progressive hepatic disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; maintenance olaparib", "response": "progression (after initial partial response)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced left breast cancer (T4N2). Core biopsy: invasive ductal carcinoma, HER2 3+ by IHC, ER positive, PR negative. No distant metastases on CT chest/abdomen/pelvis. She received neoadjuvant trastuzumab and pertuzumab with weekly paclitaxel for 6 cycles followed by mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+, ER positive, PR negative", "treatment": "trastuzumab, pertuzumab and paclitaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with rapidly growing pigmented lesion diagnosed as cutaneous melanoma. PET/CT showed distant spread to lungs and a single cerebellar metastasis; clinical stage IV. Tumor sequencing identified BRAF V600E and PD-L1 expression was high (~60%). He underwent initiation of targeted therapy with dabrafenib plus trametinib and received stereotactic radiosurgery to the brain lesion. Follow-up imaging shows partial response of extracranial disease and decrease in size of the brain metastasis.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, stage IV at presentation. Molecular testing reported BRAF V600E and MSI-H. He was started on FOLFOX with bevacizumab. After 4 cycles the CT shows interval growth of multiple hepatic lesions consistent with disease progression in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging workup shows stage IV disease with multiple cerebral metastases. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg PO daily and after 8 weeks had a CT and brain MRI demonstrating shrinkage of both the primary and intracranial lesions consistent with a partial response. No prior chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with biopsy-proven invasive ductal breast carcinoma of the left breast, clinical stage IIIB. ER+, PR+, HER2 amplified on FISH. Next-generation sequencing detected a PIK3CA H1047R mutation. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles followed by modified radical mastectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed metastatic lung adenocarcinoma (stage IV). Comprehensive NGS demonstrated EGFR L858R mutation; ALK and ROS1 negative. PD-L1 tumor proportion score 5%. He was started on osimertinib 80 mg daily in January 2024 with marked radiographic improvement of multiple pulmonary nodules and partial regression of lytic bone lesions after 8 weeks. Later developed a symptomatic brain metastasis treated with stereotactic radiosurgery; systemic therapy continued until systemic progression was considered. Plan discussed to transition to platinum-doublet chemotherapy if further progression occurs.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "31-year-old female diagnosed with metastatic cutaneous melanoma with symptomatic brain metastases. Molecular profiling positive for BRAF V600E; NRAS negative. PD-L1 expression <1% but tumor showed high TMB. She was treated with dabrafenib plus trametinib and, following partial extracranial response, transitioned to pembrolizumab for consolidation. Repeat imaging demonstrates reduction in intracranial lesions.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%, TMB-high", "treatment": "dabrafenib + trametinib followed by pembrolizumab", "response": "partial response (reduction in intracranial lesions)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma. Bronchoscopic biopsy confirmed adenocarcinoma and reflex NGS identified EGFR L858R. PD-L1 TPS was 10%. Staging scans showed pulmonary primary with multiple bone lesions and two enhancing brain metastases. He was started on osimertinib 80 mg daily in June and received stereotactic radiosurgery to the dominant brain lesion. Interval CT at 12 weeks demonstrated shrinkage of the primary and bony lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib, stereotactic radiosurgery", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man presenting with cough and weight loss. Biopsy: lung adenocarcinoma, stage IV with multiple skeletal lesions and new intracranial enhancing lesions on MRI. Molecular testing shows EGFR L858R; PD-L1 tumor proportion score 10%. Started first-line osimertinib with a radiographic partial response for 8 months, then systemic progression with enlarging brain metastases and new liver lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response followed by progression", "metastasis_site": "bone, brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology discharge summary: 54-year-old female with high\u2011grade serous ovarian carcinoma. At laparotomy optimal cytoreduction achieved; omentum and peritoneal surfaces were involved. BRCA1 pathogenic variant identified on germline testing. Pre-op CA\u2011125 was markedly elevated. Adjuvant chemotherapy with carboplatin and paclitaxel has been started; maintenance olaparib discussed. First CT after 3 cycles shows decrease in peritoneal nodularity.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; maintenance olaparib planned", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent optimal cytoreductive surgery for high-grade serous ovarian carcinoma with peritoneal carcinomatosis. Final path stage IIIC. Germline testing returned a pathogenic BRCA1 variant. She completed adjuvant carboplatin and paclitaxel with stable disease on imaging; CA-125 decreased but remained above normal and maintenance olaparib was started. Follow-up CT shows persistent peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "elevated CA-125", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma found to harbor BRAF V600E. Initially treated with nivolumab but developed extracranial progression; subsequently started on dabrafenib plus trametinib with regression of hepatic and nodal disease. Interval brain MRI, however, revealed new small metastases \u2014 overall described as a mixed response with intracranial progression. PD-L1 was 5% on prior testing.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "nivolumab; then dabrafenib and trametinib", "response": "mixed response (intracranial progression)", "metastasis_site": "liver; brain; lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presenting with cough and headaches. Staging workup showed stage IV disease with multiple intracranial and osseous lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score about 10%. Patient was started on first-line osimertinib 80 mg daily with good clinical improvement. Repeat imaging at 8 weeks showed a partial response with decreased size of both brain metastases and regression of several pulmonary nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with right breast invasive ductal carcinoma, ER+, PR+, HER2 amplified by FISH. Pathologic stage reported as II (T2N1M0). Tumor sequencing identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab. Post-treatment mammogram and PET/CT show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy, paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal breast carcinoma (clinical stage IIIB). Tumor markers: ER positive, PR negative, HER2 amplification by FISH; next-generation sequencing detected PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab with docetaxel, then underwent mastectomy and sentinel node dissection with a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with cutaneous melanoma of the shoulder. Molecular testing identified BRAF V600E. After developing pulmonary nodules and new brain metastases the disease was restaged as metastatic. He received combination dabrafenib and trametinib but progressed clinically within 6 months with enlarging lung and brain lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive moderately differentiated adenocarcinoma of the ascending colon, pT2N0M0 (stage I). Patient underwent uncomplicated right hemicolectomy with negative margins. No adjuvant chemotherapy was recommended. Surveillance CT chest/abdomen/pelvis at 6 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "right hemicolectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging CT chest and brain MRI demonstrate bilateral pulmonary nodules and a 2.5 cm enhancing cerebellar metastasis. Molecular testing returned EGFR L858R. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily; after 8 weeks there was interval shrinkage of the primary lung mass but development of a new enhancing brain lesion consistent with progression. Underwent stereotactic radiosurgery to the brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic sigmoid colon adenocarcinoma, stage IV with multiple liver lesions. Tumor profiling: MSI-H and TMB-high (28 muts/Mb); BRAF V600E mutation identified. He received first-line FOLFOX plus bevacizumab with initial partial response, progressed after 10 months and was switched to pembrolizumab given MSI-H status with subsequent durable partial response on follow-up scans.", "output": {"cancer_type": "colon adenocarcinoma (sigmoid)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (28 muts/Mb)", "treatment": "FOLFOX and bevacizumab; then pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "37-year-old man with a primary cutaneous melanoma of the right thigh, unresectable and staged as III. NGS showed BRAF V600E mutation. He began targeted therapy with dabrafenib and trametinib with an initial partial response; however, at month 8 surveillance CT there was interval progression with new pulmonary nodules and increasing size of a pelvic node consistent with acquired resistance. PD-L1 was not assessed on the specimen.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression (acquired resistance after initial partial response)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old male with newly diagnosed lung adenocarcinoma. CT chest/abdomen revealed multiple pulmonary nodules and a 1.5 cm cerebellar lesion. Molecular testing returned EGFR L858R. PD-L1 IHC reported 10%. Started osimertinib 80 mg daily in August; MRI brain after 8 weeks shows decrease in size of the cerebellar metastasis. Tolerating therapy well.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note (brief): 72M with metastatic castration-resistant prostate cancer. Extensive bone pain; radionuclide bone scan positive for multiple osseous metastases. Previously received androgen deprivation and docetaxel, now on abiraterone with prednisone with stable PSA and imaging over three months.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation and docetaxel (prior), abiraterone with prednisone (current)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old male with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. PD-L1 immunohistochemistry showed 10% tumor cell staining. He was started on dabrafenib plus trametinib; at 6 months PET/CT demonstrated complete radiographic response of pulmonary nodules and involved nodes.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung and lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with newly diagnosed lung adenocarcinoma, clinical stage IV. Presents with multiple brain and bone metastases. Comprehensive genomic profiling detected EGFR L858R and EGFR T790M. PD-L1 TPS 10% and tumor mutational burden reported as TMB-high. Started on osimertinib in combination with bevacizumab after stereotactic radiosurgery to the brain. Interval CT and MRI show a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%; TMB-high", "treatment": "osimertinib plus bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation: 70-year-old male with metastatic colorectal adenocarcinoma. CT abdomen shows multiple hepatic metastases; colonoscopy confirmed primary sigmoid tumor. Tumor genotyping identified KRAS G12D. He received 8 cycles of FOLFOX with bevacizumab but interval imaging demonstrates new hepatic lesions and rising CEA. Recommended change in systemic therapy due to radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with Stage IV lung adenocarcinoma, diagnosed in 2019. Comprehensive NGS of the tumor identified EGFR L858R and secondary T790M mutation. PD-L1 tumor proportion score reported at 60%. She was started on osimertinib in January 2020 and received stereotactic radiosurgery for a solitary cerebellar lesion. Interval CT shows marked reduction in size of pulmonary nodules and lytic lesions in the spine consistent with partial response. Sites of disease include brain and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 60%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colon adenocarcinoma. He presented with abdominal pain and imaging showed peritoneal carcinomatosis. Tumor sequencing identified BRAF V600E and the tumor was MSI-H. He progressed on adjuvant FOLFOX and was started on pembrolizumab; CT at 12 weeks demonstrates a partial response of peritoneal implants.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male diagnosed with metastatic colorectal adenocarcinoma. CT shows multiple liver metastases. Tumor sequencing identified KRAS G12D and microsatellite stable status (MSS). He started systemic therapy with FOLFOX plus bevacizumab. After three months, imaging demonstrated new hepatic lesions and rising CEA consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 55-year-old male with a history of a pigmented lesion on the back now has metastatic disease to the cerebrum. Excisional biopsy confirmed cutaneous melanoma. Molecular testing identified a BRAF V600E alteration. He received combination targeted therapy with dabrafenib plus trametinib and concurrent stereotactic radiosurgery to the brain mets. Imaging after 10 weeks shows shrinkage of intracranial lesions. No PD-L1 or TMB results are available in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "partial response (shrinkage of intracranial lesions)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with a left breast mass: core biopsy showed invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Clinical stage at presentation was IIIB with matted axillary nodes. Next-generation sequencing on the biopsy identified PIK3CA H1047R. She received neoadjuvant therapy with docetaxel, carboplatin and trastuzumab (TCH) x6 cycles followed by mastectomy. Final surgical pathology noted no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant TCH)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: Locally advanced left breast cancer, clinical T4N2 \u2014 Stage IIIB. ER negative, PR negative, HER2 amplified by FISH. PIK3CA H1047R identified on NGS. Patient received neoadjuvant TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab) followed by modified radical mastectomy. Final pathology showed no residual invasive carcinoma (pCR). No distant metastases identified pre- or post-treatment.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for colon adenocarcinoma; pathology showed T3N1 (final stage III). Tumor is MSI-stable by PCR and no actionable alterations were identified on the panel. He completed adjuvant FOLFOX (12 cycles) without complications. Surveillance CT at 6 months demonstrates no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: high-grade invasive ductal carcinoma of the right breast. FISH shows HER2 amplification; ER and PR both negative. Clinical exam and imaging prior to therapy consistent with locally advanced disease with fixation to chest wall and bulky axillary nodes. Patient received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for six cycles and subsequently underwent modified radical mastectomy. Final pathology demonstrates no residual invasive carcinoma (pathologic complete response). No distant metastatic disease identified on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP) followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman with locally advanced left breast carcinoma. Core biopsy reported ER positive, PR positive and HER2 amplification by FISH. Clinical stage III disease. She received neoadjuvant docetaxel, carboplatin with dual HER2 blockade (trastuzumab and pertuzumab) with excellent tumor shrinkage. Surgical pathology after mastectomy demonstrated a pathologic complete response. No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "III", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with castration-resistant prostate cancer presenting with progressive bone pain. History notable for prior radical prostatectomy and long-term ADT. He received docetaxel in combination with continued androgen deprivation therapy, then was transitioned to abiraterone acetate plus prednisone for rising PSA. Recent bone scan shows scattered osseous metastases without visceral disease. No molecular testing was performed and no genomic alterations reported.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel with ADT; abiraterone acetate plus prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 59-year-old male with metastatic colorectal adenocarcinoma. Initial molecular testing showed KRAS G12D mutation; MSI testing returned MSI-H and tumor mutational burden reported as TMB-high. Patient was treated with FOLFOX plus bevacizumab for disease control; because of MSI-H status he was transitioned to pembrolizumab monotherapy. Recent scans show stable disease in the liver and a new small pulmonary nodule that is being observed.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX + bevacizumab then pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman diagnosed with high-grade serous ovarian carcinoma, clinical stage IIIC with bulky peritoneal disease. Primary debulking surgery performed followed by adjuvant carboplatin and paclitaxel with bevacizumab. CA-125 was markedly elevated preoperatively and has fallen but remains above normal. BRCA testing results pending at discharge. On most recent CT there is a partial radiographic response of the peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin and paclitaxel with bevacizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with recurrent metastatic cutaneous melanoma. Initial profile showed BRAF V600E mutation; started on dabrafenib + trametinib with rapid clinical benefit but progressed after 11 months with new pulmonary nodules. Switched to nivolumab; current CT after 12 weeks shows disease that is anatomically unchanged compared with baseline post-switch.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; nivolumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female referred to thoracic oncology for newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrates multiple bilateral pulmonary nodules and a 1.5 cm enhancing lesion in the right frontal lobe suspicious for metastasis. Tumor genotyping returned positive for EGFR L858R. PD-L1 tumor proportion score 20%. Patient was started on osimertinib 80 mg daily. Interval CT at 8 weeks shows reduction in size of the lung lesions with resolution of several nodules \u2014 radiographic assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with locally advanced pancreatic ductal adenocarcinoma involving the head of pancreas and encasement of the superior mesenteric artery. Multidisciplinary tumor board labeled as unresectable locally advanced disease. She was initiated on gemcitabine with nab-paclitaxel and reported modest improvement in pain and appetite after two cycles. No molecular testing reported in the chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine with nab-paclitaxel", "response": "stable disease / symptomatic improvement", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with newly identified metastatic prostate adenocarcinoma. Presenting PSA 86 ng/mL. Bone scan positive for multiple sclerotic metastases. Androgen deprivation therapy was initiated (leuprolide depot). No next-generation sequencing or biomarker testing performed to date. Plan is to follow PSA and consider addition of docetaxel if castration-resistant progression occurs.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide)", "response": null, "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy planned for a 45-year-old woman with locally advanced (cT3N2) invasive ductal carcinoma of the breast, HER2-positive on IHC and confirmed HER2 amplification by FISH. Hormone receptors were ER-positive and PR-positive. NGS revealed a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab combined with docetaxel for six cycles, followed by mastectomy. Pathology reported a pathologic complete response.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB (cT3N2)", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with newly diagnosed lung adenocarcinoma. Staging CT and brain MRI show multiple cerebral metastases and pulmonary nodules consistent with stage IV disease. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Started on osimertinib 80 mg daily as first-line targeted therapy. Follow-up imaging at 8 weeks demonstrates reduction in size of lung lesions and decreased enhancement of brain metastases \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: 48-year-old female underwent lumpectomy for a 1.8 cm invasive ductal carcinoma. Final stage: I (pT1c N0). ER 90% positive, PR 40% positive, HER2 by IHC 3+ with confirmatory FISH showing HER2 amplification. Somatic panel detected PIK3CA H1047R. Adjuvant plan includes paclitaxel weekly for 12 weeks followed by trastuzumab for 1 year. Surgical margins negative; patient clinically NED at postop visit.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated Stage IV disease with multiple brain and bone metastases. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily. Restaging CT chest and brain MRI at 8 weeks showed decrease in size of primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 185delAG variant. CA-125 at diagnosis was 420 U/mL. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel and is currently receiving maintenance olaparib. Clinical exam and recent CA-125 are consistent with complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 420 U/mL (elevated at diagnosis)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy: invasive ductal carcinoma of the right breast, ER-/PR-, HER2 FISH positive with amplification. Clinical staging prior to treatment was IIIB with inflammatory features. Neoadjuvant therapy included dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab and pertuzumab. Patient underwent modified radical mastectomy; pathology shows no residual invasive carcinoma (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 paclitaxel with trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with stage IV lung adenocarcinoma harboring an EGFR L858R mutation. Presents with headaches; MRI confirmed multiple brain metastases and a solitary cerebellar lesion treated with stereotactic radiosurgery. Started osimertinib 80 mg daily as first-line targeted therapy. PD-L1 testing returned 10%. Follow-up CT at 8 weeks demonstrated marked reduction in size of pulmonary nodules and shrinkage of CNS lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man presents with progressive cough and weight loss. CT chest/abdomen reveals a left upper lobe mass with multiple bilateral pulmonary nodules and a solitary cerebellar lesion. Biopsy: lung adenocarcinoma, stage IV. Molecular testing: EGFR L858R. PD-L1 tumor proportion score ~10%. Patient started first-line osimertinib and received stereotactic radiosurgery to the brain lesion. Most recent scans demonstrate a partial response of thoracic disease and decreased size of the brain metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Notes: 58-year-old male status post right hemicolectomy for colon adenocarcinoma, pathology pT3N1 \u2014 stage III. Completed 6 cycles of adjuvant FOLFOX with expected treatment-related neuropathy. MSI testing returned MSS. KRAS/NRAS/BRAF panel was not available in the chart at discharge and no targeted agents were given in the adjuvant setting. Surveillance CT at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSS (microsatellite stable)", "treatment": "right hemicolectomy; adjuvant FOLFOX (6 cycles)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old with metastatic cutaneous melanoma presented with new pulmonary nodules and a solitary cerebellar metastasis. Molecular testing showed BRAF V600E mutation; PD-L1 expression was 2%. He was started on combination targeted therapy with dabrafenib and trametinib with an initial brisk clinical and radiographic partial response in the lungs and regression of the brain lesion after stereotactic radiosurgery.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%", "treatment": "dabrafenib + trametinib (plus stereotactic radiosurgery to brain)", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old male with metastatic melanoma to lung and brain. Initial molecular profiling identified BRAF V600E. He received first-line dabrafenib + trametinib with clinical benefit for 6 months, then developed new hepatic lesions and was switched to combination immunotherapy (nivolumab plus ipilimumab). Latest MRI shows progression in the liver and mixed response in the brain.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (initial); nivolumab plus ipilimumab (subsequent)", "response": "initial response then progression (mixed response)", "metastasis_site": "lung; brain; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with metastatic lung adenocarcinoma diagnosed Feb 2024. Core biopsy demonstrated EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. Staging workup consistent with stage IV disease with brain and multiple bony lesions. Patient started osimertinib 80 mg daily in March and had a partial radiographic response on first follow-up CT/MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 58-year-old male with newly diagnosed metastatic right-sided colon adenocarcinoma. Staging CT shows multiple hypodense lesions in the liver consistent with metastases. Tumor testing: BRAF V600E positive; MSI-H by PCR. Given MSI-H status patient was started on pembrolizumab 200 mg q3w as first-line systemic therapy. After 4 cycles CT shows decrease in size of hepatic lesions consistent with partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female diagnosed with stage IV lung adenocarcinoma with known EGFR L858R mutation. Baseline staging showed brain and bone metastases. PD-L1 TPS was 10%. She was started on osimertinib and received whole-brain radiotherapy for symptomatic brain lesions. Interval CT and MRI demonstrate a partial response with shrinkage of pulmonary nodules and decreased size of intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib and whole-brain radiotherapy", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology consult: 75-year-old male with newly symptomatic metastatic prostate adenocarcinoma. Presents with progressive bone pain; bone scan shows multifocal osseous metastases. Clinical stage IV. Started on androgen deprivation with leuprolide and given docetaxel q3wk for cytoreduction. Follow-up PSA declined and symptoms are controlled; overall disease assessment stable. No tumor sequencing has been performed and no molecular biomarkers reported in the record.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient status post right hemicolectomy for adenocarcinoma of the colon, pathology pT3N1 -> stage III. Molecular panel shows KRAS G12D mutation. Completed adjuvant FOLFOX x 6 cycles. Surveillance CT chest/abdomen/pelvis at 6 months shows no evidence of distant disease. No additional biomarkers reported in chart.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease (post-operative, adjuvant)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with right-sided colon adenocarcinoma presenting with multiple hepatic lesions. Tumor profiling identified BRAF V600E mutation and high microsatellite instability (MSI-H). Given MSI-H status he was started on pembrolizumab monotherapy; interval CT at 12 weeks shows shrinkage of dominant liver metastases and improved tumor markers.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with high-grade serous ovarian carcinoma with bulky omental and peritoneal disease. Surgical staging confirmed stage IIIC. Germline testing positive for a deleterious BRCA1 pathogenic variant; tumor reported HRD-positive. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with a radiographic partial response and was transitioned to maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin and paclitaxel x6; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 48-year-old female with locally advanced invasive ductal carcinoma of the left breast, ER-positive, PR-positive, HER2 amplified on FISH. Clinical stage IIIB with bulky axillary adenopathy. Biopsy also showed PIK3CA E545K mutation. She was started on neoadjuvant trastuzumab and pertuzumab in combination with docetaxel (THP) for 6 cycles. Imaging after 4 cycles shows marked tumor shrinkage but persistent nodal disease. Will proceed to surgery followed by adjuvant T-DM1 per multidisciplinary discussion.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); planned surgery; adjuvant T-DM1", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recurrent metastatic cutaneous melanoma in a 62-year-old man. Next-generation sequencing detected BRAF V600E. PET/CT demonstrated several FDG-avid lesions in the liver. PD-L1 IHC was 10%. He was started on combination targeted therapy with dabrafenib and trametinib and follow-up imaging at 12 weeks shows decreased hepatic tumor burden compatible with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with metastatic colorectal adenocarcinoma. Liver-dominant metastases on CT; colonoscopy pathology confirmed adenocarcinoma. Tumor profiling returned BRAF V600E mutation and high microsatellite instability (MSI-H) with TMB-high. He initially received FOLFOX with bevacizumab with minor shrinkage of liver lesions, then progressed and was enrolled on targeted therapy with encorafenib plus cetuximab. Given MSI-H status he subsequently received pembrolizumab on a compassionate basis. Current best overall response reported as stable disease on imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; encorafenib plus cetuximab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman diagnosed with high-grade serous ovarian carcinoma, initial stage IIIC after optimal cytoreductive surgery. Surveillance CT showed new bilateral pulmonary nodules suspicious for metastatic disease. She received adjuvant carboplatin and paclitaxel and maintenance bevacizumab; CA-125 has trended down. Somatic panel returned insufficient tissue for actionable mutations and no biomarker report available at this time.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel with bevacizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with cutaneous melanoma found to harbor BRAF V600E on PCR. Initially had widespread pulmonary nodules at presentation (stage IV) and was started on dabrafenib 150 mg bid plus trametinib 2 mg daily with rapid reduction in size of multiple nodules. After 6 months one new enlarging lung lesion appeared and was felt to represent progression; therapy was switched to nivolumab. PD-L1 5%, reported tumor mutational burden high. Clinical course described as mixed response (initial PR then progression in a solitary pulmonary site).", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib and trametinib (initial), switched to nivolumab", "response": "mixed response (initial partial response then progression)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male found to have prostate adenocarcinoma on screening biopsy, clinical stage I (T1c), Gleason 3+4=7, PSA 6.8 ng/mL. Germline testing was negative for BRCA1/2 and no somatic testing was performed. He elected active surveillance with periodic PSA checks and repeat biopsy planned in 12 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 6.8 ng/mL", "treatment": "active surveillance", "response": "under active surveillance / stable", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic summary: 64-year-old man diagnosed with localized prostate cancer after elevated PSA and prostate biopsy showing Gleason 3+4 adenocarcinoma. Clinical stage T2b (AJCC Stage II). He elected for definitive radical prostatectomy; postoperative PSA is undetectable at 0.03 ng/mL. No molecular testing was done and no distant disease was identified preoperatively.", "output": {"cancer_type": "prostate cancer", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "undetectable PSA (remission)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, presenting with multiple hepatic lesions. Tumor sequencing demonstrated KRAS G12D. Microsatellite testing was stable (MSS). Patient was treated with FOLFOX plus bevacizumab as first-line systemic therapy. Interval CT after four cycles shows enlargement of liver metastases consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with metastatic invasive ductal carcinoma of the breast. Tumor is ER negative, PR negative; HER2 amplified by FISH. She developed multiple new hepatic lesions and worsening back pain consistent with osseous involvement on bone scan. In the metastatic setting she was started on trastuzumab, pertuzumab and docetaxel after frontline anthracycline-based therapy. Interval CT shows decrease in size of liver lesions and improved pain control.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with obstructing sigmoid mass underwent colectomy. Pathology: moderately differentiated adenocarcinoma. Postoperative staging workup revealed multiple hepatic lesions consistent with metastases. Tumor testing: MSI-H by PCR; extended RAS testing pending (no actionable RAS mutation reported at time of note). Patient was started on FOLFOX plus bevacizumab. After 4 cycles, CT shows enlarging hepatic lesions and new subcentimeter pulmonary nodules.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic cutaneous melanoma found to harbor BRAF V600E. Baseline staging demonstrated multiple pulmonary nodules and several brain metastases (stage IV). He was started on dabrafenib + trametinib with marked shrinkage of extracranial disease (partial response) but developed intracranial progression requiring stereotactic radiosurgery; nivolumab was subsequently added and the patient currently has stable disease on combined systemic therapy. Tumor assay reported high tumor mutational burden.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery; nivolumab", "response": "partial response (extracranial), intracranial progression treated then stable disease", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal disease. Germline testing revealed a deleterious BRCA1 mutation. She underwent debulking surgery followed by carboplatin and paclitaxel; after six cycles she was placed on olaparib maintenance. Disease has been radiographically stable on maintenance for 10 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": null, "treatment": "debulking surgery followed by carboplatin and paclitaxel, then olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman found to have a 1.8 cm invasive ductal carcinoma on screening mammogram. ER+/PR+, HER2 negative by IHC/FISH. Underwent breast-conserving surgery with sentinel node biopsy (0/3 nodes) followed by adjuvant whole-breast radiation. Planned endocrine therapy with tamoxifen. Post-op exam and imaging show no evidence of residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy (breast-conserving surgery) and radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old with locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, HER2 immunohistochemistry 3+ and FISH showing HER2 amplification. ER and PR both positive. Next-gen sequencing identified a PIK3CA H1047R mutation. Clinical stage at presentation was IIIA (T2 N2 M0). She completed neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab with excellent clinical response; surgical pathology after mastectomy shows no residual invasive carcinoma (pCR). No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma, stage IIIC, found to carry a pathogenic BRCA1 variant (BRCA1 185delAG). She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel and then was enrolled on maintenance olaparib. CT after three cycles of chemotherapy showed decreased peritoneal disease burden with small stable implants in the liver consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "III", "gene_mutation": "BRCA1 185delAG", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Age 62 male with localized prostate adenocarcinoma, clinical stage II (T2a N0 M0). Underwent radical prostatectomy; surgical margins negative and postoperative PSA undetectable. No genomic alterations identified on available testing. Patient is on routine post-op PSA surveillance.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed pancreatic ductal adenocarcinoma with multiple hepatic lesions and progressive jaundice. Oncology notes document initiation of combination chemotherapy with FOLFIRINOX; palliative fractionated radiotherapy was later delivered to the porta hepatis for symptom control. Disease progressed on restaging scans after two cycles.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX; palliative radiotherapy", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic lung adenocarcinoma presenting with headaches and lytic bone pain. Biopsy confirmed adenocarcinoma, molecular testing positive for EGFR L858R at diagnosis with an acquired EGFR T790M on repeat liquid biopsy after progression. PD-L1 TPS reported at 30%. Staging consistent with Stage IV with brain and vertebral metastases. He was started on osimertinib 80 mg daily and achieved a radiographic partial response; after 9 months developed systemic progression and was transitioned to carboplatin and pemetrexed combination chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 TPS 30%", "treatment": "osimertinib; carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain; bone (vertebrae)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a 2.1 cm invasive ductal carcinoma of the right breast, ER positive, PR positive, HER2 amplified by FISH. Pathologic stage pT2N0 (stage IIA) after lumpectomy and sentinel node biopsy. Tumor sequencing detected PIK3CA H1047R. She received adjuvant paclitaxel with concurrent trastuzumab followed by completion of one year trastuzumab and adjuvant tamoxifen. Last clinic note: no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental and peritoneal implants. Germline testing revealed a pathogenic BRCA1 mutation and tumor profiling showed homologous recombination deficiency (HRD) positive. Patient underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel, then started maintenance olaparib. Clinical and radiographic follow-up at 12 months demonstrates complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD positive", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "complete clinical response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical oncology summary: 62-year-old male with obstructing sigmoid mass, path-confirmed stage III (T3N1M0) adenocarcinoma. Tumor testing returned MSI-H; KRAS/NRAS mutational testing not reported in the chart. Patient underwent laparoscopic sigmoid colectomy and started adjuvant FOLFOX last month. Surveillance CT currently shows no new lesions.", "output": {"cancer_type": "sigmoid adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "laparoscopic sigmoid colectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with stage IV cutaneous melanoma harboring BRAF V600E. PD-L1 expression was 5%. He was started on combination targeted therapy with dabrafenib plus trametinib and experienced rapid symptomatic improvement with a partial response. A solitary brain metastasis was treated with stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with documented BRAF V600E mutation and high tumor mutational burden (TMB-high). Multiple bilateral pulmonary nodules on staging CT. Patient started on dabrafenib plus trametinib with rapid reduction in size of lung lesions. No AJCC stage documented in the oncology note.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly progressive metastatic lung adenocarcinoma. Initial staging showed multiple pulmonary nodules with osseous and intracranial lesions. Molecular testing returned EGFR L858R; PD-L1 by IHC 10%. Patient was started on osimertinib 80 mg daily. Restaging CT and brain MRI after 8 weeks demonstrated a 40% decrease in sum of target lesions and shrinkage of a cerebellar metastasis, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with lung adenocarcinoma, stage IV. Molecular testing returned EGFR L858R; PD-L1 TPS 1%. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to a solitary cerebellar metastasis. Interval imaging at 8 weeks demonstrated marked reduction in size of pulmonary lesions and decreased enhancement of the brain lesion consistent with a partial response. Known bony lesions in the pelvis noted on baseline scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with newly metastatic prostate adenocarcinoma presenting with diffuse bony pain. PSA at diagnosis was 48 ng/mL. Bone scan showed multiple skeletal metastases. No somatic NGS results are available in the chart. He was started on combined androgen deprivation therapy with leuprolide and upfront docetaxel chemotherapy; pelvic external beam radiation was delivered to dominant nodal disease. Clinically he has had a biochemical response with falling PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 48 ng/mL", "treatment": "leuprolide (ADT) + docetaxel; pelvic external beam radiation", "response": "biochemical response (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for BRCA1 c.5266dupC. CA-125 markedly elevated at diagnosis. She underwent optimal debulking followed by carboplatin and paclitaxel and was started on olaparib maintenance. Surveillance CT at 6 months shows resolution of peritoneal implants consistent with a complete radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.5266dupC", "biomarker": "CA-125 elevated", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old premenopausal woman with locally advanced invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR positive, HER2 amplified by FISH. FoundationOne reported a PIK3CA H1047R mutation. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with marked clinical downstaging and proceeded to mastectomy; surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with unresectable cutaneous melanoma presenting with multiple subcutaneous nodules and a symptomatic cerebellar metastasis. Tumor testing demonstrated BRAF V600E. He initially received combination checkpoint blockade with nivolumab and ipilimumab but developed progression after four months. He was transitioned to targeted therapy with dabrafenib and trametinib and achieved a partial radiographic response; stereotactic radiosurgery was used for the brain lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab and ipilimumab (initial); dabrafenib and trametinib (subsequent); stereotactic radiosurgery", "response": "progression on immunotherapy; partial response to BRAF/MEK", "metastasis_site": "brain, subcutaneous soft tissue"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with invasive ductal carcinoma of the right breast, clinical stage I (T1cN0M0). Tumor ER-positive, PR-positive, HER2 amplification confirmed by FISH; PIK3CA H1047R mutation identified on NGS. She underwent lumpectomy with sentinel lymph node biopsy (negative) and completed adjuvant paclitaxel (12 cycles) with planned trastuzumab for one year. Surveillance imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "lumpectomy; sentinel lymph node biopsy; paclitaxel; trastuzumab", "response": "no evidence of disease (NED)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma, BRAF V600E\u2013positive, presenting with a solitary brain metastasis treated with stereotactic radiosurgery. He was previously treated with combination ipilimumab and nivolumab and is currently on targeted therapy with dabrafenib plus trametinib. PD-L1 was <1% on the tumor sample; tumor sequencing also reported high TMB. Recent scans show stable disease on the BRAF/MEK inhibitor combination.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%, TMB-high", "treatment": "dabrafenib and trametinib (after prior ipilimumab and nivolumab)", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital progress note: 62-year-old male with sigmoid colon adenocarcinoma, metastatic to the liver. Biopsy and NGS show KRAS G12D; MSI-stable on immunohistochemistry. He was started on FOLFOX with bevacizumab. After four cycles surveillance CT shows increase in size and number of hepatic lesions consistent with disease progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX with bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old woman with metastatic invasive ductal carcinoma of the breast. Core biopsy: ER positive, PR positive, HER2 3+ by IHC with FISH confirmation of HER2 amplification. Next-generation sequencing identified a PIK3CA H1047R mutation. CT shows multiple hypodense liver lesions consistent with metastatic disease (stage IV). She was started on first-line trastuzumab and pertuzumab with paclitaxel. After 4 cycles patient reports decreased pain and follow-up imaging documents partial response in hepatic lesions.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with metastatic invasive ductal carcinoma of the breast, ER-positive and HER2-amplified on FISH. NGS revealed a PIK3CA H1047R variant. Staging CT showed multiple hepatic lesions. She was started on first-line trastuzumab and pertuzumab in combination with docetaxel; interval scans after three cycles showed a partial response of the liver metastases.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old male with metastatic colorectal adenocarcinoma. CT abdomen shows multiple hypodense lesions in both lobes of the liver consistent with metastases. Colonoscopy had confirmed moderately differentiated adenocarcinoma; KRAS testing demonstrated KRAS G12D. He was treated with FOLFIRI plus bevacizumab but after three months there is radiographic progression with enlarging hepatic lesions and new ascites.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with biopsy-confirmed pancreatic ductal adenocarcinoma and multiple PET-avid liver lesions. Germline and somatic testing identified a pathogenic BRCA2 mutation. CA19-9 markedly elevated at diagnosis. He received FOLFIRINOX with initial radiographic benefit, but by month 4 developed progression in the hepatic lesions and was switched to gemcitabine/nab-paclitaxel followed by olaparib maintenance for BRCA2; most recent CT shows progressive disease in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (pathogenic)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel; olaparib", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging workup consistent with stage IV disease with metastatic deposits in the brain and multiple vertebral bodies. Comprehensive NGS returned EGFR L858R. PD-L1 tumor proportion score 5%. Patient started osimertinib 80 mg PO daily; first restaging CT and brain MRI after 8 weeks demonstrate a partial response with decrease in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "73-year-old man with metastatic castration-resistant prostate adenocarcinoma (mCRPC). Bone scan shows multiple sclerotic lesions. He has been on continuous leuprolide since diagnosis and, after progression, was started on enzalutamide with symptomatic improvement. PSA fell from 220 to 18 ng/mL and his symptoms are controlled; imaging demonstrates persistent bone metastases without visceral disease.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; enzalutamide", "response": "stable disease with PSA decline", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op note: 61-year-old male status post right hemicolectomy for sigmoid colon adenocarcinoma. Pathology shows tumor penetrated through muscularis propria with 4/18 regional lymph nodes positive. Final stage III (pT3N2). Tumor was MSI-stable; KRAS testing not available at the time of surgery. Patient started adjuvant FOLFOX and is currently completing cycle 6 with good tolerance; CT chest/abdomen/pelvis at 6 months shows no evidence of distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-stable", "treatment": "surgery (right hemicolectomy); adjuvant FOLFOX", "response": "no evidence of distant disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrates multiple pulmonary nodules and an enhancing lesion in the right frontal lobe consistent with metastasis. Molecular testing returned EGFR L858R; PD-L1 by IHC approximately 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the brain lesion. Follow-up CT at 8 weeks shows decrease in size of pulmonary lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma to the liver. BRAF V600E mutation identified on PCR-based testing. Patient started targeted therapy with dabrafenib and trametinib. After 6 months of therapy, MRI abdomen shows complete radiographic response of previously measurable hepatic lesions. PD-L1 was not reported in the chart.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response (radiographic)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, diagnosed 2019, now with progressive liver and bilateral lung metastases. Molecular testing returned KRAS G12D and microsatellite stable (MSS); TMB is low. He was treated with FOLFIRI plus bevacizumab in second line but interval imaging shows new hepatic deposits and rising CEA consistent with progression.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS, TMB-low", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant course for locally advanced left breast invasive ductal carcinoma. Clinical stage IIIA. Core biopsy: HER2 amplified by FISH, ER 5% (weak), PR negative. Next-gen sequencing identified PIK3CA H1047R. Patient received six cycles of TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with excellent clinical reduction in tumor size prior to lumpectomy; pathology shows near-complete response with minimal residual invasive carcinoma.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER 5%; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP)", "response": "near-complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man with locally advanced squamous cell carcinoma of the oropharynx (HPV-negative) presented with bulky primary and a single ipsilateral lymph node. He received definitive concurrent cisplatin and radiation and on 12-week post-treatment exam had no clinical evidence of disease.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin and definitive radiotherapy", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 56-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Tumor sequencing returned EGFR L858R mutation. PD-L1 tumor proportion score ~10%. Patient was started on osimertinib 80 mg PO daily two weeks ago. Interval MRI brain demonstrates decreased size of multiple intracranial metastases; bone scan unchanged. Assessment: partial response to osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 ~10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with metastatic invasive ductal carcinoma of the breast. Liver core biopsy confirmed carcinoma that is ER+, PR+, and HER2 amplified by FISH. Somatic profiling identified PIK3CA E545K. At diagnosis she was clinically staged as IV due to hepatic disease. She was started on weekly paclitaxel with trastuzumab; after 4 cycles imaging demonstrates stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel and trastuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma with dominant liver lesions. Molecular report: KRAS G12D mutation. Patient was initiated on FOLFOX plus bevacizumab; follow-up CT shows stable size of hepatic metastases compared with prior scan. No actionable mismatch repair deficiency detected on IHC; MSI status not reported in the electronic note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER-positive, PR-negative, HER2 3+ invasive ductal carcinoma presenting with bulky nodal disease and hepatic lesions. Biopsy showed PIK3CA H1047R mutation on NGS. Staging consistent with stage IV disease. She was started on first-line trastuzumab and pertuzumab with docetaxel (TPD triplet); after 6 cycles imaging demonstrated a partial response and decreased liver burden. Endocrine therapy with letrozole was planned after chemotherapy maintenance.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, ER-positive, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER-positive, PR-negative", "treatment": "trastuzumab + pertuzumab + docetaxel; planned letrozole maintenance", "response": "partial response", "metastasis_site": "liver, regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer, initially diagnosed as stage IV with diffuse sclerotic bone metastases and a left adrenal lesion identified on PET/CT. Germline testing returned a pathogenic BRCA2 variant. He received androgen deprivation therapy plus docetaxel, later progressed and was started on olaparib. Most recent scans show enlarging bone lesions and increase in size of the adrenal mass consistent with progressive disease.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": null, "treatment": "androgen deprivation therapy, docetaxel, then olaparib", "response": "progression", "metastasis_site": "bone, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: Invasive ductal carcinoma, right breast, ER positive, PR positive, HER2 amplified on FISH. Final surgical staging pT2 N1 \u2014 stage II. Tumor sequencing identified PIK3CA H1047R. Patient underwent lumpectomy with sentinel node dissection followed by adjuvant dose-dense doxorubicin/cyclophosphamide then paclitaxel; trastuzumab planned for 1 year and letrozole started. At 12-month follow-up there is no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide then paclitaxel; trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with advanced lung adenocarcinoma, stage IV at diagnosis. Molecular testing revealed EGFR L858R mutation; PD-L1 TPS 10%. He was started on first-line osimertinib. Interval CT and brain MRI show reduction in size of pulmonary and intracranial lesions with symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed lung adenocarcinoma presenting with progressive headaches. Molecular testing returned EGFR L858R mutation and PD-L1 10%. Brain MRI shows two enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant lesion. On first restaging at 8 weeks there is a reduction in size of the lung primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. BRAF V600E positive by PCR. He initially received anti\u2013PD-1 therapy (nivolumab) but progressed and was switched to dabrafenib plus trametinib. After 6 months on BRAF/MEK inhibitors he developed new CNS lesions; restaging shows systemic progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (after prior nivolumab)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma. Somatic and germline NGS revealed a deleterious BRCA2 mutation. Prior treatments included androgen deprivation therapy with leuprolide and six cycles of docetaxel; he was transitioned to olaparib for BRCA2-associated disease. Baseline imaging showed pelvic nodal enlargement consistent with nodal metastases; on therapy he has had radiographic stable disease for 6 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (mCRPC)", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "olaparib", "response": "stable disease", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma registry entry: 45-year-old male with unresectable metastatic melanoma carrying BRAF V600E. Patient received dabrafenib plus trametinib as first-line therapy. Initial tumor burden decreased but developed new neurologic symptoms and interval brain MRI confirmed progressive intracranial disease after six months of therapy; overall assessment: disease progression. Notes do not list formal AJCC stage in chart.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female status post right hemicolectomy for sigmoid colon cancer. Pathology: moderately differentiated adenocarcinoma, pT3 N1 \u2014 overall Stage III. Tumor testing identified KRAS G12D mutation; MSI testing reported microsatellite stable (MSS). She completed adjuvant FOLFOX x 12 cycles without major complications. Surveillance CT chest/abdomen at 6 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 52-year-old female with high-grade serous ovarian carcinoma, stage IIIC at diagnosis with omental caking and peritoneal implants. Germline testing positive for BRCA1 deleterious mutation. CA-125 initially 1200 U/mL. Underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with excellent clinical response; now on maintenance olaparib with CA-125 normalized and no visible disease on CT (complete response).", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "CA-125 elevated (normalized on treatment)", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with unresectable metastatic melanoma presented with multiple cerebral and extracranial lesions. Tumor sequencing identified BRAF V600E. PD-L1 by IHC was >50% and TMB reported as high. He was enrolled on a trial receiving combined dabrafenib + trametinib and pembrolizumab (targeted therapy plus PD-1 inhibitor). Early restaging shows partial response in extracranial disease but new small enhancing brain lesions consistent with mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%, TMB-high", "treatment": "dabrafenib + trametinib + pembrolizumab", "response": "mixed response (partial extracranial response, new brain lesions)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Staging CT and MRI demonstrate multiple cerebral metastases and lytic lesions in the thoracic spine consistent with metastatic disease (stage IV). NGS from the primary tumor identified EGFR L858R. PD-L1 TPS reported at 30%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy; follow-up CT at 8 weeks shows reduction in size of pulmonary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma presented with progressive dyspnea. Initial NGS showed EGFR L858R; on rebiopsy after first-line EGFR-TKI he acquired EGFR T790M. PD-L1 TPS 60% and tumor mutational burden reported as high. Staging demonstrated multiple pulmonary nodules with bone and cerebellar metastases. He was started on osimertinib, and after systemic progression received carboplatin/pemetrexed combined with pembrolizumab; stereotactic radiosurgery was performed for the cerebellar lesion. CT after 3 cycles of chemo\u2011immunotherapy showed partial response of chest disease and stable intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 60%; TMB-high", "treatment": "osimertinib; carboplatin/pemetrexed + pembrolizumab; stereotactic radiosurgery", "response": "partial response (pulmonary); stable disease (intracranial)", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with stage IV lung adenocarcinoma harboring EGFR L858R. PD-L1 was reported at 10%. She was started on osimertinib 80 mg daily; 3-month restaging CT demonstrates decreased size of pulmonary nodules and reduction in enhancing brain metastases, consistent with a partial response. Bone scan previously showed focal involvement of the right femur.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with invasive ductal carcinoma of the right breast, ER+/PR+, HER2 amplified by FISH. Tumor measures 4.2 cm and was staged clinically as IIB. She received neoadjuvant paclitaxel with concurrent trastuzumab and underwent breast-conserving surgery; pathology showed near-complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "near-complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male with newly diagnosed lung adenocarcinoma. Staging CT and brain MRI demonstrate multiple pulmonary nodules and metastases in the brain and bone consistent with stage IV disease. Tumor genotyping identified EGFR L858R; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to two intracranial lesions. Interval chest CT shows shrinkage of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib and stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with metastatic lung adenocarcinoma after CT and biopsy. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 10%. MRI showed two small brain metastases and lytic lesions in the thoracic spine. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain lesion. Follow-up imaging at 8 weeks showed decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed on core biopsy. Molecular testing returned EGFR L858R and no ALK or ROS1 rearrangement. PD-L1 10%. Staging studies show multiple cerebral and osseous lesions consistent with stage IV disease. He was started on osimertinib 80 mg daily with CNS-penetrant dosing; interval CT and brain MRI at 8 weeks demonstrated a 45% decrease in measurable disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female underwent lumpectomy for invasive ductal carcinoma. Pathology: pT2 N0, final stage IIA. ER/PR positive and HER2 amplification by FISH. Comprehensive NGS panel did not identify actionable somatic mutations. She completed adjuvant paclitaxel followed by trastuzumab; surgical margins negative and postoperative imaging shows no residual disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR positive", "treatment": "paclitaxel and trastuzumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma, liver-dominant disease on CT. Targeted genotyping has shown KRAS G12D; microsatellite status is MSS. Stage IV at diagnosis. Treated with FOLFOX (5-FU, leucovorin, oxaliplatin) plus bevacizumab for six cycles. Despite an initial fall in CEA, restaging scans show progression in the hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with stage IIIC high-grade serous ovarian carcinoma presenting with bulky peritoneal disease. Germline testing confirmed a pathogenic BRCA1 185delAG mutation. She had optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel, with normalization of CA-125 and radiographic partial response. She was transitioned to maintenance olaparib. No brain or bone metastases were identified.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 (normalized after treatment)", "treatment": "optimal cytoreductive surgery; carboplatin and paclitaxel x6; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old man with a 2.6 mm superficial spreading melanoma on the left forearm, staged as II (T2bN0M0) after wide local excision. Sentinel node biopsy was negative. No molecular testing was performed and the patient was placed on clinical surveillance; current notes indicate clear margins and no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery), sentinel node biopsy, surveillance", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old female never-smoker presented with chronic cough and unintentional weight loss. CT chest/abdomen revealed a right lower lobe mass with multiple bilateral pulmonary nodules; MRI brain identified two enhancing lesions. Core biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R mutation and PD-L1 TPS 10%. She was started on osimertinib 80 mg daily; palliative whole-brain radiotherapy was given for symptomatic brain metastases. Follow-up imaging at 8 weeks demonstrated a decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma (synchronous liver and peritoneal disease) tested MSI-H on PCR and had high TMB on sequencing. BRAF V600E mutation was detected. First-line pembrolizumab was initiated given MSI-H status with a good partial response of hepatic lesions after 3 cycles. On progression after 11 months, therapy was changed to encorafenib plus cetuximab with clinical benefit.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab first-line, later encorafenib + cetuximab", "response": "partial response to pembrolizumab; subsequent clinical benefit on encorafenib + cetuximab", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old male with a 1.2 cm cutaneous melanoma on the forearm, Breslow 1.1 mm, ulceration absent; staged as IA/IB (final staging recorded as IB). Wide local excision and negative sentinel lymph node; no mutation testing performed preoperatively. Patient remains clinically NED after surgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I (IB)", "gene_mutation": null, "biomarker": null, "treatment": "surgical excision (wide local excision, sentinel node biopsy)", "response": "no evidence of disease / complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with right-sided colon mass; biopsy confirmed adenocarcinoma. CT staging demonstrated multiple hypodense lesions in the liver consistent with metastatic disease (stage IV). Molecular testing returned BRAF V600E mutation and MSI-high status. Given MSI-H, he was started on pembrolizumab monotherapy. Interval imaging at 12 weeks showed reduction in hepatic tumor burden consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma on core biopsy. Molecular panel returned positive for EGFR L858R and no ALK/ROS1 rearrangement. PD-L1 TPS reported at 10%. MRI brain identified a single 1.5 cm enhancing lesion. She was started on osimertinib 80 mg daily and follow-up imaging at 8 weeks showed decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old female diagnosed with papillary thyroid carcinoma, stage I. Molecular testing demonstrates BRAF V600E mutation. She underwent total thyroidectomy followed by radioactive iodine ablation. Post-therapy whole body scan negative and stimulated thyroglobulin undetectable \u2014 patient is in remission and on levothyroxine suppression.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "total thyroidectomy and radioactive iodine", "response": "remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with newly discovered hepatic lesions on surveillance imaging. Core biopsy of a breast mass and liver lesion confirmed metastatic breast cancer. Tumor was ER-/PR- and HER2 3+ by IHC with FISH confirming HER2 amplification; germline testing identified a pathogenic BRCA1 variant. She was started on first-line pertuzumab + trastuzumab with docetaxel. After 3 cycles there was a clinical and radiographic decrease in liver disease burden.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IV", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "pertuzumab + trastuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic cutaneous melanoma, stage IV with multiple pulmonary nodules. Tumor NGS showed BRAF V600E. PD-L1 IHC was 10% and tumor mutational burden reported as high (TMB-high, 25 muts/Mb). Patient was started on dabrafenib plus trametinib with rapid symptomatic improvement; best radiographic response recorded as partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68\u2011year\u2011old male with sigmoid colon adenocarcinoma underwent resection; pathology pT3N1 (stage III). Tumor sequencing demonstrates KRAS G12D; mismatch repair proteins intact (MSI\u2011stable). He completed 6 cycles of adjuvant FOLFOX. Six\u2011month surveillance CT shows post\u2011operative changes without new lesions; clinically doing well and under routine follow up.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient is a 72-year-old male with metastatic prostate adenocarcinoma referred for symptom control. Bone scan negative for new lesions but pelvic CT shows enlarged pelvic and iliac lymph nodes concerning for nodal progression. He remains castrate with leuprolide and was started on abiraterone with prednisone. No somatic mutation testing available on prior records.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; abiraterone with prednisone", "response": "stable disease", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 58-year-old man with BRAF V600E\u2013mutant cutaneous melanoma. Primary lesion was excised; PET/CT later revealed multiple pulmonary nodules suspicious for metastases. He was treated with dabrafenib and trametinib with initial symptomatic benefit and a measurable partial response. At 6-month restaging a new increase in size and number of pulmonary nodules was reported indicating disease progression. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR exon 19 deletion and PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily in January 2020 with marked reduction of the primary lung lesion and intracranial disease. Most recent MRI and CT show ongoing partial response; residual metastases persist in the brain and thoracic spine.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology consult: 71-year-old man with biopsy-proven prostate adenocarcinoma, clinical T3aN0M0 (stage III). PSA at presentation 8.2 ng/mL. No genomic testing was performed and there is no history of BRCA testing. Bone scan and CT chest/abdomen/pelvis show no metastatic disease. Recommended treatment is definitive external beam radiation therapy with concurrent androgen deprivation therapy (leuprolide). Patient counseled regarding expected PSA surveillance schedule.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy and androgen deprivation (leuprolide)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old with metastatic cutaneous melanoma, BRAF V600E positive, presented with multiple pulmonary and hepatic lesions. Started combination targeted therapy with dabrafenib and trametinib after progression on prior checkpoint inhibitor. Interim CT shows shrinkage of several liver lesions and decreased PE; patient reports improved energy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with weight loss and right upper quadrant pain. Colonoscopy revealed an obstructing sigmoid colon adenocarcinoma. CT abdomen showed multiple hepatic metastases; overall stage IV. Molecular profile: BRAF V600E positive and tumor testing MSI-H; TMB-high reported. Given MSI-H status, he was started on pembrolizumab monotherapy. First restaging at 12 weeks shows stable disease by RECIST with modest decrease in some liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab monotherapy", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with stage IV lung adenocarcinoma presenting with cough and weight loss. Molecular testing showed EGFR L858R and acquired T790M; PD-L1 tumor proportion score 10%. She initially responded to osimertinib with regression of a solitary cerebellar lesion, but later developed progressive hepatic and osseous disease. Switched to combination chemotherapy and immunotherapy (carboplatin + pemetrexed + pembrolizumab). Current imaging demonstrates a partial response of extracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain (cerebellum), liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 48-year-old with ER-/PR- invasive ductal carcinoma of the right breast. Biopsy shows HER2 amplification by FISH. Patient presented with bone pain; PET/CT demonstrates multiple sclerotic lesions consistent with osseous metastases. She was started on first-line trastuzumab, pertuzumab and docetaxel. After 4 cycles the scans show no new lesions and minimal interval change in existing bony disease \u2014 overall assessed as stable disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab, and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man diagnosed with metastatic lung adenocarcinoma after CT-guided biopsy of right upper lobe mass. Molecular testing positive for EGFR L858R. PD-L1 expression reported at 20%. He was started on osimertinib 80 mg daily as first-line therapy. Follow-up CT at 8 weeks showed a marked decrease in primary tumor size and nodal burden consistent with a partial response. Brain MRI performed for new headaches revealed a 1.2 cm enhancing lesion in the left cerebellum consistent with metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with cutaneous melanoma of the left forearm, sentinel node positive; pathologic stage IIIC. Next-generation sequencing identified BRAF V600E. After wide local excision and nodal dissection the patient was started on adjuvant dabrafenib plus trametinib. At 6-month surveillance PET/CT a new 1.2 cm cerebellar metastasis and enlarging right lower lobe pulmonary nodule were noted, consistent with disease progression while on targeted therapy. Tumor mutational burden was reported as TMB-high.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib plus trametinib (adjuvant)", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for a deleterious BRCA1 mutation and HRD assay returned positive. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel for six cycles and was started on maintenance olaparib. CA-125 normalized and CT scans show no residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast (clinical T3N1). Biopsy: ER positive, PR positive, HER2 amplification by FISH; NGS identified PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma of the breast (HER2-positive)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "trastuzumab and pertuzumab with docetaxel (neoadjuvant), then surgery; adjuvant endocrine therapy planned", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed metastatic lung adenocarcinoma presented with headaches and back pain. Staging confirmed stage IV disease with multifocal brain metastases and lytic lesions in the spine. Molecular testing returned KRAS G12C and TMB-high; PD-L1 tumor proportion score 30%. He was started on combination chemo-immunotherapy with carboplatin and pemetrexed plus pembrolizumab. After 3 cycles there is a radiographic partial response with decrease in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 30%; TMB-high", "treatment": "carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone pain. Prior history includes androgen-deprivation therapy with leuprolide and six cycles of docetaxel. Germline and tumor testing revealed a deleterious BRCA2 mutation. Given progression on prior therapy he was started on olaparib. PSA and bone pain improved after 12 weeks and imaging showed reduction in size of several osseous lesions consistent with partial response.", "output": {"cancer_type": "prostate cancer (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "olaparib (after prior leuprolide and docetaxel)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old woman with locally advanced left breast cancer. Biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER positive, PR negative. Tumor genotyping identified PIK3CA H1047R. She received neoadjuvant weekly paclitaxel followed by dose-dense AC and trastuzumab; clinical exam now shows no palpable mass and MRI suggests complete clinical response. No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel; doxorubicin + cyclophosphamide (AC); trastuzumab", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old female with de novo metastatic HER2-positive invasive ductal carcinoma of the breast. Biopsy and FISH confirmed HER2 amplification; ER and PR were negative. Bone scan and PET show multiple lytic lesions in the spine and pelvis. She was initiated on first-line trastuzumab and pertuzumab with docetaxel. Tolerating therapy with radiographic disease control and overall clinical stable disease noted at 3 months.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with progressive cough found to have lung adenocarcinoma. Staging scans show multiple pulmonary nodules, bone lesions and two small enhancing brain metastases; overall staged as IV. Tumor NGS returned EGFR L858R. PD-L1 tumor proportion score 10%. Started osimertinib 80 mg daily. Interval CT/MRI at 8 weeks demonstrates decrease in size of chest lesions and near-resolution of brain mets consistent with a partial response; bone disease remains scintigraphically positive.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a 2.5 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Clinical stage was IIA (T2N0M0). She received neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) followed by breast-conserving surgery and adjuvant radiotherapy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab; surgery; adjuvant radiotherapy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neo-adjuvant clinic note: 48-year-old with locally advanced left breast cancer (T3N2) clinically staged as IIIB. Core biopsy: invasive ductal carcinoma, HER2 3+ by FISH positive, ER positive, PR negative. PIK3CA H1047R mutation identified on panel. Patient received 6 cycles of docetaxel, carboplatin with trastuzumab and pertuzumab; path report after surgery showed no residual invasive carcinoma (pathologic complete response). No distant mets identified on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma. At presentation she had bulky peritoneal disease and omental caking; CA-125 markedly elevated. Germline testing returned a deleterious BRCA1 mutation. She underwent primary debulking followed by adjuvant carboplatin and paclitaxel; given partial radiographic and tumor-marker response she was started on olaparib maintenance. Diagnosis recorded as stage IIIC with peritoneal involvement.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious germline)", "biomarker": null, "treatment": "primary debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic colorectal adenocarcinoma. Liver and peritoneal implants noted on CT. Tumor testing: KRAS G12D mutation; MSI-H by PCR. Initial therapy was FOLFOX with bevacizumab; after progression on first-line she was switched to pembrolizumab on clinical protocol. CT at 12 weeks demonstrates predominantly stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative note: 65-year-old male underwent laparoscopic sigmoid resection for adenocarcinoma. Pathology staged as T3N1 (stage III). Molecular testing identified KRAS G12D and tumor was MSI-stable. He completed 6 months of adjuvant FOLFOX with good tolerance. Surveillance CT at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colorectal adenocarcinoma (sigmoid)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgical resection; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed 2019. Comprehensive molecular profiling revealed an EGFR L858R mutation. Baseline PD-L1 tumor proportion score 10%. MRI brain demonstrated multiple enhancing lesions consistent with metastases. Patient started osimertinib 80 mg daily in June 2021 with interval CT showing a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with pancreatic ductal adenocarcinoma, stage IV with liver metastases. Germline testing confirmed a BRCA2 mutation and CA19-9 was markedly elevated at diagnosis. She received FOLFIRINOX with clinical benefit and was transitioned to olaparib maintenance; most recent CT shows stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX then olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old female with invasive ductal carcinoma of the right breast, clinical stage II (cT2N0M0). Core biopsy showed ER-positive, PR-positive, HER2 amplification by FISH. Genomic profiling identified PIK3CA H1047R. She received neoadjuvant docetaxel/carboplatin with trastuzumab; surgery report notes a pathologic complete response (pCR). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48 y/o F with left invasive ductal carcinoma, triple-negative on core biopsy (ER negative, PR negative, HER2 negative). Germline testing identified a pathogenic BRCA1 mutation. Pathology after lumpectomy: T2N0 (stage IIA). No radiologic evidence of distant disease. Plan is adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel; radiation oncology referral placed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "BRCA1 mutation", "biomarker": "ER-/PR-/HER2-", "treatment": "lumpectomy; planned adjuvant doxorubicin and cyclophosphamide followed by paclitaxel", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with metastatic colorectal adenocarcinoma presenting with a dominant liver lesion. Tumor was reported MSI-H on PCR and high tumor mutational burden. Given the mismatch repair deficiency the patient was started on pembrolizumab monotherapy with marked radiographic regression of hepatic disease and a sustained complete response on follow-up CT. KRAS/NRAS mutational status not documented in this note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Tumor board note: 52-year-old female with metastatic cutaneous melanoma harboring BRAF V600E. Pretreatment PD-L1 was 5% and tumor sequencing reported TMB-high. She presented with multiple pulmonary nodules (stage IV). Systemic therapy with dabrafenib and trametinib was started. Early imaging at 8 weeks showed a marked decrease in chest nodules (partial response), but CT at 6 months documents new enlargement of several lung lesions consistent with progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with palpable right breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH; PIK3CA E545K detected on NGS. Staging workup suggests T4N2 disease consistent with stage IIIB. She was started on neoadjuvant trastuzumab and pertuzumab with docetaxel for 6 cycles. Clinical exam and imaging demonstrated good tumor shrinkage but not complete resolution (partial response); plan for definitive mastectomy thereafter.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with clear cell renal cell carcinoma, found to have metastatic disease with an adrenal mass on staging CT. Tumor sequencing identified a pathogenic VHL frameshift mutation. He was started on sunitinib with symptomatic improvement and interval radiographic disease control reported as stable disease.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": "VHL mutation", "biomarker": null, "treatment": "sunitinib", "response": "stable disease", "metastasis_site": "adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Tumor is ER positive, PR positive and shows HER2 amplification by FISH. She received neoadjuvant carboplatin and docetaxel with trastuzumab, followed by modified radical mastectomy. Surgical pathology demonstrated a pathologic complete response. Germline BRCA testing was negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with localized prostate adenocarcinoma Gleason 3+3. Clinical stage T1cN0M0 (stage I). He elected radical prostatectomy; postoperative pathology showed negative margins and organ-confined disease. No molecular testing was performed. PSA is now undetectable post-op.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I (T1cN0M0)", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage II, with pelvic tumor and pelvic peritoneal implants at surgery. Germline testing detected a pathogenic BRCA1 mutation. Preoperative CA-125 was 360 U/mL. She underwent optimal cytoreductive (debulking) surgery and was started on adjuvant carboplatin and paclitaxel. After three cycles CA-125 has fallen to 50 U/mL and CT shows a partial clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "II", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "CA-125 360 U/mL", "treatment": "debulking surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with newly diagnosed high-grade serous ovarian carcinoma, clinical stage IIIC. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Germline BRCA testing is pending and tumor HRD assay has been requested; no molecular report available in the chart yet. Patient was started on maintenance olaparib following chemotherapy and first surveillance CT shows complete radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "surgery; carboplatin + paclitaxel; maintenance olaparib", "response": "complete radiographic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma to the liver. Molecular testing: BRAF V600E mutation and microsatellite instability-high (MSI-H), TMB-high. He received FOLFOX plus bevacizumab as induction; given MSI-H status he was switched to nivolumab and ipilimumab with durable partial response on interval scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX + bevacizumab; then nivolumab + ipilimumab", "response": "durable partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R. PD-L1 TPS reported at 10%. MRI brain demonstrates multiple enhancing lesions and PET/CT showed osseous uptake consistent with bone metastases. Patient started osimertinib 80 mg daily and at 8-week restaging had a radiographic partial response and symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old man with metastatic cutaneous melanoma. Tumor genomics: BRAF V600E positive, NRAS wild-type; PD-L1 by IHC approximately 60%; high tumor mutational burden reported. He was initially treated with dabrafenib and trametinib with significant regression of most subcutaneous and pulmonary lesions, then transitioned to pembrolizumab for durability. Brain MRI, however, showed a new enhancing cerebellar lesion despite extracranial improvement.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%; TMB-high; NRAS wild-type", "treatment": "dabrafenib + trametinib followed by pembrolizumab", "response": "mixed response (extracranial response with new brain lesion)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. PD-L1 TPS 60%. MRI showed brain metastases and CT revealed multiple pulmonary nodules. He was treated with the BRAF/MEK combination dabrafenib plus trametinib; after 6 months new symptomatic brain lesions prompted switch to nivolumab. Overall imaging is reported as mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib, then nivolumab", "response": "mixed response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma of the sigmoid colon found to have multiple pulmonary nodules on staging CT. Tumor genotyping reported KRAS G12D. No MSI testing documented in the chart. He was started on FOLFOX with bevacizumab but restaging after three months demonstrated radiographic progression in the lungs.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Baseline staging showed multiple cerebral metastases and extracranial disease consistent with stage IV. Patient started osimertinib 80 mg PO daily in January 2024. Interval brain MRI and chest CT demonstrate reduction in size of the dominant brain lesion and shrinkage of pulmonary nodules compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT shows multiple liver metastases; colonoscopy found a sigmoid primary. Tumor genomics revealed BRAF V600E and high microsatellite instability (MSI-H) with elevated TMB (TMB-high). He was treated initially with FOLFOX plus bevacizumab; after progression he was switched to pembrolizumab monotherapy. Recent imaging after 4 months demonstrates stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX plus bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma metastatic to the liver. Core biopsy of hepatic lesion confirmed colorectal primary. Molecular testing reported KRAS G12D. The patient received first-line FOLFOX plus bevacizumab but surveillance CT at 12 weeks shows interval enlargement of multiple hepatic metastases and new satellite lesions consistent with progression.", "output": {"cancer_type": "colorectal cancer", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consultation: 64-year-old male with newly diagnosed stage IV lung adenocarcinoma. Molecular testing on biopsy returned EGFR L858R mutation. PD-L1 TPS 30%. MRI brain shows two small enhancing lesions consistent with metastases; PET/CT demonstrates osseous disease. Patient was started on osimertinib 80 mg daily as first-line targeted therapy with symptomatic improvement and interval CT at 8 weeks showing a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with newly diagnosed metastatic lung adenocarcinoma. Biopsy confirmed EGFR L858R mutation and PD-L1 10%. Staging demonstrated stage IV disease with intracranial lesions. She was started on osimertinib 80 mg daily and had a brisk clinical and radiographic partial response at 8 weeks. Surveillance MRI at 6 months showed new enhancing lesions consistent with progression in the brain; systemic disease otherwise controlled.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response followed by progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "73-year-old man with biopsy-proven lung adenocarcinoma in the right lower lobe. Staging PET/CT demonstrates multiple pulmonary nodules and enhancing lesions in the cerebrum consistent with metastatic disease. Molecular testing: EGFR L858R positive. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg PO daily with improvement on interval MRI of the brain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and gait instability. Staging CT and MRI demonstrated multiple intracranial metastases and sclerotic bone lesions consistent with stage IV disease. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 5%. Patient started osimertinib 80 mg daily as first-line targeted therapy with symptomatic improvement and interval shrinkage of brain lesions on first follow-up \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "De novo metastatic breast cancer in a 48-year-old woman. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH; next\u2011generation sequencing returned PIK3CA E545K. Imaging shows multiple lytic bone lesions in the spine and pelvis. She commenced paclitaxel with trastuzumab and pertuzumab and after 3 cycles has symptomatic improvement and a partial metabolic response on PET/CT. Plan is maintenance trastuzumab thereafter.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal disease. Germline BRCA1 mutation identified on genetic testing. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. CT after completion of chemotherapy shows a decrease in peritoneal implants consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: Pt with metastatic colorectal adenocarcinoma to the liver (stage IV). Tumor sequencing detected KRAS G12D; MSI testing showed microsatellite stable (MSS). He was started on FOLFOX plus bevacizumab. CT imaging after 3 cycles demonstrated stable disease compared with baseline liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic colon adenocarcinoma with multiple liver lesions on CT. Tumor sequencing revealed BRAF V600E mutation and MSI-high status on PCR. Staging: IV at diagnosis. Started systemic therapy with FOLFIRI plus bevacizumab as first-line palliative chemo. Restaging after 2 months demonstrated increase in size of hepatic lesions and new peritoneal nodularity.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-high", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic pancreatic ductal adenocarcinoma presented with progressive weight loss and jaundice. Imaging confirmed extensive hepatic metastases consistent with stage IV disease. Patient was started on FOLFIRINOX; after three cycles there was clinical deterioration and radiographic progression. Germline and somatic testing pending; no actionable mutation reported in the current chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing revealed BRCA1 185delAG pathogenic variant. Preoperative CA-125 was 820 U/mL. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. Given BRCA1 mutation, she was started on maintenance olaparib after chemotherapy. At 6-month follow-up CA-125 normalized and CT chest/abdomen/pelvis shows no evidence of disease.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 elevated pretreatment, normalized on follow-up", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female presented with a newly diagnosed glioblastoma after craniotomy. She underwent maximal safe resection and then completed concurrent radiation with temozolomide. Molecular panel not yet resulted (MGMT methylation and IDH testing pending; no NGS reported). Early post-treatment MRI shows interval enlargement of the enhancing lesion at the resection cavity and increasing edema suspicious for progression\u2014plan is to discuss second-line options at tumor board.", "output": {"cancer_type": "glioblastoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "surgery; concurrent radiation with temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 52-year-old female with left breast invasive ductal carcinoma, ER+, PR+, HER2 amplified by FISH. Clinical stage T4bN1 (stage IIIB). Tumor NGS reported PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for 6 cycles; imaging showed marked decrease in tumor size but residual disease at surgery \u2014 described as a partial pathologic response. No distant mets identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 56-year-old male with newly diagnosed glioblastoma multiforme (right temporal). Tumor is IDH1 R132H positive; MGMT promoter unmethylated. Underwent subtotal resection followed by concurrent radiation and temozolomide per Stupp protocol. MRI at 3 months shows increase in enhancement at resection margin concerning for progression; steroids increased.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter unmethylated", "treatment": "surgery; radiation with concurrent temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female never-smoker presented with cough and headache. CT and MRI demonstrated lung adenocarcinoma with T2N2 primary and multiple brain and bony lesions consistent with metastatic disease (stage IV). Comprehensive NGS returned EGFR L858R mutation and PD-L1 10%. She was started on osimertinib 80 mg daily in February; repeat imaging at 8 weeks showed decrease in size of primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology follow-up: 68-year-old man with advanced prostate adenocarcinoma (Gleason 4+5). He had radical prostatectomy and adjuvant radiation last year but developed rising PSA and subsequent bone scans showing new sclerotic lesions consistent with metastatic spread. He received androgen\u2011deprivation therapy (leuprolide) with bicalutamide, later transitioned to abiraterone plus prednisone for castration-resistant disease. Despite systemic therapy, imaging demonstrates progression in the pelvis and multiple bones.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and bicalutamide; then abiraterone plus prednisone; prior surgery and radiation", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old male with primary cutaneous melanoma of the back treated with wide local excision. Molecular profiling later returned BRAF V600E. Over the following year he developed multiple pulmonary nodules and a symptomatic brain metastasis; he was started on dabrafenib plus trametinib with an initial mixed radiographic response but progressed after six months and was transitioned to ipilimumab and nivolumab. PD-L1 was 1% and tumor mutational burden reported as TMB-high.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%; TMB-high", "treatment": "dabrafenib and trametinib; later ipilimumab and nivolumab", "response": "progressive disease", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 45-year-old male with cutaneous melanoma of the scalp. Wide local excision with positive sentinel lymph node. Molecular testing returned BRAF V600E. Over the following months he developed symptomatic brain metastases and multiple pulmonary nodules \u2014 stage IV. Began combination targeted therapy with dabrafenib 150 mg BID and trametinib 2 mg daily. Early restaging showed partial shrinkage of lung nodules but new and enlarging cerebellar metastasis; plan to consider SRS and change systemic therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "mixed response / progressive disease (new brain lesion)", "metastasis_site": "brain; lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old male with newly diagnosed glioblastoma (WHO grade IV). IDH1-wildtype. Molecular studies demonstrate a TERT promoter mutation and MGMT promoter methylation. He underwent a subtotal resection followed by concurrent radiotherapy with temozolomide and plans for adjuvant temozolomide. MRI at 3 months post-radiation showed radiographic stable disease, with progression documented at 9 months.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "TERT promoter mutation", "biomarker": "MGMT promoter methylated", "treatment": "subtotal resection; concurrent radiotherapy with temozolomide; adjuvant temozolomide planned", "response": "stable disease then progression at 9 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital discharge summary: 72-year-old man with metastatic castration-resistant prostate adenocarcinoma to the axial skeleton. Initially treated with leuprolide and androgen deprivation; more recently progressed and started enzalutamide with temporary PSA stabilization. After biochemical progression he received 6 cycles of docetaxel with clinical stabilization of bone pain. No tumor NGS or PD-L1 testing available in chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (ADT), enzalutamide, docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman with high-grade serous ovarian carcinoma, optimal debulking achieved; pathologic stage IIIC with peritoneal implants. Germline testing returned pathogenic BRCA1 mutation. CA-125 was elevated at diagnosis and normalized after 6 cycles of carboplatin and paclitaxel. Patient was started on maintenance olaparib with continued clinical complete response on follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 (elevated at diagnosis, normalized after treatment)", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Emergency oncology note: 64-year-old presented with pancreatic ductal adenocarcinoma with liver metastases, symptomatic jaundice. Staging corresponded to metastatic disease. No actionable mutations were identified on initial NGS panel and PD-L1 testing was not performed. He was started urgently on FOLFIRINOX; after two cycles patient had clinical decline and radiographic progression.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with metastatic colorectal adenocarcinoma. Molecular testing: KRAS G12D and MSI-H with high tumor mutational burden (TMB-high). She progressed on adjuvant FOLFOX and was transitioned to pembrolizumab for metastatic disease to the liver. Interval MRI demonstrates reduction in size of hepatic lesions consistent with partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma presented with progressive dyspnea. Initial staging showed stage IV disease with multiple pulmonary nodules and new cerebellar metastases on MRI. Molecular testing reported EGFR L858R mutation; PD-L1 was 12% and tumor mutational burden high. He was started on first-line osimertinib with radiographic response for 8 months, then progressed and was transitioned to carboplatin + pemetrexed combined with pembrolizumab. Imaging after three cycles demonstrates a partial response with decreased size of lung lesions and stable brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 12%, TMB-high", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 71-year-old male with metastatic prostate adenocarcinoma presenting with diffuse osteoblastic bone metastases. He was started on leuprolide depot and abiraterone with prednisone. PSA fell from 150 to 8 ng/mL over three months; bone scan shows persistent but stable uptake in the axial skeleton. Tumor sequencing did not identify actionable somatic alterations.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) + abiraterone and prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative clinic note: 49-year-old female with locally advanced left breast cancer (T4bN1). Biopsy ER+/PR+, HER2 3+ by IHC and ISH confirmatory positive. No distant disease on staging PET-CT. She received neoadjuvant trastuzumab, pertuzumab and docetaxel for 6 cycles with excellent clinical shrinkage followed by left modified radical mastectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+ (ISH positive); ER positive; PR positive", "treatment": "neoadjuvant trastuzumab, pertuzumab and docetaxel; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: 42-year-old female with a 1.8 cm invasive ductal carcinoma of the left breast (ER+, PR+, HER2 0). Final staging pT1cN0M0 (stage I) after lumpectomy with sentinel node negative. Tumor sequencing identified PIK3CA H1047R. Patient started adjuvant tamoxifen; no radiographic evidence of disease on 6-month follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 0 (HER2-negative)", "treatment": "tamoxifen", "response": "no evidence of disease (NED)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma presenting with right-sided liver metastases. Colonoscopy confirmed primary sigmoid tumor; staging consistent with Stage IV disease. Tumor genotyping identified KRAS G12D mutation. He was treated with FOLFOX plus bevacizumab; CT after 3 months shows no new lesions and minimal decrease in target liver lesions consistent with stable disease. Carcinoembryonic antigen (CEA) downtrended but molecular biomarker panel otherwise not informative.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with newly diagnosed stage IV lung adenocarcinoma. Staging CT and brain MRI confirm multiple pulmonary nodules and two enhancing intracranial lesions consistent with metastases. Tumor sequencing identified EGFR L858R. PD-L1 tumor proportion score 20%. He was started on osimertinib 80 mg daily in March; follow-up imaging in June demonstrates decrease in size of lung lesions and intracranial metastases. Assessment documented as partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with stage IV colorectal adenocarcinoma with liver-dominant metastases. Molecular profiling: KRAS G12D mutation; microsatellite stable. Treated with FOLFIRI plus bevacizumab as first-line systemic therapy. CT at 12 weeks shows minimal change in hepatic lesions without new sites.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a 2.5 cm invasive ductal carcinoma of the left breast, clinical stage II. Tumor is ER positive, PR negative and demonstrates HER2 amplification by FISH. She received neoadjuvant doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab; subsequent lumpectomy showed no residual invasive carcinoma on pathology. No distant disease identified on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant doxorubicin and cyclophosphamide, paclitaxel with trastuzumab; lumpectomy", "response": "pathologic complete response (no residual invasive carcinoma)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a palpable left breast mass. Core biopsy showed invasive ductal carcinoma, ER-positive, PR-positive, HER2-negative (IHC 0). Staging workup consistent with T1cN1 disease \u2014 pathologic stage IIA after lumpectomy with sentinel node biopsy. PIK3CA H1047R identified on next-generation sequencing. She completed adjuvant radiation and was started on tamoxifen. Surveillance mammogram and MRI show no residual disease.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative (IHC 0)", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 72-year-old man diagnosed with metastatic sigmoid colon adenocarcinoma, stage IV with dominant hepatic lesions. Molecular profile: KRAS G12C mutation reported on PCR-based panel. Patient received first-line FOLFOX with bevacizumab for 6 cycles with initial CA19-9 decrease but interval CT shows growth of hepatic mets and new peritoneal implants. The team documents disease progression and is considering second-line options including clinical trials targeting KRAS G12C.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consultation letter: 45-year-old man with recurrent cutaneous melanoma metastatic to lung and brain. Molecular testing detected BRAF V600E. He was started on dabrafenib plus trametinib and had an initial extracranial partial response, but recent brain MRI demonstrates progression of intracranial disease. Plan is to transition to ipilimumab and nivolumab; PD-L1 testing was not performed. Staging: Stage IV disease with brain and pulmonary metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (switched to ipilimumab/nivolumab planned)", "response": "initial partial response then intracranial progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female initially staged as IIIB invasive ductal carcinoma of the left breast. Pathology: ER-positive, PR-negative; HER2 IHC 3+ with HER2 amplification confirmed by FISH. After neoadjuvant AC then paclitaxel she was started on trastuzumab. Restaging PET/CT now demonstrates new lytic lesions in the thoracic spine consistent with osseous metastases; patient is being managed systemically and disease is currently considered stable on trastuzumab plus chemotherapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-negative", "treatment": "trastuzumab with chemotherapy (AC then paclitaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colon adenocarcinoma, biopsy-proven. CT shows multiple liver lesions consistent with metastases. Tumor testing: BRAF V600E mutation and MSI-H status with high tumor mutational burden. Patient started on pembrolizumab monotherapy after discussion of immunotherapy given MSI-H; best response reported to date is stable disease on 12-week scan.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a 4 cm left breast mass. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with confirmed HER2 amplification by FISH, ER and PR negative. Clinical stage was IIIA with suspicious axillary nodes. She received neoadjuvant paclitaxel with trastuzumab for 12 weeks followed by modified radical mastectomy. Final pathology showed no residual invasive disease in the breast or nodes (pathologic complete response). No tumor sequencing was performed.", "output": {"cancer_type": "invasive ductal breast carcinoma (HER2-positive)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab followed by surgery", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal breast carcinoma. Core biopsy: ER positive, PR negative, HER2 amplified by FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. Clinical stage was IIIA with large primary and involved axillary nodes. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles, followed by lumpectomy and axillary dissection. Surgical pathology revealed no residual invasive carcinoma (pCR). No radiographic evidence of distant metastasis.", "output": {"cancer_type": "breast cancer (invasive ductal, HER2-positive)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma, stage IV at diagnosis with multiple hepatic lesions. Germline and tumor testing identified a pathogenic BRCA2 mutation. She received FOLFIRINOX for 8 cycles with radiographic partial response and then was placed on olaparib maintenance; most recent CT shows interval growth of several liver lesions consistent with progression on maintenance therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "initial partial response then progression on maintenance", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male referred for progressive dyspnea. Biopsy confirmed lung adenocarcinoma. Staging CT and brain MRI show multiple intracranial lesions consistent with metastases and bilateral pulmonary nodules; overall consistent with stage IV disease. Molecular testing returned EGFR L858R and no ALK or ROS1 rearrangement. PD-L1 TPS 10%. Patient was started on osimertinib 80 mg daily with symptomatic improvement and imaging at 8 weeks demonstrates a partial response with reduction of both intracranial and thoracic disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly biopsied lung adenocarcinoma found to harbor EGFR L858R. PD-L1 TPS reported at 10%. Staging imaging demonstrated multiple enhancing intracranial lesions consistent with metastases. He was started on osimertinib 80 mg daily with improvement in symptoms and interval decrease in size of thoracic and intracranial disease on first restaging CT/MRI \u2014 partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology and follow-up: patient underwent debulking for high-grade serous ovarian carcinoma. Final stage documented as IIIC. Germline testing returned positive for a pathogenic BRCA1 mutation; HRD assay also positive. She completed 6 cycles of carboplatin and paclitaxel with excellent clinical response and was started on maintenance olaparib. No discrete distant metastases were recorded in the note.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD positive", "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 59-year-old male with sigmoid adenocarcinoma. Surgical pathology: moderately differentiated colorectal adenocarcinoma, KRAS G12D positive, BRAF wild-type. Mismatch repair proteins intact (MSI-stable). Baseline CT shows multiple hepatic lesions consistent with metastases \u2014 stage IV disease. Started on FOLFOXIRI plus bevacizumab. After 3 cycles CEA rising and repeat CT shows interval enlargement of several liver lesions consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOXIRI and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with recurrent cutaneous melanoma. NGS identified an NRAS Q61R mutation. PD-L1 testing was not performed. She received combination ipilimumab and nivolumab for metastatic disease but progressed after two cycles with new pulmonary nodules and worsening dyspnea. Clinical impression: progressive metastatic melanoma.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old man with metastatic cutaneous melanoma positive for BRAF V600E. PD-L1 staining low (5%) but tumor shows high TMB. Multiple brain metastases identified on MRI. He was started on combination dabrafenib and trametinib; interval MRI at 4 months shows a partial intracranial and extracranial response. Plan to consider nivolumab if further progression occurs.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female status post low anterior resection for sigmoid adenocarcinoma. Pathologic stage IIIB (T3N1M0) with one out of 12 nodes positive. Tumor was MSI-high by PCR; KRAS testing was not yet resulted at discharge. She completed adjuvant FOLFOX x6. Surveillance CT at 9 months shows no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma (sigmoid)", "stage": "IIIB (T3N1M0)", "gene_mutation": null, "biomarker": "MSI-high", "treatment": "surgery (low anterior resection), adjuvant FOLFOX x6", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic cutaneous melanoma. Initial molecular profiling revealed BRAF V600E. He was started on pembrolizumab but after 12 weeks developed progression in the brain and lungs. Pembrolizumab was stopped and therapy was changed to dabrafenib plus trametinib with concurrent stereotactic radiosurgery to the dominant brain lesion. Extracranial disease shrank on targeted therapy while CNS disease required local control measures.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (initial); dabrafenib + trametinib (targeted therapy); stereotactic radiosurgery", "response": "progression on pembrolizumab then partial response to dabrafenib + trametinib (extracranial); CNS progression requiring local therapy", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with extensive peritoneal carcinomatosis and omental disease. Underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. She achieved a complete clinical response on exam and CA-125 normalized. Germline and somatic BRCA testing not performed.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel; cytoreductive surgery", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma, stage IV. MRI brain and PET/CT showed multiple enhancing lesions in the cerebrum and lytic lesions in the femur. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily with interval imaging at 8 weeks showing decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man underwent excision of a superficial spreading melanoma on the left forearm. Breslow 0.8 mm, no ulceration, sentinel node negative \u2014 staged as IA. No molecular testing was performed. Wide local excision with appropriate margins was completed and the patient remains well with no clinical or radiographic evidence of disease on follow-up.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging demonstrated multiple intracranial lesions and lytic lesions in the thoracic spine consistent with metastatic disease. Biopsy confirmed adenocarcinoma of the lung, molecular testing positive for EGFR L858R. PD-L1 tumor proportion score reported at 10%. Staged as IV at diagnosis. He was started on first-line osimertinib 80 mg daily with good initial clinical benefit and radiographic partial response on first follow-up CT brain and chest.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42M referred for metastatic cutaneous melanoma. Tumor tested positive for BRAF V600E. He was started on dabrafenib plus trametinib with good intracranial control after stereotactic radiosurgery to two lesions. However PET/CT now shows a new FDG-avid lesion in the liver consistent with progression \u2014 overall a mixed response. PD-L1 was not reported in the chart.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response (intracranial complete response, hepatic progression)", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Brief oncology summary: 70-year-old female with pancreatic ductal adenocarcinoma presenting with jaundice. Imaging shows primary pancreatic head mass with multiple hypodense liver lesions. Stage: IV. Comprehensive NGS failed to identify actionable alterations. CA 19-9 at presentation was 12,000 U/mL. She received FOLFIRINOX (modified dosing for toxicity). Restaging CT after 3 cycles demonstrated interval enlargement of hepatic metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 markedly elevated", "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left arm cutaneous melanoma, stage III, BRAF V600E positive. PD-L1 reported at 2% and tumor mutational burden described as high. Patient received adjuvant dabrafenib plus trametinib for 12 months and localized radiotherapy to a nodal recurrence. After nine months of therapy imaging showed mixed response with a new small brain metastasis requiring neurosurgical consultation.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%; TMB-high", "treatment": "dabrafenib plus trametinib; localized radiotherapy", "response": "mixed response with new brain metastasis", "metastasis_site": "brain (new); regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative clinic note: 48-year-old female with palpable right breast mass. Core biopsy: invasive ductal carcinoma, HER2-positive by FISH (HER2 amplification), ER and PR negative. Staging imaging suggests tumor fixed to chest wall \u2014 clinical stage IIIB. NGS shows PIK3CA E545K. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by mastectomy; surgical pathology showed no residual invasive disease (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; mastectomy", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old male with a 1.2 mm ulcerated superficial spreading melanoma on the left forearm. Sentinel lymph node was negative and final pathologic staging was stage I. Wide local excision with 1 cm margins performed; no adjuvant systemic therapy recommended given early stage. Patient is on dermatologic surveillance with no signs of recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology telephone note: Patient is a 78-year-old male with castration-resistant prostate adenocarcinoma by PSA rise despite ADT. No molecular testing documented in chart. He was started on abiraterone acetate with prednisone and continues with monthly monitoring of PSA. Recent PSA kinetics suggest stable disease and he reports improved bone pain on the regimen.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "abiraterone acetate + prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Multidisciplinary note: 52-year-old female with a 1.8 cm invasive ductal carcinoma of the left breast, ER positive, PR positive, HER2 amplification by FISH. Sentinel node biopsy negative (0/3). PIK3CA H1047R mutation identified on tumor panel. She underwent breast-conserving surgery and will receive adjuvant paclitaxel followed by trastuzumab per HER2-positive protocol. Postoperative course uneventful and current status: no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 47-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical T3N2. Core biopsy: HER2 amplified by FISH, ER 80% positive, PR 40% positive; next-gen panel identified PIK3CA H1047R. She received neoadjuvant trastuzumab, pertuzumab and docetaxel for six cycles with clinical nodal downstaging. Final pathology after mastectomy: no residual invasive carcinoma (pCR).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with metastatic lung adenocarcinoma diagnosed 03/2024. Molecular testing showed EGFR exon 19 deletion and acquired MET amplification on repeat biopsy. PD-L1 by IHC 10%. Imaging demonstrates multiple cerebellar lesions and lytic lesions in T8. Started combination targeted therapy with osimertinib plus crizotinib in April; patient experienced marked tumor shrinkage on first restaging. Current assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; MET amplification", "biomarker": "PD-L1 10%", "treatment": "osimertinib plus crizotinib", "response": "partial response", "metastasis_site": "brain; bone (T8)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology consult: 57-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Initially treated with pembrolizumab but developed progression in the chest with multiple pulmonary nodules; subsequently switched to targeted therapy with dabrafenib and trametinib. PD-L1 was 20% and tumor mutational burden reported as high. On targeted therapy there has been a marked radiographic response with near-complete resolution of several nodules; overall assessment is a partial response to BRAF/MEK inhibition.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%; TMB-high", "treatment": "pembrolizumab (prior); dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with metastatic lung adenocarcinoma (EGFR-mutant) diagnosed 03/2024. Molecular testing showed EGFR L858R (exon 21); PD-L1 tumor proportion score 10%. Staging at diagnosis was IV with brain and osseous metastases. She was started on osimertinib 80 mg daily in April and achieved a radiographic partial response on first follow-up. No additional systemic therapy to date.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, stage IV with dominant liver metastases. Molecular testing: KRAS G12D mutation; tumor is MSI-H and TMB-high (37 mut/Mb). Initial treatment was FOLFOX with bevacizumab achieving stable disease, then switched to pembrolizumab because of MSI-H status, with interval shrinkage of hepatic lesions consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, TMB-high (37 mut/Mb)", "treatment": "FOLFOX + bevacizumab; later pembrolizumab", "response": "stable disease on FOLFOX + bevacizumab; partial response on pembrolizumab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with invasive ductal carcinoma of the right breast. Biopsy showed HER2 overexpression (IHC 3+, FISH amplified) and NGS detected a PIK3CA H1047R mutation. Staging workup consistent with stage IV disease due to multiple hepatic lesions on CT. She was started on first-line docetaxel with trastuzumab and pertuzumab; repeat CT after 3 cycles demonstrates stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+ / FISH+)", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral: 68-year-old male with colon adenocarcinoma. Primary was resected (T3N2) last year and now presents with multiple pulmonary nodules on chest CT consistent with metastatic recurrence (stage IV). Oncology record notes KRAS testing was not performed at time of relapse and MSI testing is pending. Patient started palliative FOLFOX with bevacizumab. Interval restaging after three months demonstrates no significant change in size of lung nodules \u2014 stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX, bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic cutaneous melanoma, stage IV, BRAF V600E positive. Initiated on dabrafenib plus trametinib with marked tumor shrinkage on the first two scans; subsequent imaging noted a new adrenal metastasis. Impression: initial partial response followed by progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression", "metastasis_site": "lung and adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with symptomatic intracranial disease. Molecular testing confirmed BRAF V600E mutation. PD-L1 by IHC 5%. The patient received combination immunotherapy with nivolumab plus ipilimumab as first-line therapy; extracranial disease demonstrated a partial response but repeat MRI showed progression of brain metastases, requiring stereotactic radiosurgery. Subsequently started on dabrafenib and trametinib.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "nivolumab plus ipilimumab; later dabrafenib and trametinib", "response": "partial response extracranially; progression in brain", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pt presented with locally advanced colon adenocarcinoma, clinical T3N1 (stage III) on imaging and colonoscopy. Tumor genotyping reported KRAS G12D and MSS. She received neoadjuvant FOLFOX x4 cycles with clinical partial response and proceeded to resection; pathology showed marked treatment effect with residual ypT2N0.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "neoadjuvant FOLFOX", "response": "partial response (downstaged to ypT2N0)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and oncology summary: 54-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental disease and peritoneal carcinomatosis. Germline BRCA1 mutation identified on genetic testing. She received neoadjuvant carboplatin and paclitaxel with good CA-125 decline, underwent interval debulking with no gross residual disease, and remains with no radiographic evidence of disease on most recent follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated (declined with treatment)", "treatment": "neoadjuvant carboplatin and paclitaxel followed by interval debulking surgery", "response": "no radiographic evidence of disease / clinical complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female diagnosed with stage IV lung adenocarcinoma. NGS of the biopsy identified EGFR L858R. Baseline MRI showed multiple intracranial metastases and lytic lesions in the thoracic spine. PD-L1 expression by IHC reported at 5%. Patient started osimertinib 80 mg daily in May; follow-up CT and brain MRI demonstrate decrease in size of the primary lung mass and improvement of most brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic cutaneous melanoma, BRAF V600E positive, presenting with multiple liver and brain metastases. PD-L1 was 10%. He was started on dabrafenib plus trametinib and had an initial partial response in hepatic lesions, but brain disease progressed at 4 months and he was switched to pembrolizumab with a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "initial partial response then progression in brain (mixed response)", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman underwent optimal cytoreductive surgery for high-grade serous ovarian carcinoma, FIGO stage IIIC. She completed six cycles of adjuvant carboplatin and paclitaxel with bevacizumab added to the regimen and is currently on bevacizumab maintenance. BRCA testing results were not available at discharge and no other molecular markers were reported. Follow-up CA-125 normalized and CT shows no visible residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin + paclitaxel with bevacizumab (adjuvant + maintenance)", "response": "complete response (no visible residual disease; CA-125 normalized)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic castration-resistant prostate adenocarcinoma. Imaging shows diffuse osteoblastic lesions in the spine and pelvis. Germline testing positive for BRCA2 mutation. He was maintained on leuprolide with abiraterone until radiographic progression, then started olaparib with clinical disease stabilization and falling PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "PSA elevated", "treatment": "leuprolide and abiraterone; olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male who underwent right hemicolectomy for colon adenocarcinoma staged pT3N1 at surgery (stage III). Adjuvant FOLFOX was completed for 6 months. Tumor genotyping identified KRAS G12D. Mismatch repair proteins were intact on IHC (no MSI testing reported in note). Surveillance CT at 18 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy followed by adjuvant FOLFOX", "response": "no evidence of disease after adjuvant therapy", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Summary: 70-year-old man with metastatic colon adenocarcinoma, initially resected primary but with recurrent liver metastases. Molecular profiling showed BRAF V600E mutation and high microsatellite instability (MSI-H). Given MSI-H status he was started on pembrolizumab monotherapy. Interval CT at 12 weeks shows shrinkage of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a right breast mass. Core biopsy showed invasive ductal carcinoma, ER positive, PR negative, HER2 IHC 3+. Clinical staging was T3N1M0 (stage IIIA). NGS revealed a PIK3CA H1047R mutation. She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles followed by lumpectomy. Post-op pathology showed no residual invasive carcinoma\u2014pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER+", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery (lumpectomy)", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma (stage IV). Germline testing returned a pathogenic BRCA2 mutation. After progression on enzalutamide he was started on the PARP inhibitor olaparib. Baseline imaging had shown multiple osseous metastases and pelvic nodal disease. PSA has declined and bone scans show partial radiographic response at 6 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "enzalutamide (prior); olaparib", "response": "partial response", "metastasis_site": "bone and pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma diagnosed after right hemicolectomy for obstructing tumor. Liver CT shows multiple bilobar hepatic metastases consistent with progression. Molecular panel positive for BRAF V600E; mismatch testing reported MSI-High. He was initiated on FOLFOX plus bevacizumab. After two cycles there is radiographic progression in the liver and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male referred for metastatic colorectal adenocarcinoma. CT abdomen shows multiple hypodense liver lesions consistent with metastases. Tumor genotyping identified KRAS G12D and microsatellite stable (MSS) status. Clinical stage IV disease. He was started on FOLFIRI with bevacizumab as first-line systemic therapy. Interval imaging after three months revealed increase in size and number of hepatic lesions consistent with radiographic progression.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R mutation and PD-L1 TPS 15%. Brain MRI demonstrates multiple enhancing lesions consistent with metastases. Patient started osimertinib 80 mg daily as first-line targeted therapy; after 8 weeks CT chest shows reduction in size of pulmonary nodules and measurable partial response by RECIST. No prior systemic chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presented with headache and back pain. Imaging showed multiple cerebral lesions and lytic lesions in the thoracic spine. Biopsy confirmed adenocarcinoma, molecular testing positive for EGFR L858R and PD-L1 expression ~10%. Patient was started on osimertinib 80 mg daily with stereotactic radiosurgery to the dominant brain metastasis. Interim CT at 8 weeks demonstrated decrease in size of lung primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Biopsy confirmed EGFR L858R mutation. Initial staging showed Stage IV disease with multiple intracranial and osseous lesions. PD-L1 by IHC reported 10%. Patient started osimertinib 80 mg daily in January 2024. Follow-up CT and brain MRI at 8 weeks demonstrate marked reduction in size of the primary tumor and brain mets with improvement of bone pain \u2014 overall partial response. Continuing osimertinib, tolerating therapy without dose reduction.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72M presented with jaundice and weight loss. ERCP-obtained biopsy confirmed pancreatic ductal adenocarcinoma. Imaging shows locally advanced primary with multiple liver lesions consistent with metastatic disease (stage IV). Tumor sequencing reported KRAS G12D; CA 19-9 markedly elevated at 12,000 U/mL. He was started on FOLFIRINOX. After two cycles there is radiographic progression in the liver.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female presented with unresectable pancreatic ductal adenocarcinoma with multiple liver metastases and peritoneal nodules at diagnosis (stage IV). Tumor sequencing identified a pathogenic BRCA2 frameshift mutation. CA19-9 was markedly elevated at 14,000 U/mL. She received first-line FOLFIRINOX with symptomatic improvement but interval CT after 3 cycles showed progression of hepatic lesions; she was switched to gemcitabine/nab-paclitaxel. Overall disease status: progressive disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 frameshift", "biomarker": "CA19-9 markedly elevated (14,000 U/mL)", "treatment": "FOLFIRINOX; then gemcitabine/nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old male admitted for craniotomy for a right frontal mass. Final diagnosis: glioblastoma multiforme (WHO grade IV). Underwent maximal safe resection; started concomitant radiotherapy and temozolomide per Stupp protocol. MGMT promoter and other molecular testing pending; no extracranial disease identified. Early postop MRI shows residual enhancing tumor with early interval growth.", "output": {"cancer_type": "glioblastoma multiforme (GBM)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgery (craniotomy) + radiotherapy + temozolomide", "response": "progressive disease (early interval growth)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma harboring a BRAF V600E alteration. Presents with pathologic fracture of the femur from a lytic metastasis; skeletal survey and PET confirm bone involvement. Treated with dabrafenib and trametinib; disease progressed after 5 months with new osseous and soft tissue lesions. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castrate-sensitive metastatic prostate adenocarcinoma presenting with back pain. Bone scan shows multiple osseous metastases. He was started on leuprolide depot and received six cycles of docetaxel. PSA fell from 220 ng/mL to 18 ng/mL and symptoms improved; currently receiving androgen deprivation with clinical benefit.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "partial response / clinical benefit (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Imaging and biopsy consistent with stage IV disease. Molecular testing identified EGFR exon 21 L858R mutation and PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily with an initial partial response on first follow-up CT. Separate MRI showed small brain metastases not requiring immediate radiation.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 58-year-old man with metastatic colorectal adenocarcinoma. Tumor NGS demonstrated KRAS G12D. CT abdomen shows multiple hepatic lesions consistent with metastatic disease. He received FOLFOX plus bevacizumab for 4 cycles but interval imaging documents increase in size and number of hepatic metastases; plan to change systemic regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, stage IIIC with extensive peritoneal carcinomatosis. Germline testing revealed a pathogenic BRCA1 variant. Patient underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with clinical partial response. Maintenance therapy with olaparib was started. CA-125 has trended downward and CT shows stable small peritoneal implants on most recent scan.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated (downtrending)", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "stable disease (after partial response to chemo)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with resected sigmoid colon adenocarcinoma, pathologic stage III (T3N1). Tumor genotyping returned KRAS G12D. MSI testing was positive (MSI-H). He completed adjuvant FOLFOX and was followed with surveillance CT; interval imaging demonstrates reduction in size of mesenteric nodal disease compared with baseline consistent with partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma, liver-dominant disease. Tumor profiling identified BRAF V600E and MSI-H status on PCR-based testing. Given high microsatellite instability, the patient was started on pembrolizumab monotherapy. After three cycles CT shows no new lesions and partial shrinkage of hepatic metastases; overall assessment is stable disease by RECIST with clinical benefit.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with cutaneous melanoma on the back, bulky nodal disease and a solitary symptomatic brain lesion. Staging documented as Stage III/IV with CNS involvement. PD-L1 10%, high TMB on genomic profiling; testing did not identify BRAF or NRAS mutations and no actionable target was reported. Patient received ipilimumab plus nivolumab combination immunotherapy and stereotactic radiosurgery to the brain lesion; follow-up MRI shows complete radiologic response in the treated intracranial lesion and near-complete nodal response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 10%; TMB-high", "treatment": "ipilimumab + nivolumab; stereotactic radiosurgery", "response": "complete response (intracranial); near-complete nodal response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma with liver-dominant disease on CT. Tumor panel returned positive for KRAS G12D. He has been treated with FOLFOX plus bevacizumab and completed 8 cycles. Three-month restaging CT shows no new lesions and minimal change in size of hepatic metastases; assessment: stable disease. PD-L1 testing was not performed.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 48-year-old woman with locally advanced HER2-positive breast cancer (clinical T4N1, stage IIIB). Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER positive, PR negative. Tumor sequencing identified PIK3CA H1047R mutation. She received 6 cycles of docetaxel with trastuzumab and pertuzumab prior to planned mastectomy. Pathology after surgery reported no residual invasive carcinoma (pathologic complete response). No distant mets identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR-", "treatment": "neoadjuvant docetaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with localized prostate adenocarcinoma, clinical T2bN0M0 (stage II), Gleason 3+4. He underwent radical prostatectomy; postoperative PSA became undetectable. Because of adverse features on pathology he received adjuvant external beam radiation and a six-month course of leuprolide. No metastatic disease has been identified on imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation; leuprolide (ADT)", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology note: 48-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical T3N2. Core biopsy: ER positive, PR positive, HER2 amplified (IHC 3+ / FISH positive). She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for six cycles with excellent clinical shrinkage, proceeded to lumpectomy and axillary dissection. Surgical pathology reports no residual invasive carcinoma \u2014 pathologic complete response. Plan to continue adjuvant trastuzumab/pertuzumab to complete 1 year and start endocrine therapy with letrozole.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP); adjuvant trastuzumab/pertuzumab; letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with invasive ductal carcinoma of the left breast, clinical stage IIB. ER positive, PR negative by IHC and HER2 amplification by FISH. Tumor sequencing identified a PIK3CA E545K mutation. She received neoadjuvant paclitaxel with concurrent trastuzumab and subsequently underwent lumpectomy with sentinel node biopsy. Pathology reported no residual invasive carcinoma (pathologic complete response). No evidence of distant metastasis on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate adenocarcinoma. Germline testing positive for BRCA2 mutation. PSA has been progressively rising; bone scan showed multiple osseous metastases. He remains on androgen deprivation therapy and was started on olaparib after confirmation of BRCA2. Interim bone scans and PSA trend demonstrate partial radiographic and biochemical response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "PSA elevated", "treatment": "androgen deprivation therapy; olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology/path report snippet: Patient with advanced melanoma. BRAF V600E mutation identified on tumor genotyping. Treated initially with pembrolizumab but developed symptomatic intracranial disease; therapy changed to dabrafenib and trametinib with partial radiographic response in both brain and pulmonary metastases. Current assessment: ongoing clinical benefit on targeted therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (prior), dabrafenib and trametinib (current)", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with metastatic cutaneous melanoma, Stage IV, BRAF V600E positive. Treated with dabrafenib plus trametinib combination therapy; initial response with symptom improvement but interval CT at 6 months showed new hepatic lesions consistent with progression. PD-L1 was reported at 5% on initial biopsy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 68-year-old man with newly diagnosed metastatic lung adenocarcinoma. Staging consistent with stage IV disease with a solitary cerebellar metastasis on brain MRI. Molecular testing: EGFR L858R positive; PD-L1 10% by 22C3. Patient started first-line osimertinib and underwent stereotactic radiosurgery to the brain lesion. CT at 8 weeks demonstrates decrease in size of pulmonary and nodal disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal breast carcinoma of the left breast. Biopsy: HER2 amplification by FISH, ER positive, PR negative. Tumor panel identified PIK3CA E545K. She received neoadjuvant trastuzumab and pertuzumab with paclitaxel for six cycles followed by modified radical mastectomy and adjuvant radiation. Pathology report described minimal residual disease consistent with a near complete response. No distant disease on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + paclitaxel (neoadjuvant); surgery; adjuvant radiation", "response": "near complete response (minimal residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma with dominant liver and peritoneal disease. Molecular testing returned BRAF V600E and MSI-high; TMB was reported as high and PD-L1 expression 5%. He was started on FOLFOX plus bevacizumab and achieved stable disease after 3 months, then switched to pembrolizumab because of MSI-H and subsequently had a partial response in the hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high; PD-L1 5%", "treatment": "FOLFOX and bevacizumab (initial); pembrolizumab (subsequent)", "response": "stable disease (on FOLFOX/bevacizumab); partial response (on pembrolizumab)", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male with newly diagnosed metastatic lung adenocarcinoma. Staging scans show multiple hepatic and scattered osseous metastases consistent with stage IV disease. Molecular testing: KRAS G12C and TP53 R248Q; PD-L1 TPS 30%; TMB-high (14 muts/Mb). He was started on first-line pembrolizumab with carboplatin and pemetrexed; after 4 cycles there was mixed response in the lung but a partial response in the liver. On progression he was switched to sotorasib with ongoing partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C; TP53 R248Q", "biomarker": "PD-L1 30%; TMB-high (14 muts/Mb)", "treatment": "pembrolizumab + carboplatin + pemetrexed; then sotorasib", "response": "partial response (after sotorasib); mixed response (to chemoimmunotherapy)", "metastasis_site": "liver; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. NGS showed EGFR L858R and a concurrent TP53 R273H. PD-L1 was 10% and TMB reported as low. He had an initial partial response to first-line osimertinib for 14 months, then developed new bone and brain metastases. After CNS and osseous progression he was started on carboplatin and pemetrexed while continuing osimertinib on a compassionate-use basis; most recent scans indicate progressive disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 R273H", "biomarker": "PD-L1 10%; TMB-low", "treatment": "osimertinib; carboplatin and pemetrexed (with continuation of osimertinib)", "response": "partial response (initial); progressive disease (after chemotherapy)", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female presents with newly progressive metastatic lung adenocarcinoma. Initial biopsy confirmed adenocarcinoma; molecular testing revealed an EGFR exon 19 deletion with acquired T790M on repeat plasma testing after progression on erlotinib. PD-L1 tumor proportion score 2%. Staging PET/CT and brain MRI consistent with stage IV disease with multifocal bone and cerebellar metastases. She was switched to osimertinib 80 mg daily two months ago with interval shrinkage of pulmonary and bony lesions on CT \u2014 documented as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; EGFR T790M", "biomarker": "PD-L1 2%", "treatment": "erlotinib (prior), osimertinib", "response": "partial response", "metastasis_site": "bone, brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma (stage IV) with liver lesions on CT. Molecular testing revealed BRAF V600E. Tumor mutational burden reported as TMB-high. He received combination targeted therapy with dabrafenib and trametinib and initially achieved a partial response, but interval imaging at 6 months demonstrated progression in the liver.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular profiling returned EGFR L858R positive; PD-L1 TPS 5%. Baseline staging showed multiple pulmonary nodules with cerebellar and lytic T8 lesions on MRI \u2014 consistent with brain and bone metastases. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval imaging at 8 weeks shows decrease in size of chest lesions and reduced enhancement of the cerebellar lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with locally advanced pancreatic ductal adenocarcinoma involving the superior mesenteric artery (unresectable, cT4). CA19-9 at diagnosis 520 U/mL. Baseline molecular testing showed KRAS G12V. He received 6 cycles of modified FOLFIRINOX followed by consolidative chemoradiation. Restaging PET/CT demonstrates decrease in primary FDG uptake but persistent soft tissue abutment of SMA; overall radiologic assessment: stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12V", "biomarker": "CA19-9 520 U/mL", "treatment": "modified FOLFIRINOX; consolidative chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colorectal adenocarcinoma, stage IV, presenting with multiple pulmonary nodules. Molecular profiling demonstrates KRAS G12C mutation; mismatch repair intact (MSI-stable). He was started on first-line mFOLFOX6 with bevacizumab. Interval imaging after 3 months shows increase in size and number of lung metastases consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSI-stable", "treatment": "mFOLFOX6 and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: Patient with ulcerated cutaneous melanoma of the right thigh. Sentinel node positive \u2014 pathologic stage IIIA. Tumor sequencing identified a BRAF V600E alteration. She was started on adjuvant dabrafenib plus trametinib. Six\u2011month PET/CT showed complete metabolic response in the nodal basin. No other systemic metastases detected.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and focal weakness. Staging CT and MRI show multiple cerebral metastases and lytic lesions in the left femur; overall disease consistent with Stage IV. Molecular testing returned EGFR L858R mutation; PD-L1 expression by IHC 10%. Started first-line osimertinib 80 mg daily with stereotactic radiosurgery to dominant brain lesion. At 8-week scan there is a marked decrease in size of the pulmonary primary and brain lesions \u2014 documented partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with prostate adenocarcinoma, clinical stage III (T3bN0M0), Gleason score 4+5. Preoperative PSA was 18 ng/mL. He underwent radical prostatectomy followed by adjuvant external beam radiation and androgen deprivation therapy with leuprolide. Post-treatment PSA is undetectable. No molecular testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "PSA 18 ng/mL (pre-treatment); undetectable PSA post-treatment", "treatment": "radical prostatectomy, adjuvant radiation, leuprolide", "response": "undetectable PSA (biochemical remission)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic lung adenocarcinoma presented with headaches and new liver lesions. Molecular testing on the biopsy identified EGFR L858R and acquired EGFR T790M. PD-L1 was 5% and tumor mutational burden was low. She was started on osimertinib with an initial partial response in the chest and reduction in CNS symptoms; after 10 months she progressed with new brain and hepatic metastases and was switched to carboplatin + pemetrexed. Palliative stereotactic radiosurgery was delivered to a solitary cerebellar lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 5%; TMB-low", "treatment": "osimertinib, later carboplatin + pemetrexed; stereotactic radiosurgery", "response": "initial partial response to osimertinib, later progression", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a small left breast invasive ductal carcinoma, clinical stage I (T1N0M0). Tumor is ER positive, PR positive and shows HER2 amplification by FISH. She underwent lumpectomy with sentinel lymph node biopsy followed by adjuvant paclitaxel and trastuzumab. Surveillance mammography and MRI show no evidence of disease at 18 months post-op.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "lumpectomy; paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old female diagnosed with stage IV lung adenocarcinoma harboring an EGFR exon 19 deletion. Baseline PD-L1 was 5%. Imaging demonstrated multiple bilateral pulmonary nodules and a solitary cerebellar metastasis. She was started on osimertinib with stereotactic radiosurgery to the cerebellar lesion. Chest CT at 3 months showed shrinkage of pulmonary lesions (partial response) but at 8 months developed intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib and stereotactic radiosurgery", "response": "partial response followed by intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old man with metastatic cutaneous melanoma, stage IV at presentation with multiple pulmonary and intracranial lesions. Tumor profiling revealed BRAF V600E and PD-L1 >50%. He was started on pembrolizumab but progressed after 4 cycles. Therapy was switched to dabrafenib plus trametinib with interval imaging showing reduction in lung nodules and stable brain disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab then dabrafenib + trametinib", "response": "progression on pembrolizumab followed by partial response to dabrafenib+trametinib", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old man diagnosed with lung adenocarcinoma. Imaging and biopsy confirm stage IV disease with multiple pulmonary nodules and symptomatic brain metastases. Molecular panel returned EGFR L858R; PD-L1 tumor proportion score approximately 10%. He was started on osimertinib and received stereotactic radiosurgery to the dominant brain lesion. Interval scans after 8 weeks demonstrate decreased size of chest lesions and partial response in the brain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and lung (pulmonary nodules); bone not mentioned"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male referred to oncology for progressive cough and new headaches. CT chest/abdomen demonstrated a right upper lobe mass; biopsy confirmed lung adenocarcinoma. Molecular testing identified EGFR L858R. Baseline brain MRI showed two enhancing lesions consistent with metastases. PD-L1 IHC reported 5%. Staged as IV. Patient started osimertinib 80 mg daily; 8-week imaging showed decrease in size of primary and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy showed invasive ductal carcinoma, ER negative, PR negative; HER2 IHC 3+ with confirmed HER2 amplification by FISH. No actionable mutations were reported on the limited NGS panel sent. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for six cycles followed by mastectomy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with locally advanced pancreatic ductal adenocarcinoma, clinically staged III. Comprehensive NGS on the core biopsy showed no actionable alterations (no BRCA1/2, no targetable fusions). MSI testing was stable. He was treated with FOLFIRINOX followed by concurrent chemoradiation. Post-treatment CT demonstrates stable disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-stable", "treatment": "FOLFIRINOX and concurrent radiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old female with locally advanced invasive ductal carcinoma of the breast. Core biopsy: HER2 amplification by FISH, ER positive, PR positive; NGS identified PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab combined with dose-dense doxorubicin/cyclophosphamide followed by docetaxel. Mastectomy specimen demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and pertuzumab with dose-dense doxorubicin/cyclophosphamide followed by docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old with left invasive ductal breast carcinoma, ER/PR positive and HER2-amplified (IHC 3+). Clinical stage IIIA with fixed level I\u2013II axillary nodes. Core biopsy NGS identified PIK3CA H1047R. Patient received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with concurrent trastuzumab; underwent left mastectomy. Surgical pathology showed no residual invasive tumor (pCR). Will complete adjuvant trastuzumab to one year.", "output": {"cancer_type": "breast cancer (HER2-amplified)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin and cyclophosphamide then paclitaxel with trastuzumab; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with castration-resistant prostate adenocarcinoma and diffuse sclerotic bone metastases. Germline testing returned a pathogenic BRCA2 variant. He remains on androgen deprivation therapy and was recently started on abiraterone acetate with prednisone. No additional tumor biomarker panel is available in the chart and clinical response is pending.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "androgen deprivation therapy + abiraterone acetate (with prednisone)", "response": null, "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Admission note: 70-year-old male with metastatic colorectal adenocarcinoma with multiple hepatic and peritoneal implants. Tumor characterized as MSI-H (loss of MLH1/PMS2). Given high microsatellite instability he was started on pembrolizumab monotherapy. CT at 12 weeks shows disease that is radiographically unchanged compared with baseline; clinically stable symptoms.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma harboring a BRAF V600E mutation. Initially treated with nivolumab monotherapy but progressed; started on dabrafenib plus trametinib. Interval imaging after 6 weeks revealed increasing size of pulmonary nodules and new adrenal lesions consistent with progressive disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical T4bN2M0 (Stage IIIB). Core biopsy: HER2 amplification by FISH, ER 70%, PR 20%. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab with docetaxel for six cycles followed by mastectomy. Final pathology showed no residual invasive carcinoma (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER 70%; PR 20%", "treatment": "trastuzumab and docetaxel (neoadjuvant), followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with muscle-invasive urothelial carcinoma of the bladder. TURBT demonstrated high-grade urothelial carcinoma invading muscularis propria (clinical stage II). He underwent radical cystectomy followed by adjuvant cisplatin and gemcitabine. No molecular testing or PD-L1 result available in chart. At 6-month surveillance CT chest there are multiple new bilateral pulmonary nodules consistent with metastatic progression.", "output": {"cancer_type": "urothelial carcinoma of the bladder", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical cystectomy; cisplatin and gemcitabine", "response": "progression", "metastasis_site": "lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with metastatic clear cell renal cell carcinoma with painful lytic lesions in the left iliac bone. Staging consistent with stage IV disease. Tumor NGS demonstrates a VHL mutation. PD-L1 by IHC reported as 5%. He was started on combination nivolumab plus cabozantinib with improvement in bone pain and a partial radiographic response at 12-week restaging.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": "VHL mutation", "biomarker": "PD-L1 5%", "treatment": "nivolumab and cabozantinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation note: 48-year-old woman with metastatic invasive ductal breast carcinoma, ER-negative, PR-negative. HER2 IHC 3+ and FISH-confirmed HER2 amplification. Tumor NGS detected PIK3CA E545K. Staging CT shows multiple hypodense hepatic metastases and no obvious pulmonary disease. She was started on first-line trastuzumab, pertuzumab plus docetaxel; after four cycles the CT abdomen shows stable appearance of the liver lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology record: 58-year-old male with locally advanced oropharyngeal squamous cell carcinoma, clinical stage IVA. Treated definitively with weekly cisplatin concurrent with 70 Gy IMRT to primary and nodal basins. Post-treatment PET-CT at 12 weeks shows no hypermetabolic disease and clinical exam is without residual tumor. No molecular testing was performed and HPV status was not available in the chart.", "output": {"cancer_type": "oropharyngeal squamous cell carcinoma", "stage": "IVA", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin + radiation (70 Gy IMRT)", "response": "complete response (no residual hypermetabolic disease on PET-CT)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with new-onset seizures; MRI revealed a dominant right temporal mass. Craniotomy and resection performed \u2014 path = glioblastoma multiforme, IDH\u2011wildtype. MGMT methylation status was not reported. He received concurrent radiotherapy with temozolomide, but after three cycles MRI demonstrated interval enlargement of the enhancing lesion and new leptomeningeal enhancement consistent with progression. No formal AJCC stage assigned in the neuro\u2011oncology note.", "output": {"cancer_type": "glioblastoma multiforme", "stage": null, "gene_mutation": "IDH wild-type", "biomarker": null, "treatment": "surgery; concurrent radiation and temozolomide", "response": "progression", "metastasis_site": "leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery; pathology consistent with stage IIIC disease. She completed six cycles of carboplatin and paclitaxel with concurrent bevacizumab. Germline BRCA testing returned negative and no somatic mutation report was available. CA-125 decreased from 450 U/mL pre-op to 60 U/mL after chemotherapy. CT shows reduction in peritoneal disease burden consistent with a partial response. No distant organ metastases identified.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 decreased (450 \u2192 60 U/mL)", "treatment": "optimal debulking surgery; carboplatin and paclitaxel with bevacizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Tumor board note: 71-year-old male with metastatic colorectal adenocarcinoma. Presentation with right upper quadrant pain; CT shows multiple liver lesions consistent with metastases. Molecular profile: BRAF V600E mutation identified; MSI testing returned MSI-H. Started systemic therapy with FOLFOX plus bevacizumab. After 3 cycles, radiographic progression in the liver with rising CEA. Plan to switch to second-line therapy and consider clinical trial for BRAF-mutant disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER-/PR- invasive ductal carcinoma of the breast. Liver biopsy confirms metastatic HER2-amplified disease by FISH; NGS identifies a PIK3CA E545K mutation. She received first-line trastuzumab, pertuzumab and docetaxel. Recent CT shows no new lesions and stable hepatic disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Presents with multiple pulmonary nodules and symptomatic intracranial lesions. PD-L1 reported at 5%. He was started on dabrafenib plus trametinib; initial imaging showed tumor shrinkage but he experienced progression at 6 months and was referred for next-line immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib, trametinib", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man presenting with progressive dyspnea found to have lung adenocarcinoma with widespread osseous pain and new headaches. Imaging consistent with stage IV disease with brain and bone metastases. Tumor testing: EGFR L858R detected; PD-L1 <1%. Patient started first-line osimertinib; follow-up CT after 8 weeks demonstrates a partial response with symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with invasive ductal carcinoma of the right breast, cT2N1, pathologic stage IIB after lumpectomy. Tumor was ER+/PR+, HER2 3+ by IHC and FISH-confirmed HER2 amplification. Tumor sequencing detected PIK3CA H1047R. She received neoadjuvant paclitaxel followed by dose-dense AC and trastuzumab; surgery revealed a complete pathologic response. No distant mets identified on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant paclitaxel then doxorubicin/cyclophosphamide (dose-dense AC) and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, right-sided. Stage IV at diagnosis with multiple liver lesions. Tumor genotyping identified BRAF V600E mutation and tumor is MSI-H. Started second-line FOLFIRI with bevacizumab after progression on first-line capecitabine/oxaliplatin. CT after 3 cycles shows new hepatic lesions and rising CEA consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFIRI and bevacizumab (second-line); prior capecitabine/oxaliplatin", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with right-sided invasive ductal carcinoma, clinical stage I (T1N0). Tumor is ER+/PR+ and HER2 amplified by FISH; NGS showed a PIK3CA E545K alteration. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab. Surveillance mammography and MRI at 18 months show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy, paclitaxel, trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 46-year-old male with metastatic cutaneous melanoma with symptomatic brain metastases. Initial management included stereotactic radiosurgery to the dominant cerebellar lesion followed by combination immunotherapy with nivolumab plus ipilimumab. Molecular profiling identified BRAF V600E and PD-L1 5%; tumor sequencing also noted high TMB. After mixed response on first follow-up (central nervous system lesions improved but new hepatic lesions appeared) he was transitioned to targeted therapy with dabrafenib and trametinib.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "stereotactic radiosurgery; nivolumab and ipilimumab; dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 64-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing identified EGFR L858R mutation. PD-L1 TPS 20%. She started first-line osimertinib 80 mg daily in March and has had interval imaging showing reduction of the primary mass and intracranial lesions. Current assessment: partial response. Sites of disease include known brain and osseous metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic colorectal adenocarcinoma diagnosed on liver biopsy. Molecular profile returned BRAF V600E and MSI-H; tumor mutation burden reported as high. Given MSI-H status, pembrolizumab monotherapy was initiated. Interval imaging after 12 weeks demonstrates stable size of the hepatic lesions and no new sites of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left invasive ductal carcinoma, clinical stage IIIB. Tumor is ER-positive, PR-positive and shows HER2 amplification by FISH. Comprehensive NGS panel did not identify any actionable somatic mutations. She completed neoadjuvant paclitaxel with concurrent trastuzumab prior to surgery; post-treatment imaging documented a partial response. No evidence of distant metastatic disease on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 45-year-old man with cutaneous melanoma of the left neck, pathologic stage III disease with involved regional nodes. BRAF V600E mutation identified on PCR. PD-L1 TPS 5% by IHC. Patient was initiated on combination targeted therapy with dabrafenib and trametinib; interval PET/CT after 8 weeks shows stable disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 67-year-old male with newly diagnosed lung adenocarcinoma. Staging workup shows stage IV disease with multiple cerebral metastases. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient started on osimertinib 80 mg daily as first-line targeted therapy. On first restaging at 8 weeks there is a decrease in size of the dominant right upper lobe mass and intracranial lesions \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Brief note: 49-year-old man with squamous cell carcinoma of the oropharynx, clinical stage II. Managed with definitive concurrent chemoradiation (70 Gy plus high-dose cisplatin q3 weeks). Staging PET/CT prior to treatment did not show distant disease. Molecular profiling not performed and PD-L1 status not reported. At 3-month post-treatment visit the lesion is no longer visible on exam and repeat imaging is clear \u2014 complete clinical response.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx (head and neck)", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "definitive concurrent chemoradiation (cisplatin + radiation)", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic melanoma, stage IV with pulmonary and intracranial disease. Tumor sequencing identified BRAF V600E. He received first-line combination immunotherapy with ipilimumab plus nivolumab, achieved a complete extracranial response, but later developed intracranial progression and was started on targeted therapy with dabrafenib plus trametinib. No PD-L1 result was documented.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "ipilimumab + nivolumab; later dabrafenib + trametinib", "response": "complete extracranial response with intracranial progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colon adenocarcinoma, presented with large liver lesions in March 2021. Tumor genotyping identified KRAS G12D mutation; microsatellite testing showed MSS and TMB low. He was started on FOLFOX plus bevacizumab and has had stable disease on CT scans after three cycles with modest shrinkage of some hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; low TMB", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. Right hepatic lobe metastases were noted on staging CT. Tumor sequencing: KRAS G12D. Microsatellite testing: MSS. He was started on FOLFOX plus bevacizumab; after 6 cycles imaging revealed increase in size and number of liver lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic colorectal adenocarcinoma to the liver. Tumor testing demonstrated high microsatellite instability (MSI-H) and a high tumor mutational burden; RAS/BRAF panel returned wild-type. He was started on pembrolizumab monotherapy in the first-line setting and after 6 months of therapy has no radiographic evidence of disease on contrast CT.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with right-sided colon adenocarcinoma presenting with multiple liver lesions. Clinical stage IV. Tumor panel returned MSI-H and BRAF V600E; TMB-high reported. Initially treated with FOLFOX plus bevacizumab but CT after 4 cycles showed progression. Switched to encorafenib plus cetuximab with subsequent partial response of hepatic metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; encorafenib and cetuximab", "response": "progression on FOLFOX/bevacizumab then partial response to encorafenib/cetuximab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with resectable pancreatic ductal adenocarcinoma underwent pancreaticoduodenectomy (Whipple). Final path reported stage IB. Germline testing identified a BRCA2 pathogenic variant. She received adjuvant gemcitabine and cisplatin with normalization of CA19-9 and was transitioned to olaparib maintenance given the BRCA2 mutation.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IB", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 normalized post-treatment", "treatment": "pancreaticoduodenectomy (Whipple); adjuvant gemcitabine and cisplatin; olaparib maintenance", "response": "biochemical response (CA19-9 normalized) / no evidence of recurrence on early follow-up", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed with metastatic pancreatic ductal adenocarcinoma with multiple liver lesions. CA19-9 markedly elevated at 12,000 U/mL. Molecular testing is pending and no actionable mutation has been reported to date. He was started on modified FOLFIRINOX; first restaging CT after two cycles shows interval growth of hepatic lesions consistent with progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "modified FOLFIRINOX", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic lung adenocarcinoma presenting with new headaches. Molecular testing on the lung biopsy demonstrated EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging workup consistent with Stage IV disease with two small cerebellar metastases. He was started on osimertinib 80 mg once daily and underwent stereotactic radiosurgery to the cerebellar lesions. Interval CT at 8 weeks shows decrease in size of the primary and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain (cerebellar)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed stage IV lung adenocarcinoma. Molecular testing identified an EGFR L858R mutation; PD-L1 tumor proportion score reported as 10%. Staging CT and MRI demonstrated multiple pulmonary nodules and small cerebellar and thoracic spine metastases. He was started on osimertinib 80 mg daily as first-line targeted therapy. Interval imaging at 8 weeks showed marked decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain; spine"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with right-sided colon adenocarcinoma. Preoperative molecular profiling detected KRAS G12D mutation. Baseline CEA was 12 ng/mL. Imaging and biopsy consistent with T3N1 (Stage III) disease. He received neoadjuvant FOLFOX; repeat CT after 3 cycles demonstrated a reduction in nodal size and decrease in primary tumor bulk. He then proceeded to right hemicolectomy with regional lymph node dissection.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "CEA 12 ng/mL", "treatment": "neoadjuvant FOLFOX; right hemicolectomy", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with unresectable metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. She was started on dabrafenib plus trametinib with rapid shrinkage of pulmonary and subcutaneous lesions (initial partial response). At six months surveillance MRI brain showed new and enlarging intracranial metastases despite extracranial control; therapy was changed to combination immunotherapy (nivolumab/ipilimumab) and stereotactic radiosurgery to intracranial targets. Overall disease course described as mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; later nivolumab/ipilimumab", "response": "mixed response (initial partial response then brain progression)", "metastasis_site": "brain, lung, skin"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, biopsy-proven, presented with multiple hepatic and pulmonary metastases. Molecular testing shows KRAS G12C; MSI testing returned MSS (MSI-stable). Initial systemic therapy was CAPOX (capecitabine and oxaliplatin) plus bevacizumab. Interval scans after 3 cycles demonstrate reduction in size of dominant liver lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSI-stable", "treatment": "capecitabine and oxaliplatin (CAPOX) plus bevacizumab", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old female with recurrent cutaneous melanoma, initial staging IIIB. Recurrence involved regional nodes; molecular testing positive for BRAF V600E. PD-L1 by IHC was approximately 10%. She was started on dabrafenib plus trametinib but developed new neurologic symptoms and MRI confirmed brain metastases consistent with disease progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib plus trametinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colorectal adenocarcinoma to the liver. Molecular testing: KRAS G12D mutation; tumor is microsatellite stable (MSI-stable). He received first-line FOLFOX with bevacizumab. Restaging CT at 4 months shows interval enlargement of hepatic lesions consistent with progression. PD-L1 was not tested.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old presented with a nodular melanoma of the right thigh, sentinel node positive, clinically staged as III at resection. Molecular testing detected BRAF V600E. PD-L1 by IHC low (approximately 5%). After wide local excision and lymphadenectomy he received adjuvant nivolumab but developed symptomatic brain metastases 10 months later. He was switched to targeted therapy with dabrafenib plus trametinib; unfortunately follow-up imaging after 3 months showed new intracranial progression and extracranial growth consistent with progressive disease.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib (after prior nivolumab)", "response": "progressive disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic lung adenocarcinoma. Comprehensive genomic profiling identified EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging CT and MRI demonstrate lesions in the brain and multiple osseous sites compatible with metastatic disease (stage IV). Patient was started on osimertinib 80 mg daily in May; 8-week restaging shows a 40% reduction in measurable disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 62-year-old male with metastatic colorectal adenocarcinoma with multiple hepatic lesions. Tumor genotyping identified KRAS G12D; tumor is microsatellite stable (MSS). He started FOLFOX with bevacizumab and achieved a partial response after three cycles, now on maintenance capecitabine with stable disease. Stage IV at diagnosis.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX + bevacizumab; maintenance capecitabine", "response": "partial response then stable disease on maintenance", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with biopsy-proven lung adenocarcinoma. Staging scans consistent with metastatic disease; MRI brain demonstrates multiple enhancing lesions. Tumor sequencing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily with symptomatic improvement and interval CT/MRI shows reduction in size of intracranial and pulmonary disease compatible with a partial response. Impression: stage IV lung adenocarcinoma with brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with lung adenocarcinoma (EGFR-mutant). Staging demonstrated widespread disease with multiple brain and osseous lesions consistent with metastatic spread \u2014 clinical stage IV. Comprehensive genomic profiling identified EGFR L858R; PD-L1 by IHC 22%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval MRI after 8 weeks shows decrease in size of target lesions, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 22%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent right hemicolectomy for adenocarcinoma of the colon; final stage T3N1 (Stage III). KRAS G12D mutation detected on tumor sequencing. MSI testing reported microsatellite stable (MSS). He completed 6 months of adjuvant FOLFOX with good tolerance. Surveillance CT abdomen/pelvis at 12 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "surgery (right hemicolectomy), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma originally diagnosed in 2018. Tumor harbors EGFR L858R mutation. PD-L1 on biopsy was reported as 10%. Patient began first-line osimertinib with a partial response for approximately 9 months. Recent CT shows new hepatic and osseous lesions consistent with progression; therapy was switched to carboplatin and pemetrexed. Current impression: progressive disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed", "response": "progression", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma (stage IV) found to have BRAF V600E on tumor genotyping. At diagnosis there were bilateral pulmonary nodules and 2 enhancing cerebellar lesions. Started on targeted therapy with dabrafenib plus trametinib. Initially had a partial radiographic response, but at 7 months developed new CNS lesions and extracranial progression documented on MRI and CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 48-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast, ER+/PR+, HER2 amplified by FISH, PIK3CA H1047R identified on NGS. Clinical stage IIA (T2N0). She received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with concurrent trastuzumab, then lumpectomy and sentinel node biopsy. Final pathology reported no residual invasive carcinoma (pathologic complete response). Patient continues adjuvant trastuzumab to complete one year.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin + cyclophosphamide \u2192 paclitaxel with trastuzumab; lumpectomy; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic summary: 67-year-old man with localized prostate adenocarcinoma (Gleason 3+4) treated with radical prostatectomy followed by adjuvant external beam radiation and 6 months of leuprolide for adverse features. Post-treatment PSA is undetectable. No tumor sequencing was performed and no molecular biomarkers reported in records.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation; leuprolide", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with newly diagnosed lung adenocarcinoma. PET/CT shows multiple cerebral lesions consistent with metastases. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score ~10%. Patient started osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain lesion. Interval MRI at 8 weeks demonstrates decrease in size of brain metastases and partial response systemically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma diagnosed after presentation with cough and headaches. NGS on the primary tumor demonstrated EGFR L858R mutation. PD-L1 tumor proportion score reported as 60%. He was started on osimertinib 80 mg daily and has previously received palliative whole-brain radiation for symptomatic metastases. Interval CT and brain MRI show decreased size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic pancreatic ductal adenocarcinoma, biopsy-proven, with liver metastases at diagnosis (stage IV). Germline testing returned a BRCA2 frameshift (6174delT). He received 6 cycles of FOLFIRINOX with marked CA19-9 decline and partial radiographic response, then transitioned to olaparib maintenance. Current restaging shows disease stability on olaparib.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT (frameshift)", "biomarker": "CA19-9 elevated at baseline (declined on treatment)", "treatment": "FOLFIRINOX; olaparib (maintenance)", "response": "stable disease (after partial response to induction)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male presenting with right upper quadrant pain. CT abdomen showed multiple liver masses; biopsy confirmed metastatic colorectal adenocarcinoma. Molecular testing identified KRAS G12D. He was started on FOLFOX with bevacizumab; first restaging at 12 weeks demonstrated stable disease by RECIST with no new extrahepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male s/p sigmoid colectomy for adenocarcinoma. Final pathology T3N1 (stage III). Tumor genotyping identified KRAS G12D; microsatellite testing shows MSS. He completed adjuvant CAPOX (capecitabine + oxaliplatin) x 6 cycles without significant complications. Surveillance CT chest/abdomen/pelvis at 6 months demonstrates no residual or recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "colectomy, adjuvant CAPOX (capecitabine + oxaliplatin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with high-grade prostate adenocarcinoma, Gleason 4+4=8 presented with progressive bone pain. Bone scan confirmed multiple osseous metastases. He was started on leuprolide depot injections and bicalutamide; PSA fell from 125 ng/mL to 18 ng/mL at three months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) and bicalutamide", "response": "biochemical partial response (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with locally advanced invasive ductal carcinoma of the right breast. ER negative, PR negative, HER2 amplification by FISH; next-generation sequencing identified PIK3CA H1047R. Clinical stage was recorded as IIIA. She received neoadjuvant TCH (docetaxel, carboplatin, trastuzumab) with excellent clinical shrinkage and underwent lumpectomy. Surgical pathology demonstrated no residual invasive carcinoma.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III A", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab (TCH); lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old with metastatic colorectal adenocarcinoma, liver-predominant disease on CT. Molecular profile returned BRAF V600E mutation; tumor was MSI-H with high TMB. He initially received FOLFOX plus bevacizumab with mixed biochemical response, then was switched to combination targeted therapy with encorafenib and cetuximab given the BRAF mutation. After two months on the targeted combo the scans demonstrate stable disease in the liver and no new sites of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left breast invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH (HER2/CEP17 ratio 6.2). Clinical exam showed skin tethering and fixed axillary nodes; clinical stage IIIB. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab, then underwent left mastectomy. Final pathology reports no residual invasive tumor in the breast or nodes (pathologic complete response). No distant metastases on staging CT chest/abdomen.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with newly diagnosed lung adenocarcinoma presenting with cough and headaches. Staging workup showed stage IV disease with multiple brain and bone lesions. Molecular testing identified an EGFR exon 19 deletion; PD-L1 TPS 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy and had symptomatic improvement with radiographic partial response at 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, stage IIIC. Germline testing returned a BRCA1 pathogenic variant (c.5266dupC) and tumor HRD-positive by genomic scar assay. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel and is currently on maintenance olaparib with stable disease on the most recent CT; peritoneal deposits remain.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.5266dupC", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin + paclitaxel; maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, initially staged T3N2M1 (stage IV) with dominant liver lesions and peritoneal implants. Tumor genomics: KRAS G12D identified; microsatellite stable (MSS) and tumor mutational burden reported as low. PD-L1 testing not performed. First-line FOLFOX plus bevacizumab produced stable disease for six months, then CT demonstrated progression of hepatic lesions.", "output": {"cancer_type": "colorectal (colorectal adenocarcinoma)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "stable disease for 6 months then progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old man with metastatic castration\u2011resistant prostate cancer diagnosed after recurrence following prostatectomy. Germline testing revealed BRCA2 pathogenic variant. He was started on the PARP inhibitor olaparib with ongoing treatment and radiographic stable disease. No PD-L1 or other biomarkers assessed.", "output": {"cancer_type": "prostate cancer (castration\u2011resistant, metastatic)", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 68-year-old man with localized prostate adenocarcinoma (Gleason 3+4) underwent robotic radical prostatectomy followed by adjuvant external beam radiation due to positive margins. Clinical stage documented as II. There was no nodal or distant spread on imaging. No tumor genomic testing was performed. At last follow-up PSA undetectable and patient is without evidence of disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy followed by adjuvant external beam radiation", "response": "no evidence of disease / remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma to the liver (stage IV). Tumor testing returned MSI-H and BRAF V600E mutation. He was started on pembrolizumab monotherapy given high microsatellite instability and remains on treatment with a durable partial response on serial CT scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with metastatic cutaneous melanoma. Molecular profiling positive for BRAF V600E. Tumor demonstrated high tumor mutational burden (TMB-high) on panel testing; PD-L1 was low at 5% by IHC. Patient presented with symptomatic brain metastasis on MRI and small pulmonary nodules. Systemic therapy with dabrafenib plus trametinib was initiated. Follow-up imaging notes a mixed response with extracranial disease regression but progression of intracranial lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative clinic note: biopsy-proven invasive ductal carcinoma, ER negative, PR negative, HER2 3+ by IHC with confirmed HER2 amplification on FISH. Clinical exam consistent with skin tethering and involvement of the chest wall\u2014clinical stage IIIB. Patient received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; mastectomy specimen showed no residual invasive carcinoma (pCR).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 69-year-old male with castration-resistant prostate cancer presenting with back pain. Imaging demonstrates multiple sclerotic bone lesions and pelvic nodal involvement; overall stage IV. He remains on androgen-deprivation therapy (leuprolide) and was given docetaxel with prednisone for symptomatic disease; abiraterone was added after limited PSA decline. No actionable somatic mutations were reported on prior panel. Genomic testing results are otherwise not available.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen-deprivation therapy (leuprolide) + docetaxel and prednisone; abiraterone", "response": "limited PSA decline / stable disease", "metastasis_site": "bone; pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 58-year-old woman underwent modified radical mastectomy for a 3.6 cm invasive ductal carcinoma of the left breast with multiple positive axillary nodes. ER positive, PR positive, HER2 by FISH shows amplification. Tumor sequencing identifies PIK3CA E545K. Final stage pT2N2, clinical stage IIIB. Patient received adjuvant paclitaxel with trastuzumab and will start endocrine therapy with letrozole.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab and paclitaxel, then adjuvant letrozole", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with sigmoid colon adenocarcinoma (pT3N1) who underwent colectomy. Pathology confirmed stage III disease. Extended molecular panel detected KRAS G12D mutation; MSI testing was not reported in the chart. He completed 12 cycles of adjuvant FOLFOX and surveillance CTs at 6 and 12 months showed no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "colectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female with metastatic pancreatic ductal adenocarcinoma with multiple liver metastases at diagnosis (stage IV). Tumor NGS showed a deleterious BRCA2 germline mutation. Baseline CA 19-9 was markedly elevated. She received FOLFIRINOX with good clinical improvement and radiographic partial response; after 6 months she transitioned to olaparib maintenance given BRCA2. Current imaging documents ongoing partial response of hepatic lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious (germline)", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Summary: 45-year-old male with metastatic melanoma (AJCC stage IV) harboring BRAF V600E. He initiated dabrafenib plus trametinib with a good initial tumor shrinkage but developed new brain metastases after 9 months and was transitioned to pembrolizumab. PD-L1 was reported at 10%. Current scans after three cycles of pembrolizumab show no further growth of known lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital summary: 62-year-old male with metastatic colon adenocarcinoma presenting with increasing abdominal distension. CT abdomen/pelvis demonstrates diffuse peritoneal carcinomatosis and ascites. Tumor genotyping shows KRAS G12D. He was started on FOLFOX with bevacizumab as palliative systemic therapy. After 4 cycles, CA 19-9 is stable and imaging reports no interval progression \u2014 overall stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX with bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the right breast. Tumor is ER positive, PR negative; HER2 amplified by FISH. Clinical stage reported as IIIA. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles followed by lumpectomy. Pathology showed marked downstaging but residual invasive carcinoma in the surgical specimen.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant trastuzumab and pertuzumab with docetaxel", "response": "partial response / residual disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with a right frontal glioblastoma (WHO grade IV). He underwent subtotal resection followed by concurrent radiotherapy with temozolomide. Molecular profiling results are not available in the chart and MGMT promoter methylation was not assessed. Three-month surveillance MRI demonstrates interval radiographic progression with increased contrast enhancement at the resection cavity.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "subtotal resection, radiation and temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 64-year-old female with pancreatic ductal adenocarcinoma with peritoneal carcinomatosis. Germline testing identified BRCA2 mutation. CA19-9 markedly elevated at baseline. She received FOLFIRINOX with symptomatic improvement, transitioned to maintenance olaparib. Most recent CT shows stable peritoneal disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 71-year-old man with metastatic castration-resistant prostate adenocarcinoma (mCRPC) with extensive osseous disease. Germline/tumor testing revealed a pathogenic BRCA2 variant and HRD-positive profile. After progression on abiraterone, he was started on olaparib with improvement in pain and a falling PSA; current assessment is partial response by PSA and imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "HRD positive", "treatment": "olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed in 2023. Staging scans consistent with IV disease with multiple cerebral and osseous lesions. Tumor testing identified EGFR L858R; PD-L1 reported at 10%. Patient started osimertinib in September and received stereotactic radiosurgery to a dominant cerebellar metastasis. Most recent imaging shows decrease in size of pulmonary and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly symptomatic metastatic prostate adenocarcinoma (Gleason 4+5). Staging showed diffuse sclerotic and lytic bone lesions consistent with osseous metastases. He was started on leuprolide depot with docetaxel, later transitioned to enzalutamide for castration-resistant disease. PSA has been rising despite therapy and recent imaging is described as a mixed response with some lesions stable and others increasing in size.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "rising PSA", "treatment": "leuprolide, docetaxel, enzalutamide", "response": "mixed response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, biopsy-proven. Molecular profiling returned BRAF V600E and high microsatellite instability (MSI-H); tumor also reported TMB-high. Initial therapy was FOLFOX with bevacizumab with mixed radiographic response; on progression the patient was enrolled on targeted therapy with encorafenib plus cetuximab. Most recent CT shows stable disease in the liver and small-volume peritoneal disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 69-year-old male with metastatic right-sided colon adenocarcinoma with multiple liver lesions. Tumor genotyping: KRAS G12D mutation; tumor testing also reported MSI-H. Cancer is unresectable (stage IV). Given MSI-H status he was started on pembrolizumab monotherapy. Repeat CT at 12 weeks shows no new lesions and modest decrease in target lesions \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with pancreatic head adenocarcinoma underwent pancreaticoduodenectomy. Pathology staged the tumor as IIB (pT3N1). Tumor profiling showed a KRAS G12D mutation. Preoperative CA 19-9 was markedly elevated at 1,200 U/mL. Patient is planned for adjuvant FOLFIRINOX; no distant metastases were identified on baseline imaging.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IIB", "gene_mutation": "KRAS G12D", "biomarker": "CA 19-9 1,200 U/mL", "treatment": "adjuvant FOLFIRINOX (planned)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old presented with new-onset seizures and underwent craniotomy; pathology returned glioblastoma, WHO grade IV. Treated with concurrent radiotherapy and temozolomide per Stupp protocol. Interim MRI shows enlarging enhancing mass consistent with progression. Molecular report not available and MGMT methylation status unknown.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "radiation and temozolomide (concurrent)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC, with diffuse peritoneal carcinomatosis at diagnosis. Germline testing confirmed a deleterious BRCA1 mutation and CA-125 was markedly elevated. She underwent optimal debulking followed by carboplatin and paclitaxel and achieved a complete clinical and radiographic response; she was started on olaparib maintenance.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 55-year-old male with metastatic cutaneous melanoma. Molecular testing identified BRAF V600E. He began targeted therapy with dabrafenib and trametinib with an initial marked reduction in measurable nodal and pulmonary disease (partial response). At 9 months developed new symptomatic intracranial lesions and MRI confirmed progression in the brain; he subsequently received stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "initial partial response followed by intracranial progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Imaging shows multiple cerebellar lesions and lytic lesions in the spine. Molecular testing demonstrated EGFR L858R mutation. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant brain metastasis. Interval CT at 8 weeks shows shrinkage of pulmonary nodules and decreased size of bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old male with metastatic colon adenocarcinoma. Liver metastases on CT; biopsy confirms adenocarcinoma of colon. Molecular testing: KRAS G12D mutation; tumor is MSS (microsatellite stable). He was started on FOLFOX with bevacizumab. After 4 cycles the liver lesions are unchanged in size and carcinoembryonic antigen is stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER+/PR-/HER2-amplified invasive ductal breast carcinoma presented with new hepatic lesions on CT consistent with metastases. She was started on docetaxel in combination with trastuzumab and pertuzumab. After six cycles there is radiographic reduction in size of the liver lesions (partial response). Plan is to continue anti-HER2 maintenance therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with metastatic cutaneous melanoma presenting with multiple liver lesions. Molecular profiling identified a BRAF V600E mutation. She was started on pembrolizumab but had clinical and radiographic progression after 3 cycles (progressive disease). Therapy was changed to dabrafenib plus trametinib, with subsequent CT showing a decrease in size of hepatic lesions consistent with a partial response. PD-L1 testing was not reported.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (initial) then dabrafenib + trametinib", "response": "partial response to targeted therapy (progression on pembrolizumab)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic left-sided colorectal adenocarcinoma, stage IV with liver-predominant disease. Tumor sequencing identified KRAS G12D. Tumor characterization reported MSI-H and TMB-high. He was treated with FOLFOX plus bevacizumab initially and, given MSI-H status, was transitioned to pembrolizumab; current assessment is stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX, bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma to the liver. Tumor profiling: BRAF V600E mutation and MSI-H on PCR; tumor mutational burden reported as TMB-high. He initially received pembrolizumab given the MSI-H status and achieved a partial response for 6 months. On progression he was enrolled on combination targeted therapy with encorafenib plus cetuximab. Latest imaging after two months of the targeted combination shows mixed response with new small hepatic lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab; encorafenib + cetuximab", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. Molecular testing identified a BRAF V600E mutation; PD-L1 by IHC was low at 5%. He was started on pembrolizumab; after three cycles PET/CT demonstrated enlargement of hepatic and pulmonary metastases consistent with progressive disease. Therapy was switched to dabrafenib plus trametinib with subsequent interval scans showing decreased metabolic activity and shrinkage of several lesions \u2014 overall a mixed response with partial response to targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "mixed response (initial progressive disease on pembrolizumab, partial response on dabrafenib + trametinib)", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 44-year-old female with biopsy-proven invasive ductal carcinoma of the left breast. Core biopsy: HER2 3+ by IHC, ER negative, PR negative. Clinical exam consistent with inflammatory features; clinical stage IIIB. Patient completed 6 cycles of docetaxel/carboplatin with trastuzumab and pertuzumab prior to surgery. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Staging consistent with stage IV disease. Tumor genotyping shows KRAS G12D mutation. Baseline CEA elevated to 200 ng/mL. He was started on FOLFOX plus bevacizumab. Interval restaging after 8 weeks demonstrates stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated (200 ng/mL)", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic pancreatic ductal adenocarcinoma, biopsy-proven, presenting with multiple liver lesions and peritoneal nodularity consistent with peritoneal carcinomatosis (stage IV). Germline and somatic testing showed a pathogenic BRCA2 alteration. CA19-9 markedly elevated at diagnosis. She received FOLFIRINOX with an initial partial radiographic response, transitioned to olaparib maintenance for BRCA2, but recent scans indicate disease progression in the liver and new ascites.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "elevated CA19-9", "treatment": "FOLFIRINOX; olaparib maintenance", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 48 y/o woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB (T4bN1). Core biopsy: ER negative, PR negative, HER2 positive by FISH (HER2 amplification). Targeted panel identified PIK3CA H1047R. Patient completed 6 cycles of neoadjuvant trastuzumab, pertuzumab and docetaxel with excellent radiographic regression; at definitive mastectomy the pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old M with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Imaging showed multiple pulmonary nodules and MRI brain demonstrated two enhancing lesions. Biopsy confirmed adenocarcinoma; molecular testing returned EGFR L858R. PD-L1 tumor proportion score was 40%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the brain lesions. At first restaging CT after 8 weeks there was a marked decrease in target lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 40%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Letter: 71-year-old male with metastatic prostate adenocarcinoma, castration-sensitive at presentation with extensive osteoblastic bone metastases. Germline/somatic testing showed a deleterious BRCA2 mutation and HR deficiency. PSA prior to systemic therapy 32 ng/mL. Started androgen deprivation therapy (leuprolide) and olaparib added after discussion of PARP benefit for BRCA2 carriers; disease has been radiographically stable on restaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "PSA 32 ng/mL; HRD positive", "treatment": "androgen deprivation therapy (leuprolide) and olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with clinically localized prostate adenocarcinoma (Gleason 4+3). Clinical stage II at diagnosis. He underwent radical prostatectomy; initial post-op PSA was undetectable but at 9 months the PSA rose to 0.6 ng/mL consistent with biochemical recurrence. No tumor genomic testing was performed prior to surgery. Salvage external beam radiation was initiated and androgen deprivation with leuprolide started. Restaging CT and bone scan show no metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy then salvage radiation and leuprolide", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with metastatic colorectal adenocarcinoma. Molecular profile: BRAF V600E positive, MSI-High, TMB-high. He initially received FOLFOX plus bevacizumab with partial radiographic benefit but progressed in the liver. Second-line therapy initiated with encorafenib plus cetuximab (BRAF-directed combination). Most recent scans show stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-High; TMB-high", "treatment": "FOLFOX + bevacizumab, then encorafenib + cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with locally advanced invasive ductal breast cancer, clinical stage IIIA. Tumor is ER+/PR+ and HER2 amplification was confirmed by FISH. She completed neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab and has had a near-complete clinical response prior to surgery. No somatic sequencing was performed at this time.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "doxorubicin/cyclophosphamide then paclitaxel with trastuzumab", "response": "near-complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with stage IV lung adenocarcinoma (Nov 2023). Comprehensive NGS showed EGFR L858R mutation. PD-L1 by IHC 5%. Started osimertinib 80 mg daily in December; interval CT chest shows shrinkage of the primary and pulmonary nodules consistent with a partial response, but brain MRI demonstrates a new cerebellar metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 63-year-old man with metastatic lung adenocarcinoma presented with worsening headache and back pain. Biopsy-confirmed adenocarcinoma; molecular testing revealed EGFR L858R. PD-L1 IHC was 5%. Staging CT and MRI consistent with stage IV disease with bone and solitary brain metastases. He was started on osimertinib 80 mg daily as first-line targeted therapy and after 8 weeks has achieved a radiographic partial response with reduction of the lung primary and decreased size of bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic sigmoid colon adenocarcinoma (stage IV) with liver-only disease at presentation. Molecular testing: BRAF V600E positive and MSI-High. He received first-line FOLFOX plus bevacizumab achieving stable disease for 5 months, then progressed and was started on encorafenib plus cetuximab with a good partial response on restaging CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab (first-line); encorafenib + cetuximab (second-line)", "response": "stable disease on FOLFOX + bevacizumab, partial response to encorafenib + cetuximab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with a pigmented lesion on the left calf; wide local excision and sentinel node biopsy demonstrated melanoma, Breslow 2.8 mm, sentinel node positive \u2014 pathologic stage IIIB. Tumor sequencing identified BRAF V600E. Patient underwent complete lymph node dissection and was started on adjuvant nivolumab. Most recent PET/CT shows no distant uptake; follow-up notes document currently no clinical evidence of disease in nodal basins.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgery (wide local excision, sentinel node biopsy, completion lymph node dissection), adjuvant nivolumab", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 59-year-old male with metastatic colorectal adenocarcinoma to liver and lungs. Molecular profile: KRAS G12D, BRAF wild-type, tumor is microsatellite-stable. He received FOLFOX plus bevacizumab for 6 cycles. Restaging CT shows enlarging hepatic lesions with new pulmonary nodules \u2014 overall radiographic progression; plan is to switch systemic therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging workup confirmed stage IV disease with multiple cerebellar and frontal lobe metastases on MRI. Molecular testing returned EGFR L858R and no ALK/ROS1 rearrangement; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to two symptomatic brain lesions. Follow-up CT and MRI at 8 weeks show marked reduction in size of pulmonary primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with lung adenocarcinoma. Staging CT and MRI demonstrate multiple bilateral pulmonary nodules and a 1.8 cm cerebellar lesion consistent with brain metastasis; overall clinical stage IV. Next-generation sequencing returned EGFR L858R. PD-L1 by IHC reported 5%. Patient was started on osimertinib 80 mg daily and on first follow-up CT had a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with newly diagnosed stage IIIC high-grade serous ovarian carcinoma with diffuse peritoneal carcinomatosis and elevated CA-125. Tumor demonstrated homologous recombination deficiency (HRD) positivity but prior BRCA testing did not identify a pathogenic BRCA1/2 alteration. She underwent optimal cytoreductive surgery followed by combination chemotherapy with carboplatin and paclitaxel plus bevacizumab, then started maintenance olaparib. Imaging and CA-125 trends indicate a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HRD positive; CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin + paclitaxel + bevacizumab; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed metastatic lung adenocarcinoma (stage IV). NGS demonstrated an EGFR L858R mutation; PD-L1 TPS 10%. He was started on osimertinib 80 mg daily and reports improvement in cough and dyspnea. Interval CT and brain MRI show shrinkage of the primary lesion and marked regression of intracranial metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and was found to have multiple enhancing lesions on MRI. Biopsy confirmed metastatic lung adenocarcinoma, stage IV. Molecular testing returned EGFR L858R and PD-L1 10% (TPS). Patient was started on osimertinib 80 mg daily with radiographic improvement at first restaging \u2014 overall a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman presented with abdominal pain and hepatomegaly. Liver biopsy consistent with metastatic invasive ductal carcinoma of the breast, triple-negative (ER-, PR-, HER2-). Germline testing returned a pathogenic BRCA1 mutation. Clinical stage IV with multiple hepatic metastases. She received carboplatin and paclitaxel for 4 cycles with mixed radiographic response, then transitioned to olaparib maintenance. Current disease status documented as stable disease on latest CT.", "output": {"cancer_type": "invasive ductal carcinoma of the breast (triple-negative)", "stage": "IV", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "ER-, PR-, HER2-", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a 1.8 cm invasive ductal carcinoma of the right breast, pathologic stage I (pT1cN0). Tumor is ER-positive (95%), PR-positive (40%) and HER2 amplified by FISH. She underwent breast-conserving surgery with sentinel lymph node biopsy. Adjuvant plan includes weekly paclitaxel for 12 weeks and trastuzumab for one year, followed by endocrine therapy with letrozole. No evidence of distant disease on staging CT chest/abdomen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel; trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with peritoneal carcinomatosis. Germline testing identified a pathogenic BRCA2 mutation. CA-125 markedly elevated at diagnosis. She underwent optimal cytoreductive surgery followed by carboplatin/paclitaxel chemotherapy and is currently on maintenance olaparib. Interval CT shows reduction of peritoneal implants consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 pathogenic mutation", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with recurrent cutaneous melanoma now metastatic. Presents with multiple pulmonary nodules and a solitary cerebellar metastasis. Molecular testing detected BRAF V600E. He was started on dabrafenib plus trametinib but had radiographic progression at 4 months and was transitioned to combination ipilimumab and nivolumab. Functional status has declined and further systemic options are being discussed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then ipilimumab and nivolumab", "response": "progression", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presented with back pain and headaches. Staging PET/CT consistent with stage IV disease with multiple vertebral lesions and small enhancing cerebral metastases. Molecular testing returned EGFR L858R and PD-L1 60%. She was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain lesion. Imaging at 8 weeks shows a marked decrease in size of the primary and most metastatic sites.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. CT shows multiple lesions in the liver consistent with metastases; staged as IV. Tumor sequencing demonstrates KRAS G12D and tumor is microsatellite-stable (MSI-stable). He was started on FOLFOX plus bevacizumab. After 4 cycles the CT scan demonstrates no new lesions and minimal change in size of hepatic metastases \u2014 overall stable disease. CEA remains mildly elevated.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with a 2.1 cm left upper lobe lesion. CT-guided core biopsy confirmed lung adenocarcinoma. Tumor NGS returned EGFR exon 19 deletion. He underwent VATS left upper lobectomy with negative margins; no adjuvant systemic therapy was given. Surveillance CT at 6 months shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IA", "gene_mutation": "EGFR exon 19 deletion", "biomarker": null, "treatment": "video-assisted thoracoscopic left upper lobectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of left breast shows invasive ductal carcinoma, ER positive, PR positive and HER2 amplified by FISH. Next-generation sequencing detected PIK3CA H1047R. Clinical stage at presentation was IIIA. Patient received neoadjuvant paclitaxel with trastuzumab and achieved clinical complete response, proceeded to lumpectomy which showed no residual invasive carcinoma (pathologic complete response). Adjuvant trastuzumab planned to complete one year.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel and trastuzumab (neoadjuvant), lumpectomy, adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with intermediate-risk prostate adenocarcinoma (Gleason 4+3=7). Underwent radical prostatectomy followed by adjuvant external beam radiation therapy. No genomic sequencing was performed. PSA nadired but has risen to 2.4 ng/mL over 6 months consistent with biochemical recurrence; no radiographic evidence of distant disease on recent bone scan and CT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "PSA 2.4 ng/mL", "treatment": "radical prostatectomy and adjuvant radiation", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned positive for EGFR L858R; PD-L1 tumor proportion score 10%. She presented with headaches and MRI confirmed a solitary enhancing brain lesion consistent with metastasis. Started osimertinib 80 mg PO daily given CNS activity. Follow-up CT and brain MRI at 8 weeks demonstrate marked decrease in size of both the primary lung lesion and the intracranial lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with high-grade serous ovarian carcinoma presenting with bulky pelvic disease and extensive peritoneal carcinomatosis. Clinical stage IIIC. Germline testing identified a pathogenic BRCA1 mutation. Pre-treatment CA-125 was elevated. She received three cycles of neoadjuvant carboplatin and paclitaxel with good radiographic response, underwent interval debulking with no gross residual disease, and was started on maintenance olaparib. CA-125 normalized post-operatively and she remains in clinical remission.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline, pathogenic)", "biomarker": "CA-125 elevated pre-treatment (normalized post-op)", "treatment": "neoadjuvant carboplatin and paclitaxel; interval debulking surgery; maintenance olaparib", "response": "complete response / clinical remission", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with right-sided abdominal pain and weight loss. Colonoscopy revealed an obstructing sigmoid mass; biopsy: adenocarcinoma of the colon. Staging CT shows multiple hypodense lesions throughout the liver. Molecular panel: KRAS G12D mutation, BRAF wild-type, MSI-stable. He initiated FOLFOX plus bevacizumab. After 4 cycles the hepatic lesions have increased in size and new lesions are noted.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: patient with metastatic cutaneous melanoma initially treated with frontline pembrolizumab but developed clinical progression of nodal and subcutaneous deposits after 4 months. Tumor genotyping demonstrated BRAF V600E mutation. Switched to targeted therapy with dabrafenib plus trametinib with rapid reduction in measurable disease\u2014documented partial response. No PD-L1 result available.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (progressed) then dabrafenib + trametinib", "response": "progression on pembrolizumab, partial response to dabrafenib + trametinib", "metastasis_site": "skin and lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 48-year-old woman with metastatic hormone receptor\u2013positive, HER2-positive breast cancer. Core biopsy: ER 90%, PR 20%, HER2 amplification by FISH. She presented with progressive bony pain; bone scan positive for multiple lytic lesions. Treated with first-line trastuzumab, pertuzumab and docetaxel with significant symptomatic improvement. Endocrine therapy with letrozole planned after chemo. No comprehensive somatic panel available in this clinic note.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER 90%; PR 20%", "treatment": "trastuzumab + pertuzumab + docetaxel; letrozole planned", "response": "clinical improvement / partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 45-year-old woman with locally advanced triple-negative breast cancer (ER-/PR-/HER2-) cT3N1. She completed neoadjuvant chemotherapy with doxorubicin/cyclophosphamide (AC) followed by weekly paclitaxel. Germline testing returned positive for a pathogenic BRCA1 mutation. She underwent lumpectomy and sentinel node biopsy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases on staging PET/CT.", "output": {"cancer_type": "breast cancer (triple-negative)", "stage": "IIIB", "gene_mutation": "BRCA1", "biomarker": "ER-/PR-/HER2- (triple-negative)", "treatment": "doxorubicin/cyclophosphamide followed by paclitaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with colorectal adenocarcinoma, KRAS G12D positive on PCR-based assay. Tumor was reported MSI-stable. Presents with multiple hepatic metastases and peritoneal carcinomatosis on CT. He received first-line FOLFOX plus bevacizumab; follow-up scans show new hepatic lesions and rising tumor markers consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with metastatic colon adenocarcinoma found to harbor a KRAS G12D mutation. CT chest shows multiple new pulmonary nodules consistent with metastatic disease to the lungs. He completed six cycles of FOLFOX with bevacizumab but interval imaging documents new lesions and overall progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic lung adenocarcinoma diagnosed March 2024. NGS demonstrates EGFR L858R mutation. Baseline brain MRI showed two enhancing lesions consistent with metastases. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg PO daily; follow-up CT and MRI at 8 weeks show decrease in size of intracranial lesions and shrinkage of the primary lung mass consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man with metastatic cutaneous melanoma harboring BRAF V600E. He received pembrolizumab for 4 cycles but developed progression with multiple new pulmonary nodules and mediastinal adenopathy. Therapy was switched to dabrafenib plus trametinib; despite a transient improvement in cutaneous lesions, overall disease progressed on restaging CT with increasing pulmonary disease and new supraclavicular nodes.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung; lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma harboring BRAF V600E, presented with multiple pulmonary nodules and a symptomatic cerebellar metastasis. Staged as Stage IV. He was started on dabrafenib plus trametinib and underwent stereotactic radiosurgery to the cerebellar lesion. Systemic scans show reduction in lung lesions but interval enlargement of one brain lesion \u2014 a mixed response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology clinic note: 67-year-old male with newly diagnosed prostate adenocarcinoma. PSA at diagnosis was 18 ng/mL. Biopsy showed Gleason 4+3 in multiple cores. He underwent radical prostatectomy; final pathology consistent with organ-confined disease but margin close. Adjuvant external beam radiation to the prostatic bed was given and androgen deprivation therapy with leuprolide was started. Post-treatment PSA is undetectable on serial testing.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 18 ng/mL", "treatment": "radical prostatectomy; adjuvant radiation; leuprolide (androgen deprivation therapy)", "response": "undetectable PSA (complete biochemical response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic colon adenocarcinoma to the liver and peritoneum (stage IV). Tumor profiling identified BRAF V600E mutation and high microsatellite instability (MSI-H) with TMB-high. He received first-line FOLFOX combined with bevacizumab; following mixed radiologic response he was transitioned to pembrolizumab for MSI-H disease and has had stable disease on immunotherapy at last follow-up.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX + bevacizumab followed by pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female presented with a 2.2 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 3+ by IHC with FISH-confirmed HER2 amplification. She underwent lumpectomy and sentinel node biopsy with final path pT1c pN0 (stage I). Adjuvant therapy planned: weekly paclitaxel for 12 weeks with trastuzumab for one year. Surveillance mammogram and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: adenocarcinoma of the colon. Staging CT shows multiple hepatic lesions consistent with metastases. KRAS G12D detected on tumor sequencing. MSI testing: microsatellite stable. Patient started palliative FOLFOX with bevacizumab; after two months there is radiographic increase in size of hepatic lesions and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: Patient is a 45-year-old male with a history of cutaneous melanoma of the left forearm, initially resected, later found to have a positive axillary node consistent with Stage III disease. NGS demonstrated BRAF V600E. After nodal dissection the patient received adjuvant pembrolizumab but developed pulmonary metastases at 9 months and was transitioned to dabrafenib plus trametinib with symptomatic improvement. Most recent PET/CT shows decrease in metabolic activity of lung nodules. PD-L1 was not reportable on the specimen.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (adjuvant); dabrafenib and trametinib (for metastatic disease)", "response": "partial response (decrease in metabolic activity of lung nodules)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with de novo metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R. PD-L1 TPS 20%. Baseline brain MRI revealed multiple small enhancing metastases and bone scan consistent with osseous involvement. He was started on osimertinib 80 mg daily; the 8-week CT shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left invasive ductal carcinoma, clinical T3N1M0 (stage IIIB). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. No somatic NGS was performed on the biopsy. She completed neoadjuvant weekly paclitaxel, and was started on trastuzumab plus pertuzumab prior to planned definitive surgery.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel; trastuzumab; pertuzumab", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a palpable left breast mass. Core biopsy showed invasive ductal carcinoma, grade 2. ER positive, PR positive, HER2 negative by IHC/FISH. Staging workup consistent with stage II disease. Molecular testing identified a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy followed by adjuvant radiotherapy and was started on tamoxifen. Postoperative imaging and follow-up exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, sentinel node biopsy, adjuvant radiotherapy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a 3.5 cm right breast mass. Core biopsy: invasive ductal carcinoma, HER2-positive by IHC 3+ and confirmed HER2 amplification by FISH. ER and PR negative. Clinical staging consistent with IIIB. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab; at the time of surgery the specimen showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment for left invasive ductal breast cancer, clinical stage IIIB. Core biopsy: HER2 amplification, ER negative, PR negative; next-gen sequencing identified PIK3CA H1047R. Patient received 6 cycles of docetaxel, carboplatin and trastuzumab followed by mastectomy. Surgical pathology revealed a complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin and trastuzumab", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman with left breast invasive ductal carcinoma, clinically cT2N0 (Stage II). Tumor is ER/PR positive and HER2 IHC 3+ with FISH-confirmed HER2 amplification. No NGS panel was performed. She received neoadjuvant paclitaxel and carboplatin with trastuzumab, followed by lumpectomy. Final pathology showed only a 2 mm focus of residual invasive tumor (near\u2011complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR positive", "treatment": "neoadjuvant paclitaxel and carboplatin with trastuzumab; lumpectomy", "response": "near-complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male transferred for management of widely metastatic cutaneous melanoma. PET/CT showed multiple hepatic and osseous lesions consistent with stage IV disease. PD-L1 testing was low and reported as 1% but BRAF testing results were not available in the referral note. He was treated with ipilimumab plus nivolumab but restaging scans after 3 months demonstrated progression in the liver with new lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 1%", "treatment": "ipilimumab plus nivolumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with cutaneous melanoma, BRAF V600E positive, presented with pulmonary nodules consistent with metastatic disease. Staged as IV. Started on combination targeted therapy with dabrafenib and trametinib; treatment complicated by intermittent fevers requiring brief dose holds. Interval CT at 12 weeks demonstrates ~50% reduction in sum of target lesions \u2014 partial response. PD-L1 testing not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC at presentation with bulky peritoneal disease. Germline testing revealed a pathogenic BRCA1 variant and tumor HRD testing was positive. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with bevacizumab. Interval CT shows decrease in peritoneal implants consistent with partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel with bevacizumab (post-op)", "response": "partial response", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Record: 72-year-old male with metastatic castration-resistant prostate adenocarcinoma. Germline BRCA2 deleterious mutation (6174delT) identified; tumor testing consistent with homologous recombination deficiency (HRD positive). After progression on abiraterone, patient was started on olaparib 300 mg twice daily. Bone scan shows multifocal osteoblastic lesions in the axial skeleton; disease is currently stable on olaparib.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT", "biomarker": "HRD positive", "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with metastatic HER2-positive invasive ductal breast carcinoma. IHC/ISH demonstrated HER2 amplification (3+ by IHC and positive FISH); tumor was ER-/PR-. Tumor NGS revealed a PIK3CA E545K mutation. She has liver metastases on staging PET/CT and is classified as stage IV. She was started on trastuzumab and pertuzumab with docetaxel and has had a partial response on first restaging CT after three cycles.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification", "treatment": "trastuzumab and pertuzumab with docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (clinical stage IV) presented with progressive dyspnea. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score ~10%. She was started on osimertinib 80 mg daily in July. Interval MRI brain and CT chest show shrinkage of multiple pulmonary nodules and reduction in a 1.5 cm cerebellar metastasis compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "31-year-old male with a pigmented lesion on the left forearm excised by dermatology. Pathology: superficial spreading melanoma, Breslow 0.6 mm, no ulceration, sentinel node negative. Final stage IA. BRAF V600E mutation detected on tumor sequencing. No adjuvant therapy was recommended; patient remains on dermatology surveillance with no evidence of recurrence to date.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "IA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy (no adjuvant therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic non-small cell lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation. He was started on osimertinib 80 mg daily in January 2020. Baseline brain MRI demonstrated multiple small cerebellar and frontal metastases. After 3 months of therapy there is interval decrease in size of both pulmonary and intracranial lesions consistent with a partial response; patient remains on osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with clear cell renal cell carcinoma underwent cytoreductive nephrectomy. Post-op CT demonstrates progressive disease with metastatic deposits in the left adrenal gland and a new nodule in the contralateral lung. Comprehensive NGS reported no actionable alterations. He was started on sunitinib; first on-treatment scan documents interval progression.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "sunitinib", "response": "progression", "metastasis_site": "adrenal gland, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with recurrent cutaneous melanoma. Tumor sequencing returned BRAF V600E and reported tumor mutational burden high (TMB-high). PD-L1 by IHC was 5%. Staging identifies pulmonary nodules and two small brain metastases. He was started on dabrafenib plus trametinib with initial shrinkage of lung lesions, later transitioned to nivolumab for intracranial progression; overall assessment is mixed response with partial response in the chest but progression in the brain requiring stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 5%", "treatment": "dabrafenib and trametinib, later nivolumab", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrates multiple bilateral pulmonary nodules and lytic lesions in the pelvis consistent with metastatic disease. Tissue NGS identified EGFR L858R; concurrent PD-L1 tumor proportion score 5%. She was started on osimertinib and received stereotactic radiosurgery to a solitary 1.2 cm cerebellar metastasis. On first restaging CT at 8 weeks there is a decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib, stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma with liver-dominant disease. NGS demonstrated KRAS G12D and the tumor was microsatellite stable (MSS) with low TMB. First-line therapy was FOLFOX plus bevacizumab with initial disease control; CT scans after 4 months showed stable disease. Upon hepatic progression the patient was transitioned to regorafenib.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab; later regorafenib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma found to be BRAF V600E positive. Brain metastases were treated with stereotactic radiosurgery followed by systemic targeted therapy with dabrafenib and trametinib. PD-L1 testing returned 5%. Extracranial disease demonstrates a partial response while intracranial lesions remain stable.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "stereotactic radiosurgery; dabrafenib and trametinib", "response": "partial response (extracranial); intracranial stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 47-year-old female with left-sided invasive ductal carcinoma, ER positive, PR positive, HER2 amplification by FISH. Clinical stage IIIB (T4bN1). She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) and proceeded to mastectomy. Surgical pathology demonstrated no residual invasive carcinoma \u2014 pathologic complete response. No targeted mutation panel was performed pre-op.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with high-grade invasive ductal carcinoma of the breast. Tumor is ER positive, PR positive, and HER2 amplified by FISH. She presented with new back pain and bone scan shows multiple osseous metastases. Patient started weekly paclitaxel with trastuzumab and pertuzumab; disease has remained clinically stable on this regimen. No somatic NGS was performed.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel, trastuzumab, pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man underwent resection of a right frontal glioblastoma multiforme (WHO grade IV). Post-op molecular report: MGMT promoter methylation positive; broad NGS panel showed no actionable mutations and the report notes 'no actionable mutations detected'. He completed concurrent radiotherapy with temozolomide (Stupp protocol). Early MRI at 3 months demonstrates radiographic progression. No extracranial disease identified.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation positive", "treatment": "surgery followed by radiotherapy + temozolomide (Stupp protocol)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old with widely metastatic cutaneous melanoma presenting with multiple pulmonary nodules and new brain metastases. PD-L1 expression 60% and high tumor mutational burden reported on NGS; BRAF testing was sent but results were pending at the time of treatment decision. Patient was started on combination nivolumab plus ipilimumab but follow-up imaging after two cycles shows progression in the brain.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 60%; TMB-high", "treatment": "nivolumab plus ipilimumab", "response": "progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical note: Right hemicolectomy performed for adenocarcinoma of the ascending colon. Pathology: pT3 N2a (stage III) with 3/15 nodes involved. Mismatch repair testing: MLH1/PMS2 intact, tumor described as microsatellite stable (MSS). Extended RAS panel did not identify pathogenic variants. Plan: adjuvant FOLFOX for 6 months. No radiographic evidence of distant metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-stable (MSS)", "treatment": "right hemicolectomy; planned adjuvant FOLFOX", "response": "no evidence of disease (postoperative, planned adjuvant therapy)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy for a 48-year-old woman with ER+ (Allred 7), PR\u2013, HER2 amplified invasive ductal carcinoma of the left breast, clinical stage IIIA. She received 6 cycles of docetaxel, carboplatin with trastuzumab and pertuzumab prior to mastectomy. Final pathology demonstrated no residual invasive carcinoma (pathologic complete response). PIK3CA H1047R mutation detected on the pre-treatment panel.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma patient (cutaneous primary) with widespread disease including sclerotic lesions in the right femur consistent with bone metastasis. PD reported high tumor mutational burden (TMB-high). Given combination immunotherapy with nivolumab plus ipilimumab. No actionable driver mutation identified on panel. Recent PET/CT shows largely stable bony disease after two cycles.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "TMB-high", "treatment": "nivolumab and ipilimumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with metastatic lung adenocarcinoma after presenting with cough and weight loss. Staging CT showed multiple pulmonary nodules and two enhancing brain metastases. NGS demonstrated EGFR L858R mutation; PD-L1 TPS 15%. Patient was started on osimertinib 80 mg daily with an initial partial response by RECIST at first follow-up. Stereotactic radiosurgery was performed to the brain lesions for oligoprogression while systemic therapy continued.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung (pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with newly diagnosed metastatic colorectal adenocarcinoma. Liver biopsy molecular testing returned BRAF V600E mutation and high microsatellite instability (MSI-H) with elevated tumor mutational burden. Systemic therapy was initiated with encorafenib plus cetuximab. Follow-up scans after 8 weeks show stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "encorafenib and cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma to the liver diagnosed on CT-guided biopsy. Molecular testing returned KRAS G12D. He completed 6 cycles of FOLFOX with bevacizumab but interval imaging demonstrates growth of hepatic lesions consistent with progression. MSI testing was not available at the time of this note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX; bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 42-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Imaging at diagnosis revealed pulmonary and hepatic deposits consistent with stage IV disease. He was started on targeted therapy with dabrafenib plus trametinib and achieved a marked reduction in size of liver lesions with ongoing partial response on RECIST at 4 months.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "partial response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with T2N1 invasive ductal carcinoma of the breast (clinical stage II). Core biopsy: ER negative, PR negative, HER2 amplification by FISH; next\u2011generation sequencing identified PIK3CA H1047R. She received neoadjuvant chemotherapy with docetaxel, carboplatin plus dual HER2 blockade (trastuzumab and pertuzumab). Post\u2011operative pathology after lumpectomy showed no residual invasive tumor (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (HER2-positive invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin with trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic colon adenocarcinoma. Biopsy-proven stage IV disease with multiple hepatic lesions. Molecular profile: KRAS G12D positive; tumor also reported MSI-H on PCR. She received FOLFOX with bevacizumab as first-line therapy and achieved stable disease by RECIST at 8 weeks; liver lesions decreased in size but not meeting PR criteria.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 62-year-old woman underwent pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Final pathologic stage pT3N0. No molecular testing was performed on the specimen during admission. Plan is for adjuvant gemcitabine pending recovery; no radiographic evidence of distant spread at this time.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": null, "treatment": "Whipple procedure with planned adjuvant gemcitabine", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma presented with headaches and MRI showing multiple enhancing lesions. Initial tissue NGS identified EGFR L858R. PD-L1 by IHC reported 5%. Patient was started on osimertinib 80 mg daily with good tolerance. After 8 weeks there is radiographic shrinkage of the primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, initially stage IV at diagnosis. Molecular testing revealed a BRAF V600E mutation. Baseline imaging demonstrated multiple hepatic metastases and several enhancing brain lesions. Started on dabrafenib plus trametinib; early restaging at 8 weeks showed partial response of hepatic lesions but interval enlargement of a frontal lobe metastasis that was resected. At 5 months the patient developed new pulmonary nodules and systemic progression; plan to consider switching to immunotherapy. PD-L1 testing not reported.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; surgical resection of brain metastasis", "response": "initial partial response (liver) followed by systemic progression", "metastasis_site": "liver; brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient diagnosed with prostate adenocarcinoma, Gleason 3+4, clinical stage II (T2bN0M0). Pre-treatment PSA was 12 ng/mL. No genomic testing performed. He received definitive external beam radiation therapy and concurrent androgen deprivation with leuprolide depot. At 12-month follow-up PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "external beam radiation and leuprolide (androgen deprivation therapy)", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma. Molecular testing on the primary tumor identified KRAS G12D; microsatellite testing reported microsatellite stable (MSS). He received six cycles of FOLFOX plus bevacizumab but interval CT shows increasing size and number of pulmonary nodules consistent with disease progression. Patient is considered for second-line therapy. Stage IV disease with lung metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 69-year-old male with metastatic colorectal adenocarcinoma. CT abdomen demonstrates multiple hepatic lesions consistent with metastases; stage IV. Tumor sequencing returned KRAS G12D mutation. He was started on FOLFOX plus bevacizumab in the palliative setting. Interval scans after 3 cycles show no new lesions and slight decrease in size of dominant liver mets \u2014 overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 1.2 cm invasive ductal carcinoma of the left breast, staged as I after imaging and pathology. Tumor is ER positive, PR positive and HER2 3+ by IHC. She underwent lumpectomy with negative margins and sentinel node biopsy. Adjuvant therapy included weekly paclitaxel followed by trastuzumab planned for one year. On latest follow-up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 3+; ER+; PR+", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent wide local excision and completion lymphadenectomy for a left forearm cutaneous melanoma. Final pathology was stage IIIB with one positive regional node. BRAF V600 PCR was negative on the initial report and PD-L1 was not assessed. The patient completed a course of adjuvant high-dose interferon and is currently under surveillance with no radiographic evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision, completion lymphadenectomy, adjuvant high-dose interferon", "response": "no radiographic evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with pancreatic ductal adenocarcinoma, diagnosed with metastatic (stage IV) disease. Germline BRCA2 mutation identified; baseline CA 19-9 markedly elevated. He received first-line FOLFIRINOX with radiographic progression after 4 months and was switched to olaparib maintenance given BRCA2, with a subsequent partial response on CT and fall in CA 19-9.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX; olaparib (maintenance)", "response": "progression on FOLFIRINOX, partial response to olaparib", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the right breast: invasive ductal carcinoma, grade 3. IHC: ER negative, PR negative, HER2 3+ (amplification confirmed by FISH). Next\u2011generation sequencing identified a PIK3CA H1047R mutation. Clinical stage at presentation was IIIB with skin involvement. Patient received neoadjuvant weekly paclitaxel with trastuzumab, followed by modified radical mastectomy and adjuvant doxorubicin/cyclophosphamide. Post\u2011op imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel + trastuzumab; surgery; adjuvant doxorubicin/cyclophosphamide", "response": "complete response (no evidence of disease post\u2011op)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma. Staging CT shows widely metastatic disease consistent with stage IV. Molecular testing returned EGFR L858R; no PD-L1 testing available at this time. Patient was started on osimertinib 80 mg daily as first-line therapy. At 3-month follow-up there is radiographic partial response in the primary and reduction in a right lower lobe mass. Brain MRI pending.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma, stage IV, with multiple lesions in the liver on CT. Tumor profiling shows KRAS G12D and concurrent TP53 mutation; microsatellite testing is MSS. He was started on FOLFIRI plus bevacizumab. Follow-up CTs over 4 months indicate stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman diagnosed with high-grade serous ovarian carcinoma, surgical pathology consistent with stage IIIC disease and diffuse peritoneal carcinomatosis. Germline testing positive for BRCA1 mutation. Preoperative CA-125 was markedly elevated. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel and was started on maintenance olaparib. Subsequent CT and normalization of CA-125 indicate a complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old man with metastatic cutaneous melanoma. Stage IV at presentation with cerebral involvement. Tumor testing positive for BRAF V600E; PD-L1 testing not available. He received first-line pembrolizumab but progressed and was switched to dabrafenib plus trametinib. Most recent MRI indicates enlargement of a right frontal lesion consistent with progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (after pembrolizumab)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 62F with metastatic colorectal adenocarcinoma. Molecular testing returned KRAS G12D; tumor was reported MSI-H. She completed FOLFOX but was transitioned to pembrolizumab for MSI-high disease. Recent chest CT shows multiple new pulmonary nodules consistent with lung metastases. On pembrolizumab she has had stable disease for 4 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab (after FOLFOX)", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman presented with cough and weight loss. Imaging showed multiple bilateral pulmonary nodules and lytic lesions in the spine. Biopsy confirmed lung adenocarcinoma. Molecular testing identified EGFR L858R (exon 21) mutation; PD-L1 expression by IHC 10%. Staged as IV at diagnosis. She was started on osimertinib 80 mg daily with early symptomatic improvement and imaging at 8 weeks demonstrated a partial response. Brain MRI later showed a small asymptomatic metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided colon adenocarcinoma presenting with multiple hepatic metastases. Staging consistent with stage IV disease. Tumor profiling: MSI-H and BRAF V600E mutation. Given MSI-H status the patient was started on pembrolizumab monotherapy; interval CT shows approximately 60% reduction in size of liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Initial biopsy showed EGFR L858R; repeat biopsy at progression identified acquired EGFR T790M. PD-L1 tumor proportion score 5%. She was started on erlotinib initially with good control, then after progression was switched to osimertinib combined with carboplatin and pemetrexed for bulky nodal disease. Brain MRI demonstrated two small metastases treated with stereotactic radiosurgery. Interval chest CT shows decrease in size of pulmonary nodules and osseous lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, EGFR T790M", "biomarker": "PD-L1 5%", "treatment": "erlotinib; osimertinib + carboplatin and pemetrexed; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with newly diagnosed invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR positive, HER2 amplified by FISH (HER2/CEP17 ratio 6.2). NGS panel identified PIK3CA H1047R. Clinical staging prior to therapy: cT2 N2 M0 (stage IIIA). She was started on neoadjuvant trastuzumab with docetaxel and carboplatin; after 4 cycles there is a marked reduction in tumor size on exam and imaging consistent with partial response. No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+, PR+", "treatment": "trastuzumab with docetaxel and carboplatin (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for a pathogenic BRCA1 variant and tumor HRD-positive on genomic scar assay; somatic TP53 mutation also reported. CA-125 was markedly elevated at diagnosis. She underwent optimal debulking followed by combination chemotherapy with carboplatin and paclitaxel plus bevacizumab, and is currently on maintenance olaparib. Most recent imaging shows no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD-positive, TP53 mutation, elevated CA-125", "treatment": "carboplatin and paclitaxel with bevacizumab; maintenance olaparib", "response": "no evidence of disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with biopsy-proven lung adenocarcinoma diagnosed in January 2024. NGS on the tumor identified an EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. Staged as IV at diagnosis with both brain and bone metastases. Patient was started on osimertinib 80 mg daily in February; follow-up CT chest and brain MRI at 8 weeks demonstrated marked decrease in size of pulmonary nodules and shrinkage of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology impression: Multiple hypodense lesions in the liver consistent with metastatic disease in a patient with known colorectal primary. KRAS G12D mutation reported on tumor genotyping; tumor was MSI-H. Given MSI-H status the patient was transitioned to pembrolizumab after prior FOLFOX therapy. Most recent scan demonstrates stable size of hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male presented with jaundice and weight loss; imaging showed a pancreatic head mass with multiple hepatic lesions. Diagnosis: pancreatic ductal adenocarcinoma, stage IV. Tumor testing identified KRAS G12D; CA19-9 markedly elevated. He received 3 cycles of FOLFIRINOX but restaging CT demonstrated progression with enlarging liver metastases. He was switched to gemcitabine plus nab\u2011paclitaxel for second-line therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; gemcitabine + nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old woman with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging showed multiple brain mets and lytic lesions in the spine. Biopsy confirmed adenocarcinoma; molecular testing returned EGFR L858R and no ALK or ROS1 rearrangement. PD-L1 tumor proportion score ~10%. She was started on osimertinib 80 mg daily with stereotactic radiosurgery to the dominant brain lesion. Interval scans at 8 weeks demonstrate a partial response in the chest and decreased size of several brain nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with unresectable pancreatic ductal adenocarcinoma presenting with weight loss and jaundice. Cross-sectional imaging shows multiple liver lesions and peritoneal carcinomatosis consistent with metastatic disease (stage IV). CA19-9 is 1,240 U/mL. Given gemcitabine plus nab\u2011paclitaxel; interval CT after 2 cycles shows increase in size of hepatic lesions and new ascites \u2014 clinical progression. No genomic testing was available at time of treatment initiation.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 1,240 U/mL", "treatment": "gemcitabine + nab-paclitaxel", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with ER+/PR+ invasive ductal carcinoma of the left breast, clinical stage IIIB. Core biopsy showed HER2 amplification by FISH. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab followed by modified radical mastectomy. Pathology showed marked treatment effect with residual focal invasive carcinoma. Patient continues adjuvant trastuzumab. No next-generation sequencing was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant paclitaxel and trastuzumab; surgery (modified radical mastectomy); adjuvant trastuzumab", "response": "partial response / significant downstaging (residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy summary: 48-year-old female with locally advanced left breast cancer, clinical T3N1 (stage IIIB). Core biopsy: invasive ductal carcinoma, ER/PR negative, HER2 FISH positive (HER2 amplification). She received 6 cycles weekly paclitaxel with concurrent trastuzumab and pertuzumab prior to surgery. Mastectomy performed 06/2024 with nodes removed; pathology reports a complete pathological response (no residual invasive carcinoma). No somatic sequencing reported at this time.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel with trastuzumab and pertuzumab (neoadjuvant), surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and oncology clinic summary: 62-year-old female with high-grade serous ovarian carcinoma, optimal cytoreductive surgery achieved but peritoneal carcinomatosis noted intraoperatively. Stage documented as IIIC. Germline testing returned BRCA1 pathogenic variant. Adjuvant plan: carboplatin and paclitaxel every 3 weeks with consideration of bevacizumab maintenance; CA-125 is downtrending after two cycles. Imaging confirms diffuse peritoneal implants without distant organ metastasis.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": null, "treatment": "carboplatin and paclitaxel (with consideration of bevacizumab maintenance)", "response": "partial response (CA-125 downtrending)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with advanced cutaneous melanoma, BRAF V600E positive. Initially presented with pulmonary metastases. Treated with combination targeted therapy dabrafenib plus trametinib and achieved complete response at 4 months; subsequently developed progression at 8 months with a new right adrenal metastasis on restaging scan. PD-L1 by IHC was 30% on the diagnostic biopsy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 30% TPS", "treatment": "dabrafenib and trametinib", "response": "initial complete response then progression", "metastasis_site": "lung, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy right breast: invasive ductal carcinoma, HER2 3+ by IHC, ER negative, PR negative. Clinical exam and imaging consistent with locally advanced disease, clinical stage IIIB. Plan: neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab prior to attempted mastectomy. Tumor size has decreased on serial breast exams. No distant disease identified on CT chest/abdomen/pelvis.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+ (IHC); ER negative; PR negative", "treatment": "paclitaxel, trastuzumab, pertuzumab (neoadjuvant)", "response": "partial response (clinical)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma diagnosed after presentation with right upper quadrant pain and elevated LFTs. CT shows multiple liver lesions consistent with metastases. Tumor genotyping identified KRAS G12D. He was started on FOLFOX plus bevacizumab. Restaging at 3 months demonstrated no new lesions and minor shrinkage of dominant hepatic lesions; overall assessment: stable disease and plan to continue current chemotherapy until progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma diagnosed after right hemicolectomy. Multiple hepatic lesions on CT consistent with metastases. Tumor testing: deficient mismatch repair (MSI-H) and high tumor mutational burden; extended RAS (KRAS/NRAS) wild-type, BRAF V600E not identified. Given MSI-H status, he was started on pembrolizumab monotherapy. Interval CT after 12 weeks shows no new lesions and modest decrease in size of dominant liver metastasis consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease with liver and bone metastases. Molecular testing returned KRAS G12C and a concurrent TP53 R248Q. PD-L1 tumor proportion score 40%; tumor mutational burden reported as TMB-high. He was started on first-line pembrolizumab in combination with carboplatin and pemetrexed. After 3 cycles imaging showed a 40% reduction in measurable disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C, TP53 R248Q", "biomarker": "PD-L1 40%; TMB-high", "treatment": "pembrolizumab + carboplatin + pemetrexed", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient: 59-year-old male who underwent right hemicolectomy for adenocarcinoma of the ascending colon. Pathology: pT3N1 (3/18 nodes positive). Tumor genotyping: KRAS G12D. Received adjuvant FOLFOX for 6 months. Surveillance CT and CEA remain negative at 18 months with no clinical evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy; adjuvant FOLFOX x6 months", "response": "disease-free (no evidence of recurrence) at 18 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent core biopsy showing invasive ductal carcinoma of the breast, clinical stage I (T1N0M0). Hormone receptor testing: ER positive, PR positive, HER2 negative. Tumor genomic profiling detected PIK3CA E545K. She had lumpectomy with sentinel node biopsy followed by adjuvant radiation and was started on tamoxifen. At 12-month follow-up there is no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA E545K", "biomarker": "ER+/PR+/HER2-", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated Stage IV disease with multiple cerebral and osseous lesions. Molecular testing returned EGFR L858R mutation; PD-L1 by IHC reported 20%. Patient was started on osimertinib 80 mg daily as first-line therapy. Interim imaging at 8 weeks shows shrinkage of the primary and brain mets consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 71-year-old presented with metastatic colon adenocarcinoma, biopsy-proven liver lesions, clinical stage IV. Tumor profiling identified BRAF V600E and high microsatellite instability (MSI-H). Initial treatment was FOLFOX plus bevacizumab but CT after 3 cycles showed progression in the liver. Switched to pembrolizumab given MSI-H status; restaging after 12 weeks demonstrates stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old man with metastatic cutaneous melanoma. BRAF V600E positive on tumor panel. Presented with multiple painful osseous lesions on PET/CT consistent with skeletal metastases. He was treated with dabrafenib and trametinib; after an initial response he developed new lesions and was noted to have radiographic progression on the last scan.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic sigmoid colon adenocarcinoma presenting with multiple liver lesions. Molecular profiling: MSI-H and TMB-high; KRAS G12D detected on next-gen sequencing. Given MSI-H status he was started on pembrolizumab monotherapy as first-line systemic therapy. After three cycles CT abdomen/pelvis shows near-complete resolution of hepatic metastases and CEA normalized. Assessment at 9 months documents sustained complete response radiographically.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with stage IV lung adenocarcinoma. Molecular testing returned EGFR L858R and no ALK or ROS1 rearrangements. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily with symptomatic improvement. Repeat CT and brain MRI at 8 weeks demonstrate shrinkage of pulmonary nodules and decreased size of multiple cerebellar metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old male treated for oropharyngeal squamous cell carcinoma. Presented with a large tonsillar mass and ipsilateral neck nodes. Clinical stage IVA disease. Underwent definitive concurrent chemoradiation with high-dose cisplatin (3 cycles) and IMRT. Post-treatment exam shows persistent nodal fullness but no new distant disease on CT chest. Plan: surveillance with PET/CT in 12 weeks.", "output": {"cancer_type": "oropharyngeal squamous cell carcinoma", "stage": "IVA", "gene_mutation": null, "biomarker": null, "treatment": "concurrent chemoradiation with cisplatin and IMRT", "response": "stable disease", "metastasis_site": "cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old woman with ER+/PR+/HER2-amplified metastatic breast cancer presented with progressive right upper quadrant pain. Liver biopsy confirmed metastasis. Tumor profiling identified PIK3CA H1047R in addition to HER2 amplification and hormone receptor positivity. She received first-line combination therapy with pertuzumab, trastuzumab and docetaxel; alpelisib was added subsequently for PIK3CA-mutant disease. Imaging after 4 cycles documented a partial response in the liver lesions.", "output": {"cancer_type": "breast cancer (ER+/PR+/HER2-amplified)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "pertuzumab + trastuzumab + docetaxel; alpelisib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 68-year-old man with metastatic castration-resistant prostate adenocarcinoma. Prior radical prostatectomy; now presents with rising PSA and new symptomatic osseous lesions on bone scan. Germline/somatic testing detected deleterious BRCA2 mutation. Patient started androgen deprivation therapy and received olaparib; initial PSA decline and improvement in bone pain documented. Assessment: partial biochemical and clinical response to targeted therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (metastatic castration-resistant)", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "androgen deprivation therapy and olaparib", "response": "partial response (biochemical and clinical)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old F with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrates metastatic disease with lesions in the spine and a 1.5 cm right frontal brain metastasis \u2014 designated stage IV. FoundationOne reports EGFR L858R mutation. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg PO daily and underwent stereotactic radiosurgery to the brain lesion. CT at 12 weeks shows decrease in size of thoracic disease consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "spine, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with lung adenocarcinoma in January 2024. Staging workup consistent with stage IV disease with multiple brain and bone metastases. Tumor genotyping identified EGFR L858R. PD-L1 TPS reported at 15%. Patient was started on osimertinib 80 mg daily; first CT/MRI at 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15% (TPS)", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 42-year-old female with a 0.6 mm superficial spreading melanoma on the right forearm. Excision was performed with 1 cm margins and sentinel lymph node biopsy was negative. Final path report: Stage IA. No molecular testing was performed and there is currently no evidence of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage III (T3N1M0). Core biopsy: ER positive, PR negative, HER2 3+ by IHC with FISH-confirmed HER2 amplification. NGS detected PIK3CA H1047R. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by weekly paclitaxel with concurrent trastuzumab. At surgery there was a partial pathologic response with residual invasive carcinoma in the breast but no involved lymph nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab", "response": "partial pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with extensive peritoneal carcinomatosis at diagnosis. Germline testing positive for BRCA1 deleterious mutation. Underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; now on maintenance olaparib. Recent CT shows no measurable disease and CA-125 normalized.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 normalized", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete clinical response / no evidence of measurable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. Primary was resected previously; he now has multiple pulmonary nodules and two small brain metastases. Molecular testing demonstrates BRAF V600E and NRAS wild-type. PD-L1 expression is low (~5%). He was started on combination targeted therapy with dabrafenib and trametinib, achieving a partial response in lung disease; stereotactic radiosurgery was used for brain lesions. After further progression he received second-line nivolumab with mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery for brain metastases; later nivolumab", "response": "partial response (lung); mixed response on second-line therapy", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic cutaneous melanoma with intracranial involvement. Biopsy of a skin lesion confirmed melanoma; molecular testing detected BRAF V600E. PD-L1 testing returned 10%. He underwent stereotactic radiosurgery to the dominant brain lesion and was started on dabrafenib plus trametinib. Despite initial symptomatic improvement, 8-week MRI shows interval increase in intracranial tumor burden consistent with progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib (after stereotactic radiosurgery)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with colon adenocarcinoma s/p colectomy in 2022. Recent surveillance CT chest/abdomen reveals multiple pulmonary nodules concerning for metastatic spread. Molecular testing: KRAS G12D positive; mismatch repair intact (MSS). He received FOLFOX with bevacizumab and imaging over 6 months has shown no progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic urothelial carcinoma of the bladder, presenting with pelvic lymphadenopathy and lytic bone lesions (stage IV). Tumor panel showed no actionable somatic mutations. PD-L1 combined positive score 60% (>50%). He was started on pembrolizumab and after four cycles PET/CT demonstrated complete metabolic response of nodal disease and resolution of most bone lesions; patient remains on maintenance pembrolizumab.", "output": {"cancer_type": "urothelial carcinoma (bladder)", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 CPS 60% (>50%)", "treatment": "pembrolizumab", "response": "complete response (metabolic)", "metastasis_site": "lymph nodes, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman diagnosed with invasive ductal breast carcinoma. Core biopsy: ER positive, PR negative, HER2 amplified by FISH. Clinical stage IIIB with fixed axillary nodes. NGS reported a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with trastuzumab; imaging after 4 cycles documented a good but not complete reduction in tumor size (partial response). No distant metastases identified.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced breast cancer, ER positive, PR negative. Core biopsy: invasive ductal carcinoma, clinical stage IIIA. HER2 IHC 3+ and HER2 amplification confirmed by FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab in combination with docetaxel for six cycles, followed by lumpectomy. Pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIa", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification (IHC 3+)", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant combination)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with cutaneous melanoma of the left forearm. Wide local excision and sentinel node biopsy revealed one positive node (stage IIIA). Tumor harbors BRAF V600E mutation. He was started on adjuvant dabrafenib plus trametinib. Follow-up PET/CT demonstrates resolution of hypermetabolic uptake in the draining node basins and no distant disease\u2014assessment: complete metabolic response. PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "adjuvant dabrafenib and trametinib", "response": "complete metabolic response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with castration-sensitive metastatic prostate adenocarcinoma, stage IV at diagnosis with extensive sclerotic bone metastases. Baseline PSA 320 ng/mL. He was started on androgen-deprivation therapy and later transitioned to enzalutamide; follow-up imaging and PSA demonstrated a partial response with substantial PSA decline. No tumor sequencing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 320 ng/mL", "treatment": "androgen-deprivation therapy; enzalutamide", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with newly diagnosed metastatic lung adenocarcinoma (diagnosed 2023). Staging consistent with Stage IV disease with known brain and bone metastases. Tumor NGS reported EGFR L858R and TP53 R175H; PD-L1 TPS 20%. He received first-line carboplatin/pemetrexed plus pembrolizumab and on first restaging CT had a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, TP53 R175H", "biomarker": "PD-L1 20%", "treatment": "carboplatin/pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed metastatic lung adenocarcinoma (stage IV) found to harbor an EGFR L858R mutation. PD-L1 TPS reported at 25%. Patient was started on osimertinib 80 mg daily in January. Interval imaging and brain MRI demonstrate decrease in size of pulmonary nodules and lytic lesions in the spine; stereotactic radiosurgery performed to a solitary cerebellar metastasis. Assessment: partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 25%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Initial testing identified EGFR L858R; after progression on erlotinib a re-biopsy showed EGFR T790M. PD-L1 TPS 5%. At diagnosis she had brain and bone metastases and later developed liver lesions. She was switched to osimertinib with a partial radiographic response for 9 months, then progression in the liver was documented.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 5%", "treatment": "erlotinib; osimertinib", "response": "progression after initial partial response", "metastasis_site": "brain; bone; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with high\u2011grade serous ovarian carcinoma, germline BRCA1 deleterious mutation identified. Large-volume ascites and diffuse peritoneal carcinomatosis on CT at presentation. Preop CA-125 markedly elevated. Underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel; post-treatment imaging and CA-125 reflect a complete radiologic and biochemical response of the peritoneal disease. Stage assigned as IIIC.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated (normalized post-treatment)", "treatment": "carboplatin and paclitaxel with cytoreductive surgery", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colon adenocarcinoma to the liver. Initial NGS reported KRAS G12D mutation; mismatch repair proteins intact on immunohistochemistry (no MSI-H). He received FOLFOX with bevacizumab but follow-up imaging at 3 months demonstrated increase in size and number of hepatic metastases consistent with progression of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Brief summary: Patient with metastatic colorectal adenocarcinoma. Tumor profiling shows BRAF V600E mutation and high microsatellite instability (MSI-H) with TMB-high. Initially treated with FOLFOX plus bevacizumab; after progression therapy was changed to pembrolizumab as monotherapy. Latest scan shows stable disease. Liver metastases were present at diagnosis.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old male with cutaneous melanoma on the back, now stage IV with multiple pulmonary nodules and an adrenal deposit. Molecular testing identified BRAF V600E. Patient was started on combination targeted therapy with dabrafenib and trametinib and reported symptomatic improvement; CT chest after 6 weeks showed marked reduction in size of lung metastases. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative oncology note: 52-year-old female with left breast invasive ductal carcinoma, clinical stage IIIA (T2N2). Tumor is HER2 amplified, ER positive and PR negative. NGS detected a PIK3CA H1047R mutation. She was started on weekly paclitaxel with trastuzumab as neoadjuvant therapy; imaging after 12 weeks showed a good but incomplete radiographic response.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with borderline resectable pancreatic ductal adenocarcinoma (clinical stage III). Limited NGS performed perioperatively did not return actionable alterations (report not available), and no PD-L1 or other biomarkers were reported. He received FOLFIRINOX as initial systemic therapy followed by second-line gemcitabine plus nab\u2011paclitaxel; restaging scans showed new hepatic metastases with overall progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX followed by gemcitabine + nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male presents with newly diagnosed lung adenocarcinoma. Staging workup revealed stage IV disease with multiple bone lesions and a solitary enhancing cerebellar lesion. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and had an initial radiographic partial response at 8 weeks, but recent imaging demonstrates radiographic progression in the brain and worsening osseous disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 58-year-old female with ER+/PR+/HER2 amplified invasive ductal carcinoma of the left breast, clinical stage IIIA based on tumor size and multiple involved axillary nodes. She received 4 cycles of dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with concurrent trastuzumab and underwent lumpectomy. Surgical pathology shows no residual invasive carcinoma\u2014pathologic complete response. BRCA1/2 testing pending.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "dose-dense doxorubicin and cyclophosphamide, paclitaxel, trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 55-year-old female with a newly diagnosed intracranial mass. Craniotomy and subtotal resection performed; pathology consistent with glioblastoma, WHO grade IV. MGMT promoter unmethylated. IDH1 R132H immunostain negative (wild-type). Post-op plan: concurrent temozolomide with radiation. At 3-month follow-up there is radiographic progression with increased enhancing tumor and new leptomeningeal enhancement; patient referred for palliative bevacizumab. No extracranial metastases.", "output": {"cancer_type": "glioblastoma", "stage": "WHO grade IV", "gene_mutation": "IDH1 wild-type", "biomarker": "MGMT promoter unmethylated", "treatment": "temozolomide with radiation; later bevacizumab", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Office note: 64-year-old male with newly diagnosed prostate adenocarcinoma found on screening PSA. Biopsy: Gleason 3+4 in 2/12 cores. Clinical stage T1cN0M0 (stage I). No genomic testing was performed and no tissue biomarkers reported. He elected definitive therapy and completed external beam radiation therapy with concurrent androgen deprivation therapy (leuprolide). PSA now undetectable at 18 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "undetectable PSA (no biochemical evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male referred for treatment of metastatic lung adenocarcinoma diagnosed in 2023. Comprehensive genomic testing returned EGFR L858R. PD-L1 tumor proportion score 10%. MRI brain demonstrated multiple enhancing lesions; bone scan positive for vertebral involvement. Patient was started on osimertinib 80 mg daily as first-line therapy. Interval CT at 8 weeks shows shrinkage of primary lung mass and decreased size of brain and bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced left-sided invasive ductal breast carcinoma, clinical stage IIIB. Immunohistochemistry: ER positive, PR positive; FISH demonstrated HER2 amplification. Tumor NGS identified a PIK3CA H1047R mutation. She completed six cycles of neoadjuvant trastuzumab and pertuzumab with docetaxel and proceeded to lumpectomy \u2014 final pathology showed a pathologic complete response. No distant mets on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "trastuzumab and pertuzumab with docetaxel (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent subtotal resection of a right temporal glioblastoma multiforme. Molecular testing detected an IDH1 R132H mutation and MGMT promoter methylation. She completed concurrent radiation with temozolomide. Three-month postoperative MRI shows no interval growth of the enhancing lesion and stable postoperative changes.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation", "treatment": "subtotal resection followed by radiation and temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and treatment summary: Patient with glioblastoma (WHO grade IV) underwent subtotal resection. MGMT promoter status was not available. Tumor was positive for IDH1 R132H on immunohistochemistry. He completed concurrent radiotherapy with temozolomide followed by adjuvant temozolomide, but MRI at 4 months showed enlarging enhancing mass consistent with progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": null, "treatment": "surgical resection; concurrent radiotherapy and temozolomide, followed by adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic cutaneous melanoma, stage IV with pulmonary nodules. Tumor NGS identified a BRAF V600E mutation. She was treated with dabrafenib plus trametinib but imaging after 4 months demonstrated progression of pulmonary disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 47-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. Tumor markers: HER2 IHC 3+ consistent with HER2 amplification; ER 80% positive, PR 60% positive. NGS identifies PIK3CA H1047R. She received neoadjuvant docetaxel and carboplatin with dual HER2 blockade (trastuzumab + pertuzumab) for 6 cycles with marked tumor shrinkage; post-mastectomy pathology demonstrated a pathologic partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma presented to clinic. Tissue NGS returned EGFR L858R mutation; PD-L1 TPS 10%. Staging imaging demonstrated multiple enhancing brain lesions and lytic lesions in the thoracic spine. He was started on osimertinib 80 mg daily in January and tolerated therapy well. First restaging CT and brain MRI at 8 weeks showed a 45% decrease in measurable disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man seen in clinic for follow-up of stage IV lung adenocarcinoma. Initial molecular testing detected EGFR L858R mutation. PD-L1 was reported as 10% (TPS). Brain MRI showed two enhancing lesions; PET-CT confirmed focal bone uptake in T8. Patient started osimertinib 80 mg daily three months ago with symptomatic improvement and repeat CT shows a 45% decrease in target lesions consistent with a partial response. No prior chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent lumpectomy for invasive ductal carcinoma of the breast. Pathology: ER positive, PR positive, HER2 3+ by IHC consistent with HER2 amplification. Final pathologic stage was IIA (T2N0). She completed adjuvant docetaxel and cyclophosphamide followed by trastuzumab for one year. Latest follow-up exam and mammogram show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel and cyclophosphamide; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic sigmoid colon adenocarcinoma. Liver lesions were biopsied and molecular testing identified KRAS G12D; MMR proteins intact (MSI-stable). He was started on FOLFOX plus bevacizumab. After three cycles cross-sectional imaging shows no measurable shrinkage of hepatic disease \u2014 overall stable disease. Oncology note documents that anti-EGFR therapy is not indicated due to KRAS mutation.", "output": {"cancer_type": "colorectal (sigmoid) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with high-risk localized prostate adenocarcinoma (Gleason 4+4, clinical T3aN0M0). No molecular testing was performed. He received definitive external beam radiotherapy with concurrent androgen deprivation therapy (leuprolide). Serial PSA fell from 18 ng/mL pre-treatment to 0.4 ng/mL at 6 months follow-up, considered a biochemical response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide) and external beam radiation", "response": "biochemical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with newly diagnosed lung adenocarcinoma. Staging workup consistent with T2N3M1 (stage IV) with multiple brain and bone metastases. Molecular testing returned EGFR L858R mutation and PD-L1 TPS 10%. He was started on osimertinib 80 mg daily and tolerated therapy well. Interval CT and brain MRI at 8 weeks show decrease in size of the primary lesion and intracranial deposits consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old man with right-sided colon adenocarcinoma, pathological stage II (T3N0M0) after right hemicolectomy. Tumor testing: MSI-H (by PCR) and BRAF V600E positive on sequencing. Adjuvant FOLFOX was completed x6 cycles. Surveillance CT scans at 12 months show no disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology note: 72-year-old man diagnosed with prostate adenocarcinoma, biopsy Gleason 4+4=8, clinical stage T2cN0M0 (stage II). Initial PSA 12 ng/mL. Patient elected definitive external beam radiation therapy with concurrent androgen deprivation (leuprolide depot). At 18 month follow-up PSA rising from nadir, concern for biochemical recurrence; no imaging evidence of distant metastasis at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "external beam radiation therapy and leuprolide (androgen deprivation therapy)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with widely metastatic cutaneous melanoma. Molecular profiling identified a BRAF V600E mutation. PD-L1 by IHC was reported at 1%. He was started on combination BRAF/MEK inhibition (dabrafenib + trametinib) with initial shrinkage of several pulmonary nodules, but subsequently developed painful lytic lesions in the right femur. Therapy was switched to pembrolizumab; follow-up describes a mixed response with some lesions regressing while osseous disease progressed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib; then pembrolizumab", "response": "mixed response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with progressive cough and headache. Imaging demonstrated a right upper lobe mass; biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R mutation and PD-L1 10% (TPS). Brain MRI showed two enhancing lesions and bone scan was positive for metastatic disease. He was started on first-line osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant brain lesion. Interval CT at 8 weeks showed shrinkage of the pulmonary primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer, clinical stage IIIC. Core biopsy: invasive ductal carcinoma, HER2-amplified by FISH, ER negative, PR negative. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by docetaxel plus carboplatin with trastuzumab and pertuzumab. Patient underwent modified radical mastectomy; final pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 docetaxel + carboplatin with trastuzumab and pertuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female referred for progressive cough and weight loss. Imaging and biopsy confirm lung adenocarcinoma, stage IV with liver and brain metastases. Comprehensive NGS identified EGFR L858R. PD-L1 immunohistochemistry 10%. She was started on osimertinib 80 mg daily with initial radiographic shrinkage, but interval MRI at 9 months showed new enhancing brain lesions and clinical decline consistent with progression on osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old man with metastatic cutaneous melanoma. NGS detected BRAF V600E. He was initiated on dabrafenib plus trametinib with rapid extracranial response; PET/CT showed complete metabolic response outside the CNS. Eight months later he developed a solitary cerebellar metastasis with radiographic progression and underwent stereotactic radiosurgery. PD-L1 was not performed. Course described as mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "CT-guided biopsy confirmed lung adenocarcinoma. Staging workup consistent with stage IV disease with multiple enhancing lesions in the cerebrum and lytic lesions in the thoracic spine. Molecular testing returned EGFR L858R; PD-L1 reported at 15%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and had symptomatic improvement. Interval imaging at 8 weeks showed shrinkage of the primary and brain lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 48-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, ER positive (90%), PR positive (60%), HER2 amplified by FISH. No distant mets on CT chest/abdomen. Neoadjuvant regimen consisted of trastuzumab and pertuzumab given with docetaxel for six cycles. Patient underwent mastectomy; final pathology demonstrated no residual invasive disease (pCR). No comprehensive NGS was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic lung adenocarcinoma diagnosed 2022. Molecular testing: EGFR L858R and acquired T790M detected on plasma NGS; PD-L1 tumor proportion score 60%; tumor mutation burden reported as TMB-high. Initial therapy: osimertinib with an ongoing partial response for 8 months, then radiographic progression in the liver and bone. After progression he was started on carboplatin/pemetrexed plus pembrolizumab (chemo-immunotherapy). Current assessment: stable disease on combination chemoimmunotherapy with small residual brain metastases treated with SRS.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 60%; TMB-high", "treatment": "osimertinib; carboplatin/pemetrexed + pembrolizumab", "response": "stable disease", "metastasis_site": "liver, bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation and PD-L1 5%. She developed headaches and MRI demonstrated multiple brain metastases. Started osimertinib 80 mg daily in June 2020 after stereotactic radiosurgery; restaging CT and brain MRI at 8 weeks showed decrease in size of intracranial and pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old woman with locally advanced left breast cancer. Core biopsy confirmed invasive ductal carcinoma, HER2 positive by FISH (HER2 amplification), ER/PR negative. Clinical stage IIIB with skin involvement. She received neoadjuvant trastuzumab and pertuzumab with docetaxel x6 cycles followed by left modified radical mastectomy. Surgical pathology after chemo showed no residual invasive carcinoma (pathologic complete response). No distant disease on PET-CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant trastuzumab, pertuzumab and docetaxel followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma to the liver. Tumor NGS identified KRAS G12D. Tumor testing reported MSI\u2011H and high tumor mutational burden. He received FOLFOX plus bevacizumab initially with mixed radiographic response, then was transitioned to pembrolizumab for MSI\u2011H disease. Most recent CT shows stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX, bevacizumab, pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic cutaneous melanoma with BRAF V600E mutation. Patient initially received pembrolizumab but progressed after 4 months with new hepatic and pulmonary lesions. Tumor characterized by high TMB on NGS. Switched to targeted therapy with dabrafenib plus trametinib; follow-up imaging demonstrates interval decrease in size of liver and lung lesions consistent with partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (initial), then dabrafenib + trametinib", "response": "partial response (after targeted therapy)", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E. PD-L1 expression low (approximately 1\u20135%). He was started on dabrafenib plus trametinib; initial shrinkage of target lesions was noted but recent MRI shows new intracranial lesions and extracranial enlargement consistent with progression on targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1-5%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma. NGS demonstrated EGFR L858R mutation; PD-L1 TPS 10% by IHC. Staged as IV at diagnosis with brain and bone metastases. Started osimertinib 80 mg daily in June; first restaging CT chest and brain MRI show decrease in size of pulmonary nodules and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive NGS returned EGFR L858R; ALK and ROS1 negative. PD-L1 TPS reported at 5%. She was started on osimertinib 80 mg PO daily in the outpatient clinic. Follow-up brain MRI demonstrates shrinkage of a 1.8 cm cerebellar metastasis. Clinically there has been symptomatic improvement and RECIST assessment is consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Emergency oncology summary: 69-year-old female with locally advanced pancreatic ductal adenocarcinoma presented with worsening abdominal pain and obstructive symptoms. Imaging consistent with locally advanced, unresectable disease (clinical stage III) invading vasculature. Patient completed three cycles of gemcitabine and nab\u2011paclitaxel with concurrent palliative radiation. No somatic NGS performed prior to therapy. Despite treatment, follow-up CT shows interval progression with enlarging primary and new peritoneal nodularity. Plan to consider second-line systemic options and clinical trials.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel with palliative radiation", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 45-year-old man with metastatic melanoma harboring BRAF V600E mutation. Pretreatment PD-L1 was 10%. He was started on dabrafenib with trametinib as first-line systemic therapy. PET/CT after 12 weeks showed resolution of previously FDG-avid pulmonary nodules and lymph nodes; treating team documents a complete response and plans surveillance.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer (cT3N2). Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 immunohistochemistry 3+ with confirmed HER2 amplification on FISH. Tumor sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant carboplatin and paclitaxel in combination with trastuzumab and pertuzumab; surgical pathology after mastectomy revealed a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin and paclitaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma patient with an ulcerated primary on the left forearm. Molecular testing returned positive for BRAF V600E. He was treated with dabrafenib plus trametinib in the community and had an initial partial response of cutaneous and nodal disease. Several months later he developed new neurological symptoms and MRI revealed multiple enhancing brain metastases; systemic therapy was changed to nivolumab after stereotactic radiosurgery to the dominant lesion. No formal AJCC stage documented in the note.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; nivolumab", "response": "partial response", "metastasis_site": "brain, regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with right-sided invasive ductal breast carcinoma, ER-negative/PR-negative, HER2-amplified. She presented with vague RUQ pain; CT abdomen demonstrated multiple hepatic lesions consistent with metastatic disease. She was started on trastuzumab with weekly paclitaxel in the palliative setting. Interval imaging after 3 months shows no new lesions and minimal change in size of liver metastases \u2014 overall stable disease. No next-generation sequencing was performed on this specimen.", "output": {"cancer_type": "breast cancer (HER2-amplified invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic lung adenocarcinoma, stage IV at presentation. Molecular testing detected EGFR L858R mutation; PD-L1 expression was 10%. He was started on first-line osimertinib with good initial disease control, but after 11 months developed new CNS lesions and worsening bone pain. Restaging scans confirmed progression in brain and spine; patient was transitioned to carboplatin and pemetrexed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; then carboplatin and pemetrexed", "response": "progressive disease", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed in 2020. Biopsy confirmed EGFR L858R mutation; PD-L1 tumor proportion score 10%. Staging at diagnosis was IV with symptomatic brain metastases and multifocal bone lesions. Patient started first-line osimertinib with reduction in intracranial disease noted on interval MRI \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Node-positive locally advanced breast cancer (clinical T4 N2) \u2014 biopsy showed HER2 overexpression by IHC and confirmatory HER2 amplification by FISH. Tumor was ER-positive and PR-positive; hotspot PIK3CA H1047R mutation identified on panel testing. Neoadjuvant regimen: trastuzumab and pertuzumab with docetaxel for six cycles followed by mastectomy. Pathology revealed no residual invasive carcinoma (pCR). No distant metastases identified.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, HER2 positive (IHC 3+), ER/PR negative. Clinical stage IIIB with chest wall involvement. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) x6 cycles with marked tumor shrinkage but residual disease on imaging prior to surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+), ER/PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "partial response (significant shrinkage with residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with cutaneous melanoma of the left arm, staged as III with a single brain metastasis found on MRI. Molecular testing: BRAF V600E positive. PD-L1 was <1% but tumor showed TMB-high at 22 mut/Mb. She was treated with dabrafenib + trametinib and underwent stereotactic radiosurgery to the brain lesion. Follow-up imaging described a mixed response with regression of extracranial nodal disease but new small CNS lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (22 mut/Mb); PD-L1 <1%", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma presented with multiple liver and lung metastases, consistent with stage IV disease. Tumor harbored a BRAF V600E mutation; PD-L1 expression low (~1%). Treated with dabrafenib plus trametinib with a mixed radiographic response (pulmonary nodules decreased, hepatic lesions grew). Subsequently received pembrolizumab but developed overall progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 ~1%", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "mixed response followed by progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with stage II invasive ductal carcinoma of the left breast. Core biopsy: HER2 amplification by FISH, ER positive (90%), PR negative. PIK3CA H1047R detected on targeted panel. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab with good tumor shrinkage but residual disease at surgery \u2014 assessed radiographically as a partial response.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with newly diagnosed stage IV lung adenocarcinoma. Comprehensive NGS identified EGFR L858R. Baseline PET/CT showed multiple brain metastases and diffuse osseous lesions. He was started on first-line osimertinib and had a radiographic partial response at the 8-week scan; subsequent surveillance imaging demonstrated new hepatic lesions consistent with progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "initial partial response; subsequent progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male status post sigmoid colectomy for T3N1 colon adenocarcinoma (stage III). Pathology: moderately differentiated. No molecular testing documented in clinic notes. He completed 6 cycles of adjuvant FOLFOX without complications. CT surveillance at 12 months showed no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal breast cancer, clinical stage IIIB. Core biopsy: ER positive, PR positive, HER2 amplification by FISH. She received neoadjuvant paclitaxel with trastuzumab for six cycles, then underwent modified radical mastectomy. Surgical pathology reported no residual invasive tumor (pathologic complete response). No metastatic disease identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel; trastuzumab; modified radical mastectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with metastatic right-sided colon adenocarcinoma. Molecular profile: BRAF V600E mutation; tumor testing MSI-H and high tumor mutational burden. CT shows multiple hepatic metastases consistent with stage IV. Given prior progression on FOLFOX, patient was started on combination targeted therapy encorafenib plus cetuximab with addition of irinotecan for cytoreduction. Imaging after 6 cycles shows stable disease in the liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "encorafenib + cetuximab with irinotecan", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 70-year-old male with right-sided colon adenocarcinoma pT3N1 (stage III) status post right hemicolectomy in January. Adjuvant chemotherapy with FOLFOX was completed. MSI testing returned microsatellite stable (MSS). RAS/BRAF mutation testing was not performed at the time. Surveillance CT at 12 months is clear, CEA stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-stable (MSS)", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with metastatic colorectal adenocarcinoma presenting with multiple liver and pulmonary lesions. Next-generation sequencing returned KRAS G12D. Patient received FOLFIRI plus bevacizumab; restaging after 3 months demonstrated radiographic progression of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with newly progressive colorectal adenocarcinoma, originally staged IV on presentation with diffuse peritoneal carcinomatosis and omental caking. Mismatch repair testing returned MSI-H. First-line FOLFOX caused cumulative neuropathy, regimen switched to FOLFIRI plus bevacizumab; despite therapy the patient developed increasing ascites and symptomatic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "FOLFOX; then FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with metastatic colon adenocarcinoma. CT abdomen/pelvis shows multiple liver lesions; colonoscopy confirmed sigmoid adenocarcinoma. No molecular testing documented in chart. He was started on FOLFOX with bevacizumab. Interval CT at 12 weeks shows decrease in size of hepatic metastases consistent with a partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic and pulmonary metastases. Tumor profiling: MSI-H and TMB-high (~20 mut/Mb), PD-L1 about 1%. The molecular report did not list any actionable single-gene driver. He was started on pembrolizumab monotherapy and after 4 cycles CT shows interval decrease in size of liver and lung lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high; PD-L1 1%", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. Patient was started on dabrafenib plus trametinib with an initial partial response; however, surveillance imaging later documented intracranial progression and symptomatic brain metastases requiring stereotactic radiosurgery. No PD-L1 result was available in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly progressive metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R mutation and PD-L1 10%. He underwent stereotactic radiosurgery to the brain for symptomatic lesions and was started on osimertinib 80 mg daily. Interval CT and MRI at 8 weeks demonstrate shrinkage of both pulmonary nodules and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female, screening mammogram revealed a 1.2 cm invasive ductal carcinoma. Pathology: ER-positive, PR-positive, HER2 negative. Tumor was T1N0 after lumpectomy and sentinel node biopsy. PIK3CA H1047R identified on panel. She completed adjuvant radiotherapy and was started on tamoxifen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; adjuvant radiotherapy; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old woman with locally advanced left breast cancer, ER-positive, PR-negative, HER2 amplification on FISH, and PIK3CA E545K mutation on tumor panel. Clinical stage IIIB with large nodal conglomerate. She received neoadjuvant combination therapy with docetaxel, trastuzumab and pertuzumab for 6 cycles followed by lumpectomy and axillary dissection. Pathology after neoadjuvant therapy shows complete pathologic response (pCR). Adjuvant radiation planned and endocrine therapy with tamoxifen to follow.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER-positive; PR-negative; HER2 amplification", "treatment": "docetaxel + trastuzumab + pertuzumab; lumpectomy; adjuvant radiation; tamoxifen", "response": "complete pathologic response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma, stage IV at diagnosis. Tumor testing positive for BRAF V600E. PD-L1 expression low (~1%). He was started on dabrafenib and trametinib with an initial partial response; after 6 months developed new intracranial metastases consistent with disease progression and was transitioned to combination ipilimumab/nivolumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib (then ipilimumab/nivolumab)", "response": "partial response followed by intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast. Tumor was ER-positive, PR-positive and HER2 amplified by FISH. Next-generation sequencing detected a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab with a clinically measurable reduction in the primary lesion consistent with a partial response prior to surgery. No distant metastases identified on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "paclitaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with lung adenocarcinoma. Staging workup revealed multiple pulmonary nodules, osseous lesions on bone scan and a 1.5 cm right frontal brain metastasis. Biopsy confirmed adenocarcinoma and molecular testing returned EGFR exon 19 deletion. PD-L1 was 10% by IHC. Patient was started on osimertinib 80 mg daily; follow-up MRI and CT at 8 weeks show reduction in size of the brain lesion and shrinkage of lung and bone lesions consistent with a partial response. Stage IV disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R in exon 21. PD-L1 tumor proportion score ~30%. He was started on first-line osimertinib 80 mg daily with marked improvement in pulmonary nodules but after 10 months developed new neurologic symptoms and MRI showed multiple brain metastases consistent with intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a palpable left breast mass. Core biopsy shows invasive ductal carcinoma, ER-positive, PR-positive, HER2-negative. She underwent lumpectomy and sentinel lymph node biopsy; pathologic stage was IIA (T2 N0 M0). Tumor sequencing detected PIK3CA H1047R. She completed adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and was started on tamoxifen. Surveillance mammography and CT show no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, sentinel lymph node biopsy, doxorubicin and cyclophosphamide, paclitaxel, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma underwent debulking surgery; peritoneal carcinomatosis noted intraoperatively. Germline testing returned BRCA1 pathogenic variant. She completed adjuvant carboplatin and paclitaxel with partial radiographic response and was placed on olaparib maintenance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": null, "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the left breast, ER 90%+, PR 10%+, HER2 FISH amplified. NGS identified PIK3CA H1047R. Clinical staging prior to therapy was IIIB (T4bN1M0). Patient received neoadjuvant combination TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab). She underwent mastectomy with axillary dissection \u2014 no residual invasive carcinoma identified (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with prostate adenocarcinoma, Gleason 4+4 on biopsy. Germline testing identified a pathogenic BRCA2 variant. Circulating tumor cell assay was AR-V7 negative. PSA at baseline was 8.6 ng/mL. He was started on leuprolide depot for androgen deprivation; imaging showed no evidence of distant metastasis. The clinic note did not document a formal TNM stage.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (pathogenic)", "biomarker": "AR-V7 negative; PSA 8.6 ng/mL", "treatment": "leuprolide (androgen deprivation therapy)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with rapidly enlarging pigmented lesion on the back. Excisional biopsy: malignant melanoma. PET/CT shows multiple pulmonary nodules and a solitary hemorrhagic brain lesion; clinical stage IV. NGS returned NRAS Q61R mutation. PD-L1 expression low (1%). Patient was treated with combination ipilimumab and nivolumab; after two cycles he developed radiographic progression in the brain and enlarging lung nodules.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 1%", "treatment": "ipilimumab and nivolumab", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology consult: 71-year-old male with metastatic castration-resistant prostate adenocarcinoma and extensive symptomatic bone metastases. Germline and somatic testing identified a BRCA2 exon 11 deletion and the tumor is HRD-positive. PSA continued to rise on enzalutamide; patient was switched to olaparib. After 3 months of olaparib there is a decline in PSA and radiographic shrinkage of multiple bone lesions consistent with a partial response.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 exon 11 deletion", "biomarker": "HRD-positive", "treatment": "olaparib; prior enzalutamide", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Clinical stage IV at diagnosis. Molecular testing showed KRAS G12D and MSI-H with loss of MLH1/PMS2; TMB-high also reported. After progression on first-line FOLFOX/bevacizumab, he was transitioned to pembrolizumab monotherapy. CT at 12 weeks demonstrates stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female diagnosed with high-grade serous ovarian carcinoma with extensive peritoneal carcinomatosis and liver implants. Germline testing positive for a deleterious BRCA1 mutation and genomic scar consistent with HRD. CA-125 was elevated at presentation. She received first-line carboplatin and paclitaxel with good cytoreduction then was placed on maintenance olaparib. Imaging after three months showed a partial response with decreased peritoneal tumor burden.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 (deleterious germline)", "biomarker": "HRD positive; CA-125 elevated", "treatment": "carboplatin + paclitaxel followed by olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma, BRAF V600E positive, presented with pulmonary nodules on staging CT. PD-L1 reported at 5% and tumor mutational burden described as high. Patient was started on dabrafenib and trametinib combination therapy with rapid symptomatic improvement; interval CT at 8 weeks shows marked reduction in lung nodules consistent with partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic cutaneous melanoma diagnosed after resection of a primary back lesion. CT chest/abdomen showed pulmonary nodules. BRAF testing positive for V600E. She was started on combination targeted therapy with dabrafenib and trametinib but interval imaging after 6 weeks revealed progressive pulmonary and nodal disease; plan is to transition to immunotherapy. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung; regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "75-year-old man with metastatic prostate adenocarcinoma, Gleason 9, now with multiple painful sclerotic lesions on bone scan. PSA remains elevated despite androgen deprivation. Germline testing positive for pathogenic BRCA2 mutation. He was transitioned from leuprolide to combined leuprolide plus abiraterone acetate with prednisone; disease has been clinically stable for 6 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA elevated", "treatment": "leuprolide (ADT) and abiraterone + prednisone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IIIC high-grade serous ovarian carcinoma treated with optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. Germline and somatic BRCA testing were negative. Tumor was HRD-positive and CA-125 was elevated at diagnosis. Patient placed on maintenance olaparib after chemotherapy with no evidence of disease on CT at 12-week follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HRD-positive; CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin + paclitaxel; olaparib (maintenance)", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with invasive ductal carcinoma of the right breast, clinical stage IIIA. Tumor is ER+/PR+ and shows HER2 amplification by FISH. NGS reported a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with dual HER2-targeted therapy (trastuzumab and pertuzumab). At surgical resection there was a complete pathologic response. No distant metastases identified.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel; trastuzumab; pertuzumab (neoadjuvant)", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 39-year-old male with a 2.2 cm ulcerated pigmented lesion on the right forearm. Excision and sentinel lymph node biopsy were performed; sentinel node negative. Final stage was II. Tumor sequencing identified BRAF V600E. Given node-negative stage II disease the team recommended observation without adjuvant therapy. At 12-month follow-up there is no evidence of recurrence.", "output": {"cancer_type": "melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision and sentinel lymph node biopsy (no adjuvant therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presents with progressive cough and confusion. Imaging and biopsy confirm lung adenocarcinoma with multiple intracranial metastases. NGS shows EGFR L858R mutation; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily one month ago. Follow-up MRI demonstrates decrease in size of brain lesions and improvement in symptoms consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male presented with newly diagnosed glioblastoma (WHO grade IV). He underwent subtotal resection followed by concurrent radiotherapy and temozolomide per Stupp protocol. Institutional NGS panel reported no actionable mutations; MGMT methylation result pending. MRI at 3 months shows progressive enhancement consistent with tumor progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "subtotal resection followed by radiotherapy and temozolomide (Stupp protocol)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive NGS shows EGFR L858R and acquired EGFR T790M; PD-L1 tumor proportion score 30%; TMB 12 muts/Mb. Imaging demonstrates multiple cerebral and osseous lesions. After progression on first-line erlotinib she was started on osimertinib in combination with bevacizumab. Interval CT/MRI show decrease in size of target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, EGFR T790M", "biomarker": "PD-L1 30%, TMB 12 muts/Mb", "treatment": "osimertinib + bevacizumab (after prior erlotinib)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colon adenocarcinoma to the liver. Primary tumor was right-sided; testing demonstrated KRAS G12D and microsatellite stable (MSS). He was started on FOLFIRI plus bevacizumab. After three months CT abdomen shows enlarging hepatic lesions and rising CEA \u2014 treating team documents progressive disease and recommends transition to clinical trial.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI plus bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, biopsy-confirmed. Tumor is MSI-H (mismatch repair deficient) and TMB-high on NGS; KRAS G12D mutation identified. Imaging shows multiple hepatic lesions and peritoneal implants consistent with stage IV disease. Began pembrolizumab as first-line for MSI-H disease; interval scans at 12 weeks show stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with newly diagnosed glioblastoma (WHO grade IV). Tumor sequencing positive for IDH1 R132H and MGMT promoter methylation. Underwent subtotal resection followed by concurrent radiotherapy with temozolomide; adjuvant temozolomide is ongoing. Early postoperative surveillance MRI shows enlargement of enhancing nodule at the resection cavity consistent with progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation", "treatment": "surgery, radiation and temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital note: 42-year-old man with metastatic cutaneous melanoma, AJCC stage IV, NGS positive for BRAF V600E. He started dabrafenib plus trametinib with rapid clinical improvement and a radiographic partial response in chest and abdominal disease. Surveillance brain MRI subsequently identified two new enhancing metastases consistent with intracranial progression. PD-L1 10% and tumor mutational burden reported as TMB-high. Plan: stereotactic radiosurgery to intracranial lesions and continuation of targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib and trametinib; planned stereotactic radiosurgery", "response": "partial response systemically with intracranial progression", "metastasis_site": "brain, chest (lung) and abdominal (visceral) disease"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male with newly diagnosed lung adenocarcinoma, stage IV. Staging scans demonstrated brain and multiple bone metastases. Comprehensive NGS revealed EGFR L858R. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily; first follow-up CT and MRI show reduction in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma with documented BRAF V600E mutation. Patient developed pulmonary nodules and an enhancing cerebellar metastasis. Treated initially with combination targeted therapy (dabrafenib + trametinib) and achieved tumor shrinkage of extracranial disease; PD-L1 by IHC reported at 5%. Following intracranial progression the team discussed switching to ipilimumab plus nivolumab.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; contemplated ipilimumab + nivolumab", "response": "partial response (extracranial)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Tumor was HER2-amplified by FISH, ER and PR negative. Preoperative therapy: received TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) x 6 cycles with excellent clinical shrinkage, then underwent modified radical mastectomy. Final pathology showed pathologic complete response (pCR). Tumor NGS identified a PIK3CA H1047R mutation. Adjuvant trastuzumab was continued to complete 1 year.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; modified radical mastectomy; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with newly diagnosed high-grade serous ovarian carcinoma presenting with abdominal distension. Surgical staging confirmed FIGO IIIC disease with bulky peritoneal involvement. Germline and somatic testing identified a pathogenic BRCA1 mutation and HRD-positive status; CA-125 was markedly elevated at diagnosis. She underwent primary optimal debulking followed by adjuvant carboplatin and paclitaxel (6 cycles) and then was started on maintenance olaparib in combination with bevacizumab. At 12-month follow-up she remains in complete clinical remission with CA-125 normalized.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HRD-positive, CA-125 elevated (normalized on follow-up)", "treatment": "debulking surgery; carboplatin + paclitaxel; maintenance olaparib + bevacizumab", "response": "complete clinical remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with stage IV lung adenocarcinoma presenting with headache and back pain. Molecular testing showed an EGFR exon 19 deletion. PD-L1 TPS 10%. He was started on osimertinib. At 8 weeks there was a radiographic partial response of the thoracic disease and shrinkage of brain metastases, but 6 months later surveillance imaging demonstrated enlarging liver lesions consistent with progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response then progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: 60-year-old male underwent right hemicolectomy for a T3N0 colon adenocarcinoma diagnosed on screening colonoscopy. Final path stage II (T3N0). MSI testing returned MSI-H. Given the low-risk features and MSI-H status, multidisciplinary tumor board recommended surveillance without adjuvant chemotherapy. Six-month CT chest/abdomen/pelvis shows no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II (T3N0)", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; surveillance (no adjuvant chemotherapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. MRI brain and staging CT show multiple enhancing brain metastases and lytic lesions in the spine. Core biopsy of pulmonary mass confirmed adenocarcinoma; NGS returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Clinical stage IV at presentation. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the brain lesions. Interval CT at 8 weeks demonstrates decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic pancreatic ductal adenocarcinoma presenting with jaundice and weight loss. Imaging demonstrated a pancreatic head mass with multiple liver metastases (stage IV). Germline testing returned a pathogenic BRCA2 mutation (BRCA2 c.6174delT). He received 6 cycles of FOLFIRINOX with disease stabilization and was transitioned to maintenance olaparib. PD-L1 and other predictive biomarkers were not reported in the chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 c.6174delT (pathogenic)", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology consult: 67-year-old male with borderline resectable pancreatic adenocarcinoma. PET/CT confirms locally advanced pancreatic head mass without distant spread. Germline and somatic panel revealed no actionable alterations. CA19-9 has been rising over the past month to 560 U/mL. Multidisciplinary plan was chemoradiation with concurrent gemcitabine and capecitabine followed by reassessment. Mid-treatment imaging demonstrates increase in primary tumor size consistent with progressive disease; no metastatic lesions identified.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "concurrent chemoradiation (gemcitabine + capecitabine)", "response": "progressive disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 71-year-old man with perforated sigmoid mass found to be adenocarcinoma of the colon. At laparotomy there were multiple peritoneal implants; disease staged as metastatic. KRAS G12D detected on the targeted panel. Patient received adjuvant-style systemic therapy with FOLFOX and bevacizumab but CT at 6 months demonstrates progression of the peritoneal disease with increasing ascites.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with locally advanced, borderline resectable pancreatic ductal adenocarcinoma, clinical stage III. Germline testing revealed a BRCA2 frameshift mutation. CA 19-9 at diagnosis was markedly elevated (920 U/mL). She received neoadjuvant FOLFIRINOX with initial tumor shrinkage, then was transitioned to maintenance olaparib. At 8 months there is interval growth of the primary consistent with progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 frameshift", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX, maintenance olaparib", "response": "progressive disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Baseline staging showed multiple brain metastases and osseous lesions. Patient was started on first-line osimertinib and after 8 weeks CT and MRI demonstrate a partial response with decrease in size of cerebral and vertebral lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presented with bulky oropharyngeal squamous cell carcinoma and multiple pulmonary nodules. Staged as IV at presentation. No molecular testing was performed and PD-L1 status is not available in the chart. He received definitive concurrent cisplatin-based chemoradiation. Restaging CT demonstrates interval enlargement of several lung nodules consistent with progression.", "output": {"cancer_type": "oropharyngeal squamous cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin-based chemoradiation", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with right-sided colon mass proven to be adenocarcinoma. Staging shows multiple liver lesions and peritoneal nodules consistent with metastatic disease (stage IV). Tumor testing: BRAF V600E mutation and MSI-H. She received FOLFOXIRI plus bevacizumab as first-line therapy; after initial progression was switched to pembrolizumab with interval CT demonstrating a partial response of the hepatic metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOXIRI and bevacizumab, then pembrolizumab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female with metastatic breast cancer, ER positive, PR positive and HER2-positive (IHC 3+). Biopsy NGS identified a PIK3CA H1047R mutation. Staging showed liver and bone metastases consistent with stage IV disease. She received first-line trastuzumab and pertuzumab with docetaxel, achieving a partial response on interval CT.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 IHC 3+", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with clinical T4N1 HER2-positive invasive ductal carcinoma of the breast. Biopsy: HER2 amplification by FISH, ER positive, PR weakly positive; PIK3CA H1047R identified on targeted panel. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab for six cycles followed by mastectomy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response). No distant metastases noted.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR weakly positive", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with colon adenocarcinoma, pathologic stage II (T3N0M0) after right hemicolectomy. Tumor testing returned MSI-H. No actionable somatic mutation was identified on the 50-gene panel. She completed adjuvant FOLFOX and remains disease-free on routine surveillance.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma (stage IV) harboring BRAF V600E. Baseline PD-L1 was 5%. Started on combination targeted therapy with dabrafenib and trametinib. After four months of therapy there is resolution of the previously seen brain metastasis and complete metabolic response on PET/CT.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: high-grade serous ovarian carcinoma, optimal cytoreduction achieved. Germline testing returned a deleterious BRCA1 mutation and tumor HRD-positive status; CA-125 was elevated pre-op. The patient completed six cycles of carboplatin and paclitaxel and was placed on maintenance olaparib. Follow-up CA-125 normalized and CT scans show no residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive; CA-125 elevated (pre-treatment)", "treatment": "primary debulking surgery followed by carboplatin + paclitaxel, maintenance olaparib", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with a pigmented lesion on the left forearm found to be melanoma, Breslow thickness 3.1 mm with a positive sentinel node \u2014 stage IIIB. Tumor testing identified a BRAF V600E mutation. She received neoadjuvant dabrafenib and trametinib with excellent clinical regression and then underwent wide local excision and completion lymphadenectomy. Surgical pathology showed no residual viable tumor after targeted therapy.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib; wide local excision; lymphadenectomy", "response": "complete response (no residual viable tumor)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Notes: 48-year-old female diagnosed with invasive ductal carcinoma of the right breast, clinical stage IIB. Core biopsy: ER positive, PR positive, HER2 amplified by IHC 3+. No molecular sequencing performed. Received neoadjuvant paclitaxel with concurrent trastuzumab for 12 weeks followed by lumpectomy and sentinel node biopsy. Surgical pathology: no residual invasive tumor (ypT0N0). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+, PR+", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old man with metastatic cutaneous melanoma, BRAF V600E positive and high tumor mutational burden (TMB-high). Presents with symptomatic brain metastases and extracranial disease consistent with stage IV melanoma. Treated with combination targeted therapy: dabrafenib plus trametinib. He had prompt tumor shrinkage systemically but developed progression in the CNS after six months (initial partial response then progression).", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib plus trametinib", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with stage IV colorectal adenocarcinoma presenting with multiple hepatic lesions. Molecular profile: KRAS G12D identified, tumor MSI-H and TMB-high. He was started on pembrolizumab monotherapy as systemic treatment; after four cycles CT scan shows stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with castration-resistant prostate adenocarcinoma presenting with diffuse osteoblastic metastases to the spine and pelvis. He is maintained on leuprolide for androgen deprivation and was started on docetaxel chemotherapy; PSA fell initially but three-month imaging shows stable osseous disease. Germline BRCA testing is pending and no somatic mutation report is available in chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone (spine, pelvis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58-year-old man with metastatic clear cell renal cell carcinoma, stage IV at presentation with pulmonary and hepatic lesions. Tumor sequencing demonstrated VHL mutation. PD-L1 was reported >50%. He initiated first-line pembrolizumab plus axitinib and after 3 cycles had shrinkage of target lesions consistent with a partial response.", "output": {"cancer_type": "renal cell carcinoma", "stage": "IV", "gene_mutation": "VHL mutation", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab plus axitinib", "response": "partial response", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old man found to have clear cell renal cell carcinoma, pathologic stage T3a N0 (stage III). He underwent radical nephrectomy and was started on adjuvant sunitinib. There were no distant metastases on post-operative imaging and follow-up CTs remain stable without new lesions.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical nephrectomy; sunitinib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female underwent lumpectomy for a 1.8 cm invasive ductal carcinoma of the breast, sentinel nodes negative \u2014 final pathologic stage I (T1cN0). Tumor is ER positive, PR negative, HER2 amplified by FISH. No genomic mutation panel was performed preoperatively. Plan is adjuvant paclitaxel x 12 weekly cycles with trastuzumab for one year; patient currently has no evidence of disease on post-op imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "lumpectomy, adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female diagnosed with metastatic lung adenocarcinoma, clinical stage IV. NGS of the tumor identified EGFR L858R. PD-L1 was 10% by IHC. Baseline MRI brain demonstrated multiple small enhancing metastases and CT chest/abdomen showed several hepatic lesions. She was started on osimertinib 80 mg daily; interval imaging at 8 weeks demonstrated a partial response with reduction in size of both intracranial and liver lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly discovered metastatic colorectal adenocarcinoma presenting with multiple bilobar liver metastases. Mismatch repair testing returned MSI-H and tumor mutational burden reported as TMB-high. No actionable single-gene mutation data is available in the chart. He was started on pembrolizumab 200 mg IV q3w as first-line therapy; PET/CT at 12 weeks demonstrated near-complete metabolic resolution of hepatic lesions consistent with a complete response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with elevated PSA (8.4 ng/mL) found to have prostate adenocarcinoma on biopsy, Gleason 3+4=7. Clinical stage is II (T2bN0M0). He underwent radical prostatectomy; final path report pT2 with negative margins but focal lymphovascular invasion. No molecular testing was performed. Given adverse features he received adjuvant pelvic radiation. Recent PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant pelvic radiation", "response": "undetectable PSA (no biochemical evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: patient with metastatic melanoma originally treated with wide local excision. Molecular testing showed BRAF V600E; PD-L1 reported as 30% by IHC. After new pulmonary and brain lesions were identified the patient was started on combination dabrafenib and trametinib with good extracranial tumor control but interval MRI showed progression of a single cerebellar metastasis and symptomatic decline. Systemic therapy was switched to pembrolizumab. (Stage not recorded in this consultation note.)", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 30%", "treatment": "dabrafenib + trametinib then pembrolizumab", "response": "mixed \u2014 extracranial response with intracranial progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple liver metastases on baseline CT. Tumor sequencing identified KRAS G12C. He was started on FOLFOX and bevacizumab; interim imaging after 4 cycles demonstrates stable disease. CEA remains elevated but trending down slightly.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with metastatic breast cancer, ER/PR negative. Core biopsy of right breast and liver lesion confirmed invasive ductal carcinoma with HER2 amplification by FISH. Staging consistent with stage IV disease with multiple hypodense liver metastases. She was started on weekly paclitaxel in combination with trastuzumab and pertuzumab. After six cycles cross-sectional imaging shows stable disease.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel, trastuzumab, pertuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op note: 62-year-old male underwent right hemicolectomy for stage III (pT3N1) colon adenocarcinoma. Molecular testing returned MSI-H and KRAS G12D; TP53 R175H also reported. Patient completed 6 months of adjuvant FOLFOX with good tolerance. Surveillance CT at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D; TP53 R175H", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-sensitive prostate cancer, presents with extensive bone pain and PSA 120 ng/mL. Imaging consistent with osseous disease and pelvic nodal involvement (stage IV). He was started on luteinizing hormone\u2013releasing hormone (LHRH) agonist plus abiraterone acetate. Genomic testing not performed. Over 3 months the PSA rose and symptoms worsened.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL", "treatment": "androgen deprivation therapy (LHRH agonist) and abiraterone", "response": "progression", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. Initially treated with pembrolizumab but progressed in the lung; switched to targeted therapy with dabrafenib plus trametinib. CT after 8 weeks showed marked shrinkage of several pulmonary nodules but new enhancing lesions in the liver on MRI\u2014biopsy confirmed metastatic melanoma. Clinical course described as a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (prior); dabrafenib + trametinib", "response": "mixed response (partial response in lung, new liver metastases)", "metastasis_site": "lung; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a 1.8 cm invasive ductal carcinoma of the right breast. ER and PR positive; FISH shows HER2 amplification. Pathologic staging after lumpectomy and sentinel node biopsy was T1cN0 (stage I). She completed adjuvant paclitaxel followed by trastuzumab for one year. Surveillance exams and imaging are negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy, paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with recurrent nodal melanoma (stage III) after wide local excision. Tumor panel shows BRAF V600E. He initially received adjuvant nivolumab but developed nodal progression and was switched to targeted therapy with dabrafenib and trametinib; restaging after 10 weeks shows decreased nodal burden consistent with a partial response in regional lymph nodes.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab (prior), dabrafenib and trametinib (current)", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with progressive dyspnea. CT chest/abdomen shows a 4.2 cm RLL mass with multiple enhancing cerebellar lesions and lytic lesions in the lumbar spine. Biopsy: lung adenocarcinoma. Molecular testing returned EGFR exon 21 L858R mutation. PD-L1 immunohistochemistry reported TPS 10%. Patient was started on osimertinib 80 mg daily as first-line therapy with CNS penetration. Interval MRI after 8 weeks demonstrates decreased size of brain metastases and shrinkage of the primary lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old man with cutaneous melanoma, stage IV at diagnosis. Molecular testing positive for BRAF V600E. PD-L1 expression 20% and tumor described as TMB-high. He started combination targeted therapy with dabrafenib plus trametinib and had an initial partial response; after 9 months intracranial progression occurred and he was switched to combination immunotherapy with nivolumab plus ipilimumab.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%; TMB-high", "treatment": "dabrafenib + trametinib; nivolumab + ipilimumab", "response": "initial partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with metastatic colorectal adenocarcinoma with multiple liver metastases in January 2023. Tumor testing showed BRAF V600E mutation and MSI-H with high tumor mutational burden. She received first-line FOLFOX plus bevacizumab but progressed after four months. Therapy was changed to pembrolizumab in June 2023 with subsequent partial radiographic response of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 71-year-old male with metastatic colorectal adenocarcinoma to the liver. Tumor sequencing: KRAS G12D. MSI testing returned MSI-H and high TMB. He progressed after 6 cycles of FOLFOX plus bevacizumab and was switched to pembrolizumab monotherapy three months ago; scans show stable appearance of hepatic lesions without new sites.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab followed by pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal cancer discovered after liver lesions on CT. Tumor profiling: MSI-H and TMB-high; KRAS and BRAF sequencing reported wild-type. PD-L1 IHC low (5%). He received first-line FOLFOX plus bevacizumab with mixed radiologic response in the liver and pulmonary nodules, then was transitioned to single-agent pembrolizumab given MSI-H status with subsequent radiographic stable disease for 6 months.", "output": {"cancer_type": "colorectal cancer", "stage": "IV", "gene_mutation": "KRAS wild-type; BRAF wild-type", "biomarker": "MSI-H; TMB-high; PD-L1 5%", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease (after pembrolizumab); mixed response to FOLFOX/bevacizumab", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colorectal adenocarcinoma presenting with liver metastases (stage IV). Tumor profiling showed BRAF V600E and MSI-H by PCR. After progression on FOLFOX he was started on pembrolizumab in Sept 2023 with an initial partial response for approximately 5 months, then imaging demonstrated progression and therapy was changed to encorafenib plus cetuximab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab; later encorafenib plus cetuximab (after progression); prior FOLFOX", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic colorectal adenocarcinoma, stage IV with multiple liver lesions. Tumor testing: KRAS G12D mutation and MSI-H by PCR. She received FOLFOX with bevacizumab as first-line achieving stable hepatic disease. After progression of symptoms she was transitioned to pembrolizumab with continued radiographic stable disease on interval scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative oncology note: 48-year-old female with locally advanced left breast cancer. Biopsy positive for invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+ with FISH confirming HER2 amplification. PIK3CA sequencing identified H1047R. Neoadjuvant therapy consisted of weekly paclitaxel x12 with trastuzumab and pertuzumab, followed by lumpectomy and sentinel node biopsy. Surgical pathology after chemo showed no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases were identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with ER+/PR+ HER2-amplified invasive ductal carcinoma of the left breast, clinical stage IIIA by imaging. She completed neoadjuvant therapy with docetaxel and carboplatin in combination with trastuzumab and pertuzumab. Breast-conserving surgery performed; surgical pathology demonstrated no residual invasive tumor (pathologic complete response). Germline BRCA testing was negative and no somatic mutation panel was performed on the specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III A", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER positive (90%), PR positive (60%), HER2 FISH amplified. Clinical stage IIIA. On next-generation sequencing the tumor harbored a PIK3CA E545K mutation. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles followed by lumpectomy and sentinel node biopsy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant); lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed pancreatic ductal adenocarcinoma found to have multiple hepatic metastases on staging PET/CT (stage IV). Tumor NGS returned KRAS G12V and TP53 R248Q. Baseline CA19-9 markedly elevated. She was initiated on modified FOLFIRINOX; after two cycles interval imaging demonstrated increase in size of several liver lesions and new peritoneal nodules concerning for progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V; TP53 R248Q", "biomarker": "elevated CA19-9", "treatment": "modified FOLFIRINOX", "response": "progressive disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma, biopsy confirmed. Staging PET/CT shows multiple pulmonary nodules and several enhancing lesions in the cerebellum and T8 vertebra. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily with stereotactic radiosurgery to the cerebellar metastasis. On first restaging at 8 weeks there is a decrease in size of the lung lesions and reduced enhancement in the brain lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone (T8)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent diagnostic core biopsy for a 2.5 cm left breast mass; pathology consistent with invasive ductal carcinoma. ER and PR strongly positive, HER2 negative by IHC/FISH. Clinical stage estimated as IIA (T2N0). She had breast-conserving surgery with sentinel node biopsy followed by adjuvant radiation and started tamoxifen for endocrine therapy. At last follow-up there is no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma, biopsy-proven. Staging workup consistent with stage IV disease with multiple intracranial and osseous lesions. Molecular testing returned EGFR L858R mutation; PD-L1 by IHC 10%. Patient started osimertinib 80 mg PO daily as first-line targeted therapy. Interval MRI/CT at 12 weeks shows decrease in size of measurable lesions with improvement of brain metastases \u2014 overall partial response clinically and radiographically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R; PD-L1 expression ~10%. Baseline staging showed multiple brain and bone lesions. He was started on osimertinib 80 mg daily in August with rapid symptomatic improvement. First restaging CT/MRI after 8 weeks showed a partial response with decrease in size of index lung and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed stage IV lung adenocarcinoma. Molecular testing demonstrated an EGFR exon 21 L858R activating mutation; after 11 months on first-line erlotinib she developed progression and a plasma assay detected EGFR T790M. PD-L1 TPS was 10%. She received whole-brain RT for new CNS lesions and was switched to osimertinib with radiographic partial response in lung and intracranial disease; bone metastases are present.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib; osimertinib; whole-brain radiotherapy", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recent referral for pancreatic adenocarcinoma with peritoneal nodularity and omental implants noted on CT. Germline testing returned a pathogenic BRCA2 frameshift mutation. He completed 8 cycles of FOLFIRINOX with symptomatic improvement and was transitioned to olaparib maintenance. Most recent scans show no interval growth of peritoneal disease and the oncologist documents stable disease on maintenance PARP inhibitor.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (pathogenic)", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum (omental implants)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the left breast: invasive ductal carcinoma, ER positive, PR positive, HER2 3+ by IHC. Clinical stage IIIA. Patient received neoadjuvant therapy with docetaxel, carboplatin and trastuzumab/pertuzumab for six cycles. Mastectomy specimen shows no residual invasive carcinoma\u2014pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 3+ by IHC", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 62-year-old with metastatic melanoma originally diagnosed 18 months ago. Molecular profiling showed BRAF V600E. He was treated with dabrafenib plus trametinib with initial dramatic response but developed progressive hepatic and pulmonary lesions at 10 months; PD-L1 was 5%. He subsequently received pembrolizumab but imaging demonstrates overall progression with new brain metastases.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib, followed by pembrolizumab", "response": "progression", "metastasis_site": "liver, lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the breast. Tumor was ER-negative, PR-negative and HER2 3+ by IHC with HER2 amplification confirmed by FISH. Tumor panel also identified a PIK3CA H1047R alteration. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab with marked tumor shrinkage (near-complete clinical response) and subsequently underwent mastectomy; pathology showed only minimal residual invasive disease. No distant metastases identified.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; surgery", "response": "near-complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple liver lesions. Molecular profile: KRAS G12D and MSI-H with high tumor mutational burden (TMB-high). Initially treated with FOLFOX plus bevacizumab; after progression on chemo the patient was started on pembrolizumab due to MSI-H status. Imaging after 3 months demonstrates stable disease in the liver and peritoneum.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple pulmonary nodules. Tumor NGS returned KRAS G12D and the tumor was microsatellite stable (MSS). He received FOLFOX plus bevacizumab as first-line systemic therapy. After four cycles CT chest shows enlargement of pulmonary metastases consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX plus bevacizumab", "response": "progressive disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with nodular melanoma of the right thigh, positive regional nodes, final path stage IIIC. Molecular testing identified BRAF V600E. He was started on combination targeted therapy with dabrafenib plus trametinib. At 12-week clinical exam the palpable nodal disease resolved and PET/CT confirms metabolic complete response in the previously positive nodal basins.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic melanoma initially started on pembrolizumab. After 4 months she developed progressive hepatic lesions; biopsy confirmed metastatic melanoma. Molecular testing returned BRAF V600E and high tumor mutational burden. Pembrolizumab was discontinued for progression and patient was transitioned to dabrafenib plus trametinib with documented partial response on liver MRI. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (prior), dabrafenib + trametinib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: high-grade serous ovarian carcinoma, FIGO stage IIIC, diagnosed 2021. Germline testing revealed a pathogenic BRCA1 mutation and tumor was HRD-positive. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel, then started maintenance olaparib. Surveillance CTs and CA-125 are now without evidence of disease consistent with complete radiologic response; initial presentation included peritoneal carcinomatosis.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with new neurologic deficits. MRI revealed a right frontal mass; craniotomy and resection confirmed glioblastoma multiforme. Molecular testing identified an IDH1 R132H mutation. He completed concurrent radiotherapy with temozolomide per Stupp protocol and was later treated with bevacizumab for symptomatic recurrence. Despite therapy, imaging demonstrates radiographic progression in the resection cavity.", "output": {"cancer_type": "glioblastoma multiforme", "stage": null, "gene_mutation": "IDH1 R132H", "biomarker": null, "treatment": "radiotherapy + temozolomide; bevacizumab", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 2.1 cm cutaneous melanoma on the right upper arm and palpable ipsilateral axillary nodes. Staged as stage III after wide local excision and positive sentinel lymph node biopsy. Tumor testing: BRAF V600E mutation detected. Patient was referred for adjuvant therapy and was started on pembrolizumab; therapy was complicated by immune-related dermatitis requiring a treatment hold.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab", "response": null, "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with lung adenocarcinoma in January 2024. Molecular testing on core biopsy detected EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. Staging at diagnosis was Stage IV with multiple enhancing intracranial lesions and lytic lesions in the thoracic spine. Patient was started on osimertinib 80 mg daily and clinically improved; interval CT and brain MRI show decrease in size of pulmonary nodules and intracranial metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with invasive ductal breast cancer, ER+/PR+, HER2 negative on IHC and FISH. Pathology staged as T2N0 (stage IIA). Underwent lumpectomy with sentinel node biopsy followed by adjuvant whole-breast radiation. Genomic panel identified PIK3CA H1047R. Planned endocrine therapy with letrozole. Currently NED on most recent follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+, HER2 negative", "treatment": "lumpectomy, radiation, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive, now with painful lytic lesions in the thoracic spine. He was started on combination dabrafenib and trametinib; follow-up PET/CT at 12 weeks shows disease that is radiographically stable.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old male with a primary cutaneous melanoma. Sentinel node biopsy was positive and final staging was stage IIIA. Tumor NGS identified BRAF V600E. He had wide local excision and completion lymphadenectomy and was started on adjuvant dabrafenib plus trametinib. At 9 months he developed multiple in-transit nodules on the ipsilateral forearm consistent with recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, completion lymphadenectomy, adjuvant dabrafenib and trametinib", "response": "recurrence (in-transit metastases)", "metastasis_site": "skin (in-transit), regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Tumor board: patient with metastatic cutaneous melanoma, BRAF V600E positive. Initially treated with nivolumab monotherapy but imaging at 6 weeks showed radiographic progression with new pulmonary nodules and enlarging cerebral metastases. Patient was switched to dabrafenib plus trametinib and received stereotactic radiosurgery (SRS) to the dominant brain lesions. After starting BRAF/MEK inhibition there is a partial response of extracranial disease. PD-L1 on IHC was 1%.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1% (IHC)", "treatment": "nivolumab (initial); then dabrafenib + trametinib; stereotactic radiosurgery (SRS)", "response": "progression on nivolumab; partial response to dabrafenib + trametinib", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative/oncology summary: Patient with cutaneous melanoma, positive sentinel node (Stage III), found to harbor a BRAF V600E alteration on molecular testing. Underwent wide local excision and completion lymphadenectomy. Adjuvant targeted therapy with dabrafenib plus trametinib was initiated. Six-month PET/CT shows no FDG-avid disease consistent with a complete metabolic response. No distant metastases identified to date.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and confusion. MRI showed multiple brain metastases and CT abdomen demonstrated two hypodense liver lesions consistent with metastatic disease. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily with symptomatic improvement. Interim restaging at 8 weeks showed reduction in size of brain and liver lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left breast cancer, clinically T4 with skin involvement and fixed axillary nodes. Core biopsy: invasive ductal carcinoma, ER positive, PR positive; HER2 amplification by FISH. Staged IIIC. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab followed by modified radical mastectomy. Pathology shows marked treatment effect but residual viable tumor in the breast and nodes. No tumor genomic sequencing was performed.", "output": {"cancer_type": "breast cancer", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma (mCRPC), germline BRCA2 pathogenic variant. He has diffuse sclerotic and lytic bone metastases. After prior ADT and docetaxel, olaparib was initiated. Baseline PSA was 120 ng/mL and fell to 30 ng/mL on treatment; follow-up imaging showed shrinkage of several bony lesions consistent with a partial response.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 120 ng/mL baseline (declined to 30 ng/mL)", "treatment": "olaparib; prior docetaxel and androgen deprivation therapy", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Outpatient note: 35-year-old with biopsy-proven cutaneous melanoma presenting with cough. Staging CT shows multiple bilateral pulmonary nodules consistent with metastatic disease. Tumor sequencing identified BRAF V600E. Patient was initiated on dabrafenib and trametinib in combination. Three-month restaging CT shows decrease in size and number of lung nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Tumor profiling identified EGFR L858R mutation. PD-L1 testing reported 15%. Staged as IV with brain and bone metastases on baseline PET/CT. Patient started osimertinib 80 mg daily in April 2024 with radiographic partial response at first restaging; later developed intracranial progression and underwent stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib 80 mg daily; stereotactic radiosurgery", "response": "partial response then intracranial progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative; HER2 amplified by FISH. Clinical stage IIIC. NGS panel identified PIK3CA H1047R. She received neoadjuvant docetaxel with trastuzumab and pertuzumab for six cycles and subsequently underwent mastectomy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "docetaxel, trastuzumab and pertuzumab (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with new diagnosis of metastatic colorectal adenocarcinoma. CT abdomen/pelvis demonstrates multiple hepatic lesions. Tumor sequencing identified BRAF V600E and MSI testing returned MSI-high. Given MSI-H status, pembrolizumab was initiated as first-line systemic therapy. Restaging after 12 weeks shows decrease in hepatic target lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colon adenocarcinoma. Next-generation sequencing: KRAS G12D mutation. Tumor reported as MSI-H and TMB-high. CT abdomen/pelvis shows multiple liver metastases; overall stage IV. First-line therapy with FOLFOX plus bevacizumab given; restaging after 4 cycles demonstrates stable disease by RECIST.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage cT4N1M0 (IIIB). ER 80% positive, PR 20% positive, HER2 amplified by FISH. Tumor panel detected PIK3CA E545K. She received neoadjuvant docetaxel combined with trastuzumab and pertuzumab for six cycles followed by definitive surgery; pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel + trastuzumab + pertuzumab (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative summary and follow-up: 59-year-old female with high-grade serous ovarian carcinoma underwent cytoreductive surgery. Intra-op and CT imaging documented diffuse peritoneal carcinomatosis with omental caking (stage IIIC). She completed 6 cycles of adjuvant carboplatin and paclitaxel with excellent radiographic and CA-125 response; currently no residual disease on CT. Germline BRCA testing pending; tumor NGS not performed.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with locally advanced pancreatic ductal adenocarcinoma (T4N1, stage III). Germline testing identified a pathogenic BRCA2 variant. CA19-9 at diagnosis was 780 U/mL. He completed 8 cycles of FOLFIRINOX with good radiographic shrinkage and was transitioned to maintenance olaparib. Most recent scans show continued tumor reduction.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "CA19-9 780 U/mL", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old man with high-risk prostate adenocarcinoma (Gleason 4+5), clinical stage III (T3bN0M0). Underwent radical prostatectomy but developed biochemical recurrence with PSA rising to 6.2 ng/mL. He was started on androgen deprivation with leuprolide and received salvage radiation to the prostate bed. Follow-up PSA declined to 0.2 ng/mL.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "PSA 6.2 ng/mL (pre-treatment); PSA 0.2 ng/mL (post-treatment)", "treatment": "androgen deprivation therapy (leuprolide) and salvage radiation", "response": "biochemical response (PSA decline)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed after biopsy of a right upper lobe mass. Molecular testing identified EGFR L858R and PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily in June and had a radiographic partial response on CT at 8 weeks. Six months later MRI brain demonstrated two new enhancing lesions consistent with brain metastases; stereotactic radiosurgery was performed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic castration-resistant prostate cancer, stage IV, presenting with progressive bone pain and rising PSA. Germline testing demonstrated a deleterious BRCA2 mutation; circulating tumor cell assay was AR-V7 negative. He progressed on enzalutamide and was started on olaparib alongside continued androgen deprivation with leuprolide. Follow-up scans show stable bony disease and PSA stabilization.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "AR-V7 negative", "treatment": "enzalutamide (prior); then olaparib + leuprolide", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 62-year-old female with stage IV lung adenocarcinoma harboring EGFR L858R. PD-L1 tumor proportion score reported at 30%. She was started on osimertinib with initial control of chest disease but developed progression in the brain and bone. Therapy was changed to carboplatin and paclitaxel combined with pembrolizumab; repeat CT and MRI after 3 cycles demonstrate a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib; carboplatin and paclitaxel + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old female with metastatic, hormone receptor\u2013positive, HER2-amplified breast cancer diagnosed two years ago. Current stage IV with multiple osteoblastic lesions in the spine and pelvis. PIK3CA H1047R mutation identified on next-generation sequencing. She was initiated on trastuzumab, pertuzumab and docetaxel and is maintained on trastuzumab thereafter. Recent bone scans show no new lesions and pain is controlled.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+/PR+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 66-year-old male with metastatic colorectal adenocarcinoma, presented with right-sided colon primary. CT shows multiple hepatic lesions. Stage IV disease. Tumor genotyping identified KRAS G12D mutation; microsatellite testing MSI-stable. Baseline CEA 150 ng/mL. Started on FOLFOX with bevacizumab. After 3 cycles, CT abdomen shows no new lesions and minor shrinkage of largest liver mets \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; CEA 150 ng/mL", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R. PD-L1 tumor proportion score was 5%. He was started on osimertinib 80 mg daily as first-line targeted therapy; 8-week CT chest/abdomen showed decrease in size of target lesions consistent with a partial response. Recent brain MRI identified a new small cerebellar metastasis and PET-CT confirmed osseous metastases in the pelvis and T8.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with newly diagnosed metastatic lung adenocarcinoma. Tumor genotyping by NGS detected EGFR L858R mutation. Staging workup consistent with stage IV disease with multiple brain and bony lesions. PD-L1 tumor proportion score reported as <1%. She was started on osimertinib 80 mg daily in June. Interval CT and brain MRI demonstrate reduction in target lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of a left breast mass: invasive ductal carcinoma, ER negative, PR negative, HER2 3+ by IHC and confirmed by FISH (HER2 amplification). NGS panel identified a PIK3CA H1047R mutation. Clinically staged as IIIB. Patient received neoadjuvant trastuzumab, pertuzumab and docetaxel with excellent radiographic response followed by mastectomy; surgical specimen shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab; pertuzumab; docetaxel; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: Resected sigmoid colon adenocarcinoma with later development of peritoneal and hepatic implants. Molecular profile: MSI-H and TMB-high; KRAS/NRAS/BRAF reported as wild-type. Given the deficient mismatch repair status the patient was started on pembrolizumab monotherapy. PET/CT after 6 months shows no metabolically active disease \u2014 clinical complete response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS/NRAS/BRAF wild-type", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "peritoneum and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing: BRAF V600E mutation detected; tumor is MSI-H by PCR and TMB-high at 18 muts/Mb. Given MSI-H status he was started on pembrolizumab monotherapy as initial systemic treatment. First restaging CT at 12 weeks demonstrates stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (18 muts/Mb)", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative summary: 55-year-old male underwent subtotal resection of a right temporal glioblastoma (WHO grade IV). Molecular report: MGMT promoter methylation positive. No actionable point mutations reported on the targeted panel. Patient started standard involved-field radiotherapy with concurrent temozolomide. Early postoperative scans show no interval growth of the resection cavity and clinical course is stable.", "output": {"cancer_type": "glioblastoma (glioblastoma multiforme)", "stage": null, "gene_mutation": null, "biomarker": "MGMT promoter methylation positive", "treatment": "concurrent radiotherapy and temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with BRAF V600E mutation and high tumor mutational burden (TMB-high). Initially started on dabrafenib plus trametinib with a documented partial response at first restaging; subsequent imaging at 6 months showed new hepatic and pulmonary lesions consistent with progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old male with right-sided colon adenocarcinoma presenting with weight loss and hepatic dysfunction. Imaging confirmed multiple liver metastases (stage IV). Tumor profiling: BRAF V600E mutation and MSI-H with elevated TMB. He received first-line pembrolizumab for MSI-H disease but progressed after 4 months; subsequently started on encorafenib plus cetuximab with marked reduction in hepatic tumor burden on CT \u2014 partial response to combination targeted therapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab then encorafenib + cetuximab", "response": "progression on pembrolizumab, partial response to encorafenib + cetuximab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: HER2 amplification by FISH, ER positive, PR positive, PIK3CA H1047R mutation on NGS. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles followed by mastectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+, PR+", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP), mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed 06/2024. Core biopsy of the right upper lobe confirmed adenocarcinoma. Staging workup revealed multiple intracranial lesions and lytic lesions in the spine consistent with metastatic disease. Molecular profiling detected EGFR L858R; ALK and ROS1 were negative. PD-L1 tumor proportion score 5%. She was started on osimertinib 80 mg daily in July 2024. Serial CT and brain MRI show decrease in size and metabolic activity of target lesions. Best overall response documented as partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with newly diagnosed invasive ductal carcinoma of the left breast, clinical stage T1N0M0 (stage I). Tumor is ER positive, PR positive, HER2 IHC 0. She underwent lumpectomy with sentinel lymph node biopsy; margins negative. Adjuvant radiation completed and patient was started on tamoxifen. Currently no evidence of disease on 6-month follow-up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative (IHC 0)", "treatment": "lumpectomy, sentinel lymph node biopsy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma presented with headaches. Staging workup showed multiple enhancing lesions on brain MRI and a 3.5 cm right upper lobe mass. Molecular testing returned EGFR L858R. PD-L1 TPS was reported at 10%. Patient was started on osimertinib 80 mg daily and had symptomatic improvement; first restaging CT shows reduction in size of the primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with localized prostate adenocarcinoma detected on screening PSA. Biopsy Gleason 3+4=7, clinical stage I (T1cN0M0). He elected for radical prostatectomy which was completed without complication. Post-op PSA undetectable. No somatic sequencing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA undetectable post-op", "treatment": "radical prostatectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for pathogenic BRCA1 mutation (BRCA1 deleterious variant). Tumor flagged HRD positive. Underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; started maintenance olaparib. CA-125 normalized and surveillance CT shows no residual disease \u2014 complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious)", "biomarker": "HRD positive", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with unresectable stage III cutaneous melanoma. Molecular testing positive for BRAF V600E. PD-L1 expression <1% by IHC. Started combination targeted therapy with dabrafenib and trametinib; interval PET/CT at 6 months shows decreased nodal uptake and smaller target lesions consistent with a partial response. No visceral metastases reported, predominant nodal disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with biopsy-proven lung adenocarcinoma presented with progressive dyspnea. Molecular testing demonstrated an EGFR L858R mutation. Staging PET/CT showed multiple pulmonary nodules and several hypodense liver lesions consistent with metastatic disease; brain MRI identified two small enhancing lesions. PD-L1 tumor proportion score was 10%. Patient was started on osimertinib 80 mg daily with an initial radiographic partial response, but at 9 months developed clinical and radiographic progression with new hepatic lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with pancreatic ductal adenocarcinoma, germline BRCA2 mutation confirmed by germline testing. Presenting CT showed diffuse peritoneal nodularity consistent with peritoneal carcinomatosis and omental caking; staged as IV. He received gemcitabine plus nab-paclitaxel with symptomatic relief, CA19-9 trended down, and was transitioned to olaparib maintenance. Most recent scans show no radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel, then olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with progressive weight loss; CT shows pancreatic head mass and multiple liver metastases. EUS-FNA confirmed pancreatic ductal adenocarcinoma, stage IV. Germline testing identified a pathogenic BRCA2 variant. Tumor PD-L1 IHC was negative. He received FOLFIRINOX with good tolerance and was transitioned to maintenance olaparib. Scans after 5 months show radiographic stable disease in the liver lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "PD-L1 negative", "treatment": "FOLFIRINOX; maintenance olaparib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old man with a 1.1 mm non-ulcerated cutaneous melanoma on the right forearm. Wide local excision performed with negative margins; sentinel lymph node biopsy was negative. Tumor tested positive for BRAF V600E. No PD-L1 testing was performed and no adjuvant therapy was recommended. Patient is NED at 6-month follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma in a 58-year-old woman, surgically staged as IIIC with peritoneal carcinomatosis. Germline testing identified a pathogenic BRCA1 frameshift mutation. She completed six cycles of carboplatin and paclitaxel and was started on maintenance olaparib with ongoing complete clinical remission on follow-up exams.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic frameshift mutation", "biomarker": null, "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "complete clinical remission", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with metastatic castration-resistant prostate adenocarcinoma, extensive symptomatic bone disease. He received androgen deprivation previously and was treated with combination docetaxel plus abiraterone acetate and prednisone in the metastatic setting. Despite therapy he had increasing bone pain and rising PSA consistent with radiographic progression; bone scan confirmed progression. No tumor sequencing was available.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel plus abiraterone acetate and prednisone (on background ADT)", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with FIGO IIIC high-grade serous ovarian carcinoma. Germline testing identified a pathogenic BRCA1 variant and tumor testing was HRD-positive. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with partial response, then was started on maintenance olaparib. After 14 months on olaparib she developed symptomatic recurrence with peritoneal carcinomatosis and was switched to liposomal doxorubicin for progressive disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 germline pathogenic variant", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib; liposomal doxorubicin", "response": "progression (initial partial response followed by recurrence)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with a primary cutaneous melanoma on the right forearm (Breslow 2.4 mm, no ulceration). Wide local excision with sentinel lymph node biopsy performed; sentinel node negative. Pathologic stage II (IIA). Tumor testing detected BRAF V600E mutation. Patient managed with surgery and surveillance; no adjuvant systemic therapy planned. At 6 months there is no clinical or radiologic evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy; surveillance", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with high-grade serous ovarian carcinoma, optimally debulked at primary cytoreduction. Pathologic stage IIIC with omental and peritoneal implants. Germline testing revealed a deleterious BRCA1 mutation and tumor was HRD-positive. She received adjuvant carboplatin and paclitaxel with interval CA-125 decline and was transitioned to maintenance olaparib. Recent CT shows partial response with decreased peritoneal nodularity.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic cutaneous melanoma, BRAF V600E positive. At diagnosis there were multiple liver and pulmonary metastases; staged as IV. Patient received first-line dabrafenib with trametinib with an initial partial radiographic response. After 6 months new hepatic lesions consistent with progression were documented; treatment was switched to pembrolizumab but follow-up CT showed further progression in the liver and mixed response elsewhere.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib, then pembrolizumab", "response": "initial partial response then progressive disease (mixed response)", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 39-year-old male with metastatic cutaneous melanoma, diagnosed July 2023, presenting with multiple pulmonary nodules on staging CT consistent with lung metastases. Tumor profiling detected BRAF V600E. He received first-line pembrolizumab but developed interval progression after 12 weeks; subsequently started combination dabrafenib and trametinib with mixed radiographic response (some nodules shrink, one new lesion). PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 48-year-old woman with locally advanced, ER+/PR+/HER2-amplified invasive ductal carcinoma of the right breast, clinical stage IIIB. Tumor genotyping identified a PIK3CA H1047R mutation. She completed 6 cycles of docetaxel plus trastuzumab and pertuzumab prior to surgery. Final pathology after mastectomy showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and oncology summary: 49-year-old woman with invasive ductal breast cancer, clinical stage II (T2N0M0). ER positive, PR negative, HER2 amplification by ISH. PIK3CA H1047R identified on NGS. Underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel for 12 weeks and trastuzumab with planned 1 year total. Currently in follow-up with no evidence of disease on recent imaging.", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "lumpectomy; adjuvant paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology report: 58-year-old female with a 1.8 cm invasive ductal carcinoma of the breast. ER positive, PR positive, HER2 IHC 0 (HER2 negative). NGS panel detected a PIK3CA E545K mutation. Final pathologic stage pT2N0 (clinical stage IIA). She underwent lumpectomy with sentinel lymph node biopsy; margins negative. Adjuvant plan: endocrine therapy with letrozole; chemotherapy deferred. Six-month surveillance exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel lymph node biopsy; letrozole (adjuvant endocrine therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with pancreatic ductal adenocarcinoma found to have peritoneal carcinomatosis at diagnostic laparoscopy. CA19-9 is markedly elevated to 12,000 U/mL. No NGS results are available on chart. He was treated with modified FOLFIRINOX for palliative intent and restaging CT after four cycles shows stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "modified FOLFIRINOX", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed metastatic lung adenocarcinoma presenting with progressive headaches. Molecular testing on the biopsy returned EGFR L858R mutation and PD-L1 expression approximately 5%. Brain MRI demonstrated multiple enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily. Follow-up imaging after 8 weeks showed shrinkage of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Biopsy confirmed adenocarcinoma of the right upper lobe. Staging PET/CT shows multiple cerebral metastases and osseous lesions; overall clinical stage IV. Molecular testing returned EGFR L858R positive. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and has had interval imaging at 8 weeks demonstrating a decrease in size of the brain lesions and shrinkage of the primary \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver metastases (Stage IV). Tumor profiling: MSI-High and BRAF V600E mutation; TMB-high (18 muts/Mb). He received first-line FOLFOX plus bevacizumab with initial stable disease, then was switched to pembrolizumab monotherapy with marked reduction in hepatic lesions consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (18 muts/Mb)", "treatment": "FOLFOX + bevacizumab followed by pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female diagnosed with high-grade serous ovarian carcinoma presenting with bulky adnexal mass and diffuse peritoneal implants. Intraoperative staging consistent with stage IIIC disease. Primary cytoreductive surgery performed followed by adjuvant carboplatin and paclitaxel in combination with bevacizumab. HRD testing returned positive (HRD-high); germline and somatic BRCA testing pending at the time of discharge and not reported in the chart. Interval CT after 3 cycles shows meaningful reduction in size of peritoneal disease consistent with a partial response; CA-125 trending down.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HRD-high", "treatment": "cytoreductive surgery; carboplatin and paclitaxel with bevacizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 58-year-old male with right-sided colorectal adenocarcinoma presenting with multiple liver metastases. Tumor testing: MSI-H by PCR and KRAS G12D detected on tumor sequencing. Given MSI-H metastatic disease, patient was started on pembrolizumab monotherapy as first-line systemic therapy. Restaging CT at 12 weeks shows stable size of hepatic lesions and no new sites of disease (stable disease).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 47-year-old male with metastatic melanoma presenting with cough and elevated LFTs. PET/CT: widespread metastatic disease involving liver and bilateral lungs. Molecular testing detected BRAF V600E. PD-L1 by IHC 10%; tumor mutational burden reported as TMB-high. He was initiated on dabrafenib plus trametinib. After 12 weeks there is substantial reduction in target lesions on CT and normalization of LFTs; clinician documents a near-complete radiographic response though small residual pulmonary nodules persist.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib + trametinib", "response": "near-complete response (residual pulmonary nodules)", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left-sided invasive ductal carcinoma, ER positive, PR positive and HER2 amplified by FISH. Clinical staging was T2N0M0 (stage II). Tumor sequencing showed a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel lymph node biopsy (negative) followed by adjuvant dose-dense AC-T (doxorubicin/cyclophosphamide then paclitaxel) and is receiving adjuvant trastuzumab per protocol. Post-operative imaging demonstrates no evidence of distant disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide -> paclitaxel (AC-T); trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the breast, cT3N1 (stage IIIB). Biopsy: HER2 amplified by FISH, ER positive, PR negative, Ki-67 ~40%. Tumor sequencing identified a PIK3CA E545K mutation. She received neoadjuvant docetaxel in combination with trastuzumab and pertuzumab. Clinical exam and MRI showed marked tumor shrinkage and the surgical specimen demonstrated a pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative; Ki-67 40%", "treatment": "docetaxel + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with metastatic colorectal adenocarcinoma with dominant liver lesions. Tumor sequencing identified KRAS G12D. Immunohistochemistry and molecular testing showed microsatellite stable disease. He was treated with FOLFOX plus bevacizumab, with initial disease control followed by progression of hepatic metastases at 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": null, "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient status post right hemicolectomy for colon adenocarcinoma staged pathologically as T3N1 (stage III). Tumor profiling demonstrated a KRAS G12D mutation and MSI-H. Completed 6 months of adjuvant FOLFOX; surveillance CTs show no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old male with metastatic colorectal adenocarcinoma to the liver. Initial molecular profiling: KRAS G12D, BRAF wild-type; tumor is microsatellite stable. First-line therapy FOLFOX with bevacizumab was administered for 6 cycles. Recent imaging demonstrates new hepatic lesions and increase in size of known metastases consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX with bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man presented with progressive cough and weight loss. Imaging revealed a right upper lobe mass with multiple lesions in the brain and lytic lesions in the spine. Biopsy confirmed lung adenocarcinoma, stage IV. Next-generation sequencing identified EGFR L858R mutation. PD-L1 by IHC was 10%. He was started on first-line osimertinib and interval CT and MRI show a partial response with decreased size of the primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib (first-line)", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old woman presented with cough and headache. Imaging and biopsy confirmed lung adenocarcinoma with multiple bone lesions and a solitary cerebellar metastasis. Comprehensive genomic profiling identified EGFR L858R. PD-L1 tumor proportion score reported at 10%. She was started on osimertinib 80 mg daily; stereotactic radiosurgery was performed to the cerebellar lesion. Follow-up CT/MRI at 8 weeks showed shrinkage of pulmonary nodules and decreased enhancement of the brain lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/oncology summary: Right breast invasive ductal carcinoma, clinical stage IIIB at presentation. ER and PR positive, HER2 IHC 3+ with FISH-confirmed HER2 amplification. Next-generation sequencing identified PIK3CA H1047R. Patient received neoadjuvant trastuzumab with docetaxel followed by modified radical mastectomy. Surgical pathology reported a pathologic complete response; no distant metastatic disease noted on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab and docetaxel (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with de novo metastatic breast cancer, ER+/PR+, HER2 amplified on FISH. She presented with worsening back pain and PET/CT showed multifocal osseous uptake consistent with skeletal metastases. Started on docetaxel plus trastuzumab; after 4 cycles the scans demonstrate no new lesions and clinically stable disease. BRCA testing pending.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "ER+/PR+, HER2 amplification", "treatment": "docetaxel and trastuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old woman with cutaneous melanoma of the upper back, ulcerated with 2.1 mm Breslow. Sentinel lymph node was positive and pathologic staging reported stage IIIA. Tumor sequencing demonstrated BRAF V600E. She was started on adjuvant dabrafenib plus trametinib; interval PET/CT after 3 months showed decreased nodal FDG uptake consistent with a partial response and she will continue adjuvant therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib (adjuvant)", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic prostate adenocarcinoma. Bone scan demonstrates multifocal osseous uptake in the pelvis and spine consistent with bone metastases. PSA on presentation 150 ng/mL. He was started on androgen deprivation therapy (leuprolide) with docetaxel planned; molecular testing was not performed prior to treatment.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 150 ng/mL", "treatment": "androgen deprivation therapy (leuprolide) with docetaxel", "response": null, "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 68-year-old male with metastatic colon adenocarcinoma. Molecular testing identified KRAS G12D. Tumor testing demonstrates MSS (microsatellite stable) and low tumor mutational burden. CT shows multiple hepatic lesions consistent with liver metastases. He was started on FOLFOX with bevacizumab; interval imaging after three cycles demonstrates stable disease by RECIST.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable); TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed right temporal glioblastoma. Underwent gross total resection; neuropathology: IDH1 R132H negative, MGMT promoter methylation positive. She completed concurrent radiotherapy with daily temozolomide followed by adjuvant temozolomide. First post-treatment MRI at 3 months shows enlarging enhancing lesion at the resection cavity suspicious for progression.", "output": {"cancer_type": "glioblastoma", "stage": null, "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "surgery (gross total resection); radiotherapy with concurrent temozolomide; adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive molecular testing performed on the primary tumor identified EGFR L858R mutation. PD-L1 tumor proportion score = 10%. Patient developed neurologic symptoms; brain MRI demonstrated multiple supratentorial metastases and PET/CT showed osseous disease. He was started on osimertinib 80 mg daily in July 2020 with symptomatic improvement. Interval CT chest/abdomen at 8 weeks showed a 40% reduction in target lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old man with a 1.2 cm pigmented forearm lesion. Excisional biopsy: superficial spreading melanoma, Breslow 0.8 mm, stage I (T1b). Tumor sequencing identified BRAF V600E. He underwent wide local excision with sentinel lymph node biopsy which was negative. No adjuvant systemic therapy planned; patient remains without evidence of recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision with sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman with newly diagnosed high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing returned a deleterious BRCA1 mutation and tumor HRD-positive. Preoperative CA-125 was markedly elevated. She underwent optimal cytoreductive surgery followed by combination chemotherapy with carboplatin + paclitaxel plus bevacizumab. After six cycles she was started on maintenance olaparib given BRCA1 mutation and HRD. CT pelvis/abdomen shows no measurable disease and CA-125 has normalized consistent with complete radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation (germline)", "biomarker": "HRD-positive, CA-125 elevated (normalized on treatment)", "treatment": "cytoreductive surgery; carboplatin + paclitaxel + bevacizumab; maintenance olaparib", "response": "complete radiographic response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with progressive dyspnea. NGS detected a BRAF V600E alteration. The patient was started on dabrafenib plus trametinib but progressed after 4 months and was transitioned to nivolumab. PD-L1 testing was not reported. Imaging shows multiple pulmonary nodules and small brain metastases on MRI.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then nivolumab", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recurrent cutaneous melanoma of the left forearm. Pathology positive for BRAF V600E. Clinical stage III with nodal involvement. After wide local excision and completion lymphadenectomy the patient was started on adjuvant targeted therapy with dabrafenib plus trametinib. PET/CT at 4 months shows no FDG-avid disease\u2014interpreted as a complete metabolic response in the treated regions.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Staging demonstrated metastatic disease (stage IV) with multiple brain and bone lesions on MRI and PET. Tumor NGS returned EGFR L858R and TP53 R273H; PD-L1 by IHC was 5%. She was started on first-line osimertinib and underwent stereotactic radiosurgery to two symptomatic brain metastases. Interval imaging at 8 weeks showed a partial response with decreased size of primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 R273H", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic colorectal adenocarcinoma to the liver (stage IV). Molecular testing: KRAS G12D identified, tumor MSI-H by PCR. Initially treated with FOLFOX; progression after 6 months prompted switch to pembrolizumab. After 3 cycles of pembrolizumab CT shows no new lesions and shrinkage of several hepatic metastases \u2014 radiographic stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with headaches. Staging workup showed multiple brain mets and lytic lesions in the spine consistent with stage IV disease. Molecular testing returned EGFR L858R and no ALK/ROS1 rearrangement; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to a solitary cerebellar lesion. At 8-week follow-up there is radiographic shrinkage of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with progressive cough and weight loss. Staging workup shows stage IV disease with multiple brain and bone lesions. Molecular testing returned EGFR L858R mutation and PD-L1 tumor proportion score 30%. Patient was started on osimertinib 80 mg daily with improvement in cough and partial radiographic response on first follow-up CT and MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with recurrent cutaneous melanoma of the back. NGS panel detected BRAF V600E. Staging PET/CT confirmed osseous involvement of the lumbar spine and small pulmonary nodules; overall stage IV. She initiated combination targeted therapy with dabrafenib and trametinib. After two months there is a marked radiographic regression of the spinal lesion and symptomatic improvement consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with localized prostate adenocarcinoma, clinical stage II (cT2b). PSA at diagnosis was 12 ng/mL. No actionable variants were reported on the targeted panel. He was treated with definitive external beam radiation and androgen deprivation therapy (leuprolide). PSA has declined and disease remains clinically stable on follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "external beam radiation, androgen deprivation therapy (leuprolide)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Admission note: new diagnosis of glioblastoma, confirmed on stereotactic biopsy (WHO grade IV). Patient underwent standard concurrent chemoradiation with temozolomide (radiation 60 Gy with daily temozolomide) followed by adjuvant temozolomide cycles. MGMT promoter methylation was reported as methylated. Molecular panel results for IDH1/2 pending. MRI after chemoradiation shows no clear interval enlargement and stable enhancing lesion compared with baseline.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylated", "treatment": "concurrent radiotherapy and temozolomide, followed by adjuvant temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma. Molecular testing: KRAS G12D mutation. CT shows multiple hepatic and pulmonary metastases consistent with Stage IV disease. He was started on FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab; restaging after 4 cycles demonstrates stable disease. MSI testing was negative (MSI-stable).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male underwent radical nephrectomy for clear cell renal cell carcinoma, pathologic stage pT3a (no nodes identified), Fuhrman grade 3. Margins negative. No molecular testing was performed. Given high-risk features he was started on adjuvant sunitinib; surveillance imaging at 18 months shows no evidence of disease.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical nephrectomy; adjuvant sunitinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic cutaneous melanoma. Molecular testing identified a BRAF V600E mutation. He was initiated on dabrafenib plus trametinib; after four months he developed worsening headaches and imaging revealed new intracranial lesions and enlarging pulmonary nodules consistent with systemic progression despite targeted therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative summary and oncology note: 59-year-old woman with high-grade serous ovarian carcinoma presenting with bulky adnexal mass and extensive peritoneal carcinomatosis. Optimal debulking achieved surgically. Final FIGO stage reported as IIIC. BRCA germline testing pending but no somatic mutation reported in the pathology addendum. She completed 3 cycles of carboplatin and paclitaxel with CA-125 decline and radiographic partial response of peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel; surgical debulking", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with left breast invasive ductal carcinoma, clinical stage IIB (T2 N1 M0). ER 90%, PR 40%, HER2 FISH positive consistent with HER2 amplification. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab; endocrine therapy with letrozole was started. Recent surveillance imaging demonstrates no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive (90%); PR positive (40%)", "treatment": "lumpectomy; paclitaxel and trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed metastatic lung adenocarcinoma. Biopsy showed adenocarcinoma of the lung; next-generation sequencing detected EGFR L858R. Staging consistent with stage IV disease with multiple small enhancing lesions on brain MRI. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and MRI after 8 weeks demonstrated reduction in size of intracranial and pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old woman with locally advanced left breast cancer (cT4bN2, clinical stage IIIB). Core biopsy: invasive ductal carcinoma, ER-/PR-, HER2 IHC 3+ with confirmed HER2 amplification by FISH. Somatic testing identified a PIK3CA H1047R mutation. She received neoadjuvant carboplatin and paclitaxel with trastuzumab and pertuzumab for six cycles followed by mastectomy. Surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER-/PR-", "treatment": "neoadjuvant carboplatin and paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal breast carcinoma (cT3N2). Hormone receptors: ER 70%, PR 15%. HER2 FISH shows amplification. NGS detected PIK3CA E545K. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles, followed by mastectomy. Surgical pathology reports a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification, ER 70%, PR 15%", "treatment": "paclitaxel, trastuzumab, pertuzumab, mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: patient with metastatic colorectal adenocarcinoma with multiple liver lesions. Molecular profile shows BRAF V600E mutation and MSI-H. Initial therapy was FOLFOX but disease progressed; patient was switched to encorafenib plus cetuximab. Restaging CT after 8 weeks demonstrates stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "encorafenib and cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Mr. K is a 67-year-old with newly diagnosed metastatic lung adenocarcinoma. Molecular testing detected EGFR L858R and PD-L1 expression approximately 10%. Staging at diagnosis was IV with multiple pulmonary nodules and a 1.5 cm cerebellar lesion. He was started on osimertinib 80 mg daily with steroids for CNS symptoms. Repeat imaging at 8 weeks showed decrease in size of lung lesions and interval shrinkage of the cerebellar metastasis consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 39-year-old male with metastatic cutaneous melanoma presenting with multiple subcutaneous nodules and a 1.5 cm cerebellar lesion. Molecular testing identified an NRAS Q61K driver mutation. He received combination ipilimumab and nivolumab induction followed by maintenance nivolumab. Repeat MRI shows resolution of the cerebellar lesion and PET/CT demonstrates no FDG-avid disease \u2014 ongoing complete response noted in clinic. No PD-L1 result was reported in the lab summary.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "ipilimumab + nivolumab; maintenance nivolumab", "response": "complete response", "metastasis_site": "brain; subcutaneous soft tissue"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental disease at diagnosis. Germline testing returned a pathogenic BRCA1 variant and tumor testing showed homologous recombination deficiency (HRD positive). She underwent optimal debulking followed by adjuvant carboplatin + paclitaxel with partial radiographic response; maintenance olaparib was started in combination with bevacizumab. CA-125 normalized and CT now demonstrates no measurable disease consistent with a complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD positive; CA-125 normalization", "treatment": "debulking surgery; carboplatin + paclitaxel; maintenance olaparib + bevacizumab", "response": "complete clinical response", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with metastatic colorectal adenocarcinoma. Primary tumor in the sigmoid colon resected last year. Recent CT chest shows several new bilateral pulmonary nodules consistent with metastatic disease. Molecular profile: KRAS G12D; MSI stable. He began FOLFOX chemotherapy three weeks ago but interval imaging demonstrates growth of multiple lung nodules.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (oxaliplatin, leucovorin, 5-FU)", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presented with multiple enhancing lesions on MRI. Staging workup consistent with stage IV disease with a dominant cerebellar metastasis. Next\u2011generation sequencing of the tumor identified EGFR L858R. PD-L1 tumor proportion score reported ~10%. He was started on first-line osimertinib 80 mg daily. At the 8-week scan the primary lung mass and brain lesion have decreased in size consistent with a partial response; symptomatic improvement noted.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with newly diagnosed lung adenocarcinoma. Biopsy of the right upper lobe confirmed adenocarcinoma with EGFR L858R mutation. PD-L1 immunohistochemistry reported TPS 10%. Staging workup demonstrates Stage IV disease with multiple small brain metastases and lytic lesions in the thoracic spine. Patient was started on osimertinib 80 mg daily; 8-week CT and brain MRI show a partial response with decrease in size of the primary and several metastatic lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical oncology note: 62-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with initial clinical complete response. Eighteen months later she recurred with peritoneal implants and was started on olaparib maintenance given BRCA1 positivity; interval CT shows a partial radiographic response and CA-125 remains mildly elevated.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious germline mutation", "biomarker": "CA-125 elevated", "treatment": "olaparib (maintenance)", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 63-year-old male who underwent right hemicolectomy for sigmoid mass; final pathology: stage III colon adenocarcinoma (pT3N1). Genotyping showed KRAS G12D mutation. MSI testing reported microsatellite stable. Received adjuvant FOLFOX for 6 months with good tolerance. Surveillance CT at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III (pT3N1)", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "surgery (right hemicolectomy) and adjuvant FOLFOX", "response": "no evidence of disease (NED)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with pancreatic ductal adenocarcinoma. Germline BRCA2 mutation identified on hereditary panel. He completed six cycles of modified FOLFIRINOX with good clinical tolerance and was transitioned to olaparib maintenance. Recent CT reports decrease in the primary pancreatic mass with persistent para-aortic nodal disease. Note: no formal stage recorded in this clinic note and no additional biomarkers were reported.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "modified FOLFIRINOX; olaparib maintenance", "response": "partial response (decreased primary, persistent nodal disease)", "metastasis_site": "para-aortic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colorectal adenocarcinoma presenting with a dominant liver lesion. Molecular testing identified KRAS G12D; tumor is microsatellite stable (MSS). He was started on FOLFOX plus bevacizumab with radiographic best response of stable disease; currently on 5-FU maintenance. No brain or lung mets identified.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab (then 5-FU maintenance)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing positive for EGFR L858R. PD-L1 TPS 15%. MRI brain demonstrates multiple enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily and received whole brain radiation. Follow-up CT at 8 weeks demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib and whole brain radiation", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB. Core biopsy demonstrates HER2 amplification by FISH and ER/PR positivity. NGS panel detected a PIK3CA H1047R hotspot mutation. She received neoadjuvant paclitaxel with trastuzumab for four cycles; imaging and exam documented significant tumor reduction though the surgical specimen contained residual invasive carcinoma.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel and trastuzumab", "response": "partial response (residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology operative report: 32-year-old male with primary cutaneous melanoma of the upper back, Breslow 0.8 mm, no ulceration, staged as IA. Sentinel node biopsy negative. Tumor NGS returned BRAF V600E. Patient underwent wide local excision with 1 cm margins; no adjuvant therapy recommended. Follow-up skin exam clear.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I (IA)", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with de novo metastatic invasive ductal carcinoma of the breast. Core biopsy: ER-/PR-, HER2 amplified by FISH. FoundationOne reported PIK3CA H1047R. Staging: stage IV with multiple hepatic lesions. Treated with first-line trastuzumab and pertuzumab in combination with paclitaxel. Restaging CT after 3 cycles shows no new lesions and minimal change in hepatic disease; radiology impression: stable disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Record: 48-year-old woman with ER/PR-positive, HER2-amplified invasive ductal carcinoma of the left breast, Stage II (pT2N1). She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab for planned 1 year. Current follow-up exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy followed by adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report and plan: 57-year-old with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery; diffuse peritoneal carcinomatosis noted intraoperatively. Germline testing returned positive for BRCA1 mutation. Tumor reported HRD-positive and CA-125 was 580 U/mL pre-op. Post-op plan: carboplatin and paclitaxel x6 cycles with consideration of maintenance olaparib. Early post-treatment CT shows decreased peritoneal nodularity.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD-positive; CA-125 elevated (>500 U/mL)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; planned maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology note: Invasive ductal carcinoma of the right breast, grade 2. ER positive, PR negative, HER2 amplification confirmed by FISH. PIK3CA H1047R identified on targeted panel. Patient underwent lumpectomy and sentinel node sampling; final pathologic stage pT2 pN0 (Stage IIB). Adjuvant chemotherapy with paclitaxel followed by trastuzumab planned. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "paclitaxel and trastuzumab (adjuvant)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with resected colon adenocarcinoma, pathologic stage pT3N1M0 (stage IIIB). Tumor tested KRAS G12D and was MSI-stable. Completed adjuvant FOLFOX x6 cycles. Surveillance CT and CEA at 12 months show no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIB", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX", "response": "disease-free / no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital discharge summary: 59-year-old woman with high-grade serous ovarian carcinoma presenting with bulky adnexal mass and extensive peritoneal carcinomatosis. Surgical staging consistent with stage IIIC disease. Germline testing positive for BRCA1 pathogenic variant. She completed 6 cycles of carboplatin and paclitaxel with marked clinical and radiographic improvement and was placed on maintenance olaparib. Clinical response described as partial response with significant reduction in peritoneal disease burden.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": null, "treatment": "carboplatin, paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed lung adenocarcinoma presented with weight loss and multiple intracranial lesions on MRI. Staging confirmed stage IV disease with brain and bone involvement. Molecular testing identified EGFR L858R and secondary T790M resistance mutation; PD-L1 was 10% and TMB-low. He was started on first-line osimertinib with good CNS control for 8 months, then developed extracranial progression and was switched to platinum-based chemotherapy (carboplatin and pemetrexed) combined with pembrolizumab on a clinical protocol, achieving a partial response on first restaging CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, T790M", "biomarker": "PD-L1 10%, TMB-low", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old with clinically localized prostate adenocarcinoma, PSA at diagnosis 7.4 ng/mL, Gleason 3+4 in two cores. Staged as T2bN0M0 (stage II). Underwent radical prostatectomy followed by adjuvant external beam radiation and short-term androgen deprivation therapy with leuprolide for 6 months. On most recent follow-up PSA is undetectable (<0.1 ng/mL). No new symptoms and imaging negative for metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA undetectable (<0.1 ng/mL)", "treatment": "radical prostatectomy; adjuvant radiation; leuprolide (androgen deprivation therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma presented with headaches. Staging workup consistent with Stage IV disease with multiple brain and bone lesions. Molecular testing returned EGFR exon 19 deletion; PD-L1 tumor proportion score 10%. Started on osimertinib 80 mg daily as first-line targeted therapy with good clinical tolerance. Follow-up MRI at 8 weeks shows reduction in intracranial disease compatible with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma. Molecular testing identified BRAF V600E. PD-L1 by IHC reported 5% and tumor sequencing indicated TMB-high. He started combination targeted therapy with dabrafenib and trametinib; initial scans showed marked reduction in extracranial disease (partial response) but later developed new intracranial lesions consistent with progression and underwent stereotactic radiosurgery.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%, TMB-high", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "initial partial response then intracranial progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed after weight loss and cough. Staging PET/CT consistent with stage IV disease with multiple pulmonary nodules and enhancing lesions in the brain and lytic lesions in the thoracic spine. Molecular profile: EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily as first-line targeted therapy; after 8 weeks there is measurable shrinkage of lung masses and decreased enhancement of brain lesions on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with right breast invasive ductal carcinoma, staged IIA (T2 N0 M0) on final pathology. Core biopsy was ER-/PR-; HER2 IHC 3+ and HER2 amplification confirmed by FISH. She underwent lumpectomy with sentinel node biopsy; margins negative. Adjuvant therapy included weekly paclitaxel followed by trastuzumab for a planned 1 year. At 12-month follow-up there is no evidence of disease on clinical exam and imaging.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man diagnosed with locally advanced pancreatic ductal adenocarcinoma. Germline and somatic testing positive for BRCA2 pathogenic variant; tumor labeled HRD-positive. Received FOLFIRINOX with very good radiographic response, completed consolidative chemoradiation and was started on olaparib maintenance. Surveillance CTs demonstrate stable disease on maintenance therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2", "biomarker": "HRD positive", "treatment": "FOLFIRINOX, chemoradiation, olaparib maintenance", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic metastases. PCR-based testing positive for KRAS G12D; tumor is microsatellite stable (MSS) and TMB-low. He was started on first-line FOLFOX with bevacizumab. Restaging CT at 8 weeks shows minor reduction in size of liver lesions and no new sites of disease \u2014 overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic pancreatic ductal adenocarcinoma diagnosed 2023 with liver metastases at presentation (stage IV). Germline BRCA2 mutation identified. First-line FOLFIRINOX produced initial stable disease but CT at 5 months documented progression in the liver. Patient received second-line gemcitabine/nab-paclitaxel and was later placed on olaparib maintenance for BRCA2-positive disease; hepatic lesions remain progressive.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel; olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with history of colorectal adenocarcinoma now presenting with progressive dyspnea. Chest CT demonstrates multiple new bilateral pulmonary nodules; biopsy confirms metastatic colorectal cancer to the lung. Tumor panel identified a KRAS G12D mutation. He was started on FOLFOX with bevacizumab. After three cycles the CT shows increase in size and number of pulmonary lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX; bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with node-positive invasive ductal carcinoma of the right breast, clinical stage II. Core biopsy: ER-, PR-, HER2 IHC 3+ with confirmed HER2 amplification by FISH. She received neoadjuvant trastuzumab plus weekly paclitaxel with excellent radiographic response and went on to lumpectomy. Final pathology showed no residual invasive carcinoma (pathologic complete response). No multigene panel performed.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant trastuzumab and paclitaxel followed by lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal carcinoma to the liver. Primary colon cancer resected previously; now progressive hepatic disease on imaging. Molecular testing returned KRAS G12D. Patient received first-line FOLFOX with bevacizumab for 6 cycles but interval scans show increase in size and number of liver lesions consistent with progression; will consider second-line options. MSI testing result not available in this chart.", "output": {"cancer_type": "colorectal cancer", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left breast invasive ductal carcinoma, clinical stage IIIA (T2N2). ER positive, PR negative; HER2 IHC 3+ with FISH confirming HER2 amplification. NGS identified a PIK3CA E545K mutation. She received neoadjuvant carboplatin and docetaxel with trastuzumab for four cycles, underwent lumpectomy and axillary dissection, and final pathology revealed no residual invasive carcinoma (pathologic complete response). No distant mets identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma. Primary was resected previously; recent MRI shows multiple cerebral metastases and chest CT reveals bilateral pulmonary nodules. Tumor genotyping identified BRAF V600E. PD-L1 expression ~5%. He initially progressed on front-line pembrolizumab after 4 months and was switched to combination BRAF/MEK inhibition with dabrafenib and trametinib, with subsequent CT at 6 weeks showing marked reduction of pulmonary nodules and shrinkage of several brain lesions \u2014 assessed as partial response to targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (prior), dabrafenib and trametinib", "response": "progression on pembrolizumab then partial response on dabrafenib/trametinib", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma to the liver. PCR-based assay identified KRAS G12D; mismatch repair proteins intact (MMR proficient). He was treated with FOLFOX plus bevacizumab in the first line. Interval CT after 4 cycles shows no significant change in size of hepatic lesions consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 64-year-old man with metastatic castration-resistant prostate cancer, bone-predominant disease. Germline testing revealed a pathogenic BRCA2 mutation. He received six cycles of docetaxel with androgen-deprivation therapy, followed by maintenance olaparib. PSA has fallen from 120 to 18 ng/mL and bone scans show partial improvement of several lesions.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA 18 ng/mL (down from 120 ng/mL)", "treatment": "docetaxel; androgen-deprivation therapy; olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old man with metastatic melanoma. NGS identified BRAF V600E mutation. Treated with combination targeted therapy dabrafenib plus trametinib; PD-L1 testing not available. After 6 months on the BRAF/MEK inhibitor doublet he developed new pulmonary nodules and enlarging mediastinal nodes consistent with disease progression. Immunotherapy was considered next.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "progression", "metastasis_site": "lung (pulmonary nodules), mediastinal lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colon adenocarcinoma. Right hemicolectomy pathology: moderately differentiated adenocarcinoma. Liver lesions on CT consistent with metastases; biopsy of hepatic lesion confirms colorectal primary. Molecular testing: KRAS G12D positive; tumor is MSI-high by PCR. He completed 8 cycles of FOLFOX plus bevacizumab; most recent CT shows no new lesions and overall measurements stable compared with prior \u2014 documented stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Young adult with metastatic melanoma, biopsy-confirmed BRAF V600E. Baseline PD-L1 was 1%. He was started on dabrafenib plus trametinib and had an early partial response, but developed new neurologic symptoms and progression in an intracranial lesion after 5 months. Therapy was switched to combination immunotherapy with nivolumab and ipilimumab. Current record documents prior partial response followed by intracranial progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib; then nivolumab plus ipilimumab", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical T4N1 \u2014 treated with neoadjuvant therapy. Core biopsy: HER2 amplification by FISH and ER positive (Allred 7), PR negative. Tumor sequencing revealed PIK3CA E545K. She received weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks; post-treatment exam reports clinical complete response and surgery planned.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant paclitaxel + trastuzumab + pertuzumab", "response": "clinical complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with high-grade serous ovarian carcinoma, clinical stage IIIC with peritoneal carcinomatosis at presentation. Germline testing positive for BRCA1 5382insC. Preoperative CA-125 markedly elevated. She underwent optimal cytoreductive debulking followed by adjuvant carboplatin and paclitaxel with bevacizumab. CA-125 normalized post-treatment and CT shows no residual disease \u2014 complete clinical response at 6-month follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 5382insC", "biomarker": "CA-125 elevated (normalized after treatment)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel with bevacizumab", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with stage IV lung adenocarcinoma diagnosed on CT-guided biopsy of the right lower lobe. Tumor testing positive for EGFR L858R. PD-L1 TPS reported at 10%. Patient started first-line osimertinib 80 mg daily; follow-up CT at 8 weeks showed decrease in size of the primary and new sclerotic lesions in the spine. Brain MRI identified a 1.2 cm cerebellar metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma, BRAF V600E mutation-positive, presented with axillary node and multiple pulmonary nodules. Patient enrolled on targeted therapy with dabrafenib and trametinib; after 12 weeks PET/CT shows complete metabolic resolution of pulmonary lesions and reduction of nodal disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response (radiographic/metabolic)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with FIGO stage IIIC high-grade serous ovarian carcinoma. Germline testing revealed a deleterious BRCA1 mutation. CA-125 was markedly elevated at diagnosis. She underwent optimal debulking followed by carboplatin and paclitaxel with partial radiologic/routine marker response, then transitioned to maintenance olaparib; most recent CT shows stable peritoneal nodularity consistent with stable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma, stage IV. Staging scans show multiple cerebral metastases and lytic lesions in the thoracic spine. Comprehensive genomic profiling returned EGFR L858R and PD-L1 10%. Patient was started on osimertinib 80 mg daily. First restaging MRI/CT after 8 weeks demonstrates decrease in size of the primary lesion and brain metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with invasive ductal carcinoma of the left breast, clinical stage IIA (T2 N0 M0). Tumor markers: HER2 IHC 3+ consistent with HER2 amplification, ER positive, PR negative. Germline BRCA testing was negative. She underwent lumpectomy followed by adjuvant paclitaxel and trastuzumab. Six-month surveillance imaging and clinical exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "lumpectomy; adjuvant paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old male with metastatic colorectal adenocarcinoma. NGS identified a KRAS G12C mutation; MSI testing returned MSS (microsatellite stable). He presented with multiple liver metastases. First-line therapy with FOLFOX plus bevacizumab was initiated. After three cycles the CT scan shows interval increase in size of the dominant hepatic lesion and new satellite lesions consistent with progression. Plan to change to an irinotecan-based regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man diagnosed with locally advanced esophageal squamous cell carcinoma, clinical stage II (T2N1M0). He underwent definitive concurrent chemoradiation with weekly cisplatin and continuous infusion 5-FU followed by transthoracic esophagectomy. Post-operative PET/CT demonstrated no residual FDG-avid disease. No molecular profiling was performed.", "output": {"cancer_type": "esophageal squamous cell carcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin and 5-FU chemoradiation followed by esophagectomy", "response": "no residual disease / complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal disease. Germline testing returned a BRCA2 frameshift mutation and genomic profiling reported HRD-positive. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with radiographic complete response and was started on maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 frameshift", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with obstructing sigmoid mass underwent colectomy. Final pathology: stage III (T3N1) moderately differentiated adenocarcinoma. Molecular testing identified KRAS G12D; MMR proteins intact. He completed 6 months of adjuvant FOLFOX and was followed with surveillance CTs and CEA checks \u2014 currently without radiographic recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "surgical resection (colectomy), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with progressive cough and weight loss. Imaging demonstrated a left upper lobe mass and multiple enhancing lesions in the cerebrum and lytic lesions in the spine. Biopsy confirmed lung adenocarcinoma, stage IV. Comprehensive NGS revealed an EGFR L858R point mutation. PD-L1 TPS was 5%. He was started on osimertinib and underwent stereotactic radiosurgery to the dominant brain lesions. On follow-up CT the extracranial disease has decreased in size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response (decrease in extracranial disease)", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old male with cutaneous melanoma presenting with multiple pulmonary nodules and a solitary cerebellar metastasis, clinical stage IV. Tumor is BRAF V600E\u2013positive; PD-L1 expression ~10%. He was started on combination targeted therapy with dabrafenib and trametinib and the first restaging scan demonstrated a partial response.", "output": {"cancer_type": "melanoma (cutanous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op summary: 63-year-old male with sigmoid adenocarcinoma, pathologic stage pT3N1 (stage III). Tumor molecular testing returned MSI-High (MSI-H) and a KRAS G12D mutation; TP53 reported wild-type. Patient completed 12 cycles of adjuvant FOLFOX. Surveillance CT scans show no residual disease and CEA has normalized.", "output": {"cancer_type": "sigmoid adenocarcinoma (colon cancer)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "surgery; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with right upper quadrant pain. Imaging demonstrates multiple hepatic lesions consistent with liver metastases; overall TNM corresponds to stage IV. MSI testing returned MSI-high, patient did not have molecular profiling done at the time of diagnosis. He was started on FOLFOX with bevacizumab; disease control with minor shrinkage followed by several months of stable disease on serial CTs.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-high", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colon adenocarcinoma (stage IV) found to have KRAS G12D on tumor NGS and MSI-H by PCR. Presented with ascites and peritoneal carcinomatosis. Received 6 cycles of FOLFOX with clinical progression. Due to MSI-H status, started pembrolizumab: CT scan after 12 weeks shows decrease in peritoneal disease and symptom improvement consistent with partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX followed by pembrolizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "73-year-old man presenting with high PSA and diffuse bony pain. Workup revealed prostate adenocarcinoma with extensive osseous metastases to the spine and pelvis. Clinical stage IV at diagnosis. PSA at presentation was 142 ng/mL. No genomic next-generation sequencing was performed prior to treatment. He was started on androgen deprivation with leuprolide and six cycles of docetaxel; after 4 months disease is radiographically stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 142 ng/mL", "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone (spine and pelvis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with invasive ductal carcinoma of the right breast. Core biopsy: ER positive, PR positive, HER2 amplified by FISH; PIK3CA H1047R identified on targeted panel. Clinical stage cT2N0 (stage IIA). She received neoadjuvant doxorubicin/cyclophosphamide x4 followed by paclitaxel with trastuzumab, then lumpectomy and sentinel node biopsy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). Patient completed adjuvant trastuzumab and whole-breast radiation and is currently without evidence of disease on 6-month follow-up.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide, paclitaxel, trastuzumab; lumpectomy; adjuvant trastuzumab; radiation", "response": "pathologic complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with metastatic colorectal adenocarcinoma, stage IV with multiple liver and pulmonary metastases. Molecular profiling demonstrates KRAS G12D and MSI-H with high tumor mutational burden. Patient received first-line FOLFOX plus bevacizumab; initial imaging after 3 cycles showed stable disease, but subsequent scans documented interval progression of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 54-year-old presented with aggressive cutaneous melanoma. Sentinal node positive and PET/CT demonstrates hepatic metastases consistent with stage IV disease. Tumor testing identified BRAF V600E. He was started on dabrafenib with trametinib; initial imaging at 6 weeks showed a partial response, but at 9 months there is progression in the liver with new lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, stage IIIC with bulky peritoneal disease. Germline testing identified a deleterious BRCA1 mutation and tumor HRD testing was positive. She underwent optimal cytoreductive surgery followed by combination chemotherapy with carboplatin and paclitaxel; olaparib maintenance was initiated after completion of chemotherapy. Interval CT showed complete radiographic response of previously seen implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive", "treatment": "surgery (debulking); carboplatin + paclitaxel; olaparib maintenance", "response": "complete radiographic response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man with metastatic colorectal adenocarcinoma, stage IV with multiple liver lesions. Tumor sequencing demonstrates BRAF V600E mutation and high microsatellite instability (MSI-H) with elevated tumor mutational burden. He was started on pembrolizumab first-line and had a radiographic partial response at 12 weeks; after 9 months he developed progression confined to the liver and was transitioned to encorafenib plus cetuximab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (first-line), then encorafenib + cetuximab", "response": "initial partial response to pembrolizumab then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with metastatic disease to bilateral lungs and mediastinal lymph nodes. Tumor sequencing positive for BRAF V600E. Patient started on dabrafenib plus trametinib with rapid symptomatic improvement; CT at 12 weeks demonstrates partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lungs, mediastinal lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic lung adenocarcinoma first diagnosed in 2019. NGS returned EGFR L858R and a concurrent TP53 splice-site mutation. PD-L1 tumor proportion score reported at 10%. MRI brain demonstrated two enhancing lesions consistent with brain metastases. He was started on osimertinib 80 mg daily in 2020 with radiographic improvement of intracranial disease and a documented partial response systemically on follow-up scans.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 splice-site mutation", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "43-year-old man with stage III ulcerated cutaneous melanoma of the right forearm. Wide local excision and sentinel lymph node biopsy positive for micrometastasis; completion lymphadenectomy performed. No molecular testing was performed. Patient received adjuvant nivolumab and remains disease-free at 18-month follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "adjuvant nivolumab", "response": "no evidence of disease (disease-free)", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed lung adenocarcinoma. Biopsy shows EGFR L858R mutation. MRI brain demonstrated multiple enhancing lesions consistent with metastases. PD-L1 tumor proportion score reported as 10%. Patient was started on osimertinib 80 mg daily with initial symptomatic benefit; however, follow-up imaging at 9 months demonstrated progression in the brain. Stage IV at presentation.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 47-year-old female with locally advanced invasive ductal carcinoma of the right breast now confirmed metastatic on staging scans with hepatic lesions. Tumor was ER+, PR-, HER2 amplified by FISH; tumor genotyping identified a PIK3CA E545K mutation. Pathologic stage at presentation consistent with stage IV disease. She was started on first-line trastuzumab and pertuzumab with docetaxel. After three cycles there is a marked decrease in size of dominant liver metastases on CT chest/abdomen \u2014 assessed as partial response.", "output": {"cancer_type": "HER2-positive breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR-", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old male with metastatic cutaneous melanoma; sequencing shows BRAF V600E. PD-L1 by immunohistochemistry 5%. Baseline staging consistent with stage IV disease with multiple pulmonary nodules. Started on combination targeted therapy with dabrafenib and trametinib. Achieved a partial response for approximately 7 months but developed radiographic progression with new hepatic lesions and treatment was discontinued.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression", "metastasis_site": "lung and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: 52-year-old woman underwent lumpectomy for a 2.5 cm invasive ductal carcinoma. Pathology: ER positive, PR positive, HER2 negative (IHC 1+), stage pT2N0 (stage IIA). Genomic profiling identified a PIK3CA H1047R mutation. Patient completed adjuvant whole-breast radiation and was started on adjuvant endocrine therapy with letrozole. At 12-month follow-up there is no evidence of disease on imaging and exam.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+, HER2 negative", "treatment": "lumpectomy; radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man diagnosed with metastatic colon adenocarcinoma, stage IV with multiple liver and pulmonary metastases. Tumor profiling showed KRAS G12D and microsatellite-stable (MSS). He was started on FOLFOX plus bevacizumab. After four cycles there is a 40% decrease in target lesions consistent with a partial response. Note: cetuximab was not used because of the KRAS mutation.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "partial response", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with cough and headaches. Workup revealed stage IV lung adenocarcinoma with multiple enhancing intracranial lesions. Molecular profiling of the primary tumor identified EGFR L858R. PD-L1 was reported at 10%. She was started on osimertinib 80 mg daily. Follow-up MRI and CT at 8 weeks showed decrease in size of the primary and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic prostate adenocarcinoma and extensive sclerotic bone metastases. Germline and somatic testing revealed a deleterious BRCA2 frameshift mutation; tumor assessed as HRD-positive. Prior lines included androgen deprivation and docetaxel. He was started on olaparib and has had stable PSA and imaging over 3 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (deleterious frameshift)", "biomarker": "HRD-positive", "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC with peritoneal carcinomatosis. Germline testing revealed BRCA2 c.5946delT (frameshift) and HRD-positive status. Patient underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with a partial response on CT, and was transitioned to olaparib maintenance with stable disease on the most recent scan.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 c.5946delT (frameshift)", "biomarker": "HRD positive", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "partial response to chemo; stable disease on maintenance", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old with metastatic cutaneous melanoma harboring BRAF V600E. PD-L1 by IHC was 5%. Patient started combination targeted therapy with dabrafenib and trametinib. After two months there is clear shrinkage of nodal disease but a new small cerebellar lesion was identified \u2014 overall a mixed/multifocal picture with predominant partial tumor regression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "mixed response (predominant partial response with new intracranial lesion)", "metastasis_site": "brain and regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with metastatic cutaneous melanoma. Molecular testing identified BRAF V600E and PD-L1 IHC was 1%. She initially received pembrolizumab but developed progression with new hepatic and pulmonary lesions. Therapy was switched to dabrafenib plus trametinib with a partial radiographic response seen on CT three months later.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal breast cancer, clinical stage IIIA. Tumor was ER positive, PR negative and HER2 amplified; targeted NGS identified PIK3CA E545K. She received neoadjuvant docetaxel plus carboplatin with trastuzumab and pertuzumab followed by surgery. Surgical pathology showed complete pathological response. No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel and carboplatin with trastuzumab and pertuzumab (neoadjuvant)", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with invasive ductal carcinoma of the right breast, clinical stage IIB (T2N1). ER/PR positive, HER2 amplified by FISH. Tumor hotspot panel identified PIK3CA H1047R. She underwent lumpectomy with sentinel node dissection followed by adjuvant chemotherapy (dose-dense AC then paclitaxel) and trastuzumab for one year. Surveillance imaging and mammography show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; dose-dense doxorubicin/cyclophosphamide then paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: 48-year-old woman with ER+/PR+ invasive ductal carcinoma of the left breast with HER2 amplification diagnosed 2022. She presented with progressive back pain; bone scan and MRI revealed multiple lytic metastases in the thoracic spine and pelvis. She received weekly paclitaxel with concurrent trastuzumab, followed by left mastectomy. Currently maintained on adjuvant trastuzumab q3w with documented radiographic decrease in size of bone lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-amplified, ER+/PR+)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab; mastectomy", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with metastatic lung adenocarcinoma (stage IV) in April. Molecular testing identified EGFR L858R. Baseline PD-L1 TPS was 10%. Brain MRI showed multiple enhancing lesions consistent with metastases. Patient started osimertinib 80 mg daily and after 8 weeks has a radiographic partial response with decrease in size of lung and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Imaging at diagnosis showed multiple intracranial lesions and lytic lesions in the spine consistent with metastatic disease. She was started on osimertinib 80 mg daily with significant symptomatic improvement and interval CT/MRI demonstrating a partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 70M with colorectal adenocarcinoma metastatic to liver. NGS: KRAS G12D mutation detected. He completed 6 cycles of FOLFOX with bevacizumab; CT today demonstrates essentially unchanged hepatic disease compared with prior\u2014no new extrahepatic mets. Biomarker panel (MSI/TMB) pending. Plan: continue FOLFOX/bevacizumab until progression or intolerance.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 39-year-old male with primary cutaneous melanoma of the left forearm. Underwent wide local excision and sentinel lymph node biopsy; one sentinel node positive. Final stage recorded as IIIA. Tumor PD-L1 reported at 5%. Limited panel did not identify actionable BRAF or NRAS mutations. Adjuvant nivolumab was initiated post-op and patient remains without radiographic evidence of disease on recent follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "wide local excision; sentinel node biopsy; adjuvant nivolumab", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 59-year-old with metastatic colorectal adenocarcinoma. Presents with multiple hepatic lesions on CT consistent with metastatic disease (stage IV). Molecular testing: KRAS G12D detected; MSI-stable. First-line therapy with FOLFOX plus bevacizumab resulted in disease control for 6 months with current CT showing stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with newly diagnosed lung adenocarcinoma presented with headaches. MRI demonstrated two enhancing lesions in the left frontal lobe consistent with metastases. Biopsy of the primary lung lesion confirmed adenocarcinoma, stage IV. Molecular testing returned EGFR L858R. PD-L1 TPS 10%. Patient started osimertinib and underwent stereotactic radiosurgery to the brain lesions. At first restaging CT there is interval decrease in pulmonary and intracranial disease burden.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presenting with metastatic colorectal adenocarcinoma with multiple liver metastases and a solitary pulmonary nodule. Molecular testing: KRAS G12D mutation; microsatellite stable (MSS). Clinical stage IV. He was started on first-line FOLFOX plus bevacizumab. CT after 3 cycles shows stable disease compared with baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma to the liver. Molecular panel: KRAS G12D detected. Patient received FOLFOX with bevacizumab for six cycles. CT at 12 weeks shows unchanged hepatic lesions compared with baseline. Microsatellite status not reported in this record.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma, BRAF V600E positive, with brain metastases and pulmonary nodules at diagnosis (stage IV). Initially started on dabrafenib plus trametinib with a partial response systemically but later intracranial progression treated with stereotactic radiosurgery. Subsequently switched to pembrolizumab; most recent imaging shows stable disease on immunotherapy. PD-L1 reported at 5% tumor proportion.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5% TPS", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; pembrolizumab", "response": "mixed response initially, now stable disease", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 69-year-old male with castration-resistant prostate adenocarcinoma with diffuse sclerotic and lytic bone metastases. PSA at presentation was 72 ng/mL. Patient is on continuous androgen deprivation therapy (leuprolide) and received docetaxel for 6 cycles with palliative radiation to a painful right femoral metastasis. Clinical course described as stable disease on most recent scans.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 72 ng/mL", "treatment": "androgen deprivation therapy (leuprolide); docetaxel; palliative radiation", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R positive; PD-L1 expression 10% by TPS. Brain MRI demonstrates two enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily with clinical improvement. Interval CT and MRI show shrinkage of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma (stage IV) with KRAS G12D mutation. Tumor was microsatellite-stable on PCR. Patient started on FOLFOX with bevacizumab and achieved disease control with best response listed as stable disease on CT chest/abdomen; later progression in the liver prompted change of therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery. Operative findings notable for diffuse peritoneal carcinomatosis. Germline testing positive for BRCA1 pathogenic variant. Post-op she completed 6 cycles of carboplatin and paclitaxel with CA-125 falling but still above normal; maintenance olaparib was initiated. CT pelvis shows decreased omental caking.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed colorectal adenocarcinoma, biopsy-proven stage IV with multiple hepatic lesions and bilateral pulmonary nodules. Molecular profile: KRAS G12D, microsatellite stable (MSS). He received FOLFOX plus bevacizumab as palliative systemic therapy. After 4 cycles the CT shows increase in size of hepatic metastases and more lung nodules consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed lung adenocarcinoma. She underwent right upper lobectomy (pT2aN0) and final pathology was stage IB. Molecular testing identified an EGFR exon 19 deletion. PD-L1 testing was not performed. She was started on adjuvant osimertinib 80 mg daily. Twelve-month surveillance CT chest shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IB", "gene_mutation": "EGFR exon 19 deletion", "biomarker": null, "treatment": "right upper lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with cutaneous melanoma, presenting with palpable cervical lymphadenopathy. Excisional biopsy confirmed metastatic melanoma in regional lymph nodes. Molecular testing demonstrated BRAF V600E. He underwent wide local excision and completion lymphadenectomy followed by adjuvant dabrafenib and trametinib. Post-treatment PET/CT shows no residual hypermetabolic disease. Stage III with nodal involvement.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 59-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R; ALK and ROS1 negative. PD-L1 tumor proportion score 10%. MRI brain showed two small metastases; PET/CT demonstrates osseous lesions. Started first-line osimertinib 80 mg daily in June; repeat CT at 8 weeks shows 45% reduction in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology oncology summary: Patient with nodular melanoma of the left calf, ulcerated primary, sentinel node positive (stage IIIC). Molecular assay positive for BRAF V600E. PD-L1 by IHC ~10%. Treated with combination targeted therapy dabrafenib plus trametinib; clinic exam and PET/CT at 4 months show complete metabolic response in the draining nodal basin. No distant visceral metastases identified.", "output": {"cancer_type": "melanoma (nodular)", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 ~10%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old F diagnosed with invasive ductal carcinoma of the left breast. Pathology: ER 90%, PR 80%, HER2 IHC 0 (HER2-negative). NGS panel identified a PIK3CA H1047R hotspot mutation. Clinical staging: T2N0M0, stage IIA. She underwent lumpectomy with sentinel node biopsy followed by adjuvant whole-breast radiation and was started on letrozole. Post-op CT and mammogram show no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER-positive, PR-positive, HER2-negative", "treatment": "lumpectomy; adjuvant radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent craniotomy for a right temporal mass; pathology consistent with glioblastoma (WHO grade IV). He completed concurrent radiotherapy with temozolomide per Stupp protocol. MGMT methylation status was not reported and molecular panel was not performed. Surveillance MRI at 6 months demonstrates new enhancing nodules consistent with progression.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgery followed by radiotherapy with temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with invasive ductal carcinoma of the breast, HER2 amplification by FISH, ER+/PR+. Presented with hepatic lesions on staging CT consistent with metastases. Clinical stage IV. She received docetaxel with trastuzumab and pertuzumab; follow-up imaging shows partial response in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: 39-year-old male with nodular melanoma of the left forearm, wide local excision and completion lymphadenectomy revealed metastatic melanoma in 3/12 axillary nodes (stage IIIB). Tumor harbors BRAF V600E. Patient received adjuvant dabrafenib and trametinib on protocol. Surveillance PET/CT six months post-op shows no metabolically active disease.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "adjuvant dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative core biopsy: invasive ductal carcinoma of the right breast, HER2 IHC 3+ and confirmed HER2 amplification by FISH. ER and PR negative. Germline testing identified a pathogenic BRCA1 variant. Clinical exam and imaging consistent with locally advanced disease, clinical stage IIIB with fixed primary and multiple ipsilateral axillary nodes. Neoadjuvant therapy administered: docetaxel + carboplatin with trastuzumab and pertuzumab for six cycles with marked tumor shrinkage consistent with a partial response on repeat imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "BRCA1 pathogenic (germline)", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old with locally advanced, unresectable pancreatic ductal adenocarcinoma (clinical stage III). Germline testing returned a deleterious BRCA2 mutation. Baseline CA19-9 was 980 U/mL. He received induction FOLFIRINOX with disease control and was transitioned to maintenance olaparib. Recent CT shows stable size of the pancreatic mass without distant spread.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III (locally advanced, unresectable)", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "CA19-9 980 U/mL (elevated)", "treatment": "FOLFIRINOX induction followed by maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma. Tumor genotyping identified KRAS G12D; MSI testing returned MSI-H. Baseline CT showed multiple hepatic metastases. He was initiated on FOLFOX with bevacizumab; restaging after 4 cycles demonstrated increase in size of dominant liver lesion and new peritoneal nodules consistent with progression, and therapy was changed to an irinotecan-based regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left breast invasive ductal carcinoma, clinical stage IIIB. Tumor is HER2 amplified by FISH, ER/PR negative. NGS identified PIK3CA H1047R. Neoadjuvant regimen: docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for 6 cycles. Underwent mastectomy with sentinel node biopsy \u2014 pathology reports no residual invasive carcinoma (pathologic complete response). No distant mets identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with locally advanced left breast cancer (clinical T3N2). ER positive, PR negative; HER2 amplified by FISH. Targeted NGS identified PIK3CA H1047R. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab. Surgical pathology after completion of neoadjuvant treatment showed no residual invasive carcinoma (pathologic complete response). No distant mets identified on staging PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with left breast invasive ductal carcinoma, pathologic stage IIA (pT2N0M0). ER and PR positive, HER2 amplification by ISH. Tumor NGS reported PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant weekly paclitaxel and completed 1 year of trastuzumab without complications. On 12-month surveillance the patient is clinically well with no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy, paclitaxel, trastuzumab", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 62-year-old man with lung adenocarcinoma diagnosed 2018. NGS of the tumor demonstrated EGFR L858R mutation. PD-L1 reported at 10%. Staging at diagnosis was IV with known brain and bone metastases. He started osimertinib 80 mg daily in 2019 and has had sustained tumor shrinkage on serial CT and MRI; most recent assessment documents a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular testing returned EGFR L858R positive; T790M negative. PD-L1 tumor proportion score ~10%. MRI brain showed two small enhancing lesions and PET/CT demonstrated osseous involvement of the thoracic spine. Patient was started on osimertinib 80 mg daily in January with symptomatic improvement. First restaging CT at 8 weeks demonstrated a partial response by RECIST criteria and treatment was continued.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with metastatic pancreatic ductal adenocarcinoma with multiple liver lesions (stage IV). Germline BRCA2 mutation identified. She received first-line FOLFIRINOX with initial stable disease on imaging for four months, then progression; subsequently started gemcitabine/nab-paclitaxel and received palliative radiation to dominant liver lesion. CA19-9 markedly elevated throughout disease course.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel; palliative radiation", "response": "stable disease followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman diagnosed with high-grade serous ovarian carcinoma, FIGO stage IV with peritoneal carcinomatosis and liver metastases. Germline testing identified a deleterious BRCA1 mutation. CA-125 was markedly elevated at presentation. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with radiographic partial response and is now on maintenance olaparib with stable disease on recent CT.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 62-year-old man with newly diagnosed lung adenocarcinoma. Staging PET/CT shows extensive disease consistent with Stage IV with multiple cerebellar metastases and lytic lesions in the T8 vertebral body. Molecular testing returned EGFR exon 21 L858R. PD-L1 tumor proportion score 10%. Patient started first-line osimertinib 80 mg daily with symptomatic improvement; repeat imaging at 12 weeks demonstrates partial response. Plans discussed for stereotactic radiosurgery to the dominant brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone (T8)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided invasive ductal carcinoma, ER negative, PR negative, HER2 amplified on FISH. Clinical presentation consistent with T4b N2 disease (fixed axillary nodes) \u2014 overall clinical stage IIIB. Patient completed six cycles of neoadjuvant trastuzumab and pertuzumab in combination with docetaxel with excellent tumor regression on imaging; preparing for breast-conserving surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab, docetaxel (neoadjuvant)", "response": "complete response (radiographic/clinical)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with newly diagnosed metastatic colorectal adenocarcinoma presented with multiple liver lesions. Tumor testing returned MSI-H and high tumor mutational burden. Given MSI-H status, he was started on pembrolizumab monotherapy. Follow-up scans at 12 weeks show no new lesions and minimal shrinkage consistent with stable disease. KRAS/NRAS testing not reported in clinic note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma. Biopsy showed EGFR L858R mutation. Staging PET/CT demonstrated multiple pulmonary nodules and an enhancing cerebellar lesion consistent with metastasis \u2014 overall stage IV. PD-L1 TPS reported at 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy; repeat imaging at 8 weeks demonstrates marked reduction in size of chest lesions and decreased enhancement in the cerebellar metastasis, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrates multiple pulmonary nodules and lesions in the cerebellum and T7 vertebral body. Biopsy confirmed adenocarcinoma; molecular testing returned EGFR L858R. PD-L1 TPS 20%. Patient started osimertinib 80 mg daily as first-line targeted therapy. Interim MRI brain after 8 weeks shows decrease in size of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (T7)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor sequencing identified KRAS G12D and microsatellite stable (MSS) status. Treated with FOLFOX plus bevacizumab; restaging CT after 3 months shows stable disease of the hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 55-year-old man with metastatic cutaneous melanoma to the lungs. Primary excised last year; recent PET/CT shows multiple pulmonary nodules consistent with metastatic disease. Tumor genomics reveal BRAF V600E mutation. He was started on combined BRAF/MEK targeted therapy (dabrafenib plus trametinib) and had symptomatic improvement; interval CT shows decrease in size of pulmonary nodules \u2014 partial response. PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with primary cutaneous melanoma that had a positive sentinel lymph node and completion node dissection confirming regional nodal involvement (stage III). Tumor sequencing detected BRAF V600E. She started adjuvant dabrafenib plus trametinib. Interval CT shows persistent adenopathy in the groin with no new visceral lesions; disease has been radiographically stable on targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib; completion lymph node dissection", "response": "stable disease", "metastasis_site": "regional lymph nodes (groin)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with metastatic pancreatic ductal adenocarcinoma and rising CA19-9. CT shows multiple hepatic metastases. She received gemcitabine plus nab\u2011paclitaxel but progressed after three cycles. Germline and somatic sequencing are pending and no actionable mutation has been identified to date.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op note: 71-year-old male status post right hemicolectomy for adenocarcinoma of the ascending colon. Final path stage: pT3N1 (stage III). Tumor sequencing detected KRAS G12D. Patient completed 6 months of adjuvant FOLFOX without major complications. Surveillance CT chest/abdomen/pelvis at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. Molecular testing demonstrated EGFR L858R. PD-L1 TPS 30%. Brain MRI at diagnosis showed multiple small enhancing lesions consistent with metastases. Started osimertinib 80 mg daily in January 2020. Interval chest CT after 3 months showed decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male status post right hemicolectomy for colon adenocarcinoma, pathologic stage III (pT3N1). Molecular testing demonstrates KRAS G12D mutation; BRAF wild-type; microsatellite stable (MSS). Adjuvant FOLFOX was initiated; CT at 3 months shows a new 2.1 cm lesion in the right hepatic lobe suspicious for metastasis. Oncology plan: continue FOLFOX and discuss addition of bevacizumab. Current assessment: stable disease on therapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX; bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Invasive ductal carcinoma of the breast, ER-negative/PR-negative, HER2 amplified on FISH, diagnosed after biopsy of a right breast mass. Staging workup consistent with de novo Stage IV disease with lytic lesions in the spine and pelvis. Tumor profiling identified a PIK3CA E542K alteration. Patient was started on docetaxel with trastuzumab and pertuzumab; follow-up PET/CT after 6 cycles shows no new lesions and stable appearance of known bony disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA E542K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, trastuzumab, pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic: 71-year-old presented with right upper quadrant pain; colonoscopy confirmed adenocarcinoma of the ascending colon. Staging CT shows multiple hepatic metastases. Tumor testing: BRAF V600E mutation and MSI-H (PCR). Tumor mutational burden reported as TMB-high. Given MSI-H status patient was started on pembrolizumab monotherapy. At 12-week restaging there is a sustained partial response in the liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology report: CT A/P with contrast for known colorectal malignancy. Multiple hypoattenuating hepatic lesions consistent with metastases, largest 3.2 cm in segment VI. Molecular testing on primary tumor: KRAS G12D positive; MSI stable. Patient is being treated with FOLFOX plus bevacizumab. Comparison to prior study shows no appreciable change in size of liver lesions \u2014 disease is radiographically stable. Impression: stage IV colorectal adenocarcinoma with liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic prostate adenocarcinoma, castration-sensitive at presentation (stage IV) with multiple sclerotic bone metastases. Germline testing returned pathogenic BRCA2 mutation. Baseline PSA 125 ng/mL. He was started on androgen deprivation with leuprolide plus docetaxel chemotherapy. After 3 months PSA has fallen and scans indicate radiographic stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 125 ng/mL", "treatment": "leuprolide (androgen deprivation) + docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed lung adenocarcinoma presented with cough and headaches. CT chest/abdomen showed a 4.2 cm right upper lobe primary and multiple lytic lesions in the thoracic spine. Brain MRI demonstrated two small enhancing metastases. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 15%. He was started on osimertinib 80 mg daily as first-line therapy. Restaging at 8 weeks showed decrease in size of the lung mass and resolution of one brain lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV cutaneous melanoma presenting with symptomatic brain metastases. NGS identified a BRAF V600E mutation; PD-L1 was 5% by IHC. He was started on the BRAF/MEK inhibitor combination dabrafenib and trametinib and underwent stereotactic radiosurgery to two cerebellar lesions. Follow-up showed regression of treated brain lesions but new small pulmonary nodules \u2014 mixed response with interval intracranial control and extracranial progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response (intracranial regression, new pulmonary progression)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old woman with left invasive ductal breast carcinoma, clinical T2N2M0 (Stage III). Core biopsy: ER positive, PR negative, HER2 amplified by FISH. She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab and then underwent a left modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab; left modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed prostate adenocarcinoma, Gleason 4+3=7. Workup showed clinical stage II disease confined to the prostate on MRI. Baseline PSA was 12 ng/mL. Multidisciplinary plan: external beam radiation therapy with concurrent androgen deprivation therapy (leuprolide) for 18 months. No metastatic workup abnormalities documented at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "external beam radiation therapy and leuprolide (androgen deprivation therapy)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 48-year-old woman with locally advanced breast carcinoma. Core biopsy: invasive ductal carcinoma, HER2 3+ by IHC, ER negative, PR negative. Clinical stage was IIIB with fixed axillary nodes and skin tethering. She received neoadjuvant carboplatin and weekly paclitaxel with dual HER2 blockade (trastuzumab and pertuzumab). Surgery following chemo revealed no residual invasive tumor on the resection specimen (pCR).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "neoadjuvant carboplatin and paclitaxel + trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. Staging consistent with stage IV disease with hepatic and pulmonary lesions on CT. Started targeted therapy with dabrafenib plus trametinib; interval scans at 3 months show ~60% reduction in target lesions (partial response) and therapy is being continued.", "output": {"cancer_type": "melanoma (cutaneous melanoma)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man with painless gross hematuria found to have muscle-invasive urothelial carcinoma of the bladder. Initial TURBT showed high-grade T2 disease and clinical nodal suspicion. He underwent radical cystectomy with bilateral pelvic lymph node dissection; final pathology returned pT3N1. No comprehensive molecular profiling was performed prior to surgery. Adjuvant gemcitabine/cisplatin was started. Early postoperative imaging shows no evidence of distant metastatic disease.", "output": {"cancer_type": "urothelial carcinoma of the bladder", "stage": "pT3N1 (stage III)", "gene_mutation": null, "biomarker": null, "treatment": "radical cystectomy; adjuvant gemcitabine/cisplatin", "response": "no evidence of disease on early imaging", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a core biopsy\u2013proven invasive ductal carcinoma of the left breast. Tumor profiling: HER2 IHC 3+ with FISH amplification, ER 80%+, PR 10%, PIK3CA H1047R on NGS. Clinical stage was cT2N0 (stage IIA). She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab and proceeded to lumpectomy with sentinel node biopsy showing no residual invasive carcinoma (pathologic complete response). Planned adjuvant endocrine therapy with tamoxifen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide; paclitaxel; trastuzumab; lumpectomy; tamoxifen planned", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "74-year-old male with metastatic prostate adenocarcinoma, Gleason 4+4=8. At diagnosis he had diffuse sclerotic and lytic bone metastases; stage IV. Germline testing identified a pathogenic BRCA2 variant. Baseline PSA was 220 ng/mL. He was started on androgen deprivation therapy combined with docetaxel x6 cycles. At 6-month follow-up PSA has fallen and imaging demonstrates stable osseous disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "PSA 220 ng/mL (baseline)", "treatment": "androgen deprivation therapy and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Core biopsy of right lower lobe confirmed adenocarcinoma; molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging CT and MRI show widespread disease with multiple pulmonary nodules and enhancing lesions in the cerebellum and lytic lesions in the femur \u2014 consistent with stage IV disease. Patient started osimertinib 80 mg daily three weeks ago; interval imaging demonstrates shrinkage of target lesions and decreased size of brain metastases, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 56-year-old female presents with stage IV lung adenocarcinoma. Molecular testing of the pleural biopsy returned EGFR L858R. PD-L1 by IHC reported at 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy. Baseline staging showed metastatic disease to brain and multiple vertebral bodies. First follow-up CT and brain MRI demonstrate a partial response with decrease in pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with documented BRAF V600E mutation. Initially received pembrolizumab with mixed radiographic findings but subsequently developed new lytic lesions in T10 and the proximal femur consistent with bone metastases. Patient was transitioned to dabrafenib plus trametinib; current clinical assessment documents progressive disease with worsening pain from osseous lesions. PD-L1 testing prior to immunotherapy showed 10% tumor expression.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology follow-up: 71-year-old male with metastatic prostate adenocarcinoma presenting with diffuse sclerotic bone metastases. He began androgen deprivation therapy with leuprolide plus early docetaxel 75 mg/m2 x6 cycles. PSA initially fell but has been rising over the past 3 months, suggesting biochemical progression. No genomic testing reported to date.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation therapy); docetaxel", "response": "initial PSA decline then biochemical progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 59-year-old female with high-grade serous ovarian carcinoma, stage IV at diagnosis with bulky peritoneal disease and lesions on the liver surface. Germline testing positive for BRCA1 pathogenic variant. Baseline CA-125 markedly elevated. She received frontline carboplatin and paclitaxel with bevacizumab, achieved a partial radiographic response but later developed progression on imaging after 10 cycles; switched to olaparib maintenance was planned but clinical progression noted.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IV", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel with bevacizumab; planned olaparib maintenance", "response": "progression (after initial partial response)", "metastasis_site": "peritoneum; liver surface"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant referral: 48-year-old woman with invasive ductal carcinoma, clinical stage IIIA (T2N1). Tumor was ER-negative, PR-negative and HER2 IHC 3+ with FISH-confirmed HER2 amplification. FoundationOne panel detected a PIK3CA H1047R mutation. She received neoadjuvant docetaxel in combination with trastuzumab and pertuzumab. Surgical pathology after mastectomy revealed no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with left breast invasive ductal carcinoma, clinical stage IIA (T2N0M0). Tumor was ER positive, PR positive and HER2 negative by IHC. NGS panel detected PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant doxorubicin/cyclophosphamide then paclitaxel and adjuvant radiation; started on letrozole. Post-treatment mammogram and MRI show no evidence of disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel node biopsy; adjuvant doxorubicin/cyclophosphamide then paclitaxel; radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with metastatic lung adenocarcinoma diagnosed in 2019 presenting with progressive headaches. Comprehensive genotyping detected EGFR L858R. PD-L1 tumor proportion score reported as 10%. Brain MRI demonstrated a solitary enhancing lesion suspicious for metastasis. He was initiated on osimertinib 80 mg daily and first follow-up CT/MRI showed reduction in lesion size consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic non-small cell lung cancer (lung adenocarcinoma) diagnosed July 2024. Comprehensive genomic profiling returned EGFR L858R. PD-L1 tumor proportion score 10%. Staged as IV with both brain and bone metastases on baseline MRI and PET. Patient was started on osimertinib in August and follow-up CT/MRI demonstrates a partial response with shrinkage of pulmonary and cerebral lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Presentation: 45-year-old female with de novo metastatic breast cancer. Core biopsy showed invasive ductal carcinoma, ER-/PR-, HER2 amplified by FISH. CT abdomen demonstrates a solitary 3.2 cm lesion in the liver consistent with metastasis. She received first-line trastuzumab, pertuzumab with docetaxel; imaging after 4 cycles documents a good tumor shrinkage (partial response) and improved LFTs. No somatic sequencing reported in clinic notes.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma (stage IV) presenting with multiple bilateral pulmonary nodules and a single cerebellar lesion. Molecular testing showed EGFR L858R and PD-L1 tumor proportion score 5%. He was started on osimertinib; restaging CT after 8 weeks demonstrated significant shrinkage of lung lesions but interval growth of the brain lesion. Impression: systemic partial response with intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "mixed response (systemic partial response with intracranial progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic pancreatic ductal adenocarcinoma presented with jaundice. Germline testing returned a pathogenic BRCA2 6174delT mutation and HRD-positive signature on tumor profiling. CA19-9 was markedly elevated at diagnosis. He received combination chemotherapy with FOLFIRINOX with partial symptomatic improvement, then transitioned to maintenance olaparib. Palliative radiation was given to a painful T12 bone metastasis.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT", "biomarker": "HRD positive; CA19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib; palliative radiation", "response": "partial symptomatic improvement on FOLFIRINOX, stable disease on olaparib", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma diagnosed after cytology and imaging. BRCA1 pathogenic variant identified on germline testing; homologous recombination deficiency (HRD) positive. Patient received debulking surgery followed by carboplatin and paclitaxel with good clinical response and was started on maintenance olaparib plus bevacizumab. Stage at referral not specified; follow-up imaging shows radiographic tumor shrinkage.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": null, "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD positive", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib + bevacizumab", "response": "radiographic tumor shrinkage (partial response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old male with cutaneous melanoma, BRAF V600E positive. Presented with symptomatic brain metastases and scattered pulmonary nodules. Treated with dabrafenib plus trametinib with rapid improvement in extracranial disease (initial partial response), but recent MRI demonstrates new intracranial lesions consistent with progression; stereotactic radiosurgery was performed to the new brain lesions. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "progression after partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Man age 62 with metastatic pancreatic ductal adenocarcinoma. Baseline staging: Stage IV with multiple hepatic lesions. Germline testing identified a BRCA2 pathogenic variant. CA19-9 was markedly elevated at presentation. He received FOLFIRINOX with good tumor shrinkage (partial response) and was switched to maintenance olaparib after 6 cycles. After 5 months on maintenance he developed radiographic progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma of the upper back; molecular testing identified BRAF V600E. PD-L1 IHC reported 10%. Patient received combination targeted therapy with dabrafenib plus trametinib for 12 months. PET/CT after therapy showed complete metabolic response and patient transitioned to surveillance.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of left breast: invasive ductal carcinoma, ER positive, PR positive, HER2 amplification by FISH. Clinical exam and imaging consistent with stage IIIB disease with matted axillary nodes. Next-generation sequencing identified a PIK3CA E545K mutation. Patient received neoadjuvant chemotherapy (dose-dense doxorubicin/cyclophosphamide x4 then paclitaxel x12) with concurrent trastuzumab; tumor size decreased but not completely\u2014documented partial response. No distant metastatic disease on PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive and TMB-high on genomic profiling. Baseline imaging showed multiple pulmonary nodules consistent with lung metastases. She was started on dabrafenib plus trametinib; PET/CT at 12 weeks demonstrates complete metabolic response of the pulmonary lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colorectal adenocarcinoma, stage IV, presenting with multiple liver and pulmonary lesions. Tumor profiling demonstrated KRAS G12D and TP53 R248Q. Tumor was MSI-H with high TMB (25 mut/Mb) and PD-L1 10%. He was enrolled on a combination regimen of FOLFOX + bevacizumab with concurrent pembrolizumab; first restaging after 3 months showed stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D, TP53 R248Q", "biomarker": "MSI-H; TMB-high (25 mut/Mb); PD-L1 10%", "treatment": "FOLFOX + bevacizumab + pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with newly diagnosed pancreatic ductal adenocarcinoma, locally advanced with liver metastases on CT. CA19-9 markedly elevated. No actionable mutations reported on the initial NGS panel. He was started on systemic chemotherapy with gemcitabine plus nab-paclitaxel for stage IV disease but after two cycles CT shows progression in the liver.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with a pigmented lesion on the left thigh; excision confirmed cutaneous melanoma. Pathology and nodal staging consistent with stage III disease after a positive sentinel node. Tumor NGS identified BRAF V600E mutation. He underwent wide local excision and was started on adjuvant targeted therapy with dabrafenib plus trametinib. At 8 months post-op surveillance CT noted new pulmonary nodules consistent with metastatic progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female diagnosed with metastatic pancreatic ductal adenocarcinoma with multiple hepatic lesions at presentation (stage IV). Germline testing identified a deleterious BRCA2 mutation. She received first-line FOLFIRINOX with a documented partial response on CT and was transitioned to maintenance olaparib. Latest imaging shows continued partial response of liver lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "germline BRCA2 mutation", "biomarker": null, "treatment": "FOLFIRINOX, maintenance olaparib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral letter: Patient with cutaneous melanoma, metastatic to the lungs, BRAF V600E positive on PCR. Tumor mutational burden reported as high (TMB-high, 20 muts/Mb). Began targeted therapy with dabrafenib and trametinib. After six months of therapy there is interval growth of multiple pulmonary nodules and new intracranial lesions \u2014 progression by RECIST criteria.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic triple-negative breast cancer (ER-/PR-/HER2-) found to carry a deleterious germline BRCA1 mutation. Initial presentation included painful hepatic lesions and lytic bone mets. Started on carboplatin + paclitaxel for cytoreduction; after 4 cycles partial radiographic response of liver lesions and symptomatic improvement of bone pain. Transitioned to maintenance olaparib after good chemo tolerance.", "output": {"cancer_type": "breast cancer (triple-negative)", "stage": "IV", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "ER-/PR-/HER2-", "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, stage IIIC. Germline testing identified a deleterious BRCA1 mutation and HRD-positive status. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel and was transitioned to olaparib maintenance. Recent imaging shows no radiographic evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "germline BRCA1 deleterious mutation", "biomarker": "HRD-positive", "treatment": "surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "no evidence of disease (complete response)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, stage IIIC at presentation with bulky omental carcinomatosis and ascites. Germline testing confirmed a deleterious BRCA1 mutation. She had neoadjuvant carboplatin/paclitaxel followed by interval debulking; started maintenance olaparib and has had a partial response with decreased CA-125 and reduced omental disease burden on CT.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "BRCA1 mutation (germline)", "treatment": "neoadjuvant carboplatin and paclitaxel, interval debulking, olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old with primary cutaneous melanoma. Wide local excision performed; sentinel lymph node positive and PET/CT demonstrates regional nodal involvement without distant mets. Tumor harbors BRAF V600E. Patient started adjuvant targeted therapy with dabrafenib and trametinib. PD-L1 testing was not performed. Clinical note documents resolution of palpable nodes and no evidence of residual disease on exam.", "output": {"cancer_type": "melanoma (cutaneous melanoma)", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response (clinical)", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, initially presented with weight loss and right upper quadrant pain. CT showed multiple liver lesions and colonoscopy confirmed sigmoid primary. Tumor testing: KRAS G12D mutation and MSI-H on PCR testing. Given MSI-H status, started on pembrolizumab. Despite therapy there was radiographic progression in the liver after three cycles.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with HER2-amplified invasive ductal carcinoma of the breast (ER negative, PR negative), clinical stage IIIB. Core biopsy NGS reported PIK3CA E545K. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with dramatic clinical shrinkage, then underwent mastectomy with residual 1 mm invasive focus on pathology consistent with a near-pathologic response. Patient continues adjuvant trastuzumab.", "output": {"cancer_type": "HER2-positive invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab; surgery; adjuvant trastuzumab", "response": "pathologic partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate cancer. Germline testing identified a deleterious BRCA2 mutation. Patient has extensive bony disease and rising PSA despite ADT and prior docetaxel. He was started on olaparib and has had a measurable reduction in bone pain and decline in PSA consistent with a partial radiographic/clinical response.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 (deleterious germline)", "biomarker": null, "treatment": "olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced breast cancer (invasive ductal carcinoma). Core biopsy: ER positive, PR positive, HER2 IHC 3+ with confirmed HER2 amplification by FISH. PIK3CA H1047R mutation detected on panel. Clinically staged as IIIA. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for six cycles followed by surgery. Pathology showed complete pathological response in the breast and nodes. No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 amplification (IHC 3+, FISH+)", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 44-year-old woman with locally advanced invasive ductal carcinoma of the left breast, ER positive, PR negative, HER2 amplified on FISH. Core biopsy genotyping identified a PIK3CA H1047R mutation. Clinical stage at presentation cT3N1 (stage IIIB). She completed six cycles of neoadjuvant docetaxel with dual HER2 blockade (trastuzumab and pertuzumab) and underwent mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology consult: 78-year-old male with castrate-na\u00efve prostate adenocarcinoma presenting with diffuse bony pain. PSA at presentation 142 ng/mL. Bone scan demonstrates extensive axial skeleton uptake consistent with osseous metastases. Patient started on leuprolide depot and docetaxel chemotherapy. No actionable somatic alterations were reported on the limited targeted panel.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 142 ng/mL", "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "not yet assessed", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male with metastatic colorectal adenocarcinoma diagnosed after colonoscopy. Molecular profiling: BRAF V600E mutation and MSI-H status. CT shows multiple liver lesions consistent with metastases. Started on pembrolizumab monotherapy given MSI-H; first restaging at 12 weeks demonstrated stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with pancreatic ductal adenocarcinoma, clinical stage IIB (T3N1M0). CA 19-9 elevated to 1200 U/mL. Chart notes state no actionable mutations were reported. She started gemcitabine plus nab-paclitaxel but developed hepatic metastases and radiographic progression after two cycles.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine; nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with colon adenocarcinoma now with multiple hepatic metastases. Tumor profiling shows KRAS G12D and microsatellite stable (MSS) status. He progressed on first-line FOLFOX and was started on FOLFIRI plus bevacizumab; most recent CT demonstrates interval enlargement of the liver lesions consistent with radiographic progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and course summary: 63-year-old male with metastatic colorectal adenocarcinoma, biopsy-proven, KRAS G12D. CT shows bulky hepatic and small-volume peritoneal implants. Tumor found to be MSI-H on PCR. He received 6 cycles of FOLFOX and bevacizumab with progression, then switched to pembrolizumab given MSI-H status and achieved disease stabilization for 9 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "progression on chemotherapy, stable disease on pembrolizumab", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC with diffuse peritoneal carcinomatosis and omental cake. Germline testing positive for BRCA1 mutation; HRD assay reported positive. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel. Initially had CA-125 decline and partial radiographic response, however repeat CT now shows new liver lesions consistent with progression and rising CA-125. Plan is to start olaparib maintenance following second-look surgery.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "progression", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op summary: 58-year-old female with high-grade serous ovarian carcinoma who underwent optimal debulking. Final stage IIIC. BRCA germline testing was pending at discharge but tumor HRD testing was positive. She received adjuvant carboplatin and paclitaxel x6 cycles with clinical CR, then was placed on maintenance olaparib in combination with bevacizumab per trial protocol.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HRD positive", "treatment": "carboplatin and paclitaxel; maintenance olaparib with bevacizumab", "response": "complete response (clinical)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old female with metastatic breast cancer, ER+/PR+, HER2 amplified on FISH. Liver metastases were documented on CT and biopsy confirmed breast origin. Tumor NGS showed PIK3CA E545K. She was started on first-line trastuzumab and pertuzumab with docetaxel; after 4 cycles imaging shows minimal interval change in hepatic lesions.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma diagnosed with synchronous liver and lung metastases (stage IV). Tumor profiling: MSI-H and TMB-high (22 muts/Mb); somatic KRAS G12C mutation reported. He received FOLFOX plus bevacizumab up front and was transitioned to pembrolizumab after confirmation of MSI-H. Recent scans show stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSI-H; TMB-high (22 muts/Mb)", "treatment": "FOLFOX and bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Presents with painful lytic lesion in the left femur requiring radiation. He was started on dabrafenib plus trametinib after prior exposure to pembrolizumab. Current CT and bone survey demonstrate stable disease. PD-L1 and TMB results are not reported in the available notes.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with metastatic lung adenocarcinoma diagnosed last year. NGS identified EGFR L858R. Staging at diagnosis was IV with known brain and bone metastases. PD-L1 by IHC reported 10%. She was started on osimertinib 80 mg daily in Jan 2024 with interval imaging demonstrating a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic cutaneous melanoma (stage IV) found to harbor BRAF V600E. Presented with multiple lung nodules and a solitary brain metastasis treated with stereotactic radiosurgery. Initial systemic therapy was combined BRAF/MEK inhibition (dabrafenib + trametinib) with a rapid symptomatic and radiographic partial response; intracranial progression occurred after 9 months and he was transitioned to combination immunotherapy with ipilimumab + nivolumab. PD-L1 was 5% and NRAS was reported wild-type.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; NRAS wild-type", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab; stereotactic radiosurgery", "response": "initial partial response then intracranial progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma, BRAF V600E positive, presenting with multiple cerebral metastases. He was started on combination targeted therapy with dabrafenib and trametinib with symptomatic improvement and radiographic decrease in size of brain lesions (partial response). Immunotherapy was considered but deferred due to steroid requirement for cerebral edema.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Letter: 71-year-old male with metastatic castration-resistant prostate cancer (stage IV) with extensive osseous metastases. Germline testing identified a pathogenic BRCA2 mutation. He was treated with olaparib after progression on androgen deprivation and abiraterone. Radiographic studies remained stable on olaparib but PSA rose slowly over 6 months; AR\u2011V7 testing was not performed.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "olaparib", "response": "radiographic stable disease (biochemical progression - rising PSA)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 45-year-old man with metastatic cutaneous melanoma. Initial molecular testing showed BRAF V600E mutation and high tumor mutational burden. He was started on dabrafenib plus trametinib with an initial partial response; however, restaging at 7 months revealed new hepatic lesions and increase in size of known brain metastases consistent with progressive disease. Plan to consider clinical trial or switch to immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old male with newly diagnosed lung adenocarcinoma. Staging workup demonstrated metastatic disease to the brain and mediastinal nodes (stage IV). Molecular testing returned EGFR L858R mutation. PD-L1 expression was 5%. He was started on osimertinib 80 mg daily with significant clinical improvement and interval imaging at 8 weeks showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic lung adenocarcinoma diagnosed in 2021. Molecular testing showed EGFR L858R (exon 21) and acquired T790M on progression. PD-L1 reported 10%. Initially started on osimertinib with a confirmed partial response, later developed progression in the brain and bone in 2023 and was switched to platinum-based doublet (carboplatin and pemetrexed). Currently receiving carboplatin/pemetrexed; symptomatic brain mets treated with stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed; stereotactic radiosurgery", "response": "partial response then progression", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with obstructing right-sided colon mass. Colonoscopy and pathology confirmed adenocarcinoma. CT chest/abdomen showed regional nodal enlargement without distant disease. Final pathology after right hemicolectomy: Stage III (pN2). Tumor was KRAS G12D mutated and microsatellite stable (MSS). Patient completed 6 months of adjuvant FOLFOX. Surveillance CT at 12 months shows no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 68-year-old male with metastatic colorectal adenocarcinoma, presents with progressive right upper quadrant pain. Imaging reveals multiple liver lesions consistent with metastases (stage IV). Tumor profiling identified BRAF V600E and the tumor is MSI-H with high tumor mutational burden. Given prior intolerance to oxaliplatin, patient was started on pembrolizumab monotherapy. Interval scans show stable disease per RECIST at 12 weeks.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic castration-resistant prostate cancer with extensive sclerotic bone metastases and rising PSA despite ADT. He received six cycles of docetaxel in combination with abiraterone acetate and prednisone; last imaging shows worsening bone scan uptake and new pelvic lymphadenopathy. Denosumab given for bone protection. No tumor genomic alterations were identified on commercial panel and routine biomarkers were not sent.", "output": {"cancer_type": "prostate cancer (castration-resistant, metastatic)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel + abiraterone acetate (with prednisone); denosumab", "response": "progression", "metastasis_site": "bone; pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with biopsy-proven lung adenocarcinoma presenting with progressive headache and fractures. Staging: IV with multiple brain metastases and lytic lesions in the femur. Comprehensive molecular testing detected EGFR L858R; PD-L1 was 10% by IHC. She was started on osimertinib and underwent stereotactic radiosurgery to the intracranial lesions. Follow-up CT and MRI at 8 weeks show shrinkage of the primary and intracranial disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female diagnosed with a 1.1 mm superficial spreading melanoma of the right forearm (Breslow 1.1 mm, no ulceration), clinical stage I. Wide local excision was performed with clear margins; no sentinel lymph node biopsy was done and no systemic therapy indicated. At 12-month follow-up the patient is without evidence of disease.", "output": {"cancer_type": "superficial spreading melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic lung adenocarcinoma with multiple bone and brain metastases. NGS identified EGFR L858R. PD-L1 tumor proportion score 10%. Started first-line osimertinib and interval imaging at 8 weeks demonstrated a partial response with decrease in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the breast. Core biopsy: ER negative, PR negative, HER2 amplified by FISH. Next-generation sequencing identified PIK3CA H1047R. She received neoadjuvant paclitaxel with concurrent trastuzumab followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab; surgery (lumpectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology consult: 45-year-old woman underwent excision of a pigmented lesion on the left calf. Pathology: superficial spreading melanoma, Breslow 0.8 mm, ulceration absent, sentinel lymph node negative \u2014 Stage I (T1b). PCR-based assay positive for BRAF V600E. Wide local excision with 1 cm margins performed; no adjuvant systemic therapy recommended. Patient to be followed with clinical exams and dermatologic surveillance; currently no evidence of disease on exam.", "output": {"cancer_type": "superficial spreading melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male presented with obstructing right-sided colonic mass. Pathology: colon adenocarcinoma, T3N1, pathologic stage III. Resection performed (right hemicolectomy). Tumor sequencing identified KRAS G12D; MSI testing was microsatellite stable. He completed 6 months of adjuvant FOLFOX with routine surveillance imaging showing no distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with recurrent cutaneous melanoma now with osseous involvement. Biopsy of a sacral lesion confirmed metastatic melanoma and sequencing detected BRAF V600E. PD-L1 IHC was 1%. He was started on dabrafenib plus trametinib and interval PET/CT after 6 weeks showed decreased FDG uptake in bone lesions consistent with a partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old female referred to thoracic oncology with newly diagnosed lung adenocarcinoma. NGS of the diagnostic biopsy detected EGFR L858R mutation. PD-L1 TPS 10%. Brain MRI demonstrates two enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily; first restaging CT at 8 weeks shows a 40% decrease in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with metastatic lung adenocarcinoma (Jan 2024). Core biopsy demonstrated an EGFR exon 19 deletion. PD-L1 TPS reported at 20%. Baseline staging showed multiple cerebral metastases. Patient was started on erlotinib 150 mg daily in combination with bevacizumab q3 weeks and received stereotactic radiosurgery to the dominant brain lesion. First restaging CT/MRI at 8 weeks shows reduction in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 20%", "treatment": "erlotinib + bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with recurrent cutaneous melanoma harboring BRAF V600E. Baseline CT showed multiple bilateral pulmonary nodules and MRI detected several subcentimeter brain metastases. Started on dabrafenib with trametinib combination therapy. At first restaging (~6 weeks) there is interval enlargement of pulmonary nodules and new satellite brain lesions; plan is to transition to pembrolizumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with sigmoid colon adenocarcinoma, pathologic stage III (pT3N1) after resection. Mismatch repair proteins intact on IHC (microsatellite stable). He completed 12 cycles of adjuvant FOLFOX and remains on routine follow-up with no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "microsatellite stable (MMR intact)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for locally advanced left breast cancer: core biopsy confirmed invasive ductal carcinoma, stage IIIB. HER2 amplification was noted by FISH; ER and PR were both positive. Tumor panel revealed a PIK3CA H1047R somatic mutation. Patient received three cycles of carboplatin and docetaxel with trastuzumab and pertuzumab with marked decrease in tumor size, but residual invasive disease was found at surgery (partial response to therapy). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "carboplatin and docetaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult letter: 45-year-old man with cutaneous melanoma of the back, initially resected; subsequent PET/CT revealed distant disease. BRAF mutation testing positive for V600E. Tumor mutational burden reported as TMB-high. Patient was started on dabrafenib and trametinib combination therapy. Imaging showed extracranial shrinkage but new symptomatic brain lesions with interval neurologic decline \u2014 overall intracranial progression noted on MRI.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "progression (intracranial)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman presented with a palpable right breast mass. Core biopsy: invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH. Staging scans identified multiple hepatic lesions; liver biopsy confirmed metastatic breast carcinoma. Next-generation sequencing revealed PIK3CA H1047R. Assigned stage IV disease. She received combination therapy with docetaxel, trastuzumab and pertuzumab with good tolerance. After 6 cycles CT shows marked shrinkage of liver metastases and decreased tumor markers.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel; trastuzumab; pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high-grade serous ovarian carcinoma, stage IIIC, found to carry a germline BRCA1 pathogenic variant. Tumor testing also demonstrated homologous recombination deficiency (HRD positive). She underwent primary cytoreductive surgery followed by six cycles of carboplatin and paclitaxel and is now on maintenance olaparib. Recent CT shows decreased omental and peritoneal nodularity consistent with partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline pathogenic variant)", "biomarker": "HRD positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib (maintenance)", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. Molecular profiling: KRAS G12D detected; microsatellite status reported as MSS. Presents with multiple hepatic lesions and omental peritoneal implants on CT. Started FOLFOX plus bevacizumab; initial CT at 3 months showed shrinkage of some liver lesions but new peritoneal nodules \u2014 overall progressive disease on restaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic prostate adenocarcinoma (castration-sensitive) with diffuse osteoblastic bone metastases. Clinical stage recorded as IV. He was started on androgen deprivation with leuprolide plus docetaxel chemotherapy. PSA trends have stabilized and cross-sectional imaging at 4 months shows stable osseous disease without new lesions.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old female presented for follow-up after breast-conserving surgery. Pathology revealed invasive ductal carcinoma, ER positive, PR negative, HER2 non-amplified; final pathologic stage pT2N0 \u2014 Stage IIA. Molecular testing detected PIK3CA E545K. She completed adjuvant whole-breast radiation and was started on adjuvant letrozole. Surveillance imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR negative; HER2 non-amplified", "treatment": "breast-conserving surgery; adjuvant radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with biliary obstruction found to have pancreatic ductal adenocarcinoma. CT abdomen showed multiple hepatic lesions consistent with metastases. Clinical stage documented as Stage IV at diagnosis. CA 19-9 markedly elevated. Due to poor performance status the team did not obtain tumor NGS; he was started on modified FOLFIRINOX with initial disease stabilization for 4 months and is currently receiving maintenance capecitabine with stable disease on serial imaging.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 markedly elevated", "treatment": "modified FOLFIRINOX followed by maintenance capecitabine", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the right breast (cT2N2). Core biopsy: ER positive 80%, PR negative, HER2 IHC 3+ with HER2 amplification confirmed by FISH. Germline testing identified a pathogenic BRCA2 frameshift. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab with excellent clinical response; subsequent mastectomy showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "BRCA2 frameshift", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma, BRAF V600E positive, with brain metastases noted on MRI. PD-L1 TPS reported as >50%. Initially treated with pembrolizumab but developed intracranial progression; patient was switched to dabrafenib and trametinib with significant shrinkage of intracranial and extracranial lesions (partial response).", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic lung adenocarcinoma presented with progressive cough and headaches. Initial molecular testing showed EGFR L858R and a concurrent MET amplification. PD-L1 tumor proportion score was 30%. He was started on osimertinib with good symptomatic relief but developed progression at 8 months with new bone and brain lesions. He was switched to combination chemo-immunotherapy with carboplatin and pemetrexed plus pembrolizumab. Imaging after 3 cycles showed a partial response of the pulmonary mass and reduction in brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 30%", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 55-year-old woman with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+; FISH confirmed HER2 amplification. Clinical stage IIIB. She received neoadjuvant docetaxel, carboplatin and trastuzumab (TCH). Mastectomy specimen showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with lung adenocarcinoma (right upper lobe) with leptomeningeal and osseous involvement. Staging imaging consistent with Stage IV disease. Tumor harbors EGFR L858R on NGS and PD-L1 TPS reported at 30%. He was started on osimertinib 80 mg daily; interval MRI and PET show shrinkage of intracranial and bony lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with metastatic cutaneous melanoma. Molecular testing detected BRAF V600E. Initially treated with pembrolizumab but progressed after 4 months and was switched to combination targeted therapy with dabrafenib and trametinib. Follow-up PET/CT shows marked shrinkage of multiple pulmonary nodules consistent with a partial response. Disease is stage IV with lung metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman diagnosed with high-grade serous ovarian carcinoma, stage IIIC, with omental and peritoneal carcinomatosis at presentation. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. Germline and somatic BRCA testing are pending. Follow-up CT shows persistent omental nodularity without new sites of disease, interpreted as stable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man presented with obstructing sigmoid tumor and underwent urgent sigmoid colectomy. Final pathology pT3N1 (stage III). Mismatch repair immunohistochemistry demonstrated loss of MLH1 and PMS2 consistent with MSI-H. KRAS testing was deferred and not performed. He completed adjuvant FOLFOX for 6 months and remains with no evidence of disease on surveillance CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H (loss of MLH1/PMS2)", "treatment": "surgery (sigmoid colectomy), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old with metastatic melanoma, BRAF V600E positive, TMB-high on genomic profiling. Initially treated with pembrolizumab but progressed after four cycles with enlarging extracranial and intracranial lesions. Switched to targeted therapy with dabrafenib and trametinib; follow-up MRI and PET demonstrate regression of several lesions and symptomatic improvement \u2014 overall partial response. Staging: stage IV disease with prior brain involvement.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male status post sigmoid colectomy for colon adenocarcinoma. Final pathology T3N1 (stage III). Molecular testing reported KRAS G12D. He completed a 6-month course of adjuvant FOLFOX and is currently on routine surveillance.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (adjuvant)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presenting with cough and headache. Staging workup revealed stage IV disease with multiple brain and bone metastases. Comprehensive NGS: EGFR L858R positive; ALK and ROS1 negative. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg PO daily in January 2024. Interval CT chest and brain MRI demonstrate shrinkage of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with stage IV lung adenocarcinoma harboring EGFR L858R mutation. Baseline PD-L1 tumor proportion score 60%. Brain MRI demonstrated two enhancing lesions consistent with metastases. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant right frontal lesion. Interval chest and brain imaging at 8 weeks showed decrease in size of both intracranial and pulmonary lesions, assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed March 2024. Molecular testing returned EGFR exon 19 deletion; PD-L1 tumor proportion score 5%. Staged IV on PET/CT with multiple brain and bone metastases. Started osimertinib 80 mg daily in June 2024. Interval MRI and CT demonstrate decrease in size of intracranial lesions and pulmonary nodules \u2014 assessed as a partial response at 8-week restaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with metastatic colorectal adenocarcinoma, stage IV at diagnosis with multiple liver lesions and peritoneal nodularity. Tumor NGS: BRAF V600E mutation. MSI testing returned MSI-H. Initial treatment was FOLFOX plus bevacizumab but CT after 3 months showed progression; pembrolizumab was started and disease has been stable on immunotherapy for the last 6 months.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Thin cutaneous melanoma on the left forearm, Breslow depth 1.2 mm, Clark level IV \u2014 clinical stage I. BRAF mutation testing positive for V600E. Patient underwent wide local excision with 1 cm margins; no adjuvant therapy planned and currently under surveillance with no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with stage IV colon adenocarcinoma. NGS demonstrates BRAF V600E mutation. Patient was started on FOLFOX plus bevacizumab; initial scans showed stable disease but most recent imaging documents progression with enlarging hepatic lesions. MSI testing returned MSS (microsatellite stable).", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma. Tumor genotyping reported KRAS G12D mutation. Patient was started on FOLFOX plus bevacizumab in the palliative setting. After four cycles interval CT showed enlarging hepatic metastases and new peritoneal nodularity; clinical course consistent with progressive disease. Mismatch repair protein expression intact on IHC (MSI-stable).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with high-grade serous ovarian carcinoma, clinical stage IIIC with peritoneal carcinomatosis. Germline testing identified a pathogenic BRCA2 variant and tumor profiling also showed a TP53 mutation; homologous recombination deficiency (HRD) was positive. CA-125 markedly elevated pre-treatment. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with bevacizumab, then started maintenance olaparib in combination with bevacizumab. Restaging CT and CA-125 after six months demonstrate complete radiographic response and normalization of tumor marker.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 pathogenic variant; TP53 mutation", "biomarker": "HRD positive; CA-125 elevated (pre-treatment)", "treatment": "cytoreductive surgery; carboplatin + paclitaxel + bevacizumab; maintenance olaparib + bevacizumab", "response": "complete radiographic response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old woman diagnosed with metastatic pancreatic ductal adenocarcinoma with liver involvement. Germline testing identified a BRCA2 pathogenic variant. She received induction FOLFIRINOX with good symptom control, transitioned to maintenance olaparib given the BRCA2 mutation; disease was stable on maintenance for approximately 8 months before imaging showed progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX then maintenance olaparib", "response": "stable disease then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up: 68-year-old man with intermediate-risk prostate adenocarcinoma (Gleason 3+4) confined to the prostate on MRI, clinical stage II. He completed definitive external beam radiation therapy with concurrent androgen deprivation therapy (leuprolide depot). PSA decreased from 8.7 ng/mL pre-treatment to 0.4 ng/mL at 12 months and there is no biochemical or radiographic evidence of progression.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "no evidence of progression / biochemical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical oncology note: Patient underwent wide local excision and sentinel lymph node biopsy for a high-risk cutaneous melanoma on the left forearm. Pathology: BRAF V600E positive. No distant disease on staging PET/CT. Adjuvant therapy with dabrafenib and trametinib was initiated. Currently there is no evidence of residual or metastatic disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology note: 68-year-old male found to have low-risk prostate adenocarcinoma on TRUS biopsy (Gleason 3+3 in one core), clinical stage T1c (stage I). PSA 6.2 ng/mL. Given low-volume, low-grade disease, patient elects active surveillance with PSA monitoring and periodic mpMRI.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "active surveillance", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2021. Molecular testing showed EGFR L858R mutation. PD-L1 by IHC was 10%. She was started on osimertinib 80 mg daily and had radiographic shrinkage of the dominant right frontal lesion and improvement in symptoms. Ongoing therapy with continued CNS response; extracranial disease has decreased on repeat CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response (CNS and extracranial shrinkage)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old man with metastatic cutaneous melanoma presenting with multiple pulmonary nodules on chest CT. Tumor testing positive for BRAF V600E. He was initiated on combination dabrafenib and trametinib; after 6 weeks there is symptomatic improvement and measurable decrease in size of pulmonary metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with T2N1 invasive ductal carcinoma of the right breast. Biopsy was ER positive, PR positive and HER2 amplified by FISH. PIK3CA E545K mutation reported on NGS. She received neoadjuvant weekly paclitaxel with trastuzumab, followed by breast-conserving surgery and sentinel lymph node biopsy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: HER2 IHC 3+, ER/PR negative. She received neoadjuvant carboplatin and paclitaxel with trastuzumab, then underwent mastectomy and axillary dissection. Pathology reported no residual invasive tumor \u2014 pathologic complete response. No distant disease identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 IHC 3+ (HER2 amplification)", "treatment": "carboplatin and paclitaxel with trastuzumab (neoadjuvant), surgery", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 48F with locally advanced left breast cancer, ER-/PR-, HER2 amplified on IHC/FISH. Clinical stage IIIB with fixed axillary nodes. Received neoadjuvant doxorubicin and cyclophosphamide x4 followed by weekly paclitaxel with trastuzumab. Underwent modified radical mastectomy; final pathology shows no residual invasive carcinoma (pCR). No distant mets identified on staging PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "doxorubicin and cyclophosphamide, paclitaxel, trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery. Final pathologic stage was IIIC with extensive peritoneal disease. Germline testing returned a pathogenic BRCA1 variant and tumor testing was HRD-positive. She completed adjuvant carboplatin and paclitaxel with a partial radiographic response and was transitioned to maintenance olaparib. Follow-up scans show residual nodularity along the peritoneal surfaces.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with advanced pancreatic ductal adenocarcinoma presented with progressive jaundice. Imaging revealed multiple hypodense lesions in the liver consistent with metastases. Germline testing returned BRCA2 pathogenic variant. She received FOLFIRINOX as first-line systemic therapy but progressed after 4 months and was transitioned to palliative care; maintenance PARP inhibitor was discussed but not effective. Current impression: stage IV pancreatic adenocarcinoma with hepatic metastases and clinical progression.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (pathogenic germline)", "biomarker": null, "treatment": "FOLFIRINOX; discussion of PARP inhibitor (olaparib) but not effective", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC, extensive peritoneal carcinomatosis. Surgical debulking performed followed by adjuvant carboplatin and paclitaxel. Germline testing returned positive for a deleterious BRCA1 mutation; tumor NGS also noted TP53 mutation. She completed chemotherapy and was started on maintenance olaparib with complete clinical and radiographic response documented at 9-month follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation; TP53 mutation", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old male with sigmoid colon adenocarcinoma initially treated with left hemicolectomy; pathology showed pT4aN2 disease. Subsequent imaging revealed multiple liver metastases consistent with stage IV disease. Tumor genomic testing: BRAF V600E positive and MSI-H on PCR. He received first-line FOLFOX with bevacizumab with progression at 4 months; switched to pembrolizumab due to MSI-H status and has had interval reduction in size of hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX; bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate cancer with bone-predominant disease. Tumor sequencing reported a pathogenic BRCA2 alteration. He received ADT with docetaxel previously but developed progression in the skeleton and rising PSA. He was started on olaparib 300 mg twice daily; restaging scans at 4 months show radiographic progression with new lytic bone lesions and increasing PSA.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "olaparib; prior androgen deprivation therapy and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal breast carcinoma, ER/PR negative, HER2 amplification by FISH and PIK3CA H1047R identified on NGS. Clinical stage was IIIB with fixed axillary nodes. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by modified radical mastectomy; pathology showed a complete pathologic response in the breast and no residual tumor in axillary nodes.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "neoadjuvant paclitaxel plus trastuzumab and pertuzumab, followed by surgery", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 47-year-old woman with left breast invasive ductal carcinoma, ER+, PR+, HER2 amplification by FISH. Clinical tumor stage T2N1 (stage IIB). She completed neoadjuvant trastuzumab and docetaxel for 6 cycles with excellent tumoral regression on exam and imaging. Post-treatment mammogram demonstrates no discrete residual mass. No evidence of metastatic disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and docetaxel (neoadjuvant)", "response": "complete clinical response (no discrete residual mass)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic colorectal adenocarcinoma. Primary tumor in sigmoid colon with multiple liver metastases on CT. Molecular profiling: BRAF V600E mutation detected; microsatellite status reported as MSI-stable. He was started on FOLFIRI with bevacizumab as first-line palliative chemotherapy. After four cycles there is interval enlargement of hepatic lesions and rising CEA consistent with disease progression.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-stable", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with stage I invasive ductal carcinoma of the breast, ER+/PR+/HER2+. She underwent lumpectomy with clear margins. Genomic testing identified a PIK3CA H1047R mutation. She completed adjuvant weekly paclitaxel and is receiving trastuzumab; currently no evidence of disease on most recent exam.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy followed by adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed with lung adenocarcinoma in March 2024. Staging workup demonstrated stage IV disease with osseous involvement. Next-generation sequencing identified EGFR L858R mutation. PD-L1 TPS was 10%. He was started on osimertinib 80 mg daily in April and tolerated therapy well. Interval CT and bone scan at 6 weeks show shrinkage of the pulmonary primary and decreased tracer uptake in the femoral lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic cutaneous melanoma found to harbor BRAF V600E on targeted sequencing. PET/CT showed multiple pulmonary nodules and subcentimeter hilar nodes. Treated with dabrafenib and trametinib combination. Clinically improved breathlessness and interval CT shows partial decrease in size of lung nodules though residual disease persists.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56F diagnosed with high-grade serous ovarian carcinoma in 2019. She underwent optimal cytoreductive surgery; pathology reported widespread peritoneal implants and disease consistent with stage IIIC. Germline testing was positive for BRCA1 185delAG. She completed adjuvant carboplatin and paclitaxel x6 cycles and was started on maintenance olaparib. Nine months into maintenance there was radiologic progression with new hepatic lesions and increased peritoneal disease; biopsy confirmed recurrent high-grade serous carcinoma.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "BRCA1 mutation", "treatment": "carboplatin/paclitaxel; maintenance olaparib", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with locally advanced pancreatic ductal adenocarcinoma, germline BRCA2 mutation identified on genetic testing. Clinical stage III disease. He was treated with FOLFIRINOX followed by consolidative chemoradiation; most recent CT shows no interval progression and disease is radiographically stable.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX followed by chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/procedure note: ulcerated nodular melanoma on right shoulder, Breslow depth 3.1 mm. Sentinel node biopsy positive; completion lymphadenectomy performed. Pathologic staging consistent with stage IIIB. BRAF V600E identified on mutation testing. Patient initiated adjuvant dabrafenib plus trametinib. Surveillance CT today shows no evidence of recurrent disease.", "output": {"cancer_type": "nodular melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; completion lymphadenectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, stage IV with multiple pulmonary nodules and mediastinal lymphadenopathy. Molecular PCR returned BRAF V600E positive. Started combination targeted therapy with dabrafenib and trametinib. After three months there is interval enlargement of several lung nodules and a new hypodense liver lesion consistent with progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic chemotherapy review: 63-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver mets. KRAS mutation testing not yet available. PD-L1 by IHC 1%. Started on FOLFOX plus bevacizumab three weeks ago with good tolerance. Interval CT at 3 months shows no new lesions and minimal decrease in target liver lesions\u2014assessment: stable disease. Will continue current regimen; surgical oncology will reassess for possible hepatic resection if response improves.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 1%", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man underwent sigmoid colectomy for a T3N1 adenocarcinoma (clinical stage III). Tumor NGS identified KRAS G12D. MSI testing showed microsatellite stable (MSS). He completed adjuvant FOLFOX x 6 cycles without significant complications and surveillance CT at 6 months demonstrated no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "adjuvant FOLFOX (oxaliplatin, leucovorin, 5-FU)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging scans show primary right upper lobe mass with multiple bone and brain metastases consistent with stage IV disease. Molecular testing returned EGFR L858R sensitizing mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and has had interval shrinkage of the primary and intracranial lesions on first follow-up \u2014 assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic lung adenocarcinoma presented with progressive dyspnea. Initial biopsy confirmed EGFR L858R; after 14 months on erlotinib he developed progression and repeat testing identified EGFR T790M. PD-L1 tumor proportion score 1%. Staging at progression: IV with bilateral pulmonary nodules and new liver lesions. He was switched to osimertinib with partial response for 8 months, then started combination platinum doublet (carboplatin and pemetrexed) plus pembrolizumab on clinical consideration for systemic control after oligoprogression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 1%", "treatment": "erlotinib; osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma first diagnosed 2019. Comprehensive genomic profiling identified EGFR L858R mutation. PD-L1 tumor proportion score approximately 10%. She was started on osimertinib 80 mg daily with prompt symptomatic improvement; first restaging CT and brain MRI demonstrated a partial response with shrinkage of the primary and multiple brain lesions. Current stage IV disease with known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female referred after biopsy-proven lung adenocarcinoma of the right lower lobe. Comprehensive NGS identified EGFR L858R mutation; T790M negative. PD-L1 by IHC reported as 60%. Staging consistent with stage IV disease with MRI-confirmed brain metastases and multiple hepatic lesions on PET/CT. Patient was started on osimertinib 80 mg daily and restaging CT at 8 weeks showed a marked decrease in size of target lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man diagnosed with metastatic lung adenocarcinoma in 2023. Biopsy confirmed EGFR L858R positive tumor. Staging showed stage IV disease with brain and bone metastases. PD-L1 IHC was 10%. He was started on osimertinib 80 mg daily and follow-up CT/MRI at 8 weeks demonstrated a partial response with decreased size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology follow-up: 57-year-old male with metastatic colorectal adenocarcinoma. CT chest/abdomen 09/2024 compared to 06/2024: multiple hepatic metastases are present but stable in size. Diagnostic report notes known KRAS G12D on prior molecular panel. Patient is receiving FOLFOX plus bevacizumab; oncology documents radiographic stable disease after 4 cycles. No new extrahepatic disease identified.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old premenopausal woman with invasive ductal carcinoma of the left breast, clinical T2N0, stage II. HER2 amplification by FISH and ER/PR positive. She received neoadjuvant paclitaxel with trastuzumab for 12 weeks, followed by lumpectomy and sentinel node biopsy. Pathology after surgery showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab, surgery (lumpectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant therapy for locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative; HER2 amplification by FISH. Clinical stage IIIB based on fixed axillary nodes. Patient received neoadjuvant paclitaxel with trastuzumab and pertuzumab x6 cycles followed by lumpectomy. Surgical pathology: no residual invasive carcinoma (pCR). No evidence of distant metastasis on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; lumpectomy (surgery)", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male presented with abdominal pain. Colonoscopy showed a sigmoid mass; biopsy: adenocarcinoma. CT chest/abdomen revealed multiple liver and pulmonary metastases consistent with Stage IV disease. Molecular testing: KRAS G12D. Tumor was MSI-H and TMB-high (reported 22 muts/Mb). He was started on FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab and pembrolizumab as part of a combination protocol. Interval imaging after three months shows overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (22 muts/Mb)", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) + bevacizumab + pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old woman with a 3.2 cm right upper lobe mass. VATS right upper lobectomy performed 6 weeks ago. Final pathology: invasive lung adenocarcinoma, stage IB (pT2aN0M0). Molecular testing returned EGFR L858R. PD-L1 tumor proportion score <1%. Patient started adjuvant osimertinib 80 mg daily. At 3-month follow-up there is no radiographic evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IB", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "VATS right upper lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing detected EGFR L858R; PD-L1 was 10% by IHC. He was started on osimertinib with an initial partial response for eight months but then developed symptomatic progression with new hepatic lesions. Patient was switched to carboplatin and pemetrexed combined with pembrolizumab as second-line therapy. MRI also demonstrated brain and bony metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed with pembrolizumab", "response": "progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old with widely metastatic cutaneous melanoma. Staging scans demonstrate multiple hepatic lesions and new CNS metastases. Molecular profiling detected a BRAF V600E mutation. Patient was treated with dabrafenib plus trametinib with an initial partial radiographic response, but interval imaging at 5 months documented progression; therapy was switched to pembrolizumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (subsequently pembrolizumab)", "response": "progression", "metastasis_site": "liver and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma confirmed on core biopsy of the right upper lobe. Molecular testing returned EGFR L858R (exon 21) with acquired T790M. PD-L1 tumor proportion score <1%. MRI of the brain demonstrated multiple enhancing lesions; bone scan consistent with osseous metastases. He was started on osimertinib and follow-up CT at 8 weeks shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R. PD-L1 tumor proportion score 10%. PET/CT staging consistent with stage IV disease with cerebellar metastases and lytic lesion in T8. Patient started on osimertinib 80 mg PO daily as first-line targeted therapy. Three-month brain MRI and CT chest/abdomen show decreased size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular testing by NGS on bronchoscopic biopsy detected EGFR L858R. PD-L1 tumor proportion score 10%. Brain MRI demonstrated two enhancing lesions; bone scan positive for multifocal osseous disease. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. CT chest/abdomen at 8 weeks shows marked decrease in primary tumor and reduction in brain metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old F with progressive dyspnea. CT chest/abdomen: primary lung mass with bilateral pulmonary nodules. Histology: lung adenocarcinoma. Molecular testing positive for EGFR L858R. PD-L1 reported at 10%. Brain MRI demonstrated two small metastases; bone scan positive for a lytic lesion. Patient started osimertinib 80 mg PO daily and underwent stereotactic radiosurgery to the intracranial lesions. At 3-month follow-up CT there is decrease in size of the pulmonary nodules and symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib and stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female diagnosed with a 2.0 cm invasive ductal carcinoma of the left breast. Pathology: ER 90%, PR 80%, HER2 negative by IHC; genomic assay found PIK3CA H1047R. Sentinel lymph node negative, final pathologic stage T2N0 (stage IIA). She underwent lumpectomy with clear margins, completed adjuvant radiotherapy and was started on tamoxifen. Last follow-up: clinical exam and mammogram without evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "lumpectomy, adjuvant radiotherapy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 48-year-old woman with newly diagnosed metastatic breast cancer. Core biopsy of left breast: invasive ductal carcinoma, HER2 IHC 3+ with FISH confirming HER2 amplification, ER negative, PR negative. Staging PET/CT shows multiple lytic lesions in the pelvis and thoracic spine consistent with bone metastases. Tumor genotyping revealed PIK3CA H1047R. Treatment plan: start combination trastuzumab and pertuzumab with docetaxel. First restaging after 3 cycles shows no new lesions and minor decrease in size of bony lesions \u2014 overall assessment: stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology correspondence: Patient is a 55-year-old male with metastatic cutaneous melanoma. BRAF V600E mutation positive. PD-L1 was 40% on prior testing. He was started on combination targeted therapy with dabrafenib and trametinib given bulky pulmonary nodules; after 6 weeks CT chest shows marked reduction in multiple lung lesions \u2014 documented partial response. No CNS disease on current imaging.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 40%", "treatment": "dabrafenib; trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old M presented with obstructive jaundice and was found to have pancreatic head adenocarcinoma with multiple liver lesions on staging CT consistent with metastatic disease (stage IV). Germline testing identified a deleterious BRCA2 mutation. CA19-9 markedly elevated at diagnosis. He received FOLFIRINOX with good initial tumor marker decline and radiographic partial response; transitioned to maintenance olaparib due to BRCA2 and then developed radiographic progression in the liver after 8 months of therapy.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious (germline)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; maintenance olaparib", "response": "initial partial response then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma, originally stage IV at diagnosis with a solitary pulmonary metastasis. Tumor testing returned BRAF V600E and MSI-H with high TMB. He received FOLFOX as induction therapy and was later switched to pembrolizumab given the MSI-H status. Unfortunately scans after 6 months on immunotherapy show radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX followed by pembrolizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with high-grade serous ovarian carcinoma presented with bulky pelvic disease and omental cake. At laparotomy optimal cytoreduction achieved; pathology consistent with stage IIIC disease with diffuse peritoneal involvement. Germline testing returned a pathogenic BRCA1 variant. CA-125 was markedly elevated preoperatively. She completed 6 cycles of carboplatin and paclitaxel with normalization of CA-125 and was transitioned to maintenance olaparib. CT imaging after chemo showed complete radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "elevated CA-125 (normalized after chemo)", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old woman with locally advanced invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR positive, HER2 amplified by FISH. PIK3CA E545K mutation detected on NGS. Clinical stage IIIB with fixed axillary nodes. She completed 6 cycles neoadjuvant therapy with trastuzumab + pertuzumab combined with docetaxel, followed by left modified radical mastectomy. Pathology reports a pathologic complete response (no residual invasive carcinoma). No distant mets identified.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "trastuzumab + pertuzumab with docetaxel (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man diagnosed with prostate adenocarcinoma, clinical stage IIB, Gleason 3+4 on biopsy. He underwent radical prostatectomy; postoperative PSA is undetectable. No somatic or germline molecular testing was performed at this time. Given adverse pathologic features, adjuvant external beam radiation was administered and short-course androgen deprivation (leuprolide) is planned. Current status: no evidence of disease on PSA monitoring.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation; planned leuprolide (androgen deprivation)", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. At presentation he had multiple pulmonary nodules and a solitary cerebellar metastasis (treated with SRS). He was started on combination targeted therapy with dabrafenib and trametinib. Initial restaging at 8 weeks documented a partial response, but he developed new hepatic lesions and clinical progression at 9 months.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression at 9 months", "metastasis_site": "lung, brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with obstructing ascending colon mass underwent right hemicolectomy. Pathology: T3N1 colon adenocarcinoma (stage III). MSI testing returned MSI-high. No actionable single-gene mutation was reported on the panel. Patient completed adjuvant FOLFOX for 6 months and remains disease-free on surveillance CT and CEA at 18 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI\u2011H", "treatment": "right hemicolectomy followed by adjuvant FOLFOX", "response": "disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with high-grade serous ovarian carcinoma. Presented initially as stage III with bulky adnexal mass and omental disease; subsequent surgery confirmed peritoneal carcinomatosis. Germline testing positive for BRCA1 mutation. She underwent primary debulking followed by adjuvant carboplatin and paclitaxel and achieved a clinical complete response; however, surveillance imaging now demonstrates recurrent peritoneal implants and rising CA-125.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "III", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "primary debulking surgery; carboplatin and paclitaxel", "response": "initial complete response then subsequent progression/recurrence", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-risk prostate adenocarcinoma (Gleason 4+5) initially staged as T3bN0M0 (clinical stage III). Patient underwent radical prostatectomy followed by adjuvant external beam radiotherapy and androgen deprivation with leuprolide. At 6-month follow-up PSA rose from undetectable to 0.6 ng/mL, consistent with biochemical recurrence; no radiographic metastases identified at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant radiotherapy; leuprolide (androgen deprivation)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with history of prostate adenocarcinoma treated with radical prostatectomy two years ago (pathologic stage pT2N0). He is on intermittent androgen deprivation with leuprolide after biochemical recurrence; PSA has been rising over the last 6 months. No metastatic lesions identified on bone scan and CT. Somatic NGS did not detect actionable mutations.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy, leuprolide (androgen deprivation therapy)", "response": "biochemical recurrence (rising PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with newly diagnosed lung adenocarcinoma, metastatic at presentation. Staging workup consistent with stage IV disease with known brain and bony lesions. Comprehensive genomic profiling returned EGFR L858R positive, ALK and ROS1 negative. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily; first restaging CT chest and MRI brain at 8 weeks demonstrated decrease in the size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, stage IV at presentation with a primary right-sided colon lesion and multiple liver metastases. Tumor profiling identified KRAS G12C mutation; microsatellite status MSS and PD-L1 <1%. Treated with first-line FOLFOX plus bevacizumab. After three cycles CT shows enlargement of hepatic lesions consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "MSS; PD-L1 <1%", "treatment": "FOLFOX; bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with locally advanced breast cancer, biopsy-proven invasive ductal carcinoma, ER-negative/PR-negative and HER2 amplification by FISH. Clinical stage IIIA with fixed axillary nodes. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab in combination with docetaxel for six cycles followed by surgery; pathology showed no residual invasive carcinoma (pCR).", "output": {"cancer_type": "HER2-positive breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant trastuzumab and pertuzumab with docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male status post sigmoid colectomy for adenocarcinoma now present with rising CEA and multiple hepatic lesions on CT. Pathology review: colorectal adenocarcinoma. Mutational analysis: KRAS G12D. MSI testing returned microsatellite stable (MSS). Clinical stage IV with liver-dominant metastases. Treated with FOLFOX plus bevacizumab; after 6 cycles there is interval growth of hepatic lesions and new right lobe lesion.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma, stage IV, found to have multiple pulmonary nodules on staging CT concerning for lung metastases. Molecular testing identified KRAS G12D. He was treated with FOLFOX plus bevacizumab. Interval scans show stable size of lung nodules and decreased CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma with liver-dominant disease. Molecular testing demonstrated KRAS G12D and MSI-H by PCR; tumor mutational burden reported as high. He initially received FOLFOX plus bevacizumab but had radiographic progression and was transitioned to pembrolizumab. After four cycles of pembrolizumab the most recent scans show stable disease in the liver lesions.", "output": {"cancer_type": "colorectal (adenocarcinoma)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old with unresectable cutaneous melanoma presenting with multiple intracranial metastases. Targeted testing revealed BRAF V600E. After whole brain radiation patient was started on dabrafenib and trametinib with symptomatic benefit and shrinkage of several lesions on MRI. No PD-L1 result available in chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of a left breast mass revealed invasive ductal carcinoma, ER-negative/PR-negative, HER2-amplified. NGS detected a PIK3CA H1047R mutation. Clinical staging was IIIB with extensive skin involvement. Patient received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab; underwent mastectomy. Final pathology reported no residual invasive carcinoma (pathologic complete response). Adjuvant radiation completed per plan.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab, surgery, radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with ER+/PR+, HER2-amplified invasive ductal carcinoma of the left breast, clinical stage IIA. Core biopsy also demonstrated PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node dissection followed by adjuvant paclitaxel and trastuzumab. At the 12-month postoperative visit there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy followed by adjuvant paclitaxel and trastuzumab", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old male diagnosed with sigmoid adenocarcinoma, pT3N1 after anterior resection (stage III). Tumor was MSI-H on PCR testing; KRAS and NRAS sequencing not performed at this time. Patient completed adjuvant FOLFOX for 6 months without complications and remains clinically well at 12-month follow-up.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (anterior resection); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, stage IV at presentation. Molecular profiling identified BRAF V600E. Baseline PD-L1 5%. Started targeted therapy with dabrafenib and trametinib; imaging at 8 weeks showed marked tumor shrinkage (partial response) but progressed again at 8 months with new hepatic and pulmonary nodules. Plan discussed to switch to immunotherapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression at 8 months", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Male, 62, with recurrent stage IV squamous cell carcinoma of the oropharynx with pulmonary nodules on chest CT. PD-L1 TPS reported 60%. No comprehensive genomic testing was performed. He was started on pembrolizumab monotherapy and after 2 cycles had a partial radiographic response of the lung nodules.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 TPS 60%", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consultation: 46-year-old female with left breast invasive ductal carcinoma. Tumor involves the chest wall with fixed axillary nodes on exam. ER positive, PR positive; HER2 amplification confirmed by FISH. Clinical stage IIIB. She completed 6 cycles of neoadjuvant chemotherapy (dose-dense doxorubicin/cyclophosphamide followed by paclitaxel) combined with trastuzumab and pertuzumab. Surgical pathology after lumpectomy shows minimal residual disease. No tumor genomic sequencing was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab and pertuzumab", "response": "partial response (minimal residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly symptomatic metastatic prostate adenocarcinoma. PSA markedly elevated; bone scan reveals multiple sclerotic lesions. No somatic or germline sequencing reported in chart. He was started on androgen deprivation with leuprolide and given six cycles of docetaxel for cytoreduction. Clinical exam and PSA are stable since treatment initiation.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC diagnosed after exploratory laparotomy. Germline testing found a deleterious BRCA1 mutation. She completed six cycles of carboplatin and paclitaxel with interval normalization of CA-125 and then was started on maintenance olaparib. Imaging after three months on maintenance shows no new lesions and CA-125 is stable.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 decline and normalization", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "stable disease / biochemical improvement", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology letter: Patient with metastatic cutaneous melanoma, BRAF V600E positive. Staging scans show multiple pulmonary nodules and two enlarging cerebellar metastases. Systemic therapy with dabrafenib and trametinib was started. Chest disease has regressed on therapy, but intracranial lesions progressed and required stereotactic radiosurgery. Treating team documents a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with newly diagnosed metastatic lung adenocarcinoma (left lower lobe). Staging workup consistent with stage IV disease with multiple brain and bone lesions on MRI and PET. Molecular testing returned EGFR L858R mutation; ALK and ROS1 negative. PD-L1 reported at 5%. Patient was started on osimertinib 80 mg daily. Initial imaging after 8 weeks showed partial response in the chest but subsequent MRI demonstrated progression in the brain and new lytic bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old male with metastatic lung adenocarcinoma, Stage IV at diagnosis with multiple pulmonary nodules and a 1.5 cm cerebellar lesion. Molecular testing returned EGFR L858R and PD-L1 10% (TPS). He was started on osimertinib 80 mg daily as first-line targeted therapy and has had a partial radiographic response after 8 weeks with shrinkage of the brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Localized prostate adenocarcinoma, Gleason 7 (3+4). Clinical stage II. Patient underwent radical prostatectomy and was started on adjuvant androgen-deprivation therapy with leuprolide. Post-operative imaging shows no evidence of metastatic disease. No molecular testing was performed per chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; leuprolide (androgen-deprivation therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female presented with weight loss and right upper quadrant pain. CT abdomen showed multiple hepatic lesions and colonoscopy confirmed adenocarcinoma of the sigmoid colon. Staging consistent with stage IV colon cancer. Molecular testing: KRAS G12D mutation; MSI testing: microsatellite stable (MSS). She received FOLFOX with bevacizumab and interval scans demonstrated a partial response in the liver metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX with bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 48-year-old female underwent breast-conserving surgery for a 2.3 cm invasive ductal carcinoma. Pathology: ER strongly positive, PR positive, HER2 negative (IHC 0). Margins negative. Final stage pT2 pN0 \u2014 clinical stage IIA. Patient started adjuvant tamoxifen and radiation. No clinical or radiologic evidence of distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; adjuvant tamoxifen; radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 67-year-old female with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery. Intra-op findings included extensive peritoneal carcinomatosis. She completed six cycles of adjuvant carboplatin and paclitaxel with normalization of CA-125 and no radiographic disease on CT at 12 week follow-up. Germline and somatic BRCA testing results are pending and not available in the chart at this time.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery; carboplatin + paclitaxel", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old woman with newly diagnosed lung adenocarcinoma. Staging CT and MRI confirm Stage IV disease with multiple brain metastases and diffuse osseous involvement. Molecular testing returned an EGFR exon 19 deletion; PD-L1 TPS 10%. She was started on osimertinib 80 mg daily with palliative whole-brain radiation to symptomatic lesions. Follow-up imaging at 8 weeks showed reduction in size of both intracranial and pulmonary lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib (plus whole-brain radiation)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old premenopausal woman with locally advanced breast cancer (cT3N2). Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. She received neoadjuvant carboplatin and docetaxel with trastuzumab for 4 cycles and then underwent mastectomy. Final pathology: no residual invasive carcinoma identified (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive, PR negative", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab; mastectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 69-year-old man diagnosed with metastatic colon adenocarcinoma, primary in the sigmoid colon. Staged as IV with multiple hepatic lesions on CT. Molecular testing identified a KRAS G12D mutation; microsatellite testing was not indicative of MSI (MSS). He was treated with FOLFOX plus bevacizumab as first-line therapy but restaging at 3 months showed interval growth of liver lesions consistent with radiographic progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic pancreatic ductal adenocarcinoma, diagnosed as Stage IV at presentation. Imaging demonstrates multiple hepatic lesions consistent with liver metastases. Broad NGS panel showed no actionable mutations. He was started on gemcitabine with nab-paclitaxel but restaging after 8 weeks demonstrates interval progression in the liver and clinical decline.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old with high-grade serous ovarian carcinoma, stage IIIC at debulking. Germline testing positive for BRCA1 c.68_69delAG (185delAG). Patient completed six cycles of carboplatin and paclitaxel with optimal cytoreduction and now on olaparib maintenance for BRCA\u2011associated disease. Peritoneal implants were documented at surgery; CA-125 normalized and CT shows no residual measurable disease \u2014 clinical complete response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.68_69delAG (185delAG)", "biomarker": "HRD-positive", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the breast, ER+/PR+, HER2 amplification on FISH, clinical stage IIIB. Core biopsy also showed PIK3CA H1047R on panel testing. She received neoadjuvant docetaxel and carboplatin with concurrent trastuzumab, proceeded to mastectomy, and final pathology demonstrated a pathological complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; surgery", "response": "pathological complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 3.5 cm left breast invasive ductal carcinoma. Biopsy: ER-positive, PR-positive, HER2 amplification by FISH. Clinical stage IIIA based on nodal involvement. She received neoadjuvant paclitaxel in combination with trastuzumab and pertuzumab. Mastectomy specimen showed no residual invasive carcinoma (pathologic complete response). No distant metastases on baseline CT.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old male with metastatic cutaneous melanoma, BRAF V600E positive, PD-L1 5% and TMB-high on NGS. Presented with pulmonary and hepatic metastases (stage IV). He was started on dabrafenib plus trametinib with initial tumor shrinkage, then later enrolled on combination immunotherapy with ipilimumab and nivolumab because of interval progression in a hepatic lesion. Overall the response is heterogeneous with shrinkage of some lung nodules but progression in the liver \u2014 described as a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab", "response": "mixed response", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with invasive ductal breast carcinoma, ER positive, PR negative, HER2 amplification on FISH. Presented with right upper quadrant pain and hip pain; CT shows multiple liver lesions and lytic bone metastases. Next-generation sequencing identified a PIK3CA E545K alteration. She was treated with weekly paclitaxel in combination with trastuzumab and pertuzumab. After three cycles the CT chest/abdomen/pelvis is unchanged compared with prior \u2014 overall assessment: stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel, trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "liver and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with biopsy-proven invasive ductal carcinoma of the right breast, clinically staged T2N1 (stage IIB). Tumor ER/PR negative, HER2 amplified by FISH. She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by mastectomy. Final pathology: no residual invasive carcinoma in breast or nodes (pCR). No distant disease on staging imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant), followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment course for locally advanced breast cancer: 48-year-old woman with invasive ductal carcinoma, ER-/PR-, HER2 amplification, clinical T3N1 (stage IIIA). Tumor sequencing identified PIK3CA H1047R. She completed 6 cycles of docetaxel, carboplatin and trastuzumab followed by breast-conserving surgery. Surgical pathology revealed no residual invasive carcinoma \u2014 pathological complete response. No distant metastases noted on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with high-grade serous ovarian carcinoma presenting with bulky omental caking and peritoneal nodularity. Surgical staging documented FIGO IIIC disease with diffuse peritoneal carcinomatosis. Germline testing positive for BRCA1 185delAG and tumor reported homologous recombination deficiency (HRD) positive. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel x6 cycles, with reduction in ascites and tumor burden; placed on olaparib maintenance thereafter. Best overall response after chemotherapy documented as partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "HRD positive", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum (omental)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left breast invasive ductal carcinoma, ER negative/PR negative with HER2 amplification by FISH. Staging PET/CT demonstrates osseous metastases involving the lumbar spine and pelvis. NGS revealed a PIK3CA H1047R mutation. Patient received weekly paclitaxel with trastuzumab; after four cycles CT and bone scan show stable disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: 48-year-old female with locally advanced left breast cancer, clinical stage IIIB. Core biopsy ER+, PR+, HER2 amplified by FISH; PIK3CA E545K detected on panel. She completed 6 cycles of neoadjuvant trastuzumab + pertuzumab with docetaxel and carboplatin, tolerated treatment well. Post-op pathology showed complete pathologic response (no residual invasive carcinoma). Adjuvant endocrine therapy planned.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER+; PR+; HER2 amplification", "treatment": "trastuzumab + pertuzumab + docetaxel and carboplatin; adjuvant endocrine therapy", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old woman with newly diagnosed lung adenocarcinoma. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 TPS reported at 30%. Staging workup demonstrated multiple enhancing lesions on brain MRI consistent with metastases and an FDG-avid right lower lobe primary. Clinical stage IV. Patient was started on osimertinib 80 mg daily with interval CT and MRI showing a partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary high\u2011grade serous ovarian carcinoma presenting with abdominal distension. At laparotomy there was bulky omental disease and diffuse peritoneal carcinomatosis; FIGO IIIC. Germline testing positive for BRCA1 mutation. CA\u2011125 was markedly elevated pre\u2011treatment. She received neoadjuvant carboplatin and paclitaxel plus bevacizumab followed by interval debulking surgery. CT after 6 cycles shows decrease in peritoneal implants consistent with a partial response.", "output": {"cancer_type": "ovarian high\u2011grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel with bevacizumab; interval debulking surgery", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 68-year-old male diagnosed with lung adenocarcinoma, stage IV with multiple pulmonary nodules and brain metastases. Molecular testing returned EGFR L858R; PD-L1 TPS 5%. He was started on first-line osimertinib and had an initial partial response for approximately 8 months, then CT/PET demonstrates systemic progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5% (TPS)", "treatment": "osimertinib", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma with multiple liver lesions on CT abdomen. Tumor sequencing identified a KRAS G12D mutation. He was initiated on FOLFOX plus bevacizumab for palliative intent and has demonstrated stable disease on interval imaging at 3 months. Stage IV disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with metastatic cutaneous melanoma. Initial therapy with nivolumab resulted in mixed response and clinical progression at 12 weeks with enlarging pulmonary nodules. Tumor was BRAF V600E positive and high tumor mutational burden reported. He was switched to dabrafenib/trametinib combination therapy with interval shrinkage of lung lesions and symptomatic improvement consistent with a partial response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "nivolumab (prior); dabrafenib + trametinib (current)", "response": "partial response (after switch)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with borderline resectable pancreatic ductal adenocarcinoma, clinical stage III. Germline testing returned a pathogenic BRCA2 mutation. She received induction FOLFIRINOX, consolidative radiation, and was enrolled on trial for olaparib maintenance; CA19-9 has declined and scans demonstrate durable stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; radiation; olaparib (maintenance)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 58-year-old man with recurrent right axillary melanoma, pathologic staging consistent with stage IIIC. NGS showed BRAF V600E alteration. He underwent wide local excision and completion lymphadenectomy and was started on adjuvant targeted combination therapy with dabrafenib plus trametinib. At six-month follow up new bilateral pulmonary nodules were identified and biopsy-proven metastatic melanoma \u2014 treatment recorded as progressive disease while on dabrafenib/trametinib.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer presenting with diffuse bone metastases (spine and pelvis). Germline testing identified a BRCA2 pathogenic variant. PSA at presentation 150 ng/mL. After progression on ADT and docetaxel he was started on olaparib with symptomatic improvement and falling PSA levels.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 pathogenic mutation", "biomarker": "PSA 150 ng/mL", "treatment": "olaparib", "response": "clinical and PSA response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology consult: 54-year-old with a pigmented lesion on the right forearm. Excisional biopsy consistent with superficial spreading melanoma, Breslow 0.8 mm, no ulceration. Sentinel node negative. Wide local excision performed. No adjuvant systemic therapy recommended.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with intermediate-risk prostate adenocarcinoma, Gleason 3+4, clinical stage II. He was treated with definitive external beam radiation therapy and concurrent androgen deprivation with leuprolide. PSA has declined post-treatment and there is no evidence of metastatic disease on staging CT and bone scan.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; leuprolide (androgen deprivation)", "response": "no evidence of metastatic disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with BRAF V600E metastatic melanoma presented with widespread disease. Staging: stage IV with liver and bone metastases at diagnosis; subsequent MRI revealed new small brain metastases. Treated with combination targeted therapy \u2014 dabrafenib plus trametinib. Initial scans at 6 weeks showed a mixed picture with marked regression of hepatic lesions (partial response) but new intracranial progression requiring whole brain radiation. Course described as initial partial response followed by intracranial progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; whole brain radiation", "response": "initial partial response then intracranial progression", "metastasis_site": "liver, bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic lung adenocarcinoma (diagnosed 03/2023). Molecular testing returned EGFR L858R and an acquired EGFR T790M. PD-L1 tumor proportion score 30%. Baseline staging showed brain and bone metastases. He initially had a good response to first-line osimertinib but developed progression after 9 months and was transitioned to carboplatin and pemetrexed in combination with pembrolizumab on a clinical protocol; follow-up CT shows partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 30%", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 185delAG variant and tumor genomic profiling confirmed HRD-positive status. She underwent optimal cytoreductive surgery followed by platinum-taxane chemotherapy and is currently on olaparib maintenance with stable disease on CT.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "HRD-positive", "treatment": "debulking surgery, carboplatin and paclitaxel followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with high-grade serous ovarian carcinoma who underwent optimal debulking. Final stage IIB with scattered peritoneal implants. Germline testing returned BRCA1 185delAG pathogenic variant. She completed six cycles of carboplatin and paclitaxel and CA-125 decreased substantially. Maintenance olaparib was discussed at oncology follow-up. No PD-L1 or other tumor biomarker testing was reported in the chart.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIB", "gene_mutation": "BRCA1 185delAG", "biomarker": null, "treatment": "carboplatin and paclitaxel; olaparib discussed", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male diagnosed with metastatic colorectal adenocarcinoma with dominant hepatic lesions. Staging was IV at presentation. Tumor NGS shows KRAS G12D; MSI testing returned MSI-stable. Baseline CEA was 120 ng/mL. He was treated with FOLFOX plus bevacizumab; after six cycles CT abdomen demonstrates interval growth of the liver lesions consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; CEA 120 ng/mL", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Aggressive metastatic colon adenocarcinoma in a 68-year-old woman with progressive right upper quadrant pain. Liver biopsy confirms metastatic colorectal cancer. Molecular panel: BRAF V600E mutation identified; MSI testing returned MSI-H. Initial therapy was FOLFOX plus bevacizumab; after mixed response with persistent hepatic lesions the patient was switched to pembrolizumab because of MSI-H status. Scans after 12 weeks show disease stabilization in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX; bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman underwent right hemicolectomy for a 4.5 cm ascending colon adenocarcinoma. Pathology: T3N0, margins negative; mismatch repair testing shows MSI-H (dMMR). No lymphovascular invasion. Final stage: Stage II. Given MSI-H and otherwise low-risk features the tumor board recommended observation without adjuvant chemotherapy. Six-month CT shows no evidence of disease. KRAS/BRAF testing was not available at the time of surgery.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II (T3N0)", "gene_mutation": null, "biomarker": "MSI-H (mismatch repair deficient)", "treatment": "right hemicolectomy (surgery); observation (no adjuvant chemotherapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with metastatic colorectal adenocarcinoma with multiple liver metastases. Tumor testing: MSI-H and TMB-high; BRAF V600E mutation was reported on PCR. She progressed on first-line FOLFOX with bevacizumab and was switched to a combination approach using pembrolizumab plus encorafenib and cetuximab. Recent CT shows no new lesions and modest reduction in dominant liver lesion consistent with stable disease on current combination therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab + encorafenib + cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a 2.1 cm invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR negative; HER2 IHC 3+ with HER2 amplification confirmed by FISH. Tumor panel detected PIK3CA E545K. Clinical staging T2N0 (AJCC Stage IIA). She underwent lumpectomy with sentinel node biopsy (nodes negative). Planned adjuvant therapy: 4 cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel, then 1 year trastuzumab. Surgical pathology showed no residual invasive carcinoma in breast or nodes (pathologic complete response). No distant disease identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive; PR negative; HER2 amplification (IHC 3+)", "treatment": "lumpectomy; adjuvant doxorubicin and cyclophosphamide then paclitaxel; trastuzumab", "response": "pathologic complete response (no residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the breast. Tumor was ER-positive, PR-positive and HER2 amplified on FISH. Clinical stage at presentation was IIIC due to fixed axillary and supraclavicular nodes; no distant disease identified. NGS panel identified a PIK3CA E545K mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab prior to surgery; post-treatment imaging demonstrated reduction in tumor size.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel, trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed with localized prostate adenocarcinoma, Gleason 3+4, clinical stage II. Treated with definitive external beam radiation therapy combined with androgen deprivation therapy (leuprolide). At 6-month follow-up PSA fell to undetectable levels. No imaging evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; leuprolide (androgen deprivation therapy)", "response": "biochemical response (PSA undetectable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (concise): 57M with cutaneous melanoma of the left forearm. Wide local excision performed; sentinel node positive \u2014 final staging IIIA. Tumor PD-L1 reported at 5%. BRAF testing negative. Adjuvant pembrolizumab initiated q3 weeks. Tolerating therapy with mild fatigue; repeat CT chest/abdomen stable with no distant mets to date.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (adjuvant)", "response": "stable disease / no distant metastasis", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic colorectal adenocarcinoma to the liver. Tumor profiling: KRAS G12D mutation identified; tumor is MSI-H by PCR. Pembrolizumab was initiated as first-line systemic therapy given mismatch repair deficiency. Recent scans show no new lesions but only minor shrinkage of hepatic metastases.", "output": {"cancer_type": "colorectal (adenocarcinoma)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease / minor shrinkage", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging workup consistent with Stage IV disease with multiple enhancing brain metastases on MRI. Molecular testing: EGFR L858R detected; PD-L1 tumor proportion score ~5%. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to two lesions. On first restaging CT and brain MRI after 8 weeks, there is a decrease in size of pulmonary primary and intracranial lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with stage IV colorectal adenocarcinoma with multiple liver lesions. Tumor genotyping: KRAS G12D; tumor reported MSI-H on immunohistochemistry. He was started on FOLFOX with bevacizumab as first-line systemic therapy. After three cycles imaging shows increase in size and number of hepatic metastases consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with recurrent cutaneous melanoma. Molecular testing positive for BRAF V600E and tumor described as TMB-high. CT chest shows multiple bilateral pulmonary nodules consistent with metastatic disease. Patient started on dabrafenib plus trametinib; interval imaging demonstrates approximately 60% reduction in pulmonary nodules consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with lung adenocarcinoma in 03/2024. Staging demonstrated metastatic disease (stage IV) with multiple brain and bone lesions. Comprehensive NGS from the lung biopsy detected EGFR L858R. PD-L1 TPS reported as 10%. Patient was started on osimertinib 80 mg PO daily in April 2024. First restaging CT and MRI at 8 weeks showed reduction in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old diagnosed with metastatic cutaneous melanoma harboring BRAF V600E on molecular testing. Presented with a solitary brain metastasis treated with stereotactic radiotherapy and systemic targeted therapy with dabrafenib plus trametinib. PD-L1 testing was not performed. After three months of therapy new pulmonary nodules consistent with progressive disease were identified on chest CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; stereotactic radiotherapy", "response": "progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old male diagnosed with metastatic cutaneous melanoma. Imaging shows a single lytic lesion in the left femur consistent with bone metastasis. Molecular testing identified BRAF V600E. He was started on combination targeted therapy with dabrafenib and trametinib. Pain scores have improved and follow-up PET/CT demonstrates decreased metabolic activity of the femoral lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with metastatic breast cancer: core biopsy shows invasive ductal carcinoma, HER2 amplification by FISH, ER positive and PR positive. Tumor profiling identified a PIK3CA E545K mutation. She received first-line combination trastuzumab, pertuzumab and docetaxel with concurrent chest wall radiotherapy. Surveillance CT shows marked reduction in primary and nodal disease but persistent small hepatic lesions; continuing trastuzumab/pertuzumab maintenance.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab and docetaxel; chest wall radiotherapy", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic pancreatic ductal adenocarcinoma presenting with obstructive jaundice and multiple liver lesions. Tumor profiling identified a pathogenic BRCA2 frameshift mutation. He was started on FOLFIRINOX; after two months had initial stable disease but progressed on restaging at three months with enlarging liver mets and rising CA19-9. He was transitioned to gemcitabine/nab\u2011paclitaxel and is being considered for olaparib maintenance given the BRCA2 alteration.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 frameshift", "biomarker": null, "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel; planned olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with stage IV cutaneous melanoma with multiple pulmonary nodules. Tumor sequencing positive for BRAF V600E; PD-L1 expression low at 3% and TMB-high reported on NGS. Started on combination targeted therapy with dabrafenib plus trametinib and has had a sustained partial response on serial imaging.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 3%, TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with obstructing sigmoid mass; colonoscopy confirmed moderately differentiated adenocarcinoma. Staging CT showed multiple hypodense lesions in both liver lobes and peritoneal nodularity consistent with metastatic disease. Molecular testing returned KRAS G12D and microsatellite stable (MSS). He was started on FOLFIRI plus bevacizumab; repeat imaging after three cycles showed enlarging hepatic lesions and new ascites.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Record: 49-year-old woman with ER-/PR- invasive ductal carcinoma of the left breast, clinical stage IIIA. Core biopsy showed HER2 amplification by FISH. She completed neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with concurrent trastuzumab, then underwent modified radical mastectomy. Pathologic complete response reported on surgical specimen; no nodes positive.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification, ER negative, PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide -> paclitaxel + trastuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 10%. Brain MRI showed two small parenchymal mets and PET-CT demonstrated osseous involvement. Patient was started on first-line osimertinib with good clinical improvement and radiographic partial response at first restaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female diagnosed with metastatic lung adenocarcinoma harboring an EGFR exon 19 deletion. Initial staging was IV with multiple enhancing brain metastases on MRI. PD-L1 by IHC reported at 10%. Started first-line osimertinib 80 mg daily; interval MRI after 8 weeks demonstrates decrease in size of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old premenopausal woman with biopsy-proven invasive ductal carcinoma of the left breast, clinical stage II (T2N1). ER and PR positive, HER2 amplified by FISH. No comprehensive NGS panel was performed. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles followed by lumpectomy. Final pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma in 2019. Tissue NGS returned EGFR L858R mutation. PD-L1 IHC reported 10%. Imaging shows multiple brain and bone metastases. After first-line platinum doublet she was started on osimertinib 80 mg daily; interval MRI at 8 weeks demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with lung adenocarcinoma presented with progressive headaches and new onset bone pain. Staging demonstrated metastatic disease to brain and spine consistent with Stage IV. Molecular testing returned EGFR L858R positive; PD-L1 tumor proportion score approximately 20%. He was started on osimertinib 80 mg daily with significant symptomatic improvement and interval CT showing a partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with newly diagnosed lung adenocarcinoma. Biopsy confirmed adenocarcinoma of the right upper lobe; molecular testing detected EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging workup consistent with stage IV disease with osseous and intracranial metastases. Patient started osimertinib 80 mg daily. Restaging CT and MRI after 8 weeks demonstrate decrease in size of lung and bone lesions and reduction of enhancing brain metastases consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 62-year-old male with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E; tumor mutation burden reported as TMB-high. Initially received pembrolizumab but developed intracranial progression and was switched to dabrafenib plus trametinib with rapid symptomatic improvement. Recent brain MRI shows resolution of most lesions but a new solitary enhancing focus concerning for progression \u2014 overall mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib (after pembrolizumab)", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old man with newly diagnosed lung adenocarcinoma, clinical stage IV. MRI brain showed multiple enhancing lesions consistent with metastases. NGS of the primary tumor identified EGFR L858R mutation; PD-L1 tumor proportion score reported as 5%. He was started on osimertinib 80 mg PO daily in July 2024. Follow-up CT and brain MRI at 8 weeks demonstrated marked reduction in size of target lesions and resolution of several intracranial nodules \u2014 overall assessed as a partial response. No cytotoxic chemotherapy administered to date.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (abbreviated): Patient with recurrent cutaneous melanoma. NGS of tumor identified NRAS Q61R mutation. PD-L1 testing was not performed. He received combination immunotherapy with nivolumab and ipilimumab; follow-up imaging showed new hepatic lesions consistent with disease progression and therapy was stopped. Clinical TNM/stage not documented in this note.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "nivolumab and ipilimumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colorectal adenocarcinoma. Liver-dominant disease on CT with multiple hepatic lesions. Tumor genotyping: KRAS G12D; immunohistochemistry shows mismatch repair protein loss consistent with MSI-H. First-line therapy initiated with FOLFOX plus bevacizumab. After three cycles disease assessment demonstrates stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H (mismatch repair deficient)", "treatment": "FOLFOX; bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer. Core biopsy: invasive ductal carcinoma, ER/PR negative, HER2 amplified by FISH. PIK3CA E545K mutation detected on NGS. Staging scans showed multiple sclerotic bone lesions and two hypodense liver lesions. She was started on trastuzumab and pertuzumab with docetaxel. After 4 cycles the CT shows no new lesions and minimal decrease in target liver lesion size; overall assessment by oncology is stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma found to harbor BRAF V600E. He was treated with nivolumab plus ipilimumab and had an initial partial response but subsequently progressed with new brain and pulmonary lesions. He was started on combination targeted therapy with dabrafenib and trametinib. Baseline PD-L1 was 5% and tumor mutational burden was reported as TMB-high. After 8 weeks of BRAF/MEK therapy there was a mixed response: regression of several lung nodules but progression of intracranial disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "nivolumab + ipilimumab; dabrafenib + trametinib", "response": "mixed response (regression in lung, progression in brain)", "metastasis_site": "brain, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with castration-resistant prostate cancer originally diagnosed in 2018. Underwent radical prostatectomy and salvage radiotherapy. Recent bone scan shows multifocal osseous uptake consistent with metastatic disease. Started leuprolide depot and enzalutamide; PSA decreased from 78 to 12 over 8 weeks. No tumor genomic testing performed to date.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide depot and enzalutamide", "response": "partial response (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the left breast (clinical T3N1). Tumor was ER positive, PR positive, and HER2 amplified on FISH; comprehensive genomic profiling identified a PIK3CA H1047R mutation. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab. Surgical pathology after mastectomy showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 amplification", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 paclitaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Tumor profiling identified EGFR L858R. PD-L1 expression reported as 10%. He was started on osimertinib 80 mg daily in January 2020. Follow-up CT and MRI show decrease in the size of the primary lung mass and regression of previously noted brain and bony lesions consistent with a partial response. Patient remains on targeted therapy without new sites of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma presenting with new neurologic symptoms. MRI brain revealed multiple enhancing lesions consistent with brain metastases. Tumor testing positive for BRAF V600E. He received stereotactic radiosurgery to the dominant intracranial lesion and was started on combination immunotherapy with nivolumab and ipilimumab. First follow-up MRI shows decrease in size of intracranial disease and symptomatic improvement. PD-L1 was not reported in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab and ipilimumab (plus stereotactic radiosurgery)", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with newly diagnosed metastatic colorectal cancer with multiple liver lesions and peritoneal implants. Tumor sequencing identified a BRAF V600E mutation and MSI-high status with high TMB. She initially received FOLFOX plus bevacizumab but progressed after 4 months; therapy was switched to pembrolizumab given MSI-H. After three cycles of pembrolizumab there was a radiographic partial response in the liver lesions.", "output": {"cancer_type": "metastatic colorectal cancer", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab (initial); pembrolizumab (subsequent)", "response": "partial response (to pembrolizumab)", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 67-year-old female with metastatic clear cell renal cell carcinoma presenting with pulmonary and osseous metastases. She has stage IV disease by imaging. No actionable driver mutation was identified on NGS and PD-L1 testing was not performed. She received combination immunotherapy with nivolumab plus ipilimumab. At first restaging the disease burden is unchanged from baseline \u2014 overall assessment: stable disease.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab plus ipilimumab", "response": "stable disease", "metastasis_site": "lung, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presented with right hepatic lobe lesions. Tumor genotyping demonstrates KRAS G12D mutation; mismatch repair intact (MSS) and PD-L1 negative. Patient was started on palliative mFOLFOX6 with bevacizumab. After 4 cycles CT abdomen shows stable hepatic disease with no new extrahepatic lesions and CEA plateauing.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MMR-proficient (MSS); PD-L1 negative", "treatment": "mFOLFOX6 and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast carcinoma. Core biopsy: invasive ductal carcinoma, ER-negative, PR-negative, HER2 IHC 3+ with confirmed HER2 amplification by FISH. Clinical stage IIIB with fixed axillary nodes. Neoadjuvant treatment: docetaxel/carboplatin every 3 weeks with trastuzumab and pertuzumab; patient underwent mastectomy showing a pathologic complete response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel and carboplatin with trastuzumab and pertuzumab (neoadjuvant), mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old male with metastatic colorectal adenocarcinoma. CT abdomen shows multiple liver lesions and omental nodularity. Molecular testing: BRAF V600E mutation detected; tumor characterized as MSI-H with high tumor mutational burden. He received first-line FOLFOX plus bevacizumab but progressed after 4 months. Switched to immunotherapy with pembrolizumab; follow-up imaging after 12 weeks demonstrates reduction in size of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab (first-line), then pembrolizumab (subsequent)", "response": "partial response to pembrolizumab", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology note: patient with metastatic colorectal adenocarcinoma presenting with synchronous liver metastases. Tumor genotyping: KRAS G12D positive; microsatellite testing reported MSI-stable. Initial systemic therapy consisted of FOLFOX with bevacizumab. Despite three months of therapy, CT shows new hepatic lesions and increase in size of prior tumors consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER/PR negative. FoundationOne identified PIK3CA H1047R. CT shows multiple hepatic lesions consistent with metastases; clinical stage IV. She received 6 cycles of trastuzumab, pertuzumab and docetaxel with symptom improvement and subsequent maintenance trastuzumab. Imaging after 4 months shows no measurable disease in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab, pertuzumab and docetaxel; maintenance trastuzumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: right hemicolectomy performed for obstructing mass. Pathology: moderately differentiated adenocarcinoma of the ascending colon, pT3 N1 (stage III). Molecular testing: KRAS G12D; microsatellite stable (MSS). Patient completed adjuvant FOLFOX for 6 months and remains without radiographic evidence of disease on surveillance CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "surgery (right hemicolectomy) followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with newly diagnosed colorectal adenocarcinoma presented with right upper quadrant pain. CT demonstrates multiple liver lesions and peritoneal implants. Colonoscopy with biopsy confirms adenocarcinoma; staged as IV. Molecular profiling: BRAF V600E mutation identified; tumor shows microsatellite instability-high (MSI-H) and is reported as TMB-high. Given MSI-H status patient was started on pembrolizumab. Interval imaging after 6 cycles shows decreased size of hepatic lesions consistent with partial response.", "output": {"cancer_type": "colon (colorectal) adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma to the brain. Tumor testing positive for BRAF V600E; PD-L1 approximately 5% and TMB-high. He was started on combination targeted therapy with dabrafenib plus trametinib and had an initial partial response in both intracranial and extracranial disease; later underwent stereotactic radiosurgery for a progressing cerebellar lesion and was switched to nivolumab upon clinical progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery; nivolumab", "response": "initial partial response then subsequent progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. EGFR L858R mutation identified on PCR-based testing. PD-L1 TPS 30%. Staged as IV at diagnosis with known brain and bone involvement. Patient started osimertinib 80 mg daily in January with symptomatic improvement; first CT and MRI at 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma, metastatic at presentation. Biopsy confirmed EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging MRI and PET/CT demonstrate multiple brain lesions and osseous metastases. Patient was started on osimertinib 80 mg PO daily; first restaging at 8 weeks shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing returned EGFR L858R mutation. PD-L1 by IHC was 5%. Staging at presentation was Stage IV with brain and bone metastases. She was started on osimertinib 80 mg PO daily in March 2020. Interval CT and brain MRI demonstrate decrease in size of pulmonary and intracranial lesions consistent with a partial response; patient remains on osimertinib with clinical improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 54-year-old with high-grade serous ovarian carcinoma, stage IIIC with peritoneal carcinomatosis and omental disease. Germline testing positive for a pathogenic BRCA1 mutation. CA-125 markedly elevated at diagnosis. Patient underwent optimal debulking followed by carboplatin and paclitaxel with bevacizumab; CT after six cycles showed a partial response and CA-125 downtrending. Plan for maintenance olaparib given BRCA1.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "CA-125 elevated", "treatment": "debulking surgery; carboplatin and paclitaxel; bevacizumab; planned maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Elderly male with metastatic cutaneous melanoma harboring BRAF V600E. Initial therapy with pembrolizumab produced a short-lived partial response but intracranial progression occurred after six months. PD-L1 was reported at 1% on the baseline biopsy. He was transitioned to dabrafenib and trametinib; follow-up imaging after three months demonstrated progression with new hepatic metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "pembrolizumab (initial), then dabrafenib + trametinib", "response": "progression", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old male with stage IV cutaneous melanoma. Molecular testing positive for BRAF V600E; tumor profiling also reported high tumor mutational burden (TMB-high). Brain MRI shows two metastatic lesions and CT abdomen demonstrates multiple hepatic metastases. He was started on dabrafenib plus trametinib; after 3 months imaging revealed new hepatic lesions and interval growth of brain metastases consistent with progression. Prior therapy included ipilimumab plus nivolumab with a short-lived response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; prior ipilimumab/nivolumab", "response": "progression", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Tumor genotyping: KRAS G12D mutation; MSI testing: MSI\u2011H. Staged as IV. Initial therapy was FOLFIRI with bevacizumab resulting in stable disease on first restaging CT after 8 weeks. Given MSI\u2011H status she was transitioned to pembrolizumab due to poor tolerance of chemotherapy; disease remained controlled but hepatic lesions are persistent.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFIRI + bevacizumab (initial); pembrolizumab (subsequent)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with castration-resistant prostate cancer. Staging shows bulky pelvic lymphadenopathy consistent with nodal metastases; no visceral disease identified. Comprehensive NGS did not reveal actionable alterations. He received docetaxel previously and is currently on abiraterone with prednisone but has clinical and PSA progression.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "abiraterone + prednisone (prior docetaxel)", "response": "progressive disease", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with borderline resectable pancreatic ductal adenocarcinoma underwent induction systemic therapy. He received four cycles of gemcitabine plus nab-paclitaxel followed by consolidative chemoradiation. Imaging after therapy shows a stable, unchanged primary mass without new distant disease. The multidisciplinary tumor board recommended continued surveillance and reassessment for resection \u2014 currently recorded as stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine plus nab-paclitaxel followed by chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with locally advanced pancreatic ductal adenocarcinoma (clinical stage III) found to have a germline BRCA1 mutation. He received FOLFIRINOX with biochemical improvement and then was transitioned to olaparib maintenance. Imaging over six months shows radiographic stable disease; CA19-9 decreased by 40%. PD-L1 testing was not performed.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": "BRCA1", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male referred for oncology after CT chest/abdomen/pelvis showed a 4.2 cm right lower lobe mass and multiple enhancing lesions in the cerebellum and T8 vertebral body. Biopsy confirmed lung adenocarcinoma, stage IV. NGS returned EGFR L858R; PD-L1 tumor proportion score 2%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the cerebellar metastasis. First restaging at 8 weeks shows decreased size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 2%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male never-smoker presenting with progressive cough and weight loss. CT chest/abdomen revealed a 4.2 cm right lower lobe mass with multiple bilateral pulmonary nodules. Core biopsy confirmed lung adenocarcinoma. Molecular panel positive for EGFR L858R. PD-L1 TPS reported at 10%. Baseline brain MRI identified two small enhancing lesions consistent with metastases. Staged as IV. Patient started osimertinib 80 mg PO daily; first restaging CT at 12 weeks demonstrated decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Persistent cutaneous nodules on the back were diagnosed as metastatic melanoma. NGS reported BRAF V600E mutation. Patient initially received dabrafenib plus trametinib with short benefit, then transitioned to combination immunotherapy with nivolumab and ipilimumab after progression. Recent MRI showed new enhancing intracranial lesions and clinical deterioration consistent with systemic progression.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then nivolumab and ipilimumab", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 55-year-old female with high-grade serous ovarian carcinoma, clinical stage IIIC with bulky omental disease. Germline and somatic testing detected a deleterious BRCA1 mutation and homologous recombination deficiency (HRD)-positive signature; CA-125 was elevated at diagnosis. She received neoadjuvant carboplatin and paclitaxel for three cycles with interval debulking surgery showing residual tumor deposits in the omentum and pelvis. She was restarted on chemotherapy and then placed on maintenance olaparib. Best overall radiographic response to systemic therapy was a partial response; disease remains greatest in the omental/peritoneal surfaces.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": "HRD-positive; CA-125 elevated", "treatment": "neoadjuvant carboplatin + paclitaxel; interval debulking surgery; maintenance olaparib", "response": "partial response", "metastasis_site": "omentum; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with high-grade serous ovarian carcinoma, optimal cytoreduction achieved at debulking (stage IIIC). Germline testing positive for a pathogenic BRCA1 mutation; tumor reported HRD-positive and CA-125 was elevated pre-op. She received adjuvant carboplatin and paclitaxel with bevacizumab, then was started on maintenance olaparib plus bevacizumab per discussion for BRCA-mutant, HRD-positive disease. Follow-up scans and CA-125 are now consistent with complete radiologic response and normalization of tumor marker.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation (germline)", "biomarker": "HRD-positive; elevated CA-125 (normalized on follow-up)", "treatment": "cytoreductive surgery; carboplatin + paclitaxel + bevacizumab followed by maintenance olaparib + bevacizumab", "response": "complete radiologic response; CA-125 normalized", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with progressive cough and headaches. Imaging revealed a 4.2 cm right upper lobe mass and multiple enhancing brain lesions. Biopsy of the lung confirmed lung adenocarcinoma. NGS from the tumor detected EGFR L858R. PD-L1 tumor proportion score 10% by IHC. Staging workup consistent with stage IV disease. Patient was started on osimertinib 80 mg daily in March; interval MRI shows decrease in size of intracranial lesions and improvement in pulmonary disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with obstructing sigmoid mass. Pathology: moderately differentiated adenocarcinoma, pT3N2 (Stage III). Molecular testing: MSI-high and KRAS G12D mutation. He underwent low anterior resection with regional lymph node dissection followed by 12 cycles of adjuvant FOLFOX. Recent CT abdomen/pelvis and CEA are within normal limits; clinician notes disease-free status on last visit.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "low anterior resection and adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with HER2-positive invasive ductal breast carcinoma. NGS detected PIK3CA H1047R and FISH confirmed HER2 amplification. She presented with multiple pulmonary nodules and was treated with weekly paclitaxel in combination with trastuzumab and pertuzumab. CT after 4 cycles showed interval decrease in size of the lung nodules consistent with a partial response. Documented as metastatic (stage IV) disease.", "output": {"cancer_type": "breast cancer (HER2-positive invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "paclitaxel, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic lung adenocarcinoma (diagnosed 2019). Comprehensive genotyping identified EGFR L858R. PD-L1 by IHC 10%; tumor mutational burden reported as TMB-low. He received first-line osimertinib with good systemic control but developed CNS progression and was transitioned to combination carboplatin + pemetrexed plus pembrolizumab. Most recent CT/MRI shows reduction in thoracic disease and shrinkage of several brain lesions. Metastatic sites include brain and bone; disease currently considered stage IV.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%, TMB-low", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma confirmed by core biopsy. Liquid biopsy detected EGFR L858R; PD-L1 by 22C3 reported at 10%. She was started on osimertinib 80 mg daily three months ago with marked symptomatic improvement in cough and fatigue. Interval CT chest shows shrinkage of pulmonary target lesions; MRI brain demonstrates a new 8 mm cerebellar lesion. Plan is to continue osimertinib and refer for stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic pancreatic ductal adenocarcinoma, biopsy-proven stage IV with multiple hepatic metastases. Germline and somatic testing identified BRCA2 6174delT (frameshift); HRD assay reported high homologous recombination deficiency. After platinum-containing induction he was transitioned to olaparib maintenance, but surveillance imaging at six months showed progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT", "biomarker": "HRD-high", "treatment": "olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma. NGS identified KRAS G12D mutation. CT abdomen/pelvis demonstrates multiple hypoattenuating lesions throughout the liver consistent with hepatic metastases. He initiated FOLFOX plus bevacizumab; after 4 cycles there is a partial radiographic response and CEA has fallen from 120 to 40 ng/mL. MMR testing reported as proficient (microsatellite stable).", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MMR-proficient (microsatellite stable); CEA elevated then decreased", "treatment": "FOLFOX + bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with lung adenocarcinoma in Jan 2024. Molecular testing from core biopsy returned EGFR L858R mutation; PD-L1 TPS 10%. Baseline staging showed brain and multiple bone metastases consistent with stage IV disease. She was started on osimertinib 80 mg PO daily as first-line targeted therapy in February. Interval CT and MRI in May demonstrate reduction in size of index lesions \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a palpable right breast mass. Core biopsy: invasive ductal carcinoma, HER2-amplified, ER-negative, PR-negative. NGS detected a PIK3CA H1047R mutation. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant combination therapy with docetaxel plus trastuzumab and pertuzumab for six cycles, followed by mastectomy. Pathology at surgery showed no residual invasive carcinoma (pCR). Adjuvant T-DM1 was planned.", "output": {"cancer_type": "HER2-positive breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel + trastuzumab + pertuzumab; mastectomy; planned adjuvant T-DM1", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with progressive right upper quadrant pain found to have multiple liver lesions on CT. Biopsy confirmed colon adenocarcinoma; tumor testing revealed BRAF V600E and microsatellite instability-high (MSI-H). Clinical staging consistent with metastatic (stage IV) disease. He was started on pembrolizumab due to MSI-H status and follow-up imaging showed decreased hepatic tumor burden with a partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma, EGFR L858R-positive, presented with progressive headaches. Baseline PD-L1 was 10%. MRI brain demonstrates multiple enhancing metastases; bone scan positive for osseous disease. She was started on osimertinib 80 mg daily six weeks ago. Interval CT chest/abdomen shows significant reduction in pulmonary and nodal disease compared with baseline. Assessment: partial response on osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man with metastatic urothelial (bladder) carcinoma, stage IV with pulmonary nodules. NGS identified an FGFR3 S249C alteration. He enrolled on an erdafitinib program and achieved stable disease as best response. PD-L1 status was not reported in the chart.", "output": {"cancer_type": "urothelial carcinoma (bladder cancer)", "stage": "IV", "gene_mutation": "FGFR3 S249C", "biomarker": null, "treatment": "erdafitinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male underwent low anterior resection for sigmoid adenocarcinoma. Final pathology: T3N1 (stage IIIB). CT chest/abdomen pelvis shows no distant metastatic disease. Multidisciplinary plan is adjuvant FOLFOX for 6 months. Molecular analysis not yet available at discharge; microsatellite status pending. Patient tolerating recovery well, currently clinically disease-free following resection.", "output": {"cancer_type": "colorectal adenocarcinoma (sigmoid)", "stage": "IIIB", "gene_mutation": null, "biomarker": null, "treatment": "low anterior resection; planned adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing on core biopsy detected EGFR L858R; PD-L1 IHC reported 10%. Staging at diagnosis was IV with multiple brain and bone metastases. She was started on osimertinib in 02/2020 with symptomatic improvement and interval partial response on CT chest and MRI brain. Received stereotactic radiosurgery to a solitary cerebellar lesion. Currently on osimertinib with ongoing partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a new diagnosis of invasive ductal carcinoma of the right breast, clinical stage IIA. ER 90% positive, PR 70% positive, HER2 IHC 0 (HER2 negative). She underwent breast-conserving surgery with sentinel lymph node biopsy; margins negative. Completed adjuvant doxorubicin/cyclophosphamide followed by paclitaxel, received adjuvant whole-breast irradiation and was started on letrozole. No genomic sequencing was performed. Restaging CT shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel lymph node biopsy; adjuvant doxorubicin and cyclophosphamide then paclitaxel; radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a 0.9 mm superficial spreading melanoma of the right forearm, sentinel node negative, staged as I. Tumor molecular testing detected BRAF V600E. Underwent wide local excision with negative margins; no systemic therapy was recommended. Clinical follow-up shows complete response and no recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "wide local excision (surgery)", "response": "complete response", "metastasis_site": "none"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with high-grade serous ovarian carcinoma, stage IIIC at presentation with bulky peritoneal disease and omental implants. Germline testing revealed a deleterious BRCA1 frameshift mutation; HRD testing positive. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Given BRCA1 positivity, maintenance olaparib was started. CA-125 normalized and CT showed no measurable disease at 6-month follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious frameshift)", "biomarker": "HRD positive", "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel, then olaparib maintenance", "response": "complete response / no measurable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 63-year-old male with metastatic colorectal adenocarcinoma (primary left colon). Imaging and biopsy confirm stage IV disease with multiple hepatic metastases. Molecular report: BRAF V600E mutation; MSI-H by PCR. PD-L1 <1%. He progressed after 6 cycles of FOLFOX plus bevacizumab and was transitioned to pembrolizumab in June 2023. Subsequent CTs show marked reduction in size and number of liver lesions consistent with a partial radiographic response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; PD-L1 <1%", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Wide local excision performed for a primary cutaneous melanoma with positive sentinel lymph node \u2014 pathologic stage IIIB. Tumor sequencing identified BRAF V600E. Patient received adjuvant dabrafenib and trametinib. At six months follow-up CT there are new pulmonary nodules consistent with metastatic disease; regimen was deemed to have failed with radiographic progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with metastatic colorectal adenocarcinoma diagnosed in 2023. Imaging showed multiple liver lesions consistent with metastases (stage IV). NGS revealed KRAS G12D mutation and tumor testing reported microsatellite stable (MSS). She completed six cycles of FOLFOX plus bevacizumab with CT scans showing no new lesions but minimal shrinkage of target hepatic metastases \u2014 best overall response documented as stable disease. Plan is maintenance 5-FU infusion.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old female with high-grade serous ovarian carcinoma presenting with ascites and peritoneal carcinomatosis. Debulking surgery followed by adjuvant carboplatin and paclitaxel was completed. Follow-up CT shows decreased omental disease burden. BRCA testing was not documented in the chart.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: wide local excision of a 1.8 cm pigmented lesion on the left calf with sentinel lymph node biopsy. Final pathology: cutaneous melanoma, Breslow depth 2.6 mm, ulceration present, 1/2 sentinel nodes positive \u2014 pathologic stage III. BRAF V600E identified on PCR-based assay. Patient was referred for adjuvant therapy and started nivolumab. Follow-up at 9 months shows no clinical or radiographic evidence of residual disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": "regional (inguinal) lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old male with newly diagnosed sigmoid colon adenocarcinoma found to have multiple pulmonary nodules on staging CT consistent with metastatic disease. Tumor genotyping reported KRAS G12D; MSI testing was stable (MSI-stable). He was initiated on FOLFOX plus bevacizumab. After three cycles restaging chest CT showed no interval growth of the lung nodules \u2014 overall stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old woman diagnosed with metastatic lung adenocarcinoma. Core biopsy confirmed EGFR L858R mutation. PD-L1 TPS reported as 1%. Staging workup consistent with stage IV disease with multiple brain and osseous metastases. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and MRI after 8 weeks showed decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with prostate adenocarcinoma Gleason 4+4, baseline PSA 18 ng/mL. Clinical stage II. He underwent radical prostatectomy followed by adjuvant external beam radiotherapy and androgen deprivation with leuprolide. Post-treatment PSA is undetectable and surveillance imaging shows no evidence of disease. Molecular sequencing was not performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 18 ng/mL (baseline)", "treatment": "radical prostatectomy, adjuvant radiotherapy, leuprolide", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with multiple liver lesions and a solitary lung nodule. Molecular testing identified KRAS G12D; MSI testing reported microsatellite stable (MSS). He was treated with FOLFOX plus bevacizumab in the palliative setting. After 4 cycles there was interval growth of hepatic lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man diagnosed with metastatic cutaneous melanoma, BRAF V600E positive, with multiple pulmonary nodules consistent with lung metastases (stage IV). He received combined BRAF/MEK inhibitor therapy with dabrafenib plus trametinib as first-line targeted therapy and had a complete metabolic response on PET-CT at 12 weeks. PD-L1 and TMB testing were not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 67-year-old female initially diagnosed with high-grade serous ovarian carcinoma, FIGO Stage IIIC. Germline testing positive for deleterious BRCA1 mutation. She relapsed 10 months after front-line debulking and platinum-based chemotherapy and received carboplatin + paclitaxel with a partial radiographic response. Given BRCA1 status she was transitioned to olaparib maintenance. Disease is predominantly in the omentum and peritoneal surfaces.", "output": {"cancer_type": "ovarian carcinoma (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": null, "treatment": "carboplatin and paclitaxel; olaparib (maintenance)", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female diagnosed with high-grade serous ovarian carcinoma with extensive peritoneal carcinomatosis and metastatic implants in the liver; FIGO stage IV. Germline testing positive for BRCA1 pathogenic variant. CA-125 at diagnosis was 780 U/mL. She received neoadjuvant carboplatin and paclitaxel with interval debulking surgery and was transitioned to maintenance olaparib. Post-treatment CT shows decreased peritoneal disease and liver lesions consistent with partial response.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IV", "gene_mutation": "BRCA1", "biomarker": "CA-125 780 U/mL", "treatment": "carboplatin and paclitaxel; interval debulking surgery; maintenance olaparib", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Emergency oncology summary: 68-year-old male with pancreatic ductal adenocarcinoma, originally treated with FOLFIRINOX for metastatic disease. Germline and somatic testing showed pathogenic BRCA2 mutation. CA19-9 remains markedly elevated at 2,500 U/mL. Imaging demonstrates progressive peritoneal and hepatic implants; he was switched to olaparib maintenance after initial response but recent scans show progression of disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "CA19-9 2500 U/mL", "treatment": "FOLFIRINOX then olaparib", "response": "progression", "metastasis_site": "peritoneum and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma presenting with multiple brain metastases. Staging consistent with stage IV disease. Molecular testing reported EGFR L858R and acquired EGFR T790M; PD-L1 tumor proportion score 5%. Patient was started on osimertinib in combination with bevacizumab and underwent stereotactic radiosurgery to dominant brain lesions. Follow-up CT and brain MRI at 8 weeks demonstrate a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 5%", "treatment": "osimertinib and bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man underwent radical prostatectomy for localized prostate adenocarcinoma (clinical stage II). Pathology reports Gleason 3+4. Post-op PSA initially became undetectable but has since risen to 0.9 ng/mL on two consecutive measurements. He received salvage external beam radiation and androgen deprivation with leuprolide for biochemical recurrence.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "rising PSA (biochemical recurrence)", "treatment": "radical prostatectomy followed by salvage radiation and leuprolide", "response": "biochemical recurrence / rising PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman diagnosed with locally advanced invasive ductal carcinoma of the right breast. Core biopsy: ER-/PR-, HER2 amplified by FISH. Clinical stage IIIC with fixed axillary nodes. She received neoadjuvant trastuzumab with weekly paclitaxel for 12 weeks followed by right modified radical mastectomy and adjuvant radiation. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No evidence of distant disease on PET/CT prior to surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER-/PR-", "treatment": "neoadjuvant trastuzumab and paclitaxel, surgery, adjuvant radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic cutaneous melanoma. Initial wide local excision for a primary forearm lesion but subsequently developed multiple cerebral metastases and bilateral pulmonary nodules; overall stage IV. Molecular testing reported BRAF and NRAS wild-type; PD-L1 testing was not performed. She was started on combination ipilimumab plus nivolumab. After three cycles MRI brain shows decrease in size of several metastases and PET/CT demonstrates reduced uptake in lung nodules consistent with a partial response to immunotherapy.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent lumpectomy for a 1.2 cm invasive ductal carcinoma, T1N0. Pathology: ER+, PR+, HER2-negative by IHC/FISH. Sentinel nodes negative. Final stage I. Plan is adjuvant endocrine therapy with tamoxifen for 5 years; no chemotherapy recommended. Post-op imaging shows no evidence of residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER+, PR+, HER2-negative", "treatment": "lumpectomy; adjuvant tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma. Molecular testing: BRAF V600E positive. PD-L1 expression 5%. He started combination targeted therapy with dabrafenib and trametinib; disease was radiographically stable for four months but subsequent CT showed enlarging hepatic and pulmonary lesions consistent with progression. Stage at presentation: IV.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progression after initial stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "HPI: 42 y/o male with pigmented lesion on left forearm. Excision showed malignant melanoma, sentinel node positive. Pathologic stage IIIB with clinically palpable axillary nodal disease. Tumor testing: BRAF V600E positive. Patient was treated with dabrafenib plus trametinib for unresectable nodal disease. Interval PET/CT documents near-complete metabolic response in the axilla.", "output": {"cancer_type": "malignant melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "near-complete metabolic response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female never-smoker presented with cough and headaches. Imaging showed a left upper lobe mass with mediastinal adenopathy and multiple enhancing cerebral lesions plus lytic spinal lesions. CT-guided core biopsy confirmed lung adenocarcinoma. Comprehensive molecular testing detected EGFR L858R and PD-L1 TPS 10%. She was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain met. Interval CT and MRI at 8 weeks show marked reduction of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 68-year-old male with metastatic colorectal adenocarcinoma with known KRAS G12C. CT shows multiple hepatic lesions and a solitary pulmonary nodule. He received first-line FOLFIRI with bevacizumab with initial disease control (stable disease) then clinical progression after 9 months. Enrolled on trial of a KRAS G12C inhibitor; most recent scan shows progression of hepatic disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFIRI and bevacizumab; KRAS G12C inhibitor (clinical trial)", "response": "initial stable disease then progression", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging CT/PET demonstrates multiple bilateral pulmonary nodules and a solitary 1.8 cm cerebellar metastasis. Biopsy confirmed adenocarcinoma; molecular testing returned EGFR L858R. PD-L1 immunohistochemistry 10%. Patient was started on osimertinib 80 mg PO daily; stereotactic radiosurgery was performed to the cerebellar lesion. Clinic note: marked decrease in cough and improved performance status after 8 weeks, repeat CT shows decrease in size of target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 48-year-old woman with ER+/PR+ HER2-amplified invasive ductal carcinoma of the right breast, clinical stage II (T2N1). She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab. Surgical pathology showed no residual invasive carcinoma in the breast or nodes \u2014 pathologic complete response. No radiographic evidence of distant disease preoperatively.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging demonstrated stage IV disease with brain and bone metastases. Molecular testing returned EGFR L858R and PD-L1 10%. He received first-line carboplatin and pemetrexed for 4 cycles with symptomatic improvement, then was transitioned to osimertinib after detection of EGFR sensitizing mutation. Most recent scans show a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "carboplatin and pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old with metastatic colorectal (rectosigmoid) adenocarcinoma presenting with multiple hepatic lesions. Initial molecular testing identified BRAF V600E; MSI testing was stable. He received first-line FOLFOX with bevacizumab but had progression in the liver after 4 months. Therapy was changed to encorafenib plus cetuximab with interval CT showing reduction in hepatic tumor burden.", "output": {"cancer_type": "colorectal adenocarcinoma (rectosigmoid)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab; later encorafenib + cetuximab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with right-sided colon adenocarcinoma treated with right hemicolectomy. Pathology staged as T3N0 (stage II). Tumor testing: MSI-H by PCR and BRAF V600E mutation on NGS. Given MSI-H and negative nodes, multidisciplinary team elected surveillance without adjuvant chemotherapy. Patient remains clinically well at first post-op visit.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy (surgery) \u2014 surveillance, no adjuvant chemotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic colorectal adenocarcinoma, testing reported MSI-H. Baseline CT shows multiple liver lesions consistent with metastatic disease (stage IV). Given MSI-H status, patient started pembrolizumab monotherapy as first-line treatment. First restaging at 12 weeks showed no new lesions and overall measurements stable. RAS panel was indeterminate / not reported on the current specimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, stage IIIC. Pre-op CA-125 was 820 U/mL. Patient underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel x6 cycles. Post-treatment CT shows decrease in peritoneal implants and falling CA-125 \u2014 partial response. No tumor genomic testing performed.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated (820 U/mL)", "treatment": "carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with widely metastatic cutaneous melanoma (numerous pulmonary and hepatic lesions). Molecular testing positive for BRAF V600E. Staged as stage IV at diagnosis. Patient was started on targeted therapy with dabrafenib plus trametinib; immunotherapy deferred because of symptomatic disease burden. At first restaging after 8 weeks there was a dramatic reduction in lesion size (>70%), consistent with a brisk partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib", "response": "partial response", "metastasis_site": "lung; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 variant (BRCA1 c.68_69delAG). Underwent optimal debulking with residual pelvic nodules; peritoneal implants were noted at surgery. Completed 6 cycles carboplatin and paclitaxel with normalization of CA-125 and clinical complete response; started maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 c.68_69delAG", "biomarker": "CA-125 normalization", "treatment": "carboplatin and paclitaxel; olaparib (maintenance)", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with newly diagnosed metastatic prostate adenocarcinoma. Disease is hormone-sensitive but widely metastatic (stage IV) with multiple sclerotic bone lesions. Baseline PSA was 150 ng/mL. He was started on androgen deprivation therapy with leuprolide and received docetaxel x6 cycles. Genomic testing was deferred by the patient and no somatic mutation report is available. PSA has fallen significantly and imaging shows partial radiographic response in the spine.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 150 ng/mL", "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male underwent right hemicolectomy for adenocarcinoma. Final pathology: pT3N1 (stage III). Tumor testing returned MSI-H; RAS testing was not performed per report. He completed 12 cycles of adjuvant FOLFOX with routine surveillance CTs showing no recurrent disease to date.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (right hemicolectomy) and adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with prostate adenocarcinoma treated initially with radical prostatectomy and adjuvant radiation for high-risk disease. After biochemical recurrence he was placed on continuous androgen deprivation therapy with leuprolide. Over the next year PSA rose despite castrate testosterone levels and bone scan revealed multiple new osseous lesions consistent with metastatic castration-resistant prostate cancer (mCRPC). He was started on abiraterone plus prednisone but PSA continued to climb and clinical status declined.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "rising PSA (biochemical recurrence; castrate-resistant PSA progression)", "treatment": "radical prostatectomy; adjuvant radiation; leuprolide (ADT); abiraterone plus prednisone", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the breast (clinical stage IIIB). Core biopsy demonstrated HER2 amplification by IHC/FISH, ER 10% positive, PR negative. NGS panel detected a PIK3CA H1047R mutation. She received neoadjuvant combination therapy with trastuzumab, pertuzumab and docetaxel for six cycles with excellent tumor shrinkage, followed by mastectomy which showed a pathologic complete response. No distant mets identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive (10%), PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic lung adenocarcinoma (stage IV) found to harbor EGFR L858R on tumor sequencing. PD-L1 tumor proportion score 5%. Baseline staging showed multiple brain metastases and lytic lesions in the lumbar spine. Patient started osimertinib 80 mg daily; first restaging CT chest and MRI brain demonstrate a partial response with shrinkage of the primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic cutaneous melanoma presented with multiple pulmonary nodules and several enhancing brain lesions. Stage IV disease. Tumor genomics show BRAF V600E. He was treated initially with pembrolizumab for six months but progressed intracranially. Switched to dabrafenib plus trametinib; extracranial disease decreased while small brain metastases persist on MRI.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab then dabrafenib plus trametinib", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note: 72-year-old male underwent right hemicolectomy for stage III colon adenocarcinoma (T3N1). Tumor genotyping shows KRAS G12D; microsatellite testing MSS. Adjuvant chemotherapy with FOLFOX was completed for 6 months without significant complications. Surveillance CT at 12 months shows no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "hemicolectomy, adjuvant FOLFOX", "response": "disease-free post-adjuvant / no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology referral: 34-year-old male with 1.2 cm superficial spreading melanoma of the upper back, Breslow 0.9 mm, no ulceration. Wide local excision with 1 cm margins performed; SLNB not indicated. Molecular testing on primary lesion returned BRAF V600E. No adjuvant therapy planned; patient is currently disease-free on follow up exam.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "complete remission / disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with metastatic lung adenocarcinoma diagnosed on CT-guided biopsy in 2023. Comprehensive molecular testing returned EGFR L858R positive; PD-L1 TPS 10%. Brain MRI demonstrates a solitary enhancing right frontal lobe lesion consistent with metastasis. Patient was started on osimertinib 80 mg daily and reported improvement in headaches. First restaging CT and brain MRI at 8 weeks show shrinkage of both the primary and intracranial lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 58-year-old with metastatic colorectal adenocarcinoma. KRAS G12D identified on tumor genotyping; tumor is MSS and TMB-low. Baseline CT showed multiple hypodense lesions in the liver and several pulmonary nodules. Started first-line FOLFIRI with bevacizumab. After 4 cycles there is interval increase in size of several hepatic lesions and new pleural nodularity.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver, lung, pleura"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op pathology: 63-year-old male underwent right hemicolectomy for ascending colon adenocarcinoma, pathologic stage III (T3N1). Tumor NGS showed KRAS G12D; microsatellite testing: MSS. Patient completed adjuvant FOLFOX for 6 months. Surveillance CT at 12 months shows no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "surgery (right hemicolectomy) followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with metastatic lung adenocarcinoma (stage IV) presented with progressive headaches and back pain. Staging scans demonstrated multiple brain and osseous lesions. Molecular profiling identified EGFR L858R with an acquired T790M resistance mutation. PD-L1 TPS was 10% and tumor mutational burden reported as low. He was initially treated with carboplatin/paclitaxel plus pembrolizumab but progressed after 4 cycles and was transitioned to osimertinib with stereotactic radiosurgery to the brain metastases. CT at 8 weeks on osimertinib showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10% (TPS); TMB-low", "treatment": "carboplatin + paclitaxel + pembrolizumab; osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital discharge summary: 72-year-old male with metastatic castration-resistant prostate cancer admitted for pain control. Bone scan positive for multiple osseous metastases in pelvis and thoracic spine. He remains on androgen-deprivation therapy with leuprolide and recently completed two cycles of docetaxel; however pain and PSA rising consistent with clinical progression. No tumor sequencing available. No visceral metastases identified on CT.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen-deprivation therapy (leuprolide); docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with pancreatic ductal adenocarcinoma with hepatic metastases at presentation (Stage IV). Germline testing revealed a deleterious BRCA2 mutation. Baseline CA19-9 was 1200 U/mL. He received first-line FOLFIRINOX with initial tumor shrinkage, transitioned to maintenance olaparib for BRCA2, but recent imaging documents progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 1200 U/mL", "treatment": "FOLFIRINOX then maintenance olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma, recurrent metastatic disease. 71-year-old male with cutaneous primary previously resected; now with multiple pulmonary nodules and a new solitary cerebellar lesion. Tumor testing identified BRAF V600E. He was started on combined ipilimumab and nivolumab; after 3 cycles some lung nodules decreased while a new small brain metastasis appeared \u2014 overall described as a mixed response. BRAF-targeted therapy discussed as next option.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "mixed response", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old with a 1.1 cm superficial spreading melanoma of the right forearm, Breslow 0.9 mm, no ulceration \u2014 staged as stage I. Tumor sequencing identified BRAF V600E. The patient underwent wide local excision with clear margins and sentinel node biopsy which was negative. Follow-up skin exams and ultrasound remain clear.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy", "response": "no evidence of disease / complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma (stage IV) presenting with worsening bone pain. Circulating tumor DNA testing identified a BRCA2 truncating mutation. PD-L1 testing was not performed. He previously progressed on androgen deprivation and docetaxel, and was started on the PARP inhibitor olaparib; subsequent scans demonstrate progression with new pelvic lymphadenopathy and multiple sclerotic bone metastases.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 truncating mutation", "biomarker": null, "treatment": "olaparib (after abiraterone/androgen deprivation and docetaxel)", "response": "progression", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with BRAF V600E mutant metastatic cutaneous melanoma. He presented with pulmonary nodules and several brain metastases. Initially started on dabrafenib and trametinib with good symptomatic improvement and measurable shrinkage of lesions (partial response). After six months there was interval progression with new CNS lesions and growth of pulmonary disease, consistent with disease progression on targeted therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "partial response then progression", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 67-year-old woman with high-grade serous ovarian carcinoma presenting with bulky pelvic disease and omental caking. Germline testing returned pathogenic BRCA1 mutation. She underwent cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with partial radiographic response; started on olaparib maintenance. Evidence of widespread peritoneal carcinomatosis noted on imaging.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1", "biomarker": null, "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma (diagnosed 03/2024). Staging at presentation was IV with multiple intracranial lesions and lytic lesions in the thoracic spine. Molecular testing on the diagnostic biopsy returned an EGFR exon 19 deletion; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily with stereotactic radiosurgery to two brain metastases. Imaging at 8 weeks showed decrease in size of pulmonary and osseous lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic lung adenocarcinoma. Initial molecular testing from the biopsy demonstrated EGFR exon 21 L858R; after progression on erlotinib a plasma assay detected EGFR T790M. PD-L1 TPS 5%. Patient started osimertinib 80 mg daily; brain MRI at 8 weeks showed reduction in size of multiple cerebral lesions and PET/CT showed decreased uptake in osseous lesions. Documented response: partial response. Stage at diagnosis: IV with known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 5%", "treatment": "osimertinib (after erlotinib)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with stage IIIC high-grade serous ovarian carcinoma. Germline testing identified a pathogenic BRCA1 mutation; somatic testing showed TP53 mutation and HRD-positive status. She underwent optimal cytoreductive surgery followed by combination platinum-based chemotherapy (carboplatin and paclitaxel) with concurrent bevacizumab, then started maintenance olaparib. Follow-up CT demonstrates complete radiographic response with resolution of peritoneal disease.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline); TP53 (somatic)", "biomarker": "HRD-positive", "treatment": "carboplatin + paclitaxel + bevacizumab, followed by maintenance olaparib", "response": "complete response (radiographic)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old female with locally advanced left-sided breast cancer (clinical stage IIIB). Core biopsy: invasive ductal carcinoma, ER+, PR+, HER2 amplified by FISH. NGS showed a PIK3CA E545K mutation. She received neoadjuvant combination chemotherapy with docetaxel and carboplatin plus dual HER2-targeted therapy trastuzumab and pertuzumab. Mastectomy pathology revealed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma (stage IV) with multiple liver metastases. Tumor profiling identified BRAF V600E and high microsatellite instability (MSI-H). He was started on encorafenib plus cetuximab and restaging after 8 weeks demonstrated stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "encorafenib plus cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma. Primary tumor was sigmoid colon; CT chest/abdomen showed multiple bilateral pulmonary nodules. Molecular profile identified KRAS G12D mutation; tumor was MSI-stable. Patient received FOLFOX plus bevacizumab as first-line therapy but restaging CT at 16 weeks documented progression with growth of lung metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Man in his 60s with metastatic colon adenocarcinoma presenting with progressive pulmonary nodules. Tumor genotyping detected KRAS G12D. He received 6 cycles of FOLFOXIRI with bevacizumab; clinical notes describe stable symptoms and imaging reports indicate no significant change compared with prior exam. There is no record of MSI testing in the chart.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOXIRI + bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "40-year-old male with metastatic cutaneous melanoma. BRAF V600E mutation detected on NGS; PD-L1 5%. Patient was started on dabrafenib and trametinib after rapid progression on single-agent pembrolizumab. Follow-up imaging at 8 weeks demonstrated a 45% reduction in target lesions (partial response), predominantly in the lungs.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib (after pembrolizumab)", "response": "partial response", "metastasis_site": "lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma, BRAF V600E on tumor genotyping. PET/CT shows multiple bilateral pulmonary nodules consistent with metastases; brain MRI negative. PD-L1 by IHC 10%. He was started on dabrafenib and trametinib combination therapy; the 12-week scan demonstrates a partial response with marked decrease in number and size of lung nodules.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with newly diagnosed lung adenocarcinoma presented with headaches. Staging demonstrates T2aN2M1 (stage IV) disease with a 3.2 cm right upper lobe primary and multiple enhancing lesions on brain MRI. Molecular testing returned EGFR L858R mutation; PD-L1 not reported. She was started on osimertinib 80 mg daily and after 8 weeks repeat imaging showed decrease in size of both the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man status post low anterior resection for sigmoid colon adenocarcinoma (pT3N1) \u2014 path report grade 2. KRAS testing by targeted PCR panel was negative; MSI testing reported MSS (microsatellite stable). He completed 6 months of adjuvant FOLFOX without complications. Surveillance CT chest/abdomen/pelvis at 12 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast, cT3N2M0 (stage IIIB). Tumor was ER positive, PR positive and HER2 amplified by FISH; NGS identified PIK3CA H1047R. She received neoadjuvant dose-dense AC followed by paclitaxel with trastuzumab and pertuzumab and subsequently underwent modified radical mastectomy with pathologic complete response (no residual invasive carcinoma in the breast or nodes).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin + cyclophosphamide (AC) then paclitaxel with trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma, diagnosed stage IV with dominant hepatic lesions. Molecular testing reveals BRAF V600E mutation and high microsatellite instability (MSI-H) with elevated tumor mutational burden. First-line pembrolizumab was given due to MSI-H status with initial shrinkage of some lesions but persistent disease in the liver and peritoneum. On progression he was started on encorafenib plus cetuximab per BRAF-targeted protocol. Current assessment: mixed response with some hepatic lesions stable and small peritoneal nodules progressing.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab; encorafenib + cetuximab", "response": "mixed response / stable disease in some lesions, progression in others", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with biopsy-proven invasive ductal carcinoma of the right breast, clinically T2N1 (stage IIB). Tumor is HER2-amplified by FISH, ER-negative, PR-negative. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles. Surgical specimen after lumpectomy showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma with multiple liver lesions. Molecular testing: BRAF V600E mutation and MSI-H. He was started on FOLFOX plus bevacizumab as first-line therapy; after progression he was switched to pembrolizumab given the MSI-H status. Interval CTs on pembrolizumab demonstrate stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old with unresectable metastatic cutaneous melanoma harboring BRAF V600E. He was started on combination targeted therapy with dabrafenib and trametinib with brisk initial response of skin and nodal lesions, but developed new symptomatic brain metastases at 6 months and was deemed to have progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "73-year-old male with metastatic castration-resistant prostate cancer, bone-predominant disease. Germline and somatic testing identified a pathogenic BRCA2 alteration. He received initial ADT with leuprolide and docetaxel, later transitioned to the PARP inhibitor olaparib for biomarker-directed therapy; most recent scans show stable bony disease and falling PSA.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide), docetaxel, then olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging scans consistent with stage IV disease with multiple intracranial lesions and lytic bone lesions. Molecular testing returned EGFR L858R mutation; PD-L1 by IHC 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and has had interval shrinkage of both brain and calvarial metastases on 8-week MRI/CT consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with left-sided invasive ductal carcinoma, clinical T2N0M0 (stage II). Tumor is ER-positive, PR-positive and HER2 amplified by FISH. She underwent lumpectomy with sentinel node biopsy followed by adjuvant dose-dense doxorubicin/cyclophosphamide then paclitaxel and concurrent trastuzumab. At 18-month oncology follow-up there is no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide (AC) then paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 52-year-old man with metastatic melanoma treated initially with combination immunotherapy (nivolumab + ipilimumab). MRI brain at diagnosis showed multiple small enhancing metastases. Molecular testing did not reveal an actionable BRAF or NRAS mutation (no reportable driver mutation). Tumor genomic profiling however noted high tumor mutational burden; PD-L1 by IHC was 5%. After mixed radiographic response to immunotherapy, stereotactic radiosurgery was used for dominant brain lesions and systemic disease remained indolent \u2014 overall described as a mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "TMB-high; PD-L1 5%", "treatment": "nivolumab + ipilimumab; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presenting with metastatic colorectal adenocarcinoma with multiple liver lesions and peritoneal implants. Tumor testing returned MSI-H and PD-L1 10%. He received induction FOLFOX with bevacizumab and was later switched to pembrolizumab monotherapy because of MSI-H status. Scans after 4 cycles of pembrolizumab showed stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; PD-L1 10%", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic cutaneous melanoma. Excisional biopsy of a scalp lesion confirmed melanoma with BRAF V600E mutation. Staging PET/CT revealed multiple bilateral pulmonary nodules consistent with metastatic disease. He was started on dabrafenib plus trametinib but after 3 months there is radiographic progression with increasing size and number of lung nodules; plan to switch therapy. PD-L1 and TMB data not available in chart.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-resistant prostate adenocarcinoma presenting with progressive bone pain and rising PSA. Limited molecular panel was not performed and no tumor biomarker data are available in the chart. He was continued on androgen deprivation with leuprolide, received palliative external beam radiation to the pelvis, and was treated with six cycles of docetaxel. Clinical course over the next 4 months has been relatively stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide, palliative external beam radiation, docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report and oncology follow-up: 59-year-old male underwent sigmoid resection for adenocarcinoma staged at pT3N1 (stage III). Tumor molecular panel: KRAS G12D positive; microsatellite stable (MSS). He completed 12 cycles of adjuvant FOLFOX and remains without radiographic evidence of disease at 18 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the right breast. ER and PR strongly positive, HER2 FISH positive (HER2 amplification). Comprehensive NGS detected a PIK3CA H1047R mutation. Clinical stage IIIB with chest wall involvement and fixed axillary nodes. She received neoadjuvant docetaxel, carboplatin with dual HER2 blockade (trastuzumab and pertuzumab) and achieved a pathologic complete response at the time of mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 amplification", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma first diagnosed in 2019. Staging at progression consistent with stage IV disease with hepatic and intracranial lesions. Tumor sequencing identified EGFR L858R. PD-L1 TPS reported at 10%. She was started on osimertinib 80 mg daily in September 2019 with interval CT and brain MRI showing decrease in size of most lesions. Plan is to continue osimertinib given current benefit.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma with predominant osseous metastases. Germline and somatic testing identified a deleterious BRCA2 mutation and HRD-positive status. He previously received leuprolide and docetaxel; started olaparib maintenance thereafter with radiographic stable disease and a fall in PSA from 24 to 9 ng/mL.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "HRD-positive", "treatment": "olaparib (after leuprolide and docetaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colon adenocarcinoma presenting with multiple liver lesions. Molecular panel returned KRAS G12D; mismatch repair proficient (MSS). He was started on FOLFOX plus bevacizumab. Interval CT after 4 cycles demonstrates no new lesions and minimal shrinkage of dominant hepatic metastasis consistent with stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (mismatch repair proficient)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with invasive ductal carcinoma of the left breast. Tumor ER 90% positive, PR 50% positive, HER2 negative by IHC/FISH. Pathologic stage IIA (T2N0). NGS identified a PIK3CA H1047R mutation. She underwent breast-conserving surgery with sentinel node biopsy, adjuvant radiation, and was started on tamoxifen. Recent follow-up mammogram and exam show no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER-positive; PR-positive; HER2-negative", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Notes: 49-year-old woman with locally advanced left breast cancer, ER/PR negative, HER2 amplified on FISH. She received neoadjuvant dose-dense AC x4 then paclitaxel with trastuzumab and pertuzumab. Surgery showed no residual invasive carcinoma in the breast or nodes (pCR). Patient will continue adjuvant trastuzumab to complete 1 year. PIK3CA mutation E545K noted on panel.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "dose-dense AC; paclitaxel; trastuzumab; pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48F with metastatic invasive ductal carcinoma of the breast, ER+, PR+, HER2-amplified. She presented with new osseous lesions in the thoracic spine and pelvis on bone scan. Treated with docetaxel plus trastuzumab and pertuzumab for six cycles then maintenance trastuzumab. Most recent restaging shows stable disease. Tumor NGS panel did not identify actionable somatic mutations.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, trastuzumab, pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma diagnosed 03/2024. Biopsy confirmed adenocarcinoma with EGFR L858R mutation and PD-L1 20%. Baseline staging showed multiple vertebral lesions and a 1.5 cm cerebellar metastasis. He was started on osimertinib 80 mg daily as first-line therapy and has achieved a radiographic partial response at 8 weeks with decreased size of the brain lesion and improvement in back pain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Biopsy demonstrated EGFR L858R mutation and PD-L1 TPS 10%. MRI brain shows multiple enhancing lesions consistent with metastases. He was started on osimertinib 80 mg daily as first-line therapy in 2020. Interval CT and MRI demonstrate shrinkage of intracranial and pulmonary lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: Advanced cutaneous melanoma, AJCC stage IV at presentation. Tumor testing positive for BRAF V600E. PD-L1 expression <1%. Initially treated with pembrolizumab but progression after 3 cycles; patient was transitioned to targeted therapy with dabrafenib and trametinib, resulting in decrease in pulmonary nodules and regional lymphadenopathy \u2014 documented partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung, regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with metastatic lung adenocarcinoma in 04/2023. NGS returned EGFR L858R mutation. PD-L1 TPS reported at 10%. Staged as IV at diagnosis with known brain and bone metastases. Patient started osimertinib 80 mg PO daily; interval imaging at 3 months shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with newly diagnosed lung adenocarcinoma presenting with headache and back pain. MRI shows multiple brain metastases and PET demonstrates lytic lesions in the spine. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 25%. Patient started on osimertinib as first-line therapy with symptomatic improvement and imaging at 8 weeks shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 25%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left-sided locally advanced breast cancer (pT3N1) treated with modified radical mastectomy in 2023. Final path shows ER positive, PR positive and HER2 IHC 3+ with FISH confirming HER2 amplification. Pathologic stage recorded as IIIB. Patient received adjuvant paclitaxel with trastuzumab followed by adjuvant radiation. Surveillance imaging to date shows no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab followed by radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Tumor board note: 55-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. PD-L1 expression approximately 5%. Patient started on dabrafenib plus trametinib with an initial partial response. At month 9 there was radiographic progression with enlargement of mediastinal nodes and new brain metastases; plan discussed to switch to combination ipilimumab/nivolumab or consider clinical trials.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; planned ipilimumab/nivolumab", "response": "initial partial response then progression", "metastasis_site": "mediastinal lymph nodes, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed glioblastoma. He underwent gross total resection followed by concurrent radiotherapy with temozolomide (Stupp protocol). MGMT methylation status was not reported and no targeted molecular alterations were available in the chart. Early post-treatment MRI demonstrates radiographic progression.", "output": {"cancer_type": "glioblastoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "surgical resection; radiotherapy + temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Colorectal oncology clinic: 62-year-old male with sigmoid adenocarcinoma metastatic to the liver at presentation (stage IV). Molecular testing returned KRAS G12D mutation. He was started on first-line FOLFOX plus bevacizumab. Serial CTs over 12 weeks show disease control without new lesions \u2014 stable disease. Carcinoembryonic antigen remains elevated but trending down. No microsatellite instability reported.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old presented with new left frontal mass; craniotomy and debulking confirmed glioblastoma (WHO grade IV). No molecular profiling available at the time. Patient underwent maximal safe resection followed by concurrent radiation with temozolomide per Stupp protocol. Three-month MRI shows enlarging enhancing lesion at the resection cavity and a new enhancing focus in the contralateral frontal lobe consistent with progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgical resection; radiation with concurrent temozolomide (Stupp protocol)", "response": "progression", "metastasis_site": "brain (contralateral frontal lobe)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man presented with metastatic colorectal adenocarcinoma. Molecular testing identified KRAS G12D and MSI-stable status. Baseline CT shows multiple hepatic lesions and periportal lymphadenopathy consistent with stage IV disease. He was started on FOLFOX plus bevacizumab; after four cycles repeat imaging demonstrated interval enlargement of liver metastases consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. Presents with multiple liver lesions; biopsy confirms adenocarcinoma of colonic origin. Molecular testing: BRAF V600E positive and high microsatellite instability (MSI-H). Initial therapy was FOLFOX plus bevacizumab. After radiographic progression in the liver he was switched to pembrolizumab given MSI-H status, but recent scans show enlarging hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab, then pembrolizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT shows multiple liver lesions; biopsy confirms colon primary. Molecular testing: KRAS G12D, microsatellite stable (MSS). He was started on FOLFOX with bevacizumab. After 4 cycles there was a radiographic partial response in the liver lesions and CEA declined.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX; bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with multiple liver lesions (stage IV). Tumor profiling demonstrated BRAF V600E mutation and MSI-H. Given pembrolizumab as frontline therapy for MSI-H disease. Interval imaging after 4 cycles demonstrates approximately 40% shrinkage of hepatic lesions consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman presented with progressive jaundice. Imaging revealed a pancreatic head mass with several hypodense lesions in the liver. ERCP with stent performed. Biopsy confirmed pancreatic ductal adenocarcinoma, stage IV. Molecular testing detected KRAS G12V and a TP53 mutation. CA19-9 markedly elevated at 12,000 U/mL. She was started on gemcitabine plus nab-paclitaxel; after two cycles CT shows interval increase in size and number of hepatic lesions consistent with progression.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V; TP53 mutation", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine + nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive. Initially placed on pembrolizumab but progressed clinically after three cycles with enlarging subcutaneous nodules. Therapy was changed to dabrafenib plus trametinib with subsequent clinical and radiographic improvement of skin and nodal disease. PD-L1 testing showed 5% expression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progression on pembrolizumab followed by partial response to BRAF/MEK therapy", "metastasis_site": "skin/subcutaneous, lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old woman with newly diagnosed glioblastoma. She underwent subtotal resection followed by concurrent radiation with temozolomide. IDH1 sequencing returned wild-type. MGMT promoter methylation result is still pending. Surveillance MRI at 3 months shows new enhancing lesions concerning for progression.", "output": {"cancer_type": "glioblastoma", "stage": null, "gene_mutation": "IDH1 wild-type", "biomarker": null, "treatment": "radiation and temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma presenting with pulmonary nodules and brain metastases. BRAF testing is pending and PD-L1 was not reported. He was started on first-line pembrolizumab; follow-up CT shows regression of lung lesions but interval intracranial progression requiring stereotactic radiosurgery. Overall assessment: mixed response. Classified as stage IV melanoma.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "pembrolizumab; stereotactic radiosurgery for brain lesions", "response": "mixed response (regression in lung, progression in brain)", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with high-risk prostate adenocarcinoma (Gleason 4+5). Treated with androgen deprivation therapy and docetaxel in 2022. Germline testing positive for BRCA2 pathogenic variant; after rising PSA he was started on olaparib with stable PSA and imaging for 9 months. No distant metastatic deposits documented in clinic notes.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "androgen deprivation therapy; docetaxel; olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with a 1.8 cm invasive ductal carcinoma of the left breast. ER/PR positive, HER2 negative. Sentinel lymph node was negative and final pathologic stage was IA. She underwent lumpectomy with clear margins followed by adjuvant whole-breast radiation and was started on tamoxifen. Follow-up mammogram and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, whole-breast radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "ENT operative note: 72-year-old male with oropharyngeal squamous cell carcinoma treated definitively with intensity-modulated radiation therapy and concurrent weekly cisplatin. No molecular testing was performed and PD-L1 was not reported. Post-treatment PET/CT shows complete clinical remission.", "output": {"cancer_type": "oropharyngeal squamous cell carcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "radiation therapy with concurrent weekly cisplatin", "response": "complete clinical remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with stage IV lung adenocarcinoma. NGS identified EGFR L858R mutation. PD-L1 TPS reported as 1%. MRI brain demonstrates two enhancing lesions consistent with metastases. Patient started osimertinib 80 mg daily in January; 8-week CT and brain MRI show reduction in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma, patient found to be BRAF V600E positive on molecular testing. Started on first-line targeted therapy with dabrafenib and trametinib with excellent initial shrinkage of extracranial disease; subsequently developed new symptomatic brain metastases and required stereotactic radiosurgery. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with biopsy-proven lung adenocarcinoma in the left upper lobe. Tumor testing returned EGFR L858R positive; PD-L1 5%. Staged clinically as IA (no nodes). She underwent VATS lobectomy with negative margins and is currently NED at 6-month follow-up.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "I", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "VATS lobectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma harboring BRAF V600E alteration. Initial staging confirms stage IV disease with multiple pulmonary nodules. Tumor PD-L1 was 10% and tumor mutational burden reported as high. The patient progressed on first-line nivolumab after 4 months and was switched to combination dabrafenib plus trametinib; interval CT chest after 6 weeks shows a partial response of the lung nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib and trametinib (after progression on nivolumab)", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Mr. K is a 59-year-old with metastatic colon adenocarcinoma to the liver diagnosed on CT and biopsy. Tumor testing was notable for MSI-H and high tumor mutational burden; KRAS/NRAS/BRAF status not reported. Given MSI-H status he was started on pembrolizumab and after 4 cycles had a marked decrease in hepatic lesion size on restaging scans.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colon adenocarcinoma; biopsy demonstrated BRAF V600E mutation and high microsatellite instability (MSI-H). At diagnosis there were multiple liver metastases and diffuse peritoneal nodules consistent with stage IV disease. He received first-line FOLFOX plus bevacizumab with initial partial radiographic response. On progression he was switched to encorafenib plus cetuximab with transient disease control followed by progression of hepatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; then encorafenib + cetuximab", "response": "initial partial response then progression on targeted therapy", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma. Biopsy showed EGFR L858R and acquired T790M on repeat testing; PD-L1 was 10%. She initially received carboplatin and pemetrexed combined with pembrolizumab on a first-line regimen with a partial response, then was switched to osimertinib after T790M emerged. Imaging demonstrates brain and osseous metastases. Stage IV disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "carboplatin and pemetrexed + pembrolizumab; osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Excisional biopsy of a pigmented lesion on the right calf: nodular cutaneous melanoma, Breslow depth 4.2 mm; sentinel node positive \u2014 staged as IIIC. Molecular testing detected BRAF V600E. Patient started pembrolizumab but progressed after 4 cycles; switched to dabrafenib plus trametinib with subsequent partial response of nodal disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma (nodular)", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "progression on pembrolizumab then partial response to BRAF/MEK", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing on the primary tumor demonstrated EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. Staging consistent with stage IV disease with multiple intracranial lesions on MRI and lytic lesions on bone scan. Patient was started on osimertinib 80 mg daily in March 2020 and received stereotactic radiosurgery to the dominant brain lesion. CT at 8 weeks showed reduction in size of pulmonary nodules and improvement of brain lesions \u2014 consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib (80 mg daily) and stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, KRAS G12D identified on molecular testing. Tumor is microsatellite stable (MSS). He presented with multiple hepatic metastases noted on CT with markedly elevated CEA. Treated with FOLFOX plus bevacizumab; initial shrinkage of liver lesions followed by radiographic progression with new lesions in the right hepatic lobe. Stage IV.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Biopsy and molecular profiling identified BRAF V600E mutation; tumor was MSI-H and TMB-high. She initially received FOLFOX plus bevacizumab with limited benefit and rising CEA, and was switched to pembrolizumab monotherapy given MSI-H status. Follow-up CT after 4 months showed stable size of hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab (initial), then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with metastatic lung adenocarcinoma in 2023. Initial molecular testing demonstrated an EGFR exon 19 deletion and subsequent NGS after progression showed MET amplification as a resistance mechanism. PD-L1 by IHC was 5%. She was started on osimertinib and, after MET amplification was identified, capmatinib was added to the regimen. Prior lines included carboplatin and pemetrexed. Follow-up imaging at 12 weeks showed a partial response with shrinkage of the dominant right frontal lobe lesion and decreased size of multiple vertebral lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; MET amplification", "biomarker": "PD-L1 5%", "treatment": "osimertinib + capmatinib (prior carboplatin and pemetrexed)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with locally advanced left breast carcinoma, ER/PR positive and HER2 amplified by FISH. Core biopsy also showed a PIK3CA H1047R mutation. Clinical stage IIIB. She received neoadjuvant docetaxel and trastuzumab for six cycles followed by mastectomy. Surgical pathology demonstrated a complete pathologic response (ypT0N0). No distant metastases were identified on staging scans.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+ PR+", "treatment": "neoadjuvant docetaxel and trastuzumab, surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic renal cell carcinoma presented with widespread bony pain and cough. Biopsy confirmed clear cell RCC, stage IV with pulmonary and osseous metastases. Molecular profiling was not informative and no actionable mutation reported. He was initiated on combination immunotherapy with nivolumab and ipilimumab and shortly thereafter axitinib was added for disease control. After two cycles the patient had clinical deterioration and interval CT shows progression in the lungs and new bone lesions.", "output": {"cancer_type": "renal cell carcinoma (clear cell)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab + ipilimumab; axitinib (added)", "response": "progression", "metastasis_site": "lung, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high-grade serous ovarian carcinoma, FIGO IIIC at diagnosis, found to have germline BRCA1 deleterious mutation. Presented with extensive peritoneal carcinomatosis and ascites. Underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; started maintenance olaparib. CA-125 has decreased and CT abdomen shows partial response of peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated (declining on treatment)", "treatment": "debulking surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 49-year-old woman with metastatic breast carcinoma, ER/PR negative, HER2 3+ by IHC. Biopsy of liver lesion confirmed metastatic breast cancer. Staging: IV. Germline testing showed pathogenic BRCA1 mutation. She received trastuzumab and pertuzumab in combination with docetaxel for six cycles followed by maintenance trastuzumab. Imaging after 4 months \u2014 complete radiographic response in the liver.", "output": {"cancer_type": "breast carcinoma", "stage": "IV", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HER2 3+; ER/PR negative", "treatment": "trastuzumab and pertuzumab with docetaxel; maintenance trastuzumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left-sided colon adenocarcinoma, pathologic stage IIIC (T3N2M0) after sigmoid resection and extended lymphadenectomy. MSI testing returned MSI-high. No actionable somatic mutation report available in the chart. Patient completed 6 months of adjuvant FOLFOX and is on routine surveillance with no clinical or radiologic evidence of recurrence to date.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "MSI-high", "treatment": "surgery (sigmoid resection and lymphadenectomy), adjuvant FOLFOX", "response": "no evidence of disease / disease-free on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Brief oncology note: Metastatic melanoma, BRAF V600E positive. Patient presented with respiratory symptoms; CT chest/brain shows multiple pulmonary nodules and several enhancing brain metastases. Started on dabrafenib/trametinib doublet. After 6 months of therapy clinical decline with enlarging CNS lesions \u2014 systemic progression documented. Will consider alternative systemic therapy and clinical trials.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic cutaneous melanoma found to harbor BRAF V600E on tumor sequencing. Presents with painful right femoral lesion and imaging consistent with bone metastasis. PD-L1 testing was not performed. She was started on dabrafenib and trametinib combination therapy and interval PET/CT demonstrates decreased metabolic activity in known lesions consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic nodular melanoma of the right forearm. Molecular panel identified a BRAF V600E alteration. Imaging demonstrates multiple small cerebral lesions and numerous pulmonary nodules; overall stage IV. Started on dabrafenib 150 mg twice daily and trametinib 2 mg daily. Twelve-week MRI/CT shows no new lesions and no significant size change of index lesions \u2014 disease remains radiographically stable.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of cutaneous melanoma of the right upper arm. Surgical pathology staged as III with positive sentinel node. Molecular testing positive for BRAF V600E; PD-L1 expression approximately 5% by IHC. After wide local excision and nodal dissection patient was started on adjuvant targeted therapy with dabrafenib plus trametinib. Early follow-up scans show a partial response in the residual nodal disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "surgery; dabrafenib + trametinib (adjuvant)", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with left breast invasive ductal carcinoma, clinical stage IIA. Core biopsy ER positive, PR negative, HER2 amplified. Tumor NGS identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant dose-dense doxorubicin/cyclophosphamide then paclitaxel and trastuzumab; endocrine therapy with tamoxifen planned. Post-treatment imaging and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR-", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide then paclitaxel; trastuzumab; tamoxifen planned", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colon adenocarcinoma presenting with progressive jaundice. Molecular testing showed KRAS G12D mutation; mismatch repair testing was intact (MSI-stable). He was treated with FOLFOX plus bevacizumab in the metastatic setting but imaging after three cycles demonstrated new hepatic lesions and enlarging portal nodes consistent with progression. Final assessment: stage IV with dominant liver metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated T4N2M1 \u2014 stage IV disease with multifocal brain and osseous lesions. Molecular testing returned EGFR L858R and exon 20 wild-type; PD-L1 by IHC 1%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and received stereotactic radiosurgery to a dominant cerebellar metastasis. On first follow-up CT at 8 weeks there is reduction in size of pulmonary nodules and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female with newly diagnosed lung adenocarcinoma. PET-CT demonstrates widespread disease with lesions in the cerebellum and multiple vertebral bodies. Molecular testing returned EGFR L858R. PD-L1 by IHC reported 10% TPS. She was started on osimertinib 80 mg daily as first-line therapy and achieved a brisk symptomatic improvement. Interval MRI shows shrinkage of brain lesions and decrease in size of spinal metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma. Staging consistent with stage IV disease with multiple pulmonary nodules. Tumor profiling shows KRAS G12D; tumor is MSI-H on PCR. He received first-line FOLFOX with bevacizumab but developed progression in the lungs after 6 months and was transitioned to pembrolizumab; repeat imaging documents continued enlargement of pulmonary metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "progressive disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left breast mass, clinical stage IIIA. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Neoadjuvant regimen: docetaxel, carboplatin, trastuzumab and pertuzumab. She completed six cycles and underwent mastectomy with no residual invasive tumor on pathology.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": null, "biomarker": "ER+; PR+; HER2 amplification", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old female diagnosed with left breast invasive ductal carcinoma. Pathology: ER 95%+, PR 20%+, HER2 negative by IHC/ISH. Tumor 2.5 cm with 3 positive sentinel nodes \u2192 pathologic stage IIA. Molecular testing identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy and was started on adjuvant tamoxifen. At 18-month follow-up there is no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with new cough and weight loss. Bronchoscopic biopsy confirmed lung adenocarcinoma. Staging PET/CT showed extensive disease with osseous lesions consistent with Stage IV. Comprehensive NGS reported EGFR exon 21 L858R and acquired T790M; concurrent TP53 R273C noted. PD-L1 TPS 10%. He was started on osimertinib 80 mg daily with an initial partial response on the first CT at 8 weeks, but progressed after 9 months and was transitioned to carboplatin and pemetrexed combined with pembrolizumab on a clinical trial.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M; TP53 R273C", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed + pembrolizumab", "response": "initial partial response then progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E. He initially received pembrolizumab but developed progression after three cycles and was switched to dabrafenib plus trametinib. MRI brain showed a single enhancing lesion treated with stereotactic radiosurgery. On current assessment there has been a decrease in extracranial disease burden.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib (after pembrolizumab)", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced pancreatic ductal adenocarcinoma encasing the SMA, clinical stage III. Germline testing identified a pathogenic BRCA2 variant. CA 19-9 is elevated at 1200 U/mL. The patient received 6 cycles of FOLFIRINOX with radiographic stable disease on restaging CT; no distant metastases identified. Referred to radiation oncology for consideration of consolidative chemoradiation.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "CA 19-9 1200 U/mL", "treatment": "FOLFIRINOX; planned/considered chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with metastatic colorectal adenocarcinoma with multiple hepatic lesions. Tumor testing returned MSI-H with loss of MLH1/PMS2 by IHC. No actionable KRAS/NRAS/BRAF mutations were reported on the panel. Given MSI-high status he was started on pembrolizumab as first-line therapy and achieved radiographic complete response at 6-month restaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H (loss of MLH1/PMS2)", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with castration-resistant prostate adenocarcinoma on ADT. He reports increasing bone pain; whole-body bone scan shows extensive skeletal metastases. AR-V7 testing on circulating tumor cells is positive; comprehensive genomic panel was not performed. He was started on enzalutamide but had clinical and biochemical progression after two months and received palliative radiation to the pelvis.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": "AR-V7 positive", "treatment": "enzalutamide; palliative radiation", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old with metastatic pancreatic ductal adenocarcinoma, stage IV at presentation with multiple liver lesions. Germline testing positive for pathogenic BRCA2 mutation. CA19-9 on diagnosis 3,500 U/mL. Treated with gemcitabine plus nab-paclitaxel; after 4 cycles had further progression in hepatic lesions and was switched to platinum-based therapy and then to olaparib maintenance given BRCA2. Recent scans show stable hepatic disease on maintenance.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (pathogenic germline)", "biomarker": "CA19-9 elevated (3,500 U/mL)", "treatment": "gemcitabine/nab-paclitaxel; platinum-based chemotherapy; olaparib maintenance", "response": "stable disease on olaparib (after prior progression)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced left breast carcinoma treated in the neoadjuvant setting. Biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH; PIK3CA H1047R mutation identified on NGS. She received neoadjuvant combination TCHP (docetaxel, carboplatin, trastuzumab and pertuzumab) followed by lumpectomy. Final pathology showed a pathologic complete response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced invasive ductal carcinoma of the left breast. Clinical stage IIIA (T2 N2 M0). Hormone receptors: ER positive (80%), PR positive (50%). HER2 FISH demonstrates HER2 amplification. She received neoadjuvant paclitaxel with trastuzumab, followed by breast-conserving surgery. Final pathology reported no residual invasive carcinoma \u2014 pathologic complete response. Germline BRCA testing pending.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital discharge summary: 57-year-old with high-grade serous ovarian carcinoma, extensive peritoneal carcinomatosis at initial laparotomy, pathologic stage IIIC. Germline testing positive for deleterious BRCA1 mutation. She received six cycles of carboplatin and paclitaxel with excellent CA-125 response and near-complete radiologic resolution of peritoneal implants, and was transitioned to maintenance olaparib. Clinical exam and CT at 3 months show no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": null, "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 49-year-old female with metastatic breast cancer diagnosed last year. Biopsy of a liver lesion confirmed ductal carcinoma with HER2 amplification and PIK3CA H1047R mutation. ER positive, PR negative. She was treated with first-line trastuzumab and pertuzumab in combination with docetaxel; imaging shows a confirmed partial response in the liver metastases. Current stage recorded as IV with dominant hepatic involvement.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with increasing abdominal distension and CA-125 elevation underwent exploratory laparotomy. Findings included large bilateral ovarian masses with diffuse peritoneal implants; pathology confirmed high-grade serous ovarian carcinoma, FIGO IIIC. Germline and somatic testing identified a deleterious BRCA2 mutation. She completed cytoreductive surgery followed by carboplatin and paclitaxel with planned maintenance olaparib. Post-treatment imaging shows no measurable residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin + paclitaxel; maintenance olaparib", "response": "complete response / no measurable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 61-year-old man with clinically localized prostate adenocarcinoma, PSA 9.4 ng/mL, Gleason 3+4 on biopsy. He underwent radical prostatectomy followed by adjuvant external beam radiation due to positive margins. Follow-up PSA is undetectable and he remains without clinical evidence of disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Treatment note: 68-year-old female with metastatic pancreatic ductal adenocarcinoma, liver metastases on baseline CT. Germline testing detected BRCA2 6174delT. CA 19-9 markedly elevated at diagnosis. She received FOLFIRINOX with partial radiographic improvement, transitioned to maintenance olaparib given the BRCA2 mutation; recent scans stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with widely metastatic melanoma to liver and lungs diagnosed last year. Molecular assay positive for BRAF V600E. PD-L1 expression low at ~5%. Started on dabrafenib + trametinib combination targeted therapy with dramatic symptomatic improvement; PET-CT after 3 months demonstrates complete metabolic response in all previously avid lesions.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. NGS returned EGFR L858R and PD-L1 was 10% by IHC. Staging scans demonstrate multiple pulmonary nodules, bone lesions and enhancing brain metastases consistent with stage IV disease. Patient started osimertinib 80 mg daily in March and has had radiographic partial response with improvement in headaches.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colon adenocarcinoma to the liver. Molecular testing showed KRAS G12D and MSI-H with high tumor mutational burden; PD-L1 was low at ~5%. He was started on FOLFOX plus bevacizumab as first-line therapy; following progression he was transitioned to pembrolizumab given MSI-H and TMB-high status, with disease demonstrating stability on restaging scans.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high; PD-L1 5%", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV metastatic cutaneous melanoma with biopsy-proven BRAF V600E mutation. Baseline PET/CT demonstrated disease in lung and multiple small brain metastases. Patient started combination targeted therapy with dabrafenib plus trametinib, achieving a complete response in extracranial disease. Stereotactic radiosurgery was delivered to the brain lesions and nivolumab was initiated as consolidation. PD-L1 was reported at 5% on immunohistochemistry.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery; nivolumab", "response": "complete response (extracranial)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing identified EGFR L858R. Staging at diagnosis was IV with known brain and bone metastases. PD-L1 tumor proportion score 10%. She was started on first-line osimertinib 80 mg daily with clinical improvement; interval CT and brain MRI show decrease in size of measured lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrated multiple bilateral pulmonary nodules and enhancing lesions in the cerebellum and thoracic vertebral bodies consistent with metastatic disease. Comprehensive molecular testing identified EGFR L858R; ALK and ROS1 were negative. PD-L1 tumor proportion score reported as 10%. He was started on osimertinib 80 mg daily. At first restaging CT after 8 weeks there was a 45% reduction in target lesions consistent with a partial response. Whole brain radiation was given to the symptomatic cerebellar lesion prior to systemic therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole brain radiation", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic pancreatic ductal adenocarcinoma diagnosed with liver metastases (stage IV). Germline testing positive for BRCA1 mutation; CA19-9 markedly elevated at diagnosis. Systemic therapy initiated with FOLFIRINOX and he achieved an initial partial response on imaging, but progression occurred after 8 months. He was switched to maintenance olaparib for BRCA1 with subsequent stable disease documented for three months.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA1", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "initial partial response to FOLFIRINOX, then progression, stable disease on olaparib", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 64-year-old man diagnosed with lung adenocarcinoma in 2019. Recent PET/CT demonstrates progression with new enhancing lesions in the cerebellum and lytic lesions in the femur. Molecular testing from prior biopsy returned EGFR L858R; PD-L1 tumor proportion score approximately 10%. Patient was started on osimertinib 80 mg daily six months ago with radiographic improvement of the chest mass and reduction in brain lesion size on interval MRI. Current assessment: partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old man with metastatic cutaneous melanoma, BRAF V600E\u2013positive, stage IV with multiple pulmonary nodules. He was started on dabrafenib and trametinib (BRAF/MEK inhibitor combo) and had a complete radiographic response at 6 months. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib; trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with metastatic colorectal adenocarcinoma to the liver. Imaging and biopsy confirm stage IV disease. Molecular testing: KRAS G12D mutation identified; tumor is MSI-H by PCR and TMB-high at 18 mut/Mb. Given MSI-H status she was started on pembrolizumab monotherapy as first-line systemic therapy. Follow-up scans after 4 cycles show decrease in size of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (18 mut/Mb)", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E and high tumor mutational burden (TMB-high). MRI brain revealed a single cerebellar metastasis which was resected. He was started on adjuvant dabrafenib and trametinib; follow-up PET/CT and MRI showed no evidence of disease (complete response).", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib (adjuvant)", "response": "complete response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman with newly diagnosed lung adenocarcinoma. Tumor genotyping by PCR demonstrated EGFR L858R mutation. PD-L1 IHC reported 10% TPS. She was started on osimertinib 80 mg daily in April and interval CT chest/abdomen showed shrinkage of the primary lesion consistent with an initial partial response. However, MRI brain obtained for headaches revealed multiple enhancing lesions consistent with intracranial metastases and concern for intracranial progression despite systemic benefit.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "initial partial response; intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old with metastatic cutaneous melanoma, BRAF V600E positive on molecular testing. Baseline brain MRI showed two small metastases; patient received stereotactic radiosurgery to brain lesions and systemic therapy with dabrafenib plus trametinib. PET/CT after 3 months demonstrates decreased metabolic activity in the nodal and hepatic lesions and reduction in size of intracranial metastases consistent with partial response. PD-L1 was 5% on archival specimen.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; liver; lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic cutaneous melanoma, stage IV, with pulmonary and brain involvement. PD-L1 was reported at 10%. Treated with pembrolizumab monotherapy but progressed clinically after three months. BRAF testing was not performed prior to immunotherapy.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 10%", "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with resected colon adenocarcinoma, pathologic stage III (T3 N1). Tumor sequencing returned KRAS G12D; microsatellite testing showed MSS. Completed 6 months of adjuvant FOLFOX with bevacizumab added for clinical trial participation. Post-treatment CT chest/abdomen/pelvis demonstrates no residual disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX with bevacizumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: 68-year-old man underwent radical prostatectomy for clinically localized prostate adenocarcinoma, Gleason 3+4. Clinical stage documented as II (T2b N0). Preoperative PSA was 12 ng/mL. Final pathology revealed a positive margin and adjuvant external beam radiation was recommended. No somatic genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "radical prostatectomy; planned adjuvant external beam radiation", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a locally advanced right breast mass. Core biopsy: invasive ductal carcinoma, ER+, PR+, HER2 IHC 3+ consistent with HER2 amplification. Clinically staged as IIIB with fixed axillary nodes. She received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab. Marked reduction in size of the primary tumor was noted on exam. No distant metastases identified on staging CT chest/abdomen.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "40-year-old man with a 1.1 mm superficial spreading melanoma of the left forearm, sentinel lymph node negative \u2014 pathologic stage I. Tumor profiling identified BRAF V600E. Treated with wide local excision; no adjuvant therapy indicated. Patient remains without recurrence on follow-up.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with unresectable cutaneous melanoma, stage IV at presentation. Molecular testing positive for BRAF V600E. He initially received combination immunotherapy with nivolumab plus ipilimumab but imaging showed heterogeneous changes with new small brain metastases while some extracranial lesions shrank. Therapy was switched to targeted therapy with dabrafenib and trametinib; extracranial disease improved but brain lesions progressed. Overall assessment: mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "nivolumab + ipilimumab followed by dabrafenib + trametinib", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, FIGO stage IV due to peritoneal carcinomatosis and multiple liver implants. Germline testing returned a deleterious BRCA1 mutation. CA\u2011125 markedly elevated at diagnosis. She underwent optimal primary debulking surgery followed by six cycles of carboplatin and paclitaxel with documented partial response on CT; maintenance olaparib was initiated thereafter.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated", "treatment": "debulking surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female presented with high grade serous ovarian carcinoma with extensive peritoneal disease at presentation. Germline testing revealed a pathogenic BRCA1 mutation. She underwent optimal debulking followed by adjuvant carboplatin and paclitaxel and was transitioned to maintenance olaparib. CA-125 normalized after chemotherapy and the patient remains clinically well on maintenance with no radiologic evidence of progressive disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (pathogenic)", "biomarker": "CA-125 elevated at diagnosis (normalized post-treatment); HRD/BRCA-associated", "treatment": "carboplatin + paclitaxel; maintenance olaparib", "response": "no evidence of progressive disease / clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male status post right hemicolectomy for T3N1 colon adenocarcinoma (pathologic stage III). Molecular testing returned KRAS G12D. He completed adjuvant FOLFOX x6 cycles without significant complications. Surveillance CTs at 3 and 12 months reveal no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 59-year-old man with metastatic cutaneous melanoma. Baseline staging: multiple pulmonary nodules and several hepatic lesions. Tumor testing positive for BRAF V600E. Started on pembrolizumab as first-line therapy; initial imaging showed mixed response with shrinkage of some lung nodules but after 6 months there was progression in the liver. Patient subsequently switched to dabrafenib plus trametinib with radiologic improvement of pulmonary disease but persistent hepatic progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "mixed response with progression in liver", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Admission progress: 63-year-old man with newly diagnosed pancreatic head adenocarcinoma presenting with obstructive jaundice. Imaging shows tumor encasement of the SMA and regional nodal involvement (clinically unresectable, stage III). Germline and somatic next-generation panel did not identify actionable mutations. CA19-9 markedly elevated. Started combination gemcitabine/nab\u2011paclitaxel and consolidative chemoradiation; restaging CT demonstrates no new distant disease and tumor measurements stable compared with baseline.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel with chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma. NGS identified BRAF V600E. PD-L1 by IHC was low at 2%. He was started on combined BRAF/MEK inhibition with dabrafenib and trametinib and had a good initial tumor regression (partial response) lasting 8 months. On recent restaging there is progression in the brain and bilateral lung nodules; he was transitioned to combination immunotherapy with ipilimumab plus nivolumab but has had further progression on the latest scan. Stage IV disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%", "treatment": "dabrafenib; trametinib; ipilimumab; nivolumab", "response": "initial partial response then progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic cutaneous melanoma, BRAF V600E positive. PD-L1 reported 5% and high tumor mutational burden. She presented with symptomatic brain and bone metastases. Started on combination targeted therapy with dabrafenib plus trametinib. Six\u2011month imaging demonstrates complete radiographic response in brain, bone and cutaneous sites.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib plus trametinib", "response": "complete response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with biopsy-proven metastatic colorectal adenocarcinoma. Tumor profiling reports MSI-H and TMB-high. Multiple liver metastases on baseline CT; staged as IV. Started pembrolizumab 200 mg IV every 3 weeks as first-line immunotherapy. Follow-up CT at 12 weeks demonstrates significant reduction in hepatic lesions compatible with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Follow-up note: 71-year-old male with high-risk prostate adenocarcinoma treated with external beam radiation and long-term androgen deprivation therapy (leuprolide). Clinical stage was locally advanced with extraprostatic extension on MRI. PSA nadir achieved and currently rising slightly but no radiographic metastases on bone scan or CT. No molecular testing performed in clinic.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III (locally advanced)", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy and external beam radiation", "response": "stable disease (no radiographic metastasis)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man with metastatic colorectal adenocarcinoma with multiple liver lesions at diagnosis. Molecular testing: KRAS G12D mutation; MSI-H by PCR. He completed 8 cycles of FOLFOX with initial minor shrinkage but then radiographic progression in the liver. Switched to pembrolizumab monotherapy; 12-week restaging shows target lesions largely unchanged \u2014 adjudicated as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX (prior); pembrolizumab (current)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic follow-up: 72-year-old male with metastatic colon adenocarcinoma. Molecular testing: KRAS G12D mutation identified; tumor tested MSI-H by PCR. Baseline CT showed multiple hepatic metastases. He received FOLFOX with bevacizumab as first-line therapy but recent restaging demonstrates enlarging liver lesions consistent with radiographic progression. Stage IV at diagnosis.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with metastatic colon adenocarcinoma presenting with multiple hepatic lesions. Tumor sequencing identified KRAS G12D. He received FOLFOX plus bevacizumab as first-line systemic therapy. After six cycles CT abdomen shows interval enlargement of liver lesions consistent with radiographic progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with left-sided colon adenocarcinoma resected last year (T3N2). Routine follow-up shows new multiple hepatic lesions on MRI and biopsy-proven metastatic colorectal adenocarcinoma. Molecular testing: KRAS G12D, MSI-stable. He received first-line FOLFOX but progressed and was switched to FOLFIRI plus bevacizumab; best response recorded as stable disease on two consecutive CT scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFIRI plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old female with a 1.8 cm invasive ductal carcinoma of the right breast. ER negative, PR negative, HER2 negative (triple negative). Germline testing returned a pathogenic BRCA1 variant. She underwent lumpectomy with negative sentinel nodes (pT1cN0) and is scheduled for adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by paclitaxel.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "I", "gene_mutation": "BRCA1 (germline)", "biomarker": "ER negative; PR negative; HER2 negative", "treatment": "lumpectomy; planned adjuvant doxorubicin + cyclophosphamide then paclitaxel", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colon adenocarcinoma presenting with right upper quadrant pain. CT shows multiple hepatic lesions consistent with metastases. Tumor panel returned KRAS G12D and TP53 mutation; MSI testing reported MSI-H. He was started on FOLFOX plus bevacizumab as first-line therapy. Interval imaging after 4 cycles revealed no significant change in size of liver lesions and was read as stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 mutation", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with locally advanced squamous cell carcinoma of the oropharynx (T3N2, clinical stage IVA). He received definitive chemoradiation with high-dose cisplatin and concurrent weekly cetuximab. PD-L1 CPS returned 10. Limited targeted panel showed no actionable mutations. Post-treatment PET/CT demonstrates complete metabolic response.", "output": {"cancer_type": "squamous cell carcinoma of oropharynx", "stage": "IVA", "gene_mutation": null, "biomarker": "PD-L1 CPS 10", "treatment": "cisplatin chemoradiation + cetuximab", "response": "complete metabolic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma to the liver and peritoneum. Tumor NGS showed BRAF V600E mutation; MSI testing returned MSI-H and tumor mutational burden was reported as TMB-high. Initially started on FOLFOX with bevacizumab with radiographic stable disease. After limited benefit he was switched to encorafenib plus cetuximab (BRAF-directed combination).", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; then encorafenib plus cetuximab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with sigmoid colon adenocarcinoma complicated by progressive abdominal distension. CT abdomen/pelvis shows extensive peritoneal nodularity and omental caking consistent with peritoneal carcinomatosis (stage IV). He was started on FOLFOX plus bevacizumab as first-line therapy. Formal molecular testing was requested but results are pending. After two cycles the patient has stable symptoms and repeat imaging shows no new lesions \u2014 disease felt to be stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old man with newly diagnosed metastatic lung adenocarcinoma harboring an EGFR L858R mutation. Staging PET/CT shows multiple cerebral and osseous lesions consistent with metastases (stage IV). PD-L1 testing returned 10%. He was started on osimertinib 80 mg daily with symptomatic improvement and interval CT shows a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with unresectable pancreatic ductal adenocarcinoma. Baseline CA19-9 markedly elevated. Broad NGS panel showed no actionable alterations. She was started on gemcitabine with nab-paclitaxel; interval CT at 8 weeks demonstrated growth of the primary and new peritoneal nodularity. Therapy was stopped and patient transitioned to best supportive care.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old patient with a pancreatic head mass causing obstructive jaundice. Imaging and EUS-FNA consistent with pancreatic ductal adenocarcinoma. Tumor markers: CA19-9 1,200 U/mL. Given locally advanced appearance the tumor was deemed unresectable by the multidisciplinary team. Systemic therapy with gemcitabine and nab-paclitaxel was initiated; best response to date is stable disease. Germline and somatic BRCA testing were not completed prior to treatment and no mutational report is available.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": "CA19-9 1,200 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with pancreatic adenocarcinoma found to carry a germline BRCA2 pathogenic variant. Underwent six cycles of FOLFIRINOX with transition to maintenance olaparib. CA19-9 was markedly elevated at diagnosis and has been trending down but the oncologist documents that formal response assessment is pending. Recent CT report notes hepatic lesions suspicious for metastases.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": null, "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presented with new neurologic symptoms; MRI confirmed brain metastases. Tumor sequencing detected BRAF V600E. He was initiated on combined BRAF/MEK targeted therapy (dabrafenib plus trametinib). After an initial period of disease control there is now progressive intracranial disease on most recent scans. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent subtotal resection for a right temporal glioblastoma (WHO grade IV). Post-op notes: no IDH1 or IDH2 mutations detected on targeted testing; MGMT methylation status not available in the chart. Post-op management consisted of maximal safe resection followed by concurrent radiotherapy with temozolomide per Stupp protocol. Interval MRI at 8 weeks shows no clear radiographic progression and patient remains clinically stable.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgical resection followed by concurrent radiotherapy and temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with newly diagnosed lung adenocarcinoma presented with progressive headaches. Staging CT and brain MRI demonstrated multiple intracranial lesions consistent with metastases; clinical stage IV. Tumor NGS returned EGFR L858R mutation and PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg PO daily and underwent stereotactic radiosurgery to two right frontal lesions. Interval imaging at 8 weeks shows a partial response with shrinkage of the intracranial and thoracic disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral note: 62-year-old woman with newly diagnosed lung adenocarcinoma. Core biopsy of the right upper lobe confirmed adenocarcinoma with EGFR L858R mutation on NGS. PD-L1 TPS reported as 10%. Staging workup consistent with metastatic disease (stage IV) with lesions in the brain and multiple lytic bone lesions. Patient was started on osimertinib 80 mg daily two weeks ago and reports clinical improvement; interval MRI/CT demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old with metastatic cutaneous melanoma. Baseline testing positive for BRAF V600E. PD-L1 ~5% on IHC. He started dabrafenib and trametinib with rapid tumor shrinkage but developed new pulmonary nodules on 4-month scan and progressive neurologic symptoms; brain MRI demonstrated new metastases. Treatment changed to immunotherapy after documented systemic progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib (then switched to immunotherapy after progression)", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with newly diagnosed glioblastoma (WHO grade IV) of the right temporal lobe. Resection performed; tumor was IDH1 R132H mutant and MGMT promoter methylated. He completed concurrent radiotherapy with daily temozolomide followed by adjuvant cycles of temozolomide. Surveillance MRI at 8 months revealed radiographic progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation", "treatment": "surgery (resection), radiotherapy with concurrent temozolomide, adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with pancreatic ductal adenocarcinoma, locally advanced at diagnosis and now metastatic (stage IV) with liver lesions on CT. No actionable mutations were identified because tumor was not sent for broad NGS; no PD-L1 testing performed. He started palliative chemotherapy with gemcitabine and nab\u2011paclitaxel but CT after two cycles shows growth of hepatic lesions consistent with radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 1.2 cm invasive ductal carcinoma of the right breast, ER+/PR+, HER2 amplified; final pathology T1N0 (stage I). Tumor sequencing identified a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy (nodes negative) followed by adjuvant weekly paclitaxel x12 and trastuzumab. Follow-up mammogram and ultrasound show no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation note: 42-year-old male with cutaneous melanoma of the right forearm; wide local excision and sentinel node biopsy performed last month. Pathology: stage IIIB (one positive sentinel node). Tumor harbors BRAF V600E mutation. Given nodal involvement patient was started on adjuvant dabrafenib plus trametinib. Tolerating therapy with partial response of residual nodal disease on PET/CT; plan to continue targeted therapy for one year.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female presented with cough and headache. Imaging revealed a right upper lobe mass and multiple enhancing brain lesions. Biopsy confirmed lung adenocarcinoma, clinical stage IV. NGS panel identified EGFR L858R; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily; brain metastases were treated with stereotactic radiosurgery. Interval CT and MRI at 3 months demonstrate decrease in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with obstructive symptoms and was found to have colon adenocarcinoma with multiple liver lesions on CT. Tumor sequencing identified KRAS G12D. MSI testing showed microsatellite stable (MSS) disease and TMB is low. He was initiated on systemic chemotherapy with FOLFOX plus bevacizumab. After 4 cycles the hepatic lesions increased in size and number, consistent with radiographic progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS, TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast. ER/PR negative, HER2 IHC 3+ with confirmed HER2 amplification by FISH. Core biopsy NGS identified a PIK3CA H1047R mutation. Clinical stage at presentation was IIIA with large axillary nodes. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with good reduction in tumor size; imaging and exam document a partial clinical response prior to surgery. No distant metastases identified on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant TCHP)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIA (T2 N2 M0). Tumor is ER positive, PR positive and HER2 3+ by IHC consistent with HER2 amplification. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab. MRI after three cycles demonstrated marked tumor shrinkage; patient proceeded to lumpectomy and axillary dissection with residual 0.5 cm invasive carcinoma on pathology (clinically significant response). No distant mets identified on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin; trastuzumab; pertuzumab; surgery (lumpectomy and axillary dissection)", "response": "partial response (residual 0.5 cm)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old premenopausal woman with locally advanced invasive ductal carcinoma of the left breast. Tumor was ER positive, PR negative, HER2 IHC 3+ with HER2 amplification confirmed by FISH. Germline testing identified a pathogenic BRCA2 mutation. Clinical stage recorded as IIIB (T4b N2). She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by modified radical mastectomy; surgical pathology revealed no residual invasive carcinoma in the breast and nodes (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "HER2 amplification (IHC 3+)", "treatment": "paclitaxel, trastuzumab, pertuzumab, surgery", "response": "complete response (pathologic)", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma, debulking performed with optimal cytoreduction. Pathology staged as IIIC with extensive peritoneal carcinomatosis. Germline testing positive for BRCA1 mutation. She completed six cycles of carboplatin and paclitaxel with good tolerance and was transitioned to maintenance olaparib. CA-125 normalized and CT scan at 3 months shows no residual disease \u2014 documented complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD-positive (BRCA1)", "treatment": "carboplatin + paclitaxel; interval debulking surgery; maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma, stage IV with multifocal brain and bone metastases. Molecular testing detected EGFR L858R; ALK and ROS1 were negative. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily. First restaging CT and brain MRI after 8 weeks show shrinkage of several pulmonary nodules and decreased enhancement of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: High\u2011risk prostate adenocarcinoma, Gleason 4+5, metastatic to multiple vertebral bodies on bone scan. No next\u2011generation sequencing performed; PD-L1 not assessed. Patient started androgen deprivation therapy with leuprolide plus docetaxel for systemic disease control. PSA has declined and follow-up CT shows reduction in size of several osseous lesions \u2014 assessed as partial response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma found to harbor EGFR L858R on tumor genotyping. Presented with progressive back pain; staging CT/PET confirmed stage IV disease with multiple vertebral lesions. PD-L1 tumor proportion score reported at 20%. Patient started osimertinib 80 mg daily. Interval imaging after 8 weeks shows decrease in size of the primary lung mass and osseous lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed lung adenocarcinoma, stage IV. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg PO daily six weeks ago. Interval brain and chest MRI/CT show reduction in size of the lung primary and regression of two intracranial metastases. Clinical note documents improved dyspnea and decreased cough.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genotyping identified KRAS G12D. MSI testing returned MSI-H. He was started on pembrolizumab monotherapy and CT at 12 weeks shows reduction in size of target lesions without new sites of disease; assessment recorded as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male diagnosed with cutaneous melanoma of the right arm, initially stage IIIC. Molecular testing identified a BRAF V600E mutation. He was started on combination targeted therapy with dabrafenib and trametinib; initial clinical response was noted but imaging at 7 months demonstrated new pulmonary nodules and increase in size of existing lesions consistent with progression. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and operative report: Invasive ductal carcinoma of the left breast, HER2 amplified by FISH; ER and PR negative. Clinical stage IIIB. Patient received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for four cycles. Sentinel node biopsy and mastectomy show no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast core biopsy: invasive ductal carcinoma, ER negative, PR negative. HER2 IHC 3+ with confirmatory HER2 gene amplification by FISH. Clinical exam consistent with T3N1 disease. Tumor sequencing identified a PIK3CA H1047R mutation. Patient received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with good tolerance and underwent mastectomy. Surgical pathology shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+); ER negative; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP); mastectomy", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with localized prostate adenocarcinoma, clinical stage IIB, Gleason 4+3. He underwent definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide depot). PSA fell from 18 to 0.6 ng/mL after treatment and has been stable on follow-up. No molecular testing reported.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy and androgen deprivation (leuprolide)", "response": "stable disease (PSA decline/stable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with progressive dyspnea. Staging workup revealed stage IV disease with multiple brain metastases and lytic lesions in the thoracic spine. Molecular testing identified EGFR L858R mutation; PD-L1 TPS 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and after 8 weeks imaging showed a marked decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presenting with multiple liver metastases. Tumor tested MSI-high by PCR; extended RAS testing showed no actionable KRAS/NRAS mutations. He was started on pembrolizumab monotherapy given MSI-H status and has had interval CT with reduction in hepatic lesions described as a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma with multiple liver lesions. Molecular report: KRAS G12D and MSI-H. He was started on pembrolizumab 200 mg IV q3w given the MSI-H status. First restaging CT at 12 weeks demonstrates stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with metastatic cutaneous melanoma found to harbor BRAF V600E on NGS. She initially received dabrafenib plus trametinib with tumor shrinkage, later developed progression and was transitioned to pembrolizumab. Tumor mutational burden reported as TMB-high. Recent MRI shows new cerebellar metastases. Stage not documented in outside records.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "progression", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma. Staging workup confirms stage IV disease. Next-generation sequencing identified EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. Patient was started on osimertinib 80 mg daily six weeks ago; interval CT shows a decrease in target lesions consistent with a partial response. Prior stereotactic radiosurgery to a single brain metastasis was performed last year.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with progressive bone pain and rising PSA. Bone scan revealed multifocal osseous metastases. Prostate biopsy confirmed adenocarcinoma. He was started on androgen deprivation with leuprolide and received six cycles of docetaxel. Germline and tumor NGS did not reveal actionable somatic mutations on report. PSA fell from 180 to 25 ng/mL with improvement in pain.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA elevated (pre-treatment 180 ng/mL)", "treatment": "leuprolide (androgen deprivation) + docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 70-year-old male with metastatic colorectal adenocarcinoma, multiple hepatic metastases on CT. Tumor tested MSI-high and patient enrolled on pembrolizumab monotherapy given MSI-H status. No actionable somatic variants identified on panel testing. After 3 cycles the patient reports less pain and imaging shows shrinkage of target lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "82-year-old male with metastatic cutaneous melanoma found to harbor BRAF V600E on tumor profiling and a high tumor mutational burden (TMB-high). He initiated dabrafenib plus trametinib with an initial partial response; after 9 months new hepatic and pulmonary lesions were identified consistent with progression. He was transitioned to pembrolizumab but continues to show progressive disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib; then pembrolizumab", "response": "initial partial response followed by progressive disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67F with newly progressive metastatic lung adenocarcinoma. NGS from core biopsy returned EGFR exon 19 deletion; PD-L1 tumor proportion score 10%. Began osimertinib 80 mg PO daily in 09/2024. Interval chest CT and MRI brain demonstrate decrease in size of pulmonary and hepatic lesions consistent with a partial response. MRI brain also shows a solitary 8 mm enhancing lesion that was treated with stereotactic radiosurgery. Known bone metastases on baseline imaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone, liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma. NGS panel detected KRAS G12D. Tumor is microsatellite stable (MSS) and TMB-low. He has multiple bilobar liver metastases on CT. Patient started FOLFOX plus bevacizumab with radiographic assessments showing stable disease after 3 cycles. Stage at presentation was IV.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS, TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with metastatic lung adenocarcinoma. Comprehensive molecular testing revealed EGFR L858R and concurrent MET amplification; PD-L1 tumor proportion score 10%. She has known brain and bone metastases. After progression on first-line platinum doublet she was started on osimertinib in combination with bevacizumab. Restaging imaging after 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "MET amplification; PD-L1 10%", "treatment": "osimertinib and bevacizumab", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male status post right hemicolectomy for adenocarcinoma of the colon. Pathology and staging at diagnosis were consistent with metastatic disease after chest CT found multiple pulmonary nodules; patient is considered stage IV. Molecular profiling showed KRAS G12D and microsatellite stable (MSS). He received palliative FOLFOX with bevacizumab with disease control noted on serial CTs (no further growth of lung nodules).", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old woman diagnosed with metastatic lung adenocarcinoma in 02/2024. NGS on core biopsy demonstrated EGFR L858R mutation. PD-L1 by IHC 10%. Patient started osimertinib 80 mg daily in March with rapid symptomatic improvement; interval CT and MRI show decrease in size of pulmonary primary and intracranial lesions consistent with a partial response. Continuing targeted therapy as outpatient.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinically T4bN1M0 (stage IIIB). Core biopsy: ER positive (80%), PR positive (10%), HER2 3+ by IHC; PIK3CA H1047R detected on NGS. She completed three cycles of neoadjuvant docetaxel with trastuzumab and pertuzumab with only modest radiographic shrinkage. Bone scan shows a focal uptake in the right iliac crest consistent with metastatic disease on PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+ by IHC; ER positive; PR positive", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old woman with high-grade serous ovarian carcinoma, stage IV at diagnosis with peritoneal carcinomatosis and hepatic surface implants. Germline testing positive for BRCA1 deleterious mutation. CA-125 was 680 U/mL at baseline. She received neoadjuvant carboplatin and paclitaxel with bevacizumab followed by interval debulking, then resumed platinum-based chemotherapy. Given BRCA1, she was transitioned to maintenance olaparib after achieving a partial radiographic response. Last CT shows decreased peritoneal disease burden but persistent small hepatic implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 elevated (680 U/mL at baseline)", "treatment": "carboplatin and paclitaxel; bevacizumab; interval debulking surgery; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum, liver (hepatic implants)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma presented to clinic. Staging scans revealed metastatic disease (multiple pulmonary nodules and enhancing lesions in the cerebrum). Molecular testing on the biopsy returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily and at the 8-week CT/MRI showed a confirmed partial response with shrinkage of the dominant lung mass and decreased size of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital consult: patient with metastatic melanoma harboring BRAF V600E. Initially started on dabrafenib + trametinib with marked tumor shrinkage (PR). Subsequently developed new intracranial lesions; underwent stereotactic radiosurgery to three brain metastases and was transitioned to nivolumab. Most recent MRI shows no interval extracranial progression and intracranial disease stable.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; nivolumab", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "41-year-old man with metastatic cutaneous melanoma. Molecular testing returned a BRAF V600E mutation. PD-L1 was reported as negative on IHC. He progressed on single-agent nivolumab and was switched to targeted therapy with dabrafenib plus trametinib, after which nodal disease (axillary and cervical) showed reduction on PET/CT consistent with a partial response. No intracranial metastases identified on recent MRI.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 negative", "treatment": "dabrafenib and trametinib (after progression on nivolumab)", "response": "partial response", "metastasis_site": "axillary and cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic melanoma (stage IV) found to have multiple pulmonary nodules and a solitary cerebellar metastasis. BRAF V600E mutation identified; PD-L1 approximately 10%. He started dabrafenib plus trametinib and achieved marked shrinkage of lung lesions (partial response) but developed intracranial progression at 6 months.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 ~10%", "treatment": "dabrafenib and trametinib", "response": "initial partial response then intracranial progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral note: 65-year-old man with metastatic lung adenocarcinoma diagnosed on CT-guided biopsy. Staging PET/CT consistent with stage IV disease with multiple bone lesions and two enhancing brain metastases. Molecular profiling: EGFR L858R mutation detected; PD-L1 TPS 10%. He was started on osimertinib 80 mg daily with good symptomatic improvement. Interval imaging at 8 weeks shows decrease in size of pulmonary and osseous lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult: 52-year-old male with recurrent cutaneous melanoma. Primary tumor testing identified BRAF V600E. He was started on combination targeted therapy with dabrafenib and trametinib. After six months the patient developed progressive dyspnea and CT shows new bilateral pulmonary nodules consistent with progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology clinic note: 52-year-old woman with a 1.1 mm non-ulcerated superficial spreading melanoma on the left forearm. Wide local excision with 1-cm margins and sentinel lymph node biopsy performed; sentinel node negative (0/1). Final pathologic staging pT2a, Stage IB. No adjuvant systemic therapy recommended; patient is being followed clinically with regular skin and nodal exams and remains without recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IB", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision, sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old female with a primary cutaneous melanoma (Breslow depth 3.2 mm). Sentinel lymph node was negative and she is staged as II. Wide local excision performed. The oncology note documents enrollment onto adjuvant pembrolizumab given high-risk stage II features; no molecular mutation testing was performed. Patient is doing well at three-month follow-up with no clinical or radiographic evidence of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision and adjuvant pembrolizumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing returned an EGFR exon 19 deletion. PD-L1 tumor proportion score reported as 1%. She was started on osimertinib 80 mg daily in 2020 with good intracranial control. Most recent CT and brain MRI show decrease in target lesions consistent with a partial response. Known sites of disease include brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 58-year-old female with stage III colon adenocarcinoma (pT3 N2) resected 5/2023. Tumor genotyping reported KRAS G12D. Received adjuvant FOLFOX x12 cycles; bevacizumab added during progression of nodal disease pre-op. Restaging CT shows no distant metastases. Clinically the disease is stable with persistent nodal enlargement on imaging.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX; bevacizumab", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with clear cell renal cell carcinoma, metastatic at presentation with multiple bilateral pulmonary nodules. Tumor testing demonstrated VHL mutation; PD-L1 testing returned >50%. He was started on nivolumab plus ipilimumab as first-line systemic therapy. Interval chest CT shows increasing size and number of lung nodules compared with baseline, consistent with disease progression.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": "VHL mutation", "biomarker": "PD-L1 >50%", "treatment": "nivolumab and ipilimumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "33-year-old male with a superficial pigmented lesion on the upper back excised last month. Pathology: cutaneous melanoma, Breslow 0.7 mm, no ulceration, sentinel node negative. Wide local excision performed with 1 cm margins. No adjuvant systemic therapy recommended. Patient instructed to follow with dermatology for surveillance; most recent note documents routine follow-up with no recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no recurrence / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with metastatic colorectal adenocarcinoma status post right hemicolectomy. Liver and bilateral lung nodules were seen on staging imaging. Comprehensive genomic profiling reported KRAS G12D and high microsatellite instability (MSI-H). Given MSI-H status he was started on pembrolizumab monotherapy. Interval CT at 12 weeks showed no new lesions and minor decrease in size of several hepatic metastases consistent with stable disease by RECIST. He remains on immunotherapy with good tolerance.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient status post right hemicolectomy for Stage III colon adenocarcinoma (3 of 18 nodes positive). Molecular testing detected KRAS G12D by PCR; microsatellite testing returned MSS. Completed 6 months of adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin). Surveillance CT and CEA are currently without evidence of distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "right hemicolectomy; adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin)", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic lung adenocarcinoma (stage IV) presented with hepatic and osseous lesions. Comprehensive NGS returned KRAS G12C and PD-L1 60%. He was started on carboplatin and pemetrexed with pembrolizumab per institutional protocol. After three cycles CT and PET showed stable disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 60%", "treatment": "carboplatin and pemetrexed with pembrolizumab", "response": "stable disease", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced inflammatory breast cancer. Core biopsy showed invasive ductal carcinoma. Clinical stage IIIA. ER and PR negative; HER2 IHC 3+ and FISH positive for HER2 amplification. She received neoadjuvant carboplatin with docetaxel plus trastuzumab. The primary mass markedly decreased but residual tumor remained at the time of definitive surgery (partial response). No metastatic disease identified on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "III A", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant carboplatin, docetaxel and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with a 2.2 cm cutaneous melanoma on the left forearm, Breslow depth 2.4 mm, no ulceration. Sentinel lymph node biopsy was negative and final pathologic stage assigned was IIA. BRAF testing returned V600E positive. He underwent wide local excision with clear margins and no adjuvant systemic therapy was recommended.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with lung adenocarcinoma on CT-guided biopsy. NGS revealed EGFR L858R mutation. Staging workup consistent with stage IV disease with both brain and bone metastases. PD-L1 by IHC reported as 10%. He was started on osimertinib 80 mg daily; restaging at 8 weeks shows marked decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 48\u2011year\u2011old female with metastatic HER2-positive breast cancer. Core biopsy showed invasive ductal carcinoma, ER/PR negative, HER2 IHC 3+ and FISH amplification. NGS revealed PIK3CA E545K. Bone scan positive for multiple skeletal deposits. Patient initiated combination therapy with trastuzumab, pertuzumab and docetaxel; imaging at 12 weeks documents stable disease clinically and radiographically.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma with diffuse osteoblastic bone metastases. Germline testing revealed a BRCA2 pathogenic variant. He previously received androgen deprivation therapy, abiraterone and docetaxel; olaparib was initiated for the BRCA2 alteration. At three months there was a significant PSA decline and decreased tracer uptake on bone scan consistent with a partial response clinically.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 mutation (germline)", "biomarker": "PSA elevated at baseline; PSA decline on therapy", "treatment": "olaparib; prior ADT, abiraterone, docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with locally advanced, unresectable pancreatic ductal adenocarcinoma (clinical stage III). Germline testing returned pathogenic BRCA2 mutation. CA19-9 markedly elevated at diagnosis. He received induction FOLFIRINOX with radiographic disease control and was transitioned to maintenance olaparib due to BRCA2. Serial scans demonstrate stable disease on current therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX, maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a 2.1 cm left breast mass. Excisional pathology: invasive ductal carcinoma, ER positive, PR positive, HER2 negative by IHC/FISH. Sentinel nodes negative; pathologic staging T2 N0 M0, stage IIA. She underwent lumpectomy with clear margins followed by adjuvant chemotherapy (doxorubicin and cyclophosphamide x4 then paclitaxel x12) and is planned for endocrine therapy with letrozole. No residual disease on post-op imaging.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": null, "biomarker": "ER+, PR+, HER2-negative", "treatment": "lumpectomy; adjuvant doxorubicin and cyclophosphamide (AC) then paclitaxel; planned letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female underwent optimal cytoreductive surgery for high-grade serous ovarian carcinoma, pathologic stage IIIC. Germline testing returned a pathogenic BRCA1 mutation and tumor demonstrated HRD positivity. CA\u2011125 was elevated pre-operatively and normalized after chemotherapy. She completed six cycles of adjuvant carboplatin and paclitaxel with radiographic and biochemical complete response and was started on maintenance olaparib. No distant metastatic sites documented on post-op imaging.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD positive; CA-125 elevated pre-op", "treatment": "debulking surgery; carboplatin; paclitaxel; olaparib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with newly diagnosed lung adenocarcinoma. Core biopsy confirmed stage IV disease with multiple enhancing brain lesions on MRI consistent with metastases. Tumor NGS returned EGFR L858R. PD-L1 TPS reported at 30%. She was started on osimertinib 80 mg daily as first-line targeted therapy and had a good clinical and radiographic partial response at the 8-week CT scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 55-year-old man with widely metastatic cutaneous melanoma presenting with headaches and new liver lesions. Molecular testing: BRAF V600E positive. PD-L1 reported at 10%. He was started on pembrolizumab but developed progression of intracranial and hepatic disease; therapy was switched to dabrafenib plus trametinib. Final assessment: disease progression with multiple brain metastases and hepatic involvement.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female diagnosed with de novo metastatic breast cancer. Core biopsy: ER negative, PR negative, HER2 amplification by FISH. Imaging demonstrated bulky hepatic metastases and ipsilateral axillary adenopathy consistent with stage IV HER2-positive disease. She received paclitaxel in combination with trastuzumab and pertuzumab as first-line therapy. After six cycles CT showed complete radiographic response in the liver and clinical improvement of symptoms; plan is to continue HER2-directed therapy.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male diagnosed with metastatic lung adenocarcinoma in Jan 2024. Core biopsy confirmed adenocarcinoma; NGS returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging MRI demonstrated two enhancing brain lesions and bone metastases in the thoracic spine. Patient was started on osimertinib 80 mg daily in Feb 2024. Restaging CT at 8 weeks showed approximately 40% reduction in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma underwent primary optimal cytoreductive surgery. Pathology consistent with stage IIIC disease. Germline testing returned a deleterious BRCA1 mutation. She completed six cycles of adjuvant carboplatin and paclitaxel with documented complete clinical response and was started on maintenance olaparib. No distant metastases identified on post-treatment CT scan.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": null, "treatment": "cytoreductive surgery; carboplatin + paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic HER2-positive breast cancer. Liver biopsy confirms HER2 amplification; ER and PR are negative. Tumor NGS identified a PIK3CA H1047R mutation. She received trastuzumab and pertuzumab with docetaxel and after six cycles imaging shows a partial response of hepatic lesions. Staging at diagnosis was stage IV.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old female with metastatic melanoma (stage IV) presenting with pulmonary metastases. Tumor sequencing identified a BRAF V600E mutation. Treated with combination targeted therapy: dabrafenib plus trametinib. Interval CT shows approximately 40% reduction in target lesions consistent with a partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colon adenocarcinoma diagnosed after workup for weight loss and rising LFTs. CT shows multiple liver metastases. Tumor sequencing: KRAS G12D. He was started on FOLFOX with bevacizumab but after 4 cycles imaging demonstrates enlarging hepatic lesions and new ascites consistent with progression of disease. MSI testing was stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral letter: Patient with castrate-resistant prostate adenocarcinoma with rising PSA despite leuprolide and prior docetaxel. Germline and somatic testing identified pathogenic BRCA2 mutation. Started on olaparib 300 mg BID three months ago with stabilization of PSA and improvement in bone pain. No explicit pathologic stage listed in chart. Bone scan shows multifocal osseous involvement.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": "BRCA2", "biomarker": null, "treatment": "olaparib (after leuprolide and docetaxel)", "response": "stable disease (PSA stabilization, symptom improvement)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male admitted with a left temporal lobe mass; craniotomy confirmed glioblastoma multiforme. Molecular analysis detected IDH1 R132H. MGMT promoter methylation was positive. Patient underwent concurrent radiation with temozolomide but had radiographic progression at first post-treatment MRI and worsening neurologic deficits.", "output": {"cancer_type": "glioblastoma multiforme", "stage": null, "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation positive", "treatment": "radiation with temozolomide (concurrent)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed in 2021. Molecular testing demonstrated EGFR L858R mutation; ALK and ROS1 were negative. PD-L1 tumor proportion score reported at 5%. Imaging shows progressive disease with new brain and bony lesions. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Repeat CT and MRI at 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed glioblastoma multiforme who underwent subtotal resection. He completed concurrent radiotherapy with daily temozolomide per Stupp protocol. Molecular testing was not performed due to insufficient tissue. Surveillance MRI at 3 months shows stable postsurgical enhancing gliosis without interval tumor growth.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgical debulking followed by radiation and temozolomide", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colon adenocarcinoma, presenting with multiple liver lesions and peritoneal implants. Biopsy confirmed adenocarcinoma; molecular profile shows KRAS G12D and MSS (microsatellite stable). Staged as IV. He was started on FOLFOX with bevacizumab. After 4 cycles the CT shows no new lesions and target lesions are unchanged \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male referred for management of metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R mutation. PD-L1 by IHC was 10%. MRI brain shows multiple small enhancing lesions and bone scan positive for skeletal metastases. Patient started osimertinib 80 mg daily as first-line targeted therapy; interval CT after 3 months demonstrated a clear decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note (dermatology/oncology): 63-year-old man with recurrent metastatic cutaneous melanoma. Tissue NGS positive for BRAF V600E. He was started on pembrolizumab but progressed clinically after four doses; subsequently initiated dabrafenib plus trametinib with rapid symptomatic improvement. Brain MRI prior to targeted therapy documented two small enhancing parenchymal metastases which were observed. Latest PET/CT shows decrease in extracranial metabolic activity.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "partial response to dabrafenib/trametinib", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman diagnosed with high-grade serous ovarian carcinoma with extensive peritoneal carcinomatosis. FIGO stage IIIC. Germline testing returned a deleterious BRCA1 mutation. CA-125 was markedly elevated at presentation. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel; maintenance olaparib was started thereafter. Interval CT after three cycles showed decreased size of peritoneal implants consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed squamous non-small cell lung carcinoma presented with multiple lytic bone lesions and an adrenal lesion. PD-L1 tumor proportion score reported 60% and comprehensive genomic profiling showed no actionable driver mutation; TMB reported as high. He was started on combination therapy with carboplatin and paclitaxel plus pembrolizumab. Interim CT after 3 cycles demonstrates reduction in target lesions consistent with partial response.", "output": {"cancer_type": "squamous non-small cell lung carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 60%, TMB-high", "treatment": "carboplatin and paclitaxel plus pembrolizumab", "response": "partial response", "metastasis_site": "bone, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old male with metastatic colorectal adenocarcinoma. Tumor testing: MSI-H and TMB-high; NGS detected BRAF V600E. CT chest/abdomen shows multiple bilateral pulmonary nodules consistent with metastatic disease. Stage assigned as IV. Given MSI-H status, pembrolizumab monotherapy was initiated; first assessment demonstrates decrease in number and size of lung nodules \u2014 consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 62-year-old male with newly diagnosed lung adenocarcinoma. Staging workup consistent with metastatic disease (multiple cerebral and osseous lesions) \u2014 overall stage IV. Molecular testing returned EGFR L858R mutation and PD-L1 tumor proportion score 10%. Patient started first-line osimertinib 80 mg daily; first restaging CT and brain MRI at 8 weeks show decrease in size of index lesions consistent with a partial response. Will continue targeted therapy and repeat imaging in 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old female with papillary thyroid carcinoma, clinical stage I (T1N0M0). FNA confirmed PTC and molecular testing detected a RET/PTC1 rearrangement. Preoperative thyroglobulin was 22 ng/mL. She underwent total thyroidectomy followed by radioactive iodine ablation; post-therapy whole body scan was negative and thyroglobulin became undetectable. Patient is currently without evidence of disease.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": "RET/PTC1 rearrangement", "biomarker": "thyroglobulin 22 ng/mL (pre-op)", "treatment": "total thyroidectomy with radioactive iodine ablation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with newly diagnosed lung adenocarcinoma. Biopsy confirmed non-small cell lung cancer, molecular testing positive for EGFR L858R; PD-L1 reported at 10%. Staging PET/CT consistent with stage IV disease with multiple brain and bone metastases. She was started on osimertinib 80 mg PO daily one month ago. Interval MRI shows decrease in size of several intracranial lesions and chest CT demonstrates shrinkage of the primary mass.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic prostate adenocarcinoma, extensive sclerotic bone metastases on bone scan. Clinical stage IV disease. Genomic testing was not performed at this time per patient preference. IHC from the prostate biopsy demonstrates PTEN loss. Treatment to date: six cycles of docetaxel followed by enzalutamide for castration-resistant features; PSA remains elevated but symptoms are controlled and disease is clinically stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PTEN loss (IHC)", "treatment": "docetaxel then enzalutamide", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, initially stage IV with hepatic and osseous involvement. Tumor is BRAF V600E positive. He received pembrolizumab first-line with brief disease stabilization followed by progression in the liver. Switched to targeted therapy with dabrafenib plus trametinib; bone lesions regressed but hepatic lesions continue to enlarge and overall assessment is progressive disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progressive disease", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neuro-oncology consult: 68-year-old male status post subtotal resection of a right frontal mass. Final diagnosis glioblastoma, WHO grade IV. Molecular testing: TERT promoter mutation (C228T) present; MGMT promoter methylation detected. Tumor is IDH1 R132 wild-type. He completed concurrent radiation with temozolomide and is on adjuvant temozolomide. Surveillance MRI at 6 months demonstrated new enhancing nodular progression along the resection cavity consistent with radiographic progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": "TERT C228T", "biomarker": "MGMT promoter methylation", "treatment": "surgical resection; radiation with concurrent temozolomide; adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 39-year-old man with metastatic cutaneous melanoma presenting with multiple cerebral lesions. NGS identifies BRAF V600E. He was started on combination targeted therapy with dabrafenib and trametinib and underwent stereotactic radiosurgery to two brain metastases. Initial imaging showed reduction in extracranial disease burden but new contrast-enhancing intracranial lesions after 5 months. Patient had an initial partial radiographic response to BRAF/MEK inhibition followed by intracranial progression.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "initial partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and oncology summary: Metastatic colorectal adenocarcinoma, stage IV with multiple hepatic lesions. Molecular profile: KRAS G12D mutation detected; tumor is microsatellite-stable (MSS). Patient received FOLFIRI plus bevacizumab as first-line therapy. Interval CT after 4 months shows no new lesions and essentially unchanged size of known liver metastases \u2014 stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed stage IV lung adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 10%. Brain MRI showed two small enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval imaging at 8 weeks demonstrates significant decrease in size of the index lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology clinic note: 52-year-old man with ulcerated melanoma of the left forearm, staged as IIB after wide local excision and sentinel node negative. Tumor harbored BRAF V600E on molecular panel. Given risk features, patient enrolled for adjuvant pembrolizumab. After 12 months of therapy he remains clinically disease-free with negative surveillance skin and lymph node exams.", "output": {"cancer_type": "melanoma", "stage": "IIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; pembrolizumab (adjuvant)", "response": "disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old male with metastatic cutaneous melanoma. Molecular testing confirmed BRAF V600E mutation; NRAS was wild-type. PD-L1 expression was low (<1%). He was initiated on combination targeted therapy with dabrafenib and trametinib; imaging at 10 weeks documented a significant reduction in subcutaneous nodules and nodal disease (partial response), but he subsequently developed symptomatic brain metastases consistent with intracranial progression.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%; NRAS wild-type", "treatment": "dabrafenib + trametinib (then intracranial progression)", "response": "partial response followed by intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man diagnosed with metastatic colorectal adenocarcinoma with multiple liver lesions and peritoneal implants. Tumor profiling returned BRAF V600E and MSI-H. He received FOLFOX plus bevacizumab with mixed radiographic response, then was transitioned to encorafenib plus cetuximab with disease stabilization for five months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; then encorafenib + cetuximab", "response": "stable disease on encorafenib + cetuximab (mixed response to FOLFOX/bevacizumab)", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic colorectal adenocarcinoma presenting with ascites and peritoneal carcinomatosis. Tumor testing returned BRAF V600E and high microsatellite instability (MSI-H). Given MSI-H status he was started on pembrolizumab monotherapy; after three cycles there was a radiographic partial response of peritoneal implants.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-treatment summary: 48-year-old woman with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplification by FISH. Targeted sequencing identified PIK3CA H1047R. Clinical stage corresponds to T4b N2 (stage IIIB). Plan is neoadjuvant chemotherapy with docetaxel and carboplatin combined with trastuzumab and pertuzumab. After three cycles there has been marked clinical shrinkage of the primary \u2014 assessed as a partial response. No distant metastatic disease on CT chest/abdomen/pelvis.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "docetaxel and carboplatin; trastuzumab; pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with palpable left breast mass. Core biopsy: invasive ductal carcinoma, grade 3, ER negative, PR negative; HER2 positive by FISH with HER2/CEP17 ratio 6.0. Clinical stage cT3N1M0. She completed six cycles of neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab with good clinical shrinkage and subsequently underwent modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma (ypT0N0).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA (cT3N1M0)", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response (ypT0N0)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female presented with pancreatic ductal adenocarcinoma with extensive hepatic metastases and peritoneal implants. Tumor panel did not identify actionable mutations. CA19-9 markedly elevated. She was started on gemcitabine plus nab-paclitaxel; restaging after two cycles demonstrated radiographic progression with increasing size and number of liver lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine + nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative/pathology summary: 46-year-old woman with locally advanced invasive ductal carcinoma of the right breast, HER2 amplified on FISH. ER positive, PR negative. Clinical stage prior to therapy was IIIA (T2 N2 M0). She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles. Underwent modified radical mastectomy; final pathology reports a pathologic complete response (no residual invasive carcinoma). No somatic mutation panel was performed on the pre-treatment core biopsy.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 55-year-old man with metastatic cutaneous melanoma (stage IV) diagnosed last year. Molecular profiling: BRAF V600E positive; PD-L1 10%. Initially treated with pembrolizumab but developed new brain mets and enlarging liver lesions after 4 months (progression). Switched to targeted therapy with dabrafenib plus trametinib; follow-up PET/CT shows reduction in liver lesions but persistent small enhancing brain lesions \u2014 overall mixed response.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma. CT abdomen shows multiple hypodense lesions throughout the liver consistent with metastatic disease. Tumor sequencing returned KRAS G12D and MSI-high by PCR. Given MSI-H status he was started on pembrolizumab monotherapy. Follow-up CT at 12 weeks shows no new lesions and minimal change in size of known lesions\u2014assessment: stable disease.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic colorectal adenocarcinoma. Primary sigmoid tumor with carcinomatosis and multiple peritoneal implants on CT; peritoneal biopsy positive. Molecular profiling shows KRAS G12D mutation; MSI testing is stable. Staged as IV. Patient started on FOLFOX with bevacizumab; CT at 12 weeks demonstrates stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core needle biopsy: invasive ductal carcinoma of the breast. ER negative, PR negative, HER2 3+ by IHC with confirmatory HER2 amplification on FISH. Clinical notes indicate chest wall involvement; staged as IIIB. The patient received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles. Surgical specimen demonstrated no residual invasive carcinoma \u2014 pathologic complete response. No distant metastatic disease identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "paclitaxel; trastuzumab; pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male diagnosed with lung adenocarcinoma in 2022 presenting with headaches and back pain. Staging workup showed stage IV disease with brain and bone metastases. Molecular testing: EGFR L858R and acquired EGFR T790M detected on plasma NGS; PD-L1 reported at 30% and TMB-high (12 muts/Mb). Treatment course: started osimertinib and after oligoprogressive brain mets received stereotactic radiosurgery; bevacizumab was added to osimertinib in a clinical protocol. Most recent imaging demonstrates a sustained partial response in thoracic disease and reduction of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 30%; TMB-high (12 muts/Mb)", "treatment": "osimertinib + bevacizumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic colon adenocarcinoma presenting with multiple liver metastases. Mismatch repair testing demonstrated MSI-H. Comprehensive NGS reported no actionable mutations (KRAS and BRAF wild-type; no targetable alterations identified). He was started on pembrolizumab monotherapy; restaging CT at 12 weeks showed stable size of the hepatic lesions and clinical benefit without shrinkage.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 68-year-old man with metastatic castration-resistant prostate cancer, extensive bone metastases. Germline testing identified a pathogenic BRCA2 mutation and tumor testing showed HRD-positive status. After prior androgen-signaling inhibitors, he was started on olaparib. PSA initially declined but rose at 6 months and radiographic imaging confirmed progression.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 (pathogenic germline)", "biomarker": "HRD-positive", "treatment": "olaparib (after androgen-signaling inhibitor)", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 68-year-old F diagnosed with lung adenocarcinoma in 01/2024. Comprehensive NGS identified EGFR L858R mutation; ALK and ROS1 negative. PD-L1 TPS reported at 10%. Staging PET/CT shows bilateral pulmonary nodules and a 2.1 cm cerebellar lesion consistent with metastasis \u2014 clinical stage IV. Patient started osimertinib 80 mg PO daily; dexamethasone given for brain edema. First CT/MRI at 8 weeks demonstrated decrease in size of index lung nodules and reduced enhancement of the cerebellar lesion \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female diagnosed with stage IV lung adenocarcinoma. Tumor genotyping returned EGFR L858R. PD-L1 by IHC is 5%. She was started on osimertinib 80 mg daily after presentation with neurologic symptoms; MRI confirmed brain and leptomeningeal metastases. Interim CT chest shows a partial response in the pulmonary disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with metastatic lung adenocarcinoma diagnosed May 2024. Tumor sequencing identified an EGFR L858R mutation. Baseline MRI brain demonstrated two small enhancing metastases and bone scan positive for multifocal osseous disease. PD-L1 tumor proportion score reported at 5%. Patient was started on osimertinib 80 mg daily in June; 8-week CT and brain MRI show shrinkage of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing of the biopsy identified EGFR L858R. PD-L1 tumor proportion score reported at 10%. MRI showed multiple enhancing brain lesions and PET/CT demonstrated osseous metastases. She was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and brain MRI at 8 weeks demonstrated shrinkage of pulmonary nodules and decreased enhancement in intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative/pathology report: 48-year-old woman with biopsy-proven invasive ductal carcinoma of the left breast. ER 90%, PR 60%, HER2 amplified by FISH (HER2/CEP17 ratio 3.4). Pre-treatment NGS identified a PIK3CA H1047R mutation. Clinical stage prior to therapy was IIIA. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab, then underwent modified radical mastectomy; final pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chemotherapy visit: Patient with high\u2011grade serous ovarian carcinoma underwent debulking last year. Tumor sequencing demonstrated a deleterious BRCA1 frameshift mutation and genomic instability consistent with HRD. CA\u2011125 remains elevated. She completed 6 cycles carboplatin and paclitaxel with bevacizumab and is now on maintenance olaparib. Disease has been stable by CT for 4 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": "BRCA1 (deleterious frameshift)", "biomarker": "HRD positive; CA-125 elevated", "treatment": "carboplatin and paclitaxel with bevacizumab (completed); maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man referred for elevated PSA and prostate cancer. Biopsy: adenocarcinoma, Gleason 3+4=7. Clinical exam and imaging consistent with localized disease, clinical stage II (T2bN0M0). Pre-op PSA 7.4 ng/mL. Underwent radical prostatectomy; margins negative. No somatic mutation testing was performed. Received adjuvant pelvic radiation for adverse pathologic features. Patient currently has undetectable PSA and no biochemical recurrence.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 7.4 ng/mL (pre-op); postoperative undetectable PSA", "treatment": "radical prostatectomy; adjuvant pelvic radiation", "response": "no biochemical recurrence / undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing identified EGFR L858R. PD-L1 TPS reported at 10%. Staging shows multiple brain metastases and osseous disease on MRI and bone scan. Patient was started on osimertinib and underwent stereotactic radiosurgery to a solitary cerebellar lesion. Interval CT chest/abdomen shows decrease in size of pulmonary nodules and shrinkage of brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib + stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Biopsy and plasma NGS demonstrated EGFR exon 19 deletion and acquired EGFR T790M. PD-L1 TPS reported at 20% and TMB-high (13 muts/Mb). Staging CT/MRI consistent with stage IV disease with multiple cerebellar metastases treated with stereotactic radiosurgery and lytic lesions in the femur. Patient was started on osimertinib; first restaging CT after 8 weeks shows shrinkage of target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; EGFR T790M", "biomarker": "PD-L1 20%; TMB-high (13 muts/Mb)", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress: 68-year-old male with biopsy-proven colorectal adenocarcinoma with peritoneal carcinomatosis. Tumor NGS shows KRAS G12D and PCR-based testing returned MSI-H. Initial therapy was FOLFOX plus bevacizumab; restaging after 4 months showed progression. Switched to pembrolizumab monotherapy as second-line for MSI-H disease and repeat CT at 12 weeks demonstrates shrinkage of peritoneal implants \u2014 partial response noted.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab (second-line)", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with high-grade serous ovarian carcinoma, bulky pelvic disease with omental caking consistent with stage IIIC. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. BRCA testing was not performed and no molecular biomarkers were reported in the chart. Post-treatment imaging showed no definite residual disease and CA-125 normalized to within the reference range.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "carboplatin + paclitaxel (surgery followed by adjuvant chemotherapy)", "response": "complete clinical response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma, liver-dominant disease at presentation. Tumor profiling identified KRAS G12D and MSI-H on PCR. Given the MSI-H status he was started on pembrolizumab monotherapy and has had disease control with stable disease on scans at 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with metastatic cutaneous melanoma with cerebral and pulmonary metastases. Tumor sequencing positive for BRAF V600E. She received first-line pembrolizumab but developed intracranial progression; therapy was changed to dabrafenib and trametinib with marked shrinkage of extracranial lesions. PD-L1 and TMB were not reported in the pathology addendum.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (initial), then dabrafenib and trametinib", "response": "mixed response (progression on pembrolizumab, partial response on dabrafenib + trametinib)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH, ER positive, PR negative. Next-generation sequencing identified a PIK3CA E545K mutation. She received neoadjuvant combination therapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) followed by definitive surgery. Pathology after surgery showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with newly diagnosed prostate adenocarcinoma, Gleason 3+4 on biopsy. Clinical staging consistent with stage II disease. PSA at diagnosis was 18 ng/mL. He received definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide). On follow-up PSA is 0.2 ng/mL and he remains without radiographic evidence of metastasis.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 18 ng/mL (diagnosis); PSA 0.2 ng/mL (follow-up)", "treatment": "external beam radiation; androgen deprivation therapy (leuprolide)", "response": "biochemical response (PSA down to 0.2 ng/mL)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with a new diagnosis of invasive ductal carcinoma of the left breast. Tumor is ER positive, PR positive and HER2 negative by IHC/ISH. Pathology staged as IIA (T2N0M0). Molecular testing identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant radiation and was started on tamoxifen. Post-op imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative pathology: 48-year-old female with a 2.8 cm invasive ductal carcinoma of the right breast, stage IIA (T2N0M0). Tumor is ER positive (90%), PR positive (20%), HER2 negative by IHC (0). Molecular testing identified a PIK3CA H1047R mutation. Patient underwent lumpectomy with sentinel node biopsy followed by adjuvant radiation and is planned for endocrine therapy with letrozole.", "output": {"cancer_type": "invasive ductal carcinoma of the right breast", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy with sentinel node biopsy; adjuvant radiation; planned letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. PD-L1 expression was tested and reported <1%. Imaging shows multiple brain metastases including one hemorrhagic lesion. He was treated with dabrafenib in combination with trametinib; after an initial response the disease progressed at 6 months with new intracranial and pulmonary lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old man with widely metastatic cutaneous melanoma. Tumor profiling shows BRAF V600E mutation; PD-L1 tumor staining <1%. Staging CT demonstrates multiple bilateral pulmonary nodules consistent with metastatic disease. He was started on dabrafenib plus trametinib and had a marked decrease in size of the lung nodules with a partial response at the 8-week scan.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presenting with ascites. CT demonstrates multiple peritoneal nodules and hepatic metastases consistent with stage IV disease. Tumor testing returned MSI-H by PCR and TMB-high (22 muts/Mb). No actionable somatic point mutations were identified on the panel. He was started on pembrolizumab monotherapy and has had a sustained complete radiographic response at 12 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high (22 muts/Mb)", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "peritoneum; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 FISH positive (HER2 amplification). Multidisciplinary team recommended neoadjuvant therapy with trastuzumab, pertuzumab and docetaxel x6 cycles followed by surgery. No germline testing recorded in this note. Preoperative imaging showed marked clinical response with near-complete resolution of the primary mass. No distant mets identified on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "clinical complete response (near-complete)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented to the ER with progressive jaundice and weight loss; imaging revealed a pancreatic head mass with multiple liver hypodense lesions. Diagnosed pancreatic ductal adenocarcinoma, stage IV. No targeted sequencing was performed due to rapid clinical decline. Started palliative gemcitabine and nab-paclitaxel; after three cycles the scans show interval growth of hepatic lesions and new ascites consistent with progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with metastatic colorectal adenocarcinoma. CT abdomen/pelvis shows omental caking and ascites consistent with peritoneal carcinomatosis. Tumor genotyping revealed KRAS G12D; microsatellite testing was MSS. He received FOLFOX plus bevacizumab as first-line systemic therapy. Follow-up imaging demonstrates interval enlargement of peritoneal implants \u2014 clinical impression: progression of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old male with newly diagnosed colorectal adenocarcinoma presenting with multiple hepatic lesions on CT consistent with metastases. NGS revealed a KRAS G12D mutation. He underwent hepatic artery embolization for dominant liver lesion and was treated systemically with FOLFOX; bevacizumab was added to the regimen. Interval imaging documents increase in size of several hepatic metastases consistent with progression. MSI status was not available in the clinic note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab; hepatic artery embolization", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: 55-year-old with metastatic cutaneous melanoma, primary excised last year. Now with pulmonary nodules and small bilateral adrenal deposits \u2014 stage IV. Tumor sequencing shows NRAS Q61R mutation. PD-L1 was 20% and tumor mutational burden reported as TMB-high. She was started on pembrolizumab monotherapy. At 12 weeks the scans demonstrate minor change without new lesions; overall disease is felt to be stable.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 20%; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "lung, adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male diagnosed with localized prostate adenocarcinoma (Gleason 3+4). Clinical stage was T2cN0M0 (stage II). He underwent radical prostatectomy with negative margins. Post-op surveillance showed a rising PSA and he was started on leuprolide depot for biochemical recurrence. No genomic testing was performed and no imaging evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; androgen deprivation therapy (leuprolide)", "response": "stable PSA on ADT", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old man with metastatic cutaneous melanoma. Tumor sequencing detected BRAF V600E. Baseline PD-L1 was reported at 60%. He was started on dabrafenib plus trametinib and achieved a partial response for approximately six months; later progression occurred with new intracranial metastases and pembrolizumab was initiated.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib; later pembrolizumab", "response": "initial partial response followed by progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with newly diagnosed lung adenocarcinoma, stage IV. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Imaging demonstrates brain and bone metastases. She was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to two cerebellar lesions. At 12-week restaging CT/MRI there is a decrease in size of pulmonary and osseous lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing identified a BRAF V600E mutation and the tumor was MSI-H. He received first-line FOLFOX with bevacizumab, then was switched to pembrolizumab due to MSI-H status. After 4 cycles of pembrolizumab there was progression in the liver and plans were made to start encorafenib plus cetuximab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female referred for locally advanced breast cancer. Core biopsy showed invasive ductal carcinoma, ER-/PR-, HER2 IHC 3+ with confirmed HER2 amplification by FISH. Clinical exam and imaging consistent with T2N2 disease (clinical stage IIIA). Patient received neoadjuvant chemotherapy with dose-dense AC followed by weekly paclitaxel combined with trastuzumab and pertuzumab. She proceeded to mastectomy with sentinel node sampling; final pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+ / FISH+), ER negative, PR negative", "treatment": "dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic non-small cell lung cancer (adenocarcinoma). Initial staging revealed multiple pulmonary nodules with brain and bone lesions consistent with metastases. Tumor NGS returned EGFR L858R. PD-L1 by IHC was 10%. He was started on osimertinib 80 mg PO daily; restaging CT and brain MRI at 8 weeks showed decrease in size of the lung and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "non-small cell lung cancer (adenocarcinoma)", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain; bone; lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note and oncology plan: 71-year-old male with right-sided colon adenocarcinoma, stage III (pT3N1). Tumor testing: MSI-H and BRAF V600E positive. He underwent right hemicolectomy in January and completed adjuvant FOLFOX for 6 months. Surveillance CT scans are negative and CEA normalized; patient currently has no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma with numerous hepatic metastases. Tumor testing returned MSI-H on PCR and PD-L1 CPS 5%. Extended RAS panel was negative and no actionable point mutations were reported. He was started on FOLFOX in combination with pembrolizumab per multidisciplinary tumor board. After three months the patient has radiographic stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; PD-L1 5%", "treatment": "FOLFOX plus pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with newly diagnosed localized prostate adenocarcinoma, clinical stage T2bN0 (stage II), Gleason 3+4. Germline testing positive for BRCA2 pathogenic variant. Underwent robotic radical prostatectomy followed by adjuvant radiation due to positive margins. PSA undetectable post-treatment.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "radical prostatectomy; adjuvant radiation", "response": "complete response / PSA undetectable", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old with high-grade serous ovarian carcinoma presenting with bulky peritoneal disease. Operative note: optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel x6 cycles. No germline or somatic BRCA testing available in chart. Post-chemotherapy CT shows no measurable residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "no measurable residual disease (complete clinical response)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with metastatic cutaneous melanoma. Biopsy of a supraclavicular node showed BRAF V600E mutation. Staging consistent with stage IV with small pulmonary nodules and a single 8 mm cerebellar metastasis. Patient started combination targeted therapy with dabrafenib and trametinib and underwent stereotactic radiosurgery to the brain lesion. Follow-up imaging revealed complete response of extracranial disease but persistent enhancement in the brain lesion consistent with a mixed response. Tumor mutational burden was reported as high (TMB-high).", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIA. Core biopsy: ER positive, PR negative, HER2 amplified (IHC 3+; FISH positive). Tumor NGS showed PIK3CA H1047R mutation. Received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) x6 cycles followed by lumpectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER+, PR-", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic papillary thyroid carcinoma. Sequencing identified BRAF V600E. He initially received radioactive iodine but had persistent pulmonary nodules; subsequently started on lenvatinib with radiographic disease control on first follow-up. No formal stage documented in current note.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "radioactive iodine; lenvatinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma presented with progressive cough and 10 lb weight loss. Staging PET/CT demonstrated extensive disease with multiple brain and bone lesions consistent with metastases; clinical stage IV. Molecular testing identified EGFR L858R mutation. PD-L1 TPS reported at 10%. He was started on first-line osimertinib 80 mg daily. Follow-up CT and MRI at 8 weeks showed decrease in size of pulmonary nodules and CNS lesions, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with hepatic lesions and peritoneal implants. Tumor sequencing: BRAF V600E mutation. MSI testing returned MSI-H and TMB-high. Patient received FOLFOX plus bevacizumab as cytotoxic backbone, then transitioned to pembrolizumab given MSI-H status. Imaging after 3 months of pembrolizumab demonstrated a partial radiographic response in the liver lesions and decreased peritoneal disease burden.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab followed by pembrolizumab", "response": "partial response", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer (clinical T4N1, treated as stage IIIB). Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH; PIK3CA H1047R mutation detected on NGS. Neoadjuvant regimen was combination trastuzumab and pertuzumab with docetaxel for six cycles followed by definitive surgery. Postop pathology showed no residual invasive tumor (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old male with newly diagnosed metastatic non-small cell lung cancer (adenocarcinoma). Staging workup consistent with Stage IV disease with osseous and intracranial lesions. Molecular testing returned EGFR exon 19 deletion; PD-L1 tumor proportion score 20% and blood-based TMB reported as high. Patient received 4 cycles of carboplatin and pemetrexed with pembrolizumab (chemo-immunotherapy) with a partial radiographic response in the chest but subsequent CNS progression; switched to osimertinib after EGFR result. Current plan: continue osimertinib and stereotactic radiosurgery to brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 20%; TMB-high", "treatment": "carboplatin + pemetrexed + pembrolizumab \u2192 osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV cutaneous melanoma presenting with multiple pulmonary nodules and supratentorial brain metastases. Molecular testing positive for BRAF V600E. PD-L1 expression was reported at 5% on tumor cells. He was started on dabrafenib plus trametinib with symptomatic improvement and radiographic partial response for five months; on progression he was switched to combination ipilimumab and nivolumab and currently has stable disease on interval imaging.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; ipilimumab and nivolumab", "response": "stable disease", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 63-year-old woman with metastatic breast cancer, initially ER positive/PR negative, HER2 amplification on FISH. Biopsy of a symptomatic vertebral lesion confirmed metastatic carcinoma. NGS revealed a PIK3CA H1047R mutation. She received docetaxel with trastuzumab and pertuzumab; current scans after 3 cycles show disease control without new lesions.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress visit: 69-year-old male with metastatic prostate adenocarcinoma, known bone metastases and rising PSA. Staged as IV at diagnosis. No somatic mutation testing available in chart. Patient started on androgen deprivation therapy with leuprolide and oral enzalutamide; PSA has stabilized and scans show no new lesions \u2014 disease clinically stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; enzalutamide", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 68-year-old male with metastatic colorectal adenocarcinoma, stage IV with peritoneal carcinomatosis. Tumor sequencing identified BRAF V600E mutation and tumor is MSI-H on PCR testing. Initial therapy with FOLFOX and bevacizumab produced stable disease; because of MSI-H, pembrolizumab was commenced and imaging has shown sustained stable disease on three-month intervals.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric artery, consistent with unresectable stage III disease. CA19-9 elevated to 900 U/mL at diagnosis. Germline/NGS testing was not performed. He received FOLFIRINOX x6 cycles followed by consolidative chemoradiation with capecitabine. Interval imaging demonstrates stable disease without distant metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 900 U/mL", "treatment": "FOLFIRINOX, chemoradiation with capecitabine", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with unresectable melanoma harboring a BRAF V600E mutation who presented with a painful sacral lesion confirmed to be metastatic melanoma. He was treated with dabrafenib and trametinib with symptomatic improvement and radiographic stable disease for nine months; PD-L1 testing was not performed prior to therapy.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with right-sided colon adenocarcinoma presenting with multiple liver metastases. Tumor sequencing identified a BRAF V600E mutation and MSI-H status on PCR-based testing. He started FOLFOX plus bevacizumab and had radiographic stable disease on the first two CT scans. At 6 months the liver disease progressed and therapy was switched to pembrolizumab on protocol; most recent scan documents progressive hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; later pembrolizumab", "response": "initial stable disease then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with locally advanced invasive ductal carcinoma of the right breast. Tumor is ER-positive, PR-positive and HER2 amplified by FISH. NGS detected PIK3CA H1047R. She received neoadjuvant trastuzumab, pertuzumab and docetaxel for six cycles followed by lumpectomy. Surgical pathology showed marked tumor reduction consistent with a partial response to neoadjuvant therapy. No distant metastases identified on staging scans.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER-positive, PR-positive", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant) followed by surgery", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 68-year-old with metastatic colorectal adenocarcinoma to the liver. Molecular profiling: KRAS G12D mutation; tumor is MSI-H and PD-L1 about 10%. Patient initially received FOLFOX plus bevacizumab with mixed response in hepatic lesions, then was switched to pembrolizumab given MSI-H status. After 4 cycles of pembrolizumab there is a measurable partial response of the dominant hepatic metastasis.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H, PD-L1 10%", "treatment": "FOLFOX plus bevacizumab; then pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma, extensive osseous metastases on bone scan. Clinical stage IV. He received six cycles of docetaxel followed by abiraterone acetate with prednisone. No tumor NGS was performed and AR-V7 testing was not available at our center. PSA has declined and cross-sectional imaging shows stable osseous disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel followed by abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male referred for progressive colorectal cancer. CT shows multiple liver metastases and several new pulmonary nodules. Biopsy confirms colorectal adenocarcinoma, stage IV. Next-generation sequencing identified KRAS G12D; tumor is microsatellite stable (MSS). Patient was started on FOLFOX with bevacizumab; interval imaging after three cycles demonstrated increase in size and number of lesions consistent with radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma diagnosed after weight loss and cough. Biopsy: lung adenocarcinoma, stage IV with multiple bone and brain lesions on PET/MRI. Molecular testing: EGFR L858R; PD-L1 tumor proportion score ~10%. He was started on osimertinib and had an initial partial response in thoracic disease and improvement of bone pain, but progressed intracranially after 14 months and was switched to platinum-based chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 ~10%", "treatment": "osimertinib (then switched to platinum-based chemotherapy after progression)", "response": "initial partial response, later progression", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with low-risk prostate adenocarcinoma, clinical stage T1cN0M0 (stage I). PSA at diagnosis was 6.8 ng/mL. He underwent radical prostatectomy with negative margins and undetectable PSA post\u2011op. Germline and somatic testing were not performed. No radiographic evidence of metastasis.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "complete response / undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with ulcerated cutaneous melanoma of the back. Sentinel lymph node positive; final staging IIIC. Molecular testing detected BRAF V600E. He completed adjuvant therapy with dabrafenib plus trametinib for one year and surveillance scans at 6 and 12 months show no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "complete response / no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic visit note: 62-year-old male diagnosed with lung adenocarcinoma after biopsy of right upper lobe mass. Staging workup demonstrated multiple small brain metastases on MRI and bilateral pulmonary nodules consistent with stage IV disease. Molecular testing returned EGFR L858R mutation (PCR) and PD-L1 15% TPS. He was started on osimertinib 80 mg daily. Interval CT and brain MRI at 8 weeks show decrease in size of the primary lesion and partial resolution of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, biopsy positive for BRAF V600E. Tumor testing reported MSI-H and TMB-high. Predominant disease in the liver consistent with stage IV disease. Initiated pembrolizumab monotherapy; interval imaging at 12 weeks documented a partial response with shrinkage of hepatic metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 62-year-old female diagnosed with lung adenocarcinoma in 2023. Staging workup demonstrated stage IV disease with multiple intracranial lesions and lytic lesions in the pelvis. Molecular testing returned EGFR L858R and PD-L1 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. After 3 months of treatment there is a documented partial response on CT chest and reduction in brain metastases on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female diagnosed with high-grade serous ovarian carcinoma, optimally cytoreduced at primary debulking. Pathology staged as IIIC. Germline testing revealed a deleterious BRCA1 frameshift mutation. Postoperative therapy consisted of carboplatin and paclitaxel for six cycles followed by maintenance olaparib. CA-125 normalized with therapy and surveillance CT at 3 months shows no evidence of residual disease \u2014 clinical complete response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious)", "biomarker": "CA-125 elevated at diagnosis, normalized on treatment", "treatment": "debulking surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital note: 78-year-old man with metastatic castration-resistant prostate adenocarcinoma with diffuse sclerotic bone metastases. He is on androgen deprivation therapy and completed six cycles of docetaxel. PSA on admission 92 ng/mL (down from 180 prior to chemo). No genomic alterations reported on chart. Clinician assessment: disease clinically stable on current regimen.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 92 ng/mL", "treatment": "androgen deprivation therapy and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Initial NGS showed an EGFR exon 19 deletion; after progression on erlotinib, repeat biopsy identified secondary EGFR T790M. PD-L1 was 10% by IHC. Patient was started on osimertinib in combination with bevacizumab and has had a partial response with shrinkage of intracranial and osseous lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib; osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female diagnosed with metastatic lung adenocarcinoma in 11/2023. NGS returned EGFR L858R mutation and PD-L1 tumor proportion score about 10%. MRI brain demonstrates multiple enhancing lesions consistent with CNS metastases. Patient started osimertinib 80 mg PO daily; repeat CT and brain MRI at 8 weeks show decrease in size of pulmonary nodules and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score was 10%. She presented with headaches and MRI confirmed multiple brain metastases. Started osimertinib 80 mg daily in January 2020 with marked radiographic improvement of pulmonary lesions and reduction of intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman diagnosed with ER-positive, PR-negative, HER2 3+ invasive ductal carcinoma of the left breast. Core biopsy molecular testing demonstrated PIK3CA H1047R. Clinical stage was recorded as IIB. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab, underwent lumpectomy and sentinel node biopsy and final pathology showed a pathological complete response. Continues adjuvant trastuzumab per protocol.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER+, PR-", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab, lumpectomy", "response": "pathologic complete response", "metastasis_site": "none"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 38-year-old with cutaneous melanoma on the right forearm, Breslow 1.8 mm, ulceration absent. Sentinel node negative; pathologic stage II. Wide local excision performed with clear margins. PD-L1 by IHC low at ~5%. BRAF testing was negative. Patient placed on active surveillance; no systemic therapy administered.", "output": {"cancer_type": "melanoma", "stage": "II", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "wide local excision; active surveillance", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "ED/oncology note: 71-year-old male with metastatic colorectal adenocarcinoma, stage IV, KRAS G12D mutation identified on tumor NGS. CT shows multiple hepatic lesions and bilateral pulmonary nodules. He was started on FOLFOX plus bevacizumab two months ago. CEA has risen from 18 to 32 ng/mL and interval imaging demonstrates increase in size of liver metastases \u2014 overall assessment: progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA rising", "treatment": "FOLFOX plus bevacizumab", "response": "progressive disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced breast cancer. Core biopsy showed invasive ductal carcinoma, ER-positive, PR-negative, and IHC demonstrated strong HER2 overexpression with confirmed HER2 amplification by FISH. Clinical stage was IIIA with fixed axillary nodes. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for six cycles followed by mastectomy. Surgical pathology reported no residual invasive tumor (pathologic complete response). No molecular sequencing was performed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP), mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with headaches and was found to have metastatic lung adenocarcinoma. NGS revealed an EGFR L858R mutation. PD-L1 TPS was reported at 10%. Brain MRI showed a 1.5 cm cerebellar metastasis. He was started on osimertinib 80 mg daily as first-line therapy; 12-week restaging CT/MRI demonstrated marked reduction in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology follow-up: 59-year-old male with cutaneous melanoma of the right forearm, sentinel node positive. Final pathologic stage IIIB. Molecular testing: NRAS Q61K identified. PD-L1 on tumor cells approximately 5%. Patient was started on nivolumab monotherapy; 12-week review documents shrinkage of nodal disease but residual palpable axillary nodes \u2014 overall assessment: stable disease by RECIST.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "NRAS Q61K", "biomarker": "PD-L1 5%", "treatment": "nivolumab", "response": "stable disease", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 59F diagnosed with locally advanced pancreatic ductal adenocarcinoma with encasement of the portal vein and satellite lesions in the liver on staging CT consistent with metastatic progression. Tumor markers: CA 19-9 elevated to 1,200 U/mL. She received palliative gemcitabine plus nab-paclitaxel and short-course focal radiation for pain control. Despite therapy, scans show interval enlargement of hepatic metastases and new ascites.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 elevated (1200 U/mL)", "treatment": "gemcitabine and nab-paclitaxel; palliative radiation", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology records for a 59-year-old female with high-grade serous ovarian carcinoma. Optimal debulking followed by adjuvant carboplatin and paclitaxel x6 resulted in partial radiographic response; ascites decreased but CT shows persistent peritoneal implants. Germline testing returned BRCA1 pathogenic variant. Patient started maintenance olaparib. Final pathology staged disease as IIIC.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": null, "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed metastatic lung adenocarcinoma who presented with cough and weight loss. Imaging shows multiple pulmonary nodules and enhancing lesions in the cerebellum and thoracic spine consistent with metastases. Tumor sequencing returned EGFR L858R and PD-L1 10% by IHC. She was started on osimertinib 80 mg daily in April and received stereotactic radiosurgery to the brain lesion. Interval CT and MRI demonstrate decrease in size of the lung lesions and improvement in bone pain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male referred to oncology for metastatic clear cell renal cell carcinoma. CT abdomen shows a 6-cm left renal mass with extension into the ipsilateral adrenal and several enlarged retroperitoneal lymph nodes. No targeted genomic testing documented in the chart. He was started on pembrolizumab plus axitinib; clinic notes report symptomatic improvement with decreased flank pain. Stage not recorded on referral.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "pembrolizumab and axitinib", "response": "symptomatic improvement", "metastasis_site": "adrenal gland, retroperitoneal lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female diagnosed with lung adenocarcinoma. Staging PET/CT confirmed stage IV disease with intracranial and osseous metastases. Molecular testing from biopsy showed EGFR L858R mutation. PD-L1 expression reported at 5% (22C3). Patient was started on osimertinib 80 mg PO daily. Interval imaging at 3 months demonstrates decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with unresectable metastatic melanoma presenting with multiple lung nodules. Tumor sequencing identified BRAF V600E. He initially received pembrolizumab but progressed after four cycles and was transitioned to dabrafenib plus trametinib. Interval scans show enlarging pulmonary lesions consistent with progressive disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib plus trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recurrent cutaneous melanoma of the left forearm with palpable axillary nodes. Molecular testing positive for BRAF V600E. Patient initially underwent wide local excision and was started on adjuvant pembrolizumab but developed multiple new pulmonary nodules on restaging CT. Therapy was changed to dabrafenib plus trametinib; despite targeted therapy the lung lesions progressed.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung, axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with metastatic prostate adenocarcinoma, bone pain and widespread osteoblastic lesions on bone scan. Germline and somatic testing identified a deleterious BRCA2 frameshift. He was treated with androgen deprivation therapy plus docetaxel and subsequently transitioned to olaparib for maintenance. PSA has stabilized and repeat imaging shows no new osseous lesions; clinical status recorded as stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (deleterious frameshift)", "biomarker": null, "treatment": "androgen deprivation therapy, docetaxel, then olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: 48-year-old female with metastatic invasive ductal carcinoma of the breast. ER positive, PR negative; HER2 amplification by FISH. FoundationOne report identified a PIK3CA H1047R mutation. Staging at diagnosis was IV with multiple hepatic lesions. She commenced first-line docetaxel with trastuzumab and pertuzumab. After three cycles, CT shows decrease in target liver lesions compared with baseline.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Liquid biopsy positive for EGFR L858R; tumor PD-L1 expression 10% by IHC. Baseline staging showed lesions in lung and single cerebellar metastasis treated with stereotactic radiosurgery. Started first-line osimertinib 80 mg daily in June; interval CT at 3 months demonstrates decrease in target lesions consistent with partial response. No chemotherapy given to date.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed lung adenocarcinoma. Presenting with cough and weight loss; CT chest/abdomen demonstrates primary right upper lobe mass and multiple enhancing lesions in the brain and bones consistent with metastases. Biopsy confirms adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 TPS 10%. He was started on osimertinib 80 mg daily as first-line therapy and after 8 weeks shows reduction in size of the pulmonary lesion and decreased cerebral edema on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with rising PSA referred for urology. Biopsy: acinar adenocarcinoma of the prostate with Gleason 3+4 in 3 cores. Clinical stage T2b. PSA 9.8 ng/mL. No genomic testing performed. Underwent radical prostatectomy followed by adjuvant pelvic radiation given close margins. Post-treatment PSA undetectable and patient is without evidence of disease at 6-month follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy followed by adjuvant pelvic radiation", "response": "no evidence of disease (PSA undetectable) at 6 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic invasive ductal carcinoma of the breast. Core biopsy: ER+/PR+, HER2 3+ (IHC). Staging CT shows multiple hepatic lesions consistent with liver metastases. Next-generation sequencing identified a PIK3CA H1047R mutation. She was treated with first-line trastuzumab and pertuzumab in combination with paclitaxel; follow-up scans after 3 months indicate stable disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+ (IHC); ER+/PR+", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male with locally advanced, borderline resectable pancreatic adenocarcinoma involving the superior mesenteric vessels \u2014 staged as III. Multidisciplinary tumor board recommended systemic therapy with gemcitabine plus nab-paclitaxel with concurrent chemoradiation. Interim imaging after two months shows stable disease; there is no evidence of distant metastatic spread.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel with concurrent radiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic pancreatic ductal adenocarcinoma diagnosed 2022. Initial staging consistent with stage IV disease with multiple liver metastases. Germline testing revealed a deleterious BRCA2 mutation. She received first-line FOLFIRINOX with good initial clinical benefit and then was placed on maintenance olaparib. After six months of maintenance therapy she developed radiographic progression with enlarging hepatic lesions and new peritoneal nodules documented on CT.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib (maintenance)", "response": "progressive disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman diagnosed with HER2-positive invasive ductal carcinoma of the left breast. Initial workup showed extensive axillary nodal involvement and multiple hepatic lesions; overall staging recorded as stage IV. IHC: HER2 3+, ER/PR negative confirming HER2 amplification. She received docetaxel and carboplatin with trastuzumab followed by maintenance trastuzumab and pertuzumab. Recent liver MRI demonstrates no interval growth of the known lesions (stable disease).", "output": {"cancer_type": "HER2-positive breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+)", "treatment": "docetaxel, carboplatin and trastuzumab; maintenance trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. Staging CT and MRI demonstrated stage IV disease with brain and bone metastases at presentation. Molecular testing returned EGFR L858R mutation and PD-L1 tumor proportion score 60%. She was started on osimertinib 80 mg daily and had a partial response on first follow-up imaging at 8 weeks; later developed liver progression and was switched to carboplatin and pemetrexed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib; carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma on the left forearm, Breslow depth 2.6 mm with ulceration. Sentinel lymph node was negative. Molecular testing identified BRAF V600E. Clinical stage IIA. Patient treated with wide local excision with negative margins; no adjuvant systemic therapy recommended. Surveillance dermatology and imaging show no evidence of recurrence to date.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and follow-up oncology note: 65-year-old with high-grade serous ovarian carcinoma, underwent optimal cytoreductive surgery with omentectomy. Final pathology: FIGO stage IIIC with omental and peritoneal implants. Germline testing positive for deleterious BRCA1 mutation; HRD assay reported positive. Patient received adjuvant carboplatin and paclitaxel x6 and is currently on maintenance olaparib with no radiographic evidence of disease \u2014 complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline deleterious mutation)", "biomarker": "HRD-positive", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and discharge summary: 68-year-old man underwent elective sigmoid colectomy for adenocarcinoma. Final pathologic stage pT3N1 (stage III). He completed adjuvant FOLFOX for 12 cycles without complication. Surveillance CT at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III (pT3N1)", "gene_mutation": null, "biomarker": null, "treatment": "adjuvant FOLFOX x12", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report and discharge summary: 56-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for BRCA1 185delAG. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel. Currently on olaparib maintenance; CA-125 has normalized and CT chest/abdomen/pelvis shows no evidence of disease \u2014 complete clinical response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 (elevated at diagnosis, now normalized)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: patient with cutaneous melanoma of the right scalp, sentinel node positive \u2192 pathologic stage III. Molecular profiling detected BRAF V600E. He underwent wide local excision and completion lymphadenectomy, followed by adjuvant targeted therapy with dabrafenib plus trametinib. Recent PET/CT demonstrated resolution of prior nodal FDG uptake. Clinician documents complete response in the regional nodal basin.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, completion lymphadenectomy, adjuvant dabrafenib + trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma clinic: 52-year-old male with unresectable metastatic cutaneous melanoma. Baseline staging demonstrated multiple cerebral metastases and extracranial disease \u2014 overall stage IV. Tumor sequencing revealed BRAF V600E. He commenced dabrafenib with trametinib and had a dramatic reduction of extracranial disease with complete radiographic response at 12 weeks. Three months later he developed progressive headaches and MRI confirmed new intracranial progression; whole brain radiation was administered.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; whole brain radiation", "response": "initial complete response extracranially, then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging CT shows multiple lung nodules and a lytic lesion in T8; MRI brain demonstrates two small enhancing metastases. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 TPS 10%. Patient started on osimertinib 80 mg daily with symptomatic improvement. First restaging CT at 8 weeks shows interval decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with metastatic lung adenocarcinoma (stage IV) after CT and brain MRI. Tumor genotyping returned EGFR L858R and PD-L1 TPS 15%. She was started on osimertinib 80 mg PO daily in January. Interval imaging demonstrates decrease in size of the primary and intracranial lesions consistent with a partial response. Known sites of disease include multiple brain metastases and lytic lesions in the thoracic spine.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dictated consult: 47-year-old with recurrent cutaneous melanoma of the back. Molecular testing positive for BRAF V600E. PET-CT demonstrates multiple pulmonary nodules most suspicious for metastatic disease. Patient started on dabrafenib with trametinib; PET at 12 weeks shows complete metabolic response. No formal AJCC stage assigned in the chart at this visit.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with metastatic HER2-positive breast cancer, ER+/PR-. NGS identified a PIK3CA H1047R mutation and FISH confirmed HER2 amplification. Bone scan shows diffuse osteoblastic bone lesions. She was started on docetaxel with trastuzumab and pertuzumab as first-line therapy. After four cycles the disease is radiographically stable.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR-", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female with metastatic sigmoid colon adenocarcinoma presenting with bulky right hepatic lobe lesions. Staging consistent with stage IV disease. Tumor profiling: BRAF V600E mutation and MSI-high; tumor mutational burden reported as TMB-high. She was started on pembrolizumab because of MSI-H and achieved an initial partial response; after progression in the liver she was switched to encorafenib plus cetuximab with subsequent disease stabilization.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab; later encorafenib + cetuximab", "response": "initial partial response to pembrolizumab; later stable disease on encorafenib + cetuximab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male diagnosed with glioblastoma (WHO grade IV) of the right temporal lobe. Molecular testing showed an IDH1 R132H mutation and MGMT promoter methylation positive. He underwent maximal safe resection followed by concurrent radiation with temozolomide and was enrolled on tumor-treating fields. Despite therapy the most recent MRI shows local progression at the resection cavity.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": "IDH1 R132H", "biomarker": "MGMT promoter methylation positive", "treatment": "surgical resection; concurrent radiation and temozolomide; tumor-treating fields", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative record and genetics consult for a 55-year-old female with high-grade serous ovarian carcinoma. At laparotomy there was omental caking and widespread peritoneal implants consistent with FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 variant. Preoperative CA-125 was 980 U/mL. She underwent optimal cytoreductive (debulking) surgery and was started on adjuvant carboplatin and paclitaxel. CT after three cycles shows decrease in volume of peritoneal disease \u2014 partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated (980 U/mL)", "treatment": "primary debulking surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum and omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with sigmoid adenocarcinoma status post resection. Final pathology: tumor with 6/18 positive lymph nodes consistent with stage III disease. Tumor was microsatellite stable (MSS). Extended RAS and BRAF testing reported wild-type (no actionable mutation identified). Patient completed 12 cycles of adjuvant FOLFOX. Surveillance CT at 3 months shows postoperative changes without new distant lesions; disease considered stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSS", "treatment": "FOLFOX", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 67-year-old male with history of prostate cancer status post radical prostatectomy two years ago. Recent PSA rise prompted oncology referral; he was started on androgen deprivation therapy with leuprolide. No molecular testing or metastatic workup documented in the note. Clinician documents biochemical recurrence.", "output": {"cancer_type": "prostate cancer", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation therapy)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma with rising PSA despite ADT. Germline and somatic testing identified a deleterious BRCA2 mutation. He previously received docetaxel and abiraterone; he was transitioned to the PARP inhibitor olaparib. Imaging shows multiple sclerotic bone lesions but current notes do not document TNM stage or biomarker panel beyond BRCA2.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": null, "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "olaparib (after prior docetaxel and abiraterone)", "response": "stable disease (PSA rising previously, on current therapy monitoring)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with newly diagnosed lung adenocarcinoma presenting with headaches. Staging PET/CT consistent with stage IV disease with multiple intracranial lesions. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient started on osimertinib 80 mg daily with CNS-penetrant dosing and has had shrinkage of target lesions on first restaging \u2014 consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology notes: 52-year-old woman with palpable right breast mass; core biopsy showed invasive ductal carcinoma, ER+/PR+/HER2-amplified. Clinical stage prior to therapy cT2N0 (stage IIA). NGS panel detected PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab for 12 weeks and then underwent breast-conserving surgery. Pathology reported no residual invasive carcinoma (pathologic complete response). Adjuvant trastuzumab was continued to complete 1 year.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with a 1.2 cm superficial spreading cutaneous melanoma on the upper back. Breslow depth 0.9 mm, no ulceration, sentinel lymph node biopsy negative. Wide local excision was performed with negative margins; no adjuvant systemic therapy recommended and patient enters dermatologic surveillance. No evidence of recurrent or metastatic disease on current exam.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IA", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated an EGFR L858R mutation. PD-L1 was 5% by IHC. He was started on osimertinib 80 mg daily in January 2020 with clinical improvement; follow-up CT chest/abdomen shows decrease in size of pulmonary nodules consistent with a partial response. Brain MRI in June identified a solitary cerebellar metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old with de novo metastatic breast cancer, ER/PR negative, HER2 amplified on FISH. Staging showed multiple hypodense lesions in the liver on CT consistent with hepatic metastases (stage IV). NGS identified a PIK3CA H1047R mutation. Treated first-line with docetaxel in combination with trastuzumab and pertuzumab. Most recent PET/CT after 3 cycles demonstrates reduction in size and SUV of hepatic lesions \u2014 partial response to therapy.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing identified EGFR exon 21 L858R. PD-L1 tumor proportion score 10%. Began osimertinib 80 mg daily as first-line TKI therapy in January 2020. Serial imaging demonstrates decreased size of multiple pulmonary nodules and reduction in size of brain metastases and lytic lesions in the thoracic spine consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology consult: 45-year-old man with cutaneous melanoma, ulcerated primary of the back and palpable nodes. Staging PET/CT demonstrated pulmonary and small cerebellar metastases consistent with stage IV disease. Tumor testing returned BRAF V600E and high tumor mutational burden (TMB-high). He received first-line pembrolizumab but after two cycles had clinical progression with enlarging cerebellar lesion and new lung nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab", "response": "progressive disease", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular testing returned EGFR exon 21 L858R. PD-L1 tumor proportion score 10%. Staging workup consistent with stage IV disease. Osimertinib 80 mg daily was started in January; interval CT chest/abdomen shows decrease in size of primary and bone lesions. Brain MRI demonstrates two small enhancing metastases (left cerebellar and right frontal). Clinical assessment: partial response to osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging showed multiple enhancing lesions in the brain and lytic lesions in the thoracic spine. Biopsy confirmed metastatic lung adenocarcinoma, EGFR L858R mutation positive on PCR. PD-L1 IHC was 15%. Patient was started on osimertinib 80 mg daily with symptomatic improvement after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/Oncology letter: 35-year-old male with a 1.2 mm superficial spreading melanoma on the left forearm, staged as IA (T1bN0M0) after excision and negative sentinel lymph node. NGS returned BRAF V600E. No adjuvant therapy was recommended; patient observed with serial skin checks and lymph node exams. At last visit the surgical site is healed and there is no clinical evidence of disease.", "output": {"cancer_type": "melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy (negative)", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with advanced ovarian high-grade serous carcinoma. At laparotomy she had optimal cytoreduction; peritoneal and omental tumor implants were present. Final stage IIIC. Germline testing identified a deleterious BRCA2 mutation. Pre-op CA-125 was 120 U/mL. She completed 6 cycles of carboplatin and paclitaxel with complete radiographic and CA-125 normalization and was placed on maintenance olaparib. Current status: complete response on maintenance.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 deleterious germline mutation", "biomarker": "CA-125 120 U/mL (pre-treatment, normalized after therapy)", "treatment": "optimal cytoreductive surgery; carboplatin and paclitaxel (6 cycles); maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and oncology correspondence for a 62-year-old male with metastatic colon adenocarcinoma. Molecular testing: KRAS G12D mutation identified; microsatellite stable. Baseline CEA 72 ng/mL. Liver lesions biopsied and consistent with metastatic colorectal primary. He was initiated on FOLFOX with bevacizumab; after 4 cycles CT abdomen shows no significant change in hepatic lesions \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic cutaneous melanoma. NGS showed BRAF V600E and a high tumor mutational burden (TMB-high). Baseline CT demonstrated pulmonary and hepatic metastases. He started dabrafenib plus trametinib with a mixed radiographic response\u2014several lesions regressed but new small pulmonary nodules appeared; he was switched to pembrolizumab and subsequently had shrinkage of most measurable lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; then pembrolizumab", "response": "mixed response (initial), subsequent partial response", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing confirmed an EGFR exon 19 deletion. Staging at presentation was IV with multiple cerebral metastases. PD-L1 by IHC was 5%. Patient started osimertinib 80 mg daily in May; interval CT chest and MRI brain after eight weeks demonstrate marked decrease in target lesions consistent with a partial response. No prior cytotoxic chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 42-year-old female with ER-positive, PR-negative invasive ductal carcinoma of the left breast. Clinical stage IIIA at presentation. FISH shows HER2 amplification; tumor NGS identified PIK3CA H1047R. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks with marked reduction in tumor size. Underwent lumpectomy; pathology reported residual disease consistent with a partial (pathologic) response. No evidence of distant metastasis on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab; lumpectomy", "response": "partial response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma. Liver-dominant disease on staging CT with multiple hepatic lesions. Molecular testing shows KRAS G12D and microsatellite stable (MSS). CEA elevated at 45 ng/mL. He was started on FOLFIRI with bevacizumab; first restaging CT at 12 weeks showed unchanged size of most lesions consistent with stable disease.", "output": {"cancer_type": "colon cancer (colorectal adenocarcinoma)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable); elevated CEA", "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal breast carcinoma, clinical stage IIIB. Tumor markers: ER positive, PR positive, HER2 amplified by FISH; next\u2011generation sequencing detected a PIK3CA E545K mutation. She received neoadjuvant therapy consisting of docetaxel and carboplatin in combination with dual HER2 blockade (trastuzumab + pertuzumab), then underwent mastectomy with no residual invasive cancer (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER+; PR+; HER2 amplification", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with metastatic cutaneous melanoma harboring BRAF V600E mutation. PD-L1 testing reported 10% expression; tumor was described as TMB-high. She began targeted therapy with dabrafenib and trametinib and achieved an extracranial partial response, but at month 8 developed progressive intracranial disease requiring stereotactic radiosurgery. Systemic therapy was continued with plan to switch if further systemic progression occurs.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%, TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery to brain", "response": "initial partial response followed by intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with unresectable stage IV cutaneous melanoma with brain metastases. Tumor profiling positive for BRAF V600E; PD-L1 >50% and TMB-high reported. He was treated initially with dabrafenib plus trametinib with rapid symptomatic improvement but later developed intracranial progression and was switched to combination immunotherapy with ipilimumab and nivolumab, which produced a partial radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male found to have muscle-invasive urothelial carcinoma of the bladder on TURBT; clinical staging consistent with stage II disease. No comprehensive molecular testing was performed prior to definitive therapy. He underwent radical cystectomy with bilateral pelvic lymph node dissection followed by adjuvant cisplatin-based chemotherapy. Post-operative imaging shows no evidence of disease.", "output": {"cancer_type": "urothelial carcinoma of bladder", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical cystectomy and adjuvant cisplatin-based chemotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma. PET/CT showed pulmonary nodules and multiple intracranial metastases. Tumor sequencing positive for BRAF V600E; tumor mutational burden reported as TMB-high. He was started on dabrafenib and trametinib; after 4 months the extracranial disease is stable by RECIST but brain lesions are being monitored. Given limited intracranial response, nivolumab was added to the plan pending multidisciplinary review.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib; nivolumab planned", "response": "stable disease (extracranial); limited intracranial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a primary cutaneous melanoma of the left forearm, sentinel node positive, staged IIIB. Molecular testing detected BRAF V600E. He underwent wide local excision and then adjuvant targeted therapy with dabrafenib plus trametinib for 12 months. Last clinic note: no evidence of recurrence on exam and imaging.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 62-year-old female presents with newly progressive headaches. MRI shows multiple enhancing lesions consistent with metastatic disease. Lung biopsy confirmed lung adenocarcinoma. Molecular testing identified EGFR L858R mutation. PD-L1 TPS 10%. Patient started osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant brain lesion. Interval CT at 8 weeks demonstrates decrease in intracranial and thoracic disease burden.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery (SRS)", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chief complaint: palpable left breast mass. Biopsy: invasive ductal carcinoma, ER+, PR+, HER2 amplified. Clinical stage IIB (T2 N1 M0). PIK3CA H1047R mutation identified on panel. Patient received neoadjuvant docetaxel and carboplatin with trastuzumab for three cycles prior to lumpectomy; post-op course uneventful and adjuvant trastuzumab planned. Imaging showed decrease in tumor size but persistent involved axillary nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; lumpectomy; adjuvant trastuzumab", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: Core biopsy showed invasive ductal carcinoma, ER positive, PR negative, HER2 amplified (IHC 3+ / confirmed by FISH). Clinical stage before therapy was IIIB. Next-generation sequencing identified a PIK3CA H1047R hotspot mutation. Patient received neoadjuvant trastuzumab, pertuzumab and docetaxel for six cycles followed by modified radical mastectomy and adjuvant radiation. Surgical specimen revealed no residual invasive carcinoma (pathologic complete response). No distant mets identified on preop PET/CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "trastuzumab, pertuzumab and docetaxel; surgery; radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER positive (80%), PR negative. Molecular testing identified a PIK3CA H1047R mutation. She received neoadjuvant combination therapy with trastuzumab, pertuzumab and docetaxel for six cycles. Surgery report states no residual invasive carcinoma on final pathology \u2014 pathologic complete response. No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER-positive, PR-negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47 y/o female with left breast invasive ductal carcinoma, ER positive, PR positive, HER2 amplified. Clinical stage IIB. She received neoadjuvant chemotherapy with docetaxel and carboplatin in combination with trastuzumab, then underwent lumpectomy and sentinel node biopsy. Surgical pathology reported no residual invasive carcinoma consistent with pathologic complete response (pCR). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; lumpectomy", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of a left breast mass: invasive ductal carcinoma. ER positive, PR negative by IHC; HER2 amplification confirmed by FISH. Tumor profiling detected a PIK3CA H1047R mutation. Clinical exam and imaging place disease at stage IIIC with bulky axillary nodal involvement. Neoadjuvant therapy with trastuzumab plus weekly paclitaxel was initiated. After three cycles there is interval shrinkage of the primary and axillary nodes (partial response) and surgery is planned.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIC", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab and paclitaxel", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with de novo metastatic invasive ductal breast carcinoma. CT abdomen showed multiple hepatic lesions consistent with metastases. Biopsy demonstrated HER2 amplification; ER and PR were negative. She was initiated on first-line trastuzumab and pertuzumab with paclitaxel. Interval imaging after 3 cycles reports overall stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with unresectable metastatic cutaneous melanoma. NGS identified NRAS Q61K; PD-L1 testing 20% and tumor mutation burden reported as TMB-high. Brain MRI showed two small asymptomatic metastases. He was started on dual immunotherapy with nivolumab and ipilimumab and has had a documented partial response on interval imaging.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": "PD-L1 20%, TMB-high", "treatment": "nivolumab + ipilimumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 3 cm palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER 80%, PR 20%, HER2 positive by FISH (HER2 amplification). Clinical stage II (cT2N0). FoundationOne panel performed on the biopsy did not identify any actionable somatic mutations. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab and proceeded to lumpectomy; surgical pathology shows a pathologic complete response (pCR).", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing identified an EGFR L858R mutation; PD-L1 was 10% by IHC. Brain MRI demonstrated multiple enhancing lesions and PET/CT showed osseous uptake consistent with bone metastases. He was started on osimertinib 80 mg daily with symptomatic improvement and interval CT shows reduction in target lesions consistent with a partial response. Stereotactic radiosurgery was delivered to the dominant brain metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old woman with de novo metastatic breast cancer. Core biopsy from the liver lesion showed invasive ductal carcinoma, ER negative, PR negative, HER2 amplified by FISH. PIK3CA E545K mutation detected on NGS. Clinical stage IV with bone and hepatic metastases. First-line therapy: docetaxel with trastuzumab and pertuzumab. After four cycles there is a documented partial response on CT with decrease in size of both liver and bone lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel; trastuzumab; pertuzumab", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man diagnosed with metastatic colorectal adenocarcinoma after colonoscopy for obstruction. CT shows multiple liver lesions and peritoneal nodularity. Next-generation sequencing demonstrated KRAS G12D mutation. Tumor was MSI-H on PCR and had TMB-high at 18 mut/Mb. He received first-line FOLFOX with bevacizumab but after 4 months there was radiographic progression in the liver. Given MSI-H status he was switched to pembrolizumab and has had stable disease on scans for 6 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (18 mut/Mb)", "treatment": "FOLFOX with bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man underwent right hemicolectomy for an obstructing mass. Final pathology: moderately differentiated adenocarcinoma, pT3N1 (stage III). Molecular testing: KRAS G12D detected; BRAF wild-type; microsatellite stability (MSI-stable). He completed 12 cycles of adjuvant FOLFOX without complication. Surveillance CT chest/abdomen/pelvis at 9 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT abdomen reveals multiple hypodense lesions in the liver consistent with hepatic metastases. Colonoscopy confirmed sigmoid primary. Tumor panel: KRAS and BRAF mutations not detected; microsatellite stable (MSS). Staged as IV at diagnosis. He was started on FOLFOX plus bevacizumab but follow-up imaging after 3 months shows increase in size and number of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female diagnosed with invasive ductal carcinoma of the right breast, clinical stage II (T2N0). Core biopsy: ER positive, PR negative, HER2 3+ by IHC (FISH confirmed HER2 amplification). Tumor panel identified a PIK3CA H1047R mutation. She underwent lumpectomy with clear margins and sentinel node negative, and is receiving adjuvant weekly paclitaxel followed by trastuzumab for 1 year. Most recent clinic note: no evidence of disease on post-op imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+ (amplification); ER+", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT scans show multiple liver lesions and pulmonary nodules consistent with stage IV disease. Tumor profiling returned MSI-H and TMB-high; RAS testing was not reported on the initial report. He received first-line FOLFOX plus bevacizumab with stable disease, then pembrolizumab as second-line immunotherapy with a partial response lasting approximately 9 months before clinical progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX plus bevacizumab (first-line), then pembrolizumab (second-line)", "response": "stable disease on FOLFOX+bevacizumab; partial response to pembrolizumab then progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47 y/o woman with a 4.2 cm right breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 amplified by FISH. Clinical staging: T4bN1, stage IIIB. She received neoadjuvant paclitaxel with trastuzumab for six cycles and then underwent modified radical mastectomy. Final pathology shows no residual invasive carcinoma in the breast or nodes (pathologic complete response). No distant mets on PET/CT prior to surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab; surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old man with a 2.2 mm cutaneous melanoma on the left forearm, ulceration absent and sentinel node negative \u2014 staged as IIA. BRAF testing returned V600E. Underwent wide local excision with clear margins; no adjuvant systemic therapy was given and patient is on active surveillance. Twelve-month follow-up shows no clinical or imaging evidence of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed metastatic prostate adenocarcinoma, castration-sensitive at presentation. PSA was 120 ng/mL. Bone scan positive for multiple osseous metastases. He was started on androgen deprivation with leuprolide and given six cycles of docetaxel; PSA has fallen but remains detectable. No tumor sequencing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL", "treatment": "androgen deprivation therapy (leuprolide) and docetaxel", "response": "partial biochemical response / decreased PSA", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with metastatic pancreatic ductal adenocarcinoma, ECOG 1, stage IV with multiple hepatic metastases. External NGS reported no actionable alterations. CA 19-9 was markedly elevated at diagnosis. He was treated with gemcitabine plus nab-paclitaxel but restaging CT after three cycles demonstrated interval progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man diagnosed with cutaneous melanoma, stage III. Molecular profiling identified a BRAF V600E mutation and the tumor had a high tumor mutational burden (TMB-high, 25 muts/Mb). PD-L1 was reported at 5%. He underwent wide local excision with sentinel lymph node biopsy and was started on adjuvant targeted therapy with dabrafenib and trametinib. Follow-up imaging at 12 weeks shows stable disease with no distant visceral metastasis.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with newly diagnosed lung adenocarcinoma. Staging CT and brain MRI demonstrate multiple cerebral metastases consistent with stage IV disease. Molecular testing identified EGFR L858R mutation; PD-L1 TPS 10%. Patient started osimertinib 80 mg daily with symptomatic improvement and interval imaging showing reduction in pulmonary nodules consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic lung adenocarcinoma diagnosed 03/2023. Biopsy confirmed EGFR L858R mutation. Staging at diagnosis showed multiple intracranial lesions consistent with brain metastases (overall TNM equivalent to stage IV). PD-L1 reported at 15%. He was started on osimertinib 80 mg daily as first\u2011line targeted therapy with marked symptomatic improvement and interval shrinkage of brain lesions on first follow-up imaging \u2014 partial response by RECIST.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate adenocarcinoma, stage IV at presentation. Germline testing revealed a deleterious BRCA2 mutation. Bone scan shows multiple sclerotic lesions in the pelvis and spine. He received docetaxel with initial PSA decline, then transitioned to olaparib maintenance for BRCA2; after 6 months developed radiographic progression in the spine.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA rising", "treatment": "docetaxel; olaparib", "response": "initial response then progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genotyping: KRAS G12D; microsatellite testing: MSS. Treated with FOLFOX plus bevacizumab as first-line therapy. Interval CT after 3 cycles demonstrates no new lesions and minimal change in target hepatic lesions consistent with stable disease; plan to continue current regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with high-risk prostate adenocarcinoma (clinical stage III) underwent radical prostatectomy. Pathology showed extraprostatic extension. Adjuvant intensity-modulated radiation therapy was delivered and androgen deprivation with monthly leuprolide was started. PSA was undetectable post-op but rose to 0.4 ng/mL at 6 months consistent with biochemical recurrence. No genomic testing performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant IMRT; leuprolide", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male status post low anterior resection for a pT3N1 colorectal adenocarcinoma; path report designated stage III disease. Tumor profiling showed KRAS G12D mutation; MSI testing was stable (MSI-stable) and TP53 mutation also reported. He completed 6 months of adjuvant FOLFOX and surveillance CT scans remain clear.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgery (low anterior resection), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castrate-resistant prostate cancer, metastatic to bone. Germline testing revealed a deleterious BRCA2 mutation. He received androgen deprivation with leuprolide followed by enzalutamide; after radiographic progression with new lytic bone lesions he was started on olaparib. PSA rose despite therapy and scans show progressive osseous disease.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "leuprolide; enzalutamide; olaparib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right hemicolectomy for colon adenocarcinoma; pathology T3N2M1 (stage IV) with synchronous liver metastasis. Tumor testing: MSI-H by PCR and KRAS G12D mutation identified. Patient started FOLFOX chemotherapy for metastatic disease. Interval CT after 3 cycles shows no new lesions and minor decrease in size of hepatic metastasis \u2014 overall stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX (systemic chemotherapy)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old with a 0.9 mm non-ulcerated cutaneous melanoma on the left forearm, staged as IA (stage I). Sentinel node negative. Targeted testing identified a BRAF V600E mutation. Patient underwent wide local excision with clear margins and is on routine dermatologic surveillance with no clinical evidence of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent right hemicolectomy for a 2.8 cm ascending colon adenocarcinoma. Pathology: pT1 N0, stage I. MSI testing returned MSI-high. Given the early stage and node-negative status, no adjuvant chemotherapy was recommended and surveillance was planned. NGS did not identify an actionable driver.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgical resection only (right hemicolectomy)", "response": "disease-free / surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 63-year-old male underwent right hemicolectomy for an obstructing ascending colon mass. Pathology: moderately differentiated colon adenocarcinoma, 3/18 nodes positive consistent with stage III disease. Molecular testing returned KRAS G12D. Patient completed adjuvant FOLFOX x 6 cycles and remains without radiographic evidence of disease on surveillance scans.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with high-grade serous ovarian carcinoma, FIGO IIIC, presenting with extensive peritoneal carcinomatosis and elevated CA-125. Germline testing revealed a deleterious BRCA1 mutation and tumor testing was HRD-positive. She underwent debulking followed by combination carboplatin and paclitaxel and was transitioned to maintenance olaparib due to BRCA1 mutation and HRD. Imaging shows a partial response with declining CA-125.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious)", "biomarker": "HRD-positive; elevated CA-125", "treatment": "carboplatin and paclitaxel \u2192 maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presenting with progressive cough. Biopsy of the right lower lobe confirmed lung adenocarcinoma. Staging workup consistent with stage IV disease. Tumor NGS identified EGFR L858R mutation and PD-L1 tumor proportion score 20%. He was started on osimertinib up front. Restaging CT at 8 weeks showed reduction in pulmonary nodules and measurable shrinkage of mediastinal nodes (partial response). Subsequent brain MRI demonstrated two small cerebellar metastases; PET showed increased uptake in multiple ribs.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colorectal adenocarcinoma. Primary tumor in the sigmoid colon; NGS demonstrates KRAS G12D. CEA at presentation was 120 ng/mL. Patient progressed on adjuvant FOLFOX and was transitioned to FOLFIRI plus bevacizumab in the metastatic setting. Recent CT shows enlarging hepatic lesions and new pulmonary nodules.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 120 ng/mL", "treatment": "FOLFIRI plus bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old male with unresectable metastatic melanoma. Tumor testing positive for BRAF V600E. PET/CT demonstrates osseous uptake in the lumbar spine and proximal femur consistent with bone metastases. He was started on dabrafenib with trametinib; early scans demonstrate a partial radiographic response. PD-L1 testing was not sent.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 49-year-old woman with left breast invasive ductal carcinoma, clinical stage T3N1 \u2014 overall stage IIIB. Core biopsy: ER positive, PR positive, HER2 amplified by FISH. Somatic panel reported PIK3CA H1047R. She received neoadjuvant doxorubicin + cyclophosphamide followed by paclitaxel, then underwent lumpectomy and sentinel node dissection. Patient was started on adjuvant trastuzumab; surgical pathology shows no residual invasive tumor (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "doxorubicin + cyclophosphamide then paclitaxel (neoadjuvant); trastuzumab (adjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy: invasive ductal carcinoma of the breast, ER negative, PR negative, HER2 amplification by FISH. Next-generation sequencing detected PIK3CA H1047R. Clinical staging prior to therapy was IIIA (T3N1). Patient received neoadjuvant therapy with paclitaxel plus trastuzumab and pertuzumab. Post\u2011operative pathology after mastectomy: no residual invasive carcinoma identified \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel + trastuzumab + pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man presented with right upper quadrant pain; imaging and biopsy confirmed metastatic colorectal adenocarcinoma with multiple liver metastases. Molecular testing found KRAS G12D. He completed six cycles of FOLFOX with bevacizumab and interval imaging demonstrated shrinkage of hepatic lesions. MSI status was not reported in the chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging scans demonstrate widespread disease consistent with stage IV. NGS of the tumor identified EGFR L858R mutation. PD-L1 IHC reported 10% TPS. Patient started osimertinib 80 mg PO daily in July 2024. At the 12-week oncology follow-up there was a marked decrease in size of pulmonary nodules and regression of several intracranial lesions on MRI consistent with a partial response. Bone scan positive for osseous involvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with lung adenocarcinoma after CT-guided biopsy. Staging studies reveal Stage IV disease with lytic lesions in the spine and multiple small enhancing brain metastases on MRI. Molecular testing returned EGFR L858R; PD-L1 TPS 10%. He was started on osimertinib 80 mg PO daily in January. Interval CT and brain MRI show reduction in size of the primary and regression of several bone lesions consistent with a partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 38-year-old with ulcerated cutaneous melanoma of the left forearm, Breslow depth 3.2 mm, sentinel node biopsy negative \u2014 staged as IIB (stage II). Underwent wide local excision with clear margins. BRAF testing was not performed at the time and no systemic therapy was given; patient is on dermatologic and surgical surveillance. Six-month visit shows no recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision; sentinel lymph node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for a 49-year-old female with locally advanced left-sided breast cancer (cT3N1). Core biopsy: invasive ductal carcinoma, ER+, PR-, HER2 IHC 3+ confirmed HER2 amplification by FISH. PIK3CA H1047R mutation detected on panel. She received 6 cycles of docetaxel and carboplatin with trastuzumab and pertuzumab prior to surgery. Final pathology after mastectomy showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT demonstrated multiple pulmonary nodules and a solitary enhancing cerebellar lesion consistent with brain metastasis; overall consistent with stage IV disease. Molecular testing of the biopsy returned EGFR L858R. Patient was started on osimertinib 80 mg daily with good clinical tolerance. Follow-up MRI at 8 weeks shows interval decrease in size of the cerebellar lesion and shrinkage of lung nodules consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with a primary melanoma of the right thigh. Sentinel node was positive and final staging was IIIB. Tumor sequencing identified a BRAF V600E mutation. He underwent wide local excision and completion lymphadenectomy and subsequently started adjuvant dabrafenib plus trametinib. Serial imaging at 6 months shows no evidence of distant metastatic disease and decreased nodal uptake.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "no evidence of distant metastatic disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma presented to clinic. Molecular testing: BRAF V600E positive. Started on combination targeted therapy (dabrafenib and trametinib). CT at 8 weeks documented marked shrinkage of several lesions (PR), but at 6 months there is radiographic progression in the liver with rising LFTs. Final oncologist assessment: progressive disease with new hepatic metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma on the posterior trunk treated with wide local excision; sentinel node biopsy was positive for a 1.2 cm metastasis (stage IIIA). Tumor genotyping identified BRAF V600E. The patient began adjuvant dabrafenib plus trametinib and completed 12 months with nodal clearance on imaging. Surveillance CT at 14 months demonstrated new bilateral pulmonary nodules consistent with metastatic progression; he was switched to combination ipilimumab and nivolumab. PD-L1 was 5% on archival tissue.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib (adjuvant); later ipilimumab + nivolumab (for progression)", "response": "initial complete nodal response on adjuvant therapy then progression (new pulmonary metastases)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman diagnosed with metastatic lung adenocarcinoma. CT chest/abdomen shows primary right upper lobe mass with multiple hepatic lesions and multiple enhancing brain metastases. Molecular testing returned EGFR L858R and PD-L1 10%. Patient started osimertinib 80 mg daily; stereotactic radiosurgery performed to two symptomatic brain lesions. Interval imaging at 8 weeks demonstrates decrease in size of lung and liver lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma. Staging workup consistent with Stage IV disease with multiple enhancing lesions in the brain and sclerotic lesions in the spine. Molecular testing returned EGFR L858R; ALK and ROS1 negative. PD-L1 tumor proportion score 10%. Patient started first-line osimertinib 80 mg daily and received stereotactic radiosurgery to a dominant left frontal lesion. Interval imaging at 8 weeks shows decrease in size of the lung primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT shows multiple lesions consistent with Stage IV disease with brain and axial skeleton involvement. Molecular testing identified EGFR L858R mutation; PD-L1 TPS reported as 30%. Patient started first-line osimertinib 80 mg PO daily with symptomatic improvement. First restaging at 8 weeks demonstrates a marked decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30% (TPS)", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neuro-oncology consult note: 42-year-old man presented with new-onset seizures. MRI brain revealed a left temporal ring-enhancing mass. Patient underwent craniotomy and subtotal resection; surgical pathology consistent with glioblastoma (WHO grade IV). He completed adjuvant external beam radiation with concurrent temozolomide per Stupp protocol. Three-month follow-up MRI demonstrates increased enhancing nodular disease at the resection margin consistent with progression. Molecular testing results are pending and no actionable mutation has been identified to date.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgical resection, radiation therapy with concurrent temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT demonstrates multiple liver lesions consistent with metastases; disease staged as IV. Molecular profiling from liver biopsy shows BRAF V600E mutation and high microsatellite instability (MSI-H). He was started on pembrolizumab monotherapy. Initial imaging after 12 weeks showed a partial response, but repeat scans at 6 months revealed new hepatic lesions and progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "progression after initial partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma, stage IV, presenting with multiple brain and osseous metastases. Molecular testing identified an EGFR L858R mutation; PD-L1 TPS was 5%. Patient was started on osimertinib 80 mg daily. After 3 months of therapy there is a radiographic reduction in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with intermediate-risk prostate adenocarcinoma (clinical T2bN0M0). Germline testing returned positive for a pathogenic BRCA2 variant. He was treated with definitive external beam radiation therapy with concurrent leuprolide; PSA fell from 18 ng/mL to 1.2 ng/mL at 6 months. No radiographic evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": null, "treatment": "external beam radiation and leuprolide (androgen deprivation)", "response": "biochemical response (PSA decline)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic colorectal adenocarcinoma. Molecular testing returned KRAS G12D and MSI-stable. CT abdomen shows multiple lesions in the liver consistent with metastatic disease; diagnosed as stage IV. Started on FOLFOX plus bevacizumab. Restaging CT after three cycles showed no significant change in size of hepatic lesions \u2014 overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with newly diagnosed lung adenocarcinoma. CT and MRI staging demonstrate multiple intracranial lesions and lytic bony disease; overall stage IV. Core biopsy of the lung lesion was positive for EGFR L858R mutation. PD-L1 tumor proportion score reported at 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy. Interval MRI at 8 weeks showed reduction in size of brain metastases and decreased uptake in bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with high-grade serous ovarian carcinoma, optimal debulking performed; pathologic stage IIIC with extensive peritoneal disease. Germline testing positive for BRCA1 185delAG. She completed six cycles of carboplatin and paclitaxel and was transitioned to olaparib maintenance. CT shows decreased peritoneal implants compared with baseline.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "BRCA1 mutation", "treatment": "surgery (debulking), carboplatin and paclitaxel, olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with newly diagnosed colorectal adenocarcinoma invading through the bowel wall with multiple lesions in the liver on CT. Colonoscopy biopsy: KRAS G12D mutation; MSI testing shows microsatellite stable (MSS). Staged as metastatic (stage IV) with hepatic metastases. Started first-line FOLFOX with bevacizumab. After 4 cycles imaging shows increase in size of dominant liver lesion and new peritoneal nodules\u2014treatment assessment: disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab", "response": "progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man presenting with progressive cough and weight loss. Biopsy from a right lower lobe lesion confirmed lung adenocarcinoma. Staging CT and brain MRI demonstrate multiple pulmonary nodules and several enhancing brain metastases consistent with stage IV disease. Molecular testing returned EGFR L858R; PD-L1 TPS <1%. He was started on osimertinib 80 mg daily. At 8-week restaging scans there is shrinkage of intracranial and thoracic lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 <1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 43-year-old female diagnosed with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: ER negative, PR negative, HER2 amplified by FISH. PIK3CA H1047R mutation was reported on NGS. She received neoadjuvant carboplatin and docetaxel with concurrent trastuzumab; surgery revealed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the left breast. ER-negative, PR-negative and HER2 amplification by FISH. Clinical stage IIIA. She completed neoadjuvant paclitaxel with trastuzumab and had marked clinical shrinkage. Underwent lumpectomy with pathologic complete response and finished adjuvant trastuzumab to complete 1 year of HER2-directed therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer underwent neoadjuvant therapy. Core biopsy showed invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles followed by lumpectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man presented with progressive cough and weight loss. Chest CT showed a 4.5 cm right upper lobe mass and brain MRI revealed multiple enhancing lesions. CT-guided biopsy: lung adenocarcinoma, staged as IV. Tumor panel detected EGFR L858R; PD-L1 TPS 1%. Patient was started on osimertinib 80 mg daily. Follow-up MRI at 8 weeks demonstrates decrease in size of both brain lesions and the primary \u2014 partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary invasive ductal carcinoma of the left breast, ER positive, PR positive. HER2 amplification confirmed by FISH. Patient presents with diffuse bone pain; radionuclide bone scan and plain films show multifocal osseous lesions. She received docetaxel with trastuzumab and pertuzumab for first-line metastatic therapy and remains on maintenance trastuzumab q3 weeks. Latest CT/PET indicates stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, trastuzumab and pertuzumab (maintenance trastuzumab)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma (stage IV) harboring BRAF V600E. PD-L1 by IHC reported 10%. Presents with symptomatic brain metastases and multiple liver lesions. Treated with dabrafenib + trametinib and stereotactic radiosurgery to two intracranial lesions. Systemic disease initially responded (partial response) but developed intracranial progression at 5 months.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response systemically; intracranial progression", "metastasis_site": "brain and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma with BRAF V600E on NGS and high tumor mutational burden (TMB-high). Patient had baseline pulmonary nodules; started on dabrafenib plus trametinib. PD-L1 testing was not performed. Recent CT chest documents complete radiographic resolution of lung lesions and clinician documents 'complete response' on current visit.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Initial molecular testing identified EGFR L858R. He started first-line osimertinib with durable control for 14 months but then progressed with new liver lesions on CT. Repeat biopsy demonstrated PD-L1 15% and high TMB. He was transitioned to combination carboplatin and pemetrexed with pembrolizumab. Imaging after 3 cycles showed a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%; TMB-high", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated stage IV disease with multiple brain metastases and osseous involvement. Molecular testing revealed EGFR L858R. PD-L1 by IHC reported as 10%. She was started on osimertinib 80 mg daily. Interval CT and MRI at 3 months show marked decrease in size of pulmonary nodules and resolving brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man diagnosed with high-risk prostate adenocarcinoma (Gleason 4+4) with extracapsular extension on MRI. No distant metastatic disease identified on staging CT and bone scan. He underwent radical prostatectomy followed by adjuvant external beam radiation and androgen deprivation with leuprolide.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy, adjuvant external beam radiation, androgen deprivation therapy (leuprolide)", "response": "no evidence of distant disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer (clinical stage IIIA). Core biopsy: HER2 amplified by FISH, ER and PR negative. FoundationOne panel detected PIK3CA H1047R. She received neoadjuvant pertuzumab, trastuzumab and paclitaxel. Post-treatment MRI shows marked reduction in tumor size but not complete eradication \u2014 assessed as partial response prior to surgery.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "pertuzumab, trastuzumab and paclitaxel", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 37-year-old woman with cutaneous melanoma found to harbor BRAF V600E on tumor sequencing. PD-L1 by IHC reported at 1%. Baseline PET/CT shows multiple bilateral pulmonary nodules suspicious for metastatic disease. She was started on dabrafenib plus trametinib; interval imaging at 8 weeks shows reduction in size of the lung nodules and an overall partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with metastatic colorectal adenocarcinoma. Colonoscopy biopsy confirmed poorly differentiated adenocarcinoma; CT shows lung nodules and peritoneal implants. Tumor is MSI-H on PCR and high tumor mutational burden reported. KRAS/NRAS testing was pending and not available at time of note. He received FOLFOX with bevacizumab but had radiographic progression after 3 months; therapy was switched to pembrolizumab with subsequent disease stabilization.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX + bevacizumab then pembrolizumab", "response": "progression on FOLFOX/bevacizumab, then stable disease on pembrolizumab", "metastasis_site": "lung, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male presented with metastatic pancreatic ductal adenocarcinoma, stage IV at diagnosis with liver and peritoneal implants. Molecular profiling showed KRAS G12V and TP53 mutation. CA19-9 markedly elevated. He received first-line gemcitabine plus nab-paclitaxel with initial stable disease by RECIST but after four cycles there was radiographic progression. He was transitioned to second-line liposomal irinotecan with 5-FU.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V; TP53 mutation", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel; then liposomal irinotecan with 5-FU", "response": "progression after initial stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma. Primary sigmoid tumor was resected last year. Tumor genotyping identified KRAS G12D. CT abdomen shows multiple hypodense lesions throughout the liver consistent with metastases. Patient was started on FOLFOX plus bevacizumab; interval imaging after three cycles demonstrates no significant change in lesion size.", "output": {"cancer_type": "colorectal (sigmoid) adenocarcinoma", "stage": null, "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and chemo summary: 55-year-old woman presented with abdominal distension and CA-125 elevation. Laparoscopy revealed high-grade serous carcinoma involving both ovaries with omental caking and extensive peritoneal implants. Clinical stage III disease. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with normalization of CA-125 and no visible residual disease on imaging. BRCA testing was not reported in the chart and no molecular biomarkers are documented.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old man with a 0.8 mm superficial spreading melanoma on the left forearm. No ulceration, sentinel lymph node biopsy negative \u2014 staged as IA. Molecular testing returned BRAF V600E. Patient underwent wide local excision with 1 cm margins and no adjuvant therapy was recommended. On clinic follow up there is no clinical or imaging evidence of residual disease.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy (no adjuvant therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with colon adenocarcinoma treated with right hemicolectomy. Final pathology: T3N0, Stage II. Tumor testing showed MSI-H. Given high-risk features the patient received adjuvant FOLFOX for 6 cycles. Surveillance CT at 12 months showed no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic prostate adenocarcinoma, Gleason 4+5. Bone scan demonstrates diffuse osteoblastic metastases. He was started on androgen deprivation therapy with leuprolide and then abiraterone acetate plus prednisone. PSA fell from 420 to 8 ng/mL over six months and bone disease remains radiographically stable. Comprehensive molecular testing has not yet been completed / results pending.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation) and abiraterone acetate with prednisone", "response": "stable disease (PSA decline)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent resection of an ulcerated cutaneous melanoma of the left forearm. Pathology revealed nodal involvement (stage IIIB). Tumor testing identified a BRAF V600E mutation. Managed with wide local excision, completion lymphadenectomy and adjuvant dabrafenib plus trametinib. Returned 18 months later with recurrent nodal disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, completion lymphadenectomy, adjuvant dabrafenib and trametinib", "response": "progression/recurrence", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of present illness: 64-year-old female with newly diagnosed lung adenocarcinoma. Biopsy confirmed EGFR L858R mutation. Staging PET/CT shows multiple pulmonary nodules and a 2.5 cm cerebellar lesion consistent with metastasis \u2014 overall stage IV. PD-L1 by IHC 10%. Patient received stereotactic radiosurgery to the brain lesion followed by osimertinib 80 mg daily. Most recent CT chest/abdomen shows decrease in size of target lesions; clinic documents a partial response at 8-week follow-up.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "stereotactic radiosurgery; osimertinib", "response": "partial response", "metastasis_site": "brain, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with stage III colon adenocarcinoma status post right hemicolectomy for a T3N1 lesion. Tumor genotyping returned positive for KRAS G12D. He completed 12 cycles of adjuvant FOLFOX without complications and has no radiographic evidence of distant disease on follow-up CT chest/abdomen/pelvis.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma, stage IV with multiple liver metastases. Tumor sequencing showed a BRCA2 pathogenic variant and KRAS G12V. CA19-9 is markedly elevated. She was started on gemcitabine with nab-paclitaxel but progressed after three cycles and was transitioned to FOLFIRINOX; most recent scans show radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V; BRCA2 pathogenic variant", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel; FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer with diffuse sclerotic bone metastases. Germline/somatic testing identified a BRCA2 frameshift mutation (c.5676_5677del). PSA was 62 ng/mL. He had prior androgen deprivation and docetaxel, and was started on the PARP inhibitor olaparib. After 4 months on olaparib his PSA and scans are unchanged from baseline (stable disease).", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 frameshift (c.5676_5677del)", "biomarker": "PSA 62 ng/mL", "treatment": "olaparib (prior androgen deprivation; prior docetaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology report: right hemicolectomy for a 4.2 cm ascending colon adenocarcinoma, final path pT3N0 (stage II). Tumor testing shows high microsatellite instability (MSI-H). Comprehensive NGS not performed so no specific oncogenic mutation was reported. Patient was offered adjuvant 5-FU\u2013based chemotherapy but declined and remains on surveillance; most recent CT at 6 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": null, "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old presented with metastatic invasive ductal breast carcinoma. Tumor was ER-negative, PR-negative, HER2 amplified by FISH. PIK3CA H1047R mutation also reported on sequencing. Staging workup revealed lytic lesions in the spine and pelvis. She received docetaxel with trastuzumab and pertuzumab; after six cycles transitioned to maintenance HER2-directed therapy. Most recent bone scan shows stable disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, trastuzumab and pertuzumab (followed by maintenance trastuzumab/pertuzumab)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with newly diagnosed lung adenocarcinoma presented with headaches. Staging workup consistent with stage IV disease with multiple brain metastases and a lytic lesion in the femur. Molecular testing returned EGFR L858R sensitizing mutation; PD-L1 TPS 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to dominant brain lesion. Interval imaging at 8 weeks demonstrated a decrease in size of primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic castration-resistant prostate adenocarcinoma. He progressed after androgen-deprivation therapy, docetaxel and abiraterone. Germline and somatic testing identified a BRCA2 frameshift mutation. Circulating tumor assay was positive for AR-V7. He was started on olaparib but restaging scans show new hepatic lesions and worsening osseous disease consistent with progression.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 frameshift", "biomarker": "AR-V7 positive", "treatment": "androgen-deprivation therapy, docetaxel, abiraterone, olaparib", "response": "progression", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with left invasive ductal carcinoma, clinical stage IIA (T2N0). ER and PR positive, HER2 negative by IHC/FISH. Tumor genomic profiling identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant dose-dense AC x4 then weekly paclitaxel. Endocrine therapy with letrozole was initiated. Post-treatment imaging and clinical exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+; PR+; HER2-negative", "treatment": "lumpectomy; adjuvant doxorubicin/cyclophosphamide (AC) then paclitaxel; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with newly identified metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. Imaging shows multiple liver lesions consistent with metastases. Immunohistochemistry indicates loss of MLH1 and PMS2 consistent with mismatch repair deficiency; MSI-H confirmed. He was started on FOLFOX with bevacizumab; first interval scan showed stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H (mismatch repair deficiency)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old with a 0.8 cm pigmented lesion on the forearm removed by dermatology. Pathology: superficial spreading melanoma, Breslow 0.6 mm, no ulceration, sentinel node not indicated \u2014 stage I. Molecular testing identified BRAF V600E in the specimen. Patient had wide local excision with clear margins and remains clinically free of disease on follow-up exam.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "complete response / clinically disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic melanoma initially treated with first-line nivolumab but experienced progression with new vertebral lesions. Tumor sequencing demonstrated BRAF V600E. He was transitioned to dabrafenib plus trametinib; repeat PET/CT at 12 weeks showed partial metabolic response in the spine lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB not reported", "treatment": "dabrafenib and trametinib (after prior nivolumab)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver metastases. Tumor testing showed MSI-H and TMB-high. KRAS reported as wild-type (no activating mutation identified). He was treated with pembrolizumab monotherapy due to MSI-H status and achieved a near-complete metabolic response on follow-up PET at 4 months. Clinical stage recorded as IV at diagnosis.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "near-complete metabolic response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma presented with multiple hepatic lesions. Liquid biopsy returned positive for KRAS G12C. He was started on FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab. Interval CT after three cycles showed increase in size of several liver lesions consistent with progressive disease. MSI testing was attempted but the result was inconclusive and not available in the chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFOX (5-FU, leucovorin, oxaliplatin) plus bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, presenting with multiple liver lesions. Molecular testing: KRAS G12D, microsatellite stable (MSS), low TMB. He was started on FOLFIRI plus bevacizumab. Interval CT after 3 cycles demonstrates increase in size and number of hepatic metastases consistent with progression. Plan is to consider clinical trials given KRAS-mutant disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing returned EGFR exon 21 L858R mutation. Staging at presentation was IV with multiple enhancing lesions in the brain and lytic disease in the lumbar spine. PD-L1 tumor proportion score 15% by IHC. Patient started osimertinib 80 mg daily in January 2020 with interval CT/MRI showing a sustained partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with metastatic invasive ductal breast carcinoma, ER-positive, PR-positive and HER2 amplification on FISH. Patient has painful right iliac crest lesion consistent with bone metastasis. Started first-line therapy with weekly paclitaxel in combination with trastuzumab and pertuzumab; zoledronic acid added for bone disease. Clinical notes do not report a specific somatic gene mutation in the chart.", "output": {"cancer_type": "breast carcinoma (invasive ductal)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-positive", "treatment": "paclitaxel with trastuzumab and pertuzumab; zoledronic acid", "response": null, "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed pancreatic ductal adenocarcinoma, metastatic at presentation (stage IV) with multiple hypodense lesions in the liver on CT. Tumor sequencing showed KRAS G12V. CA19-9 markedly elevated at 15,000 U/mL. He was started on gemcitabine plus nab-paclitaxel, but first restaging after two cycles documented interval growth of hepatic metastases and new ascites consistent with progressive disease. PD-L1 testing was not performed.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V", "biomarker": "CA19-9 markedly elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male status post right hemicolectomy for colon adenocarcinoma, pathology pT3N1 (stage III). Molecular testing identified KRAS G12D; MSI testing was stable (MSS). Patient completed adjuvant FOLFOX and is undergoing routine surveillance with CT chest/abdomen/pelvis; no distant metastases identified to date.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with obstructing sigmoid colon mass. Pathology: moderately differentiated adenocarcinoma, pT3N1 (stage III). Tumor sequencing identified KRAS G12D; mismatch repair intact (MSS). He underwent low anterior resection followed by adjuvant FOLFOX x6 cycles. Surveillance CT at 6 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "surgery (low anterior resection) and adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old male with metastatic cutaneous melanoma harboring BRAF V600E. He received frontline pembrolizumab but progressed after 4 months and was transitioned to targeted therapy with dabrafenib plus trametinib, achieving an initial partial response on CT. Surveillance MRI later identified a solitary cerebellar metastasis which was treated with stereotactic radiosurgery.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab followed by dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging CT/PET demonstrated widespread disease with multiple brain and bone lesions consistent with metastatic spread. NGS of the biopsy identified EGFR L858R mutation; PD-L1 tumor proportion score reported at 10%. He was started on osimertinib 80 mg daily in January 2024 with rapid symptomatic improvement. Interval MRI and PET after 8 weeks show reduction in size of the primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with invasive ductal carcinoma of the right breast, ER+/PR+ and HER2 amplification by FISH. Tumor NGS showed PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab and subsequently underwent lumpectomy. Post-operative scans note new lytic lesions in the lumbar spine consistent with osseous metastases. Patient is on bisphosphonate therapy and continues trastuzumab; most recent oncologic assessment documents stable disease.", "output": {"cancer_type": "breast cancer", "stage": null, "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel and trastuzumab; lumpectomy; bisphosphonates", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the right breast, HER2 amplified on FISH, ER/PR negative. Clinical stage IIIA. She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by lumpectomy and sentinel node biopsy. Surgical pathology showed no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab, surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old with a 2.2 cm pigmented lesion on the left forearm; wide local excision and sentinel node biopsy positive for melanoma with one involved node (stage IIIB). Tumor is BRAF V600E positive; PD-L1 5% and tumor shows high TMB. Patient was started on adjuvant dabrafenib plus trametinib combination for one year and remains recurrence-free at 12 months follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib (adjuvant)", "response": "no evidence of disease / recurrence-free at 12 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with cutaneous melanoma of the left forearm, later found to have metastatic disease to the cerebellum. Tumor sequencing identified BRAF V600E. The patient was started on dabrafenib plus trametinib; first restaging MRI after 6 weeks demonstrated shrinkage of the dominant cerebellar lesion and decreased PET uptake in pulmonary nodules consistent with a partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital course: 70-year-old female with metastatic pancreatic ductal adenocarcinoma presenting with progressive jaundice and multiple liver metastases. No actionable alterations identified on panel testing. She received systemic therapy with gemcitabine plus nab-paclitaxel and palliative external beam radiation to the porta hepatis. Interval imaging shows disease stable compared with prior scan.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel; palliative radiation", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology clinic note: 68-year-old man diagnosed with prostate adenocarcinoma, Gleason 4+4=8 on transrectal biopsy. Clinical stage T2bN0M0 (stage II). He underwent definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide). PSA decreased from 12 ng/mL pre-treatment to undetectable at 6-month follow-up. No tumor molecular testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "PSA undetectable (complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with high-grade serous ovarian carcinoma with extensive peritoneal carcinomatosis documented at laparoscopy. Germline testing returned a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; maintenance olaparib was started and interval CTs show sustained complete radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": "BRCA1 deleterious mutation", "biomarker": null, "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic: 67-year-old male with metastatic colorectal adenocarcinoma to the liver. Molecular profile shows KRAS G12D mutation and MSI-stable. He started palliative chemotherapy with FOLFIRI plus bevacizumab. After 6 months of treatment CT shows new hepatic lesions and an increase in existing liver metastases; therapy considered progressive disease and plan is to change regimen.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFIRI and bevacizumab", "response": "disease progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 72-year-old male admitted for obstructive jaundice; workup revealed pancreatic head adenocarcinoma with metastatic lesions in the liver. Staged as IV pancreatic ductal adenocarcinoma. Multidisciplinary tumor board recommended systemic chemotherapy with modified FOLFIRINOX; patient received two cycles with clinical benefit but developed cumulative neuropathy and was transitioned to gemcitabine-based therapy as an outpatient. Germline testing pending and no actionable somatic mutation was identified on the initial tumor panel.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "modified FOLFIRINOX followed by gemcitabine-based therapy", "response": "clinical benefit then treatment modification", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 48-year-old female with locally advanced (IIIB) invasive ductal breast carcinoma. Biopsy positive for HER2 amplification (IHC 3+/FISH+) with ER+, PR+ status and a PIK3CA H1047R mutation on NGS. She received trastuzumab + pertuzumab with docetaxel x6 cycles, underwent mastectomy with sentinel node biopsy and is planned for adjuvant letrozole. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab + pertuzumab + docetaxel; planned letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma, stage IV. Molecular testing identified EGFR L858R. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg PO daily in September; interval CT and MRI showed a partial response of the thoracic disease but a new cerebellar lesion was treated with SRS. Ongoing bone pain corresponds to multiple osseous metastases on bone scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone; brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary ulcerated cutaneous melanoma of the left thigh with positive sentinel lymph node(s); pathologic stage IIIC after wide local excision and completion lymphadenectomy. Tumor sequencing detected BRAF V600E mutation. The patient was started on adjuvant dabrafenib and trametinib. PD-L1 testing was not performed. Surveillance imaging to date shows no evidence of distant metastatic disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female presented with a 1.8 cm palpable mass in the left breast. Core biopsy showed invasive ductal carcinoma. ER 90%, PR 20%, HER2 IHC 1+ (ISH negative). NGS panel detected PIK3CA H1047R. She underwent lumpectomy with sentinel lymph node biopsy (nodes negative) and completed adjuvant whole-breast radiation. Started tamoxifen for endocrine therapy. Post-operative imaging: no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER 90%; PR 20%; HER2 negative (IHC 1+)", "treatment": "lumpectomy; sentinel lymph node biopsy; adjuvant radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate cancer (mCRPC), stage IV with diffuse sclerotic bone metastases. Germline testing revealed a deleterious BRCA2 mutation. After prior docetaxel and abiraterone therapy he was started on the PARP inhibitor olaparib. PSA declined from 320 to 45 ng/mL and follow-up bone scan/CT demonstrates a partial radiographic response.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "PSA 320 ng/mL baseline, decline to 45 ng/mL after treatment", "treatment": "olaparib (after prior docetaxel and abiraterone)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op note: 61-year-old male with resected right-sided colon adenocarcinoma, pathologic stage III (pT3N1). Molecular panel demonstrates KRAS G12D mutation; tumor is MSI-stable. Patient completed adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin) x12 cycles without major complications. Surveillance CT and CEA at 6 months show no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX (oxaliplatin, 5-FU, leucovorin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 48-year-old female with locally advanced invasive ductal carcinoma of the right breast, ER positive, PR positive, HER2 amplification on FISH. Clinical stage IIIB with extensive nodal disease. She received neoadjuvant trastuzumab, pertuzumab and docetaxel (TCHP) and had marked tumor shrinkage on exam and imaging. No somatic gene panel abnormalities reported in chart.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "marked tumor shrinkage (partial response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging workup consistent with stage IV disease with multiple bilateral pulmonary nodules and a single 1.5 cm cerebellar metastasis. Molecular testing demonstrated EGFR L858R mutation; ALK and ROS1 negative. Patient started on osimertinib 80 mg daily. Follow-up CT and MRI at 8 weeks show decrease in size of target lesions and shrinkage of the cerebellar lesion after stereotactic radiosurgery. Overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old man with metastatic cutaneous melanoma. Initial molecular testing returned BRAF V600E positive and PD-L1 approximately 10%. He was started on dabrafenib plus trametinib with rapid symptomatic improvement (partial response on first scan). After 9 months developed new enhancing brain lesions and extracranial progression; therapy switched to single-agent nivolumab. Prior to BRAF/MEK therapy he had pulmonary nodules and a solitary cerebellar metastasis treated with SRS.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib + trametinib; nivolumab", "response": "initial partial response then progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular profile: KRAS G12D positive, microsatellite stable (MSS), low tumor mutational burden. He was started on FOLFIRI plus bevacizumab; CT scans after 3 months showed no new lesions and modest shrinkage of existing metastases consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable), TMB-low", "treatment": "FOLFIRI + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 78-year-old man with metastatic prostate adenocarcinoma (Gleason 4+5) with extensive osteoblastic metastases involving the pelvis and thoracic spine. PSA elevated at 214 ng/mL. Staging consistent with stage IV disease. He received leuprolide depot and six cycles of docetaxel; current bone scan shows no new lesions and modest decrease in uptake at known sites, assessed as stable disease. No somatic mutation testing was performed and no biomarker results are available.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 45-year-old man with metastatic cutaneous melanoma, initially stage IV at diagnosis. Tumor sequencing showed BRAF V600E mutation and high tumor mutational burden. He was started on dabrafenib plus trametinib with rapid symptomatic improvement and CT RECIST assessment showing a partial response. At 6 months, new MRI demonstrates progressive intracranial lesions consistent with disease progression despite extracranial control; brain metastases were treated with stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery for brain mets", "response": "initial partial response then intracranial progression", "metastasis_site": "brain (and lungs noted extracranially)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic cutaneous melanoma. Initial therapy with pembrolizumab resulted in progression after 4 cycles. Molecular testing revealed BRAF V600E mutation and high tumor mutational burden; PD-L1 between 1-5%. She was switched to targeted therapy with dabrafenib plus trametinib. Post-switch imaging shows reduction of pulmonary and hepatic lesions but enlarging cerebellar metastasis requiring stereotactic radiosurgery. The course is best described as a mixed response with extracranial partial response and intracranial progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 1-5%", "treatment": "pembrolizumab (initial); then dabrafenib + trametinib; stereotactic radiosurgery to cerebellar lesion", "response": "mixed response (partial response extracranial, progression intracranial)", "metastasis_site": "lung; liver; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "CT-guided biopsy of RLL mass confirmed lung adenocarcinoma. Molecular testing positive for EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging workup consistent with metastatic disease (stage IV) with known brain and bone lesions on MRI and bone scan. Patient started osimertinib 80 mg PO daily; interval CT at 8 weeks demonstrates decrease in size of pulmonary mass and multiple bone lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the left breast, clinical stage IIIB. IHC shows HER2 3+ with confirmatory FISH positive for HER2 amplification; ER 40% positive, PR 10% positive. Patient underwent neoadjuvant chemotherapy with weekly paclitaxel followed by modified radical mastectomy and then planned adjuvant trastuzumab. No comprehensive genomic panel was performed on the specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel, trastuzumab, surgery (modified radical mastectomy)", "response": null, "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with newly diagnosed lung adenocarcinoma. NGS returned EGFR L858R mutation and PD-L1 10% (TPS). Brain MRI demonstrates multiple parenchymal metastases and bone scan positive for osseous disease. Staged as IV at presentation. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Restaging CT at 3 months shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. Staging workup consistent with Stage IV disease with multiple intracranial lesions. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy with good clinical improvement and interval imaging at 8 weeks showing a partial response in both lung and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology addendum: Left breast, invasive ductal carcinoma, grade 3. ER negative, PR negative; HER2 amplified by FISH (HER2/CEP17 ratio 6.1). Clinical stage reported as IIB. NGS panel detected PIK3CA H1047R. Plan discussed at tumor board: neoadjuvant trastuzumab with weekly paclitaxel prior to definitive surgery. Oncology appointment scheduled to review systemic therapy options.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab and paclitaxel (neoadjuvant)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation note: Patient with metastatic cutaneous melanoma with multiple pulmonary nodules on chest CT. Tumor testing positive for BRAF V600E. High tumor mutational burden reported; patient was treated with dabrafenib and trametinib with marked reduction in lung nodules, then transitioned to nivolumab for consolidation. Recent PET/CT shows near-complete metabolic response. (Stage not documented in referral letter.)", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib; nivolumab", "response": "near-complete metabolic response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (melanoma): Patient is a 49-year-old male diagnosed with unresectable metastatic melanoma. Tumor testing demonstrates BRAF V600E mutation. He started combination targeted therapy with dabrafenib and trametinib. Initial PET/CT showed excellent metabolic response in cutaneous and nodal disease, however interval brain MRI at 3 months revealed a 1.2 cm enhancing lesion consistent with intracranial metastasis while extracranial disease remained controlled. Clinical assessment: mixed response. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "brain, skin, lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with invasive ductal carcinoma of the left breast diagnosed on core biopsy. Clinical stage IIA (T2N0M0). ER positive, PR negative, HER2 non-amplified by IHC/FISH. Next-generation sequencing identified PIK3CA E545K. She underwent lumpectomy with sentinel node biopsy followed by adjuvant radiotherapy and was started on letrozole. Twelve-month surveillance exam and imaging show no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive, PR negative, HER2 non-amplified", "treatment": "lumpectomy with sentinel node biopsy, adjuvant radiotherapy, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 54-year-old male with unresectable metastatic cutaneous melanoma, BRAF V600E positive. PD-L1 reported at 10%. Patient was started on dabrafenib plus trametinib. Eight-week restaging CT shows approximately 45% reduction in target lesions. Therapy tolerated with mild fever and arthralgia.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male diagnosed with metastatic colorectal adenocarcinoma, stage IV with multiple hepatic lesions. Next-generation sequencing detected KRAS G12D. MSI testing returned MSS and tumor mutational burden reported as low. He was treated with FOLFIRI plus bevacizumab; follow-up CT after three cycles demonstrates interval enlargement of several liver metastases consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; low TMB", "treatment": "FOLFIRI plus bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. Tumor profiling positive for BRAF V600E and PD-L1 approximately 5%. He was treated with combination targeted therapy dabrafenib plus trametinib. After 6 months patient developed new neurologic symptoms and brain MRI confirmed progressive intracranial disease despite systemic therapy.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib", "response": "progression (intracranial progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with localized prostate adenocarcinoma, Gleason 4+3, clinical stage II. Germline testing identified a pathogenic BRCA2 mutation. He elected radical prostatectomy followed by salvage external beam radiation and short-course androgen deprivation therapy for adverse pathology. Post-treatment PSA is undetectable at 6 months follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": "germline BRCA2", "biomarker": null, "treatment": "radical prostatectomy, salvage external beam radiation, androgen deprivation therapy", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with newly diagnosed lung adenocarcinoma, stage IV with multiple brain and bone metastases. Tumor NGS identified EGFR L858R. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily and reports symptomatic improvement; first restaging CT/MRI demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Initial molecular testing identified an EGFR L858R mutation; after clinical progression a repeat biopsy detected the resistance mutation T790M. PD-L1 TPS reported as 20%. He received first-line erlotinib with disease control for 14 months and was transitioned to osimertinib for T790M-positive progression. Stereotactic radiosurgery was performed for a solitary cerebellar metastasis. Current imaging on osimertinib shows shrinkage of pulmonary nodules and decrease in the brain lesion size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, T790M", "biomarker": "PD-L1 20%", "treatment": "erlotinib; osimertinib; stereotactic radiosurgery (SRS)", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic pancreatic ductal adenocarcinoma, stage IV with dominant liver metastases. Germline testing revealed a pathogenic BRCA2 variant. She received FOLFIRINOX with a partial radiographic response for 6 months and was transitioned to maintenance olaparib. PD-L1 and other immunologic biomarkers were not reported in the chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX (induction), olaparib (maintenance)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old woman with high-grade serous ovarian carcinoma presented with bulky pelvic disease and omental caking. Surgical staging revealed stage IIIC disease with peritoneal and omental implants. Germline testing identified a pathogenic BRCA1 mutation. CA-125 was markedly elevated preoperatively. She received neoadjuvant carboplatin and paclitaxel with partial radiographic response, proceeded to interval debulking, and is now planned for maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic (germline)", "biomarker": "elevated CA-125; HRD-positive", "treatment": "neoadjuvant carboplatin + paclitaxel; interval debulking surgery; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old premenopausal woman underwent lumpectomy for a 1.2 cm invasive ductal carcinoma. Pathology: ER positive, PR positive, HER2 negative. Sentinel lymph node biopsy was negative and final stage was I. Tumor next-generation sequencing identified a PIK3CA H1047R mutation. She was started on adjuvant tamoxifen and remains without evidence of disease at 18 months.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy and adjuvant tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent lumpectomy for a 1.8 cm invasive ductal carcinoma, ER+/PR+, HER2 amplified by IHC/FISH. Pathology staged tumor as pT1cN0 (stage I). She completed adjuvant paclitaxel followed by a planned 1-year trastuzumab, and is currently without evidence of disease on follow-up exams.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. NGS identified EGFR L858R; PD-L1 testing reported 10%. Currently stage IV with new intracranial lesions on MRI. Patient started osimertinib 80 mg daily in 2020. Follow-up imaging and clinical notes document a reduction in size of cerebral metastases and symptomatic improvement in cough and dyspnea.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with metastatic ER+/PR+/HER2-amplified breast cancer, presenting with multiple hepatic and osseous metastases. Core biopsy confirmed HER2 overexpression (IHC 3+) and amplification on FISH; tumor also harbors a PIK3CA H1047R mutation on sequencing. She was treated front-line with trastuzumab + pertuzumab combined with docetaxel (CLEOPATRA regimen) with radiologic partial response, and was later switched to ado-trastuzumab emtansine (T-DM1) at progression.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab + pertuzumab + docetaxel; ado-trastuzumab emtansine (T-DM1)", "response": "partial response", "metastasis_site": "liver; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic right-sided colon adenocarcinoma, stage IV at presentation. Molecular testing demonstrated BRAF V600E mutation and microsatellite instability-high (MSI-H). Multiple bilateral pulmonary nodules consistent with metastatic disease. Given pembrolizumab monotherapy due to MSI-H status; CT chest after 3 cycles shows reduction in size and number of lung nodules consistent with a partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with a left breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 3+ by IHC and confirmed HER2 amplification by FISH. Clinical exam consistent with fixation to chest wall; staged as IIIB. She received neoadjuvant chemotherapy with docetaxel, carboplatin plus trastuzumab and pertuzumab for 6 cycles. Underwent modified radical mastectomy \u2014 final pathology showed no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing on the biopsy showed EGFR L858R mutation and PD-L1 10% (22C3). Staging was consistent with stage IV disease with multiple enhancing lesions on brain MRI. Patient started osimertinib 80 mg daily as first-line targeted therapy; 3-month CT/MRI demonstrates decrease in size of both pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced breast carcinoma presenting with large fixed left breast mass and matted axillary nodes. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 3+ by IHC confirming HER2 amplification. Multidisciplinary plan: neoadjuvant chemotherapy with docetaxel plus trastuzumab and pertuzumab. Patient completed 6 cycles and underwent mastectomy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant docetaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative notes: 62-year-old male with sigmoid colon adenocarcinoma, underwent left hemicolectomy for an obstructing tumor. Pathology: pT4aN2 with multiple positive nodes. CT at 3 months shows two new hypodense lesions in the liver suspicious for metastases. Tumor genotyping: KRAS G12D positive; microsatellite testing MSS (microsatellite stable). He was started on FOLFOX with bevacizumab. Interval imaging after 4 cycles shows no significant change in the hepatic lesions\u2014stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with newly diagnosed lung adenocarcinoma. Staging workup demonstrates Stage IV disease with multiple enhancing brain lesions and lytic lesions in the thoracic spine. Comprehensive NGS returned EGFR L858R positive; ALK and ROS1 negative. PD-L1 tumor proportion score reported at 10%. He was started on osimertinib 80 mg daily. First restaging CT chest and brain MRI at 8 weeks showed reduction in size of the primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 38-year-old with metastatic cutaneous melanoma. Initially treated with pembrolizumab but had disease progression with enlarging hepatic lesions. Molecular testing later showed BRAF V600E mutation; therapy changed to dabrafenib plus trametinib with symptomatic improvement and CT at 6 weeks consistent with partial response. Brain MRI shows two small metastases. PD-L1 reported at 70% TPS.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 70%", "treatment": "pembrolizumab (initial), then dabrafenib + trametinib", "response": "partial response (after targeted therapy)", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with a 0.8 mm cutaneous melanoma, non-ulcerated; sentinel lymph node negative. BRAF V600E mutation was detected on PCR. Wide local excision performed; no adjuvant therapy was given. Patient is clinically disease-free at 18-month follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with metastatic lung adenocarcinoma in 2023. Staging at diagnosis was IV with multiple brain and bony lesions. Molecular testing showed EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient progressed on first-line osimertinib and was switched to combination chemotherapy with carboplatin and pemetrexed plus pembrolizumab. Interval CT and MRI demonstrate reduction in pulmonary and intracranial disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology addendum: Core biopsy of right breast shows invasive ductal carcinoma, grade 3. Clinical stage recorded as IIIB with chest wall involvement. HER2 testing by IHC/ISH demonstrates HER2 amplification; estrogen receptor strongly positive, progesterone receptor negative. Patient received neoadjuvant paclitaxel weekly with trastuzumab; underwent modified radical mastectomy. Surgical pathology after chemo showed no residual invasive carcinoma in the breast or nodes \u2014 pathologic complete response. No distant mets identified on staging scans.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant paclitaxel and trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female presented with a bulky left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical exam and imaging consistent with skin involvement; staged as IIIB. Germline BRCA testing was negative. She received neoadjuvant trastuzumab with weekly paclitaxel, proceeded to modified radical mastectomy; final pathology showed no residual invasive tumor (pCR). Follow-up exams without evidence of disease.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and paclitaxel followed by modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right hemicolectomy performed for colon adenocarcinoma, pathologic stage III (pT3N1). Tumor NGS shows KRAS G12D mutation; mismatch repair proteins intact (microsatellite stable). Patient completed adjuvant FOLFOX (5-FU/leucovorin/oxaliplatin) for 6 months. Surveillance CT at 18 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MMR intact)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with stage IV lung adenocarcinoma diagnosed in 2019. Comprehensive genomic profiling returned EGFR L858R. PD-L1 tumor proportion score 1%. She was started on osimertinib 80 mg daily; MRI showed brain metastases at baseline and PET identified osseous disease. Follow-up CT/MRI after 3 months demonstrates decrease in size of primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer with progressive bone pain and multiple sclerotic bone metastases on bone scan. Germline testing revealed pathogenic BRCA2 truncating mutation. PSA has risen to 120 ng/mL despite prior docetaxel and abiraterone. Patient was started on olaparib but interval imaging demonstrates radiographic progression.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 (deleterious)", "biomarker": "PSA 120 ng/mL", "treatment": "olaparib (after prior docetaxel and abiraterone)", "response": "progressive disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. CT abdomen demonstrates multiple hypodense hepatic lesions consistent with liver metastases and new ascites. PCR panel identified a KRAS G12D mutation. Patient started FOLFOX with bevacizumab; follow-up imaging after 3 cycles shows interval enlargement of hepatic lesions and clinical decline consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 68-year-old M with metastatic colorectal adenocarcinoma (liver-dominant disease). Tumor genotyping: KRAS G12D. MSI testing: microsatellite stable (MSS). Treated with FOLFOX + bevacizumab in the palliative setting; recent CT shows new hepatic lesions and rising CEA consistent with progression. Plan to consider second-line irinotecan-based regimen.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple hepatic lesions. Tumor profiling returned MSI-H and BRAF V600E mutation; TMB-high (18 muts/Mb). He was started on pembrolizumab as first-line systemic therapy. CT at 12 weeks demonstrates stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (18 muts/Mb)", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with abdominal distension. Exploratory CT shows diffuse peritoneal carcinomatosis and enlarged para\u2011aortic lymph nodes. Initial pathology: KRAS G12D on PCR. Tumor reported MSI\u2011H on immunohistochemistry and high TMB. He received first\u2011line FOLFOX but had radiographic progression after 3 months and was switched to pembrolizumab given MSI\u2011H status. On pembrolizumab the most recent scans show a partial response with reduced peritoneal disease and improvement in ascites.", "output": {"cancer_type": "colon (colorectal) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX (prior); pembrolizumab (current)", "response": "partial response", "metastasis_site": "peritoneum, para-aortic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative/discharge summary: 66-year-old male with high-risk prostate adenocarcinoma, Gleason 4+4, clinical T3aN0 (stage III). Germline testing returned positive for a pathogenic BRCA2 variant. He underwent radical prostatectomy followed by adjuvant external beam radiotherapy with concurrent androgen deprivation (leuprolide). Post-operative PSA is undetectable and there is no radiologic evidence of metastatic disease at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 germline pathogenic variant", "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiotherapy; leuprolide (androgen deprivation therapy)", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic letter: Mr. K is a 72-year-old diagnosed with metastatic castration-sensitive prostate adenocarcinoma with symptomatic bone pain. PSA is >100 ng/mL at diagnosis. He was started on androgen deprivation therapy (leuprolide) and received six cycles of docetaxel. Pain improved and PSA declined substantially \u2014 partial biochemical and radiographic response. No tumor genomic panel was sent at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA >100 ng/mL", "treatment": "leuprolide and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male referred for metastatic colorectal adenocarcinoma with liver-dominant disease. Molecular profile: BRAF V600E positive, KRAS wild-type, high microsatellite instability (MSI-H) and TMB-high on comprehensive genomic profiling. Initial therapy was FOLFOX with bevacizumab achieving stable disease. On progression he was enrolled on encorafenib plus cetuximab for BRAF-mutant disease; given MSI-H status immunotherapy with pembrolizumab was later initiated. Current imaging shows partial hepatic response but new peritoneal implants.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E; KRAS wild-type", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab; pembrolizumab", "response": "partial response; stable disease (prior)", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: ER negative, PR negative; HER2 amplification by FISH. She received neoadjuvant paclitaxel with trastuzumab for 6 cycles and then underwent modified radical mastectomy. Surgical pathology reported pathologic complete response (pCR). No evidence of distant metastasis on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel and trastuzumab; modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with borderline resectable pancreatic ductal adenocarcinoma. Baseline CA19-9 elevated at 420 U/mL. Germline testing returned a pathogenic BRCA2 mutation. He received 4 cycles of neoadjuvant FOLFIRINOX with radiographic shrinkage of the primary (partial response) and subsequently underwent pancreaticoduodenectomy with R0 resection. Post-op plan was adjuvant gemcitabine discussed at tumor board.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "II", "gene_mutation": "BRCA2 (pathogenic, germline)", "biomarker": "CA19-9 420 U/mL", "treatment": "neoadjuvant FOLFIRINOX, pancreaticoduodenectomy (Whipple); planned adjuvant gemcitabine", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man presented with progressive cough and weight loss. Workup revealed lung adenocarcinoma with EGFR L858R mutation. Staging scans showed metastatic disease (stage IV) with multiple brain metastases. PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg PO daily. Interval CT chest and MRI brain at 8 weeks demonstrated reduction in size of pulmonary nodules and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male diagnosed with a 1.2 mm superficial spreading melanoma of the left upper arm, Breslow 1.2 mm, no ulceration; staged as IB. Molecular testing detected a BRAF V600E mutation. He underwent wide local excision with negative sentinel node and declined adjuvant systemic therapy. Follow-up dermatology visits document no recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "IB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no recurrence / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with a sigmoid mass on colonoscopy. CT chest/abdomen/pelvis showed multiple hepatic lesions suspicious for metastases; biopsy confirmed colorectal adenocarcinoma. Overall assessment: stage IV. Tumor genotyping identified KRAS G12D. He was started on FOLFIRI with bevacizumab. After two months of therapy the liver lesions have enlarged and new peritoneal nodularity is present, consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with metastatic lung adenocarcinoma (EGFR L858R) diagnosed 2019. She initially had a durable response to osimertinib for 14 months then progressed; repeat NGS demonstrated acquired MET amplification. PD-L1 by IHC was 5%. She was started on combination osimertinib + crizotinib and follow-up imaging showed decrease in intracranial and osseous lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 5%", "treatment": "osimertinib and crizotinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old woman with high-grade serous ovarian carcinoma, BRCA1 pathogenic germline mutation and positive homologous recombination deficiency (HRD). She completed debulking surgery followed by 6 cycles of carboplatin and paclitaxel with good clinical response. Given BRCA1 and HRD positivity she was started on maintenance olaparib in combination with bevacizumab. No explicit stage listed in the operative note; CT abdomen pelvis did not document extra-abdominal metastases.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD-positive", "treatment": "carboplatin + paclitaxel; maintenance olaparib + bevacizumab", "response": "good clinical response to platinum-based chemotherapy", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a 2.8 cm invasive ductal carcinoma of the left breast. Pathology staged as IIA; tumor is ER positive, PR positive and HER2 amplified by FISH. Tumor sequencing revealed a PIK3CA H1047R hotspot mutation. Patient underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant paclitaxel with trastuzumab and is to continue adjuvant letrozole. Recent follow-up exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; paclitaxel and trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma (stage IV). NGS detected BRAF V600E; PD-L1 was 10% and tumor mutational burden reported as high. He received first-line dabrafenib plus trametinib with initial nodal clearance but subsequently developed brain metastases and was transitioned to combination immune checkpoint blockade with ipilimumab plus nivolumab. Response has been mixed with shrinkage of some extracranial lesions and progression intracranially.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib and trametinib; ipilimumab and nivolumab", "response": "mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note (shorthand): 55M with widely metastatic melanoma. Numerous pulmonary nodules on chest CT and subcutaneous nodules on trunk. PD-L1 tumor proportion reported at 80%. BRAF testing pending; started combination immunotherapy with nivolumab and ipilimumab. After 12 weeks there is >50% decrease in measurable lung nodules and improvement of cutaneous disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 80%", "treatment": "nivolumab and ipilimumab", "response": "partial response", "metastasis_site": "lung; skin/subcutaneous"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the right breast. Core biopsy: ER negative, PR negative, HER2 3+ by IHC confirming HER2 amplification. Clinical stage was IIIA with fixed axillary nodes. She received neoadjuvant carboplatin and weekly paclitaxel with trastuzumab for six cycles followed by mastectomy; surgical pathology reported complete pathological response with no residual invasive carcinoma.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "carboplatin and paclitaxel with trastuzumab (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive. Treated with dabrafenib plus trametinib resulting in rapid shrinkage of skin lesions and nodal disease (RECIST partial response). After 9 months developed progressive intracranial disease and underwent stereotactic radiosurgery to multiple brain lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response followed by progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left breast cancer (cT3N1). Core biopsy: invasive ductal carcinoma, HER2 IHC 3+, ER negative, PR negative. PIK3CA H1047R identified on NGS. She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab for 6 cycles, proceeded to mastectomy; surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 IHC 3+, ER negative, PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal carcinomatosis. Germline testing confirmed a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with measurable decrease in CA-125 and radiographic partial response; maintenance olaparib was started. PD-L1 and TMB were not reported for this case.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious)", "biomarker": null, "treatment": "debulking surgery; carboplatin and paclitaxel followed by olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology consult: 65-year-old with localized prostate adenocarcinoma, clinical stage T2b (overall stage II). PSA at presentation 12 ng/mL. Underwent robotic radical prostatectomy; pathology reported Gleason 3+4. Early postop course notable for rising PSA consistent with biochemical recurrence. No systemic therapy started yet.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "radical prostatectomy", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male diagnosed with locally advanced, unresectable pancreatic head adenocarcinoma staged as III (T4N1M0). CA19-9 is elevated at 420 U/mL. Comprehensive NGS panel did not identify actionable mutations (no KRAS or BRCA alterations reported). He was treated with gemcitabine plus nab-paclitaxel with concurrent radiotherapy; interval imaging after three months shows stable disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 420 U/mL", "treatment": "gemcitabine and nab-paclitaxel with radiotherapy", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old woman with stage IIIC high-grade serous ovarian carcinoma presenting with abdominal distension and omental caking. Underwent debulking surgery followed by adjuvant carboplatin and paclitaxel. CT after three cycles showed reduction in peritoneal implants consistent with partial response. Germline BRCA testing pending; somatic mutation testing not reported.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "debulking surgery, carboplatin and paclitaxel (adjuvant)", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 64-year-old man with metastatic lung adenocarcinoma harboring EGFR L858R. Baseline staging was IV with known brain and bone metastases. PD-L1 by IHC reported at 10%. He was started on osimertinib 80 mg PO daily as first-line targeted therapy in June. Restaging CT chest/abdomen and brain MRI at 8 weeks demonstrated decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old male presented with progressive cough and headache. CT chest and brain MRI demonstrated a right upper lobe mass with multiple enhancing brain metastases and lytic lesions in the thoracic spine. Biopsy confirmed lung adenocarcinoma. NGS returned EGFR L858R and PD-L1 10%. Stage IV at diagnosis. Started osimertinib 80 mg daily; first follow-up at 8 weeks shows decreased size of intracranial lesions and shrinking primary \u2014 consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage III colon adenocarcinoma (T3 N1 M0) s/p right hemicolectomy. Tumor testing returned MSI-H with loss of MLH1/PMS2; next-generation sequencing identified KRAS G12D and TP53 R273H. She completed 6 months of adjuvant FOLFOX. Surveillance CTs show no distant metastases and CEA has been stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D; TP53 R273H", "biomarker": "MSI-H (loss of MLH1/PMS2)", "treatment": "FOLFOX (adjuvant)", "response": "no evidence of distant metastasis / stable post-adjuvant", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate cancer (stage IV) presenting with worsening bone pain and rising PSA. Germline and somatic testing identified a pathogenic BRCA2 truncating mutation and HRR deficiency. Prior lines included androgen deprivation therapy and docetaxel; he was started on olaparib and has had a decline in PSA and symptomatic improvement noted as a partial response on bone scan after 3 months.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "HRR deficiency", "treatment": "androgen deprivation therapy, docetaxel, olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old female with papillary thyroid carcinoma, classic variant, staged as I (T1N0M0). Tumor harbors BRAF V600E on molecular testing. She underwent total thyroidectomy followed by radioactive iodine ablation. Post-therapy thyroglobulin is undetectable and neck ultrasound is unremarkable.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": "undetectable thyroglobulin post-therapy", "treatment": "total thyroidectomy; radioactive iodine ablation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with pancreatic ductal adenocarcinoma presenting with obstructive jaundice. Exploratory laparoscopy identified diffuse peritoneal seeding; cytology positive for adenocarcinoma. No actionable mutations reported on initial panel. She has been started on gemcitabine with nab-paclitaxel and received biliary stent placement. Most recent CA 19-9 is mildly elevated and imaging shows stable peritoneal implants.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel; biliary stent", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left breast mass. Core biopsy: invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH. NGS panel identified a PIK3CA H1047R mutation. Clinical staging was IIB (T2N1). She received neoadjuvant paclitaxel with trastuzumab for 12 weeks and had a partial radiographic response prior to lumpectomy; final pathology showed residual invasive disease in the breast and one positive sentinel node.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab, then lumpectomy", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old female with metastatic lung adenocarcinoma. Biopsy of the right upper lobe confirmed adenocarcinoma with EGFR L858R (exon 21) mutation. PD-L1 immunohistochemistry reported TPS 10%. MRI brain demonstrated three small metastases and PET-CT showed osseous involvement of the thoracic spine. Patient started osimertinib 80 mg daily in March; 8-week CT showed ~45% reduction in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma (diagnosed stage IV). Tumor sequencing revealed a pathogenic BRCA2 frameshift mutation. After prior docetaxel he was started on the PARP inhibitor olaparib; PSA fell from 88 to 28 ng/mL and cross-sectional imaging has shown stable disease for six months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic frameshift", "biomarker": null, "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative note: 62-year-old male underwent right hemicolectomy for colon adenocarcinoma in March 2023. Pathology: pT3N1, moderately differentiated, margins negative. Final stage was III. Patient completed 12 cycles of adjuvant FOLFOX without complication and is now on routine surveillance. Most recent CT chest/abdomen/pelvis shows no evidence of disease. MSI testing not reported in chart.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "surgery (right hemicolectomy) and adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy: invasive ductal carcinoma of the right breast, ER positive, PR positive, HER2 IHC 3+ and confirmed HER2 amplification by FISH. Clinical stage at presentation cT2N1, overall stage IIIA. Neoadjuvant therapy consisted of docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) x6 cycles. Patient underwent lumpectomy and sentinel node biopsy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). Plan: complete adjuvant trastuzumab to one year and start adjuvant letrozole. No somatic NGS mutations reported.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab; surgery (lumpectomy); planned adjuvant trastuzumab and letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman underwent core biopsy showing invasive ductal carcinoma of the left breast. Tumor was ER positive, PR positive, HER2 negative by FISH. Pathology later revealed a PIK3CA H1047R hotspot mutation. She had breast-conserving surgery with sentinel node biopsy followed by adjuvant radiotherapy and was started on tamoxifen. No distant disease identified on staging; plan is routine surveillance.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy (breast-conserving surgery), adjuvant radiotherapy, tamoxifen", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with advanced cutaneous melanoma. Initial molecular testing showed BRAF V600E mutation. Patient received combination targeted therapy with dabrafenib and trametinib and had an objective partial response; after 9 months scans documented new pulmonary nodules and enlarging liver lesions consistent with progression. PD-L1 expression was 5% on archival specimen. Patient subsequently discontinued targeted therapy due to progression and started on pembrolizumab in second line.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; then pembrolizumab", "response": "initial partial response, then progression", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 59-year-old female with pancreatic ductal adenocarcinoma metastatic to the liver at diagnosis (multiple hepatic lesions). Germline testing revealed pathogenic BRCA2 mutation. CA 19-9 at presentation was markedly elevated. She received 8 cycles of FOLFIRINOX with initial tumor shrinkage, but recent imaging demonstrates progression in the liver. Patient was switched to gemcitabine/nab-paclitaxel and is being considered for PARP inhibitor maintenance if disease stabilizes.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "elevated CA 19-9", "treatment": "FOLFIRINOX; gemcitabine/nab-paclitaxel (planned PARP inhibitor consideration)", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Presentation: 70-year-old male with sigmoid colon mass and enlarged mesenteric nodes. Biopsy: colon adenocarcinoma, clinically T3N2 (stage III). Tumor sequencing identified BRAF V600E; MSI testing returned MSI-H. Patient completed 6 cycles of neoadjuvant FOLFOX with interval CT showing decrease in tumor size and nodal burden consistent with partial response; scheduled for right hemicolectomy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "neoadjuvant FOLFOX", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed lung adenocarcinoma presenting with cough and headaches. Imaging shows multiple bilateral pulmonary nodules and enhancing lesions in the cerebellum; overall clinical stage IV. Comprehensive NGS of the primary tumor identified EGFR L858R mutation. PD-L1 tumor proportion score reported as 10%. Patient was started on osimertinib 80 mg daily. Interval CT and brain MRI at 3 months demonstrated decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; lung (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man presented with progressive cough and weight loss. Imaging and biopsy confirmed lung adenocarcinoma, stage IV with multiple pulmonary nodules. Comprehensive NGS returned EGFR L858R; PD-L1 by IHC reported as 60%. He was started on osimertinib 80 mg daily as first-line therapy. Follow-up CT at 8 weeks demonstrated reduction in target lesions consistent with a partial response. Brain MRI showed two small enhancing metastases and bone scan was positive for osseous disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology clinic note: 45-year-old man with a 2.1 mm non-ulcerated melanoma of the upper back. Wide local excision and sentinel lymph node biopsy performed; sentinel node negative. Molecular testing on the primary returned BRAF V600E positive. No adjuvant immunotherapy was recommended given negative nodes and patient enrolled in surveillance program. Current status: clinically disease-free.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, sentinel lymph node biopsy (surgery only)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology progress note: 67-year-old man found to have localized prostate adenocarcinoma, Gleason 3+4=7, clinical stage T1c (stage I). PSA at diagnosis 8.7 ng/mL. No genomic testing was performed. He underwent robot-assisted radical prostatectomy; final margins negative, pelvic lymph nodes negative. Post-op PSA undetectable and patient is on surveillance without adjuvant therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 8.7 ng/mL (diagnostic)", "treatment": "robot-assisted radical prostatectomy", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky peritoneal disease. Germline testing positive for BRCA1 mutation. CA-125 was markedly elevated pre-treatment and normalized after surgery and chemotherapy. Patient underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; now on maintenance olaparib with excellent clinical and radiographic response.", "output": {"cancer_type": "ovarian cancer (high-grade serous carcinoma)", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 (elevated pre-treatment, normalized after therapy)", "treatment": "cytoreductive surgery, carboplatin + paclitaxel, maintenance olaparib", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma, liver-dominant disease on CT abdomen. Tumor testing shows BRAF V600E mutation and is MSI-H with high tumor mutational burden (TMB-high). He was started on pembrolizumab monotherapy given MSI-H status and declined targeted BRAF therapy; 12-week restaging demonstrated stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma with pathogenic germline BRCA2 mutation. Presented with extensive peritoneal carcinomatosis and large-volume ascites; underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel. Now on maintenance olaparib with CA-125 returned to normal. Stage not clearly documented in the available notes.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": null, "gene_mutation": "BRCA2 mutation", "biomarker": "CA-125 (normalized)", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic pancreatic ductal adenocarcinoma presented with obstructive jaundice and multiple hepatic lesions. Germline testing identified a pathogenic BRCA2 mutation. She received modified FOLFIRINOX with good biochemical response and platinum sensitivity and was transitioned to maintenance olaparib. Most recent imaging shows stable hepatic disease but persistent pain control issues.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "modified FOLFIRINOX; olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 52-year-old woman with T3N1M0 invasive ductal carcinoma of the right breast, HER2 IHC 3+ and ER/PR negative. Tumor genotyping identified a PIK3CA H1047R mutation. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by weekly paclitaxel with concurrent trastuzumab. Pathology after mastectomy showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "doxorubicin/cyclophosphamide; paclitaxel; trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": "none"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma, liver and peritoneal implants on CT consistent with Stage IV. Tumor profiling: MSI-H, BRAF V600E positive, KRAS wild-type; TMB-intermediate. Initial therapy was FOLFOX with bevacizumab with limited disease control; subsequently started pembrolizumab due to MSI-H status and achieved stable disease for 6 months. On further progression of hepatic lesions patient began encorafenib plus cetuximab with a partial radiographic response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; KRAS wild-type; TMB-intermediate", "treatment": "FOLFOX + bevacizumab (first-line); pembrolizumab (for MSI-H); then encorafenib + cetuximab", "response": "stable disease (to pembrolizumab); partial response (to encorafenib + cetuximab)", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old premenopausal woman diagnosed with invasive ductal breast carcinoma, clinical stage II (T2N0). Tumor was ER positive, PR negative and showed HER2 amplification by FISH. She received neoadjuvant paclitaxel with trastuzumab, proceeded to lumpectomy with sentinel node biopsy; pathology demonstrated no residual invasive tumor (pathologic complete response). Patient is planned for adjuvant hormonal therapy with tamoxifen. No evidence of metastatic disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab, lumpectomy, tamoxifen", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, multiple liver lesions on baseline CT. Staged as IV. Tumor genotyping demonstrates KRAS G12D. Baseline CEA was 150 ng/mL. He was started on FOLFOX with bevacizumab; first restaging CT at 12 weeks shows no new lesions and overall size of hepatic metastases stable compared with baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with metastatic prostate adenocarcinoma presenting with back pain and multiple sclerotic bone lesions. Biopsy confirmed Gleason 4+5 disease. Germline and tumor testing identified a BRCA2 frameshift mutation. He was started on androgen deprivation therapy with leuprolide and received six cycles of docetaxel. Disease is currently radiographically stable with persistent involvement of lumbar vertebrae.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 frameshift", "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide) and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent left hemicolectomy for a stage II (T3N0) sigmoid colon adenocarcinoma. Tumor testing reported MSI-H (microsatellite instability-high) and a BRAF V600E mutation on tumor sequencing. Given MSI-H and node-negative status, the patient opted for surveillance rather than adjuvant fluoropyrimidine-based chemotherapy. CEA remains within normal limits and there is no radiologic recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "surgical resection (left hemicolectomy); no adjuvant chemotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. Tumor is ER positive, PR negative and HER2 amplified by FISH; PIK3CA E545K identified on targeted panel. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with good clinical shrinkage and subsequently underwent mastectomy with axillary dissection \u2014 pathology showed pathologic complete response (pCR).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male diagnosed with metastatic cutaneous melanoma. Tumor sequencing detected BRAF V600E. PD-L1 by IHC was 5% TPS. Presenting with multiple pulmonary nodules consistent with stage IV disease. He was started on targeted therapy with dabrafenib and trametinib and achieved a partial response at the 6-week scan.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid colon adenocarcinoma underwent low anterior resection: pathology pT3 N1 (stage III). Tumor testing showed KRAS G12D mutation and proficient MMR (MSI-stable). Adjuvant FOLFOX was administered. Surveillance CT noted a 1.2 cm indeterminate lesion in segment IV of the liver that has been stable on interval imaging.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "low anterior resection; adjuvant FOLFOX", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma (EGFR testing positive for L858R). Staging CT and MRI brain demonstrate multiple intracranial metastases and lytic lesions in the thoracic spine \u2014 consistent with stage IV disease. PD-L1 by IHC was 10%. Patient was started on osimertinib 80 mg daily. Eight-week restaging CT shows reduction in size of the primary and most brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, stage IV. Molecular testing showed KRAS G12D mutation, MSI-H and TMB-high. He was treated initially with FOLFOX plus bevacizumab with best response of stable disease; on progression in the liver and lungs he was switched to pembrolizumab monotherapy and achieved a partial response in hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with locally advanced pancreatic ductal adenocarcinoma (stage III) found to harbor a pathogenic BRCA2 mutation. Treated with 6 cycles of FOLFIRINOX with radiographic disease control and then transitioned to olaparib maintenance. Current scans show no interval progression and the patient remains on maintenance therapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 pathogenic mutation", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease/on maintenance with radiographic disease control", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, liver-dominant disease. Initial molecular profiling identified BRAF V600E mutation and MSI-H. Received first-line FOLFOX with bevacizumab but imaging after 3 cycles showed progression in the liver. Switched to pembrolizumab given MSI-high status, with subsequent interval imaging demonstrating a durable partial response and decreased CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab (progression), then pembrolizumab", "response": "progression on chemotherapy; durable partial response on pembrolizumab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left invasive ductal carcinoma, clinical stage IIIB. ER 80% positive, PR 10% positive, HER2 IHC 3+ with FISH confirming HER2 amplification. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles and proceeded to mastectomy. Final pathology: no residual invasive carcinoma (pathologic complete response). Staging scans showed no distant disease.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+, PR+", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Sentinel oncology consult: 55-year-old man with metastatic melanoma to the brain and lung. Mutation testing positive for BRAF V600E; PD-L1 expression reported at 5%. He was started on combination targeted therapy with dabrafenib + trametinib; after mixed radiographic response an anti-PD-1 (nivolumab) was added sequentially. Imaging shows decrease in pulmonary nodules but new small brain metastases, overall best response described as mixed response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib; nivolumab", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male status post low anterior resection for sigmoid adenocarcinoma, pathologic stage T3N1M0 (stage III). Tumor reported as microsatellite stable (MSS); KRAS testing was deferred. He completed adjuvant FOLFOX for 6 cycles and surveillance CT at 12 months demonstrates no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSS", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with recurrent cutaneous melanoma found to harbor BRAF V600E on comprehensive NGS and a TMB-high signature. Started on dabrafenib plus trametinib with an initial partial response, but CT at 7 months demonstrated new hepatic lesions and multiple brain metastases consistent with progression. He was transitioned to combination ipilimumab/nivolumab; imaging after 3 cycles showed a heterogeneous/mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib; later ipilimumab + nivolumab", "response": "initial partial response then progression; mixed response to subsequent immunotherapy", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Staging at diagnosis was IV. Molecular testing on the biopsy returned EGFR L858R mutation; PD-L1 tumor proportion score reported as 10%. She was started on osimertinib 80 mg daily in January 2020. Interval CT and MRI showed reduction in primary and intracranial lesions consistent with partial response. Ongoing treatment; bone pain improved.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple liver and pulmonary metastases. Tumor profiling identified BRAF V600E and the tumor is MSI-H with TMB-high. After progression on FOLFOX plus bevacizumab he was started on encorafenib and cetuximab; follow-up imaging revealed radiographic progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX plus bevacizumab; encorafenib and cetuximab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Initial NGS reported EGFR L858R and after progression a repeat biopsy identified EGFR T790M. PD-L1 was 10% by IHC. He presented with headaches and back pain; MRI confirmed brain metastases and multiple osseous lesions. Patient was switched to osimertinib following progression on erlotinib and achieved a partial response on CT at 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib (after erlotinib)", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with obstructing sigmoid mass; pathology: moderately differentiated colorectal adenocarcinoma. CT abdomen/pelvis demonstrates multiple hepatic lesions and ascites. Molecular testing detected KRAS G12D mutation. Patient received FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab as first-line therapy. Interval imaging after 3 months showed progression with enlarging liver metastases and new peritoneal nodularity.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) plus bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 52-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. He underwent combination targeted therapy with dabrafenib and trametinib achieving a rapid partial response in subcutaneous nodules and visceral disease. After 7 months progression occurred in the lung and he was switched to ipilimumab plus nivolumab. PD-L1/TMB data not available in chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then ipilimumab plus nivolumab", "response": "partial response (initial), then progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male underwent colonoscopy for rectal bleeding; biopsy showed moderately differentiated adenocarcinoma of the sigmoid. Surgery performed with low anterior resection; pathology pT3N0. Tumor tested MSI-high by PCR. No targeted NGS was performed at this time. Given stage II MSI-H and clear margins the tumor board recommended observation without adjuvant chemotherapy. Surveillance colonoscopy and CT at 12 months show no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II (pT3N0)", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (low anterior resection), surveillance (no adjuvant chemotherapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric artery. Multidisciplinary tumor board recommended upfront chemoradiation; patient received concurrent capecitabine with radiation followed by gemcitabine and nab\u2011paclitaxel. Imaging shows stable disease by RECIST after 4 months and disease remains unresectable. No actionable mutations were reported in the initial note.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "concurrent chemoradiation (capecitabine) followed by gemcitabine + nab-paclitaxel", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for a 44-year-old female with high-grade invasive ductal carcinoma of the left breast, ER+/PR+, HER2 amplification on FISH, clinical stage IIIA (T2N2M0). Next-generation sequencing identified a PIK3CA H1047R alteration. She completed six cycles of docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) prior to surgery. Mastectomy specimen showed no residual invasive carcinoma \u2014 pathologic complete response reported.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: invasive ductal carcinoma, right breast. ER negative, PR negative, HER2 3+ by IHC with FISH-confirmed HER2 amplification. Clinical staging at presentation was IIIB. Patient underwent modified radical mastectomy and completed adjuvant chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) x6. Most recent surveillance imaging and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification (HER2 3+)", "treatment": "docetaxel, carboplatin and trastuzumab (TCH)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 47-year-old man with widely metastatic cutaneous melanoma. Initial molecular testing positive for BRAF V600E. Prior therapy included pembrolizumab for 4 months with mixed response, then started on dabrafenib and trametinib. Recent brain MRI for new headaches shows multiple enhancing lesions consistent with intracranial metastases and interval growth of several extracranial nodules \u2014 treating team documents systemic progression.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (after pembrolizumab)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Staging PET/CT showed multiple pulmonary nodules and a 1.8 cm cerebellar lesion consistent with metastasis. Molecular testing identified EGFR L858R and PD-L1 was 5% by 22C3. She was started on osimertinib 80 mg PO daily; stereotactic radiosurgery was performed to the brain lesion. Follow-up CT at 8 weeks demonstrated decrease in size of dominant lung mass and resolution of several nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with stage IV lung adenocarcinoma found to harbor EGFR L858R on next-generation sequencing. PD-L1 expression by IHC was 10%. MRI brain demonstrated multiple enhancing lesions and PET/CT showed osseous metastases. She was started on osimertinib 80 mg daily. First restaging after 8 weeks shows ~40% reduction in measurable disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with recurrent cutaneous melanoma. Initial excision performed last year; molecular testing now positive for BRAF V600E and high tumor mutational burden (TMB-high). He was started on pembrolizumab first-line but progressed after 4 cycles with new pulmonary nodules and an adrenal lesion. Therapy was changed to dabrafenib plus trametinib with subsequent shrinkage of target lesions on CT.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (initial); dabrafenib plus trametinib (subsequent)", "response": "progression on pembrolizumab; partial response to dabrafenib + trametinib", "metastasis_site": "lung; adrenal"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and hip pain. Staging workup consistent with stage IV disease with multiple cerebral and osseous lesions. Molecular testing returned EGFR L858R and T790M mutations; ALK and ROS1 negative. PD-L1 TPS 10%. He was started on osimertinib in combination with bevacizumab on a compassionate-use protocol. Interval MRI at 8 weeks showed decreased size of brain metastases and improvement in bone pain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib + bevacizumab", "response": "partial response (decreased brain lesions, symptomatic improvement)", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 70-year-old male with locally advanced pancreatic ductal adenocarcinoma involving the head of the pancreas, borderline resectable clinically staged as III. Tumor markers: CA19-9 markedly elevated. Comprehensive NGS reported no actionable alterations. He received 8 cycles of FOLFIRINOX with radiographic stable disease, followed by consolidative chemoradiation. No distant metastases at this time.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colon adenocarcinoma. Molecular testing showed KRAS G12C mutation. Baseline CEA was 120 ng/mL and tumor was microsatellite-stable. CT demonstrates multiple hypodense liver lesions consistent with metastases. He received FOLFOX with bevacizumab; restaging after 4 cycles indicates stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "CEA 120 ng/mL; MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old with metastatic cutaneous melanoma, BRAF V600E positive. Initially treated with dabrafenib and trametinib with tumor shrinkage, later developed progression in the lungs and was transitioned to combination nivolumab and ipilimumab. Recent PET/CT shows decreased uptake in several pulmonary nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib then nivolumab and ipilimumab", "response": "partial response (decreased metabolic activity in pulmonary nodules)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with metastatic cutaneous melanoma, BRAF V600E positive, presented with multiple brain and lung metastases (stage IV). PD-L1 by IHC was 10% and the tumor had high TMB. She underwent stereotactic radiosurgery to intracranial lesions and started dabrafenib plus trametinib with an initial partial response; after intracranial progression she was transitioned to nivolumab and achieved stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "stereotactic radiosurgery; dabrafenib and trametinib; nivolumab", "response": "initial partial response then progression; stable disease on nivolumab", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic cutaneous melanoma. NGS showed BRAF V600E mutation. He initially declined adjuvant therapy and later developed symptomatic intracranial and pulmonary metastases; overall stage IV at progression. He was started on dabrafenib and trametinib combination therapy. After six months of targeted therapy he developed new brain metastases and extracranial progression documented on MRI and chest CT.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with newly diagnosed stage IV lung adenocarcinoma. Molecular testing returned EGFR L858R mutation and PD-L1 10%. Patient was started on osimertinib 80 mg daily with good tolerability. Follow-up CT at 8 weeks showed decrease in pulmonary nodules and response in brain metastases on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 62-year-old man with metastatic colorectal adenocarcinoma, BRAF V600E detected on PCR panel. Tumor also reported MSI-H. Baseline CT showed multiple liver metastases, consistent with stage IV disease. After intolerance to FOLFOX, patient was transitioned to pembrolizumab monotherapy. Follow-up imaging demonstrates decreased size of hepatic lesions \u2014 partial response to pembrolizumab.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with invasive ductal breast carcinoma, HER2-amplified, ER positive and PR positive. Staging scans revealed osseous disease with uptake in the thoracic spine. Tumor sequencing identified a PIK3CA E545K mutation. She was treated with trastuzumab and docetaxel; interval imaging has shown no new lesions and overall disease stability.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 68-year-old male status-post right hemicolectomy for colon adenocarcinoma. Pathology: pT3N1 (2/15 nodes positive) \u2014 stage III disease. Tumor panel identified a KRAS G12D mutation. Preoperative CEA was 12 ng/mL. The patient completed adjuvant FOLFOX and surveillance CTs show no radiographic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "CEA 12 ng/mL", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease post-resection", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with newly diagnosed lung adenocarcinoma, stage IV. MRI brain showed multiple enhancing lesions consistent with metastases. Molecular testing returned EGFR L858R and PD-L1 10%. Patient was started on osimertinib 80 mg daily; whole brain radiation was deferred. CT at 8 weeks demonstrated decrease in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic HER2-positive invasive ductal breast cancer, liver metastases on staging CT. Biopsy showed HER2 amplification by FISH and a PIK3CA H1047R mutation. She completed 6 cycles of docetaxel with trastuzumab and pertuzumab with interval CT demonstrating decrease in hepatic lesions consistent with partial response; plan for maintenance trastuzumab and pertuzumab.", "output": {"cancer_type": "breast cancer (invasive ductal, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced right breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER negative, PR negative, HER2 3+ by IHC consistent with HER2 amplification. Tumor sequencing identified a PIK3CA E545K mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles and subsequently underwent modified radical mastectomy. Surgical pathology reported pathologic complete response. No evidence of distant metastatic disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male diagnosed with sigmoid colon adenocarcinoma. Surgical pathology pT3 N1 M0 (Stage III). Tumor genotyping positive for KRAS G12D; microsatellite testing shows MSS (microsatellite stable). He underwent low anterior resection followed by 6 months of adjuvant FOLFOX. Surveillance imaging at 12 months shows no evidence of recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "surgery (low anterior resection); adjuvant FOLFOX", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presented with fatigue and weight loss; workup revealed metastatic colorectal adenocarcinoma with multiple liver lesions. Staging consistent with stage IV disease. Molecular profiling demonstrated KRAS G12D. He was treated with FOLFOX plus bevacizumab; interval CT at 12 weeks showed enlarging hepatic lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Unresectable metastatic melanoma diagnosed on skin biopsy with BRAF V600E mutation detected by PCR. Patient was started on pembrolizumab but imaging at 12 weeks showed new pulmonary nodules and rising LDH; therapy was changed to dabrafenib plus trametinib. Following two months of targeted therapy there has been a partial response of the pulmonary metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (initial), then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed metastatic lung adenocarcinoma. Biopsy confirmed EGFR L858R and concurrent MET amplification on NGS. PD-L1 5% by IHC; TMB low. Patient was started on osimertinib in combination with bevacizumab as first-line therapy given brain and bone involvement. Interval CT and MRI at 8 weeks showed shrinkage of pulmonary and osseous lesions consistent with a partial response. Stage IV disease with known metastases to bone and brain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 5%; TMB low", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma, stage IV. NGS demonstrated EGFR L858R mutation. PD-L1 tumor proportion score 5%. Patient was started on osimertinib 80 mg PO daily. Follow-up CT at 8 weeks showed a decrease in size of the primary right upper lobe mass and reduction in multiple brain metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Mr. K is a 71-year-old with sigmoid colon adenocarcinoma. Molecular testing identified KRAS G12D. He presented with abdominal distension and was found to have peritoneal carcinomatosis with omental implants and ascites on CT, consistent with stage IV disease. He received FOLFOX with bevacizumab as palliative systemic therapy. Interval scans after 4 months showed no volumetric reduction but no new disease \u2014 best response documented as stable disease prior to eventual clinical progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with early localized prostate adenocarcinoma (clinical T1cN0M0, stage I). Preoperative PSA was 12 ng/mL. No genomic testing was performed. He underwent robotic radical prostatectomy with negative margins. Post-op plan: PSA surveillance; patient currently with undetectable PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (pre-op); undetectable post-op", "treatment": "robotic radical prostatectomy", "response": "no evidence of disease / undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/oncology summary: 52-year-old woman with locally advanced right invasive ductal carcinoma. ER negative, PR negative; HER2 IHC 3+ with FISH-confirmed HER2 amplification. Clinical exam consistent with fixed axillary nodes \u2014 stage IIIB. She received neoadjuvant weekly paclitaxel followed by trastuzumab and pertuzumab; anthracycline-based AC was planned but held due to neutropenia. Interval breast ultrasound shows approx 40% decrease in tumor dimensions. No distant mets identified on staging CT chest/abdomen/pelvis.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right calf cutaneous melanoma (Breslow 3.2 mm, Clark level IV) classified as stage II by surgical oncology. Patient underwent wide local excision and sentinel lymph node biopsy; nodes negative. BRAF testing was not performed and no adjuvant systemic therapy was given. Surveillance dermatology and imaging show no distant spread.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision and sentinel lymph node biopsy", "response": "no evidence of distant disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with poorly differentiated colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genotyping identified KRAS G12C mutation; EGFR-targeted therapy was not recommended. He was treated with FOLFOX plus bevacizumab. Interval CT shows no new lesions and minimal size change consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with cough and weight loss. Imaging and biopsy confirmed stage IV lung adenocarcinoma (diagnosed 01/2024). Comprehensive NGS returned EGFR L858R mutation (T790M negative). PD-L1 TPS 10%. Brain MRI identified two enhancing metastases in the left frontal lobe; bone scan showed lytic lesions in T7 and T8. She completed stereotactic radiosurgery to the brain lesions and was started on osimertinib 80 mg PO daily. Prior to targeted therapy she received one cycle of carboplatin/pemetrexed for symptom control. CT at 8 weeks demonstrates decrease in size of the primary and intracranial lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery (brain); prior carboplatin/pemetrexed", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Tumor NGS demonstrated EGFR L858R mutation. Patient started osimertinib 80 mg daily in Feb 2020 with radiographic partial response on serial CTs. Recent brain MRI identifies a new solitary cerebellar metastasis and she remains stage IV. PD-L1 testing was not performed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor testing reported MSI-H and TMB-high. KRAS/NRAS testing was deferred because of inadequate tissue. He was started on FOLFOX plus bevacizumab; interval CT at 8 weeks showed increase in size and number of hepatic metastases consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic invasive ductal carcinoma of the breast. Biopsy shows HER2 amplification by FISH with ER positive, PR negative immunohistochemistry. Tumor sequencing identified PIK3CA H1047R. She was treated with first-line docetaxel in combination with trastuzumab and pertuzumab. Imaging after 4 cycles demonstrates partial response of the hepatic and skeletal lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR-", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: Left breast invasive ductal carcinoma, clinical stage IIIA. Tumor ER negative, PR negative; FISH positive for HER2 amplification. Received 6 cycles of TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with good clinical shrinkage prior to mastectomy. Surgical pathology reports pathologic complete response. No distant mets on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with metastatic lung adenocarcinoma diagnosed in January. Tumor genotyping revealed EGFR L858R. Baseline staging was IV with two small enhancing brain metastases on MRI. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily and at first restaging after 3 months had a partial response with shrinkage of pulmonary nodules and resolution of one brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma. Initial treatment with pembrolizumab achieved only stable disease; molecular testing later identified BRAF V600E. He was transitioned to dabrafenib plus trametinib, with CT at 12 weeks showing marked shrinkage of hepatic and pulmonary metastases consistent with partial response. Later assessments will determine durability.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58-year-old male with metastatic cutaneous melanoma. Baseline testing positive for BRAF V600E. Initially started on pembrolizumab; achieved a partial response but progressed after 10 months with new pulmonary nodules. Transitioned to targeted therapy with dabrafenib plus trametinib, with interval CT showing reduction in lung lesions. PD-L1 reported at 10% on archival tissue.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab followed by dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high-grade prostate adenocarcinoma treated initially with radical prostatectomy in 2017. Developed castration-resistant disease with new lytic lesions in the lumbar spine and pelvis on bone scan in 2021. Currently on androgen deprivation (leuprolide) with addition of docetaxel for symptomatic osseous progression. Germline BRCA testing pending and somatic testing not yet performed. PSA rising over the last two measurements, impression: radiographic progression in bone.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 45-year-old male with a 0.8 mm superficial spreading melanoma on the right forearm, staged as stage I. Wide local excision performed with clear margins. Molecular testing detected BRAF V600E. Given thin lesion and negative margins, no adjuvant therapy recommended and patient remains disease free on follow-up.", "output": {"cancer_type": "melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant oncology note: 48-year-old female with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB (T4N1M0). Tumor is HER2 amplified (IHC 3+, FISH positive) and ER/PR negative. Tumor genotyping identified a PIK3CA H1047R mutation. She completed 6 cycles of docetaxel with trastuzumab and pertuzumab prior to surgery. Post-treatment imaging and clinical exam show no residual palpable disease \u2014 clinical complete response prior to mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+, FISH+)", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with recurrent metastatic (stage IV) invasive ductal carcinoma of the breast. Tumor is ER-/PR-, HER2 amplified by FISH and harbors a PIK3CA H1047R mutation. She underwent mastectomy and adjuvant chemotherapy previously; on recurrence with multiple liver lesions she was transitioned to ado-trastuzumab emtansine (T-DM1). Restaging after three cycles shows stable disease in the liver.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "ado-trastuzumab emtansine (T-DM1)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 58-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Presents with multiple pulmonary nodules and several enhancing brain metastases; staged as IV. Treated first-line with pembrolizumab 200 mg IV q3w achieving stable disease for approximately 4 months. On interval MRI there was intracranial progression and patient was switched to targeted therapy with dabrafenib and trametinib, after which imaging showed a partial response of extracranial and intracranial lesions. Baseline tumor sequencing reported high tumor mutational burden.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (initial) then dabrafenib + trametinib", "response": "stable disease on pembrolizumab then partial response on dabrafenib + trametinib", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 62-year-old male with newly diagnosed lung adenocarcinoma. Staging workup demonstrates metastatic disease with multiple brain and lytic bone lesions \u2014 PET/CT consistent with stage IV. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily two weeks ago with symptomatic improvement and interval imaging showing a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma presented to clinic. Tissue NGS demonstrated EGFR L858R mutation. She was started on osimertinib 80 mg daily two months ago with marked radiographic improvement in the chest consistent with a partial response. Recent MRI after a witnessed seizure shows multiple brain metastases and lytic lesions in the thoracic spine. PD-L1 tumor proportion score on the original biopsy was 10%. Plan is to continue osimertinib and schedule stereotactic radiosurgery to the dominant cerebellar lesion. Stage IV disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: 43-year-old woman with locally advanced right breast carcinoma, ER-/PR- by IHC, HER2 amplification confirmed by FISH. Staging imaging suggested T4bN2 disease (clinically stage IIIB). She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by mastectomy. Surgical pathology reported no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant), followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: patient with metastatic cutaneous melanoma who was started on combination immunotherapy (pembrolizumab plus ipilimumab). BRAF testing was negative on the original panel. PD-L1 by IHC was 1%. Despite two doses, interval MRI revealed enlarging cerebral metastases and overall clinical deterioration consistent with progression. No formal stage listed in the outside records.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": null, "biomarker": "PD-L1 1%", "treatment": "pembrolizumab + ipilimumab", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma (biopsy-confirmed). Molecular testing returned EGFR L858R mutation; PD-L1 TPS 10%. Staging CT/MRI consistent with stage IV disease with intracranial and osseous lesions. Patient was started on osimertinib 80 mg daily. Follow-up scans at 8 weeks demonstrate decreased size of the primary right upper lobe mass and shrinkage of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with recurrent cutaneous melanoma, BRAF V600E positive. Initially resected as stage IIIC; recent PET/CT shows new bilateral pulmonary nodules and subcutaneous metastases consistent with stage IV conversion. Patient received a course of adjuvant pembrolizumab after surgery but developed progressive skin and lung disease and was switched to dabrafenib plus trametinib with a subsequent partial radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (adjuvant), then dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung, skin (subcutaneous)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma of the upper back. Molecular panel positive for BRAF V600E. Staging showed pulmonary nodules consistent with metastatic disease (stage IV). The patient was started on dabrafenib and trametinib combination therapy; follow\u2011up PET\u2011CT demonstrates complete metabolic response in the chest. Programmed death ligand testing was not performed.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "complete response (complete metabolic response on PET\u2011CT)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 39-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Baseline PET/CT showed osseous involvement of the femur and pelvis. He started combined BRAF/MEK inhibition with dabrafenib and trametinib. Tumor markers and repeat PET at 12 weeks show decreased metabolic activity in bony lesions consistent with a partial response. PD-L1 by IHC reported as 10%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 55-year-old male originally underwent wide local excision and completion lymphadenectomy for a primary cutaneous melanoma of the right calf, staged at IIIC. At that time BRAF testing was not performed. He received adjuvant nivolumab for 12 months. Six months after completing adjuvant therapy he developed multiple painful in-transit nodules on the leg and new pulmonary nodules; biopsy confirmed recurrent melanoma. Assessment: progressive disease following prior adjuvant immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "adjuvant nivolumab", "response": "progressive disease", "metastasis_site": "lung; in-transit nodules"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male referred for elevated PSA of 10 ng/mL and abnormal DRE. Prostate biopsy showed adenocarcinoma Gleason 3+4 in multiple cores. Clinical stage T2bN0M0 (stage II). He underwent radical prostatectomy last month; postoperative PSA is undetectable. No genomic panel was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 10 ng/mL (pre-op); undetectable PSA post-op", "treatment": "radical prostatectomy", "response": "complete response (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postmenopausal female with left-sided invasive ductal carcinoma cT2N0, ER+/PR+/HER2- (clinical stage II). Tumor profiling identified a PIK3CA H1047R mutation. She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant radiotherapy and endocrine therapy with letrozole. Routine follow-up exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, radiotherapy, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer presenting with multiple liver lesions. Tumor is ER+/PR+, HER2 3+ by IHC, no actionable somatic mutation identified on NGS report. Clinical stage IV. She was started on first-line pertuzumab, trastuzumab and docetaxel; interval CT at 12 weeks shows stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+); ER+/PR+", "treatment": "pertuzumab, trastuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with pancreatic ductal adenocarcinoma. Imaging initially read as locally advanced, staged as III. Tumor sequencing demonstrates KRAS G12D. CA 19-9 markedly elevated at diagnosis. Treated with FOLFIRINOX x6 with interval PET showing partial metabolic response; underwent consolidative chemoradiation. On subsequent restaging there is new peritoneal nodularity concerning for progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by consolidative chemoradiation", "response": "initial partial response then progression (peritoneal disease)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with newly diagnosed metastatic breast cancer, ER 15%, PR negative, HER2 IHC 3+ and FISH-confirmed HER2 amplification. NGS identified a PIK3CA H1047R mutation. She presented with multiple hepatic metastases and started first-line combination therapy with pertuzumab, trastuzumab and docetaxel. After six cycles CT shows ~40% shrinkage of liver lesions and plan is to continue maintenance trastuzumab and pertuzumab. Documented best response: partial response.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER 15%; PR negative", "treatment": "pertuzumab; trastuzumab; docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma (stage IV) with a KRAS G12D mutation identified on molecular profiling. Tumor was reported as MSI-High and TMB-high (approximately 15 muts/Mb). After progression on first-line FOLFOX, he was started on pembrolizumab; scans at 6 months show stable disease with indeterminate decrease in hepatic lesion size. Known metastases to the liver and right lower lobe of the lung.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (~15 muts/Mb)", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with stage III cutaneous melanoma of the right forearm with involvement of regional lymph nodes. Molecular sequencing detected BRAF V600E. He underwent wide local excision and lymph node dissection and was started on adjuvant dabrafenib plus trametinib. Six-month surveillance imaging shows no distant metastasis but a small increase in size of a residual nodal lesion; oncology documents best overall response as stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgery (wide local excision and lymph node dissection); adjuvant dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female presented with a palpable left breast mass. Core biopsy confirmed invasive ductal carcinoma, ER+/PR+, HER2 IHC 3+. Staging imaging consistent with T2N1 disease, clinical stage IIA. NGS identified a PIK3CA H1047R mutation. Patient received neoadjuvant doxorubicin and cyclophosphamide x4 followed by paclitaxel with clinical downstaging. She underwent lumpectomy with sentinel node biopsy; pathology showed pathologic complete response (pCR). Adjuvant trastuzumab planned for 1 year. No distant disease on PET-CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 positive (IHC 3+), ER positive, PR positive", "treatment": "neoadjuvant doxorubicin and cyclophosphamide, paclitaxel; lumpectomy; adjuvant trastuzumab", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. NGS: NRAS Q61R; BRAF wild-type. Tumor mutational burden reported as TMB-high (~22 mutations/Mb). He received combination immunotherapy with ipilimumab and nivolumab but after two cycles developed multiple new pulmonary nodules and rising LDH consistent with progressive disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "TMB-high", "treatment": "ipilimumab and nivolumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and focal weakness. Staging workup demonstrated multiple enhancing lesions in the cerebrum and lytic lesions in the femur consistent with metastatic disease. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily with stereotactic radiosurgery to the dominant brain metastasis. Interval imaging at 8 weeks shows reduction in size of both brain and bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, liver-dominant disease on PET/CT. Molecular testing revealed BRAF V600E and high microsatellite instability (MSI-H). Given MSI-H status he was started on pembrolizumab monotherapy. Interval imaging at 12 weeks shows substantial shrinkage of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed metastatic lung adenocarcinoma. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. Staging consistent with stage IV disease with multiple enhancing brain metastases and lytic lesions in the thoracic spine. Treatment started with osimertinib 80 mg daily in January 2024. Follow-up MRI at 8 weeks showed decreased size of intracranial lesions and improvement in bone pain \u2014 assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female with high-grade serous ovarian carcinoma, clinical stage IIIC with extensive peritoneal carcinomatosis and omental disease. Germline testing positive for a pathogenic BRCA1 variant. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel and is now on olaparib maintenance. CA-125 normalized and CT shows complete radiographic response after chemotherapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated at presentation (normalized after treatment)", "treatment": "cytoreductive surgery, carboplatin and paclitaxel, olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman underwent lumpectomy for a 1.2 cm invasive ductal carcinoma, final pathology T1N0 (stage I). Tumor was ER+/PR+, HER2 3+ by IHC (HER2 amplification confirmed by FISH). Sentinel nodes negative. She completed adjuvant paclitaxel and trastuzumab and was started on adjuvant letrozole. Follow-up at 18 months: no evidence of disease on clinical exam and imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy, adjuvant paclitaxel and trastuzumab, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high-grade serous ovarian carcinoma, stage IIIC at diagnosis with extensive peritoneal disease. Germline BRCA1 pathogenic variant identified; CA-125 elevated pre-treatment. Received neoadjuvant carboplatin and paclitaxel with addition of bevacizumab followed by interval debulking; CT shows a good but incomplete radiographic response with residual peritoneal implants\u2014assessment: partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (pathogenic germline)", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel with bevacizumab (neoadjuvant)", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old with high-grade serous ovarian carcinoma underwent optimal debulking for bulky pelvic disease. Final stage IIIC. She completed adjuvant combination chemotherapy with carboplatin and paclitaxel followed by maintenance bevacizumab. CA-125 normalized post-treatment and CT scans at 3 months show no measurable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery then carboplatin + paclitaxel with maintenance bevacizumab", "response": "complete clinical response (no measurable disease, CA-125 normalized)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with resectable pancreatic head adenocarcinoma, clinical stage II (T2N0). Pre-op CA 19-9 was 820 U/mL. He underwent a Whipple procedure with negative margins; no actionable mutations were identified on tumor NGS. He received adjuvant gemcitabine, but 3-month surveillance CT shows a new 1.5 cm hepatic lesion concerning for metastatic recurrence.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "CA 19-9 820 U/mL", "treatment": "Whipple procedure; adjuvant gemcitabine", "response": "suspected metastatic recurrence / progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 61-year-old man with clinically localized prostate cancer, PSA 12 ng/mL, biopsy Gleason 3+4 in two cores. Underwent radical prostatectomy; pathology reported pT2b with negative margins. Post-op PSA undetectable, but low-volume biochemical recurrence at 0.4 ng/mL prompted salvage radiotherapy. No metastatic disease seen on bone scan.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (pre-op); postoperative detectable PSA 0.4 ng/mL", "treatment": "radical prostatectomy, salvage radiotherapy", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic pancreatic ductal adenocarcinoma found to have a pathogenic BRCA2 germline mutation. Baseline CA 19-9 markedly elevated. Imaging confirmed widespread hepatic and peritoneal disease (stage IV). She received gemcitabine plus nab-paclitaxel with an initial partial radiographic response, then transitioned to maintenance olaparib given BRCA2; after 9 months there was interval disease progression with new peritoneal implants.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine + nab-paclitaxel, maintenance olaparib", "response": "initial partial response followed by progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed stage IV lung adenocarcinoma. Molecular testing identified EGFR L858R; PD-L1 tumor proportion score reported as 10%. Baseline imaging demonstrated brain and bone metastases. He was started on osimertinib as first-line therapy and had a radiographic partial response at first follow-up (8 weeks) but developed hepatic progression at month 10.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "initial partial response then progression", "metastasis_site": "brain and bone; liver (progression)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer (cT4bN1) \u2014 ER negative / PR negative; HER2 IHC 3+ and HER2 amplification confirmed by FISH. She received neoadjuvant trastuzumab and pertuzumab with docetaxel x6 cycles followed by modified radical mastectomy. Final pathology shows no residual invasive carcinoma in the breast or nodes (pCR). No genomic driver mutation reported on panel.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant) followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old woman with a 0.9 mm pigmented lesion of the upper back, diagnosed as cutaneous melanoma, Breslow 0.9 mm, ulceration absent. Clinical stage IB (T1bN0M0). BRAF V600E mutation detected on PCR. Wide local excision with 1 cm margins was performed and nodes were clinically negative; no adjuvant systemic therapy recommended. PD-L1 testing was not performed. Patient remains free of disease on follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed prostate adenocarcinoma, Gleason 3+4=7. Clinical staging T2bN0M0 consistent with stage IIA. PSA at diagnosis 7.8 ng/mL. He underwent radical prostatectomy last month; surgical margins negative, pelvic nodes negative. Post-operative PSA now undetectable. No adjuvant radiation planned at this time.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIA (T2bN0M0)", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "undetectable PSA post-op", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma, stage IV. Liver-dominant disease on CT. NGS shows KRAS G12D mutation; tumor is microsatellite stable (MSS). Started FOLFOX plus bevacizumab. Restaging CT after 3 cycles: no appreciable decrease in lesion size, overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with invasive ductal carcinoma of the breast, ER positive / PR negative, HER2-amplified. Initially treated with lumpectomy and axillary node dissection. On recent restaging she has new hepatic lesions consistent with metastatic disease; liver biopsy confirms HER2 amplification. Started on docetaxel with trastuzumab and pertuzumab. After four cycles there is a radiologic partial response with decreased size of liver lesions. No somatic genomic panel was available in the chart.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, trastuzumab, pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 45-year-old female with right-sided invasive ductal carcinoma, ER-positive, PR-positive, HER2 IHC 3+ confirmed by FISH (HER2 amplification). Pathologic stage after lumpectomy and sentinel node biopsy: pT2 pN0 \u2014 stage IIA. Somatic testing detected PIK3CA H1047R. Patient completed lumpectomy with clear margins and negative nodes; adjuvant paclitaxel planned followed by one year of trastuzumab. Currently postsurgical surveillance with no evidence of disease on first follow-up exam.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+; PR+; HER2 amplification (IHC 3+)", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with recurrent cutaneous melanoma presenting with pulmonary nodules and several enhancing brain lesions. Tumor testing positive for BRAF V600E; NRAS wild-type. PD-L1 by IHC reported at 5% and TMB described as high. He was started on combination dabrafenib + trametinib (BRAF/MEK inhibitors) with rapid extracranial tumor shrinkage but developed intracranial progression requiring stereotactic radiosurgery. Subsequently he received combination immunotherapy with nivolumab + ipilimumab. Overall course: extracranial partial response, intracranial disease controlled post-SRS.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%, TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery; then nivolumab + ipilimumab", "response": "partial response (extracranial), intracranial disease controlled after SRS", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with borderline resectable pancreatic head adenocarcinoma underwent germline testing which identified a pathogenic BRCA2 mutation. Staging was consistent with locally advanced disease (stage III) without distant metastases. He received neoadjuvant FOLFIRINOX with good radiographic response allowing a Whipple procedure; final pathology achieved R0 resection. Post-op he completed adjuvant gemcitabine and is being considered for maintenance olaparib given the BRCA2 mutation.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "neoadjuvant FOLFIRINOX; Whipple (pancreaticoduodenectomy); adjuvant gemcitabine; planned olaparib", "response": "partial radiographic response to neoadjuvant therapy; R0 resection", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman presented with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 IHC 3+ and FISH consistent with HER2 amplification. Staged clinically as IIIA. Tumor NGS identified PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by lumpectomy; surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel + trastuzumab + pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic lung adenocarcinoma presented in January 2024. Molecular testing identified EGFR L858R and PD-L1 tumor proportion score ~10%. Staging showed stage IV disease with multiple brain and bone metastases. He was started on osimertinib 80 mg daily and steroids for symptomatic brain mets. Follow-up CT chest and brain MRI at 8 weeks demonstrated marked reduction in size of pulmonary nodules and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 62-year-old male with metastatic lung adenocarcinoma diagnosed by core biopsy of right lower lobe. Staging PET/CT showed pulmonary mass and multiple intracranial lesions consistent with metastases. Molecular testing positive for EGFR L858R mutation; PD-L1 TPS approximately 5%. He was started on osimertinib with an initial partial response of thoracic disease, but interval MRI at 6 months demonstrated progression in the brain with enlarging cerebellar metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 ~5%", "treatment": "osimertinib", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman presented with progressive cough and headache. Imaging and biopsy confirmed lung adenocarcinoma, stage IV with brain metastasis. Molecular testing identified EGFR L858R and PD-L1 10%. Patient was started on osimertinib 80 mg daily; whole brain radiotherapy was given for symptomatic lesions. CT after 8 weeks demonstrates a partial response of the thoracic disease and reduction in intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole brain radiotherapy", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical staging at presentation recorded as IIIB. She received neoadjuvant docetaxel, carboplatin and trastuzumab with marked tumor shrinkage and subsequently underwent modified radical mastectomy. No distant metastases on staging CT. Germline sequencing results pending.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin and trastuzumab; surgery (mastectomy)", "response": "partial response (marked tumor shrinkage)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic non-small cell lung cancer (adenocarcinoma). Staging workup consistent with stage IV disease with multiple brain metastases and lytic lesions in the thoracic spine. Molecular testing identified EGFR L858R mutation. PD-L1 tumor proportion score approximately 10%. Patient was started on osimertinib 80 mg daily; after 8 weeks imaging demonstrates a marked decrease in target lesions \u2014 overall assessment: partial response.", "output": {"cancer_type": "non-small cell lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 48-year-old woman with a 3.2 cm invasive ductal carcinoma of the right breast, clinically T2N2M0 (stage III). ER/PR negative, HER2 IHC 3+ and confirmed HER2 amplification by FISH. She received neoadjuvant dose-dense doxorubicin + cyclophosphamide followed by paclitaxel with trastuzumab. Mastectomy specimen showed no residual invasive carcinoma (pCR). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR negative", "treatment": "dose-dense doxorubicin + cyclophosphamide, paclitaxel, trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer. Core biopsy of the left breast: invasive ductal carcinoma, ER 80%+, PR 20%+, HER2 IHC 3+ consistent with HER2 amplification. Staging CT shows multiple hypodense liver lesions consistent with hepatic metastases. Genomic profiling returned PIK3CA H1047R. Patient started on first-line trastuzumab, pertuzumab and docetaxel; after 4 cycles the CT abdomen shows decrease in size of liver lesions \u2014 partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right thigh primary cutaneous melanoma with positive sentinel node, pathologic stage IIIB. Molecular testing detected BRAF V600E. Patient underwent wide local excision and completion lymphadenectomy. Adjuvant targeted therapy with dabrafenib plus trametinib was initiated. Follow-up PET/CT is negative for FDG-avid disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; completion lymphadenectomy; adjuvant dabrafenib and trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old man presented with jaundice and weight loss. Imaging showed a pancreatic head mass with multiple liver lesions; biopsy confirmed pancreatic ductal adenocarcinoma, stage IV. Germline testing identified a deleterious BRCA2 mutation. Baseline CA 19-9 was markedly elevated. He received six cycles of FOLFIRINOX with significant tumor shrinkage (partial response) and then transitioned to olaparib maintenance given the BRCA2 mutation; after 5 months on olaparib there was radiographic progression in the liver.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation (germline)", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "initial partial response to FOLFIRINOX, followed by progression on olaparib", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, ER-negative, PR-negative, HER2 3+ by IHC with HER2 amplification confirmed by FISH. Clinical stage cT3N1M0 (stage III). She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles followed by left mastectomy. Final pathology showed no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "III", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic cutaneous melanoma (stage IV) found to be BRAF V600E positive. PD-L1 testing returned 60% tumor cell expression. Multiple pulmonary nodules consistent with metastases on chest CT. He was started on dabrafenib plus trametinib. After three months of therapy there is interval enlargement of pulmonary nodules and new lesions \u2014 overall progression of disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with pancreatic ductal adenocarcinoma found to have diffuse peritoneal nodularity at diagnostic laparoscopy consistent with peritoneal carcinomatosis. Germline testing positive for BRCA2 pathogenic variant. CA 19-9 markedly elevated. He received 8 cycles of FOLFIRINOX with cytostatic effect and was transitioned to olaparib maintenance; disease has been stable on CT scans over the last 4 months.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 mutation (germline)", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX then olaparib maintenance", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. Core biopsy: HER2 amplification by FISH, ER positive, PR negative, and PIK3CA H1047R on tumor panel. Neoadjuvant paclitaxel plus trastuzumab was administered for 12 weeks; interval imaging prior to surgery showed a marked decrease in primary tumor size consistent with a partial response. No distant spread identified on staging PET-CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the breast. Core biopsy: ER 80% positive, PR negative, HER2 IHC 3+; next-generation sequencing identified a PIK3CA H1047R mutation. Clinical stage was IIIA (T2 N2 M0). She completed 12 weeks of neoadjuvant paclitaxel with trastuzumab and proceeded to lumpectomy with axillary dissection \u2014 pathology reported a pathologic complete response (pCR). No evidence of distant metastasis on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER positive", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old with a 1.2 cm pigmented lesion on the right forearm diagnosed as superficial spreading melanoma, stage I after wide local excision and negative sentinel lymph node biopsy. Tumor genotyping identified BRAF V600E. No adjuvant systemic therapy was given. Patient remains clinically well with no evidence of recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (no adjuvant systemic therapy)", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple hepatic lesions on CT. Molecular testing demonstrated a KRAS G12D mutation. He was started on mFOLFOX6 plus bevacizumab. After six cycles the CT shows new hepatic lesions and enlargement of existing metastases consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "mFOLFOX6 and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic progress: 49-year-old male with metastatic melanoma. Initial mutation panel showed BRAF V600E. He was started on dabrafenib plus trametinib and achieved a brisk partial response in the lungs and nodal disease. After 9 months on combination therapy the patient developed progressive disease with new hepatic lesions on MRI. Tumor mutational burden reported as TMB-high; PD-L1 was 60% by IHC.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 60%", "treatment": "dabrafenib + trametinib", "response": "progression after initial partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female presented with jaundice and weight loss; imaging revealed a pancreatic head mass and multiple liver lesions. Biopsy confirmed pancreatic ductal adenocarcinoma, stage IV. Molecular report: KRAS G12V. CA19-9 markedly elevated at 12,000 U/mL. She was started on gemcitabine plus nab-paclitaxel; after two cycles restaging CT shows interval progression with enlarging hepatic metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V", "biomarker": "CA19-9 12,000 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic castration-resistant prostate cancer with extensive sclerotic bone metastases. Treated initially with androgen-deprivation and enzalutamide; genomic testing not yet available. He was started on olaparib after clinical progression on hormonal therapy; PSA fell transiently but subsequent scans show new bone lesions consistent with progressive disease.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen-deprivation therapy, enzalutamide, olaparib", "response": "progressive disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Young adult with a 1.2 mm superficial spreading cutaneous melanoma, staged as stage I (Breslow 1.2 mm, no ulceration). Sentinel lymph node biopsy was negative. Tumor sequencing identified a BRAF V600E mutation. Patient underwent wide local excision with clear margins and did not receive systemic therapy; surveillance only.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male presented with obstructing sigmoid mass. Biopsy confirmed colon adenocarcinoma. Staging CT shows multiple liver lesions consistent with metastases (stage IV). NGS identified KRAS G12D; mismatch repair testing: MSS. He was started on FOLFOX plus bevacizumab. Follow-up imaging at 3 months reveals interval enlargement of hepatic metastases consistent with disease progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT shows multiple liver lesions consistent with metastases. Tumor genotyping: KRAS G12D. Serum CEA markedly elevated to 150 ng/mL. Started on FOLFOX plus bevacizumab; after three cycles CT shows increase in size and number of hepatic lesions and rising CEA \u2014 assessment: disease progression on first-line therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated (150 ng/mL)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital consult: 64-year-old male with locally advanced pancreatic ductal adenocarcinoma, borderline resectable at presentation (clinical stage III). Tumor board notes: no actionable mutations identified on commercial NGS panel. CA 19-9 elevated to 1,200 U/mL. He completed two cycles of gemcitabine plus nab-paclitaxel followed by stereotactic body radiation (SBRT). Surveillance imaging now shows new hypodense lesions in the liver concerning for metastatic spread and rising CA 19-9; clinician documents interval progression and referral to palliative care for symptom management.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine plus nab-paclitaxel; SBRT", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB. Core biopsy: ER negative, PR negative, HER2 amplified by FISH. Comprehensive NGS did not identify actionable point mutations. She received neoadjuvant carboplatin and docetaxel with dual HER2 blockade (trastuzumab and pertuzumab) and proceeded to mastectomy with pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "carboplatin and docetaxel; trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with stage IV lung adenocarcinoma harboring EGFR L858R. Initial therapy with osimertinib produced a partial response with shrinkage of the primary and intracranial lesions; she also had sclerotic bone metastases on PET. On radiographic progression she received combination pemetrexed, carboplatin and pembrolizumab. PD-L1 by IHC was 10%.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; pemetrexed + carboplatin + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 52-year-old male with widely metastatic cutaneous melanoma diagnosed last year. Treated with combination immunotherapy (nivolumab + ipilimumab) with initial shrinkage of subcutaneous nodules, followed by dabrafenib + trametinib after clinical progression. Latest imaging demonstrates new pulmonary nodules and leptomeningeal symptoms. No molecular testing was available in the chart and PD-L1 was not reported.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab + ipilimumab followed by dabrafenib + trametinib", "response": "initial response then progression", "metastasis_site": "lung, leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV sigmoid colon adenocarcinoma; molecular profiling identified KRAS G12D and microsatellite stable (MSS). Baseline CT showed multiple hepatic lesions consistent with metastatic disease. Started FOLFOX plus bevacizumab; interval imaging demonstrates enlarging liver metastases consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "Microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with lung adenocarcinoma in 2019. Staging at presentation was IV with brain and bone metastases. Molecular testing on the biopsy identified EGFR L858R; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily in January 2020 and repeat imaging after 8 weeks showed decreased size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (stage IV) diagnosed on core biopsy. NGS revealed EGFR L858R. PD-L1 TPS reported at 30%. She presented with symptomatic brain and vertebral bone metastases and was started on osimertinib 80 mg daily with symptomatic improvement and radiographic reduction in lesion size. Best overall response recorded as partial response on RECIST; later MRI demonstrated new progressive intracranial disease after 14 months.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old man with locally advanced pancreatic ductal adenocarcinoma, staged IIB on CT and endoscopic ultrasound. CA19-9 elevated at 1,200 U/mL. Tumor sequencing was inconclusive and no actionable mutation was reported. He completed four cycles of FOLFIRINOX followed by chemoradiation with capecitabine. Restaging CT after therapy showed stable disease without distant metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": "CA19-9 1,200 U/mL", "treatment": "FOLFIRINOX; chemoradiation with capecitabine", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma diagnosed after debulking. Germline testing positive for pathogenic BRCA1 185delAG. At presentation disease was stage IIIC with bulky peritoneal carcinomatosis. Patient received frontline carboplatin and paclitaxel with good radiographic response and then started maintenance olaparib. CA-125 decreased and imaging after 3 cycles of maintenance showed partial response in the peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "HRD positive (BRCA1-associated)", "treatment": "carboplatin and paclitaxel followed by maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic castration-resistant prostate cancer (mCRPC). Germline and tumor testing identified a deleterious BRCA2 mutation. He has diffuse sclerotic bone metastases and rising pain despite prior abiraterone. Started olaparib; PSA has stabilized and scans show no new lesions \u2014 clinical impression: disease control with stable radiology.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant prostate cancer)", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presented with progressive pulmonary nodules. Tumor sequencing detected BRAF V600E. Initially treated with single-agent nivolumab but developed radiographic progression in the lungs after 12 weeks. Therapy was changed to dabrafenib plus trametinib with subsequent shrinkage of the lung lesions (partial response). Molecular pathology also reported high tumor mutational burden.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "nivolumab; dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: Right breast core biopsy reveals invasive ductal carcinoma, ER positive, PR positive, HER2 3+ by IHC with HER2 amplification confirmed by FISH. Clinical staging prior to surgery was IIIA (T2N2M0). NGS panel identified PIK3CA E545K. Patient underwent modified radical mastectomy followed by adjuvant paclitaxel and trastuzumab and radiation therapy. Post-treatment surveillance imaging and exam show no evidence of disease (clinical complete response).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "surgery, paclitaxel, trastuzumab, radiation", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma referred for second opinion. Molecular profile: KRAS G12D positive, BRAF wild-type, microsatellite stable (MSS). CT abdomen shows multiple hypodense lesions in both hepatic lobes consistent with liver metastases. Overall stage IV. Treatment initiated with FOLFOXIRI plus bevacizumab; first CT restaging after 2 months demonstrates no new lesions and minimal change in size of known metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOXIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with biopsy-proven lung adenocarcinoma. Staging CT chest/abdomen showed multiple bilateral pulmonary nodules and MRI brain identified two cerebellar lesions consistent with metastases. Next-generation sequencing returned EGFR L858R positive; ALK and ROS1 negative. PD-L1 tumor proportion score 15%. Patient started osimertinib 80 mg PO daily. First restaging at 8 weeks demonstrated a partial response with shrinkage of pulmonary lesions and decrease in size of brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Baseline PD-L1 was 10%. He initially received nivolumab monotherapy but developed new pulmonary nodules and worsening bone pain after 4 months. Therapy was switched to dabrafenib plus trametinib, with subsequent symptomatic improvement and a confirmed partial response on imaging.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "nivolumab followed by dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presented with a solitary cerebellar metastasis. Tumor sequencing identified a BRAF V600E mutation. The brain lesion was resected followed by systemic therapy with dabrafenib plus trametinib. No PD-L1 testing was performed. Subsequent MRI showed near-complete radiographic response in the resection cavity and extracranial disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgical resection; dabrafenib and trametinib", "response": "near-complete radiographic response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female presented with jaundice and weight loss. Imaging and biopsy consistent with pancreatic ductal adenocarcinoma with liver lesions; stage IV at diagnosis. Germline and somatic testing identified pathogenic BRCA2 mutation. She received FOLFIRINOX with radiographic partial response and marked CA19-9 decline, then transitioned to maintenance olaparib. Current assessment: ongoing partial response in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "elevated CA19-9 (tumor marker)", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 54 y/o woman with locally advanced left breast cancer, clinically T4N2M0 consistent with stage IIIB. Core biopsy: invasive ductal carcinoma, ER positive (90%), PR negative, HER2 amplified by FISH. Tumor next-generation sequencing detected PIK3CA H1047R. Patient started on trastuzumab + pertuzumab in combination with docetaxel prior to planned mastectomy. Marked shrinkage of the primary and decrease in axillary adenopathy on exam (partial response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with newly diagnosed lung adenocarcinoma. Staging workup shows stage IV disease with multiple brain and osseous lesions on MRI and PET-CT. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient started first-line osimertinib 80 mg daily with good tolerance. Interim imaging at 8 weeks demonstrates decrease in size of pulmonary mass and resolution of several brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female never-smoker presented with progressive dyspnea. Biopsy confirmed lung adenocarcinoma. Staging PET/CT showed multiple pulmonary nodules and several enhancing lesions in the cerebrum consistent with metastases. Molecular testing identified an EGFR L858R mutation; PD-L1 TPS 10%. She was started on osimertinib 80 mg daily with clinical improvement and CT at 8 weeks demonstrating a decrease in size of target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with a 3 cm cutaneous melanoma on the left thigh. Sentinel lymph node biopsy was positive and disease was staged as stage III. BRAF V600E mutation identified on PCR. She was started on adjuvant therapy with dabrafenib plus trametinib. Recent clinic notes document decreased nodal size on ultrasound and the patient is tolerating therapy well.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response (decrease in nodal size)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a history of cutaneous melanoma, pathologic stage IIIC at diagnosis. NGS of the primary lesion detected an NRAS Q61K mutation. Given high-risk features he was treated with combination immunotherapy (ipilimumab plus nivolumab). After two cycles imaging showed no new organ metastases and the disease was considered radiographically stable. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female diagnosed with high-grade serous ovarian carcinoma. At laparotomy she was stage IIIC with bulky omental and pelvic peritoneal disease. Germline testing identified a deleterious BRCA1 mutation. She underwent optimal primary debulking followed by adjuvant carboplatin and paclitaxel and is on maintenance olaparib with ongoing partial radiographic response. Disease most prominent in the omentum and pelvic peritoneum.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "germline BRCA1 mutation", "biomarker": "HRD-positive", "treatment": "primary debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "omentum, pelvic peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology clinic: 67-year-old man with clinically localized prostate adenocarcinoma, PSA 18 ng/mL at presentation. Biopsy Gleason 3+4 in three cores. Clinical stage II. Underwent robotic radical prostatectomy followed by adjuvant external beam radiation for positive margin. Currently PSA undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 18 ng/mL (presenting); postoperative PSA undetectable", "treatment": "radical prostatectomy; adjuvant external beam radiation", "response": "no evidence of disease (PSA undetectable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic cutaneous melanoma, multiple hepatic and pulmonary lesions on staging (stage IV). Tumor tested positive for BRAF V600E. He progressed on first\u2011line pembrolizumab after 4 months with new symptomatic liver lesions, then was started on dabrafenib plus trametinib. Interval imaging after 6 weeks shows decrease in size of target liver and lung lesions consistent with a partial response; patient reports decreased fatigue. PD-L1 was reported as 5% on the archival specimen.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (prior), then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presents with cough and weight loss; biopsy confirmed lung adenocarcinoma. Staging CT and PET consistent with metastatic disease to the brain and right iliac bone \u2014 stage IV. Molecular testing: EGFR L858R; PD-L1 TPS 5%. He was started on osimertinib 80 mg daily with stereotactic radiosurgery to a solitary brain lesion. Interval imaging at 8 weeks demonstrates a partial response in the chest and decreased size of brain metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib, stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade glioma diagnosed as glioblastoma (WHO grade IV) in a 62-year-old female. Underwent maximal safe resection; tumor was MGMT promoter methylation positive. Received concurrent radiation with temozolomide followed by adjuvant temozolomide. Early follow-up MRI at 3 months demonstrates radiographic progression. No actionable molecular drivers reported in the chart.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "surgical resection followed by concurrent chemoradiation with temozolomide and adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral letter: 43-year-old woman with locally advanced invasive ductal carcinoma of the left breast, ER+/PR+, HER2 amplified by IHC/FISH; clinical stage IIIB (T4bN1). NGS identified a PIK3CA H1047R mutation. She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by lumpectomy and sentinel node biopsy. Pathology: no residual invasive carcinoma in breast or nodes \u2014 pathologic complete response. No distant metastases on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel and trastuzumab (neoadjuvant) with surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with cutaneous melanoma of the left forearm, now metastatic to lung and brain. BRAF V600E mutation identified on tumor sequencing; tumor mutational burden high (TMB-high, 22 muts/Mb). Initially treated with combination nivolumab/ipilimumab immunotherapy. After mixed radiologic response (regression of some lung nodules, growth of one cerebellar lesion) the patient was started on dabrafenib and trametinib. Recent scan report documents heterogeneous changes consistent with mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (22 muts/Mb)", "treatment": "nivolumab + ipilimumab; later dabrafenib + trametinib", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 71-year-old man with metastatic colon adenocarcinoma. CT abdomen shows multiple hepatic lesions consistent with metastatic disease; colonoscopy confirmed adenocarcinoma of the sigmoid colon. Stage IV at presentation. Tumor genotyping identified KRAS G12D. MSI testing: MSS. He was started on FOLFOX with bevacizumab. After 4 cycles the CT shows no new lesions and size of dominant hepatic metastasis is unchanged compared with prior \u2014 assessment is stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital discharge diagnosis: Metastatic colorectal adenocarcinoma. Tumor profiling demonstrated KRAS G12D mutation; microsatellite status reported as MSS. CT abdomen/pelvis shows multiple bilobar hepatic metastases and small-volume peritoneal nodularity. Patient was treated with FOLFOX plus bevacizumab in the palliative setting but interval imaging shows growth of hepatic lesions and new ascites consistent with progression of disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with castrate-resistant prostate adenocarcinoma and progressive bony disease. Bone scan showed new blastic lesions in the spine and pelvis. He was started on continued androgen-deprivation with leuprolide and addition of abiraterone acetate. No molecular testing reported in chart. PSA has been stable on therapy at recent follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Initial biopsy identified EGFR L858R. She developed new-onset seizures and MRI showed multiple enhancing brain lesions consistent with metastases. Patient started osimertinib 80 mg daily last year with marked reduction in chest disease and shrinkage of intracranial lesions; most recent RECIST assessment documented a partial response. PD-L1 staining was 10% on the diagnostic sample. Stage IV at presentation.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma diagnosed after presentation with right upper quadrant pain. CT showed multiple liver lesions and small pulmonary nodules consistent with metastatic disease (stage IV). Tumor genotyping identified KRAS G12D; MSI testing was stable. He received FOLFOX plus bevacizumab as first-line therapy but interval scans demonstrated growth of hepatic metastases and rising CEA consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; CEA elevated", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "MD note: 58-year-old male diagnosed with cutaneous melanoma involving the left forearm, sentinel node positive \u2014 stage III at presentation. Tumor genomics showed NRAS Q61R; PD-L1 by IHC 5%. He underwent wide local excision and completion lymphadenectomy and was started on adjuvant nivolumab. Six months later surveillance CT revealed new bilateral pulmonary nodules concerning for recurrence \u2014 PET/CT confirmed metastatic disease consistent with progressive disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 5%", "treatment": "surgery (wide local excision, lymphadenectomy) and adjuvant nivolumab", "response": "progressive disease (recurrence with pulmonary metastases)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: 45\u2011year\u2011old woman with a 2.6 cm invasive ductal carcinoma of the right breast. ER positive, PR positive, HER2 amplified by FISH (ratio 5.2). Final pathologic staging pT2N0, clinical stage IIA. Tumor sequencing later detected PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy and completed adjuvant paclitaxel followed by trastuzumab. Surveillance exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "75-year-old man presenting with progressive back pain found to have prostate adenocarcinoma with Gleason score 4+5 and diffuse sclerotic bone lesions. Clinical stage IV. No actionable alterations reported on limited somatic panel. He was started on androgen deprivation with leuprolide and received docetaxel for cytoreduction. PSA has fallen and scans at 4 months show stable bone disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with newly diagnosed lung adenocarcinoma, clinical stage IV with multiple intracranial and osseous lesions. Molecular testing returned EGFR L858R on PCR; PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily as first-line targeted therapy. Interval CT and MRI after 8 weeks demonstrate decrease in size of pulmonary nodules and improving brain metastases \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with locally advanced pancreatic ductal adenocarcinoma, clinically stage III. CA 19-9 elevated to 750 U/mL. Germline BRCA2 mutation identified. Received neoadjuvant FOLFIRINOX with good tumor shrinkage, underwent Whipple with R0 margins, and is on maintenance olaparib. Surveillance scans to date show no distant metastasis.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III (locally advanced)", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA 19-9 elevated (750 U/mL)", "treatment": "neoadjuvant FOLFIRINOX, Whipple procedure (R0), maintenance olaparib", "response": "R0 resection; no evidence of distant disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female diagnosed with left breast invasive ductal carcinoma, clinical stage II (T2N0). Hormone receptor testing: ER positive, PR positive. HER2 was amplified by FISH. She received neoadjuvant paclitaxel with trastuzumab for 12 weeks followed by lumpectomy. Surgical pathology revealed no residual invasive carcinoma consistent with a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old man with metastatic lung adenocarcinoma (diagnosed 2019) presented with progressive cough and weight loss. Molecular testing by PCR identified EGFR L858R mutation. PD-L1 TPS reported at 5%. Staging at presentation: stage IV with MRI brain showing a 1.2 cm cerebellar metastasis. He was started on osimertinib 80 mg PO daily in January 2020. Interval CT after 8 weeks showed decrease in size of target pulmonary lesions consistent with a partial response; brain lesion treated with stereotactic radiosurgery. Last note documents ongoing clinical benefit but small new enhancing focus in cerebellum concerning for intracranial progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma (stage IV) found to harbor a BRAF V600E mutation. Initially started on dabrafenib plus trametinib with decreasing size of several pulmonary nodules but development of a new small hepatic lesion on interval CT \u2014 characterized by the team as a mixed response. PD-L1 was not performed. Nivolumab was added subsequently.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; later nivolumab", "response": "mixed response", "metastasis_site": "lung; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions. Next-generation sequencing identified KRAS G12D mutation; BRAF was wild-type. Tumor testing demonstrated high microsatellite instability (MSI-H). Given MSI-H status, he was started on pembrolizumab monotherapy. Restaging at 12 weeks shows marked reduction in size and number of liver lesions consistent with partial response. Stage IV with dominant liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced breast cancer. Core biopsy: ER positive, PR positive, HER2 amplified by FISH; NGS detected PIK3CA H1047R. Clinical stage recorded as IIIB. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles. Mastectomy specimen showed no residual invasive carcinoma \u2014 pathologic complete response. No distant disease on staging CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant); mastectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Imaging demonstrated multiple bilateral pulmonary nodules and a 2.5 cm metastasis in the left frontal lobe. Molecular testing returned EGFR L858R activating mutation; PD-L1 TPS 10%. Started first-line osimertinib 80 mg daily with symptomatic improvement of headaches. First restaging CT/MRI shows decrease in size of primary and brain lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. Initial colectomy 2018 followed by adjuvant FOLFOX. Recurrence with peritoneal nodules in 2021; biopsy shows MSI-H and BRAF V600E mutation. He received palliative FOLFOX + bevacizumab with progression and was switched to pembrolizumab given MSI-H status; current scans demonstrate stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab (after FOLFOX + bevacizumab)", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a deleterious BRCA1 variant (185delAG) and tumor is HRD-positive. She underwent primary debulking followed by carboplatin and paclitaxel combined with bevacizumab, then was started on maintenance olaparib plus bevacizumab per protocol. CA-125 normalized and follow-up CT shows complete clinical response of peritoneal and omental disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG (germline)", "biomarker": "HRD-positive, CA-125 elevated (now normalized)", "treatment": "primary debulking; carboplatin + paclitaxel + bevacizumab; maintenance olaparib + bevacizumab", "response": "complete clinical response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with Stage II (T2N0M0) invasive ductal breast carcinoma. Tumor was ER+/PR+ and HER2 3+ by IHC; genomic testing detected a PIK3CA H1047R mutation. She received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab, then lumpectomy and sentinel node biopsy showing no residual invasive disease (pathologic complete response). She was started on adjuvant letrozole and will continue trastuzumab to complete 1 year.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+/PR+, HER2 3+", "treatment": "dose-dense doxorubicin and cyclophosphamide; paclitaxel; trastuzumab; lumpectomy; letrozole", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Baseline PD-L1 60%. He was started on pembrolizumab but after 4 cycles developed clinical and radiographic progression with new brain and pulmonary lesions. Pembrolizumab was discontinued; stereotactic radiosurgery was performed for the brain metastases and systemic therapy was switched to dabrafenib plus trametinib. Subsequent imaging shows partial response in the lung lesions and reduction in intracranial disease burden.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "pembrolizumab; stereotactic radiosurgery; dabrafenib and trametinib", "response": "progression on pembrolizumab then partial response to dabrafenib/trametinib", "metastasis_site": "brain and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 53-year-old man with recurrent cutaneous melanoma. Initial adjuvant course of nivolumab was complicated by progressive intracranial disease; brain MRI confirmed multiple metastases. Tumor genomics: BRAF V600E positive. Patient progressed on immunotherapy and was transitioned to targeted therapy with dabrafenib plus trametinib; interval MRI shows reduction in size of several intracranial lesions. Overall the course: progression on PD-1 inhibitor, partial intracranial response to BRAF/MEK inhibitors.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 negative", "treatment": "nivolumab; dabrafenib and trametinib", "response": "progression on immunotherapy; partial response to BRAF/MEK inhibitors", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed lung adenocarcinoma, stage IV. Staging CT and MRI demonstrated multiple brain and bone metastases. Comprehensive NGS returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. First follow-up imaging showed decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old man who underwent right hemicolectomy for colon adenocarcinoma, pathologic stage IIIB (pT3 N1). Molecular studies showed MSI-H by PCR and a KRAS G12D mutation on next-generation sequencing. He completed adjuvant FOLFOX chemotherapy. On routine surveillance imaging 7 months later new liver lesions were identified and biopsy confirmed metastatic colon cancer; therapy was changed to pembrolizumab with interval imaging demonstrating a partial response of the hepatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case summary: 67-year-old male with metastatic castration-resistant prostate cancer (mCRPC) with bone-predominant disease. Germline and tumor testing identified a deleterious BRCA2 frameshift. Homologous recombination deficiency (HRD) assay was positive. He received continuous ADT with docetaxel and abiraterone/prednisone combination with a >50% PSA decline, then transitioned to maintenance olaparib given BRCA2 mutation. Latest scan shows decreased sclerosis of several vertebral lesions.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant prostate cancer)", "stage": "IV", "gene_mutation": "BRCA2 (deleterious frameshift)", "biomarker": "HRD-positive", "treatment": "androgen deprivation therapy + docetaxel + abiraterone/prednisone; olaparib", "response": "partial biochemical/radiographic response (PSA decline >50%)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative summary and pathology: 68-year-old male with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiation (cisplatin + 5-FU with concurrent external beam radiation) followed by transthoracic esophagectomy. Surgical pathology revealed no residual invasive carcinoma in the resection specimen.", "output": {"cancer_type": "esophageal squamous cell carcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "concurrent cisplatin and 5-FU with external beam radiation followed by esophagectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female diagnosed with ER+/PR+ HER2-amplified invasive ductal carcinoma of the breast. Clinical staging prior to treatment was IIIC due to bulky ipsilateral axillary lymph node involvement on PET/CT (multiple FDG-avid axillary nodes). She received neoadjuvant docetaxel, carboplatin with trastuzumab and pertuzumab. Post-neoadjuvant imaging and exam show reduction in nodal size and decreased FDG uptake consistent with a partial response in the axillary nodes.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed lung adenocarcinoma presented with multifocal bone pain and headaches. Biopsy confirmed non-small cell lung cancer, adenocarcinoma. Molecular testing: EGFR L858R positive; PD-L1 tumor proportion score 10%. He was started on osimertinib for EGFR-mutant disease with initial clinical benefit, but after 9 months developed progressive brain and vertebral metastases and was switched to carboplatin/pemetrexed plus pembrolizumab. Imaging after two cycles showed a partial response in the lung and stable intracranial disease after stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed plus pembrolizumab", "response": "partial response; stable intracranial disease", "metastasis_site": "brain, bone (vertebrae)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old with unresectable metastatic cutaneous melanoma presented with multiple bilateral pulmonary nodules and a solitary cerebellar metastasis. PD-L1 expression 20%, tumor mutational burden reported as TMB-high. No actionable driver mutation was identified on panel testing. He received combination ipilimumab plus nivolumab and after three cycles has a complete radiographic response including resolution of the brain lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 20%; TMB-high", "treatment": "ipilimumab + nivolumab", "response": "complete response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive NGS showed EGFR L858R mutation and PD-L1 tumor proportion score 10%. He presented with new headaches and MRI brain demonstrated multiple enhancing parenchymal lesions consistent with cerebral metastases. Osimertinib 80 mg daily was started in January 2020 with marked improvement in pulmonary nodules and reduction in size of several brain lesions on follow-up imaging. Clinical assessment documents symptomatic benefit and radiographic partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (Stage IV) presenting with cough and weight loss. Tumor sequencing identified EGFR L858R; PD-L1 by IHC 10%. Osimertinib 80 mg daily was started in March 2024. First restaging CT at 8 weeks shows decrease in size of pulmonary and hepatic target lesions consistent with a partial response. Brain MRI demonstrates a few small asymptomatic parenchymal metastases; bone scan positive for a femoral lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing identified a pathogenic BRCA1 frameshift mutation. Patient underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with clinical complete response and was started on olaparib maintenance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic frameshift", "biomarker": null, "treatment": "carboplatin and paclitaxel; olaparib (maintenance)", "response": "complete response", "metastasis_site": "peritoneal implants"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma of the left forearm, originally node-positive (stage IIIC), BRAF V600E on PCR-based testing. Patient completed one year of adjuvant pembrolizumab with no evidence of disease but developed new pulmonary nodules on surveillance scans 14 months later. Therapy was switched to dabrafenib plus trametinib with documented reduction in size of lung metastases after 8 weeks of targeted therapy \u2014 partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (adjuvant) then dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic pancreatic ductal adenocarcinoma diagnosed after ERCP and biopsy. At presentation there were multiple liver lesions and peritoneal nodules. Germline testing revealed a pathogenic BRCA2 mutation. Baseline CA19-9 markedly elevated. He received 6 cycles of modified FOLFIRINOX with disease control, then was transitioned to maintenance olaparib. Imaging shows stable size of hepatic metastases after 3 months on olaparib.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (pathogenic germline)", "biomarker": "CA19-9 elevated", "treatment": "modified FOLFIRINOX; maintenance olaparib", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old F diagnosed with invasive ductal carcinoma of the right breast, clinical Stage I (T1bN0). Tumor is ER positive, PR positive, HER2 negative on IHC; molecular testing detected PIK3CA H1047R. She underwent lumpectomy with sentinel lymph node biopsy (negative) followed by adjuvant whole-breast radiotherapy and has been started on adjuvant endocrine therapy with letrozole. No evidence of disease on recent imaging.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy, sentinel lymph node biopsy, adjuvant radiotherapy, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV colorectal adenocarcinoma presenting with multiple liver metastases. Molecular profile: KRAS G12D mutation; tumor is MSI-H and TMB-high. Enrolled on a clinical trial and started on pembrolizumab combined with irinotecan and bevacizumab. CT after 3 cycles shows stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab + irinotecan + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with stage IV colorectal adenocarcinoma presenting with diffuse peritoneal carcinomatosis and ascites. Tumor profiling detected a KRAS G12D mutation. He received FOLFOX plus bevacizumab but recent CT shows interval progression of peritoneal disease. MSI testing was negative and no actionable fusions were reported.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old F with locally advanced breast cancer, clinically node-positive, staged IIIB. Core biopsy: invasive ductal carcinoma, ER negative, PR negative; HER2 amplified by FISH. Received neoadjuvant TCH protocol (docetaxel, carboplatin, trastuzumab) with marked tumor shrinkage, then mastectomy followed by adjuvant radiation. No distant mets identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel, carboplatin, trastuzumab (neoadjuvant); mastectomy; radiation", "response": "partial response / marked tumor shrinkage", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 39-year-old man with metastatic cutaneous melanoma. Baseline molecular profiling identified BRAF V600E. PD-L1 by IHC was reported as >50%. He received dabrafenib plus trametinib with initial tumor shrinkage but later developed radiographic progression in the lungs. Therapy was switched to pembrolizumab; current assessment documents progressive disease in pulmonary nodules.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib and trametinib followed by pembrolizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 36-year-old with a pigmented lesion on right forearm, biopsy-confirmed cutaneous melanoma pT1b (Stage I). Tumor NGS detected BRAF V600E. Patient underwent wide local excision with 1 cm margins; no sentinel node biopsy performed. No adjuvant therapy recommended; follow-up exam at 3 months shows no signs of recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology note: 39-year-old female with a 1.2 cm ulcerated melanoma of the upper back, biopsy Breslow 2.1 mm. Wide local excision performed; sentinel node negative. Final stage recorded as II (T2b N0). BRAF V600E identified on targeted sequencing. PD-L1 testing not performed. Patient was observed without adjuvant systemic therapy and remains clinically well at 6-month follow-up with no signs of recurrence.", "output": {"cancer_type": "melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy (observation/no systemic therapy)", "response": "complete response / no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with ER+/PR+ HER2-amplified invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy molecular panel detected PIK3CA H1047R. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks followed by modified radical mastectomy. Surgical pathology shows ypT0N0 \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel + trastuzumab + pertuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old female presented with a pigmented lesion on the left forearm. Excisional biopsy: superficial spreading melanoma, Breslow 0.6 mm, no ulceration \u2014 pathologic stage IA. Wide local excision with margins performed; BRAF V600E mutation identified on PCR from the specimen. No adjuvant systemic therapy was recommended. Patient is clinically free of disease at follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 59-year-old with unresectable cutaneous melanoma with pulmonary nodules. Baseline molecular panel positive for BRAF V600E. Tumor reported TMB-high on sequencing and PD-L1 40% by IHC. She initially received pembrolizumab but progressed after 4 months and was switched to dabrafenib plus trametinib. Interval scans show disease stabilization without interval growth.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 40%", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with newly diagnosed metastatic lung adenocarcinoma presented with cough and headaches. Biopsy confirmed lung adenocarcinoma, molecular testing positive for EGFR L858R. PD-L1 TPS reported 30%. Staging workup consistent with stage IV disease with enhancing lesions in the cerebellum and lytic lesions in the spine. Patient was started on osimertinib 80 mg daily as first-line therapy and received stereotactic radiosurgery to the dominant brain metastasis. Interval CT at 8 weeks shows decrease in size of pulmonary and bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 47-year-old woman with left-sided invasive ductal carcinoma. ER positive, PR negative, HER2 IHC 3+ on core biopsy. Clinical stage recorded as IIIB based on skin involvement. She completed 6 cycles neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with marked radiographic shrinkage but residual palpable disease; plan is mastectomy. No genomic sequencing was performed prior to surgery.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 55-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Imaging demonstrates involvement of the axial skeleton with a lytic lesion in the femur and additional spinal metastases. He was placed on targeted therapy with dabrafenib and trametinib; after 2 months there is radiographic progression with new osseous lesions and rising LDH \u2014 treatment failure.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "LDH elevation", "treatment": "dabrafenib + trametinib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with new-onset jaundice found to have a pancreatic head mass. Biopsy: pancreatic ductal adenocarcinoma. Staging workup demonstrated multiple hypodense liver lesions consistent with metastatic disease \u2014 stage IV. Germline testing positive for BRCA2 mutation. CA19-9 markedly elevated at diagnosis. He received first-line gemcitabine plus nab-paclitaxel; after initial minor response the disease progressed on restaging at 4 months with enlarging liver metastases and rising CA19-9.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the left breast, ER positive, PR positive, HER2 amplified. Clinical note documents fixed axillary nodes and skin tethering \u2014 clinical stage IIIB. Neoadjuvant therapy consisted of docetaxel, carboplatin and trastuzumab followed by modified radical mastectomy. Final pathology reported no residual invasive tumor (pathologic complete response). Patient will continue adjuvant trastuzumab to complete 1 year of therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin and trastuzumab; surgery (modified radical mastectomy)", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative note: 63-year-old male with T3N1 colon adenocarcinoma (stage III) underwent right hemicolectomy. Tumor sequencing identified KRAS G12D mutation. Mismatch repair proteins intact on IHC (microsatellite stable). He completed adjuvant FOLFOX six cycles and follow-up CT at 18 months shows no recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (mismatch repair intact)", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, synchronous liver lesions on CT and biopsy-proven involvement of the right hepatic lobe. Molecular testing showed KRAS G12D mutation and high microsatellite instability (MSI-H). Started on first-line FOLFOX with bevacizumab. After 3 months imaging demonstrates no new lesions and mild shrinkage of dominant hepatic metastasis \u2014 categorized as stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma, stage IV, presenting with multiple hepatic and pulmonary metastases. Somatic profiling detected KRAS G12D and TP53 R273H. Tumor was MSI-stable and PD-L1 <1% by IHC. He was treated with FOLFOX (5-FU/leucovorin/oxaliplatin) in combination with bevacizumab. Interval CT after four cycles showed no significant change in disease burden \u2014 stable disease per RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 R273H", "biomarker": "MSI-stable; PD-L1 <1%", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic invasive ductal carcinoma of the breast. ER/PR negative, HER2 amplified on FISH; PIK3CA E545K identified on NGS. Imaging demonstrates multiple hepatic lesions consistent with metastatic disease (stage IV). She began first-line therapy with docetaxel in combination with trastuzumab and pertuzumab. After 4 cycles the CT shows no new lesions and target lesions are unchanged in size.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 39-year-old male with stage III cutaneous melanoma of the right thigh with palpable inguinal lymphadenopathy. Nodal biopsy positive for metastatic melanoma; molecular testing positive for BRAF V600E. Patient received neoadjuvant dabrafenib and trametinib with excellent response \u2014 clinically the nodes are no longer palpable and PET/CT shows resolution of FDG activity in involved nodes. Status: complete response to targeted therapy prior to surgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with BRAF V600E mutation, initially treated with dabrafenib plus trametinib. Patient progressed in the lungs and brain after 6 months on targeted therapy; subsequently started combination immunotherapy with nivolumab and ipilimumab with partial response of pulmonary lesions and stabilization of brain metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (initial); then nivolumab + ipilimumab", "response": "progression on targeted therapy; partial response/stable disease on immunotherapy", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 54-year-old female with metastatic pancreatic ductal adenocarcinoma found to carry a germline BRCA2 deleterious mutation. Liver lesions were present at diagnosis. She received FOLFIRINOX combination chemotherapy with a radiographic partial response and was transitioned to maintenance olaparib due to BRCA2 mutation. Current scans show ongoing disease control.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2", "biomarker": null, "treatment": "FOLFIRINOX; maintenance olaparib", "response": "partial response; ongoing disease control", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neuropathology consult: Glioblastoma multiforme (WHO grade IV) resection specimen positive for TERT promoter C228T mutation; MGMT promoter methylated. IDH1 R132H immunostain negative. Patient underwent standard concurrent radiation with daily temozolomide followed by adjuvant temozolomide. Surveillance MRI at six months demonstrated expansion of the resection cavity and new enhancing nodules concerning for tumor progression.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": "TERT promoter C228T", "biomarker": "MGMT promoter methylated", "treatment": "radiation with temozolomide (concurrent and adjuvant)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with newly diagnosed metastatic prostate adenocarcinoma, Gleason score 9, presenting with diffuse bone pain and multiple osseous lesions on bone scan. He was started on androgen deprivation therapy with leuprolide in combination with docetaxel for metastatic castration-sensitive disease. PSA fell significantly and his pain has improved; disease is currently clinically stable. No tumor genomic testing has been resulted yet.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide) + docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer (T4bN1) referred for neoadjuvant therapy. Biopsy showed ER+, PR+, and HER2 amplification; tumor genotyping identified a PIK3CA H1047R mutation. She completed neoadjuvant docetaxel in combination with trastuzumab and pertuzumab, followed by modified radical mastectomy. Pathology reported no residual invasive carcinoma (pathologic complete response). Patient was started on adjuvant endocrine therapy with tamoxifen.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel + trastuzumab + pertuzumab; surgery; tamoxifen", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart review: 47-year-old woman with metastatic invasive ductal breast carcinoma, ER+/PR+, HER2 amplification by FISH. Presented with new right upper quadrant pain; CT abdomen demonstrates multiple hepatic lesions consistent with liver metastases. Tumor genomic profiling identified PIK3CA E545K. She received trastuzumab, pertuzumab and docetaxel as first-line systemic therapy with radiographic stable disease after 3 cycles.", "output": {"cancer_type": "breast cancer (invasive ductal)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic castration-resistant prostate cancer presenting with diffuse osteoblastic bone metastases. Somatic testing identified a deleterious BRCA2 truncating mutation. Prior treatments included androgen deprivation therapy and docetaxel; on progression he was started on the PARP inhibitor olaparib and has had stable disease on scans for 9 months.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 mutation (truncating)", "biomarker": null, "treatment": "olaparib (after ADT and docetaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genotyping: KRAS G12D; microsatellite status: MSS (MSI-stable). He initiated FOLFOX plus bevacizumab. After 4 cycles CT shows no new lesions and slight decrease in largest hepatic lesion \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal breast carcinoma, clinical stage IIIA. Core biopsy: HER2 amplification by FISH, ER positive (80%), PR positive (20%), and PIK3CA E545K mutation on NGS. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with good tolerance, then lumpectomy and adjuvant radiation. Surgical pathology reported pathologic complete response (pCR).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP); surgery; adjuvant radiation", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic colorectal adenocarcinoma diagnosed January 2023 with multiple liver lesions. Tumor profiling: KRAS G12D, MSI-H and TMB-high. Initial therapy was FOLFOX plus bevacizumab with short-term stable disease then progression in the liver. Given MSI-H status he was switched to pembrolizumab and achieved a confirmed partial response on interval imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX plus bevacizumab (first-line); pembrolizumab (after progression)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presented with obstructing right-sided colon mass. Pathology: moderately differentiated colon adenocarcinoma, T3N1 (stage III). Underwent right hemicolectomy; tumor genotyping revealed KRAS G12D and tumor was microsatellite stable (MSS). Started adjuvant FOLFOX q14 days. Surveillance CT at 12 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "right hemicolectomy and adjuvant FOLFOX", "response": "no evidence of disease at 12 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing: KRAS G12D mutation; MSI testing shows MSS. He was started on first-line FOLFOX with bevacizumab. Interval CT after 4 cycles demonstrates approximately 35% reduction in sum of target lesions in the liver consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with metastatic invasive ductal carcinoma of the breast, HER2-positive (HER2 amplification) and ER/PR negative. Staging demonstrated multiple hypodense liver lesions consistent with metastases (stage IV). NGS revealed PIK3CA H1047R. She was treated with docetaxel in combination with trastuzumab and pertuzumab; interval CT after 3 cycles shows a partial response in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma. Molecular testing identified EGFR L858R mutation. Staging workup consistent with stage IV disease with hemorrhagic lesion treated with stereotactic radiosurgery to the cerebrum and lytic lesions in the spine. Patient started osimertinib 80 mg qd as first-line targeted therapy. Three-month restaging CT/PET shows decrease in size of primary and bone lesions consistent with a partial response; brain lesion radiographically controlled after SRS.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5% (TPS)", "treatment": "osimertinib; stereotactic radiosurgery (SRS)", "response": "partial response", "metastasis_site": "brain, bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma (left lower lobe). Staging workup demonstrated Stage IV disease with multiple enhancing brain lesions on MRI consistent with metastases. Tumor genotyping returned EGFR L858R. PD-L1 by IHC reported 5% TPS. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the two largest brain mets. First follow-up PET/CT at 8 weeks showed decrease in size of the pulmonary mass and partial resolution of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Medical oncology follow-up: 54-year-old with metastatic breast cancer now with new hepatic lesions. Original tumor was ER/PR-negative, HER2-positive by FISH. NGS identified a PIK3CA H1047R mutation in addition to HER2 amplification. She received weekly paclitaxel with trastuzumab as first-line systemic therapy for metastatic disease; interval imaging demonstrates stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel and trastuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with newly diagnosed lung adenocarcinoma. Staging workup shows stage IV disease with multiple enhancing brain metastases on MRI. Comprehensive genomic profiling identified EGFR L858R and PD-L1 reported at 10%. Patient was started on osimertinib 80 mg daily; first restaging CT and brain MRI after 8 weeks demonstrate a partial response with shrinkage of intracranial and pulmonary lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH. NGS identifies a PIK3CA H1047R mutation. She received neoadjuvant doxorubicin and cyclophosphamide \u00d74 followed by paclitaxel with concurrent trastuzumab; displays a marked reduction in tumor size on exam and imaging (partial response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel plus trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic note: 45-year-old with invasive ductal breast cancer, clinical stage IIIB. Core biopsy: ER positive, PR negative, HER2 amplification by FISH; next-generation sequencing identified PIK3CA H1047R. She received neoadjuvant trastuzumab and paclitaxel for 6 cycles with a clinical partial response and was referred for mastectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab and paclitaxel (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma. Initial diagnosis March 2023, biopsy confirmed adenocarcinoma of the right upper lobe. Plasma NGS detected EGFR L858R; ALK and ROS1 negative. PD-L1 by IHC 10%. He was started on osimertinib 80 mg PO daily in April. Staging at diagnosis was IV with known brain and bone involvement. Most recent restaging CT and MRI (6/2024) show interval decrease in size of pulmonary nodules and reduced enhancement of cerebral lesions consistent with a partial response to osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with locally advanced pancreatic ductal adenocarcinoma encasing the superior mesenteric artery, clinical stage III. No actionable mutations were reported in the available chart; formal molecular testing is pending. He received neoadjuvant gemcitabine/nab-paclitaxel with concurrent external beam radiation. Interval CT shows stable disease without distant metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "neoadjuvant gemcitabine/nab-paclitaxel with concurrent external beam radiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male referred for elevated PSA and prostate biopsy showing adenocarcinoma, Gleason 3+4 in multiple cores. Pre-op PSA 8.2 ng/mL. Clinical stage approximated as II. No molecular sequencing was performed. The patient underwent radical prostatectomy; post-operative PSA is undetectable on first follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 8.2 ng/mL (pre-op); undetectable post-op PSA", "treatment": "radical prostatectomy", "response": "undetectable PSA post-op", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with weight loss and abdominal pain. Colonoscopy showed a sigmoid mass; biopsy = adenocarcinoma. CT chest/abdomen/pelvis demonstrates multiple hepatic lesions and several pulmonary nodules consistent with metastases. Clinical staging consistent with Stage IV colorectal adenocarcinoma. NGS: KRAS G12D; mismatch repair intact (MSS). CEA 150 ng/mL at diagnosis. He was started on FOLFOX plus bevacizumab; after 4 cycles imaging demonstrates interval progression in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; CEA 150 ng/mL", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with high-grade serous ovarian carcinoma, stage IIIC with bulky peritoneal disease. Germline testing positive for a deleterious BRCA1 mutation; tumor panel demonstrates TP53 mutation and is HRD-positive. She underwent optimal debulking followed by carboplatin and paclitaxel with bevacizumab, and was started on olaparib maintenance. CT shows decreased omental/peritoneal disease consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation; TP53 mutation", "biomarker": "HRD-positive", "treatment": "debulking surgery followed by carboplatin, paclitaxel and bevacizumab; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old woman underwent primary debulking for high-grade serous ovarian carcinoma. Operative note and pathology consistent with FIGO stage IIIC disease with extensive peritoneal carcinomatosis. Germline testing returned a deleterious BRCA1 mutation. Pre-op CA-125 was markedly elevated. She completed 6 cycles of adjuvant carboplatin and paclitaxel with interval CT showing decreased peritoneal disease burden.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "elevated CA-125", "treatment": "optimal cytoreductive surgery followed by carboplatin + paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presented with symptomatic headaches. MRI demonstrated multiple enhancing brain metastases. Initial systemic therapy with pembrolizumab resulted in clinical progression after 3 cycles; BRAF V600E mutation identified on tumor sequencing and patient was transitioned to dabrafenib plus trametinib with interval shrinkage of intracranial disease. Prior PD-L1 testing not documented but tumor mutational burden reported high.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (initial, progressed), then dabrafenib and trametinib", "response": "partial response to dabrafenib/trametinib", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma harboring BRAF V600E. Baseline PD-L1 was 5% and tumor mutational burden reported as low. He was initiated on dabrafenib plus trametinib with rapid symptomatic improvement and a partial response at 8 weeks. After 9 months a new MRI demonstrated brain metastases and extracranial progression; therapy was changed to combination immunotherapy with ipilimumab and nivolumab. Clinical course described as mixed response with intracranial progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-low", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab", "response": "mixed response (intracranial progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with left breast invasive ductal carcinoma, clinical stage IIIA. Tumor is ER positive, PR positive and HER2 amplified by IHC/FISH. Received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles. Mastectomy specimen demonstrates no residual invasive carcinoma (pathologic complete response). No evidence of distant metastasis on staging studies.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic melanoma. Molecular testing positive for BRAF V600E; PD-L1 reported at ~10% and tumor had high TMB. He initially achieved a partial response on dabrafenib plus trametinib but developed hepatic and osseous progression. He was switched to combination immunotherapy with nivolumab and ipilimumab and is now in ongoing complete response on imaging.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib and trametinib; then nivolumab and ipilimumab", "response": "complete response (after immunotherapy)", "metastasis_site": "liver and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with newly diagnosed lung adenocarcinoma. Imaging and biopsy consistent with stage IV disease with multiple intracranial lesions. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 10%. Started first-line osimertinib 80 mg daily in July after stereotactic radiosurgery to dominant brain metastasis. Clinically improved with reduction in cough and decreased size of CNS lesions on first restaging \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Thin cutaneous melanoma excised from the left forearm, path reported as stage I (Breslow 1.1 mm). Sentinel lymph node was negative. Tumor genotyping performed and BRAF V600E was detected. Patient treated with wide local excision alone and remains with no evidence of disease on follow-up exam.", "output": {"cancer_type": "melanoma", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the right breast. Clinical stage IIA. ER positive, PR negative; HER2 amplified by FISH (HER2 3+). She underwent breast-conserving surgery with sentinel node biopsy followed by adjuvant paclitaxel for 12 weeks and trastuzumab for a year. Recent follow-up mammogram and clinic exam show no palpable disease and clear imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive, PR negative", "treatment": "lumpectomy, paclitaxel, trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology operative & follow-up note: 67-year-old male underwent radical prostatectomy for Gleason 4+4 prostate adenocarcinoma; final pathologic stage pT2N0 (stage II). Post-op PSA was undetectable but now rising to 0.6 ng/mL on two consecutive measurements. No actionable somatic variants were reported on targeted panel. Patient initiated androgen deprivation therapy with leuprolide; no radiographic metastases identified on bone scan and CT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; leuprolide (androgen deprivation therapy)", "response": "biochemical recurrence (rising PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal female diagnosed with locally advanced left breast invasive ductal carcinoma. Core biopsy: ER negative, PR negative, HER2 amplified by FISH; NGS detected PIK3CA H1047R. Clinical stage IIIB with involvement of skin and underlying chest wall. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles and then underwent modified radical mastectomy. Surgical pathology demonstrated a near-complete response with a 5 mm residual invasive focus (ypT1cN0).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP); surgery", "response": "near-complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with multiple liver lesions. Molecular profile: KRAS G12D positive, tumor is MSI-H by PCR. Initial stage IV at diagnosis. Given MSI-H status, he was started on pembrolizumab 200 mg IV every 3 weeks. Follow-up CT at 12 weeks demonstrates radiographic stable disease in the liver lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and left leg weakness. Staging CT and brain MRI showed multiple enhancing lesions; PET/CT demonstrated widespread osseous uptake. Molecular testing: EGFR L858R and acquired T790M on repeat biopsy. PD-L1 by IHC 10%. He was started on first-line erlotinib, progressed after 9 months and switched to osimertinib with interval partial response on restaging scans.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib then osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with high-grade serous ovarian carcinoma presented with abdominal distension. CT abdomen/pelvis demonstrated omental caking and multiple peritoneal implants consistent with peritoneal metastases; she was staged FIGO IIIC. She received neoadjuvant carboplatin and paclitaxel followed by interval debulking surgery with near-complete radiographic response and normalization of CA-125. Tumor panel did not reveal any actionable mutations.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevation (subsequently normalized)", "treatment": "carboplatin and paclitaxel followed by interval debulking surgery", "response": "near-complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed lung adenocarcinoma presented with cough and headaches. Staging PET/CT showed multiple pulmonary nodules and enhancing cerebellar lesion consistent with metastasis; overall stage IV. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the brain lesion. At the first restaging CT at 8 weeks there is a 40% decrease in size of measurable lung lesions \u2014 reported as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and oncology summary: 62-year-old man with cutaneous melanoma of the back, sentinel node positive, now with pulmonary nodules on staging CT confirming metastatic disease (AJCC stage IV). Tumor sequencing: BRAF V600E. He was started on dabrafenib and trametinib; after two months there is decreased size of several lung metastases. No PD-L1 or other immuno-biomarker reported in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 48-year-old woman with left invasive ductal carcinoma, ER positive, PR positive. HER2 amplified (3+ by IHC, FISH positive). Biopsy genotyping identified PIK3CA H1047R. She received neoadjuvant chemotherapy with docetaxel, carboplatin and concurrent trastuzumab for six cycles followed by lumpectomy and sentinel node sampling. Surgical specimen demonstrated significant treatment effect consistent with a partial response. No distant metastatic disease identified on staging CT chest/abdomen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant); lumpectomy", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E\u2013positive, initially treated with combination dabrafenib and trametinib. Early imaging showed partial shrinkage of subcutaneous nodules, but at 6 months there was clinical and radiographic progression with new brain metastases and leptomeningeal involvement. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain; leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic colorectal adenocarcinoma presenting with multiple hepatic lesions on CT. Tumor sequencing identified a KRAS G12D mutation. She was treated with FOLFOX plus bevacizumab; after three months scans demonstrate interval enlargement of the liver masses consistent with progressive disease. MSI status was not reported in the chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 70-year-old male with metastatic colorectal adenocarcinoma diagnosed after right hepatectomy for dominant liver lesion. Primary tumor testing identified BRAF V600E. Tumor showed high microsatellite instability (MSI-H) and was reported TMB-high. Patient initially received FOLFIRI with bevacizumab with mixed radiographic results; given MSI-H status he was transitioned to pembrolizumab. Most recent CT shows stable hepatic disease without new sites of spread.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFIRI and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the left breast: invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+ with confirmed HER2 amplification by FISH. Clinical stage was IIIB with fixed axillary nodes. Patient received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) x6 cycles. Surgery (modified radical mastectomy) yielded ypT0N0 \u2014 complete pathological response. Next-generation sequencing on biopsy detected PIK3CA H1047R variant of uncertain significance (reported as likely pathogenic).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; surgery (modified radical mastectomy)", "response": "complete pathological response (ypT0N0)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant clinic note: 45-year-old female with biopsy-proven invasive ductal carcinoma of the left breast, cT3N2 (clinical stage IIIC). IHC shows HER2 3+ and FISH confirms HER2 amplification; ER and PR negative. She received six cycles of paclitaxel with trastuzumab and pertuzumab prior to surgery. Mastectomy specimen shows no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old female with newly diagnosed lung adenocarcinoma presented with headaches. Staging PET/CT and brain MRI confirm stage IV disease with multiple cerebellar and supratentorial metastases. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. Started first-line osimertinib 80 mg daily in July. Interval MRI at 8 weeks demonstrates decreased size of the dominant cerebellar lesion and reduced enhancement elsewhere\u2014partial response clinically and radiographically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided colon adenocarcinoma, stage II (T3N0) resected via right hemicolectomy. Tumor testing: BRAF V600E mutation detected and microsatellite instability high (MSI-H). Given MSI-H status and node-negative disease, multidisciplinary team elected observation without adjuvant chemotherapy. Surveillance CT at 6 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy (no adjuvant chemotherapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old with a nodular pigmented lesion on the upper back. Excision revealed cutaneous melanoma, stage IIB (T3bN0M0) with one ulcerated focus. Tumor sequencing detected NRAS Q61K. Patient underwent wide local excision with sentinel node mapping; no nodes were positive. Given high-risk features, adjuvant nivolumab was started. Follow-up exam shows healing wounds and no clinical or radiographic evidence of spread.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIB", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy; adjuvant nivolumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old premenopausal woman with locally advanced right breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: HER2 3+ by IHC, ER negative, PR negative. NGS panel detected PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab for four cycles with reduction in tumor size and partial clinical response; plan for modified radical mastectomy pending.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+ by IHC; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with progressive dyspnea found to have lung adenocarcinoma with multiple lesions on CT. Clinical stage IV at diagnosis. Molecular testing demonstrated an EGFR exon 19 deletion. PD-L1 tumor proportion score 10%. He was started on osimertinib with an initial partial response on interval imaging, but later developed new intracranial lesions and vertebral metastases consistent with progression; subsequently transitioned to platinum-doublet chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib; later platinum-doublet chemotherapy", "response": "partial response followed by progression", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman referred for management of locally advanced pancreatic ductal adenocarcinoma. She is clinically T4 with encasement of the superior mesenteric artery and CA 19-9 elevated. CT abdomen demonstrates multiple small hepatic lesions concerning for metastases. Tumor genomic panel did not identify actionable alterations and PD-L1 was not reported. Initiated systemic therapy with gemcitabine plus nab-paclitaxel followed by consolidative radiation; follow-up imaging shows mixed response with overall disease stabilization.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel with consolidative radiation", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with newly diagnosed prostate adenocarcinoma. PSA at diagnosis 12.4 ng/mL; TRUS biopsy Gleason score 3+4=7. Clinical exam and imaging consistent with T2bN0M0 (AJCC Stage II). No genomic testing was performed. He received external beam radiation therapy with six months of concurrent androgen deprivation (leuprolide). Early post-treatment PSA declined to 0.6 ng/mL and bone scan showed no metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II (T2bN0M0)", "gene_mutation": null, "biomarker": "PSA 12.4 ng/mL (pre-treatment); post-treatment PSA 0.6 ng/mL", "treatment": "external beam radiation therapy; androgen deprivation therapy (leuprolide)", "response": "biochemical response (PSA reduction)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Note: 71M with metastatic prostate adenocarcinoma, Gleason 4+4 at diagnosis. Bone scan demonstrates multiple sclerotic lesions; PSA rising despite ADT. Germline and somatic testing identified a pathogenic BRCA2 truncating mutation. He is maintained on leuprolide with addition of enzalutamide and completed 6 cycles of docetaxel last year; current clinical assessment reports disease clinically stable on systemic therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "leuprolide with enzalutamide (and prior docetaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed metastatic lung adenocarcinoma (diagnosed 02/2024). Molecular testing returned EGFR L858R with acquired T790M. PD-L1 TPS 10%. Started osimertinib in March with symptomatic improvement and interval partial response on CT at 8 weeks. MRI brain at diagnosis showed two small cerebellar metastases; stereotactic radiosurgery planned to the brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with metastatic lung adenocarcinoma (stage IV) presenting with headaches and back pain. Biopsy confirmed EGFR L858R mutation. PD-L1 expression 10%. Patient started osimertinib 80 mg daily as first-line targeted therapy and experienced a rapid clinical improvement; first CT at 8 weeks showed a 45% reduction in target lesions consistent with a partial response. MRI showed small enhancing metastases in the brain and sclerotic lesions in the thoracic spine.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with metastatic lung adenocarcinoma harboring an activating EGFR L858R mutation. Brain MRI demonstrated two enhancing lesions consistent with metastases. Staged as IV. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and MRI at 8 weeks show marked decrease in size of the pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with pancreatic ductal adenocarcinoma, borderline resectable, clinical stage IIB. CA19-9 is elevated at 480 U/mL. Tumor sequencing to date did not reveal any reportable somatic mutations. He received neoadjuvant gemcitabine plus nab-paclitaxel with short-course focused radiation. Interval CT after 4 months shows stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": "elevated CA19-9", "treatment": "gemcitabine + nab-paclitaxel; radiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old male with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. CT abdomen shows multiple hepatic lesions. Immunohistochemistry and PCR demonstrated MSI-H status and high tumor mutational burden. No actionable RAS/RAF mutations identified on panel. He was started on pembrolizumab and after 4 cycles has marked shrinkage of liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female underwent screening colonoscopy that revealed a 3 cm sigmoid mass. Biopsy: adenocarcinoma. She had a laparoscopic sigmoid resection; final stage was pT2N0 (stage I). MSI testing returned MSI-H. No adjuvant chemotherapy was given. On surveillance CTs there is no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgical resection (sigmoid colectomy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male presenting with progressive cough. Imaging and biopsy confirm lung adenocarcinoma. Staging workup demonstrates widespread disease consistent with stage IV with metastases in the brain and multiple vertebral bone lesions. Comprehensive NGS shows EGFR L858R. PD-L1 TPS reported as 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and interval CT and MRI at 8 weeks showed a marked decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Referral letter: Patient with metastatic colorectal adenocarcinoma presenting with multiple hepatic metastases. Biopsy-proven KRAS G12D mutation identified on tumor sequencing. Disease classified as stage IV. Initiated on systemic therapy with FOLFIRI plus bevacizumab; first restaging CT at 8 weeks shows approximately 30% decrease in sum of target lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma. Liver biopsy confirmed metastatic colon primary; molecular testing identified KRAS G12D. CT shows multiple hepatic metastases consistent with Stage IV disease. Patient began palliative FOLFOXIRI; after three cycles interval imaging demonstrates enlarging hepatic lesions and new peritoneal implants consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOXIRI", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. Tumor sequencing returned KRAS G12D mutation. MRI shows multiple bilobar liver metastases. Microsatellite testing: MSS. Treated with FOLFIRI plus bevacizumab; CT after 4 months showed stable disease but repeat imaging at 9 months demonstrated progression within the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI and bevacizumab", "response": "initial stable disease, then progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIA. Tumor is HER2-amplified by FISH, ER-negative, PR-negative. Somatic testing identified a PIK3CA H1047R mutation. She completed six cycles of neoadjuvant pertuzumab, trastuzumab and docetaxel (THP) and at definitive mastectomy pathology showed no residual invasive carcinoma (pathologic complete response). No distant mets identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER negative, PR negative", "treatment": "pertuzumab + trastuzumab + docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Summary: 52-year-old F with locally advanced invasive ductal carcinoma of the right breast, clinical T3N1 (Stage IIIA). Core biopsy demonstrated HER2 amplification by FISH and ER/PR negative. Next-generation sequencing identified a PIK3CA H1047R hotspot mutation. She received neoadjuvant paclitaxel weekly with trastuzumab for 12 weeks followed by surgery. Surgical pathology reported no residual invasive tumor consistent with a pathologic complete response.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with metastatic lung adenocarcinoma (stage IV) on CT. NGS returned EGFR L858R and PD-L1 10%. She was started on osimertinib 80 mg daily. Eight-week restaging CT and brain MRI demonstrate marked shrinkage of pulmonary nodules and regression of a cerebellar metastasis, with bone lesions unchanged \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 52-year-old woman with ER+/PR+/HER2+ invasive ductal carcinoma of the right breast. Pathology: pT2N0 (stage II). Tumor genomics identified a PIK3CA H1047R hotspot mutation. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel x12 weeks and trastuzumab planned for 12 months; endocrine therapy with letrozole started. Last clinic note: no palpable disease and post-op imaging negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy; paclitaxel; trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 63-year-old man with metastatic lung adenocarcinoma, stage IV at presentation (diagnosed 03/2024). Comprehensive NGS revealed EGFR L858R mutation. PD-L1 TPS 10%. Patient started osimertinib 80 mg daily in April and received stereotactic radiosurgery to a solitary cerebellar metastasis. Restaging CT and brain MRI after 8 weeks show reduction in size of pulmonary lesions and decreased perfusion in brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, FIGO stage IIIC. Germline testing positive for BRCA2 6174delT. CA-125 markedly elevated at diagnosis. She received carboplatin and paclitaxel with interval debulking surgery and is now on olaparib maintenance. CT shows reduced peritoneal implants consistent with partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 6174delT", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel followed by olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: 52-year-old female with a 1.8 cm invasive ductal carcinoma, ER positive, PR positive, HER2 negative by IHC (0). Sentinel lymph node biopsy negative. Clinical stage II (T1cN0). Underwent breast-conserving surgery followed by adjuvant radiation and 4 cycles of doxorubicin and cyclophosphamide followed by paclitaxel. Tumor sequencing not performed. Patient is tolerating endocrine therapy (letrozole) and has no evidence of disease on recent surveillance imaging.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "II", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; adjuvant radiation; doxorubicin and cyclophosphamide then paclitaxel; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presented with headaches. MRI shows multiple enhancing lesions consistent with brain metastases. Molecular testing on core biopsy identified EGFR L858R mutation. PD-L1 TPS reported as 10%. Patient was started on osimertinib 80 mg daily and at first restaging CT/MRI after 8 weeks there was a reduction in size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed high-grade serous ovarian carcinoma, stage IV with peritoneal and hepatic implants. Germline testing returned a pathogenic BRCA1 mutation. She completed six cycles of carboplatin and paclitaxel with documented partial radiologic response and was transitioned to maintenance olaparib. CA-125 fell from 800 U/mL at diagnosis to 120 U/mL. Current imaging: decreased peritoneal disease but persistent liver implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 elevated (decreasing)", "treatment": "carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma (stage IV) found to harbor EGFR L858R and secondary T790M on NGS. PD-L1 tumor proportion score was 60%. She was started on osimertinib with a partial response in the lungs and brain. With oligoprogression she later received carboplatin and pemetrexed in combination with pembrolizumab. Recent PET/CT shows hepatic lesions and stable extracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 60%", "treatment": "osimertinib; carboplatin and pemetrexed; pembrolizumab", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old female with locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, ER 90%+, PR 40%+, HER2 IHC 3+ and confirmed HER2 amplification by FISH. Next-generation sequencing detected PIK3CA H1047R. Clinical stage IIIB (skin involvement and fixed axillary nodes). She completed 6 cycles neoadjuvant paclitaxel with trastuzumab and pertuzumab with good clinical shrinkage. Patient underwent modified radical mastectomy; pathology showed no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER+, PR+", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old with metastatic colorectal adenocarcinoma diagnosed after right hepatectomy for dominant liver lesion. Pathology shows KRAS G12D mutation; tumor is microsatellite stable (MSS). Baseline CEA elevated at 45 ng/mL. He was treated with FOLFOX plus bevacizumab with disease stabilized on first two CT scans but minimal shrinkage of hepatic lesions. Clinical note: continued on same regimen with plans for maintenance.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; CEA elevated", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast invasive ductal carcinoma. Core biopsy: ER+, PR+, HER2 amplified by IHC/FISH. Clinical stage IIIB with fixed nodal disease. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by weekly paclitaxel with concurrent trastuzumab. Mastectomy specimen after neoadjuvant therapy showed no residual invasive carcinoma (pathologic complete response). No distant metastases were identified on PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Tumor genotyping demonstrates KRAS G12D mutation and MSI-High status. Given MSI-H, he was started on pembrolizumab monotherapy as first-line treatment. Restaging CT after three cycles shows no new lesions and overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-High", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma (diagnosed 2019) presented with worsening headaches. Molecular testing returned EGFR L858R. Staging demonstrated stage IV disease with multiple brain and bone lesions. Tumor PD-L1 was 1%. He was started on osimertinib 80 mg daily; interval imaging at 8 weeks showed a partial response and his symptoms improved.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female referred to thoracic oncology after biopsy-proven lung adenocarcinoma. PET/CT demonstrated bilateral pulmonary nodules and enhancing cerebellar lesion; MRI confirmed a 1.8 cm metastasis in the right cerebellum and a sclerotic lesion at T8. NGS showed EGFR exon 19 deletion. PD-L1 TPS reported at 5%. She was started on osimertinib 80 mg PO daily as front-line targeted therapy. Neurologic symptoms improved and interval CT at 8 weeks demonstrated decrease in size of lung lesions and stability of bone lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma, stage IV with dominant liver lesions. Tumor testing returned MSI-H by PCR; comprehensive NGS did not identify actionable KRAS/NRAS/BRAF mutations. After progression on adjuvant FOLFOX he was switched to pembrolizumab monotherapy. Interval CT at 12 weeks demonstrates a notable decrease in hepatic tumor burden consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old man with metastatic cutaneous melanoma, BRAF V600E positive, initially treated with dabrafenib plus trametinib. Extracranial disease in the lungs and skin showed shrinkage, but surveillance brain MRI later detected new small metastases that were managed with stereotactic radiosurgery. Oncology documents describe a mixed response: extracranial partial response with CNS progression. PD-L1 was 15% on archival tissue.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 15%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery (for brain mets)", "response": "mixed response (extracranial response with CNS progression)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT consistent with metastatic disease (T2N2M1) with multiple brain and bone lesions. Molecular testing identified EGFR L858R. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily in January; initial scans showed tumor shrinkage but most recent MRI demonstrates enlarging intracranial lesions consistent with progression. Plan to consider stereotactic radiosurgery and change systemic therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progressive disease", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old woman with locally advanced breast cancer presenting with chest wall involvement and fixed axillary nodes. Core biopsy confirmed invasive ductal carcinoma, ER/PR negative. HER2 testing by IHC/FISH shows HER2 amplification. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles and subsequently underwent mastectomy; no residual invasive carcinoma identified on pathology (pathologic complete response).", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with right-sided colon adenocarcinoma diagnosed after obstruction. CT abdomen/pelvis demonstrates multiple hepatic metastases; no extrahepatic disease identified. Pathology: moderately differentiated adenocarcinoma. Molecular panel: KRAS G12D positive, NRAS and BRAF wild type. MSI testing reported as microsatellite stable. He received FOLFOX plus bevacizumab in the adjuvant/metastatic setting but restaging after 3 months showed interval growth of several liver lesions consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX; bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with muscle-invasive urothelial carcinoma of the bladder with hepatic metastases at diagnosis (stage IV). Initial therapy was gemcitabine and cisplatin with transient shrinkage, then progression in the liver. Tumor NGS returned FGFR3 S249C; PD-L1 IHC 5% (low). He was started on oral erdafitinib under expanded access but follow-up imaging demonstrated further growth of hepatic lesions.", "output": {"cancer_type": "urothelial carcinoma (bladder)", "stage": "IV", "gene_mutation": "FGFR3 S249C", "biomarker": "PD-L1 5%", "treatment": "gemcitabine and cisplatin; erdafitinib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old F with metastatic lung adenocarcinoma (diagnosed 03/2023). Staging consistent with stage IV disease. NGS revealed EGFR exon 19 deletion. PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy. After 8 weeks there is shrinkage of the primary and interval improvement of multiple brain and bone lesions on MRI and CT \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma harboring BRAF V600E. Baseline PD-L1 was 50% and tumor mutational burden reported as TMB-high (18 muts/Mb). He began dabrafenib + trametinib with rapid shrinkage of several nodules; pembrolizumab was added later for oligoprogression. Clinical course: systemic nodules regressed but intracranial lesions progressed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 50%, TMB-high", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma. Staging CT/PET consistent with metastatic disease to the brain and multiple osseous lesions. Biopsy confirmed adenocarcinoma; NGS identified EGFR L858R. PD-L1 TPS reported at 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and has had interval imaging at 8 weeks demonstrating a decrease in size of pulmonary and skeletal lesions\u2014consistent with a partial response. Brain lesion treated with stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent right hemicolectomy for a T3N1 adenocarcinoma of the colon (stage III). Completed 12 cycles of adjuvant FOLFOX without significant complications. Mismatch repair testing reported proficient MMR (microsatellite stable). No actionable somatic alterations were detected on the panel used. Surveillance CT chest/abdomen/pelvis at 6 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-stable (proficient MMR)", "treatment": "surgery (right hemicolectomy) followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65M with metastatic lung adenocarcinoma presenting with cough and weight loss. Staging CT and PET consistent with stage IV disease. Molecular testing positive for EGFR L858R mutation. PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily with brisk radiographic improvement \u2014 interval CT shows decreased size of primary and target lesions consistent with partial response. Brain MRI demonstrates a single small parenchymal metastasis; bone scan positive for two lytic lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: 48-year-old woman with a 2.5 cm palpable right breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical stage IIB. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles followed by wide local excision and sentinel node biopsy. Surgical specimen shows no residual invasive carcinoma or nodal disease (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with weight loss and right upper quadrant pain. Biopsy confirmed colorectal adenocarcinoma, stage IV at diagnosis with multiple liver and pulmonary lesions. Tumor profiling returned BRAF V600E and high microsatellite instability (MSI-H). After progression on FOLFOX plus bevacizumab he was enrolled on targeted therapy with encorafenib plus cetuximab and achieved a partial radiographic response on first restaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; encorafenib + cetuximab", "response": "partial response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old woman with FIGO stage IIB high-grade serous ovarian carcinoma. She was found to be BRCA2 germline positive on genetic testing. Pre-treatment CA-125 was 320 U/mL. Underwent optimal cytoreductive surgery followed by systemic therapy with carboplatin and paclitaxel. After three cycles CT shows decreased omental and peritoneal implants; CA-125 has fallen to 72 U/mL. Assessment: partial response to platinum doublet.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "II (FIGO IIB)", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA-125 320 U/mL (fell to 72 U/mL)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "omentum / peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 57-year-old female with metastatic pancreatic ductal adenocarcinoma diagnosed six months ago. At presentation she had multiple liver metastases and a CA19-9 of 3,500 U/mL. Germline testing returned a pathogenic BRCA2 mutation. She received FOLFIRINOX with initial disease control (stable disease on imaging) and was transitioned to maintenance olaparib. Most recent scan shows ongoing stable disease in the liver lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 3500 U/mL", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with castration-resistant prostate cancer, known bone metastases on bone scan. He remains on leuprolide for androgen suppression and received 6 cycles of docetaxel chemotherapy. PSA rising despite treatment and scans show progression of osseous disease. No molecular testing performed at this time.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate cancer (mCRPC). Germline testing revealed a deleterious BRCA2 mutation. He has progressive bone pain and rising PSA; imaging demonstrates multiple osseous metastases. After prior abiraterone and docetaxel, he was started on olaparib and received palliative radiotherapy to the pelvis. PSA has declined and follow-up scans indicate a partial radiographic response.", "output": {"cancer_type": "prostate cancer (mCRPC)", "stage": "IV", "gene_mutation": "BRCA2 (deleterious germline)", "biomarker": "PSA rising (then declining after therapy)", "treatment": "olaparib; prior abiraterone and docetaxel; palliative radiation", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma, stage IV at presentation with multiple pulmonary nodules and cerebellar metastases. Molecular testing revealed EGFR L858R mutation; PD-L1 expression 5%. Started on first-line osimertinib with steroid taper for brain mets. Imaging at 8 weeks shows partial response of lung lesions and reduction in intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female initially diagnosed with metastatic lung adenocarcinoma in 2019. Molecular testing returned EGFR L858R mutation. She received first-line carboplatin and pemetrexed with partial response, later developed progressive disease with new brain and bone lesions and was switched to osimertinib 80 mg daily. PD-L1 tumor proportion score reported at 5%. Most recent CT/MRI shows decreased thoracic disease burden with improvement but persistent small CNS lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "carboplatin and pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note: 62-year-old male underwent right hemicolectomy for T3N2M0 colon adenocarcinoma (stage III). Tumor profiling identified KRAS G12D mutation and MSI testing returned microsatellite stable (MSS). He completed 12 cycles of adjuvant FOLFOX without complications. Surveillance CT A/P at 6 months shows no recurrent or metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX (12 cycles)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old with newly discovered pancreatic ductal adenocarcinoma. CT showed diffuse peritoneal nodularity and ascites; no actionable mutations reported on the limited panel performed. Baseline CA 19-9 markedly elevated. The patient began combination chemotherapy with gemcitabine and nab-paclitaxel. After two cycles imaging demonstrates stable size of peritoneal implants and persistent ascites.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 elevated", "treatment": "gemcitabine; nab-paclitaxel", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report: 65-year-old female with high-grade serous ovarian carcinoma, stage IIIC. Germline testing revealed a BRCA1 pathogenic mutation. Preoperative CA-125 markedly elevated. At laparotomy there was diffuse peritoneal carcinomatosis with omental caking and implants throughout the abdomen. She received adjuvant carboplatin and paclitaxel with addition of bevacizumab; repeat CT abdomen shows decreased peritoneal disease burden consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; bevacizumab", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 70-year-old male with metastatic colorectal adenocarcinoma presenting with worsening RUQ pain. CT abdomen shows multiple hypodense lesions in the liver consistent with metastases. Tumor genotyping returned KRAS G12D; MSI testing reported MSI-H. He was started on FOLFOX plus bevacizumab as first-line therapy; restaging CT after three cycles demonstrates interval enlargement of hepatic lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma presenting with headaches and back pain. Staging workup demonstrates metastatic disease to brain and bone consistent with stage IV disease. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score was reported as 40%. She was started on osimertinib 80 mg daily as first-line targeted therapy and after 8 weeks has a radiographic partial response with decreased size of the dominant lung mass and resolution of several brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 40%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: 72-year-old male underwent partial colectomy for a sigmoid mass. Pathology: moderately differentiated adenocarcinoma invading through the muscularis propria into pericolic fat, no nodal involvement (0/18). Final stage II (T3N0). Tumor was MSI-high by PCR; KRAS and NRAS sequencing were not performed at this time. Adjuvant FOLFOX discussed and agreed upon. No evidence of distant disease on staging CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgical resection (partial colectomy), adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R mutation. PD-L1 TPS 10%. Staging showed stage IV disease with symptomatic brain metastases. She was started on osimertinib 80 mg daily with significant radiographic shrinkage of pulmonary and cerebral lesions \u2014 documented as a partial response on first follow-up.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Note: 52-year-old with pigmented lesion on left forearm. Excisional biopsy confirmed cutaneous melanoma, Breslow 0.9 mm, no ulceration. Sentinel node negative. Pathologic stage IB. Tumor sequencing identified BRAF V600E. Given thin, non-ulcerated lesion with negative nodes, patient was managed with wide local excision and observation; no adjuvant systemic therapy recommended. Latest dermatology visit: no recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; observation (no adjuvant therapy)", "response": "no evidence of disease / no recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Breast oncology summary: 48-year-old woman with left breast mass, core biopsy confirmed invasive ductal carcinoma, HER2 amplified by FISH, ER/PR negative. Clinical stage T2N1 (stage IIB). Patient received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab. Surgical pathology after lumpectomy showed no residual invasive carcinoma (pathologic complete response). No molecular hotspot mutations identified on panel.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER+/PR+, HER2 amplified by IHC and confirmed by FISH. Clinical stage IIA (T1cN1). She received neoadjuvant doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab. Lumpectomy pathology shows no residual invasive carcinoma (pathologic complete response). No distant mets on staging imaging.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male presented with weight loss and RUQ pain. Colonoscopy found an obstructing sigmoid mass; biopsy consistent with adenocarcinoma. Staging CT revealed multiple hepatic lesions. Tumor genotyping: BRAF V600E positive and tumor is MSI-H with high TMB. He was started on pembrolizumab monotherapy per discussion with tumor board and has had interval reduction in liver lesions on first restaging scan.", "output": {"cancer_type": "colorectal (sigmoid) adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response (reduction in liver lesions)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with resected sigmoid colon adenocarcinoma, pathologic stage III (N1). Tumor testing identified KRAS G12D mutation and MSI-stable status. Underwent right hemicolectomy followed by adjuvant FOLFOX. Surveillance CT now shows a 2.1 cm lesion in the liver suspicious for metastasis and rising CEA. Repeat imaging after 4 cycles of FOLFOX shows no interval growth (stable disease radiographically).", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX (adjuvant / systemic chemotherapy)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 68-year-old man with newly diagnosed prostate adenocarcinoma, clinical stage II (cT2bN0M0), Gleason 3+4=7. Multidisciplinary team recommended definitive external beam radiation with concurrent androgen suppression; leuprolide depot administered for 6 months. Patient declined genomic testing and no molecular biomarkers were reported. On most recent follow-up there is no clinical evidence of progression.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation and leuprolide (androgen suppression)", "response": "no evidence of progression / clinically controlled", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with sigmoid colon adenocarcinoma, pathologic stage III (T3 N1). Tumor testing returned KRAS G12D and MMR proficient / microsatellite stable. He underwent laparoscopic sigmoid resection followed by adjuvant FOLFOX x 6 cycles. Surveillance CT at 6 months shows no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma (sigmoid)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MMR proficient (microsatellite stable)", "treatment": "surgery and adjuvant FOLFOX", "response": "no radiographic evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with left-sided invasive ductal carcinoma, ER+/PR+, HER2 amplified by IHC 3+ and FISH+. Clinical stage IIIB. Tumor sequencing identified a PIK3CA H1047R mutation. She completed neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab and on exam and imaging there is no residual palpable disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "clinical complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman presented with de novo metastatic breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Staging CT demonstrated multiple lesions in the liver and suspicious axillary nodes (stage IV). FoundationOne testing identified a PIK3CA H1047R mutation. She received first-line docetaxel with trastuzumab and pertuzumab; after six cycles imaging showed stable disease but progression in the liver was noted at 9 months. Treatment was changed to ado-trastuzumab emtansine (T-DM1).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel + trastuzumab + pertuzumab; later T-DM1", "response": "initial stable disease then progression (progression)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female underwent lumpectomy for invasive ductal carcinoma. Final pathology: pT1cN0, ER positive, PR positive, HER2 negative by IHC/FISH -> clinical stage IIA. No genomic panel was performed. Adjuvant radiation completed and started tamoxifen for endocrine therapy. At 18-month follow up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with confirmatory FISH showing HER2 amplification, ER negative, PR negative. NGS detected a PIK3CA H1047R mutation. She received neoadjuvant chemotherapy with docetaxel in combination with trastuzumab and pertuzumab for six cycles. Mastectomy pathology after therapy showed no residual invasive carcinoma (pathologic complete response). No distant metastases were identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with unresectable cutaneous melanoma. PD-L1 reported as 1% and tumor mutational burden labeled as TMB-high on NGS panel. BRAF and NRAS testing were not done during initial workup. He was started on pembrolizumab for metastatic disease involving cervical lymph nodes and a small cerebellar metastasis; after 6 months imaging shows disease stability.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 1%; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "lymph nodes; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female presented with a 2.5 cm right upper lobe mass. CT-guided biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R positive. She underwent VATS lobectomy with negative nodes; pathologic stage IB. PD-L1 TPS 1%. Adjuvant osimertinib 80 mg daily was started per tumor board. Follow-up CT at 6 months shows no evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IB", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "VATS lobectomy; adjuvant osimertinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male referred to thoracic oncology with metastatic lung adenocarcinoma diagnosed January 2024. Comprehensive NGS demonstrated an EGFR exon 19 deletion. PD-L1 TPS reported at 10%. He was started on osimertinib 80 mg daily in February; interim CT in June showed shrinkage of multiple pulmonary nodules and hepatic lesions consistent with a partial response. Interval brain MRI identified two new cerebellar metastases. Current stage: IV.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old female with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 amplification by FISH. Nodal ultrasound suspicious for level II axillary nodes. Clinical stage cT3N1 (approx stage IIIB). She completed neoadjuvant chemotherapy with docetaxel and carboplatin plus trastuzumab; repeat imaging prior to surgery showed marked tumor shrinkage. Pathology after mastectomy: no residual invasive carcinoma in the breast and nodes (pCR). PIK3CA H1047R identified on sequencing of the diagnostic specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER negative, PR negative", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; mastectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 45-year-old woman with locally advanced breast cancer, core biopsy: invasive ductal carcinoma, ER-negative, PR-negative, HER2 amplified by FISH. Tumor measured 5.2 cm on MRI with suspicious axillary nodes. Clinical stage IIIB. She received neoadjuvant chemotherapy with weekly paclitaxel followed by dose-dense doxorubicin/cyclophosphamide in combination with trastuzumab and pertuzumab. Surgical pathology after modified radical mastectomy showed no residual invasive carcinoma (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel; dose-dense doxorubicin/cyclophosphamide; trastuzumab; pertuzumab; modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic pancreatic ductal adenocarcinoma presenting with liver metastases (stage IV). Germline testing revealed BRCA2 pathogenic variant. He achieved a good clinical response to FOLFIRINOX induction and was transitioned to maintenance olaparib for BRCA-mutated disease. CA19-9 has declined substantially and CT shows reduction of hepatic lesions at 3 months.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX induction, maintenance olaparib (PARP inhibitor)", "response": "partial response / radiographic reduction", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative consultation: 48-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy: HER2 amplification by FISH; ER/PR negative. Plan is neoadjuvant chemotherapy with docetaxel, carboplatin plus trastuzumab and pertuzumab. Post-therapy imaging and surgical pathology demonstrated no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female with recurrent metastatic breast cancer. Core biopsy of hepatic lesion confirmed invasive ductal carcinoma, ER+, PR-, HER2 3+ by IHC consistent with HER2 amplification. She was started on first-line trastuzumab + pertuzumab with weekly paclitaxel. Most recent CT shows disease is unchanged compared with baseline.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op consultation: 52-year-old with unilateral adnexal mass diagnosed as high-grade serous ovarian carcinoma, FIGO stage I (IA) after staging laparotomy. Germline testing revealed a pathogenic BRCA1 mutation. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and omental staging, received 3 cycles of adjuvant carboplatin/paclitaxel, and has been started on olaparib maintenance. CA-125 normalized post\u2011op and there is no radiographic disease on CT.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "I", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 normalized", "treatment": "surgery (TAH-BSO and staging); carboplatin/paclitaxel; olaparib maintenance", "response": "complete response / no radiographic disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma harboring EGFR L858R mutation. Staging is IV with multiple enhancing brain metastases on MRI. PD-L1 by IHC reported as 1%. Patient started osimertinib 80 mg daily and showed a partial response at the 8-week scan with reduction in intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with metastatic cutaneous melanoma. BRAF testing positive for V600E. PD-L1 expression 5% by IHC. He received targeted therapy with dabrafenib and trametinib; initial PET/CT showed decrease in extracranial disease but three months later developed symptomatic brain lesions and was noted to have systemic progression.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "29-year-old man with a 2.1 mm non-ulcerated cutaneous melanoma on the back. Sentinel lymph node biopsy was negative and the case was staged as IB. Patient declined molecular testing so no BRAF/NRAS result is available. He underwent wide local excision with clear margins and no adjuvant therapy was given.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IB", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing positive for EGFR L858R; later developed T790M. PD-L1 by IHC 10%, TMB-low. Patient received first-line osimertinib with good CNS control, subsequently added bevacizumab for progressive pleural disease. Current imaging shows decreased intracranial lesions and smaller nodal disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%, TMB-low", "treatment": "osimertinib; osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain, pleura, lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 43-year-old man with stage III nodal melanoma. Primary lesion excised with completion lymphadenectomy. Molecular testing positive for BRAF V600E. He received adjuvant dabrafenib plus trametinib for 12 months with initial good control; eight months after stopping targeted therapy he developed enlarging regional nodes and a new pulmonary nodule. He was transitioned to single-agent nivolumab but interval imaging showed further growth consistent with progressive disease.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (adjuvant); nivolumab (subsequent)", "response": "progressive disease", "metastasis_site": "regional lymph nodes, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male presenting with colorectal adenocarcinoma and multiple liver lesions. Mismatch repair testing shows MSI-H. Comprehensive genomic profiling was not performed at the time of treatment decision. Staged as IV. He was started on pembrolizumab monotherapy and follow-up imaging at 12 weeks demonstrated significant reduction in hepatic disease consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 60-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC, with diffuse peritoneal carcinomatosis. Germline testing identified a pathogenic BRCA1 deletion; tumor profiling also documented TP53 mutation. Baseline CA-125 was 980 U/mL. She completed 6 cycles of carboplatin and paclitaxel with good cytoreduction and CA-125 decline; started on maintenance olaparib. CT shows partial radiographic response of peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic deletion; TP53 mutation", "biomarker": "CA-125 elevated (980 U/mL)", "treatment": "carboplatin + paclitaxel followed by maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic HER2-positive breast cancer. Core biopsy: invasive ductal carcinoma, ER 80%+, PR 20%+, HER2 IHC 3+ with FISH-confirmed HER2 amplification. NGS revealed PIK3CA H1047R mutation. Clinical stage at diagnosis was IV with multiple axillary nodes and bone metastases. Treated up front with trastuzumab and pertuzumab in combination with docetaxel; after progression on maintenance trastuzumab/pertuzumab she received alpelisib plus fulvestrant for PIK3CA-mutant disease with mixed response.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and pertuzumab + docetaxel; alpelisib + fulvestrant", "response": "mixed response", "metastasis_site": "bone; axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female presenting with locally advanced pancreatic ductal adenocarcinoma with peritoneal nodules and multiple hepatic metastases. Staging: IV. Germline testing returned pathogenic BRCA2 mutation; CA19-9 markedly elevated at diagnosis. She received FOLFIRINOX with radiographic tumor shrinkage and CA19-9 decline, then was transitioned to olaparib maintenance. Most recent scan shows stable disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated; HRD-positive", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female diagnosed with pancreatic ductal adenocarcinoma with biopsy-proven hepatic metastases. Performance status declined and she was started on gemcitabine plus nab-paclitaxel. No actionable mutations were reported on initial testing and no molecular biomarkers were documented in the chart. After three cycles CT shows progression with increasing size and number of liver lesions and new peritoneal nodularity.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with de novo stage IV colorectal adenocarcinoma presenting with multiple liver lesions. Molecular profiling showed BRAF V600E mutation and MSI-H; tumor also reported TMB-high. He received FOLFOX plus bevacizumab with stable disease on first restaging before switching to pembrolizumab for MSI-H disease.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX; bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Record: 54-year-old woman diagnosed with locally advanced breast cancer (cT3N1) treated neoadjuvantly. Tumor was ER-positive, PR-positive and HER2 amplified on IHC/FISH. No molecular sequencing performed. She received combination therapy with trastuzumab and pertuzumab plus docetaxel for six cycles followed by modified radical mastectomy. Pathology showed marked tumor regression and no residual nodal disease; patient considered to have a clinical complete response prior to surgery.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER-positive, PR-positive, HER2 amplification", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 64-year-old male found to have localized prostate adenocarcinoma on biopsy (Gleason 3+4). Clinical examination and imaging were consistent with organ-confined disease (stage II). No tumor genomic testing was performed. He underwent radical prostatectomy with pelvic lymph node dissection followed by adjuvant external beam radiation for close margins. Post-treatment follow-up has shown no clinical evidence of recurrent disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; pelvic lymph node dissection; adjuvant external beam radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with newly diagnosed metastatic lung adenocarcinoma, Stage IV. Baseline brain MRI demonstrated multiple enhancing cerebellar and cortical lesions and PET/CT showed lytic lesions in the thoracic spine. Comprehensive NGS returned EGFR L858R. PD-L1 TPS 5%. She was started on osimertinib 80 mg daily as first-line therapy. Interval imaging at 3 months shows decrease in size of the primary lung mass and improvement in brain and bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. NGS reported KRAS G12D. CEA elevated at 42 ng/mL. Patient was treated with FOLFOX plus bevacizumab; follow-up CT chest/abdomen shows enlargement of multiple pulmonary nodules consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 42 ng/mL", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with metastatic melanoma. BRAF V600E mutation identified on tumor sequencing. Initially started on dabrafenib plus trametinib with a good partial response, but progressed after 7 months with new liver lesions. Switched to pembrolizumab and has achieved stable disease on two-monthly scans.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib, pembrolizumab", "response": "initial partial response then progression; stable disease on pembrolizumab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed metastatic lung adenocarcinoma. PET/CT (01/2024) demonstrated bilateral pulmonary nodules and a 1.8 cm cerebellar metastasis; MRI confirms additional lytic lesions in the thoracic spine. Tumor NGS detected EGFR L858R. PD-L1 TPS reported at 5%. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the cerebellar lesion. Interval CT at 8 weeks showed shrinkage of target lung lesions and decreased enhancement of the brain lesion consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Presents with multiple pulmonary nodules and a 1.2 cm cerebellar metastasis treated with stereotactic radiosurgery. PD-L1 testing returned 5%. Systemic therapy with dabrafenib plus trametinib was initiated. Three-month imaging shows shrinkage of several lung lesions but appearance of a new 2 cm liver lesion \u2014 overall described by the oncologist as a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "lung, brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT scan shows multiple liver metastases. Tumor sequencing demonstrates BRAF V600E. Mismatch repair testing by IHC was absent for MLH1 and PMS2 consistent with MSI-H; TMB reported as 22 mutations/Mb (TMB-high). After progression on FOLFOX, he was started on pembrolizumab monotherapy with complete radiographic resolution of hepatic lesions on follow-up imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old female with unresectable stage IV cutaneous melanoma presenting with multiple pulmonary nodules. Molecular profiling identified a BRAF V600E mutation. She was started on dabrafenib plus trametinib. Two-month follow-up CT shows marked decrease in size of pulmonary metastases. PD-L1 testing was not performed prior to treatment.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-resistant prostate cancer now with progressive bone pain and rising PSA. Imaging confirms multiple lytic and blastic bone metastases. He remains on androgen deprivation therapy and was treated with docetaxel in combination with abiraterone for six cycles. PSA continued to climb and the disease is considered progressing on current systemic therapy.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy + docetaxel + abiraterone", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female presented with a 2.1 cm palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER+, PR+, HER2 non-amplified. Tumor sent for genomics: PIK3CA H1047R identified. Pathologic staging after lumpectomy and sentinel lymph node biopsy was T2N0M0 (Stage IIA). She received adjuvant doxorubicin/cyclophosphamide x4 followed by weekly paclitaxel and local radiation. Endocrine therapy with tamoxifen was started; Oncotype DX 18. At 18-month follow-up there is no evidence of disease on exam and imaging.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 non-amplified", "treatment": "lumpectomy; doxorubicin and cyclophosphamide; paclitaxel; radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Staging MRI and PET showed multiple enhancing brain metastases and lytic lesions in the thoracic spine consistent with stage IV disease. Comprehensive genomic profiling identified EGFR L858R. PD-L1 tumor proportion score was 10%. She was started on osimertinib 80 mg daily as first-line therapy. At 8-week restaging CT there was a 40% reduction in sum of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Tissue NGS returned EGFR L858R and PD-L1 tumor proportion score ~10%. He was enrolled on a trial and started osimertinib in combination with bevacizumab as first-line systemic therapy. Interval imaging after 3 months showed decreased primary tumor burden and shrinkage of multiple brain lesions and sclerotic changes in thoracic vertebra \u2014 overall a partial response. Continues on osimertinib + bevacizumab without new symptoms.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma. Liver biopsy demonstrated BRAF V600E mutation and MSI-high status. Given the MSI-H result he was treated with pembrolizumab monotherapy; after six cycles there was a complete radiographic response and resolution of peritoneal nodularity.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Biopsy showed EGFR L858R mutation. PD-L1 TPS was 10%. He was started on osimertinib 80 mg daily with marked shrinkage of pulmonary and hepatic lesions (partial response at 3 months). Later developed a solitary brain metastasis treated with stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old with metastatic cutaneous melanoma harboring BRAF V600E mutation. Staged as IV with multiple brain metastases and pulmonary nodules. PD-L1 10% and NGS reported TMB-high. Was treated up front with dabrafenib + trametinib and had stereotactic radiosurgery to the brain lesions; on mixed radiographic response she subsequently received ipilimumab plus nivolumab. Status described by oncology as mixed response / heterogenous response across sites.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery; then ipilimumab + nivolumab", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with newly diagnosed metastatic colorectal adenocarcinoma, liver-dominant disease consistent with stage IV. Molecular profile: KRAS G12D mutation, MSI-high and TMB-high on NGS. He received first-line FOLFOX for 6 cycles with disease control and then transitioned to pembrolizumab given MSI-H status; most recent CT shows stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-high; TMB-high", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 58-year-old male with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing identified EGFR L858R. Staged IV at diagnosis with brain and bone metastases. Started osimertinib 80 mg daily in January; interval CT chest and MRI brain show decrease in size of multiple pulmonary nodules and shrinking intracranial lesions consistent with a partial response. PD-L1 reported at 10%.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant chemotherapy administered for locally advanced breast cancer: core biopsy showed invasive ductal carcinoma, HER2 amplification by FISH and ER+/PR+. Patient received 12 weeks of weekly paclitaxel with trastuzumab, followed by modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant paclitaxel and trastuzumab, followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Path report / clinic note: Core biopsy of left breast demonstrates invasive ductal carcinoma, ER positive, PR negative. HER2 is amplified by FISH (HER2/CEP17 ratio 3.1). Clinical tumor was staged as IIIB due to dermal involvement. Next-generation sequencing identified PIK3CA H1047R. Neoadjuvant therapy with docetaxel, carboplatin and trastuzumab was initiated; interval imaging after 4 cycles shows a partial radiographic response prior to planned surgery.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic pancreatic ductal adenocarcinoma, Stage IV at diagnosis with liver and peritoneal implants. Germline BRCA2 mutation identified on genetic testing. He received six cycles of FOLFIRINOX with significant CA19-9 decline and radiographic partial response; transitioned to maintenance olaparib. On maintenance he has had stable disease radiographically for approximately 7 months with CA19-9 trending down compared with baseline.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated (declining on therapy)", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing showed EGFR L858R. Baseline PD-L1 was 10%. He developed new headaches and MRI demonstrated multiple small brain metastases; bone scan was positive for osseous disease. He was started on osimertinib 80 mg daily and first restaging CT/MRI after 8 weeks demonstrated a partial radiographic response with shrinkage of intracranial and skeletal lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with unresectable cutaneous melanoma, clinical stage III. Tumor is BRAF V600E positive. He initiated dabrafenib plus trametinib and achieved a partial response, but after 9 months developed progression with new brain metastases; PD-L1 by IHC was 5%. He was transitioned to pembrolizumab but had further clinical decline.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later pembrolizumab", "response": "progression after initial partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER positive (90%), PR positive (40%), HER2 3+ by IHC with confirmed HER2 amplification by FISH. Hot-spot NGS detected PIK3CA H1047R. Clinical stage recorded as IIIB with bulky axillary nodes. Neoadjuvant therapy: trastuzumab + pertuzumab in combination with docetaxel for 6 cycles. Imaging and exam show excellent response with marked tumor shrinkage and near-complete clinical response prior to planned surgery; residual axillary nodal disease on ultrasound.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive (90%); PR positive (40%); HER2 amplification (IHC 3+ / FISH+) ", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "near-complete clinical response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chemotherapy summary: 55-year-old with locally advanced pancreatic adenocarcinoma (no distant metastases on imaging), germline BRCA2 pathogenic variant detected. Clinical stage III at presentation. Received eight cycles of FOLFIRINOX with radiographic stability; patient transitioned to maintenance olaparib given BRCA2 status, currently clinically stable.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX then maintenance olaparib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with newly diagnosed lung adenocarcinoma. Imaging and biopsy consistent with stage IV disease with multiple brain metastases. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 5%. Patient started on osimertinib 80 mg daily and has had symptomatic improvement. Interval MRI at 8 weeks shows decreased size of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 64-year-old male with metastatic cutaneous melanoma. NGS returned BRAF V600E positive. He underwent stereotactic radiosurgery to a solitary cerebellar metastasis and was started on dabrafenib with trametinib combination therapy. Early follow-up MRI demonstrates reduction in size of the cerebellar lesion. Original stage at diagnosis is not documented in this note.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presented with jaundice and weight loss. Imaging revealed a pancreatic head mass with multiple hepatic lesions consistent with metastatic pancreatic ductal adenocarcinoma. No next-generation sequencing was performed at diagnosis. He was started on gemcitabine with nab\u2011paclitaxel. First restaging CT at 8 weeks showed stable size of hepatic and pancreatic lesions.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colon adenocarcinoma, multiple hepatic lesions on baseline CT. Molecular testing: KRAS G12D mutation; tumor reported as MSI-high and TMB-high. He was started on FOLFOX with bevacizumab and achieved stable disease after 3 months; given MSI-H status he was switched to pembrolizumab and subsequently experienced a durable partial response in the liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV cutaneous melanoma found to have NRAS Q61R mutation on tumor panel. Staging CT showed multiple bilateral pulmonary nodules consistent with metastatic disease. He received combination immunotherapy with nivolumab and ipilimumab and achieved a period of stable disease prior to later progression. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "nivolumab and ipilimumab", "response": "stable disease (followed by progression)", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed stage IV lung adenocarcinoma. Molecular testing returned EGFR L858R; PD-L1 by IHC was 10%. Baseline staging showed multiple brain and osseous lesions. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Follow-up CT and MRI at 8 weeks demonstrate decrease in size of thoracic and brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with metastatic cutaneous melanoma, BRAF V600E positive on PCR. PET/CT revealed multiple bilateral pulmonary nodules consistent with metastatic disease. He initiated combination targeted therapy with dabrafenib and trametinib. Follow-up imaging demonstrated complete resolution of measurable pulmonary nodules; clinical assessment recorded a complete response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with sigmoid adenocarcinoma underwent low anterior resection. Pathology: pT3N2 (stage IIIC) with 4/15 nodes positive. Tumor is KRAS G12D and microsatellite stable (MSS). Adjuvant FOLFOX was started. At 6-month CT the patient is without radiographic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "surgery (low anterior resection); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with pancreatic ductal adenocarcinoma, biopsy-confirmed liver metastases at presentation (stage IV). NGS reported KRAS G12D. No molecular biomarkers were reported in the chart. He received FOLFIRINOX for four cycles then was switched to gemcitabine/nab-paclitaxel due to toxicity. Interval CT after 8 cycles shows overall stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRINOX followed by gemcitabine/nab-paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB. Core biopsy: HER2 amplification by FISH, ER positive, PR negative. Next-generation sequencing identified PIK3CA E545K. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for 6 cycles followed by modified radical mastectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). No distant disease identified on pre-op staging.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology note (concise): 55-year-old man with ulcerated cutaneous melanoma initially staged IIIC. BRAF V600E mutation identified on PCR. Started on combination dabrafenib plus trametinib; achieved complete clinical response at 4 months but developed new pulmonary nodules at month 9 with biopsy-proven metastatic melanoma indicating progression on targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib", "response": "initial complete response followed by progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (diagnosed 2023) presented with progressive dyspnea. Staging demonstrated stage IV disease with multiple brain and osseous lesions. Comprehensive tumor profiling identified EGFR L858R mutation; PD-L1 tumor proportion score was 10%. She was started on osimertinib 80 mg daily and after 8 weeks CT/MRI showed shrinkage of the primary and metastatic sites consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 59-year-old male with newly diagnosed glioblastoma (WHO grade IV) in the right temporal lobe. Surgical report notes subtotal resection. Molecular testing reported MGMT promoter methylation positive; IDH1 R132H was negative on immunohistochemistry. Patient completed concurrent radiotherapy with temozolomide per Stupp protocol. Early post-treatment MRI demonstrates interval enlargement of the enhancing lesion with increased surrounding edema \u2014 concern for progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation", "treatment": "radiation and temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with newly diagnosed lung adenocarcinoma, clinical stage IV. Molecular testing identified EGFR L858R mutation. PD-L1 tumor proportion score reported at 20%. Patient started osimertinib 80 mg daily in January 2024 and underwent stereotactic radiosurgery to a 1.5 cm cerebellar metastasis. Imaging after 8 weeks shows decrease in size of pulmonary and osseous lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma (AJCC stage IV) harboring BRAF V600E noted on next\u2011generation sequencing. PD-L1 immunohistochemistry >50%. Initial therapy was the targeted doublet dabrafenib plus trametinib with a brisk cutaneous and nodal reduction (partial response), but intracranial progression prompted switch to combination immunotherapy with nivolumab and ipilimumab. Subsequent PET/CT and brain MRI showed durable complete response of extracranial disease and stable small brain lesions.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib + trametinib; then nivolumab + ipilimumab", "response": "partial response to targeted therapy; complete response after immunotherapy", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old man who was diagnosed with right-sided colon adenocarcinoma. He underwent right hemicolectomy; pathology returned pT3N2 (stage III) with multiple positive regional lymph nodes. Molecular testing shows BRAF V600E mutation and high microsatellite instability (MSI-H). He completed 6 cycles of adjuvant FOLFOX with bevacizumab and tolerated treatment well; current status: no radiographic evidence of metastatic disease on surveillance CT.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX with bevacizumab", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma found to have multiple hepatic lesions and a pulmonary nodule. Tumor NGS shows KRAS G12D; mismatch repair testing: microsatellite stable (MSS). He was started on FOLFOX with bevacizumab; interval CT after 4 cycles demonstrates no significant change in size of target lesions and overall disease is assessed as stable.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate adenocarcinoma. PSA now 92 ng/mL. Bone scan with multiple sclerotic metastases. Tumor sequencing did not reveal actionable somatic alterations; circulating tumor cell assay positive for AR-V7. He progressed on abiraterone and was started on docetaxel with improvement in bone pain but rising PSA \u2014 described as a mixed response clinically.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "AR-V7 positive; PSA 92 ng/mL", "treatment": "docetaxel (prior abiraterone)", "response": "mixed response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: metastatic melanoma, BRAF V600E positive. Prior resection of primary lesion; now with lung and hepatic metastases (stage IV). PD-L1 by IHC reported at 10%. Patient received pembrolizumab as first-line immunotherapy and had an initial partial response in pulmonary nodules but developed new hepatic lesions after 4 months (initial partial response followed by progression). Switched to targeted therapy with dabrafenib plus trametinib.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "pembrolizumab; then dabrafenib plus trametinib", "response": "initial partial response followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 55-year-old man with metastatic cutaneous melanoma, BRAF V600E on molecular testing. PD-L1 TPS 5%. He presented with new headaches; MRI brain revealed a 1.2 cm cerebellar metastasis and several subcentimeter cortical lesions. He received stereotactic radiosurgery to the cerebellar lesion and was started on dabrafenib plus trametinib. PET/CT shows marked reduction of extracranial disease burden (partial response) and post-SRS MRI shows stable intracranial lesions.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response (extracranial); stable intracranial disease / mixed response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man presented with progressive cough and weight loss. Imaging showed a right upper lobe mass and multiple enhancing lesions in the brain and thoracic spine. Biopsy confirmed lung adenocarcinoma, stage IV. Molecular testing detected EGFR L858R mutation. He was started on osimertinib 80 mg daily with clinical and radiographic partial response at the 8-week scan.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, spine"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case summary: 70-year-old male with metastatic castration-resistant prostate adenocarcinoma with extensive sclerotic bone metastases. Germline and somatic testing identified a pathogenic BRCA2 mutation. He was started on androgen deprivation therapy (leuprolide) initially and transitioned to olaparib after confirmation of BRCA2 and progression on first-line agents; prior docetaxel was given in the hormone-sensitive setting. Current imaging shows controlled bony disease without new lesions and clinical status is stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV (metastatic castration-resistant)", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide) and olaparib; prior docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with high-grade invasive ductal carcinoma of the right breast, clinically T2N1 (stage III). Core biopsy: ER positive, PR negative, HER2 amplified by FISH. Tumor sequencing reveals PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for 6 cycles followed by lumpectomy. Final pathology showed no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases identified on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "III", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab; surgery (lumpectomy)", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with progressive cough and weight loss. CT chest/abdomen revealed a 4.2 cm right upper lobe mass and multiple enhancing lesions in the cerebrum. Bronchoscopic biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R. PD-L1 TPS reported at 10%. Given intracranial disease and sensitizing EGFR mutation, patient was started on osimertinib 80 mg daily. Follow-up MRI at 8 weeks showed decrease in size of the primary and brain lesions consistent with a partial response. Plan: continue osimertinib; consider stereotactic radiosurgery for residual brain metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: Ms. R is a 62-year-old with metastatic lung adenocarcinoma diagnosed 2023. Molecular testing demonstrated EGFR L858R mutation. PD-L1 TPS reported at 10%. She was started on osimertinib 80 mg daily in January with symptomatic improvement. Interval MRI showed decreased size of several cerebellar and parietal metastases and resolution of shortness of breath. Most recent CT chest/abdomen demonstrated regression of pulmonary nodules and stable hepatic lesions. Current assessment: partial response to osimertinib; continues therapy. Past treatments: none prior to TKI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old man with widely metastatic melanoma. Tumor sequencing identified BRAF V600E. He began combination targeted therapy with dabrafenib and trametinib. After 4 months of therapy PET/CT shows resolution of several pulmonary nodules and a near-complete metabolic response. Plan is to continue current regimen with close surveillance.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "near-complete metabolic response / complete response in lung lesions", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic cutaneous melanoma originally excised from the left scapular region. Staging PET/CT shows pulmonary nodules and new intracranial lesions. Tumor sequencing detected BRAF V600E mutation. He was started on dabrafenib plus trametinib with an initial tumor response but developed CNS progression at six months and is being considered for combination checkpoint blockade. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (initial); planned ipilimumab/nivolumab", "response": "progression (CNS progression after initial response)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with biopsy-proven pancreatic ductal adenocarcinoma presenting with obstructive jaundice. CT shows a 4.2 cm head of pancreas mass and multiple hypodense lesions in both hepatic lobes consistent with metastases. Tumor NGS has not been performed and germline BRCA testing is pending. He was started on gemcitabine plus nab-paclitaxel but interval imaging demonstrates progression with increasing hepatic tumor burden.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine + nab-paclitaxel", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old F with metastatic lung adenocarcinoma presented with headaches and bone pain. Biopsy confirmed stage IV disease with an EGFR exon 19 deletion and PD-L1 ~10% by IHC. She was started on osimertinib as first-line targeted therapy; interval MRI and PET show decreased size of intracranial lesions and improvement in lytic bone disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with ER+/PR+/HER2-amplified invasive ductal carcinoma of the right breast. Pre-op NGS showed PIK3CA H1047R. She underwent modified radical mastectomy with axillary dissection (path pT3N1), received adjuvant doxorubicin/cyclophosphamide x4 then paclitaxel, and completed a year of trastuzumab. Surveillance imaging and exam show no evidence of disease at 18-month follow-up.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "surgery (modified radical mastectomy), adjuvant doxorubicin/cyclophosphamide then paclitaxel, trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man underwent subtotal resection of a right temporal glioblastoma (WHO grade IV). Postoperatively he received concurrent chemoradiation with temozolomide per Stupp protocol followed by adjuvant temozolomide. Molecular profiling did not reveal actionable driver mutations; MGMT methylation status unavailable at discharge. Surveillance MRI at 6 months shows increased enhancing tumor consistent with progression. There is no evidence of extracranial spread.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgical resection followed by radiation with concurrent and adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer. Presents with diffuse bone pain and multiple sclerotic lesions on bone scan. PSA at entry 128 ng/mL. He has been on androgen deprivation therapy followed by docetaxel then radium-223 for symptomatic bony disease; rising PSA and clinico-radiographic progression noted last month.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 128 ng/mL", "treatment": "androgen deprivation therapy, docetaxel, radium-223", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology/oncology summary: Stage IV colon adenocarcinoma with multiple hepatic lesions and a solitary pulmonary nodule consistent with metastases. Molecular profile: BRAF V600E mutation; deficient mismatch repair/MSI-H. Initially treated with FOLFOX plus bevacizumab; after progression was switched to pembrolizumab given MSI-H status. Most recent restaging shows stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H (mismatch repair deficient)", "treatment": "FOLFOX + bevacizumab then pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man diagnosed with de novo metastatic prostate adenocarcinoma, stage IV with bone-only metastases on bone scan. He was started on androgen deprivation with leuprolide plus docetaxel, later transitioned to abiraterone. No somatic or germline genomic testing was performed and no molecular biomarkers were reported. Latest CT/bone scan show stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; docetaxel; abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic cutaneous melanoma, stage IV, presenting with multiple intracranial lesions. Molecular profiling positive for BRAF V600E. He received first-line dabrafenib plus trametinib with rapid extracranial tumor shrinkage but developed intracranial progression at 6 months and was transitioned to pembrolizumab; subsequent scans showed disease progression. PD-L1 was reported at 10%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib + trametinib; pembrolizumab", "response": "initial partial response (extracranial) then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man referred for metastatic colorectal adenocarcinoma. Imaging shows multiple liver metastases consistent with stage IV disease. Molecular testing: KRAS G12D mutation identified; tumor also reported MSI-H. Started FOLFOX plus bevacizumab in March; after 4 months repeat CT demonstrates new hepatic lesions and rising CEA consistent with radiographic progression. Patient being considered for second-line therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old male with metastatic colorectal adenocarcinoma. Biopsy of a liver lesion confirmed adenocarcinoma consistent with colon primary; KRAS G12D mutation detected on NGS. Tumor has high microsatellite instability (MSI-H) and high tumor mutational burden (TMB-high). He was switched from FOLFOX to pembrolizumab given MSI-H status. After 12 weeks of immunotherapy the CT abdomen shows mixed response with stable size of majority of hepatic lesions but new small peritoneal implants \u2014 overall assessment: stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (after FOLFOX)", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with metastatic pancreatic ductal adenocarcinoma. Staging showed multiple hepatic lesions consistent with metastatic disease (stage IV). Germline and somatic testing identified a deleterious BRCA2 mutation. CA19-9 markedly elevated at diagnosis. She received first-line FOLFIRINOX with an initial partial response, transitioned to olaparib maintenance due to BRCA2 positivity, but recent scans demonstrate progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "elevated CA19-9", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "progression (after initial partial response)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a new diagnosis of invasive ductal carcinoma of the right breast. Core biopsy reports ER-positive, PR-positive, HER2-negative disease. Clinical stage is I (T1N0M0). She underwent lumpectomy with sentinel lymph node biopsy last month; margins were negative. She was started on adjuvant endocrine therapy with tamoxifen. At 6-month follow-up there is no evidence of disease on physical exam and breast imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel lymph node biopsy; tamoxifen (adjuvant endocrine therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with metastatic breast cancer. Core biopsy confirmed invasive ductal carcinoma with HER2 overexpression by IHC/FISH and positive ER (Allred 7), PR negative. Next-generation sequencing identified a PIK3CA E545K hotspot mutation. She was treated with first-line trastuzumab and pertuzumab combined with weekly paclitaxel. CT at 12 weeks shows stable size of hepatic lesions without new disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed stage IV lung adenocarcinoma. Tumor sequencing identified EGFR L858R. PD-L1 by IHC 10%. She was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to a solitary cerebellar metastasis. Interval CT and brain MRI at 8 weeks show shrinkage of the primary right lower lobe mass and the treated brain lesion \u2014 overall assessment: partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with BRAF V600E mutation. Baseline PET/CT demonstrated multiple pulmonary nodules consistent with metastatic disease. Patient was started on targeted therapy with dabrafenib and trametinib and had rapid tumor shrinkage on first restaging. PD-L1 testing was not performed. Follow-up imaging documents a near-complete radiographic response in the chest.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "near-complete radiographic response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic colorectal adenocarcinoma. Diagnosed T3N2M1 with multiple hepatic metastases. Molecular profile notable for KRAS G12D mutation; mismatch repair testing shows microsatellite stable (MSS). Patient received FOLFOX with bevacizumab; most recent CT shows no new lesions and modest decrease in size of liver mets consistent with stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with progressive cough and weight loss. Imaging demonstrated multiple pulmonary nodules and hepatic lesions consistent with metastatic lung adenocarcinoma, clinical stage IV. Comprehensive NGS returned EGFR L858R and concurrent TP53 R175H; PD-L1 tumor proportion score 60% and TMB-high (12 mut/Mb). Patient was started on carboplatin plus pemetrexed in combination with pembrolizumab. After three cycles CT shows a partial response. Metastatic sites include liver and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 R175H", "biomarker": "PD-L1 60%; TMB-high (12 mut/Mb)", "treatment": "carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma diagnosed after pulmonary wedge resection for a lung mass. Tumor sequencing identified BRAF V600E. Tumor mutational burden reported as TMB-high. Patient received dabrafenib plus trametinib with an initial partial response, but interval scans at 6 months documented new bilateral pulmonary nodules and increase in size of prior lesions consistent with disease progression. PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 1.2 cm invasive ductal carcinoma, ER positive, PR negative. HER2 amplification confirmed by FISH. Tumor staged as T1N0 (stage I) after lumpectomy and negative sentinel node. She completed adjuvant paclitaxel and has been on trastuzumab for 1 year with no evidence of disease on surveillance mammography and exam.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "lumpectomy; sentinel node biopsy; adjuvant paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with invasive ductal carcinoma of the breast, clinical stage IIIA. Core biopsy: HER2 amplification by FISH, ER positive, PR negative; PIK3CA H1047R mutation identified on sequencing. She received neoadjuvant TCH (docetaxel, carboplatin, trastuzumab) for six cycles followed by lumpectomy and sentinel node dissection. Surgical pathology shows no residual invasive cancer (pathologic complete response). Adjuvant trastuzumab planned to complete 1 year.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel/carboplatin/trastuzumab (TCH), surgery, adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided colon adenocarcinoma in a 67-year-old man. Pathology after right hemicolectomy: stage III (T3N1). Tumor testing returned MSI-H and a concurrent BRAF V600E mutation. Patient completed adjuvant FOLFOX with no radiographic evidence of disease on surveillance CT at 6 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy followed by adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with widely metastatic cutaneous melanoma presented with progressive right upper quadrant pain. PET/CT showed multiple hepatic metastases. Tumor sequencing identified BRAF V600E. The patient received pembrolizumab initially but developed radiographic progression in the liver and was switched to dabrafenib plus trametinib; overall response has been mixed with shrinking pulmonary nodules but enlarging dominant liver lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab, then dabrafenib and trametinib", "response": "mixed response (pulmonary response, hepatic progression)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with locally advanced sigmoid colon adenocarcinoma, clinical stage III, was found to be MSI-H on PCR testing and harbors a BRAF V600E mutation on NGS. He received three cycles of neoadjuvant FOLFOX prior to planned resection. Interval CT shows decrease in primary tumor size without distant spread.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "neoadjuvant FOLFOX", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F with de novo metastatic breast cancer, ER+/PR+/HER2-amplified disease presenting with hepatic metastases. Staging consistent with stage IV breast cancer. She was started on first-line trastuzumab and pertuzumab combined with docetaxel. Interval scans after 12 weeks show no new disease and minimal change in liver lesions \u2014 overall assessment: stable disease. NGS panel did not reveal actionable point mutations.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with ER+/PR+ invasive ductal carcinoma of the breast, clinical stage II (cT2N1). Core biopsy NGS shows PIK3CA H1047R and HER2 amplification by FISH. She received neoadjuvant dose-dense AC x4 cycles followed by paclitaxel with trastuzumab and pertuzumab. Lumpectomy pathology demonstrated a pathologic complete response. Planned to continue trastuzumab to complete one year.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant dose-dense AC then paclitaxel + trastuzumab and pertuzumab; lumpectomy; adjuvant trastuzumab planned", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 55-year-old with high-grade serous ovarian carcinoma, stage IIIC at diagnosis with bulky peritoneal disease. Germline testing positive for BRCA1 pathogenic variant. Underwent optimal cytoreductive surgery followed by six cycles of carboplatin/paclitaxel with documented clinical partial response and decreased CA-125. Patient was started on maintenance olaparib given BRCA1 status; ongoing surveillance shows interval shrinkage of peritoneal implants.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HRD-positive (BRCA1)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma. Liver lesion biopsy consistent with colon primary. Molecular profile: KRAS G12D; tumor is MSI-H with high tumor mutational burden. Stage IV disease with multiple hepatic and peritoneal implants. Initially treated with FOLFOX plus bevacizumab achieving stable disease, then transitioned to pembrolizumab for MSI-H disease with subsequent partial response in the liver lesions on interval imaging.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "partial response (after initial stable disease)", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma with symptomatic brain and bilateral lung metastases. NGS detected BRAF V600E; NRAS wild-type. PD-L1 was 10% and tumor mutational burden was high (\u224825 muts/Mb). He was treated with dabrafenib plus trametinib with a good extracranial partial response but mixed intracranial response; two progressing brain lesions were managed with stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (25 muts/Mb); PD-L1 10%", "treatment": "dabrafenib + trametinib; stereotactic radiosurgery", "response": "partial response with mixed intracranial response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with de novo metastatic pancreatic ductal adenocarcinoma, stage IV with multiple hepatic lesions. Germline BRCA2 mutation identified; CA19-9 was 1,200 U/mL at baseline. Treated with first-line FOLFIRINOX with initial disease stabilization, but imaging showed progression after 6 months. Switched to olaparib maintenance with limited clinical benefit.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation (germline)", "biomarker": "CA19-9 1,200 U/mL", "treatment": "FOLFIRINOX, olaparib", "response": "progressive disease after initial stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female presenting with progressive cough. Imaging and biopsy confirm lung adenocarcinoma with EGFR L858R mutation. Staging CT shows multiple pulmonary nodules and enhancing lesions in the cerebellum consistent with brain metastases \u2014 overall consistent with stage IV disease. PD-L1 by IHC 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and had a CT at 8 weeks showing a decrease in size of index lesions (partial response).", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic invasive ductal carcinoma of the breast. Tumor is ER positive, PR negative; HER2 amplified by FISH. Next-generation sequencing showed PIK3CA H1047R mutation. Imaging demonstrates multiple hypoattenuating liver lesions consistent with metastases; clinical stage IV. Treated with first-line combination trastuzumab + pertuzumab + docetaxel with good clinical benefit. On progression she was transitioned to fulvestrant + alpelisib for PIK3CA-mutant, HR-positive disease and continues on targeted endocrine therapy with ongoing decrease in hepatic disease measured on CT (partial response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel; later fulvestrant + alpelisib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 71-year-old male underwent right hemicolectomy for a T3N1 colon adenocarcinoma consistent with stage III disease. Tumor genotyping identified BRAF V600E and high microsatellite instability (MSI-H). Patient completed adjuvant FOLFOX for 6 months. Follow-up CTs and CEA remain without evidence of recurrence at 14 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "surgery (right hemicolectomy) followed by adjuvant FOLFOX", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman underwent right hemicolectomy for T3N0 colon adenocarcinoma. Pathology: MSI-H and BRAF V600E positive on tumor sequencing. Given high-risk features discussed in tumor board, adjuvant FOLFOX was recommended and initiated. To date there is no radiographic evidence of distant metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma (stage IV) involving lungs and cerebellum. Tumor profiling identified BRAF V600E and a high tumor mutational burden. Initially treated with pembrolizumab but developed radiographic progression with new brain lesions. Therapy changed to dabrafenib plus trametinib; extracranial disease decreased and the pulmonary nodules partially regressed. Brain metastases were managed with stereotactic radiosurgery and are radiographically stable.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab followed by dabrafenib + trametinib; stereotactic radiosurgery", "response": "progression on pembrolizumab; partial response to dabrafenib+trametinib; intracranial stabilization", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 71-year-old male with metastatic colorectal adenocarcinoma diagnosed after hepatic lesions were biopsied. Molecular panel: KRAS G12D detected; tumor characterized as MSI-H and TMB-high. He was started on FOLFOX plus bevacizumab; at 12-week restaging CT the liver lesions are unchanged in size consistent with stable disease. Plan is to continue current regimen.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man diagnosed with metastatic lung adenocarcinoma. Staging at diagnosis was IV with multiple enhancing brain metastases on MRI. Molecular testing identified EGFR L858R mutation; PD-L1 was 10%. He was started on osimertinib 80 mg daily as first-line targeted therapy and interval imaging demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with high-risk prostate adenocarcinoma, Gleason 4+4, presenting with back pain. Bone scan and CT show multiple sclerotic lesions consistent with osseous metastases. PSA at diagnosis was 112 ng/mL. He was started on androgen deprivation with leuprolide plus upfront docetaxel; later transitioned to enzalutamide after PSA rise. Recent imaging showed progression of known bone lesions.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 112 ng/mL", "treatment": "androgen deprivation therapy (leuprolide), docetaxel, then enzalutamide", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presented with headaches and multiple enhancing lesions on MRI. Staging consistent with stage IV disease. Molecular testing returned EGFR L858R activating mutation; PD-L1 tumor proportion score 5%. Patient was started on osimertinib 80 mg daily with early radiographic improvement \u2014 repeat CT at 8 weeks shows decrease in size of pulmonary and intracranial lesions. Plan to continue osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing returned EGFR L858R. PD-L1 tumor proportion score ~30%. Patient started first-line osimertinib 80 mg daily with radiographic shrinkage of pulmonary and hepatic lesions at 8 weeks consistent with a partial response. New small enhancing cerebellar lesion noted on MRI \u2014 brain metastasis under stereotactic radiosurgery planning.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with locally advanced pancreatic ductal adenocarcinoma, clinically staged as III. Germline testing identified a deleterious BRCA2 frameshift (BRCA2 c.6174delT). He received FOLFIRINOX induction followed by consolidation chemoradiation. Despite therapy the most recent CT shows local progression at the pancreatic head; CA19-9 rising. PD-L1 testing was not performed.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 c.6174delT (germline)", "biomarker": null, "treatment": "FOLFIRINOX followed by chemoradiation", "response": "progressive disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate adenocarcinoma and rising PSA. Germline testing returned a pathogenic BRCA2 variant. He was treated sequentially with abiraterone plus prednisone followed by docetaxel chemotherapy. PSA fell initially but new sclerotic bone lesions appeared on follow-up imaging consistent with a mixed response.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": null, "treatment": "abiraterone (with prednisone); docetaxel", "response": "mixed response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colorectal adenocarcinoma to the liver. NGS showed KRAS G12D and high microsatellite instability (MSI-H) with a high tumor mutational burden. After progression on FOLFOX plus bevacizumab he was switched to pembrolizumab and interval CT demonstrates a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab (after FOLFOX + bevacizumab)", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. MRI brain demonstrates two metastatic lesions; bone scan positive for multiple lytic lesions. Patient started osimertinib 80 mg PO daily and received palliative whole-brain radiation to symptomatic lesions. Interval CT at 8 weeks shows decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiation", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with sigmoid colon adenocarcinoma who underwent sigmoidectomy for a T3N1 lesion. Tumor testing reported MSI-H and IHC loss of MLH1/PMS2. KRAS mutation testing returned G12D. He completed adjuvant FOLFOX and surveillance CTs have shown no measurable disease at 18 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H (MLH1/PMS2 loss)", "treatment": "surgery (sigmoidectomy); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the left breast demonstrated invasive ductal carcinoma, HER2 amplified, ER/PR negative. Clinical stage cT3N1 (stage IIIB). NGS panel identified PIK3CA E545K. The patient received neoadjuvant TCH (docetaxel, carboplatin, trastuzumab) for six cycles followed by lumpectomy. Surgical pathology revealed no residual invasive carcinoma (ypT0N0) \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Biopsy confirmed EGFR L858R mutation. PD-L1 tumor proportion score 10%. Patient presented with multiple brain and bone metastases and received whole-brain radiation to symptomatic lesions. He was started on osimertinib 80 mg PO daily as first-line targeted therapy. Interim CT and bone scan show decrease in size of pulmonary nodules and improvement in osteoblastic lesions \u2014 assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiation", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with widely metastatic cutaneous melanoma. Tumor sequencing identified BRAF V600E; PD-L1 reported as <1%. He initiated dabrafenib plus trametinib and had clinical improvement, but progressed at 6 months with new pulmonary and brain metastases. Therapy was changed to nivolumab; most recent scans show stable disease on immunotherapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib; subsequently nivolumab", "response": "progression on targeted therapy; stable disease on nivolumab", "metastasis_site": "lungs, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with progressively worsening jaundice and weight loss found to have pancreatic ductal adenocarcinoma with extensive liver lesions and malignant ascites. Clinical stage IV at presentation. CA19-9 markedly elevated at 12,000 U/mL. Patient was clinically unfit for tumor genomic profiling; systemic therapy with FOLFIRINOX was initiated but repeat CT after two cycles showed increase in size and number of hepatic metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver, peritoneum (ascites)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma of the right shoulder with nodal disease and pulmonary metastases. NGS identified BRAF V600E. Patient was started on dabrafenib and trametinib; first follow-up PET/CT demonstrated partial response in the lung nodules. No prior checkpoint inhibitor therapy had been given.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 39-year-old with metastatic melanoma, BRAF V600E positive. Initially started pembrolizumab but had clinical progression with enlarging pulmonary nodules and new hepatic lesions; subsequently switched to dabrafenib/trametinib with mixed radiographic response (some pulmonary nodules shrink, liver lesions stable). PD-L1 by IHC 2%. Stage IV at diagnosis.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%", "treatment": "pembrolizumab followed by dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 57-year-old male with metastatic colon adenocarcinoma (stage IV) with multiple liver lesions. Tumor sequencing shows KRAS G12D; MSI testing reported MSS. He has been receiving FOLFIRI plus bevacizumab for 4 months with interval imaging showing no new lesions and minor shrinkage of dominant hepatic metastasis \u2014 overall stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFIRI plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with metastatic cutaneous melanoma. NGS demonstrated BRAF V600E mutation and tumor mutational burden reported as TMB-high. She initiated first-line combination immunotherapy with nivolumab plus ipilimumab. At 12-week assessment there was regression of hepatic metastases but new small brain metastases \u2014 overall described as a mixed response. Therapy was changed to dabrafenib and trametinib; systemic disease subsequently showed marked reduction while intracranial disease required stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "nivolumab + ipilimumab; then dabrafenib + trametinib; stereotactic radiosurgery for brain mets", "response": "mixed response (systemic partial response after switch; intracranial progression requiring SRS)", "metastasis_site": "liver; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 65-year-old male with metastatic colorectal adenocarcinoma to the liver diagnosed in late 2022. Staged as IV at presentation. Tumor sequencing identified KRAS G12D. Patient was started on FOLFOX with bevacizumab; interval imaging after three months showed decrease in hepatic lesions consistent with a partial response. After nine months there was radiographic progression in the liver and new peritoneal disease; plan to consider clinical trial. No MSI result uploaded to chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "initial partial response then progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma (stage IV) with BRAF V600E mutation and PD-L1 ~10% by IHC. Presents with bone lesions and a solitary cerebellar metastasis. Patient started combination targeted therapy with dabrafenib plus trametinib and received stereotactic radiosurgery to the brain lesion. Systemic disease showed an initial partial response, intracranial disease was mixed; later the patient was switched to ipilimumab plus nivolumab with overall disease stabilization.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; later ipilimumab and nivolumab", "response": "initial partial response extracranially, mixed intracranial response, later stable disease", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with HER2-positive metastatic breast cancer (IHC 3+, ER/PR negative) presented with new hepatic lesions on CT. Biopsy confirmed metastatic ductal carcinoma. Treatment initiated with trastuzumab, pertuzumab and docetaxel. Interval imaging after 3 cycles shows shrinkage of liver mets. Plan to continue combination therapy.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+); ER/PR negative", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male status post anterior resection for sigmoid adenocarcinoma, pathologic stage III (T3N1M0). Tumor was KRAS G12D mutant and microsatellite stable (MSI-stable). He completed adjuvant FOLFOX. On surveillance CT at 18 months there are multiple new hepatic lesions consistent with metastases and rising CEA \u2014 consistent with disease progression in the liver.", "output": {"cancer_type": "sigmoid adenocarcinoma (colon cancer)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgery (anterior resection); adjuvant FOLFOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with left invasive ductal carcinoma. Pathology: ER positive, PR positive, HER2 amplification; pathologic stage IIA (T2N0M0) after lumpectomy. Tumor panel identified a PIK3CA H1047R mutation. She completed adjuvant docetaxel and trastuzumab; currently on surveillance with no evidence of disease at 12 months.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel and trastuzumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old male who underwent right hemicolectomy for adenocarcinoma of the colon, staged pT3N1 (stage III). Tumor testing returned MSI-H and high tumor mutational burden. KRAS and NRAS reporting were deferred at the time of discharge. Adjuvant therapy consisted of FOLFOX for 6 months; upon early recurrence on surveillance CT in the liver he was enrolled on combination FOLFOX plus pembrolizumab and experienced stable disease for 4 months before progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOX; FOLFOX + pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presented with right upper quadrant pain. Biopsy of liver lesion confirmed metastatic colorectal adenocarcinoma. Molecular testing: KRAS G12D and TP53 R248Q identified; tumor was microsatellite stable (MSS). He was treated with FOLFOX plus bevacizumab. Interval CT after 3 months showed no size progression compared with baseline consistent with stable disease confined to the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D; TP53 R248Q", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 45-year-old female with left-sided, high-grade invasive ductal carcinoma. Core biopsy: HER2 amplification by FISH (HER2/CEP17 ratio 6.2); ER/PR negative. Nodal disease palpable in the axilla. Clinical stage recorded as IIIB. NGS panel detected a PIK3CA E545K mutation. She began neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab. After four cycles there is a measurable decrease in primary tumor and axillary nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with obstructing sigmoid mass found to be adenocarcinoma of the colon. CT shows multiple liver lesions consistent with metastatic disease (stage IV). He was started on FOLFOX plus bevacizumab. Report notes that extended RAS/BRAF panel was sent; no actionable mutations were identified on the initial report and MSI testing returned microsatellite stable. After three cycles the disease progressed radiographically with enlarging hepatic deposits.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old female with invasive ductal carcinoma of the left breast, ER+/PR+, HER2 IHC 0, clinically staged as IIA (pT2 N0) after lumpectomy and sentinel node biopsy. NGS identified PIK3CA H1047R. She completed adjuvant whole-breast radiotherapy and was started on tamoxifen. Six-month follow-up exam and imaging show no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2-negative (IHC 0)", "treatment": "lumpectomy, sentinel node biopsy, adjuvant radiotherapy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: Patient with cutaneous melanoma presenting with pulmonary nodules. Staged as metastatic (stage IV). Limited mutational panel did not reveal an actionable alteration and BRAF testing was non-diagnostic \u2014 no driver mutation identified. PD-L1 TPS was 80%. Started pembrolizumab 200 mg q3w; after 6 cycles PET/CT shows complete metabolic response of the lung lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 80%", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with pancreatic ductal adenocarcinoma complicated by peritoneal carcinomatosis. Germline testing returned a pathogenic BRCA2 mutation. She received modified FOLFIRINOX with a short-lived radiographic response followed by clinical progression of ascites; subsequently started on olaparib on a compassionate-use basis. Staging documentation in the chart is incomplete.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "modified FOLFIRINOX; olaparib", "response": "initial response then progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 39-year-old male with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E mutation; PD-L1 expression low/negative. He was started on combination dabrafenib and trametinib; initial response was impressive with reduction of hepatic lesions, but progressed after 7 months with new pulmonary nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 low/negative", "treatment": "dabrafenib and trametinib", "response": "initial partial response then progression", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/oncology report: Right breast core biopsy: invasive ductal carcinoma, inflammatory clinical presentation. IHC: HER2 3+; FISH confirms HER2 amplification. ER and PR negative. Clinical stage assigned as IIIB (inflammatory). Neoadjuvant regimen initiated \u2014 docetaxel with dual HER2 blockade (trastuzumab, pertuzumab). After three cycles there is marked reduction in erythema and tumor bulk but residual palpable disease remains.", "output": {"cancer_type": "breast cancer (invasive ductal, inflammatory)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with high-risk prostate adenocarcinoma (PSA 18 ng/mL, clinical stage T3bN0). He underwent radical prostatectomy followed by adjuvant external beam radiation therapy to the prostatic fossa. Post-treatment PSA is undetectable and there is no radiographic evidence of metastatic disease on CT and bone scan.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant external beam radiation therapy", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old female with a pigmented lesion on the back excised by dermatology. Pathology: superficial spreading melanoma, Breslow 1.2 mm, no ulceration; sentinel node negative \u2014 staged as I. BRAF V600E mutation detected on tumor PCR. Wide local excision performed with negative margins. No adjuvant therapy was recommended; patient is on dermatologic and surgical oncology surveillance.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, sentinel node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with prostate adenocarcinoma detected on PSA screening, clinical stage I (T1cN0M0). Underwent robot-assisted radical prostatectomy. Pathology confirmed organ-confined disease, postoperative PSA undetectable at 6 months. Targeted panel reported no actionable genomic alterations.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "robot-assisted radical prostatectomy", "response": "no evidence of disease (PSA undetectable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital summary: 72-year-old man with metastatic prostate adenocarcinoma with extensive sclerotic lesions in the spine and pelvis consistent with bone metastases. PSA at presentation was 72 ng/mL. He was started on androgen deprivation with leuprolide and oral abiraterone, with symptomatic improvement and stabilization of PSA. Next-generation sequencing not performed / no somatic mutations reported.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 72 ng/mL", "treatment": "leuprolide and abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the left breast with clinical T3N1 disease. Core biopsy: ER negative, PR negative, HER2 IHC 3+ consistent with HER2 amplification. She received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with concurrent trastuzumab, then underwent modified radical mastectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 paclitaxel + trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old woman with high-grade serous ovarian carcinoma stage IIIC with bulky omental and peritoneal disease. Germline testing identified a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; CA-125 fell from markedly elevated to within normal limits. She remains on maintenance olaparib with persistent radiologic complete response on CT surveillance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated at diagnosis (normalized on treatment)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum and omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic lung adenocarcinoma (stage IV) presented with progressive headaches. MRI brain demonstrated multiple enhancing lesions consistent with brain metastases. Tumor NGS identified EGFR L858R. PD-L1 reported at 10%. She was started on osimertinib 80 mg daily; after 3 months of therapy MRI shows interval decrease in size of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 48-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical T3N1M0 at presentation (cStage IIIA). Tumor was HER2 IHC 3+ and FISH-positive; ER and PR negative. She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for six cycles. She underwent surgery with complete pathologic response (pCR) in the breast and nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER-/PR-", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 47-year-old woman with HER2-positive metastatic breast cancer. Core biopsy confirmed invasive ductal carcinoma, ER+/PR+, HER2 amplification by FISH. Presents with newly identified hepatic lesions on CT consistent with liver metastases. She was started on first-line trastuzumab and pertuzumab in combination with paclitaxel and has had interval shrinkage of liver lesions (PR). No genomic sequencing performed.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab, paclitaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma diagnosed at laparotomy with omental caking and peritoneal implants; germline BRCA1 deleterious mutation confirmed. CA-125 was elevated at diagnosis. Classified as stage IIIC, she underwent optimal debulking followed by carboplatin and paclitaxel and is currently on maintenance olaparib with decreased peritoneal disease noted on CT \u2014 partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious germline mutation", "biomarker": "CA-125 elevated at diagnosis", "treatment": "debulking surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with metastatic pancreatic ductal adenocarcinoma, stage IV on initial CT with multiple liver lesions. CA 19\u20119 markedly elevated to 12,000 U/mL. Tumor panel reported no actionable alterations. She was started on gemcitabine plus nab\u2011paclitaxel; after four cycles the scans showed interval progression and worsening liver function.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA 19-9 markedly elevated", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with metastatic lung adenocarcinoma diagnosed 03/2023. Comprehensive NGS on the biopsy detected EGFR L858R. PD-L1 TPS was 10%. She was started on osimertinib 80 mg daily as first-line targeted therapy; symptomatic improvement noted and interval CT and MRI demonstrate reduction in size of pulmonary nodules and cerebellar lesion. Prior whole-brain radiation was given for symptomatic brain metastases; denosumab used for bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old M with metastatic colorectal adenocarcinoma who presented with progressive right upper quadrant pain. CT shows multiple new hepatic lesions and interval growth of pulmonary nodules consistent with metastatic disease. Molecular testing: KRAS G12D; microsatellite stable (MSS). Patient received FOLFOX plus bevacizumab; latest scan demonstrates progression with increase in size and number of liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic lung adenocarcinoma presented with weight loss and bone pain. CT chest/abdomen showed multiple hepatic and osseous lesions consistent with stage IV disease. Molecular testing returned KRAS G12C positive; PD-L1 expression >50% and TMB-high reported on NGS panel. He was started on pembrolizumab in combination with carboplatin and pemetrexed with a documented partial response after 3 cycles. On progression of a solitary liver lesion he was switched to sotorasib with ongoing clinical benefit.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "pembrolizumab with carboplatin and pemetrexed; later sotorasib", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed prostate adenocarcinoma referred for management. PSA was 18 ng/mL. Digital rectal exam was suspicious for extracapsular extension but bone scan was negative. He was started on leuprolide depot monthly and scheduled for radiotherapy planning. Clinician documents good PSA decline on therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation therapy); planned radiotherapy", "response": "PSA decline", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old female with progressive metastatic lung adenocarcinoma. NGS of the tumor detected EGFR L858R. PD-L1 TPS reported at 20%. Staging PET/CT demonstrates multiple cerebral and osseous lesions consistent with metastatic disease; overall stage IV. Patient was switched to osimertinib 80 mg daily after progression on first-line erlotinib. Interval CT chest and MRI brain at 8 weeks show decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib (after erlotinib)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (concise): Metastatic melanoma, BRAF V600E positive. Prior pembrolizumab discontinued for immune-related colitis. Started on dabrafenib + trametinib combination. Initial restaging after 8 weeks showed shrinkage of multiple pulmonary nodules and improvement in right frontal brain lesion after stereotactic radiosurgery, documented as partial response. On follow-up at 6 months there is radiographic progression in the lung with new pleural deposits; plan to discuss switching systemic therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (after pembrolizumab)", "response": "initial partial response then progression", "metastasis_site": "lung, brain, pleura"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma to the liver. Tumor testing returned MSI-H (dMMR) and BRAF V600E mutation. Given pembrolizumab as second-line therapy because of MSI-H status; follow-up CT shows marked decrease in size of several hepatic lesions consistent with partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H (dMMR)", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed lung adenocarcinoma presented with progressive headaches. Brain MRI demonstrated multiple enhancing lesions consistent with metastatic disease to the brain. Staging was clinical stage IV. Molecular testing identified an EGFR exon 19 deletion; PD-L1 tumor proportion score was 10%. He was started on osimertinib 80 mg daily and after 8 weeks had symptomatic improvement with a radiologic partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "41-year-old man underwent subtotal resection of a right temporal mass; pathology consistent with glioblastoma (WHO grade IV). MGMT promoter methylation testing returned positive. IDH1 immunostain was negative. He completed concurrent radiotherapy with temozolomide (Stupp protocol) but developed radiographic progression at 6 months and was referred for second-line options.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation positive", "treatment": "surgical resection; radiation with concurrent temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed invasive ductal carcinoma of the right breast. Tumor was ER 90%, PR 60%, HER2 negative (IHC 0). Pathology after lumpectomy and sentinel node biopsy: pT2N0 (stage IIA). Molecular testing reported PIK3CA H1047R. She completed adjuvant AC-T chemotherapy and was started on adjuvant letrozole. At 12-month follow-up there is no evidence of disease on imaging and exam.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "lumpectomy, sentinel node biopsy, adjuvant AC-T (doxorubicin/cyclophosphamide followed by paclitaxel), letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified (IHC 3+ / FISH positive). PIK3CA E545K identified on NGS panel. Patient received neoadjuvant combination therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles, followed by lumpectomy and adjuvant single-agent trastuzumab planned. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "ER positive, PR positive, HER2 amplification (IHC 3+ / FISH+)", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant); lumpectomy; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Biopsy of the left breast demonstrated invasive ductal carcinoma, ER positive, PR positive, HER2 3+ by IHC with FISH-confirmed HER2 amplification. Clinical stage at presentation was IIIB with fixed axillary disease. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel in combination with trastuzumab followed by lumpectomy; surgical pathology returned without residual invasive carcinoma (pathologic complete response). Adjuvant radiation was completed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab; surgery; radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal carcinoma presented with right upper quadrant pain. CT shows multiple liver lesions; biopsy confirms adenocarcinoma consistent with colon primary. Tumor testing is MSI-H and TMB-high; extended RAS and BRAF testing were reported as wild-type. Staged as IV disease. Given MSI-H, patient started pembrolizumab monotherapy with objective partial response at first reassessment.", "output": {"cancer_type": "colorectal carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presented with progressive right upper quadrant pain. Imaging confirmed multiple hepatic metastases. Colonoscopy primary biopsy: KRAS G12D mutation; CEA 150 ng/mL. MSI testing was microsatellite stable. He received palliative FOLFOX combined with bevacizumab but interval scans after 3 cycles documented disease progression in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 150 ng/mL", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Note: 45-year-old female with a 1.2 cm invasive ductal carcinoma of the left breast, pathology AJCC stage I. Tumor ER positive, PR negative, HER2 IHC 3+ with FISH confirmation. She underwent lumpectomy with negative sentinel lymph nodes and completed adjuvant whole-breast radiation; endocrine therapy with tamoxifen was initiated. No genomic panel was performed. At 12-month follow-up there is no radiographic evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "ER positive; PR negative; HER2 3+", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly diagnosed lung adenocarcinoma, clinical stage IV with multiple brain and bone metastases. Molecular testing returned positive for EGFR L858R. PD-L1 expression reported at 5%. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to a solitary cerebellar lesion. Interim CT chest/abdomen shows decrease in size of pulmonary nodules and no new extracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with metastatic breast cancer, ER+/PR+, HER2-amplified. Imaging shows multiple liver lesions consistent with metastatic disease. She was started on first-line trastuzumab and pertuzumab with docetaxel; tolerating therapy. PET-CT after 4 cycles shows decrease in size of hepatic metastases. Plan to continue maintenance trastuzumab/pertuzumab after stopping chemotherapy.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab and pertuzumab with docetaxel; maintenance trastuzumab/pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR positive, HER2 amplified (IHC 3+ / FISH positive). Molecular profiling identified a PIK3CA H1047R mutation. Clinical stage at presentation was IIIA with bulky ipsilateral axillary lymph node involvement. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab. Post-treatment MRI showed no residual enhancing mass and subsequent surgery demonstrated a pathologic complete response in the breast and axillary nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive, with metastatic deposits in the lungs and brain. Therapy was initiated with dabrafenib plus trametinib. After 8 weeks there was marked regression of pulmonary nodules and near-complete extracranial response, but new small cerebellar lesions were seen on MRI \u2014 overall a mixed response. Patient subsequently underwent stereotactic radiosurgery to the brain lesions.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old male diagnosed with stage IV lung adenocarcinoma harboring an EGFR L858R mutation. Baseline staging CT demonstrated multiple pulmonary nodules and lytic lesions in the thoracic spine; brain MRI confirmed several intracranial metastases. PD-L1 testing reported 2%. He was started on osimertinib 80 mg daily in March. Interval MRI shows decrease in size of brain lesions and improvement in bone pain. Assessment: partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 2%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman with metastatic pancreatic ductal adenocarcinoma presenting with multiple liver metastases. Germline testing revealed a pathogenic BRCA2 mutation. Baseline CA19-9 was markedly elevated. She received FOLFIRINOX with a partial radiographic response in the liver after four cycles and was transitioned to olaparib maintenance. On last follow-up she remains clinically stable with stable liver lesions on CT.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant (germline)", "biomarker": "elevated CA19-9", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "partial response to FOLFIRINOX then stable disease on olaparib", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with recurrent invasive ductal breast carcinoma, ER+/PR+, HER2 amplified by FISH. PET-CT shows multiple hypodense lesions in the liver consistent with metastases. No actionable mutations identified on commercial NGS panel. She was started on trastuzumab and weekly paclitaxel with good tolerability; recent imaging after 3 cycles shows decrease in size of hepatic lesions, reported as a partial response. Clinical stage recorded as IV.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab and paclitaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old with recurrent cutaneous melanoma presenting with multiple new pulmonary nodules and subcutaneous implants. PD-L1 testing returned 2% and tumor mutational burden reported as TMB-high (20 muts/Mb). Broad NGS panel did not identify actionable driver mutations. Patient was treated with combination immunotherapy (nivolumab plus ipilimumab) and has had an ongoing complete clinical and radiographic response on surveillance scans.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "TMB-high; PD-L1 2%", "treatment": "nivolumab + ipilimumab", "response": "complete response", "metastasis_site": "lung; subcutaneous tissue"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with localized prostate adenocarcinoma, Gleason 3+4, clinical stage II (cT2bN0M0). Pre-operative PSA 14 ng/mL. He underwent open radical prostatectomy; post-op PSA was undetectable. Short-course androgen deprivation therapy with leuprolide was given for 6 months as adjuvant therapy. No genomic sequencing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 14 ng/mL (pre-op); undetectable post-op PSA", "treatment": "radical prostatectomy; adjuvant leuprolide (ADT)", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Postoperative note: 59-year-old woman underwent right hemicolectomy for an obstructing colon mass. Final pathology: moderately differentiated adenocarcinoma, 6/14 nodes positive, pT3N2 (stage IIIC). Molecular panel shows KRAS G12D; tumor is microsatellite stable (MSS). She was referred for adjuvant chemotherapy and completed 12 cycles of FOLFOX (oxaliplatin, 5-FU, leucovorin). Surveillance CT at 6 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "surgery (right hemicolectomy); adjuvant FOLFOX (oxaliplatin/5-FU/leucovorin)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and was found to have multiple enhancing lesions on brain MRI. Biopsy of the primary lung lesion confirmed adenocarcinoma. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 5%. Patient was started on osimertinib 80 mg daily with marked symptomatic improvement and interval imaging at 8 weeks showing a partial response of both lung and intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 63-year-old male underwent Whipple for pancreatic head adenocarcinoma after neoadjuvant FOLFIRINOX. Pathology: invasive ductal-type pancreatic adenocarcinoma, 3.1 cm, 2/16 nodes positive, stage IIB. Molecular profile (NGS) identified KRAS G12D and TP53 R175H. No PD-L1 testing performed. Patient remains on surveillance; scans at 6 months show no distant disease but persistent postoperative changes.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": "KRAS G12D; TP53 R175H", "biomarker": null, "treatment": "neoadjuvant FOLFIRINOX; Whipple (surgical resection)", "response": "no evidence of distant disease (postoperative stable status)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation letter: 48-year-old man with metastatic cutaneous melanoma. BRAF V600E detected on tumor panel. PD-L1 by IHC low at 5%. He received first-line dabrafenib plus trametinib with marked regression of several subcutaneous nodules, but new small hepatic lesions appeared on interval CT \u2014 overall described as a mixed response. Discussed options including switch to checkpoint combination therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "mixed response", "metastasis_site": "liver, skin/subcutaneous"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male underwent urgent resection for an obstructing sigmoid mass. Pathology: moderately differentiated adenocarcinoma, pT3N1 (stage III). Tumor testing returned MSI-H and BRAF V600E positive on PCR/NGS. Completed adjuvant FOLFOX for 6 months and is now on surveillance with serial CEA and CT; current scans show no residual or recurrent disease.", "output": {"cancer_type": "colorectal adenocarcinoma (sigmoid)", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "surgical resection (sigmoid colectomy); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old woman with newly diagnosed invasive ductal carcinoma of the right breast. Tumor is ER-positive, PR-positive and HER2-negative by IHC. NGS panel identified a PIK3CA H1047R mutation. Pathology reported pT1cN1M0, consistent with stage IIA. She underwent breast-conserving surgery with sentinel lymph node biopsy followed by adjuvant radiation and was started on tamoxifen. Post-treatment PET/CT shows no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER-positive; PR-positive; HER2-negative", "treatment": "lumpectomy (breast-conserving surgery), sentinel lymph node biopsy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with high-grade serous ovarian carcinoma, stage IIIC, with extensive peritoneal carcinomatosis at presentation. Germline testing returned a pathogenic BRCA1 variant. She underwent interval debulking followed by adjuvant carboplatin and paclitaxel with bevacizumab maintenance. Follow-up CT shows stable peritoneal disease.", "output": {"cancer_type": "ovarian cancer", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": null, "treatment": "carboplatin and paclitaxel with bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging CT shows widespread disease consistent with stage IV with multiple brain and osseous lesions. Molecular testing returned EGFR L858R and an acquired T790M on repeat biopsy; PD-L1 reported at 10%. He was started on osimertinib with good symptomatic control but developed progression on the chest CT after 8 months. He was then enrolled on a second-line regimen combining carboplatin and pemetrexed with pembrolizumab. On first restaging after two cycles he had a partial response in the lung and decrease in brain lesion size.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin and pemetrexed with pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the right breast, ER-positive, PR-negative. HER2 FISH demonstrated HER2 amplification; PIK3CA E545K mutation identified on next-generation sequencing. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by lumpectomy. Pathology after surgery showed no residual invasive carcinoma.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-volume metastatic melanoma with BRAF V600E detected on PCR. Prior checkpoint blockade with ipilimumab followed by pembrolizumab resulted in progression. Baseline profiling noted TMB-high. Patient was transitioned to dabrafenib plus trametinib with interval CT showing partial response of hepatic and pulmonary metastases. Clinical stage IV.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "ipilimumab, pembrolizumab (prior); dabrafenib plus trametinib (current)", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: 61-year-old male underwent right hemicolectomy for an obstructing sigmoid mass. Final pathology: moderately differentiated adenocarcinoma, involvement of 3 of 15 nodes consistent with Stage IIIB. Tumor tested MSI-H by PCR. KRAS/BRAF mutation testing not performed at this time. He completed adjuvant FOLFOX and remains on surveillance with no radiographic evidence of recurrence at 14 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIB", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (right hemicolectomy); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation note: 63-year-old with metastatic cutaneous melanoma with multiple intracranial lesions and pulmonary nodules. PD-L1 ~10% on IHC and TMB-high reported. No actionable driver mutation was identified on the melanoma panel. Patient received combined ipilimumab + nivolumab and underwent stereotactic radiosurgery to two brain metastases. Imaging after 3 cycles demonstrates a mixed response with shrinkage of some lung nodules and growth of a cerebellar lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 10%; TMB-high", "treatment": "ipilimumab + nivolumab; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female diagnosed with stage I (pT1bN0M0) lung adenocarcinoma after CT-guided biopsy. Molecular testing returned EGFR L858R. She underwent right upper lobectomy with lymph node sampling and was started on adjuvant osimertinib 80 mg daily per discussion with thoracic oncology. Follow-up CT at 6 months shows no radiographic evidence of disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "I", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "right upper lobectomy; adjuvant osimertinib 80 mg daily", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male status post right hemicolectomy for T2N0 colon adenocarcinoma (stage I). MSI testing returned MSI-H. No adjuvant chemotherapy was recommended given stage and pathology. Somatic mutation panel results are pending and to date no actionable mutations have been reported.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy (surgery only)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with locally advanced left breast mass. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER negative, PR negative. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant doxorubicin/cyclophosphamide x4 cycles followed by weekly paclitaxel with concurrent trastuzumab, then left modified radical mastectomy. Surgical pathology reported no residual invasive carcinoma in breast or nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab; surgery (modified radical mastectomy)", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Biopsy molecular profile: BRAF V600E mutation; tumor is MSI-H and TMB-high. Initial therapy was FOLFOX plus bevacizumab with a good radiographic reduction in size of hepatic lesions, then transitioned to pembrolizumab given MSI-H status. Most recent CT shows partial response of liver metastases and improvement of tumor markers.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with metastatic colon adenocarcinoma presenting with multiple liver metastases. Tumor molecular profile: MSI-High and TMB-high. Patient started pembrolizumab 200 mg IV every 3 weeks as first-line immunotherapy. After 4 cycles there is overall decrease in size of dominant hepatic lesions but a new small peritoneal implant \u2014 radiology impression: overall stable disease. No actionable KRAS/NRAS/BRAF alterations reported on panel.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, initially staged IV with multiple liver lesions. Molecular testing returned KRAS G12D and MSI-high (MSI-H). Systemic therapy with FOLFOX plus bevacizumab was started; after 12 weeks imaging shows shrinkage of some lesions but overall stable disease by RECIST. CEA has decreased from baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 2.5 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER-positive, PR-negative; HER2 amplification by FISH. She underwent lumpectomy with sentinel node biopsy; final path pT2N0 (stage IIA). Completed adjuvant paclitaxel and trastuzumab and remains on routine surveillance with no evidence of disease.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-negative", "treatment": "lumpectomy with sentinel node biopsy, adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed lung adenocarcinoma, stage IV. MRI brain demonstrated a 1.8 cm cerebellar metastasis and CT chest shows multiple bilateral pulmonary nodules. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the brain lesion. First restaging CT at 8 weeks showed a 40% reduction in target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Procedure note / oncology summary: Patient with metastatic cutaneous melanoma harboring BRAF V600E. Initially received pembrolizumab for six months with mixed response; therapy was transitioned to targeted therapy with dabrafenib plus trametinib one month ago. Latest PET/CT shows stable pulmonary nodules but a persistent cerebellar metastasis requiring stereotactic radiosurgery. Overall assigned stage IV disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "brain (cerebellum), lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and postoperative note: 72-year-old male with Gleason 4+4 prostate adenocarcinoma treated with radical prostatectomy in 2021 followed by adjuvant external beam radiation. Pathologic stage reported pT3a N0 M0 (clinical stage III). On recent follow-up his PSA has risen from 0.1 to 1.2 over 6 months and a bone scan shows new focal uptake in the pelvis concerning for osseous metastasis. No genomic sequencing or PD-L1 testing was performed during workup. Patient was referred to medical oncology for systemic therapy consideration.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy, adjuvant radiotherapy", "response": "progression (biochemical recurrence with new bone lesions)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent pancreaticoduodenectomy (Whipple) for a pancreatic head adenocarcinoma. Final pathologic stage IB (T2N0M0). Germline BRCA1/2 testing was negative. No MSI or PD-L1 testing was performed. Adjuvant gemcitabine was planned; patient recovered uneventfully from surgery and was discharged with no documented metastatic disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IB", "gene_mutation": null, "biomarker": null, "treatment": "pancreaticoduodenectomy (Whipple); planned adjuvant gemcitabine", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "73-year-old man with metastatic castration-resistant prostate cancer, extensive symptomatic bone metastases. He was treated with androgen deprivation (leuprolide) and six cycles of docetaxel, then started on enzalutamide for rising PSA. Germline and somatic testing were negative for BRCA1/2 and no actionable mutations were identified. He received radium-223 for bone pain and palliative external beam radiation to a pelvic lesion. Clinical course over the last 6 months shows rising PSA and radiographic progression in the skeleton.", "output": {"cancer_type": "prostate adenocarcinoma (mCRPC)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (ADT); docetaxel; enzalutamide; radium-223; palliative radiotherapy", "response": "progressive disease (rising PSA and bone progression)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with newly diagnosed sigmoid colon adenocarcinoma with multiple hepatic lesions on CT, consistent with metastases. Formalin-fixed tumor testing demonstrated KRAS G12D mutation; MSI testing reported microsatellite stable (MSS). Clinical stage documented as stage IV. He was initiated on FOLFOX with bevacizumab. Restaging CT after 4 cycles shows no new lesions and minimal decrease in sum of target lesions \u2014 radiology reads as stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 64-year-old female with metastatic lung adenocarcinoma diagnosed 03/2023. Molecular testing identified EGFR L858R (exon 21). Baseline staging showed multiple bilateral pulmonary nodules and a 2.5 cm cerebellar metastasis. PD-L1 IHC 10%. Patient started osimertinib 80 mg daily in April with good tolerance. First CT at 8 weeks demonstrates decrease in target lesions consistent with a partial response; MRI brain shows reduction of cerebellar lesion. Continued on targeted therapy and surveillance MRI scheduled.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Initially treated with dabrafenib + trametinib achieving a partial response, but developed clinical and radiographic progression in the lungs and new brain metastases after 9 months; subsequently transitioned to nivolumab. CT chest shows multiple pulmonary nodules increasing in size.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; then nivolumab", "response": "initial partial response followed by progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with newly diagnosed metastatic lung adenocarcinoma. Staging CT showed multiple bilateral pulmonary nodules and lesions in the liver and brain consistent with metastases. Comprehensive NGS detected a KRAS G12C mutation; PD-L1 IHC was 60% and tumor mutational burden reported as high. He was started on first-line carboplatin and pemetrexed with pembrolizumab. After three cycles there is radiographic partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 60%; TMB-high", "treatment": "carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain; liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Liver biopsy confirmed adenocarcinoma consistent with colorectal primary. Comprehensive genomic profiling identified KRAS G12D; BRAF negative. MSI testing returned microsatellite stable (MSS). He was started on FOLFOX with bevacizumab and after three cycles CT scan demonstrated stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with stage IV lung adenocarcinoma; tumor testing identified EGFR L858R and PD-L1 10%. She was started on osimertinib and had an extracranial partial response but developed new brain metastases after 11 months with intracranial progression and received whole-brain radiation.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiation", "response": "initial partial response then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 67-year-old male with newly diagnosed lung adenocarcinoma. Biopsy confirms adenocarcinoma of the lung. Staging PET/CT shows multiple lesions in the brain and lytic lesions in the spine consistent with metastatic disease; clinical stage IV. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score is 15%. Patient started osimertinib 80 mg daily with symptomatic improvement. First restaging CT shows decrease in size of pulmonary and brain lesions \u2014 overall partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old with cutaneous melanoma found to harbor BRAF V600E on targeted testing. Patient presented with metastatic disease involving lung and brain (stage IV). He received dabrafenib plus trametinib with rapid extracranial complete response; brain lesions were treated with stereotactic radiosurgery and remain controlled. PD-L1 by IHC was 1%.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "complete response (extracranial)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: patient with metastatic melanoma started on targeted therapy after molecular profiling identified BRAF V600E. Therapy initiated with dabrafenib and trametinib; initial PET/CT demonstrates decreased FDG uptake in several nodal lesions. No explicit AJCC stage recorded in the outpatient note; sites of disease not enumerated beyond 'nodal lesions' in the report.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIA. Tumor is ER positive, PR positive and HER2 amplification was confirmed by FISH. She received neoadjuvant weekly paclitaxel with trastuzumab, followed by lumpectomy and adjuvant radiation. Surgical pathology reported marked treatment effect with no residual invasive carcinoma. No comprehensive genomic sequencing was performed.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel and trastuzumab, surgery, radiation", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old man with metastatic cutaneous melanoma. Initial treatment with pembrolizumab resulted in progression with new lytic lesions in the femur. Tumor testing showed BRAF V600E mutation and PD-L1 approximately 5%. He was switched to targeted therapy with dabrafenib plus trametinib and has had a decrease in bone pain and partial radiographic improvement of osseous metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "pembrolizumab (prior); dabrafenib and trametinib", "response": "progression on immunotherapy, partial response to targeted therapy", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, HER2 3+ by IHC and FISH amplified, ER 80% and PR 20%. NGS detected PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab followed by mastectomy; pathology reported a complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel + trastuzumab + pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic castration-resistant prostate adenocarcinoma, stage IV, with extensive osteoblastic bone metastases. Germline testing identified a deleterious BRCA2 mutation. He received initial androgen deprivation therapy with docetaxel, later progressed and was started on olaparib. Follow-up scans after 4 months on olaparib showed radiographic progression.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "androgen deprivation therapy and docetaxel; then olaparib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions consistent with metastases and staged IV. Tumor genotyping returned KRAS G12D. He was started on FOLFIRI with bevacizumab. After three months of combination therapy the CT shows overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, ER-negative/PR-negative, HER2 amplified by FISH. She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by modified radical mastectomy. Final pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on pre-op PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "neoadjuvant paclitaxel and trastuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presenting with weight loss and cough. Staging workup consistent with Stage IV disease; PET/CT shows bone and brain metastases. Comprehensive NGS returned EGFR exon 19 deletion; PD-L1 expression 10%. Patient started osimertinib 80 mg daily as first-line targeted therapy. CT at 8 weeks demonstrates a partial response with decreased size of the primary lesion and bone mets.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old with castration-resistant prostate cancer and worsening bone pain. Germline and somatic testing identified pathogenic BRCA2 alteration; no EGFR/ALK testing performed. He was started on the PARP inhibitor olaparib with treatment-related anemia but imaging after 12 weeks showed stable osseous disease and PSA rise was modest.", "output": {"cancer_type": "prostate cancer", "stage": null, "gene_mutation": "BRCA2", "biomarker": null, "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic colorectal adenocarcinoma diagnosed after workup of weight loss. CT shows multiple lesions in the right and left hepatic lobes consistent with liver metastases. Tumor profiling revealed KRAS G12D mutation; MSI testing reported microsatellite stable (MSS). He was started on palliative FOLFOX with bevacizumab. After 4 cycles the restaging CT demonstrated no significant change in size of hepatic lesions compared with baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative oncology note: 48-year-old woman with locally advanced invasive ductal carcinoma of the left breast (clinically T3N1). Core biopsy: ER positive, PR negative, HER2 amplified by FISH; PIK3CA E545K identified on panel. She completed six cycles of neoadjuvant therapy with trastuzumab, pertuzumab and docetaxel with excellent clinical response and proceeded to modified radical mastectomy last week. Surgical pathology reported no residual invasive carcinoma in the breast or nodes (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with right-sided invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH. Clinical stage IIIA (T2 N2 M0). She received neoadjuvant trastuzumab with weekly paclitaxel followed by lumpectomy and axillary node dissection; final pathology showed no residual invasive carcinoma (pCR). No comprehensive somatic NGS was performed.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "III A", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab and paclitaxel (neoadjuvant), surgery", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology consult: 68-year-old man with intermediate-risk prostate adenocarcinoma (clinical stage II) and baseline PSA 12 ng/mL. He received definitive external beam radiation combined with androgen deprivation therapy (leuprolide). At 18-month follow-up his PSA has risen and is consistent with biochemical recurrence; no metastatic lesions identified on current bone scan.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (baseline); rising PSA indicating biochemical recurrence", "treatment": "external beam radiation therapy and androgen deprivation therapy (leuprolide)", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 58-year-old male status post right hemicolectomy for adenocarcinoma of the colon, pathologic stage III (pT3N1). Tumor genotyping demonstrates KRAS G12D. Mismatch repair testing: microsatellite stable (MSS). He completed adjuvant FOLFOX (12 cycles). Surveillance CT scans at 6 and 12 months show no new lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and treatment summary: 67-year-old woman with high-grade serous ovarian carcinoma, extensive peritoneal carcinomatosis at presentation. Germline testing positive for a deleterious BRCA1 mutation. Clinical stage IIIC. Underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with excellent tumor marker decline; CA-125 normalized post-treatment. She was placed on olaparib maintenance and remains without radiographic evidence of disease at last follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (deleterious germline)", "biomarker": "CA-125 (normalized)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical/radiographic remission", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with pancreatic ductal adenocarcinoma found on staging laparoscopy to have diffuse peritoneal carcinomatosis. Disease was classified as Stage IV. He received first-line gemcitabine with nab-paclitaxel and had a palliative celiac plexus block for pain control. NGS attempted but failed due to low tumor cellularity and no molecular biomarkers were reported in the chart. Clinical course marked by worsening ascites and radiographic progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel; palliative celiac plexus block", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female, never smoker, presents with progressive cough. CT chest: 5.2 cm right lower lobe mass with multiple enhancing lesions in the cerebrum and lytic lesions in T8. Biopsy: lung adenocarcinoma. Molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 10%. Started on osimertinib 80 mg daily December 2024. Interval MRI shows decrease in size of brain mets and shrinkage of the primary lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a 3.2 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical stage IIA (T2N0). She underwent lumpectomy followed by adjuvant paclitaxel and trastuzumab; endocrine therapy with letrozole was initiated. No sequencing was performed. On follow-up exam and imaging there is no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy; paclitaxel; trastuzumab; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology note: 49-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB with fixed axillary nodes. Tumor is ER positive, PR negative, HER2 amplified (IHC 3+). Molecular testing identified a PIK3CA H1047R mutation. She was started on neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles. Post-treatment imaging shows significant reduction in primary mass and partial clinical response; axillary core remains PET-avid. Plan for surgery and continuation of HER2-targeted therapy.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; HER2 amplification (IHC 3+)", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with high-grade serous ovarian carcinoma, stage IIIC at initial debulking with diffuse peritoneal implants. Germline testing identified a pathogenic BRCA1 variant. Tumor HRD testing returned HRD-high. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel with partial radiographic response and was started on maintenance olaparib.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-high", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneal carcinomatosis"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology follow-up: 65-year-old female with high-grade serous ovarian carcinoma underwent optimal cytoreductive surgery. Intraoperatively there was diffuse peritoneal carcinomatosis with tumor implants on the omentum and pelvis (stage IIIC). Germline testing revealed a pathogenic BRCA1 variant. Post-op she completed 6 cycles of carboplatin and paclitaxel with CA-125 falling but persistent small-volume peritoneal disease on CT. Patient was started on maintenance olaparib with current status described as stable disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated (prior to treatment)", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female diagnosed with metastatic lung adenocarcinoma (stage IV) in 03/2024. Molecular testing returned EGFR L858R mutation and PD-L1 5%. Patient was started on osimertinib 80 mg daily in April and has had interval imaging showing marked decrease in size of pulmonary lesions and improvement of known bone metastases; brain MRI demonstrates small treated metastases. Clinical assessment: partial response to therapy, tolerating treatment well.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma. Biopsy sequencing showed BRAF V600E mutation. Tumor was MSI-H by PCR and TMB-high (22 mut/Mb). Staging was IV at diagnosis with multiple hepatic lesions. He was started on pembrolizumab monotherapy given MSI-H status. CT scans at 12 weeks demonstrated no new lesions and small decrease in some hepatic mets consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high (22 mut/Mb)", "treatment": "pembrolizumab monotherapy", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 78-year-old male with newly diagnosed metastatic prostate adenocarcinoma, Gleason 4+5=9. Bone scan shows multiple osseous metastases with severe pain. He was started on androgen deprivation therapy with leuprolide and received six cycles of docetaxel. PSA fell significantly; repeat imaging at 3 months shows stable osseous disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast carcinoma (clinical T2N2) treated in the neoadjuvant setting. Core biopsy showed invasive ductal carcinoma, ER+/PR+, HER2 amplified by FISH and next-generation sequencing identified a PIK3CA E545K variant. She received neoadjuvant paclitaxel with dual HER2 blockade (trastuzumab plus pertuzumab) for 12 weeks followed by lumpectomy and axillary dissection. Final pathology reports a pathologic complete response (pCR). No distant spread identified on PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA (clinical T2N2)", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; lumpectomy and axillary dissection", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with palpable right breast mass. Core biopsy: invasive ductal carcinoma, ER/PR negative, HER2 amplification by FISH. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by weekly paclitaxel with concurrent trastuzumab; surgical specimen showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER/PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide, paclitaxel, trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: 48-year-old woman with locally advanced invasive ductal carcinoma, ER positive, PR negative, HER2 amplified (FISH ratio 6.2). Clinical stage IIIB with skin involvement. Core biopsy also showed PIK3CA E545K mutation. She received 6 cycles of weekly paclitaxel with trastuzumab followed by mastectomy; final pathology reported no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab; mastectomy", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female diagnosed with stage IV lung adenocarcinoma in 2019. Initial genotyping identified EGFR L858R; on progression a repeat biopsy detected the resistance mutation T790M. PD-L1 by IHC was 2%. She started first-line erlotinib, progressed after 11 months, then was switched to osimertinib with a documented partial response. MRI at diagnosis showed brain metastases and PET identified bone involvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 2%", "treatment": "erlotinib; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated EGFR L858R mutation; PD-L1 by IHC was 10%. She was started on osimertinib 80 mg daily in January 2020. Interval brain MRI and CT chest/abdomen show shrinkage of the lung primary and multiple intracranial lesions \u2014 overall assessment: partial response. Staging: IV with known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma (Stage IV) with multiple hepatic metastases. Molecular testing revealed KRAS G12D mutation; tumor was MSI-high and TMB-high. He was started on FOLFOX plus bevacizumab with initial disease control but one dominant liver lesion progressed and he was switched to pembrolizumab. Current best overall response by RECIST is stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-high; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology report for a 70-year-old man: right hemicolectomy for adenocarcinoma of the ascending colon. Final path stage pT3N1 (Stage III). Tumor panel showed KRAS G12D. He completed adjuvant FOLFOX and is on surveillance with CT scans showing no residual disease. MSI status not available in the chart.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with history of right-sided colon adenocarcinoma. Post-op CT reveals multiple hepatic lesions consistent with metastases. Initial tumor sample was inadequate for extended genotyping (no actionable mutations reported). Mismatch repair testing showed proficient MMR (MSI-stable). He was started on FOLFOX plus bevacizumab; after two months imaging demonstrates interval increase in size of liver metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-stable (proficient MMR)", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma presented with new neurologic symptoms. Staging confirmed stage IV disease with brain and pulmonary metastases. NGS identified an NRAS Q61R mutation; BRAF testing was negative. PD-L1 was 10% on archival tissue. Treated with ipilimumab plus nivolumab; after three cycles MRI demonstrated progression in several brain lesions and enlarging pulmonary nodules.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 10%", "treatment": "ipilimumab and nivolumab", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology/treatment summary: 48-year-old woman with right breast invasive ductal carcinoma, clinical stage IIIA. Tumor testing: HER2 amplification by FISH, ER positive, PR negative. Received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks followed by mastectomy. Surgical pathology shows no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Medical oncology summary: 67-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IV at diagnosis with bulky peritoneal disease and liver implants. Germline testing positive for pathogenic BRCA1 mutation. CA-125 markedly elevated pre-treatment. She received neoadjuvant carboplatin and paclitaxel with bevacizumab, had interval debulking surgery, then started olaparib maintenance. Initial CT after chemotherapy showed partial response but progression of hepatic lesions at 9 months.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1 (pathogenic)", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel; bevacizumab; interval debulking surgery; olaparib maintenance", "response": "initial partial response then progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic castration-resistant prostate cancer presented with progressive bone pain. Bone scan shows multiple sclerotic metastases. Patient previously on androgen-deprivation therapy; transitioned to docetaxel chemotherapy. During first three cycles PSA rose and imaging demonstrated increasing osseous burden consistent with progression.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a 2.5 cm invasive ductal carcinoma of the left breast. Tumor was ER positive, PR negative, and HER2 amplified by FISH; NGS showed a PIK3CA E545K mutation. She underwent lumpectomy with sentinel node biopsy (T2N0M0, stage IIA) and received adjuvant paclitaxel followed by trastuzumab. Postoperative imaging and clinical exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive", "treatment": "lumpectomy, paclitaxel, trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed after biopsy of a right lower lobe mass. Staging workup consistent with stage IV disease with brain and osseous metastases. Molecular testing detected EGFR L858R; PD-L1 reported 1%. He was started on osimertinib 80 mg daily with an initial partial response on first CT at 8 weeks but interval MRI showed progression in the cerebellar lesion and new bone pain over 6 months.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with locally advanced invasive ductal carcinoma of the breast. Tumor is ER-positive, PR-negative and HER2-amplified by FISH. Clinical stage IIIA with involved axillary lymph nodes. She received neoadjuvant paclitaxel with trastuzumab followed by mastectomy; pathology showed good treatment effect with residual nodal disease. No somatic sequencing result available at this time.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant), followed by surgery", "response": "good clinical response / treatment effect (residual nodal disease)", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male found to have prostate adenocarcinoma on biopsy (Gleason 3+4). Clinical stage T1cN0M0 (stage I). PSA at diagnosis was 7.2 ng/mL. He underwent radical prostatectomy; final pathology showed organ-confined disease with negative margins. No systemic therapy was given and PSA is undetectable on 6-month post-op surveillance.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 7.2 ng/mL", "treatment": "radical prostatectomy", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma (stage IV) diagnosed in 2023. Molecular profiling returned positive for EGFR L858R. PD-L1 tumor proportion score was 10%. Baseline staging showed multiple brain metastases and osseous lesions. He was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and brain MRI at 8 weeks demonstrated a partial response with decrease in size of dominant lung lesion and regression of several brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with a 0.8 mm superficial spreading melanoma on the right forearm, Breslow 0.8 mm, sentinel node negative. Wide local excision performed; no adjuvant therapy recommended and patient is on routine dermatology follow-up with no clinical recurrence noted.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R and PD-L1 TPS 10%. He presented with headaches and an MRI showed multiple enhancing lesions consistent with brain metastases and a lytic lesion at T8 suspicious for bone metastasis. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval CT and brain MRI after 8 weeks demonstrate decrease in size of lung nodules and partial resolution of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with right-sided colon adenocarcinoma presenting with hepatic and pulmonary metastases. Pathology and molecular testing: BRAF V600E positive; tumor is MSI-H by PCR. Staged as IV. Treated with first-line FOLFOX plus bevacizumab. Interval imaging at three months demonstrates radiographic progression in the liver.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with metastatic invasive ductal carcinoma, HER2-positive, ER+/PR-. Biopsy of hepatic lesions confirmed breast primary with HER2 amplification by FISH and a concurrent PIK3CA H1047R mutation on NGS. Patient received first-line trastuzumab and pertuzumab with docetaxel; after six cycles restaging CT demonstrated progression in the liver and new ascites.", "output": {"cancer_type": "invasive ductal breast carcinoma (HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology: adenocarcinoma of the ascending colon, 4.2 cm, invades through muscularis propria into pericolic fat, 0/18 nodes involved \u2014 stage II (T3N0). MSI testing positive (MSI\u2011H). Patient underwent right hemicolectomy with curative intent; multidisciplinary tumor board recommended surveillance given MSI\u2011H and node negative status, no adjuvant chemotherapy planned. Recent CEA normal.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II (T3N0)", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy (surgical resection)", "response": "no evidence of disease on surveillance", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT consistent with stage IV disease with numerous osseous lesions and several enhancing brain metastases. Molecular panel returned positive for EGFR exon 19 deletion; PD-L1 TPS 10%. She was started on osimertinib 80 mg daily. Interval CT and MRI at 8 weeks show decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 TPS 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of colon adenocarcinoma with hepatic progression. Patient underwent right hemicolectomy in 2020; now has multiple liver lesions on CT consistent with metastases. NGS panel: KRAS G12D identified. MSI testing was not performed. Started on FOLFOX with bevacizumab; first restaging CT shows ~35% decrease in sum of target liver lesions consistent with a partial response. Clinical stage: IV with liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast mass biopsy: invasive ductal carcinoma, clinical stage II. Tumor is ER positive, PR positive and HER2 amplified by FISH. NGS panel detected a PIK3CA H1047R mutation. She received neoadjuvant therapy with docetaxel and carboplatin combined with trastuzumab for HER2-targeted therapy. Preoperative imaging showed a 60% reduction in tumor size; proceeded to lumpectomy.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT shows multiple low-density liver lesions consistent with metastases (stage IV). Molecular workup: MSI-H and TMB-high; tumor harbors BRAF V600E. Given MSI-H status he was started on pembrolizumab monotherapy. Follow-up CT at 6 months demonstrates marked shrinkage of liver metastases consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with newly metastatic prostate adenocarcinoma, castration-sensitive at presentation with extensive osseous disease. PSA on baseline labs was 220 ng/mL. He was started on leuprolide depot and received docetaxel 75 mg/m2 for 6 cycles with palliative external beam radiation to the sacrum. Repeat bone scan at 4 months demonstrates stable disease clinically and radiographically.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 220 ng/mL", "treatment": "leuprolide; docetaxel; palliative external beam radiotherapy", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old male with newly diagnosed lung adenocarcinoma. Molecular testing returned EGFR L858R mutation. PD-L1 TPS was 5%. Staging workup demonstrates multiple enhancing lesions in the cerebellum and lytic lesions in the thoracic spine consistent with metastatic disease. Clinical stage: IV. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant cerebellar lesion. At first restaging CT at 8 weeks there is a decrease in size of pulmonary and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain (cerebellum), bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with newly diagnosed metastatic colorectal adenocarcinoma (stage IV) presenting with multiple bilobar liver lesions. Tumor profiling: BRAF V600E positive, KRAS wild-type, MSI-stable. Started first-line FOLFOX plus bevacizumab. After 4 cycles CT shows interval progression in the liver and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-stable; CEA elevated", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with high-grade serous ovarian carcinoma, optimally debulked at laparotomy (stage IIIC) with diffuse peritoneal carcinomatosis noted intraoperatively. CA-125 was markedly elevated pre-op and has declined to normal range following six cycles of adjuvant carboplatin and paclitaxel. PARP inhibitor maintenance was discussed but germline/somatic BRCA testing pending at last visit.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevation (normalized after chemo)", "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "complete clinical response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant evaluation: 48-year-old woman with locally advanced invasive ductal breast carcinoma, clinical stage IIIB. Tumor is ER positive, PR negative and shows HER2 amplification by FISH. NGS identified a PIK3CA E545K mutation. She received neoadjuvant docetaxel combined with carboplatin plus trastuzumab and pertuzumab and subsequently underwent mastectomy; final pathology demonstrated a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (neoadjuvant); surgery", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-resistant prostate adenocarcinoma. Bone scan demonstrates multiple sclerotic lesions in the spine and pelvis consistent with osseous metastases (stage IV). He was treated initially with androgen deprivation therapy followed by docetaxel; upon progression he received enzalutamide but has clinically progressive disease with rising PSA and new painful vertebral lesions.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy; docetaxel; enzalutamide", "response": "progressive disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. He underwent right hemicolectomy for obstructing tumor; pathology confirmed metastatic disease to the liver on staging CT. Molecular testing shows KRAS G12D mutation; NRAS and BRAF wild-type. MSI testing reported microsatellite stable. Systemic therapy initiated with FOLFIRI plus bevacizumab. Interval imaging and rising CEA indicate new hepatic lesions consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic cutaneous melanoma. Staging PET/CT demonstrated innumerable pulmonary nodules and multiple liver lesions; overall stage IV. Tumor sequencing identified a BRAF V600E mutation and PD-L1 tumor proportion score of 5%. He was started on targeted therapy with dabrafenib and trametinib. After six months on therapy repeat imaging showed new hepatic lesions and enlargement of existing metastases consistent with disease progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed metastatic colorectal adenocarcinoma presenting with multiple pulmonary nodules. He was started emergently on FOLFOX plus bevacizumab while molecular profiling is pending; RAS and BRAF results not yet available. After three cycles there is radiographic progression in the lungs.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology: 45-year-old woman underwent left mastectomy for invasive ductal carcinoma. Tumor is ER positive, PR positive and HER2 3+ by IHC. Clinical stage recorded as IIIA (T2 N2 M0). Tumor NGS shows PIK3CA H1047R. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with marked clinical shrinkage; surgical specimen reveals no residual invasive carcinoma \u2014 pathologic complete response. No evidence of distant spread on pre-op imaging.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER+, PR+", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic melanoma. BRAF V600E mutation was detected on tumor genotyping. He started on dabrafenib plus trametinib and had complete regression of multiple cutaneous lesions, but after 9 months developed new pulmonary nodules. Therapy was changed to pembrolizumab; best response to checkpoint blockade was stable disease.", "output": {"cancer_type": "melanoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: Patient is a 46-year-old man with cutaneous melanoma of the left forearm, stage IIIC after wide local excision and positive sentinel node. Adjuvant nivolumab was initiated. Comprehensive tumor panel did not identify BRAF, NRAS, or KIT mutations; PD-L1 testing was not performed. Most recent PET/CT demonstrates no evidence of disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab (adjuvant)", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 54-year-old man with metastatic cutaneous melanoma. Molecular testing identified BRAF V600E; NRAS wild-type. PD-L1 by IHC was 10% and tumor mutational burden reported as high. He was started on combination targeted therapy with dabrafenib and trametinib with excellent symptomatic improvement of an ulcerating primary; stereotactic radiosurgery was performed for a single 8 mm cerebellar metastasis. Follow-up imaging planned in 8 weeks.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%; TMB-high", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": null, "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female presented with obstructive jaundice. CT demonstrates a pancreatic head mass with peritoneal nodularity; biopsy consistent with pancreatic ductal adenocarcinoma. Staging consistent with metastatic (stage IV) disease. CA19-9 markedly elevated. She was initiated on gemcitabine with nab-paclitaxel; after two cycles her performance status declined and repeat imaging showed interval progression with increase in peritoneal disease and biliary obstruction. No molecular testing or PD-L1 testing was performed on the specimen.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman underwent lumpectomy for a 2.4 cm invasive ductal carcinoma. Pathology: ER+/PR+, HER2 negative, PIK3CA mutation detected on panel. Tumor staged as IIA (T2N0). She completed adjuvant whole-breast radiation and was started on adjuvant letrozole. At 6-month follow-up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA mutation", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy, adjuvant radiation, letrozole", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions on CT and an elevated CEA. Tumor NGS reported KRAS G12D. Mismatch repair testing was not yet available in the chart. He received first-line FOLFOX plus bevacizumab with radiographic stable disease after three months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV, liver-predominant disease. Tumor sequencing returned BRAF V600E and demonstrated MSI-H with TMB-high; PD-L1 was 5%. He was started on first-line pembrolizumab given the MSI-H status but progressed after 4 months and was transitioned to encorafenib plus cetuximab. Recent CT shows enlarging hepatic lesions consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high; PD-L1 5%", "treatment": "pembrolizumab; encorafenib and cetuximab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female presenting with de novo metastatic breast cancer. Core biopsy: invasive ductal carcinoma, ER/PR negative, HER2 amplified by FISH. Staging PET/CT shows multiple sclerotic bone lesions. She received carboplatin and paclitaxel in combination with trastuzumab and pertuzumab; now on maintenance trastuzumab. Interval scans after 4 cycles show stable osseous disease clinically and radiographically.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "carboplatin and paclitaxel with trastuzumab and pertuzumab; maintenance trastuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with T3N1M0 sigmoid colon adenocarcinoma. Tumor NGS identified KRAS G12D and mismatch repair testing was intact (MSI-stable). He underwent sigmoid resection with lymphadenectomy followed by adjuvant FOLFOX chemotherapy; surveillance scans currently show no evidence of disease.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgery; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV at presentation. Liver-dominant metastases on CT with multiple lesions in both lobes. Tumor genotyping showed KRAS G12D mutation; microsatellite testing returned MSS. First-line FOLFOX plus bevacizumab was given. After 6 cycles there is radiographic progression in the right hepatic lobe and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with biopsy-proven lung adenocarcinoma. Molecular testing detected EGFR L858R. PD-L1 tumor proportion score reported at 10%. Staging CT/MRI consistent with metastatic disease including cerebellar lesions and a lytic T7 vertebral lesion \u2014 overall stage IV. Patient was started on osimertinib 80 mg daily as first-line targeted therapy. Interval imaging at 3 months demonstrates decrease in size of intracranial and osseous lesions with clinical improvement in pain, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old woman with locally advanced invasive ductal carcinoma of the breast. Tumor is ER positive, PR positive and HER2 3+ by IHC with HER2 amplification confirmed by FISH. Clinical stage IIIB with chest wall fixation. She received neoadjuvant paclitaxel with trastuzumab and proceeded to mastectomy. Surgical pathology showed residual invasive carcinoma; downstaging from pre-treatment size but not a complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab; mastectomy", "response": "partial pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic lung adenocarcinoma diagnosed in 2023. Biopsy confirmed adenocarcinoma; molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 10%. Staging at diagnosis was IV with multiple brain and bone lesions on MRI and PET. Patient started osimertinib 80 mg daily in October \u2014 after 10 weeks imaging shows decrease in size of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiation oncology summary and systemic therapy record: 45-year-old woman with metastatic melanoma to brain treated initially with surgical resection of a left parietal lesion followed by fractionated brain radiation. Tumor genotyping identified BRAF V600E. She received dabrafenib plus trametinib with an initial partial response in extracranial disease but developed new progressive intracranial lesions after 5 months. PD-L1 testing showed 5% expression. Patient was transitioned to combination ipilimumab and nivolumab for progressive disease in the CNS.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib (then switched to ipilimumab + nivolumab)", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with newly diagnosed lung adenocarcinoma. Staging workup demonstrated stage IV disease with multiple brain and bone metastases. Molecular testing reported EGFR L858R on tumor NGS and PD-L1 5% by IHC. He was started on osimertinib 80 mg daily; interval imaging after 8 weeks showed a partial response with reduction in both pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer (mCRPC). PSA at presentation 150 ng/mL. Prior androgen-deprivation therapy followed by progression with symptomatic bone pain and multiple sclerotic lesions on bone scan consistent with osseous metastases. Germline and somatic testing reported a deleterious BRCA2 frameshift (BRCA2 c.6174delT). He was started on olaparib after failing enzalutamide; after 3 months on olaparib the patient had a partial radiographic response and PSA declined by 60%.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 c.6174delT", "biomarker": "PSA 150 ng/mL (declined 60% on treatment)", "treatment": "olaparib (after ADT and enzalutamide)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology and molecular report: Right hemicolectomy for adenocarcinoma of the colon \u2014 pT3 N1 (stage III). Tumor testing detected KRAS G12D. MSI testing returned microsatellite stable (MSS). Patient completed adjuvant FOLFOX x6 and surveillance CT at 12 months shows no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative report: 66-year-old man underwent radical prostatectomy for organ-confined prostate adenocarcinoma, Gleason 3+4. Final pathologic stage pT2b (stage II) with negative margins. No molecular testing was performed. No adjuvant therapy planned.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": "no adjuvant therapy planned; post-op evaluation without evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58 y/o M with metastatic colon adenocarcinoma to the liver. KRAS codon 12 mutation (G12D) identified on prior NGS. Patient started on FOLFOX + bevacizumab in October. Latest restaging shows hepatic lesions largely unchanged in size compared with baseline \u2014 overall stable disease. MSI testing returned microsatellite stable. Patient remains on treatment with plan to continue until progression or toxicity.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with new diagnosis of glioblastoma (WHO grade IV) after subtotal resection of a left temporal mass. Patient proceeded with standard of care: concurrent radiation with temozolomide followed by adjuvant temozolomide. MGMT methylation status pending; no actionable mutations reported in the operative note. Surveillance MRI at 4 months post-RT demonstrates interval enlargement of enhancing disease consistent with progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "maximal safe resection; radiation therapy with concurrent temozolomide; adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic castration-resistant prostate cancer. Germline testing identified a deleterious BRCA2 mutation. After prior ADT and docetaxel with clinical progression, he was started on olaparib 300 mg twice daily. At 3-month follow-up PSA fell by ~50% and bone scan showed improvement of several osseous lesions consistent with a partial response. Metastatic disease predominantly in the skeleton.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 deleterious germline mutation", "biomarker": null, "treatment": "olaparib", "response": "partial response (PSA decline and bone scan improvement)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with metastatic colon adenocarcinoma to the liver. Tumor was reported MSI-H on immunohistochemistry and TMB-high on sequencing. First-line FOLFOX plus bevacizumab produced stable disease for 4 months but progressive hepatic growth prompted switch to pembrolizumab monotherapy for MSI-H disease, with interval shrinkage of dominant hepatic lesion on restaging.", "output": {"cancer_type": "metastatic colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX and bevacizumab (first-line); pembrolizumab (second-line)", "response": "stable disease on FOLFOX/bevacizumab; partial response to pembrolizumab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47F presenting with T2N1M0 invasive ductal carcinoma of the left breast (clinical stage IIB). Tumor is ER positive, PR positive and HER2 amplified by FISH. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab. Pathology at lumpectomy showed no residual invasive disease (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient status post low anterior resection for sigmoid colon adenocarcinoma, pathologic stage III (T3N1). Tumor testing returned MSI-H and a BRAF V600E mutation. The patient completed 6 months of adjuvant FOLFOX chemotherapy and remains on routine surveillance with CTs showing no recurrent or metastatic disease at 12 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed 03/2023. Molecular testing returned EGFR L858R. Staging at diagnosis was IV with multiple brain and bone lesions on MRI and PET/CT. PD-L1 tumor proportion score 15%. He was started on osimertinib 80 mg daily in January 2024 with interval CT and brain MRI showing a radiographic partial response after two months of therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colon adenocarcinoma, initially stage IV, presented with liver and peritoneal disease. Molecular testing revealed BRAF V600E and MSI-H. He received frontline FOLFOX plus bevacizumab with initial disease control, then was transitioned to pembrolizumab due to the MSI-H status; most recent CT shows stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the left breast demonstrated invasive ductal carcinoma, ER negative, PR negative, HER2 3+ by IHC and confirmed HER2 amplification by FISH. Clinically T3N2M0; multidisciplinary team recommended neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab). Patient completed 6 cycles and proceeded to mastectomy \u2014 final pathology shows no residual invasive tumor (pCR).", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP) followed by mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Baseline staging showed multiple pulmonary nodules and two liver lesions. PD-L1 expression was 5%. He received first-line dabrafenib plus trametinib, achieving a partial response for about 9 months, followed by systemic progression; immunotherapy with pembrolizumab was initiated and produced a period of disease stability prior to further progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later pembrolizumab", "response": "initial partial response then progression", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Cutaneous melanoma of the right forearm, Breslow depth 2.3 mm with ulceration, clinically staged as Stage II. Wide local excision with 1 cm margins was performed. Molecular testing was deferred and is not available in the record. No adjuvant systemic therapy given; patient remains clinically disease-free at 18-month follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of right breast mass: invasive ductal carcinoma, ER 90%, PR 30%, HER2 IHC 3+ with FISH-confirmed HER2 amplification. NGS panel detected PIK3CA H1047R. Clinical staging was cT2N2M0 (stage IIIA). Patient received neoadjuvant dose-dense doxorubicin/cyclophosphamide x4 then paclitaxel with concurrent trastuzumab; imaging showed reduction in tumor dimensions prior to surgery consistent with a partial response. Patient proceeded to lumpectomy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "doxorubicin/cyclophosphamide then paclitaxel with trastuzumab (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic: 45-year-old man with metastatic cutaneous melanoma. Molecular testing positive for BRAF V600E. Tumor mutational burden reported as TMB-high. He started combination targeted therapy with dabrafenib and trametinib after diagnosis of progressive disease with multiple hepatic and pulmonary metastases. After two cycles there is a measurable reduction in target lesions consistent with partial response on CT.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female presented with progressive dyspnea. Workup revealed stage IV lung adenocarcinoma with EGFR L858R at diagnosis and acquired T790M on repeat biopsy. PD-L1 by IHC was 10%. She received first-line erlotinib with initial control but developed brain and bone metastases; therapy was switched to osimertinib with subsequent partial response on interval imaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib followed by osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical summary: Patient with metastatic castration-resistant prostate cancer, known germline BRCA2 mutation. Prior therapy included ADT and docetaxel. Started on olaparib with subsequent PSA stabilization; imaging shows sclerotic lesions in the thoracic spine. PD-L1 testing not performed.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": null, "gene_mutation": "BRCA2", "biomarker": null, "treatment": "olaparib", "response": "stable disease (PSA stabilization)", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic colorectal adenocarcinoma with multiple liver metastases on CT. Tumor genotyping identified a KRAS G12D mutation. She was treated with FOLFOX plus bevacizumab and achieved disease stabilization for approximately 8 months before maintenance 5-FU was continued. No BRAF V600E or NTRK fusions were detected.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab (maintenance 5-FU)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with recurrent metastatic invasive ductal carcinoma of the breast. Core biopsy: HER2 IHC 3+ with confirmed HER2 amplification by FISH. ER/PR negative. FoundationOne identified PIK3CA H1047R mutation. Staging consistent with Stage IV disease with multiple hepatic and osseous lesions. Treated with first-line docetaxel in combination with trastuzumab and pertuzumab. After 4 cycles the patient had mixed clinical improvement and radiographic stable disease, subsequently converted to a partial response on follow-up imaging.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "docetaxel + trastuzumab + pertuzumab", "response": "stable disease -> partial response", "metastasis_site": "liver; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left breast invasive ductal carcinoma, clinically T2N2 \u2014 overall stage IIIA. Tumor is ER-positive, PR-positive and HER2 amplified (IHC 3+, FISH positive). FoundationOne NGS identified a PIK3CA E545K mutation. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) and then lumpectomy; surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed on CT-guided biopsy of the right upper lobe. Molecular testing returned EGFR L858R. Baseline staging showed multiple small cerebral metastases on MRI. PD-L1 tumor proportion score reported at 30%. He was started on osimertinib 80 mg daily and at the 8-week scan there is a decrease in size of the dominant RUL mass and shrinkage of brain lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with documented BRAF V600E mutation. Staging demonstrated extensive nodal and pulmonary involvement at diagnosis; PD-L1 was <1%. Patient was treated with dabrafenib plus trametinib with marked symptomatic improvement and reduction in target lesions (partial response), but developed new brain metastases after 9 months with radiographic progression in the CNS.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib", "response": "initial partial response followed by progression (brain)", "metastasis_site": "lung; lymph nodes; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic castration-resistant prostate cancer with extensive symptomatic bone disease. Germline testing identified BRCA2 loss consistent with HRR deficiency. After progression on docetaxel and androgen-deprivation therapy, he was started on olaparib with stabilization of disease and a decline in PSA noted over three months.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "HRR-deficient", "treatment": "olaparib (after docetaxel)", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed metastatic castration-sensitive prostate adenocarcinoma, Gleason score 9. Bone scan showed multiple osseous metastases. Baseline PSA 250 ng/mL. Patient started on androgen deprivation therapy with leuprolide and received 6 cycles of docetaxel. No tumor genomic testing performed. PSA fell to 40 ng/mL and follow-up CT showed no new lesions; disease considered stable on current therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 250 ng/mL (baseline)", "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment for a 48-year-old with left invasive ductal carcinoma of the breast. Tumor was ER-positive, PR-negative and HER2 amplification confirmed by FISH. Clinical staging was IIIB with inflammatory features. She received dose-dense doxorubicin and cyclophosphamide x4 followed by paclitaxel plus trastuzumab, then proceeded to mastectomy. Final pathology reported a complete pathologic response. No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-negative", "treatment": "dose-dense doxorubicin/cyclophosphamide then paclitaxel + trastuzumab", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 52-year-old man with metastatic cutaneous melanoma (stage IV) found to harbor BRAF V600E. Began dabrafenib with trametinib in July with rapid tumor shrinkage but at 6 months developed new pulmonary nodules and leptomeningeal disease consistent with progression. He was switched to pembrolizumab; however, subsequent scans and MRI show interval progression in the brain and lungs.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib; pembrolizumab", "response": "progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, initially treated with pembrolizumab. Baseline testing showed BRAF V600E mutation and high tumor mutational burden (TMB\u2011high). After an initial partial response on immunotherapy, systemic progression was documented and patient was transitioned to dabrafenib plus trametinib combination; subsequent imaging showed mixed response with progression in the liver and new brain metastases.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab then dabrafenib plus trametinib", "response": "initial partial response then progression", "metastasis_site": "liver and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with de novo metastatic breast cancer. Liver biopsy: invasive ductal carcinoma, HER2 3+ by IHC, ER negative, PR negative. NGS identified PIK3CA H1047R. Staging consistent with stage IV disease with multiple liver lesions and sclerotic bone metastases. She received first-line trastuzumab, pertuzumab and docetaxel with an initial partial response; after 10 cycles CT shows progression and therapy was changed to ado-trastuzumab emtansine (T-DM1).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel; later ado-trastuzumab emtansine (T-DM1)", "response": "progression after initial partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with widely metastatic prostate adenocarcinoma. Bone scan and MRI show multiple osseous metastases throughout the axial skeleton. Baseline PSA was 120 ng/mL. He was started on androgen deprivation with leuprolide depot and abiraterone plus low-dose prednisone. After three months PSA has fallen and symptoms are improved \u2014 clinical status consistent with stable disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 120 ng/mL (baseline)", "treatment": "leuprolide and abiraterone", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old with metastatic colorectal adenocarcinoma. Stage IV at diagnosis with multiple bilobar liver lesions. Tumor testing: KRAS G12D; microsatellite stable. Baseline CEA elevated. Started on FOLFOX with bevacizumab. Interval imaging demonstrates stable disease after 3 months of therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable; elevated CEA", "treatment": "FOLFOX with bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Imaging consistent with stage IV disease with multiple brain and bone lesions. Comprehensive NGS returned EGFR L858R mutation; PD-L1 reported at 10%. Patient started osimertinib 80 mg PO daily in March 2024. First restaging CT and MRI at 8 weeks showed decrease in size of pulmonary and cerebral lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with metastatic colon adenocarcinoma, diagnosed after hepatic lesions were found on surveillance. Biopsy confirmed colon primary; KRAS G12D was identified on NGS. Baseline CT shows multiple liver metastases. He was started on FOLFOX with bevacizumab. After 3 months on therapy the disease is radiographically stable with minor decrease in size of some hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX with bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 58-year-old woman with metastatic cutaneous melanoma. BRAF V600E mutation identified on tumor sequencing; PD-L1 was reported as negative. She received first-line dabrafenib plus trametinib, but after six months CT and brain MRI showed new hepatic lesions and a cerebellar metastasis with rising LDH. Impression: disease progression; plan to switch to ipilimumab/nivolumab.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 negative", "treatment": "dabrafenib and trametinib (initial); plan ipilimumab/nivolumab", "response": "progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma, BRAF V600E\u2013positive. Baseline profiling showed high tumor mutational burden and PD-L1 10%. He presented with symptomatic brain metastases and started on combination dabrafenib and trametinib; pembrolizumab was added after a mixed systemic response. Systemic disease initially had a partial response but intracranial lesions progressed despite treatment.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high; PD-L1 10%", "treatment": "dabrafenib + trametinib; pembrolizumab added", "response": "initial partial response systemically with intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic colon adenocarcinoma presenting with multiple liver lesions. Tumor NGS shows KRAS G12D mutation. MSI testing returned MSI-H and tumor mutational burden reported as TMB-high (18 mut/Mb). He was started on FOLFOX as first-line systemic chemotherapy; restaging after 4 cycles showed stable disease in the hepatic lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high (18 mut/Mb)", "treatment": "FOLFOX", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIA (T2 N2 M0). Tumor markers: ER negative, PR negative, HER2 amplification by FISH. NGS identified a PIK3CA H1047R mutation. She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks followed by lumpectomy and sentinel node dissection; surgical pathology reported a pathologic complete response (pCR). No distant metastases identified on staging PET-CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 54-year-old man with metastatic cutaneous melanoma. Molecular testing detected BRAF V600E. Baseline PD-L1 by IHC was 5% and tumor sequencing reported high TMB. He was treated initially with targeted therapy (dabrafenib + trametinib) which produced a rapid extracranial partial response but he developed new brain metastases after 6 months. He was subsequently transitioned to combination immunotherapy with nivolumab and ipilimumab. Overall the course has been described as a mixed response with intracranial progression and extracranial improvement.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib + trametinib (targeted) then nivolumab + ipilimumab (immunotherapy)", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma. CT abdomen shows multiple hepatic lesions consistent with liver metastases. Tumor sequencing identified KRAS G12D; MSI testing reported microsatellite stable. Started on FOLFOX plus bevacizumab. After four cycles there is interval progression in size and number of liver mets compared with baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX; bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: Patient with metastatic melanoma, BRAF V600E positive, initially started on dabrafenib and trametinib combination therapy. Baseline staging showed liver and brain metastases. After an initial mixed response, most recent MRI and CT show interval growth of hepatic lesions and new brain mets consistent with progression; plan is to discontinue BRAF/MEK inhibitors and consider immunotherapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Notes: 49F with bulky left breast mass, core biopsy = invasive ductal carcinoma. ER strongly positive, PR positive, and HER2 IHC 3+ with confirmed HER2 amplification on FISH. Nodal ultrasound and MRI place disease at clinical stage IIIA (T2N2). NGS found a PIK3CA H1047R mutation. Patient received neoadjuvant docetaxel with trastuzumab and pertuzumab; underwent lumpectomy with sentinel node dissection and achieved pathologic complete response. No distant mets identified.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, trastuzumab and pertuzumab; surgery", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Breast oncology note: 48-year-old female with a 3.2 cm palpable mass in the right breast. Core biopsy: invasive ductal carcinoma, ER positive, PR positive. HER2 amplified by FISH. Clinical stage II (T2N0M0). She received neoadjuvant weekly paclitaxel with trastuzumab for 12 weeks prior to surgery. She underwent lumpectomy and sentinel node biopsy; pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging imaging.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab followed by lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with biopsy-proven invasive ductal breast carcinoma, clinical stage IV at presentation. Tumor is ER-positive, PR-negative and HER2-amplified by FISH. PET-CT showed multiple hepatic lesions and lytic foci in the pelvis. She was started on first-line trastuzumab, pertuzumab and paclitaxel with interval decrease in size of liver lesions after three cycles consistent with a partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-positive; PR-negative", "treatment": "trastuzumab, pertuzumab and paclitaxel", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old male with newly diagnosed lung adenocarcinoma presenting with headaches and back pain. MRI showed multiple enhancing brain lesions and PET/CT identified osseous disease. Molecular testing returned EGFR L858R and PD-L1 1%. He was started on osimertinib 80 mg daily with significant symptomatic improvement and interval CT shows reduction in size of pulmonary, brain and bony lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Tumor is HER2 amplified by FISH, ER-positive and PR-positive; tumor genomics identified a PIK3CA E545K alteration. She received neoadjuvant combination therapy with docetaxel, carboplatin, trastuzumab and pertuzumab followed by mastectomy. Pathology reported significant residual disease but no distant metastases.", "output": {"cancer_type": "invasive ductal carcinoma of the breast (HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "partial response (significant residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with a primary cutaneous melanoma of the back, pathologic stage IIIC. Molecular testing positive for BRAF V600E; PD-L1 by IHC 10%. He received dabrafenib and trametinib with a partial response and later was transitioned to pembrolizumab in the adjuvant setting. Imaging documents pulmonary nodules and enlarged regional lymph nodes.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib and trametinib; pembrolizumab", "response": "partial response", "metastasis_site": "lung; regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly identified metastatic lung adenocarcinoma. NGS panel demonstrated EGFR L858R. PD-L1 tumor proportion score 5%. He was started on osimertinib 80 mg daily in June; interval CT chest/abdomen at 8 weeks shows decrease in size of the lung mass and nodal disease consistent with a partial response. Brain MRI demonstrates two enhancing lesions and bone scan positive for multiple foci.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with high-risk prostate adenocarcinoma (Gleason 4+4) status post radical prostatectomy. Pathologic stage was III with seminal vesicle invasion. He received adjuvant pelvic radiation. Limited somatic panel showed no actionable mutations; hormone receptor assays not applicable. He currently has a rising PSA consistent with biochemical recurrence; CT chest/abdomen and bone scan show no radiographic metastases.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy and adjuvant pelvic radiation", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: 48-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIA. Cancer is ER positive, PR negative, HER2 amplified by FISH. Foundation testing also shows a PIK3CA H1047R hotspot mutation and pathogenic TP53 mutation. She received 6 cycles of docetaxel + carboplatin with trastuzumab and pertuzumab (TCHP) prior to surgery. Post-op pathology: no residual invasive carcinoma (pathologic complete response). No radiographic evidence of distant disease.", "output": {"cancer_type": "invasive ductal breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R; TP53 mutation", "biomarker": "HER2 amplification; ER+; PR-", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant TCHP was given for locally advanced breast cancer: patient is ER-positive/PR-positive and HER2 amplified by IHC/FISH. She completed docetaxel, carboplatin with trastuzumab and pertuzumab prior to surgery with marked tumor shrinkage. Post-op plan includes radiation and endocrine therapy (letrozole). Genomic panel pending \u2014 no actionable mutations reported yet.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP); letrozole; radiation", "response": "marked tumor shrinkage after neoadjuvant therapy", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old with metastatic colorectal adenocarcinoma, presented with multiple liver lesions and peritoneal nodularity. Stage IV at diagnosis. Tumor testing: MSI-H and TMB-high. No actionable KRAS/NRAS/BRAF mutation was detected on panel. Given the high microsatellite instability, patient was started on pembrolizumab in combination with modified FOLFOX (5-FU/leucovorin/oxaliplatin) under a clinical trial protocol. After 4 cycles there is interval decrease in hepatic disease consistent with partial response. CEA trending down.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab plus modified FOLFOX (5-FU/leucovorin/oxaliplatin)", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male diagnosed with localized prostate adenocarcinoma, clinical stage I, Gleason 3+4. PSA at diagnosis 4.8 ng/mL. No genomic testing was performed. Patient opted for active surveillance with PSA checks and repeat MRI. To date PSA values remain stable and there are no findings concerning for metastasis.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 4.8 ng/mL", "treatment": "active surveillance", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced breast cancer treated in the neoadjuvant setting. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER positive, PR negative. Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant trastuzumab and pertuzumab with docetaxel and carboplatin for 6 cycles prior to surgery and achieved a good radiographic decrease in tumor burden though residual disease remained on imaging.", "output": {"cancer_type": "HER2-positive breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant trastuzumab + pertuzumab with docetaxel and carboplatin", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with a rapidly enlarging left breast mass. Core biopsy: invasive ductal carcinoma, ER 80%, PR 0%, HER2 IHC 3+; FISH confirmed HER2 amplification. NGS detected a PIK3CA H1047R mutation. Clinical exam and imaging consistent with stage IIIB (T4bN1). She received neoadjuvant trastuzumab, pertuzumab and paclitaxel followed by modified radical mastectomy; final pathology reported a pathologic complete response. Adjuvant radiation was completed.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive (80%); PR negative (0%)", "treatment": "trastuzumab + pertuzumab + paclitaxel; surgery; radiation", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old male with newly diagnosed lung adenocarcinoma presented with headache and left-sided weakness. Staging workup consistent with stage IV disease with multiple cerebral metastases. Molecular testing identified EGFR L858R mutation; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and had marked clinical improvement with radiographic partial response at first follow-up MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 45-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER 80%, PR 30%, HER2 positive by FISH (HER2 amplification). Clinical stage cT4bN1 (stage IIIB). She received 6 cycles of neoadjuvant docetaxel/carboplatin/trastuzumab and underwent modified radical mastectomy last month. Surgical pathology reported significant tumor downstaging but residual invasive disease. Adjuvant radiation planned. No molecular sequencing performed.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER 80%, PR 30%, HER2 amplification", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab; surgery; planned radiation", "response": "partial response / residual disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with newly diagnosed lung adenocarcinoma presenting with cough and seizures. Staging showed multiple pulmonary nodules and brain and bone lesions; clinical stage IV. NGS identified EGFR L858R. PD-L1 IHC reported 10%. She was started on osimertinib 80 mg daily; at first restaging CT/MRI after 3 months there is a marked decrease in size of lung lesions and resolution of several brain metastases \u2014 overall partial response. Bone lesions have decreased in metabolic activity on PET.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with localized prostate adenocarcinoma Gleason 4+4 (cT2b N0 M0). Germline testing returned pathogenic BRCA2. He underwent radical prostatectomy followed by adjuvant external beam radiation therapy. PSA is undetectable at 12-month follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "radical prostatectomy and adjuvant external beam radiation", "response": "undetectable PSA / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Aggressive metastatic cutaneous melanoma with confirmed BRAF V600E on PCR. PD-L1 reported at 5%. Initial therapy was dabrafenib with trametinib combination targeted therapy; after 4 months patient developed new pulmonary nodules and was felt to have clinical progression. Plan is to transition to pembrolizumab pending insurance authorization.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib (initial); plan for pembrolizumab", "response": "progressive disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic pancreatic ductal adenocarcinoma, initial staging shows stage IV disease with multiple liver lesions. Baseline CA19-9 was 1,200 U/mL. Germline testing identified a pathogenic BRCA2 mutation. He started gemcitabine plus nab-paclitaxel as first-line therapy; imaging after 2 months showed an initial partial response but progression in the liver at 4 months. He subsequently received olaparib on a compassionate-use basis but interval scans demonstrate progressive disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 1200 U/mL", "treatment": "gemcitabine/nab-paclitaxel; olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castrate-resistant prostate adenocarcinoma metastatic to bone. Bone scan and PET show multifocal osseous disease involving pelvis and proximal femurs. Patient started on androgen deprivation with leuprolide and received six cycles of docetaxel; on progression he was switched to enzalutamide for symptomatic control. No molecular testing reported in chart. Clinical status currently stable on imaging and pain medications.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation); docetaxel; enzalutamide", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology correspondence: Patient with metastatic cutaneous melanoma with multiple pulmonary nodules identified on staging CT. Molecular testing demonstrated BRAF V600E. He was initiated on targeted therapy with dabrafenib and trametinib. Follow-up imaging at 6 weeks showed significant reduction of several dominant lung nodules consistent with a partial response. PD-L1 status not available in chart. Stage IV disease.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment for a 48-year-old woman with HER2-positive invasive ductal carcinoma of the left breast, clinical stage IIB. Core biopsy: ER negative, PR negative, HER2 amplification by FISH. She received carboplatin and paclitaxel with trastuzumab x4 cycles and proceeded to lumpectomy; surgical pathology revealed complete pathologic response. No radiographic evidence of distant metastasis.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "carboplatin and paclitaxel with trastuzumab; surgery (lumpectomy)", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB. Core biopsy: ER positive, PR positive, HER2 amplification by FISH. PIK3CA H1047R mutation identified on NGS panel. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP), proceeded to mastectomy and axillary dissection \u2014 pathology showed complete pathological response. Adjuvant radiation was planned.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; mastectomy; adjuvant radiation", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a 2.1 cm invasive ductal carcinoma of the left breast. ER positive, PR positive, HER2 negative by IHC (0). Next-generation sequencing detected PIK3CA E545K. Pathologic staging pT2 N0 M0 (Stage IIA). She underwent lumpectomy with sentinel lymph node biopsy; margins negative, and was started on adjuvant tamoxifen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; tamoxifen", "response": "no evidence of residual disease post\u2011op", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Staging workup showed multiple bilateral pulmonary nodules and a 2.5 cm enhancing lesion in the right temporal lobe consistent with metastatic disease. Biopsy confirmed adenocarcinoma; molecular testing returned EGFR L858R. PD-L1 by IHC was 10%. He was started on osimertinib 80 mg daily as first-line therapy. Follow-up CT at 10 weeks demonstrated a decrease in size of the dominant lung mass and resolution of several smaller nodules, consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: ER positive, PR negative, HER2 IHC 3+ and FISH-confirmed HER2 amplification. Tumor sequencing identified a PIK3CA E545K mutation. She received neoadjuvant paclitaxel with trastuzumab for six cycles followed by mastectomy. Final pathology after surgery showed a complete pathological response with no residual invasive carcinoma and no distant metastases.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant paclitaxel and trastuzumab, mastectomy", "response": "pathological complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented with obstructing sigmoid mass and synchronous liver lesions. Biopsy confirmed metastatic colorectal adenocarcinoma. No molecular profiling was available at the time of initial therapy. He received FOLFOX plus bevacizumab with initial symptomatic benefit but progressed on imaging at 6 months and was started on regorafenib with radiographic progression documented on next scan.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX plus bevacizumab; later regorafenib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Ms. A is a 62-year-old with metastatic lung adenocarcinoma (diagnosed 2019). Molecular testing returned EGFR L858R. She presents with two cerebellar metastases treated with stereotactic radiosurgery; systemic therapy with osimertinib 80 mg daily was started. Interval MRI shows radiographic stable disease in the brain. PD-L1 was never performed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed lung adenocarcinoma presented with headache and focal weakness. Staging scans show multiple cerebral metastases and lytic lesions in the thoracic spine. Molecular testing returned EGFR L858R (exon 21) and PD-L1 10%. He was started on first-line osimertinib 80 mg daily and received stereotactic radiosurgery to a dominant brain lesion. Follow-up CT at 8 weeks demonstrated reduction in size of pulmonary and CNS lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent low anterior resection for sigmoid colon adenocarcinoma. Pathology returned pT3N1 (stage III). Tumor NGS detected KRAS G12D. He completed adjuvant FOLFOX x12 cycles without complications. Surveillance CT at 6 months shows no distant metastatic disease and CEA stable.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "surgical resection; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative summary and plan: 59-year-old female with high-grade serous ovarian carcinoma, stage IIIC with diffuse peritoneal disease and omental caking. Germline testing positive for BRCA1 deleterious mutation; HRD assay positive. Pre-op CA-125 elevated. She underwent optimal debulking and was started on adjuvant carboplatin and paclitaxel with bevacizumab; maintenance olaparib planned given BRCA1 and HRD. CT after 3 cycles shows interval decrease in peritoneal implants consistent with partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD-positive; elevated CA-125", "treatment": "carboplatin + paclitaxel + bevacizumab; maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma (stage IV) presented with progressive dyspnea. Molecular testing: EGFR L858R detected on initial biopsy; after 10 months on erlotinib developed acquired T790M. PD-L1 tumor proportion score 60%. Brain MRI demonstrated multiple small enhancing lesions and bone scan positive for osseous disease. Switched to osimertinib with interval partial response on first follow-up CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 60%", "treatment": "erlotinib; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with prostate adenocarcinoma on biopsy, clinical stage T2b N0 M0 (stage II). Underwent robot-assisted radical prostatectomy with pelvic lymph node dissection. Post-operative PSA is undetectable. No somatic or germline genomic testing was performed; no molecular markers reported in the chart. Because of adverse pathologic features he received adjuvant pelvic radiotherapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy with pelvic lymph node dissection; adjuvant pelvic radiotherapy", "response": "undetectable PSA (biochemical remission)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female diagnosed with stage IV lung adenocarcinoma. Molecular testing identified an EGFR L858R mutation and PD-L1 expression of 10%. MRI brain showed multiple enhancing lesions consistent with brain metastases. She was started on osimertinib orally and follow-up imaging after 8 weeks demonstrated a partial response of both thoracic and intracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma presented with cough and weight loss. PET/CT demonstrated multiple pulmonary nodules and a 2.8 cm left lower lobe mass with brain and bone lesions consistent with metastatic disease. Biopsy confirmed adenocarcinoma; molecular testing showed EGFR L858R and PD-L1 10%. He initially received osimertinib with good symptomatic benefit, then on progression was transitioned to carboplatin and pemetrexed combined with pembrolizumab. Latest scan shows a partial response of pulmonary lesions and stability of brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; then carboplatin and pemetrexed with pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma, cutaneous primary on the left scalp; staging workup consistent with stage IV disease after detection of a 1.5 cm cerebellar metastasis. Tumor harbors BRAF V600E; PD-L1 approximately 5%. The patient underwent surgical resection of the brain lesion followed by stereotactic radiosurgery and systemic therapy with dabrafenib plus trametinib. Imaging at 8 weeks demonstrated a partial radiographic response.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "surgical resection and stereotactic radiosurgery; dabrafenib plus trametinib", "response": "partial response", "metastasis_site": "brain (cerebellum)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma to the liver diagnosed after right-sided abdominal pain and weight loss. Molecular profiling identified KRAS G12D mutation. Patient was started on FOLFIRI with bevacizumab; interval CT shows stable size of hepatic lesions after 3 months. MSI testing was not available at time of initial treatment.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman diagnosed with high-grade serous ovarian carcinoma presenting with bulky peritoneal carcinomatosis and ascites (stage IIIC). CA-125 markedly elevated pre-operatively. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with partial radiographic response of the peritoneal disease. BRCA testing pending / not available in the record.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the right breast showed invasive ductal carcinoma, ER negative, PR negative, HER2 amplification by FISH. Clinical stage at diagnosis was IIB (T2 N1). Patient received neoadjuvant chemotherapy with docetaxel and carboplatin in combination with trastuzumab and pertuzumab. On surgical pathology after mastectomy there was no residual invasive disease (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: 49-year-old F with palpable left breast mass. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+, ER/PR negative. Next-generation sequencing identified PIK3CA H1047R. Clinical stage IIIB (T4bN1). Received 6 cycles of docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP). Mastectomy specimen: no residual invasive carcinoma \u2014 pathologic complete response (pCR).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+, ER/PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic cutaneous melanoma harboring BRAF V600E; NRAS reported as wild-type. PD-L1 expression approximately 60%. He was started on targeted combination therapy with dabrafenib plus trametinib. After oligoprogression in the brain he received stereotactic radiosurgery and was given sequential ipilimumab plus nivolumab. Extracranial disease has decreased in size on imaging.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; ipilimumab and nivolumab", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma harboring BRAF V600E mutation. Primary lesion was resected from the scalp; PD-L1 was reported at approximately 5%. He was treated with dabrafenib plus trametinib with an initial partial response lasting six months, followed by development of new pulmonary nodules and radiographic progression; subsequent therapy was changed to pembrolizumab but the disease continued to progress.", "output": {"cancer_type": "melanoma (cutaneous melanoma)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later pembrolizumab", "response": "initial partial response followed by progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 71-year-old male with metastatic colorectal adenocarcinoma, KRAS G12D positive on tumor genotyping. Baseline staging showed multiple liver metastases consistent with stage IV disease. Tumor was microsatellite-stable on PCR. Patient was initiated on FOLFOX plus bevacizumab. Interim CT at 12 weeks shows minor decrease in dominant hepatic lesion but overall disease burden unchanged \u2014 treatment assessment: stable disease. Continuing same regimen.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 67-year-old male with metastatic colorectal adenocarcinoma. Primary resection in 2022; now with multiple liver lesions and peritoneal nodularity. Tumor genotyping revealed KRAS G12D and MSS by MSI testing; PD-L1 TPS 1%. He received FOLFOX plus bevacizumab for 6 cycles but CT shows interval growth of hepatic metastases and new ascites \u2014 treatment deemed progressive disease and plan is switch to irinotecan-based therapy.", "output": {"cancer_type": "colorectal (colon) adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS, PD-L1 1%", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic cutaneous melanoma. Tumor testing positive for BRAF V600E and reported PD-L1 ~20%; tumor mutational burden described as TMB-high. Staging: IV with known brain metastases and pulmonary nodules. He was started on targeted therapy with dabrafenib plus trametinib. Systemic disease shows marked shrinkage while several small intracranial lesions persist\u2014overall described by the team as a mixed response (near-complete extracranial response, residual brain disease).", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%; TMB-high", "treatment": "dabrafenib and trametinib", "response": "mixed response (near-complete extracranial response; persistent intracranial disease)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old male with pancreatic ductal adenocarcinoma found to carry a germline BRCA2 6174delT mutation. He completed six cycles of FOLFIRINOX with radiographic disease control and CA19-9 decline, then was transitioned to maintenance olaparib. Most recent clinic note documents ongoing disease stabilization on olaparib with good tolerance to therapy.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 6174delT (germline)", "biomarker": "HRD-positive", "treatment": "FOLFIRINOX; olaparib (maintenance)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical T3N1 (stage IIIA). Tumor was ER-negative, PR-negative and HER2 amplified by FISH. She received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for six cycles followed by mastectomy. Surgical pathology showed no residual invasive carcinoma consistent with a pathologic complete response.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple hepatic and pulmonary lesions. Molecular testing: KRAS G12D mutation, MSI-H, and tumor mutational burden high. He was treated with FOLFOX plus bevacizumab initially; after mixed radiographic changes he was switched to pembrolizumab given MSI-H status. Best overall response documented as stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male underwent right hemicolectomy for a cecal adenocarcinoma. Final staging pT3N2 (stage IIIC). Tumor testing returned MSI-H by PCR; KRAS, NRAS and BRAF sequencing were not reported in the note. He completed adjuvant FOLFOX x 12 and currently there is no radiologic evidence of residual disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male status post sigmoid colectomy for colon adenocarcinoma, pathologic stage III (pT3N1). Tumor profiling demonstrated KRAS G12D; microsatellite stable (MSS). Completed adjuvant FOLFOX without complications; current surveillance CTs show no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colon adenocarcinoma (KRAS G12D) presenting with multiple hepatic metastases on baseline CT. He was initiated on FOLFOX plus bevacizumab. Repeat imaging at 3 months demonstrates interval growth of the liver lesions consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old male diagnosed with metastatic clear cell renal cell carcinoma. Presents with weight loss and bone pain; scans show pulmonary nodules and lytic vertebral lesions. Started treatment with nivolumab and ipilimumab per tumor board recommendation. No targeted mutation testing has been completed; PD-L1 and other biomarkers not available in chart. First restaging CT at 10 weeks demonstrates overall disease stability.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab + ipilimumab", "response": "stable disease", "metastasis_site": "lung, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with unresectable metastatic melanoma to the lungs. Biopsy confirmed BRAF V600E mutation. He was started on combination targeted therapy with dabrafenib plus trametinib. Initial follow-up PET/CT at 8 weeks showed a partial response in pulmonary nodules, but surveillance imaging at 9 months documented disease progression with new nodal deposits.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib (combination)", "response": "partial response then progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 48-year-old woman with metastatic ER+/PR- breast cancer, confirmed HER2 amplification by FISH. Biopsy also identified a PIK3CA E545K mutation. She presented with worsening back pain; bone scan revealed multiple sclerotic lesions in the thoracic spine consistent with osseous metastases. Therapy initiated: first-line trastuzumab and pertuzumab in combination with docetaxel. Interim restaging CT after 3 cycles demonstrates reduction in size of vertebral lesions and improvement in pain \u2014 assessing partial response clinically and radiographically.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Gynecologic oncology summary: 63-year-old female with high-grade serous ovarian carcinoma presenting with bulky omental disease and ascites. Surgical/pathologic stage IIIC. Germline testing returned pathogenic BRCA1 mutation. Pre-treatment CA-125 was 980 U/mL. She received neoadjuvant carboplatin and paclitaxel with partial radiographic response, underwent interval optimal cytoreductive surgery, and is now on maintenance olaparib with normalization of CA-125 and no radiographic evidence of residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "CA-125 elevated (980 U/mL) pre-treatment", "treatment": "neoadjuvant carboplatin and paclitaxel; interval debulking surgery; maintenance olaparib", "response": "complete clinical response (normalized CA-125; no radiographic disease)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colon adenocarcinoma. KRAS G12D was identified on tumor sequencing after right hemicolectomy. CEA remains elevated on serial labs. After detection of multiple pulmonary nodules the patient was treated with FOLFOX plus bevacizumab; interval imaging demonstrates no new lesions and modest shrinkage of existing nodules consistent with stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA elevated", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "H&P: 35-year-old man with primary cutaneous melanoma of the left forearm, sentinel node positive, staged as III. Molecular profiling identified NRAS Q61K. He underwent wide local excision and lymph node dissection and was started on adjuvant nivolumab in combination with ipilimumab; after two cycles developed new neurologic symptoms and MRI confirmed brain metastases with radiographic progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "surgery; nivolumab and ipilimumab (adjuvant)", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 59-year-old female with biopsy-proven lung adenocarcinoma harboring EGFR L858R. Staging workup demonstrates stage IV disease with multiple brain metastases on MRI and lytic lesions in the thoracic spine. PD-L1 TPS reported at 5%. Patient started osimertinib 80 mg PO daily as first-line targeted therapy. Follow-up CT at 8 weeks shows decrease in size of target lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology clinic note: 56-year-old female with a primary cutaneous melanoma on the upper back, Breslow thickness 2.6 mm, sentinel node negative \u2014 staged as IIB. Next-generation sequencing detected a BRAF V600E alteration. She underwent wide local excision with clear margins; no adjuvant systemic therapy was recommended and the patient remains disease free at 18 months follow-up.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "disease free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic castration-resistant prostate adenocarcinoma, extensive osseous disease on bone scan. No actionable somatic mutations were reported on tumor panel. He was treated with androgen deprivation therapy initially, then received docetaxel for symptomatic bone metastases. PSA continued to rise and new spinal metastasis was seen on MRI; treatment was changed to enzalutamide for progressive disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy, docetaxel, then enzalutamide", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op note: 58-year-old male underwent right hemicolectomy for colon adenocarcinoma. Pathology: T3N1 (one of 18 nodes positive). Final stage: III. Tumor sequencing shows KRAS G12D mutation. MSI testing was negative. Patient completed 6 months of adjuvant FOLFOX without complications. Surveillance CT at 12 months demonstrates no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man diagnosed with intermediate-risk prostate adenocarcinoma (Gleason 3+4), clinical stage II. He underwent definitive external beam radiation with 18 months of concurrent leuprolide. On follow-up the PSA is 0.6 ng/mL and clinically there is no evidence of distant spread. No genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 0.6 ng/mL", "treatment": "external beam radiation and leuprolide (androgen deprivation therapy)", "response": "stable / biochemical response (PSA low but detectable)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult for metastatic melanoma: biopsy confirmed BRAF V600E mutation. PD-L1 by IHC 5%; comprehensive NGS reported high tumor mutational burden. Staging CT and brain MRI show pulmonary nodules and a single cerebellar metastasis. Patient initiated combination immunotherapy with nivolumab and ipilimumab. Interim imaging shows decrease in size of lung nodules and partial response of intracranial lesion.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "nivolumab + ipilimumab", "response": "partial response", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 48-year-old female presented with a 2.5 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. She received neoadjuvant docetaxel, carboplatin and trastuzumab for 6 cycles with radiologic downsizing and then underwent lumpectomy. Surgical pathology reported no residual invasive carcinoma (ypT0). No distant disease on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab followed by lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with primary cutaneous melanoma of the back; workup revealed multiple extracranial metastases and two small brain lesions on MRI \u2014 staged as Stage IV melanoma. Tumor testing positive for BRAF V600E; PD-L1 reported at 10%. He was treated with dabrafenib plus trametinib; first restaging CT showed a partial response of extracranial disease. Brain lesions were addressed with stereotactic radiosurgery and remain radiographically stable.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib plus trametinib; stereotactic radiosurgery to brain", "response": "partial response (extracranial); brain metastases stable", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with locally advanced pancreatic ductal adenocarcinoma (T4, Stage III) found to harbor a pathogenic BRCA2 6174delT germline mutation. Baseline CA 19-9 elevated. He received neoadjuvant modified FOLFIRINOX with short-lived clinical benefit but interval imaging demonstrated progression of the primary lesion and vascular encasement despite platinum-based chemotherapy.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 6174delT", "biomarker": "elevated CA 19-9", "treatment": "modified FOLFIRINOX (platinum-based chemotherapy)", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB (cT3N2M0). Core biopsy: ER positive (90%), PR negative, HER2 amplified by FISH. She completed neoadjuvant pertuzumab and trastuzumab with docetaxel x6 cycles and went on to mastectomy; final pathology reported a pathologic complete response (pCR). No germline testing mutation reported in chart.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "ER positive; PR negative; HER2 amplification", "treatment": "neoadjuvant pertuzumab + trastuzumab + docetaxel; mastectomy", "response": "pathologic complete response (pCR)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIA. Core biopsy: ER+, PR+, HER2 amplified by FISH. She received neoadjuvant docetaxel and carboplatin combined with trastuzumab and pertuzumab for 6 cycles and subsequently underwent modified radical mastectomy. Surgical pathology revealed no residual invasive carcinoma \u2014 pathologic complete response. No distant metastases identified on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+, PR+", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left breast invasive ductal carcinoma, ER+/PR+, HER2 amplification on FISH. Clinical stage IIA (T1cN1M0). She underwent lumpectomy with sentinel node biopsy followed by adjuvant weekly paclitaxel x12 and planned trastuzumab. Postoperative imaging shows no evidence of residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male diagnosed with metastatic pancreatic ductal adenocarcinoma, germline BRCA2 mutation identified. Staged as IV with liver and peritoneal deposits. He received first-line FOLFIRINOX with an initial partial response and was transitioned to olaparib maintenance given BRCA2. After approximately 9 months on olaparib surveillance imaging demonstrated progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "initial partial response then progression on maintenance", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 72\u2011year\u2011old man with de novo metastatic prostate adenocarcinoma (mCSPC) with extensive osseous involvement. Germline testing positive for BRCA2. Baseline PSA was 250 ng/mL. He received leuprolide plus docetaxel for six cycles followed by continuation of ADT. PSA declined to 12 ng/mL and repeat bone scan demonstrates decreased uptake in multiple sites consistent with a partial response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "PSA 250 ng/mL (declined to 12 ng/mL)", "treatment": "leuprolide and docetaxel (followed by ADT maintenance)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the breast (clinical stage IIIA). ER-positive, PR-negative. HER2 IHC 3+ with confirmatory FISH showing HER2 amplification. Tumor panel detected PIK3CA H1047R. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab and had a good clinical response before mastectomy. No distant metastases identified on staging scans.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant) followed by surgery", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with metastatic invasive ductal breast carcinoma. Tumor is ER+/PR+ and FISH shows HER2 amplification; genomic profiling identified a PIK3CA H1047R mutation. CT abdomen showed multiple new hepatic lesions. Patient was started on paclitaxel with trastuzumab and pertuzumab; interval scans demonstrate shrinkage of liver metastases.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with metastatic pancreatic ductal adenocarcinoma. Germline testing showed pathogenic BRCA2. Baseline CA19-9 elevated. He received FOLFIRINOX with initial disease control (stable disease) in the liver, then was switched to maintenance olaparib given the BRCA2 mutation. Latest CT demonstrates stable hepatic metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "elevated CA19-9", "treatment": "FOLFIRINOX, olaparib (maintenance)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "53-year-old female with newly diagnosed invasive ductal carcinoma of the right breast. Imaging and pathology indicate a 3.2 cm primary, sentinel nodes negative, final pathologic stage pT2N0 \u2014 clinical stage IIA. Tumor is ER negative, PR negative, HER2 amplified by FISH. Molecular testing returned a PIK3CA H1047R mutation. She underwent lumpectomy with clear margins and completed adjuvant paclitaxel for 12 weeks followed by 1 year of trastuzumab. Follow-up mammography and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with recurrent colorectal adenocarcinoma presenting with dominant liver metastases. Tumor profiling shows MSI-H and TMB-high (18 mut/Mb). External report noted no actionable RAS or BRAF alterations on the submitted panel. He received first-line FOLFOX plus bevacizumab; following progression the patient was switched to pembrolizumab and has had disease control on immunotherapy. Current assessment: stable disease on pembrolizumab. Stage IV.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high (18 mut/Mb)", "treatment": "FOLFOX; bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma presented with synchronous liver and lung metastases, overall stage IV. Tumor profiling demonstrated KRAS G12D and MSI-H by PCR with high tumor mutational burden. After progression on first-line FOLFOX/bevacizumab the patient was switched to pembrolizumab; most recent scans indicate stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX/bevacizumab (prior), pembrolizumab (current)", "response": "stable disease", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with HER2-amplified metastatic breast cancer (ER/PR negative) presenting with new back pain. Staging CT demonstrates multiple lytic vertebral lesions consistent with bone metastases. Tumor sequencing identified PIK3CA H1047R. She is receiving docetaxel with trastuzumab and pertuzumab; interval imaging after 4 cycles shows stable disease.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast invasive ductal carcinoma, stage II (pT2N0). Tumor was ER-positive, PR-positive and showed HER2 amplification by FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy followed by adjuvant chemotherapy with docetaxel and carboplatin and trastuzumab for HER2-targeted therapy. Twelve months post-treatment she remains with no evidence of disease on clinical exam and surveillance imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy, docetaxel, carboplatin, trastuzumab", "response": "no evidence of disease (complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old male with locally advanced pancreatic adenocarcinoma, clinical stage III. Started systemic therapy with gemcitabine and nab-paclitaxel and achieved a partial radiographic response on CT. CA19-9 was markedly elevated at 2500 U/mL. No distant metastases identified on staging scans; no somatic molecular testing was performed.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "CA19-9 2500 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic colorectal carcinoma with multiple liver lesions. Tumor was reported as mismatch repair deficient (MSI-H) and TMB-high on comprehensive genomic profiling; PD-L1 not reported. He was started on pembrolizumab monotherapy given MSI-H disease and has had sustained stable disease on scans for 9 months. KRAS testing not available in this report.", "output": {"cancer_type": "colorectal carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op pathology and multidisciplinary note: Invasive ductal carcinoma of the left breast, clinical stage IIIB (T4bN1). ER 90%/PR 60% by IHC; HER2 3+ by IHC with confirmatory FISH showing HER2 amplification. Tumor sequencing shows PIK3CA H1047R. Patient received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) with excellent clinical response; surgical specimen demonstrates no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female presenting with newly diagnosed lung adenocarcinoma. Staging workup consistent with stage IV disease. Molecular testing identified an EGFR L858R mutation; PD-L1 by IHC was 10%. She was started on osimertinib 80 mg daily. After 8 weeks of therapy there is interval decrease in the size of the primary and intracranial lesions consistent with a partial response. Known sites of disease include brain and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with sigmoid colon adenocarcinoma, pT3N1 (stage III) after resection. Tumor profiling showed KRAS G12D; MSI testing was reported MSS. He completed 6 months of adjuvant FOLFOX and remains disease-free on surveillance CTs at 12 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "adjuvant FOLFOX", "response": "disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old woman with newly diagnosed lung adenocarcinoma. Staging CT and MRI confirm stage IV disease with multiple enhancing lesions in the cerebrum consistent with brain metastases. Molecular testing returned EGFR L858R positive. PD-L1 staining was 10%. Patient started first-line osimertinib 80 mg daily; initial restaging at 8 weeks showed a partial response with shrinkage of the dominant right frontal lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with metastatic pancreatic ductal adenocarcinoma diagnosed by EUS biopsy. CA19-9 markedly elevated at diagnosis. Imaging demonstrated multiple liver metastases consistent with stage IV disease. The chart notes no actionable mutations were reported on the limited panel. He received modified FOLFIRINOX followed by consolidative radiotherapy to the primary and continued systemic therapy, but restaging shows overall disease progression in the liver.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "modified FOLFIRINOX followed by consolidative radiotherapy", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma with pathogenic germline BRCA1 mutation identified on testing; tumor reported HRD-positive. Patient underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with a very good clinical radiographic response. She was enrolled on maintenance therapy with olaparib in combination with bevacizumab per protocol. No distant metastases were documented on postoperative imaging.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": null, "gene_mutation": "BRCA1 mutation", "biomarker": "HRD-positive", "treatment": "carboplatin + paclitaxel; olaparib + bevacizumab (maintenance)", "response": "complete clinical/radiographic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48-year-old woman with locally advanced invasive ductal carcinoma of the left breast, ER+, PR+, HER2 amplified. Clinical stage IIIB with chest wall involvement. Received neoadjuvant weekly paclitaxel \u00d712 followed by dose-dense AC and concurrent trastuzumab and pertuzumab. Underwent mastectomy with sentinel node biopsy; surgical pathology reported no residual invasive carcinoma (pathologic complete response). BRCA testing negative.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel, doxorubicin/cyclophosphamide (AC), trastuzumab, pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old woman with invasive ductal carcinoma of the left breast, clinical stage II (T2N0). Tumor is ER positive, PR positive and shows HER2 amplification by FISH. Somatic PIK3CA H1047R mutation reported on targeted panel. She underwent lumpectomy followed by adjuvant weekly paclitaxel and trastuzumab and completed planned therapy; surveillance mammogram and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with metastatic lung adenocarcinoma. Initial testing showed EGFR L858R with an acquired T790M on repeat biopsy; PD-L1 expression 5%. After progression on first-line erlotinib she was started on osimertinib in combination with bevacizumab. Staging at diagnosis was IV with known brain and bone metastases. Interval imaging after 8 weeks demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 5%", "treatment": "osimertinib + bevacizumab (prior erlotinib)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma to the liver. KRAS G12D mutation identified on PCR-based panel. Tumor was reported as MSI-stable. Initial regimen was FOLFOX with bevacizumab; after 4 cycles CT shows no new lesions and minor shrinkage of hepatic metastases \u2014 overall assessment stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX with bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up: 58-year-old woman with metastatic lung adenocarcinoma (diagnosed 2019). Molecular testing positive for EGFR L858R. PD-L1 tumor proportion score 10%. Patient started osimertinib 80 mg daily in January 2020. Stereotactic radiosurgery was performed to a solitary cerebellar lesion. Interval chest CT demonstrates >30% reduction of target lesions compared with baseline.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced left breast tumor. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH (3+). Clinical stage IIIB (tumor fixed to chest wall). She received neoadjuvant trastuzumab with docetaxel followed by mastectomy and adjuvant radiation. Post-operative imaging shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification, ER positive", "treatment": "trastuzumab and docetaxel; surgery; radiation", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing demonstrated an EGFR exon 19 deletion. PD-L1 tumor proportion score reported as 5%. She was started on osimertinib 80 mg daily in January 2020. Interval MRI shows decreased size of brain metastases and improvement in painful lytic lesions in the femur. Overall impression: partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man presented with progressive cough and weight loss. CT and PET identified a right upper lobe nodule with mediastinal nodes and multiple lytic lesions in the spine. Biopsy: lung adenocarcinoma, EGFR L858R positive, ALK negative. PD-L1 tumor proportion score 5%. Staged as IV. Started first-line osimertinib with good symptomatic improvement and interval shrinkage of the primary and bone lesions on first follow-up \u2014 partial response documented.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "bone, mediastinal lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with metastatic castration-resistant prostate cancer (mCRPC) with extensive sclerotic bone metastases. Genomic profiling detected a deleterious BRCA2 frameshift. Tumor was HRD-positive. He was continued on androgen deprivation therapy and started on olaparib with symptomatic improvement and decline in PSA; imaging showed partial radiographic response of bone disease at 12 weeks.", "output": {"cancer_type": "metastatic castration-resistant prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 (deleterious frameshift)", "biomarker": "HRD-positive", "treatment": "androgen deprivation therapy; olaparib", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic colorectal adenocarcinoma. Molecular testing: BRAF V600E mutation; tumor MSI-H on PCR and high tumor mutational burden. Baseline imaging shows multiple hepatic metastases and peritoneal implants; clinical stage IV. Received combination chemotherapy FOLFOXIRI + bevacizumab but therapy was complicated by neuropathy and poor tolerance. Given MSI-H status she was switched to pembrolizumab monotherapy. Best response to pembrolizumab has been stable disease by RECIST at 12 weeks.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "FOLFOXIRI + bevacizumab; then pembrolizumab", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, Stage IV with multiple liver metastases. Molecular testing reported KRAS G12D and MSI-H. Given MSI-H status he was started on pembrolizumab 200 mg every 3 weeks as second-line therapy; interval CT demonstrates reduction in size of hepatic lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 48-year-old man with a 0.9 mm pigmented lesion on the forearm. Excisional biopsy shows superficial spreading melanoma, Breslow depth 0.9 mm, no ulceration. Sentinel node negative. BRAF V600E detected on molecular testing. Wide local excision performed with clear margins. Patient is under observation.", "output": {"cancer_type": "cutaneous melanoma", "stage": "I (stage IA)", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "complete remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed on core biopsy. Molecular testing returned EGFR L858R mutation and PD-L1 10% (SP263). Staging at presentation was IV with multiple pulmonary nodules and new enhancing lesions on MRI of the brain. She was started on osimertinib 80 mg daily and received stereotactic radiosurgery to a solitary cerebellar metastasis. Interval CT at 8 weeks shows decrease in size of pulmonary lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma presented with multiple pulmonary nodules and two symptomatic brain metastases. Molecular profiling detected a BRAF V600E mutation. He was started on dabrafenib and trametinib with rapid clinical improvement; stereotactic radiosurgery was performed to the dominant brain lesion. On the current regimen the disease is stable by RECIST criteria.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib plus trametinib; stereotactic radiosurgery", "response": "stable disease", "metastasis_site": "brain and lung (pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 46-year-old with metastatic triple-negative breast cancer. ER/PR negative, HER2 non-amplified on IHC/FISH. Germline testing revealed a pathogenic BRCA1 variant. CT abdomen shows multiple hypodense hepatic lesions consistent with metastatic disease. She received carboplatin plus gemcitabine with radiographic tumor shrinkage and was transitioned to maintenance olaparib due to BRCA1 mutation.", "output": {"cancer_type": "breast cancer (triple-negative)", "stage": "IV", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "ER-negative; PR-negative; HER2-negative", "treatment": "carboplatin and gemcitabine; maintenance olaparib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with high-grade serous ovarian carcinoma, FIGO IIIC. Germline testing identified a deleterious BRCA1 mutation and tumor was HRD-positive; CA-125 markedly elevated pre-treatment. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel and then was started on olaparib maintenance. CT at 12 weeks showed reduction in peritoneal implants and omental disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious germline mutation", "biomarker": "HRD positive; CA-125 elevated", "treatment": "cytoreductive surgery; carboplatin + paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with newly diagnosed lung adenocarcinoma. Staging workup demonstrates stage IV disease with multiple enhancing lesions in the cerebrum consistent with brain metastases. Molecular testing returned EGFR exon 19 deletion. PD-L1 by IHC reported 10%. He was started on osimertinib 80 mg daily and after 8 weeks had a RECIST partial response with reduction in the size of the dominant right upper lobe mass and decreased cerebral edema.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced right breast cancer (clinical T4bN1). Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. NGS identified PIK3CA H1047R. She received neoadjuvant docetaxel, carboplatin and trastuzumab followed by right modified radical mastectomy. Surgical pathology reported a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin and trastuzumab followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology report: 34-year-old male with a 1.2 cm pigmented lesion on the forearm. Excisional biopsy revealed superficial spreading melanoma, Breslow depth 0.9 mm, no ulceration. Sentinel node biopsy deferred; staged as IA (stage I). Wide local excision performed with clear margins. BRAF testing reported V600E mutation. No adjuvant therapy recommended.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recurrent right-sided invasive ductal carcinoma, ER+/PR+, HER2-amplified. Imaging shows multiple hypodense hepatic lesions consistent with metastases. Clinical stage IV disease. Patient initiated first-line trastuzumab and pertuzumab with docetaxel. After three cycles there are no new lesions on CT and tumor markers are stable.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab; pertuzumab; docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and genetics summary: High-risk prostate adenocarcinoma (pT3 disease) with extraprostatic extension. Germline testing positive for BRCA2 pathogenic variant. Underwent radical prostatectomy followed by adjuvant external beam radiation and androgen deprivation therapy with leuprolide. Post-treatment PSA is undetectable and patient is currently NED on surveillance imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIIB", "gene_mutation": "BRCA2 (germline)", "biomarker": "PSA undetectable (post-treatment)", "treatment": "radical prostatectomy, adjuvant radiation, androgen deprivation therapy (leuprolide)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old presented with progressive abdominal pain and weight loss. Colonoscopy confirmed adenocarcinoma of the sigmoid colon. CT shows multiple hepatic lesions consistent with metastases. Tumor sequencing: KRAS G12D; MSI testing: microsatellite stable. Patient started on FOLFOX with bevacizumab; first evaluation after 8 weeks demonstrated new liver lesions and rising CEA.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Initial NGS showed EGFR L858R; on repeat plasma testing at progression she was found to have acquired T790M. PD-L1 tumor proportion score reported as 1%. She received first-line erlotinib and after CNS and osseous progression was switched to osimertinib 80 mg daily in August 2020 with interval decrease in size of brain and bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R and T790M", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with colorectal adenocarcinoma with multiple hepatic metastases. KRAS testing returned G12D; CEA elevated to 120 ng/mL. He completed 6 cycles of FOLFOX plus bevacizumab but restaging CT demonstrates interval growth of liver lesions and new satellite nodules.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CEA 120 ng/mL", "treatment": "FOLFOX plus bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female status post Whipple for pancreatic ductal adenocarcinoma (T3N1). Pathology: moderately differentiated adenocarcinoma. She completed 6 cycles of adjuvant gemcitabine. Surveillance CT now shows new peritoneal nodules and moderate ascites consistent with recurrent disease. Chart review reveals no germline or somatic BRCA testing has been documented. CA 19-9 has been rising. Referred to medical oncology for systemic therapy options.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": null, "treatment": "surgery (Whipple); adjuvant gemcitabine", "response": "recurrence", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman underwent diagnostic core biopsy that revealed invasive ductal carcinoma of the right breast, pT2N0 (clinical stage IIA). ER 90% positive, PR 70% positive, HER2 amplified by FISH. She had lumpectomy with sentinel lymph node biopsy; margins negative. Received adjuvant paclitaxel followed by trastuzumab planned for 1 year. Post-operative imaging and exam show no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "lumpectomy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op clinic: 48-year-old female with biopsy-proven invasive ductal carcinoma, clinical stage IIIB (T4bN2). Core biopsy: ER negative, PR negative, HER2 IHC 3+ (FISH positive). She completed neoadjuvant dose-dense AC x4 followed by paclitaxel with trastuzumab and pertuzumab. Underwent modified radical mastectomy \u2014 pathology shows no residual invasive carcinoma (ypT0N0). Oncology note documents pathologic complete response after combined chemo + HER2-directed therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+ (FISH amplified); ER-/PR-", "treatment": "dose-dense doxorubicin + cyclophosphamide then paclitaxel with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: unresectable stage III cutaneous melanoma of the left arm. Molecular profile positive for BRAF V600E. PD-L1 not reported. Patient started combination targeted therapy with dabrafenib and trametinib two months ago; marked regression of dermal and subcutaneous nodules documented on exam. Brain MRI negative for metastatic disease.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "near-complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old woman with a primary cutaneous melanoma, sentinel node positive \u2014 pathologic stage III. Molecular testing detected a BRAF V600E mutation. She underwent wide local excision and nodal dissection and was started on adjuvant targeted therapy with dabrafenib and trametinib. After 6 months on therapy she developed new pulmonary nodules and PET/CT confirmed disease progression. PD-L1 was not reported.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "38-year-old woman with a 1.2 mm superficial spreading melanoma on the right forearm. Wide local excision with 1 cm margins was performed; sentinel lymph node negative. Pathology stage corresponds to clinical stage II. BRAF testing was not reported in the clinic note and no systemic therapy was recommended given negative sentinel node and clear margins. Patient is followed in clinic with dermatology and oncology.", "output": {"cancer_type": "superficial spreading melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op core biopsy: invasive ductal carcinoma of the breast. ER 80%, PR 60%, HER2 amplified by FISH. Clinical exam consistent with fixed axillary nodes; clinical stage IIIB. Comprehensive NGS detected PIK3CA H1047R. Patient received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles followed by modified radical mastectomy. Surgical pathology: no residual invasive carcinoma identified (pathologic complete response). No distant metastases were seen on staging CT.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old with metastatic pancreatic ductal adenocarcinoma, staged IV at presentation with multiple liver lesions. Baseline CA 19-9 was markedly elevated to 4,800 U/mL. Tumor sequencing showed KRAS G12D. He received 3 cycles of FOLFIRINOX but interval CT demonstrates increase in size and number of hepatic metastases consistent with progression.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "CA 19-9 markedly elevated (4,800 U/mL)", "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with recurrent cutaneous melanoma found to be BRAF V600E positive on PCR. Staging demonstrated symptomatic brain and hepatic metastases. He was started on dabrafenib and trametinib; interval imaging at 8 weeks showed significant tumor regression (partial response) but there was disease progression at 8 months with new extracranial lesions.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response then progression at 8 months", "metastasis_site": "brain and liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced left breast invasive ductal carcinoma, hormone receptor negative, HER2 FISH-positive (HER2 amplification). Core biopsy also noted a PIK3CA H1047R mutation. Clinical stage was T3N1 (stage III). She received neoadjuvant chemotherapy (dose-dense doxorubicin/cyclophosphamide followed by docetaxel) in combination with trastuzumab and pertuzumab. Patient underwent mastectomy; surgical pathology shows no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "III", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 docetaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant plan for left breast invasive ductal carcinoma, clinical stage IIIA (T2N2). Core biopsy: HER2 amplification by FISH, ER negative, PR negative. Tumor also harbors PIK3CA H1047R on sequencing. Patient received weekly paclitaxel with concurrent trastuzumab for 12 weeks followed by lumpectomy and sentinel lymph node biopsy. Surgical pathology: no residual invasive carcinoma identified \u2014 pathologic complete response (pCR).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with stage IIIA invasive ductal breast carcinoma. Tumor was ER-negative, PR-negative and HER2 IHC 3+ with confirmed HER2 amplification on FISH. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with concurrent trastuzumab. Surgical pathology demonstrated a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "doxorubicin, cyclophosphamide, paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with metastatic cutaneous melanoma. Molecular profiling revealed BRAF V600E mutation. PD-L1 by IHC reported at 60% TPS. He was started on dabrafenib plus trametinib and achieved a good partial response for approximately 8 months, then developed progressive brain and pulmonary metastases and was switched to pembrolizumab; however subsequent scans demonstrated further progression. Stage IV disease with brain and lung metastases.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib; then pembrolizumab", "response": "initial partial response then progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology: right hemicolectomy performed for adenocarcinoma of the ascending colon, pT3 N1 (stage III). Tumor testing shows MSI-high. Extended mutational panel results pending and KRAS/NRAS/BRAF testing has not been completed at this time. Patient started adjuvant FOLFOX and is undergoing routine surveillance; 6-month CTs show no distant disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-high", "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with left breast invasive ductal carcinoma, ER positive / PR positive and HER2 amplification on FISH. Clinical stage IIB based on imaging and physical exam. Core biopsy also showed a PIK3CA E545K mutation. She received neoadjuvant trastuzumab, pertuzumab and docetaxel for six cycles; surgical pathology after mastectomy revealed a pathologic complete response (no residual invasive tumor).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48 y/o F with left breast mass. Core biopsy: invasive ductal carcinoma, ER negative, PR negative. HER2 amplification confirmed by FISH. Clinical stage IIIB due to fixed axillary nodes. Neoadjuvant therapy consisted of docetaxel, carboplatin and trastuzumab for 6 cycles; patient underwent mastectomy with pathologic complete response (no residual invasive carcinoma).", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "docetaxel, carboplatin and trastuzumab (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old premenopausal woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. ER and PR positive; HER2 amplified by FISH. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by docetaxel with trastuzumab and pertuzumab. Surgical pathology demonstrated a pathologic complete response. No distant metastases identified on staging scans.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant doxorubicin + cyclophosphamide followed by docetaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male status post right hemicolectomy for moderately differentiated colon adenocarcinoma. Pathology: stage III (T3 N1 M0). Tumor testing showed MSI-H and high tumor mutational burden. He completed 6 cycles of adjuvant FOLFOX without complications. Surveillance CT at 6 months demonstrates no evidence of recurrent disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with high-risk localized prostate adenocarcinoma (clinical stage III). He underwent radical prostatectomy and was started on androgen deprivation therapy with leuprolide; adjuvant external beam radiation was delivered for positive margins. No genomic testing documented in the chart. PSA at 6-month post-treatment follow-up is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy, leuprolide (androgen deprivation therapy), external beam radiation", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colorectal adenocarcinoma, stage IV, liver-dominant disease with multiple hepatic lesions. Molecular testing: KRAS G12D positive. Tumor is microsatellite stable (MSS) and tumor mutational burden reported as low. He was treated with FOLFOX plus bevacizumab for six cycles; initial scans showed stable disease but interval imaging at 4 months revealed new hepatic lesions and growth of existing deposits consistent with progression. Oncology plans to move to irinotecan-based therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable); TMB-low", "treatment": "FOLFOX + bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 70-year-old with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Staging: IV. Tumor profiling returned MSI-H and TMB-high; KRAS testing result not available from outside lab. Initial therapy included FOLFOX plus bevacizumab with mixed radiographic benefit, subsequently switched to pembrolizumab monotherapy given MSI-H status. Current scans show stable disease in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic lung adenocarcinoma originally found to harbor EGFR L858R. After first-line erlotinib he progressed and repeat biopsy demonstrated acquired T790M. PD-L1 immunohistochemistry was 10%. Patient was started on osimertinib 80 mg daily; interval imaging at 8 weeks shows shrinkage of pulmonary and intracranial lesions consistent with a partial response. Known metastases to brain and bone.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "High-grade serous ovarian carcinoma, clinical stage IIIC, diagnosed by core biopsy and elevated CA-125. Germline testing returned positive for BRCA1 pathogenic variant. Patient received neoadjuvant carboplatin and paclitaxel with a partial radiographic response followed by interval debulking surgery; omental and peritoneal implants were documented intraoperatively. Bevacizumab maintenance was discussed.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "elevated CA-125", "treatment": "neoadjuvant carboplatin and paclitaxel; interval debulking surgery; planned bevacizumab", "response": "partial response to neoadjuvant chemotherapy", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with newly diagnosed high-grade serous ovarian carcinoma, surgical staging reported FIGO IIIC with bulky pelvic disease and positive omental implant. Germline testing returned BRCA1 pathogenic variant; somatic TP53 mutation reported on tumor panel. She completed six cycles of carboplatin and paclitaxel with near-complete CA-125 normalization and was started on maintenance olaparib. Clinically doing well on maintenance with disease controlled on imaging.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline); TP53 (somatic)", "biomarker": null, "treatment": "carboplatin and paclitaxel; maintenance olaparib", "response": "disease controlled / partial response (near-complete CA-125 normalization)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic lung adenocarcinoma diagnosed June 2024. Comprehensive genomic profiling returned EGFR L858R and no other actionable alterations. PD-L1 tumor proportion score 5%. MRI brain demonstrated two small enhancing lesions; bone scan positive for lytic lesions in the thoracic spine. Patient started osimertinib 80 mg daily in July with symptomatic improvement and radiographic partial response on first CT at 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: Patient with metastatic cutaneous melanoma, BRAF V600E positive, previously treated with pembrolizumab with clinical progression. Transitioned to targeted therapy with dabrafenib plus trametinib. PD-L1 by IHC was 5%. Recent imaging after 8 weeks on BRAF/MEK therapy shows no measurable tumor shrinkage but no new lesions \u2014 overall stable disease. MRI brain demonstrates two metastatic deposits.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant note: 48-year-old woman with left breast mass, core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 amplification by FISH. Clinical stage IIIA (T2N2). Patient received 6 cycles paclitaxel plus trastuzumab prior to surgery. Lumpectomy performed; surgical pathology shows no residual invasive tumor (pathologic complete response). No distant mets identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab; surgery (lumpectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Letter to referring physician: 72-year-old man with metastatic castration-resistant prostate cancer (mCRPC). Genetic testing revealed a deleterious BRCA2 mutation; no other actionable fusions identified. He progressed after docetaxel and enzalutamide and was started on olaparib. PSA and restaging bone scan show partial radiographic and biochemical response with decreased uptake in several osseous lesions. Stage at diagnosis treated as IV.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant prostate cancer)", "stage": "IV", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": null, "treatment": "olaparib (after docetaxel and enzalutamide)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with locally advanced invasive ductal carcinoma of the right breast, cT3N2M0. Core biopsy: HER2 amplification by FISH, ER negative, PR negative. She received neoadjuvant therapy with trastuzumab and pertuzumab in combination with docetaxel for six cycles followed by surgery and adjuvant radiation. Surgical pathology after resection revealed no residual invasive carcinoma (pathologic complete response) but persistent involved axillary lymph nodes were noted prior to therapy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab and pertuzumab + docetaxel; surgery; radiation", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital summary: Patient with metastatic cutaneous melanoma presented with symptomatic disease. BRAF V600E positive by PCR. Began first-line targeted therapy with dabrafenib plus trametinib and achieved an initial partial response; however disease progressed at 7 months with new intracranial and pulmonary metastases. He was switched to combination ipilimumab and nivolumab. Latest radiology reports the patient with progressive disease while on targeted therapy prior to switch.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib; later ipilimumab and nivolumab", "response": "progression (after initial partial response)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 40-year-old male with metastatic cutaneous melanoma (AJCC stage IV) found to harbor BRAF V600E. Initially treated with dabrafenib and trametinib with a partial response lasting ~6 months; subsequent scans demonstrated progression with new pulmonary nodules and multiple brain metastases. He was transitioned to combined ipilimumab and nivolumab.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (then ipilimumab + nivolumab)", "response": "initial partial response followed by progression", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Primary cutaneous melanoma on the left forearm, Breslow thickness 3.5 mm, no palpable nodes, sentinel node negative \u2014 staged as IIB. Tumor genotyping positive for BRAF V600E. Patient underwent wide local excision and has been started on adjuvant pembrolizumab given high-risk Stage II features. Currently tolerating therapy without clinical recurrence.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; adjuvant pembrolizumab", "response": "no clinical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic lung adenocarcinoma presented with progressive headaches and new bone pain. Initial biopsy demonstrated adenocarcinoma of the lung, stage IV with multiple brain and bone lesions. Molecular testing returned EGFR L858R and concurrent MET amplification; PD-L1 by IHC 10%. He was started on osimertinib, with partial radiographic response in the chest but persistent brain mets; after progression in the CNS a MET inhibitor (savolitinib) was added to osimertinib as combination targeted therapy with interval improvement on MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "MET amplification; PD-L1 10%", "treatment": "osimertinib; osimertinib + savolitinib (combination)", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 47-year-old premenopausal female with locally advanced invasive ductal carcinoma of the right breast, clinical stage IIIB. ER negative, PR negative. FISH demonstrates HER2 amplification. Patient received neoadjuvant TCH (docetaxel, carboplatin, trastuzumab) x6 with clinical complete response. Underwent modified radical mastectomy; pathology shows no residual invasive carcinoma (pathologic complete response). Will continue trastuzumab to complete 1 year.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab (TCH); modified radical mastectomy; adjuvant trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic colon adenocarcinoma. Liver biopsy confirmed moderately differentiated adenocarcinoma; PCR panel detected KRAS G12D. Microsatellite testing reported stable (no MSI-H). Patient was started on FOLFOX with bevacizumab. After four cycles CT scan shows persistent hepatic lesions with no new sites and overall stable disease per RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with invasive ductal breast cancer, ER-positive, PR-negative. FISH shows HER2 amplification and NGS identified a PIK3CA H1047R mutation. Clinical stage cT2N1M0 (stage IIIA). She received neoadjuvant paclitaxel in combination with trastuzumab followed by lumpectomy and axillary dissection; surgical pathology demonstrated a pathologic complete response. Continuing adjuvant trastuzumab.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive", "treatment": "paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colon adenocarcinoma presenting with multiple hepatic lesions and pulmonary nodules. Tumor sequencing identified KRAS G12D. MSI testing returned MSI-H and tumor mutational burden reported as high. He received first-line mFOLFOX6 with bevacizumab with heterogeneous shrinkage of some hepatic metastases but progression of others; subsequently started pembrolizumab with radiographic partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "mFOLFOX6 + bevacizumab, then pembrolizumab", "response": "mixed response to chemotherapy, partial response to pembrolizumab", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with progressive cough and weight loss. Biopsy of a right upper lobe mass consistent with lung adenocarcinoma. Staging CT and MRI brain show hepatic and multiple intracranial lesions consistent with metastatic disease, overall stage IV. Molecular testing: EGFR L858R. PD-L1 TPS 10%. He was started on osimertinib and underwent stereotactic radiosurgery to two brain metastases. Follow-up imaging at 8 weeks demonstrates decrease in size of lung primary and liver lesions consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed metastatic lung adenocarcinoma (stage IV). Plasma NGS detected an EGFR L858R mutation. PD-L1 by IHC was 10% TPS. He was started on osimertinib 80 mg daily. Follow-up CT at 8 weeks showed a 45% reduction in measurable pulmonary nodules consistent with a partial response. MRI brain demonstrated a small left frontal metastasis; bone scan positive for thoracic spine lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma. Molecular testing returned NRAS Q61K mutation. The patient developed multiple pulmonary nodules and was started on combination immunotherapy with nivolumab and ipilimumab. Interval CT imaging demonstrates no new disease and measurements are stable; overall assessment is stable disease. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "nivolumab and ipilimumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma (stage IV) presenting with progressive cough and 10-kg weight loss. Comprehensive genomic profiling identified EGFR L858R. PD-L1 IHC reported 10% tumor proportion score. Staging MRI/CT demonstrated multiple brain metastases and lytic lesions in the thoracic spine. He was started on osimertinib 80 mg daily as first-line systemic therapy. Follow-up CT and MRI at 8 weeks show decrease in size of pulmonary nodules and partial regression of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old woman diagnosed with high-grade serous ovarian carcinoma with bulky peritoneal and omental disease. Surgical staging consistent with IIIC. Germline testing positive for BRCA1 185delAG. She underwent primary debulking followed by adjuvant carboplatin and paclitaxel with partial radiographic response; CA-125 declined but small residual peritoneal implants remain. Subsequently started on olaparib maintenance.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 elevated at diagnosis (declined with treatment)", "treatment": "primary debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "partial response", "metastasis_site": "peritoneum; omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old man with bulky, unresectable stage IV cutaneous melanoma with pulmonary and nodal involvement. Next-generation sequencing identified a BRAF V600E mutation. He was started on combination targeted therapy with dabrafenib plus trametinib and achieved a rapid partial response of the pulmonary nodules and mediastinal nodes. PD-L1 and TMB were not reported.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung; mediastinal lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note: 62-year-old male underwent right hemicolectomy for stage III colon adenocarcinoma (T3N1). Tumor testing identified KRAS G12D mutation; mismatch repair proteins intact (MSI-stable). He completed 12 cycles of adjuvant FOLFOX and on most recent surveillance CT there is no radiographic evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with 3 months of weight loss and right upper quadrant pain. Colonoscopy revealed an obstructing sigmoid tumor; biopsy confirmed colorectal adenocarcinoma. Staging CT showed multiple hepatic metastases (stage IV). Molecular testing identified KRAS G12D and reported microsatellite stable (MSS) with low TMB. After initial FOLFOX, disease progressed and he was started on FOLFIRI plus bevacizumab; CT after three cycles showed interval growth of liver lesions consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFIRI and bevacizumab (after progression on FOLFOX)", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presented with progressive dyspnea and headaches. Staging CT and MRI confirmed stage IV disease with multiple brain metastases and lytic lesions in the femur. Tumor panel returned positive for EGFR L858R; PD-L1 reported at 10%. Patient was started on osimertinib 80 mg daily. Interval CT at 8 weeks demonstrates a marked decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 52-year-old male with metastatic cutaneous melanoma. Molecular analysis detected BRAF V600E mutation. He was started on combination targeted therapy with dabrafenib and trametinib. Baseline scans showed pulmonary and hepatic metastases; brain MRI later revealed two enhancing lesions. PD-L1 was 5% on archival tissue. After four months on therapy there was progressive enlargement of hepatic lesions and new brain metastases consistent with disease progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver and brain (also lung involvement)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "New oncology consult: 48-year-old woman diagnosed with metastatic breast cancer. Core biopsy of a liver lesion confirmed invasive ductal carcinoma; ER/PR negative. FISH demonstrated HER2 amplification. Patient was started on first-line docetaxel with trastuzumab and pertuzumab. Interval CT of the abdomen after 2 cycles shows decrease in size and number of hepatic lesions consistent with partial response.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, stage IV, found to harbor KRAS G12D on PCR-based testing. Tumor also reported MSI-H with high tumor mutational burden. Multiple liver lesions and peritoneal implants were present at diagnosis. Given MSI-H status, pembrolizumab monotherapy was initiated and interval CT after three cycles showed a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing revealed KRAS G12D mutation and MSS (microsatellite stable). First-line therapy with FOLFOX plus bevacizumab was given for 6 cycles, but interval imaging shows growth of hepatic metastases consistent with progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with node-positive cutaneous melanoma, BRAF V600E detected on molecular testing. Clinical stage recorded as IIIB after wide local excision and therapeutic lymphadenectomy. Adjuvant targeted therapy with dabrafenib and trametinib was started post-operatively; patient is tolerating therapy and imaging has not yet been performed to assess response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. NGS from biopsy reported EGFR L858R mutation; PD-L1 IHC 15%. She was started on osimertinib 80 mg daily in April. Baseline brain MRI demonstrated a 1.2 cm cerebellar lesion and PET/CT showed osseous disease. Interval CT thorax/abdomen after 8 weeks demonstrated ~40% reduction in target pulmonary nodules and decrease in size of bone lesions. Clinically improved with decreased cough.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old premenopausal woman with left breast invasive ductal carcinoma, clinical stage IIB. Tumor is ER positive, PR positive and HER2 amplified by FISH. NGS panel detected a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab, followed by lumpectomy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging showed multiple cerebral and vertebral lesions consistent with metastatic disease. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 30%. Patient was started on osimertinib 80 mg daily with good tolerance and interval CT at 8 weeks demonstrated a decrease in size of pulmonary nodules and improvement of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old male with HPV-positive (p16+) oropharyngeal squamous cell carcinoma, clinical stage IVA. Treated definitively with concurrent high-dose cisplatin and external beam radiation. Twelve-week post-treatment PET/CT shows complete metabolic response with no residual FDG-avid disease. No somatic mutation testing was performed on the primary tumor.", "output": {"cancer_type": "oropharyngeal squamous cell carcinoma", "stage": "IVA", "gene_mutation": null, "biomarker": "p16 positive (HPV-associated)", "treatment": "concurrent cisplatin and radiation", "response": "complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 62-year-old man with metastatic colon adenocarcinoma with multiple hepatic metastases identified on CT. Tumor sequencing shows KRAS G12D. MSI testing negative (MSI-stable). Patient started on FOLFOX plus bevacizumab. First restaging shows no new lesions and a small decrease in the dominant segment IV lesion \u2014 overall: stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with right breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative. HER2 IHC 3+ consistent with HER2 amplification. Clinical stage IIIB disease. Next-generation sequencing identified a PIK3CA H1047R mutation. She completed neoadjuvant paclitaxel in combination with trastuzumab and subsequently underwent mastectomy with pathologic complete response in the specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 IHC 3+; ER+; PR-", "treatment": "neoadjuvant paclitaxel and trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with newly diagnosed metastatic prostate adenocarcinoma. Bone scan showed multiple skeletal metastases and pelvic nodal enlargement. Somatic panel did not reveal actionable mutations; no molecular biomarkers reported. He was started on androgen deprivation with degarelix and systemic abiraterone acetate with symptomatic improvement and PSA stabilization.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "degarelix and abiraterone", "response": "stable disease", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and pathology summary: 62-year-old male underwent right hemicolectomy for colon adenocarcinoma. Final pathology pT3N1, pathologic stage III. Tumor testing revealed KRAS G12D mutation and high microsatellite instability (MSI-H). Patient completed surgery and tolerated adjuvant FOLFOX; currently on surveillance with no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "surgery; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed invasive ductal carcinoma of the left breast. Core biopsy: ER-positive, PR-positive, HER2 negative by IHC/FISH. Clinical staging consistent with IIA (T2N0M0). Tumor sequencing identified PIK3CA H1047R. She underwent lumpectomy with sentinel lymph node biopsy; margins negative. Adjuvant radiation planned and endocrine therapy with letrozole to follow. No evidence of distant disease on staging CT.", "output": {"cancer_type": "invasive ductal carcinoma of the left breast", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER-positive; PR-positive; HER2 negative", "treatment": "lumpectomy; sentinel lymph node biopsy; adjuvant radiation; letrozole", "response": "no evidence of distant disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with pancreatic ductal adenocarcinoma and multiple liver metastases (stage IV). Germline BRCA2 mutation identified on testing. She received first-line gemcitabine plus nab-paclitaxel with an initial partial response, later progressed and after platinum reinduction was transitioned to olaparib maintenance. Most recent CT shows stable disease; CA19-9 remains elevated but trending down.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated", "treatment": "gemcitabine and nab-paclitaxel; olaparib", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 52-year-old with cutaneous melanoma, recurrent nodal disease now with pulmonary and intracranial lesions consistent with metastatic spread (stage IV). Next\u2011generation sequencing shows NRAS Q61R mutation. PD-L1 and TMB were not reported on the pathology addendum. Patient was started on combination immunotherapy with ipilimumab plus nivolumab. On first follow-up imaging there is partial regression of several pulmonary nodules and symptomatic improvement after stereotactic radiosurgery to the dominant brain metastasis.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "ipilimumab and nivolumab; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male presented with right-sided abdominal pain and weight loss. Colonoscopy found a proximal colon adenocarcinoma. CT showed multiple liver lesions and peritoneal studding consistent with metastatic disease (stage IV). Tumor profiling: MSI-H and TMB-high; BRAF V600E mutation detected. Given MSI-H status he was started on pembrolizumab monotherapy. Interval imaging after 4 cycles demonstrated ~40% reduction in hepatic tumor burden meeting criteria for partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with locally advanced pancreatic ductal adenocarcinoma abutting the SMA (stage III). Germline testing positive for BRCA2 deleterious mutation. He received neoadjuvant FOLFIRINOX with radiographic partial response and then proceeded to chemoradiation; now on olaparib maintenance given BRCA2 status. PD-L1 testing not documented and there are no radiologic signs of distant metastasis at this time.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; chemoradiation; olaparib maintenance", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "ED triage note: 71-year-old man with hematuria. TURBT performed; final report consistent with high-grade urothelial carcinoma of the bladder. Clinical stage reported as II (muscle-invasive disease confined to bladder wall). PD-L1 by IHC (SP263) returned approximately 60% tumor cell staining. No actionable sequencing alterations were identified on panel. Given comorbidity profile, immunotherapy with pembrolizumab was initiated. On first re-eval at 12 weeks patient has radiographic stable disease.", "output": {"cancer_type": "urothelial carcinoma of the bladder", "stage": "II", "gene_mutation": null, "biomarker": "PD-L1 60%", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female diagnosed with left invasive ductal carcinoma, clinical stage IIA (T2N0M0). Tumor was ER positive, PR positive and HER2 negative. Tumor sequencing identified PIK3CA H1047R. She underwent lumpectomy followed by adjuvant chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel) and adjuvant radiation, and is receiving tamoxifen. Recent surveillance shows no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; doxorubicin and cyclophosphamide followed by paclitaxel; adjuvant radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presenting with headaches. Staging workup consistent with stage IV disease with multiple brain metastases on MRI. Tumor genotyping returned EGFR L858R; PD-L1 by IHC 5%. Patient was started on osimertinib 80 mg daily with symptomatic improvement and interval MRI at 8 weeks shows a partial response in intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old woman with metastatic pancreatic ductal adenocarcinoma, stage IV at presentation with multiple liver lesions. Germline testing identified a pathogenic BRCA2 mutation. Baseline CA 19-9 was markedly elevated. She received first-line FOLFIRINOX with partial tumor shrinkage then transitioned to maintenance olaparib due to BRCA2. Latest CT shows disease control without new lesions.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease / disease control", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old male with right-sided colon adenocarcinoma presenting with hepatic lesions and peritoneal nodularity. Staging consistent with metastatic disease (stage IV). Tumor testing: BRAF V600E mutation and MSI-H with high tumor mutational burden. Immunotherapy with pembrolizumab was initiated; interval imaging after 12 weeks demonstrates marked shrinkage of liver metastases consistent with partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with metastatic ER+/PR+ invasive ductal carcinoma of the breast. HER2 amplification confirmed by FISH and baseline tumor sequencing identified a PIK3CA E545K mutation. Imaging demonstrates multiple hypodense lesions in the liver consistent with metastases. She received first-line trastuzumab and pertuzumab with docetaxel, transitioned to maintenance trastuzumab plus letrozole. Best overall response documented as a partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab, docetaxel; maintenance trastuzumab and letrozole", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R mutation. Patient was started on osimertinib 80 mg PO daily three months ago. Baseline MRI showed two small brain metastases treated with stereotactic radiosurgery and bone metastases treated with palliative radiotherapy. Interval CT chest/abdomen shows decrease in size of pulmonary nodules and no new visceral lesions \u2014 overall assessment: partial response to osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with metastatic cutaneous melanoma, stage IV. Next-generation sequencing identified BRAF V600E mutation; PD-L1 was low at 5%. He was treated with the BRAF/MEK combination dabrafenib plus trametinib and achieved a partial response for approximately 9 months before systemic progression with new pulmonary and cerebral lesions. He was then started on combination checkpoint inhibition (nivolumab plus ipilimumab) with a mixed radiographic response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later nivolumab and ipilimumab", "response": "initial partial response then progression; mixed response to immunotherapy", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 55-year-old male with metastatic cutaneous melanoma, BRAF V600E positive and TMB-high. Presents with symptomatic brain metastasis that was resected and then treated with stereotactic radiosurgery. Systemic therapy with ipilimumab and nivolumab was initiated; extracranial lesions have shrunk while one pulmonary lesion enlarged \u2014 described as a mixed response. Stage IV disease at presentation.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "ipilimumab and nivolumab; surgical resection of brain metastasis; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced invasive ductal breast cancer. Core biopsy: ER positive, PR negative, HER2 amplified by FISH. NGS showed a PIK3CA H1047R mutation. Multidisciplinary tumor board recommended neoadjuvant combination therapy \u2014 trastuzumab and pertuzumab with docetaxel for 6 cycles. Imaging and exam after completion show marked tumor reduction but residual disease on MRI.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab; pertuzumab; docetaxel (neoadjuvant combination)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with locally advanced pancreatic ductal adenocarcinoma, borderline unresectable at presentation (stage III). She completed 6 cycles of FOLFIRINOX followed by consolidative chemoradiation. CA 19-9 began to rise post-treatment and CT shows new small peritoneal nodules consistent with metastatic disease. No molecular testing results available in chart.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX; chemoradiation", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man underwent right hemicolectomy for T3N1 colon adenocarcinoma (pathologic stage III). Tumor genotyping demonstrated KRAS G12D mutation; MSI testing was MSS (MSI-stable). He completed 6 months of adjuvant FOLFOX; bevacizumab was added on a trial. Surveillance CTs show no evidence of distant disease; surgical nodes were positive at time of resection.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "right hemicolectomy; adjuvant FOLFOX \u00b1 bevacizumab", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with right-sided colon adenocarcinoma found to have multiple liver metastases on staging CT (clinical stage IV). Tumor profiling reported MSI-H and a concurrent BRAF V600E mutation. Given the MSI-high status she was started on pembrolizumab monotherapy. Interval imaging at 4 months shows marked reduction in size and number of hepatic lesions and falling CEA levels consistent with a partial response.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45F presented with a palpable right breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR negative. FISH positive for HER2 amplification. Clinical stage cT2N1 (stage IIB). FoundationOne NGS identified PIK3CA H1047R. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) \u00d76 cycles followed by lumpectomy; surgical pathology showed pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the right breast (clinical T2N1). Core biopsy: ER+, PR+, HER2 amplified; PIK3CA H1047R identified on panel. She received neoadjuvant paclitaxel weekly x12 with trastuzumab and pertuzumab followed by lumpectomy and sentinel node sampling. Surgical pathology revealed no residual invasive carcinoma \u2014 pathologic complete response. No distant disease on baseline staging.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel, trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man diagnosed with localized prostate adenocarcinoma Gleason 3+4, clinical stage I (T1c). PSA at presentation was 12 ng/mL. Germline testing negative for BRCA1/2. He underwent radical prostatectomy; postoperative PSA became undetectable and there is no evidence of nodal or distant disease on imaging.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (post-op undetectable)", "treatment": "radical prostatectomy", "response": "undetectable PSA", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of a left breast mass demonstrated invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Clinical stage was IIIB with skin involvement. Tumor molecular profiling detected a PIK3CA H1047R hotspot mutation. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab, underwent mastectomy, and surgical pathology revealed a complete pathologic response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant), mastectomy", "response": "complete pathologic response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic melanoma, multiple pulmonary nodules and subcutaneous deposits. Molecular profiling identified NRAS Q61K. PD-L1 testing was not reported. He received combination immunotherapy with ipilimumab and nivolumab. Recent CT shows interval enlargement of several lung nodules but regression of superficial subcutaneous lesions \u2014 overall described by the team as a mixed response with new shortness of breath prompting change in plan.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "ipilimumab and nivolumab", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology letter: 37-year-old woman with left breast invasive ductal carcinoma, clinical stage IIIB with chest wall involvement. Hormone receptor testing ER positive / PR negative and HER2 3+ by IHC (HER2 amplification confirmed by FISH). She received neoadjuvant dose-dense doxorubicin/cyclophosphamide x4 then paclitaxel with trastuzumab, followed by mastectomy and adjuvant pertuzumab for 6 months. Recent imaging shows near complete resolution of axillary adenopathy.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 3+ (HER2 amplification); ER+ / PR-", "treatment": "doxorubicin/cyclophosphamide, paclitaxel, trastuzumab, pertuzumab, mastectomy", "response": "near complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with obstructing sigmoid mass and multiple liver lesions. Biopsy confirmed colon adenocarcinoma, staged as IV. Molecular testing returned KRAS G12D mutation and mismatch repair proficient (microsatellite stable, MSS). He was initiated on FOLFIRI plus bevacizumab; restaging CT after three cycles showed stable disease in the liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFIRI and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress: 59-year-old man with metastatic colorectal adenocarcinoma. Primary tumor was resected; subsequent CT chest shows several new pulmonary nodules concerning for metastases. Somatic testing identified KRAS G12D. He was initiated on FOLFOX with bevacizumab. Patient has had stable disease on two CTs over 3 months. MSI status not reported in this note.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of right breast mass: invasive ductal carcinoma, grade 2. ER 80% positive, PR 10% positive, HER2 IHC 3+ with confirmed HER2 amplification by FISH. Nodal disease on ultrasound; clinical stage cT3N1 (IIIB). Patient received neoadjuvant AC x4 cycles followed by weekly paclitaxel for 12 weeks with concurrent trastuzumab; uncomplicated course. Surgical specimen after lumpectomy and sentinel node biopsy demonstrated no residual invasive carcinoma \u2014 ypT0N0 (pathologic complete response). PIK3CA H1047R noted on targeted panel.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification, ER positive, PR positive", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab (neoadjuvant)", "response": "pathological complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female referred for progressive dyspnea and headaches. CT chest and brain MRI demonstrate metastatic lung adenocarcinoma with multiple cerebral lesions and lytic bone lesions. Staged as IV at diagnosis. Next-generation sequencing identified EGFR L858R; PD-L1 TPS 10%. Patient was started on osimertinib and received whole-brain radiation for symptomatic disease. Interim imaging at 3 months demonstrates decrease in size of pulmonary and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiation", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hospital summary: 67-year-old male admitted with progressive jaundice. Biopsy confirmed pancreatic ductal adenocarcinoma with germline BRCA2 mutation. Staging CT demonstrated multiple hepatic lesions consistent with metastases \u2014 stage IV. He received 6 cycles of FOLFIRINOX with initial decrease in CA19-9, transitioned to maintenance olaparib given BRCA2. Most recent scan shows interval enlargement of liver lesions and rising tumor markers consistent with disease progression.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX; maintenance olaparib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease with multiple brain and bone lesions. Molecular testing returned an EGFR exon 19 deletion (EGFR del19); PD-L1 tumor proportion score approximately 10%. Patient was started on osimertinib 80 mg daily as first-line targeted therapy and at 8-week imaging showed decrease in size of pulmonary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic pancreatic ductal adenocarcinoma presenting with multiple liver lesions (stage IV). Germline BRCA2 mutation identified. CA 19-9 markedly elevated at diagnosis. Treated with FOLFIRINOX x6 cycles with initial tumor shrinkage, then transitioned to olaparib maintenance; most recent CT shows stable disease in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 62-year-old man diagnosed with metastatic colorectal adenocarcinoma with dominant liver metastases. Tumor profiling identified BRAF V600E and high microsatellite instability (MSI-H) with elevated TMB. He initially received FOLFOX plus bevacizumab with disease control, then progressed and was transitioned to encorafenib plus cetuximab per BRAF-directed therapy. Best overall response on targeted therapy was stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX with bevacizumab; later encorafenib plus cetuximab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 67-year-old male with progressive cough. Biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R and concurrent TP53 R273C. PD-L1 TPS 5%. Staging scans show multiple bilateral pulmonary nodules and a 1.5 cm enhancing lesion in the cerebellum consistent with brain metastasis; overall stage IV. Started osimertinib 80 mg daily; after first restaging MRI and CT at 8 weeks there is a decrease in size of both intracranial and thoracic lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; TP53 R273C", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain; lungs (bilateral pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with localized prostate adenocarcinoma (Gleason 3+4), clinical stage IIA. He underwent radical prostatectomy followed by adjuvant external beam radiation and androgen deprivation therapy with leuprolide. Serial PSA levels have been stable since completion of therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant radiation; leuprolide (androgen deprivation)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old woman with locally advanced pancreatic ductal adenocarcinoma abutting the superior mesenteric vessels consistent with stage III disease. Germline testing identified a pathogenic BRCA2 mutation. She received 8 cycles of FOLFIRINOX with radiographic stable disease and decreased CA19-9; given platinum sensitivity she was transitioned to maintenance olaparib. Latest CT shows no new distant mets; disease remains stable.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": "BRCA2 (pathogenic)", "biomarker": "CA19-9 decreased", "treatment": "FOLFIRINOX followed by maintenance olaparib", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic cutaneous melanoma, stage IV with multiple lung nodules. Molecular testing positive for BRAF V600E. He was initially treated with pembrolizumab but showed clinical and radiographic progression after 4 cycles with new pulmonary and subcutaneous lesions; therapy was changed to dabrafenib plus trametinib with subsequent partial response on CT and symptomatic improvement. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (initial) then dabrafenib + trametinib", "response": "progression on pembrolizumab; partial response to dabrafenib+trametinib", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old male with a history of cutaneous melanoma presenting with new neurologic symptoms. MRI demonstrated a right frontal lobe metastasis; chest CT shows multiple pulmonary nodules. Biopsy of the primary skin lesion revealed NRAS Q61K mutation. He underwent stereotactic radiosurgery to the brain lesion and was started on pembrolizumab. After three cycles the oncology note documents a mixed response: some pulmonary nodules decreased in size but a new liver lesion was identified consistent with progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "stereotactic radiosurgery; pembrolizumab", "response": "mixed response with new progression", "metastasis_site": "brain, lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Case note: 45-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIA. Tumor is ER positive, PR positive and shows HER2 amplification by FISH. Somatic panel revealed a PIK3CA E545K mutation. She received neoadjuvant trastuzumab and pertuzumab in combination with docetaxel and underwent mastectomy with pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA E545K", "biomarker": "ER+, PR+, HER2 amplification", "treatment": "trastuzumab and pertuzumab with docetaxel", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed 2019. NGS showed EGFR L858R. Initially started on osimertinib with CNS control for 14 months. On progression with new bone and brain lesions he was switched to combination carboplatin/pemetrexed plus pembrolizumab. PD-L1 TPS reported as 10%. After 3 cycles imaging reveals mixed response with shrinkage of lung nodules but growth of brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "mixed response", "metastasis_site": "bone, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with localized prostate adenocarcinoma detected on screening. PSA at diagnosis 12 ng/mL. Biopsy Gleason 3+4 in three cores. Clinical stage T2a (stage I/II). After multidisciplinary discussion he elected definitive therapy with radical prostatectomy followed by salvage external beam radiation and ADT with leuprolide due to rising PSA post-op. No somatic mutation testing available in chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I/II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL", "treatment": "radical prostatectomy then salvage external beam radiation and leuprolide", "response": "biochemical recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic colorectal adenocarcinoma. NGS identified a KRAS G12D mutation. Tumor testing showed MSI-H. CT abdomen demonstrates multiple hepatic metastases. Patient started FOLFOX plus bevacizumab; restaging after 4 cycles shows stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with metastatic castration-resistant prostate cancer with extensive osteoblastic bone metastases. He has been on leuprolide with addition of enzalutamide; PSA has been rising despite therapy. No actionable alterations were reported on the commercial NGS panel. He was transitioned to docetaxel chemotherapy but after three cycles imaging and PSA indicate progression.", "output": {"cancer_type": "prostate cancer (castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": "rising PSA", "treatment": "leuprolide; enzalutamide; docetaxel chemotherapy", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart: 62-year-old male with metastatic cutaneous melanoma. Next-generation sequencing identified BRAF V600E mutation. He initiated combination targeted therapy with dabrafenib and trametinib. After 3 months the patient reports worsening pain and imaging shows new hepatic lesions with enlargement of prior liver metastases \u2014 overall disease progression. PD-L1 testing not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with locally advanced, unresectable pancreatic ductal adenocarcinoma encasing the SMA (clinical stage III). CA19-9 on presentation was 1200 U/mL. Tumor NGS showed KRAS G12D and a TP53 frameshift. She was started on FOLFIRINOX systemic therapy with subsequent consolidative chemoradiation; restaging CT now demonstrates radiographic stability of the primary mass and no distant metastases identified.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D; TP53 mutation", "biomarker": "CA 19-9 elevated (1200 U/mL)", "treatment": "FOLFIRINOX; consolidative chemoradiation", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative note: right hemicolectomy for colon adenocarcinoma. Pathology: T4a N2, stage IIIC. MSI testing returned MSI-high. KRAS/NRAS testing not yet performed; NGS pending. Patient completed 12 cycles of adjuvant FOLFOX without complications. Surveillance CT shows no radiographic evidence of distant metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "MSI-high", "treatment": "FOLFOX (adjuvant)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male found to have stage III (T3N1M0) colon adenocarcinoma on hemicolectomy. Tumor NGS identified KRAS G12D; microsatellite testing reported MSS. He completed adjuvant FOLFOX for six months. Surveillance imaging at 18 months shows no distant metastatic disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "right hemicolectomy; adjuvant FOLFOX x6 months", "response": "no evidence of disease on surveillance imaging", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man seen for progressive cough and weight loss. Biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Staging PET/CT and brain MRI show multiple cerebral metastases and lytic lesions in the thoracic spine consistent with metastatic disease \u2014 overall stage IV. Patient started first-line osimertinib with good symptomatic improvement.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male presenting with cough and weight loss. Imaging revealed a left upper lobe mass and multiple hepatic and osseous lesions; brain MRI shows two enhancing lesions. Biopsy: lung adenocarcinoma. NGS: EGFR L858R with acquired T790M. PD-L1 TPS 10%. Started erlotinib initially, switched to osimertinib 80 mg daily after T790M identified. Initial shrinkage of chest and liver lesions (partial response) but recent restage shows enlarging brain metastases consistent with radiographic progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "erlotinib; osimertinib", "response": "progression (after initial partial response)", "metastasis_site": "brain; liver; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right forearm nodular melanoma, wide local excision performed. Sentinel node biopsy positive for tumor in one regional lymph node \u2014 staged as III. Targeted panel showed no actionable BRAF mutation; PD-L1 testing was not performed. Patient was started on adjuvant nivolumab per tumor board recommendation. Follow-up imaging at 6 months demonstrates stable postsurgical changes and no new distant disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision and adjuvant nivolumab", "response": "stable disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with cutaneous melanoma, primary resected with positive sentinel node (AJCC stage III). PD-L1 staining was 5% on the tumor. Extended molecular panel did not identify any actionable driver mutations. She received adjuvant combination immunotherapy with nivolumab + ipilimumab (four doses) but subsequently developed immune-related colitis and required steroids. Surveillance imaging now shows new intracranial lesions consistent with progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "nivolumab + ipilimumab (adjuvant)", "response": "progressive disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma to the liver. Biopsy shows KRAS G12D mutation and mismatch repair proteins retained (MSS). He started on FOLFOX with bevacizumab; after 4 months CT shows stable disease by RECIST with no new lesions. Next steps discussed include continuation of systemic therapy and possible hepatic resection if response improves.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (mismatch repair intact)", "treatment": "FOLFOX (5-FU/leucovorin/oxaliplatin) with bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female diagnosed with invasive ductal carcinoma of the right breast. Pathology: stage IIA (pT2 N0), ER positive, PR positive, HER2 negative, Ki-67 ~15%. PIK3CA H1047R identified on next-generation sequencing. She underwent lumpectomy with negative sentinel node and adjuvant radiotherapy; endocrine therapy with tamoxifen planned. No evidence of distant disease on staging CT.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative; Ki-67 15%", "treatment": "lumpectomy, radiotherapy, tamoxifen (adjuvant endocrine therapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with locally advanced left breast invasive ductal carcinoma, clinical stage IIIB. Core biopsy NGS returned PIK3CA E545K. Tumor was ER positive, PR negative; HER2 IHC 3+ with confirmatory FISH showing HER2 amplification. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) followed by mastectomy. Surgical pathology demonstrated a pathologic complete response. No distant metastatic disease identified on staging CT chest/abdomen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification (IHC 3+); ER positive, PR negative", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab; mastectomy", "response": "complete response (pathologic complete response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman with metastatic lung adenocarcinoma, diagnosed stage IV. Molecular testing identified EGFR L858R on the diagnostic biopsy. She was started on erlotinib and had a partial response for 14 months; on clinical progression plasma testing showed emergent EGFR T790M and she was switched to osimertinib with subsequent stable disease. PD-L1 was 5% on the initial sample. Imaging shows known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 5%", "treatment": "erlotinib; osimertinib", "response": "initial partial response then stable disease after osimertinib", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old male found to have a 0.6 mm superficial spreading melanoma on the left forearm. Wide local excision with clear margins performed; sentinel node was negative. Tumor PCR showed BRAF V600E mutation. No adjuvant therapy was recommended given stage I disease; patient placed on dermatologic and oncology surveillance.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old man with metastatic cutaneous melanoma. Primary resected previously; now presents with multiple pulmonary nodules and a solitary cerebellar metastasis. Molecular testing found a BRAF V600E mutation. He was started on dabrafenib and trametinib. After two months of therapy CT shows marked decrease in the size and number of pulmonary nodules and improvement in performance status; clinician documents partial response. Neurosurgery deferred and SRS planned for the brain lesion if not completely resolved.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. ER 80% and PR 30% by IHC; HER2 FISH positive (amplification). Tumor panel identified PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab combined with docetaxel for 6 cycles followed by mastectomy; pathology revealed a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "trastuzumab, pertuzumab, and docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R mutation positive; PD-L1 tumor proportion score 10%. MRI brain demonstrated multiple small enhancing metastases and bone scan revealed lytic lesions in the left femur. Patient started osimertinib 80 mg daily in June 2020 with marked reduction in size of pulmonary and intracranial lesions on first follow-up imaging consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with primary cutaneous melanoma of the left forearm; sentinel lymph node was positive. NGS panel shows NRAS Q61K mutation. Treated with combination checkpoint blockade (ipilimumab and nivolumab) and later single-agent pembrolizumab, but subsequent physical exam and ultrasound show multiple new in-transit lesions and growth of nodal disease consistent with progression. PD-L1 testing not reported in chart and formal AJCC stage not recorded in this note.", "output": {"cancer_type": "cutaneous melanoma", "stage": null, "gene_mutation": "NRAS Q61K", "biomarker": null, "treatment": "ipilimumab + nivolumab, then pembrolizumab", "response": "progression", "metastasis_site": "in-transit lesions, regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with metastatic cutaneous melanoma. Molecular profiling showed BRAF V600E mutation and a high tumor mutational burden (~20 mut/Mb); PD-L1 was 1%. He started combination targeted therapy with dabrafenib and trametinib. Disease remained radiographically stable for 6 months; a single cerebellar metastasis was treated with stereotactic radiosurgery.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (~20 mut/Mb); PD-L1 1%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery (brain)", "response": "stable disease", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. He presented with multiple brain metastases and enlarged cervical nodes. Systemic therapy with dabrafenib plus trametinib was started; extracranial disease showed marked shrinkage consistent with a partial response. Whole brain radiotherapy was administered for symptomatic intracranial disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; whole brain radiotherapy", "response": "partial response (extracranial); intracranial disease treated with WBRT", "metastasis_site": "brain, cervical lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colon adenocarcinoma to the liver. CT-guided biopsy confirmed adenocarcinoma; molecular profiling showed KRAS G12D mutation and microsatellite stable (MSS) status. He was started on FOLFOX plus bevacizumab. First restaging at 12 weeks showed no new lesions and tumor markers stable \u2014 radiographic assessment reported stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic lung adenocarcinoma diagnosed in 2019. Comprehensive genomic profiling revealed EGFR L858R mutation. PD-L1 expression was reported at 10%. He was started on osimertinib in 2020 with rapid symptomatic improvement and shrinkage of pulmonary lesions. MRI and PET show metastatic deposits in the brain and lytic lesions in the femur. Most recent assessment documents a partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 48-year-old female with biopsy-proven invasive ductal carcinoma of the left breast, ER+/PR+, HER2 amplified by FISH. Clinical stage IIIA at presentation with a 4.5 cm primary and fixed axillary nodes. NGS showed a PIK3CA H1047R mutation. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) for six cycles followed by modified radical mastectomy. Surgical path reported no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab (TCHP); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female status post right hemicolectomy for colon adenocarcinoma. Pathology: pT3N0 M0 (stage II). Molecular panel: KRAS G12D detected; mismatch repair proteins intact and MSI-stable. Because of lymphovascular invasion and T3 depth the patient received adjuvant FOLFOX for 6 cycles. Surveillance CT and CEA are currently negative.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man presented to thoracic oncology with newly diagnosed lung adenocarcinoma. Staging workup demonstrated metastatic disease with multiple brain lesions and lytic lesions in the thoracic spine; overall clinical stage IV. Molecular testing returned EGFR L858R and no ALK or ROS1 rearrangement. PD-L1 tumor proportion score approximately 10%. He was started on osimertinib and received stereotactic radiosurgery to the dominant brain metastases. First restaging CT at 8 weeks shows reduction in size of lung primary and several nodal sites consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic melanoma, stage IV at diagnosis. Tumor harbors a BRAF V600E mutation. Initially treated with pembrolizumab but progressed after 4 months; subsequently started on dabrafenib plus trametinib with PET/CT showing partial response in pulmonary nodules and reduction in several hepatic lesions. After 9 months on targeted therapy there is radiographic progression in the liver consistent with treatment failure.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; dabrafenib plus trametinib", "response": "partial response then progression", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with metastatic cutaneous melanoma, stage IV. NGS revealed BRAF V600E mutation; PD-L1 reported >50%. He was started on dabrafenib and trametinib with significant shrinkage of pulmonary nodules but developed new brain metastases treated with stereotactic radiosurgery. Subsequent pembrolizumab produced mixed radiographic response with some lesions regressing and others progressing.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery; pembrolizumab", "response": "mixed response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with left-sided invasive ductal carcinoma, clinical stage II. ER positive, PR positive, HER2 amplification by IHC/FISH. She completed neoadjuvant paclitaxel with trastuzumab followed by lumpectomy and sentinel node biopsy showing no residual invasive disease (pathologic complete response). No distant metastasis identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant paclitaxel and trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed lung adenocarcinoma presenting with cough and weight loss. Staging workup demonstrates stage IV disease with multiple brain and bone metastases. Tumor molecular testing returned EGFR L858R mutation and PD-L1 10% (TPS). He was started on osimertinib 80 mg daily. Interval MRI and CT after 3 months show shrinkage of the primary and intracranial lesions \u2014 overall assessment: partial response to therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman status post lumpectomy for invasive ductal carcinoma of the breast, pathologic stage IIA. Tumor is ER-positive, PR-positive and HER2 amplified by FISH. She completed adjuvant paclitaxel and is receiving trastuzumab planned for 1 year. Surgical margins were negative and current clinical assessment is no evidence of disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "lumpectomy; paclitaxel; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma found to harbor BRAF V600E. Tumor shows high tumor mutational burden. Baseline staging demonstrated multiple hepatic and pulmonary metastases. He was started on pembrolizumab but progressed at first restaging (3 months) and was transitioned to dabrafenib plus trametinib. On targeted therapy the lung lesions have regressed while liver lesions have increased in size \u2014 overall a mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab; dabrafenib and trametinib", "response": "mixed response (partial response in lung, progression in liver)", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old man with newly diagnosed lung adenocarcinoma, stage IV with multiple enhancing brain metastases. Molecular testing returned positive for EGFR L858R; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant cerebellar lesion. Interval imaging at 8 weeks shows shrinkage of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 62-year-old man with unresectable metastatic melanoma. PD-L1 by IHC was 60%. Comprehensive NGS panel showed no actionable mutations. Patient was started on combination nivolumab/ipilimumab but after two doses developed clinical deterioration with new pulmonary nodules and leptomeningeal symptoms; scans consistent with progressive disease.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 60%", "treatment": "nivolumab and ipilimumab", "response": "progressive disease", "metastasis_site": "lung and leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology letter: Patient with metastatic colorectal adenocarcinoma presenting with multiple liver metastases (stage IV). Tumor sequencing: MSI-H and BRAF V600E mutation; KRAS wild-type. Initially treated with FOLFOX chemotherapy, with radiographic progression after 4 cycles. Given MSI-H status, therapy was changed to pembrolizumab monotherapy. Restaging CT after 3 months demonstrates no significant change in liver lesions \u2014 overall assessment: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with newly diagnosed metastatic colorectal adenocarcinoma, stage IV with multiple hepatic lesions. Tumor testing identified KRAS G12D mutation and the tumor is microsatellite stable. He was started on FOLFOX with bevacizumab; CT after 4 cycles demonstrates stable disease compared with baseline.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive on PCR. Baseline staging showed multiple pulmonary nodules and a solitary cerebellar metastasis. Began targeted therapy with dabrafenib and trametinib; pulmonary nodules decreased but brain lesion progressed at 4 months. Switched to pembrolizumab and referred for stereotactic radiosurgery to the cerebellar lesion.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; then pembrolizumab (and stereotactic radiosurgery)", "response": "mixed response with CNS progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with newly diagnosed sigmoid colon adenocarcinoma. Tumor molecular profiling identified KRAS G12D; BRAF and NRAS wild-type. Staging CT showed multiple hepatic lesions consistent with metastatic disease. He was started on FOLFOX plus bevacizumab; after 4 cycles restaging scans demonstrated stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "49-year-old female with metastatic breast cancer. Core biopsy revealed invasive ductal carcinoma, ER/PR negative, HER2 IHC 3+ with confirmed HER2 amplification by FISH. NGS identified a coexisting PIK3CA H1047R mutation. Imaging shows multiple hepatic lesions consistent with liver metastases. Clinical stage IV. Treated with docetaxel plus trastuzumab and pertuzumab; PET/CT after 6 cycles shows complete metabolic response in the liver.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "docetaxel, trastuzumab and pertuzumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed on bronchoscopy in 2022. Comprehensive NGS returned EGFR L858R positive; PD-L1 tumor proportion score reported as 0%. Staging workup consistent with stage IV disease with brain and bony metastases. Patient started osimertinib 80 mg daily in June 2023 and interval MRI/CT shows a partial response with reduction in size of intracranial and vertebral lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 0%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with sigmoid colon adenocarcinoma, pT3N1 (stage III) after anterior resection. Tumor testing: KRAS G12D positive and MSI-H on PCR. Completed adjuvant FOLFOX for 6 cycles. Surveillance CT and CEA are currently negative and patient is clinically NED.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with left breast invasive ductal carcinoma, clinical stage IIA (cT2N0M0). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. Tumor NGS identified a PIK3CA H1047R mutation. She received neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide x4 followed by paclitaxel x12 with concurrent trastuzumab. She subsequently underwent lumpectomy and sentinel node biopsy; surgical pathology reported no residual invasive carcinoma (pathologic complete response). Plan to continue trastuzumab to complete one year.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant doxorubicin + cyclophosphamide then paclitaxel with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consultation: 52-year-old man with metastatic cutaneous melanoma. Molecular testing detected BRAF V600E. Patient presents with symptomatic brain metastases and extracranial nodal disease. He was started on dabrafenib with trametinib; tolerated therapy well with shrinkage of extracranial nodes on exam. PD-L1 testing not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with high-grade serous ovarian carcinoma who underwent optimal debulking. Surgical staging was IIIC with visible peritoneal disease. Tumor NGS identified pathogenic BRCA1 mutation and concurrent TP53 mutation; HRD positive. Patient completed adjuvant carboplatin and paclitaxel x6 cycles and was started on maintenance olaparib. Follow-up CT shows no residual disease and CA-125 normalized \u2014 complete response post-treatment.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation; TP53 mutation", "biomarker": "HRD positive", "treatment": "carboplatin + paclitaxel followed by maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with metastatic pancreatic ductal adenocarcinoma, stage IV at diagnosis. Baseline CA19-9 was markedly elevated to 12,000 U/mL. Germline and tumor profiling returned pathogenic BRCA2 mutation. CT shows multiple hepatic metastases and peritoneal studding. He received FOLFIRINOX with an initial partial radiographic response, then transitioned to olaparib maintenance. Most recent scans show progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; olaparib (maintenance)", "response": "progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 39-year-old man with ulcerated cutaneous melanoma on the left forearm. Sentinel lymph node was positive \u2192 pathologic stage IIIB. BRAF V600E mutation confirmed on PCR. Patient underwent wide local excision with completion lymphadenectomy and was started on adjuvant dabrafenib and trametinib for one year. Surveillance PET/CT shows no radiographic evidence of disease. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "surgery (wide local excision, lymphadenectomy) and adjuvant dabrafenib + trametinib", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44F with HER2-positive metastatic breast cancer (ER-/PR-). Presented with pathologic fracture of the left femur; imaging shows multiple sclerotic bone metastases. IHC HER2 3+ and HER2 FISH positive (HER2 amplification). NGS detected PIK3CA E545K. She was treated with weekly paclitaxel in combination with trastuzumab and pertuzumab. After 6 months on therapy the disease is radiographically stable.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel, trastuzumab, pertuzumab", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology note: 36-year-old woman with a pigmented lesion on the left forearm. Excisional biopsy: superficial spreading melanoma, Breslow 0.9 mm, ulceration absent, sentinel node negative \u2014 clinical stage I. Molecular testing shows BRAF V600E mutation. Patient underwent wide local excision; no adjuvant therapy recommended. At 1-year follow-up there are no signs of recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB. Tumor was ER/PR negative and HER2 amplified by FISH. Baseline NGS showed PIK3CA H1047R and TP53 R175H. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab followed by mastectomy; final pathology demonstrated a complete pathological response.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R; TP53 R175H", "biomarker": "HER2 amplification; ER-/PR-", "treatment": "paclitaxel with trastuzumab and pertuzumab (neoadjuvant), surgery", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with metastatic colon adenocarcinoma presenting with multiple hepatic lesions. Tumor profiling: MSI-H and TMB-high; BRAF V600E mutation detected. Initially treated with FOLFOXIRI plus bevacizumab, with early progression, then switched to pembrolizumab in combination with ipilimumab. Restaging CT after three months showed interval growth of liver metastases.", "output": {"cancer_type": "colon adenocarcinoma", "stage": null, "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOXIRI plus bevacizumab; then pembrolizumab plus ipilimumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old woman diagnosed with high-grade serous ovarian carcinoma after exploratory laparotomy. Germline testing was positive for a deleterious BRCA1 mutation and tumor was HRD-positive. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with bevacizumab and was started on olaparib maintenance because of BRCA1. CA-125 normalized after completion of chemotherapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive; CA-125 elevated at diagnosis", "treatment": "cytoreductive surgery; carboplatin + paclitaxel + bevacizumab; olaparib maintenance", "response": "complete response (CA-125 normalized)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced breast cancer (clinical T3N1) treated neoadjuvantly. Core biopsy demonstrated HER2 amplification by FISH, ER positive (90%), PR positive (40%). Next-generation sequencing showed a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles followed by mastectomy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response). No distant metastases were identified.", "output": {"cancer_type": "breast cancer (HER2-positive, ER+/PR+)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+ 90%; PR+ 40%", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with a 2.1 cm invasive ductal carcinoma of the left breast, ER positive, PR positive, HER2 non-amplified on FISH. Pathology staged as T1cN0M0 (stage I). Tumor profiling identified a PIK3CA H1047R hotspot mutation. She underwent lumpectomy with sentinel lymph node biopsy, adjuvant whole-breast radiation, and was started on tamoxifen. Postoperative surveillance shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel node biopsy; adjuvant radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with localized prostate adenocarcinoma (clinical stage IIB, Gleason 4+3). He underwent radical prostatectomy in May 2023; margins were positive but lymph nodes negative. Adjuvant external beam radiation was completed November 2023. No tumor NGS was performed and no molecular biomarker data are available. On most recent follow-up his PSA is undetectable and there is no radiographic evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIB", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy and adjuvant external beam radiation", "response": "complete response (no evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man underwent urgent right hemicolectomy for a obstructing ascending colon mass. Pathology: moderately differentiated adenocarcinoma, pT3N0 (stage II). Tumor testing: MSI-high by PCR with loss of MLH1 and PMS2 on IHC. KRAS and BRAF mutational panels were negative/not detected. Given the MSI-H status and low-risk features, no adjuvant chemotherapy was administered and patient is on surveillance.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II (pT3N0)", "gene_mutation": null, "biomarker": "MSI-high; MMR deficiency (MLH1/PMS2 loss)", "treatment": "surgical resection (right hemicolectomy), no adjuvant chemotherapy", "response": "no evidence of disease (surveillance)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old woman with high-grade serous ovarian carcinoma, stage IIIC at presentation with bulky peritoneal carcinomatosis. Germline testing positive for BRCA1 5382insC pathogenic variant. CA-125 markedly elevated pre-treatment. She underwent 6 cycles of carboplatin and paclitaxel with interval debulking surgery followed by maintenance olaparib. Follow-up CT shows no residual disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 5382insC (germline)", "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel, interval debulking surgery, maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Presentation: 70-year-old male with progressive jaundice and weight loss. Imaging demonstrates a large pancreatic head mass with multiple hypodense lesions in the liver consistent with metastatic pancreatic ductal adenocarcinoma, stage IV. No actionable mutations were identified on commercial NGS panel. He was started on gemcitabine plus nab\u2011paclitaxel; after two cycles there was clinical deterioration and imaging confirmed interval growth of hepatic metastases.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine plus nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma. Staging workup shows T2N2M1 disease consistent with Stage IV. Molecular testing returned EGFR exon 19 deletion. PD-L1 tumor proportion score approximately 10%. Patient was started on osimertinib after prior induction with carboplatin/pemetrexed; most recent imaging demonstrates a partial response with shrinkage of the dominant right upper lobe mass. Brain MRI showed two small asymptomatic metastases; PET/CT also shows focal uptake in the T8 vertebral body.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib (after carboplatin/pemetrexed)", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 59-year-old with metastatic right-sided colon adenocarcinoma with multiple hepatic metastases. Tumor profiling: BRAF V600E mutation; high microsatellite instability (MSI-H) and TMB-high. Given MSI-H/TMB-high status, he was started on pembrolizumab as first-line systemic therapy and has had a durable partial response on serial imaging over 8 months.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "durable partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with locally advanced invasive ductal carcinoma of the breast (stage IIIB). Core biopsy: HER2 amplified, ER positive, PR negative. Next-generation sequencing identified a PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles with excellent clinical response, proceeded to mastectomy; adjuvant therapy included T-DM1. Final pathology reported a pathologic complete response in the breast and nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant); mastectomy; adjuvant T-DM1", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man presented with weight loss and right upper quadrant pain. Biopsy confirmed colon adenocarcinoma. Staging studies show multiple liver lesions consistent with metastatic disease (stage IV). Tumor testing returned BRAF V600E mutation and MSI-H by PCR. Patient was started on FOLFOX with bevacizumab but CT after 4 cycles showed progression in the liver.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma presenting with headache and back pain. Staging workup revealed multiple intracranial lesions and lytic lesions in the thoracic spine consistent with metastatic disease. Molecular testing returned EGFR L858R and concurrent MET amplification; PD-L1 tumor proportion score 30%. She was started on osimertinib in combination with bevacizumab given CNS disease and suspected VEGF-driven progression. On first restaging at 8 weeks there is a measurable decrease in the size of both brain metastases and spine lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "MET amplification; PD-L1 30%", "treatment": "osimertinib + bevacizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old female presented with pancreatic ductal adenocarcinoma with synchronous liver metastases diagnosed February 2024. Germline and tumor testing demonstrated a deleterious BRCA2 mutation. She received eight cycles of modified FOLFIRINOX with radiographic partial response and then transitioned to maintenance olaparib in June 2024. On olaparib the most recent scans show stable disease and the patient remains clinically well.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "modified FOLFIRINOX; then maintenance olaparib", "response": "stable disease (after partial response to FOLFIRINOX)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 48-year-old woman with locally advanced invasive ductal carcinoma of the breast, cT4bN1M0 (stage IIIB). Core biopsy: HER2 amplification by FISH, ER positive, PR positive; somatic PIK3CA E545K mutation identified on NGS. She received neoadjuvant trastuzumab and pertuzumab with paclitaxel for 4 cycles and went to surgery. Pathology at lumpectomy showed a pathologic complete response in the breast; there had been bulky ipsilateral axillary lymph node involvement on initial imaging.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant trastuzumab and pertuzumab with paclitaxel", "response": "pathologic complete response", "metastasis_site": "axillary lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult: 55-year-old male with rapidly enlarging pigmented scalp lesion. Excisional biopsy consistent with metastatic melanoma. Staging PET/CT demonstrates multiple cerebral lesions and regional nodal involvement. NGS showed an NRAS Q61R mutation; BRAF testing was negative. He was started on combination immunotherapy with nivolumab plus ipilimumab. After two cycles the scans indicate new brain lesions and growth of existing nodal disease despite therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": null, "treatment": "nivolumab plus ipilimumab", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, stage IV, with bulky liver metastases. Tumor profiling returned BRAF V600E and high microsatellite instability (MSI-H) with TMB-high. He was started on pembrolizumab and had an initial radiographic response but later progressed in the liver. Second-line targeted combination therapy with encorafenib plus cetuximab was initiated and disease has remained stable on the latest scans.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab; encorafenib + cetuximab", "response": "stable disease (on encorafenib + cetuximab) after progression on pembrolizumab", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with a palpable left breast mass. Core biopsy: invasive ductal carcinoma, clinical stage IIA (T2N0). ER positive, PR negative, HER2 amplified by FISH. Next-gen sequencing detected a PIK3CA H1047R mutation. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) and proceeded to lumpectomy and sentinel node biopsy. Surgical pathology showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 62-year-old male with newly diagnosed lung adenocarcinoma. Staging workup demonstrates metastatic disease with multiple brain lesions and a 3.2 cm right lower lobe primary \u2014 overall stage IV. Molecular testing returned EGFR L858R mutation; PD-L1 reported at 5%. Started on osimertinib 80 mg daily as first-line targeted therapy. Follow-up MRI at 8 weeks shows decrease in size of intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma to the liver. Mismatch repair testing: MSI-H. Tumor mutational burden reported as TMB-high. Extended molecular panel detected BRAF V600E mutation; KRAS and NRAS were wild-type. Given MSI-H/TMB-high status, patient was started on pembrolizumab. Imaging at 12 weeks shows marked shrinkage of hepatic lesions and declining CEA \u2014 ongoing partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma. Staging PET/CT shows multiple bilateral pulmonary nodules and enhancing cerebellar lesion consistent with metastasis. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the brain lesion. Interval CT at 8 weeks demonstrates decrease in size of target lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% (TPS)", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with stage II (T2N0) invasive ductal breast cancer of the left breast. Tumor is ER positive, PR positive, HER2 negative by IHC/FISH. Somatic panel identified a PIK3CA H1047R mutation. She underwent lumpectomy with sentinel node biopsy followed by adjuvant doxorubicin/cyclophosphamide then paclitaxel (AC\u2192T) and will start adjuvant letrozole. Post-treatment imaging and exam show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2-negative", "treatment": "lumpectomy; adjuvant AC\u2192T (doxorubicin/cyclophosphamide then paclitaxel); letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast mass (cT4bN1) consistent with invasive ductal carcinoma, clinical stage IIIB. Core biopsy: ER negative, PR negative; HER2 amplification by FISH. She received neoadjuvant weekly paclitaxel in combination with trastuzumab and pertuzumab. Clinical exam prior to surgery noted near-complete regression and the patient proceeded to mastectomy. Final pathology reported a pathologic complete response. No tumor sequencing results reported in this note.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel; trastuzumab; pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging PET/CT shows multiple intracranial lesions consistent with metastases. Molecular testing returned EGFR L858R; ALK and ROS1 negative. PD-L1 tumor proportion score ~10%. Patient started first-line osimertinib 80 mg daily and stereotactic radiosurgery to the dominant brain mets. Most recent scan at 8 weeks demonstrates a partial response in the lung primary and decreased size of brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man with newly diagnosed metastatic prostate adenocarcinoma, clinical stage IV, presenting with bony pain. PSA 68 ng/mL at diagnosis. No genomic sequencing available. He was started on androgen deprivation therapy with leuprolide and received palliative docetaxel. Interim bone scan after 4 cycles shows decreased uptake in multiple foci consistent with partial response.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 68 ng/mL", "treatment": "leuprolide and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology summary: 64-year-old male with metastatic pancreatic ductal adenocarcinoma, biopsy proven. At diagnosis he had multiple hepatic lesions and peritoneal nodularity consistent with Stage IV disease. Germline testing identified pathogenic BRCA2 mutation. CA 19-9 markedly elevated. He received first-line FOLFIRINOX for four cycles with initial symptomatic improvement but restaging CT now shows interval increase in hepatic lesions and new ascites. Plan is to transition to gemcitabine/nab-paclitaxel and consider platinum re-challenge given BRCA2 status if clinical benefit is achieved.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA 19-9 elevated", "treatment": "FOLFIRINOX; planned gemcitabine/nab-paclitaxel", "response": "progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with stage IV cutaneous melanoma of the right forearm. Tumor NGS identified BRAF V600E and a high tumor mutational burden (TMB-high). At diagnosis there were multiple osseous lesions and two enhancing brain metastases. He started combination BRAF/MEK targeted therapy with dabrafenib and trametinib and achieved an early partial response extracranially; however interval brain MRI at 6 months demonstrated progression of intracranial disease and overall mixed response with clinical progression in the CNS. He was transitioned to combined ipilimumab and nivolumab.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib + trametinib (followed by ipilimumab + nivolumab)", "response": "initial partial response extracranially then intracranial progression (mixed response/progression)", "metastasis_site": "bone and brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with biopsy-proven lung adenocarcinoma. Staging CT and brain MRI demonstrate multiple intracranial metastases consistent with stage IV disease. Tumor NGS returned positive for EGFR L858R; PD-L1 tumor proportion score reported as 10%. Patient started osimertinib 80 mg PO daily 4 weeks ago with clinical improvement in headaches and interval MRI showing decreased size of several brain lesions \u2014 overall assessed as a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER negative, PR negative. NGS panel identified PIK3CA E545K. She received neoadjuvant trastuzumab and pertuzumab together with docetaxel for 6 cycles, then underwent mastectomy and sentinel node biopsy with a pathologic complete response (no residual invasive carcinoma).", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel (neoadjuvant); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic colorectal adenocarcinoma presenting with multiple liver lesions. Molecular testing: BRAF V600E mutation and MSI-H; tumor was reported as TMB-high. He was started on combination therapy with encorafenib plus cetuximab together with FOLFIRI given symptomatic hepatic disease. First restaging CT shows no new lesions and shrinkage of dominant right lobe deposit \u2014 overall stable disease per RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "encorafenib + cetuximab + FOLFIRI", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Breast clinic note: 48-year-old woman diagnosed with locally advanced invasive ductal carcinoma, clinical stage IIIB. Core biopsy: HER2 amplification by FISH, ER positive, PR negative. NGS identified PIK3CA H1047R mutation. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles and proceeded to mastectomy; final pathology showed a pathologic complete response.", "output": {"cancer_type": "invasive ductal breast carcinoma", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab and pertuzumab with docetaxel (neoadjuvant); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old with metastatic cutaneous melanoma diagnosed after excision of a scalp lesion. PET/CT shows pulmonary nodules and several intracranial metastases. Molecular testing demonstrates a BRAF V600E mutation. The patient received first-line dabrafenib plus trametinib with shrinkage of some lung lesions, but intracranial disease progressed and he was switched to pembrolizumab; response has been mixed with improvement in extracranial disease but persistent brain lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib followed by pembrolizumab", "response": "mixed response (extracranial improvement, intracranial progression)", "metastasis_site": "lung; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 62-year-old with high-grade serous ovarian carcinoma, optimal cytoreductive surgery performed for stage IIIC disease with omental and peritoneal involvement. Germline testing returned positive for a pathogenic BRCA1 5382insC variant. Patient completed adjuvant carboplatin and paclitaxel x6 cycles and was placed on maintenance olaparib. CA-125 normalized and recent CT shows no evidence of residual disease \u2014 clinical complete response to therapy.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 5382insC", "biomarker": "CA-125 (normalized) ; BRCA1 pathogenic variant", "treatment": "debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with biopsy-proven invasive ductal carcinoma of the left breast. ER positive, PR positive; HER2 IHC 3+ with FISH amplification. Clinical staging showed T4b disease consistent with stage IIIB. NGS identified PIK3CA H1047R. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab for six cycles. Post-treatment imaging and exam demonstrated near-complete clinical response; mastectomy revealed pathologic complete response with no residual invasive tumor. No distant disease on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER+; PR+", "treatment": "paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Medical oncology note: 67-year-old man with castration-resistant prostate cancer presenting with worsening bone pain. Germline and somatic testing identified a pathogenic BRCA2 frameshift mutation. Previously received androgen-deprivation therapy and docetaxel; started on olaparib for BRCA2-associated disease with partial PSA and radiographic improvement after 3 months. Bone scan shows multiple osseous lesions.", "output": {"cancer_type": "prostate cancer", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "olaparib (after prior docetaxel and ADT)", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "64-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Biopsy showed EGFR L858R mutation and PD-L1 10% by IHC. Staging at diagnosis was IV with brain and bone metastases. Patient has been on osimertinib 80 mg daily since August 2020 with marked decrease in intracranial lesions and regression of several osseous mets \u2014 overall a partial response on most recent scans.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 63-year-old man with locally advanced esophageal squamous cell carcinoma. He completed definitive concurrent chemoradiation with weekly carboplatin AUC2 and paclitaxel while receiving 50.4 Gy radiation. Post-treatment endoscopy showed significant tumor regression. Molecular testing was not performed at the time and there was no radiographic evidence of distant spread.", "output": {"cancer_type": "esophageal squamous cell carcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "concurrent chemoradiation (weekly carboplatin + paclitaxel with radiation)", "response": "partial response / significant tumor regression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic pancreatic ductal adenocarcinoma found on biopsy of a pancreatic head mass. Germline testing positive for BRCA2 pathogenic variant. She completed 8 cycles of FOLFIRINOX with partial radiographic benefit and was transitioned to maintenance olaparib. Recent CA19-9 is down from baseline and follow-up imaging demonstrates no interval progression; patient clinically doing well on oral PARP therapy.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": null, "gene_mutation": "BRCA2 (germline)", "biomarker": null, "treatment": "FOLFIRINOX, olaparib (maintenance)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man presenting with progressive cough and weight loss. Imaging revealed a right lower lobe mass and widespread disease consistent with stage IV lung adenocarcinoma (T2N3M1c). Molecular panel positive for EGFR L858R; ALK and ROS1 negative. PD-L1 TPS 1%. MRI of the brain showed multiple small enhancing lesions and bone scan confirmed osseous involvement. He was started on osimertinib and had symptomatic improvement; CT at 8 weeks documented a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 68-year-old man with metastatic castration-resistant prostate adenocarcinoma, prior ADT and radiotherapy to the prostate. No somatic or germline genomic testing performed. Currently receiving docetaxel chemotherapy followed by abiraterone acetate for systemic disease control; recent bone scan demonstrates new sclerotic lesions and symptomatic progression with rising PSA.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "docetaxel and abiraterone", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with BRAF V600E-mutant metastatic melanoma. Presented with multiple pulmonary and one cerebellar metastasis treated with stereotactic radiosurgery. He was started on combination targeted therapy with dabrafenib and trametinib up front. Early follow-up PET/CT demonstrates a marked metabolic response with >50% reduction in FDG uptake and near-complete resolution of several targets consistent with a partial response.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "lung and cerebellum (brain)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 59-year-old man with metastatic colon adenocarcinoma, biopsy-confirmed. Molecular profile: KRAS G12D mutation, tumor is MSI-H. Initially treated with FOLFOX for three months with radiographic progression in the liver; transitioned to pembrolizumab with subsequent disease stabilization on restaging CT at 12 weeks.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced breast cancer (invasive ductal carcinoma) biopsy showing HER2 amplification (IHC 3+), ER negative, PR negative. Nodal disease on imaging consistent with clinical stage IIIB. Tumor sequencing identified PIK3CA H1047R. She received neoadjuvant paclitaxel and carboplatin in combination with trastuzumab for 6 cycles followed by mastectomy. Surgical pathology demonstrated pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification (IHC 3+); ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and carboplatin with trastuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left breast cancer, ER+/PR+, HER2-amplified invasive ductal carcinoma, clinical stage IIIB. Core biopsy demonstrated PIK3CA H1047R mutation in NGS panel. She received neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab for 6 cycles, proceeded to mastectomy with axillary dissection. Pathology after surgery showed a pathological complete response (pCR). No distant disease identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant carboplatin and docetaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathological complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with newly diagnosed metastatic lung adenocarcinoma, stage IV. Tumor genotyping identified EGFR L858R; PD-L1 was 10%. He was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery for a symptomatic brain metastasis. Imaging showed an initial partial response at 3 months but recent scans demonstrate interval growth consistent with progression. Bone and liver lesions present on PET/CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed metastatic lung adenocarcinoma. Initial molecular panel did not detect EGFR, ALK or ROS1 alterations and no actionable driver was reported. PD-L1 expression by IHC: TPS 60%. Tumor mutational burden reported as TMB-high (18 muts/Mb). Staging workup consistent with Stage IV disease with multiple pulmonary nodules, two small brain metastases on MRI, and lytic lesions in the pelvis. Patient started on carboplatin + pemetrexed + pembrolizumab combination; received stereotactic radiosurgery to the brain lesions. After 3 cycles there is interval decrease in target lesions on CT chest/abdomen consistent with partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 TPS 60%, TMB-high (18 muts/Mb)", "treatment": "carboplatin + pemetrexed + pembrolizumab, stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone, lung (pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female with metastatic lung adenocarcinoma was found to harbor EGFR exon 21 L858R with an acquired T790M on repeat biopsy after progression on erlotinib. PD-L1 IHC reported 2%. Brain MRI demonstrated multiple small parenchymal metastases and bone scan showed uptake in the spine. She was started on osimertinib 80 mg daily with clinical improvement and interval CT chest/abdomen at 8 weeks showed decreased size of pulmonary nodules consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; T790M", "biomarker": "PD-L1 2%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced left breast cancer (T4bN1). Core biopsy: invasive ductal carcinoma, ER+, PR-, HER2 amplified by FISH. Tumor NGS showed PIK3CA H1047R and a deleterious BRCA2 frameshift. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab for 12 weeks followed by mastectomy. Surgical pathology revealed no residual invasive carcinoma (pathologic complete response). No radiographic metastases identified pre-op.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R; BRCA2 frameshift", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab, then mastectomy", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "35-year-old woman with a rapidly enlarging pigmented lesion on the upper arm. Excisional biopsy: cutaneous melanoma, unresectable nodal involvement consistent with stage IIIC. Molecular testing positive for BRAF V600E; PD-L1 expression <1%. Started on combined targeted therapy with dabrafenib and trametinib \u2014 initially had complete clinical response, but surveillance MRI later revealed new brain metastases and overall clinical progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 <1%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old male with cutaneous melanoma found to have a BRAF V600E mutation. PET/CT showed multiple pulmonary nodules consistent with metastatic disease. He was started on dabrafenib plus trametinib. Early follow-up CT after 6 weeks demonstrated a marked decrease in size of the lung lesions consistent with a partial response.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer, core biopsy ER 80%+, PR 60%, HER2 IHC 3+ confirming HER2 amplification. Nodal disease on ultrasound consistent with clinical stage IIIB. Next-generation sequencing detected PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles followed by lumpectomy and axillary dissection. Path report documents a pathological complete response. BRCA1/2 germline testing was negative.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER 80%, PR 60%, HER2 amplification (IHC 3+)", "treatment": "trastuzumab and pertuzumab with docetaxel (neoadjuvant), surgery", "response": "pathological complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old with sigmoid colon adenocarcinoma, pathologic staging pT3N2 consistent with stage III disease. Received 6 cycles of neoadjuvant FOLFOX prior to resection. Molecular testing reported KRAS G12D and microsatellite-stable (MSI-stable). Interval CT showed reduction in nodal burden but residual tumor \u2014 interpreted as a partial response to chemotherapy.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old with locally advanced breast cancer\u2014invasive ductal carcinoma, HER2 amplified, ER negative, PR negative. Clinical stage IIIA. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab. Mastectomy pathology after chemo showed no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 58-year-old female presented with a 2.5 cm left breast mass. Core biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 negative by IHC and FISH. Surgical pathology after lumpectomy: invasive carcinoma 2.4 cm, 1/15 sentinel nodes positive, final stage IIA (pT2N1). Molecular testing identified PIK3CA H1047R. Patient completed adjuvant radiation and has been started on letrozole. Current status: no evidence of disease on 6\u2011month follow up.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, adjuvant radiation, letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with metastatic lung adenocarcinoma diagnosed 12/2023. Molecular testing returned EGFR L858R; T790M negative. PD-L1 TPS 10%. MRI brain demonstrates two enhancing lesions consistent with metastases. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to both intracranial lesions. At 8-week follow-up CT/PET there is decrease in size of pulmonary nodules and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with newly diagnosed metastatic prostate adenocarcinoma. Bone scan demonstrated multiple sclerotic lesions consistent with osseous metastases. Germline and tumor testing showed a pathogenic BRCA2 mutation. PSA at diagnosis was 380 ng/mL. He was started on androgen deprivation with leuprolide and received six cycles of docetaxel followed by salvage enzalutamide. Imaging over 4 months shows stable bony disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA 380 ng/mL", "treatment": "leuprolide, docetaxel, then enzalutamide", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old F with metastatic lung adenocarcinoma diagnosed 2019. NGS panel returned EGFR L858R; PD-L1 tumor proportion score 10%. Baseline brain MRI demonstrated two enhancing lesions consistent with metastases. Patient started osimertinib 80 mg daily in Jan 2020. Three-month restaging CT/MRI showed decrease in size of both intracranial and pulmonary disease. Impression: partial response to EGFR TKI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma. Staging CT and brain MRI at diagnosis demonstrated multiple enhancing lesions consistent with brain metastases. Molecular testing returned EGFR L858R positive; PD-L1 tumor proportion score 10%. Patient was staged as IV and started osimertinib 80 mg daily as first-line targeted therapy. After 6 months of therapy there is radiographic progression in the CNS with enlarging parietal lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Admission: 59-year-old male with obstructing sigmoid colon mass. Biopsy = moderately differentiated adenocarcinoma. CT chest/abdomen/pelvis reveals multiple liver lesions consistent with metastases \u2014 consistent with stage IV disease. Tumor genotype: KRAS G12D positive; MSI testing shows microsatellite stable (MSS). PD-L1 by IHC negative. Started FOLFOX with bevacizumab; after three cycles repeat CT shows stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS); PD-L1 negative", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Summary: 60-year-old female with metastatic gastric adenocarcinoma (HER2 IHC 3+ / FISH positive) presenting with multiple liver metastases. She received trastuzumab in combination with capecitabine and oxaliplatin (XELOX). CT after three cycles showed no new lesions and minimal shrinkage of target liver lesions \u2014 overall stable disease. No comprehensive next-generation sequencing was performed at the time.", "output": {"cancer_type": "gastric adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification (IHC 3+, FISH positive)", "treatment": "trastuzumab with capecitabine and oxaliplatin (XELOX)", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for T3N0 colon adenocarcinoma, final pathologic stage II. Mismatch repair testing showed MSI-H. Given the stage and MSI-H status the team elected observation and no adjuvant chemotherapy. Surveillance CT at 12 months demonstrates no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy (no adjuvant chemotherapy)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with a rapidly enlarging right breast mass. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH; ER and PR negative. Clinical staging recorded as T4bN2M0 (stage IIIB). She received neoadjuvant chemotherapy with docetaxel plus trastuzumab and pertuzumab for 6 cycles followed by mastectomy. Surgical pathology revealed no residual invasive carcinoma\u2014pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "neoadjuvant docetaxel with trastuzumab and pertuzumab followed by surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology progress: 55-year-old man with metastatic cutaneous melanoma, BRAF V600E on molecular testing. Presents with cough and multiple pulmonary nodules on chest CT consistent with lung metastases. Treated with dabrafenib plus trametinib for BRAF-mutant disease; best response was stable disease over 4 months. PD-L1 was reported as 60% on initial biopsy.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old man presenting with progressive back pain. Imaging demonstrates metastatic prostate adenocarcinoma with multiple osseous lesions and pelvic lymphadenopathy. No somatic genomic testing has been performed to date. He was started on androgen deprivation therapy (leuprolide) and received palliative radiation to T8; docetaxel chemotherapy planned. Repeat CT after 3 cycles shows decreased size of several bone lesions with symptomatic improvement.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "androgen deprivation therapy (leuprolide), palliative radiation, docetaxel planned", "response": "partial response", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO IIIC with diffuse peritoneal carcinomatosis at presentation. CA-125 markedly elevated. She received neoadjuvant carboplatin and paclitaxel with interval cytoreductive surgery. No pathogenic BRCA1/2 mutation was detected on germline testing. Post-op imaging shows a complete radiographic response of bulky peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "CA-125 elevated", "treatment": "carboplatin and paclitaxel with interval cytoreductive surgery", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing of the bronchoscopic biopsy returned EGFR L858R. PD-L1 by IHC was 10%. Patient was started on osimertinib 80 mg daily and tolerated therapy well. First restaging CT and MRI brain after 8 weeks show a 45% decrease in measurable pulmonary nodules and stable small enhancing brain metastases; patient reports improvement in cough and bone pain. Plan: continue osimertinib.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly diagnosed lung adenocarcinoma. Staging workup consistent with stage IV disease with multiple enhancing lesions in the cerebrum and osseous involvement. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 5%. She was started on osimertinib 80 mg daily and stereotactic radiosurgery to a dominant brain metastasis. Interim imaging at 8 weeks shows a decrease in size of pulmonary nodules and partial regression of intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver metastases. Molecular testing returned KRAS G12D mutation and was MSI-H with high TMB. After progression on first-line FOLFOX, he was switched to pembrolizumab monotherapy given MSI-H status. Restaging after 4 cycles shows no new lesions and minor interval shrinkage of some hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male presenting with progressive back pain found to have metastatic prostate adenocarcinoma with multiple osseous lesions on bone scan. PSA markedly elevated. Clinical staging consistent with stage IV disease. He was started on androgen deprivation therapy with leuprolide and received six cycles of docetaxel; palliative radiotherapy given to T12 for cord compression symptoms. No genomic testing performed. Repeat imaging at 4 months demonstrates radiographic stability of spinal and pelvic bone lesions.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide (androgen deprivation), docetaxel, palliative radiotherapy to T12", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "46-year-old woman with locally advanced invasive ductal breast carcinoma (ER+, PR+, HER2 amplified), clinically staged as IIIA with fixed axillary nodes. Neoadjuvant regimen included docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles. NGS identified a PIK3CA H1047R mutation. She proceeded to lumpectomy and axillary dissection; surgical pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified on staging PET/CT.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+, PR+", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic summary: 58M with recurrent cutaneous melanoma involving regional nodes; pathologic stage IIIC at initial nodal dissection. Tumor harbors BRAF V600E mutation. Initially started on pembrolizumab but after 4 cycles had radiographic progression with new pulmonary nodules. Therapy was switched to dabrafenib plus trametinib with subsequent radiologic partial response noted on PET/CT.", "output": {"cancer_type": "melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib and trametinib", "response": "progression on pembrolizumab then partial response on dabrafenib/trametinib", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology / oncology summary: Invasive ductal carcinoma of the left breast, HER2-positive by IHC/FISH, ER/PR negative. Staging imaging demonstrates multiple hepatic lesions consistent with metastases. Tumor genomics identified PIK3CA H1047R. Patient started first-line systemic therapy with trastuzumab plus weekly paclitaxel. After 3 cycles, restaging CT shows disease that is radiographically stable.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "trastuzumab and paclitaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 47-year-old female with de novo metastatic breast cancer. Core biopsy of liver lesion confirmed invasive ductal carcinoma, HER2 amplification by FISH; ER/PR negative. Patient was staged as stage IV at presentation with multiple hepatic lesions on CT. She initiated first-line therapy with docetaxel plus trastuzumab and pertuzumab. Interim imaging after three cycles shows marked reduction in hepatic tumor burden consistent with partial response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note (brief): 71-year-old male with metastatic colon adenocarcinoma with new hepatic lesions on CT. Primary was resected previously. Extended molecular panel results are pending and not available in chart at this visit. Patient initiated FOLFOX plus bevacizumab. First restaging CT at 6 weeks shows no significant change in size of liver lesions \u2014 stable disease by RECIST. KRAS/NRAS/BRAF testing not recorded here.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFOX; bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with castration-resistant prostate adenocarcinoma. Originally diagnosed with Gleason 9 disease; now with multifocal osseous metastases and pelvic nodal involvement consistent with stage IV. He was treated with enzalutamide and later received docetaxel for rising PSA. Serial bone scans and CT imaging have remained stable for nine months. No genomic sequencing was performed and no tumor biomarker testing beyond PSA was available in the record.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "enzalutamide and docetaxel", "response": "stable disease", "metastasis_site": "bone and pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 45-year-old male with recurrent metastatic cutaneous melanoma, BRAF V600E positive. He initially received nivolumab with partial benefit but later progressed in the lungs; therapy was transitioned to dabrafenib 150 mg BID plus trametinib 2 mg daily. Interim CT at 6 weeks shows no new lesions and slight decrease in target pulmonary nodules; assessment is stable disease. Tumor mutational burden reported as high (18 muts/Mb).", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high (18 muts/Mb)", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Young adult with ulcerated pigmented lesion on the upper arm found to be cutaneous melanoma with palpable ipsilateral axillary nodes. Pathology staged as III with multiple positive sentinel nodes. Molecular testing identified BRAF V600E. He received adjuvant targeted therapy with dabrafenib plus trametinib. After 6 months of therapy there was clinical progression with new satellite nodules and enlarging nodal disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 48-year-old woman with locally advanced left breast cancer. Core biopsy showed invasive ductal carcinoma with HER2 amplification by FISH; clinical stage IIIB. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab. Post-mastectomy pathology reported no residual invasive carcinoma (pathologic complete response). PET/CT negative for distant disease.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Staging CT and MRI show multiple pulmonary nodules and a 1.5 cm cerebellar lesion consistent with metastasis. Molecular testing returned EGFR L858R and PD-L1 10%. Patient was started on osimertinib 80 mg daily with good tolerability. At first restaging at 8 weeks there was a decrease in size of the lung lesions and the brain lesion \u2014 overall assessment: partial response. Plan is to continue targeted therapy and consider stereotactic radiosurgery to the brain lesion if needed.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and lung (pulmonary nodules)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man diagnosed with intermediate-risk prostate adenocarcinoma, Gleason 3+4, clinical stage T2b. Pre-op PSA 12 ng/mL. He underwent radical prostatectomy followed by adjuvant intensity-modulated radiation therapy and short-course androgen deprivation with leuprolide. Post-treatment PSA is undetectable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL pre-treatment", "treatment": "radical prostatectomy, adjuvant radiation, androgen deprivation therapy (leuprolide)", "response": "undetectable PSA (biochemical response)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presented with headaches and worsening back pain. Staging workup showed metastatic disease to the brain and thoracic spine. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. He was started on osimertinib as first-line therapy with good symptomatic improvement; first restaging CT and MRI show decrease in size of intracranial and osseous lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, spine (bone)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma, liver-dominant disease, initially progressed on FOLFOX. Tumor profiling showed BRAF V600E mutation and MSI-H status with high tumor mutational burden. Given MSI-H, pembrolizumab was started as second-line therapy and the patient achieved a durable complete radiographic response of the liver lesions after 4 months.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab", "response": "complete response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Chart note: 48-year-old female with metastatic breast cancer, HER2-positive on FISH (HER2 amplification). ER/PR positive. Bone scan demonstrates multiple sclerotic lesions in thoracic spine and pelvis consistent with osseous metastases. She was initiated on trastuzumab and docetaxel; monthly zoledronic acid was added for bone disease. Latest restaging CT shows no new lesions and overall stable disease. No comprehensive somatic mutation panel available.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification", "treatment": "trastuzumab and docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old with metastatic pancreatic ductal adenocarcinoma presenting with progressive jaundice and weight loss. CT shows multiple hepatic lesions consistent with mets (largest 4.2 cm). Germline and somatic testing identified BRCA2 truncating mutation. CA19-9 markedly elevated. He received FOLFIRINOX with partial radiographic response and was transitioned to olaparib maintenance; recent imaging shows stable disease on maintenance.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 truncating mutation", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX followed by olaparib maintenance", "response": "partial response to chemo, stable disease on maintenance", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 58-year-old man with metastatic pancreatic ductal adenocarcinoma, presented with jaundice and weight loss. Imaging shows multiple hepatic lesions consistent with metastatic disease (stage IV). CA19-9 markedly elevated. Molecular testing not performed due to poor performance status. He was started on gemcitabine plus nab-paclitaxel; after two cycles there was clinical decline and radiographic progression in the liver.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "CA19-9 elevated", "treatment": "gemcitabine plus nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with locally advanced colon adenocarcinoma, clinical stage III (cT3N1). Molecular testing shows KRAS G12D; tumor is microsatellite stable (MSS). He received neoadjuvant FOLFOX for bulky nodal disease and on interval CT imaging the disease is stable compared with baseline.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX (neoadjuvant)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with metastatic castration-resistant prostate adenocarcinoma with extensive sclerotic bone metastases on bone scan. PSA is 32 ng/mL and AR\u2011V7 testing returned negative. He had prior orchiectomy and was started on enzalutamide; after a transient PSA decline he progressed clinically and was transitioned to docetaxel chemotherapy with ongoing androgen deprivation. Most recent scan shows stable osseous disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 32 ng/mL; AR-V7 negative", "treatment": "enzalutamide (prior); docetaxel (current) with androgen deprivation", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed lung adenocarcinoma presented with headaches. Staging CT and brain MRI show multiple cerebellar metastases and bilateral pulmonary nodules consistent with stage IV disease. Tumor genotyping demonstrated EGFR L858R. PD-L1 was reported at 60%. He was started on osimertinib with good clinical improvement and interval imaging after 8 weeks showed a partial response in the chest and decreased size of intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with high-grade prostate adenocarcinoma (Gleason 4+5) presented with symptomatic bone pain. Staging confirms osseous metastases to spine and pelvis consistent with metastatic prostate cancer, stage IV. PSA at diagnosis was 150 ng/mL. Germline testing positive for BRCA2 mutation. He was started on androgen deprivation with leuprolide plus docetaxel chemotherapy; early follow-up documents biochemical progression and worsening bone pain.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "PSA 150 ng/mL", "treatment": "leuprolide (androgen deprivation) and docetaxel", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with cutaneous melanoma metastatic to lung and brain (stage IV). Molecular testing positive for BRAF V600E; PD-L1 TPS >50%. He initially received pembrolizumab but developed intracranial progression after 3 months. Therapy was changed to dabrafenib plus trametinib with good clinical improvement and partial response on systemic imaging.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab followed by dabrafenib + trametinib", "response": "progression on pembrolizumab then partial response to BRAF/MEK inhibitor", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and oncology summary: 61-year-old man underwent subtotal resection for a right temporal glioblastoma. Post-op MRI consistent with residual enhancing tumor; final diagnosis glioblastoma, WHO grade IV. He was treated with concurrent radiotherapy and temozolomide followed by adjuvant temozolomide per Stupp protocol. Surveillance imaging shows interval enlargement of the enhancing mass concerning for progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgery; radiation with concurrent and adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing showed EGFR L858R by PCR. PD-L1 TPS was 10%. At presentation he had bone metastases and developed brain metastases later. He was started on osimertinib 80 mg daily in June 2019 with an initial radiographic partial response; interval imaging in July 2020 demonstrated progression in the brain and extracranial sites and plans were made to change systemic therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "initial partial response followed by progression", "metastasis_site": "bone; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced right breast invasive ductal carcinoma. Clinical T3N1 disease (stage IIIB). ER 80%+, PR 30%+, HER2 IHC 3+ with confirmed HER2 amplification by FISH. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for six cycles with excellent clinical response and subsequently underwent mastectomy. Final pathology shows no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast invasive ductal carcinoma (HER2-positive)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab, pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma presented with right upper quadrant pain. Biopsy confirmed lung adenocarcinoma, molecular testing showed KRAS G12C and tumor PD-L1 30%; TMB-high noted on comprehensive NGS. Staging PET/CT showed widespread hepatic and osseous disease consistent with stage IV. He was started on combination therapy with carboplatin, pemetrexed and pembrolizumab (4 cycles) with concurrent maintenance pembrolizumab planned. Interim CT after 3 cycles demonstrated a 40% reduction in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 30%, TMB-high", "treatment": "carboplatin + pemetrexed + pembrolizumab (chemoimmunotherapy); maintenance pembrolizumab", "response": "partial response", "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old premenopausal woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: ER positive, PR positive, HER2 IHC 3+ with FISH-confirmed HER2 amplification. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) followed by mastectomy; surgical pathology returned ypT0N0 indicating a complete pathologic response.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP)", "response": "complete pathologic response (ypT0N0)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man with metastatic lung adenocarcinoma (diagnosed 2018). Staging: IV with brain and bone metastases. Comprehensive NGS revealed EGFR L858R and MET amplification. PD-L1 tumor proportion score 15%; TMB low. He was started on osimertinib first-line with a partial response, but developed intracranial progression and was switched to combination carboplatin + pemetrexed and pembrolizumab. Imaging now shows reduction in extracranial disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "MET amplification; PD-L1 15%; TMB-low", "treatment": "osimertinib; carboplatin + pemetrexed + pembrolizumab", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right hemicolectomy performed for colon adenocarcinoma, pathologic stage III (pT3N1). Tumor testing returned MSI-H by PCR. Patient completed adjuvant FOLFOX x 6 cycles. No actionable mutations were identified on the institutional NGS panel and the patient remains on surveillance with no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with metastatic lung adenocarcinoma (cT4N2M1) presenting with cough and weight loss. Molecular testing showed KRAS G12C and a high tumor mutational burden (TMB-high, 22 muts/Mb); PD-L1 TPS 70%. He received first-line pembrolizumab with carboplatin and pemetrexed and achieved a partial response. After 10 months there was oligoprogression with new brain and bone lesions; therapy was switched to sotorasib with palliative stereotactic radiosurgery to the brain mets.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": "PD-L1 70%; TMB-high (22 muts/Mb)", "treatment": "pembrolizumab + carboplatin and pemetrexed; sotorasib; stereotactic radiosurgery", "response": "partial response (to first-line); progression/oligoprogression (brain and bone)", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology consult: 52-year-old man with a 0.6 mm superficial spreading melanoma on the left forearm, margins clear after wide local excision; sentinel lymph node negative. Final stage I. Tumor next-generation sequencing detected BRAF V600E. No adjuvant systemic therapy was given and patient remains clinically well with no recurrence at 6-month follow-up.", "output": {"cancer_type": "cutaneous melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male presented with obstructing right colon mass. Pathology: moderately differentiated adenocarcinoma, final pathologic staging T3N1 (stage III). Somatic testing reported KRAS G12D. He underwent right hemicolectomy followed by adjuvant FOLFOX for 6 months and is currently on routine surveillance with no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "right hemicolectomy, adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with stage IV cutaneous melanoma presented with multiple pulmonary nodules and symptomatic brain metastases. Molecular testing positive for BRAF V600E. PD-L1 was 80% and tumor mutational burden was high. He received combination immunotherapy with ipilimumab plus nivolumab and had an initial systemic partial response; persistent CNS disease required craniotomy and stereotactic radiosurgery. After intracranial progression he was started on dabrafenib plus trametinib.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 80%; TMB-high", "treatment": "ipilimumab + nivolumab; stereotactic radiosurgery; dabrafenib + trametinib", "response": "initial partial response systemically; intracranial progression", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old woman presented with high-grade serous ovarian carcinoma with omental caking and peritoneal implants; CT and operative findings were consistent with stage IIIC disease. Germline testing positive for a pathogenic BRCA1 variant (BRCA1 185delAG). CA-125 markedly elevated at diagnosis. She received neoadjuvant carboplatin and paclitaxel with bevacizumab, underwent interval debulking, and had a partial radiographic response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "III", "gene_mutation": "BRCA1 185delAG", "biomarker": "CA-125 elevated", "treatment": "neoadjuvant carboplatin and paclitaxel with bevacizumab, interval debulking surgery", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "41-year-old woman with invasive ductal carcinoma of the left breast, clinical stage IIA. Core biopsy: ER positive, PR negative, HER2 amplification by FISH. Tumor sequencing reported PIK3CA H1047R. She received neoadjuvant docetaxel and carboplatin with trastuzumab followed by lumpectomy; pathology after surgery showed no residual invasive carcinoma (pathologic complete response). No radiographic evidence of distant disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Tissue NGS demonstrated EGFR L858R. She presented with headaches and MRI confirms multiple intracranial metastases. PD-L1 by IHC was 10%. Osimertinib 80 mg once daily was started July 2020 with clinical improvement and interval decrease in size of pulmonary and brain lesions on CT/MRI \u2014 documented partial response on first restaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 54-year-old female with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, HER2 amplification by FISH; ER/PR negative. Neoadjuvant regimen: weekly paclitaxel with trastuzumab for 12 weeks prior to definitive surgery. Post-op pathology demonstrated no residual invasive tumor in the breast or nodes (pathologic complete response). No distant disease identified on staging CT prior to chemo.", "output": {"cancer_type": "breast cancer", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "paclitaxel and trastuzumab (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 70-year-old male with metastatic colorectal adenocarcinoma presenting with progressive jaundice. CT demonstrates multiple hypodense liver lesions consistent with hepatic metastases; colon primary previously resected. Tumor is MSI-stable by PCR. KRAS testing was not informative / failed and no actionable mutation identified. He was started on FOLFIRI with bevacizumab; after 3 cycles there is radiographic progression of hepatic disease and rising CEA consistent with progressive disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "MSI-stable", "treatment": "FOLFIRI and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma presented to clinic. Biopsy confirmed lung adenocarcinoma, stage IV with multiple hepatic lesions. Molecular testing returned EGFR L858R mutation. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily three weeks ago. Interval CT shows decrease in size of liver metastases and shrinkage of the primary lung mass.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neurosurgery summary: 55-year-old male underwent resection of a right temporal mass; pathology consistent with glioblastoma, WHO grade IV. IDH1 was wildtype on testing; MGMT promoter methylation was positive. He completed concomitant radiation with daily temozolomide and then adjuvant temozolomide. Surveillance MRI at 9 months shows increased enhancing tumor consistent with progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylation positive", "treatment": "surgery; radiation with concurrent and adjuvant temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 59-year-old man with metastatic colorectal adenocarcinoma presented with progressive abdominal pain. CT abdomen showed multiple hypodense hepatic lesions concerning for metastases; colonoscopy confirmed a sigmoid primary. Molecular profiling revealed KRAS G12D. He was treated with FOLFOX plus bevacizumab for 4 cycles but restaging shows increase in size and number of liver lesions \u2014 assessment: progressive disease. Patient is being considered for second-line therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative pathology report: 48-year-old male underwent low anterior resection for sigmoid adenocarcinoma. Final pathology pT3N1 (AJCC Stage III). PCR panel detected KRAS G12D. MSI testing by PCR shows microsatellite stable (MSS). Patient completed 12 cycles of adjuvant FOLFOX. Post-op CT chest/abdomen/pelvis shows no evidence of distant metastatic disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "FOLFOX (adjuvant)", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma. Liver-dominant metastases at presentation (stage IV). Tumor testing: MSI-H and TMB-high; KRAS is wild-type. PD-L1 by IHC ~1%. He received induction FOLFOX with bevacizumab for tumor control and was transitioned to pembrolizumab after six cycles for continued disease control. Most recent scans demonstrate stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS wild-type", "biomarker": "MSI-H; TMB-high; PD-L1 ~1%", "treatment": "FOLFOX + bevacizumab induction, then pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic colorectal adenocarcinoma, multiple liver lesions on CT consistent with stage IV disease. Molecular testing reported KRAS G12D mutation and microsatellite testing was MSS (microsatellite stable). He was started on FOLFOX plus bevacizumab as first-line therapy; restaging after three months showed radiographic progression in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with castration-resistant prostate adenocarcinoma and rising PSA despite LHRH agonist. Imaging demonstrates enlarged pelvic and retroperitoneal lymph nodes consistent with nodal metastases. He underwent bilateral orchiectomy and was started on enzalutamide; external beam radiation delivered to bulky pelvic nodes. PSA has decreased and scans are unchanged compared with prior.", "output": {"cancer_type": "prostate adenocarcinoma (castration-resistant)", "stage": "IV (N1)", "gene_mutation": null, "biomarker": "elevated PSA", "treatment": "orchiectomy; enzalutamide; pelvic radiation", "response": "stable disease", "metastasis_site": "pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "A 62-year-old man with metastatic cutaneous melanoma of unknown primary, multiple pulmonary nodules and a solitary cerebellar metastasis. PD-L1 was 10% and TMB was high. He received combination immunotherapy with ipilimumab plus nivolumab and completed four doses with a complete radiographic response of lung lesions and CNS disease. No driver mutation testing was documented in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 10%; TMB-high", "treatment": "ipilimumab + nivolumab", "response": "complete response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Biopsy-confirmed pancreatic ductal adenocarcinoma. Germline testing negative for BRCA1/2; somatic panel not available. Patient completed 4 cycles of modified FOLFIRINOX followed by chemoradiation but developed new peritoneal implants on follow-up and was transitioned to best supportive care.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": null, "treatment": "modified FOLFIRINOX; chemoradiation", "response": "progression", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinical note: 54-year-old woman with ER+/PR+ HER2-amplified metastatic breast cancer presenting with multiple liver lesions. NGS identified a PIK3CA H1047R mutation. Stage IV at diagnosis. She received first-line trastuzumab and pertuzumab with docetaxel; after six cycles the CT liver lesions are unchanged compared with prior \u2014 assessment: stable disease. Patient tolerating therapy with manageable toxicities.", "output": {"cancer_type": "metastatic breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. Staged as IV at diagnosis with known brain and bone metastases. She was started on osimertinib 80 mg daily in January 2024 with radiographic partial response on first restaging CT chest/abdomen and brain MRI.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV with multiple liver metastases. Molecular testing shows KRAS G12D mutation and microsatellite stable (MSS). He was started on FOLFOX plus bevacizumab; CT at 16 weeks shows overall disease control without shrinkage of target lesions consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man presented with metastatic lung adenocarcinoma, stage IV. Comprehensive genomic profiling demonstrated an EGFR exon 19 deletion. PD-L1 tumor proportion score reported as 1%. He was started on osimertinib as first-line therapy. Interval CT and MRI show shrinkage of the primary lesion and decreased size of multiple brain and bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma. Liver and bilateral pulmonary metastases were noted on staging scans consistent with stage IV disease. Tumor profiling identified BRAF V600E mutation; tumor is MSI-H and TMB-high. He was started on pembrolizumab in combination with FOLFOX and bevacizumab as first-line therapy. After three months the multidisciplinary review documented stable disease by RECIST.", "output": {"cancer_type": "metastatic colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab + FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male referred with metastatic colorectal adenocarcinoma. Presenting CT demonstrated omental thickening and extensive peritoneal nodularity consistent with peritoneal carcinomatosis. Tumor genotyping identified KRAS G12D; BRAF and NRAS wild-type. Microsatellite testing showed MMR proficient (microsatellite stable). He was initiated on FOLFOX with bevacizumab and after three months has radiographic stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MMR proficient (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with unresectable metastatic cutaneous melanoma, presenting with multiple pulmonary nodules. BRAF testing is pending. Given high tumor burden he was started on pembrolizumab monotherapy. After four cycles there is a mixed radiographic response: several nodules have decreased in size while one new subcentimeter pulmonary lesion has appeared.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "pembrolizumab", "response": "mixed response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 49-year-old woman with locally advanced left breast cancer, clinical stage IIIB. Core biopsy: invasive ductal carcinoma, HER2 amplified by FISH, ER 80% positive, PR 40% positive, Ki-67 35%. Tumor sequencing identified a PIK3CA H1047R mutation. She completed four cycles of neoadjuvant trastuzumab and pertuzumab with docetaxel and tolerated therapy well. Post-treatment imaging showed near-complete radiographic response and she underwent mastectomy with sentinel node biopsy; pathology returned a complete pathological response (pCR). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive; Ki-67 35%", "treatment": "neoadjuvant trastuzumab + pertuzumab + docetaxel; mastectomy", "response": "complete pathological response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for a T3 colon adenocarcinoma. Final pathologic stage was II (T3N0M0). Tumor testing returned MSI-H (high microsatellite instability) by PCR. Given the MSI-H and node-negative status the team recommended observation without adjuvant 5-FU\u2013based chemotherapy. Surveillance CT chest/abdomen at 6 months showed no evidence of recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "surgery (right hemicolectomy), no adjuvant chemotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed metastatic lung adenocarcinoma (stage IV). Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. Baseline imaging showed brain and osseous metastases. She was started on osimertinib 80 mg PO daily and had a radiographic partial response at 8 weeks but developed new hepatic lesions on subsequent scan consistent with progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "progression", "metastasis_site": "brain, bone, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 48-year-old woman with locally advanced invasive ductal carcinoma of the left breast. Core biopsy: ER positive, PR positive, HER2 amplification by FISH. Nodal disease found on ultrasound; clinical stage IIIA. Molecular panel identified a PIK3CA H1047R mutation. She received neoadjuvant weekly paclitaxel with concurrent trastuzumab for 12 weeks with good clinical shrinkage of the primary tumor. Plan is definitive mastectomy next month.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma. Staging scans show multiple enhancing lesions in the cerebrum consistent with intracranial metastases. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. She was started on oral osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain lesion. Interval MRI at 8 weeks demonstrates reduction in size of several brain metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man with locally advanced, unresectable pancreatic adenocarcinoma (T4N1, clinically considered stage III). Limited NGS panel did not identify actionable alterations and no molecular biomarker testing was available. He completed eight cycles of FOLFIRINOX with disease control and then received consolidative chemoradiation with capecitabine; most recent CT shows stable disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "III (locally advanced/unresectable)", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX x8 cycles followed by chemoradiation with capecitabine", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (dermatology/oncology): 52-year-old man with unresectable cutaneous melanoma involving the subcutaneous tissues and regional nodes (stage III, unresectable). PD-L1 staining reported as 5% TPS. Given concerns about comorbidities the team initiated pembrolizumab 200 mg q3w. Serial clinical assessment and imaging show reduction in nodal disease and improved symptoms consistent with a partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "III (unresectable)", "gene_mutation": null, "biomarker": "PD-L1 5% TPS", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma presenting with bulky pelvic mass and diffuse peritoneal carcinomatosis; clinical stage IIIC. She underwent optimal cytoreductive surgery (no gross residual >1 cm) followed by adjuvant carboplatin and paclitaxel every 3 weeks. CA-125 fell but imaging shows residual omental and peritoneal implants consistent with partial response. Germline and somatic BRCA testing reported as pending in the chart.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "cytoreductive surgery followed by carboplatin and paclitaxel", "response": "partial response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma diagnosed in 2019 now with progressive CNS symptoms. Molecular testing returned EGFR L858R; PD-L1 10% TPS. She was started on osimertinib 80 mg daily in March; interval brain MRI in July shows decreased size of several intracranial metastases and smaller pulmonary nodules. Assessment: partial response to targeted therapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology note: 45-year-old man with a 2.3 mm mitotic rate 2 melanoma of the upper back. Wide local excision performed with 1 cm margins; sentinel lymph node biopsy negative. Molecular testing identified BRAF V600E. No adjuvant therapy recommended given negative nodes and stage IIB disease; routine surveillance planned.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; sentinel node biopsy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic colorectal adenocarcinoma with multiple hepatic lesions. Molecular testing demonstrates KRAS G12D mutation and microsatellite-stable (MSI-stable) status. He was started on FOLFOX plus bevacizumab. Restaging CT after three months shows stable disease by RECIST criteria.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with stage IV lung adenocarcinoma with brain and bone metastases. Initial PD-L1 was 30% by IHC. He was started on pembrolizumab combined with carboplatin and pemetrexed as first-line therapy and achieved a partial response. Molecular testing later returned EGFR L858R; after progression on chemoimmunotherapy he was switched to osimertinib with radiographic tumor shrinkage.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "pembrolizumab + carboplatin + pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic colon adenocarcinoma. NGS returned BRAF V600E and high microsatellite instability (MSI-H) with elevated TMB. Initial therapy was pembrolizumab given MSI-H status, but after 4 months there was radiographic progression in the liver and peritoneum. She was switched to targeted combination therapy with encorafenib plus cetuximab. Follow-up imaging after 8 weeks showed no further growth of lesions consistent with stable disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H, TMB-high", "treatment": "pembrolizumab (initial); encorafenib + cetuximab (subsequent)", "response": "stable disease", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old man with metastatic colorectal adenocarcinoma. CT shows multiple liver lesions consistent with metastases. Tumor profiling: BRAF V600E mutation and high microsatellite instability (MSI-H). Initially treated with FOLFOX plus bevacizumab, transitioned to pembrolizumab after progression. Most recent scans indicate interval growth of the liver lesions and new ascites \u2014 overall: disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX + bevacizumab; pembrolizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man found to have a 1.2 cm papillary thyroid carcinoma on ultrasound-guided FNA. Pathology after total thyroidectomy reported classic papillary carcinoma, pT1a, staged as I. He received radioactive iodine ablation post-operatively. No actionable mutations reported on the surgical specimen and no PD-L1 testing available. Patient is clinically well with undetectable thyroglobulin and no radiographic evidence of disease.", "output": {"cancer_type": "papillary thyroid carcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "total thyroidectomy, radioactive iodine ablation", "response": "no evidence of disease (remission)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced right breast cancer (clinical T3N2). Neoadjuvant therapy with weekly paclitaxel plus trastuzumab was administered followed by modified radical mastectomy. Pathology after surgery revealed no residual invasive carcinoma (pathologic complete response). ER negative, PR negative; HER2 IHC 3+ with HER2 amplification confirmed by FISH. No distant metastatic disease on staging CT. No comprehensive genomic sequencing performed.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab; modified radical mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note (concise): 55-year-old with metastatic cutaneous melanoma presenting with multiple pulmonary nodules and a cerebellar lesion. PD-L1 reported at 5%. BRAF testing was deferred due to inadequate tissue and therefore no BRAF mutation result is available. Started pembrolizumab monotherapy; after 4 cycles there is clinical decline and interval imaging documents progression of pulmonary and brain disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 5%", "treatment": "pembrolizumab", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with metastatic colorectal adenocarcinoma. Molecular testing: BRAF V600E mutation and MSI-H; high tumor mutational burden reported. He presented with multiple hepatic lesions and peritoneal carcinomatosis. Pembrolizumab was initiated as first-line therapy for MSI-H disease; follow-up CT after three cycles showed stable disease, but interval imaging at 4 months documented radiographic progression of several liver lesions. He was subsequently referred for targeted therapy options.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease then progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing returned EGFR L858R positive. PD-L1 by IHC was 10%. Patient started first-line osimertinib 80 mg daily in January 2020 with radiographic partial response and symptomatic improvement. Brain MRI at baseline showed two enhancing lesions consistent with metastases; stereotactic radiosurgery performed to the larger lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old with high-grade serous ovarian carcinoma, FIGO stage IIIC. At primary cytoreduction there was diffuse peritoneal carcinomatosis. Germline testing revealed a pathogenic BRCA1 variant. She completed optimal debulking followed by six cycles of carboplatin and paclitaxel and is currently on maintenance olaparib. Recent CT shows no measurable residual disease \u2014 radiographic complete response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": null, "treatment": "optimal cytoreductive surgery, carboplatin and paclitaxel, maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old male with metastatic cutaneous melanoma. Tumor sequencing revealed BRAF V600E. PD-L1 IHC reported >50%. He presented with multiple hepatic metastases at diagnosis (stage IV) and was started on dabrafenib plus trametinib. Initial reduction in tumor burden followed by radiographic progression at 8 months with enlarging liver lesions.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: Patient admitted for progressive jaundice and weight loss. Imaging and EUS confirm pancreatic ductal adenocarcinoma with hepatic lesions. Given poor performance status, tumor sequencing was not completed during admission. Palliative chemotherapy with gemcitabine plus nab-paclitaxel was started but follow-up CT shows interval increase in size of hepatic metastases consistent with progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "disease progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female with newly progressive metastatic lung adenocarcinoma. Initial genotyping showed EGFR L858R and she had an excellent response to erlotinib for 11 months. On progression a repeat biopsy identified EGFR T790M; PD-L1 IHC returned 10% and tumor mutational burden reported as low. MRI brain demonstrated two small cerebellar metastases and PET/CT showed lytic lesions in the thoracic spine. She was switched to osimertinib with interval imaging showing a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%; TMB-low", "treatment": "erlotinib; osimertinib", "response": "partial response", "metastasis_site": "brain; bone (thoracic spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old man presented with progressive dyspnea. CT chest revealed a 4.2 cm right upper lobe mass and multiple bilateral pulmonary nodules. Brain MRI demonstrated three enhancing lesions concerning for metastases. Core biopsy of the lung lesion confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R positive, ALK negative. PD-L1 TPS reported at 10%. He was started on osimertinib 80 mg daily. Follow-up imaging at 8 weeks showed decrease in size of the lung lesions and shrinkage of the brain metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with lung adenocarcinoma presenting with multiple pulmonary nodules and intracranial lesions. Staged IV. Molecular testing returned EGFR L858R mutation; PD-L1 10% by IHC. Started osimertinib 80 mg daily; 8-week restaging CT/MRI demonstrated decreased size of both brain and lung lesions consistent with a partial response. Tolerating therapy without dose reductions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old man with metastatic cutaneous melanoma. Tumor sequencing showed BRAF V600E mutation; PD-L1 was low at 5%. He initiated targeted therapy with dabrafenib and trametinib and had an initial partial response with shrinkage of pulmonary nodules. After 6 months he developed radiographic progression with new brain metastases and increasing pulmonary disease; subsequent treatment with pembrolizumab was started but imaging after two cycles documented further progression.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later pembrolizumab", "response": "initial partial response followed by progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old premenopausal woman with a large right breast mass. Core biopsy: invasive ductal carcinoma, ER-negative, PR-negative, HER2 amplification by FISH. Targeted sequencing identified PIK3CA H1047R. Clinically staged IIIB due to fixed axillary nodes. She received neoadjuvant trastuzumab, pertuzumab and docetaxel followed by mastectomy; surgical pathology showed no residual invasive tumor (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic lung adenocarcinoma diagnosed in 2023. Molecular testing identified EGFR L858R and PD-L1 expression 10%. Staging at presentation was consistent with stage IV disease with multiple brain and bone lesions. She was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to a left frontal metastasis. Interval imaging after 8 weeks demonstrated a partial response with shrinkage of the primary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male diagnosed with glioblastoma multiforme (WHO grade IV) presenting with a left frontal enhancing mass. Underwent subtotal resection followed by concurrent radiotherapy and temozolomide per Stupp protocol. MGMT promoter methylation status was not reported and no actionable mutations were identified on pathology report. Post-treatment MRI demonstrates enlargement of the enhancing lesion consistent with progression. No extracranial disease identified.", "output": {"cancer_type": "glioblastoma multiforme", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "surgery, radiation, temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with metastatic lung adenocarcinoma (stage IV) presented with headaches and back pain. Comprehensive molecular testing identified EGFR L858R and EGFR T790M. PD-L1 TPS was 10% and tumor mutational burden reported as low. She initially received pembrolizumab in combination with carboplatin and pemetrexed resulting in stable disease. After radiographic progression in the brain and bone she was switched to osimertinib and achieved a partial response in intracranial and osseous lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%; TMB-low", "treatment": "pembrolizumab; carboplatin and pemetrexed; osimertinib", "response": "initial stable disease; partial response after osimertinib", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with stage IV lung adenocarcinoma diagnosed after presenting with progressive cough and weight loss. Molecular testing revealed EGFR L858R and PD-L1 30% by IHC. MRI demonstrated multiple brain metastases and PET showed osseous involvement. He progressed on first-line carboplatin/pemetrexed and was transitioned to osimertinib with a partial response on first follow-up CT.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 30%", "treatment": "osimertinib; prior carboplatin and pemetrexed", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided invasive ductal carcinoma, ER positive, PR positive, HER2 3+ with FISH-confirmed HER2 amplification. Clinical stage IIIB at presentation. Hotspot panel detected PIK3CA H1047R. She received neoadjuvant trastuzumab and pertuzumab with docetaxel for six cycles and had a near-complete clinical response; mastectomy revealed a 10 mm residual invasive focus and adjuvant radiation is planned.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab, pertuzumab and docetaxel (neoadjuvant)", "response": "partial response (near-complete clinical response with residual disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 47-year-old woman with HER2-positive metastatic breast cancer, initially pT2N1M1. Cross-sectional imaging demonstrates multiple hepatic lesions consistent with liver metastases. Tumor profiling: HER2 amplification by FISH and PIK3CA H1047R mutation; ER/PR negative. Patient received first-line trastuzumab and pertuzumab with docetaxel; after four cycles CT shows decrease in size of dominant hepatic lesions \u2014 documented partial response. Plan to continue HER2-directed therapy.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification", "treatment": "trastuzumab, pertuzumab, docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology report: 42-year-old man underwent excision of a pigmented lesion on the left forearm. Final diagnosis: superficial spreading melanoma, Breslow depth 0.9 mm, no ulceration, mitotic rate low. Sentinel lymph node biopsy negative. BRAF V600E mutation identified on PCR testing. Patient was treated with wide local excision with clear margins and observed without adjuvant therapy. Follow-up exam: no evidence of recurrence.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "IB", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision, sentinel node biopsy (no adjuvant therapy)", "response": "no evidence of recurrence", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with left invasive ductal carcinoma of the breast, ER/PR negative, HER2 3+ by IHC with FISH-confirmed HER2 amplification. NGS revealed a PIK3CA H1047R mutation. Clinical stage was recorded as IIIA. She received neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) and underwent mastectomy with axillary dissection; pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastatic disease identified on staging scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER/PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP); mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with metastatic colorectal adenocarcinoma. Molecular testing demonstrates KRAS G12D mutation and high microsatellite instability (MSI-H). He received FOLFOX with bevacizumab for 12 cycles with initial tumor shrinkage but recent surveillance imaging shows new bilateral pulmonary nodules and enlarging liver lesions consistent with disease progression.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "lung, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology follow-up for a 59-year-old male with metastatic colorectal adenocarcinoma. Imaging shows dominant hepatic lesions. Molecular testing: KRAS G12D mutation; microsatellite stable (MSS); TMB-low. Classified as stage IV. Systemic therapy initiated with FOLFOX plus bevacizumab. First restaging after three cycles demonstrates stable disease by RECIST.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFOX plus bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology: invasive ductal carcinoma of the right breast, 1.2 cm. ER positive, PR positive; HER2 IHC equivocal with FISH confirming HER2 amplification. Clinical stage pT1b N0 (stage I). Patient underwent lumpectomy with sentinel node biopsy and adjuvant radiation. Adjuvant trastuzumab initiated with plan for 1-year therapy. Most recent clinic note documents no evidence of disease on exam and imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; radiation; trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man presents with metastatic lung adenocarcinoma diagnosed on core biopsy. Molecular testing detected EGFR L858R mutation. PD-L1 TPS reported at 10%. Staging showed multiple intracranial lesions consistent with metastases and extracranial disease, overall stage IV. He was started on osimertinib 80 mg daily; interval MRI at 8 weeks demonstrates decrease in size of the dominant brain lesion and reduction in pulmonary nodules.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with left breast invasive ductal carcinoma, clinical stage IIA (T2N0). Core biopsy: ER positive, PR positive, HER2 amplified by FISH. PIK3CA H1047R mutation identified on panel. She received neoadjuvant docetaxel, carboplatin and trastuzumab for 4 cycles followed by lumpectomy and sentinel node biopsy. Surgical pathology reports no residual invasive carcinoma consistent with a pathologic complete response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab, lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old woman with high-grade serous ovarian carcinoma, FIGO stage IIIC at diagnosis with bulky peritoneal carcinomatosis. Germline testing revealed a deleterious BRCA1 mutation. She underwent optimal cytoreductive surgery followed by adjuvant carboplatin and paclitaxel with normalization of CA-125 and subsequent maintenance olaparib. At 12 months she has no radiographic evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "CA-125 elevated at diagnosis then normalized", "treatment": "debulking surgery followed by carboplatin and paclitaxel; maintenance olaparib", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman with invasive ductal breast carcinoma, clinical stage IIA. Tumor is ER+/PR+ and HER2-amplified; NGS identified a PIK3CA E545K mutation. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab, and completed a year of trastuzumab. Currently on surveillance with no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy and sentinel node biopsy; adjuvant paclitaxel and trastuzumab", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "44-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. Presents with symptomatic brain and pulmonary metastases. Baseline PD-L1 by IHC reported at 1%. He was started on combination targeted therapy with dabrafenib plus trametinib and experienced a brisk clinical and radiographic partial response in the lungs but later developed progressive brain lesions and was transitioned to nivolumab.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib; later nivolumab", "response": "initial partial response to dabrafenib+trametinib; progression in brain", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Breast clinic note: 48-year-old woman with left invasive ductal carcinoma, clinical stage IIIB (T4bN1). ER 90% positive, PR negative, HER2 FISH demonstrates amplification. NGS on core biopsy identified PIK3CA H1047R. She completed 6 cycles of neoadjuvant paclitaxel with trastuzumab and pertuzumab; MRI shows decrease in tumor size but residual disease. Surgical resection planned.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly diagnosed lung adenocarcinoma presented with progressive cough and headache. Staging PET/CT demonstrated bilateral pulmonary nodules and multiple enhancing lesions in the brain and lytic lesions in the spine consistent with metastatic disease. Core biopsy of the lung primary confirmed adenocarcinoma with EGFR L858R on NGS. PD-L1 by IHC was 10%. He was started on osimertinib 80 mg daily; first restaging CT at 8 weeks shows a partial response clinically and radiographically.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV cutaneous melanoma with nodal and pulmonary involvement. Molecular testing positive for BRAF V600E. PD-L1 reported at 5% and tumor mutational burden described as TMB-high. Patient initiated on targeted combination therapy with dabrafenib plus trametinib. After 8 weeks therapy the patient has a complete metabolic response on PET-CT with no new lesions; continuing combination targeted therapy.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib plus trametinib", "response": "complete response", "metastasis_site": "lymph nodes, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old with a 1.2 cm pigmented lesion on the right forearm, biopsy confirmed superficial spreading melanoma, Breslow 0.9 mm, no ulceration. Staged as I and treated with wide local excision with negative margins; sentinel node negative. No systemic therapy indicated; patient remains clinically free of disease at 18-month follow-up.", "output": {"cancer_type": "melanoma (superficial spreading)", "stage": "I", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision (surgery)", "response": "complete response / no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old male with metastatic lung adenocarcinoma (stage IV). NGS identified EGFR L858R. PD-L1 tumor proportion score reported as 10%. Patient started osimertinib 80 mg daily in July; received stereotactic radiosurgery to a solitary cerebellar metastasis. First restaging CT and brain MRI at 8 weeks show decrease in size of pulmonary primary and regression of brain lesion \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neoadjuvant treatment course for T2N2 invasive ductal carcinoma of the breast: tumor was HER2 amplified, ER negative, PR negative, and next\u2011generation sequencing detected a PIK3CA H1047R hotspot mutation. Patient completed 6 cycles of docetaxel and carboplatin in combination with trastuzumab and pertuzumab prior to surgery. Surgical pathology reported a pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "docetaxel and carboplatin with trastuzumab and pertuzumab (neoadjuvant)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with metastatic colorectal adenocarcinoma. Primary colon tumor genotyping demonstrates KRAS G12D. Patient was treated with FOLFOX plus bevacizumab as first-line therapy. Staging scans show multiple pulmonary nodules consistent with metastatic disease; CEA is elevated. Microsatellite testing: MSS.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult note: 55-year-old male with metastatic cutaneous melanoma, biopsy-proven BRAF V600E mutation. Presents with painful left femoral lesion; imaging confirms lytic osseous metastasis. Clinical stage IV. Initiated targeted therapy with dabrafenib and trametinib. Early scans showed shrinkage of several subcutaneous nodules but subsequent imaging at 10 weeks demonstrated new osseous and nodal lesions consistent with progressive disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib, trametinib", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology and plan: 45-year-old female with left breast invasive ductal carcinoma, ER+/PR+/HER2-amplified, clinical stage II (T2N0M0). Patient underwent lumpectomy with sentinel lymph node biopsy; margins negative, sentinel nodes negative. Adjuvant therapy recommended: docetaxel and cyclophosphamide x4 cycles followed by trastuzumab for 1 year and radiation to the breast. Currently recovering post-op with no measurable disease on breast imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "lumpectomy; docetaxel and cyclophosphamide; trastuzumab; radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old G3P3 with high-grade serous ovarian carcinoma presented with bulky intra-abdominal disease and omental caking. Germline testing identified a pathogenic BRCA1 mutation and the tumor was HRD-positive. She underwent primary debulking surgery followed by adjuvant carboplatin and paclitaxel x6; CA-125 normalized and CT showed no residual disease. She was started on olaparib maintenance and remains in complete clinical remission on recent follow-up.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic mutation", "biomarker": "HRD-positive; CA-125 elevated at diagnosis", "treatment": "primary debulking surgery; carboplatin and paclitaxel; olaparib maintenance", "response": "complete clinical response", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with metastatic lung adenocarcinoma diagnosed in 2020. Molecular testing revealed EGFR L858R mutation; PD-L1 reported at 10%. She started first-line osimertinib with initial symptomatic improvement but recent imaging shows enlargement of a cerebellar lesion and new leptomeningeal disease. Transitioned to palliative whole-brain radiation and systemic therapy was discontinued due to clinical deterioration.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; whole-brain radiation", "response": "progression", "metastasis_site": "brain (cerebellum, leptomeninges)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic colorectal adenocarcinoma. CT abdomen demonstrates multiple hypodense liver lesions consistent with metastases. Tumor profiling shows KRAS G12D. MSI testing reported microsatellite stable (MSS). Started on FOLFOX with bevacizumab. Interval CT at 12 weeks shows no new lesions and essentially unchanged size of hepatic metastases = stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma. Broad-panel sequencing revealed BRAF V600E and a high tumor mutational burden (TMB-high). Initially started on pembrolizumab given symptomatic disease; after radiographic progression in the liver therapy was switched to dabrafenib plus trametinib. Hepatic lesions shrank substantially on targeted therapy but new small brain metastases were detected on MRI after six months. Clinical course described mixed response with interval CNS progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab then dabrafenib + trametinib", "response": "mixed response with CNS progression", "metastasis_site": "liver, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man with unresectable metastatic melanoma harboring BRAF V600E. PD-L1 expression approximately 60%. He was started on dabrafenib plus trametinib with an initial partial response, but at 7 months developed radiographic progression in the femur with new lytic lesions. Plan is to switch to anti\u2013PD-1 therapy.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 60%", "treatment": "dabrafenib + trametinib", "response": "progression after initial partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for adenocarcinoma of the cecum, final pathologic stage III (pT3N1). Comprehensive NGS showed no RAS or BRAF mutations; MSI testing returned MSI-high (MSI-H). He started adjuvant FOLFOX and is tolerating therapy; surveillance imaging shows no recurrent disease so far.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy; adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Initial presentation: 63-year-old man with cough and weight loss. Imaging showed a 4.2 cm right upper lobe mass and multiple enhancing brain lesions. Biopsy: lung adenocarcinoma. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 5%. Staged as IV (metastatic to brain). Patient was started on osimertinib 80 mg daily with excellent systemic shrinkage (partial response) but after 9 months developed new symptomatic intracranial progression requiring stereotactic radiosurgery. Systemic therapy continued thereafter with clinical deterioration over subsequent months.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "initial partial response, then intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "32-year-old male with cutaneous melanoma on the back. Staging workup demonstrates metastatic disease to the lungs, consistent with stage IV melanoma. Molecular testing identified NRAS Q61R; BRAF was wild-type. PD-L1 tumor proportion score approximately 5%. Treated with combination immunotherapy (nivolumab plus ipilimumab) with interval CT showing partial response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "NRAS Q61R", "biomarker": "PD-L1 TPS 5%", "treatment": "nivolumab and ipilimumab", "response": "partial response", "metastasis_site": "lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient underwent right hemicolectomy for a pT2N0 colon adenocarcinoma (stage I). MSI testing returned MSI-H. Margins negative and no high-risk features; multidisciplinary team recommended surveillance without adjuvant chemotherapy. Follow-up imaging to date shows no recurrence.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "right hemicolectomy (surgery only)", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right-sided colorectal adenocarcinoma presenting with multiple hepatic lesions. Tumor sequencing identified BRAF V600E and the tumor was MSI-H; TMB reported as TMB-high. Patient was started on pembrolizumab because of MSI-H status. Follow-up scans at 12 weeks show shrinkage of liver metastases consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old man with metastatic castration-resistant prostate adenocarcinoma. Has been on androgen deprivation with leuprolide for several years and started enzalutamide when PSA rose. Bone scan demonstrates multiple osseous lesions. PSA continues to climb despite therapy.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "leuprolide; enzalutamide", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with newly diagnosed lung adenocarcinoma, staged IV at presentation with multiple brain and bony lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line therapy. Follow-up CT and MRI at 8 weeks demonstrated a decrease in size of the pulmonary primary and intracranial metastases consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER negative, PR negative, HER2 IHC 3+ (consistent with HER2 amplification). Clinical stage IIIB with fixed axillary nodes. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles and subsequently underwent mastectomy. Surgical pathology showed no residual invasive carcinoma \u2014 pathologic complete response. No actionable single-gene mutations reported on the limited panel.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old female with newly diagnosed lung adenocarcinoma. Staging workup demonstrated metastatic disease with multiple enhancing lesions in the cerebrum consistent with brain metastases. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 5%. Patient was started on osimertinib 80 mg daily. Follow-up MRI at 8 weeks shows interval decrease in size of brain lesions \u2014 partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 TPS 5%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "50-year-old with metastatic cutaneous melanoma presenting with multiple bilateral pulmonary nodules. PD-L1 expression reported >50% and comprehensive genomic profiling did not identify a targetable driver mutation. Tumor had high tumor mutational burden. He received combination immunotherapy with nivolumab and ipilimumab as first-line therapy and achieved a complete response on interval CT after four cycles.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 >50%; TMB-high", "treatment": "nivolumab + ipilimumab", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Radiology follow-up: 42-year-old man with metastatic cutaneous melanoma. Baseline PCR-based testing reported BRAF V600E mutation. Patient was started on dabrafenib and trametinib. Current chest CT demonstrates a ~40% decrease in sum of diameters of measurable pulmonary nodules compared with prior, compatible with partial response. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with a pigmented lesion on the left forearm proven to be melanoma with multiple involved regional nodes (sentinel positive). Molecular testing identified BRAF V600E. He received neoadjuvant targeted therapy with dabrafenib and trametinib for 8 weeks prior to wide local excision and lymphadenectomy. Imaging and operative assessment documented shrinkage of the primary and nodal disease consistent with a partial response.", "output": {"cancer_type": "melanoma", "stage": "III", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "neoadjuvant dabrafenib and trametinib; wide local excision and lymphadenectomy", "response": "partial response", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology summary: 59-year-old presenting with right-sided colon adenocarcinoma with synchronous liver lesions. Clinical stage IV. Tumor profiling shows BRAF V600E mutation and MSI-H. Patient was treated with FOLFOX plus bevacizumab; interval imaging after three cycles demonstrates progression in the liver lesions.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old female with metastatic lung adenocarcinoma diagnosed by core biopsy. NGS returned EGFR L858R mutation. PD-L1 TPS reported at 10%. Baseline staging CT and brain MRI demonstrated multifocal brain metastases and lytic bony lesions. Patient was started on osimertinib 80 mg daily; first restaging at 8 weeks showed decrease in size of pulmonary and intracranial lesions with improvement in pain.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female with metastatic lung adenocarcinoma diagnosed 2019. Molecular testing returned EGFR L858R. PD-L1 reported at 10%. Staging at diagnosis was IV with multiple enhancing lesions on brain MRI. She was started on osimertinib 80 mg daily in Jan 2020 with dramatic symptomatic improvement. Most recent scan shows decreased size of primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 70-year-old male with metastatic colorectal adenocarcinoma diagnosed after hepatic lesion biopsy. Tumor testing: BRAF V600E identified on PCR; MSI testing reported MSI-H. Baseline disease included multiple liver mets. He received FOLFOX plus bevacizumab for 6 cycles with radiographic restaging showing stable disease; given MSI-H status he was transitioned to pembrolizumab maintenance. Current plan is continued immunotherapy with close surveillance of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab followed by pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female diagnosed with locally advanced invasive ductal breast carcinoma, ER positive, PR positive and HER2 amplified, clinical stage IIIB. Pre-treatment NGS identified a PIK3CA H1047R mutation. She received neoadjuvant paclitaxel with concurrent trastuzumab and pertuzumab for six cycles, followed by mastectomy. Pathology review revealed pathologic complete response with no residual invasive disease and negative nodes.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease. Tumor sequencing identified EGFR L858R. PD-L1 TPS reported at 60%. He was started on osimertinib with symptomatic improvement and CT at 8 weeks demonstrating a partial response. After 11 months developed progressive intracranial disease and received stereotactic radiosurgery to the brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 60% (TPS)", "treatment": "osimertinib; stereotactic radiosurgery", "response": "initial partial response followed by intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History of metastatic lung adenocarcinoma diagnosed 2019 with bilateral pulmonary nodules and liver lesions. PD-L1 by IHC >50% and tumor mutational burden reported as TMB-high (12 muts/Mb). No actionable driver mutations identified on comprehensive NGS. After progression on first-line carboplatin/pemetrexed the patient was started on combination therapy with carboplatin, pemetrexed and pembrolizumab. Interval CT after three cycles demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 >50%; TMB-high", "treatment": "carboplatin, pemetrexed and pembrolizumab", "response": "partial response", "metastasis_site": "liver, lungs"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with newly progressive lung adenocarcinoma. Initial staging at diagnosis showed metastatic disease with both brain and bone lesions. Molecular testing returned EGFR L858R and secondary T790M. PD-L1 reported at 10%. She completed two cycles of carboplatin and pemetrexed, then was transitioned to osimertinib 80 mg daily due to T790M. Follow-up CT and MRI after 8 weeks demonstrate marked reduction in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R, EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "carboplatin and pemetrexed; osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Metastatic cutaneous melanoma with BRAF V600E mutation identified on tumor sequencing. Patient had high tumor mutational burden (TMB-high). Initially started on dabrafenib plus trametinib with a brisk partial response lasting about 10 months; subsequent restaging documented progression in both lung and brain. Therapy was switched to pembrolizumab; extracranial disease has stabilized but new intracranial lesions have appeared and required stereotactic radiosurgery. Overall response to immunotherapy described as mixed response.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "dabrafenib and trametinib followed by pembrolizumab; stereotactic radiosurgery", "response": "mixed response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male with metastatic cutaneous melanoma, BRAF V600E positive. Baseline staging revealed pulmonary nodules and multiple brain metastases. He was started on pembrolizumab but demonstrated clinical and radiologic progression after 3 cycles. Therapy was switched to dabrafenib plus trametinib; follow-up imaging showed partial response of extracranial disease while intracranial disease had mixed response and was managed with stereotactic radiosurgery.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab; then dabrafenib and trametinib; stereotactic radiosurgery", "response": "initial progression on pembrolizumab, partial response to BRAF/MEK inhibition (mixed intracranial response)", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "51-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Biopsy shows HER2 amplification and hormone receptor positivity (ER+, PR+). NGS detected PIK3CA H1047R. She received neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab (TCHP) and had a partial response on post-treatment imaging.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male diagnosed with metastatic colorectal adenocarcinoma. Molecular testing: KRAS G12D mutation detected; mismatch repair proteins intact (MSI-stable). Imaging demonstrates multiple hepatic metastases consistent with liver-dominant stage IV disease. Treated with FOLFOX plus bevacizumab; best response documented as stable disease after four cycles.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old with newly diagnosed glioblastoma (WHO grade IV). Molecular workup showed a TERT promoter mutation and MGMT promoter methylation positive. Patient received concurrent radiotherapy with temozolomide (Stupp protocol). Six months post-treatment MRI shows new enhancing lesions with leptomeningeal spread consistent with progression.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": "TERT promoter mutation", "biomarker": "MGMT promoter methylation positive", "treatment": "radiotherapy with concurrent temozolomide (Stupp protocol)", "response": "progression", "metastasis_site": "leptomeningeal spread (central nervous system)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old female with newly diagnosed lung adenocarcinoma, biopsy-confirmed. Staging workup demonstrated metastatic disease with lesions in the cerebellum and multiple lytic lesions in the thoracic spine consistent with bone metastases \u2014 overall stage IV. Molecular testing returned EGFR L858R; PD-L1 reported at 1%. She was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the cerebellar lesion. Interval CT and MRI at 8 weeks show a decrease in size of the primary mass and the brain lesion.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male underwent right hemicolectomy for adenocarcinoma of the cecum. Pathology: pT3N1, final stage III. Tumor NGS demonstrated KRAS G12D mutation; MSI testing was MSI-stable. He started adjuvant FOLFOX and is currently on cycle 8 with surveillance CTs showing no evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old male with metastatic cutaneous melanoma. Primary lesion excised in 2018; developed symptomatic brain metastases in 2021. Tumor sequencing identified a BRAF V600E alteration. He was started on dabrafenib plus trametinib and achieved rapid radiologic complete response of intracranial lesions; remains on targeted therapy with imaging showing no evidence of disease. PD-L1 testing was not performed.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "28-year-old male with metastatic cutaneous melanoma. Molecular testing confirmed BRAF V600E. PD-L1 20% and TMB-high were reported on the report. Brain MRI revealed two small metastases; he underwent stereotactic radiosurgery and was started on combination dabrafenib and trametinib. Interval imaging at 3 months showed complete radiographic resolution of measurable disease.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%; TMB-high", "treatment": "stereotactic radiosurgery to brain metastases and dabrafenib plus trametinib", "response": "complete response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female with newly diagnosed lung adenocarcinoma. Staging workup confirms Stage IV disease with multiple enhancing lesions in the cerebrum consistent with brain metastases. Molecular testing returned EGFR L858R positive. PD-L1 TPS was 10%. Patient was started on osimertinib 80 mg daily and had interval MRI at 8 weeks showing decrease in size of brain lesions \u2014 overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: Patient with cutaneous melanoma of the left forearm. Primary excision and sentinel node biopsy were performed \u2014 one sentinel node positive. Final pathologic stage IIIA. Tumor harbors BRAF V600E mutation. Adjuvant targeted therapy with dabrafenib and trametinib was started. Surveillance PET/CT at 6 months shows no distant uptake; disease remains radiographically stable. PD-L1 testing not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIA", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 48-year-old woman underwent lumpectomy and sentinel node biopsy for a 2.8 cm invasive ductal carcinoma. Final pathology: T2 N1, stage II disease. ER positive (90%), PR positive (60%), HER2 negative by IHC/FISH. Tumor genomic panel identified a PIK3CA H1047R mutation. She completed adjuvant chemotherapy with doxorubicin and cyclophosphamide x4 cycles followed by paclitaxel x12 and has been started on endocrine therapy with tamoxifen. No evidence of distant metastasis on baseline CT chest/abdomen/pelvis.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; doxorubicin and cyclophosphamide; paclitaxel; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with ER-/PR- invasive ductal breast carcinoma, clinical stage IIIC with supraclavicular nodal involvement. Core biopsy: HER2 amplification by FISH. Started neoadjuvant weekly paclitaxel with trastuzumab. After four cycles there is marked reduction in primary tumor size on ultrasound \u2014 reported as partial response. Germline BRCA1/2 testing negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "paclitaxel and trastuzumab", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man diagnosed with metastatic colorectal adenocarcinoma, stage IV with multiple liver metastases. Molecular testing revealed KRAS G12D; tumor is microsatellite stable (MSS) and TMB-low. He was started on FOLFOX plus bevacizumab and follow-up CT at 12 weeks demonstrated stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; TMB-low", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Gynecologic oncology: 59-year-old female with newly diagnosed high-grade serous ovarian carcinoma with bulky omental disease and malignant ascites. Clinical stage IIIC. Germline testing returned a deleterious BRCA1 mutation and tumor HRD-positive. She underwent interval debulking after 3 cycles of carboplatin and paclitaxel with suboptimal residual disease and was started on maintenance olaparib after partial radiographic response.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 deleterious mutation", "biomarker": "HRD-positive", "treatment": "neoadjuvant carboplatin and paclitaxel, interval debulking surgery, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum/omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with newly diagnosed diffuse large B\u2011cell lymphoma presenting with B symptoms. Bone marrow biopsy positive for involvement; staging consistent with stage IV disease. FISH demonstrates a MYC rearrangement. The patient completed six cycles of R-CHOP and end-of-treatment PET-CT shows no hypermetabolic disease consistent with a complete response.", "output": {"cancer_type": "diffuse large B-cell lymphoma", "stage": "IV", "gene_mutation": null, "biomarker": "MYC rearrangement (FISH positive)", "treatment": "R-CHOP (6 cycles)", "response": "complete response", "metastasis_site": "bone marrow"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with metastatic colon adenocarcinoma. Molecular profile: BRAF V600E mutation; tumor is MSI-H and TMB-high. He received first-line FOLFOX plus bevacizumab but progressed after 6 months. Switched to targeted combination of encorafenib plus cetuximab; current CT shows multiple hepatic metastases and scattered peritoneal nodules with no interval enlargement.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab (prior); encorafenib + cetuximab (current)", "response": "stable disease", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology telephone encounter: 70-year-old man with metastatic prostate adenocarcinoma, bone-predominant metastases on bone scan. Known germline BRCA2 pathogenic variant. PSA currently 120 ng/mL. He was started on androgen deprivation therapy with leuprolide and received six cycles of docetaxel; disease remains clinically stable with ongoing ADT.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic germline variant", "biomarker": "PSA 120 ng/mL", "treatment": "leuprolide (androgen deprivation therapy); docetaxel", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man diagnosed with metastatic lung adenocarcinoma in 2023. Comprehensive NGS returned EGFR L858R; PD-L1 tumor proportion score 10%. Presented with headaches and back pain \u2014 MRI confirmed brain metastases and PET identified osseous lesions. He was started on osimertinib 80 mg daily. Interim CT chest/abdomen at 8 weeks demonstrated shrinkage of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man with newly diagnosed metastatic lung adenocarcinoma, stage IV. Molecular testing identified EGFR L858R. PD-L1 tumor proportion score reported as 10%. Brain MRI demonstrated multiple enhancing lesions; PET/CT showed osseous involvement of the thoracic spine. He was started on osimertinib 80 mg daily as first-line targeted therapy. Follow-up CT at 8 weeks showed decrease in size of the primary and intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology / oncology summary: Invasive ductal carcinoma of the right breast, ER+, PR+, HER2 amplified by FISH. Staging workup demonstrates hepatic lesions suspicious for metastases. NGS panel identified PIK3CA E545K. Patient started trastuzumab + pertuzumab with weekly paclitaxel; plan for continued HER2-directed therapy. Interim restaging CT shows decrease in size of liver lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab, pertuzumab, paclitaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma patient, 52-year-old female, biopsy-proven cutaneous malignant melanoma with pulmonary nodules on CT consistent with metastases. Tumor genotyping showed BRAF V600E. She was initiated on dabrafenib plus trametinib with rapid symptom improvement and CT after 6 weeks shows decrease in size of lung nodules; assessment documented as partial response. PD-L1 not reported.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old male with obstructing sigmoid mass underwent left hemicolectomy. Pathology: moderately differentiated adenocarcinoma, T3N1 (stage III). Mismatch repair testing shows microsatellite stable (MSS). KRAS testing was not available at the time of discharge. Planned adjuvant chemotherapy with FOLFOX (oxaliplatin, 5-FU/leucovorin). No radiographic evidence of distant metastasis after surgery.", "output": {"cancer_type": "colon adenocarcinoma (sigmoid)", "stage": "III", "gene_mutation": null, "biomarker": "MSS (microsatellite stable)", "treatment": "surgery (left hemicolectomy); planned adjuvant FOLFOX (oxaliplatin + 5-FU/leucovorin)", "response": "no evidence of distant metastasis postoperatively", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with a history of sigmoid colon adenocarcinoma now with new pulmonary nodules on surveillance CT suspicious for metastatic disease. Biopsy of a lung lesion confirmed colorectal origin. NGS identified KRAS G12D. Patient started systemic therapy with FOLFOX and bevacizumab. Most recent scan shows no new lesions and slight decrease in size of existing nodules.", "output": {"cancer_type": "colon adenocarcinoma", "stage": null, "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Neuro-oncology note: 45-year-old male presented with a right frontal mass; resection revealed glioblastoma. Standard concurrent chemoradiation was given (temozolomide with external beam radiotherapy). MGMT promoter was reported methylated. No actionable IDH1/2 mutation detected on panel. Despite standard therapy, MRI at 6 months shows tumor regrowth consistent with progression.", "output": {"cancer_type": "glioblastoma", "stage": "IV", "gene_mutation": null, "biomarker": "MGMT promoter methylated", "treatment": "concurrent temozolomide and radiotherapy", "response": "progression at 6 months", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-op summary: 65-year-old male diagnosed with organ-confined prostate adenocarcinoma, clinical stage II (cT2bN0M0), Gleason 3+4=7. Underwent radical prostatectomy followed by adjuvant external beam radiotherapy for adverse pathology. No genomic sequencing was performed and no metastatic disease identified on staging scans. Latest PSA undetectable \u2014 no evidence of disease in follow-up clinic.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy and adjuvant external beam radiation", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "New diagnosis of metastatic breast cancer in a 47-year-old woman. Core biopsy shows invasive ductal carcinoma, ER-negative, PR-negative, HER2-amplified by FISH. Staging scans reveal multiple hepatic metastases; clinical stage IV at presentation. Tumor NGS detected a PIK3CA H1047R mutation. She was started on trastuzumab with weekly paclitaxel; interim PET/CT shows near-complete metabolic response in the liver with disappearance of several lesions and is documented as complete response in the liver lesions.", "output": {"cancer_type": "breast cancer", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-negative; PR-negative", "treatment": "trastuzumab and paclitaxel", "response": "complete response (hepatic lesions)", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with newly diagnosed lung adenocarcinoma, stage IV. Baseline staging showed multiple brain metastases and lytic lesions in the spine. Tumor NGS returned EGFR L858R (T790M negative). PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the dominant brain lesions. Interval CT at 3 months demonstrated decrease in size of the primary and pulmonary nodules consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old male with a 1.8 mm ulcerated melanoma on the left forearm, staged as II (T2bN0M0) after wide local excision and negative sentinel lymph node biopsy. Molecular testing was not performed and no systemic adjuvant therapy was administered. Patient is seen in clinic and is clinically disease-free.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "wide local excision", "response": "disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma, BRAF V600E positive. PD-L1 IHC 1%. Patient started combination targeted therapy with dabrafenib and trametinib and had a rapid clinical benefit with complete radiographic response at 3 months. After 14 months on therapy he developed new pulmonary nodules consistent with disease progression.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 1%", "treatment": "dabrafenib and trametinib", "response": "progression after initial complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: Patient with stage IV cutaneous melanoma harboring a BRAF V600E mutation was started on combination targeted therapy (dabrafenib plus trametinib). Eight-week CT chest/abdomen showed shrinkage of extracranial lesions (partial response), however surveillance brain MRI identified two new enhancing lesions consistent with intracranial progression for which stereotactic radiosurgery was recommended. Overall described as mixed response with CNS progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "mixed response (extracranial partial response with intracranial progression)", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female diagnosed with metastatic lung adenocarcinoma. Initial biopsy showed EGFR L858R; repeat biopsy after progression identified acquired EGFR T790M. PD-L1 testing returned 10%. She was started on first-line osimertinib with a radiographic partial response for 12 months, followed by progression in the liver and brain. Patient was transitioned to platinum-doublet chemotherapy.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; EGFR T790M", "biomarker": "PD-L1 10%", "treatment": "osimertinib; platinum-doublet chemotherapy", "response": "progression after initial partial response", "metastasis_site": "liver; brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with metastatic colorectal adenocarcinoma after presentation with weight loss and abdominal pain. CT shows multiple hepatic lesions consistent with metastases. Tumor sequencing identified KRAS G12D; microsatellite testing reported MSS (microsatellite stable). Clinical stage IV. Started on FOLFOX plus bevacizumab. After four months of therapy there is radiographic progression in the liver.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old man diagnosed with localized prostate adenocarcinoma, Gleason 3+4, clinical stage II. PSA at diagnosis 8.2 ng/mL. Patient elected to proceed with radical prostatectomy; final pathology showed organ-confined disease with negative margins. No genomic testing was performed.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 8.2 ng/mL", "treatment": "radical prostatectomy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with sigmoid colon adenocarcinoma, initially diagnosed with synchronous hepatic metastases. Clinical stage IV. Molecular profile from primary tumor: KRAS G12D; MSI-stable. First-line systemic therapy was FOLFOX with bevacizumab. After 4 months there is interval enlargement of multiple hepatic lesions and new peritoneal nodularity indicative of disease progression.", "output": {"cancer_type": "colon cancer (sigmoid adenocarcinoma)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver; peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma presenting with multiple liver lesions (stage IV). Molecular testing: KRAS G12D detected; tumor reported as MSI-H. He received first-line FOLFOX plus bevacizumab with radiographic stable disease for 6 months. Given MSI-H status he was transitioned to pembrolizumab and has maintained stable disease on immunotherapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "FOLFOX and bevacizumab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with pancreatic ductal adenocarcinoma found to have a germline BRCA2 pathogenic variant. CA 19-9 markedly elevated at diagnosis. Staging CT showed peritoneal carcinomatosis and several hypodense lesions in the liver (stage IV). She received FOLFIRINOX induction with excellent radiologic and tumor marker decline and was transitioned to maintenance olaparib. Most recent imaging and CA19-9 indicate a partial response.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX then maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative note: 36-year-old woman with locally advanced left breast invasive ductal carcinoma, clinically T3N1 (stage IIIB). Core biopsy: ER+, PR+, HER2 amplification by FISH; PIK3CA H1047R detected on NGS. She received neoadjuvant docetaxel and carboplatin with dual HER2 blockade (trastuzumab and pertuzumab). At time of mastectomy pathology showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel and carboplatin with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic colorectal adenocarcinoma. Molecular testing: KRAS G12D mutation; tumor is microsatellite stable (MSS). CT abdomen shows multiple hepatic metastases. He received 6 cycles of FOLFOX with bevacizumab but interval scans demonstrate increase in size and number of liver lesions consistent with progression. PD-L1 status not available in chart.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "microsatellite stable (MSS)", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 62-year-old former smoker with progressive cough. Bronchoscopy biopsy confirmed lung adenocarcinoma. Staging PET/CT showed multiple bilateral pulmonary nodules and cranial MRI demonstrated 2 small cerebellar metastases; overall stage IV. Genotyping returned EGFR L858R; PD-L1 tumor proportion score ~10%. He was started on osimertinib 80 mg daily as first-line targeted therapy. Interval imaging at 8 weeks showed decrease in size of brain and lung lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with muscle-invasive bladder cancer that progressed to metastatic disease with osseous lesions. PD-L1 expression >50% and TMB-high on comprehensive profiling. No oncogenic mutations were reported on the available panel. Enrolled on a protocol and received combination cisplatin and gemcitabine with pembrolizumab but developed clinical and radiographic progression after three months.", "output": {"cancer_type": "bladder cancer", "stage": "IV", "gene_mutation": null, "biomarker": "PD-L1 >50%; TMB-high", "treatment": "cisplatin and gemcitabine with pembrolizumab", "response": "progression", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male with newly diagnosed lung adenocarcinoma presented with cough and weight loss. Staging PET/CT demonstrated multiple pulmonary nodules and enhancing lesions in the cerebellum and lumbar vertebrae. Molecular testing returned EGFR L858R and T790M was negative. PD-L1 expression by IHC was 5%. He was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the cerebellar metastasis. At first imaging (8 weeks) there was a decrease in target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 5%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone (lumbar vertebrae)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 71-year-old male with stage IV sigmoid colon adenocarcinoma presenting with synchronous hepatic metastases and bilateral pulmonary nodules. Molecular testing by PCR identified a KRAS G12D mutation. He was initiated on palliative FOLFOX with bevacizumab. After three months the CT shows interval increase in size and number of hepatic lesions consistent with disease progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "39-year-old man with stage IV cutaneous melanoma and known brain metastases. Molecular profiling identified BRAF V600E; PD-L1 expression was >50% and TMB-high. He was treated with dabrafenib plus trametinib with an initial partial systemic response but developed new intracranial lesions and was started on ipilimumab combined with nivolumab, after which disease stabilized albeit with an episode of immune-related colitis.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%; TMB-high", "treatment": "dabrafenib and trametinib; ipilimumab and nivolumab", "response": "initial partial response then stable disease after immunotherapy", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "36-year-old female with newly diagnosed invasive ductal carcinoma of the right breast, clinical stage I (T1cN0M0). Tumor is ER-positive, PR-positive, HER2 non-amplified by FISH. NGS panel identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant radiation and was started on letrozole. Post-op imaging shows no residual disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER-positive; PR-positive; HER2 non-amplified", "treatment": "lumpectomy; radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old with metastatic cutaneous melanoma. Biopsy of axillary node positive for melanoma harboring BRAF V600E. PD-L1 reported at 5% and tumor mutational burden described as high. Initially received dabrafenib + trametinib with rapid symptomatic improvement but then developed new pulmonary nodules after 6 months (progression on BRAF/MEK). Switched to pembrolizumab with subsequent partial response on interval imaging; brain MRI shows no CNS disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%; TMB-high", "treatment": "dabrafenib and trametinib (initial), then pembrolizumab", "response": "progression on BRAF/MEK, partial response to pembrolizumab", "metastasis_site": "lungs and axillary lymph node"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male with pancreatic ductal adenocarcinoma, advanced at presentation with peritoneal and hepatic implants consistent with stage IV disease. No molecular testing was performed at the community hospital prior to initiation of systemic therapy. He received gemcitabine and nab-paclitaxel but progressed clinically after two cycles.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man presented with progressive cough and weight loss. CT chest/abdomen demonstrated a 4.2 cm right lower lobe mass with multiple bilateral pulmonary nodules. Bronchoscopic biopsy: lung adenocarcinoma. Molecular testing positive for EGFR L858R; PD-L1 tumor proportion score ~10%. MRI brain confirms two enhancing lesions. Patient started osimertinib 80 mg PO daily in April; first restaging at 8 weeks showed shrinkage of the primary and resolution of one brain lesion \u2014 assessed as partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Locally advanced invasive ductal carcinoma of the left breast, ER positive, PR negative. FISH showed HER2 amplification. Next-generation sequencing identified a PIK3CA H1047R mutation on the diagnostic core. She received neoadjuvant chemotherapy with docetaxel, carboplatin plus trastuzumab and pertuzumab. Following surgery the pathology report documented ypT0N0 \u2014 pathologic complete response.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Hematology consult: 48-year-old male admitted with newly diagnosed acute myeloid leukemia. Bone marrow biopsy shows 30% blasts; molecular panel detects FLT3-ITD and NPM1 mutation. Patient received induction with cytarabine and daunorubicin (7+3) plus midostaurin. Post-induction marrow at day 28 shows no morphologic leukemia and peripheral counts recovering consistent with complete remission. Staging as per leukemia protocol \u2014 not applicable.", "output": {"cancer_type": "acute myeloid leukemia", "stage": null, "gene_mutation": "FLT3-ITD; NPM1", "biomarker": null, "treatment": "cytarabine and daunorubicin (7+3) with midostaurin", "response": "complete remission", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old female with metastatic pancreatic ductal adenocarcinoma. Germline and somatic testing identified a pathogenic BRCA2 frameshift (BRCA2 6174delT) and tumor profiling demonstrated homologous recombination deficiency (HRD-positive). She received FOLFIRINOX with initial radiographic partial response, transitioned to maintenance olaparib, but progressed after 9 months with new liver and peritoneal disease.", "output": {"cancer_type": "pancreatic adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 6174delT", "biomarker": "HRD-positive", "treatment": "FOLFIRINOX; maintenance olaparib", "response": "progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with locally advanced left breast cancer. Core biopsy: invasive ductal carcinoma, ER positive, PR negative, HER2 amplified by FISH. Clinical stage IIIA. She received neoadjuvant weekly paclitaxel with trastuzumab and pertuzumab; surgical specimen showed pathologic complete response. No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel, trastuzumab, pertuzumab", "response": "complete response (pathologic)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old man with metastatic cutaneous melanoma. NGS demonstrated BRAF V600E mutation. Initial therapy was combination dabrafenib and trametinib with symptomatic improvement; subsequent surveillance imaging revealed new pulmonary nodules and intracranial progression after 6 months. PD-L1 testing was not performed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib + trametinib", "response": "progression after initial response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "42-year-old woman found to have a 2.3 cm left breast mass. Biopsy: invasive ductal carcinoma, ER positive, PR positive, HER2 negative by IHC/FISH. NGS identified a PIK3CA H1047R alteration. Clinical staging: T1cN0M0 (stage I). She underwent lumpectomy with sentinel node biopsy; nodes negative. Adjuvant endocrine therapy with tamoxifen was started. Three-month surgical follow-up: no evidence of residual disease.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; sentinel lymph node biopsy; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic castration-resistant prostate cancer (mCRPC), stage IV with diffuse osteoblastic bone metastases. Germline testing identified a deleterious BRCA2 mutation. PSA at presentation was 98 ng/mL. He received androgen deprivation (leuprolide) and prior docetaxel; subsequently started on olaparib with radiographic and PSA assessment at 12 weeks consistent with stable disease.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": "BRCA2 deleterious (germline)", "biomarker": "PSA 98 ng/mL", "treatment": "leuprolide; docetaxel (prior); olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old male with newly diagnosed prostate adenocarcinoma, Gleason 4+3=7, clinical T2a. Baseline PSA was 12 ng/mL. He underwent robotic radical prostatectomy followed by salvage external beam radiation and androgen deprivation therapy with leuprolide. Post-treatment PSA is undetectable and bone scan is negative.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": "PSA 12 ng/mL (baseline); post-treatment undetectable PSA", "treatment": "radical prostatectomy, external beam radiation, leuprolide (ADT)", "response": "no evidence of disease (undetectable PSA)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic colorectal adenocarcinoma, stage IV at presentation with liver and pulmonary metastases. Molecular testing: BRAF V600E mutation; tumor classified as MSI-H and TMB-high. He was started on the targeted combination encorafenib + cetuximab; later switched to pembrolizumab for MSI-H disease. Imaging after 3 months on encorafenib/cetuximab showed mixed nodal shrinkage but persistent liver lesions consistent with overall stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "encorafenib + cetuximab; pembrolizumab", "response": "stable disease", "metastasis_site": "liver and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with high-grade serous ovarian carcinoma, stage IIIC with peritoneal carcinomatosis. Germline testing identified a deleterious BRCA2 mutation and tumor HRD was positive. She underwent neoadjuvant carboplatin and paclitaxel with interval debulking surgery achieving excellent cytoreduction, followed by platinum-based consolidation and initiation of olaparib maintenance. CA-125 normalized and imaging shows complete clinical response in the abdomen.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA2 deleterious mutation", "biomarker": "HRD-positive; CA-125 elevated at diagnosis then normalized", "treatment": "carboplatin + paclitaxel; interval debulking surgery; olaparib maintenance", "response": "complete clinical response (abdominal)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man with newly diagnosed prostate adenocarcinoma, clinical stage IIA. Germline testing revealed a pathogenic BRCA2 mutation. He underwent definitive external beam radiation with concurrent androgen deprivation therapy (leuprolide). PSA has fallen and the patient remains clinically stable at 12-month follow-up without evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IIA", "gene_mutation": "BRCA2", "biomarker": null, "treatment": "external beam radiation; androgen deprivation therapy (leuprolide)", "response": "stable disease / PSA decline", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with locally advanced pancreatic ductal adenocarcinoma now with hepatic metastases on staging CT, consistent with metastatic disease. There is no actionable mutation reported in the clinic note. He was started on combination FOLFIRINOX but had clinical and radiographic progression after two cycles.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "FOLFIRINOX", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with newly diagnosed lung adenocarcinoma presents with headaches. Staging workup shows multiple cerebral metastases and lytic lesions in the thoracic spine consistent with metastatic disease (stage IV). Molecular testing returned EGFR L858R positive; PD-L1 by IHC 10%. Patient started osimertinib 80 mg daily and tolerated therapy well with symptomatic improvement of pain and partial reduction of brain lesions on first follow-up imaging.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 64-year-old woman with metastatic lung adenocarcinoma diagnosed 2019. Current stage IV disease with new enhancing lesions on MRI consistent with brain metastases. Molecular testing returned EGFR L858R mutation; PD-L1 TPS 12%. Patient started osimertinib 80 mg daily 6 weeks ago with interval shrinkage of intracranial lesions on repeat imaging \u2014 described as a partial response. No other actionable alterations reported.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 12%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with metastatic cutaneous melanoma. Next-generation sequencing detected BRAF V600E. Baseline PD-L1 was 5%. He was started on combination BRAF/MEK inhibition with dabrafenib and trametinib and had a complete metabolic response on PET at 3 months. At month 9 he developed new symptomatic brain metastases and extracranial progression; stereotactic radiosurgery was delivered to the intracranial lesions and systemic therapy was changed.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; stereotactic radiosurgery", "response": "initial complete response then subsequent progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology telephone note: Patient with recurrent metastatic melanoma of unknown primary presenting with multiple pulmonary nodules. Molecular profiling: BRAF V600E positive. Began combination oral therapy with dabrafenib and trametinib. After three months, clinical progression with new subcentimeter brain metastasis and worsening pulmonary disease; plan to switch therapy. PD-L1 testing not performed.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with a bulky left breast mass. Core biopsy: invasive ductal carcinoma, HER2 3+ by IHC, ER negative, PR negative. Next-generation sequencing identified a PIK3CA H1047R mutation. Clinical stage at presentation approximately IIIB (inflammatory features). She received neoadjuvant trastuzumab and pertuzumab in combination with weekly paclitaxel followed by dose-dense AC; underwent modified radical mastectomy with pathologic complete response (no residual invasive carcinoma). No distant metastases identified on staging CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma, HER2-positive)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 3+; ER negative; PR negative", "treatment": "neoadjuvant trastuzumab and pertuzumab plus paclitaxel (then dose-dense AC); surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old man diagnosed with localized prostate adenocarcinoma, Gleason 3+4, clinical stage II, PSA 8 ng/mL. Managed with definitive external beam radiation therapy and six months of androgen deprivation (leuprolide). PSA at 12-month follow-up is 0.5 ng/mL and disease is clinically stable.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation; androgen deprivation therapy (leuprolide)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old woman underwent primary debulking for high-grade serous ovarian carcinoma. Operative notes documented extensive peritoneal carcinomatosis; disease was FIGO IIIC. BRCA germline testing was negative and no actionable somatic mutations were reported on the panel. She completed six cycles of adjuvant carboplatin and paclitaxel and follow-up CT at 6 months shows no evidence of disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": null, "treatment": "surgery (debulking) and adjuvant carboplatin and paclitaxel", "response": "no evidence of disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old female with newly diagnosed HER2-positive metastatic breast cancer. Biopsy confirms invasive ductal carcinoma, ER positive / PR negative, HER2 amplification by FISH. NGS shows a PIK3CA E545K mutation. She underwent staging that showed multifocal liver and osseous metastases. The tumor board recommended first-line combination therapy with trastuzumab, pertuzumab and docetaxel. Patient received three cycles and tolerated treatment well; follow-up assessment pending.", "output": {"cancer_type": "breast cancer (HER2-positive)", "stage": "IV", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab + pertuzumab + docetaxel", "response": null, "metastasis_site": "liver, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "59-year-old man diagnosed with prostate adenocarcinoma, Gleason score 3+4 on biopsy. Clinical stage T2bN0M0 (stage II). He underwent radical retropubic prostatectomy. No molecular testing or biomarker data are available in the chart and there is no evidence of metastatic disease.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Core biopsy confirmed adenocarcinoma, EGFR L858R positive on PCR; PD-L1 tumor proportion score ~10%. Staged as IV with brain and bone lesions on initial staging MRI and PET-CT. Started first-line osimertinib with evidence of intracranial response; interval CT at 6 months shows overall partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female referred to thoracic oncology for newly diagnosed metastatic lung adenocarcinoma. Tissue NGS returned EGFR L858R; PD-L1 testing not performed. MRI brain shows two enhancing cerebellar metastases; PET/CT demonstrates additional lytic lesion in T8. Patient started osimertinib 80 mg daily and had stereotactic radiosurgery to the cerebellar lesions. Restaging CT at 8 weeks demonstrates ~40% reduction in sum of target lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone (T8)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. CT shows multiple liver lesions consistent with metastases; colonoscopy confirmed primary sigmoid tumor. Molecular profiling: KRAS G12D positive; mismatch repair testing reported microsatellite stable (MSS). He was treated with FOLFOX and bevacizumab; initial CT at 12 weeks showed partial response but progressed at 9 months with new hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "initial partial response followed by progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with metastatic castration-resistant prostate cancer (Stage IV) presenting with diffuse osseous metastases and pelvic lymphadenopathy. Baseline PSA 145 ng/mL. Germline and somatic testing show BRCA2 loss. He underwent surgical castration and was treated with leuprolide and abiraterone plus prednisone; initial PSA decline was followed by radiographic progression at 10 months.", "output": {"cancer_type": "prostate adenocarcinoma (metastatic castration-resistant prostate cancer)", "stage": "IV", "gene_mutation": "BRCA2 loss", "biomarker": "PSA 145 ng/mL", "treatment": "surgical castration, leuprolide, abiraterone and prednisone", "response": "progression", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female presented with high-grade serous ovarian carcinoma, FIGO stage IIIC with bulky omental disease at diagnosis. Germline testing identified a pathogenic BRCA1 mutation. CA-125 was elevated to 560 U/mL preoperatively. She underwent optimal cytoreductive surgery followed by carboplatin and paclitaxel; bevacizumab was added and continued as maintenance. Interval CT shows a marked decrease in omental and peritoneal disease consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "CA-125 560 U/mL", "treatment": "cytoreductive surgery; carboplatin and paclitaxel; bevacizumab (maintenance)", "response": "partial response", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with high-grade serous ovarian carcinoma, FIGO IIIC with extensive peritoneal carcinomatosis. Germline testing revealed a pathogenic BRCA1 variant; baseline CA-125 markedly elevated. She received three cycles of neoadjuvant carboplatin and paclitaxel followed by interval debulking surgery and then maintenance olaparib. CT and CA-125 after surgery show partial radiographic response and a declining tumor marker.", "output": {"cancer_type": "ovarian cancer (high-grade serous)", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "CA-125 elevated", "treatment": "neoadjuvant carboplatin and paclitaxel, interval debulking surgery, maintenance olaparib", "response": "partial response", "metastasis_site": "peritoneum (peritoneal carcinomatosis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "34-year-old with metastatic cutaneous melanoma presented with cough and headaches. MRI and PET showed pulmonary nodules and two small brain metastases. Tumor sequencing detected BRAF V600E; PD-L1 expression 5%. Patient started on dabrafenib and trametinib combination therapy and achieved a complete clinical and radiographic response at 16 weeks with resolution of brain lesions.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib + trametinib", "response": "complete response", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, HER2 IHC 3+ with HER2 amplification on FISH; ER negative, PR negative. Clinical exam and imaging consistent with stage IIIC disease with bulky axillary and supraclavicular lymphadenopathy. She received neoadjuvant dose-dense doxorubicin/cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab, then underwent mastectomy. Surgical pathology revealed no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIC", "gene_mutation": null, "biomarker": "HER2 amplification; ER negative; PR negative", "treatment": "neoadjuvant doxorubicin/cyclophosphamide then paclitaxel with trastuzumab and pertuzumab; mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 45-year-old man with a nodular melanoma on the left upper arm. Wide local excision and sentinel node biopsy performed \u2014 one positive node in the axilla. Final staging stage IIIB. BRAF V600E mutation detected on tumor sequencing; PD-L1 expression ~5%. He was initiated on combined targeted therapy with dabrafenib and trametinib. Early clinical follow-up notes shrinkage of nodal mass consistent with partial response.", "output": {"cancer_type": "melanoma", "stage": "IIIB", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "partial response", "metastasis_site": "regional lymph nodes (axilla)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with metastatic colorectal adenocarcinoma presenting with right upper quadrant pain. Liver biopsy (March) confirmed adenocarcinoma; molecular profile: BRAF V600E mutation detected and MSI-H on PCR; tumor mutational burden reported as high. He was started on pembrolizumab monotherapy given MSI-H status. First restaging at 12 weeks shows predominantly unchanged size of hepatic lesions \u2014 radiographic impression: stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H; TMB-high", "treatment": "pembrolizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with newly diagnosed metastatic prostate adenocarcinoma, PSA 185 ng/mL. Bone scan demonstrates multiple sclerotic metastases throughout the lumbar spine and pelvis. Started androgen deprivation therapy with leuprolide plus docetaxel chemotherapy. Tumor genomic testing not yet revealing actionable somatic mutations.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": null, "biomarker": "PSA 185 ng/mL", "treatment": "leuprolide and docetaxel", "response": null, "metastasis_site": "bone (lumbar spine, pelvis)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Post-operative note: 64-year-old male with prostate adenocarcinoma, clinical stage II, underwent radical prostatectomy. No tumor genomic testing was performed. Adjuvant androgen deprivation therapy with leuprolide was started. Post-op PSA is undetectable at 3-month follow-up.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy; adjuvant leuprolide (androgen deprivation therapy)", "response": "undetectable PSA / complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old man with newly diagnosed colon adenocarcinoma metastatic to the liver (stage IV). Tumor genotyping shows KRAS G12D; MSI testing: microsatellite stable (MSI-stable). Started FOLFOX with bevacizumab in the metastatic setting. Most recent CT demonstrates multiple hepatic lesions without appreciable change compared with baseline.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Right breast invasive ductal carcinoma, clinical stage II (T2N0M0). Tumor was ER+, PR-, HER2 positive by IHC and confirmed HER2 amplification on FISH. Patient underwent breast-conserving surgery followed by adjuvant chemotherapy with docetaxel and trastuzumab. Surgical specimen after neoadjuvant core biopsy and surgery showed no residual invasive carcinoma (pathologic complete response reported). No mutation testing performed on this specimen.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR-", "treatment": "docetaxel and trastuzumab; breast-conserving surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 49-year-old female with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER 85% positive, PR 30% positive, HER2 by FISH shows amplification (HER2/CEP17 ratio 6.1). Patient received neoadjuvant weekly paclitaxel x12 with trastuzumab and pertuzumab; underwent modified radical mastectomy. Final pathology after surgery shows no residual invasive carcinoma (pCR). BRCA testing pending; no somatic mutation listed in chart.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification, ER+, PR+", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 48 yo F with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER+, PR-, HER2 3+ by IHC and confirmed HER2 amplification on FISH. Staging imaging consistent with T4bN1 disease \u2014 clinically stage IIIB. Neoadjuvant regimen planned: trastuzumab + pertuzumab with dose-dense docetaxel for 6 cycles. After 4 cycles there is decrease in tumor size clinically; patient reports improved pain. No distant mets identified on PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "trastuzumab, pertuzumab, docetaxel (neoadjuvant)", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Progress note: 57-year-old man with metastatic cutaneous melanoma, BRAF V600E positive, presented with lung and multiple brain metastases. PD-L1 reported 20%. Started on dabrafenib plus trametinib; extracranial lesions had a prompt partial response but MRI showed intracranial progression after 6 months with new enhancing cerebellar lesions. Plan discussed for stereotactic radiosurgery to brain lesions and consideration of immunotherapy on progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 20%", "treatment": "dabrafenib + trametinib; planned stereotactic radiosurgery", "response": "mixed response (partial response extracranial; intracranial progression)", "metastasis_site": "brain; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male with sigmoid colon adenocarcinoma initially treated with low anterior resection. Pathology showed KRAS G12D mutation. He was MSS on PCR testing. Eighteen months post-op surveillance CT identified a solitary 2.5 cm pulmonary nodule concerning for metastasis; PET confirmed uptake. He was started on FOLFOX plus bevacizumab for metastatic disease. Current scans show stable disease after four cycles.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "57-year-old female presented with metastatic lung adenocarcinoma diagnosed after biopsy of a right lower lobe mass. Molecular testing returned EGFR L858R mutation and PD-L1 10%. Staging at presentation was IV with known brain and osseous involvement. She was started on osimertinib 80 mg daily as first-line targeted therapy. Interval scans at 3 months demonstrate decrease in size of pulmonary and bony lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Path report and surgical oncology note: 48-year-old woman with left breast invasive ductal carcinoma, ER+/PR+ and HER2 amplified on FISH. Pre-op genotyping identified a PIK3CA E545K hotspot mutation. She received neoadjuvant paclitaxel with trastuzumab and pertuzumab with good clinical tumor regression and underwent lumpectomy. Final pathology shows no residual invasive carcinoma (ypT0), nodes negative.", "output": {"cancer_type": "breast invasive ductal carcinoma", "stage": "IIA", "gene_mutation": "PIK3CA E545K", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab; lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with metastatic cutaneous melanoma harboring BRAF V600E mutation. PD-L1 by IHC reported as >50%. He received pembrolizumab as first-line immunotherapy and interval CT chest demonstrated decrease in size and number of pulmonary nodules consistent with a partial response in the lungs.", "output": {"cancer_type": "melanoma (cutaneous)", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 >50%", "treatment": "pembrolizumab", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "71-year-old man with metastatic prostate adenocarcinoma presenting with extensive sclerotic bone metastases and pelvic nodal involvement; clinical stage IV. Tumor genomic testing identified a deleterious BRCA2 mutation. He was started on androgen-deprivation therapy with leuprolide and received docetaxel; after biochemical and radiographic progression he was transitioned to olaparib with an initial partial radiographic response followed by progression at 9 months.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": null, "treatment": "leuprolide; docetaxel; olaparib", "response": "initial partial response then progression", "metastasis_site": "bone, pelvic lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with right breast invasive ductal carcinoma, clinical stage II (T2N0). Tumor was ER positive, PR negative; HER2 amplification by FISH reported. Tumor sequencing identified PIK3CA H1047R. She received neoadjuvant paclitaxel plus trastuzumab followed by lumpectomy; surgical pathology demonstrated a complete pathological response (no residual invasive carcinoma).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "II", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR negative", "treatment": "neoadjuvant paclitaxel and trastuzumab, lumpectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old male with right temporal glioblastoma (WHO grade IV). Underwent subtotal resection followed by concurrent external beam radiation with temozolomide per Stupp protocol. IDH1/2 testing not performed and MGMT methylation status unavailable in chart. First post\u2011treatment MRI demonstrates clear radiographic progression and clinical decline.", "output": {"cancer_type": "glioblastoma (WHO grade IV)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "subtotal resection; radiation with temozolomide", "response": "progression", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old male underwent sigmoid colectomy for T3N1 sigmoid adenocarcinoma (stage III). Tumor molecular testing: KRAS G12D mutation; MSI-stable. He completed 12 cycles of adjuvant FOLFOX without complications and surveillance CTs have shown no evidence of distant metastasis. Pathology confirmed one involved pericolic lymph node.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "surgical resection (sigmoid colectomy); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": "regional lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female with high-grade serous ovarian carcinoma presenting with bulky pelvic disease and carcinomatosis consistent with FIGO stage IIIC. Germline testing identified a deleterious BRCA1 mutation and tumor testing showed homologous recombination deficiency (HRD-positive). She underwent debulking surgery followed by adjuvant carboplatin and paclitaxel with excellent radiologic and CA-125 response; maintenance olaparib was started. Most recent follow-up notes indicate a complete clinical and radiographic response with resolution of peritoneal disease.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 mutation", "biomarker": "HRD-positive", "treatment": "debulking surgery followed by carboplatin and paclitaxel; olaparib maintenance", "response": "complete response", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma, BRAF V600E positive on PCR. Initially treated with dabrafenib and trametinib with rapid tumor shrinkage; therapy later changed to nivolumab due to tolerance issues. PET/CT demonstrates decreasing uptake in multiple osseous lesions. No PD-L1 or other biomarker testing documented in the chart.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib; later nivolumab", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Core biopsy of the left breast revealed invasive ductal carcinoma, ER positive, PR positive and HER2 amplified by FISH. Clinical staging prior to neoadjuvant therapy was IIIB (tumor fixed to chest wall). PIK3CA H1047R mutation identified on NGS. Patient completed 6 cycles of paclitaxel with trastuzumab and pertuzumab as neoadjuvant therapy and proceeded to mastectomy; final pathology reported no residual invasive tumor \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant paclitaxel with trastuzumab and pertuzumab, mastectomy", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 54-year-old woman with left breast invasive ductal carcinoma, ER+, PR+, HER2 amplification by FISH. Clinically fixed axillary nodes; clinical stage IIIA. She received neoadjuvant paclitaxel with concurrent trastuzumab and had a marked reduction in tumor size. Underwent modified radical mastectomy last month; no distant disease on imaging. No somatic mutation panel was performed.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIA", "gene_mutation": null, "biomarker": "ER positive; PR positive; HER2 amplification", "treatment": "neoadjuvant paclitaxel and trastuzumab; modified radical mastectomy", "response": "partial response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Recent clinic note: 54-year-old female with ER+/PR+ HER2-amplified invasive ductal carcinoma initially treated with lumpectomy and adjuvant chemo. Now presents with jaundice and imaging showing multiple hepatic lesions consistent with metastases. Biopsy confirms recurrent breast cancer, PIK3CA H1047R on panel. Plan is to start weekly paclitaxel with trastuzumab; outpatient infusion scheduled. Disease appears limited to the liver on current scans.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "paclitaxel with trastuzumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Unresectable metastatic cutaneous melanoma with pulmonary nodules and new intracranial lesions. Molecular testing identified BRAF V600E. PD-L1 by IHC was low (~5%). He was started on dabrafenib plus trametinib after prior wide local excision; restaging at 6 months showed growth of lung nodules and new brain metastases \u2014 therapy deemed to be associated with progression.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; prior wide local excision", "response": "progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "58-year-old female diagnosed with cutaneous melanoma found to harbor BRAF V600E on molecular testing. PD-L1 by IHC approximately 5%. She commenced dabrafenib and trametinib and achieved a brisk partial response; after 9 months developed new pulmonary and intracranial lesions consistent with progression and was switched to nivolumab but did not derive clinical benefit.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 ~5%", "treatment": "dabrafenib + trametinib (then nivolumab after progression)", "response": "initial partial response then progression", "metastasis_site": "lung, brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with newly progressive colorectal adenocarcinoma. Initial molecular panel: KRAS G12D. Tumor characterized as MSI-H with a high tumor mutational burden. He received FOLFOX (5-FU/leucovorin/oxaliplatin) in combination with bevacizumab for 6 cycles with partial shrinkage of the primary but progression of several hepatic metastases; immunotherapy with pembrolizumab was started thereafter with mixed response on PET/CT.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX + bevacizumab, then pembrolizumab", "response": "mixed response", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old man presenting with progressive cough and weight loss. Biopsy confirmed lung adenocarcinoma. Staging scans show bilateral pulmonary nodules and a 1.5 cm cerebellar lesion consistent with metastasis (AJCC Stage IV). Tumor genotyping identified EGFR L858R. PD-L1 TPS 10%. Patient started osimertinib 80 mg daily and underwent stereotactic radiosurgery to the cerebellar metastasis. At three-month follow-up there was marked shrinkage of the lung lesions (partial response) but new leptomeningeal enhancement suspicious for CNS progression.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response (pulmonary) with new CNS progression", "metastasis_site": "brain (cerebellum); leptomeninges"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with newly diagnosed lung adenocarcinoma presenting with headaches and back pain. Staging workup consistent with stage IV disease with multiple brain metastases and lytic lesions in the spine. Tumor sequencing detected EGFR L858R mutation. PD-L1 tumor proportion score 10%. He was started on osimertinib with significant symptomatic improvement and interval imaging at 8 weeks demonstrated a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain; bone (spine)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient presents with metastatic colorectal adenocarcinoma. Colonoscopy primary in transverse colon; CT shows multiple hepatic lesions and peritoneal nodularity. Tumor is BRAF V600E mutant and MSI-H on immunohistochemistry/PCR. She was treated with pembrolizumab in the first-line setting given mismatch repair deficiency and initially achieved a partial radiographic response, but after 10 months developed clinical progression with enlarging liver metastases.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "pembrolizumab", "response": "initial partial response followed by progression", "metastasis_site": "liver, peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old male presents with metastatic colorectal adenocarcinoma with liver and lung metastases. Molecular profile: KRAS G12D positive, MSI-H and tumor mutation burden high. Initial treatment was FOLFOX with bevacizumab; upon progression the patient was switched to pembrolizumab monotherapy. Best response noted on immunotherapy is stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H; TMB-high", "treatment": "FOLFOX with bevacizumab, then pembrolizumab", "response": "stable disease", "metastasis_site": "liver; lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old male presented with right upper quadrant pain. Biopsy confirmed colorectal adenocarcinoma with synchronous liver lesions. Clinical stage IV at presentation. Comprehensive NGS returned KRAS G12D; tumor was MSI-stable. He was started on FOLFOX plus bevacizumab. Interval CT at 3 months consistent with stable disease.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable", "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old male with metastatic lung adenocarcinoma diagnosed March 2024. Core biopsy shows EGFR L858R and MET amplification; PD-L1 reported at 5%. Staging CT and brain MRI confirm extracranial disease with brain and bone lesions. Patient was started on osimertinib plus bevacizumab after initial platinum doublet; 6-week restaging demonstrates a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R; MET amplification", "biomarker": "PD-L1 5%", "treatment": "osimertinib and bevacizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 68-year-old male referred for metastatic colon cancer. CT shows multiple hypodense lesions in the liver consistent with metastatic disease (stage IV). Tumor sequencing returned KRAS G12D. He was initiated on FOLFOX plus bevacizumab; interim CT at 8 weeks demonstrates stable disease by RECIST. MSI testing was not informative in the report.", "output": {"cancer_type": "colon cancer", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old female presents with newly diagnosed lung adenocarcinoma. Staging workup demonstrated stage IV disease with multiple brain and bony metastases. Comprehensive molecular testing returned an EGFR exon 19 deletion; PD-L1 IHC reported 10% tumor cell staining. She was started on osimertinib 80 mg daily and at first restaging CT/MRI showed symptomatic improvement and a partial radiographic response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with recurrent cutaneous melanoma presenting with pulmonary nodules. Molecular testing identified BRAF V600E. Tumor mutational burden reported as TMB-high (above laboratory threshold). Prior single-agent pembrolizumab produced interval progression after 3 months, so therapy was switched to dabrafenib and trametinib. On follow-up CT the pulmonary lesions decreased in size; clinical assessment: partial response.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "TMB-high", "treatment": "pembrolizumab (prior); dabrafenib + trametinib (current)", "response": "partial response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old man diagnosed with metastatic lung adenocarcinoma, stage IV. Tumor harbors EGFR L858R on molecular testing; PD-L1 expression is 10%. He was started on osimertinib and had a partial radiographic response at first restaging (8 weeks), but later developed progression in the brain with new enhancing lesions and received stereotactic radiosurgery.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib (and stereotactic radiosurgery for brain mets)", "response": "initial partial response then progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colon adenocarcinoma, initially diagnosed with multiple hepatic metastases and bilateral pulmonary nodules consistent with stage IV disease. Tumor profiling revealed KRAS G12D mutation and the tumor is microsatellite stable (MSS). He received eight cycles of FOLFOX with bevacizumab; after an initial period of disease control the most recent CT shows interval enlargement of liver lesions consistent with progression.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS", "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Melanoma history: 48-year-old female with metastatic cutaneous melanoma. Initial therapy with pembrolizumab led to early progression after 3 cycles. BRAF testing returned positive for V600E. She was switched to targeted therapy with dabrafenib and trametinib; after 6 weeks there is interval shrinkage of pulmonary nodules and decrease in cerebral edema on MRI. PET/CT shows decreased FDG uptake in multiple pulmonary and nodal lesions.", "output": {"cancer_type": "metastatic melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "pembrolizumab (prior); dabrafenib + trametinib (current)", "response": "partial response", "metastasis_site": "lung; brain; lymph nodes"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Discharge summary: 67-year-old man admitted with progressive cough and headaches. CT chest revealed right lower lobe mass with multiple bilateral pulmonary nodules. MRI brain demonstrates two enhancing lesions consistent with metastases. Core biopsy of lung mass: adenocarcinoma, molecular testing positive for EGFR L858R. PD-L1 TPS reported at 10%. Patient was started on osimertinib 80 mg PO daily as first-line systemic therapy with symptomatic improvement. Interval imaging at 8 weeks shows decrease in size of lung nodules and brain lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "60-year-old male status post sigmoid colectomy for adenocarcinoma. Pathology showed pT3N1 disease consistent with stage III colon cancer. Mismatch repair testing returned MSI-H. No actionable somatic mutations were reported in the operative note. He completed 6 months of adjuvant FOLFOX; surveillance CTs and CEA remain without evidence of recurrence.", "output": {"cancer_type": "sigmoid colon adenocarcinoma", "stage": "III", "gene_mutation": null, "biomarker": "MSI-H", "treatment": "adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pathology and treatment summary: 47-year-old with palpable left breast mass. Core biopsy: invasive ductal carcinoma, ER positive (90%), PR positive (60%), HER2 negative (IHC 0). Staged preoperatively as IIA (T2N0). Genomic profiling identified PIK3CA H1047R mutation. Patient underwent lumpectomy with sentinel node biopsy followed by adjuvant whole-breast radiation and was started on tamoxifen. Post-treatment mammogram shows post-op changes, no residual tumor identified.", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER+, PR+, HER2 negative", "treatment": "lumpectomy; sentinel node biopsy; adjuvant radiation; tamoxifen", "response": "no evidence of residual tumor", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62-year-old female with metastatic lung adenocarcinoma found to harbor an EGFR L858R mutation. She presented with new headaches and MRI demonstrated multiple enhancing lesions consistent with brain metastases. PD-L1 was reported at 1%. She was started on osimertinib 80 mg daily; follow-up CT after 8 weeks showed decrease in size of pulmonary nodules and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 1%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Staging and PET/CT show multiple pulmonary nodules with brain and bone lesions consistent with metastatic disease. Molecular testing returned EGFR L858R; PD-L1 tumor proportion score 10%. She was started on osimertinib 80 mg daily as first-line therapy and had symptomatic improvement. Interval MRI shows decreased size of brain lesions and PET shows regression of several bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Consult: 58-year-old male status post right hemicolectomy for adenocarcinoma of the ascending colon, pathologic staging pT3N1 (Stage III). Tumor genotyping identified KRAS G12D. MSI testing: MSS. Adjuvant FOLFOX was completed for 6 months with routine CEA surveillance; currently no radiographic evidence of disease.", "output": {"cancer_type": "colon adenocarcinoma", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-stable (MSS)", "treatment": "surgery (right hemicolectomy); adjuvant FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old female diagnosed with high-grade serous ovarian carcinoma, FIGO stage IV with peritoneal carcinomatosis and multiple hepatic implants. Germline BRCA1 pathogenic variant confirmed. Baseline CA-125 markedly elevated. She received neoadjuvant carboplatin and paclitaxel with bevacizumab, underwent interval debulking surgery, and was started on maintenance olaparib. CT after six cycles showed interval decrease in peritoneal disease and liver implants consistent with a partial response.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IV", "gene_mutation": "BRCA1", "biomarker": "elevated CA-125", "treatment": "carboplatin and paclitaxel, bevacizumab, interval debulking, olaparib", "response": "partial response", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the breast, clinical stage IIIB. Core biopsy: HER2 IHC 3+ with confirmed HER2 amplification by FISH; ER positive, PR positive. Tumor sequencing identified PIK3CA H1047R mutation. She received neoadjuvant therapy with docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles followed by mastectomy. Surgical pathology reported no residual invasive tumor (pathologic complete response).", "output": {"cancer_type": "invasive ductal carcinoma of the breast", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "docetaxel, carboplatin, trastuzumab and pertuzumab; surgery (mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with metastatic castration-resistant prostate cancer (mCRPC), Gleason score 9, bone-only metastases on whole-body bone scan. Prior androgen-deprivation therapy with leuprolide and one line of docetaxel chemotherapy. Comprehensive NGS panel did not identify BRCA1/2, ATM or other actionable mutations. Patient was started on olaparib off-label and has had stable disease clinically and on PSA at three-month follow up.", "output": {"cancer_type": "prostate cancer (metastatic castration-resistant)", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "olaparib", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old with metastatic colorectal adenocarcinoma presenting with multiple hepatic metastases. Tumor sequencing detected KRAS G12D; tumor is microsatellite stable (MSS). CEA elevated at diagnosis. He received first-line FOLFIRI with bevacizumab and interval imaging showed ~30% shrinkage of liver lesions consistent with a partial response.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS; CEA elevated", "treatment": "FOLFIRI and bevacizumab", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Urology clinic note: 59\u2011year\u2011old man with elevated PSA 8.4 ng/mL. Transrectal biopsy demonstrates prostate adenocarcinoma Gleason 3+4 in 2 of 12 cores, organ\u2011confined disease consistent with clinical T1c (stage I). No molecular testing was performed. He elected definitive external beam radiation therapy combined with short\u2011term androgen deprivation (leuprolide). PSA is declining on follow up and there is no evidence of metastatic spread.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "I", "gene_mutation": null, "biomarker": null, "treatment": "external beam radiation; leuprolide (androgen deprivation)", "response": "stable disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Preoperative core biopsy demonstrated invasive ductal carcinoma of the left breast. IHC HER2 3+ with FISH confirming HER2 amplification; ER and PR negative. Clinical stage recorded as IIIB given large primary and skin involvement. Patient received neoadjuvant chemotherapy with docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) for six cycles followed by lumpectomy and axillary sentinel node evaluation. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification, ER negative, PR negative", "treatment": "docetaxel, carboplatin, trastuzumab, pertuzumab (neoadjuvant), surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced invasive ductal carcinoma of the left breast, ER-positive and PR-positive. HER2 amplified by FISH. Core biopsy NGS detected PIK3CA H1047R. Clinical stage recorded as IIIB with fixed axillary nodes. She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP). Final surgical pathology after mastectomy showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IIIC ulcerated cutaneous melanoma on the left forearm with confirmed BRAF V600E mutation. Primary wide local excision and sentinel node biopsy were performed. Eleven months later multiple pulmonary nodules consistent with metastatic recurrence were documented. The patient was treated with dabrafenib and trametinib with an initial partial response on chest CT, but progression occurred after 7 months and therapy was switched to combination nivolumab plus ipilimumab. PD-L1 was reported at 5% on IHC.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib; later nivolumab plus ipilimumab", "response": "partial response then progression", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology progress note: 58-year-old male with metastatic colorectal adenocarcinoma. Initial diagnosis December 2022 with liver-dominant metastases; stage IV. Tumor profiling showed BRAF V600E and high microsatellite instability (MSI-H). Patient received first-line FOLFIRI with bevacizumab, later progressed and was started on encorafenib plus cetuximab. Recent CT shows enlarging hepatic target lesions and new peritoneal nodularity \u2014 overall assessment: progression on targeted therapy.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "MSI-H", "treatment": "FOLFIRI and bevacizumab; encorafenib plus cetuximab", "response": "progression", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with invasive ductal carcinoma of the right breast, ER positive, PR positive, HER2 amplified by FISH. Clinical stage IIB (T2N1M0). She underwent lumpectomy with axillary node dissection followed by adjuvant chemotherapy (docetaxel and cyclophosphamide) and trastuzumab. Surgical pathology after neoadjuvant chemo showed no residual invasive carcinoma (pathologic complete response).", "output": {"cancer_type": "breast cancer", "stage": "IIB", "gene_mutation": null, "biomarker": "ER+, PR+, HER2 amplification", "treatment": "lumpectomy; docetaxel and cyclophosphamide; trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "61-year-old female with metastatic lung adenocarcinoma diagnosed in 2019. Tissue NGS returned EGFR L858R mutation and PD-L1 was 10% TPS by IHC. Staging at presentation was IV with brain and bone metastases on MRI and PET-CT. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to a cerebellar lesion. Interval CT at 3 months demonstrates decrease in size of pulmonary nodules and regression of several bone lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10% TPS", "treatment": "osimertinib, stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "62\u2011year\u2011old female referred for management of metastatic lung disease. Diagnosis: lung adenocarcinoma, stage IV at presentation. Tumor NGS identified EGFR L858R mutation (T790M negative). PD\u2011L1 tumor proportion score 10%. She started osimertinib 80 mg daily as first\u2011line systemic therapy and at 3\u2011month CT had a radiographic partial response. Brain MRI revealed two small cerebellar metastases treated with stereotactic radiosurgery; bone scan positive for lytic lesions in the pelvis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female referred for neoadjuvant therapy after biopsy-proven invasive ductal breast cancer, clinically T2N1. Core biopsy: ER+, PR+, HER2 amplification by FISH. Next-generation sequencing identified a PIK3CA H1047R hotspot mutation. No distant disease on staging PET/CT. Plan: neoadjuvant trastuzumab and pertuzumab with docetaxel for 6 cycles. Interim exam after 3 cycles: good clinical shrinkage of the breast mass. Patient is scheduled for lumpectomy pending response to completion of therapy.", "output": {"cancer_type": "breast cancer", "stage": "II (T2N1 clinical)", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "trastuzumab; pertuzumab; docetaxel (neoadjuvant)", "response": "partial response (clinical)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "78-year-old male with metastatic prostate adenocarcinoma presented with diffuse bone pain; bone scan showed multiple sclerotic bone metastases. Germline testing revealed a BRCA2 frameshift mutation and circulating tumor cell assay was positive for AR-V7. He was started on androgen deprivation with leuprolide plus docetaxel chemotherapy. PSA fell from 320 to 45 ng/mL and repeat imaging after 6 cycles showed a partial radiographic response. Documented as stage IV.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "AR-V7 positive", "treatment": "leuprolide and docetaxel", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Surgical pathology from left breast lumpectomy: invasive ductal carcinoma, 1.8 cm, grade 2. Margins negative. Sentinel lymph node biopsy 0/2. ER 90%, PR 40%, HER2 FISH negative. NGS panel identified PIK3CA H1047R. Patient underwent lumpectomy followed by adjuvant whole-breast radiation and was started on tamoxifen. At 18-month oncology follow-up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive, PR positive, HER2 negative", "treatment": "lumpectomy, adjuvant radiation, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with locally advanced breast cancer. Core biopsy: invasive ductal carcinoma, ER-positive, PR-negative, HER2 amplification by FISH. PIK3CA H1047R mutation reported on targeted panel. Clinical stage IIIB (large fixed axillary nodes and chest wall involvement). She received neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab for 6 cycles followed by modified radical mastectomy. Final pathology revealed no residual invasive carcinoma (pathologic complete response). No distant disease identified on PET/CT.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER-positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with locally advanced invasive ductal carcinoma of the left breast, ER positive and PR positive on IHC; HER2 IHC 3+ consistent with HER2 amplification. Clinical stage IIIB with fixed axillary nodes. Received neoadjuvant doxorubicin and cyclophosphamide x4 followed by paclitaxel with concurrent trastuzumab. Mastectomy specimen showed no residual invasive carcinoma \u2014 pathologic complete response.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old woman with newly diagnosed lung adenocarcinoma, stage IV. Molecular testing returned EGFR exon 19 deletion. PD-L1 by IHC was 5%. She was started on osimertinib 80 mg daily in Jan 2024. Interval MRI brain and PET/CT show shrinkage of intracranial and osseous lesions with overall partial response to therapy; patient remains on osimertinib with ongoing clinical benefit.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 5%", "treatment": "osimertinib 80 mg daily", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old female with a left breast mass underwent lumpectomy. Final pathology: invasive ductal carcinoma, pathologic stage IIA (T2N0M0). Hormone receptors: ER positive (90%), PR positive (60%); HER2 negative by IHC. Germline testing identified a pathogenic BRCA2 variant. She completed adjuvant doxorubicin and cyclophosphamide (AC) x4 followed by radiation and was started on tamoxifen. Surveillance imaging at 12 months shows no evidence of disease.", "output": {"cancer_type": "breast cancer", "stage": "IIA", "gene_mutation": "BRCA2 pathogenic variant", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy; adjuvant doxorubicin and cyclophosphamide (AC) x4; radiation; tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old male with metastatic pancreatic ductal adenocarcinoma found to have a deleterious germline BRCA2 mutation. At diagnosis he had stage IV disease with hepatic and peritoneal metastases. CA19-9 was markedly elevated. He completed 6 cycles of FOLFIRINOX with radiographic stable disease, then was switched to maintenance olaparib; serial CT scans demonstrate continued stable disease.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 (germline)", "biomarker": "CA19-9 elevated", "treatment": "FOLFIRINOX; maintenance olaparib", "response": "stable disease", "metastasis_site": "liver and peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology report: 54-year-old presented with a 3.2 mm non-ulcerated cutaneous melanoma on the right forearm, staged as stage II after pathology. Sentinel node biopsy was negative. Molecular testing detected BRAF V600E. Patient underwent wide local excision and was started on adjuvant nivolumab for high-risk stage II disease. At 18-month follow-up the patient remains disease-free.", "output": {"cancer_type": "cutaneous melanoma", "stage": "II", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "wide local excision; nivolumab (adjuvant)", "response": "disease-free", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old female with locally advanced left breast cancer, ER positive / PR positive, HER2 amplification on FISH. Core biopsy also showed PIK3CA H1047R mutation. Clinical stage IIIB. She received neoadjuvant chemotherapy with docetaxel, carboplatin plus trastuzumab and pertuzumab (6 cycles). Surgery after chemo revealed no residual invasive carcinoma (pathologic complete response). No distant disease identified on staging scans.", "output": {"cancer_type": "breast cancer", "stage": "IIIB", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel + carboplatin + trastuzumab + pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old man underwent resection for sigmoid colon adenocarcinoma. Final pathology pT3N1 (Stage III). Tumor genotyping identified KRAS G12D; tumor testing returned MSI-H. He completed adjuvant FOLFOX for 12 cycles. Surveillance CTs at 18 months post-treatment show no radiographic recurrence.", "output": {"cancer_type": "colon adenocarcinoma (sigmoid)", "stage": "III", "gene_mutation": "KRAS G12D", "biomarker": "MSI-H", "treatment": "anterior resection; FOLFOX", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "45-year-old woman with de novo metastatic right-sided invasive ductal breast cancer, ER-/PR-, HER2 amplification on IHC/FISH. Staging scans show multiple hepatic lesions consistent with metastases (stage IV). She received first-line trastuzumab, pertuzumab and docetaxel every 3 weeks. After 4 cycles there is a 40% reduction in sum of diameters of measurable liver lesions by RECIST \u2014 described as a partial response in the oncology note.", "output": {"cancer_type": "breast cancer (invasive ductal)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER-/PR-", "treatment": "trastuzumab, pertuzumab and docetaxel", "response": "partial response", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male with metastatic colorectal cancer presenting with right upper quadrant pain. CT abdomen showed multiple hypodense hepatic lesions. Colonoscopy confirmed adenocarcinoma of the sigmoid colon. Tumor sequencing identified KRAS G12D mutation. Patient was started on FOLFOX with bevacizumab; disease currently classified as stable disease on restaging after 3 months. Microsatellite testing returned MSS.", "output": {"cancer_type": "colorectal adenocarcinoma (sigmoid)", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX + bevacizumab", "response": "stable disease", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with pancreatic ductal adenocarcinoma, stage IV, with peritoneal carcinomatosis at diagnosis. Germline testing revealed a deleterious BRCA2 mutation. CA 19-9 was markedly elevated at baseline. She completed six cycles of modified FOLFIRINOX with a partial radiographic response and was transitioned to maintenance olaparib with ongoing disease stability on follow-up scans.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "BRCA2 mutation", "biomarker": "CA19-9 elevated", "treatment": "modified FOLFIRINOX followed by olaparib", "response": "stable disease", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "54-year-old man with newly diagnosed lung adenocarcinoma presented with headaches and back pain. Imaging showed multiple brain and vertebral lesions; biopsy confirmed metastatic adenocarcinoma. NGS returned EGFR L858R. He was started on osimertinib with significant symptomatic improvement and interval imaging shows a partial response after 8 weeks.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": null, "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with metastatic breast cancer presenting with worsening back pain. Core biopsy: invasive ductal carcinoma, ER positive, PR positive; HER2 amplification by FISH. NGS identified a PIK3CA H1047R mutation. Bone scan showed multiple lytic foci in the thoracic spine. She was treated with weekly paclitaxel in combination with trastuzumab and pertuzumab and received palliative radiotherapy to T6\u2013T8. Restaging after three cycles demonstrated a partial radiographic response in the spine lesions.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel; trastuzumab; pertuzumab; palliative radiotherapy to spine", "response": "partial response", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "65-year-old male with newly progressed metastatic lung adenocarcinoma. Initial treatment was carboplatin/pemetrexed combined with pembrolizumab for 4 cycles with a documented partial response on CT chest. Subsequent re-biopsy of a progressing lesion revealed EGFR exon 19 deletion; PD-L1 tumor proportion score 30%, TMB-low. Patient was transitioned to osimertinib with subsequent stable disease. Brain MRI showed a 1.2 cm enhancing lesion consistent with metastasis.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 30%, TMB-low", "treatment": "carboplatin + pemetrexed + pembrolizumab; later osimertinib", "response": "partial response to chemoimmunotherapy, then stable disease on osimertinib", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and treatment summary: 59-year-old female with high-grade serous ovarian carcinoma, surgically staged as IIIC with bulky peritoneal disease. Germline testing positive for pathogenic BRCA1 mutation and tumor homologous recombination deficiency (HRD) positive; CA-125 elevated pre-treatment. She completed interval cytoreductive surgery followed by adjuvant carboplatin and paclitaxel combined with bevacizumab. Given BRCA1 and HRD positivity she was initiated on maintenance olaparib after chemotherapy and has no radiographic evidence of disease on most recent CT.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 pathogenic variant", "biomarker": "HRD-positive; CA-125 elevated pre-treatment", "treatment": "carboplatin + paclitaxel + bevacizumab \u2192 maintenance olaparib", "response": "complete response (no radiographic evidence of disease)", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Clinic note: 54-year-old male with squamous cell carcinoma of the oropharynx (p16 negative) presented with bulky cervical adenopathy. Staged as T1N2bM0 (Stage IVA). He underwent definitive concurrent chemoradiation with high-dose cisplatin completed last month. On exam and flexible nasoendoscopy there is no palpable neck disease and mucosal primary looks regressed \u2014 clinical complete response documented.", "output": {"cancer_type": "squamous cell carcinoma of the oropharynx", "stage": "IVA", "gene_mutation": null, "biomarker": "p16 negative", "treatment": "definitive concurrent chemoradiation with cisplatin", "response": "clinical complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 52-year-old female diagnosed with invasive ductal carcinoma of the left breast. Clinical stage was IIA (T2N0M0). Core biopsy showed ER-positive (90%), PR-positive (60%), HER2 negative (IHC 0). Next-generation sequencing identified a PIK3CA H1047R mutation. She underwent breast-conserving surgery with sentinel node biopsy, followed by adjuvant radiation and started on adjuvant letrozole. Post-operative surveillance exams show no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy (breast-conserving surgery); radiation; letrozole", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old female with newly diagnosed lung adenocarcinoma. Staging workup confirms Stage IV disease with multiple brain and bone metastases. Molecular profiling returned an EGFR exon 19 deletion. PD-L1 tumor proportion score 10%. Started osimertinib 80 mg daily in July. Interval CT chest and MRI brain demonstrate decrease in size of the primary and resolving intracranial lesions consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "66-year-old female with newly diagnosed lung adenocarcinoma. Baseline staging revealed multiple enhancing lesions in the cerebrum consistent with metastatic disease. Molecular testing returned EGFR L858R and PD-L1 15%. She was started on osimertinib 80 mg daily in July. Interval MRI at 8 weeks showed reduction in size of the brain lesions and shrinkage of the primary right upper lobe mass.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 15%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic lung adenocarcinoma diagnosed May 2024. Molecular testing returned EGFR exon 19 deletion. PD-L1 TPS reported at 60%. He was started on osimertinib 80 mg PO daily and bevacizumab IV q3w in July. Interval MRI shows decreased size of CNS lesions and PET/CT documents reduction in osseous disease burden. Assessment: partial response to targeted therapy. Stage IV disease with known brain and bone metastases.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR exon 19 deletion", "biomarker": "PD-L1 TPS 60%", "treatment": "osimertinib; bevacizumab", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female diagnosed with high-grade serous ovarian carcinoma presenting with bulky omental and peritoneal tumor burden; staged IIIC at laparotomy. Germline testing returned a deleterious BRCA1 mutation and tumor profiling showed homologous recombination deficiency (HRD) positive. She underwent optimal cytoreductive surgery followed by six cycles of carboplatin and paclitaxel with a documented partial response on CT and CA-125 decline. Maintenance olaparib was started, but CA-125 subsequently rose and scans at 10 months showed progression.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": "BRCA1 (germline)", "biomarker": "HRD positive", "treatment": "debulking surgery; carboplatin and paclitaxel; maintenance olaparib", "response": "partial response followed by progression", "metastasis_site": "peritoneum, omentum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "52-year-old man with bulky nodal melanoma of the right shoulder and in-transit metastases. Pathology staged as IIIC. BRAF V600E mutation identified on targeted testing. PD-L1 expression low at 5%. He was initiated on targeted therapy with dabrafenib and trametinib. After three months of therapy, cross-sectional imaging shows no further growth of target lesions \u2014 classified as stable disease.", "output": {"cancer_type": "cutaneous melanoma", "stage": "IIIC", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 5%", "treatment": "dabrafenib and trametinib", "response": "stable disease", "metastasis_site": "regional lymph nodes (in-transit metastases)"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Operative and discharge summary: 67-year-old male with squamous cell carcinoma of the lateral tongue, clinical stage II. He underwent partial glossectomy with negative margins and selective neck dissection, followed by adjuvant external beam radiotherapy. No molecular or biomarker testing was performed. At 12-week clinic follow-up there is no clinical or radiographic evidence of disease.", "output": {"cancer_type": "squamous cell carcinoma of the tongue (head and neck)", "stage": "II", "gene_mutation": null, "biomarker": null, "treatment": "surgery (partial glossectomy, neck dissection) and adjuvant radiotherapy", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "56-year-old female with high-grade serous ovarian carcinoma, stage IV at presentation with peritoneal carcinomatosis and hepatic implants. Germline testing positive for BRCA1 mutation. CA-125 markedly elevated (>500 U/mL). She received carboplatin and paclitaxel with bevacizumab; transitioned to olaparib maintenance. Disease progressed after 6 months on maintenance with radiographic enlargement of peritoneal and liver lesions.", "output": {"cancer_type": "ovarian high-grade serous carcinoma", "stage": "IV", "gene_mutation": "BRCA1 mutation", "biomarker": "CA-125 >500 U/mL", "treatment": "carboplatin and paclitaxel with bevacizumab; olaparib maintenance", "response": "progression", "metastasis_site": "peritoneum, liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "70-year-old female diagnosed with clear cell renal cell carcinoma, metastatic at presentation with pulmonary and osseous lesions. She underwent cytoreductive nephrectomy and then was started on combination immunotherapy with nivolumab plus ipilimumab. Follow-up imaging shows a partial radiographic response. No molecular testing was performed and no PD-L1 result is available.", "output": {"cancer_type": "clear cell renal cell carcinoma", "stage": "IV", "gene_mutation": null, "biomarker": null, "treatment": "nivolumab and ipilimumab", "response": "partial response", "metastasis_site": "lung, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "55-year-old female with invasive ductal carcinoma of the left breast. Tumor measured 2.4 cm, sentinel node biopsy positive (2/14). ER positive, PR positive, HER2 negative by IHC; pathologic stage IIA. NGS identified PIK3CA H1047R. She underwent lumpectomy with sentinel lymph node dissection followed by adjuvant whole-breast radiotherapy and tamoxifen. Post-treatment PET/CT shows no evidence of disease.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIA", "gene_mutation": "PIK3CA H1047R", "biomarker": "ER positive; PR positive; HER2 negative", "treatment": "lumpectomy, sentinel node dissection, adjuvant radiotherapy, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient is a 65-year-old man diagnosed with metastatic lung adenocarcinoma. Staging workup consistent with stage IV disease with lesions in the brain and multiple lytic bone lesions. Molecular testing returned EGFR L858R mutation; PD-L1 tumor proportion score 10%. He was started on osimertinib 80 mg daily and after two months had interval decrease in thoracic and intracranial disease on imaging consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain, bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "69-year-old female with newly diagnosed metastatic lung adenocarcinoma. Core biopsy (right upper lobe) positive for EGFR L858R mutation; PD-L1 IHC reported 10%. Staging PET/CT consistent with stage IV disease with multifocal bone lesions and two enhancing brain metastases. Patient was started on osimertinib 80 mg daily and underwent stereotactic radiosurgery to the dominant brain lesion. Interval CT at 8 weeks demonstrates shrinkage of the pulmonary primary and nodal disease with decreased size of several bone lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain and bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic cutaneous melanoma found to harbor BRAF V600E mutation. PD-L1 staining was low at 2%. Treated with combination dabrafenib and trametinib; after 4 months there is progression with new osseous lesions and enlarging pulmonary nodules. Stage at diagnosis was IV.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 2%", "treatment": "dabrafenib and trametinib", "response": "progression", "metastasis_site": "bone and lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "47-year-old woman with locally advanced invasive ductal carcinoma of the left breast, clinical stage IIIB with fixed axillary nodes. Tumor was ER-positive, PR-positive and HER2 amplified on IHC/ISH. Neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) was completed followed by left modified radical mastectomy. Surgical pathology reported no residual invasive carcinoma (pathologic complete response). Germline BRCA testing was negative.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IIIB", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab; surgery (modified radical mastectomy)", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Dermatology/oncology correspondence: 45-year-old with metastatic cutaneous melanoma, BRAF V600E positive on molecular testing. Initially started on pembrolizumab but developed grade 3 immune colitis requiring steroid taper; therapy was stopped. The patient was transitioned to targeted therapy with dabrafenib plus trametinib. Interval PET-CT demonstrates complete metabolic response with resolution of previously noted pulmonary nodules. Currently continuing targeted oral therapy with good tolerance.", "output": {"cancer_type": "metastatic cutaneous melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": null, "treatment": "dabrafenib and trametinib (prior pembrolizumab)", "response": "complete response", "metastasis_site": "lung"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Stage IV metastatic cutaneous melanoma with symptomatic cerebellar metastasis. Molecular testing positive for BRAF V600E; PD-L1 by IHC reported at 10%. The patient was started on dabrafenib plus trametinib with prompt clinical improvement, then transitioned to combination immunotherapy with ipilimumab and nivolumab for consolidation. Three-month restaging showed partial response in extracranial lesions but new intracranial progression requiring repeat stereotactic radiosurgery.", "output": {"cancer_type": "melanoma", "stage": "IV", "gene_mutation": "BRAF V600E", "biomarker": "PD-L1 10%", "treatment": "dabrafenib + trametinib; ipilimumab + nivolumab; stereotactic radiosurgery", "response": "partial response (extracranial); intracranial progression", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Patient with metastatic colorectal adenocarcinoma (left-sided) with new painful vertebral lesions and focal uptake on bone scan. Tumor NGS reported KRAS G12D. MSI testing: microsatellite stable. He received FOLFOX plus bevacizumab for 4 cycles but imaging shows progression in the spine.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12D", "biomarker": "MSS (microsatellite stable)", "treatment": "FOLFOX and bevacizumab", "response": "progressive disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old man with metastatic lung adenocarcinoma diagnosed in 2019. Molecular testing showed EGFR L858R mutation; PD-L1 tumor proportion score 20%. He initially received erlotinib but progressed after 10 months and was switched to osimertinib 80 mg daily with a partial response. MRI shows both brain and osseous metastases. Listed as stage IV disease.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 20%", "treatment": "osimertinib (prior erlotinib)", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man with a 40 pack-year smoking history presented with progressive cough and headaches. CT chest revealed multiple nodules in both lungs and MRI brain showed two enhancing lesions. Core biopsy confirmed lung adenocarcinoma. Molecular testing returned EGFR L858R positive; ALK and ROS1 negative. PD-L1 tumor proportion score 10%. Patient was started on osimertinib 80 mg daily. Follow-up imaging at 8 weeks demonstrates reduction in size of pulmonary and intracranial lesions.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "History: 62-year-old female with newly diagnosed lung adenocarcinoma. Imaging shows multiple enhancing lesions in the right frontal lobe and a lytic lesion in T8. Biopsy confirmed adenocarcinoma consistent with lung primary. Molecular testing returned EGFR L858R mutation. PD-L1 TPS 10%. Staged as IV at diagnosis. Patient was started on osimertinib 80 mg daily and received stereotactic radiosurgery to the brain metastasis. On 8-week restaging CT the lung lesion decreased in size by 45%, extracranial disease stable.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%", "treatment": "osimertinib; stereotactic radiosurgery", "response": "partial response", "metastasis_site": "brain; bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "67-year-old male with metastatic pancreatic ductal adenocarcinoma, stage IV at presentation with multiple liver lesions on CT. Tumor profiling identified KRAS G12V and TP53 mutation; no actionable fusions detected. CA19-9 elevated to 2,500 U/mL. He received gemcitabine plus nab-paclitaxel as first-line therapy, but CT after two cycles demonstrates interval increase in size and number of hepatic metastases and a rising CA19-9 consistent with clinical progression.", "output": {"cancer_type": "pancreatic ductal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12V; TP53 mutation", "biomarker": "CA19-9 2500 U/mL", "treatment": "gemcitabine and nab-paclitaxel", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "48-year-old woman diagnosed with invasive ductal carcinoma of the left breast (stage I, T1bN0). Tumor is ER+/PR+, HER2 amplification by FISH. Tumor sequencing identified PIK3CA H1047R. She underwent lumpectomy with sentinel node biopsy followed by adjuvant paclitaxel and trastuzumab and was started on tamoxifen. Follow-up mammogram and exam show no evidence of disease.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "I", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+/PR+", "treatment": "lumpectomy, paclitaxel, trastuzumab, tamoxifen", "response": "no evidence of disease", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Pre-op note: 47-year-old woman with clinical stage IIIC invasive ductal carcinoma of the left breast, ER positive, PR positive, HER2 amplification by FISH. Core biopsy showed a concurrent PIK3CA H1047R mutation on targeted panel. She completed six cycles of neoadjuvant docetaxel with dual HER2 blockade (trastuzumab and pertuzumab). Lumpectomy performed May 2024 \u2014 surgical pathology demonstrates no residual invasive carcinoma (pathologic complete response). No distant metastases were identified on staging PET/CT.", "output": {"cancer_type": "invasive ductal carcinoma (breast cancer)", "stage": "IIIC", "gene_mutation": "PIK3CA H1047R", "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant docetaxel with trastuzumab and pertuzumab", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "63-year-old male with newly diagnosed metastatic colorectal adenocarcinoma. Tumor genotyping identified KRAS G12C. Cross-sectional imaging demonstrates multiple hypodense lesions in both hepatic lobes consistent with liver metastases. The patient was initiated on FOLFOX with bevacizumab. Restaging after three cycles shows increase in size and number of hepatic lesions.", "output": {"cancer_type": "colorectal adenocarcinoma", "stage": "IV", "gene_mutation": "KRAS G12C", "biomarker": null, "treatment": "FOLFOX and bevacizumab", "response": "progression", "metastasis_site": "liver"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "72-year-old man underwent radical prostatectomy for prostate adenocarcinoma, Gleason score 4+4=8. Surgical margins were negative and lymphovascular invasion was not identified. No adjuvant radiation or systemic therapy was planned; no genomic testing or staging beyond prostatectomy report is documented in the chart.", "output": {"cancer_type": "prostate adenocarcinoma", "stage": null, "gene_mutation": null, "biomarker": null, "treatment": "radical prostatectomy", "response": null, "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "68-year-old presented with increasing abdominal girth and CA-125 elevation. Exploratory laparotomy revealed high-grade serous ovarian carcinoma with bulky peritoneal disease. Optimal cytoreductive surgery performed; final stage recorded as IIIC. Patient started adjuvant carboplatin and paclitaxel with good clinical improvement and falling CA-125. Germline BRCA testing was not completed prior to chemotherapy; plan for testing after recovery.", "output": {"cancer_type": "high-grade serous ovarian carcinoma", "stage": "IIIC", "gene_mutation": null, "biomarker": "elevated CA-125", "treatment": "cytoreductive surgery; adjuvant carboplatin and paclitaxel", "response": "partial response (clinical improvement and falling CA-125)", "metastasis_site": "peritoneum"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Left breast invasive ductal carcinoma, ER positive, PR positive, HER2 amplified by FISH. Clinical staging T2N1 (stage IIA). Patient received neoadjuvant anthracycline/cyclophosphamide followed by paclitaxel with concurrent trastuzumab prior to surgery. Germline testing was negative and comprehensive tumor panel reported no actionable somatic mutations. Surgical pathology after neoadjuvant therapy showed no residual invasive carcinoma (pathologic complete response). No distant metastases identified.", "output": {"cancer_type": "invasive ductal carcinoma (breast)", "stage": "IIA", "gene_mutation": null, "biomarker": "HER2 amplification; ER+; PR+", "treatment": "neoadjuvant doxorubicin/cyclophosphamide \u2192 paclitaxel with trastuzumab; surgery", "response": "pathologic complete response", "metastasis_site": null}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology clinic note: 48-year-old woman with de novo metastatic breast cancer. Biopsy of right breast and axillary node confirmed invasive ductal carcinoma with HER2 amplification by FISH; ER 80% positive, PR 30% positive. Imaging shows multifocal bony involvement (thoracic spine and pelvis). She was initiated on weekly paclitaxel with trastuzumab and pertuzumab. After 4 cycles the disease remains radiographically stable and pain is controlled with zoledronic acid. No somatic sequencing was reported in the chart.", "output": {"cancer_type": "breast cancer (invasive ductal carcinoma)", "stage": "IV", "gene_mutation": null, "biomarker": "HER2 amplification; ER positive; PR positive", "treatment": "paclitaxel; trastuzumab; pertuzumab; zoledronic acid", "response": "stable disease", "metastasis_site": "bone"}}
{"instruction": "Extract all cancer-related entities from the text.", "input": "Oncology consult: 65-year-old female with metastatic lung adenocarcinoma (stage IV) diagnosed 11/2023. NGS from the diagnostic biopsy identified EGFR L858R. PD-L1 by IHC reported 10% and TMB-low. Baseline brain MRI showed multiple small parenchymal metastases. She was started on osimertinib 80 mg PO daily in January 2024. Interval CT and brain MRI after three months demonstrate approximately 60% reduction in measurable disease consistent with a partial response.", "output": {"cancer_type": "lung adenocarcinoma", "stage": "IV", "gene_mutation": "EGFR L858R", "biomarker": "PD-L1 10%; TMB-low", "treatment": "osimertinib", "response": "partial response", "metastasis_site": "brain"}}
